assays_assay_id,assays_src_id,assays_description,assays_assay_tissue,assays_bao_format,assays_src_assay_id,assays_assay_organism,assays_assay_category,assays_curated_by,assays_doc_id,assays_assay_test_type,assays_relationship_type,assays_confidence_score,assays_chembl_id,assays_cell_id,assays_tissue_id,assays_variant_id
1,1,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 30 uM,,BAO_0000019,,,,Autocuration,11087,,H,8,CHEMBL615117,,,
2,1,Compound was evaluated for its ability to mobilize calcium in 1321NI cells,,BAO_0000219,,,,Autocuration,684,,U,0,CHEMBL615118,,,
3,1,,,BAO_0000019,,,,Autocuration,15453,,U,0,CHEMBL615119,,,
4,1,Binding affinity against A2 adenosine receptor in bovine striatal membranes using [3H]CGS-21680,,BAO_0000249,,Bos taurus,,Autocuration,17841,,H,4,CHEMBL615120,,,
5,1,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),,BAO_0000219,,Homo sapiens,,Intermediate,17430,,N,1,CHEMBL615121,163.0,,
6,1,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),,BAO_0000219,,Homo sapiens,,Intermediate,17430,,N,1,CHEMBL615122,163.0,,
7,1,Cytotoxic Activity was evaluated against 143B (TK-) tumor cells,,BAO_0000219,,Mus musculus,,Intermediate,13799,,N,1,CHEMBL615123,163.0,,
8,1,In vitro cell cytotoxicity was determined against 143B cell line,,BAO_0000219,,Homo sapiens,,Expert,17774,,N,1,CHEMBL615124,163.0,,
9,1,Inhibitory activity against tumor osteosarcoma cell line 143B after 72 hr continuous exposure to compound,,BAO_0000219,,Homo sapiens,,Intermediate,3801,,N,1,CHEMBL615125,163.0,,
10,1,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,,BAO_0000219,,Homo sapiens,,Intermediate,17430,,N,1,CHEMBL615126,163.0,,
11,1,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,,BAO_0000219,,Homo sapiens,,Intermediate,17430,,N,1,CHEMBL615127,163.0,,
12,1,In vitro cell cytotoxicity was determined against 143B-LTK cell line,,BAO_0000219,,Homo sapiens,,Expert,17774,,N,1,CHEMBL615128,163.0,,
13,1,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,BAO_0000218,,Staphylococcus aureus,,Intermediate,11324,,N,1,CHEMBL857900,,,
14,1,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,BAO_0000218,,Staphylococcus aureus,,Intermediate,11324,,N,1,CHEMBL615129,,,
15,1,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,BAO_0000218,,Staphylococcus aureus,,Intermediate,11324,,N,1,CHEMBL615130,,,
16,1,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,BAO_0000218,,Staphylococcus aureus,,Intermediate,11324,,N,1,CHEMBL615131,,,
17,1,Inhibition of cytochrome P450 progesterone 15-alpha hydroxylase,,BAO_0000357,,Rattus norvegicus,,Expert,11347,,D,9,CHEMBL884521,,,
18,1,Concentration that cause 50% activation of human reticulocyte 15-lipoxygenase (15-HLO),,BAO_0000357,,,,Autocuration,16474,,H,8,CHEMBL615132,,,
19,1,Inhibition of partially purified 15-lipoxygenase from human leukocytes,,BAO_0000019,,,,Autocuration,10091,,H,8,CHEMBL615133,,,
20,1,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),,BAO_0000357,,,,Autocuration,16474,,H,8,CHEMBL615134,,,
21,1,Compound was evaluated for the percent increase in activation concentration of human reticulocyte 15-lipoxygenase (15-HLO),,BAO_0000357,,,,Autocuration,16474,,H,8,CHEMBL615135,,,
22,1,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),,BAO_0000357,,,,Autocuration,16474,,H,8,CHEMBL615136,,,
23,1,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,,BAO_0000357,,,,Autocuration,16474,,H,8,CHEMBL615137,,,
24,1,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,,BAO_0000357,,,,Autocuration,16474,,H,8,CHEMBL615138,,,
25,1,"Inhibitory concentration against 15-lipoxygenase, by inhibiting 15-HETE production by human umbilical vein endothelial cells (HUVEC) stimulated by calcium ionophore A 23187 at concentration of 10e-5 M.",,BAO_0000219,,,,Autocuration,14352,,U,0,CHEMBL836324,,,
26,1,In vitro inhibitory activity of compound on rabbit reticulocyte 15-lipoxygenase,,BAO_0000357,,Oryctolagus cuniculus,,Autocuration,5646,,H,8,CHEMBL615139,,,
27,1,Inhibition of rabbit reticulocyte 15-lipoxygenase by compound (30 uM),,BAO_0000357,,Oryctolagus cuniculus,,Autocuration,5646,,H,8,CHEMBL615140,,,
28,1,Inhibitory activity against 15-lipoxygenase in rat polymorphonuclear leukocytes,,BAO_0000219,,,,Autocuration,10997,,H,8,CHEMBL615141,,,
29,1,Inhibitory activity against 15-lipoxygenase was determined obtained from soya bean,,BAO_0000357,,soya bean,,Autocuration,6309,,H,8,CHEMBL615142,,,
30,1,Inhibitory activity against soybean 15-lipoxygenase was evaluated,,BAO_0000357,,Glycine max,,Autocuration,167,,H,8,CHEMBL615143,,,
31,1,Inhibitory activity against soybean 15-lipoxygenase was evaluated at 100 uM,,BAO_0000357,,Glycine max,,Autocuration,167,,H,8,CHEMBL615144,,,
32,1,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 10 uM,,BAO_0000357,,Glycine max,,Autocuration,11087,,H,8,CHEMBL872867,,,
33,1,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 100 uM,,BAO_0000357,,Glycine max,,Autocuration,11087,,H,8,CHEMBL615145,,,
34,1,Compound was tested in vitro for inhibition of 15-lipoxygenase soybean,,BAO_0000357,,Glycine max,,Autocuration,13622,,H,8,CHEMBL615146,,,
35,1,Compound at 100 uM was tested in vitro for inhibition of 15-lipoxygenase soybean,,BAO_0000357,,Glycine max,,Autocuration,13622,,H,8,CHEMBL615147,,,
36,1,Inhibition of cytochrome P450 progesterone 16-alpha hydroxylase,,BAO_0000019,,Rattus norvegicus,,Autocuration,11347,,U,0,CHEMBL615148,,,
37,1,Binding affinity against bacterial 16S rRNA using mass spectrometry based assay,,BAO_0000019,,Escherichia coli,,Autocuration,5926,,U,0,CHEMBL615149,,,
38,1,Dissociation constant with dimeric 16S rRNA RNA construct B,,BAO_0000019,,,,Autocuration,4567,,U,0,CHEMBL615150,,,
39,1,Dissociation constant towards 16S rRNA construct A,,BAO_0000225,,,,Intermediate,3782,,M,3,CHEMBL615151,,,
40,1,Dissociation constant towards 16S rRNA construct B,,BAO_0000225,,,,Intermediate,3782,,M,3,CHEMBL615152,,,
41,1,Binding affinity of aminoglycoside to 16S ribosomal RNA A-site in Escherichia coli,,BAO_0000225,,Escherichia coli,,Expert,4466,,M,3,CHEMBL615153,,,
42,1,Binding affinity for the 16S ribosomal RNA A-site of Escherichia coli,,BAO_0000225,,Escherichia coli,,Expert,6592,,M,3,CHEMBL615154,,,
43,1,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,BAO_0000019,,,,Autocuration,898,,H,8,CHEMBL615155,,,
44,1,Inhibitory constant against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,BAO_0000019,,,,Autocuration,898,,H,8,CHEMBL615156,,,
45,1,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,,BAO_0000019,,Homo sapiens,,Autocuration,13163,,H,8,CHEMBL615157,,,
46,1,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,,BAO_0000019,,Homo sapiens,,Autocuration,13163,,H,8,CHEMBL615158,,,
47,1,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",,BAO_0000019,,Rattus norvegicus,,Expert,10691,,D,9,CHEMBL615159,,,
48,1,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",,BAO_0000019,,Rattus norvegicus,,Expert,10691,,D,9,CHEMBL615172,,,
49,1,"Percent inhibition of 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",,BAO_0000019,,Rattus norvegicus,,Expert,10691,,D,9,CHEMBL615173,,,
50,1,"Percent inhibition of Steroid 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",,BAO_0000019,,Rattus norvegicus,,Expert,10691,,D,9,CHEMBL615174,,,
51,1,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,BAO_0000019,,,,Autocuration,898,,H,8,CHEMBL884518,,,
52,1,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1),,BAO_0000357,,,,Autocuration,912,,H,8,CHEMBL615175,,,
53,1,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 1 uM concentration,,BAO_0000357,,,,Autocuration,912,,H,8,CHEMBL615176,,,
54,1,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 10 uM concentration,,BAO_0000357,,,,Autocuration,912,,H,8,CHEMBL615177,,,
55,1,Selectivity ratio of binding affinity towards mu to delta receptors of rat brain membranes,,BAO_0000249,,Rattus norvegicus,,Autocuration,15103,,D,5,CHEMBL615178,,,
56,1,Cytotoxicity against ovarian cancer cell line (1A-9) of humans was determined,,BAO_0000219,,Homo sapiens,,Intermediate,5116,,N,1,CHEMBL615179,506.0,,
57,1,Functional antagonism by electrical assays in Xenopus oocytes expressing 1A/2A NMDA receptor subtype,,BAO_0000219,,Rattus norvegicus,,Autocuration,14578,,D,7,CHEMBL615180,,,
58,1,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2B NMDA receptor,,BAO_0000219,,Rattus norvegicus,,Autocuration,14578,,D,7,CHEMBL615181,,,
59,1,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2C NMDA receptor,,BAO_0000219,,Rattus norvegicus,,Autocuration,14578,,D,7,CHEMBL615182,,,
60,1,In vitro effective concentration required to reduce the number of human ovarian cancer (1A9) after 3-day incubation,,BAO_0000219,,Homo sapiens,,Expert,4787,,N,1,CHEMBL615183,506.0,,
61,1,In vitro effective concentration required to reduce the number of human ovarian cancer cells (1A9) after 3-day incubation,,BAO_0000219,,Homo sapiens,,Intermediate,4787,,N,1,CHEMBL615184,506.0,,
62,1,Cytotoxic activity against human ovarian cancer (1A9) cell line,,BAO_0000219,,Homo sapiens,,Intermediate,3547,,N,1,CHEMBL615185,506.0,,
63,1,Cytotoxic activity against human ovarian cancer (1A9) cell line; ND=Not determined,,BAO_0000219,,Homo sapiens,,Intermediate,3547,,N,1,CHEMBL615186,506.0,,
64,1,Effective dose of compound against replication of 1A9 cell line was evaluated,,BAO_0000219,,Homo sapiens,,Intermediate,6726,,N,1,CHEMBL615187,506.0,,
65,1,In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line,,BAO_0000219,,Homo sapiens,,Expert,3455,,N,1,CHEMBL885343,506.0,,
66,1,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line),,BAO_0000219,,Homo sapiens,,Intermediate,5726,,N,1,CHEMBL615188,506.0,,
67,1,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line); NA is not active,,BAO_0000219,,Homo sapiens,,Intermediate,5726,,N,1,CHEMBL615189,506.0,,
68,1,In vitro percent inhibition evaluated against human ovarian cancer (1A9 cell line) at >20 ug/mL,,BAO_0000219,,Homo sapiens,,Intermediate,5726,,N,1,CHEMBL615190,506.0,,
69,1,Inhibitory activity against Taxol resistant 1A9 cell lines,,BAO_0000219,,Homo sapiens,,Intermediate,3395,,N,1,CHEMBL615191,506.0,,
70,1,Cytotoxicity against human ovarian cancer (1A9) cell lines.,,BAO_0000219,,Homo sapiens,,Expert,3415,,N,1,CHEMBL615192,506.0,,
71,1,Percentage inhibition of human ovarian cancer (1A9) cell lines.,,BAO_0000219,,Homo sapiens,,Expert,3415,,N,1,CHEMBL827083,506.0,,
72,1,Effective dose required for inhibitory activity against 1A9 human tumor cell line.,,BAO_0000219,,Homo sapiens,,Expert,17099,,N,1,CHEMBL615193,506.0,,
73,1,Percent inhibition against 1A9 human tumor cell line at 0.10 ug/mL,,BAO_0000219,,Homo sapiens,,Intermediate,17099,,N,1,CHEMBL615194,506.0,,
74,1,Percent inhibition against 1A9 human tumor cell line at <0.00008 ug/mL,,BAO_0000219,,Homo sapiens,,Intermediate,17099,,N,1,CHEMBL615195,506.0,,
75,1,Percent inhibition against 1A9 human tumor cell line at >10 ug/mL,,BAO_0000219,,Homo sapiens,,Intermediate,17099,,N,1,CHEMBL615196,506.0,,
76,1,Inhibitory concentration against Jurkat cells,,BAO_0000219,,Homo sapiens,,Intermediate,17721,,N,1,CHEMBL615197,503.0,,
77,1,In vitro anticancer activity against 2 NCI SCLC cell lines; inactive,,BAO_0000019,,,,Intermediate,1229,,U,0,CHEMBL615198,,,
78,1,Inhibition of cytochrome P450 progesterone 2-alpha-hydroxylase,,BAO_0000357,,Rattus norvegicus,,Expert,11347,,D,9,CHEMBL615199,,,
79,1,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",,BAO_0000357,,,,Expert,17117,,H,8,CHEMBL615200,,,
80,1,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",,BAO_0000357,,,,Expert,17117,,H,8,CHEMBL615201,,,
81,1,"In vitro inhibition of human 2,3-oxidosqualene cyclase at 100 nM.",,BAO_0000357,,,,Expert,17117,,H,8,CHEMBL615202,,,
82,1,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Candida albicans microsomes",,BAO_0000251,,Candida albicans,,Autocuration,11375,,H,8,CHEMBL615203,,,
83,1,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Candida albicans microsomes",,BAO_0000251,,Candida albicans,,Autocuration,11375,,H,8,CHEMBL615204,,,
84,1,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Saccharomyces cerevisiae microsomes",,BAO_0000251,,Saccharomyces cerevisiae,,Autocuration,11375,,H,8,CHEMBL615205,,,
85,1,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Saccharomyces cerevisiae microsomes",,BAO_0000251,,Saccharomyces cerevisiae,,Autocuration,11375,,H,8,CHEMBL615206,,,
86,1,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in pig liver microsomes",Liver,BAO_0000251,,Sus scrofa,,Autocuration,11375,,H,8,CHEMBL615207,,2107.0,
87,1,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase",,BAO_0000019,,Rattus norvegicus,,Autocuration,791,,H,8,CHEMBL827084,,,
88,1,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase (OSC)",,BAO_0000019,,Rattus norvegicus,,Autocuration,791,,H,8,CHEMBL615208,,,
89,1,"Evaluated for its activity to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase, activity expressed as Ki",,BAO_0000019,,Rattus norvegicus,,Autocuration,791,,H,8,CHEMBL615209,,,
90,1,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in rat liver microsomes",Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,11375,,D,9,CHEMBL615210,,2107.0,
91,1,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,11375,,D,9,CHEMBL615211,,2107.0,
92,1,"Compound was evaluated for inhibitory activity against 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,153,,D,9,CHEMBL615212,,2107.0,
93,1,Molar concentration needed to give 50% prevention of 2-5A (Adenosine dependent endoribonuclease),,BAO_0000357,,,,Expert,8269,,H,8,CHEMBL615213,,,
94,1,Molar concentration required to displace 50% of the radiolabeled probe from 2-5A (Adenosine dependent endoribonuclease) in endonuclease-nitrocellulose complex,,BAO_0000357,,,,Expert,8269,,H,8,CHEMBL615273,,,
95,1,In vitro cytotoxic concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,,BAO_0000219,,Homo sapiens,,Expert,17653,,N,1,CHEMBL615274,726.0,,
96,1,50% Effective concentration of compound required for inhibiting intracellular viral replicative intermediate DNA in HBV-transfected 2.2.15 cell line.,,BAO_0000219,,Homo sapiens,,Intermediate,14277,,N,1,CHEMBL615275,726.0,,
97,1,Antiviral activity against Hepatitis B virus in 2.2.15 cell line,,BAO_0000219,,Homo sapiens,,Intermediate,1717,,N,1,CHEMBL615276,726.0,,
98,1,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells,,BAO_0000219,,Homo sapiens,,Intermediate,14091,,N,1,CHEMBL615277,726.0,,
99,1,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells; Not determined,,BAO_0000219,,Homo sapiens,,Intermediate,14091,,N,1,CHEMBL615326,726.0,,
100,1,In vitro effective concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,,BAO_0000218,,Hepatitis B virus,,Expert,17653,,N,1,CHEMBL883130,,,
101,1,Ability to inhibit the episomal HBV-DNA in 2.2.15 cells.,,BAO_0000219,,Homo sapiens,,Intermediate,13105,,N,1,CHEMBL884519,726.0,,
102,1,Concentration required to inhibit 50% of 2.2.15 cell line,,BAO_0000219,,Homo sapiens,,Intermediate,1717,,N,1,CHEMBL615327,726.0,,
103,1,Anti viral activity against 2.2.15 cells (concentration required to reduce the log phase cell growth by 50%).,,BAO_0000219,,Homo sapiens,,Intermediate,13105,,N,1,CHEMBL615328,726.0,,
104,1,Cytotoxic activity of compound against uninfected 2.2.15 cells.,,BAO_0000218,,Homo sapiens,,Intermediate,13600,,N,1,CHEMBL615329,,,
105,1,Anti hepatitis-B virus activity was evaluated in 2.2.15 cells.,,BAO_0000218,,Homo sapiens,,Intermediate,13467,,N,1,CHEMBL615330,,,
106,1,"Inhibition of the replication of HBV in 2.2.15 cells, by DNA hybridization assay",,BAO_0000218,,Hepatitis B virus,,Expert,17477,,N,1,CHEMBL615331,,,
107,1,In vitro anti-HBV activity in 2.2.15 cells,,BAO_0000218,,Homo sapiens,,Intermediate,1593,,N,1,CHEMBL615332,,,
108,1,In vitro anti-HBV activity in 2.2.15 cells; Not determined,,BAO_0000218,,Homo sapiens,,Intermediate,1593,,N,1,CHEMBL615333,,,
109,1,The compound was tested in vitro for the anti-HBV activity against 2.2.15 cells,,BAO_0000218,,Homo sapiens,,Intermediate,15089,,N,1,CHEMBL615334,,,
110,1,The compound was tested in vitro for the anti-HBV activity in 2.2.15 cells,,BAO_0000218,,Homo sapiens,,Intermediate,15089,,N,1,CHEMBL615335,,,
111,1,Cytotoxicity in 2.2.15 cells,,BAO_0000218,,Homo sapiens,,Intermediate,1593,,N,1,CHEMBL615336,,,
112,1,Cytotoxicity in 2.2.15 cells; Not determined,,BAO_0000218,,Homo sapiens,,Intermediate,1593,,N,1,CHEMBL615337,,,
113,1,Inhibitory activity of compound against hepatitis B virus (HBV) in growing cultures of 2.2.15 cells,,BAO_0000218,,Homo sapiens,,Intermediate,13600,,N,1,CHEMBL615338,,,
114,1,The growth inhibition activity for the compound was evaluated in 2.2.15 cells.,,BAO_0000218,,Homo sapiens,,Intermediate,13467,,N,1,CHEMBL615339,,,
115,1,Selectivity index was determined from the ratio of IC50 to the EC50 values evaluated in 2.2.15 cells.,,BAO_0000218,,Homo sapiens,,Intermediate,13467,,N,1,CHEMBL615340,,,
116,1,Antiviral activity against HBV was determined in 2.215 cell line,,BAO_0000219,,Homo sapiens,,Intermediate,14764,,N,1,CHEMBL615341,726.0,,
117,1,Inhibition of 20-HETE synthesis in human renal microsomes,,BAO_0000251,,Homo sapiens,,Autocuration,6531,,U,0,CHEMBL615342,,,
118,1,Inhibitory activity against 20-HETE production from arachidonic acid using human renal microsome 20-HETE synthase.,,BAO_0000019,,,,Autocuration,17322,,U,0,CHEMBL615343,,,
119,1,Inhibitory concentration against 2008 (ovarian) cells,,BAO_0000219,,Homo sapiens,,Intermediate,17072,,N,1,CHEMBL615344,388.0,,
120,1,50% Growth inhibitory concentration( GI 50 ) by using 2008 human ovarian carcinoma cell lines.,,BAO_0000219,,Homo sapiens,,Intermediate,16936,,N,1,CHEMBL615345,388.0,,
121,1,Compound was tested for 50% growth inhibitory concentration by using human ovarian carcinoma cell lines (2008),,BAO_0000219,,Homo sapiens,,Intermediate,16936,,N,1,CHEMBL615346,388.0,,
122,1,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells,,BAO_0000219,,Homo sapiens,,Intermediate,17146,,N,1,CHEMBL615347,388.0,,
123,1,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells; not detected,,BAO_0000219,,Homo sapiens,,Intermediate,17146,,N,1,CHEMBL615348,388.0,,
124,1,In vitro inhibition of 2008/R ovarian cancer cell line,,BAO_0000219,,Homo sapiens,,Intermediate,10797,,N,1,CHEMBL827085,561.0,,
125,1,In vitro inhibition of 2008/R ovarian cancer cell line; NA= Not achievable,,BAO_0000219,,Homo sapiens,,Intermediate,10797,,N,1,CHEMBL615349,561.0,,
126,1,In vitro inhibition of 2008/S ovarian cancer cell line,,BAO_0000219,,Homo sapiens,,Intermediate,10797,,N,1,CHEMBL615350,389.0,,
127,1,In vitro inhibition of 2008/S ovarian cancer cell line; NA= Not achievable,,BAO_0000219,,Homo sapiens,,Intermediate,10797,,N,1,CHEMBL615351,389.0,,
128,1,Tested in vitro for inhibition of chymotrypsin like activity of purified human 20S proteasome,,BAO_0000220,,Homo sapiens,,Expert,4823,,S,2,CHEMBL615352,,,
129,1,Compound was evaluated for inhibitory activity against 20S proteasome from human liver and brain,,BAO_0000220,,Homo sapiens,,Intermediate,12912,,S,2,CHEMBL615353,,,
130,1,Inhibition of chymotrypsin-like activity of 20S proteasome,,BAO_0000220,,,,Expert,2957,,S,2,CHEMBL615354,,,
131,1,Inhibition of chymotrypsin-like activity of 20S proteasome; value ranges from 10-20 uM,,BAO_0000220,,,,Expert,2957,,S,2,CHEMBL615355,,,
132,1,Inhibitory activity against 20S proteosome,,BAO_0000220,,,,Intermediate,3260,,S,2,CHEMBL615356,,,
133,1,Compound was tested for inhibitory activity against tryptase,,BAO_0000019,,Homo sapiens,,Autocuration,3451,,U,0,CHEMBL615357,,,
134,1,Concentration required to inhibit 50% of extracellular circular replication of HBV DNA using 2215 cell line,,BAO_0000219,,Homo sapiens,,Intermediate,13885,,N,1,CHEMBL615358,726.0,,
135,1,Concentration required to inhibit 50% of intracellular circular replication of HBV DNA using 2215 cell line,,BAO_0000219,,Homo sapiens,,Intermediate,13885,,N,1,CHEMBL827086,726.0,,
136,1,Compound was tested for the inhibition of Alpha-glucosidase,,BAO_0000019,,,,Autocuration,3676,,U,0,CHEMBL615359,,,
137,1,Inhibitory concentration against human neutrophil elastase (HNE),,BAO_0000357,,,,Autocuration,6043,,H,8,CHEMBL615360,,,
138,1,Change in heart rate was expressed in percent at at a dose 0.002 mg/kg iv in anesthetized rat,Heart,BAO_0000218,,Rattus norvegicus,,Autocuration,11140,,U,0,CHEMBL615361,,948.0,
139,1,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,,BAO_0000019,,,,Autocuration,10543,,H,8,CHEMBL615362,,,
140,1,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,,BAO_0000019,,,,Expert,10543,,H,8,CHEMBL615363,,,
141,1,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,,BAO_0000357,,,,Autocuration,10543,,H,8,CHEMBL615364,,,
142,1,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,,BAO_0000019,,,,Expert,10543,,H,8,CHEMBL615365,,,
143,1,In Vitro evaluation for the growth inhibition of Subline (P388/AMSA) Leukemia cell lines,,BAO_0000219,,Mus musculus,,Intermediate,11365,,N,1,CHEMBL615366,524.0,,
144,1,In Vitro evaluation for the growth inhibition of Subline (P388/CP) Leukemia cell lines,,BAO_0000219,,Mus musculus,,Intermediate,11365,,N,1,CHEMBL615367,524.0,,
145,1,Compound was evaluated for the inhibition of cell replication human peripheral blood lymphocytes (PBL's).,,BAO_0000219,,Homo sapiens,,Intermediate,11803,,N,1,CHEMBL615368,554.0,,
146,1,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells,,BAO_0000019,,Ovis aries,,Autocuration,11803,,U,0,CHEMBL615369,,,
147,1,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells.,,BAO_0000019,,Ovis aries,,Autocuration,11803,,U,0,CHEMBL615370,,,
148,1,Compound is evaluated in vitro for the inhibition single mutant of HIV-1 RT (Y181C),,BAO_0000357,,,,Autocuration,12278,,H,8,CHEMBL615673,,,
149,1,Compound was evaluated for its inhibitory effect on thymidine [3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-5,,BAO_0000019,,Homo sapiens,,Autocuration,8249,,U,0,CHEMBL615674,,,
150,1,Compound was evaluated for its inhibitory effect on thymidine [3H]-dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-6,,BAO_0000019,,Homo sapiens,,Autocuration,8249,,U,0,CHEMBL615675,,,
151,1,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in at conc. 10e-7,,BAO_0000219,,Homo sapiens,,Autocuration,8249,,U,0,CHEMBL615676,635.0,,
152,1,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM cells in culture at conc. 10e-4,,BAO_0000219,,Homo sapiens,,Autocuration,8249,,U,0,CHEMBL615677,635.0,,
153,1,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-5,,BAO_0000219,,Homo sapiens,,Autocuration,8249,,U,0,CHEMBL615678,635.0,,
154,1,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-6,,BAO_0000219,,Homo sapiens,,Autocuration,8249,,U,0,CHEMBL615679,635.0,,
155,1,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM/MTX cells in at conc. 10e-7.,,BAO_0000019,,Homo sapiens,,Autocuration,8249,,U,0,CHEMBL615680,,,
156,1,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-4,,BAO_0000019,,Homo sapiens,,Autocuration,8249,,U,0,CHEMBL615681,,,
157,1,In vitro binding affinity towards (alpha-4)2(beta-2)3 neuronal nicotinic acetylcholine receptor in P2 membrane fractions of rat forebrain,,BAO_0000249,,,,Autocuration,16992,,H,6,CHEMBL857972,,,
158,1,Minimum inhibitory concentration of compound against Streptococcus pyogenus septicemia in the mouse,,BAO_0000218,,Streptococcus pyogenes,,Intermediate,10543,,N,1,CHEMBL857899,,,
159,1,Antiviral activity against 07/1 strain of thymidine kinase negative (TK-) Varicella-Zoster Virus (VZV),,BAO_0000218,,Human herpesvirus 3,,Intermediate,17833,,N,1,CHEMBL615371,,,
160,1,Antiviral activity against 07/1 strain of VZV in HEL (human erythroleukemia) cells.,,BAO_0000218,,vericilla zoster virus,,Expert,17290,,N,1,CHEMBL615372,468.0,,
161,1,Antiviral activity against 07/1 strain of VZV; ND: No data,,BAO_0000218,,vericilla zoster virus,,Intermediate,17290,,N,1,CHEMBL615373,,,
162,1,Antiviral activity against 07/1 strain of VZV; ND=No data,,BAO_0000218,,vericilla zoster virus,,Intermediate,17290,,N,1,CHEMBL615374,,,
163,1,"Antibacterial activity was determined against gram negative organism, Enterobacter cloacae (MA2646)",,BAO_0000218,,escherichia cloac,,Intermediate,10932,,N,1,CHEMBL615375,,,
164,1,Ratio of Ki at A2 to Ki at A1 receptors,,BAO_0000019,,,,Autocuration,9707,,U,0,CHEMBL615376,,,
165,1,"In vitro inhibition of 1,3-beta-glucan synthase in Candida albicans membrane assay.",,BAO_0000249,,Candida albicans,,Expert,2346,,H,8,CHEMBL615377,,,
166,1,"Inhibition of 1,3-beta-glucan synthase",,BAO_0000357,,Candida glabrata CBS 138,,Expert,2205,,H,8,CHEMBL615378,,,
167,1,Inhibition of growth of 1-87 human tumor cell line,,BAO_0000219,,Homo sapiens,,Intermediate,11900,,N,1,CHEMBL615379,832.0,,
168,1,Inhibition of 1-lipoxygenase (LOX)in RBL cells,,BAO_0000219,,Rattus norvegicus,,Expert,14864,,D,9,CHEMBL615380,,,
169,1,Inhibitory activity against soybean 1-lipoxygenase (SLO),,BAO_0000357,,Glycine max,,Autocuration,16474,,D,9,CHEMBL615381,,,
170,1,Inhibitory activity against soybean 1-lipoxygenase (SLO); no effect,,BAO_0000357,,Glycine max,,Autocuration,16474,,D,9,CHEMBL615382,,,
171,1,% inhibition against soybean 1-lipoxygenase (SLO),,BAO_0000357,,Glycine max,,Autocuration,16474,,D,9,CHEMBL615383,,,
172,1,percent inhibition against soybean 1-lipoxygenase (SLO);NI is no inhibition,,BAO_0000357,,Glycine max,,Autocuration,16474,,D,9,CHEMBL615384,,,
173,1,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 10:90,,BAO_0000357,,Glycine max,,Autocuration,3094,,D,9,CHEMBL615385,,,
174,1,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 1:99,,BAO_0000357,,Glycine max,,Autocuration,3094,,D,9,CHEMBL615386,,,
175,1,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 25:75,,BAO_0000357,,Glycine max,,Autocuration,3094,,D,9,CHEMBL615387,,,
176,1,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 35:65,,BAO_0000357,,Glycine max,,Autocuration,3094,,D,9,CHEMBL615388,,,
177,1,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 50:50,,BAO_0000357,,Glycine max,,Autocuration,3094,,D,9,CHEMBL615214,,,
178,1,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 76:24,,BAO_0000357,,Glycine max,,Autocuration,3094,,D,9,CHEMBL827087,,,
179,1,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 87:13,,BAO_0000357,,Glycine max,,Autocuration,3094,,D,9,CHEMBL615215,,,
180,1,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 89:11,,BAO_0000357,,Glycine max,,Autocuration,3094,,D,9,CHEMBL615216,,,
181,1,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 95:5,,BAO_0000357,,Glycine max,,Autocuration,3094,,D,9,CHEMBL615217,,,
182,1,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 97:3,,BAO_0000357,,Glycine max,,Autocuration,3094,,D,9,CHEMBL615218,,,
183,1,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 99:1,,BAO_0000357,,Glycine max,,Autocuration,3094,,D,9,CHEMBL615219,,,
184,1,Evaluated for inhibitory activity on 10-formyltetrahydrofolate synthetase(L cell) at folate substrate concentration of 100 uM,,BAO_0000019,,Mus musculus,,Autocuration,10413,,U,0,CHEMBL615220,,,
185,1,Cells were harvested and were assayed for luciferase and -galactosidase activities (Transcriptional activity),,BAO_0000219,,Mus musculus,,Intermediate,16929,,N,1,CHEMBL615221,294.0,,
186,1,In vitro anticancer activity against 11 NCI NSCLC cell lines; inactive,,BAO_0000019,,,,Intermediate,1229,,U,0,CHEMBL615222,,,
187,1,In vitro inhibitory activity against human 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),,BAO_0000357,,,,Autocuration,16587,,H,8,CHEMBL615223,,,
188,1,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),,BAO_0000357,,,,Autocuration,16587,,H,8,CHEMBL615224,,,
189,1,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA).,,BAO_0000357,,,,Autocuration,16587,,H,8,CHEMBL615225,,,
190,1,Ability to convert [3H]cortisol to the tritium labeled cortisone in the presence of human 11 beta hydroxysteroid dehydrogenase type 2,,BAO_0000357,,,,Autocuration,16587,,H,8,CHEMBL615226,,,
191,1,Inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 2 at a concentration of 0.2 mM; NI means no inhibition,,BAO_0000357,,,,Autocuration,16587,,H,8,CHEMBL615227,,,
192,1,Evaluated for inhibition of bovine adrenal cortical mitochondrial 11 beta-hydroxylase,,BAO_0000019,,Bos taurus,,Expert,8058,,D,9,CHEMBL615228,,,
193,1,Effect on adrenal 11-beta-hydroxylase activity at 10e-4 M; No significant effect,,BAO_0000357,,Rattus norvegicus,,Expert,9065,,D,9,CHEMBL615229,,,
194,1,Inhibition of 11 beta-hydroxylase from rat adrenal gland,Adrenal gland,BAO_0000357,,Rattus norvegicus,,Expert,8865,,D,9,CHEMBL615230,,2369.0,
195,1,Inhibition of rat adrenal 11-beta-hydroxylase,,BAO_0000357,,Rattus norvegicus,,Expert,9066,,D,9,CHEMBL615231,,,
196,1,Inhibition of rat adrenal 11-beta-hydroxylase,,BAO_0000357,,Rattus norvegicus,,Expert,8394,,D,9,CHEMBL884520,,,
197,1,Inhibition of rat adrenal 11-beta-hydroxylase at 10e-5 M,,BAO_0000357,,Rattus norvegicus,,Expert,8394,,D,9,CHEMBL615232,,,
198,1,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 1 of wistar rat liver cytosol at 10 uM was determined using [3H]cortisone,,BAO_0000019,,,,Autocuration,6431,,H,8,CHEMBL615233,,,
199,1,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,,BAO_0000357,,,,Autocuration,6431,,H,8,CHEMBL827088,,,
200,1,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,,BAO_0000357,,,,Autocuration,6431,,H,8,CHEMBL615234,,,
201,1,Compound was tested for the percent of inhibition against 12-LO at 10 uM,,BAO_0000019,,,,Autocuration,9295,,H,8,CHEMBL615235,,,
202,1,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,BAO_0000019,,,,Autocuration,10193,,H,8,CHEMBL615236,,,
203,1,Compound was tested in vitro for inhibition of 12-LO human platelet,,BAO_0000019,,,,Autocuration,13622,,H,8,CHEMBL615237,,,
204,1,Inhibitory concentration against human platelet 12-lipoxygenase,,BAO_0000019,,,,Autocuration,12079,,H,8,CHEMBL615238,,,
205,1,Compound at 100 uM was tested in vitro for inhibition of 12-LO human platelet,,BAO_0000019,,,,Autocuration,13622,,H,8,CHEMBL615239,,,
206,1,Inhibitory concentration against human platelet 12-lipoxygenase,,BAO_0000019,,Homo sapiens,,Autocuration,12079,,D,9,CHEMBL615240,,,
207,1,Tested for inhibition of 12-LO (12-lipoxygenase) as an inhibitor of 12(S)-HETE biosynthesis in mouse epidermal homogenates,,BAO_0000019,,,,Expert,13500,,H,8,CHEMBL615241,,,
208,1,Inhibitory activity against conversion of [1-14C]arachidonic acid to 12-HPETE and its reduction product 12-HETE by porcine leukocyte type 12-lipoxygenase,,BAO_0000357,,,,Expert,13723,,H,8,CHEMBL615242,,,
209,1,Inhibitory activity against human platelet 12-lipoxygenase (12-HLO),,BAO_0000019,,,,Autocuration,16474,,H,8,CHEMBL615243,,,
210,1,Inhibitory activity against human platelet 12-lipoxygenase,,BAO_0000019,,,,Autocuration,1630,,H,8,CHEMBL615244,,,
211,1,Inhibitory activity against human platelet 12-lipoxygenase was evaluated,,BAO_0000019,,,,Autocuration,167,,H,8,CHEMBL615245,,,
212,1,% inhibition against human platelet 12-lipoxygenase (12-HLO),,BAO_0000019,,,,Autocuration,16474,,H,8,CHEMBL615246,,,
213,1,Inhibitory activity against human platelet 12-lipoxygenase was evaluated at 100 uM,,BAO_0000019,,,,Autocuration,167,,H,8,CHEMBL615247,,,
214,1,percent inhibition against human platelet 12-lipoxygenase (12-HLO); NI is no inhibition,,BAO_0000019,,,,Autocuration,16474,,H,8,CHEMBL615248,,,
215,1,Inhibitory activity towards porcine 12-lipoxygenase,,BAO_0000357,,,,Autocuration,10091,,H,8,CHEMBL615249,,,
216,1,Tested for inhibition against porcine 12-LO,,BAO_0000357,,,,Autocuration,11966,,H,8,CHEMBL615250,,,
217,1,Inhibition of 12-lipoxygenase was evaluated in rat platelets stimulated by thrombin up to a concentration of 10 uM; NE means No effect,,BAO_0000019,,,,Autocuration,951,,H,8,CHEMBL615251,,,
218,1,Inhibitory activity against 12-lipoxygenase in rat platelet rich plasma,,BAO_0000019,,,,Autocuration,10997,,H,8,CHEMBL615252,,,
219,1,In vitro inhibition of rat platelet 12-lipoxygenase,,BAO_0000019,,,,Expert,10193,,H,8,CHEMBL828340,,,
220,1,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,BAO_0000019,,,,Autocuration,10193,,H,8,CHEMBL615253,,,
221,1,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 100 uM,,BAO_0000019,,,,Autocuration,10193,,H,8,CHEMBL615254,,,
222,1,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 30 uM,,BAO_0000019,,,,Autocuration,10193,,H,8,CHEMBL615255,,,
223,1,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,BAO_0000019,,,,Autocuration,10193,,H,8,CHEMBL615256,,,
224,1,In vitro inhibitory activity against rat platelet 12-lipoxygenase,,BAO_0000019,,,,Autocuration,10193,,H,8,CHEMBL615257,,,
225,1,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 100 uM,,BAO_0000019,,,,Autocuration,11087,,H,8,CHEMBL615258,,,
226,1,Cytotoxic activity in a panel of Human ovarian tumor 41M cell line after 96h of drug exposure,,BAO_0000219,,Homo sapiens,,Intermediate,15569,,N,1,CHEMBL615259,621.0,,
227,1,In vitro antitumor activity against 41M cell line.,,BAO_0000219,,Homo sapiens,,Expert,12989,,N,1,CHEMBL615260,621.0,,
228,1,cytotoxicity against 41M cells incubated for 24 hr in MTT assay.,,BAO_0000219,,Homo sapiens,,Intermediate,16745,,N,1,CHEMBL615261,621.0,,
229,1,Cytotoxic activity in a panel of Human ovarian tumor 41M/CDDP cell line after 96h of drug exposure,,BAO_0000219,,Homo sapiens,,Intermediate,15569,,N,1,CHEMBL615262,621.0,,
230,1,In vitro antitumor activity against 41McisR cell line.,,BAO_0000219,,Homo sapiens,,Expert,12989,,N,1,CHEMBL615263,621.0,,
231,1,Resistant factor was determined between IC50 of cisplatin-resistant human tumor cell lines to that of 41McisR cell line,,BAO_0000219,,Homo sapiens,,Expert,12989,,N,1,CHEMBL838393,621.0,,
232,1,cytotoxicity against 41McisR cells incubated for 24 hr in MTT assay,,BAO_0000219,,Homo sapiens,,Intermediate,16745,,N,1,CHEMBL615264,621.0,,
233,1,Inhibition of 5'-inosine monophosphate dehydrogenase type I (IMPDH I),,BAO_0000357,,Homo sapiens,,Expert,6210,,D,9,CHEMBL615265,,,
234,1,Inhibition of 5'-inosine monophosphate dehydrogenase type II (IMPDH II),,BAO_0000357,,Homo sapiens,,Expert,6210,,D,9,CHEMBL615266,,,
235,1,Inhibitory activity against inosine 5'-inosine monophosphate dehydrogenase type II (IMPDH II),,BAO_0000357,,,,Expert,6226,,H,8,CHEMBL615267,,,
236,1,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase,,BAO_0000357,,,,Expert,17855,,H,8,CHEMBL615268,,,
237,1,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase; nd = Not determined,,BAO_0000357,,,,Expert,17855,,H,8,CHEMBL615269,,,
238,1,Initial dissociation constant towards human 5'-methylthioadenosine phosphorylase,,BAO_0000357,,,,Expert,17855,,H,8,CHEMBL615270,,,
239,1,"Evaluated for inhibitory activity on 5,10-Methenyl Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",,BAO_0000357,,,,Autocuration,10413,,H,8,CHEMBL615271,,,
240,1,"Inhibitory activity against 5,10-methylenetetrahydrofolate dehydrogenase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",,BAO_0000357,,Escherichia coli,,Autocuration,10413,,H,8,CHEMBL615272,,,
241,1,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",,BAO_0000357,,Escherichia coli,,Autocuration,10413,,H,8,CHEMBL615103,,,
242,1,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM;NT=Not tested",,BAO_0000357,,Escherichia coli,,Autocuration,10413,,H,8,CHEMBL615104,,,
243,1,"Evaluated for inhibitory activity on 5,10-Methylene Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",,BAO_0000357,,,,Autocuration,10413,,H,8,CHEMBL615105,,,
244,1,"Evaluated for inhibitory activity on 5,10-methylenetetrahydrofolate dehydrogenase(L cell) at folate substrate concentration of 100 uM",,BAO_0000357,,,,Autocuration,10413,,H,8,CHEMBL872866,,,
245,1,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,BAO_0000357,,Sus scrofa,,Autocuration,7587,,H,8,CHEMBL615106,,,
246,1,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (A,porcine liver) enzyme.",,BAO_0000019,,Sus scrofa,,Autocuration,7587,,H,8,CHEMBL615107,,,
247,1,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-4 M inhibitory concentration",,BAO_0000357,,Sus scrofa,,Autocuration,7587,,H,8,CHEMBL615108,,,
248,1,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-5 M inhibitory concentration",,BAO_0000357,,Sus scrofa,,Autocuration,7587,,H,8,CHEMBL615109,,,
249,1,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,BAO_0000357,,Sus scrofa,,Autocuration,7587,,H,8,CHEMBL615110,,,
250,1,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",,BAO_0000019,,Sus scrofa,,Autocuration,7587,,H,8,CHEMBL840105,,,
251,1,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-5 M inhibitory concentration",,BAO_0000019,,Sus scrofa,,Autocuration,7587,,H,8,CHEMBL615111,,,
252,1,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-6 M inhibitory concentration",,BAO_0000019,,Sus scrofa,,Autocuration,7587,,H,8,CHEMBL615112,,,
253,1,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-7 M inhibitory concentration",,BAO_0000019,,Sus scrofa,,Autocuration,7587,,H,8,CHEMBL615113,,,
254,1,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme.",,BAO_0000019,,Sus scrofa,,Autocuration,7587,,H,8,CHEMBL615114,,,
255,1,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,BAO_0000357,,Sus scrofa,,Autocuration,7587,,H,8,CHEMBL615115,,,
256,1,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",,BAO_0000019,,Sus scrofa,,Autocuration,7587,,H,8,CHEMBL615116,,,
257,1,"Compound was tested for in vitro inhibition of 5,10-Methylene Tetrahydrofolate Cyclohydrolase, competitive against (+)-L-5,10-methenyltetrahydrofolate",,BAO_0000357,,,,Autocuration,7323,,H,8,CHEMBL615698,,,
258,1,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme at 10E-4 M inhibitory concentration",,BAO_0000019,,Sus scrofa,,Autocuration,7587,,U,0,CHEMBL615699,,,
259,1,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme.",,BAO_0000019,,Sus scrofa,,Autocuration,7587,,U,0,CHEMBL615700,,,
260,1,Inhibition of 5-Desaturase involved in ergosterol biosynthesis,,BAO_0000357,,Saccharomyces cerevisiae,,Expert,13750,,H,8,CHEMBL615701,,,
261,1,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,,BAO_0000019,,Rattus norvegicus,,Autocuration,7662,,U,0,CHEMBL615702,,,
262,1,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,,BAO_0000019,,Rattus norvegicus,,Autocuration,7662,,U,0,CHEMBL615703,,,
263,1,"Irreversible inhibition of Walker 256 FUDR phosphorylase; expressed as Vo/Vi, velocity without inhibitor to that of velocity with inhibitor",,BAO_0000019,,Rattus norvegicus,,Autocuration,7662,,U,0,CHEMBL615704,,,
264,1,"Tested for 5-HT 3 receptor antagonist potency by ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",,BAO_0000019,,,,Autocuration,12211,,H,6,CHEMBL615705,,,
265,1,"Compound was tested for its 5-HT 3 receptor antagonist potency by their ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",,BAO_0000019,,,,Autocuration,12211,,H,6,CHEMBL615706,,,
266,1,Relative ability to increase cholinergically mediated contractions in isolated ileum of guinea pig,Ileum,BAO_0000221,,Cavia porcellus,,Intermediate,12211,,D,9,CHEMBL615707,,2116.0,
267,1,Stimulatory activity of intragastric pressure was tested in the rat,,BAO_0000019,,,,Expert,12211,,H,8,CHEMBL615708,,,
268,1,% Decrease of 5-HT carrier-receptor -bound radioactivity using paroxetine as a radioligand.,,BAO_0000357,,,,Autocuration,15453,,H,8,CHEMBL615709,,,
269,1,Dose to reduce neuronal firing against 5-HT cells in rats (iv),,BAO_0000218,,Rattus norvegicus,,Autocuration,11884,,U,0,CHEMBL615710,,,
270,1,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,,BAO_0000019,,,,Autocuration,7185,,H,8,CHEMBL615711,,,
271,1,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine,,BAO_0000357,,Homo sapiens,,Expert,6876,,D,9,CHEMBL615712,,,
272,1,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine; No data,,BAO_0000357,,Homo sapiens,,Expert,6876,,D,9,CHEMBL836325,,,
273,1,Inhibition of high affinity 5-HT uptake at concentration of 1 uM,,BAO_0000019,,,,Autocuration,11863,,H,8,CHEMBL615713,,,
274,1,Inhibition constant of high-affinity 5-HT uptake,,BAO_0000357,,,,Autocuration,11863,,H,8,CHEMBL615714,,,
275,1,Michaelis-Menten constant was reported for high affinity transport of 5-HT,,BAO_0000019,,,,Autocuration,11863,,H,8,CHEMBL615715,,,
276,1,Maximum rate was determined for high affinity transport of 5-HT,,BAO_0000019,,,,Autocuration,11863,,H,8,CHEMBL615716,,,
277,1,Compound was tested for agonistic activity against 5-HT uptake,,BAO_0000019,,,,Autocuration,4639,,H,4,CHEMBL615717,,,
278,1,Inhibition affinity against 5-HT-1B receptor in rat frontal cortex using radio binding assay,,BAO_0000019,,,,Expert,15796,,H,8,CHEMBL881818,,,
279,1,Inhibition affinity against 5-HT-1D receptor in bovine caudate nucleus using radio binding assay,,BAO_0000357,,Bos taurus,,Expert,15796,,H,8,CHEMBL884540,,,
280,1,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,,BAO_0000224,,Rattus norvegicus,,Autocuration,12801,,D,5,CHEMBL615718,,,
281,1,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1 using [3H]5-HT as radioligand,,BAO_0000224,,,,Autocuration,12801,,H,4,CHEMBL615719,,,
282,1,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M,,BAO_0000249,,,,Autocuration,12120,,H,4,CHEMBL615720,,,
283,1,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M.,,BAO_0000249,,,,Autocuration,12120,,H,4,CHEMBL615721,,,
284,1,Displacement of binding of [3H]-5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,BAO_0000019,,,,Autocuration,11963,,H,4,CHEMBL615722,,,
285,1,Dose required to reduce neuronal firing of 5-HT1A cells by 50%,,BAO_0000019,,,,Autocuration,11701,,H,8,CHEMBL615723,,,
286,1,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,Hippocampus,BAO_0000221,,,,Autocuration,9995,,H,8,CHEMBL615724,,10000000.0,
287,1,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,Hippocampus,BAO_0000221,,,,Autocuration,9995,,H,8,CHEMBL615725,,10000000.0,
288,1,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,Hippocampus,BAO_0000221,,,,Autocuration,9995,,H,8,CHEMBL615726,,10000000.0,
289,1,Antagonistic activity at postsynaptic 5-HT1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (.26-3.52),,BAO_0000218,,,,Autocuration,16394,In vivo,H,8,CHEMBL615727,,,
290,1,Effect on forskolin stimulated adenylate cyclase activity at 5-HT1D receptor of guinea pig substantia nigra.,,BAO_0000019,,Cavia porcellus,,Intermediate,11574,,D,9,CHEMBL615728,,,
291,1,Binding affinity towards 5-HT1F (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,BAO_0000219,,,,Autocuration,15779,,H,8,CHEMBL857971,449.0,,
292,1,Compound was tested for the displacement of [125I]DOI from clone human 5-hydroxytryptamine 2A receptor,,BAO_0000357,,,,Autocuration,15363,,H,8,CHEMBL615729,,,
293,1,Efficacy against 5-hydroxytryptamine 2A receptor,,BAO_0000019,,Rattus norvegicus,,Expert,15363,,D,9,CHEMBL615730,,,
294,1,Intrinsic activity towards 5-HT2A receptor of rat tail artery,,BAO_0000019,,,,Expert,15329,,H,8,CHEMBL615731,,,
295,1,Relative potency towards 5-HT2A receptor of rat tail artery,,BAO_0000019,,,,Expert,15329,,H,8,CHEMBL615732,,,
296,1,Blocking 5-HT2A receptor-mediated contractions of rat tail artery,,BAO_0000019,,,,Expert,15329,,H,8,CHEMBL615733,,,
297,1,Partial agonism at 5-HT2A receptor was evaluated in presence of ketanserin (3-10 nM) in isolated rat tail artery,,BAO_0000019,,,,Expert,15329,,H,8,CHEMBL615734,,,
298,1,Compound was tested for the intrinsic activity against 5-HT2A receptors of rat tail artery.,,BAO_0000019,,,,Autocuration,15329,,H,8,CHEMBL615735,,,
299,1,Effectiveness in blocking 5-HT2A receptor-mediated contractions of rat tail artery,,BAO_0000019,,,,Expert,15329,,H,8,CHEMBL615736,,,
300,1,Evaluated for the agonistic activity against 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,Ileum,BAO_0000221,,Cavia porcellus,,Intermediate,273,,D,9,CHEMBL615737,,2116.0,
301,1,Agonistic activity against Serotonin 5-HT4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI),Ileum,BAO_0000221,,Cavia porcellus,,Intermediate,273,,D,9,CHEMBL615738,,2116.0,
302,1,Evaluated for the agonistic activity against Serotonin 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,Ileum,BAO_0000221,,Cavia porcellus,,Intermediate,273,,D,9,CHEMBL615739,,2116.0,
303,1,The binding affinity was measured on 5-hydroxytryptamine 4 receptor using [3H]- GR-113808 as radioligand.,,BAO_0000357,,,,Autocuration,12092,,H,8,CHEMBL615278,,,
304,1,Antagonist activity against 5-HT4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,,BAO_0000019,,Rattus norvegicus,,Expert,1317,,D,9,CHEMBL615279,,,
305,1,Binding affinity against 5-hydroxytryptamine 4 receptor,,BAO_0000357,,,,Expert,12409,,H,8,CHEMBL615280,,,
306,1,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of chick intestine,,BAO_0000019,,Gallus gallus,,Autocuration,11126,,U,0,CHEMBL615281,,,
307,1,Inhibitory effect (10e-6 M) on the 25-OH-D3-1-hydroxylase activity,,BAO_0000019,,Homo sapiens,,Autocuration,11126,,U,0,CHEMBL615282,,,
308,1,25-OH-D3-1-hydroxylase activity (10e-6 M) was measured as %control,,BAO_0000019,,Homo sapiens,,Autocuration,11126,,U,0,CHEMBL615283,,,
309,1,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of human HL-60 cells,,BAO_0000219,,Homo sapiens,,Autocuration,11126,,N,1,CHEMBL615284,649.0,,
310,1,Inhibitory effect (10e-6 M) on the 25-hydroxyvitamin D3-1-hydroxylase activity,,BAO_0000019,,Homo sapiens,,Autocuration,11126,,U,0,CHEMBL615285,,,
311,1,25-hydroxyvitamin D3-1-hydroxylase activity (10e-6 M) was measured as %control,,BAO_0000019,,Homo sapiens,,Autocuration,11126,,U,0,CHEMBL615286,,,
312,1,Displacement of [3H]-Ro- 15-1788 from human GABA-A alpha-1-beta-3-gamma-2 receptor subunits expressed in Xenopus oocytes,,BAO_0000219,,Homo sapiens,,Autocuration,17807,,D,7,CHEMBL615287,,,
313,1,Chymotryptic inhibitory activity against 26S proteasome,,BAO_0000220,,,,Intermediate,16575,,S,2,CHEMBL615288,,,
314,1,Inhibitory activity against 26S proteasome degradation of IkB,,BAO_0000220,,,,Intermediate,15407,,S,2,CHEMBL615289,,,
315,1,In vitro inhibition of 2780/DOX ovarian cancer cell line,,BAO_0000219,,Homo sapiens,,Intermediate,10797,,N,1,CHEMBL615290,478.0,,
316,1,In vitro inhibition of 2780/S ovarian cancer cell line,,BAO_0000219,,Homo sapiens,,Intermediate,10797,,N,1,CHEMBL884522,478.0,,
317,1,Relative activity on the cellular accumulation of vincristine in multidrug-resistant (MDR) human ovarian cancer 2780AD cells,,BAO_0000019,,Homo sapiens,,Autocuration,3469,,U,0,CHEMBL615291,,,
318,1,Association constant for binding to AATT 28-mer AATT hairpin,,BAO_0000225,,,,Intermediate,16037,,M,3,CHEMBL615292,,,
319,1,Kinetically Defined Association Constant for 28-mer AATT hairpin.,,BAO_0000225,,,,Intermediate,16037,,M,3,CHEMBL615293,,,
320,1,Reaction Rate Parameter for 28-mer AATT hairpin,,BAO_0000225,,,,Intermediate,16037,,M,3,CHEMBL615294,,,
321,1,Reaction Rate Parameter for 28-mer AATT hairpin,,BAO_0000225,,,,Intermediate,16037,,M,3,CHEMBL615295,,,
322,1,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 1),,BAO_0000019,,Homo sapiens,,Autocuration,16524,,U,0,CHEMBL825021,,,
323,1,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 2),,BAO_0000019,,Homo sapiens,,Autocuration,16524,,U,0,CHEMBL615296,,,
324,1,Inhibitory concentration by single cycle replication assay using envelope deficient HIV-1,,BAO_0000019,,Homo sapiens,,Autocuration,16524,,U,0,CHEMBL615297,,,
325,1,Cytotoxicity against cell line 2SC/20 determined by MTT test,,BAO_0000019,,Cricetulus griseus,,Autocuration,16758,,U,0,CHEMBL615298,,,
326,1,Cytotoxicity against cell line 2SC/20 of hamster determined by MTT test,,BAO_0000019,,Cricetulus griseus,,Autocuration,16758,,U,0,CHEMBL615299,,,
327,1,Inhibitory concentration against the growth of 2SC/20 cell line after 72 hr of drug exposure by MTT test,,BAO_0000019,,Cricetulus griseus,,Autocuration,16758,,U,0,CHEMBL615300,,,
328,1,Binding affinity on 3 beta-hydroxysteroid dehydrogenase,,BAO_0000357,,,,Autocuration,14360,,H,8,CHEMBL615301,,,
329,1,Binding affinity for 3-beta-hydroxysteroid dehydrogenase,,BAO_0000357,,Homo sapiens,,Expert,14360,,D,9,CHEMBL615302,,,
330,1,Selectivity ratio of ID50 in liver and heart,,BAO_0000019,,Rattus norvegicus,,Autocuration,9964,,U,0,CHEMBL615303,,,
331,1,"Selectivity, ratio of relative ID50 in liver and heart",,BAO_0000019,,,,Autocuration,9964,,H,8,CHEMBL615304,,,
332,1,Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to T3,,BAO_0000019,,,,Autocuration,9964,,H,8,CHEMBL615305,,,
333,1,"Binding affinity to the receptor was determined in nuclei of heart In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,BAO_0000218,,,,Autocuration,9964,,H,8,CHEMBL615306,,,
334,1,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,BAO_0000218,,,,Autocuration,9964,,H,8,CHEMBL615307,,,
335,1,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,BAO_0000218,,,,Autocuration,9964,In vivo,H,8,CHEMBL615308,,,
336,1,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,BAO_0000218,,,,Autocuration,9964,In vivo,H,8,CHEMBL615309,,,
337,1,"Binding affinity to the thyroid hormone receptor was determined in vitro in isolated nuclei of rat liver relative to 3,5,3' triiodothyronine",,BAO_0000019,,,,Autocuration,9964,,U,0,CHEMBL615310,,,
338,1,Binding affinity to the receptor was determined in vitro in isolated nuclei of rat liver relative to T3,,BAO_0000019,,,,Autocuration,9964,,H,8,CHEMBL615311,,,
339,1,"Binding affinity to thyroid hormone receptor beta, relative to 3,5,3' triiodothyronine receptor, in isolated nuclei of heart",,BAO_0000019,,Homo sapiens,,Autocuration,9964,,U,0,CHEMBL615312,,,
340,1,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,,BAO_0000019,,,,Autocuration,9964,,H,8,CHEMBL615313,,,
341,1,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,,BAO_0000019,,,,Autocuration,9964,,H,8,CHEMBL615314,,,
342,1,"Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to 3,5,3' triiodothyronine receptor",,BAO_0000019,,,,Autocuration,9964,,H,8,CHEMBL615315,,,
343,1,"In vivo binding affinity for 3,5,3'' triiodothyronine receptor of heart nuclei 1 hr after intravenous administration",,BAO_0000218,,Rattus norvegicus,,Autocuration,9964,,U,0,CHEMBL615316,,,
344,1,Binding affinity to the receptor was determined in nuclei of heart in vivo 1 hour after intravenous administration relative to T3,,BAO_0000218,,,,Autocuration,9964,In vivo,H,8,CHEMBL615317,,,
345,1,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,BAO_0000218,,,,Autocuration,9964,,H,8,CHEMBL615318,,,
346,1,"In vivo binding affinity for 3,5,3' triiodothyronine receptor of liver nuclei 1 hour after intravenous administration",,BAO_0000218,,Rattus norvegicus,,Autocuration,9964,,U,0,CHEMBL615319,,,
347,1,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",,BAO_0000019,,,,Autocuration,9964,,H,8,CHEMBL615320,,,
348,1,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",,BAO_0000019,,,,Autocuration,9964,,H,8,CHEMBL615321,,,
349,1,"Inhibition of [125I]L-T3 binding to rat hepatic 3,5,3''-triiodo-L-thyronine receptor",,BAO_0000019,,Rattus norvegicus,,Autocuration,3796,,U,0,CHEMBL615322,,,
350,1,Inhibition constant for binding to Co2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,,BAO_0000357,,Escherichia coli,,Autocuration,4251,,H,8,CHEMBL615323,,,
351,1,Inhibition constant for binding to Zn2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,,BAO_0000357,,Escherichia coli,,Autocuration,4251,,H,8,CHEMBL615407,,,
352,1,Kinetics expressed as Michaelis-Menten constant against Co2+ form of 3-dehydroquinate synthase purified from Escherichia coli,,BAO_0000357,,Escherichia coli,,Autocuration,4251,,H,8,CHEMBL857267,,,
353,1,Kinetics expressed as Michaelis-Menten constant against Zn2+ form of 3-dehydroquinate synthase purified from Escherichia coli,,BAO_0000357,,Escherichia coli,,Autocuration,4251,,H,8,CHEMBL615408,,,
354,1,Type of inhibition of 3-dehydroquinate synthase was determined; R - Slowly reversible,,BAO_0000357,,,,Autocuration,166,,H,8,CHEMBL615409,,,
355,1,Compound was evaluated for its inhibitory constant against 3-dehydroquinate synthase,,BAO_0000357,,,,Autocuration,17861,,H,8,CHEMBL615410,,,
356,1,Inhibition constant against 3-dehydroquinate synthase,,BAO_0000357,,,,Autocuration,166,,H,8,CHEMBL615411,,,
357,1,Association rate constant against 3-dehydroquinate synthase,,BAO_0000357,,,,Autocuration,166,,H,8,CHEMBL615412,,,
358,1,Rate constant against 3-dehydroquinate synthase,,BAO_0000357,,,,Autocuration,166,,H,8,CHEMBL615413,,,
359,1,Inhibitory activity against fuc-TVII,,BAO_0000019,,,,Autocuration,3548,,U,0,CHEMBL615414,,,
360,1,Ability of compound (2.5 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,9877,,D,9,CHEMBL615415,,2107.0,
361,1,Ability of compound (2500 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,9877,,D,9,CHEMBL615416,,2107.0,
362,1,Ability of compound (250 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,9877,,D,9,CHEMBL615417,,2107.0,
363,1,Ability of compound (25 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,9877,,D,9,CHEMBL615418,,2107.0,
364,1,Ability of compound at 0 uM to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,9877,,D,9,CHEMBL615419,,2107.0,
365,1,Ability of compound to inhibit the activity of 3-hydroxy-3-methylglutarylcoenzyme A(HMGR) reductase in rat liver microsomes,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,9877,,D,9,CHEMBL615420,,2107.0,
366,1,Percentage inhibition of 3-hydroxy-3-methyl glutaryl coenzyme A reductase in rat liver microsomes at 250 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,9877,,D,9,CHEMBL615421,,2107.0,
367,1,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 0 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,9877,,D,9,CHEMBL615422,,2107.0,
368,1,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2.5 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,9877,,D,9,CHEMBL615423,,2107.0,
369,1,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2500 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,9877,,D,9,CHEMBL872868,,2107.0,
370,1,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 25 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,9877,,D,9,CHEMBL615424,,2107.0,
371,1,Inhibitory activity against 3-phosphoglycerate kinase.,,BAO_0000224,,,,Autocuration,3003,,H,4,CHEMBL825022,,,
372,1,Binding affinity was evaluated towards 3-phosphoglycerate kinase at 37 degrees Celsius in 0.1 m NaCl pH 7.1,,BAO_0000224,,,,Autocuration,3003,,H,4,CHEMBL615425,,,
373,1,"Michaelis-Menten constant with 1,3-bisphosphoglyceric acid (1,3-BPG) against 3-phosphoglycerate kinase",,BAO_0000224,,,,Autocuration,3003,,H,4,CHEMBL615426,,,
374,1,Inhibition of human 3-phosphoinositide-dependent protein kinase 1 at 10 uM,,BAO_0000357,,Homo sapiens,,Expert,17185,,D,9,CHEMBL615427,,,
375,1,Cytotoxicity on 3677 melanoma cells,,BAO_0000219,,Homo sapiens,,Intermediate,6072,,N,1,CHEMBL615428,844.0,,
376,1,Cytotoxicity on 3677 melanoma cells in combination with L-49-sFv-bL,,BAO_0000219,,Homo sapiens,,Intermediate,6072,,N,1,CHEMBL615429,844.0,,
377,1,Antitumor activity against Mouse colon 38 at 500 ug/disk in disk diffusion assay,,BAO_0000219,,Mus musculus,,Intermediate,5018,,N,1,CHEMBL615430,700.0,,
378,1,Compound was evaluated for inhibition of tumor cell growth using sulforhodamine-B assay in 38 human cell lines,,BAO_0000019,,Homo sapiens,,Intermediate,2852,,U,0,CHEMBL615431,,,
379,1,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; NT= Not tested,,BAO_0000218,,,,Autocuration,8663,,U,0,CHEMBL615432,798.0,,
380,1,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; reproducible significant activity.,,BAO_0000218,,,,Autocuration,8663,,U,0,CHEMBL615433,798.0,,
381,1,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease,,BAO_0000019,,Human rhinovirus 14,,Expert,3245,,D,9,CHEMBL615434,,,
382,1,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease; NI means No inhibition to 50 uM,,BAO_0000218,,Human rhinovirus sp.,,Intermediate,3245,,N,1,CHEMBL615435,,,
383,1,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as KI,,BAO_0000218,,human rhinovirus type 14,,Intermediate,3877,,N,1,CHEMBL615436,,,
384,1,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as kinact,,BAO_0000218,,human rhinovirus type 14,,Intermediate,3877,,N,1,CHEMBL615437,,,
385,1,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,BAO_0000019,,Human rhinovirus 14,,Expert,5861,,D,9,CHEMBL615438,,,
386,1,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,BAO_0000019,,Human rhinovirus 14,,Expert,5861,,D,9,CHEMBL615439,,,
387,1,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,BAO_0000019,,Human rhinovirus 14,,Expert,5861,,D,9,CHEMBL615440,,,
388,1,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay; inactive,,BAO_0000019,,Human rhinovirus 14,,Expert,5861,,D,9,CHEMBL615441,,,
389,1,Compound was tested for the inhibitory activity of compound towards human rhinovirus 3C protease,,BAO_0000218,,Enterovirus,,Intermediate,13748,,N,1,CHEMBL615641,,,
390,1,Compound was tested for the inhibitory activity of compound towards human rhinovirus-16 3C protease,,BAO_0000218,,Enterovirus,,Intermediate,13748,,N,1,CHEMBL872065,,,
391,1,Compound was tested for the inhibitory activity of compound towards human rhinovirus-2 3C protease,,BAO_0000218,,Enterovirus,,Intermediate,13748,,N,1,CHEMBL825023,,,
392,1,Compound was tested for the inhibitory activity of compound towards human rhinovirus-89 3C protease,,BAO_0000218,,Enterovirus,,Intermediate,13748,,N,1,CHEMBL615642,,,
393,1,Inhibition of human rhinovirus 3C protease,,BAO_0000357,,Human rhinovirus B,,Expert,13748,,H,8,CHEMBL615643,,,
394,1,Compound was tested for inhibition of a proteinase 3CL pro of human coronavirus; Inhibited,,BAO_0000019,,Homo sapiens,,Autocuration,17699,,U,0,CHEMBL615644,,,
395,1,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 100 mg/kg (Dose range 200-12.5),,BAO_0000218,,Mus musculus,,Intermediate,7145,,N,1,CHEMBL615645,833.0,,
396,1,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 128 mg/kg (Dose range 256-16),,BAO_0000218,,Mus musculus,,Intermediate,7145,,N,1,CHEMBL615646,833.0,,
397,1,Compound tested for toxicity against 3EM 37 Mouse Ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (10/10),,BAO_0000218,,Mus musculus,,Intermediate,7145,,N,1,CHEMBL615647,833.0,,
398,1,Compound tested for toxicity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (6/6),,BAO_0000218,,Mus musculus,,Intermediate,7145,,N,1,CHEMBL615648,833.0,,
399,1,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as animal weight difference of the treated and the control (T-C) at OD of 100 mg/kg,,BAO_0000218,,Mus musculus,,Intermediate,7145,,N,1,CHEMBL615649,833.0,,
400,1,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as percentage of cured animals at OD of 100 mg/kg,,BAO_0000218,,Mus musculus,,Intermediate,7145,,N,1,CHEMBL615650,833.0,,
401,1,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing 15 mg/kg b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,,BAO_0000218,,Mus musculus,,Intermediate,5325,,N,1,CHEMBL615651,847.0,,
402,1,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,,BAO_0000218,,Mus musculus,,Intermediate,5325,,N,1,CHEMBL615652,847.0,,
403,1,In vivo anti-tumor and anti-metastatic activity following p.o. administration b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor; Not tested.,,BAO_0000218,,Mus musculus,,Expert,5325,,N,1,CHEMBL615653,847.0,,
404,1,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 1 uM dose,,BAO_0000219,,Mus musculus,,Intermediate,16169,,N,1,CHEMBL615654,847.0,,
405,1,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 10 uM dose,,BAO_0000219,,Mus musculus,,Intermediate,16169,,N,1,CHEMBL615655,847.0,,
406,1,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 250 uM dose,,BAO_0000219,,Mus musculus,,Intermediate,16169,,N,1,CHEMBL825024,847.0,,
407,1,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 50 uM dose,,BAO_0000219,,Mus musculus,,Intermediate,16169,,N,1,CHEMBL615656,847.0,,
408,1,accumulation of compound in 3LL cells was measured with DFMO by ICP-AES at 50 uM dose,,BAO_0000219,,Mus musculus,,Intermediate,16169,,N,1,CHEMBL615657,847.0,,
409,1,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 1 uM dose,,BAO_0000219,,Mus musculus,,Intermediate,16169,,N,1,CHEMBL615658,847.0,,
410,1,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 10 uM dose,,BAO_0000219,,Mus musculus,,Intermediate,16169,,N,1,CHEMBL615659,847.0,,
411,1,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 250 uM dose,,BAO_0000219,,Mus musculus,,Intermediate,16169,,N,1,CHEMBL615660,847.0,,
412,1,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,,BAO_0000219,,Mus musculus,,Intermediate,16169,,N,1,CHEMBL615661,847.0,,
413,1,accumulation of compound in 3LL cells was measured without DFMO by ICP-AES at 50 uM dose,,BAO_0000219,,Mus musculus,,Intermediate,16169,,N,1,CHEMBL615662,847.0,,
414,1,Effect on the growth of 3LL cells by DFMO pretreatment at 48 hr incubation,,BAO_0000219,,Mus musculus,,Intermediate,16169,,N,1,CHEMBL615663,847.0,,
415,1,Effect on the growth of 3LL cells was evaluated using an MTT assay at 48 hour incubation,,BAO_0000219,,Mus musculus,,Intermediate,16169,,N,1,CHEMBL615664,847.0,,
416,1,Effect on the growth of 3LL cells was evaluated using an MTT assay at 72 hour incubation,,BAO_0000219,,Mus musculus,,Intermediate,16169,,N,1,CHEMBL615665,847.0,,
417,1,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,,BAO_0000219,,Mus musculus,,Intermediate,16169,,N,1,CHEMBL615666,847.0,,
418,1,putrescine levels in 3LL cells after the treatment of 1 uM of Compound,,BAO_0000219,,Mus musculus,,Intermediate,16169,,N,1,CHEMBL615667,847.0,,
419,1,putrescine levels in 3LL cells after the treatment of 10 uM of Compound,,BAO_0000219,,Mus musculus,,Intermediate,16169,,N,1,CHEMBL615668,847.0,,
420,1,putrescine levels in 3LL cells after the treatment of 250 uM of Compound,,BAO_0000219,,Mus musculus,,Intermediate,16169,,N,1,CHEMBL615669,847.0,,
421,1,putrescine levels in 3LL cells after the treatment of 50 uM of Compound,,BAO_0000219,,Mus musculus,,Intermediate,16169,,N,1,CHEMBL615670,847.0,,
422,1,spermidine levels in 3LL cells after the treatment of 1 uM of Compound,,BAO_0000219,,Mus musculus,,Intermediate,16169,,N,1,CHEMBL836739,847.0,,
423,1,spermidine levels in 3LL cells after the treatment of 10 uM of Compound,,BAO_0000219,,Mus musculus,,Intermediate,16169,,N,1,CHEMBL615671,847.0,,
424,1,spermidine levels in 3LL cells after the treatment of 250 uM of Compound,,BAO_0000219,,Mus musculus,,Intermediate,16169,,N,1,CHEMBL615672,847.0,,
425,1,spermidine levels in 3LL cells after the treatment of 50 uM of Compound,,BAO_0000219,,Mus musculus,,Intermediate,16169,,N,1,CHEMBL615791,847.0,,
426,1,spermine levels in 3LL cells after the treatment of 1 uM of Compound,,BAO_0000219,,Mus musculus,,Intermediate,16169,,N,1,CHEMBL615792,847.0,,
427,1,spermine levels in 3LL cells after the treatment of 10 uM of Compound,,BAO_0000219,,Mus musculus,,Intermediate,16169,,N,1,CHEMBL615793,847.0,,
428,1,spermine levels in 3LL cells after the treatment of 250 uM of Compound,,BAO_0000219,,Mus musculus,,Intermediate,16169,,N,1,CHEMBL615794,847.0,,
429,1,spermine levels in 3LL cells after the treatment of 50 uM of Compound,,BAO_0000219,,Mus musculus,,Intermediate,16169,,N,1,CHEMBL615795,847.0,,
430,1,Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50%,,BAO_0000219,,Homo sapiens,,Intermediate,15547,,N,1,CHEMBL615590,971.0,,
431,1,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible minimal activity,,BAO_0000218,,,,Autocuration,8663,,U,0,CHEMBL615591,,,
432,1,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible significant activity.,,BAO_0000218,,,,Autocuration,8663,,U,0,CHEMBL615592,,,
433,1,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; NT= Not tested,,BAO_0000218,,,,Autocuration,8663,,U,0,CHEMBL615593,,,
434,1,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; reproducible significant activity.,,BAO_0000218,,,,Autocuration,8663,,U,0,CHEMBL615594,,,
435,1,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,,BAO_0000219,,Mus musculus,,Intermediate,4504,,N,1,CHEMBL615595,723.0,,
436,1,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,,BAO_0000219,,Mus musculus,,Intermediate,4504,,N,1,CHEMBL615596,723.0,,
437,1,Inhibition of 6 nM bombesin induced [3H]thymidine incorporation measured in swiss 3T3 cells using a mitogenicity assay,,BAO_0000219,,,,Expert,12695,,H,8,CHEMBL615597,723.0,,
438,1,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; na=Not active,,BAO_0000219,,Mus musculus,,Intermediate,12695,,N,1,CHEMBL615598,723.0,,
439,1,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; nt=Not tested,,BAO_0000219,,Mus musculus,,Intermediate,12695,,N,1,CHEMBL615599,723.0,,
440,1,Effective dose against murine 3T3 fibroblasts cells,,BAO_0000219,,Mus musculus,,Expert,17642,,N,1,CHEMBL615600,723.0,,
441,1,Dose required against murine 3T3 fibroblasts cells; 1-10 uM,,BAO_0000219,,Mus musculus,,Expert,17642,,N,1,CHEMBL615601,723.0,,
442,1,Cytotoxic effect on 3T3 cells,,BAO_0000219,,Mus musculus,,Expert,12340,,N,1,CHEMBL615602,723.0,,
443,1,Cytotoxic effect on 3T3 cells,,BAO_0000219,,Mus musculus,,Expert,12340,,N,1,CHEMBL615603,723.0,,
444,1,Compound was tested for the concentration necessary to inhibit swiss 3T3 Mouse Fibroblast cell growth rate by 50%.,,BAO_0000219,,Mus musculus,,Intermediate,12716,,N,1,CHEMBL615604,723.0,,
445,1,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,,BAO_0000219,,Mus musculus,,Intermediate,6277,,N,1,CHEMBL615605,723.0,,
446,1,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration; nd=No data,,BAO_0000219,,Mus musculus,,Intermediate,6277,,N,1,CHEMBL615606,723.0,,
447,1,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration,,BAO_0000219,,Mus musculus,,Expert,6277,,N,1,CHEMBL884526,723.0,,
448,1,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.d.=no data,,BAO_0000219,,Mus musculus,,Expert,6277,,N,1,CHEMBL615607,723.0,,
449,1,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.t.=not tested,,BAO_0000219,,Mus musculus,,Intermediate,6277,,N,1,CHEMBL615608,723.0,,
450,1,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration,,BAO_0000219,,Mus musculus,,Expert,6277,,N,1,CHEMBL615609,723.0,,
451,1,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.d.=no data,,BAO_0000219,,Mus musculus,,Expert,6277,,N,1,CHEMBL615682,723.0,,
452,1,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.t.=not tested,,BAO_0000219,,Mus musculus,,Intermediate,6277,,N,1,CHEMBL615683,723.0,,
453,1,In vivo inhibition of H-ras-transformed 3T3 fibroblasts in nude mouse tumor models,,BAO_0000218,,Mus musculus,,Expert,17780,,N,1,CHEMBL615684,723.0,,
454,1,Inhibition of PDGF-dependent autophosphorylation of PDGF-R in mouse BALB/c3T3 cells,,BAO_0000219,,Mus musculus,,Autocuration,12751,,D,7,CHEMBL615685,,,
455,1,Inhibition of Swiss 3T3 Mouse fibroblast proliferation,,BAO_0000219,,Mus musculus,,Expert,12380,,N,1,CHEMBL615686,723.0,,
456,1,Inhibitory activity against 3T3 cell line,,BAO_0000219,,Mus musculus,,Intermediate,14892,,N,1,CHEMBL615687,723.0,,
457,1,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured,,BAO_0000219,,Mus musculus,,Intermediate,12695,,N,1,CHEMBL884523,723.0,,
458,1,Ability of peptide to inhibit binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane.,,BAO_0000019,,,,Expert,12695,,H,8,CHEMBL615688,,,
459,1,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured; nt=Not tested,,BAO_0000219,,Mus musculus,,Intermediate,12695,,N,1,CHEMBL615689,723.0,,
460,1,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells was measured,,BAO_0000219,,Mus musculus,,Intermediate,12695,,N,1,CHEMBL615690,723.0,,
461,1,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells,,BAO_0000019,,,,Expert,12695,,H,8,CHEMBL615691,,,
462,1,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells; nt=Not tested,,BAO_0000019,,,,Expert,12695,,H,8,CHEMBL615692,,,
463,1,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,,BAO_0000219,,Mus musculus,,Intermediate,6277,,N,1,CHEMBL615693,723.0,,
464,1,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line was determined using NR coloration; n.d.=no data,,BAO_0000219,,Mus musculus,,Expert,6277,,N,1,CHEMBL615324,723.0,,
465,1,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells,,BAO_0000219,,Homo sapiens,,Expert,4959,,D,9,CHEMBL615325,723.0,,
466,1,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells (Not tested),,BAO_0000219,,Homo sapiens,,Expert,4959,,D,9,CHEMBL615490,723.0,,
467,1,Inhibition of ligand induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells,,BAO_0000219,,Homo sapiens,,Expert,4959,,D,9,CHEMBL615491,723.0,,
468,1,Inhibition of ligand-induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells (Not tested),,BAO_0000219,,Homo sapiens,,Expert,4959,,D,9,CHEMBL615492,723.0,,
469,1,Inhibitory concentration of compound rwas calculated on 3T3 cells by [3H]Thd incorporation,,BAO_0000219,,Mus musculus,,Intermediate,12082,,N,1,CHEMBL615493,723.0,,
470,1,Inhibitory concentration of compound was calculated on 3T3 cells by [14C]Leu incorporation,,BAO_0000219,,Mus musculus,,Intermediate,12082,,N,1,CHEMBL615494,723.0,,
471,1,Inhibitory concentration of compound was calculated on 3T3 cells by using clonal assay,,BAO_0000219,,Mus musculus,,Intermediate,12082,,N,1,CHEMBL615495,723.0,,
472,1,Inhibitory concentration was calculated on 3T3 cells by using growth assay,,BAO_0000219,,Mus musculus,,Intermediate,12082,,N,1,CHEMBL615496,723.0,,
473,1,In vitro cytotoxicity was evaluated in mouse embryo BALB/c 3T3 cells,,BAO_0000219,,Mus musculus,,Intermediate,2643,,N,1,CHEMBL615497,723.0,,
474,1,Inhibition of Swiss 3T3 mouse fibroblast proliferation,,BAO_0000219,,Mus musculus,,Expert,11926,,N,1,CHEMBL615498,723.0,,
475,1,The compound was tested for cytotoxicity against 3T3 fibroblast murine cell line.,,BAO_0000219,,Mus musculus,,Intermediate,15204,,N,1,CHEMBL615499,723.0,,
476,1,Effective concentration required to inhibit the growth of murine 3T3 fibroblasts,,BAO_0000219,,Mus musculus,,Expert,15992,,N,1,CHEMBL835522,723.0,,
477,1,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014); Not tested,,BAO_0000219,,Mus musculus,,Intermediate,16279,,N,1,CHEMBL615500,723.0,,
478,1,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,BAO_0000219,,Mus musculus,,Intermediate,16279,,N,1,CHEMBL615501,723.0,,
479,1,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,BAO_0000219,,Mus musculus,,Intermediate,16279,,N,1,CHEMBL615502,723.0,,
480,1,cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,BAO_0000219,,Mus musculus,,Intermediate,16279,,N,1,CHEMBL615503,723.0,,
481,1,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,BAO_0000219,,Mus musculus,,Intermediate,16279,,N,1,CHEMBL615504,723.0,,
482,1,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,BAO_0000219,,Mus musculus,,Intermediate,16279,,N,1,CHEMBL615505,723.0,,
483,1,Inhibition of swiss 3T3 mouse fibroblast proliferation,,BAO_0000219,,Mus musculus,,Expert,12831,,N,1,CHEMBL615506,723.0,,
484,1,Compound was tested for sublethal concentrations in 3T3 mouse fibroblast lysis.,,BAO_0000219,,Mus musculus,,Intermediate,13497,,N,1,CHEMBL615507,723.0,,
485,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,BAO_0000218,,,,Intermediate,13715,,N,1,CHEMBL615508,620.0,,
486,1,Concentration required to stimulate glucose uptake in 3T3-L1 adipocytes after 48 hr incubation,,BAO_0000219,,Mus musculus,,Intermediate,13618,,N,1,CHEMBL615509,620.0,,
487,1,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 0.3 uM,,BAO_0000219,,Mus musculus,,Intermediate,11902,,N,1,CHEMBL615510,620.0,,
488,1,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 3 uM,,BAO_0000219,,Mus musculus,,Intermediate,11902,,N,1,CHEMBL615511,620.0,,
489,1,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 30 uM,,BAO_0000219,,Mus musculus,,Intermediate,11902,,N,1,CHEMBL615512,620.0,,
490,1,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 24 hr",,BAO_0000218,,Mus musculus,,Intermediate,14840,,N,1,CHEMBL615513,620.0,,
491,1,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 3 hr",,BAO_0000218,,Mus musculus,,Intermediate,14840,,N,1,CHEMBL615514,620.0,,
492,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes,,BAO_0000219,,,,Intermediate,13715,,N,1,CHEMBL615515,620.0,,
493,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,,BAO_0000219,,,,Intermediate,13715,,N,1,CHEMBL615516,620.0,,
494,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,BAO_0000219,,,,Intermediate,13715,,N,1,CHEMBL615517,620.0,,
495,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,,BAO_0000219,,,,Intermediate,13715,,N,1,CHEMBL615518,620.0,,
496,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,BAO_0000219,,,,Intermediate,13715,,N,1,CHEMBL615519,620.0,,
497,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.3 uM dose.,,BAO_0000218,,,,Intermediate,13715,,N,1,CHEMBL615520,620.0,,
498,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.5 uM dose.,,BAO_0000218,,,,Intermediate,13715,,N,1,CHEMBL615521,620.0,,
499,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,,BAO_0000218,,,,Intermediate,13715,,N,1,CHEMBL615522,620.0,,
500,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,BAO_0000218,,,,Intermediate,13715,,N,1,CHEMBL615523,620.0,,
501,1,In vitro measurements 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,,BAO_0000218,,,,Expert,13715,,N,1,CHEMBL615524,620.0,,
502,1,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,BAO_0000218,,,,Expert,13715,,N,1,CHEMBL615525,620.0,,
503,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,,BAO_0000218,,,,Intermediate,13715,,N,1,CHEMBL615526,620.0,,
504,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,BAO_0000218,,,,Intermediate,13715,,N,1,CHEMBL615527,620.0,,
505,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 300 uM dose.,,BAO_0000218,,,,Intermediate,13715,,N,1,CHEMBL615528,620.0,,
506,1,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,BAO_0000218,,,,Expert,13715,,N,1,CHEMBL615529,620.0,,
507,1,In vitro by measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,BAO_0000218,,,,Expert,13715,,N,1,CHEMBL615530,620.0,,
508,1,In vitro measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,,BAO_0000218,,,,Expert,13715,,N,1,CHEMBL615531,620.0,,
509,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,,BAO_0000219,,,,Intermediate,13715,,N,1,CHEMBL615532,620.0,,
510,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,BAO_0000219,,,,Intermediate,13715,,N,1,CHEMBL615533,620.0,,
511,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,,BAO_0000219,,,,Intermediate,13715,,N,1,CHEMBL615534,620.0,,
512,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,,BAO_0000218,,,,Intermediate,13715,,N,1,CHEMBL615535,620.0,,
513,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,BAO_0000218,,,,Intermediate,13715,,N,1,CHEMBL615536,620.0,,
514,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,BAO_0000218,,,,Intermediate,13715,,N,1,CHEMBL615537,620.0,,
515,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,BAO_0000218,,,,Intermediate,13715,,N,1,CHEMBL615538,620.0,,
516,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,,BAO_0000218,,,,Intermediate,13715,,N,1,CHEMBL836166,620.0,,
517,1,Inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells,,BAO_0000219,,,,Expert,6411,,H,8,CHEMBL615539,620.0,,
518,1,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; ND = No data,,BAO_0000219,,Mus musculus,,Intermediate,6411,,N,1,CHEMBL615540,620.0,,
519,1,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; Na = Not active,,BAO_0000219,,,,Expert,6411,,H,8,CHEMBL615541,620.0,,
520,1,Insulin-sensitizing activity; triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 1 uM expressed as percent activity of pioglitazone,,BAO_0000219,,Mus musculus,,Expert,3966,,N,1,CHEMBL615542,620.0,,
521,1,Compound was tested for insulin-sensitizing activity by measuring triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 10 uM expressed as percent activity of pioglitazone,,BAO_0000219,,Mus musculus,,Intermediate,3966,,N,1,CHEMBL615543,620.0,,
522,1,Stimulation of adipogenesis in 3T3-L1 cells is expressed as concentration equivalent to the [ 1-14C] uptake counts after treatment with 0.2 ug/mL troglitazone,,BAO_0000219,,Mus musculus,,Expert,15556,,N,1,CHEMBL615544,620.0,,
523,1,Effective concentration for enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,,BAO_0000219,,Mus musculus,,Expert,5845,,N,1,CHEMBL615545,620.0,,
524,1,Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,,BAO_0000219,,Mus musculus,,Expert,14422,,N,1,CHEMBL615546,620.0,,
525,1,Percentage of rosiglitazone response for insulin-sensitizing activity at 1 uM concentration in 3T3-L1 cells,,BAO_0000219,,Mus musculus,,Expert,5845,,N,1,CHEMBL615547,620.0,,
526,1,In vitro glucose transport activity in 3T3-LI adipocytes at 10 uM concentration.,,BAO_0000219,,Mus musculus,,Expert,14508,,N,1,CHEMBL615548,620.0,,
527,1,In vitro glucose transport activity in 3T3-LI adipocytes at 3 uM concentration.,,BAO_0000219,,Mus musculus,,Expert,14508,,N,1,CHEMBL615549,620.0,,
528,1,In vitro glucose transport activity in 3T3-LI adipocytes at 30 uM concentration.,,BAO_0000219,,Mus musculus,,Expert,14508,,N,1,CHEMBL615550,620.0,,
529,1,Inhibitory activity against rat fibroblast (3Y1) cell line,,BAO_0000219,,Rattus norvegicus,,Intermediate,6349,,N,1,CHEMBL615551,1118.0,,
530,1,Mean concentration causing inhibition of cell growth in 3Y1 cells.,,BAO_0000219,,Rattus norvegicus,,Expert,15899,,N,1,CHEMBL615552,1118.0,,
531,1,Cytotoxicity in 3Y1 cells.,,BAO_0000219,,Rattus norvegicus,,Expert,15899,,N,1,CHEMBL615553,1118.0,,
532,1,Cytostatic effect in 3Y1 cells.,,BAO_0000219,,Rattus norvegicus,,Expert,15899,,N,1,CHEMBL615554,1118.0,,
533,1,"Mean averaged concentration for total growth inhibition, which signifies cytostatic effect",,BAO_0000219,,Rattus norvegicus,,Intermediate,15899,,N,1,CHEMBL615555,1118.0,,
534,1,Concentration to inhibit growth of normal rat fibroblast cells (3Y1-B cells) after 72 h exposure,,BAO_0000219,,Rattus norvegicus,,Expert,17038,,N,1,CHEMBL615556,1118.0,,
535,1,In vitro inhibitory activity against human adrenal 3-beta hydroxy-delta 5-teroid isomerase,,BAO_0000019,,,,Autocuration,12421,,U,0,CHEMBL615557,,,
536,1,Inhibition of recombinant human adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,,BAO_0000019,,,,Autocuration,12947,,U,0,CHEMBL615558,,,
537,1,Inhibition of recombinant rat adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,,BAO_0000019,,,,Autocuration,12947,,U,0,CHEMBL872066,,,
538,1,In vitro inhibition against of 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) from pig liver by the enol borate method,,BAO_0000019,,Sus scrofa,,Expert,4896,,D,9,CHEMBL615559,,,
539,1,In vitro inhibitory concentration required against 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) taken from pig liver,,BAO_0000019,,,,Autocuration,6148,,H,8,CHEMBL615560,,,
540,1,Inhibition of pig liver 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) enzyme,,BAO_0000019,,,,Autocuration,16432,,H,8,CHEMBL615561,,,
541,1,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver,,BAO_0000019,,,,Expert,4978,,H,8,CHEMBL857062,,,
542,1,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver; (observed value),,BAO_0000019,,,,Expert,4978,,H,8,CHEMBL615562,,,
543,1,In vitro inhibitory activity against HPPD(4-hydroxyphenylpyruvate Dioxygenase) from pig liver using enol borate assay method,,BAO_0000019,,,,Autocuration,3723,,H,8,CHEMBL615563,,,
544,1,Compound was evaluated for complete competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD),,BAO_0000357,,,,Autocuration,3518,,H,8,CHEMBL615564,,,
545,1,In vitro inhibition of 4-hydroxyphenylpyruvate dioxygenase obtained from purified pig liver by enol-borate method,,BAO_0000019,,,,Autocuration,4164,,H,8,CHEMBL615565,,,
546,1,Inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated,,BAO_0000019,,,,Autocuration,3518,,H,8,CHEMBL615566,,,
547,1,Inhibition of 4-hydroxyphenylpyruvate dioxygenase of purified pig liver by enol-borate method,,BAO_0000019,,Sus scrofa,,Expert,4164,,D,9,CHEMBL615567,,,
548,1,The inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated.,,BAO_0000019,,,,Autocuration,3518,,H,8,CHEMBL615568,,,
549,1,Compound was evaluated for competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) (complete inhibition was observed at a concentration of 0.5-1.0 mM),,BAO_0000357,,,,Autocuration,3518,,H,8,CHEMBL615569,,,
550,1,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver,,BAO_0000019,,,,Autocuration,4978,,H,8,CHEMBL615570,,,
551,1,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver; (observed value),,BAO_0000019,,,,Autocuration,4978,,H,8,CHEMBL615571,,,
552,1,Binding affinity against melatonin (MT1) receptor (pC1),,BAO_0000224,,,,Autocuration,6455,,H,4,CHEMBL615572,,,
553,1,Compound was tested for inhibitory activity against 5-hydroxytryptamine 1 receptor,,BAO_0000019,,,,Autocuration,2222,,U,0,CHEMBL615573,,,
554,1,Inhibition of [3H]- 5-HT binding to 5-hydroxytryptamine 1 receptor at 10e-5 M,,BAO_0000019,,,,Autocuration,13020,,U,0,CHEMBL615574,,,
555,1,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1 receptor of central nervous system,,BAO_0000019,,,,Autocuration,13021,,U,0,CHEMBL615575,,,
556,1,Inhibitory activity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand at 10e-5 M concentration,,BAO_0000357,,,,Autocuration,14532,,H,8,CHEMBL615576,,,
557,1,Binding affinity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,,BAO_0000357,,,,Autocuration,14118,,H,8,CHEMBL615577,,,
558,1,Binding affinity at 5-hydroxytryptamine 1A receptor in bovine hippocampal preparation using [3H]8-OH-DPAT,Hippocampus,BAO_0000221,,,,Autocuration,11884,,H,8,CHEMBL615578,,10000000.0,
559,1,Binding affinity against 5-hydroxytryptamine 1A receptor was measured using [3H]8-OH-DPAT as radioligand,,BAO_0000357,,,,Expert,13969,,H,8,CHEMBL615579,,,
560,1,Binding affinity for 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Expert,13392,,H,8,CHEMBL615580,,,
561,1,Affinity towards 5-hydroxytryptamine 1A receptor in membranes from bovine hippocampus using [3H]OH-DPAT,,BAO_0000019,,,,Expert,14430,,H,8,CHEMBL615581,,,
562,1,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,Hippocampus,BAO_0000221,,,,Autocuration,12248,,H,8,CHEMBL615582,,10000000.0,
563,1,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,Hippocampus,BAO_0000221,,,,Autocuration,12249,,H,8,CHEMBL615583,,10000000.0,
564,1,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,Hippocampus,BAO_0000221,,,,Autocuration,9995,,H,8,CHEMBL615584,,10000000.0,
565,1,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,Hippocampus,BAO_0000221,,,,Autocuration,9995,,H,8,CHEMBL833691,,10000000.0,
566,1,In vitro inhibition of azido-[125I]-IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,Hippocampus,BAO_0000221,,,,Autocuration,9995,,H,8,CHEMBL615585,,10000000.0,
567,1,In vitro inhibition of [125I]IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,Hippocampus,BAO_0000221,,,,Autocuration,9995,,H,8,CHEMBL615586,,10000000.0,
568,1,In vitro inhibition of [125I]IPAPP (2.5 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,Hippocampus,BAO_0000221,,,,Autocuration,9995,,H,8,CHEMBL884524,,10000000.0,
569,1,Inhibitory concentration against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,Hippocampus,BAO_0000221,,,,Autocuration,12249,,H,8,CHEMBL615587,,10000000.0,
570,1,"Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",Hippocampus,BAO_0000221,,,,Autocuration,11799,,H,8,CHEMBL615588,,10000000.0,
571,1,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampal membranes,,BAO_0000249,,Rattus norvegicus,,Expert,14331,,D,9,CHEMBL615589,,,
572,1,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of bovine hippocampus.,Hippocampus,BAO_0000221,,Bos taurus,,Expert,11884,,H,8,CHEMBL615442,,10000000.0,
573,1,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (0.5 nM) ligand in hippocampus + frontal bovine was determined,Hippocampus,BAO_0000221,,,,Autocuration,14331,,H,8,CHEMBL615443,,10000000.0,
574,1,Compound was evaluated for its ability to displace [3H]DPAT from 5-HT1A receptor in homogenates of bovine hippocampus,Hippocampus,BAO_0000221,,,,Autocuration,11701,,H,8,CHEMBL615444,,10000000.0,
575,1,Ability to displace [3H]-DPAT from 5-hydroxytryptamine 1A receptor in homogenates of bovine hippocampus.,Hippocampus,BAO_0000221,,,,Expert,11701,,H,8,CHEMBL615445,,10000000.0,
576,1,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in bovine hippocampus,Hippocampus,BAO_0000221,,,,Autocuration,12248,,H,8,CHEMBL615446,,10000000.0,
577,1,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in CHO cells,,BAO_0000219,,,,Autocuration,12248,,H,8,CHEMBL615447,449.0,,
578,1,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,Hippocampus,BAO_0000221,,,,Expert,12248,,H,8,CHEMBL615448,,10000000.0,
579,1,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,Hippocampus,BAO_0000221,,,,Expert,12249,,H,8,CHEMBL615449,,10000000.0,
580,1,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,BAO_0000219,,,,Autocuration,12248,,H,8,CHEMBL615450,449.0,,
581,1,"Binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",Hippocampus,BAO_0000221,,,,Expert,11799,,H,8,CHEMBL615451,,10000000.0,
582,1,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,,BAO_0000357,,,,Autocuration,634,,H,8,CHEMBL615452,,,
583,1,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,Hippocampus,BAO_0000221,,,,Autocuration,9995,,H,8,CHEMBL615453,,10000000.0,
584,1,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,Hippocampus,BAO_0000221,,,,Autocuration,9995,,H,8,CHEMBL615454,,10000000.0,
585,1,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,Hippocampus,BAO_0000221,,,,Autocuration,9995,,H,8,CHEMBL615455,,10000000.0,
586,1,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,Hippocampus,BAO_0000221,,,,Autocuration,9995,,H,8,CHEMBL615456,,10000000.0,
587,1,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,Hippocampus,BAO_0000221,,,,Autocuration,9995,,H,8,CHEMBL615457,,10000000.0,
588,1,In vivo binding affinity towards [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus.,Hippocampus,BAO_0000218,,,,Expert,12210,,H,8,CHEMBL615458,,10000000.0,
589,1,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,Hippocampus,BAO_0000221,,,,Expert,13311,,H,8,CHEMBL615459,,10000000.0,
590,1,"Tested in vitro for the inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor, expressed in cloned CHO cells.",,BAO_0000219,,Homo sapiens,,Expert,2331,,D,9,CHEMBL615460,449.0,,
591,1,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig,,BAO_0000019,,Cavia porcellus,,Autocuration,1375,,H,8,CHEMBL615461,,,
592,1,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig; NT means not tested,,BAO_0000019,,Cavia porcellus,,Autocuration,1375,,H,8,CHEMBL615462,,,
593,1,Effect on forskolin stimulated adenylate cyclase activity at 5-hydroxytryptamine 1A receptor of guinea pig hippocampus.,Hippocampus,BAO_0000221,,Cavia porcellus,,Autocuration,11574,,H,8,CHEMBL615463,,10000000.0,
594,1,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,Ileum,BAO_0000221,,Cavia porcellus,,Autocuration,12867,,H,8,CHEMBL615464,,2116.0,
595,1,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,Ileum,BAO_0000221,,Cavia porcellus,,Autocuration,12867,,H,8,CHEMBL615465,,2116.0,
596,1,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,Ileum,BAO_0000221,,Cavia porcellus,,Autocuration,12867,,H,8,CHEMBL615466,,2116.0,
597,1,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,Ileum,BAO_0000221,,Cavia porcellus,,Autocuration,12867,,H,8,CHEMBL615467,,2116.0,
598,1,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,Ileum,BAO_0000221,,Cavia porcellus,,Autocuration,12867,,H,8,CHEMBL615468,,2116.0,
599,1,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor; Inactive at dose level of 1.0 uM,Ileum,BAO_0000221,,Cavia porcellus,,Autocuration,12867,,H,8,CHEMBL615469,,2116.0,
600,1,Binding affinity against 5-hydroxytryptamine 1A receptor,,BAO_0000357,,Cavia porcellus,,Autocuration,11574,,H,8,CHEMBL615470,,,
601,1,Compound is evaluated for in vitro receptor binding affinity against 5-hydroxytryptamine 1A receptor,,BAO_0000357,,Cavia porcellus,,Autocuration,13114,,H,8,CHEMBL615471,,,
602,1,Binding affinity was determined against 5-hydroxytryptamine 1A receptor,,BAO_0000357,,Cavia porcellus,,Autocuration,13181,,H,8,CHEMBL615472,,,
603,1,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,Hippocampus,BAO_0000221,,Cavia porcellus,,Autocuration,10639,,H,8,CHEMBL883242,,10000000.0,
604,1,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,Hippocampus,BAO_0000221,,Cavia porcellus,,Autocuration,10639,,H,8,CHEMBL615473,,10000000.0,
605,1,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),,BAO_0000218,,Cricetulus griseus,,Autocuration,11883,,H,8,CHEMBL615474,449.0,,
606,1,Fraction involved in salt bridge interactions with Asp3:11 part of the 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Autocuration,17785,,H,8,CHEMBL615475,,,
607,1,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-HT 1A receptor in HeLa cells; value ranges from 85-370,,BAO_0000219,,,,Autocuration,1558,,H,8,CHEMBL615476,308.0,,
608,1,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1A receptor in HeLa cells; value ranges from 95-320,,BAO_0000219,,,,Autocuration,1558,,H,8,CHEMBL615477,308.0,,
609,1,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,,BAO_0000019,,,,Autocuration,15740,,H,8,CHEMBL615478,,,
610,1,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,,BAO_0000219,,,,Autocuration,17624,,H,8,CHEMBL615160,449.0,,
611,1,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,,BAO_0000219,,,,Expert,17624,,H,8,CHEMBL615161,449.0,,
612,1,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=Not determined,,BAO_0000219,,,,Autocuration,17624,,H,8,CHEMBL615162,449.0,,
613,1,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=not determined,,BAO_0000219,,,,Autocuration,17624,,H,8,CHEMBL615163,449.0,,
614,1,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,BAO_0000219,,,,Expert,17624,,H,8,CHEMBL615164,449.0,,
615,1,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,BAO_0000219,,,,Expert,17624,,H,8,CHEMBL615165,449.0,,
616,1,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells; nd=not determined,,BAO_0000219,,,,Autocuration,17624,,H,8,CHEMBL615166,449.0,,
617,1,In vitro potency at human 5-hydroxytryptamine 1A receptor in inhibiting forskolin-stimulated accumulation of intracellular cAMP,,BAO_0000219,,,,Autocuration,14256,,H,8,CHEMBL615167,,,
618,1,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,,BAO_0000219,,Homo sapiens,,Expert,3445,,D,9,CHEMBL615168,308.0,,
619,1,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells; Inverse,,BAO_0000219,,Homo sapiens,,Expert,3445,,D,9,CHEMBL615169,308.0,,
620,1,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor,,BAO_0000219,,Homo sapiens,,Expert,17200,,D,9,CHEMBL615170,449.0,,
621,1,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor; Not determined,,BAO_0000219,,Homo sapiens,,Expert,17200,,D,9,CHEMBL615171,449.0,,
622,1,Eudisimic ratio(ER) is the antilog of the defference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,,BAO_0000019,,,,Autocuration,15180,,H,8,CHEMBL615694,,,
623,1,Eudisimic ratio(ER) is the antilog of the difference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,,BAO_0000019,,,,Autocuration,15180,,H,8,CHEMBL615695,,,
624,1,"Percent of maximum effect on binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,BAO_0000019,,,,Autocuration,16026,,H,8,CHEMBL615696,,,
625,1,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,BAO_0000219,,,,Autocuration,2759,,H,8,CHEMBL615697,449.0,,
626,1,Agonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),,BAO_0000219,,Homo sapiens,,Expert,2759,,D,9,CHEMBL859410,449.0,,
627,1,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),,BAO_0000219,,,,Autocuration,2759,,H,8,CHEMBL615841,449.0,,
628,1,Agonistic efficacy in adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),,BAO_0000219,,Homo sapiens,,Expert,2759,,D,9,CHEMBL615842,449.0,,
629,1,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,BAO_0000219,,,,Autocuration,2759,,H,8,CHEMBL835003,449.0,,
630,1,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 1),,BAO_0000219,,,,Autocuration,2759,,H,8,CHEMBL615843,449.0,,
631,1,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),,BAO_0000219,,Homo sapiens,,Expert,2759,,D,9,CHEMBL615979,449.0,,
632,1,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),,BAO_0000219,,,,Autocuration,2759,,H,8,CHEMBL615980,449.0,,
633,1,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),,BAO_0000219,,Homo sapiens,,Expert,2759,,D,9,CHEMBL615981,449.0,,
634,1,Percent efficacy against cloned human 5-hydroxytryptamine 1A receptor normalized to the maximal 5-HT response,,BAO_0000019,,Homo sapiens,,Expert,3445,,D,9,CHEMBL615982,,,
635,1,"Agonist activity at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,BAO_0000019,,Homo sapiens,,Expert,5272,,D,9,CHEMBL615983,,,
636,1,"Agonist activity at the 5-hydroxytryptamine 1A receptor in vitro using a [35S]GTP-gamma-S, No data",,BAO_0000019,,Homo sapiens,,Expert,5272,,D,9,CHEMBL615984,,,
637,1,"Agonist activity at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S,",,BAO_0000019,,Homo sapiens,,Expert,5272,,D,9,CHEMBL615985,,,
638,1,Agonistic effect against 5-HT1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,BAO_0000219,,,,Autocuration,17624,,H,8,CHEMBL615986,449.0,,
639,1,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,BAO_0000219,,,,Autocuration,17624,,H,8,CHEMBL615987,449.0,,
640,1,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,,BAO_0000219,,,,Autocuration,17624,,H,8,CHEMBL615988,449.0,,
641,1,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,BAO_0000219,,,,Expert,17624,,H,8,CHEMBL615989,449.0,,
642,1,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,,BAO_0000219,,,,Autocuration,17624,,H,8,CHEMBL615990,449.0,,
643,1,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=not determined,,BAO_0000219,,,,Autocuration,17624,,H,8,CHEMBL615991,449.0,,
644,1,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,BAO_0000219,,,,Autocuration,17624,,H,8,CHEMBL615992,449.0,,
645,1,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=Not determined,,BAO_0000219,,,,Autocuration,17624,,H,8,CHEMBL615993,449.0,,
646,1,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,BAO_0000219,,,,Expert,17624,,H,8,CHEMBL615994,449.0,,
647,1,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=not determined,,BAO_0000219,,,,Autocuration,17624,,H,8,CHEMBL615995,449.0,,
648,1,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,BAO_0000219,,,,Autocuration,17624,,H,8,CHEMBL615996,449.0,,
649,1,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35]GTPgammaS as radioligand in CHO cells relative to 5-HT; nd=Not determined,,BAO_0000219,,,,Autocuration,17624,,H,8,CHEMBL615997,449.0,,
650,1,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,BAO_0000019,,,,Autocuration,6563,,H,8,CHEMBL615998,,,
651,1,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,BAO_0000019,,,,Autocuration,6563,,H,8,CHEMBL615999,,,
652,1,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,,BAO_0000019,,,,Autocuration,6563,,H,8,CHEMBL616000,,,
653,1,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,BAO_0000219,,,,Autocuration,17296,,H,8,CHEMBL616001,722.0,,
654,1,"Evaluated for stimulation at 1 uM concentration expressed as percent of the maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine",,BAO_0000019,,Homo sapiens,,Expert,6876,,D,9,CHEMBL616002,,,
655,1,"Stimulation of percent maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine at 1 uM; nd = not determined",,BAO_0000019,,,,Expert,6876,,H,8,CHEMBL616003,,,
656,1,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor,,BAO_0000019,,Homo sapiens,,Expert,5272,,D,9,CHEMBL616004,,,
657,1,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor; No data,,BAO_0000019,,Homo sapiens,,Expert,5272,,D,9,CHEMBL616005,,,
658,1,"Maximal response as a result of 5-HT1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,BAO_0000019,,,,Autocuration,5548,,H,8,CHEMBL616006,,,
659,1,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding",,BAO_0000019,,,,Expert,5548,,H,8,CHEMBL616007,,,
660,1,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,BAO_0000019,,,,Autocuration,5548,,H,8,CHEMBL616008,,,
661,1,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,BAO_0000019,,,,Autocuration,5548,,H,8,CHEMBL616009,,,
662,1,"Maximal stimulation of expressed human 5-hydroxytryptamine 1A receptor assayed by [35S]GTP-gamma-S, binding",,BAO_0000019,,,,Expert,5929,,H,8,CHEMBL616010,,,
663,1,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND means not determined",,BAO_0000019,,Homo sapiens,,Expert,5929,,D,9,CHEMBL616011,,,
664,1,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND=Not determined",,BAO_0000019,,Homo sapiens,,Expert,5929,,D,9,CHEMBL615740,,,
665,1,"Maximal stimulation was expressed as percentage of the maximal 5-HT response in the [35S]GTP-gamma-S, binding assay on 5-hydroxytryptamine 1A receptor",,BAO_0000019,,,,Autocuration,16245,,H,8,CHEMBL615741,,,
666,1,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",,BAO_0000019,,,,Expert,5640,,H,8,CHEMBL615742,,,
667,1,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Emin (%): not determined",,BAO_0000019,,,,Autocuration,5640,,H,8,CHEMBL615743,,,
668,1,Antagonist activity was measured against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay,,BAO_0000219,,,,Autocuration,14509,,H,8,CHEMBL615744,449.0,,
669,1,Antagonist activity against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay.,,BAO_0000219,,,,Expert,14509,,H,8,CHEMBL615745,449.0,,
670,1,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,BAO_0000357,,,,Autocuration,15331,,H,8,CHEMBL615746,,,
671,1,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,BAO_0000357,,,,Autocuration,15331,,H,8,CHEMBL615747,,,
672,1,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,BAO_0000019,,,,Autocuration,6563,,H,8,CHEMBL615748,,,
673,1,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay; NA indicates not available",,BAO_0000019,,,,Autocuration,6563,,H,8,CHEMBL615749,,,
674,1,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,,BAO_0000019,,,,Autocuration,6563,,H,8,CHEMBL615750,,,
675,1,Forskolin stimulated cAMP assessment of agonist activity for 5-hydroxytryptamine 1A receptor,,BAO_0000019,,Homo sapiens,,Expert,6563,,D,9,CHEMBL616259,,,
676,1,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,BAO_0000019,,,,Autocuration,6563,,H,8,CHEMBL616260,,,
677,1,Antagonism of 5-hydroxytryptamine 1A receptor determined in vitro,,BAO_0000019,,Homo sapiens,,Expert,5272,,D,9,CHEMBL616261,,,
678,1,"Antagonism of 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,BAO_0000019,,Homo sapiens,,Expert,5272,,D,9,CHEMBL616262,,,
679,1,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",,BAO_0000019,,Homo sapiens,,Expert,5272,,D,9,CHEMBL616263,,,
680,1,Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro; No data,,BAO_0000019,,Homo sapiens,,Expert,5272,,D,9,CHEMBL616264,,,
681,1,Antagonism at the 5-hydroxytryptamine 1A receptor in vitro,,BAO_0000019,,Homo sapiens,,Expert,5272,,D,9,CHEMBL616265,,,
682,1,"Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,BAO_0000019,,Homo sapiens,,Expert,5272,,D,9,CHEMBL616266,,,
683,1,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",,BAO_0000019,,Homo sapiens,,Expert,5272,,D,9,CHEMBL616267,,,
684,1,Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro; No data,,BAO_0000019,,Homo sapiens,,Expert,5272,,D,9,CHEMBL616268,,,
685,1,Inhibition of human 5-hydroxytryptamine 1A receptor,,BAO_0000357,,Homo sapiens,,Expert,16146,,D,9,CHEMBL616269,,,
686,1,Binding affinity against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,BAO_0000219,,,,Autocuration,17624,,H,8,CHEMBL884528,449.0,,
687,1,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor alpha expressed in HEK 293 cells,,BAO_0000219,,,,Expert,13706,,D,9,CHEMBL616270,722.0,,
688,1,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1A receptor stably expressed in CHO cells,,BAO_0000219,,,,Autocuration,15250,,H,8,CHEMBL616271,449.0,,
689,1,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,BAO_0000219,,,,Autocuration,17624,,H,8,CHEMBL616272,449.0,,
690,1,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in human CYP3A4 assay,,BAO_0000357,,,,Expert,6861,,H,8,CHEMBL616273,,,
691,1,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,,BAO_0000357,,Homo sapiens,,Expert,17200,,D,9,CHEMBL616274,,,
692,1,Inhibition concentration against 5-HT 1A receptor using cAMP as radioligand in CHO cells,,BAO_0000219,,,,Autocuration,17624,,H,8,CHEMBL616275,449.0,,
693,1,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,BAO_0000219,,,,Autocuration,17624,,H,8,CHEMBL616276,449.0,,
694,1,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,,BAO_0000218,,Rattus norvegicus,,Autocuration,12058,In vivo,U,0,CHEMBL616277,,,
695,1,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration; Inactive,,BAO_0000218,,Rattus norvegicus,,Autocuration,12058,In vivo,U,0,CHEMBL616278,,,
696,1,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration,,BAO_0000218,,Rattus norvegicus,,Autocuration,12058,In vivo,U,0,CHEMBL616279,,,
697,1,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,,BAO_0000218,,Rattus norvegicus,,Autocuration,12058,In vivo,U,0,CHEMBL616280,,,
698,1,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Partial response at the highest dose tested,,BAO_0000218,,Rattus norvegicus,,Autocuration,12058,In vivo,U,0,CHEMBL616281,,,
699,1,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,,BAO_0000218,,Rattus norvegicus,,Autocuration,12058,In vivo,U,0,CHEMBL616282,,,
700,1,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration,,BAO_0000218,,Rattus norvegicus,,Autocuration,12058,In vivo,U,0,CHEMBL616283,,,
701,1,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration; Inactive,,BAO_0000218,,Rattus norvegicus,,Autocuration,12058,In vivo,U,0,CHEMBL616284,,,
702,1,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration,,BAO_0000218,,Rattus norvegicus,,Autocuration,12058,In vivo,U,0,CHEMBL616285,,,
703,1,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; Inactive,,BAO_0000218,,Rattus norvegicus,,Autocuration,12058,In vivo,U,0,CHEMBL616286,,,
704,1,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; partial response at the highest dose tested,,BAO_0000218,,Rattus norvegicus,,Autocuration,12058,In vivo,U,0,CHEMBL616287,,,
705,1,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration,,BAO_0000218,,Rattus norvegicus,,Autocuration,12058,In vivo,U,0,CHEMBL616288,,,
706,1,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Inactive,,BAO_0000218,,Rattus norvegicus,,Autocuration,12058,In vivo,U,0,CHEMBL616289,,,
707,1,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Partial response at the highest dose tested,,BAO_0000218,,Rattus norvegicus,,Autocuration,12058,In vivo,U,0,CHEMBL615610,,,
708,1,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration,,BAO_0000218,,Rattus norvegicus,,Autocuration,12058,In vivo,U,0,CHEMBL615611,,,
709,1,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Inactive,,BAO_0000218,,Rattus norvegicus,,Autocuration,12058,In vivo,U,0,CHEMBL615612,,,
710,1,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Partial response at the highest dose tested,,BAO_0000218,,Rattus norvegicus,,Autocuration,12058,In vivo,U,0,CHEMBL615613,,,
711,1,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; partial response at the highest dose tested,,BAO_0000218,,Rattus norvegicus,,Autocuration,12058,In vivo,U,0,CHEMBL615614,,,
712,1,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,,BAO_0000218,,Rattus norvegicus,,Autocuration,12058,In vivo,U,0,CHEMBL615615,,,
713,1,Affinity in displacing [125I](R)-DOI from rat cortical homogenate 5-HT2 receptor.,,BAO_0000019,,,,Autocuration,11440,,H,4,CHEMBL615616,,,
714,1,Binding affinity towards 5-HT 7 receptor in rat hypothalamus membranes using [3H]5-CT as radioligand,Hypothalamus,BAO_0000249,,,,Autocuration,6238,,H,8,CHEMBL615617,,1898.0,
715,1,Inhibitory activity against 5-HT1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data,,BAO_0000019,,,,Autocuration,10046,,H,8,CHEMBL615618,,,
716,1,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data.,,BAO_0000019,,,,Autocuration,10046,,H,8,CHEMBL615619,,,
717,1,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,,BAO_0000019,,,,Expert,10046,,H,8,CHEMBL615620,,,
718,1,"Inhibitory activity against human whole blood, LTB4 5-lipoxygenase was evaluated",,BAO_0000357,,,,Autocuration,167,,H,8,CHEMBL615621,,,
719,1,"Inhibitory activity against intact human PMNL, LTB4 5-lipoxygenase was evaluated",,BAO_0000357,,,,Autocuration,167,,H,8,CHEMBL615622,,,
720,1,Compound was evaluated for the inhibition of 5-LO (lipoxygenase),,BAO_0000019,,,,Autocuration,11520,,H,8,CHEMBL615623,,,
721,1,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,BAO_0000019,,,,Autocuration,11520,,H,8,CHEMBL615624,,,
722,1,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,BAO_0000019,,,,Autocuration,11520,,H,8,CHEMBL615625,,,
723,1,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,BAO_0000019,,,,Autocuration,11520,,H,8,CHEMBL767045,,,
724,1,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN,,BAO_0000019,,Cavia porcellus,,Autocuration,135,,H,8,CHEMBL615626,,,
725,1,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN; not active at the highest concentration (3 ug/mL) tested; No activity,,BAO_0000019,,Cavia porcellus,,Autocuration,135,,H,8,CHEMBL615627,,,
726,1,The compound was tested for inhibitory activity against 5-Lipoxygenase in guinea pig polymorphonuclear leukocytes,,BAO_0000019,,Cavia porcellus,,Autocuration,11311,,H,8,CHEMBL615628,,,
727,1,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,,BAO_0000357,,Cavia porcellus,,Autocuration,10193,,H,8,CHEMBL615629,,,
728,1,Inhibitory concentration against 5-lipoxygenase from human whole blood,,BAO_0000357,,Homo sapiens,,Expert,12281,,D,9,CHEMBL615630,,,
729,1,The compound was tested for inhibitory activity against 5-Lipoxygenase in human polymorphonuclear leukocytes[PMNS],,BAO_0000219,,,,Autocuration,11311,,H,8,CHEMBL615631,,,
730,1,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,,BAO_0000218,,,,Autocuration,12576,,H,8,CHEMBL615632,,,
731,1,Inhibitory concentration against 5-lipoxygenase from mouse macrophage,,BAO_0000357,,,,Autocuration,12281,,H,8,CHEMBL615633,,,
732,1,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,,BAO_0000218,,,,Autocuration,12576,,H,8,CHEMBL615634,,,
733,1,Inhibition of arachidonate 5-lipoxygenase purified from porcine leukocytes.,,BAO_0000019,,Sus scrofa,,Expert,11089,,H,8,CHEMBL615635,,,
734,1,In vitro inhibition of rat 5-Lipoxygenase,,BAO_0000357,,,,Expert,11006,,H,8,CHEMBL615636,,,
735,1,Inhibitory activity against 5-Lipoxygenase,,BAO_0000357,,Rattus norvegicus,,Expert,11481,,D,9,CHEMBL615637,,,
736,1,Inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells,,BAO_0000219,,,,Expert,10864,,H,8,CHEMBL615638,702.0,,
737,1,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),,BAO_0000219,,,,Autocuration,3595,,H,8,CHEMBL615639,702.0,,
738,1,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat RBL-1,,BAO_0000219,,,,Autocuration,11311,,H,8,CHEMBL615640,702.0,,
739,1,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat blood,,BAO_0000019,,,,Autocuration,11311,,H,8,CHEMBL615796,,,
740,1,The compound was tested for inhibitory activity against 5-Lipoxygenase receptor in rat polymorphonuclear leukocytes[PMNS],,BAO_0000219,,,,Autocuration,11311,,H,8,CHEMBL615845,,,
741,1,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,,BAO_0000357,,,,Autocuration,11006,,H,8,CHEMBL615846,,,
742,1,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,,BAO_0000219,,,,Autocuration,3595,,H,8,CHEMBL615847,702.0,,
743,1,The compound was tested for inhibition of isolated 5-Lipoxygenase,,BAO_0000357,,,,Autocuration,11311,,H,8,CHEMBL615848,,,
744,1,Ratio of IC50 against 5-LO and COX,,BAO_0000019,,Rattus norvegicus,,Autocuration,11481,,U,0,CHEMBL615849,,,
745,1,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,,BAO_0000357,,,,Autocuration,11006,,H,8,CHEMBL615850,,,
746,1,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM; range is 20-35%,,BAO_0000357,,,,Autocuration,11006,,H,8,CHEMBL615851,,,
747,1,The compound was tested for inhibition against 5-Lipoxygenase in rat polymorphonuclear leukocytes at 10 uM concentration,,BAO_0000219,,,,Autocuration,11311,,H,8,CHEMBL615852,,,
748,1,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) ex vivo,,BAO_0000019,,,,Autocuration,11006,,H,8,CHEMBL615853,,,
749,1,Compound was tested for the inhibition of type 2 5-alpha-reductase of human prostates,Prostate gland,BAO_0000357,,,,Autocuration,4288,,H,8,CHEMBL884527,,2367.0,
750,1,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-4 M inhibitory concentration,,BAO_0000019,,Columba livia,,Autocuration,7587,,U,0,CHEMBL872871,,,
751,1,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-5 M inhibitory concentration,,BAO_0000019,,Columba livia,,Autocuration,7587,,U,0,CHEMBL615854,,,
752,1,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme.,,BAO_0000019,,Columba livia,,Autocuration,7587,,U,0,CHEMBL767046,,,
753,1,Compound was evaluated for the inhibition of 5-aminoimidazole-4-carboxamide ribonucleotide transformylase obtained from human at 100 uM,,BAO_0000357,,,,Autocuration,11249,,H,8,CHEMBL615855,,,
754,1,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT); NT = Not Tested,,BAO_0000019,,Rattus norvegicus,,Expert,8003,,D,9,CHEMBL615856,,,
755,1,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),,BAO_0000019,,Rattus norvegicus,,Expert,8003,,D,9,CHEMBL615857,,,
756,1,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),,BAO_0000019,,Rattus norvegicus,,Expert,8003,,D,9,CHEMBL615858,,,
757,1,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,Hippocampus,BAO_0000221,,,,Expert,12416,,H,8,CHEMBL615859,,10000000.0,
758,1,Binding affinity towards human 5-hydroxytryptamine 1 receptor,,BAO_0000357,,,,Autocuration,16293,,H,8,CHEMBL615860,,,
759,1,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,BAO_0000019,,Oryctolagus cuniculus,,Autocuration,13047,,U,0,CHEMBL615861,,,
760,1,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,BAO_0000019,,Oryctolagus cuniculus,,Autocuration,13047,,U,0,CHEMBL615862,,,
761,1,Binding affinity against 5-hydroxytryptamine 1D receptor using rabbit saphenous vein assay.,,BAO_0000019,,Oryctolagus cuniculus,,Autocuration,13047,,U,0,CHEMBL615863,,,
762,1,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,,BAO_0000019,,Oryctolagus cuniculus,,Autocuration,13047,,U,0,CHEMBL615864,,,
763,1,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,Hippocampus,BAO_0000221,,,,Autocuration,10085,,H,4,CHEMBL615865,,10000000.0,
764,1,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,Hippocampus,BAO_0000221,,,,Autocuration,10085,,H,4,CHEMBL615866,,10000000.0,
765,1,Ability to bind at serotonin 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,Hippocampus,BAO_0000221,,,,Autocuration,10085,,H,4,CHEMBL615867,,10000000.0,
766,1,Ability to inhibit binding of titreated serotonin to the 5-hydroxytryptamine 1 receptor in rat brain frontal cortex membranes,,BAO_0000249,,,,Autocuration,9841,,H,4,CHEMBL615868,,,
767,1,Binding affinity towards 5-hydroxytryptamine 1 receptor in brain cortical membranes of rat,,BAO_0000249,,Rattus norvegicus,,Autocuration,8822,,D,5,CHEMBL615869,,,
768,1,Binding affinity towards 5-hydroxytryptamine 1 receptor in rat frontal cortex homogenates using [3H]5-HT as a radioligand,,BAO_0000019,,Rattus norvegicus,,Autocuration,9806,,D,5,CHEMBL615870,,,
769,1,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as a radioligand from rat frontal cortex homogenates,,BAO_0000019,,Rattus norvegicus,,Autocuration,9806,,D,5,CHEMBL615871,,,
770,1,Binding affinity towards 5-hydroxytryptamine 1 receptor was measured using radioligand ([3H]5-HT) binding assay,,BAO_0000224,,,,Autocuration,8868,,H,4,CHEMBL615872,,,
771,1,Binding affinity towards hippocampus 5-hydroxytryptamine 1 receptor was measured using radioligand [3H]5-HT,Hippocampus,BAO_0000221,,,,Autocuration,9036,,H,4,CHEMBL833492,,10000000.0,
772,1,Compound was evaluated for the inhibition of [3H]5-HT (concentration of 12 nM) specific binding to rat hippocampus,Hippocampus,BAO_0000221,,,,Autocuration,11374,,H,4,CHEMBL615873,,10000000.0,
773,1,Inhibitory activity against 5-hydroxytryptamine 1 receptor by 3H ligand binding experiments.,,BAO_0000224,,,,Autocuration,10881,,H,4,CHEMBL615479,,,
774,1,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat,,BAO_0000019,,,,Autocuration,8822,,H,4,CHEMBL615480,,,
775,1,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat cortical membrane homogenates using radioligand ([3H]5-HT) binding assay.,,BAO_0000249,,Rattus norvegicus,,Autocuration,9806,,D,5,CHEMBL615481,,,
776,1,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,BAO_0000019,,,,Autocuration,15463,,H,4,CHEMBL872869,,,
777,1,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,BAO_0000019,,,,Autocuration,15463,,H,4,CHEMBL615482,,,
778,1,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,Brain,BAO_0000221,,,,Autocuration,14542,,H,4,CHEMBL615483,,955.0,
779,1,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,Brain,BAO_0000221,,,,Autocuration,14542,,H,4,CHEMBL615484,,955.0,
780,1,Percent inhibition of 5-hydroxytryptamine 1 receptor from rat cortex membrane using [3H]- serotonin as radioligand at 33 uM,,BAO_0000019,,,,Autocuration,8569,,H,4,CHEMBL615485,,,
781,1,Inhibition of [3H]5-HT radioligand binding against 5-hydroxytryptamine 1 receptor,,BAO_0000224,,Rattus norvegicus,,Autocuration,10062,,D,5,CHEMBL615486,,,
782,1,Ancillary Binding affinity towards rat 5-hydroxytryptamine 1 receptor,,BAO_0000224,,,,Autocuration,4771,,H,4,CHEMBL615487,,,
783,1,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,BAO_0000224,,,,Autocuration,10062,,H,4,CHEMBL615488,,,
784,1,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,BAO_0000224,,,,Autocuration,10062,,H,4,CHEMBL615489,,,
785,1,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,BAO_0000224,,,,Autocuration,10062,,H,4,CHEMBL615389,,,
786,1,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,,BAO_0000019,,,,Autocuration,15463,,H,4,CHEMBL615390,,,
787,1,Binding affinity towards central 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,,BAO_0000019,,,,Autocuration,15463,,H,4,CHEMBL615391,,,
788,1,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined,,BAO_0000224,,,,Autocuration,9098,,H,4,CHEMBL615392,,,
789,1,Affinity for 5-hydroxytryptamine 1 receptor,,BAO_0000019,,Rattus norvegicus,,Autocuration,3070,,U,0,CHEMBL615393,,,
790,1,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex,Brain,BAO_0000221,,,,Autocuration,14542,,H,4,CHEMBL615394,,955.0,
791,1,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,Brain,BAO_0000221,,,,Autocuration,14542,,H,4,CHEMBL615395,,955.0,
792,1,Compound was evaluated for 5-hydroxytryptamine 1 receptor binding,,BAO_0000224,,,,Autocuration,6398,,H,4,CHEMBL615396,,,
793,1,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 1 receptor in rat brain using [3H]HT radioligand assay,Brain,BAO_0000221,,,,Autocuration,1344,,H,4,CHEMBL615397,,955.0,
794,1,Displacement of binding of [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,BAO_0000019,,,,Autocuration,11963,,H,4,CHEMBL615398,,,
795,1,Displacement of [3H]spiperone from 5-hydroxytryptamine 1 receptor of rat cortex,,BAO_0000019,,Rattus norvegicus,,Autocuration,8908,,U,0,CHEMBL615399,,,
796,1,Evaluated for binding affinity towards rat cortical membranes at 5-hydroxytryptamine 1 receptor binding site by using [3H]-5-HT as a radioligand.,,BAO_0000019,,,,Autocuration,9098,,H,4,CHEMBL615400,,,
797,1,Binding affinity for 5-hydroxytryptamine 1 receptor of rat prefrontal cortex,,BAO_0000019,,Rattus norvegicus,,Autocuration,8841,,D,5,CHEMBL615401,,,
798,1,Displacement of [3H]5-HT from 5-hydroxytryptamine 1 receptor of rat cortical membrane homogenates,,BAO_0000019,,Rattus norvegicus,,Autocuration,8814,,U,0,CHEMBL615402,,,
799,1,The ability to inhibit [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cortex,,BAO_0000019,,,,Autocuration,11752,,H,4,CHEMBL615403,,,
800,1,The binding affinity was measured on serotonin 5-hydroxytryptamine 1 receptor in rat brain tissue,Brain,BAO_0000221,,,,Autocuration,11642,,H,4,CHEMBL615404,,955.0,
801,1,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1 receptor by displacing [3H]5-HT radioligand in rat cerebral cortex,,BAO_0000019,,,,Autocuration,11642,,H,4,CHEMBL615781,,,
802,1,Tested for 5-hydroxytryptamine 1 receptor binding ability by displacement of [3H]5-HT from rat brain synaptosomes,Brain,BAO_0000220,,,,Autocuration,9231,,H,4,CHEMBL615782,,955.0,
803,1,Inhibition constant (1 uM) was measured on 5-hydroxytryptamine 1 receptor/uptake using [3H]- serotonin as radioligand in rat brain cortex.,Brain,BAO_0000221,,,,Autocuration,11351,,H,4,CHEMBL615783,,955.0,
804,1,Compound was tested for binding affinity against 5-HT1 receptor,,BAO_0000019,,,,Autocuration,4639,,U,0,CHEMBL873481,,,
805,1,Inhibitory concentration against 5-hydroxytryptamine 1 receptor,,BAO_0000019,,,,Autocuration,1205,,U,0,CHEMBL615784,,,
806,1,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,,BAO_0000357,,,,Expert,10025,,H,8,CHEMBL615785,,,
807,1,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",,BAO_0000249,,,,Autocuration,13241,,H,8,CHEMBL615786,,,
808,1,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,,BAO_0000218,,,,Autocuration,16245,In vivo,H,8,CHEMBL615787,,,
809,1,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,,BAO_0000218,,,,Autocuration,16245,In vivo,H,8,CHEMBL615788,,,
810,1,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor,,BAO_0000019,,,,Autocuration,12438,,H,8,CHEMBL767044,,,
811,1,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,,BAO_0000218,,,,Autocuration,16245,In vivo,H,8,CHEMBL615789,,,
812,1,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,,BAO_0000218,,,,Autocuration,16245,In vivo,H,8,CHEMBL615790,,,
813,1,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats,,BAO_0000019,,,,Autocuration,15740,,H,8,CHEMBL615813,,,
814,1,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 10 uM concentration,,BAO_0000219,,,,Autocuration,15535,,H,8,CHEMBL615814,,,
815,1,Percent inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation in GH4ZD10 cells expressing 5-HT1A receptor at 50 uM relative to 5-HT,,BAO_0000219,,,,Expert,15535,,H,8,CHEMBL615815,,,
816,1,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 50 uM concentration; No effect,,BAO_0000219,,,,Autocuration,15535,,H,8,CHEMBL615816,,,
817,1,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes expressed as Hill values,,BAO_0000249,,,,Expert,9888,,H,8,CHEMBL615817,,,
818,1,Ability to bind at 5-hydroxytryptamine 1A receptor of rat hippocampus by displacing [3H]8-OH-DPAT,Hippocampus,BAO_0000221,,,,Autocuration,10085,,H,8,CHEMBL615818,,10000000.0,
819,1,Ability to bind at serotonin 5-hydroxytryptamine 1A receptors of rat hippocampus by displacing [3H]8-OH-DPAT,Hippocampus,BAO_0000221,,,,Autocuration,10085,,H,8,CHEMBL615819,,10000000.0,
820,1,Binding affinity against 5-hydroxytryptamine 1A receptor (5-HT1A) by displacement of [3H]8-OH-DPAT from rat hippocampus membranes,,BAO_0000249,,,,Expert,17331,,H,8,CHEMBL615820,,,
821,1,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]8-OH-DPAT,Hippocampus,BAO_0000221,,Rattus norvegicus,,Expert,10845,,D,9,CHEMBL615821,,10000000.0,
822,1,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,Hippocampus,BAO_0000221,,Rattus norvegicus,,Expert,10845,,D,9,CHEMBL615822,,10000000.0,
823,1,Binding affinity against 5-hydroxytryptamine 1A receptor using in rat hippocampal tissue using [3H]8-OH-DPAT as radioligand,Hippocampus,BAO_0000221,,,,Expert,10845,,H,8,CHEMBL615823,,10000000.0,
824,1,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor; IA-Inactive,Hippocampus,BAO_0000221,,Rattus norvegicus,,Expert,10845,,D,9,CHEMBL615824,,10000000.0,
825,1,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,Hippocampus,BAO_0000221,,Rattus norvegicus,,Expert,10845,,D,9,CHEMBL615825,,10000000.0,
826,1,Binding affinity towards rat 5-hydroxytryptamine 1A receptor was evaluated using [3H]8-OH-DPAT as radioligand,,BAO_0000357,,,,Expert,13730,,H,8,CHEMBL615826,,,
827,1,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using [3H]8-OH-DPAT as radioligand,,BAO_0000249,,,,Expert,13508,,H,8,CHEMBL615827,,,
828,1,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus membrane using [3H]8-OH-DPAT as radioligand,Hippocampus,BAO_0000249,,,,Expert,13508,,H,8,CHEMBL615828,,10000000.0,
829,1,Binding affinity by measuring displacement of [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,Hippocampus,BAO_0000221,,,,Expert,12073,,H,8,CHEMBL615829,,10000000.0,
830,1,Binding affinity to 5-hydroxytryptamine 1A receptor of rat hippocampus with [3H]8-OH-DPAT as radioligand,Hippocampus,BAO_0000221,,,,Autocuration,4671,,H,8,CHEMBL615830,,10000000.0,
831,1,Binding affinity towards serotonin 5-HT1A receptor was determined in rat hippocampus using [3H]8-OH-DPAT as ligand,Hippocampus,BAO_0000221,,,,Expert,13631,,H,8,CHEMBL615831,,10000000.0,
832,1,Binding affinity was measured against serotonin 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Autocuration,12438,,H,8,CHEMBL615832,,,
833,1,Binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH- DPAT as radioligand,,BAO_0000019,,,,Autocuration,10483,,H,8,CHEMBL615833,,,
834,1,Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]-8-OH- DPAT as radioligand,Hippocampus,BAO_0000221,,,,Autocuration,10483,,H,8,CHEMBL615834,,10000000.0,
835,1,Binding affinity against 5-hydroxytryptamine 1A (5-HT1A) receptor in rat hippocampus membranes,,BAO_0000249,,,,Intermediate,12352,,H,8,CHEMBL615835,,,
836,1,Binding affinity was measured at the serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampal membrane.,Hippocampus,BAO_0000249,,,,Autocuration,14732,,H,8,CHEMBL615836,,10000000.0,
837,1,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand.,,BAO_0000019,,Rattus norvegicus,,Expert,11049,,D,9,CHEMBL615837,,,
838,1,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand; ND-Not determined,,BAO_0000019,,Rattus norvegicus,,Expert,11049,,D,9,CHEMBL615838,,,
839,1,"Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding (NSB)",,BAO_0000249,,,,Expert,13657,,H,8,CHEMBL615839,,,
840,1,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH-DPAT as radioligand,,BAO_0000019,,,,Autocuration,11473,,H,8,CHEMBL884525,,,
841,1,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonin 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,,BAO_0000249,,,,Autocuration,2014,,H,8,CHEMBL615840,,,
842,1,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,Hippocampus,BAO_0000221,,,,Expert,3086,,H,8,CHEMBL615405,,10000000.0,
843,1,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,BAO_0000019,,,,Expert,15854,,H,8,CHEMBL615406,,,
844,1,Affinity for 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,Hippocampus,BAO_0000221,,,,Expert,10922,,H,8,CHEMBL615900,,10000000.0,
845,1,Inhibition of [3H]8-OH-DPAT binding at serotonin 5-hydroxytryptamine 1A receptor from rat hippocampus tissue.,Hippocampus,BAO_0000221,,,,Expert,13346,,H,8,CHEMBL615901,,10000000.0,
846,1,In vitro inhibition of [3H]8-OH-DPAT binding to rat 5-HT 1a receptors.,,BAO_0000357,,,,Expert,15311,,H,8,CHEMBL615902,,,
847,1,Compound was measured for affinity at 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,Hippocampus,BAO_0000221,,,,Autocuration,10922,,H,8,CHEMBL615903,,10000000.0,
848,1,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor<br>at 1 uM,,BAO_0000357,,,,Autocuration,10025,,H,8,CHEMBL615904,,,
849,1,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,,BAO_0000357,,,,Expert,10025,,H,8,CHEMBL615905,,,
850,1,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,,BAO_0000019,,,,Autocuration,9742,,H,8,CHEMBL615906,,,
851,1,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,,BAO_0000019,,,,Autocuration,9742,,H,8,CHEMBL615907,,,
852,1,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,BAO_0000019,,,,Expert,12304,,H,8,CHEMBL615908,,,
853,1,In vitro affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT in rat hippocampus,Hippocampus,BAO_0000221,,,,Autocuration,15789,,H,8,CHEMBL615909,,10000000.0,
854,1,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]-8-OH-DPAT as the radioligand",,BAO_0000019,,,,Autocuration,9912,,H,8,CHEMBL615910,,,
855,1,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand.",,BAO_0000019,,,,Autocuration,9912,,H,8,CHEMBL615911,,,
856,1,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand",,BAO_0000019,,,,Autocuration,9912,,H,8,CHEMBL615912,,,
857,1,In vitro binding affinity for serotonin 5-hydroxytryptamine 1A receptor fof rat cerebral cortex using [3H]8-OH-DPAT as radioligand,,BAO_0000019,,,,Expert,16693,,H,8,CHEMBL615913,,,
858,1,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,BAO_0000357,,,,Expert,13276,,H,8,CHEMBL615914,,,
859,1,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,Hippocampus,BAO_0000221,,,,Autocuration,12678,,H,8,CHEMBL615915,,10000000.0,
860,1,In vitro binding affinity towards the 5-hydroxytryptamine 1A receptor was evaluated,,BAO_0000357,,,,Autocuration,11825,,H,8,CHEMBL615916,,,
861,1,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 1A receptor by displacement of [3H]- tetralin,,BAO_0000357,,,,Expert,12443,,H,8,CHEMBL615917,,,
862,1,In vitro inhibitory activity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Expert,13830,,H,8,CHEMBL615918,,,
863,1,In vitro inhibitory concentration against radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane.,Hippocampus,BAO_0000249,,,,Expert,14286,,H,8,CHEMBL615919,,10000000.0,
864,1,In vitro radioligand binding assay on 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,Hippocampus,BAO_0000221,,Rattus norvegicus,,Expert,14356,,D,9,CHEMBL615920,,10000000.0,
865,1,Inhibition concentration against 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Autocuration,15306,,H,8,CHEMBL615921,,,
866,1,Inhibitory concentration against 5-hydroxytryptamine 1A receptor (Inactive at >1000 nM concentration),,BAO_0000357,,,,Expert,15306,,H,8,CHEMBL615922,,,
867,1,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",,BAO_0000249,,Rattus norvegicus,,Expert,16616,,D,9,CHEMBL881290,,,
868,1,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Residual radioligand binding higher than 50%",Hippocampus,BAO_0000221,,,,Autocuration,3651,,H,8,CHEMBL615923,,10000000.0,
869,1,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,Hippocampus,BAO_0000221,,,,Autocuration,14331,,H,8,CHEMBL615924,,10000000.0,
870,1,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,Hippocampus,BAO_0000221,,,,Autocuration,14331,,H,8,CHEMBL615925,,10000000.0,
871,1,Inhibition of radiolabeled [3H]-8-OH-DPAT ligand binding to 5-hydroxytryptamine 1A receptor,,BAO_0000357,,Rattus norvegicus,,Expert,14178,,D,9,CHEMBL615926,,,
872,1,Displacement of [3H]8-OH-DPAT from rat cortex 5-hydroxytryptamine 1A receptor,,BAO_0000019,,Rattus norvegicus,,Expert,10639,,D,9,CHEMBL615927,,,
873,1,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,Hippocampus,BAO_0000221,,,,Autocuration,12306,,H,8,CHEMBL615928,,10000000.0,
874,1,Inhibitory activity against 5-hydroxytryptamine 1A receptor subtype,,BAO_0000357,,Rattus norvegicus,,Expert,1348,,D,9,CHEMBL615929,,,
875,1,Inhibitory activity against [3H]DPAT binding to 5-HT1A receptor in rat hippocampus,Hippocampus,BAO_0000221,,,,Autocuration,13605,,H,8,CHEMBL615930,,10000000.0,
876,1,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,BAO_0000219,,,,Autocuration,17624,,H,8,CHEMBL615931,449.0,,
877,1,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,BAO_0000219,,,,Autocuration,17624,,H,8,CHEMBL615932,449.0,,
878,1,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,BAO_0000219,,,,Autocuration,17624,,H,8,CHEMBL615933,449.0,,
879,1,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Autocuration,15267,,H,8,CHEMBL615934,,,
880,1,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT; Not tested,,BAO_0000357,,,,Autocuration,16532,,H,8,CHEMBL615935,,,
881,1,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,BAO_0000019,,,,Autocuration,6563,,H,8,CHEMBL615936,,,
882,1,Ability to displace [3H]-8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor at a concentration of 1 uM,,BAO_0000219,,,,Autocuration,4751,,H,8,CHEMBL615937,449.0,,
883,1,Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Autocuration,15463,,H,8,CHEMBL615938,,,
884,1,In vitro binding affinity against human 5-hydroxytryptamine 1A receptor at a concentration of 100 (nM),,BAO_0000357,,,,Autocuration,3805,,H,8,CHEMBL615797,,,
885,1,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,BAO_0000357,,,,Autocuration,5640,,H,8,CHEMBL615798,,,
886,1,Inhibition of [3H]8-OH-DPAT binding to human 5-hydroxytryptamine 1A receptor at 1000 nM compound concentration,,BAO_0000357,,,,Autocuration,6563,,H,8,CHEMBL872870,,,
887,1,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand at 100 nM concentration,,BAO_0000357,,,,Autocuration,5548,,H,8,CHEMBL615799,,,
888,1,Percent binding affinity against 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Autocuration,6347,,H,8,CHEMBL615800,,,
889,1,Intrinsic activity for human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,BAO_0000219,,,,Autocuration,17296,,H,8,CHEMBL615801,722.0,,
890,1,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the absence of endothelium,,BAO_0000019,,,,Autocuration,13047,,H,8,CHEMBL615802,,,
891,1,Dissociation constant against human 5-hydroxytryptamine 1A receptor receptor,,BAO_0000357,,,,Autocuration,15740,,H,8,CHEMBL615803,,,
892,1,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",,BAO_0000019,,,,Expert,5640,,H,8,CHEMBL835002,,,
893,1,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Ki (nM): not determined",,BAO_0000019,,,,Autocuration,5640,,H,8,CHEMBL615804,,,
894,1,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor,,BAO_0000219,,,,Expert,17211,,H,8,CHEMBL615805,308.0,,
895,1,Ability to displace [3H]8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor,,BAO_0000219,,,,Autocuration,4751,,H,8,CHEMBL615806,449.0,,
896,1,Affinity towards human 5-hydroxytryptamine 1A serotonin receptor,,BAO_0000357,,Homo sapiens,,Expert,6491,,D,9,CHEMBL615807,,,
897,1,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT-as radioligand,,BAO_0000357,,,,Autocuration,4707,,H,8,CHEMBL615808,,,
898,1,Binding affinity against 5-hydroxytryptamine 1A receptor,,BAO_0000357,,Homo sapiens,,Expert,13910,,D,9,CHEMBL615809,,,
899,1,Binding affinity against 5-hydroxytryptamine 1A receptor in HeLa cells was determined using [3H]5-HT,,BAO_0000219,,,,Autocuration,16190,,H,8,CHEMBL615810,308.0,,
900,1,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,BAO_0000357,,,,Autocuration,16633,,H,8,CHEMBL615811,,,
901,1,Binding affinity against [3H]- -8-OH-DPAT -labeled 5-hydroxytryptamine 1A sites in cloned CHO cells,,BAO_0000219,,,,Autocuration,11898,,H,8,CHEMBL615812,449.0,,
902,1,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,BAO_0000219,,,,Autocuration,11898,,H,8,CHEMBL615751,449.0,,
903,1,Binding affinity against human 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Autocuration,14331,,H,8,CHEMBL615752,,,
904,1,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand,,BAO_0000219,,,,Expert,17624,,H,8,CHEMBL615753,449.0,,
905,1,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand; nd=not determined,,BAO_0000219,,,,Autocuration,17624,,H,8,CHEMBL615754,449.0,,
906,1,Binding affinity of compound to human 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Autocuration,3307,,H,8,CHEMBL615755,,,
907,1,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,,BAO_0000219,,Homo sapiens,,Expert,6563,,D,9,CHEMBL615756,449.0,,
908,1,Binding affinity for 5-hydroxytryptamine 1A receptor in HeLa transfected cell type using [3H]8-OH-DPAT as radioligand,,BAO_0000019,,,,Autocuration,14165,,H,8,CHEMBL615757,,,
909,1,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,,BAO_0000357,,,,Autocuration,5732,,H,8,CHEMBL615758,,,
910,1,In vitro affinity at human cloned 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,,BAO_0000357,,,,Expert,13366,,H,8,CHEMBL615759,,,
911,1,Binding affinity towards human 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Autocuration,17626,,H,8,CHEMBL615760,,,
912,1,Binding affinity towards human 5-hydroxytryptamine 1A receptor by the displacement of [3H]5-HT radioligand from the cloned receptor expressed in HeLa cells,,BAO_0000219,,,,Expert,6588,,H,8,CHEMBL615761,308.0,,
913,1,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]-5-HT as radioligand,,BAO_0000357,,,,Autocuration,16209,,H,8,CHEMBL872104,,,
914,1,Binding affinity towards recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,BAO_0000357,,,,Autocuration,15463,,H,8,CHEMBL615762,,,
915,1,Binding affinity towards recombinant human Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,BAO_0000357,,,,Autocuration,15463,,H,8,CHEMBL615763,,,
916,1,Binding affinity for recombinant human 5-hydroxytryptamine 1A receptor using [3H]5-HT as radioligand.,,BAO_0000357,,,,Autocuration,14770,,H,8,CHEMBL615764,,,
917,1,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines (He La),,BAO_0000219,,,,Autocuration,16245,,H,8,CHEMBL615765,1167.0,,
918,1,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines(He La),,BAO_0000019,,,,Autocuration,16245,,H,8,CHEMBL615766,,,
919,1,Binding affinity towards 5-HT1A receptor using [3H]8-OH-DPAT as radioligand,,BAO_0000357,,,,Autocuration,5548,,H,8,CHEMBL615767,,,
920,1,Binding affinity was determined towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,BAO_0000357,,,,Expert,5548,,H,8,CHEMBL615768,,,
921,1,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,BAO_0000357,,,,Autocuration,5548,,H,8,CHEMBL615769,,,
922,1,Binding affinity was evaluated at 5-hydroxytryptamine 1A receptor labeled with [3H]-8-OH-DPAT,,BAO_0000357,,,,Expert,6876,,H,8,CHEMBL615770,,,
923,1,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,BAO_0000357,,,,Autocuration,2598,,H,8,CHEMBL615771,,,
924,1,Binding affinity to human 5-hydroxytryptamine 1A receptor was measured using [3H]-8-hydroxy-2-(di-n-propylamine) tetraline [3H]8-OH-DPAT) as radioligand,,BAO_0000357,,,,Expert,17785,,H,8,CHEMBL615772,,,
925,1,Binding affinity towards 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Autocuration,6013,,H,8,CHEMBL615773,,,
926,1,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,,BAO_0000357,,,,Expert,5929,,H,8,CHEMBL615774,,,
927,1,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,BAO_0000357,,,,Autocuration,16633,,H,8,CHEMBL615775,,,
928,1,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,,BAO_0000357,,,,Autocuration,1558,,H,8,CHEMBL615776,,,
929,1,Binding affinity towards human cloned 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,BAO_0000357,,,,Expert,16026,,H,8,CHEMBL615777,,,
930,1,Binding affinity was measured on 5-hydroxytryptamine 1A receptor in AK cells transfected with human 5-HT1A gene labeled with [3H]-8-OH-DPAT,,BAO_0000219,,,,Autocuration,12469,,H,8,CHEMBL615778,,,
931,1,Binding affinity was measured on cloned Human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,BAO_0000357,,Homo sapiens,,Expert,15874,,D,9,CHEMBL615779,,,
932,1,Binding affinity was measured on cloned human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,BAO_0000357,,,,Autocuration,15874,,H,8,CHEMBL615780,,,
933,1,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Autocuration,3935,,H,8,CHEMBL616298,,,
934,1,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Autocuration,15818,,H,8,CHEMBL616299,,,
935,1,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells.,,BAO_0000219,,,,Autocuration,13706,,H,8,CHEMBL616300,485.0,,
936,1,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1A receptor in CHO-K1 cells,,BAO_0000219,,,,Expert,13729,,H,8,CHEMBL616301,485.0,,
937,1,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor,,BAO_0000019,,,,Autocuration,15413,,H,8,CHEMBL616302,,,
938,1,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 1),,BAO_0000019,,,,Autocuration,15413,,H,8,CHEMBL616117,,,
939,1,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 2),,BAO_0000019,,,,Autocuration,15413,,H,8,CHEMBL616118,,,
940,1,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor by Panlabs assay,,BAO_0000019,,,,Autocuration,15413,,H,8,CHEMBL616119,,,
941,1,Displacement of specific [3H]- 5-HT binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,,BAO_0000219,,Homo sapiens,,Expert,3445,,D,9,CHEMBL616120,308.0,,
942,1,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Autocuration,15740,,H,8,CHEMBL616121,,,
943,1,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor receptor,,BAO_0000357,,,,Autocuration,15740,,H,8,CHEMBL616122,,,
944,1,In vitro binding affinity tested on human 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Autocuration,17626,,H,8,CHEMBL616123,,,
945,1,In vitro binding affinity to human 5-hydroxytryptamine 1A receptor,,BAO_0000357,,Homo sapiens,,Expert,4234,,D,9,CHEMBL616124,,,
946,1,In vitro binding affinity at 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,,BAO_0000357,,,,Expert,5640,,H,8,CHEMBL616125,,,
947,1,In vitro binding affinity towards Human 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT,,BAO_0000357,,Rattus norvegicus,,Expert,5272,,H,8,CHEMBL616126,,,
948,1,In vitro binding affinity towards cloned human 5-hydroxytryptamine 1A receptor expressed in Chinese hamster ovary (CHO) cells using [3H]8-OH-DPAT as radioligand,,BAO_0000219,,,,Autocuration,4622,,H,8,CHEMBL616127,449.0,,
949,1,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor,,BAO_0000019,,,,Expert,17085,,H,8,CHEMBL616128,,,
950,1,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,,BAO_0000357,,,,Autocuration,3025,,H,8,CHEMBL616129,,,
951,1,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Expert,15315,,H,8,CHEMBL616130,,,
952,1,Inhibition of [3H]- OH-DPAT binding against 5-hydroxytryptamine 1A receptor from human recombinant,,BAO_0000357,,,,Autocuration,15267,,H,8,CHEMBL616131,,,
953,1,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor serotonergic receptor in human HeLa cells,,BAO_0000219,,,,Autocuration,17158,,H,8,CHEMBL616132,308.0,,
954,1,Receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor in HeLa cells,,BAO_0000219,,Homo sapiens,,Expert,14214,,D,9,CHEMBL616133,308.0,,
955,1,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,BAO_0000357,,,,Autocuration,17133,,H,8,CHEMBL616134,,,
956,1,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT,,BAO_0000357,,,,Autocuration,16532,,H,8,CHEMBL616135,,,
957,1,Affinity for 5-hydroxytryptamine 1A receptor subtype,,BAO_0000357,,Homo sapiens,,Expert,2391,,D,9,CHEMBL616136,,,
958,1,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes,,BAO_0000019,,,,Autocuration,14447,,H,8,CHEMBL616137,,,
959,1,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes.,,BAO_0000019,,,,Autocuration,14447,,H,8,CHEMBL872105,,,
960,1,The compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor receptor,,BAO_0000357,,,,Autocuration,15086,,H,8,CHEMBL616138,,,
961,1,Binding affinity for cloned human 5-hydroxytryptamine 1A receptor,,BAO_0000357,,Homo sapiens,,Expert,13051,,D,9,CHEMBL616139,,,
962,1,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor; Not active",,BAO_0000019,,,,Autocuration,16026,,H,8,CHEMBL616140,,,
963,1,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor; ND means not determined,,BAO_0000019,,,,Expert,17085,,H,8,CHEMBL616141,,,
964,1,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,BAO_0000357,,,,Autocuration,17133,,H,8,CHEMBL616142,,,
965,1,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; ND means Not determined,,BAO_0000357,,,,Autocuration,17133,,H,8,CHEMBL616143,,,
966,1,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,BAO_0000219,,,,Autocuration,17211,,H,8,CHEMBL616144,308.0,,
967,1,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT=not tested,,BAO_0000219,,,,Autocuration,17211,,H,8,CHEMBL616145,308.0,,
968,1,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,BAO_0000219,,,,Autocuration,17211,,H,8,CHEMBL616012,308.0,,
969,1,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,BAO_0000219,,,,Autocuration,17211,,H,8,CHEMBL616013,308.0,,
970,1,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,BAO_0000019,,,,Autocuration,16394,,H,8,CHEMBL616014,,,
971,1,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,BAO_0000019,,,,Autocuration,16394,,H,8,CHEMBL616015,,,
972,1,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,BAO_0000019,,,,Autocuration,16394,,H,8,CHEMBL616016,,,
973,1,Antagonist induction of hypothermia by 8-OH-DPAT in 5-hydroxytryptamine 1A receptor after subcutaneous administration; NT is not tested,,BAO_0000218,,,,Autocuration,16394,In vivo,H,8,CHEMBL616017,,,
974,1,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]-8-OH-DPAT binding in Chinese hamster ovary cell line; NT is not tested,,BAO_0000019,,,,Autocuration,16394,,H,8,CHEMBL616018,,,
975,1,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor receptor; Not tested,,BAO_0000019,,,,Autocuration,15740,,H,8,CHEMBL616019,,,
976,1,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor; Not tested,,BAO_0000019,,,,Autocuration,15740,,H,8,CHEMBL616020,,,
977,1,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Autocuration,15740,,H,8,CHEMBL858018,,,
978,1,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,BAO_0000219,,,,Autocuration,17296,,H,8,CHEMBL616021,722.0,,
979,1,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at 1 uM.",,BAO_0000019,,,,Expert,5640,,H,8,CHEMBL616022,,,
980,1,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means Not determined",,BAO_0000019,,,,Autocuration,5640,,H,8,CHEMBL616023,,,
981,1,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means not determined",,BAO_0000019,,,,Autocuration,5640,,H,8,CHEMBL616024,,,
982,1,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; Not determined",,BAO_0000019,,,,Autocuration,5640,,H,8,CHEMBL616025,,,
983,1,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,BAO_0000219,,,,Autocuration,2759,,H,8,CHEMBL616026,449.0,,
984,1,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT",,BAO_0000019,,,,Autocuration,16394,,H,8,CHEMBL616027,,,
985,1,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared to 5-HT",,BAO_0000019,,Homo sapiens,,Expert,16394,,D,9,CHEMBL616028,,,
986,1,Percent efficacy against human 5-hydroxytryptamine 1A receptor relative to maximal 5-HT response,,BAO_0000019,,Homo sapiens,,Expert,3445,,D,9,CHEMBL616029,,,
987,1,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by incubating human 5-hydroxytryptamine 1A receptor transfected CHO cells with [3H]8-OH-DPAT,,BAO_0000219,,,,Expert,4316,,H,8,CHEMBL616030,449.0,,
988,1,In vitro inhibition of [3H]8-OH-DPAT binding to human cloned 5-hydroxytryptamine 1A receptor on CHO cell membranes.,,BAO_0000019,,,,Expert,4316,,H,8,CHEMBL616031,,,
989,1,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,,BAO_0000019,,Homo sapiens,,Expert,15180,,D,9,CHEMBL616032,,,
990,1,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,,BAO_0000019,,Homo sapiens,,Expert,15180,,D,9,CHEMBL616033,,,
991,1,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,BAO_0000019,,,,Autocuration,15042,,H,8,CHEMBL616034,,,
992,1,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,BAO_0000019,,,,Autocuration,15042,,H,8,CHEMBL616035,,,
993,1,Maximum binding affinity was evaluated as ([35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,,BAO_0000019,,,,Autocuration,15042,,H,8,CHEMBL616036,,,
994,1,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,BAO_0000019,,,,Autocuration,15042,,H,8,CHEMBL616037,,,
995,1,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,BAO_0000019,,,,Autocuration,15042,,H,8,CHEMBL616038,,,
996,1,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,BAO_0000019,,,,Autocuration,15042,,H,8,CHEMBL616039,,,
997,1,Agonist efficacy was evaluated as [35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,,BAO_0000019,,,,Autocuration,15042,,H,8,CHEMBL616040,,,
998,1,Concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,,BAO_0000219,,Homo sapiens,,Expert,15180,,D,9,CHEMBL616041,308.0,,
999,1,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,,BAO_0000219,,Homo sapiens,,Expert,15180,,D,9,CHEMBL616042,308.0,,
1000,1,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,,BAO_0000219,,Homo sapiens,,Expert,15180,,D,9,CHEMBL616043,308.0,,
1001,1,"Potency (pD2) for the stimulation of [35S]GTP-gamma-S, binding on 5-hydroxytryptamine 1A receptor",,BAO_0000019,,,,Autocuration,16245,,H,8,CHEMBL616044,,,
1002,1,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,BAO_0000019,,,,Autocuration,16026,,H,8,CHEMBL616045,,,
1003,1,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,BAO_0000219,,,,Autocuration,17296,,H,8,CHEMBL616046,722.0,,
1004,1,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),,BAO_0000219,,,,Autocuration,2759,,H,8,CHEMBL616047,449.0,,
1005,1,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells,,BAO_0000219,,,,Autocuration,2759,,H,8,CHEMBL616048,449.0,,
1006,1,Potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 1),,BAO_0000219,,Homo sapiens,,Expert,2759,,D,9,CHEMBL616049,449.0,,
1007,1,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),,BAO_0000219,,,,Autocuration,2759,,H,8,CHEMBL616050,449.0,,
1008,1,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor,,BAO_0000219,,,,Expert,15419,,H,8,CHEMBL616051,,,
1009,1,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor; Not tested,,BAO_0000219,,,,Autocuration,15419,,H,8,CHEMBL616212,,,
1010,1,"ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,BAO_0000019,,,,Autocuration,16026,,H,8,CHEMBL616213,,,
1011,1,Ability to bind to 5-hydroxytryptamine 1A receptor from cloned human expressed in Ha7 cells,,BAO_0000219,,,,Expert,1414,In vitro,H,8,CHEMBL616214,,,
1012,1,Ability to bind to 5-hydroxytryptamine 1A receptor subtype from cloned human expressed in Ha7 cells,,BAO_0000219,,,,Expert,1414,In vitro,H,8,CHEMBL616215,,,
1013,1,Binding activity radioligand.,,BAO_0000357,,,,Autocuration,12861,,H,8,CHEMBL616216,,,
1014,1,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,BAO_0000019,,,,Autocuration,12861,,H,8,CHEMBL616217,,,
1015,1,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Autocuration,5104,,H,8,CHEMBL616218,,,
1016,1,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Autocuration,5105,,H,8,CHEMBL616219,,,
1017,1,binding affinity towards human recombinant 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Autocuration,16312,,H,8,CHEMBL616220,,,
1018,1,Displacement of [3H]8-hydroxy-2-(di-n-propylamino)tetralin from human 5-hydroxytryptamine 1A receptor,,BAO_0000357,,Homo sapiens,,Expert,15180,,D,9,CHEMBL833493,,,
1019,1,Ability to displace the radioligand [3H]-8-OH-DPAT from human 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Autocuration,5033,,H,8,CHEMBL616221,,,
1020,1,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,,BAO_0000219,,Homo sapiens,,Expert,16909,,D,9,CHEMBL616222,449.0,,
1021,1,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor,,BAO_0000019,,,,Autocuration,2590,,H,8,CHEMBL616223,,,
1022,1,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor; Not determined,,BAO_0000019,,,,Autocuration,2590,,H,8,CHEMBL616224,,,
1023,1,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding in Chinese hamster ovary cell line,,BAO_0000019,,,,Expert,16394,,H,8,CHEMBL616225,,,
1024,1,Binding affinity to human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]-8-OH- DPAT as radioligand,,BAO_0000219,,Homo sapiens,,Expert,4540,,D,9,CHEMBL616226,722.0,,
1025,1,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells,,BAO_0000219,,,,Autocuration,17296,,H,8,CHEMBL616227,722.0,,
1026,1,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells using [3H]8-OH-DPAT as radioligand,,BAO_0000219,,,,Autocuration,17296,,H,8,CHEMBL616228,722.0,,
1027,1,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,,BAO_0000219,,,,Autocuration,15779,,H,8,CHEMBL616229,722.0,,
1028,1,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand; ND means no data,,BAO_0000219,,,,Autocuration,15779,,H,8,CHEMBL616230,722.0,,
1029,1,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;ND means no data.,,BAO_0000219,,,,Autocuration,15779,,H,8,CHEMBL616231,722.0,,
1030,1,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,,BAO_0000357,,,,Autocuration,6166,,H,8,CHEMBL616232,,,
1031,1,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,,BAO_0000219,,,,Autocuration,15779,,H,8,CHEMBL616233,722.0,,
1032,1,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT as the radioligand,,BAO_0000219,,,,Autocuration,4199,,H,8,CHEMBL857973,722.0,,
1033,1,Compound was evaluated for its ability to displace [3H]8-OH-DPAT binding from human 5-hydroxytryptamine 1A receptor in mammalian cells,,BAO_0000219,,,,Autocuration,15316,,H,8,CHEMBL616234,,,
1034,1,Compound was tested for binding affinity against human 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Autocuration,14875,,H,8,CHEMBL616235,,,
1035,1,Binding affinity at human cloned 5-hydroxytryptamine 1A receptor expressed in HeLa cells by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,,BAO_0000219,,,,Expert,14727,,H,8,CHEMBL616236,308.0,,
1036,1,Binding affinity at native 5-hydroxytryptamine 1A receptor in rat by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,,BAO_0000019,,,,Expert,14727,,H,8,CHEMBL616237,,,
1037,1,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor in human cloned receptors in HEK 293 cells using [3H]8-OH-DPAT,,BAO_0000219,,,,Autocuration,15146,,H,8,CHEMBL616238,722.0,,
1038,1,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1A receptor in HEK 293 using [3H]5-CT as a radioligand,,BAO_0000219,,,,Autocuration,5213,,H,8,CHEMBL616239,722.0,,
1039,1,In vitro binding affinity at human recombinant 5-hydroxytryptamine 1A receptor in mammalian cells using 3[H]8-OH-DPAT as the radioligand,,BAO_0000219,,,,Autocuration,16429,,H,8,CHEMBL616240,,,
1040,1,The binding affinity was evaluated on cloned human 5-hydroxytryptamine 1A receptor expressed in HeLa cells by using DPAT as radioligand.,,BAO_0000219,,Homo sapiens,,Expert,15042,,D,9,CHEMBL616241,308.0,,
1041,1,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT.,,BAO_0000219,,,,Autocuration,14818,,H,8,CHEMBL616242,722.0,,
1042,1,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1A receptor in HEK293 cells, using [3H]8-OH-DPAT as radioligand",,BAO_0000219,,,,Autocuration,4829,,H,8,CHEMBL616243,722.0,,
1043,1,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Expert,17200,,D,9,CHEMBL616244,,,
1044,1,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor,,BAO_0000357,,Homo sapiens,,Autocuration,13051,,D,9,CHEMBL616245,,,
1045,1,Binding affinity towards 5-HT1B receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,,BAO_0000357,,,,Autocuration,5486,,H,8,CHEMBL616246,,,
1046,1,Binding affinity against 5-HT1D receptor,,BAO_0000357,,,,Autocuration,5254,,H,8,CHEMBL616247,,,
1047,1,Binding affinity against 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Autocuration,5254,,H,8,CHEMBL616248,,,
1048,1,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,BAO_0000357,,,,Autocuration,15331,,H,8,CHEMBL616249,,,
1049,1,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,,BAO_0000357,,Homo sapiens,,Autocuration,13506,,H,8,CHEMBL616250,,,
1050,1,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Autocuration,15267,,H,8,CHEMBL616251,,,
1051,1,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 15 min after administration of the compound,,BAO_0000218,,,,Autocuration,16616,In vivo,H,8,CHEMBL616252,,,
1052,1,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 30 min after administration of the compound,,BAO_0000218,,,,Autocuration,16616,In vivo,H,8,CHEMBL616253,,,
1053,1,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 60 min after administration of the compound,,BAO_0000218,,,,Autocuration,16616,In vivo,H,8,CHEMBL616254,,,
1054,1,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 15 min,,BAO_0000218,,Mus musculus,,Expert,16616,,D,9,CHEMBL616255,,,
1055,1,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 30 min,,BAO_0000218,,Mus musculus,,Expert,16616,,D,9,CHEMBL832872,,,
1056,1,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 60 min,,BAO_0000218,,Mus musculus,,Expert,16616,,D,9,CHEMBL616256,,,
1057,1,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 15 min,,BAO_0000218,,Mus musculus,,Expert,16616,,D,9,CHEMBL616257,,,
1058,1,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 30 min,,BAO_0000218,,Mus musculus,,Expert,16616,,D,9,CHEMBL616258,,,
1059,1,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 60 min,,BAO_0000218,,Mus musculus,,Expert,16616,,D,9,CHEMBL616384,,,
1060,1,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,Hippocampus,BAO_0000221,,,,Autocuration,10297,,H,8,CHEMBL616385,,10000000.0,
1061,1,Inhibitory activity against serotonin 5-hydroxytryptamine 1A receptor from mice.,,BAO_0000357,,,,Expert,13704,,H,8,CHEMBL616386,,,
1062,1,Inhibitory activity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,Hippocampus,BAO_0000221,,Mus musculus,,Expert,10297,,D,9,CHEMBL616387,,10000000.0,
1063,1,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,Hippocampus,BAO_0000221,,,,Autocuration,10297,,H,8,CHEMBL616388,,10000000.0,
1064,1,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,Hippocampus,BAO_0000221,,Mus musculus,,Expert,10297,,D,9,CHEMBL616389,,10000000.0,
1065,1,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,Hippocampus,BAO_0000221,,,,Autocuration,10297,,H,8,CHEMBL616390,,10000000.0,
1066,1,Compound was tested for binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as a radioligand,,BAO_0000357,,,,Autocuration,217,,H,8,CHEMBL616391,,,
1067,1,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,Hippocampus,BAO_0000221,,Mus musculus,,Expert,10297,,D,9,CHEMBL616392,,10000000.0,
1068,1,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor,,BAO_0000357,,Sus scrofa,,Autocuration,4921,,H,8,CHEMBL616393,,,
1069,1,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor; ND denotes not determined,,BAO_0000357,,Sus scrofa,,Autocuration,4921,,H,8,CHEMBL616394,,,
1070,1,Binding affinity of compound measured for 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT-labeled porcine brain homogenates,,BAO_0000019,,Sus scrofa,,Autocuration,4996,,H,8,CHEMBL616395,,,
1071,1,Compound was evaluated for the binding affinity at 5- HT1A receptor,,BAO_0000357,,Sus scrofa,,Autocuration,12918,,H,8,CHEMBL616396,,,
1072,1,Compound was tested in vitro for its ability to compete with [3H]8-OH-DPAT at 5-hydroxytryptamine 1A receptor in porcine brain homogenate,,BAO_0000019,,Sus scrofa,,Autocuration,5333,,H,8,CHEMBL872907,,,
1073,1,In vitro for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in porcine brain homogenate,,BAO_0000019,,Sus scrofa,,Autocuration,4437,,H,8,CHEMBL616397,,,
1074,1,Compound was tested for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in pig cortex,,BAO_0000019,,Sus scrofa,,Autocuration,1742,,H,8,CHEMBL616398,,,
1075,1,Displacement of [3H]- 8-OH-DPAT from porcine 5-hydroxytryptamine 1A receptor,,BAO_0000357,,Sus scrofa,,Expert,16688,,H,8,CHEMBL616399,,,
1076,1,Binding activity radioligand.,,BAO_0000357,,Sus scrofa,,Autocuration,12861,,H,8,CHEMBL857065,,,
1077,1,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,,BAO_0000019,,Sus scrofa,,Expert,12861,,H,8,CHEMBL616400,,,
1078,1,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,,BAO_0000019,,Sus scrofa,,Autocuration,12861,,H,8,CHEMBL616401,,,
1079,1,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor from pig cortex,,BAO_0000019,,,,Expert,12490,,H,8,CHEMBL616402,,,
1080,1,Displacement of [3H]8-OH-DPAT from pig cortex 5-hydroxytryptamine 1A receptor,,BAO_0000019,,Sus scrofa,,Expert,11828,,H,8,CHEMBL616403,,,
1081,1,Binding affinity for 5-hydroxytryptamine 1A receptor in piglet hippocampus using [3H]8-OH-DPAT,Hippocampus,BAO_0000221,,Sus scrofa,,Autocuration,11866,,H,8,CHEMBL616404,,10000000.0,
1082,1,Binding affinity towards 5-hydroxytryptamine 1A receptor in pig frontal cortex membranes using [8H]-OH-DPAT,,BAO_0000249,,Sus scrofa,,Autocuration,12827,,H,8,CHEMBL616405,,,
1083,1,Binding affinity was evaluated by 5-hydroxytryptamine 1A receptor agonism in the pig cortex by displacing 8-OH-DPAT,,BAO_0000019,,Sus scrofa,,Autocuration,12918,,H,8,CHEMBL616406,,,
1084,1,Agonistic activity against 5-hydroxytryptamine 1A receptor in pig cortex using [3H]8-OH-DPAT,,BAO_0000019,,Sus scrofa,,Expert,12919,,H,8,CHEMBL616407,,,
1085,1,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the presence of endothelium,,BAO_0000019,,Oryctolagus cuniculus,,Autocuration,13047,,H,8,CHEMBL616408,,,
1086,1,Inhibition activity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using radio binding assays,,BAO_0000249,,Rattus norvegicus,,Expert,15796,,D,9,CHEMBL616409,,,
1087,1,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Less active",Hippocampus,BAO_0000221,,Rattus norvegicus,,Expert,3651,,D,9,CHEMBL616410,,10000000.0,
1088,1,Tested for the effect on binding at 5-hydroxytryptamine 1A receptor; No activity,,BAO_0000357,,,,Autocuration,188,,H,8,CHEMBL616411,,,
1089,1,"Antagonist activity to stimulate binding of [35S]GTP-gamma-S, to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",,BAO_0000249,,Rattus norvegicus,,Expert,16616,,D,9,CHEMBL616412,,,
1090,1,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",Hippocampus,BAO_0000249,,Rattus norvegicus,,Expert,16616,,D,9,CHEMBL616413,,10000000.0,
1091,1,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,Hippocampus,BAO_0000221,,,,Autocuration,12306,,H,8,CHEMBL616414,,10000000.0,
1092,1,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding,Hippocampus,BAO_0000221,,Rattus norvegicus,,Expert,17167,,D,9,CHEMBL616415,,10000000.0,
1093,1,Binding affinity measured at the 5-hydroxytryptamine 1A receptor by the inhibition of [3H]8-OH-DPAT binding to rat cortex using unlabeled buspirone for nonspecific binding.,,BAO_0000019,,,,Autocuration,14776,,H,8,CHEMBL616416,,,
1094,1,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand.,,BAO_0000357,,,,Expert,12158,,H,8,CHEMBL616417,,,
1095,1,Binding affinity of [3H]- -8-OH-DPAT labelled towards Rat Hippocampal 5-hydroxytryptamine 1A receptor using radioligand binding assay,,BAO_0000357,,,,Autocuration,13481,,H,8,CHEMBL616418,,,
1096,1,Binding affinity of [3H]-8-OH-DPAT towards 5-hydroxytryptamine 1A receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,,BAO_0000219,,,,Autocuration,13427,In vitro,H,8,CHEMBL616419,,,
1097,1,Binding affinity of compound against 5-hydroxytryptamine 1A receptor binding site using radioligand [3H]8-OH-DPAT,,BAO_0000357,,,,Autocuration,10210,,H,8,CHEMBL616420,,,
1098,1,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,,BAO_0000249,,,,Autocuration,10205,,H,8,CHEMBL616421,,,
1099,1,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,,BAO_0000249,,,,Autocuration,10205,,H,8,CHEMBL616422,,,
1100,1,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor in rat striatal membranes by [3H]OH-DPAT displacement.,,BAO_0000249,,,,Expert,10205,,H,8,CHEMBL616423,,,
1101,1,Binding affinity for 5-hydroxytryptamine 1A receptor with [3H]5-HT,,BAO_0000357,,Rattus norvegicus,,Expert,12280,,D,9,CHEMBL616424,,,
1102,1,Binding affinity to the rat 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Expert,17386,,H,8,CHEMBL616425,,,
1103,1,Binding affinity was tested on 5-hydroxytryptamine 1A receptor using radioligand [3H]5-HT binding assay.,,BAO_0000357,,,,Expert,13654,,H,8,CHEMBL616426,,,
1104,1,Binding affinity against 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as the radioligand.,Hippocampus,BAO_0000221,,,,Autocuration,14423,,H,8,CHEMBL616427,,10000000.0,
1105,1,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus tissue.,Hippocampus,BAO_0000221,,,,Autocuration,15412,,H,8,CHEMBL616428,,10000000.0,
1106,1,Binding affinity by measuring displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,Hippocampus,BAO_0000221,,,,Autocuration,12073,,H,8,CHEMBL616290,,10000000.0,
1107,1,Displacement of [3H]8-OH-DPAT from rat striata 5-hydroxytryptamine 1A receptor,,BAO_0000357,,Rattus norvegicus,,Expert,4101,,D,9,CHEMBL616052,,,
1108,1,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Autocuration,10062,,H,8,CHEMBL616053,,,
1109,1,Binding affinity towards 5-HT 1A receptor in rat cerebral cortex membranes using [3H]8-OH-DPAT as radioligand,,BAO_0000249,,,,Autocuration,6238,,H,8,CHEMBL616054,,,
1110,1,Binding affinity towards 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Autocuration,16273,,H,8,CHEMBL616055,,,
1111,1,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in competitive binding assay,,BAO_0000357,,,,Autocuration,11139,,H,8,CHEMBL616056,,,
1112,1,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,,BAO_0000019,,,,Expert,16796,,H,8,CHEMBL616057,,,
1113,1,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,Brain,BAO_0000221,,Rattus norvegicus,,Expert,9548,,D,9,CHEMBL616058,,955.0,
1114,1,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,Brain,BAO_0000221,,,,Autocuration,10381,,H,8,CHEMBL616059,,955.0,
1115,1,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hypocampus membrane using [3H]8-OH-DPAT as radioligand,,BAO_0000249,,,,Autocuration,13408,,H,8,CHEMBL616060,,,
1116,1,Binding affinity towards 5-hydroxytryptamine 1A receptor in the rat brain (hippocampus) using [3H]8-OH-DPAT,Hippocampus,BAO_0000221,,Rattus norvegicus,,Expert,13825,,D,9,CHEMBL616061,,10000000.0,
1117,1,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]-8-hydroxy-2-(di-n-propylamine) tetralin (8-OH-DPAT) as a radioligand,Hippocampus,BAO_0000221,,,,Expert,11147,,H,8,CHEMBL616062,,10000000.0,
1118,1,Binding affinity towards 5-hydroxytryptamine 1A receptor sites in cortical membranes using [3H]8-OH-DPAT as radioligand,,BAO_0000249,,,,Autocuration,10552,,H,8,CHEMBL616063,,,
1119,1,"Binding affinity towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",Striatum,BAO_0000249,,,,Autocuration,10552,,H,8,CHEMBL616064,,2435.0,
1120,1,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cortex membranes,,BAO_0000249,,Rattus norvegicus,,Expert,17136,,D,9,CHEMBL616065,,,
1121,1,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cerebral cortex membranes,,BAO_0000249,,Rattus norvegicus,,Expert,5778,,D,9,CHEMBL616066,,,
1122,1,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,Hippocampus,BAO_0000221,,,,Autocuration,13481,,H,8,CHEMBL616067,,10000000.0,
1123,1,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; Not tested,Hippocampus,BAO_0000221,,,,Autocuration,13481,,H,8,CHEMBL616068,,10000000.0,
1124,1,Binding affinity against rat hippocampal 5-hydroxytryptamine 1A (5-HT1A) receptor determined using [3H]8-OH-DPAT as radioligand,Hippocampus,BAO_0000221,,,,Intermediate,13630,,H,8,CHEMBL616069,,10000000.0,
1125,1,Binding was determined on 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,BAO_0000249,,,,Expert,16245,,H,8,CHEMBL616070,,,
1126,1,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand,Hippocampus,BAO_0000221,,,,Autocuration,14509,,H,8,CHEMBL616071,,10000000.0,
1127,1,Binding affinity against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.,Hippocampus,BAO_0000221,,,,Expert,14509,,H,8,CHEMBL616072,,10000000.0,
1128,1,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.; ND = Not determined,Hippocampus,BAO_0000221,,,,Autocuration,14509,,H,8,CHEMBL616073,,10000000.0,
1129,1,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand; ND = Not determined,Hippocampus,BAO_0000221,,,,Autocuration,14509,,H,8,CHEMBL616074,,10000000.0,
1130,1,Binding affinity was evaluated by determining in vitro displacement of [3H]8-OH-DPAT from the central 5-hydroxytryptamine 1A receptor recognition site in rat frontal cortex homogenate.,,BAO_0000019,,,,Expert,14256,,H,8,CHEMBL616075,,,
1131,1,Binding affinity was evaluated by using [3H]8-OH-DPAT radioligand by using competitive binding assay on 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Autocuration,11139,,H,8,CHEMBL616076,,,
1132,1,Binding affinity for 5-HT1A measured by displacing [3H]8-OH-DPAT from rat cortical membranes; Not determined,,BAO_0000019,,Rattus norvegicus,,Expert,11047,,D,9,CHEMBL616077,,,
1133,1,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes,,BAO_0000019,,Rattus norvegicus,,Expert,11047,,D,9,CHEMBL616078,,,
1134,1,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes;ND-Not determined,,BAO_0000019,,Rattus norvegicus,,Expert,11047,,D,9,CHEMBL616079,,,
1135,1,Binding affinity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,,BAO_0000219,,Rattus norvegicus,,Expert,2395,,D,9,CHEMBL616080,485.0,,
1136,1,Binding affinity towards 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Autocuration,9699,,H,8,CHEMBL616081,,,
1137,1,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [125I]trans-8-OH-PIPAT in membrane homogenates of hippocampal tissue of rat brain,Hippocampus,BAO_0000221,,Rattus norvegicus,,Expert,12028,,D,9,CHEMBL616082,,10000000.0,
1138,1,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in membrane homogenates of hippocampal tissue of rat brain,Hippocampus,BAO_0000221,,,,Autocuration,12028,,H,8,CHEMBL616083,,10000000.0,
1139,1,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,BAO_0000019,,,,Autocuration,5815,,H,8,CHEMBL616084,,,
1140,1,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates,,BAO_0000019,,,,Expert,16616,,H,8,CHEMBL616085,,,
1141,1,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT,,BAO_0000019,,,,Autocuration,5815,,H,8,CHEMBL616086,,,
1142,1,"Binding affinity towards 5-hydroxytryptamine 1A receptor using 0.1 nM [3H]-8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tet-ralin), from rat hippocampal homogenate",Hippocampus,BAO_0000221,,,,Autocuration,2761,,H,8,CHEMBL616087,,10000000.0,
1143,1,Binding affinity was determined against 5-hydroxytryptamine 1A receptor using [3H]WB-4101,,BAO_0000357,,,,Expert,13133,,H,8,CHEMBL616088,,,
1144,1,Binding affinity was determined against 5-hydroxytryptamine 1A receptor was determined in male Sprague-Dawley rat brain.,,BAO_0000019,,,,Autocuration,10444,,H,8,CHEMBL616089,,,
1145,1,Binding affinity was measured against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT by lysergic acid amides,,BAO_0000357,,Rattus norvegicus,,Expert,13278,,D,9,CHEMBL616090,,,
1146,1,Binding affinity was measured on cloned rat 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,BAO_0000357,,,,Autocuration,15874,,H,8,CHEMBL616091,,,
1147,1,"Binding affinity of the compound towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",Striatum,BAO_0000249,,,,Autocuration,10552,,H,8,CHEMBL616092,,2435.0,
1148,1,Binding constant against 5-hydroxytryptamine 1A receptor (in vitro),,BAO_0000357,,,,Autocuration,11130,,H,8,CHEMBL616093,,,
1149,1,Binding constant against 5-hydroxytryptamine 1A receptor (in vivo),,BAO_0000218,,,,Autocuration,11130,In vivo,H,8,CHEMBL616094,,,
1150,1,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex,Brain,BAO_0000221,,,,Autocuration,14542,,H,8,CHEMBL616095,,955.0,
1151,1,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,BAO_0000357,,Rattus norvegicus,,Expert,13670,,D,9,CHEMBL616096,,,
1152,1,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes,,BAO_0000249,,,,Expert,9888,,H,8,CHEMBL616097,,,
1153,1,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus membranes,,BAO_0000249,,Rattus norvegicus,,Expert,3678,,D,9,CHEMBL616098,,,
1154,1,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,Hippocampus,BAO_0000221,,,,Autocuration,11332,,H,8,CHEMBL616099,,10000000.0,
1155,1,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 1A receptor receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,Hippocampus,BAO_0000221,,,,Autocuration,11332,,H,8,CHEMBL616100,,10000000.0,
1156,1,Ability to displace [3H]-8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Expert,1185,,H,8,CHEMBL616101,,,
1157,1,Binding affinity at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes by [3H]8-OH-DPAT displacement.,,BAO_0000249,,,,Expert,2014,,H,8,CHEMBL616102,,,
1158,1,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Autocuration,1185,,H,8,CHEMBL616103,,,
1159,1,Compound was evaluated for its binding affinity against 5-hydroxytryptamine 1A receptor from rat cerebral cortex,,BAO_0000019,,,,Expert,14429,,H,8,CHEMBL616104,,,
1160,1,"Binding affinity to 5-hydroxytryptamine 1A receptor (5-HT 1A receptor, serotonin receptor) from rat cortex using [3H]8-OH-DPAT as radioligand",,BAO_0000019,,,,Expert,16288,,H,8,CHEMBL616105,,,
1161,1,Displacement of [3H]prazosin from rat cortex membrane 5-hydroxytryptamine 1A receptor,,BAO_0000019,,Rattus norvegicus,,Expert,5432,,D,9,CHEMBL616106,,,
1162,1,Compound was evaluated for its binding affinity with 5-hydroxytryptamine 1A receptor using membranes prepared from rat cerebral cortex,,BAO_0000019,,,,Autocuration,14429,,H,8,CHEMBL616107,,,
1163,1,Binding affinity towards rat 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand.,,BAO_0000357,,,,Expert,13672,,H,8,CHEMBL616108,,,
1164,1,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,Hippocampus,BAO_0000221,,,,Expert,11296,,H,8,CHEMBL616109,,10000000.0,
1165,1,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site.,,BAO_0000357,,,,Autocuration,11296,,H,8,CHEMBL616110,,,
1166,1,Binding affinity against rat 5-hydroxytryptamine 1A receptor in CHO cells.,,BAO_0000219,,,,Expert,14749,,H,8,CHEMBL616111,449.0,,
1167,1,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat brain using [3H]-8-OH-DPAT as radioligand,,BAO_0000019,,,,Expert,15086,,H,8,CHEMBL616112,,,
1168,1,Compound was tested for the Binding affinity against rat hippocampal 5-hydroxytryptamine 1A receptor by Radio ligand [3H]8-OH-DPAT binding assay.,Hippocampus,BAO_0000221,,,,Autocuration,13462,,H,8,CHEMBL616113,,10000000.0,
1169,1,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,,BAO_0000019,,,,Autocuration,15363,,H,8,CHEMBL616114,,,
1170,1,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,,BAO_0000019,,,,Autocuration,15363,,H,8,CHEMBL616115,,,
1171,1,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Autocuration,10796,,H,8,CHEMBL616116,,,
1172,1,Binding affinity for 5-hydroxytryptamine 1A receptor in rat brain tissue using [3H]8-OH-DPAT as radioligand,Brain,BAO_0000221,,,,Expert,12816,,H,8,CHEMBL615844,,955.0,
1173,1,In vitro displacement of [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,Hippocampus,BAO_0000221,,,,Expert,13542,,H,8,CHEMBL615939,,10000000.0,
1174,1,In vitro ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor sites of rat brain cortex.,,BAO_0000019,,,,Expert,13308,,H,8,CHEMBL615940,,,
1175,1,In vitro affinity at 5-hydroxytryptamine 1A receptor of rat hippocampus by [3H]8-OH-DPAT displacement.,Hippocampus,BAO_0000221,,,,Expert,13541,,H,8,CHEMBL615941,,10000000.0,
1176,1,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-HT1A receptor of rat hippocampus and the value ranges from 9 - 12,Hippocampus,BAO_0000221,,,,Autocuration,10058,,H,8,CHEMBL615942,,10000000.0,
1177,1,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,Hippocampus,BAO_0000221,,,,Autocuration,10058,,H,8,CHEMBL615943,,10000000.0,
1178,1,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 12 to 17,Hippocampus,BAO_0000221,,,,Autocuration,10058,,H,8,CHEMBL615944,,10000000.0,
1179,1,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 391-841,Hippocampus,BAO_0000221,,,,Autocuration,10058,,H,8,CHEMBL615945,,10000000.0,
1180,1,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 17.,Hippocampus,BAO_0000221,,,,Autocuration,10058,,H,8,CHEMBL615946,,10000000.0,
1181,1,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 20.,Hippocampus,BAO_0000221,,,,Autocuration,10058,,H,8,CHEMBL615947,,10000000.0,
1182,1,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 245 to 736,Hippocampus,BAO_0000221,,,,Autocuration,10058,,H,8,CHEMBL615948,,10000000.0,
1183,1,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 25 - 84,Hippocampus,BAO_0000221,,,,Autocuration,10058,,H,8,CHEMBL615949,,10000000.0,
1184,1,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 48 to 59,Hippocampus,BAO_0000221,,,,Autocuration,10058,,H,8,CHEMBL615950,,10000000.0,
1185,1,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 3 -5,Hippocampus,BAO_0000221,,,,Autocuration,10058,,H,8,CHEMBL615951,,10000000.0,
1186,1,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 15 - 31,Hippocampus,BAO_0000221,,,,Autocuration,10058,,H,8,CHEMBL615952,,10000000.0,
1187,1,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 27 - 42,Hippocampus,BAO_0000221,,,,Autocuration,10058,,H,8,CHEMBL615953,,10000000.0,
1188,1,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 6 - 13,Hippocampus,BAO_0000221,,,,Autocuration,10058,,H,8,CHEMBL615954,,10000000.0,
1189,1,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,Hippocampus,BAO_0000221,,Rattus norvegicus,,Expert,10058,,D,9,CHEMBL615955,,10000000.0,
1190,1,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.; ND is No Data.,Hippocampus,BAO_0000221,,,,Autocuration,10058,,H,8,CHEMBL615956,,10000000.0,
1191,1,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus. and the value ranges from 16 - 27,Hippocampus,BAO_0000221,,,,Autocuration,10058,,H,8,CHEMBL615957,,10000000.0,
1192,1,Displacement of [3H]2-(di-N-propylamino)-8-hydroxytetralin from central 5-hydroxytryptamine 1A receptor recognition sites in rat frontal cortex homogenates.,,BAO_0000019,,,,Expert,12879,,H,8,CHEMBL615958,,,
1193,1,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate,,BAO_0000019,,,,Expert,11964,,H,8,CHEMBL615959,,,
1194,1,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 1),,BAO_0000019,,,,Autocuration,11964,,H,8,CHEMBL615960,,,
1195,1,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 2),,BAO_0000019,,,,Autocuration,11964,,H,8,CHEMBL615961,,,
1196,1,Evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,Brain,BAO_0000221,,,,Expert,9548,,H,8,CHEMBL615962,,955.0,
1197,1,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand.,,BAO_0000019,,,,Expert,9098,,H,8,CHEMBL615963,,,
1198,1,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand; ND is no data.,,BAO_0000019,,,,Autocuration,9098,,H,8,CHEMBL615964,,,
1199,1,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand;ND means no data,,BAO_0000019,,,,Autocuration,9098,,H,8,CHEMBL615965,,,
1200,1,In vitro displacement of radioactively labeled ligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor site in CHO cells,,BAO_0000219,,,,Expert,13248,,H,8,CHEMBL615966,449.0,,
1201,1,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat cortical membranes,,BAO_0000249,,,,Expert,3147,,H,8,CHEMBL615967,,,
1202,1,In vitro binding affinity against 5-hydroxytryptamine 1A receptor of rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,,BAO_0000019,,,,Expert,13949,,H,8,CHEMBL615968,,,
1203,1,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),,BAO_0000218,,,,Autocuration,11883,,H,8,CHEMBL615969,449.0,,
1204,1,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (agonist) as radioligand (sc),,BAO_0000218,,,,Autocuration,11883,,H,8,CHEMBL615970,,,
1205,1,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT,,BAO_0000357,,Rattus norvegicus,,Expert,11883,,D,9,CHEMBL615971,,,
1206,1,In vitro binding affinity at 5-HT1A receptors assayed by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,BAO_0000249,,,,Expert,15535,,H,8,CHEMBL615972,,,
1207,1,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes + cortex,,BAO_0000249,,,,Autocuration,15535,,H,8,CHEMBL615973,,,
1208,1,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes+cortex,,BAO_0000249,,,,Autocuration,15535,,H,8,CHEMBL615974,,,
1209,1,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,,BAO_0000219,,Homo sapiens,,Expert,16372,,D,9,CHEMBL615975,449.0,,
1210,1,In vitro binding affinity for 5-hydroxytryptamine 1A receptor in rat hippocampal membranes by [125I]-labeled agonist displacement.,,BAO_0000249,,,,Expert,14608,,H,8,CHEMBL615976,,,
1211,1,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus,Hippocampus,BAO_0000221,,Rattus norvegicus,,Expert,4795,,D,9,CHEMBL872106,,10000000.0,
1212,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,BAO_0000357,,,,Autocuration,13863,,H,8,CHEMBL615977,,,
1213,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=100-230,,BAO_0000357,,,,Autocuration,13863,,H,8,CHEMBL615978,,,
1214,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=12-14,,BAO_0000357,,,,Autocuration,13863,,H,8,CHEMBL616166,,,
1215,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=16-20,,BAO_0000357,,,,Autocuration,13863,,H,8,CHEMBL616167,,,
1216,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=160-430,,BAO_0000357,,,,Autocuration,13863,,H,8,CHEMBL616168,,,
1217,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=174-224,,BAO_0000357,,,,Autocuration,13863,,H,8,CHEMBL616169,,,
1218,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=184-503,,BAO_0000357,,,,Autocuration,13863,,H,8,CHEMBL616170,,,
1219,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=19-23,,BAO_0000357,,,,Autocuration,13863,,H,8,CHEMBL616171,,,
1220,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=2.2-3.2,,BAO_0000357,,,,Autocuration,13863,,H,8,CHEMBL616172,,,
1221,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=2.7-3.6,,BAO_0000357,,,,Autocuration,13863,,H,8,CHEMBL616173,,,
1222,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=20-23,,BAO_0000357,,,,Autocuration,13863,,H,8,CHEMBL616174,,,
1223,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=21-28,,BAO_0000357,,,,Autocuration,13863,,H,8,CHEMBL616175,,,
1224,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=240-760,,BAO_0000357,,,,Autocuration,13863,,H,8,CHEMBL616176,,,
1225,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=39-87,,BAO_0000357,,,,Autocuration,13863,,H,8,CHEMBL616177,,,
1226,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=4.6-5.2,,BAO_0000357,,,,Autocuration,13863,,H,8,CHEMBL616178,,,
1227,1,Inhibitory activity tested in vitro at 5-hydroxytryptamine 1A receptor binding site in rat,,BAO_0000019,,,,Autocuration,9742,,H,8,CHEMBL616179,,,
1228,1,Inhibitory concentration against 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Autocuration,12073,,H,8,CHEMBL616180,,,
1229,1,Inhibitory concentration against binding of 5-hydroxytryptamine 1A receptor from striata of male Wistar rats by displacement of [3H]8-OH-DPAT,,BAO_0000357,,,,Autocuration,4101,,H,8,CHEMBL616181,,,
1230,1,Inhibitory concentration against radioligand [3H]hydroxy-2-(di-n-propylamino)-tetralin binding to 5-hydroxytryptamine 1A receptor in rat,,BAO_0000019,,,,Autocuration,15360,,H,8,CHEMBL616182,,,
1231,1,Inhibitory concentration against radioligand [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,Hippocampus,BAO_0000221,,,,Autocuration,11576,,H,8,CHEMBL616183,,10000000.0,
1232,1,Inhibition of the 5-hydroxytryptamine 1A receptor in rat dorsal raphe,,BAO_0000019,,,,Expert,5834,,H,8,CHEMBL615874,,,
1233,1,Inhibitory concentration against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,,BAO_0000219,,Rattus norvegicus,,Expert,2395,,D,9,CHEMBL615875,485.0,,
1234,1,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand,,BAO_0000019,,,,Autocuration,1375,,H,8,CHEMBL615876,,,
1235,1,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand; NT means not tested,,BAO_0000019,,,,Autocuration,1375,,H,8,CHEMBL615877,,,
1236,1,The compound was evaluated for the ability to displace [3H]- 8-OH -DPAT from 5-hydroxytryptamine 1A receptor ( striata of male wistar rats),,BAO_0000357,,,,Autocuration,3967,,H,8,CHEMBL615878,,,
1237,1,Binding affinity towards 5-hydroxytryptamine 1A receptor binding site using [3H]8-OH-DPAT. ,,BAO_0000357,,,,Expert,12884,,H,8,CHEMBL615879,,,
1238,1,Binding affinity towards 5-hydroxytryptamine 1A receptor using receptor binding assay,,BAO_0000357,,,,Expert,2343,,H,8,CHEMBL615880,,,
1239,1,"The compound was tested in vitro for inhibitory activity against 5-HT1A receptor in rats, using [3H]8-OH-DPAT as radioligand",,BAO_0000019,,,,Autocuration,11511,,H,8,CHEMBL615881,,,
1240,1,"Inhibitory activity against 5-hydroxytryptamine 1A receptor in rats, using [3H]8-OH-DPAT as radioligand",,BAO_0000019,,Rattus norvegicus,,Expert,11511,,D,9,CHEMBL615882,,,
1241,1,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat,,BAO_0000218,,,,Autocuration,16394,In vivo,H,8,CHEMBL615883,,,
1242,1,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.10-6.20),,BAO_0000218,,,,Autocuration,16394,In vivo,H,8,CHEMBL615884,,,
1243,1,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.60),,BAO_0000218,,,,Autocuration,16394,In vivo,H,8,CHEMBL615885,,,
1244,1,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.80),,BAO_0000218,,,,Autocuration,16394,In vivo,H,8,CHEMBL615886,,,
1245,1,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.37-4.27),,BAO_0000218,,,,Autocuration,16394,In vivo,H,8,CHEMBL615887,,,
1246,1,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-2.70),,BAO_0000218,,,,Autocuration,16394,In vivo,H,8,CHEMBL615888,,,
1247,1,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-4),,BAO_0000218,,,,Autocuration,16394,In vivo,H,8,CHEMBL615889,,,
1248,1,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.45-4.51),,BAO_0000218,,,,Autocuration,16394,In vivo,H,8,CHEMBL615890,,,
1249,1,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.50-5.30),,BAO_0000218,,,,Autocuration,16394,In vivo,H,8,CHEMBL615891,,,
1250,1,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.60-1.60),,BAO_0000218,,,,Autocuration,16394,In vivo,H,8,CHEMBL615892,,,
1251,1,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.72-2.87),,BAO_0000218,,,,Autocuration,16394,In vivo,H,8,CHEMBL615893,,,
1252,1,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.80-5.80),,BAO_0000218,,,,Autocuration,16394,In vivo,H,8,CHEMBL615894,,,
1253,1,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (1.50-16.5),,BAO_0000218,,,,Autocuration,16394,In vivo,H,8,CHEMBL615895,,,
1254,1,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (2.20-30.5),,BAO_0000218,,,,Autocuration,16394,In vivo,H,8,CHEMBL615896,,,
1255,1,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges is not computable,,BAO_0000218,,,,Autocuration,16394,In vivo,H,8,CHEMBL615897,,,
1256,1,"Percent increase of R(+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",,BAO_0000249,,Rattus norvegicus,,Expert,16616,,D,9,CHEMBL615898,,,
1257,1,% inhibition towards 5-HT1A receptor from rat hippocampal membranes,,BAO_0000019,,,,Autocuration,16796,,H,8,CHEMBL615899,,,
1258,1,% inhibition towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,,BAO_0000019,,,,Autocuration,16796,,H,8,CHEMBL616291,,,
1259,1,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor.,,BAO_0000357,,,,Autocuration,15629,,H,8,CHEMBL616292,,,
1260,1,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",,BAO_0000249,,,,Autocuration,13241,,H,8,CHEMBL616293,,,
1261,1,Measurement of binding affinity by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,Hippocampus,BAO_0000221,,,,Expert,12073,,H,8,CHEMBL616294,,10000000.0,
1262,1,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane,Hippocampus,BAO_0000249,,,,Autocuration,14286,,H,8,CHEMBL616295,,10000000.0,
1263,1,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex at 10 uM,Brain,BAO_0000221,,,,Autocuration,14542,,H,8,CHEMBL616296,,955.0,
1264,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,,BAO_0000019,,,,Autocuration,13630,,H,8,CHEMBL616297,,,
1265,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0+ 1 uM 5-HT.,,BAO_0000019,,,,Autocuration,13630,,H,8,CHEMBL616605,,,
1266,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.01 uM+ 1 uM 5-HT.,,BAO_0000019,,,,Autocuration,13630,,H,8,CHEMBL616606,,,
1267,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,,BAO_0000019,,,,Autocuration,13630,,H,8,CHEMBL616607,,,
1268,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,,BAO_0000019,,,,Expert,13630,,H,8,CHEMBL616608,,,
1269,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM+ 1 uM 5-HT.,,BAO_0000019,,,,Autocuration,13630,,H,8,CHEMBL616609,,,
1270,1,Effect against 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at 0.1 uM dose,,BAO_0000019,,Rattus norvegicus,,Expert,13630,,D,9,CHEMBL616610,,,
1271,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,,BAO_0000019,,,,Autocuration,13630,,H,8,CHEMBL616611,,,
1272,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 1 uM 5-HT.,,BAO_0000019,,,,Expert,13630,,H,8,CHEMBL616612,,,
1273,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 0.1 uM 5-HT.,,BAO_0000019,,,,Autocuration,13630,,H,8,CHEMBL616613,,,
1274,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM,,BAO_0000019,,,,Expert,13630,,H,8,CHEMBL616614,,,
1275,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM+ 10 uM 5-HT.,,BAO_0000019,,,,Autocuration,13630,,H,8,CHEMBL616615,,,
1276,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,,BAO_0000019,,,,Expert,13630,,H,8,CHEMBL616616,,,
1277,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 0.1 uM 5-HT.,,BAO_0000019,,,,Autocuration,13630,,H,8,CHEMBL616617,,,
1278,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,,BAO_0000019,,,,Autocuration,13630,,H,8,CHEMBL616618,,,
1279,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 1 uM 5-HT.,,BAO_0000019,,,,Autocuration,13630,,H,8,CHEMBL616619,,,
1280,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 3 uM 5-HT.,,BAO_0000019,,,,Expert,13630,,H,8,CHEMBL616620,,,
1281,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,,BAO_0000019,,,,Expert,13630,,H,8,CHEMBL616621,,,
1282,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 30 uM,,BAO_0000019,,,,Autocuration,13630,,H,8,CHEMBL616622,,,
1283,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM,,BAO_0000019,,,,Expert,13630,,H,8,CHEMBL616146,,,
1284,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM+ 50 uM 5-HT.,,BAO_0000019,,,,Autocuration,13630,,H,8,CHEMBL832873,,,
1285,1,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM,,BAO_0000019,,,,Autocuration,13630,,H,8,CHEMBL616147,,,
1286,1,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,,BAO_0000019,,,,Autocuration,13630,,H,8,CHEMBL872872,,,
1287,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,,BAO_0000019,,,,Autocuration,13630,,H,8,CHEMBL616148,,,
1288,1,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue,Hippocampus,BAO_0000221,,,,Autocuration,9783,,H,8,CHEMBL616149,,10000000.0,
1289,1,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue at 1 uM,Hippocampus,BAO_0000221,,,,Expert,9783,,H,8,CHEMBL616150,,10000000.0,
1290,1,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membranes at 10e-7 M,,BAO_0000249,,Rattus norvegicus,,Expert,14331,,D,9,CHEMBL616151,,,
1291,1,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue at 1 uM,Hippocampus,BAO_0000221,,,,Expert,15260,,H,8,CHEMBL872873,,10000000.0,
1292,1,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 0.1 uM concentration,Hippocampus,BAO_0000221,,,,Autocuration,15260,,H,8,CHEMBL616670,,10000000.0,
1293,1,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 1 uM concentration,Hippocampus,BAO_0000221,,,,Autocuration,15260,,H,8,CHEMBL616671,,10000000.0,
1294,1,"Percent inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",,BAO_0000249,,Rattus norvegicus,,Expert,16616,,D,9,CHEMBL884861,,,
1295,1,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor,,BAO_0000357,,,,Autocuration,15629,,H,8,CHEMBL616672,,,
1296,1,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,,BAO_0000019,,,,Autocuration,15086,,H,8,CHEMBL616673,,,
1297,1,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,,BAO_0000019,,,,Expert,5717,,H,8,CHEMBL616674,,,
1298,1,Binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,,BAO_0000357,,,,Autocuration,12652,,H,8,CHEMBL616675,,,
1299,1,In vitro binding affinity for 5-hydroxytryptamine 1A receptor was determined by measuring specific inhibition of [125I]-binding to rat hippocampal membrane preparations,Hippocampus,BAO_0000221,,,,Autocuration,14608,,H,8,CHEMBL616676,,10000000.0,
1300,1,Inhibition of binding of [125I]-8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,Hippocampus,BAO_0000221,,,,Autocuration,12306,,H,8,CHEMBL616677,,10000000.0,
1301,1,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,Hippocampus,BAO_0000221,,,,Autocuration,12306,,H,8,CHEMBL616678,,10000000.0,
1302,1,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,BAO_0000357,,Rattus norvegicus,,Expert,15247,,D,9,CHEMBL616679,,,
1303,1,Ability to bind to central serotonin 5-hydroxytryptamine 1A receptor in vitro in hippocampus of the rat brain using [3H]8-OH-DPAT radioligand,Hippocampus,BAO_0000221,,,,Expert,17529,,H,8,CHEMBL616680,,10000000.0,
1304,1,Ability to displace [3H]- -OH-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,Hippocampus,BAO_0000221,,,,Autocuration,14826,,H,8,CHEMBL616681,,10000000.0,
1305,1,Ability to displace [3H]- -(OH)-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,Hippocampus,BAO_0000221,,,,Autocuration,14826,,H,8,CHEMBL616682,,10000000.0,
1306,1,Ability to displace [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,Hippocampus,BAO_0000221,,,,Autocuration,13241,,H,8,CHEMBL616683,,10000000.0,
1307,1,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor,Hippocampus,BAO_0000221,,,,Autocuration,14093,,H,8,CHEMBL616684,,10000000.0,
1308,1,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor; Not tested,Hippocampus,BAO_0000221,,,,Autocuration,14093,,H,8,CHEMBL616685,,10000000.0,
1309,1,Affinity at [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in rat brain homogenate was determined,Brain,BAO_0000221,,,,Autocuration,14442,,H,8,CHEMBL616686,,955.0,
1310,1,Affinity for 5-hydroxytryptamine 1A receptor site,,BAO_0000357,,,,Autocuration,9919,,H,8,CHEMBL616687,,,
1311,1,Affinity for 5-hydroxytryptamine 1A receptor site,,BAO_0000357,,,,Autocuration,9919,,H,8,CHEMBL616688,,,
1312,1,Affinity in displacing [3H]8-OH-DPAT from rat hippocampal 5-HT1A receptor.,Hippocampus,BAO_0000221,,,,Autocuration,11440,,H,8,CHEMBL616689,,10000000.0,
1313,1,Affinity on 5-hydroxytryptamine 1A receptor labeled by [3H]8-OH-DPAT,,BAO_0000357,,,,Autocuration,11257,,H,8,CHEMBL616690,,,
1314,1,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand,,BAO_0000357,,,,Expert,10330,,H,8,CHEMBL616691,,,
1315,1,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus mambranes,Hippocampus,BAO_0000221,,Rattus norvegicus,,Expert,17331,,D,9,CHEMBL616692,,10000000.0,
1316,1,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane,,BAO_0000249,,,,Expert,16567,,H,8,CHEMBL616693,,,
1317,1,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",,BAO_0000019,,Rattus norvegicus,,Expert,12058,,D,9,CHEMBL616694,,,
1318,1,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal tissue,Hippocampus,BAO_0000221,,,,Autocuration,9699,,H,8,CHEMBL616695,,10000000.0,
1319,1,Binding affinity against 5-hydroxytryptamine 1A receptor of rat was determined using [3H]8-OH-DPAT in binding assay,,BAO_0000357,,,,Autocuration,9547,,H,8,CHEMBL616696,,,
1320,1,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]DOB as radioligand,,BAO_0000357,,,,Autocuration,10330,,H,8,CHEMBL616697,,,
1321,1,Binding affinity against rat 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Autocuration,14331,,H,8,CHEMBL616698,,,
1322,1,Binding affinity against rat brain 5-hydroxytryptamine 1A receptor,,BAO_0000019,,Rattus norvegicus,,Expert,14060,,D,9,CHEMBL616949,,,
1323,1,Binding affinity against the 5-hydroxytryptamine 1A receptor labelled with [3H]8-OH-DPAT in rat hippocampal homogenates,Hippocampus,BAO_0000221,,,,Autocuration,14744,,H,8,CHEMBL616950,,10000000.0,
1324,1,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,,BAO_0000357,,,,Autocuration,13506,,H,8,CHEMBL832875,,,
1325,1,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,Brain,BAO_0000221,,,,Expert,10862,,H,8,CHEMBL616951,,955.0,
1326,1,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,Brain,BAO_0000221,,,,Expert,10862,,H,8,CHEMBL616952,,955.0,
1327,1,Binding affinity at rat 5-hydroxytryptamine 1A receptor by [3H]WB-4101 displacement.,,BAO_0000357,,,,Expert,10062,,H,8,CHEMBL616953,,,
1328,1,Binding affinity for 5-hydroxytryptamine 1A receptor by use of [3H]8-OH-DPAT in male rat,,BAO_0000357,,,,Autocuration,12073,,H,8,CHEMBL616954,,,
1329,1,GTPgammaS radioligand binding assay,,BAO_0000357,,,,Autocuration,14875,,H,8,CHEMBL616955,,,
1330,1,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,,BAO_0000357,,,,Autocuration,2391,,H,8,CHEMBL616956,,,
1331,1,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Partial agonist,,BAO_0000019,,,,Autocuration,2391,,H,8,CHEMBL616957,,,
1332,1,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Slient antagonist,,BAO_0000019,,,,Autocuration,2391,,H,8,CHEMBL616958,,,
1333,1,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,,BAO_0000357,,,,Autocuration,2391,,H,8,CHEMBL616959,,,
1334,1,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,,BAO_0000357,,,,Autocuration,2391,,H,8,CHEMBL616960,,,
1335,1,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; silent antagonist,,BAO_0000019,,,,Autocuration,2391,,H,8,CHEMBL616961,,,
1336,1,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor,,BAO_0000219,,,,Expert,17211,,H,8,CHEMBL616962,308.0,,
1337,1,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor receptor,,BAO_0000219,,,,Autocuration,17211,,H,8,CHEMBL616963,308.0,,
1338,1,Affinity towards human 5-hydroxytryptamine 1B serotonin receptor,,BAO_0000357,,Homo sapiens,,Expert,6491,,D,9,CHEMBL616524,,,
1339,1,Binding affinity against 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,,BAO_0000219,,,,Autocuration,16190,,H,8,CHEMBL616525,449.0,,
1340,1,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]5-CT as radioligand,,BAO_0000019,,,,Autocuration,14165,,H,8,CHEMBL872908,,,
1341,1,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]GR-125743 as radioligand,,BAO_0000019,,,,Autocuration,14165,,H,8,CHEMBL616526,,,
1342,1,Binding affinity to cloned human 5-hydroxytryptamine 1B receptor,,BAO_0000357,,Homo sapiens,,Expert,4234,,D,9,CHEMBL616527,,,
1343,1,Binding affinity towards human 5-hydroxytryptamine 1B receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,,BAO_0000219,,,,Expert,6328,,H,8,CHEMBL616528,,,
1344,1,Binding affinity for recombinant human 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,BAO_0000357,,,,Autocuration,14770,,H,8,CHEMBL616529,,,
1345,1,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1B receptor using [3H]5-CT as radioligand,,BAO_0000357,,,,Autocuration,2598,,H,8,CHEMBL616530,,,
1346,1,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,,BAO_0000357,,,,Expert,6897,,H,8,CHEMBL616531,,,
1347,1,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,,BAO_0000357,,,,Autocuration,6897,,H,8,CHEMBL616532,,,
1348,1,Binding affinity towards 5-hydroxytryptamine 1B receptor,,BAO_0000357,,,,Autocuration,6013,,H,8,CHEMBL616533,,,
1349,1,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,,BAO_0000357,,,,Expert,5843,,H,8,CHEMBL616534,,,
1350,1,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT trifluoroacetate as radioligand,,BAO_0000357,,,,Expert,14454,,H,8,CHEMBL616535,,,
1351,1,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT radioligand,,BAO_0000357,,,,Autocuration,16209,,H,8,CHEMBL616536,,,
1352,1,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1B receptor,,BAO_0000357,,,,Autocuration,3935,,H,8,CHEMBL616537,,,
1353,1,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1B receptor in CHO-K1 cells,,BAO_0000219,,,,Expert,13729,,H,8,CHEMBL616538,485.0,,
1354,1,Agonist activity to the human recombinant 5-hydroxytryptamine 1B receptor,,BAO_0000019,,,,Expert,14251,,H,8,CHEMBL616539,,,
1355,1,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor,,BAO_0000019,,,,Expert,17085,,H,8,CHEMBL616540,,,
1356,1,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,,BAO_0000357,,,,Autocuration,3025,,H,8,CHEMBL616429,,,
1357,1,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor,,BAO_0000357,,,,Expert,15315,,H,8,CHEMBL616430,,,
1358,1,Receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor in Cos-7 cells,,BAO_0000219,,Homo sapiens,,Expert,14214,,D,9,CHEMBL616431,,,
1359,1,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,,BAO_0000357,,Homo sapiens,,Expert,3804,,D,9,CHEMBL616432,,,
1360,1,Affinity for 5-hydroxytryptamine 1B receptor subtype,,BAO_0000357,,Homo sapiens,,Expert,2391,,D,9,CHEMBL616433,,,
1361,1,Binding affinity for human 5-hydroxytryptamine 1B receptor,,BAO_0000357,,Homo sapiens,,Expert,4175,,D,9,CHEMBL616434,,,
1362,1,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand; Not determined,,BAO_0000219,,,,Autocuration,17296,,H,8,CHEMBL616435,449.0,,
1363,1,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor; ND means not determined,,BAO_0000019,,,,Expert,17085,,H,8,CHEMBL616436,,,
1364,1,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,,BAO_0000219,,,,Autocuration,17211,,H,8,CHEMBL616437,308.0,,
1365,1,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT=not tested,,BAO_0000219,,,,Autocuration,17211,,H,8,CHEMBL616438,308.0,,
1366,1,Ability to displace [3H]-5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,,BAO_0000219,,,,Autocuration,17211,,H,8,CHEMBL616439,308.0,,
1367,1,Binding activity against human 5-hydroxytryptamine 1B receptor; NT means not tested,,BAO_0000357,,Homo sapiens,,Expert,15926,,D,9,CHEMBL616440,,,
1368,1,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor; not tested,,BAO_0000219,,,,Autocuration,16312,,H,8,CHEMBL616441,485.0,,
1369,1,Selectivity ratio against cloned human 5-HT1B receptor to that of h5-HT1D receptor,,BAO_0000357,,,,Expert,5843,,H,8,CHEMBL616442,,,
1370,1,Selectivity ratio against cloned human 5-hydroxytryptamine 1B receptor to that of human 5-hydroxytryptamine 1D receptor,,BAO_0000357,,,,Autocuration,5843,,H,8,CHEMBL616443,,,
1371,1,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor,,BAO_0000219,,,,Expert,16312,,H,8,CHEMBL616444,485.0,,
1372,1,Binding activity against human 5-hydroxytryptamine 1B receptor,,BAO_0000357,,Homo sapiens,,Expert,15926,,D,9,CHEMBL616445,,,
1373,1,Binding activity against human 5-hydroxytryptamine 1B receptor,,BAO_0000357,,Homo sapiens,,Expert,15926,,D,9,CHEMBL616446,,,
1374,1,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,,BAO_0000219,,Homo sapiens,,Expert,4540,,D,9,CHEMBL616447,449.0,,
1375,1,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor was determined,,BAO_0000357,,,,Autocuration,6166,,H,8,CHEMBL616448,,,
1376,1,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand,,BAO_0000219,,,,Autocuration,17296,,H,8,CHEMBL616449,449.0,,
1377,1,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells,,BAO_0000219,,,,Autocuration,17296,,H,8,CHEMBL616450,449.0,,
1378,1,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells using [3H]5-CT as radioligand,,BAO_0000219,,,,Autocuration,17296,,H,8,CHEMBL857974,449.0,,
1379,1,Binding affinity towards 5-hydroxytryptamine 1B (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,BAO_0000219,,,,Autocuration,15779,,H,8,CHEMBL616451,449.0,,
1380,1,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,BAO_0000219,,,,Autocuration,15779,,H,8,CHEMBL616452,449.0,,
1381,1,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand;ND means no data.,,BAO_0000219,,,,Autocuration,15779,,H,8,CHEMBL616453,449.0,,
1382,1,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as the radioligand,,BAO_0000219,,,,Autocuration,4199,,H,8,CHEMBL616454,449.0,,
1383,1,Binding affinity for human 5-hydroxytryptamine 1B receptor,,BAO_0000357,,Homo sapiens,,Expert,14875,,D,9,CHEMBL616455,,,
1384,1,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,,BAO_0000219,,,,Autocuration,15146,,H,8,CHEMBL616456,449.0,,
1385,1,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1B receptor in CHO using [3H]5-HT as a radioligand,,BAO_0000357,,,,Autocuration,5213,,H,8,CHEMBL616457,,,
1386,1,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,,BAO_0000219,,,,Autocuration,14818,,H,8,CHEMBL616458,449.0,,
1387,1,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1B receptor in CHO cells, using [3H]5-HT as radioligand",,BAO_0000219,,,,Autocuration,4829,,H,8,CHEMBL616459,449.0,,
1388,1,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 1 uM,,BAO_0000019,,,,Expert,14454,,H,8,CHEMBL616460,,,
1389,1,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 10 uM,,BAO_0000019,,,,Expert,14454,,H,8,CHEMBL616461,,,
1390,1,"Effect of compound on [35S]GTP-gamma-S, radioligand binding CHO cells expressing human 5-hydroxytryptamine 1B receptor",,BAO_0000219,,,,Autocuration,14875,,H,8,CHEMBL616462,449.0,,
1391,1,"Effect of compound on [35S]GTP-gamma-S, radioligand binding in CHO cells expressing human 5-hydroxytryptamine 1B receptor",,BAO_0000219,,,,Autocuration,14875,,H,8,CHEMBL616463,449.0,,
1392,1,"Compound was tested for maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-HT.",,BAO_0000019,,,,Autocuration,15250,,H,8,CHEMBL616464,,,
1393,1,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells.,,BAO_0000219,,,,Autocuration,15250,,H,8,CHEMBL616465,449.0,,
1394,1,The compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,,BAO_0000357,,,,Autocuration,15086,,H,8,CHEMBL832874,,,
1395,1,5-hydroxytryptamine 1B receptor agonist potency determined in rabbit saphenous vein contraction model,,BAO_0000019,,Oryctolagus cuniculus,,Autocuration,3025,,H,8,CHEMBL616184,,,
1396,1,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein (RbSV).,,BAO_0000019,,Oryctolagus cuniculus,,Autocuration,14998,,H,8,CHEMBL616185,,,
1397,1,"Binding affinity against vascular 5-hydroxytryptamine 1B receptor, measured using ring preparations of rabbit saphenous vein (RbSV)",,BAO_0000019,,Oryctolagus cuniculus,,Intermediate,14998,,H,8,CHEMBL616186,,,
1398,1,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein(RbSV).,,BAO_0000019,,Oryctolagus cuniculus,,Autocuration,14998,,H,8,CHEMBL616187,,,
1399,1,Binding affinity towards 5-hydroxytryptamine 1B receptor was measured using [3H]5-HT as radioligand,,BAO_0000357,,,,Expert,13969,,H,8,CHEMBL616188,,,
1400,1,Binding affinity for 5-hydroxytryptamine 1B receptor,,BAO_0000357,,,,Intermediate,13392,,D,9,CHEMBL873475,,,
1401,1,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Less active,Striatum,BAO_0000019,,Rattus norvegicus,,Expert,3651,,D,9,CHEMBL616189,,2435.0,
1402,1,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,,BAO_0000357,,,,Expert,10025,,H,8,CHEMBL616190,,,
1403,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=48-77,,BAO_0000357,,,,Autocuration,13863,,H,8,CHEMBL616191,,,
1404,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=63-95,,BAO_0000357,,,,Autocuration,13863,,H,8,CHEMBL616192,,,
1405,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=710-980,,BAO_0000357,,,,Autocuration,13863,,H,8,CHEMBL616193,,,
1406,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=78-140,,BAO_0000357,,,,Autocuration,13863,,H,8,CHEMBL616194,,,
1407,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=85-130,,BAO_0000357,,,,Autocuration,13863,,H,8,CHEMBL616195,,,
1408,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=89-280,,BAO_0000357,,,,Autocuration,13863,,H,8,CHEMBL616196,,,
1409,1,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampus membrane.,Hippocampus,BAO_0000249,,,,Autocuration,4622,,H,8,CHEMBL616197,,10000000.0,
1410,1,Binding affinity at 5-hydroxytryptamine 1A (5-HT1A) receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand,,BAO_0000019,,,,Intermediate,14911,,H,8,CHEMBL616198,,,
1411,1,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,Hippocampus,BAO_0000221,,,,Autocuration,12678,,H,8,CHEMBL616199,,10000000.0,
1412,1,In vitro binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampal homogenate by [125I](R)-(+)-trans-8-OH-PIPAT displacement.,Hippocampus,BAO_0000221,,,,Expert,12678,,H,8,CHEMBL616200,,10000000.0,
1413,1,In vitro binding affinity to rat hippocampal 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,Hippocampus,BAO_0000221,,,,Expert,14235,,H,8,CHEMBL616201,,10000000.0,
1414,1,In vitro binding affinity towards 5-hydroxytryptamine 1A r receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,Hippocampus,BAO_0000221,,,,Expert,14949,,H,8,CHEMBL616202,,10000000.0,
1415,1,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,Hippocampus,BAO_0000221,,,,Expert,14949,,H,8,CHEMBL616203,,10000000.0,
1416,1,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; ND=not determined,Hippocampus,BAO_0000221,,,,Expert,14949,,H,8,CHEMBL616204,,10000000.0,
1417,1,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; Not determined,Hippocampus,BAO_0000221,,,,Expert,14949,,H,8,CHEMBL616205,,10000000.0,
1418,1,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; not determined,Hippocampus,BAO_0000221,,,,Expert,14949,,H,8,CHEMBL616206,,10000000.0,
1419,1,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,,BAO_0000249,,,,Expert,16118,,H,8,CHEMBL616207,,,
1420,1,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes,,BAO_0000249,,,,Autocuration,3268,,H,8,CHEMBL616208,,,
1421,1,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes; Inactive,,BAO_0000249,,,,Autocuration,3268,,H,8,CHEMBL616209,,,
1422,1,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using radioligand [3H]-8-OH-DPAT,,BAO_0000357,,,,Expert,16117,,H,8,CHEMBL616210,,,
1423,1,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue.,Hippocampus,BAO_0000221,,,,Expert,9783,,H,8,CHEMBL616211,,10000000.0,
1424,1,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue; NT=Not tested,Hippocampus,BAO_0000221,,,,Autocuration,9783,,H,8,CHEMBL616504,,10000000.0,
1425,1,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,Hippocampus,BAO_0000221,,Rattus norvegicus,,Expert,14356,,D,9,CHEMBL616505,,10000000.0,
1426,1,Inhibition constant of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,,BAO_0000019,,,,Autocuration,15740,,H,8,CHEMBL616506,,,
1427,1,Inhibition of binding of [125I]8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,Hippocampus,BAO_0000221,,,,Autocuration,12306,,H,8,CHEMBL872107,,10000000.0,
1428,1,Displacement of [3H]5-HT from rat hippocampal 5-hydroxytryptamine 1A receptor with 10e-6 M ketanserin,Hippocampus,BAO_0000221,,Rattus norvegicus,,Expert,13348,,D,9,CHEMBL616507,,10000000.0,
1429,1,Inhibitory activity against 5-hydroxytryptamine 1A receptor in rat cortical membranes using [3H]8-OH-DPAT as a radioligand,,BAO_0000249,,,,Autocuration,10394,,H,8,CHEMBL616303,,,
1430,1,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue,Hippocampus,BAO_0000221,,,,Autocuration,15260,,H,8,CHEMBL616304,,10000000.0,
1431,1,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,Hippocampus,BAO_0000221,,,,Expert,10046,,H,8,CHEMBL616305,,10000000.0,
1432,1,Antagonist activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor,Hippocampus,BAO_0000221,,,,Intermediate,15260,,H,8,CHEMBL616306,,10000000.0,
1433,1,Inhibitory affinity constant against 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Autocuration,12851,,H,8,CHEMBL616307,,,
1434,1,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat brain hippocampus,Hippocampus,BAO_0000221,,Rattus norvegicus,,Expert,2148,,D,9,CHEMBL881829,,10000000.0,
1435,1,Affinity against the 5-hydroxytryptamine receptor 1A using [3H]WB-4101.,,BAO_0000357,,,,Expert,13134,,H,8,CHEMBL616308,,,
1436,1,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain,,BAO_0000019,,,,Autocuration,12462,,H,8,CHEMBL616309,,,
1437,1,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain tissue,,BAO_0000019,,,,Expert,12462,,H,8,CHEMBL616310,,,
1438,1,Tested for affinity against 5-hydroxytryptamine 1A receptors using [3H]8-OH-DPAT in homogenized rat cloned CHO cells,,BAO_0000219,,,,Autocuration,12462,,H,8,CHEMBL616311,449.0,,
1439,1,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand,,BAO_0000357,,,,Expert,11933,,H,8,CHEMBL616312,,,
1440,1,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand; ND is Not Determined,,BAO_0000357,,,,Autocuration,11933,,H,8,CHEMBL616313,,,
1441,1,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,Hippocampus,BAO_0000221,,Rattus norvegicus,,Expert,403,,D,9,CHEMBL616314,,10000000.0,
1442,1,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus,Hippocampus,BAO_0000221,,,,Autocuration,15538,,H,8,CHEMBL616315,,10000000.0,
1443,1,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; NA means Not Active,Hippocampus,BAO_0000221,,,,Autocuration,15538,,H,8,CHEMBL616567,,10000000.0,
1444,1,Tested for binding affinity by measuring displacement of [3H]-8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; ND means Not Determined,Hippocampus,BAO_0000221,,,,Autocuration,15538,,H,8,CHEMBL616568,,10000000.0,
1445,1,Binding affinity to displace [3H]2-(di-N-propylamino)-8-hydroxy-tetralin from 5-hydroxytryptamine 1A (5-HT1A) receptor in rat frontal cortex homogenates,,BAO_0000019,,,,Intermediate,12464,,H,8,CHEMBL616569,,,
1446,1,Binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand assay.,,BAO_0000357,,,,Expert,1455,,H,8,CHEMBL616570,,,
1447,1,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,,BAO_0000357,,,,Autocuration,12652,,H,8,CHEMBL616571,,,
1448,1,Tested for the inhibitory activity against 5-hydroxytryptamine 1A receptor in rat hippocampal,Hippocampus,BAO_0000221,,,,Autocuration,12639,,H,8,CHEMBL616572,,10000000.0,
1449,1,Tested in vitro for binding affinity by measuring its ability to inhibit [3H]8-OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes.,,BAO_0000249,,,,Expert,13949,,H,8,CHEMBL616573,,,
1450,1,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT,,BAO_0000357,,Rattus norvegicus,,Expert,12463,,D,9,CHEMBL616574,,,
1451,1,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation,Hippocampus,BAO_0000221,,,,Expert,14829,,H,8,CHEMBL616575,,10000000.0,
1452,1,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation; ND=not determined,Hippocampus,BAO_0000221,,,,Autocuration,14829,,H,8,CHEMBL872108,,10000000.0,
1453,1,The binding affinity was measured on 5-hydroxytryptamine 1A receptor using [3H]- 8-OH-DPAT as radioligand.,,BAO_0000357,,,,Autocuration,12092,,H,8,CHEMBL616576,,,
1454,1,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 1 mM of MnCl2,,BAO_0000249,,,,Autocuration,403,,H,8,CHEMBL616577,,,
1455,1,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 3*10e-5 M GTP gamma S,,BAO_0000249,,,,Autocuration,403,,H,8,CHEMBL616578,,,
1456,1,Binding affinity at 5-hydroxytryptamine 1A receptor from striata of wistar rats by [3H]- 8-OH -DPAT displacement.,,BAO_0000357,,,,Expert,3967,,H,8,CHEMBL616579,,,
1457,1,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat brain synaptosomal preparations,,BAO_0000019,,Rattus norvegicus,,Expert,12771,,D,9,CHEMBL616580,,,
1458,1,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,,BAO_0000019,,,,Autocuration,15086,,H,8,CHEMBL616581,,,
1459,1,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,Hippocampus,BAO_0000221,,,,Autocuration,14909,,H,8,CHEMBL616582,,10000000.0,
1460,1,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,Hippocampus,BAO_0000221,,,,Expert,14949,,H,8,CHEMBL616583,,10000000.0,
1461,1,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]8-OH-DPAT,Hippocampus,BAO_0000221,,Rattus norvegicus,,Expert,2309,,D,9,CHEMBL616584,,10000000.0,
1462,1,Binding affinity towards 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Expert,4170,,H,8,CHEMBL616585,,,
1463,1,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 from rat hippocampus,Hippocampus,BAO_0000221,,Rattus norvegicus,,Expert,11642,,D,9,CHEMBL616586,,10000000.0,
1464,1,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 radioligand in rat hippocampus,Hippocampus,BAO_0000221,,,,Autocuration,11642,,H,8,CHEMBL616587,,10000000.0,
1465,1,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]-8-OH-DPAT as radioligand,Hippocampus,BAO_0000221,,,,Autocuration,12953,,H,8,CHEMBL616588,,10000000.0,
1466,1,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand.,Hippocampus,BAO_0000221,,,,Autocuration,12953,,H,8,CHEMBL616589,,10000000.0,
1467,1,Binding affinity for 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand,Hippocampus,BAO_0000221,,,,Expert,12953,,H,8,CHEMBL616590,,10000000.0,
1468,1,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1A receptor expressed in CHO cells, by using [3H]8-OH-DPAT as radioligand.",,BAO_0000219,,,,Expert,12903,,H,8,CHEMBL616591,449.0,,
1469,1,Displacement of the radioligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Expert,12536,,H,8,CHEMBL616592,,,
1470,1,The inhibition activity of 5-HT1A at 1 uM,,BAO_0000357,,,,Autocuration,10058,,H,8,CHEMBL616593,,,
1471,1,"Binding affinity against 5-hydroxytryptamine 1A receptor from CHO-K1 cells, using [3H]8-OH-DPAT as the radioligand.",,BAO_0000219,,,,Expert,12902,,H,8,CHEMBL616594,485.0,,
1472,1,Binding affinities against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membrane,,BAO_0000249,,,,Expert,14057,,H,8,CHEMBL616595,,,
1473,1,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-HT 1A receptor site.,,BAO_0000357,,,,Autocuration,11296,,H,8,CHEMBL616596,,,
1474,1,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,Hippocampus,BAO_0000221,,,,Autocuration,11296,,H,8,CHEMBL616597,,10000000.0,
1475,1,Ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,Hippocampus,BAO_0000221,,,,Expert,11296,,H,8,CHEMBL616598,,10000000.0,
1476,1,Antagonist activity to stimulate binding of [35S]-GTP-gamma S binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes,,BAO_0000249,,Rattus norvegicus,,Expert,16616,,D,9,CHEMBL616599,,,
1477,1,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",Hippocampus,BAO_0000249,,Rattus norvegicus,,Expert,16616,,D,9,CHEMBL616600,,10000000.0,
1478,1,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not -determined.,,BAO_0000019,,,,Autocuration,16567,,H,8,CHEMBL616601,,,
1479,1,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not defined.,,BAO_0000019,,,,Autocuration,16567,,H,8,CHEMBL616602,,,
1480,1,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not determined.,,BAO_0000019,,,,Autocuration,16567,,H,8,CHEMBL616603,,,
1481,1,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND means not determined.,,BAO_0000019,,,,Autocuration,16567,,H,8,CHEMBL616604,,,
1482,1,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; No data,,BAO_0000249,,,,Autocuration,17136,,H,8,CHEMBL616316,,,
1483,1,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; Not determined,,BAO_0000249,,,,Autocuration,17136,,H,8,CHEMBL616317,,,
1484,1,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates; ND means No data,,BAO_0000019,,Rattus norvegicus,,Expert,16616,,D,9,CHEMBL616318,,,
1485,1,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes,Hippocampus,BAO_0000221,,,,Autocuration,17331,,H,8,CHEMBL616319,,10000000.0,
1486,1,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes; Not tested,Hippocampus,BAO_0000221,,,,Autocuration,17331,,H,8,CHEMBL616320,,10000000.0,
1487,1,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding; Not tested,Hippocampus,BAO_0000221,,Rattus norvegicus,,Expert,17167,,D,9,CHEMBL616321,,10000000.0,
1488,1,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,,BAO_0000019,,,,Autocuration,15740,,H,8,CHEMBL616322,,,
1489,1,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; not tested,,BAO_0000019,,,,Autocuration,15740,,H,8,CHEMBL616323,,,
1490,1,Ratio of binding affinity to 5-HT 1A and D2 receptor,,BAO_0000357,,,,Autocuration,4671,,H,8,CHEMBL616324,,,
1491,1,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,Hippocampus,BAO_0000221,,,,Autocuration,10058,,H,8,CHEMBL616325,,10000000.0,
1492,1,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,Hippocampus,BAO_0000221,,,,Autocuration,10058,,H,8,CHEMBL616326,,10000000.0,
1493,1,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.,Hippocampus,BAO_0000221,,,,Autocuration,10058,,H,8,CHEMBL616327,,10000000.0,
1494,1,Percentage inhibition against 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Autocuration,12073,,H,8,CHEMBL616328,,,
1495,1,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),,BAO_0000249,,,,Autocuration,2759,,H,8,CHEMBL858110,,,
1496,1,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),,BAO_0000249,,,,Autocuration,2759,,H,8,CHEMBL616329,,,
1497,1,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),,BAO_0000249,,,,Autocuration,2759,,H,8,CHEMBL616330,,,
1498,1,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),,BAO_0000249,,,,Autocuration,2759,,H,8,CHEMBL616331,,,
1499,1,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,,BAO_0000249,,,,Autocuration,2759,,H,8,CHEMBL616332,,,
1500,1,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,Brain,BAO_0000249,,,,Autocuration,9737,,H,8,CHEMBL857063,,955.0,
1501,1,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [3H]8-OH-DPAT as a radioligand,,BAO_0000019,,,,Autocuration,9737,,H,8,CHEMBL616333,,,
1502,1,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT as radioligand.,,BAO_0000019,,,,Expert,5717,,H,8,CHEMBL616334,,,
1503,1,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,Hippocampus,BAO_0000221,,,,Autocuration,12253,,H,8,CHEMBL616335,,10000000.0,
1504,1,Affinity pKi for 5-hydroxytryptamine 1A receptor was measured in rat cortex homogenates.,,BAO_0000019,,,,Autocuration,14025,,H,8,CHEMBL616336,,,
1505,1,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cerebral cortical membrane using [3H]-8-OH-DPAT as radioligand.,,BAO_0000249,,,,Expert,10425,,H,8,CHEMBL616337,,,
1506,1,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cortex homogenates.,,BAO_0000019,,,,Autocuration,14998,,H,8,CHEMBL616338,,,
1507,1,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]- 8-hydri\oxy-2-(di-n-propylamino)tetraline) binding assay,Hippocampus,BAO_0000221,,,,Autocuration,13694,,H,8,CHEMBL616339,,10000000.0,
1508,1,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]8-hydroxy-2-(di-n-propylamino)-tetraline) binding assay,Hippocampus,BAO_0000221,,,,Autocuration,13694,,H,8,CHEMBL616340,,10000000.0,
1509,1,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined,,BAO_0000357,,,,Autocuration,4342,,H,8,CHEMBL616341,,,
1510,1,Binding affinity against rat 5-hydroxytryptamine 1A receptor,,BAO_0000357,,Rattus norvegicus,,Expert,12936,,D,9,CHEMBL616342,,,
1511,1,Inhibition of [3H]2-(di-N-propylamino)-8-hydroxytetralin binding to 5-HT1A receptor of rat frontal cortex homogenates,,BAO_0000019,,Rattus norvegicus,,Expert,13144,,D,9,CHEMBL616343,,,
1512,1,Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement,,BAO_0000019,,,,Expert,13343,,H,8,CHEMBL616344,,,
1513,1,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,BAO_0000357,,,,Expert,12132,,H,8,CHEMBL616345,,,
1514,1,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]8-OH-DPAT as a radioligand,,BAO_0000019,,,,Expert,15419,,H,8,CHEMBL616346,,,
1515,1,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,Hippocampus,BAO_0000221,,,,Autocuration,1479,,H,8,CHEMBL616347,,10000000.0,
1516,1,In vitro by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor on rat cortical membrane,,BAO_0000019,,,,Expert,14287,,H,8,CHEMBL616348,,,
1517,1,Binding affinity at 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Expert,13116,,H,8,CHEMBL616349,,,
1518,1,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat frontal cortex membranes,,BAO_0000249,,Rattus norvegicus,,Expert,2759,,D,9,CHEMBL616152,,,
1519,1,Compound was tested for inhibition constant against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,,BAO_0000249,,,,Autocuration,2759,,H,8,CHEMBL616153,,,
1520,1,"Binding affinity for rat cortex 5-hydroxytryptamine 1A receptor, by displacement of 0.2 nM [3H]8-OH-DPAT radioligand",,BAO_0000019,,,,Expert,14748,,H,8,CHEMBL616154,,,
1521,1,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,BAO_0000019,,,,Autocuration,12304,,H,8,CHEMBL616155,,,
1522,1,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT,Hippocampus,BAO_0000221,,Rattus norvegicus,,Expert,12409,,D,9,CHEMBL616156,,10000000.0,
1523,1,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus with [3H]8-OH-DPAT,Hippocampus,BAO_0000221,,Rattus norvegicus,,Expert,12409,,D,9,CHEMBL616157,,10000000.0,
1524,1,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]-SB 207710 as radioligand,Hippocampus,BAO_0000221,,,,Autocuration,13267,,H,8,CHEMBL616158,,10000000.0,
1525,1,The compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,BAO_0000357,,,,Autocuration,15194,,H,8,CHEMBL616159,,,
1526,1,pKi value against rat 5-hydroxytryptamine 1A receptor.,,BAO_0000357,,,,Expert,14256,,H,8,CHEMBL616160,,,
1527,1,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is define as non-determined.,,BAO_0000019,,,,Autocuration,16567,,H,8,CHEMBL616161,,,
1528,1,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,,BAO_0000019,,,,Autocuration,15740,,H,8,CHEMBL616162,,,
1529,1,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,,BAO_0000357,,Rattus norvegicus,,Expert,13278,,D,9,CHEMBL616163,,,
1530,1,Inhibition of specific [3H]OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,BAO_0000249,,,,Expert,1970,,H,8,CHEMBL616164,,,
1531,1,Concentration of compound required to inhibit cortical 5-hydroxytryptamine 1A receptor binding sites in rat brain was evaluated,Brain,BAO_0000221,,,,Autocuration,10034,,H,8,CHEMBL616165,,955.0,
1532,1,Inhibitory activity against 5-hydroxytryptamine 1A receptor isolated from rat hippocampus membranes membrane using [3H]5-HT as radioligand in the presence of 10e-6 M ketanserin as 5-HT2 blocker,,BAO_0000019,,Rattus norvegicus,,Autocuration,13348,,H,8,CHEMBL616355,,,
1533,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,,BAO_0000019,,,,Autocuration,13630,,H,8,CHEMBL616356,,,
1534,1,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,Brain,BAO_0000221,,,,Autocuration,10862,,H,8,CHEMBL616357,,955.0,
1535,1,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",,BAO_0000019,,,,Autocuration,12058,,H,8,CHEMBL616358,,,
1536,1,Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Autocuration,4639,,H,8,CHEMBL616359,,,
1537,1,Percent decrease in 5-hydroxytryptamine 1A receptor binding using 8-OH-DPAT,,BAO_0000357,,,,Expert,15453,,H,8,CHEMBL616360,,,
1538,1,Binding affinity towards 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Expert,4820,,H,8,CHEMBL616361,,,
1539,1,Tested for binding affinity for 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Autocuration,1089,,H,8,CHEMBL616362,,,
1540,1,The compound was evaluated for its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in cellular brain membranes,,BAO_0000249,,,,Autocuration,386,,H,8,CHEMBL616363,,,
1541,1,Inhibition of binding towards 5-hydroxytryptamine 1A receptor at 100 nM concentration,,BAO_0000357,,,,Autocuration,6011,,H,8,CHEMBL616364,,,
1542,1,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Autocuration,5014,,H,8,CHEMBL616365,,,
1543,1,Binding affinity for 5-hydroxytryptamine 1A receptor determined using [3H]8-OH-DPAT as radioligand,,BAO_0000357,,,,Expert,4402,,H,8,CHEMBL616366,,,
1544,1,Binding affinity towards 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Expert,17066,,H,8,CHEMBL872906,,,
1545,1,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1A receptor; inactive at 10 uM,,BAO_0000357,,,,Autocuration,17515,,H,8,CHEMBL616367,,,
1546,1,Binding affinity against 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Autocuration,2474,,H,8,CHEMBL616368,,,
1547,1,Binding affinity to 5-hydroxytryptamine 1A receptor was determined,,BAO_0000357,,,,Autocuration,4775,,H,8,CHEMBL616369,,,
1548,1,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H]-(+)-8-OH-DPAT.,,BAO_0000357,,Homo sapiens,,Expert,14294,,D,9,CHEMBL616370,,,
1549,1,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H](+)-8-OH-DPAT; inactive,,BAO_0000357,,Homo sapiens,,Expert,14294,,D,9,CHEMBL616371,,,
1550,1,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,BAO_0000219,,,,Autocuration,12249,,H,8,CHEMBL616372,449.0,,
1551,1,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor expressed in CHO cell membranes,,BAO_0000219,,,,Expert,11376,,H,8,CHEMBL616373,,,
1552,1,Compound was measured in vivo for its binding affinity at 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,BAO_0000218,,,,Autocuration,2474,In vivo,H,8,CHEMBL616374,,,
1553,1,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,Hippocampus,BAO_0000221,,,,Autocuration,13311,,H,8,CHEMBL616375,,10000000.0,
1554,1,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1A receptor was determined,,BAO_0000357,,,,Autocuration,4373,,H,8,CHEMBL616376,,,
1555,1,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT.,,BAO_0000357,,,,Expert,1633,,H,8,CHEMBL857064,,,
1556,1,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,,BAO_0000357,,,,Autocuration,11866,,H,8,CHEMBL616377,,,
1557,1,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,,BAO_0000357,,,,Autocuration,4373,,H,8,CHEMBL616378,,,
1558,1,Evaluated for the binding affinity to 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Autocuration,4687,,H,8,CHEMBL616379,,,
1559,1,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Autocuration,16946,,H,8,CHEMBL616380,,,
1560,1,Binding affinity against 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT radioligand,,BAO_0000357,,,,Autocuration,13291,,H,8,CHEMBL616381,,,
1561,1,Compound was evaluated for the affinity at 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Autocuration,14159,,H,8,CHEMBL616382,,,
1562,1,Compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor by using [3H]DPAT as radioligand,,BAO_0000357,,,,Autocuration,10812,,H,8,CHEMBL616383,,,
1563,1,In vitro binding affinity against 5-hydroxytryptamine 1A receptor in CHO cells,,BAO_0000219,,Mus musculus,,Expert,3032,,D,9,CHEMBL616350,449.0,,
1564,1,Inhibition of 5-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Autocuration,16655,,H,8,CHEMBL616351,,,
1565,1,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand at 10e-5 M concentration,,BAO_0000357,,,,Autocuration,14532,,H,8,CHEMBL616352,,,
1566,1,Binding affinity against 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Autocuration,13944,,H,8,CHEMBL616353,,,
1567,1,Binding affinity against serotonergic 5-HT1a receptor,,BAO_0000357,,,,Autocuration,13033,,H,8,CHEMBL616354,,,
1568,1,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by using [3H]8-OH-DPAT as radioligand,,BAO_0000357,,,,Autocuration,10321,,H,8,CHEMBL616508,,,
1569,1,Binding affinity for 5-hydroxytryptamine 1A receptor,,BAO_0000357,,Mus musculus,,Expert,2968,,D,9,CHEMBL616559,,,
1570,1,Binding affinity at 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Autocuration,13964,,H,8,CHEMBL616560,,,
1571,1,"Binding affinity towards 5-hydroxytryptamine 1A receptor receptor, using [3H]5-HT as radioligand.",,BAO_0000357,,,,Autocuration,15527,,H,8,CHEMBL616561,,,
1572,1,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,BAO_0000219,,,,Autocuration,12248,,H,8,CHEMBL616562,449.0,,
1573,1,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,BAO_0000219,,,,Autocuration,12249,,H,8,CHEMBL616563,449.0,,
1574,1,Compound was tested for binding affinity using [3H]8-OH-DPAT against 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Autocuration,15120,,H,8,CHEMBL616564,,,
1575,1,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by using [3H]-8-OH-DPAT as radioligand,,BAO_0000357,,,,Autocuration,13313,,H,8,CHEMBL616565,,,
1576,1,In vivo binding affinity was evaluated against 5-hydroxytryptamine 1A receptor,,BAO_0000218,,,,Autocuration,2613,,H,8,CHEMBL616566,,,
1577,1,The binding affinity towards 5-hydroxytryptamine 1A receptor; No affinity,,BAO_0000357,,,,Autocuration,16700,,H,8,CHEMBL616989,,,
1578,1,Ability to displace [125I]iodosulpiride from 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Autocuration,2201,,H,8,CHEMBL857975,,,
1579,1,Binding affinity against 5-hydroxytryptamine 1A receptor,,BAO_0000357,,Mus musculus,,Expert,1274,,D,9,CHEMBL616990,,,
1580,1,Compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor using radioligand binding assay,,BAO_0000357,,,,Autocuration,1317,,H,8,CHEMBL616991,,,
1581,1,Tested against 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Autocuration,12146,,H,8,CHEMBL616992,,,
1582,1,The compound's binding affinity against 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Autocuration,14059,,H,8,CHEMBL616993,,,
1583,1,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein,,BAO_0000019,,Oryctolagus cuniculus,,Expert,14025,,H,8,CHEMBL616994,,,
1584,1,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein(RbSV); NS=non surmountable,,BAO_0000019,,Oryctolagus cuniculus,,Autocuration,14025,,H,8,CHEMBL616995,,,
1585,1,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1B receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,,BAO_0000219,,Gorilla gorilla,,Intermediate,14447,,D,9,CHEMBL616996,722.0,,
1586,1,5-HT1B agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,,BAO_0000218,,Cavia porcellus,,Autocuration,3025,In vivo,H,8,CHEMBL616997,,,
1587,1,5-hydroxytryptamine 1B receptor agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,,BAO_0000218,,Cavia porcellus,,Autocuration,3025,In vivo,H,8,CHEMBL616998,,,
1588,1,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery,,BAO_0000019,,Cavia porcellus,,Autocuration,15329,,H,8,CHEMBL616999,,,
1589,1,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery; n.d. indicates Not determined,,BAO_0000019,,Cavia porcellus,,Autocuration,15329,,H,8,CHEMBL617000,,,
1590,1,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig,,BAO_0000019,,Cavia porcellus,,Autocuration,15847,,H,8,CHEMBL617001,,,
1591,1,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig; ND means not done,,BAO_0000019,,Cavia porcellus,,Autocuration,15847,,H,8,CHEMBL858111,,,
1592,1,Intrinsic activity for Antagonism of 5-hydroxytryptamine 1B receptor-mediated stimulation of [35S]GTP gamma S binding,,BAO_0000019,,,,Autocuration,14165,,H,8,CHEMBL617002,,,
1593,1,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine (5-CT),,BAO_0000019,,,,Autocuration,14214,,H,8,CHEMBL617003,,,
1594,1,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine(5-CT),,BAO_0000019,,,,Autocuration,14214,,H,8,CHEMBL617004,,,
1595,1,Agonist activity at 5-hydroxytryptamine 1B receptor by measuring the inhibition of forskolin-stimulated cAMP formation,,BAO_0000019,,Homo sapiens,,Expert,14214,,D,9,CHEMBL617005,,,
1596,1,Inhibition of forskolin-stimulated c-AMP formation by human 5-hydroxytryptamine 1B receptor expressed in CHO-K1 cells,,BAO_0000219,,Homo sapiens,,Expert,13729,,D,9,CHEMBL616623,485.0,,
1597,1,Effective concentration determined by measuring inhibition of forskolin-stimulated c-AMP formation at 5-hydroxytryptamine 1B receptor stably transfected in CHO cell lines,,BAO_0000219,,,,Autocuration,3025,,H,8,CHEMBL616624,449.0,,
1598,1,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,,BAO_0000357,,,,Autocuration,2391,,H,8,CHEMBL883243,,,
1599,1,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; full agonist,,BAO_0000019,,,,Autocuration,2391,,H,8,CHEMBL616625,,,
1600,1,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1B receptor",,BAO_0000219,,,,Expert,14956,,H,8,CHEMBL616626,449.0,,
1601,1,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line,,BAO_0000219,,,,Autocuration,2598,,H,8,CHEMBL616627,449.0,,
1602,1,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Antagonist,,BAO_0000219,,,,Autocuration,2598,,H,8,CHEMBL616628,449.0,,
1603,1,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Full Agonist,,BAO_0000219,,,,Autocuration,2598,,H,8,CHEMBL616629,449.0,,
1604,1,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Partial Agonist,,BAO_0000219,,,,Autocuration,2598,,H,8,CHEMBL616630,449.0,,
1605,1,"Efficacy was evaluated relative to human 5-HT1B receptor using [35S]GTP-gamma-S, as radioligand",,BAO_0000019,,,,Expert,14956,,H,8,CHEMBL616631,,,
1606,1,"Efficacy of compound was evaluated relative to human 5-hydroxytryptamine 1B receptor using [35S]GTP-gamma-S, as radioligand",,BAO_0000019,,,,Autocuration,14956,,H,8,CHEMBL616632,,,
1607,1,Percentage Maximal inhibition obtained with 1 uM 5-HT against 5-hydroxytryptamine 1B receptor,,BAO_0000357,,Homo sapiens,,Expert,14214,,D,9,CHEMBL616633,,,
1608,1,Ability to displace [3H]5-HT from recombinant human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells determined in vitro,,BAO_0000219,,,,Expert,3463,,H,8,CHEMBL616634,449.0,,
1609,1,Affinity of compound towards 5-hydroxytryptamine 1B receptor was evaluated using radioligand binding technique,,BAO_0000357,,,,Autocuration,15331,,H,8,CHEMBL616635,,,
1610,1,Binding affinity against 5-hydroxytryptamine 1B receptor,,BAO_0000357,,Homo sapiens,,Expert,16146,,D,9,CHEMBL885358,,,
1611,1,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1B receptor expressed in CHO cells,,BAO_0000219,,Homo sapiens,,Expert,14159,,D,9,CHEMBL616636,449.0,,
1612,1,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells by [3H]5-HT binding displacement.,,BAO_0000219,,,,Expert,14158,,H,8,CHEMBL616637,449.0,,
1613,1,Compound was evaluated for the affinity at 5-hydroxytryptamine 1B receptor,,BAO_0000357,,,,Autocuration,14159,,H,8,CHEMBL616638,,,
1614,1,Displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,,BAO_0000219,,,,Expert,15250,,H,8,CHEMBL616639,449.0,,
1615,1,Binding affinity at cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells by [3H]5-HT displacement.,,BAO_0000219,,,,Expert,15250,,H,8,CHEMBL616640,449.0,,
1616,1,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,,BAO_0000219,,,,Expert,15331,,H,8,CHEMBL616641,449.0,,
1617,1,Displacement of [3H]5-HT binding from cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells.,,BAO_0000219,,,,Expert,15332,,H,8,CHEMBL616642,449.0,,
1618,1,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1B receptor expressed in CHO cells,,BAO_0000219,,,,Expert,14956,,H,8,CHEMBL616643,449.0,,
1619,1,In vitro binding affinity against human 5-hydroxytryptamine 1B receptor at a concentration of 100 (nM),,BAO_0000357,,,,Autocuration,3805,,H,8,CHEMBL616644,,,
1620,1,Intrinsic activity for each compound is calculated as a percentage of the 5-hydroxytryptamine 1B receptor response,,BAO_0000357,,,,Autocuration,14875,,H,8,CHEMBL616645,,,
1621,1,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,BAO_0000019,,Oryctolagus cuniculus,,Autocuration,14454,,H,8,CHEMBL616646,,,
1622,1,Tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,BAO_0000019,,Oryctolagus cuniculus,,Expert,14454,,H,8,CHEMBL616647,,,
1623,1,Affinity at 5-hydroxytryptamine 1D receptor (For sumatriptan = Ki (nM)-12+/-1.9),,BAO_0000357,,,,Autocuration,16288,,H,8,CHEMBL616509,,,
1624,1,Affinity at 5-hydroxytryptamine 1D receptor from calf caudate using [3H]5-HT as radioligand (For sumatriptan = Ki(nM)-12+/-1.9),,BAO_0000357,,,,Autocuration,16288,,H,8,CHEMBL616510,,,
1625,1,Binding affinity against calf caudate 5-hydroxytryptamine 1D receptor,,BAO_0000357,,,,Autocuration,16312,,H,8,CHEMBL616511,,,
1626,1,Inhibitory activity against 5-hydroxytryptamine 1D receptor subtype,,BAO_0000357,,Bos taurus,,Expert,1348,,H,8,CHEMBL616512,,,
1627,1,Inhibitory concentration required against 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT,,BAO_0000357,,Bos taurus,,Autocuration,5834,,H,8,CHEMBL616513,,,
1628,1,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,Striatum,BAO_0000019,,Bos taurus,,Autocuration,13366,,H,8,CHEMBL616514,,2435.0,
1629,1,Ability to bind to 5-hydroxytryptamine 1D receptor of calf substantia nigra,,BAO_0000357,,Bos taurus,,Expert,1414,,H,8,CHEMBL616515,,,
1630,1,Binding affinity against 5-hydroxytryptamine 1D receptor in calf caudate homogenates.,,BAO_0000019,,Bos taurus,,Autocuration,14998,,H,8,CHEMBL616516,,,
1631,1,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,,BAO_0000357,,Bos taurus,,Autocuration,11473,,H,8,CHEMBL616517,,,
1632,1,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,,BAO_0000357,,Bos taurus,,Autocuration,11473,,H,8,CHEMBL616518,,,
1633,1,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,,BAO_0000357,,Bos taurus,,Autocuration,10639,,H,8,CHEMBL616519,,,
1634,1,Inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,,BAO_0000357,,Bos taurus,,Autocuration,10639,,H,8,CHEMBL616520,,,
1635,1,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand,,BAO_0000357,,Bos taurus,,Autocuration,1375,,H,8,CHEMBL616521,,,
1636,1,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand; NT means not tested,,BAO_0000357,,Bos taurus,,Autocuration,1375,,H,8,CHEMBL616522,,,
1637,1,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,,BAO_0000357,,Bos taurus,,Autocuration,16532,,H,8,CHEMBL884531,,,
1638,1,Binding affinity towards 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand,,BAO_0000357,,Bos taurus,,Autocuration,11147,,H,8,CHEMBL616523,,,
1639,1,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,Striatum,BAO_0000019,,Bos taurus,,Autocuration,13366,,H,8,CHEMBL616731,,2435.0,
1640,1,Binding affinity was determined against 5-hydroxytryptamine 1D receptor in bovine caudate homogenate,,BAO_0000019,,Bos taurus,,Autocuration,10444,,H,8,CHEMBL616732,,,
1641,1,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT,,BAO_0000357,,Bos taurus,,Autocuration,16532,,H,8,CHEMBL616733,,,
1642,1,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,,BAO_0000357,,Bos taurus,,Autocuration,16532,,H,8,CHEMBL616734,,,
1643,1,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP,,BAO_0000249,,Bos taurus,,Autocuration,12827,,H,8,CHEMBL616735,,,
1644,1,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP; Not determined,,BAO_0000249,,Bos taurus,,Autocuration,12827,,H,8,CHEMBL616736,,,
1645,1,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,BAO_0000019,,Bos taurus,,Expert,12919,,H,8,CHEMBL616737,,,
1646,1,Affinity pKi for 5-hydroxytryptamine 1D receptor was measured in calf caudate homogenate,,BAO_0000019,,Bos taurus,,Autocuration,14025,,H,8,CHEMBL616738,,,
1647,1,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,BAO_0000019,,Bos taurus,,Expert,12919,,H,8,CHEMBL616739,,,
1648,1,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,BAO_0000019,,Bos taurus,,Expert,12919,,H,8,CHEMBL616740,,,
1649,1,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,BAO_0000019,,Bos taurus,,Expert,12919,,H,8,CHEMBL616741,,,
1650,1,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1D receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,,BAO_0000219,,Gorilla gorilla,,Autocuration,14447,,H,8,CHEMBL616742,722.0,,
1651,1,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra,,BAO_0000019,,Cavia porcellus,,Intermediate,1375,,D,9,CHEMBL616743,,,
1652,1,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra; NT means not tested,,BAO_0000019,,Cavia porcellus,,Intermediate,1375,,D,9,CHEMBL616744,,,
1653,1,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptor by the agonist GR-46611,,BAO_0000019,,Cavia porcellus,,Intermediate,12409,,D,9,CHEMBL616745,,,
1654,1,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,BAO_0000019,,Cavia porcellus,,Intermediate,12409,,D,9,CHEMBL616746,,,
1655,1,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611; range is 2-9,,BAO_0000019,,Cavia porcellus,,Intermediate,12409,,D,9,CHEMBL616747,,,
1656,1,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-0.4,,BAO_0000019,,Cavia porcellus,,Intermediate,12409,,D,9,CHEMBL616748,,,
1657,1,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-1.2,,BAO_0000019,,Cavia porcellus,,Intermediate,12409,,D,9,CHEMBL616648,,,
1658,1,Binding affinity against 5-hydroxytryptamine 1D receptor,,BAO_0000357,,Cavia porcellus,,Intermediate,11574,,D,9,CHEMBL616649,,,
1659,1,Binding affinity towards guinea pig 5-hydroxytryptamine 1D receptor was determined,,BAO_0000357,,Cavia porcellus,,Intermediate,1558,,D,9,CHEMBL616650,,,
1660,1,Compound at 3 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,BAO_0000218,,Cavia porcellus,,Intermediate,12409,,D,9,CHEMBL616651,,,
1661,1,Compound at 45 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,BAO_0000218,,Cavia porcellus,,Intermediate,12409,,D,9,CHEMBL616652,,,
1662,1,Compound at 50 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,BAO_0000218,,Cavia porcellus,,Intermediate,12409,,D,9,CHEMBL616653,,,
1663,1,Compound at oral dose of 45 mg/kg was tested for percent inhibition against 5-hydroxytryptamine 1D receptor causes hypothermia in guinea pig,,BAO_0000218,,Cavia porcellus,,Intermediate,12409,,D,9,CHEMBL616654,,,
1664,1,Binding affinity of 5-hydroxytryptamine 1D receptor using [3H]-8-HT in guinea pig cortex,,BAO_0000019,,Cavia porcellus,,Intermediate,12253,,D,9,CHEMBL616655,,,
1665,1,Binding affinity against guinea pig 5-hydroxytryptamine 1D receptor,,BAO_0000357,,Cavia porcellus,,Intermediate,12936,,D,9,CHEMBL616656,,,
1666,1,Binding affinity was determined against 5-hydroxytryptamine 4 receptor using [125I]SB 207710 as radioligand from piglet hippocampal membranes,,BAO_0000019,,Cavia porcellus,,Autocuration,13181,,H,8,CHEMBL616657,,,
1667,1,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor in guinea-pig striatum in presence of BMY-7378 and mesulergine,Striatum,BAO_0000357,,Cavia porcellus,,Intermediate,12409,,D,9,CHEMBL616658,,2435.0,
1668,1,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of guinea pig substantia nigra,,BAO_0000357,,Cavia porcellus,,Intermediate,10639,,D,9,CHEMBL616659,,,
1669,1,Binding affinity against 5-hydroxytryptamine 1D receptor,,BAO_0000357,,,,Autocuration,5254,,H,8,CHEMBL616660,,,
1670,1,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta,,BAO_0000357,,,,Autocuration,13051,,H,8,CHEMBL616661,,,
1671,1,Maximum stimulation of [35S]GTP gamma-S binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor,,BAO_0000019,,,,Expert,3463,,H,8,CHEMBL616662,,,
1672,1,Ability to inhibit forskolin-stimulated adenylate cyclase in a cell line expressing human 5-hydroxytryptamine 1D receptor,,BAO_0000019,,,,Autocuration,15315,,H,8,CHEMBL616663,,,
1673,1,Ability to inhibit forskolin-stimulated adenylate cyclase activity in Chinese hamster ovary (CHO) stable cell lines expressing human 5-hydroxytryptamine 1D receptor,,BAO_0000019,,,,Autocuration,6011,,H,8,CHEMBL616664,,,
1674,1,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing 5-hydroxytryptamine 1D receptor",,BAO_0000219,,Homo sapiens,,Expert,14159,,D,9,CHEMBL881820,449.0,,
1675,1,"Compound was evaluated for the stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor.",,BAO_0000219,,,,Autocuration,14159,,H,8,CHEMBL616665,449.0,,
1676,1,Agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,,BAO_0000219,,,,Expert,15250,,H,8,CHEMBL616666,449.0,,
1677,1,Compound was tested for measuring agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor,,BAO_0000219,,,,Autocuration,15250,,H,8,CHEMBL616667,449.0,,
1678,1,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",,BAO_0000219,,,,Expert,15331,,H,8,CHEMBL616668,449.0,,
1679,1,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",,BAO_0000219,,Homo sapiens,,Expert,15332,,D,9,CHEMBL616669,449.0,,
1680,1,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the human 5-hydroxytryptamine 1D receptor.",,BAO_0000219,,,,Expert,15332,,H,8,CHEMBL617040,449.0,,
1681,1,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor",,BAO_0000219,,,,Autocuration,3294,,H,8,CHEMBL617041,449.0,,
1682,1,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor.",,BAO_0000219,,,,Expert,14158,,H,8,CHEMBL617042,449.0,,
1683,1,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor",,BAO_0000219,,,,Expert,14956,,H,8,CHEMBL617043,449.0,,
1684,1,Compound was evaluated for its agonistic activity on 5-hydroxytryptamine 1D receptor,,BAO_0000019,,,,Autocuration,12469,,H,8,CHEMBL617044,,,
1685,1,Measurement of agonist-induced [35S]-GTP gamma-S binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,,BAO_0000219,,,,Expert,3463,,H,8,CHEMBL617045,449.0,,
1686,1,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",,BAO_0000219,,Homo sapiens,,Expert,15250,,D,9,CHEMBL617046,449.0,,
1687,1,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",,BAO_0000219,,Homo sapiens,,Expert,15250,,D,9,CHEMBL617047,449.0,,
1688,1,"Efficacy was evaluated relative to human 5-hydroxytryptamine 1D receptor using [35S]GTP-gamma-S, as radioligand",,BAO_0000019,,,,Expert,14956,,H,8,CHEMBL617048,,,
1689,1,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor.",,BAO_0000019,,,,Autocuration,14159,,H,8,CHEMBL616897,,,
1690,1,"Maximum stimulation of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1D receptor relative to 5-HT",,BAO_0000019,,Homo sapiens,,Expert,14159,,D,9,CHEMBL616898,,,
1691,1,Percent efficacy relative to 5-HT treatment of CHO cells expressing 5-HT 1d receptor,,BAO_0000219,,Homo sapiens,,Expert,14499,,D,9,CHEMBL858201,449.0,,
1692,1,Intrinsic activity for 5-hydroxytryptamine 1D receptor,,BAO_0000019,,,,Autocuration,15315,,H,8,CHEMBL616899,,,
1693,1,Ability to displace [3H]- -5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in chinese hamster cells (CHO cells),,BAO_0000219,,,,Autocuration,3294,In vitro,H,8,CHEMBL616900,,,
1694,1,Ability to displace [3H]-5-HT from recombinant human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells determined in vitro,,BAO_0000219,,,,Expert,3463,,H,8,CHEMBL616901,449.0,,
1695,1,Affinity of compound towards 5-hydroxytryptamine 1D receptor was evaluated using radioligand binding technique,,BAO_0000357,,,,Autocuration,15331,,H,8,CHEMBL616902,,,
1696,1,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,BAO_0000219,,Homo sapiens,,Expert,14159,,D,9,CHEMBL616903,449.0,,
1697,1,Binding affinity by displacement to human cloned 5-hydroxytryptamine 1D receptor in CHO cells by [3H]5-HT displacement.,,BAO_0000219,,,,Expert,14158,,H,8,CHEMBL616904,449.0,,
1698,1,Compound was evaluated for the affinity at 5-hydroxytryptamine 1D receptor,,BAO_0000357,,,,Autocuration,14159,,H,8,CHEMBL616905,,,
1699,1,Binding affinity at human cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells by [3H]5-HT displacement.,,BAO_0000219,,,,Expert,15250,,H,8,CHEMBL616906,449.0,,
1700,1,Displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,BAO_0000219,,,,Expert,15250,,H,8,CHEMBL616907,449.0,,
1701,1,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,BAO_0000219,,,,Expert,15331,,H,8,CHEMBL616908,449.0,,
1702,1,Displacement of [3H]5-HT binding from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,BAO_0000219,,Homo sapiens,,Expert,15332,,D,9,CHEMBL616909,449.0,,
1703,1,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,BAO_0000219,,Homo sapiens,,Expert,14499,,D,9,CHEMBL616910,449.0,,
1704,1,Displacement of [3H]5-HT binding to the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,BAO_0000219,,,,Expert,15332,,H,8,CHEMBL616911,449.0,,
1705,1,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,BAO_0000219,,,,Expert,14956,,H,8,CHEMBL616912,449.0,,
1706,1,In vitro binding affinity against human 5-hydroxytryptamine 1D receptor at a concentration of 100 (nM),,BAO_0000357,,,,Autocuration,3805,,H,8,CHEMBL616913,,,
1707,1,Inhibition of [3H]5-HT binding to human 5-hydroxytryptamine 1D receptor expressed in CHO cells at 1 uM,,BAO_0000219,,Homo sapiens,,Expert,6011,,D,9,CHEMBL616914,449.0,,
1708,1,Binding affinity against 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,,BAO_0000219,,,,Autocuration,16190,,H,8,CHEMBL616915,449.0,,
1709,1,Binding affinity for 5-hydroxytryptamine 1D receptor in Cos-7 transfected cell type using [3H]5-CT as radioligand,,BAO_0000019,,,,Autocuration,14165,,H,8,CHEMBL616916,,,
1710,1,Binding affinity to cloned human 5-hydroxytryptamine 1D receptor,,BAO_0000357,,Homo sapiens,,Expert,4234,,D,9,CHEMBL616917,,,
1711,1,"Binding affinity towards 5-HT1D receptor, using [3H]5-HT as radioligand.",,BAO_0000357,,,,Autocuration,15527,,H,8,CHEMBL616918,,,
1712,1,Binding affinity towards human 5-hydroxytryptamine 1D receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,,BAO_0000219,,,,Expert,6328,,H,8,CHEMBL616919,,,
1713,1,Binding affinity towards human 5-hydroxytryptamine 1D receptor was determined using [3H]5-HT as radioligand,,BAO_0000357,,,,Autocuration,16209,,H,8,CHEMBL616920,,,
1714,1,Binding affinity for recombinant human 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand.,,BAO_0000357,,,,Autocuration,14770,,H,8,CHEMBL872914,,,
1715,1,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1D receptor using [3H]-5-CT as radioligand,,BAO_0000357,,,,Autocuration,2598,,H,8,CHEMBL616921,,,
1716,1,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1D receptor,,BAO_0000357,,,,Expert,6897,,H,8,CHEMBL616922,,,
1717,1,Binding affinity towards 5-hydroxytryptamine 1D receptor,,BAO_0000357,,,,Autocuration,6013,,H,8,CHEMBL616923,,,
1718,1,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,,BAO_0000357,,,,Expert,5843,,H,8,CHEMBL616924,,,
1719,1,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand,,BAO_0000357,,,,Expert,14454,,H,8,CHEMBL875909,,,
1720,1,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; Not determined,,BAO_0000357,,,,Autocuration,14454,,H,8,CHEMBL616925,,,
1721,1,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; not determined,,BAO_0000357,,,,Autocuration,14454,,H,8,CHEMBL616926,,,
1722,1,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1D receptor,,BAO_0000357,,,,Autocuration,15818,,H,8,CHEMBL616927,,,
1723,1,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1D receptor in CHO-K1 cells,,BAO_0000219,,,,Expert,13729,,H,8,CHEMBL616928,485.0,,
1724,1,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in Chinese hamster ovary cells (CHO cells),,BAO_0000219,,Homo sapiens,,Expert,6011,In vitro,D,9,CHEMBL616929,,,
1725,1,In vitro binding affinity to human 5-hydroxytryptamine 1D receptor,,BAO_0000357,,Homo sapiens,,Expert,4234,,D,9,CHEMBL616930,,,
1726,1,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,,BAO_0000019,,,,Expert,17085,,H,8,CHEMBL616931,,,
1727,1,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,,BAO_0000357,,,,Autocuration,3025,,H,8,CHEMBL616932,,,
1728,1,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor,,BAO_0000357,,,,Expert,15315,,H,8,CHEMBL616933,,,
1729,1,Receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor in Cos-7 cells,,BAO_0000219,,Homo sapiens,,Expert,14214,,D,9,CHEMBL616934,,,
1730,1,Binding affinity for human 5-hydroxytryptamine 1D receptor,,BAO_0000357,,Homo sapiens,,Expert,3804,,D,9,CHEMBL616935,,,
1731,1,The binding affinity towards the 5-hydroxytryptamine 1D receptor; No affinity,,BAO_0000357,,,,Autocuration,16700,,H,8,CHEMBL616936,,,
1732,1,Affinity for 5-hydroxytryptamine 1D receptor subtype,,BAO_0000357,,Homo sapiens,,Expert,2391,,D,9,CHEMBL616937,,,
1733,1,Binding affinity for human 5-hydroxytryptamine 1D receptor,,BAO_0000357,,Homo sapiens,,Expert,4175,,D,9,CHEMBL616938,,,
1734,1,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,,BAO_0000019,,,,Autocuration,17085,,H,8,CHEMBL616939,,,
1735,1,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor; ND means not determined,,BAO_0000019,,,,Expert,17085,,H,8,CHEMBL616940,,,
1736,1,Binding activity against human 5-hydroxytryptamine 1D receptor; NT means not tested,,BAO_0000357,,Homo sapiens,,Expert,15926,,D,9,CHEMBL616941,,,
1737,1,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; Not tested,,BAO_0000219,,,,Autocuration,16312,,H,8,CHEMBL616942,485.0,,
1738,1,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; not tested,,BAO_0000219,,,,Autocuration,16312,,H,8,CHEMBL616943,485.0,,
1739,1,Selectivity towards 5-HT1D and to that of 5-HT1B in CHO cells,,BAO_0000219,,,,Autocuration,14956,,H,4,CHEMBL616944,449.0,,
1740,1,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by the 5-HT",,BAO_0000019,,,,Autocuration,3294,,H,8,CHEMBL616945,,,
1741,1,Binding activity radioligand.,,BAO_0000357,,,,Autocuration,12861,,H,8,CHEMBL616946,,,
1742,1,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,BAO_0000019,,,,Autocuration,12861,,H,8,CHEMBL616947,,,
1743,1,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor,,BAO_0000219,,,,Expert,16312,,H,8,CHEMBL616948,485.0,,
1744,1,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,,BAO_0000357,,,,Autocuration,5104,,H,8,CHEMBL616851,,,
1745,1,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,,BAO_0000357,,,,Autocuration,5105,,H,8,CHEMBL616852,,,
1746,1,Measured as -log Ka on 5-hydroxytryptamine 1D receptor,,BAO_0000357,,,,Autocuration,14499,,H,8,CHEMBL616853,,,
1747,1,Binding activity against human 5-hydroxytryptamine 1D receptor,,BAO_0000357,,Homo sapiens,,Expert,15926,,D,9,CHEMBL616854,,,
1748,1,Binding affinity to human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,,BAO_0000219,,Homo sapiens,,Expert,4540,,D,9,CHEMBL616855,449.0,,
1749,1,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]-5-HT as radioligand.,,BAO_0000219,,,,Autocuration,15779,,H,8,CHEMBL616856,449.0,,
1750,1,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,BAO_0000219,,,,Autocuration,15779,,H,8,CHEMBL616857,449.0,,
1751,1,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,,BAO_0000357,,,,Autocuration,6166,,H,8,CHEMBL616858,,,
1752,1,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand.,,BAO_0000219,,,,Autocuration,15779,,H,8,CHEMBL616859,449.0,,
1753,1,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]-5-HT as radioligand.;ND means no data.,,BAO_0000219,,,,Autocuration,15779,,H,8,CHEMBL616860,449.0,,
1754,1,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,,BAO_0000219,,,,Autocuration,17451,,H,8,CHEMBL616861,722.0,,
1755,1,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,,BAO_0000219,,,,Autocuration,17451,,H,8,CHEMBL616541,722.0,,
1756,1,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand; Not determined,,BAO_0000219,,,,Autocuration,17451,,H,8,CHEMBL616542,722.0,,
1757,1,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as the radioligand,,BAO_0000219,,,,Autocuration,4199,,H,8,CHEMBL616543,449.0,,
1758,1,Binding affinity for human 5-hydroxytryptamine 1D receptor,,BAO_0000357,,Homo sapiens,,Expert,14875,,D,9,CHEMBL616544,,,
1759,1,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT,,BAO_0000219,,,,Autocuration,15146,,H,8,CHEMBL616545,449.0,,
1760,1,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1D receptor in CHO using [3H]5-HT as a radioligand,,BAO_0000357,,,,Autocuration,5213,,H,8,CHEMBL616546,,,
1761,1,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT.,,BAO_0000219,,,,Autocuration,14818,,H,8,CHEMBL616547,449.0,,
1762,1,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells, using [3H]5-HT as radioligand",,BAO_0000219,,,,Autocuration,4829,,H,8,CHEMBL616548,449.0,,
1763,1,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 1 uM,,BAO_0000019,,,,Expert,14454,,H,8,CHEMBL616549,,,
1764,1,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 10 uM,,BAO_0000019,,,,Expert,14454,,H,8,CHEMBL616550,,,
1765,1,Binding affinity against 5-HT2C receptor,,BAO_0000357,,,,Autocuration,5254,,H,8,CHEMBL857066,,,
1766,1,Binding affinity against 5-hydroxytryptamine 1D receptor,,BAO_0000357,,,,Autocuration,5254,,H,8,CHEMBL616551,,,
1767,1,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,,BAO_0000357,,,,Autocuration,10639,,H,8,CHEMBL616552,,,
1768,1,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,,BAO_0000019,,,,Autocuration,10639,,H,8,CHEMBL832876,,,
1769,1,"Binding affinity for 5-hydroxytryptamine 1B receptor in rat cortex, striatum and globus pallidus",,BAO_0000019,,,,Expert,12352,,H,8,CHEMBL616553,,,
1770,1,Binding affinity towards 5-HT1B was determined,,BAO_0000357,,,,Autocuration,9098,,H,8,CHEMBL616554,,,
1771,1,Affinity towards 5-hydroxytryptamine 1B receptor in membranes from rat frontal cortex using [3H]5-HT,,BAO_0000019,,,,Expert,14430,,H,8,CHEMBL616555,,,
1772,1,"Binding affinity to 5-HT1B receptors using rat cortex+striatum + globus pallidus,[3H]-5-OH-tryptamine, and serotonin for NSB",,BAO_0000019,,,,Expert,13657,,H,8,CHEMBL616556,,,
1773,1,"Compound was evaluated for binding affinity on 5-HT1B receptors using rat cortex+striatum+ globus pallidus,[ 3H]-5-OH-tryptamine, and serotonin for NSB.",,BAO_0000019,,,,Autocuration,13657,,H,8,CHEMBL616557,,,
1774,1,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,BAO_0000019,,,,Expert,15854,,H,8,CHEMBL616558,,,
1775,1,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT,,BAO_0000019,,Rattus norvegicus,,Expert,10639,,D,9,CHEMBL616749,,,
1776,1,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,,BAO_0000357,,,,Autocuration,10025,,H,8,CHEMBL616750,,,
1777,1,"Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol, binds to 5-hydroxytryptamine 1B receptor at 1 uM",,BAO_0000357,,,,Autocuration,10025,,H,8,CHEMBL616751,,,
1778,1,In vitro inhibitory concentration against radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,,BAO_0000249,,,,Autocuration,14286,,H,8,CHEMBL616752,,,
1779,1,Inhibition of [3H]-5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Residual radioligand binding higher than 50%,Striatum,BAO_0000019,,,,Autocuration,3651,,H,8,CHEMBL616753,,2435.0,
1780,1,Inhibition of radiolabeled [3H]-5-HT ligand binding to 5-hydroxytryptamine 1B receptor,,BAO_0000357,,Rattus norvegicus,,Expert,14178,,D,9,CHEMBL616754,,,
1781,1,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT as the radioligand.,,BAO_0000019,,,,Autocuration,10639,,H,8,CHEMBL616755,,,
1782,1,Inhibitory activity against [3H]5-HT binding to 5-HT1B receptor in rat striatum,Striatum,BAO_0000019,,,,Autocuration,13605,,H,8,CHEMBL616756,,2435.0,
1783,1,Inhibitory concentration required against 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT,Striatum,BAO_0000019,,,,Autocuration,5834,,H,8,CHEMBL616757,,2435.0,
1784,1,compound was measured for affinity against 5-hydroxytryptamine 1B receptor labelled with [3H]5-HT radioligand in striatum tissue,Striatum,BAO_0000357,,,,Autocuration,10922,,H,8,CHEMBL616758,,2435.0,
1785,1,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,,BAO_0000249,,,,Autocuration,14286,,H,8,CHEMBL616759,,,
1786,1,In vitro binding affinity towards the 5-hydroxytryptamine 1B receptor at 10 e-6 M,,BAO_0000357,,,,Autocuration,11825,,H,8,CHEMBL616760,,,
1787,1,Ability to displace [3H]5-HT bound to 5-hydroxytryptamine 1B receptor in rat striatum,Striatum,BAO_0000019,,,,Autocuration,14826,,H,8,CHEMBL616761,,2435.0,
1788,1,Binding affinity against 5-HT1B serotonin receptor in rat striatum,Striatum,BAO_0000019,,,,Autocuration,9699,,H,8,CHEMBL616762,,2435.0,
1789,1,Binding affinity against 5-hydroxytryptamine 1B receptor in membranes of Rat cerebral cortex,,BAO_0000019,,,,Autocuration,14423,,H,8,CHEMBL616763,,,
1790,1,Binding affinity at rat 5-hydroxytryptamine 1B receptor by [3H]5-HT displacement.,,BAO_0000357,,,,Expert,10062,,H,8,CHEMBL872909,,,
1791,1,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,,BAO_0000357,,,,Autocuration,10062,,H,8,CHEMBL616764,,,
1792,1,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor,,BAO_0000357,,Rattus norvegicus,,Expert,12280,,D,9,CHEMBL616765,,,
1793,1,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum,Striatum,BAO_0000357,,,,Autocuration,15412,,H,8,CHEMBL616766,,2435.0,
1794,1,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum.,Striatum,BAO_0000357,,,,Autocuration,15412,,H,8,CHEMBL616767,,2435.0,
1795,1,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,,BAO_0000357,,,,Autocuration,10062,,H,8,CHEMBL616768,,,
1796,1,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,,BAO_0000357,,,,Autocuration,11147,,H,8,CHEMBL616769,,,
1797,1,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat was determined using 50 uL of [125I]ICYP in binding assay,,BAO_0000019,,,,Autocuration,9547,,H,8,CHEMBL616770,,,
1798,1,Binding affinity was determined against 5-hydroxytryptamine 1B receptor was determined in male Sprague-Dawley rat brain.,,BAO_0000019,,,,Autocuration,10444,,H,8,CHEMBL616771,,,
1799,1,Binding affinity was measured on 5-hydroxytryptamine 1B receptor in rat striatum labeled with [3H]5-HT,Striatum,BAO_0000019,,,,Autocuration,12469,,H,8,CHEMBL616772,,2435.0,
1800,1,Binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand.,,BAO_0000019,,,,Expert,9098,,H,8,CHEMBL616773,,,
1801,1,Compound was evaluated for the binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand; ND is no data.,,BAO_0000019,,,,Autocuration,9098,,H,8,CHEMBL616774,,,
1802,1,Evaluated for binding affinity towards 5-hydroxytryptamine 1B receptor,,BAO_0000357,,,,Autocuration,9699,,H,8,CHEMBL616775,,,
1803,1,Inhibitory activity against 5-hydroxytryptamine 1B receptor in rat cortical membranes using [3H]5-HT as a radioligand,,BAO_0000249,,,,Autocuration,10394,,H,8,CHEMBL616776,,,
1804,1,The binding affinity was measured on 5-hydroxytryptamine 1B receptor using [3H]- serotonin as radioligand.,,BAO_0000357,,,,Autocuration,12092,,H,8,CHEMBL616777,,,
1805,1,The binding affinity towards the receptor rat 5-hydroxytryptamine 1B receptor; No affinity,,BAO_0000357,,,,Autocuration,16700,,H,8,CHEMBL616778,,,
1806,1,Binding affinity against 5-hydroxytryptamine 1B receptor in rat striatal membranes using [3H]5-HT as radioligand,,BAO_0000249,,Rattus norvegicus,,Expert,403,,D,9,CHEMBL616779,,,
1807,1,Binding affinity towards 5-hydroxytryptamine 1B receptor,,BAO_0000357,,Rattus norvegicus,,Expert,12771,,D,9,CHEMBL616780,,,
1808,1,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1B receptor by displacing [3H]serotonin radioligand in rat cerebral cortex,,BAO_0000019,,,,Autocuration,11642,,H,8,CHEMBL616781,,,
1809,1,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand,,BAO_0000357,,,,Autocuration,12953,,H,8,CHEMBL616782,,,
1810,1,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand.,,BAO_0000357,,,,Autocuration,12953,,H,8,CHEMBL616783,,,
1811,1,Binding affinity for 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT as radioligand,Striatum,BAO_0000019,,,,Expert,12953,,H,8,CHEMBL616784,,2435.0,
1812,1,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand; Nonactive at 10 uM,,BAO_0000357,,,,Autocuration,12953,,H,8,CHEMBL616785,,,
1813,1,Binding affinity against 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,Brain,BAO_0000249,,,,Autocuration,9737,,H,8,CHEMBL857067,,955.0,
1814,1,Binding affinity against 5-HT1B receptor in rat frontal cortex using [3H]-5-HT in presence of 0.1 uM [3H]-8-OH-DPAT as a radioligand,,BAO_0000019,,,,Autocuration,9737,,H,8,CHEMBL616786,,,
1815,1,Binding affinity towards 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,Brain,BAO_0000249,,,,Autocuration,9737,,H,8,CHEMBL616787,,955.0,
1816,1,Binding affinity towards 5-hydroxytryptamine 2C receptor of porcine choroid plexus using [3H]mesulergine,,BAO_0000357,,,,Autocuration,12827,,H,8,CHEMBL616788,,,
1817,1,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-hydroxytryptamine 1B receptor,,BAO_0000357,,,,Autocuration,5033,,H,8,CHEMBL616789,,,
1818,1,Displacement of [3H]5-HT from 5-HT1B receptor of rat frontal cortex homogenate,,BAO_0000019,,Rattus norvegicus,,Expert,9786,,D,9,CHEMBL616790,,,
1819,1,Binding affinity at 5-hydroxytryptamine 1B receptor,,BAO_0000357,,,,Expert,13116,,H,8,CHEMBL616791,,,
1820,1,In vitro binding affinity at 5-hydroxytryptamine 1B receptor in rat striatal muscles using [125I](-)-iodocyanopindolol as the radioligand,,BAO_0000019,,,,Autocuration,16429,,H,8,CHEMBL616792,,,
1821,1,In vitro binding affinity towards 5-hydroxytryptamine 1B receptor in rat striatal membrane with [125I]- iodocyanopindolol,,BAO_0000249,,Rattus norvegicus,,Expert,12409,,D,9,CHEMBL616793,,,
1822,1,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,,BAO_0000357,,,,Autocuration,15194,,H,8,CHEMBL616794,,,
1823,1,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,BAO_0000357,,,,Autocuration,15194,,H,8,CHEMBL616795,,,
1824,1,Binding affinity towards 5-HT2 receptor by the displacement of [3H]-ketanserin] in rat cerebral cortex,,BAO_0000019,,,,Autocuration,5486,,H,4,CHEMBL616796,,,
1825,1,Compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,,BAO_0000357,,,,Autocuration,4639,,H,8,CHEMBL616797,,,
1826,1,The compound was evaluated for its ability to displace [3H]5-HT from 5-hydroxytryptamine 1B receptor in cellular brain membranes,,BAO_0000249,,,,Autocuration,386,,H,8,CHEMBL616798,,,
1827,1,Compound was measured for its binding affinity at 5-hydroxytryptamine 1B receptor at a concentration of 100 nM using [125I]CYP as radioligand,,BAO_0000357,,,,Autocuration,2474,,H,8,CHEMBL616799,,,
1828,1,Inhibition of binding towards 5-hydroxytryptamine 1B receptor at 100 nM concentration,,BAO_0000357,,,,Autocuration,6011,,H,8,CHEMBL616800,,,
1829,1,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1B receptor,,BAO_0000357,,,,Autocuration,5014,,H,8,CHEMBL616801,,,
1830,1,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1B receptor; inactive at 10 uM,,BAO_0000357,,,,Autocuration,17515,,H,8,CHEMBL616802,,,
1831,1,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1B receptor was determined,,BAO_0000357,,,,Autocuration,4373,,H,8,CHEMBL616803,,,
1832,1,Binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]5-HT.,,BAO_0000357,,,,Expert,1633,,H,8,CHEMBL857068,,,
1833,1,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]ketanserin.,,BAO_0000357,,,,Autocuration,1633,,H,8,CHEMBL616804,,,
1834,1,Binding affinity for 5-hydroxytryptamine 1B receptor was determined,,BAO_0000357,,,,Autocuration,4373,,H,8,CHEMBL616805,,,
1835,1,Evaluated for the binding affinity to 5-hydroxytryptamine 1B receptor,,BAO_0000357,,,,Autocuration,4687,,H,8,CHEMBL616806,,,
1836,1,Binding affinity against 5-hydroxytryptamine 1B receptor,,BAO_0000357,,,,Autocuration,11574,,H,8,CHEMBL616807,,,
1837,1,Binding affinity for 5-hydroxytryptamine 1B receptor was determined by using [3H]5-HT as radioligand,,BAO_0000357,,,,Autocuration,10321,,H,8,CHEMBL616808,,,
1838,1,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,BAO_0000357,,,,Autocuration,15527,,H,8,CHEMBL616809,,,
1839,1,Inhibitory constant against 5-hydroxytryptamine 1B receptor using with [125I]- cyanopindolol radioligand,,BAO_0000357,,,,Autocuration,17200,,H,8,CHEMBL616810,,,
1840,1,Binding affinity against 5-hydroxytryptamine 1B receptor - 5-hydroxytryptamine 1D receptor using [3H]5-HT as the radioligand.,,BAO_0000224,,,,Autocuration,14423,,H,4,CHEMBL616811,,,
1841,1,Inhibitory concentration required against 5-hydroxytryptamine 1C receptor in bovine choroid plexus using [3H]mesulergine,,BAO_0000357,,Bos taurus,,Autocuration,5834,,H,8,CHEMBL616812,,,
1842,1,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,,BAO_0000357,,Sus scrofa,,Autocuration,11473,,H,8,CHEMBL616813,,,
1843,1,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1C receptor in pig choroid plexus using [3H]mesulergine as radioligand,,BAO_0000357,,Sus scrofa,,Autocuration,11473,,H,8,CHEMBL616814,,,
1844,1,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,,BAO_0000357,,Sus scrofa,,Autocuration,10639,,H,8,CHEMBL616815,,,
1845,1,inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,,BAO_0000357,,Sus scrofa,,Autocuration,10639,,H,8,CHEMBL616816,,,
1846,1,Binding affinity of compound towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine (1.2 nM) ligand in choroid Plexus pig was determined,,BAO_0000357,,Sus scrofa,,Autocuration,14331,,H,8,CHEMBL616817,,,
1847,1,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1C receptor,,BAO_0000357,,Sus scrofa,,Autocuration,10796,,H,8,CHEMBL616818,,,
1848,1,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 2C receptor binding site by using [3H]-MES as a radioligand.,,BAO_0000357,,Sus scrofa,,Expert,9098,,H,8,CHEMBL616819,,,
1849,1,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 1C receptor of pig choroid Plexus,,BAO_0000357,,Sus scrofa,,Expert,14331,,H,8,CHEMBL616820,,,
1850,1,Displacement of [3H]mesulergine from pig cortex 5-hydroxytryptamine 1C receptor,,BAO_0000019,,Sus scrofa,,Expert,11828,,H,8,CHEMBL616821,,,
1851,1,Binding affinity for 5-hydroxytryptamine 1C receptor in piglet choroid plexus using [3H]5-HT,,BAO_0000357,,Sus scrofa,,Autocuration,11866,,H,8,CHEMBL616822,,,
1852,1,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,,BAO_0000019,,Oryctolagus cuniculus,,Autocuration,13047,,H,8,CHEMBL616823,,,
1853,1,Tested for the effect on binding at 5-hydroxytryptamine 1C receptor; No activity,,BAO_0000357,,Rattus norvegicus,,Autocuration,188,,D,9,CHEMBL616824,,,
1854,1,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,,BAO_0000357,,Rattus norvegicus,,Autocuration,11825,,D,9,CHEMBL616825,,,
1855,1,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,,BAO_0000357,,Rattus norvegicus,,Autocuration,11825,,D,9,CHEMBL616826,,,
1856,1,Binding affinity against 5-hydroxytryptamine 1C receptor in rat using [3H]mesulergine as radioligand,,BAO_0000019,,Rattus norvegicus,,Expert,11624,,D,9,CHEMBL616827,,,
1857,1,Binding affinity towards 5-hydroxytryptamine 1C receptor using [125 I]-SCH23982 as radioligand in competitive binding assay,,BAO_0000357,,Rattus norvegicus,,Autocuration,11139,,D,9,CHEMBL616828,,,
1858,1,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,,BAO_0000357,,Rattus norvegicus,,Autocuration,11147,,D,9,CHEMBL616829,,,
1859,1,Binding affinity was determined against 5-hydroxytryptamine 1C receptor was determined in male Sprague-Dawley rat brain.,,BAO_0000019,,Rattus norvegicus,,Autocuration,10444,,D,9,CHEMBL616830,,,
1860,1,Binding affinity against 5-hydroxytryptamine 1C receptor,,BAO_0000357,,Rattus norvegicus,,Expert,11624,,D,9,CHEMBL616831,,,
1861,1,"Compound was tested for binding affinity towards 5-HT1C (5-HT1C) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,BAO_0000019,,Rattus norvegicus,,Autocuration,11662,,D,9,CHEMBL616832,,,
1862,1,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,BAO_0000019,,Rattus norvegicus,,Autocuration,11662,,D,9,CHEMBL616833,,,
1863,1,"Binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,BAO_0000019,,Rattus norvegicus,,Expert,11662,,D,9,CHEMBL616834,,,
1864,1,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,BAO_0000019,,Rattus norvegicus,,Autocuration,11662,,D,9,CHEMBL829595,,,
1865,1,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 1C receptor binding site by using [3H]- MES as a radioligand.,,BAO_0000357,,Rattus norvegicus,,Autocuration,9098,,D,9,CHEMBL616835,,,
1866,1,Inhibitory activity against 5-hydroxytryptamine 1C receptor in rat cortical membranes using [3H]mesulergine as a radioligand,,BAO_0000249,,Rattus norvegicus,,Autocuration,10394,,D,9,CHEMBL872910,,,
1867,1,Tested for binding affinity against 5-hydroxytryptamine 1C receptor from rat frontal cortical regions using [3H]mesulergine as radioligand,,BAO_0000357,,,,Expert,11933,,H,8,CHEMBL616836,,,
1868,1,The binding affinity was measured on 5-hydroxytryptamine 1C receptor using [3H]- serotonin as radioligand.,,BAO_0000357,,Rattus norvegicus,,Autocuration,12092,,D,9,CHEMBL616837,,,
1869,1,Binding affinity of 5-hydroxytryptamine 1C receptor using [3H]- ketanserin in rat frontal cortex,,BAO_0000019,,Rattus norvegicus,,Autocuration,12253,,D,9,CHEMBL616466,,,
1870,1,Binding affinity towards rat 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand expressed in 293 cells,,BAO_0000219,,Rattus norvegicus,,Autocuration,12253,,D,9,CHEMBL616467,722.0,,
1871,1,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,,BAO_0000357,,,,Autocuration,1558,,H,8,CHEMBL616468,,,
1872,1,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,,BAO_0000357,,,,Autocuration,2474,,H,8,CHEMBL616469,,,
1873,1,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,,BAO_0000357,,,,Autocuration,2474,,H,8,CHEMBL616470,,,
1874,1,Binding affinity against 5-hydroxytryptamine 1C receptor,,BAO_0000357,,,,Autocuration,11574,,H,8,CHEMBL616471,,,
1875,1,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,,BAO_0000357,,,,Autocuration,1558,,H,8,CHEMBL616472,,,
1876,1,Binding affinity against 5-hydroxytryptamine 1C receptor,,BAO_0000357,,,,Autocuration,13944,,H,8,CHEMBL616473,,,
1877,1,Binding affinity against serotonergic 5-HT1c receptor,,BAO_0000357,,,,Autocuration,13033,,H,8,CHEMBL616474,,,
1878,1,Binding affinity for 5-hydroxytryptamine 1C receptor was determined by using [3H]- mesulergine as radioligand,,BAO_0000357,,,,Autocuration,10321,,H,8,CHEMBL616475,,,
1879,1,Binding affinity for 5-hydroxytryptamine 1C receptor was determined,,BAO_0000357,,,,Autocuration,11866,,H,8,CHEMBL616476,,,
1880,1,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,BAO_0000019,,Oryctolagus cuniculus,,Autocuration,14454,,H,8,CHEMBL616477,,,
1881,1,Binding affinity against 5-hydroxytryptamine 2 receptor using [125I]DOI as radioligand.,,BAO_0000224,,,,Autocuration,11574,,H,4,CHEMBL616478,,,
1882,1,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ket as radioligand.,,BAO_0000224,,,,Autocuration,11574,,H,4,CHEMBL616479,,,
1883,1,Binding affinity towards serotonin 5-HT2 receptor was determined in rat cortex using [3H]spiperone as ligand,,BAO_0000019,,,,Autocuration,13631,,H,4,CHEMBL616480,,,
1884,1,Binding affinity towards 5-hydroxytryptamine 2 receptor as antagonism of serotonin-induced contractions in rat jugular vein,,BAO_0000019,,Rattus norvegicus,,Autocuration,9630,,D,5,CHEMBL616481,,,
1885,1,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain cortical membranes,,BAO_0000249,,Rattus norvegicus,,Autocuration,8822,,D,5,CHEMBL616482,,,
1886,1,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain using [3H]spiroperidol,Brain,BAO_0000221,,Rattus norvegicus,,Autocuration,9064,,D,5,CHEMBL884713,,955.0,
1887,1,Binding affinity towards 5-hydroxytryptamine 2 receptor measured using radioligand ([3H]spiperone) binding assay,,BAO_0000224,,,,Autocuration,8868,,H,4,CHEMBL616483,,,
1888,1,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- spiroperidol,,BAO_0000224,,,,Autocuration,9064,,H,4,CHEMBL616484,,,
1889,1,Binding affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenates by [3H]-spiperone displacement.,,BAO_0000019,,,,Autocuration,9806,,H,4,CHEMBL616485,,,
1890,1,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,BAO_0000224,,,,Autocuration,9098,,H,4,CHEMBL616486,,,
1891,1,Binding affinity towards 5-hydroxytryptamine 2 receptor was measured using radioligand ([3H]spiperone) binding assay,,BAO_0000224,,,,Autocuration,8868,,H,4,CHEMBL616487,,,
1892,1,Binding affinity at serotonin 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,,BAO_0000224,,,,Autocuration,12765,,H,4,CHEMBL616488,,,
1893,1,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,BAO_0000019,,,,Autocuration,11049,,H,4,CHEMBL616489,,,
1894,1,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,BAO_0000019,,,,Autocuration,11049,,H,4,CHEMBL616490,,,
1895,1,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]-Ketanserin as radioligand; not determined,,BAO_0000019,,,,Autocuration,11049,,H,4,CHEMBL616491,,,
1896,1,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand; ND-Not determined,,BAO_0000019,,,,Autocuration,11049,,H,4,CHEMBL616492,,,
1897,1,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,BAO_0000019,,,,Autocuration,11049,,H,4,CHEMBL616493,,,
1898,1,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [125I]DOI as radioligand,,BAO_0000019,,,,Autocuration,11473,,H,4,CHEMBL616494,,,
1899,1,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [3H]ketanserin as radioligand,,BAO_0000019,,,,Autocuration,11473,,H,4,CHEMBL616495,,,
1900,1,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat pre frontal cortex,,BAO_0000019,,,,Autocuration,3086,,H,4,CHEMBL616496,,,
1901,1,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,BAO_0000019,,,,Autocuration,11049,,H,4,CHEMBL616497,,,
1902,1,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,BAO_0000019,,,,Autocuration,11049,,H,4,CHEMBL616498,,,
1903,1,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 2 receptor of rat anterior cortex using [3H]ketanserin as the radioligand,,BAO_0000019,,,,Autocuration,10639,,H,4,CHEMBL616499,,,
1904,1,Compound was measured for affinity at 5-hydroxytryptamine 2 receptor in rat cortical by [3H]spiroperidol displacement.,,BAO_0000019,,,,Autocuration,10922,,H,4,CHEMBL616500,,,
1905,1,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,Brain,BAO_0000221,,Rattus norvegicus,,Autocuration,9064,,D,5,CHEMBL616501,,955.0,
1906,1,Compound was tested for its inhibitory effect on the binding profile in 5-hydroxytryptamine 2 receptor using [3H]spiroperidol in rat brain.,Brain,BAO_0000221,,,,Autocuration,10748,,H,4,CHEMBL616502,,955.0,
1907,1,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor from rat cortical membranes.,,BAO_0000249,,,,Autocuration,11614,,H,4,CHEMBL884529,,,
1908,1,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,,BAO_0000249,,,,Autocuration,11615,,H,4,CHEMBL616503,,,
1909,1,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor,,BAO_0000224,,,,Autocuration,11615,,H,4,CHEMBL616964,,,
1910,1,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor from rat cortical membranes.,,BAO_0000249,,,,Autocuration,11614,,H,4,CHEMBL616965,,,
1911,1,Inhibition of [3H]ketanserin binding to rat 5-hydroxytryptamine 2 receptors.,,BAO_0000224,,,,Autocuration,11702,,H,4,CHEMBL616966,,,
1912,1,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor; NT=Not tested,,BAO_0000224,,,,Autocuration,11702,,H,4,CHEMBL616967,,,
1913,1,Inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor,,BAO_0000224,,Rattus norvegicus,,Autocuration,11702,,D,5,CHEMBL616968,,,
1914,1,Compound was tested for the inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor; NT=Not tested,,BAO_0000224,,,,Autocuration,11702,,H,4,CHEMBL616969,,,
1915,1,Inhibition of [3H]ketanserin binding at 5-hydroxytryptamine 2 receptor from rat frontal cortex.,,BAO_0000019,,,,Autocuration,13346,,H,4,CHEMBL884530,,,
1916,1,Concentration necessary to achieve half maximal inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor,,BAO_0000224,,,,Autocuration,10025,,H,4,CHEMBL616970,,,
1917,1,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,,BAO_0000224,,,,Autocuration,10025,,H,4,CHEMBL616971,,,
1918,1,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",,BAO_0000224,,,,Autocuration,10025,,H,4,CHEMBL616972,,,
1919,1,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]-spiperone,,BAO_0000224,,,,Autocuration,9036,,H,4,CHEMBL616973,,,
1920,1,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]spiperone; IA=Inactive,,BAO_0000224,,,,Autocuration,9036,,H,4,CHEMBL616974,,,
1921,1,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.,,BAO_0000019,,,,Autocuration,9161,,H,4,CHEMBL616975,,,
1922,1,Inhibition of binding of radioligand [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cerebral cortex,,BAO_0000019,,,,Autocuration,12304,,H,4,CHEMBL616976,,,
1923,1,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand.,,BAO_0000224,,,,Autocuration,13276,,H,4,CHEMBL616977,,,
1924,1,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,,BAO_0000224,,,,Autocuration,11825,,H,4,CHEMBL616978,,,
1925,1,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 2 receptor by displacement of [3H]- ketanserin,,BAO_0000224,,,,Autocuration,12443,,H,4,CHEMBL616979,,,
1926,1,In vitro inhibitory activity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor,,BAO_0000224,,,,Autocuration,13830,,H,4,CHEMBL616980,,,
1927,1,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes,,BAO_0000249,,,,Autocuration,9592,,H,4,CHEMBL616981,,,
1928,1,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes; Not tested,,BAO_0000249,,,,Autocuration,9592,,H,4,CHEMBL616982,,,
1929,1,Inhibitory activity against 5-hydroxytryptamine 2 receptor by 3H ligand binding experiments.,,BAO_0000224,,,,Autocuration,10881,,H,4,CHEMBL616983,,,
1930,1,Inhibitory activity against [3H]spiroperidol binding to 5-HT2 receptor in rat cortex,,BAO_0000019,,,,Autocuration,13605,,H,4,CHEMBL616984,,,
1931,1,Inhibitory activity against 5-hydroxytryptamine 2 receptor,,BAO_0000224,,Rattus norvegicus,,Autocuration,11624,,D,5,CHEMBL616985,,,
1932,1,Inhibitory concentration against 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,,BAO_0000224,,,,Autocuration,4101,,H,4,CHEMBL616986,,,
1933,1,Inhibitory concentration against binding of 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,,BAO_0000224,,,,Autocuration,4101,,H,4,CHEMBL616987,,,
1934,1,Inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat,,BAO_0000019,,,,Autocuration,15360,,H,4,CHEMBL616988,,,
1935,1,Inhibitory concentration against radioligand [3H]spiperone binding to 5-hydroxytryptamine 2 receptor in rat cortex,,BAO_0000019,,,,Autocuration,11576,,H,4,CHEMBL617243,,,
1936,1,Inhibitory concentration required against 5-hydroxytryptamine 2 receptor in rat cortex using [3H]spiperone,,BAO_0000019,,,,Autocuration,5834,,H,4,CHEMBL617244,,,
1937,1,Inhibitory concentration against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,,BAO_0000219,,Rattus norvegicus,,Autocuration,2395,,D,5,CHEMBL617245,485.0,,
1938,1,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,,BAO_0000249,,,,Autocuration,11965,,H,4,CHEMBL617246,,,
1939,1,The compound was evaluated for the ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor ( striata of male wistar rats),,BAO_0000224,,,,Autocuration,3967,,H,4,CHEMBL617546,,,
1940,1,The concentration required to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat brain membranes (in vitro),,BAO_0000249,,,,Autocuration,11130,,H,4,CHEMBL617547,,,
1941,1,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,,BAO_0000219,,,,Autocuration,13427,In vitro,H,4,CHEMBL617548,,,
1942,1,Binding affinity towards 5-hydroxytryptamine 2 receptor,,BAO_0000224,,,,Autocuration,9443,,H,4,CHEMBL617549,,,
1943,1,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,,BAO_0000224,,,,Autocuration,9443,,H,4,CHEMBL617550,,,
1944,1,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,,BAO_0000224,,,,Autocuration,11825,,H,4,CHEMBL617551,,,
1945,1,Percent inhibition of binding of 1.0 nM [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e -5 M,,BAO_0000249,,,,Autocuration,12120,,H,4,CHEMBL617552,,,
1946,1,Percent inhibition of binding of 1.0 nM [3H]-ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e-5 M.,,BAO_0000249,,,,Autocuration,12120,,H,4,CHEMBL617553,,,
1947,1,Tested for antagonistic activity against 5-hydroxytryptamine 2 receptor from rat thoracic aorta,Thoracic aorta,BAO_0000019,,,,Autocuration,11963,,H,4,CHEMBL617554,,1515.0,
1948,1,Binding affinity for membrane-bound 5-hydroxytryptamine 2 receptor,,BAO_0000019,,,,Autocuration,9069,,H,4,CHEMBL617555,,,
1949,1,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,,BAO_0000224,,,,Autocuration,8868,,H,4,CHEMBL617556,,,
1950,1,Inhibitory constant against human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,,BAO_0000357,,,,Autocuration,17200,,H,8,CHEMBL617557,,,
1951,1,Inhibitory constant against human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,,BAO_0000357,,,,Autocuration,17200,,H,8,CHEMBL617558,,,
1952,1,Binding affinity against 5-hydroxytryptamine 1D receptor was measured using [3H]5-HT as radioligand,,BAO_0000357,,,,Expert,13969,,H,8,CHEMBL617559,,,
1953,1,Binding affinity for 5-hydroxytryptamine 1D receptor,,BAO_0000357,,,,Expert,13392,,D,9,CHEMBL617560,,,
1954,1,Compound was tested for its ability to displace [125I]GTI binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,BAO_0000249,,,,Autocuration,1742,,H,8,CHEMBL617561,,,
1955,1,Compound was tested for its ability to displace [3H]-5-HT binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,BAO_0000249,,,,Autocuration,1742,,H,8,CHEMBL617562,,,
1956,1,Binding affinity against 5-hydroxytryptamine 1D receptor using [3H]5-HT in pig striatum + frontalCortex,Striatum,BAO_0000357,,,,Autocuration,14331,,H,8,CHEMBL617563,,2435.0,
1957,1,Relative agonist efficacy against 1 uM 5-hydroxytryptamine 1D receptor,,BAO_0000019,,,,Autocuration,12861,,H,8,CHEMBL617564,,,
1958,1,Binding activity against 5-hydroxytryptamine 1D receptor from pig caudate membrane using [3H]5-HT as radioligand,,BAO_0000019,,,,Expert,12861,,H,8,CHEMBL617565,,,
1959,1,Binding activity radioligand.,,BAO_0000357,,,,Autocuration,12861,,H,8,CHEMBL856076,,,
1960,1,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,BAO_0000019,,,,Autocuration,12861,,H,8,CHEMBL617566,,,
1961,1,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,BAO_0000019,,,,Expert,12861,,H,8,CHEMBL875911,,,
1962,1,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,,BAO_0000019,,,,Autocuration,12861,,H,8,CHEMBL617567,,,
1963,1,Compound was tested for the displacement of [3H]-5-HT to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,BAO_0000249,,,,Autocuration,675,,H,8,CHEMBL617568,,,
1964,1,Displacement of [3H]5-HT binding to 5-hydroxytryptamine 1D receptor from pig caudate membrane,,BAO_0000019,,,,Expert,12490,,H,8,CHEMBL617569,,,
1965,1,Displacement of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1D receptor in pig caudate membrane,,BAO_0000249,,,,Expert,11828,,H,8,CHEMBL617570,,,
1966,1,Binding affinity for 5-hydroxytryptamine 1D receptor in piglet caudate using [3H]5-HT,,BAO_0000357,,,,Autocuration,11866,,H,8,CHEMBL617571,,,
1967,1,In Vitro Binding affinity againist 5-hydroxytryptamine 1D receptor by displacing [125I]GTI from pig caudate,,BAO_0000357,,Sus scrofa,,Autocuration,773,,H,8,CHEMBL617572,,,
1968,1,The compound was tested for intrinsic activity against 5-HT1D receptor,,BAO_0000357,,Oryctolagus cuniculus,,Expert,13047,,H,8,CHEMBL617573,,,
1969,1,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,BAO_0000019,,Oryctolagus cuniculus,,Autocuration,13047,,H,8,CHEMBL617574,,,
1970,1,The compound was tested for binding affinity against 5-HT1D receptor,,BAO_0000357,,Oryctolagus cuniculus,,Expert,13047,,H,8,CHEMBL617575,,,
1971,1,Tested for the effect on binding at 5-hydroxytryptamine 1D receptor; No activity,,BAO_0000357,,,,Autocuration,188,,H,8,CHEMBL617576,,,
1972,1,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of rat substantia nigra,,BAO_0000019,,,,Autocuration,10639,,H,8,CHEMBL617577,,,
1973,1,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor,,BAO_0000019,,,,Autocuration,12438,,H,8,CHEMBL617578,,,
1974,1,Binding affinity was measured against serotonin 5-hydroxytryptamine 1D receptor,,BAO_0000357,,,,Autocuration,12438,,H,8,CHEMBL617579,,,
1975,1,Binding affinity towards 5-hydroxytryptamine 1D receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,BAO_0000019,,,,Expert,15854,,H,8,CHEMBL617580,,,
1976,1,Inhibitory activity against 5-hydroxytryptamine 1D receptor in rat cortical membranes using [3H]5-HT as a radioligand,,BAO_0000249,,,,Autocuration,10394,,H,8,CHEMBL617581,,,
1977,1,The binding affinity was measured on 5-hydroxytryptamine 1D receptor using [3H]- serotonin as radioligand.,,BAO_0000357,,,,Autocuration,12092,,H,8,CHEMBL617582,,,
1978,1,Binding affinity to 5-hydroxytryptamine 1D receptor in the rat forebrain by [3H]- SB-204269 displacement.,,BAO_0000019,,,,Expert,3389,,H,8,CHEMBL617583,,,
1979,1,Inhibition of binding towards 5-hydroxytryptamine 1D receptor at 100 nM concentration,,BAO_0000357,,,,Autocuration,6011,,H,8,CHEMBL617584,,,
1980,1,Compound was tested for binding affinity against 5-hydroxytryptamine 1D receptor,,BAO_0000357,,,,Autocuration,4639,,H,8,CHEMBL617585,,,
1981,1,Compound was measured for its binding affinity at 5-hydroxytryptamine 1D receptor at a concentration of 10 uM using [3H]5-HT as radioligand,,BAO_0000357,,,,Autocuration,2474,,H,8,CHEMBL875912,,,
1982,1,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1D receptor,,BAO_0000357,,,,Autocuration,5014,,H,8,CHEMBL617586,,,
1983,1,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1D receptor; inactive at 10 uM,,BAO_0000357,,,,Autocuration,17515,,H,8,CHEMBL617587,,,
1984,1,Binding affinity for 5-hydroxytryptamine 1D receptor was determined,,BAO_0000357,,,,Autocuration,11866,,H,8,CHEMBL617588,,,
1985,1,Evaluated for the binding affinity against 5-hydroxytryptamine 1D receptor,,BAO_0000357,,,,Autocuration,4687,,H,8,CHEMBL857980,,,
1986,1,Tested against 5-hydroxytryptamine 1D receptor,,BAO_0000357,,,,Autocuration,12146,,H,8,CHEMBL617589,,,
1987,1,Binding affinity for 5-hydroxytryptamine 1D receptor was determined by using [3H]5-HT as radioligand,,BAO_0000357,,,,Autocuration,10321,,H,8,CHEMBL617590,,,
1988,1,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,,BAO_0000219,,,,Autocuration,13267,,H,8,CHEMBL617591,722.0,,
1989,1,Binding affinity against 5-Hydroxytryptamine 1D receptor,,BAO_0000357,,Homo sapiens,,Expert,1274,,D,9,CHEMBL617592,,,
1990,1,,,BAO_0000357,,,,Autocuration,15250,,H,8,CHEMBL617593,,,
1991,1,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,BAO_0000219,,,,Autocuration,13706,,H,8,CHEMBL617594,485.0,,
1992,1,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,BAO_0000219,,,,Autocuration,13706,,H,8,CHEMBL617595,485.0,,
1993,1,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line.,,BAO_0000219,,,,Autocuration,13706,,H,8,CHEMBL617596,722.0,,
1994,1,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,,BAO_0000219,,,,Autocuration,13706,,H,8,CHEMBL617597,722.0,,
1995,1,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,,BAO_0000019,,,,Autocuration,13047,,H,8,CHEMBL617598,,,
1996,1,Binding affinity of compound against 5-HT1Dalpha Binding affinity of compound against 5-HT1D alpha receptors in human,,BAO_0000357,,,,Autocuration,13366,,H,8,CHEMBL872916,,,
1997,1,In vitro affinity human cloned 5-hydroxytryptamine 1D receptor alpha by [3H]5-HT displacement.,,BAO_0000357,,,,Expert,13366,,H,8,CHEMBL617599,,,
1998,1,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor alpha was determined,,BAO_0000357,,,,Autocuration,1558,,H,8,CHEMBL617091,,,
1999,1,"Binding affinity against 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells, using [3H]-5-HT as the radioligand.",,BAO_0000219,,,,Expert,12902,,H,8,CHEMBL617092,485.0,,
2000,1,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,BAO_0000219,,,,Autocuration,13706,,H,8,CHEMBL617093,485.0,,
2001,1,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor alpha measured as the reduction of forskolin-stimulated cAMP.,,BAO_0000019,,,,Autocuration,13706,,H,8,CHEMBL617094,,,
2002,1,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,BAO_0000019,,,,Autocuration,13706,,H,8,CHEMBL617095,,,
2003,1,Compound was tested for its agonist activity against human 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,BAO_0000019,,,,Autocuration,14251,,H,8,CHEMBL617096,,,
2004,1,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,BAO_0000019,,,,Autocuration,14251,,H,8,CHEMBL617097,,,
2005,1,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,BAO_0000019,,,,Autocuration,14251,,H,8,CHEMBL617098,,,
2006,1,In vitro binding affinity towards 5-HT1D alpha receptor by using [3H]5-HT as radioligand,,BAO_0000357,,,,Autocuration,13313,,H,8,CHEMBL617301,,,
2007,1,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]5-HT as radioligand,,BAO_0000357,,,,Autocuration,13313,,H,8,CHEMBL617302,,,
2008,1,Selectivity towards 5-hydroxytryptamine 1D receptor beta to that of 5-hydroxytryptamine 1D receptor alpha,,BAO_0000357,,,,Autocuration,13366,,H,8,CHEMBL617303,,,
2009,1,Binding affinity to recombinant human 5-hydroxytryptamine 1D receptor alpha,,BAO_0000357,,,,Expert,13051,,H,8,CHEMBL617304,,,
2010,1,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor alpha expressed in CHO cells, by using [3H]5-HT as radioligand",,BAO_0000219,,,,Expert,12903,,H,8,CHEMBL617305,449.0,,
2011,1,Binding affinity was measured on 5-hydroxytryptamine 1D receptor alpha in COS cells transfected with human 5-HT1D alpha gene labeled with [3H]5-HT,,BAO_0000219,,Homo sapiens,,Autocuration,12469,,D,9,CHEMBL617306,,,
2012,1,Binding affinity (in vitro) against 5-hydroxytryptamine 1D receptor alpha using radio-ligand binding assay,,BAO_0000357,,,,Autocuration,5619,,H,8,CHEMBL617307,,,
2013,1,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,,BAO_0000019,,Oryctolagus cuniculus,,Autocuration,13047,,H,8,CHEMBL617308,,,
2014,1,Binding affinities against 5-hydroxytryptamine 1D receptor alpha,,BAO_0000357,,,,Autocuration,16633,,H,8,CHEMBL617309,,,
2015,1,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,,BAO_0000357,,,,Autocuration,16633,,H,8,CHEMBL617310,,,
2016,1,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,,BAO_0000357,,,,Autocuration,16633,,H,8,CHEMBL617311,,,
2017,1,Binding affinity towards 5-hydroxytryptamine 1D receptor alpha using [3H]8-OH-DPAT as radioligand,,BAO_0000357,,,,Autocuration,16633,,H,8,CHEMBL617312,,,
2018,1,Affinity against 5-hydroxytryptamine 1D receptor alpha,,BAO_0000357,,,,Autocuration,3269,,H,8,CHEMBL617313,,,
2019,1,Binding affinity against 5-hydroxytryptamine 1D receptor alpha,,BAO_0000357,,,,Expert,12409,,H,8,CHEMBL617314,,,
2020,1,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,BAO_0000019,,,,Autocuration,13706,,H,8,CHEMBL617315,,,
2021,1,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line.,,BAO_0000219,,,,Autocuration,13706,,H,8,CHEMBL617316,722.0,,
2022,1,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,,BAO_0000219,,,,Autocuration,13706,,H,8,CHEMBL617317,722.0,,
2023,1,"The compound was tested in vitro for binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",,BAO_0000219,,,,Autocuration,12903,,H,8,CHEMBL617318,449.0,,
2024,1,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,,BAO_0000019,,,,Autocuration,13047,,H,8,CHEMBL617319,,,
2025,1,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,BAO_0000357,,,,Expert,13366,,D,9,CHEMBL617320,,,
2026,1,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,BAO_0000357,,,,Expert,13366,,D,9,CHEMBL617321,,,
2027,1,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,BAO_0000357,,,,Expert,13366,,D,9,CHEMBL617322,,,
2028,1,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined using [3H]8-OH-DPAT as radioligand,,BAO_0000357,,,,Autocuration,13366,,H,8,CHEMBL616862,,,
2029,1,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor was determined using [3H]8-OH-DPAT as radioligand,,BAO_0000357,,,,Autocuration,13366,,H,8,CHEMBL616863,,,
2030,1,Binding affinity was measured on 5-hydroxytryptamine 1D receptor beta in CHO cells transfected with human 5-HT1D beta gene labeled with [3H]5-HT,,BAO_0000219,,,,Autocuration,12469,,H,8,CHEMBL616864,449.0,,
2031,1,Compound was tested for binding affinity against cloned human 5-HT1D beta receptor expressed in CHO-K1 cells.,,BAO_0000219,,,,Autocuration,13706,,H,8,CHEMBL616865,485.0,,
2032,1,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells.,,BAO_0000219,,,,Autocuration,13706,,H,8,CHEMBL616866,485.0,,
2033,1,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,BAO_0000019,,,,Autocuration,13706,,H,8,CHEMBL616867,,,
2034,1,"Binding affinity against 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells, using [3H]5-HT as the radioligand.",,BAO_0000219,,,,Expert,12902,,H,8,CHEMBL616868,485.0,,
2035,1,Binding affinity for cloned human 5-hydroxytryptamine 1D receptor beta,,BAO_0000357,,,,Expert,13051,,H,8,CHEMBL616869,,,
2036,1,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",,BAO_0000219,,,,Expert,12903,,H,8,CHEMBL616870,449.0,,
2037,1,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.24-0.55,,BAO_0000219,,,,Autocuration,1558,,H,8,CHEMBL616871,485.0,,
2038,1,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.6-2.0,,BAO_0000219,,,,Autocuration,1558,,H,8,CHEMBL616872,485.0,,
2039,1,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 2.8-6.5,,BAO_0000219,,,,Autocuration,1558,,H,8,CHEMBL616873,485.0,,
2040,1,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 30-70,,BAO_0000219,,,,Autocuration,1558,,H,8,CHEMBL616838,485.0,,
2041,1,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined,,BAO_0000357,,,,Autocuration,1558,,H,8,CHEMBL616839,,,
2042,1,Binding affinity against 5-hydroxytryptamine 3 receptor using rabbit saphenous vein assay.,,BAO_0000019,,Oryctolagus cuniculus,,Autocuration,13047,,H,8,CHEMBL616840,,,
2043,1,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]-5-HT as radioligand,,BAO_0000357,,,,Autocuration,13313,,H,8,CHEMBL616841,,,
2044,1,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor beta by using [3H]5-HT as radioligand,,BAO_0000357,,,,Autocuration,13313,,H,8,CHEMBL616842,,,
2045,1,Binding affinity against 5-hydroxytryptamine 1D receptor beta,,BAO_0000357,,,,Expert,12409,,H,8,CHEMBL857976,,,
2046,1,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1E receptor stably expressed in CHO cells,,BAO_0000219,,,,Autocuration,15250,,H,8,CHEMBL616843,449.0,,
2047,1,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype,,BAO_0000357,,Homo sapiens,,Expert,1348,,D,9,CHEMBL616844,,,
2048,1,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype; NA denotes data not available,,BAO_0000357,,,,Autocuration,1348,,H,8,CHEMBL616845,,,
2049,1,Binding affinity to cloned human 5-hydroxytryptamine 1E receptor,,BAO_0000357,,Homo sapiens,,Expert,4234,,D,9,CHEMBL616846,,,
2050,1,Binding affinity towards human 5-hydroxytryptamine 1E receptor was determined using [3H]5-HT as radioligand,,BAO_0000357,,,,Autocuration,16209,,H,8,CHEMBL616847,,,
2051,1,Binding affinity was determined against 5-hydroxytryptamine 1E receptor in human cortical homogenate,,BAO_0000019,,,,Autocuration,10444,,H,8,CHEMBL616848,,,
2052,1,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1E receptor,,BAO_0000357,,,,Autocuration,3935,,H,8,CHEMBL616849,,,
2053,1,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1E receptor,,BAO_0000357,,,,Autocuration,15818,,H,8,CHEMBL872911,,,
2054,1,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1E receptor,,BAO_0000019,,,,Autocuration,17085,,H,8,CHEMBL616850,,,
2055,1,Binding affinity against human 5-hydroxytryptamine 1E receptor expressed in CHO cells,,BAO_0000219,,Homo sapiens,,Expert,12936,,D,9,CHEMBL616699,449.0,,
2056,1,Binding affinity towards cloned human 5-hydroxytryptamine 1E receptor was determined,,BAO_0000357,,,,Autocuration,6166,,H,8,CHEMBL616700,,,
2057,1,Binding affinity towards 5-hydroxytryptamine 1E receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,BAO_0000219,,,,Autocuration,15779,,H,8,CHEMBL616701,449.0,,
2058,1,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand.,,BAO_0000219,,,,Autocuration,15779,,H,8,CHEMBL616702,449.0,,
2059,1,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand;ND means no data.,,BAO_0000219,,,,Autocuration,15779,,H,8,CHEMBL616703,449.0,,
2060,1,Binding affinity was determined against 5-hydroxytryptamine 1D receptor,,BAO_0000357,,,,Autocuration,13181,,H,8,CHEMBL616704,,,
2061,1,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as the radioligand,,BAO_0000219,,,,Autocuration,4199,,H,8,CHEMBL616705,449.0,,
2062,1,Compound was tested for binding affinity against human 5-hydroxytryptamine 1E receptor,,BAO_0000357,,,,Autocuration,14875,,H,8,CHEMBL616706,,,
2063,1,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]-5-HT,,BAO_0000219,,,,Autocuration,15146,,H,8,CHEMBL616707,449.0,,
2064,1,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1E receptor in CHO using [3H]5-HT as a radioligand,,BAO_0000357,,,,Autocuration,5213,,H,8,CHEMBL616708,,,
2065,1,Tested for binding affinity towards cloned human 5-hydroxytryptamine 1E receptor using [3H]5-HT as radioligand,,BAO_0000357,,,,Autocuration,12146,,H,8,CHEMBL616709,,,
2066,1,The binding affinity (pKi) measured against 5-hydroxytryptamine 1E receptor (cloned human receptors in CHO cells) using [3H]5-HT1E as radioligand,,BAO_0000219,,,,Autocuration,13267,,H,8,CHEMBL616710,449.0,,
2067,1,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT.,,BAO_0000219,,,,Autocuration,14818,,H,8,CHEMBL616711,449.0,,
2068,1,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells, using [3H]5-HT as radioligand",,BAO_0000219,,,,Autocuration,4829,,H,8,CHEMBL616712,449.0,,
2069,1,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1E receptor was determined,,BAO_0000357,,,,Autocuration,4373,,H,8,CHEMBL616713,,,
2070,1,Binding affinity for 5-hydroxytryptamine 1E receptor was determined,,BAO_0000357,,,,Autocuration,4373,,H,8,CHEMBL616714,,,
2071,1,Compound was evaluated for the affinity at 5-hydroxytryptamine 1E receptor,,BAO_0000357,,,,Autocuration,14159,,H,8,CHEMBL616715,,,
2072,1,Binding affinity towards 5-hydroxytryptamine 1E receptor,,BAO_0000357,,,,Autocuration,16633,,H,8,CHEMBL616716,,,
2073,1,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-HT1F receptor",,BAO_0000019,,,,Autocuration,17085,,H,8,CHEMBL616717,,,
2074,1,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-hydroxytryptamine 1F receptor",,BAO_0000019,,,,Expert,17085,,H,8,CHEMBL616718,,,
2075,1,In vitro effective concentration for inhibition of skolin-stimulated adenylate cyclase in cell line expressing human 5-hydroxytryptamine 1F receptor,,BAO_0000019,,,,Autocuration,16209,,H,8,CHEMBL875905,,,
2076,1,In vitro agonist potency against human 5-hydroxytryptamine 1F receptor,,BAO_0000019,,,,Autocuration,16209,,H,8,CHEMBL616719,,,
2077,1,"Maximum stimulation of of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine 1F receptor",,BAO_0000019,,,,Expert,17085,,H,8,CHEMBL616720,,,
2078,1,Compound was evaluated for the affinity at 5-hydroxytryptamine 1F receptor,,BAO_0000357,,,,Autocuration,14159,,H,8,CHEMBL616721,,,
2079,1,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1F receptor stably expressed in CHO cells,,BAO_0000219,,,,Autocuration,15250,,H,8,CHEMBL616722,449.0,,
2080,1,In vitro binding affinity against human 5-hydroxytryptamine 1F receptor at a concentration of 100 (nM),,BAO_0000357,,,,Autocuration,3805,,H,8,CHEMBL616723,,,
2081,1,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT radioligand,,BAO_0000219,,,,Autocuration,16190,,H,8,CHEMBL616724,449.0,,
2082,1,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT radioligand,,BAO_0000357,,,,Autocuration,16190,,H,8,CHEMBL616725,,,
2083,1,Binding affinity towards human 5-hydroxytryptamine 1F receptor,,BAO_0000357,,,,Autocuration,16209,,H,8,CHEMBL616726,,,
2084,1,Binding affinity towards human 5-hydroxytryptamine 1F receptor was determined,,BAO_0000357,,,,Autocuration,16209,,H,8,CHEMBL616727,,,
2085,1,Binding affinity towards human 5-hydroxytryptamine 1F receptor using [3H]-5-HT radioligand,,BAO_0000357,,,,Autocuration,16209,,H,8,CHEMBL616728,,,
2086,1,In vitro binding affinity for human 5-hydroxytryptamine 1F receptor,,BAO_0000357,,,,Autocuration,6866,,H,8,CHEMBL616729,,,
2087,1,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1F receptor,,BAO_0000019,,,,Expert,17085,,H,8,CHEMBL616730,,,
2088,1,Binding affinity towards human recombinant 5-hydroxytryptamine 1F receptor,,BAO_0000357,,,,Autocuration,16312,,H,8,CHEMBL617125,,,
2089,1,Binding affinity towards cloned human 5-hydroxytryptamine 1F receptor was determined,,BAO_0000357,,,,Autocuration,6166,,H,8,CHEMBL857977,,,
2090,1,Binding affinity towards 5-hydroxytryptamine 1F receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,BAO_0000219,,,,Autocuration,15779,,H,8,CHEMBL617126,449.0,,
2091,1,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1F receptor in CHO cells using [3H]-5-HT as the radioligand,,BAO_0000219,,,,Autocuration,4199,,H,8,CHEMBL617127,449.0,,
2092,1,Compound was tested for binding affinity against human 5-hydroxytryptamine 1F receptor,,BAO_0000357,,,,Autocuration,14875,,H,8,CHEMBL617128,,,
2093,1,Compound was tested for its binding affinity against 5-hydroxytryptamine 1F receptor in human cloned receptors in CHO cells using [3H]5-HT,,BAO_0000219,,,,Autocuration,15146,,H,8,CHEMBL617129,449.0,,
2094,1,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT as a radioligand,,BAO_0000357,,,,Autocuration,5213,,H,8,CHEMBL617130,,,
2095,1,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT.,,BAO_0000219,,,,Autocuration,14818,,H,8,CHEMBL617131,449.0,,
2096,1,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",,BAO_0000219,,,,Autocuration,4829,,H,8,CHEMBL617132,449.0,,
2097,1,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",,BAO_0000219,,,,Autocuration,4829,,H,8,CHEMBL617133,449.0,,
2098,1,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1F receptor was determined,,BAO_0000357,,,,Autocuration,4373,,H,8,CHEMBL617134,,,
2099,1,Binding affinity for 5-hydroxytryptamine 1F receptor was determined,,BAO_0000357,,,,Autocuration,4373,,H,8,CHEMBL617135,,,
2100,1,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1F receptor,,BAO_0000357,,,,Autocuration,5014,,H,8,CHEMBL617136,,,
2101,1,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]-ketanserin as radioligand",,BAO_0000019,,,,Autocuration,11662,,H,4,CHEMBL617137,,,
2102,1,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",,BAO_0000019,,,,Autocuration,11662,,H,4,CHEMBL617138,,,
2103,1,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,BAO_0000019,,,,Autocuration,11662,,H,4,CHEMBL617139,,,
2104,1,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,,BAO_0000019,,,,Autocuration,14093,,H,8,CHEMBL617140,,,
2105,1,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-HT2 receptor 1 hr after oral administration",,BAO_0000218,,,,Autocuration,11200,In vivo,H,4,CHEMBL617141,,,
2106,1,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,BAO_0000019,,,,Autocuration,11200,,H,4,CHEMBL858112,,,
2107,1,Binding affinity towards 5-hydroxytryptamine 2 receptor in calf frontal cortex,,BAO_0000019,,,,Intermediate,12352,,H,8,CHEMBL617142,,,
2108,1,"Binding affinity to 5-hydroxytryptamine 2 receptor using calf frontal cortex, [3H]- ketanserin, and spiperone for NSB",,BAO_0000019,,Bos taurus,,Autocuration,13657,,U,0,CHEMBL617143,,,
2109,1,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex at 10e-7 M,,BAO_0000019,,Bos taurus,,Autocuration,14331,,U,0,CHEMBL617144,,,
2110,1,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex,,BAO_0000019,,Bos taurus,,Autocuration,14331,,U,0,CHEMBL617145,,,
2111,1,Binding affinity of compound towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin (0.8 nM) ligand in frontal cortex bovine was determined,,BAO_0000019,,,,Autocuration,14331,,U,0,CHEMBL617146,,,
2112,1,Binding affinity for serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin in guinea pig frontal cortex,,BAO_0000019,,Cavia porcellus,,Autocuration,12685,,H,4,CHEMBL617147,,,
2113,1,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of guinea pig frontal cortex membranes,,BAO_0000019,,Cavia porcellus,,Autocuration,14389,,H,4,CHEMBL617148,,,
2114,1,Compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin from guinea pig frontal cortex,,BAO_0000019,,Cavia porcellus,,Autocuration,14386,,H,4,CHEMBL617149,,,
2115,1,Binding affinity towards cloned human 5-hydroxytryptamine 2 receptor was determined,,BAO_0000224,,,,Autocuration,5732,,H,4,CHEMBL617150,,,
2116,1,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,BAO_0000224,,,,Autocuration,16293,,H,4,CHEMBL617151,,,
2117,1,In vitro binding affinity of compound against neuronal 5-hydroxytryptamine 2 receptor,,BAO_0000224,,,,Autocuration,2078,,H,4,CHEMBL617201,,,
2118,1,Binding affinity towards 5-HT7 receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,,BAO_0000357,,,,Autocuration,5486,,H,8,CHEMBL617202,,,
2119,1,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,,BAO_0000218,,,,Autocuration,11820,In vivo,H,4,CHEMBL617203,,,
2120,1,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,,BAO_0000019,,,,Autocuration,10297,,H,4,CHEMBL617204,,,
2121,1,Inhibitory activity against serotonin 5-hydroxytryptamine 2 receptor from mice.,,BAO_0000224,,,,Autocuration,13704,,H,4,CHEMBL617205,,,
2122,1,Inhibitory activity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in mouse cerebral cortex,,BAO_0000019,,Mus musculus,,Autocuration,10297,,D,5,CHEMBL617206,,,
2123,1,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,,BAO_0000218,,,,Autocuration,11820,In vivo,H,4,CHEMBL617207,,,
2124,1,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]-ketanserin in mouse cerebral cortex,,BAO_0000019,,Mus musculus,,Autocuration,10297,,D,5,CHEMBL617208,,,
2125,1,The compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2 receptor,,BAO_0000224,,,,Autocuration,11555,,H,4,CHEMBL617209,,,
2126,1,In vitro binding affinity for serotonin 5-hydroxytryptamine (5-HT) 2 receptors,,BAO_0000224,,,,Autocuration,11555,,H,4,CHEMBL617210,,,
2127,1,The compound was tested in vitro for its binding affinity towards serotonin 5-hydroxytryptamine 2 receptor; nd = no data,,BAO_0000224,,,,Autocuration,11555,,H,4,CHEMBL617211,,,
2128,1,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,,BAO_0000019,,Mus musculus,,Autocuration,10297,,D,5,CHEMBL617212,,,
2129,1,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin,,BAO_0000224,,Sus scrofa,,Autocuration,16688,,H,4,CHEMBL617213,,,
2130,1,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin with 10 uM prazosin,,BAO_0000224,,Sus scrofa,,Autocuration,16688,,H,4,CHEMBL617214,,,
2131,1,Compound was tested in vitro for its ability to compete with [3H]-ketanserin at 5-hydroxytryptamine 2 receptor in porcine brain homogenate,,BAO_0000221,,,,Autocuration,5333,,U,0,CHEMBL617215,,,
2132,1,In vitro for its ability to displace [3H]- ketanserin from 5-hydroxytryptamine 2 receptor in porcine brain homogenate,,BAO_0000221,,,,Autocuration,4437,,U,0,CHEMBL617216,,,
2133,1,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2 receptor,,BAO_0000357,,Sus scrofa,,Autocuration,5033,,H,8,CHEMBL617217,,,
2134,1,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,,BAO_0000019,,,,Autocuration,15267,,H,4,CHEMBL617218,,,
2135,1,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,,BAO_0000019,,,,Autocuration,15267,,H,4,CHEMBL872913,,,
2136,1,Binding affinity against 5-hydroxytryptamine 2 receptor from rat cortical synaptosomal membrane using radioligand [3H]ketanserin.,,BAO_0000019,,,,Autocuration,11820,,H,4,CHEMBL617219,,,
2137,1,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,,BAO_0000224,,,,Autocuration,9069,,H,4,CHEMBL873482,,,
2138,1,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; ND means no data,,BAO_0000019,,Rattus norvegicus,,Autocuration,9162,,D,5,CHEMBL617220,,,
2139,1,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein.,,BAO_0000019,,,,Autocuration,9162,,H,4,CHEMBL617221,,,
2140,1,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; no appreciable 5-HT2 receptor affinity,,BAO_0000019,,,,Autocuration,9162,,H,4,CHEMBL617222,,,
2141,1,Antagonistic activity against (5-hydroxytryptamine 2 receptor) serotonin-induced contractions in the rat jugular vein,,BAO_0000019,,,,Autocuration,10428,,H,4,CHEMBL875906,,,
2142,1,Binding affinity to the 5-hydroxytryptamine 2 receptor assayed by antagonism of serotonin-induced contractions in the rat jugular vein,,BAO_0000019,,,,Autocuration,9628,,H,4,CHEMBL617223,,,
2143,1,Binding affinity against serotonin 5-hydroxytryptamine 2 receptor,,BAO_0000224,,,,Autocuration,12704,,H,4,CHEMBL617224,,,
2144,1,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,,BAO_0000224,,Rattus norvegicus,,Autocuration,15453,,D,5,CHEMBL617225,,,
2145,1,Tested for the effect on binding at 5-hydroxytryptamine 2 receptor; No activity,,BAO_0000224,,,,Autocuration,188,,H,4,CHEMBL617226,,,
2146,1,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.4 nM dose of [3H]- spiperone as a radioligand.,,BAO_0000224,,,,Autocuration,10349,,H,4,CHEMBL617227,,,
2147,1,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.6 nM dose of [3H]- spiperone as a radioligand.,,BAO_0000224,,,,Autocuration,10349,,H,4,CHEMBL617228,,,
2148,1,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,,BAO_0000224,,,,Autocuration,8868,,H,4,CHEMBL617229,,,
2149,1,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,,BAO_0000224,,,,Autocuration,10025,,H,4,CHEMBL617230,,,
2150,1,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",,BAO_0000224,,,,Autocuration,10025,,H,4,CHEMBL617231,,,
2151,1,Compound was tested for the inhibition of quipazine binding at 5-HT2 receptor,,BAO_0000224,,,,Autocuration,11702,,H,4,CHEMBL617232,,,
2152,1,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor,,BAO_0000224,,,,Autocuration,11702,,H,4,CHEMBL617233,,,
2153,1,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor; NT=Not tested,,BAO_0000224,,,,Autocuration,11702,,H,4,CHEMBL617234,,,
2154,1,Compound was tested for the inhibition of quipazine induced head twitches in rats,,BAO_0000019,,,,Autocuration,11702,,H,4,CHEMBL617235,,,
2155,1,Compound was tested for the inhibition of quipazine induced head twitches in rats; NT=Not tested,,BAO_0000019,,,,Autocuration,11702,,H,4,CHEMBL617236,,,
2156,1,Ability to bind at 5-hydroxytryptamine 2 receptor of rat hippocampus by displacing [3H]spiperone,Hippocampus,BAO_0000221,,,,Autocuration,10085,,H,4,CHEMBL617237,,10000000.0,
2157,1,Ability to bind at serotonin 5-hydroxytryptamine 2 receptors of rat hippocampus by displacing [3H]spiperone,Hippocampus,BAO_0000221,,,,Autocuration,10085,,H,4,CHEMBL617238,,10000000.0,
2158,1,Displacement of [3H]spiroperidol from 5-hydroxytryptamine 2 receptor in rat brain,Brain,BAO_0000221,,Rattus norvegicus,,Autocuration,9630,,D,5,CHEMBL617239,,955.0,
2159,1,Ability to inhibit binding of [3H]KET to 5-hydroxytryptamine 2 receptor in rat cortex,,BAO_0000019,,,,Autocuration,11070,,H,4,CHEMBL617240,,,
2160,1,Ability to inhibit binding of titreated spiperone to 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,,BAO_0000249,,,,Autocuration,9841,,H,4,CHEMBL617241,,,
2161,1,Ability to inhibit binding of titreated spiperone to the 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,,BAO_0000249,,,,Autocuration,9841,,H,4,CHEMBL875907,,,
2162,1,Affinity for 5-hydroxytryptamine 2 receptor binding sites by its ability to displace [3H]spiperone from rat frontal cortex.,,BAO_0000019,,,,Autocuration,13291,,H,4,CHEMBL617242,,,
2163,1,Antagonistic activity against 5-hydroxytryptamine 2 receptor on rat frontal cortex membrane.,,BAO_0000019,,,,Autocuration,10590,,H,4,CHEMBL617152,,,
2164,1,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,Brain,BAO_0000221,,Rattus norvegicus,,Autocuration,9064,,D,5,CHEMBL617153,,955.0,
2165,1,Binding affinity at 5-hydroxytryptamine 2 receptor by the inhibition of binding to [3H]ketanserin in rat cortical membranes,,BAO_0000249,,Rattus norvegicus,,Autocuration,12268,,D,5,CHEMBL617154,,,
2166,1,Binding affinity against 5-hydroxytryptamine 2 receptor in rat brain using [3H]ketanserin as radioligand,Brain,BAO_0000221,,,,Autocuration,13508,,H,4,CHEMBL617155,,955.0,
2167,1,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,,BAO_0000019,,,,Autocuration,11279,,H,4,CHEMBL617156,,,
2168,1,In vitro antagonistic activity against the contraction induced by 5-HT through 5-HT2 receptor in rat thoracic aortic strips,,BAO_0000019,,,,Autocuration,11200,,H,4,CHEMBL617157,,,
2169,1,In vitro antagonistic activity tested against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,BAO_0000019,,,,Autocuration,11200,,H,4,CHEMBL617158,,,
2170,1,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,,BAO_0000019,,,,Autocuration,11200,,H,4,CHEMBL617159,,,
2171,1,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,,BAO_0000019,,,,Autocuration,11200,,H,4,CHEMBL617160,,,
2172,1,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,BAO_0000019,,,,Autocuration,11200,,H,4,CHEMBL858113,,,
2173,1,Tested for 5-hydroxytryptamine 2 receptor binding ability by displacement of [3H]spiperone from rat brain frontal cortex synaptosomes,Brain,BAO_0000220,,,,Autocuration,9231,,H,4,CHEMBL617247,,955.0,
2174,1,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,,BAO_0000019,,,,Autocuration,9737,,H,4,CHEMBL617248,,,
2175,1,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,Brain,BAO_0000249,,,,Autocuration,9737,,H,4,CHEMBL617249,,955.0,
2176,1,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex,,BAO_0000019,,,,Autocuration,9737,,H,4,CHEMBL617250,,,
2177,1,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,,BAO_0000019,,,,Autocuration,9737,,H,4,CHEMBL617251,,,
2178,1,isplacement of [3H]DOB from rat cortex homogenate 5-hydroxytryptamine 2 receptor,,BAO_0000019,,Rattus norvegicus,,Autocuration,11828,,D,5,CHEMBL617252,,,
2179,1,Binding affinity of 5-hydroxytryptamine 2 receptor using [3H]- ketanserin in rat frontal cortex,,BAO_0000019,,,,Autocuration,12253,,H,4,CHEMBL617006,,,
2180,1,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat frontal cortex,,BAO_0000019,,,,Autocuration,12253,,H,4,CHEMBL617007,,,
2181,1,"5-hydroxytryptamine 2 receptor antagonistic activity at concentrations of<br>3,10 and 30 uM on the rat tail artery.",,BAO_0000019,,,,Autocuration,11279,,H,4,CHEMBL617008,,,
2182,1,Binding affinity for 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- ketanserin,,BAO_0000019,,,,Autocuration,11866,,H,4,CHEMBL617009,,,
2183,1,Binding affinity against 5-hydroxytryptamine 2 receptor in serotonin-induced contraction of the rat aorta,,BAO_0000224,,Rattus norvegicus,,Autocuration,14424,,D,5,CHEMBL617010,,,
2184,1,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,,BAO_0000019,,Rattus norvegicus,,Autocuration,15180,,D,5,CHEMBL857978,,,
2185,1,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,,BAO_0000019,,Rattus norvegicus,,Autocuration,15180,,D,5,CHEMBL617011,,,
2186,1,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat frontal cortex homogenate,,BAO_0000019,,Rattus norvegicus,,Autocuration,9786,,D,5,CHEMBL617012,,,
2187,1,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand.,,BAO_0000224,,,,Autocuration,12132,,H,4,CHEMBL617013,,,
2188,1,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in rat cerebral cortex membrane,,BAO_0000249,,,,Autocuration,5486,,H,4,CHEMBL617014,,,
2189,1,Compound was evaluated for its ability to displace [3H]ketanserin binding from cloned rat cerebral cortex membranes 5-hydroxytryptamine 2 receptor,,BAO_0000019,,,,Autocuration,15316,,H,4,CHEMBL617015,,,
2190,1,In vitro binding affinity to 5-hydroxytryptamine 2 receptor of rat cerebral cortex membranes using [3H]ketanserin as the radioligand,,BAO_0000019,,,,Autocuration,16429,,H,4,CHEMBL617016,,,
2191,1,pKi value for 5-hydroxytryptamine 2 receptor binding site,,BAO_0000224,,,,Autocuration,14617,,H,4,CHEMBL617017,,,
2192,1,Inhibitory constant (1 uM) was measured on 5-hydroxytryptamine 2 receptor/uptake using [3H]- ketanserin as radioligand in rat brain cortex.,Brain,BAO_0000221,,,,Autocuration,11351,,H,4,CHEMBL617018,,955.0,
2193,1,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,,BAO_0000019,,,,Autocuration,11279,,H,4,CHEMBL617019,,,
2194,1,Binding affinity at 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,BAO_0000019,,,,Autocuration,9523,,H,4,CHEMBL617020,,,
2195,1,Binding affinity at 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,BAO_0000019,,,,Autocuration,9523,,H,4,CHEMBL617021,,,
2196,1,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,BAO_0000019,,,,Autocuration,9523,,H,4,CHEMBL617022,,,
2197,1,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,BAO_0000019,,,,Autocuration,9523,,H,4,CHEMBL617023,,,
2198,1,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,BAO_0000019,,,,Autocuration,9523,,H,4,CHEMBL617024,,,
2199,1,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,BAO_0000019,,,,Autocuration,9523,,H,4,CHEMBL617025,,,
2200,1,Hill coefficient of compound was determined,,BAO_0000224,,,,Autocuration,9523,,H,4,CHEMBL617026,,,
2201,1,Ancillary Binding affinity towards rat 5-hydroxytryptamine 2 receptor,,BAO_0000019,,,,Autocuration,4771,,U,0,CHEMBL617027,,,
2202,1,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-ketanserin) from 5-hydroxytryptamine 2 receptor of rat cerebral cortex membrane,,BAO_0000019,,Rattus norvegicus,,Autocuration,5033,,D,5,CHEMBL617028,,,
2203,1,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand,,BAO_0000019,,,,Expert,10845,,H,8,CHEMBL617029,,,
2204,1,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand; IA-Inactive,,BAO_0000019,,,,Expert,10845,,H,8,CHEMBL875908,,,
2205,1,Affinity at 5-hydroxytryptamine 2 receptor (For ketanserin = Ki(nM)= 0.7+/-0.09),,BAO_0000357,,,,Autocuration,16288,,H,8,CHEMBL617030,,,
2206,1,Affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex using [3H]ketanserin as radioligand (For ketanserin = Ki(nM)=0.7+/-0.09),,BAO_0000019,,,,Autocuration,16288,,H,8,CHEMBL617031,,,
2207,1,Binding affinity for 5-hydroxytryptamine 2 receptor of rat cortical membrane using [3H]DOB radioligand,,BAO_0000019,,,,Autocuration,16190,,H,8,CHEMBL617032,,,
2208,1,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 2 receptor using radioligand [3H]ketanserin,,BAO_0000224,,Rattus norvegicus,,Autocuration,12463,,D,5,CHEMBL617033,,,
2209,1,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand",,BAO_0000224,,,,Autocuration,9699,,H,4,CHEMBL617034,,,
2210,1,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand,,BAO_0000224,,,,Autocuration,9699,,H,4,CHEMBL617035,,,
2211,1,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,BAO_0000019,,,,Autocuration,11662,,H,4,CHEMBL617036,,,
2212,1,Inhibitory concentration against 5-hydroxytryptamine 2 receptor,,BAO_0000224,,,,Autocuration,1205,,H,4,CHEMBL617037,,,
2213,1,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2 receptor from mammalian clones expressed in CHO cell membranes using [3H]-ketanserin as radioligand,,BAO_0000219,,,,Autocuration,11376,,U,0,CHEMBL617038,,,
2214,1,"Binding affinity towards 5-hydroxytryptamine 2 receptor expressed in CHO cell membranes using [3H]ketanserin (60 Ci/mmol, 1 nM)",,BAO_0000219,,,,Autocuration,11376,,H,4,CHEMBL617039,,,
2215,1,Compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor,,BAO_0000224,,,,Autocuration,4639,,H,4,CHEMBL617161,,,
2216,1,Compound was tested for inhibitory activity against 5-hydroxytryptamine 2 receptor,,BAO_0000224,,,,Autocuration,2222,,H,4,CHEMBL617162,,,
2217,1,Compound was tested for its affinity towards 5-hydroxytryptamine 2 receptor,,BAO_0000224,,,,Autocuration,1558,,H,4,CHEMBL617163,,,
2218,1,Tested for binding affinity for 5-hydroxytryptamine 2 receptor,,BAO_0000224,,,,Autocuration,1089,,H,4,CHEMBL617164,,,
2219,1,The compound was evaluated for its ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor in cellular brain membranes,,BAO_0000249,,,,Autocuration,386,,H,4,CHEMBL617165,,,
2220,1,Compound was measured for its binding affinity at 5-hydroxytryptamine 2 receptor at a concentration of 10 uM using [3H]ketanserin as radioligand,,BAO_0000224,,,,Autocuration,2474,,H,4,CHEMBL617166,,,
2221,1,Binding affinity towards 5-HT2 receptor,,BAO_0000224,,,,Autocuration,17066,,H,4,CHEMBL617167,,,
2222,1,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,BAO_0000224,,,,Autocuration,959,,H,4,CHEMBL872912,,,
2223,1,Compound was evaluated for 5-hydroxytryptamine 2 receptor binding,,BAO_0000224,,,,Autocuration,6398,,H,4,CHEMBL617168,,,
2224,1,In vitro binding affinity against rat 5-hydroxytryptamine 2 receptor.,,BAO_0000224,,,,Autocuration,11889,,H,4,CHEMBL617169,,,
2225,1,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,,BAO_0000224,,,,Autocuration,4221,,H,4,CHEMBL617170,,,
2226,1,The compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor using ketanserin as radioligand,,BAO_0000224,,,,Autocuration,11026,,H,4,CHEMBL617171,,,
2227,1,Binding affinity for 5-hydroxytryptamine 2 receptor was determined,,BAO_0000224,,,,Autocuration,11866,,H,4,CHEMBL617172,,,
2228,1,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,,BAO_0000224,,,,Autocuration,4221,,H,4,CHEMBL617173,,,
2229,1,In Vitro binding affinity for 5-hydroxytryptamine 2 receptor,,BAO_0000019,,,,Autocuration,13950,,U,0,CHEMBL617174,,,
2230,1,5-hydroxytryptamine 2 receptor binding affinity,,BAO_0000224,,,,Autocuration,1263,,H,4,CHEMBL617175,,,
2231,1,Binding affinity against 5-hydroxytryptamine 2 receptor was determined using [ [3H]spiperone radioligand,,BAO_0000357,,,,Autocuration,13291,,H,8,CHEMBL617176,,,
2232,1,Compound was tested for the binding affinity against 5-hydroxytryptamine 2 receptor by using [3H]ketanserin as radioligand,,BAO_0000357,,,,Autocuration,10812,,H,8,CHEMBL617177,,,
2233,1,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,,BAO_0000224,,,,Autocuration,13020,,H,4,CHEMBL617178,,,
2234,1,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of central nervous system,,BAO_0000224,,,,Autocuration,13021,,H,4,CHEMBL617179,,,
2235,1,Ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,,BAO_0000224,,,,Autocuration,13020,,H,4,CHEMBL617180,,,
2236,1,Inhibitory activity against 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand at 10e-5 M concentration,,BAO_0000357,,,,Autocuration,14532,,H,8,CHEMBL617181,,,
2237,1,Binding affinity against 5-hydroxytryptamine 2 receptor,,BAO_0000357,,,,Autocuration,13944,,H,8,CHEMBL617182,,,
2238,1,Binding affinity against 5-hydroxytryptamine 2 receptor,,BAO_0000357,,,,Autocuration,14331,,H,8,CHEMBL617183,,,
2239,1,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,,BAO_0000357,,,,Autocuration,14118,,H,8,CHEMBL617184,,,
2240,1,Binding affinity against serotonergic 5-HT2 receptor,,BAO_0000357,,,,Autocuration,13033,,H,8,CHEMBL617185,,,
2241,1,Binding affinity for 5-hydroxytryptamine 2 receptor was determined by using [3H]ketanserin as radioligand,,BAO_0000357,,,,Autocuration,10321,,H,8,CHEMBL617186,,,
2242,1,Compound was evaluated for the binding affinity at 5- HT2 receptor,,BAO_0000357,,,,Autocuration,12918,,H,8,CHEMBL617187,,,
2243,1,Compound was tested for binding affinity using [3H]ketanserin against 5-hydroxytryptamine 2 receptor,,BAO_0000357,,,,Autocuration,15120,,H,8,CHEMBL617188,,,
2244,1,In vivo binding affinity was evaluated against 5-hydroxytryptamine 2 receptor,,BAO_0000218,,,,Autocuration,2613,,H,8,CHEMBL617189,,,
2245,1,Inhibitory activity against cloned human 5-HT2 receptor,,BAO_0000224,,Homo sapiens,,Autocuration,13378,,D,5,CHEMBL617190,,,
2246,1,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells",,BAO_0000219,,Homo sapiens,,Autocuration,2331,,D,5,CHEMBL617191,449.0,,
2247,1,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells.",,BAO_0000219,,Homo sapiens,,Autocuration,2331,,D,5,CHEMBL617192,449.0,,
2248,1,"Tested in vitro for the inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; Inactive",,BAO_0000219,,Homo sapiens,,Autocuration,2331,,D,5,CHEMBL617193,449.0,,
2249,1,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; not tested",,BAO_0000219,,Homo sapiens,,Autocuration,2331,,D,5,CHEMBL617194,449.0,,
2250,1,Binding affinity towards 5-hydroxytryptamine 2 receptor,,BAO_0000224,,,,Autocuration,4170,,H,4,CHEMBL617195,,,
2251,1,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,,BAO_0000224,,,,Autocuration,15453,,H,4,CHEMBL881830,,,
2252,1,Binding affinity towards 5-hydroxytryptamine 2 receptor,,BAO_0000357,,,,Autocuration,1479,,H,8,CHEMBL617196,,,
2253,1,Binding affinity towards 5-hydroxytryptamine 2- receptor using [3H]ketanserin as radioligand in competitive binding assay,,BAO_0000224,,,,Autocuration,11139,,H,4,CHEMBL617197,,,
2254,1,Binding affinity against 5-hydroxytryptamine 2A receptor was measured using [3H]ketanserin as radioligand,,BAO_0000357,,,,Expert,13969,,H,8,CHEMBL617198,,,
2255,1,Binding affinity towards 5-hydroxytryptamine 2A receptor,,BAO_0000357,,,,Expert,13392,,H,8,CHEMBL873476,,,
2256,1,Affinity towards 5-hydroxytryptamine 2A receptor in membranes from bovine frontal cortex using [3H]ketanserin,,BAO_0000019,,,,Expert,14430,,H,8,CHEMBL617199,,,
2257,1,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,,BAO_0000357,,Cavia porcellus,,Autocuration,13181,,H,8,CHEMBL617200,,,
2258,1,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,BAO_0000357,,,,Autocuration,17200,,H,8,CHEMBL617484,,,
2259,1,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,BAO_0000357,,,,Autocuration,17200,,H,8,CHEMBL617485,,,
2260,1,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,BAO_0000357,,,,Autocuration,17200,,H,8,CHEMBL617486,,,
2261,1,Binding affinity analysed on 5-HT 2A human clone using [3H]ketanserin as radioligand,,BAO_0000357,,,,Autocuration,13463,,H,8,CHEMBL858022,,,
2262,1,Effective concentration against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,,BAO_0000219,,,,Autocuration,6347,,H,8,CHEMBL617049,449.0,,
2263,1,Functional activity against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader,,BAO_0000219,,Homo sapiens,,Expert,6857,,D,9,CHEMBL617050,449.0,,
2264,1,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,,BAO_0000219,,,,Autocuration,4176,,H,8,CHEMBL617051,,,
2265,1,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line; no data,,BAO_0000219,,,,Autocuration,4176,,H,8,CHEMBL617052,,,
2266,1,Functional antagonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,,BAO_0000219,,,,Autocuration,4176,,H,8,CHEMBL617053,,,
2267,1,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand, expressed as Emax",,BAO_0000219,,,,Autocuration,6347,,H,8,CHEMBL617054,449.0,,
2268,1,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells, expressed as Emax",,BAO_0000219,,,,Autocuration,6347,,H,8,CHEMBL617055,449.0,,
2269,1,Affinity of compound towards human 5-hydroxytryptamine 2A receptor was evaluated using radioligand binding technique,,BAO_0000357,,,,Autocuration,15331,,H,8,CHEMBL882924,,,
2270,1,Inhibition of human 5-hydroxytryptamine 2A receptor,,BAO_0000357,,Homo sapiens,,Expert,16146,,D,9,CHEMBL617056,,,
2271,1,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,BAO_0000219,,,,Autocuration,15250,,H,8,CHEMBL617057,449.0,,
2272,1,Inhibitory concentration against human 5-HT2A receptor in BEK cells,,BAO_0000219,,,,Expert,13631,,H,8,CHEMBL617058,,,
2273,1,In vitro binding affinity against human 5-hydroxytryptamine 2A receptor at a concentration of 100 (nM),,BAO_0000357,,,,Autocuration,3805,,H,8,CHEMBL617059,,,
2274,1,Ability to displace [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor was determined,,BAO_0000219,,,,Autocuration,4011,,H,8,CHEMBL617060,449.0,,
2275,1,Displacement of [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor.,,BAO_0000219,,,,Expert,4012,,H,8,CHEMBL617061,449.0,,
2276,1,Ability to displace [125I]R91150 from human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells,,BAO_0000219,,,,Expert,6366,,H,8,CHEMBL617062,307.0,,
2277,1,Ability to displace [3H]ketanserin binding to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,BAO_0000219,,,,Expert,15949,,H,8,CHEMBL617063,449.0,,
2278,1,Agonist activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand,,BAO_0000019,,,,Autocuration,14093,,H,8,CHEMBL617064,,,
2279,1,Agonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,BAO_0000019,,,,Autocuration,13481,,H,8,CHEMBL617065,,,
2280,1,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,,BAO_0000219,,,,Autocuration,6347,,H,8,CHEMBL617066,449.0,,
2281,1,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand; Nd means not done,,BAO_0000219,,,,Autocuration,6347,,H,8,CHEMBL617067,449.0,,
2282,1,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]-Ketanserin radioligand,,BAO_0000019,,,,Autocuration,14093,,H,8,CHEMBL617068,,,
2283,1,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand; Not tested,,BAO_0000019,,,,Autocuration,14093,,H,8,CHEMBL617069,,,
2284,1,Antagonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,BAO_0000019,,,,Autocuration,13481,,H,8,CHEMBL617070,,,
2285,1,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [125 I]DOI as radioligand,,BAO_0000357,,,,Autocuration,14442,,H,8,CHEMBL617071,,,
2286,1,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,BAO_0000357,,,,Autocuration,14442,,H,8,CHEMBL872915,,,
2287,1,Binding activity against cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand.,,BAO_0000357,,,,Autocuration,14755,,H,8,CHEMBL617072,,,
2288,1,Binding affinity against 5-hydroxytryptamine 2A receptor in humans,,BAO_0000357,,,,Autocuration,16441,,H,8,CHEMBL617073,,,
2289,1,Binding affinity against the cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand,,BAO_0000357,,,,Autocuration,14744,,H,8,CHEMBL617074,,,
2290,1,Binding affinity for displacement of [3H]ketanserin to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,BAO_0000219,,,,Expert,16659,,H,8,CHEMBL617075,449.0,,
2291,1,Binding affinity of compound to human 5-hydroxytryptamine 2A receptor,,BAO_0000357,,,,Autocuration,3307,,H,8,CHEMBL617076,,,
2292,1,Affinity for human 5-hydroxytryptamine 2A receptor expressed in mammalian cell line,,BAO_0000019,,Homo sapiens,,Expert,6857,,D,9,CHEMBL617077,,,
2293,1,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand.,,BAO_0000357,,,,Expert,5635,,H,8,CHEMBL617078,,,
2294,1,Binding affinity to cloned human 5-hydroxytryptamine 2A receptor,,BAO_0000357,,Homo sapiens,,Expert,4234,,D,9,CHEMBL617079,,,
2295,1,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,,BAO_0000357,,,,Autocuration,15527,,H,8,CHEMBL617080,,,
2296,1,Binding affinity towards human 5-hydroxytryptamine 2A receptor by the displacement of [3H]ketanserin radioligand from the cloned receptor expressed in CHO cells,,BAO_0000219,,,,Expert,6588,,H,8,CHEMBL617081,449.0,,
2297,1,Binding affinity towards human 5-HT2A receptor in BEK cells,,BAO_0000219,,,,Expert,13631,,H,8,CHEMBL617082,,,
2298,1,Binding affinity towards human serotonin 5-hydroxytryptamine 2A receptor,,BAO_0000357,,,,Autocuration,17723,,H,8,CHEMBL617083,,,
2299,1,Binding affinity for recombinant human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,,BAO_0000357,,,,Autocuration,14770,,H,8,CHEMBL617084,,,
2300,1,Binding affinity for human 5-hydroxytryptamine 2A receptor,,BAO_0000357,,Homo sapiens,,Expert,16293,,D,9,CHEMBL617085,,,
2301,1,Binding affinity towards human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,BAO_0000357,,,,Autocuration,16209,,H,8,CHEMBL617086,,,
2302,1,Binding affinity was measured on 5-hydroxytryptamine 2A receptor in GF6 cells transfected with human 5-HT2A gene labeled with [3H]ketanserin,,BAO_0000219,,,,Autocuration,12469,,H,8,CHEMBL617087,,,
2303,1,Compound was tested for the displacement of [125I]-DOI from clone human 5-hydroxytryptamine 2A receptor,,BAO_0000357,,,,Autocuration,15363,,H,8,CHEMBL617088,,,
2304,1,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2A receptor,,BAO_0000357,,,,Autocuration,15363,,H,8,CHEMBL617089,,,
2305,1,"Tested on genetically transfected COS7 cell membranes selectively expressing human 5-hydroxytryptamine 2A receptor, using [3H]ketanserin as radioligand",,BAO_0000019,,,,Expert,16441,,H,8,CHEMBL617090,,,
2306,1,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in human using [3H]ketanserin as radioligand,,BAO_0000357,,,,Autocuration,8,,H,8,CHEMBL617513,,,
2307,1,In vitro binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells was determined using [3H]ketanserin as radioligand,,BAO_0000219,,,,Autocuration,4176,,H,8,CHEMBL617514,722.0,,
2308,1,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2A receptor,,BAO_0000019,,,,Autocuration,17085,,H,8,CHEMBL617515,,,
2309,1,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,BAO_0000357,,,,Autocuration,17200,,H,8,CHEMBL617516,,,
2310,1,Inhibitory constant determined against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,BAO_0000357,,Homo sapiens,,Expert,17200,,D,9,CHEMBL617517,,,
2311,1,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in CHO cells,,BAO_0000219,,Homo sapiens,,Expert,4013,,D,9,CHEMBL617518,449.0,,
2312,1,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor,,BAO_0000357,,,,Autocuration,5088,,H,8,CHEMBL617519,,,
2313,1,Displacement of [3H]DOB from human 5-hydroxytryptamine 2A receptor,,BAO_0000357,,Homo sapiens,,Expert,5088,,D,9,CHEMBL617520,,,
2314,1,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]DOB as labeled ligand; binding data not obtained,,BAO_0000357,,,,Autocuration,5088,,H,8,CHEMBL617521,,,
2315,1,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor,,BAO_0000357,,Homo sapiens,,Expert,5088,,D,9,CHEMBL617522,,,
2316,1,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand,,BAO_0000357,,,,Autocuration,5088,,H,8,CHEMBL617523,,,
2317,1,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,BAO_0000357,,,,Autocuration,5088,,H,8,CHEMBL617524,,,
2318,1,Ability to displace 0.75 nM [3H]ketanserin in 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenate,,BAO_0000019,,,,Autocuration,9786,,H,4,CHEMBL617525,,,
2319,1,Ability to inhibit [3H]spiperone binding to 5-hydroxytryptamine 2 receptor determined in rat,,BAO_0000019,,Rattus norvegicus,,Autocuration,9205,,D,5,CHEMBL617526,,,
2320,1,Affinity on 5-hydroxytryptamine 2 receptor labeled by [125I]DOI,,BAO_0000224,,,,Autocuration,11257,,H,4,CHEMBL617527,,,
2321,1,Affinity towards [3H]- DOB -labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,,BAO_0000019,,,,Autocuration,9362,,H,4,CHEMBL617528,,,
2322,1,Affinity towards [3H]- ketanserin-labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,,BAO_0000019,,,,Autocuration,9362,,H,4,CHEMBL617529,,,
2323,1,Inhibition of 5-hydroxytryptamine 2 induced vasoconstriction of rat caudal artery.,,BAO_0000224,,,,Autocuration,10590,,H,4,CHEMBL617530,,,
2324,1,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,,BAO_0000019,,,,Autocuration,10468,,H,4,CHEMBL617531,,,
2325,1,Binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortex using [125]-(R)-DOI as radioligand,,BAO_0000019,,,,Autocuration,13050,,H,4,CHEMBL617532,,,
2326,1,Binding affinity against 5-hydroxytryptamine 2 receptor in rat using [3H]ketanserin as radioligand,,BAO_0000019,,,,Autocuration,11624,,H,4,CHEMBL617533,,,
2327,1,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,,BAO_0000019,,,,Autocuration,10468,,H,4,CHEMBL617534,,,
2328,1,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,,BAO_0000224,,,,Autocuration,10330,,H,4,CHEMBL617535,,,
2329,1,Binding affinity at rat 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,,BAO_0000224,,,,Autocuration,10062,,H,4,CHEMBL617536,,,
2330,1,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,,BAO_0000224,,,,Autocuration,11642,,H,4,CHEMBL617537,,,
2331,1,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,,BAO_0000224,,,,Autocuration,10062,,H,4,CHEMBL617538,,,
2332,1,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,,BAO_0000219,,,,Autocuration,13427,In vitro,H,4,CHEMBL617539,,,
2333,1,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,BAO_0000224,,Rattus norvegicus,,Autocuration,12280,,D,5,CHEMBL617540,,,
2334,1,Binding affinity for 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]ketanserin,,BAO_0000224,,Rattus norvegicus,,Autocuration,4101,,D,5,CHEMBL617541,,,
2335,1,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 2 receptor,,BAO_0000224,,,,Autocuration,10062,,H,4,CHEMBL617542,,,
2336,1,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]DOB as,,BAO_0000224,,,,Autocuration,11147,,H,4,CHEMBL617543,,,
2337,1,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,,BAO_0000219,,Rattus norvegicus,,Autocuration,2395,,D,5,CHEMBL617544,485.0,,
2338,1,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,,BAO_0000219,,Rattus norvegicus,,Autocuration,2395,,D,5,CHEMBL617545,485.0,,
2339,1,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand,,BAO_0000019,,Rattus norvegicus,,Autocuration,9098,,D,5,CHEMBL617413,,,
2340,1,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand.,,BAO_0000019,,,,Autocuration,9098,,H,4,CHEMBL617414,,,
2341,1,Binding affinity to 5-hydroxytryptamine 2 receptor of rat cortical membranes using [3H]- DOB; ND means no data.,,BAO_0000019,,Rattus norvegicus,,Autocuration,9098,,D,5,CHEMBL617415,,,
2342,1,Binding affinity towards 5-hydroxytryptamine 2 receptor,,BAO_0000224,,,,Autocuration,9443,,H,4,CHEMBL617416,,,
2343,1,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,,BAO_0000224,,,,Autocuration,9443,,H,4,CHEMBL617417,,,
2344,1,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand in rat frontal cortex",,BAO_0000019,,,,Autocuration,9699,,H,4,CHEMBL617418,,,
2345,1,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand in rat frontal cortex,,BAO_0000019,,,,Autocuration,9699,,H,4,CHEMBL617419,,,
2346,1,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,BAO_0000224,,,,Autocuration,9098,,H,4,CHEMBL617420,,,
2347,1,Affinity for 5-hydroxytryptamine 2 receptor,,BAO_0000224,,Rattus norvegicus,,Autocuration,3070,,D,5,CHEMBL617421,,,
2348,1,Binding affinity towards serotonin 5-hydroxytryptamine 2 receptor of rat determined using 0.5 nM of [3H]ketanserin in binding assay,,BAO_0000224,,,,Autocuration,9547,,H,4,CHEMBL617422,,,
2349,1,Binding affinity was determined against 5-hydroxytryptamine 2 receptor from male Sprague-Dawley rat brain.,,BAO_0000019,,,,Autocuration,10444,,H,4,CHEMBL617423,,,
2350,1,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor from rat tissue homogenate,,BAO_0000019,,,,Autocuration,14617,,H,4,CHEMBL617424,,,
2351,1,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor rat tissue homogenate,,BAO_0000019,,,,Autocuration,14617,,H,4,CHEMBL617425,,,
2352,1,Binding constant against 5-hydroxytryptamine 2 receptor (in vitro),,BAO_0000224,,,,Autocuration,11130,,H,4,CHEMBL617426,,,
2353,1,Binding constant against 5-hydroxytryptamine 2 receptor (in vivo),,BAO_0000218,,,,Autocuration,11130,In vivo,H,4,CHEMBL617427,,,
2354,1,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat brain,Brain,BAO_0000221,,,,Autocuration,14542,,H,4,CHEMBL617428,,955.0,
2355,1,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2 receptor from rat,,BAO_0000224,,,,Autocuration,2797,,H,4,CHEMBL617429,,,
2356,1,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,,BAO_0000019,,,,Autocuration,11332,,H,4,CHEMBL617430,,,
2357,1,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,,BAO_0000019,,,,Autocuration,11332,,H,4,CHEMBL617431,,,
2358,1,Compound was evaluated for its ability to displace 0.25 nM [125I](R)-DOI from binding sites in rat frontal cortex.,Frontal cortex,BAO_0000019,,,,Autocuration,10752,,H,4,CHEMBL617432,,1870.0,
2359,1,Ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,,BAO_0000224,,,,Autocuration,1185,,H,4,CHEMBL617433,,,
2360,1,Compound was evaluated for its ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,,BAO_0000224,,,,Autocuration,1185,,H,4,CHEMBL617434,,,
2361,1,Binding affinity against 5-Hydroxy tryptamine 2 (5-hydroxytryptamine 2)receptor,,BAO_0000224,,Rattus norvegicus,,Autocuration,11624,,D,5,CHEMBL617435,,,
2362,1,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 2 receptor in rat cortex using [3H]ketanserin radioligand assay,,BAO_0000019,,,,Autocuration,1344,,H,4,CHEMBL617436,,,
2363,1,Binding affinity against 5-hydroxytryptamine 2 receptor in rat striatum using [3H]-RP62203,Striatum,BAO_0000019,,Rattus norvegicus,,Autocuration,15453,,D,5,CHEMBL617437,,2435.0,
2364,1,"Binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",,BAO_0000019,,,,Autocuration,11662,,H,4,CHEMBL617438,,,
2365,1,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,BAO_0000019,,,,Autocuration,11662,,H,4,CHEMBL617439,,,
2366,1,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 2 receptor,,BAO_0000224,,,,Autocuration,10796,,H,4,CHEMBL617440,,,
2367,1,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,,BAO_0000224,,,,Autocuration,9069,,H,4,CHEMBL617441,,,
2368,1,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortical membrane homogenates,,BAO_0000019,,Rattus norvegicus,,Autocuration,8814,,D,5,CHEMBL872918,,,
2369,1,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortex,,BAO_0000019,,Rattus norvegicus,,Autocuration,8908,,D,5,CHEMBL617442,,,
2370,1,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,,BAO_0000019,,,,Autocuration,9098,,H,4,CHEMBL617443,,,
2371,1,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 (5-HT2) receptor using [3H]KET as a radioligand,,BAO_0000019,,,,Autocuration,9098,,H,4,CHEMBL617444,,,
2372,1,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,,BAO_0000019,,,,Autocuration,9098,,H,4,CHEMBL617445,,,
2373,1,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.,,BAO_0000019,,,,Autocuration,9098,,H,4,CHEMBL617446,,,
2374,1,Binding affinity to 5-hydroxytryptamine 2 receptor in rat frontal cortical membranes by [3H]- KET displacement.,,BAO_0000249,,,,Autocuration,9098,,H,4,CHEMBL617447,,,
2375,1,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.;ND is not determined,,BAO_0000019,,,,Autocuration,9098,,H,4,CHEMBL617448,,,
2376,1,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand;ND means no data,,BAO_0000019,,,,Autocuration,9098,,H,4,CHEMBL617449,,,
2377,1,In vitro binding affinity at 5-hydroxytryptamine 2 receptor in rat cortical tissue by [3H]spiperone displacement; No data.,,BAO_0000019,,,,Autocuration,9161,,H,4,CHEMBL617450,,,
2378,1,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 165 to 263,,BAO_0000019,,,,Autocuration,9161,,H,4,CHEMBL617451,,,
2379,1,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 2.4 to 5.3,,BAO_0000019,,,,Autocuration,9161,,H,4,CHEMBL617452,,,
2380,1,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue.,,BAO_0000019,,,,Autocuration,9161,,H,4,CHEMBL617453,,,
2381,1,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 140 to 980,,BAO_0000019,,,,Autocuration,9161,,H,4,CHEMBL617660,,,
2382,1,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 76 to 299,,BAO_0000019,,,,Autocuration,9161,,H,4,CHEMBL617661,,,
2383,1,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue; value may range from 12 to 66,,BAO_0000019,,,,Autocuration,9161,,H,4,CHEMBL617662,,,
2384,1,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 136 to 220,,BAO_0000019,,,,Autocuration,9161,,H,4,CHEMBL872919,,,
2385,1,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 197 to 341,,BAO_0000019,,,,Autocuration,9161,,H,4,CHEMBL617663,,,
2386,1,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 23 to 187,,BAO_0000019,,,,Autocuration,9161,,H,4,CHEMBL617664,,,
2387,1,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 29 to 132,,BAO_0000019,,,,Autocuration,9161,,H,4,CHEMBL617665,,,
2388,1,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 6 to 75,,BAO_0000019,,,,Autocuration,9161,,H,4,CHEMBL617666,,,
2389,1,In vitro binding affinity on 5-hydroxytryptamine 2 receptor is inhibition of binding of [125I]- I-LSD to P11 cells,,BAO_0000019,,,,Autocuration,12094,,H,4,CHEMBL617667,,,
2390,1,In vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat striatal membranes by [3H]ketanserin displacement.,,BAO_0000249,,,,Autocuration,12018,,H,4,CHEMBL617668,,,
2391,1,Inhibitory activity against 5-hydroxytryptamine 2 receptor in rat cortical membranes using [3H]ketanserin as a radioligand,,BAO_0000249,,,,Autocuration,10394,,H,4,CHEMBL617669,,,
2392,1,Inhibitory activity against rat cortical 5-hydroxytryptamine 2 receptor,,BAO_0000224,,,,Autocuration,15260,,H,4,CHEMBL617670,,,
2393,1,Inhibitory constant against 5-hydroxytryptamine 2 receptor,,BAO_0000224,,Rattus norvegicus,,Autocuration,11624,,D,5,CHEMBL617671,,,
2394,1,Percentage specific displacement of radioligand [3H]-ketanserin from 5-hydroxytryptamine 2 receptor,,BAO_0000224,,,,Autocuration,13654,,H,4,CHEMBL617672,,,
2395,1,Potency to displace [3H]- Spiperone from 5-hydroxytryptamine 2 receptor in rat striatum,,BAO_0000019,,,,Autocuration,9541,,H,4,CHEMBL617673,,,
2396,1,Tested for binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortical regions using [3H]ketanserin as radioligand,,BAO_0000224,,,,Autocuration,11933,,H,4,CHEMBL617674,,,
2397,1,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex,,BAO_0000019,,,,Autocuration,15538,,H,4,CHEMBL617675,,,
2398,1,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; NA means Not Active,,BAO_0000019,,,,Autocuration,15538,,H,4,CHEMBL617676,,,
2399,1,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; not determined,,BAO_0000019,,,,Autocuration,15538,,H,4,CHEMBL617677,,,
2400,1,Displacement of [3H]ketanserin from rat prefrontal cortex 5-hydroxytryptamine 2 receptor,,BAO_0000019,,,,Autocuration,8841,,D,5,CHEMBL617678,,,
2401,1,Binding affinity to 5-hydroxytryptamine 2 receptor using [3H]ketanserin radioligand assay.,,BAO_0000224,,,,Autocuration,1455,,H,4,CHEMBL617679,,,
2402,1,Tested for its binding affinity to Tested for its binding affinity to 5-hydroxytryptamine 2 receptor using [3H]-ketanserin radioligand assay using [3H]-ketanserin radioligand assay,,BAO_0000224,,,,Autocuration,1455,,H,4,CHEMBL617680,,,
2403,1,The ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat whole brain,,BAO_0000019,,,,Autocuration,11752,,H,4,CHEMBL617681,,,
2404,1,The binding affinity was measured on 5-hydroxytryptamine 2 receptor in rat brain tissue,Brain,BAO_0000221,,,,Autocuration,11642,,H,4,CHEMBL617682,,955.0,
2405,1,The binding affinity was measured on 5-hydroxytryptamine 2 receptor using [3H]- spiperone as radioligand.,,BAO_0000224,,,,Autocuration,12092,,H,4,CHEMBL617683,,,
2406,1,Binding affinity at 5-hydroxytryptamine 2 receptor from striata wistar rats by [3H]ketanserin displacement.,,BAO_0000224,,,,Autocuration,3967,,H,4,CHEMBL617684,,,
2407,1,Binding affinity towards 5-hydroxytryptamine 2 receptor,,BAO_0000224,,Rattus norvegicus,,Autocuration,12771,,D,5,CHEMBL617685,,,
2408,1,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [3H]ketanserin radioligand in rat cerebral cortex,,BAO_0000019,,,,Autocuration,11642,,H,4,CHEMBL617686,,,
2409,1,The compound was tested in vitro for binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [125]I-LSD radioligand,,BAO_0000224,,,,Autocuration,11628,,H,4,CHEMBL617687,,,
2410,1,Percentage specific displacement of radioligand [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,BAO_0000224,,,,Autocuration,13654,,H,4,CHEMBL617688,,,
2411,1,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,BAO_0000019,,,,Autocuration,11200,,H,4,CHEMBL617689,,,
2412,1,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,BAO_0000019,,,,Autocuration,11200,,H,4,CHEMBL617690,,,
2413,1,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",,BAO_0000218,,,,Autocuration,11200,In vivo,H,4,CHEMBL617691,,,
2414,1,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",,BAO_0000218,,,,Autocuration,11200,In vivo,H,4,CHEMBL617692,,,
2415,1,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",,BAO_0000218,,,,Autocuration,11200,In vivo,H,4,CHEMBL617693,,,
2416,1,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",,BAO_0000218,,,,Autocuration,11200,In vivo,H,4,CHEMBL617694,,,
2417,1,Affinity for 5-hydroxytryptamine 2A receptor in rat brain cortex by ability to displace [3H]ketanserin,Brain,BAO_0000221,,,,Expert,15436,,H,8,CHEMBL857985,,955.0,
2418,1,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,BAO_0000019,,Rattus norvegicus,,Expert,15436,,D,9,CHEMBL617695,,,
2419,1,Affinity pKi for 5-hydroxytryptamine 2A receptor was measured in rat cortex homogenates,,BAO_0000019,,,,Autocuration,14025,,H,8,CHEMBL617696,,,
2420,1,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor was determined,,BAO_0000357,,,,Autocuration,4342,,H,8,CHEMBL617697,,,
2421,1,Displacement of [3H]ketanserin from 5-HT2A receptor of rat frontal cortex,,BAO_0000019,,Rattus norvegicus,,Expert,13735,,D,9,CHEMBL617257,,,
2422,1,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,,BAO_0000357,,Rattus norvegicus,,Expert,5816,,D,9,CHEMBL617258,,,
2423,1,Binding affinity was evaluated in vitro by displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor on rat cortical membrane,,BAO_0000019,,,,Expert,14287,,H,8,CHEMBL617259,,,
2424,1,In vitro affinity against serotonin ( 5-hydroxytryptamine 2A receptor ) receptor,,BAO_0000357,,,,Autocuration,15738,,H,8,CHEMBL617260,,,
2425,1,In vitro affinity against serotonin 5-hydroxytryptamine 2A receptor,,BAO_0000357,,Rattus norvegicus,,Expert,15738,,D,9,CHEMBL617261,,,
2426,1,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]-ketanserin as radioligand,,BAO_0000019,,,,Autocuration,15026,,H,8,CHEMBL617262,,,
2427,1,Half-maximal inhibition of [3H]- Ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,,BAO_0000019,,,,Expert,16647,,H,8,CHEMBL617263,,,
2428,1,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat tissue homogenate,,BAO_0000019,,,,Autocuration,16647,,H,8,CHEMBL617264,,,
2429,1,Displacement of [3H]-ketanserin from rat brain 5-hydroxytryptamine 2A receptor,,BAO_0000019,,Rattus norvegicus,,Expert,13345,,D,9,CHEMBL617265,,,
2430,1,Inhibition constant for in vitro inhibition of [3H]ketanserin binding to rat frontal cortex membranes 5-hydroxytryptamine 2A receptor,,BAO_0000249,,,,Autocuration,1543,,H,8,CHEMBL617266,,,
2431,1,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor rat frontal cortex membrane,,BAO_0000019,,,,Autocuration,12444,,H,8,CHEMBL617267,,,
2432,1,Inhibitory constant on 5-hydroxytryptamine 2A receptor of Rat frontal cortex,,BAO_0000019,,,,Expert,16404,,H,8,CHEMBL617268,,,
2433,1,Inhibitory constant on human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,,BAO_0000219,,,,Autocuration,16404,,H,8,CHEMBL617269,449.0,,
2434,1,Kinetic inhibition constant evaluated by measuring serotonergic activity,,BAO_0000357,,,,Expert,15577,,H,8,CHEMBL617323,,,
2435,1,Serotonergic activity of the compound.,,BAO_0000357,,,,Autocuration,15577,,H,8,CHEMBL617324,,,
2436,1,Tested in vitro for its ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat frontal cortex membranes,,BAO_0000249,,,,Autocuration,2495,,H,8,CHEMBL617325,,,
2437,1,The binding affinity was evaluated on 5-hydroxytryptamine 2A receptor expressed in rat cortex by using [3H]ketanserin as radioligand.,,BAO_0000019,,Rattus norvegicus,,Expert,15042,,D,9,CHEMBL617326,,,
2438,1,In vitro ability to displace [3H]ketanserin binding from 5-hydroxytryptamine 2A receptor in rat striatal membrane.,,BAO_0000249,,,,Expert,15026,,H,8,CHEMBL617327,,,
2439,1,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,BAO_0000019,,Rattus norvegicus,,Expert,12919,,D,9,CHEMBL617328,,,
2440,1,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,BAO_0000019,,Rattus norvegicus,,Expert,12919,,D,9,CHEMBL617329,,,
2441,1,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,BAO_0000019,,Rattus norvegicus,,Expert,12919,,D,9,CHEMBL617330,,,
2442,1,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,BAO_0000357,,,,Autocuration,15194,,H,8,CHEMBL617331,,,
2443,1,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand.,,BAO_0000357,,,,Autocuration,15194,,H,8,CHEMBL617332,,,
2444,1,Binding affinity towards 5-hydroxytryptamine 2A receptor,,BAO_0000357,,,,Expert,4820,,H,8,CHEMBL617333,,,
2445,1,Binding affinity against serotonin 5-hydroxytryptamine 2A receptor was determined using human [125I]-eotaxin,,BAO_0000357,,,,Autocuration,6736,,H,8,CHEMBL617334,,,
2446,1,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.000001 mol/L,,BAO_0000357,,,,Autocuration,5163,,H,8,CHEMBL617335,,,
2447,1,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.00001 mol/L,,BAO_0000357,,,,Autocuration,5163,,H,8,CHEMBL617336,,,
2448,1,Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration,,BAO_0000357,,,,Autocuration,6011,,H,8,CHEMBL617337,,,
2449,1,Percent inhibition against 5-hydroxytryptamine 2A receptor using [3H]ketanserin at 1 uM,,BAO_0000357,,Homo sapiens,,Expert,14294,,D,9,CHEMBL617338,,,
2450,1,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2A receptor,,BAO_0000357,,,,Autocuration,5014,,H,8,CHEMBL617339,,,
2451,1,Binding affinity towards 5-hydroxytryptamine 2A receptor,,BAO_0000357,,,,Expert,17066,,H,8,CHEMBL617340,,,
2452,1,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor; inactive at 10 uM,,BAO_0000357,,,,Autocuration,17515,,H,8,CHEMBL617341,,,
2453,1,Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptor,,BAO_0000357,,,,Expert,6736,,H,8,CHEMBL617342,,,
2454,1,Affinity for 5-hydroxytryptamine 2A receptor,,BAO_0000357,,,,Expert,5163,,H,8,CHEMBL617343,,,
2455,1,Binding affinity was performed using [3H]ketanserin as the radioligand and stably transfected NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor (GF-62 cells).,,BAO_0000219,,,,Expert,16911,,H,8,CHEMBL617344,723.0,,
2456,1,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,,BAO_0000357,,,,Expert,6841,,H,8,CHEMBL617345,,,
2457,1,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand.,,BAO_0000357,,,,Expert,6119,,H,8,CHEMBL617346,,,
2458,1,Compound was evaluated for its binding against 5-hydroxytryptamine 2A receptor,,BAO_0000357,,,,Autocuration,3962,,H,8,CHEMBL617347,,,
2459,1,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2A receptor was determined,,BAO_0000357,,,,Autocuration,4373,,H,8,CHEMBL617348,,,
2460,1,Binding affinity relative to indolopiperidine (compound 1)for 5-hydroxytryptamine 2A receptor was determined,,BAO_0000357,,,,Autocuration,4373,,H,8,CHEMBL617349,,,
2461,1,Compound was evaluated for its inverse agonist activity against 5-hydroxytryptamine 2A receptor,,BAO_0000019,,,,Autocuration,3962,,H,8,CHEMBL617350,,,
2462,1,Binding affinity towards 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin,,BAO_0000357,,,,Expert,1633,,H,8,CHEMBL872339,,,
2463,1,Binding affinity for 5-hydroxytryptamine 2A receptor was determined,,BAO_0000357,,,,Autocuration,4373,,H,8,CHEMBL617351,,,
2464,1,Binding affinity towards serotonin 5-hydroxytryptamine 2A receptor,,BAO_0000357,,,,Expert,6576,,H,8,CHEMBL617352,,,
2465,1,Evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor,,BAO_0000357,,,,Autocuration,4687,,H,8,CHEMBL617353,,,
2466,1,Ability to displace [3H]-ketanserin from 5-hydroxytryptamine 2A receptor,,BAO_0000357,,,,Autocuration,16946,,H,8,CHEMBL617354,,,
2467,1,Compound was evaluated for the affinity at 5-hydroxytryptamine 2A receptor,,BAO_0000357,,,,Autocuration,14159,,H,8,CHEMBL617355,,,
2468,1,In vitro binding affinity against 5-hydroxytryptamine 2A receptor in CHO cells,,BAO_0000219,,Mus musculus,,Expert,3032,,H,8,CHEMBL617356,449.0,,
2469,1,Inhibition of ketanserin binding to 5-hydroxytryptamine 2A receptor,,BAO_0000357,,,,Autocuration,16655,,H,8,CHEMBL617357,,,
2470,1,Binding affinity at 5-hydroxytryptamine 2A receptor,,BAO_0000357,,,,Autocuration,13964,,H,8,CHEMBL617358,,,
2471,1,Binding affinity towards Serotonin 5-hydroxytryptamine 2A receptor,,BAO_0000357,,,,Expert,16989,,H,8,CHEMBL617359,,,
2472,1,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor was determined,,BAO_0000357,,,,Autocuration,16117,,H,8,CHEMBL617360,,,
2473,1,The binding affinity towards 5-hydroxytryptamine 2A receptor; No affinity,,BAO_0000357,,,,Autocuration,16700,,H,8,CHEMBL875913,,,
2474,1,Affinity against 5-hydroxytryptamine 2A receptor,,BAO_0000357,,,,Autocuration,3269,,H,8,CHEMBL617361,,,
2475,1,Binding affinity against 5-Hydroxytryptamine 2A receptor,,BAO_0000357,,Homo sapiens,,Expert,1274,,D,9,CHEMBL617362,,,
2476,1,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using radioligand binding assay,,BAO_0000357,,,,Autocuration,1317,,H,8,CHEMBL617363,,,
2477,1,Tested against 5-hydroxytryptamine 2A receptor,,BAO_0000357,,,,Autocuration,12146,,H,8,CHEMBL617364,,,
2478,1,Binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,,BAO_0000224,,,,Autocuration,12652,,H,4,CHEMBL617365,,,
2479,1,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H] ketanserin,,BAO_0000224,,,,Autocuration,12652,,H,4,CHEMBL617366,,,
2480,1,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor agonist [125I]- - (+/-)DOI,,BAO_0000224,,,,Autocuration,12652,,H,4,CHEMBL617367,,,
2481,1,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,,BAO_0000224,,,,Autocuration,12652,,H,4,CHEMBL617368,,,
2482,1,Selectivity ratio towards 5-hydroxytryptamine 2A receptor to Dopamine receptor D2 (5-HT2A/D2 ),,BAO_0000357,,,,Autocuration,16647,,H,8,CHEMBL617369,,,
2483,1,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND means no data,,BAO_0000219,,Homo sapiens,,Expert,15851,,D,9,CHEMBL617370,722.0,,
2484,1,Functional activity against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader,,BAO_0000219,,Homo sapiens,,Expert,6857,,D,9,CHEMBL617371,449.0,,
2485,1,In vitro binding affinity against human 5-HT2B receptor at a concentration of 100 (nM),,BAO_0000357,,,,Autocuration,3805,,H,8,CHEMBL617372,,,
2486,1,Affinity towards human 5-hydroxytryptamine 2B serotonin receptor,,BAO_0000357,,Homo sapiens,,Expert,6491,,D,9,CHEMBL617373,,,
2487,1,Agonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT radioligand,,BAO_0000019,,,,Autocuration,14093,,H,8,CHEMBL617374,,,
2488,1,Agonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]-5-HT as radioligand,,BAO_0000019,,,,Autocuration,13481,,H,8,CHEMBL617375,,,
2489,1,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand,,BAO_0000019,,,,Autocuration,14093,,H,8,CHEMBL617376,,,
2490,1,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand; Not tested,,BAO_0000019,,,,Autocuration,14093,,H,8,CHEMBL617377,,,
2491,1,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine radioligand,,BAO_0000019,,,,Autocuration,14093,,H,8,CHEMBL617378,,,
2492,1,Antagonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,,BAO_0000019,,,,Autocuration,13481,,H,8,CHEMBL617379,,,
2493,1,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine as radioligand,,BAO_0000357,,,,Autocuration,14442,,H,8,CHEMBL617380,,,
2494,1,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT 2B as radioligand,,BAO_0000357,,,,Autocuration,14442,,H,8,CHEMBL617381,,,
2495,1,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,,BAO_0000357,,,,Autocuration,14442,,H,8,CHEMBL617382,,,
2496,1,The compound evaluated for its affinity against 5-hydroxytryptamine 2A receptor,,BAO_0000357,,,,Autocuration,12369,,H,8,CHEMBL617383,,,
2497,1,Affinity against 5-hydroxytryptamine 2A receptor (D) labeled with [125I]DOI.,,BAO_0000357,,,,Expert,12369,,H,8,CHEMBL617384,,,
2498,1,Affinity against 5-hydroxytryptamine 2A receptor (K) labeled with [3H]ketanserin.,,BAO_0000357,,,,Expert,12369,,H,8,CHEMBL617385,,,
2499,1,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes,,BAO_0000019,,,,Autocuration,14447,,H,8,CHEMBL617386,,,
2500,1,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes.,,BAO_0000019,,,,Autocuration,14447,,H,8,CHEMBL617387,,,
2501,1,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,BAO_0000219,,,,Autocuration,17451,,H,8,CHEMBL617388,723.0,,
2502,1,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,BAO_0000219,,,,Autocuration,6857,,H,8,CHEMBL617389,449.0,,
2503,1,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,BAO_0000219,,Homo sapiens,,Expert,6857,,D,9,CHEMBL617390,449.0,,
2504,1,Selectivity ratio of binding affinity of 5-hydroxytryptamine 2A receptor to that of 5-hydroxytryptamine 2C receptor.,,BAO_0000224,,,,Autocuration,5635,,H,4,CHEMBL617391,,,
2505,1,Binding activity radioligand.,,BAO_0000357,,,,Autocuration,12861,,H,8,CHEMBL617392,,,
2506,1,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,BAO_0000019,,,,Autocuration,12861,,H,8,CHEMBL617393,,,
2507,1,Binding affinity for human cloned 5-HT2A receptor expressed in L929 cells using [125I]R91150 as radioligand,,BAO_0000219,,,,Autocuration,5105,,H,8,CHEMBL617394,307.0,,
2508,1,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,,BAO_0000219,,,,Expert,5104,,H,8,CHEMBL617395,307.0,,
2509,1,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,,BAO_0000219,,,,Expert,5105,,H,8,CHEMBL617396,307.0,,
2510,1,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand; Not tested,,BAO_0000219,,,,Autocuration,5105,,H,8,CHEMBL617397,307.0,,
2511,1,Binding affinity against 5-HT2A receptor,,BAO_0000357,,,,Autocuration,5254,,H,8,CHEMBL617398,,,
2512,1,Binding affinity against 5-hydroxytryptamine 2A receptor,,BAO_0000357,,,,Autocuration,5254,,H,8,CHEMBL617399,,,
2513,1,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,,BAO_0000219,,,,Autocuration,13267,,H,8,CHEMBL617400,722.0,,
2514,1,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,,BAO_0000219,,,,Autocuration,13267,,H,8,CHEMBL617401,722.0,,
2515,1,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells,,BAO_0000219,,Homo sapiens,,Expert,14157,,D,9,CHEMBL617402,722.0,,
2516,1,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,BAO_0000219,,Homo sapiens,,Expert,12936,,D,9,CHEMBL617403,722.0,,
2517,1,Binding affinity against human 5-hydroxytryptamine 2A receptor using displacement of [3H]5-HT,,BAO_0000357,,,,Expert,14068,,H,8,CHEMBL617404,,,
2518,1,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,BAO_0000219,,Homo sapiens,,Expert,12936,,D,9,CHEMBL857981,722.0,,
2519,1,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,BAO_0000219,,Homo sapiens,,Expert,12936,,D,9,CHEMBL617405,722.0,,
2520,1,Binding affinity to human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]- ketanserin as radioligand,,BAO_0000219,,Homo sapiens,,Expert,4540,,D,9,CHEMBL617253,722.0,,
2521,1,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor.,,BAO_0000357,,,,Expert,6166,,H,8,CHEMBL617254,,,
2522,1,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,,BAO_0000219,,,,Autocuration,17296,,H,8,CHEMBL617255,722.0,,
2523,1,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,,BAO_0000219,,,,Autocuration,17296,,H,8,CHEMBL617256,722.0,,
2524,1,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]ketanserin as radioligand,,BAO_0000219,,,,Autocuration,17296,,H,8,CHEMBL616874,722.0,,
2525,1,Binding affinity towards 5-hydroxytryptamine 2A receptor (human cloned receptor) in HEK 293 cells using [3H]ketanserin as radioligand.,,BAO_0000219,,Homo sapiens,,Expert,15779,,D,9,CHEMBL616875,722.0,,
2526,1,Binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells using [3H]ketanserin as radioligand,,BAO_0000219,,,,Expert,14391,,H,8,CHEMBL616876,722.0,,
2527,1,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2A in HEK293 cells, using [3H]ketanserin as radioligand.",,BAO_0000219,,,,Expert,15851,,H,8,CHEMBL616877,722.0,,
2528,1,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells; compound is insoluble,,BAO_0000219,,Homo sapiens,,Expert,15851,,D,9,CHEMBL616878,722.0,,
2529,1,Binding affinity towards human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by displacement of [3H]ketanserin,,BAO_0000219,,,,Expert,3832,,H,8,CHEMBL616879,722.0,,
2530,1,In vitro binding affinity at human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by [3H]ketanserin displacement.,,BAO_0000219,,,,Expert,3833,,H,8,CHEMBL616880,722.0,,
2531,1,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,BAO_0000219,,Homo sapiens,,Expert,12936,,D,9,CHEMBL616881,722.0,,
2532,1,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand,,BAO_0000219,,,,Autocuration,17451,,H,8,CHEMBL616882,723.0,,
2533,1,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,BAO_0000219,,,,Autocuration,17451,,H,8,CHEMBL616883,723.0,,
2534,1,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,BAO_0000219,,,,Autocuration,17451,,H,8,CHEMBL616884,723.0,,
2535,1,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]ketanserin as the radioligand,,BAO_0000219,,,,Autocuration,4199,,H,8,CHEMBL616885,722.0,,
2536,1,Compound was evaluated for displacement of [3H]ketanserin from human cloned 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells,,BAO_0000219,,,,Autocuration,1883,,H,8,CHEMBL616886,485.0,,
2537,1,Displacement of [3H]-ketanserin from human cloned 5-hydroxytryptamine 2A receptor expressed in CHO-K1 cells.,,BAO_0000219,,,,Expert,1883,,H,8,CHEMBL616887,485.0,,
2538,1,Binding affinity for human 5-hydroxytryptamine 2A receptor,,BAO_0000357,,Homo sapiens,,Expert,14875,,D,9,CHEMBL616888,,,
2539,1,Compound was tested for its binding affinity against 5-hydroxytryptamine 2A receptor in human cloned receptors in HEK 293 cells using [3H]ketanserin,,BAO_0000219,,,,Autocuration,15146,,H,8,CHEMBL616889,722.0,,
2540,1,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2A receptor in HEK 293 using [3H]ketanserin as a radioligand,,BAO_0000219,,,,Autocuration,5213,,H,8,CHEMBL616890,722.0,,
2541,1,Inhibitory constant for human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,,BAO_0000219,,Homo sapiens,,Expert,16404,,D,9,CHEMBL616891,449.0,,
2542,1,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2A receptor in HEK293 cells using [3H]-ketanserin.,,BAO_0000219,,,,Autocuration,14818,,H,8,CHEMBL616892,722.0,,
2543,1,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2A receptor in HEK293 cells, using [3H]ketanserin as radioligand",,BAO_0000219,,,,Autocuration,4829,,H,8,CHEMBL616893,722.0,,
2544,1,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2A receptor in 3T3 cells,,BAO_0000219,,,,Autocuration,12652,,H,8,CHEMBL616894,723.0,,
2545,1,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells,,BAO_0000219,,,,Expert,4682,,H,8,CHEMBL616895,723.0,,
2546,1,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2A receptor,,BAO_0000019,,,,Autocuration,12652,,H,8,CHEMBL616896,,,
2547,1,Ability to displace [3H]-Ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor,,BAO_0000357,,,,Autocuration,4921,,H,8,CHEMBL617099,,,
2548,1,Ability to displace [3H]ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor; ND denotes not determined,,BAO_0000357,,,,Autocuration,4921,,H,8,CHEMBL617100,,,
2549,1,Binding affinity against rabbit aorta 5-HT2A receptor,,BAO_0000357,,Oryctolagus cuniculus,,Autocuration,16312,,H,8,CHEMBL884532,,,
2550,1,Binding affinity for 5-hydroxytryptamine 2A receptor of rabbit aorta ring preparations,,BAO_0000357,,Oryctolagus cuniculus,,Expert,14998,,H,8,CHEMBL617101,,,
2551,1,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 2A receptor in the rabbit saphenous aorta,,BAO_0000357,,Oryctolagus cuniculus,,Expert,14025,,H,8,CHEMBL617102,,,
2552,1,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,,BAO_0000019,,Oryctolagus cuniculus,,Autocuration,13047,,H,8,CHEMBL617103,,,
2553,1,The compound was tested for binding affinity against 5-HT2A receptor,,BAO_0000357,,Oryctolagus cuniculus,,Expert,13047,,H,8,CHEMBL617104,,,
2554,1,Compound was evaluated for displacement of [3H]ketanserin from cloned rat 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells.,,BAO_0000219,,,,Autocuration,1883,,H,8,CHEMBL857979,485.0,,
2555,1,Binding affinity analysed towards 5-HT 2A in rat jugular vein,,BAO_0000019,,,,Autocuration,13463,,H,8,CHEMBL857502,,,
2556,1,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,,BAO_0000019,,,,Autocuration,13463,,H,8,CHEMBL617105,,,
2557,1,Binding affinity analysed on 5-HT 2A in rat stomach fundus.,Stomach,BAO_0000019,,,,Autocuration,13463,,H,8,CHEMBL858021,,945.0,
2558,1,Binding affinity for 5-HT 2A in rat stomach fundus,Stomach,BAO_0000019,,Rattus norvegicus,,Expert,13463,,D,9,CHEMBL875910,,945.0,
2559,1,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,,BAO_0000019,,,,Autocuration,13463,,H,8,CHEMBL617106,,,
2560,1,Ability to stimulate phosphoinositide hydrolysis in NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor,,BAO_0000219,,,,Expert,16326,,H,8,CHEMBL617107,723.0,,
2561,1,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2A receptor,,BAO_0000019,,,,Autocuration,14093,,H,8,CHEMBL617108,,,
2562,1,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast expressing 5-hydroxytryptamine 2A receptor,,BAO_0000019,,,,Autocuration,14093,,H,8,CHEMBL617109,,,
2563,1,Evaluated for the effective concentration at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,,BAO_0000357,,,,Autocuration,15740,,H,8,CHEMBL617110,,,
2564,1,Functional potency at the rat 5-hydroxytryptamine 2A receptor as effective concentration EC50 for stimulating Phosphoinositide accumulation,,BAO_0000357,,,,Autocuration,16633,,H,8,CHEMBL617111,,,
2565,1,In vitro relative agonist activity against 5-hydroxytryptamine 2A using PI assay in rat vascular smooth muscle cells,,BAO_0000019,,Rattus norvegicus,,Expert,17200,,D,9,CHEMBL617112,,,
2566,1,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,BAO_0000357,,,,Autocuration,17133,,H,8,CHEMBL617113,,,
2567,1,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,BAO_0000357,,,,Autocuration,17133,,H,8,CHEMBL617114,,,
2568,1,Tested for its ability to activate phospholipase c by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,BAO_0000357,,,,Autocuration,17133,,H,8,CHEMBL617115,,,
2569,1,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,BAO_0000219,,,,Autocuration,17200,,H,8,CHEMBL617116,,,
2570,1,Efficacy at 5-hydroxytryptamine 2A receptor,,BAO_0000019,,,,Autocuration,15363,,H,8,CHEMBL617117,,,
2571,1,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),,BAO_0000357,,,,Autocuration,17200,,H,8,CHEMBL617118,,,
2572,1,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),,BAO_0000357,,Rattus norvegicus,,Expert,17200,,D,9,CHEMBL617119,,,
2573,1,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor determined by using PI assay (Emax),,BAO_0000357,,Rattus norvegicus,,Expert,17200,,D,9,CHEMBL617120,,,
2574,1,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,BAO_0000219,,Rattus norvegicus,,Expert,17200,,D,9,CHEMBL617121,,,
2575,1,The receptor (5-hydroxytryptamine 2A) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,BAO_0000219,,,,Autocuration,17200,,H,8,CHEMBL617122,,,
2576,1,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor,,BAO_0000019,,,,Autocuration,17211,,H,8,CHEMBL617123,,,
2577,1,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes,,BAO_0000019,,,,Expert,17331,,H,8,CHEMBL617124,,,
2578,1,Binding affinity to serotonin 5-hydroxytryptamine 2A receptors using a radioligand [3H]ketanserin binding assay in rat cortical membranes,,BAO_0000249,,,,Expert,13565,,H,8,CHEMBL617600,,,
2579,1,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was evaluated using [3H]- ketanserin as radioligand,,BAO_0000357,,,,Expert,13730,,H,8,CHEMBL617601,,,
2580,1,In vitro affinity towards 5-hydroxytryptamine 2A receptor using [3H]spiroperidol as radioligand in cortex,,BAO_0000019,,,,Expert,12416,,H,8,CHEMBL882923,,,
2581,1,Compound was tested for it's binding affinity towards 5-hydroxytryptamine 2A receptor,,BAO_0000357,,,,Autocuration,15295,,H,8,CHEMBL617602,,,
2582,1,Compound was tested for its ability to displace [3H]DOB from 5-hydroxytryptamine 2A receptor in rat cortex homogenates,,BAO_0000019,,,,Autocuration,1742,,H,8,CHEMBL617603,,,
2583,1,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor,,BAO_0000357,,,,Autocuration,15295,,H,8,CHEMBL617604,,,
2584,1,Binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]ketanserin as radioligand,,BAO_0000019,,,,Expert,14970,,H,8,CHEMBL617605,,,
2585,1,In vitro binding affinity for serotonin 5-hydroxytryptamine 2A receptor of rat cerebral cortex using [3H]ketanserin as radioligand,,BAO_0000019,,,,Expert,16693,,H,8,CHEMBL617606,,,
2586,1,Inhibition of [3H]ketanserin binding to rat frontal cortex membrane 5-hydroxytryptamine 2A receptor,,BAO_0000019,,Rattus norvegicus,,Expert,14776,,D,9,CHEMBL617607,,,
2587,1,In vitro inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cortical membrane,,BAO_0000249,,,,Autocuration,14286,,H,8,CHEMBL617455,,,
2588,1,In vitro inhibition of [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,,BAO_0000019,,Rattus norvegicus,,Expert,17200,,D,9,CHEMBL617456,,,
2589,1,Inhibitory concentration against 5-hydroxytryptamine 2A receptor (Inactive at >1000 nM concentration),,BAO_0000357,,,,Expert,15306,,H,8,CHEMBL617457,,,
2590,1,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2A receptor,,BAO_0000357,,Rattus norvegicus,,Expert,14178,,D,9,CHEMBL617458,,,
2591,1,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor from rat brain,,BAO_0000019,,Rattus norvegicus,,Expert,14229,,D,9,CHEMBL617459,,,
2592,1,Binding affinity towards 5-hydroxytryptamine 2A receptor binding site using [3H]ketanserin. ,,BAO_0000357,,,,Expert,12884,,H,8,CHEMBL617460,,,
2593,1,"Binding affinity for 5-hydroxytryptamine 2A receptor, activity is expressed as IC50 values.",,BAO_0000357,,,,Expert,13149,,H,8,CHEMBL617461,,,
2594,1,Displacement of [3H]ketanserin from rat cortical membrane 5-hydroxytryptamine 2A receptor at 10e-7 M,,BAO_0000019,,Rattus norvegicus,,Expert,15295,,D,9,CHEMBL617462,,,
2595,1,Intrinsic activity was determined at 5-hydroxytryptamine 2A receptor which is percentage response given compared with the response produced by 10 uM serotonin.,,BAO_0000357,,,,Autocuration,15740,,H,8,CHEMBL617463,,,
2596,1,"Compound was tested for binding affinity at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate using [125I]-2,5-Dimethoxy -4-iodoamphetamine (DOI).",,BAO_0000019,,,,Autocuration,15185,,H,8,CHEMBL617464,,,
2597,1,"Compound was tested for binding affinity using [3H]MDL-100,907 at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate.",,BAO_0000019,,,,Autocuration,15185,,H,8,CHEMBL617465,,,
2598,1,Ability to bind to central serotonin 5-hydroxytryptamine 2A receptor in vitro in cortex of the rat brain using [3H]ketanserin radioligand,,BAO_0000019,,,,Expert,17529,,H,8,CHEMBL617466,,,
2599,1,Ability to displace [3H]- ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,,BAO_0000019,,,,Autocuration,14826,,H,8,CHEMBL617467,,,
2600,1,Displacement of [3H]ketanserin (0.5 nM) from rat cerebral cortex 5-hydroxytryptamine 2A receptors,,BAO_0000019,,,,Expert,17211,,H,8,CHEMBL617468,,,
2601,1,Ability to displace [3H]ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,,BAO_0000019,,,,Autocuration,14826,,H,8,CHEMBL617469,,,
2602,1,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,,BAO_0000019,,,,Autocuration,14093,,H,8,CHEMBL617470,,,
2603,1,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor; Not tested,,BAO_0000019,,,,Autocuration,14093,,H,8,CHEMBL617471,,,
2604,1,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor in NIH3T3 cell line membranes,,BAO_0000219,,,,Expert,13246,,H,8,CHEMBL617472,723.0,,
2605,1,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor.,,BAO_0000357,,,,Expert,13246,,H,8,CHEMBL617473,,,
2606,1,Affinity 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,BAO_0000019,,Rattus norvegicus,,Expert,15436,,D,9,CHEMBL617474,,,
2607,1,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,BAO_0000019,,Rattus norvegicus,,Expert,15436,,D,9,CHEMBL617475,,,
2608,1,Affinity at [3H]ketanserin-labeled 5-hydroxytryptamine 2A receptor in rat brain homogenate was determined,Brain,BAO_0000221,,,,Autocuration,14442,,H,8,CHEMBL617476,,955.0,
2609,1,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2A receptor,,BAO_0000357,,,,Expert,12457,,H,8,CHEMBL617477,,,
2610,1,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2A receptor,,BAO_0000219,,,,Expert,12457,,H,8,CHEMBL617478,723.0,,
2611,1,"Antagonistic activity measured for 5-hydroxytryptamine 2A receptor using [3H]-MDL- 100,907 as radioligand in rat cortical homogenates.",,BAO_0000221,,,,Autocuration,14755,,H,8,CHEMBL617479,,,
2612,1,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was determined using [125I]- DOI as radioligand,,BAO_0000357,,,,Autocuration,4707,,H,8,CHEMBL617480,,,
2613,1,Binding affinity against 5-hydroxytryptamine 2A receptor,,BAO_0000357,,,,Expert,13297,,H,8,CHEMBL617481,,,
2614,1,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat prefrontal cerebral cortex mambranes,,BAO_0000019,,,,Expert,17331,,H,8,CHEMBL617482,,,
2615,1,Binding affinity against 5-hydroxytryptamine 2A receptor from rat forebrain using [3H]ketanserin as radioligand,,BAO_0000019,,,,Autocuration,4664,,H,8,CHEMBL617483,,,
2616,1,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,BAO_0000357,,,,Autocuration,16633,,H,8,CHEMBL621528,,,
2617,1,Binding affinity against 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells using [3H]ketanserin,,BAO_0000219,,Rattus norvegicus,,Expert,4664,,D,9,CHEMBL621529,723.0,,
2618,1,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,BAO_0000357,,,,Expert,16133,,H,8,CHEMBL621530,,,
2619,1,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,BAO_0000357,,,,Expert,16133,,H,8,CHEMBL621531,,,
2620,1,Binding affinity against rat brain 5-hydroxytryptamine 2A receptor,,BAO_0000019,,Rattus norvegicus,,Expert,14060,,D,9,CHEMBL621532,,,
2621,1,Binding affinity at cloned rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,BAO_0000357,,,,Expert,16326,,H,8,CHEMBL621533,,,
2622,1,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,BAO_0000219,,,,Expert,16659,,H,8,CHEMBL621534,449.0,,
2623,1,Binding affinity measured at the 5-hydroxytryptamine 2A receptor by the inhibition of [3H]ketanserin binding to rat cortex using unlabeled mianserin for nonspecific binding.,,BAO_0000019,,,,Autocuration,14776,,H,8,CHEMBL621535,,,
2624,1,Binding affinity of [3H]- ketanserin labelled towards Rat cortical 5-hydroxytryptamine 2A receptor using radioligand binding assay,,BAO_0000357,,,,Autocuration,13481,,H,8,CHEMBL621536,,,
2625,1,Binding affinity of compound was tested for 5-hydroxytryptamine 2A receptor,,BAO_0000357,,,,Autocuration,17386,,H,8,CHEMBL621537,,,
2626,1,Binding affinity for 5-hydroxytryptamine 2A receptor,,BAO_0000357,,Rattus norvegicus,,Expert,6611,,D,9,CHEMBL621538,,,
2627,1,Binding affinity against 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as the radioligand.,,BAO_0000019,,,,Autocuration,14423,,H,8,CHEMBL621539,,,
2628,1,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex,,BAO_0000019,,,,Autocuration,15412,,H,8,CHEMBL621540,,,
2629,1,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex.,,BAO_0000019,,,,Autocuration,15412,,H,8,CHEMBL621541,,,
2630,1,Binding affinity towards 5-HT 2A receptor in rat cerebral frontal cortex membranes using [3H]ketanserin as radioligand,,BAO_0000019,,,,Autocuration,6238,,H,8,CHEMBL621542,,,
2631,1,Binding affinity at 5-hydroxytryptamine 2A receptor of rat.,,BAO_0000357,,,,Expert,6648,,H,8,CHEMBL621543,,,
2632,1,Binding affinity towards 5-hydroxytryptamine 2A receptor sites by using [3H]ketanserin as radioligand,,BAO_0000357,,,,Expert,5667,,H,8,CHEMBL621544,,,
2633,1,Binding affinity for 5-hydroxytryptamine 2A serotonin receptor,,BAO_0000357,,Rattus norvegicus,,Expert,6611,,D,9,CHEMBL621545,,,
2634,1,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,BAO_0000357,,,,Autocuration,13481,,H,8,CHEMBL621546,,,
2635,1,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand; Not tested,,BAO_0000357,,,,Autocuration,13481,,H,8,CHEMBL621547,,,
2636,1,Displacement of [3H]ketanserin from NIH3T3 cells stably expressing rat 5-hydroxytryptamine 2A receptor,,BAO_0000219,,,,Expert,15558,,H,8,CHEMBL618692,723.0,,
2637,1,Binding affinity towards 5-hydroxytryptamine 2A receptor,,BAO_0000357,,,,Autocuration,6013,,H,8,CHEMBL618693,,,
2638,1,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,BAO_0000357,,,,Autocuration,16633,,H,8,CHEMBL872922,,,
2639,1,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor from fundus tissue was determined using [3H]mesulergine as radioligand,,BAO_0000357,,,,Autocuration,6013,,H,8,CHEMBL618694,,,
2640,1,Binding affinity for rat 5-hydroxytryptamine 2A receptor using [3H]DOB,,BAO_0000357,,Rattus norvegicus,,Expert,6013,,D,9,CHEMBL618695,,,
2641,1,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor was determined using [3H]DOB as radioligand; ND=No data,,BAO_0000357,,,,Autocuration,6013,,H,8,CHEMBL618696,,,
2642,1,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor by [3H]ketanserin displacement.,,BAO_0000357,,,,Expert,6013,,H,8,CHEMBL618697,,,
2643,1,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]DOB as radioligand,,BAO_0000357,,,,Autocuration,6013,,H,8,CHEMBL618892,,,
2644,1,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]ketanserin as radioligand,,BAO_0000357,,,,Autocuration,6013,,H,8,CHEMBL618893,,,
2645,1,Binding affinity towards rat 5-hydroxytryptamine 2A receptor,,BAO_0000357,,,,Autocuration,16293,,H,8,CHEMBL618894,,,
2646,1,Binding affinity towards rat 5-hydroxytryptamine 2A receptor expressed in NIH3T3 cells using [3H]ketanserin as radioligand,,BAO_0000219,,,,Expert,17175,,H,8,CHEMBL618895,723.0,,
2647,1,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,,BAO_0000357,,Rattus norvegicus,,Expert,13278,,D,9,CHEMBL618896,,,
2648,1,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2A receptor in homogenate of caudate putamen tissue from rat brain,Caudate-putamen,BAO_0000019,,,,Autocuration,3682,,H,8,CHEMBL618897,,5383.0,
2649,1,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand,,BAO_0000357,,,,Autocuration,2014,,H,8,CHEMBL618898,,,
2650,1,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand; Not determined,,BAO_0000357,,,,Autocuration,2014,,H,8,CHEMBL618899,,,
2651,1,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2A receptor in cloned rat cell culture,,BAO_0000357,,,,Autocuration,4932,,H,8,CHEMBL618900,,,
2652,1,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2A receptor in cloned rat prefrontal cortex homogenate,,BAO_0000019,,,,Autocuration,4932,,H,8,CHEMBL618901,,,
2653,1,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2A receptor,,BAO_0000357,,,,Autocuration,3935,,H,8,CHEMBL618902,,,
2654,1,Displacement of [3H]8-OH-DPAT from rat hippocampus membrane 5-hydroxytryptamine 2A receptor,Hippocampus,BAO_0000221,,Rattus norvegicus,,Expert,5432,,D,9,CHEMBL618903,,10000000.0,
2655,1,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2A receptor,,BAO_0000357,,,,Autocuration,15818,,H,8,CHEMBL618904,,,
2656,1,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand.,,BAO_0000357,,,,Autocuration,13672,,H,8,CHEMBL618905,,,
2657,1,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]-ketanserin radioligand.,,BAO_0000357,,,,Autocuration,13672,,H,8,CHEMBL618906,,,
2658,1,Binding affinity against rat 5-hydroxytryptamine 2A receptor in NIH3T3 cells.,,BAO_0000219,,,,Expert,14749,,H,8,CHEMBL618907,723.0,,
2659,1,Compound was tested for the Binding affinity against rat frontal cortex 5-hydroxytryptamine 2A receptor by Radio ligand [3H]ketanserin binding assay.,,BAO_0000019,,,,Autocuration,13462,,H,8,CHEMBL618908,,,
2660,1,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,,BAO_0000357,,,,Autocuration,15740,,H,8,CHEMBL617909,,,
2661,1,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,,BAO_0000019,,,,Expert,16647,,H,8,CHEMBL617910,,,
2662,1,In vitro ability to displace [3H]ketanserin from 5-hydroxytryptamine 2A receptor in rat brain.,Brain,BAO_0000221,,,,Autocuration,13345,,H,8,CHEMBL617911,,955.0,
2663,1,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,BAO_0000249,,,,Autocuration,16740,,H,8,CHEMBL872923,,,
2664,1,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,BAO_0000249,,,,Autocuration,16740,,H,8,CHEMBL617912,,,
2665,1,In vitro binding affinity at 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat cortex,,BAO_0000019,,Rattus norvegicus,,Expert,15535,,D,9,CHEMBL617913,,,
2666,1,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,BAO_0000249,,,,Expert,16740,,H,8,CHEMBL617914,,,
2667,1,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,BAO_0000249,,,,Autocuration,16740,,H,8,CHEMBL617915,,,
2668,1,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane,,BAO_0000249,,,,Autocuration,16740,,H,8,CHEMBL617916,,,
2669,1,Displacement of [3H]- Ketanserin from rat cortex 5-hydroxytryptamine 2A receptor,,BAO_0000019,,Rattus norvegicus,,Expert,4795,,D,9,CHEMBL617917,,,
2670,1,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand,,BAO_0000019,,,,Expert,8,,H,8,CHEMBL617918,,,
2671,1,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand; Not active at 10-5 M,,BAO_0000019,,,,Autocuration,8,,H,8,CHEMBL617919,,,
2672,1,In vitro inhibitory constant against [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,,BAO_0000019,,Rattus norvegicus,,Expert,17200,,D,9,CHEMBL617920,,,
2673,1,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor of rat brain cortex,,BAO_0000019,,Rattus norvegicus,,Expert,2148,,D,9,CHEMBL617921,,,
2674,1,"Relative binding affinity for D2 receptor and 5-hydroxytryptamine 2A receptor, ratio of Ki",,BAO_0000224,,Rattus norvegicus,,Expert,13345,,D,5,CHEMBL617922,,,
2675,1,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,BAO_0000357,,,,Autocuration,5088,,H,8,CHEMBL617923,,,
2676,1,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,BAO_0000357,,,,Autocuration,5088,,H,8,CHEMBL617924,,,
2677,1,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2A receptor using [125 I]-DOI as radioligand,,BAO_0000357,,,,Autocuration,17133,,H,8,CHEMBL617925,,,
2678,1,In vitro binding to 5-hydroxytryptamine 2A receptor using [125 I]-DOI,,BAO_0000357,,Rattus norvegicus,,Expert,17133,,D,9,CHEMBL617926,,,
2679,1,The binding affinity at 5-hydroxytryptamine 2A receptor was determined using [3H]ketanserin,,BAO_0000357,,,,Autocuration,16532,,H,8,CHEMBL617927,,,
2680,1,The compound was tested for binding affinity against 5-hydroxytryptamine 2A receptor,,BAO_0000357,,,,Autocuration,15086,,H,8,CHEMBL617928,,,
2681,1,Binding affinity for 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,BAO_0000019,,Rattus norvegicus,,Expert,2309,,D,9,CHEMBL617929,,,
2682,1,Binding affinity to 5-hydroxytryptamine 2A receptor from rat cortex assayed using [3H]ketanserin as radioligand.,,BAO_0000019,,,,Expert,12953,,H,8,CHEMBL617930,,,
2683,1,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as radioligand.; Nonactive at 10 uM,,BAO_0000019,,,,Autocuration,12953,,H,8,CHEMBL617931,,,
2684,1,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]-ketanserin as radioligand; Nonactive at 10 uM,,BAO_0000019,,,,Autocuration,12953,,H,8,CHEMBL617932,,,
2685,1,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells; ND is No Data,,BAO_0000219,,,,Autocuration,16659,,H,8,CHEMBL617933,449.0,,
2686,1,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,,BAO_0000019,,,,Autocuration,16740,,H,8,CHEMBL617934,,,
2687,1,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,,BAO_0000019,,,,Autocuration,16740,,H,8,CHEMBL617935,,,
2688,1,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor; Not determined,,BAO_0000357,,,,Autocuration,17133,,H,8,CHEMBL617936,,,
2689,1,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor; NT=not tested,,BAO_0000019,,,,Autocuration,17211,,H,8,CHEMBL617937,,,
2690,1,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes; Not tested,,BAO_0000019,,,,Autocuration,17331,,H,8,CHEMBL617938,,,
2691,1,Compound was evaluated for effective dose measured in nmol/kg following a dose of 0.04 mg/kg and 0.093 uM/kg (95%CI); range 32-63,,BAO_0000218,,,,Autocuration,16633,,H,8,CHEMBL617939,,,
2692,1,Compound was evaluated for the percentage of rats disrupted following a dose of 0.04 mg/kg and 0.097 uM/kg,,BAO_0000218,,,,Autocuration,16633,,H,8,CHEMBL617940,,,
2693,1,Compound was evaluated for the percentage of rats disrupted following a dose of 0.08 mg/kg and 0.194 uM/kg,,BAO_0000218,,,,Autocuration,16633,,H,8,CHEMBL617941,,,
2694,1,Ratio of pKi of 5-HT2A to that of 5-HT2C receptor,,BAO_0000357,,,,Expert,15026,,H,8,CHEMBL617942,,,
2695,1,Ratio of pKi of 5-HT2A to that of D2 receptor,,BAO_0000357,,,,Expert,15026,,H,8,CHEMBL617943,,,
2696,1,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,,BAO_0000224,,,,Expert,16404,,H,4,CHEMBL617944,,,
2697,1,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,,BAO_0000224,,,,Expert,16404,,H,4,CHEMBL617945,,,
2698,1,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor,,BAO_0000224,,,,Expert,16404,,H,4,CHEMBL617946,,,
2699,1,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor; ND is no data,,BAO_0000357,,,,Autocuration,16404,,H,8,CHEMBL617947,,,
2700,1,Percent maximal 5-HT stimulation at cloned rat 5-hydroxytryptamine 2A receptor (phosphoinositide hydrolysis study) at a conc of 100 uM,,BAO_0000357,,,,Expert,16326,,H,8,CHEMBL617948,,,
2701,1,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat,,BAO_0000019,,,,Autocuration,15847,,H,8,CHEMBL858116,,,
2702,1,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat; ND means not done,,BAO_0000019,,,,Autocuration,15847,,H,8,CHEMBL617949,,,
2703,1,Effectiveness of compound in blocking 5-hydroxytryptamine 2A receptor-mediated contractions of rat tail artery,,BAO_0000019,,,,Autocuration,15329,,H,8,CHEMBL617950,,,
2704,1,Negative log concentration of antagonist on 5-hydroxytryptamine 2A receptor in rat thoracic aorta,Thoracic aorta,BAO_0000019,,,,Expert,16404,,H,8,CHEMBL617951,,1515.0,
2705,1,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta,Thoracic aorta,BAO_0000019,,,,Expert,16404,,H,8,CHEMBL617952,,1515.0,
2706,1,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta; ND is not determined.,Thoracic aorta,BAO_0000019,,,,Autocuration,16404,,H,8,CHEMBL617953,,1515.0,
2707,1,Binding activity radioligand.,,BAO_0000357,,,,Autocuration,12861,,H,8,CHEMBL617954,,,
2708,1,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,BAO_0000019,,,,Expert,12861,,H,8,CHEMBL617955,,,
2709,1,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,,BAO_0000019,,,,Autocuration,12861,,H,8,CHEMBL857071,,,
2710,1,Displacement of [3H]DOB binding to 5-hydroxytryptamine 2A receptor from rat cortex homogenate,,BAO_0000019,,,,Expert,12490,,H,8,CHEMBL617270,,,
2711,1,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930,,BAO_0000219,,,,Autocuration,12827,,H,8,CHEMBL617271,339.0,,
2712,1,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930; Not determined,,BAO_0000219,,,,Autocuration,12827,,H,8,CHEMBL617272,339.0,,
2713,1,Binding affinity was evaluated by 5-hydroxytryptamine 2A receptor agonism in the rat cortex by displacing ketanserin,,BAO_0000019,,,,Autocuration,12918,,H,8,CHEMBL617273,,,
2714,1,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]-ketanserin,,BAO_0000019,,Rattus norvegicus,,Expert,12919,,D,9,CHEMBL617274,,,
2715,1,Binding affinity towards human serotonin 5-hydroxytryptamine 2C receptor,,BAO_0000357,,,,Autocuration,17723,,H,8,CHEMBL617275,,,
2716,1,Binding affinity towards 5-hydroxytryptamine 2C receptor,,BAO_0000357,,,,Autocuration,6013,,H,8,CHEMBL617276,,,
2717,1,Binding affinity towards human 5-hydroxytryptamine 2C receptor,,BAO_0000357,,,,Autocuration,16293,,H,8,CHEMBL617277,,,
2718,1,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,,BAO_0000019,,,,Expert,3857,,H,8,CHEMBL617278,,,
2719,1,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor; Not determined,,BAO_0000019,,,,Expert,3857,,H,8,CHEMBL617279,,,
2720,1,Binding affinity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,,BAO_0000019,,,,Expert,3857,,H,8,CHEMBL617280,,,
2721,1,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,,BAO_0000357,,,,Autocuration,15363,,H,8,CHEMBL617281,,,
2722,1,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,,BAO_0000357,,,,Autocuration,15363,,H,8,CHEMBL617282,,,
2723,1,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]mesulergine,,BAO_0000019,,,,Expert,16441,,H,8,CHEMBL617283,,,
2724,1,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]-mesulergine; ND is No Data.,,BAO_0000019,,,,Expert,16441,,H,8,CHEMBL617284,,,
2725,1,In vitro binding affinity towards human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells was determined using [3H]mesulergine as radioligand,,BAO_0000219,,,,Autocuration,4176,,H,8,CHEMBL617285,722.0,,
2726,1,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2C receptor,,BAO_0000019,,,,Autocuration,17085,,H,8,CHEMBL617286,,,
2727,1,Inhibitory constant against cloned human 5-hydroxytryptamine 2C receptor using with [125I]- DOI radioligand,,BAO_0000357,,Homo sapiens,,Expert,17200,,D,9,CHEMBL617287,,,
2728,1,Binding affinity towards human 5-hydroxytryptamine 2C receptor.,,BAO_0000357,,,,Expert,5088,,H,8,CHEMBL617288,,,
2729,1,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]DOB as radioligand,,BAO_0000357,,,,Autocuration,5088,,H,8,CHEMBL617289,,,
2730,1,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,BAO_0000357,,,,Autocuration,5088,,H,8,CHEMBL872917,,,
2731,1,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,,BAO_0000357,,,,Autocuration,5088,,H,8,CHEMBL617290,,,
2732,1,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,BAO_0000219,,,,Autocuration,16659,,H,8,CHEMBL617291,449.0,,
2733,1,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells; ND is no data,,BAO_0000219,,,,Autocuration,16659,,H,8,CHEMBL617292,449.0,,
2734,1,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,BAO_0000219,,,,Autocuration,17451,,H,8,CHEMBL617293,723.0,,
2735,1,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,BAO_0000219,,Homo sapiens,,Expert,6857,,D,9,CHEMBL617294,449.0,,
2736,1,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,,BAO_0000019,,,,Expert,3857,,H,8,CHEMBL617295,,,
2737,1,Binding activity radioligand.,,BAO_0000357,,,,Autocuration,12861,,H,8,CHEMBL617296,,,
2738,1,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,BAO_0000019,,,,Autocuration,12861,,H,8,CHEMBL617297,,,
2739,1,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand,,BAO_0000219,,,,Expert,5104,,H,8,CHEMBL617298,449.0,,
2740,1,Binding affinity at human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells by [3H]mesulergine displacement.,,BAO_0000219,,,,Expert,5105,,H,8,CHEMBL617299,449.0,,
2741,1,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand; NT means not tested,,BAO_0000219,,,,Autocuration,5105,,H,8,CHEMBL617300,449.0,,
2742,1,Binding affinity against 5-HT2C receptor,,BAO_0000357,,,,Autocuration,5254,,H,8,CHEMBL617454,,,
2743,1,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,,BAO_0000219,,,,Autocuration,13267,,H,8,CHEMBL617505,722.0,,
2744,1,Displacement of [3H]mesulergine from 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells,,BAO_0000219,,Homo sapiens,,Expert,14157,,D,9,CHEMBL617506,722.0,,
2745,1,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,,BAO_0000219,,Homo sapiens,,Expert,12936,,D,9,CHEMBL617507,722.0,,
2746,1,Binding affinity against human 5-hydroxytryptamine 2C receptor using displacement of [3H]DOB,,BAO_0000357,,,,Expert,14068,,H,8,CHEMBL617508,,,
2747,1,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,,BAO_0000219,,Homo sapiens,,Expert,12936,,D,9,CHEMBL857982,722.0,,
2748,1,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand,,BAO_0000219,,Homo sapiens,,Expert,4540,,D,9,CHEMBL617509,722.0,,
2749,1,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand; Nd means not determined,,BAO_0000219,,Homo sapiens,,Expert,4540,,D,9,CHEMBL617510,722.0,,
2750,1,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor was determined,,BAO_0000357,,,,Autocuration,6166,,H,8,CHEMBL617511,,,
2751,1,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptors in HEK 293 cells using [3H]mesulergine as radioligand,,BAO_0000219,,,,Autocuration,17296,,H,8,CHEMBL617512,722.0,,
2752,1,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]mesulergine as radioligand,,BAO_0000219,,,,Autocuration,17296,,H,8,CHEMBL617749,722.0,,
2753,1,Binding affinity towards 5-HT2C (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,BAO_0000219,,,,Autocuration,15779,,H,8,CHEMBL617750,722.0,,
2754,1,Binding affinity towards 5-hydroxytryptamine 2C receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,BAO_0000219,,,,Autocuration,15779,,H,8,CHEMBL617751,722.0,,
2755,1,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells using [3H]mesulergine as radioligand,,BAO_0000219,,,,Expert,14391,,H,8,CHEMBL617752,722.0,,
2756,1,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand",,BAO_0000219,,,,Autocuration,15779,,H,8,CHEMBL617753,722.0,,
2757,1,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2C in HEK293 cells, using [3H]mesulergine as radioligand.",,BAO_0000219,,,,Expert,15851,,H,8,CHEMBL617754,722.0,,
2758,1,Displacement of [3H]mesulergine from human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells; compound insoluble,,BAO_0000219,,Homo sapiens,,Expert,15851,,D,9,CHEMBL617755,722.0,,
2759,1,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand; no data",,BAO_0000219,,,,Autocuration,15779,,H,8,CHEMBL617756,722.0,,
2760,1,Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by displacement of [3H]mesulergine,,BAO_0000219,,,,Expert,3832,,H,8,CHEMBL617757,722.0,,
2761,1,In vitro binding affinity at human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by [3H]mesulergine displacement.,,BAO_0000219,,,,Expert,3833,,H,8,CHEMBL617758,722.0,,
2762,1,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand,,BAO_0000219,,,,Autocuration,17451,,H,8,CHEMBL617759,723.0,,
2763,1,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine as the radioligand,,BAO_0000219,,,,Autocuration,4199,,H,8,CHEMBL617760,722.0,,
2764,1,Displacement of [3H]mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO-K1 cells,,BAO_0000219,,,,Expert,1883,,H,8,CHEMBL617761,485.0,,
2765,1,Binding affinity against 5-hydroxytryptamine 2C receptor,,BAO_0000357,,Homo sapiens,,Expert,4321,,D,9,CHEMBL617762,,,
2766,1,Compound was tested for binding affinity against human 5-hydroxytryptamine 2C receptor,,BAO_0000357,,,,Autocuration,14875,,H,8,CHEMBL617763,,,
2767,1,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine,,BAO_0000219,,,,Autocuration,15146,,H,8,CHEMBL857983,722.0,,
2768,1,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2C receptor in HEK 293 using [3H]mesulergine as a radioligand,,BAO_0000219,,,,Autocuration,5213,,H,8,CHEMBL617764,722.0,,
2769,1,Inhibitory constant on human 5-hydroxytryptamine 2C receptor transfected in to HeLa cells,,BAO_0000219,,,,Autocuration,16404,,H,8,CHEMBL617765,308.0,,
2770,1,Selectivity as the ratio of Ki value towards 5-hydroxytryptamine 2C receptor to that of pA2 value towards 5-hydroxytryptamine 2B receptor,,BAO_0000019,,,,Autocuration,13267,,H,8,CHEMBL617766,,,
2771,1,The binding affinity (pKi) measured against 5-hydroxytryptamine 3 receptor of rat hippocampus and entorhinal cortex using [3H]granisetron as radioligand,Hippocampus,BAO_0000221,,,,Autocuration,13267,,H,8,CHEMBL617767,,10000000.0,
2772,1,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2C receptor in HEK293 cells using [3H]mesulergine.,,BAO_0000219,,,,Autocuration,14818,,H,8,CHEMBL617768,722.0,,
2773,1,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]5-mesulergine as radioligand",,BAO_0000219,,,,Autocuration,4829,,H,8,CHEMBL617769,722.0,,
2774,1,Binding affinity analysed on 5-HT 2C in human clone using [3H]mesulergine as radioligand,,BAO_0000357,,,,Autocuration,13463,,H,8,CHEMBL858023,,,
2775,1,Binding affinity analysed on 5-HT 2C in rat stomach fundus,Stomach,BAO_0000019,,,,Autocuration,13463,,H,8,CHEMBL617770,,945.0,
2776,1,Binding affinity analysed towards 5-HT 2C in rat stomach fundus,Stomach,BAO_0000019,,,,Autocuration,13463,,H,8,CHEMBL617771,,945.0,
2777,1,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2C receptor in A9 cells,,BAO_0000219,,,,Autocuration,12652,,H,8,CHEMBL617772,625.0,,
2778,1,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,,BAO_0000219,,,,Autocuration,4682,,H,8,CHEMBL617773,723.0,,
2779,1,Binding affinity to 5-hydroxytryptamine 2C receptor measured using radioligand [3H]Mesulergine in stably transfected NIH3T3 cells,,BAO_0000219,,,,Autocuration,4682,,H,8,CHEMBL617850,723.0,,
2780,1,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,,BAO_0000219,,,,Autocuration,4682,,H,8,CHEMBL617851,723.0,,
2781,1,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2C receptor,,BAO_0000019,,,,Autocuration,12652,,H,8,CHEMBL617852,,,
2782,1,Binding affinity analysed on 5-HT 2C in rat stomach fundus.,Stomach,BAO_0000019,,Mus musculus,,Autocuration,13463,,H,8,CHEMBL858024,,945.0,
2783,1,Binding affinity towards 5-HT 2C receptor in rat stomach fundus,Stomach,BAO_0000019,,Rattus norvegicus,,Expert,13463,,D,9,CHEMBL617853,,945.0,
2784,1,Binding affinity against 5-Hydroxytryptamine 2C Receptor was measured using [3H]N-methyl-mesulergine as radioligand,,BAO_0000357,,,,Expert,13969,,H,8,CHEMBL617854,,,
2785,1,Binding affinity for 5-hydroxytryptamine 2C receptor,,BAO_0000357,,Sus scrofa,,Expert,13392,,H,8,CHEMBL873477,,,
2786,1,Binding affinity towards 5-hydroxytryptamine 2C receptor,,BAO_0000357,,,,Expert,13392,,H,8,CHEMBL617855,,,
2787,1,Affinity towards 5-hydroxytryptamine 2C receptor in membranes from pig choroid plexus using [3H]N-methyl-mesulergine,,BAO_0000019,,,,Expert,14430,,H,8,CHEMBL617856,,,
2788,1,Compound was tested for its ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor in pig cortex,,BAO_0000019,,,,Autocuration,1742,,H,8,CHEMBL617857,,,
2789,1,In vitro inhibitory concentration against radioligand [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in pig cortical membrane,,BAO_0000249,,,,Autocuration,14286,,H,8,CHEMBL617858,,,
2790,1,Binding affinity towards pig 5-hydroxytryptamine 2C receptor,,BAO_0000357,,,,Autocuration,5619,,H,8,CHEMBL617859,,,
2791,1,The compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,,BAO_0000357,,,,Autocuration,15086,,H,8,CHEMBL617860,,,
2792,1,Binding activity radioligand.,,BAO_0000357,,,,Autocuration,12861,,H,8,CHEMBL617861,,,
2793,1,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,BAO_0000019,,,,Expert,12861,,H,8,CHEMBL617862,,,
2794,1,Binding activity against 5-hydroxytryptamine 3 receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,,BAO_0000019,,,,Autocuration,12861,,H,8,CHEMBL617863,,,
2795,1,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT,,BAO_0000249,,,,Autocuration,12827,,H,8,CHEMBL617864,,,
2796,1,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT; Not determined,,BAO_0000249,,,,Autocuration,12827,,H,8,CHEMBL617649,,,
2797,1,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,,BAO_0000019,,Sus scrofa,,Expert,12919,,H,8,CHEMBL617650,,,
2798,1,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,,BAO_0000019,,Sus scrofa,,Expert,12919,,H,8,CHEMBL617651,,,
2799,1,In vitro binding affinity at 5-hydroxytryptamine 2C receptor in pig choroid plexus using 3[H]mesulergine as the radioligand,,BAO_0000357,,Sus scrofa,,Autocuration,16429,,H,8,CHEMBL617652,,,
2800,1,In Vitro Binding affinity againist 5-hydroxytryptamine 2C receptor by displacing [3H]mesulergine from pig cortex,,BAO_0000019,,Sus scrofa,,Autocuration,773,,H,8,CHEMBL857072,,,
2801,1,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2C receptor,,BAO_0000357,,Sus scrofa,,Autocuration,5033,,H,8,CHEMBL617653,,,
2802,1,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,BAO_0000019,,,,Autocuration,12861,,H,8,CHEMBL617654,,,
2803,1,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2C receptor,,BAO_0000019,,,,Autocuration,14093,,H,8,CHEMBL617655,,,
2804,1,Binding affinity towards 5-HT2C receptor from rat using [3H]mesulergine as radioligand,,BAO_0000357,,,,Expert,14970,,H,8,CHEMBL617656,,,
2805,1,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand,,BAO_0000357,,,,Autocuration,14970,,H,8,CHEMBL617657,,,
2806,1,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand; Not tested,,BAO_0000357,,,,Autocuration,14970,,H,8,CHEMBL617658,,,
2807,1,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2C receptor,,BAO_0000357,,Rattus norvegicus,,Expert,14178,,D,9,CHEMBL617659,,,
2808,1,Inhibition of radiolabeled [3H]mesulergine ligand binding to 5-hydroxytryptamine 2C receptor,,BAO_0000357,,Rattus norvegicus,,Expert,14178,,D,9,CHEMBL617838,,,
2809,1,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in rat brain membranes,,BAO_0000249,,Rattus norvegicus,,Expert,14229,,D,9,CHEMBL617839,,,
2810,1,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine; Not tested,,BAO_0000357,,,,Autocuration,16532,,H,8,CHEMBL617840,,,
2811,1,Ability to displace [3H]mesulergine bound to 5-hydroxytryptamine 2C receptor in rat cortex,,BAO_0000019,,,,Autocuration,14826,,H,8,CHEMBL617841,,,
2812,1,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-HT2C receptor,,BAO_0000019,,,,Autocuration,17211,,H,8,CHEMBL875915,,,
2813,1,Displacement of [3H]mesulergine (0.5 nM) from rat 5-hydroxytryptamine 2C receptor expressed in SR-3T3 cells,,BAO_0000219,,,,Expert,17211,In vitro,H,8,CHEMBL617842,,,
2814,1,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor in NIH3T3 cell line membranes,,BAO_0000219,,,,Expert,13246,,H,8,CHEMBL617843,723.0,,
2815,1,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor.,,BAO_0000357,,,,Expert,13246,,H,8,CHEMBL617844,,,
2816,1,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2C receptor,,BAO_0000357,,,,Expert,12457,,H,8,CHEMBL617845,,,
2817,1,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2C receptor,,BAO_0000219,,,,Expert,12457,,H,8,CHEMBL617846,723.0,,
2818,1,Binding affinity towards rat 5-hydroxytryptamine 2C receptor was determined using [125I]- DOI as radioligand,,BAO_0000357,,,,Autocuration,4707,,H,8,CHEMBL617847,,,
2819,1,Binding affinity against 5-hydroxytryptamine 2C receptor,,BAO_0000357,,,,Expert,13297,,H,8,CHEMBL617848,,,
2820,1,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,BAO_0000357,,,,Autocuration,16633,,H,8,CHEMBL617849,,,
2821,1,Binding affinity against rat 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,BAO_0000357,,,,Expert,16133,,H,8,CHEMBL621507,,,
2822,1,Binding affinity at cloned rat 5-hydroxytryptamine 2C receptor using [3H]DOI as radioligand,,BAO_0000357,,,,Expert,16326,,H,8,CHEMBL621508,,,
2823,1,Binding affinity against 5-hydroxytryptamine 2C receptor from rat cortex using [3H]mesulergine as the radioligand.,,BAO_0000019,,,,Autocuration,14423,,H,8,CHEMBL621509,,,
2824,1,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex,,BAO_0000019,,,,Autocuration,15412,,H,8,CHEMBL621510,,,
2825,1,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex.,,BAO_0000019,,,,Autocuration,15412,,H,8,CHEMBL621511,,,
2826,1,Displacement of [3H]mesulergine from A9 cells stably expressing rat 5-hydroxytryptamine 2C receptor,,BAO_0000219,,,,Expert,15558,,H,8,CHEMBL621512,625.0,,
2827,1,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,BAO_0000357,,,,Autocuration,16633,,H,8,CHEMBL621513,,,
2828,1,Binding affinity towards cloned rat 5-hydroxytryptamine 2C receptor from fundus tissue by [3H]mesulergine displacement.,,BAO_0000357,,,,Expert,6013,,H,8,CHEMBL621514,,,
2829,1,Binding affinity towards rat 5-hydroxytryptamine 2C receptor expressed in A-9 cells using [3H]mesulergine as radioligand,,BAO_0000219,,,,Expert,17175,In vitro,H,8,CHEMBL621515,,,
2830,1,Binding affinity was measured on 5-hydroxytryptamine 2C receptor in J1 cells transfected with rat 5-HT2C gene labeled with [3H]mesulergine,,BAO_0000219,,,,Autocuration,12469,,H,8,CHEMBL621516,,,
2831,1,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2C receptor in homogenate of caudate putamen tissue from rat brain,Caudate-putamen,BAO_0000019,,,,Autocuration,3682,,H,8,CHEMBL621517,,5383.0,
2832,1,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2C receptor in cloned rat cell culture,,BAO_0000357,,,,Autocuration,4932,,H,8,CHEMBL621518,,,
2833,1,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2C receptor in cloned rat prefrontal cortex homogenate; ND denotes no data,,BAO_0000019,,,,Autocuration,4932,,H,8,CHEMBL621519,,,
2834,1,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2C receptor,,BAO_0000357,,,,Autocuration,3935,,H,8,CHEMBL621520,,,
2835,1,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2C receptor,,BAO_0000357,,,,Autocuration,15818,,H,8,CHEMBL621521,,,
2836,1,Compound was evaluated for its binding affinity towards rat r5-hydroxytryptamine 2C receptor,,BAO_0000357,,,,Autocuration,15818,,H,8,CHEMBL621522,,,
2837,1,Binding affinity against rat 5-hydroxytryptamine 2C receptor in A-9 cells.,,BAO_0000219,,,,Expert,14749,,H,8,CHEMBL621523,,,
2838,1,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2C receptor,,BAO_0000357,,,,Autocuration,15740,,H,8,CHEMBL621524,,,
2839,1,In vitro binding to 5-hydroxytryptamine 2C receptor using [125 I]-DOI,,BAO_0000357,,Rattus norvegicus,,Expert,17133,,D,9,CHEMBL621525,,,
2840,1,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine,,BAO_0000357,,,,Autocuration,16532,,H,8,CHEMBL872921,,,
2841,1,The compound evaluated for its affinity against 5-hydroxytryptamine 2C receptor,,BAO_0000357,,,,Autocuration,12369,,H,8,CHEMBL621526,,,
2842,1,Affinity against 5-hydroxytryptamine 2C receptor in J1 cells transfected with the rat 5-HT2C gene labeled with [3H]mesulergine.,,BAO_0000219,,,,Expert,12369,,H,8,CHEMBL621527,,,
2843,1,Binding affinity against 5-hydroxytryptamine 2C receptor in rat choroid plexus using [3H]N-methyl-mesulergine,,BAO_0000019,,Rattus norvegicus,,Expert,2309,,D,9,CHEMBL617865,,,
2844,1,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor,,BAO_0000357,,,,Autocuration,12953,,H,8,CHEMBL617866,,,
2845,1,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor from rat cortex using [3H]-citalopram as radioligand; Nonactive at 10 uM,,BAO_0000019,,,,Autocuration,12953,,H,8,CHEMBL617867,,,
2846,1,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand; Nonactive at 10 uM,,BAO_0000357,,,,Autocuration,12953,,H,8,CHEMBL617487,,,
2847,1,Binding affinity for 5-hydroxytryptamine 2C receptor,,BAO_0000357,,,,Expert,12953,,H,8,CHEMBL617488,,,
2848,1,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2C receptor using [125 I]-DOI as radioligand; Not determined,,BAO_0000357,,,,Autocuration,17133,,H,8,CHEMBL617489,,,
2849,1,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT denotes not tested,,BAO_0000019,,,,Autocuration,17211,,H,8,CHEMBL617490,,,
2850,1,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT=not tested,,BAO_0000019,,,,Autocuration,17211,,H,8,CHEMBL617491,,,
2851,1,Affinity pKi for 5-hydroxytryptamine 2C receptor was measured in rat cortex homogenates.,,BAO_0000019,,,,Autocuration,14025,,H,8,CHEMBL617492,,,
2852,1,Binding affinity against 5-hydroxytryptamine 2C receptor in rat cortex homogenates.,,BAO_0000019,,,,Autocuration,14998,,H,8,CHEMBL617493,,,
2853,1,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2C receptor was determined,,BAO_0000357,,,,Autocuration,4342,,H,8,CHEMBL617494,,,
2854,1,Displacement of [3H]mesulergine from rat 5-HT2C receptor expressed in HEK293,,BAO_0000019,,Rattus norvegicus,,Expert,13735,,D,9,CHEMBL617495,,,
2855,1,Binding affinity was determined against cloned human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,,BAO_0000357,,,,Autocuration,13181,,H,8,CHEMBL617496,,,
2856,1,Compound was evaluated for displacement of [3H]mesulergine from cloned rat 5-hydroxytryptamine 2C receptor in transfected CHO-K1 cells.,,BAO_0000219,,,,Autocuration,1883,,H,8,CHEMBL617497,485.0,,
2857,1,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,BAO_0000357,,,,Autocuration,15194,,H,8,CHEMBL617498,,,
2858,1,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand.,,BAO_0000357,,,,Autocuration,15194,,H,8,CHEMBL617499,,,
2859,1,Compound tested for relative response using 0.1 uM 5-HT as agonist against 5-hydroxytryptamine 2C receptor,,BAO_0000019,,,,Autocuration,14579,,H,8,CHEMBL617500,,,
2860,1,Compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,,BAO_0000357,,,,Autocuration,4639,,H,8,CHEMBL617501,,,
2861,1,Binding affinity towards 5-hydroxytryptamine 2C receptor,,BAO_0000357,,,,Expert,4820,,H,8,CHEMBL617502,,,
2862,1,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand; Not Tested,,BAO_0000357,,,,Autocuration,14442,,H,8,CHEMBL617503,,,
2863,1,Binding activity against cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand.,,BAO_0000357,,,,Autocuration,14755,,H,8,CHEMBL617504,,,
2864,1,Binding affinity against the cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand,,BAO_0000357,,,,Autocuration,14744,,H,8,CHEMBL617406,,,
2865,1,Affinity for human 5-hydroxytryptamine 2B receptor expressed in mammalian cell line,,BAO_0000019,,Homo sapiens,,Expert,6857,,D,9,CHEMBL617407,,,
2866,1,Binding affinity towards human 5-hydroxytryptamine 2B receptor using [3H]5-HT as radioligand,,BAO_0000357,,,,Autocuration,16209,,H,8,CHEMBL617408,,,
2867,1,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,,BAO_0000357,,,,Autocuration,15363,,H,8,CHEMBL617409,,,
2868,1,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,,BAO_0000357,,,,Autocuration,15363,,H,8,CHEMBL617410,,,
2869,1,Compound was tested for the displacement of [3H]5-HT from cloned human 5-hydroxytryptamine 2B receptor,,BAO_0000357,,,,Autocuration,15363,,H,8,CHEMBL617411,,,
2870,1,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2B receptor,,BAO_0000019,,,,Autocuration,17085,,H,8,CHEMBL617412,,,
2871,1,Inhibitory constant against cloned human 5-hydroxytryptamine 2B receptor using with [125I]- DOI radioligand,,BAO_0000357,,Homo sapiens,,Expert,17200,,D,9,CHEMBL617774,,,
2872,1,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,,BAO_0000219,,Homo sapiens,,Expert,15851,,D,9,CHEMBL617775,722.0,,
2873,1,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,,BAO_0000219,,Homo sapiens,,Expert,15851,,D,9,CHEMBL617776,722.0,,
2874,1,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,BAO_0000219,,Homo sapiens,,Expert,6857,,D,9,CHEMBL617777,449.0,,
2875,1,Rleative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,BAO_0000219,,Homo sapiens,,Expert,6857,,D,9,CHEMBL617778,449.0,,
2876,1,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,BAO_0000219,,,,Autocuration,15779,,H,8,CHEMBL617779,722.0,,
2877,1,Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells using [3H]5-HT as radioligand.,,BAO_0000219,,,,Expert,15851,,H,8,CHEMBL617780,722.0,,
2878,1,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand; no data",,BAO_0000219,,,,Autocuration,15779,,H,8,CHEMBL617781,722.0,,
2879,1,Displacement of [3H]5-HT from 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells,,BAO_0000219,,Homo sapiens,,Expert,14157,,D,9,CHEMBL617782,722.0,,
2880,1,Binding affinity to human cloned 5-HT2B receptor in HEK 293 cells using [3H]- -5-HT as radioligand,,BAO_0000219,,Homo sapiens,,Expert,4540,,D,9,CHEMBL617783,722.0,,
2881,1,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor was determined,,BAO_0000357,,,,Autocuration,6166,,H,8,CHEMBL617784,,,
2882,1,Binding affinity towards 5-hydroxytryptamine 2B receptor (human cloned receptor) in HEK 293 cells using [3H]5-HT as radioligand.,,BAO_0000219,,,,Autocuration,15779,,H,8,CHEMBL617785,722.0,,
2883,1,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells using [3H]5-HT as radioligand,,BAO_0000219,,,,Expert,14391,,H,8,CHEMBL857984,722.0,,
2884,1,Binding affinity towards human cloned 5-HT2B receptor of HEK293 cells by displacement of [3H]5-HT,,BAO_0000219,,,,Expert,3832,,H,8,CHEMBL617786,722.0,,
2885,1,In vitro binding affinity at human cloned 5-hydroxytryptamine 2B receptor of HEK293 cells by [3H]5-HT displacement.,,BAO_0000219,,,,Expert,3833,,H,8,CHEMBL617787,722.0,,
2886,1,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells,,BAO_0000219,,Homo sapiens,,Expert,15851,,D,9,CHEMBL617788,722.0,,
2887,1,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; compound is insoluble,,BAO_0000219,,Homo sapiens,,Expert,15851,,D,9,CHEMBL617789,722.0,,
2888,1,Compound was evaluated for binding affinity against human cloned 5-HT2B receptor in HEK 293 cells using [3H]5-HT as the radioligand,,BAO_0000219,,,,Autocuration,4199,,H,8,CHEMBL617790,722.0,,
2889,1,Displacement of [3H]-5-5HT from human cloned 5-hydroxytryptamine 2B receptor expressed in CHO-K1 cells,,BAO_0000219,,,,Expert,1883,,H,8,CHEMBL617791,485.0,,
2890,1,Binding affinity against 5-hydroxytryptamine 2B receptor,,BAO_0000357,,,,Expert,4321,,H,8,CHEMBL617608,,,
2891,1,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 2B receptor in HEK 293 cells using [3H]5-HT,,BAO_0000219,,,,Autocuration,15146,,H,8,CHEMBL617609,722.0,,
2892,1,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2B receptor in HEK 293 using [3H]ketanserin as a radioligand,,BAO_0000219,,,,Autocuration,5213,,H,8,CHEMBL617610,722.0,,
2893,1,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2B receptors in HEK293 cells using [3H]5-HT.,,BAO_0000219,,,,Autocuration,14818,,H,8,CHEMBL617611,722.0,,
2894,1,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,BAO_0000219,,,,Autocuration,4829,,H,8,CHEMBL617612,722.0,,
2895,1,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,BAO_0000219,,,,Autocuration,4829,,H,8,CHEMBL617613,722.0,,
2896,1,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 2B receptor in the endothelium intact rabbit jugular vein.,,BAO_0000019,,Oryctolagus cuniculus,,Autocuration,14025,,H,8,CHEMBL617614,,,
2897,1,Binding affinity analysed for 5-HT 2B receptor in rat stomach fundus,Stomach,BAO_0000019,,,,Expert,13463,,H,8,CHEMBL617615,,945.0,
2898,1,Affinity against 5-hydroxytryptamine 2B receptor in the isolated rat stomach fundus,Stomach,BAO_0000357,,,,Expert,7259,,H,8,CHEMBL858114,,945.0,
2899,1,Affinity against serotonergic receptor in the isolated rat stomach fundus,Stomach,BAO_0000357,,,,Autocuration,7259,,H,8,CHEMBL617616,,945.0,
2900,1,Antagonistic activity against 5-hydroxytryptamine 2B receptor obtained from rat stomach fundus preparation,Stomach,BAO_0000019,,Rattus norvegicus,,Expert,7185,,D,9,CHEMBL617617,,945.0,
2901,1,Antagonistic against 5-hydroxytryptamine 2B receptor,,BAO_0000019,,Rattus norvegicus,,Expert,7185,,D,9,CHEMBL875914,,,
2902,1,Antagonistic affinity measured as pA2 value on 5-hydroxytryptamine 2B receptor of the rat stomach fundus,Stomach,BAO_0000019,,,,Autocuration,13267,,H,8,CHEMBL617618,,945.0,
2903,1,Inhibition of 5-HT binding to 5-HT2B receptor of Rat stomach fundus,Stomach,BAO_0000357,,Rattus norvegicus,,Expert,13735,,D,9,CHEMBL617619,,945.0,
2904,1,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor,,BAO_0000019,,,,Autocuration,15738,,H,8,CHEMBL617620,,,
2905,1,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor; No data,,BAO_0000019,,,,Autocuration,15738,,H,8,CHEMBL617621,,,
2906,1,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B) receptor,,BAO_0000019,,,,Autocuration,15738,,H,8,CHEMBL617622,,,
2907,1,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,Stomach,BAO_0000357,,Rattus norvegicus,,Expert,12936,,D,9,CHEMBL617623,,945.0,
2908,1,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,Stomach,BAO_0000357,,Rattus norvegicus,,Expert,12936,,D,9,CHEMBL617624,,945.0,
2909,1,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,Stomach,BAO_0000357,,Rattus norvegicus,,Expert,12936,,D,9,CHEMBL617625,,945.0,
2910,1,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,Stomach,BAO_0000357,,Rattus norvegicus,,Expert,12936,,D,9,CHEMBL617626,,945.0,
2911,1,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,Stomach,BAO_0000019,,,,Autocuration,16404,,H,8,CHEMBL617627,,945.0,
2912,1,Negative log concentration of antagonist was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,Stomach,BAO_0000019,,,,Expert,16404,,H,8,CHEMBL617628,,945.0,
2913,1,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is No Data.,Stomach,BAO_0000019,,,,Autocuration,16404,,H,8,CHEMBL617629,,945.0,
2914,1,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is not determined.,Stomach,BAO_0000019,,,,Autocuration,16404,,H,8,CHEMBL858115,,945.0,
2915,1,Antagonistic activity on 5-hydroxytryptamine 2B receptor of Rat stomach fundus;ND is not determined,Stomach,BAO_0000019,,Rattus norvegicus,,Expert,16404,,D,9,CHEMBL617630,,945.0,
2916,1,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat thoracic aorta; ND is not determined,Thoracic aorta,BAO_0000019,,,,Autocuration,16404,,H,8,CHEMBL617631,,1515.0,
2917,1,The binding affinity of compound to 5-HT receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,,BAO_0000357,,,,Autocuration,7483,,H,8,CHEMBL617632,,,
2918,1,The binding affinity to 5-hydroxytryptamine 2B receptor of rat fundus,,BAO_0000357,,,,Expert,7483,,H,8,CHEMBL617633,,,
2919,1,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,,BAO_0000357,,,,Autocuration,7483,,H,8,CHEMBL617634,,,
2920,1,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus; Unable to determine valid PA2 value due to slope of Schild plot,,BAO_0000357,,,,Autocuration,7483,,H,8,CHEMBL617635,,,
2922,1,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,Stomach,BAO_0000019,,Rattus norvegicus,,Autocuration,16404,,D,9,CHEMBL617637,,945.0,
2923,1,Binding affinity against 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Autocuration,6347,,H,8,CHEMBL617638,,,
2924,1,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2B receptor was determined,,BAO_0000357,,,,Autocuration,4373,,H,8,CHEMBL617639,,,
2925,1,Binding affinity for 5-hydroxytryptamine 2B receptor was determined,,BAO_0000357,,,,Autocuration,4373,,H,8,CHEMBL617640,,,
2926,1,Evaluated for the binding affinity to 5-HT 2B receptor,,BAO_0000357,,,,Autocuration,4687,,H,8,CHEMBL617641,,,
2927,1,Ability to displace [3H]5-HT from 5-hydroxytryptamine 2B receptor,,BAO_0000357,,,,Autocuration,16946,,H,8,CHEMBL617642,,,
2928,1,Binding affinities against 5-hydroxytryptamine 2B receptor,,BAO_0000357,,,,Autocuration,16633,,H,8,CHEMBL617643,,,
2929,1,Binding affinities towards 5-hydroxytryptamine 2B receptor,,BAO_0000357,,,,Autocuration,16633,,H,8,CHEMBL617644,,,
2930,1,Binding affinity towards 5-hydroxytryptamine 2B receptor using [125I]DOI as radioligand,,BAO_0000357,,,,Autocuration,16633,,H,8,CHEMBL617645,,,
2931,1,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,,BAO_0000357,,,,Expert,15026,,H,8,CHEMBL617646,,,
2932,1,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,,BAO_0000357,,Bos taurus,,Autocuration,15738,,H,8,CHEMBL617647,,,
2933,1,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10E-6 M,,BAO_0000357,,Bos taurus,,Autocuration,15738,,H,8,CHEMBL617648,,,
2934,1,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10e-6 M,,BAO_0000357,,Bos taurus,,Autocuration,15738,,H,8,CHEMBL617875,,,
2935,1,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at concentration of 10e-6 M,,BAO_0000357,,Bos taurus,,Autocuration,15738,,H,8,CHEMBL617876,,,
2936,1,Inhibitory constant was determined on 5-hydroxytryptamine 2C receptor of Bovine choroid plexus,,BAO_0000357,,Bos taurus,,Expert,16404,,H,8,CHEMBL617877,,,
2937,1,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,,BAO_0000357,,Bos taurus,,Expert,15026,,H,8,CHEMBL617878,,,
2938,1,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,,BAO_0000357,,Bos taurus,,Autocuration,15738,,H,8,CHEMBL617879,,,
2939,1,Binding affinity against guinea pig cortex 5-HT2C receptor in the presence of [3H]mesulergine,,BAO_0000019,,Cavia porcellus,,Autocuration,16312,,H,8,CHEMBL617880,,,
2940,1,Binding affinity towards 5-HT4 receptor by the displacement of [3H]GR-113808 in guinea-pig striatum,Striatum,BAO_0000357,,Cavia porcellus,,Intermediate,5486,,D,9,CHEMBL617881,,2435.0,
2941,1,Binding affinity against 5-HT1A receptor,,BAO_0000357,,,,Autocuration,5254,,H,8,CHEMBL857073,,,
2942,1,Agonistic activity for 5-HT2c (5-HT2C) by measuring [3H]inositol monophosphate fromation in CHO cells in which the human 5-HT2C receptor subtype was stably expressed,,BAO_0000219,,,,Expert,3857,,H,8,CHEMBL617882,449.0,,
2943,1,Functional activity against human 5-hydroxytryptamine 2C receptor expressed in CHO cells using fluorometric imaging plate reader,,BAO_0000219,,Homo sapiens,,Expert,6857,,D,9,CHEMBL617883,449.0,,
2944,1,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2c receptor cell line,,BAO_0000219,,,,Autocuration,4176,,H,8,CHEMBL617884,,,
2945,1,Agonistic binding efficacy against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand,,BAO_0000219,,,,Autocuration,6347,,H,8,CHEMBL617885,449.0,,
2946,1,"Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand, expressed as Emax",,BAO_0000219,,,,Autocuration,6347,,H,8,CHEMBL617886,449.0,,
2947,1,Inhibition of human 5-hydroxytryptamine 2C receptor,,BAO_0000357,,Homo sapiens,,Expert,16146,,D,9,CHEMBL617887,,,
2948,1,In vitro binding affinity against human 5-hydroxytryptamine 2C receptor at a concentration of 100 (nM),,BAO_0000357,,,,Autocuration,3805,,H,8,CHEMBL617888,,,
2949,1,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,,BAO_0000019,,,,Autocuration,3857,,H,8,CHEMBL617889,,,
2950,1,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor,,BAO_0000357,,,,Autocuration,5635,,H,8,CHEMBL617890,,,
2951,1,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,,BAO_0000357,,,,Autocuration,5635,,H,8,CHEMBL617891,,,
2952,1,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,,BAO_0000357,,,,Autocuration,5635,,H,8,CHEMBL617892,,,
2953,1,Displacement of [H]-mesulergine from CHO cells expressing human 5-hydroxytryptamine 2C receptor.,,BAO_0000219,,,,Expert,4012,,H,8,CHEMBL617893,449.0,,
2954,1,Ability to displace [3H]- mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells,,BAO_0000219,,,,Expert,6366,,H,8,CHEMBL617894,449.0,,
2955,1,Ability to displace [3H]mesulergine binding to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,BAO_0000219,,,,Expert,15949,,H,8,CHEMBL617895,449.0,,
2956,1,Ability to displace [3H]mesulergine (0.5 nM) from CHO cells of human 5-hydroxytryptamine 2C receptor,,BAO_0000219,,,,Autocuration,17211,,H,8,CHEMBL617896,449.0,,
2957,1,Affinity towards human 5-hydroxytryptamine 2C serotonin receptor,,BAO_0000357,,Homo sapiens,,Expert,6491,,D,9,CHEMBL617897,,,
2958,1,Agonist activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand,,BAO_0000019,,,,Autocuration,14093,,H,8,CHEMBL617898,,,
2959,1,Agonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,BAO_0000019,,,,Autocuration,13481,,H,8,CHEMBL617899,,,
2960,1,Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI ,,BAO_0000219,,Rattus norvegicus,,Expert,6347,,H,8,CHEMBL617900,449.0,,
2961,1,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand,,BAO_0000019,,,,Autocuration,14093,,H,8,CHEMBL617901,,,
2962,1,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand; Not tested,,BAO_0000019,,,,Autocuration,14093,,H,8,CHEMBL617902,,,
2963,1,Antagonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,BAO_0000019,,,,Autocuration,13481,,H,8,CHEMBL617903,,,
2964,1,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [125 I]DOI as radioligand,,BAO_0000357,,,,Autocuration,14442,,H,8,CHEMBL617904,,,
2965,1,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand,,BAO_0000357,,,,Autocuration,14442,,H,8,CHEMBL617905,,,
2966,1,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand;not tested,,BAO_0000357,,,,Autocuration,14442,,H,8,CHEMBL617906,,,
2967,1,Binding activity against cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand.,,BAO_0000357,,,,Autocuration,14755,,H,8,CHEMBL617907,,,
2968,1,Binding affinity against the cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand,,BAO_0000357,,,,Autocuration,14744,,H,8,CHEMBL617908,,,
2969,1,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,BAO_0000219,,,,Expert,16659,,H,8,CHEMBL620617,449.0,,
2970,1,Affinity for human 5-hydroxytryptamine 2C receptor expressed in mammalian cell line,,BAO_0000019,,Homo sapiens,,Expert,6857,,D,9,CHEMBL620618,,,
2971,1,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand.,,BAO_0000357,,,,Expert,5635,,H,8,CHEMBL620619,,,
2972,1,Binding affinity to cloned human 5-hydroxytryptamine 2C receptor,,BAO_0000357,,Homo sapiens,,Expert,4234,,D,9,CHEMBL620620,,,
2973,1,Binding affinity towards human 5-HT2C receptor was determined using [125I]- DOI as radioligand,,BAO_0000357,,,,Autocuration,16209,,H,8,CHEMBL620621,,,
2974,1,Binding affinity for 5-HT3 receptor by displacement of [3H]-LY 278584 in rat cerebral cortex membranes,,BAO_0000249,,Rattus norvegicus,,Autocuration,5778,,D,7,CHEMBL872920,,,
2975,1,Binding affinity towards rat 5-hydroxytryptamine 3 receptor was evaluated,,BAO_0000223,,,,Autocuration,5094,,H,6,CHEMBL620622,,,
2976,1,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 in rat posterior cortex,,BAO_0000019,,Rattus norvegicus,,Autocuration,809,,D,7,CHEMBL620623,,,
2977,1,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex,,BAO_0000019,,,,Autocuration,1578,,H,6,CHEMBL620624,,,
2978,1,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex; Not tested,,BAO_0000019,,,,Autocuration,809,,H,6,CHEMBL620625,,,
2979,1,Binding affinity was measured on 5-hydroxytryptamine 3 receptor in NG-108 cells labeled with [3H]GR-65630,,BAO_0000219,,,,Autocuration,12469,,H,6,CHEMBL620626,,,
2980,1,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex,,BAO_0000019,,,,Autocuration,14290,,H,6,CHEMBL621307,,,
2981,1,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex.,,BAO_0000019,,,,Autocuration,14290,,H,6,CHEMBL621308,,,
2982,1,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-5-HT,,BAO_0000223,,,,Autocuration,10609,,H,6,CHEMBL621309,,,
2983,1,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]GR-65630,,BAO_0000223,,,,Autocuration,10609,,H,6,CHEMBL621310,,,
2984,1,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-ketanserin,,BAO_0000223,,,,Autocuration,10609,,H,6,CHEMBL621311,,,
2985,1,"Compound was evaluated for its in vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",,BAO_0000249,,,,Autocuration,15253,,H,6,CHEMBL621502,,,
2986,1,"In vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",,BAO_0000249,,,,Autocuration,15253,,H,6,CHEMBL621503,,,
2987,1,Displacement of the 5-hydroxytryptamine 3 receptor ligand [3H]GR-65630 from rat brain cortical membranes.,,BAO_0000249,,,,Autocuration,11683,,H,6,CHEMBL621504,,,
2988,1,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor,,BAO_0000223,,,,Autocuration,12092,,H,6,CHEMBL621505,,,
2989,1,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,,BAO_0000019,,,,Autocuration,1946,,H,6,CHEMBL621506,,,
2990,1,Ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15.,,BAO_0000223,,,,Autocuration,11623,,H,6,CHEMBL619781,,,
2991,1,Compound was evaluated for its ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15. ,,BAO_0000223,,,,Autocuration,11623,,H,6,CHEMBL619782,,,
2992,1,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex,,BAO_0000019,,,,Autocuration,14788,,H,6,CHEMBL619783,,,
2993,1,Displacement of [3H]ketanserin from rat cortex 5-HT3 receptor,,BAO_0000019,,Rattus norvegicus,,Autocuration,5432,,D,7,CHEMBL619784,,,
2994,1,Ability to displace [3H]granisetron specifically bound to 5-hydroxytryptamine 3 receptor in rat cortical membrane,,BAO_0000249,,,,Autocuration,14826,,H,6,CHEMBL619785,,,
2995,1,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,,BAO_0000223,,,,Autocuration,2222,,H,6,CHEMBL619786,,,
2996,1,Displacement of binding of [3H]-BRL 43694 to 5-hydroxytryptamine 3 receptor in rat cerebral cortex,,BAO_0000019,,,,Autocuration,11963,,H,6,CHEMBL619787,,,
2997,1,In vitro affinity for 5-hydroxytryptamine 3 (5-HT3) receptor by displacement of [3H]BRL-43694 from rat entorhinal cortex,,BAO_0000019,,,,Autocuration,14145,,H,6,CHEMBL872925,,,
2998,1,In vitro binding affinity at serotonin 5-hydroxytryptamine 3 receptor in rat cortex by [3H]granisetron displacement.,,BAO_0000019,,,,Autocuration,17819,,H,6,CHEMBL619788,,,
2999,1,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]- 1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,,BAO_0000249,,,,Autocuration,10394,,H,6,CHEMBL619789,,,
3000,1,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]-1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,,BAO_0000249,,,,Autocuration,10394,,H,6,CHEMBL619790,,,
3001,1,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,,BAO_0000019,,,,Autocuration,15034,,H,6,CHEMBL619791,,,
3002,1,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,,BAO_0000019,,,,Autocuration,691,,H,6,CHEMBL619792,,,
3003,1,Displacement of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortical membranes,,BAO_0000249,,,,Autocuration,12092,,H,6,CHEMBL619793,,,
3004,1,Inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor,,BAO_0000223,,Rattus norvegicus,,Autocuration,11752,,D,7,CHEMBL619794,,,
3005,1,The ability to inhibit [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortices,Brain,BAO_0000221,,,,Autocuration,11752,,H,6,CHEMBL619795,,955.0,
3006,1,Binding affinity at 5-hydroxytryptamine 3 receptor in rat posterior cortex by [3H]-BRL 43694 displacement.,,BAO_0000019,,,,Autocuration,301,,H,6,CHEMBL619796,,,
3007,1,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584,,BAO_0000223,,,,Autocuration,16532,,H,6,CHEMBL620448,,,
3008,1,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,,BAO_0000223,,,,Autocuration,16532,,H,6,CHEMBL620449,,,
3009,1,The binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand.,,BAO_0000223,,,,Autocuration,12092,,H,6,CHEMBL620450,,,
3010,1,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630,,BAO_0000223,,,,Autocuration,11684,,H,6,CHEMBL620451,,,
3011,1,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630.,,BAO_0000223,,,,Autocuration,11684,,H,6,CHEMBL620631,,,
3012,1,Binding affinity for 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand,,BAO_0000019,,,,Autocuration,12953,,H,6,CHEMBL620632,,,
3013,1,The compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand; NA means Not active,,BAO_0000019,,,,Autocuration,12953,,H,6,CHEMBL620633,,,
3014,1,The compound was tested for their binding affinity towards 5-hydroxytryptamine 3 receptor; Nonactive at 10 uM,,BAO_0000223,,,,Autocuration,12953,,H,6,CHEMBL620634,,,
3015,1,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,,BAO_0000019,,,,Autocuration,12861,,H,6,CHEMBL620635,,,
3016,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 0.5 hours in urethane-anesthetized rats,,BAO_0000218,,,,Autocuration,11454,In vivo,H,6,CHEMBL620636,,,
3017,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 1 hour in urethane-anesthetized rats,,BAO_0000218,,,,Autocuration,11454,In vivo,H,6,CHEMBL620637,,,
3018,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 3 hours in urethane-anesthetized rats,,BAO_0000218,,,,Autocuration,11454,In vivo,H,6,CHEMBL620638,,,
3019,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 6 hours in urethane-anesthetized rats,,BAO_0000218,,,,Autocuration,11454,In vivo,H,6,CHEMBL620639,,,
3020,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 0.5 hours in urethane-anesthetized rats,,BAO_0000218,,,,Autocuration,11454,In vivo,H,6,CHEMBL620640,,,
3021,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 1 hour in urethane-anesthetized rats,,BAO_0000218,,,,Autocuration,11454,In vivo,H,6,CHEMBL620641,,,
3022,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 16 hours in urethane-anesthetized rats,,BAO_0000218,,,,Autocuration,11454,In vivo,H,6,CHEMBL620642,,,
3023,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 3 hours in urethane-anesthetized rats,,BAO_0000218,,,,Autocuration,11454,In vivo,H,6,CHEMBL620643,,,
3024,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 6 hours in urethane-anesthetized rats,,BAO_0000218,,,,Autocuration,11454,In vivo,H,6,CHEMBL620644,,,
3025,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 0.5 hours in urethane-anesthetized rats,,BAO_0000218,,,,Autocuration,11454,In vivo,H,6,CHEMBL620645,,,
3026,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 1 hour in urethane-anesthetized rats,,BAO_0000218,,,,Autocuration,11454,In vivo,H,6,CHEMBL620646,,,
3027,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 3 hours in urethane-anesthetized rats,,BAO_0000218,,,,Autocuration,11454,In vivo,H,6,CHEMBL620647,,,
3028,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 6 hours in urethane-anesthetized rats,,BAO_0000218,,,,Autocuration,11454,In vivo,H,6,CHEMBL620648,,,
3029,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 0.5 hours in urethane-anesthetized rats,,BAO_0000218,,,,Autocuration,11454,In vivo,H,6,CHEMBL620649,,,
3030,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 3 hours in urethane-anesthetized rats,,BAO_0000218,,,,Autocuration,11454,In vivo,H,6,CHEMBL620650,,,
3031,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 1 hour in urethane-anesthetized rats,,BAO_0000218,,,,Autocuration,11454,In vivo,H,6,CHEMBL620651,,,
3032,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 3 hours in urethane-anesthetized rats,,BAO_0000218,,,,Autocuration,11454,In vivo,H,6,CHEMBL872875,,,
3033,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 1 hour in urethane-anesthetized rats,,BAO_0000218,,,,Autocuration,11454,In vivo,H,6,CHEMBL620652,,,
3034,1,5-hydroxytryptamine 3 receptor antagonist activity was confirmed by its ability to antagonize 5-HT evoked tachycardia of rabbit isolated heart,,BAO_0000019,,,,Autocuration,10609,,H,6,CHEMBL620653,,,
3035,1,Binding activity against 5-hydroxytryptamine 2A receptor from rat cortex homogenates using [3H]DOB as radioligand.,,BAO_0000019,,,,Autocuration,12861,,H,6,CHEMBL857076,,,
3036,1,Inhibition of [3H]-Q-ICS 205-930 binding to rat cortex homogenate 5-hydroxytryptamine 3 receptor,,BAO_0000019,,Rattus norvegicus,,Autocuration,12861,,D,7,CHEMBL620654,,,
3037,1,Binding activity radioligand.,,BAO_0000223,,,,Autocuration,12861,,H,6,CHEMBL620655,,,
3038,1,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor in rat brain membranes,,BAO_0000249,,,,Autocuration,10728,,H,6,CHEMBL620656,,,
3039,1,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes.,,BAO_0000249,,,,Autocuration,10728,,H,6,CHEMBL620657,,,
3040,1,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.000001 mol/L,,BAO_0000357,,,,Autocuration,5163,,H,8,CHEMBL620658,,,
3041,1,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.00001 mol/L,,BAO_0000357,,,,Autocuration,5163,,H,8,CHEMBL620659,,,
3042,1,Inhibition of binding towards 5-hydroxytryptamine 2C receptor at 100 nM concentration,,BAO_0000357,,,,Autocuration,6011,,H,8,CHEMBL620660,,,
3043,1,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2C receptor,,BAO_0000357,,,,Autocuration,5014,,H,8,CHEMBL620661,,,
3044,1,Binding affinity of compound towards 5-hydroxytryptamine 2C receptor,,BAO_0000357,,,,Autocuration,5635,,H,8,CHEMBL620662,,,
3045,1,Affinity for 5-hydroxytryptamine 2C receptor,,BAO_0000357,,,,Expert,5163,,H,8,CHEMBL620663,,,
3046,1,Binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,BAO_0000357,,,,Autocuration,6841,,H,8,CHEMBL620664,,,
3047,1,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand.,,BAO_0000357,,,,Expert,6119,,H,8,CHEMBL620665,,,
3048,1,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2C receptor was determined,,BAO_0000357,,,,Autocuration,4373,,H,8,CHEMBL620666,,,
3049,1,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]-Ketanserin,,BAO_0000357,,,,Autocuration,1633,,H,8,CHEMBL620667,,,
3050,1,Binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]N-methyl-mesulergine,,BAO_0000357,,,,Expert,1633,,H,8,CHEMBL620668,,,
3051,1,Binding affinity for 5-hydroxytryptamine 2C receptor was determined,,BAO_0000357,,,,Autocuration,4373,,H,8,CHEMBL620669,,,
3052,1,Binding affinity towards serotonin 5-hydroxytryptamine 2C receptor,,BAO_0000357,,,,Expert,6576,,H,8,CHEMBL620670,,,
3053,1,Evaluated for the binding affinity to 5-hydroxytryptamine 2C receptor,,BAO_0000357,,,,Autocuration,4687,,H,8,CHEMBL620671,,,
3054,1,Tested agains t5-hydroxytryptamine 2C receptor in experiment 1,,BAO_0000357,,,,Autocuration,12146,,H,8,CHEMBL620672,,,
3055,1,Tested against 5-hydroxytryptamine 2C receptor in experiment 2,,BAO_0000357,,,,Autocuration,12146,,H,8,CHEMBL620673,,,
3056,1,Ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor,,BAO_0000357,,,,Autocuration,16946,,H,8,CHEMBL620674,,,
3057,1,Compound was evaluated for the affinity at 5-hydroxytryptamine 2C receptor,,BAO_0000357,,,,Autocuration,14159,,H,8,CHEMBL620675,,,
3058,1,The binding affinity towards 5-hydroxytryptamine 2C receptor; No affinity,,BAO_0000357,,,,Autocuration,16700,,H,8,CHEMBL620676,,,
3059,1,Affinity against 5-hydroxytryptamine 2C receptor,,BAO_0000357,,,,Autocuration,3269,,H,8,CHEMBL621382,,,
3060,1,Binding affinity against 5-hydroxytryptamine 2C receptor,,BAO_0000357,,Homo sapiens,,Expert,1274,,D,9,CHEMBL621383,,,
3061,1,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2C receptor using radioligand binding assay,,BAO_0000357,,,,Autocuration,1317,,H,8,CHEMBL621384,,,
3062,1,Inhibitory concentration required against 5-HT3 receptor in bovine area postrema using [3H]GR-65630,,BAO_0000357,,Bos taurus,,Autocuration,5834,,H,8,CHEMBL621385,,,
3063,1,Binding affinity towards 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand,,BAO_0000357,,Bos taurus,,Autocuration,11147,,H,8,CHEMBL617989,,,
3064,1,Antagonistic potency against serotonin 5-hydroxytryptamine 3 receptor in GPI assay,,BAO_0000019,,Cavia porcellus,,Expert,14145,,H,4,CHEMBL617990,,,
3065,1,Binding affinity to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,Ileum,BAO_0000221,,Cavia porcellus,,Autocuration,10561,,H,4,CHEMBL875085,,2116.0,
3066,1,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig,,BAO_0000019,,Cavia porcellus,,Autocuration,15847,,H,4,CHEMBL617991,,,
3067,1,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig; ND means not done,,BAO_0000019,,Cavia porcellus,,Autocuration,15847,,H,4,CHEMBL617992,,,
3068,1,Potency to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,Ileum,BAO_0000221,,Cavia porcellus,,Autocuration,10561,,H,4,CHEMBL617993,,2116.0,
3069,1,In vitro binding affinity was measured for 5-hydroxytryptamine 3 receptor in the guinea pig ileum.,Ileum,BAO_0000221,,Cavia porcellus,,Autocuration,11454,,H,4,CHEMBL617994,,2116.0,
3070,1,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea colon at a concentration 0.01 uM,,BAO_0000019,,Cavia porcellus,,Autocuration,4639,,H,4,CHEMBL617995,,,
3071,1,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.1 uM,,BAO_0000019,,Cavia porcellus,,Autocuration,4639,,H,4,CHEMBL617996,,,
3072,1,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM,,BAO_0000019,,Cavia porcellus,,Autocuration,4639,,H,4,CHEMBL617997,,,
3073,1,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM in the presence of 30 uM MDL 72222,,BAO_0000019,,Cavia porcellus,,Autocuration,4639,,H,4,CHEMBL617998,,,
3074,1,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 0.01 uM,,BAO_0000019,,Cavia porcellus,,Autocuration,4639,,H,4,CHEMBL617999,,,
3075,1,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 1 uM,,BAO_0000019,,Cavia porcellus,,Autocuration,4639,,H,4,CHEMBL618000,,,
3076,1,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum",Ileum,BAO_0000221,,Cavia porcellus,,Autocuration,15253,,H,4,CHEMBL617815,,2116.0,
3077,1,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum.",Ileum,BAO_0000221,,Cavia porcellus,,Autocuration,15253,,H,4,CHEMBL617816,,2116.0,
3078,1,Tested for the antagonistic activity against 5-hydroxytryptamine 3 receptor from guinea pig ileum,Ileum,BAO_0000221,,Cavia porcellus,,Autocuration,11963,,H,4,CHEMBL617817,,2116.0,
3079,1,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum,Ileum,BAO_0000221,,Cavia porcellus,,Autocuration,1946,,H,4,CHEMBL617818,,2116.0,
3080,1,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum; Not tested,Ileum,BAO_0000221,,Cavia porcellus,,Autocuration,1946,,H,4,CHEMBL617819,,2116.0,
3081,1,Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15,,BAO_0000223,,Cavia porcellus,,Autocuration,12045,,H,4,CHEMBL617820,,,
3082,1,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,Ileum,BAO_0000221,,Cavia porcellus,,Autocuration,1559,,H,4,CHEMBL617821,,2116.0,
3083,1,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),Ileum,BAO_0000221,,Cavia porcellus,,Autocuration,273,,H,4,CHEMBL617822,,2116.0,
3084,1,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor of isolated guinea pig ileum (GPI),Ileum,BAO_0000221,,Cavia porcellus,,Autocuration,273,,H,4,CHEMBL617823,,2116.0,
3085,1,Tested for antagonistic activity on 5-hydroxytryptamine 3 receptor mediated effects of 5-HT in guinea pig isolated ileum,Ileum,BAO_0000221,,Cavia porcellus,,Autocuration,188,,H,4,CHEMBL617824,,2116.0,
3086,1,Agonistic activity against 5-hydroxytryptamine 3 receptor in guinea pig ileum assay,Ileum,BAO_0000221,,Cavia porcellus,,Autocuration,12919,,H,4,CHEMBL617825,,2116.0,
3087,1,5-hydroxytryptamine 3 receptor agonism in the guinea pig ileum by functional 5-HT3 receptor assay,Ileum,BAO_0000221,,Cavia porcellus,,Autocuration,12918,,H,4,CHEMBL617826,,2116.0,
3088,1,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,Ileum,BAO_0000221,,Cavia porcellus,,Autocuration,1559,,H,4,CHEMBL617827,,2116.0,
3089,1,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),Ileum,BAO_0000221,,Cavia porcellus,,Autocuration,273,,H,4,CHEMBL617828,,2116.0,
3090,1,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,Ileum,BAO_0000221,,Cavia porcellus,,Autocuration,1559,,H,4,CHEMBL617829,,2116.0,
3091,1,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum; Not determined,Ileum,BAO_0000221,,Cavia porcellus,,Autocuration,1559,,H,4,CHEMBL617830,,2116.0,
3092,1,Binding affinity towards 5-hydroxytryptamine 3 receptor of guinea pig ileum; not determined,Ileum,BAO_0000221,,Cavia porcellus,,Autocuration,1559,,H,4,CHEMBL617831,,2116.0,
3093,1,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor in guinea pig ileum.,Ileum,BAO_0000221,,Cavia porcellus,,Autocuration,14424,,H,4,CHEMBL617832,,2116.0,
3094,1,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,,BAO_0000019,,Cavia porcellus,,Autocuration,13181,,U,0,CHEMBL617833,,,
3095,1,Binding affinity towards 5-HT1A receptor by the displacement of [3H]-8-OH-DPAT] in human recombinant receptors in mammalian cell,,BAO_0000357,,,,Autocuration,5486,,H,8,CHEMBL617834,,,
3096,1,Affinity towards human 5-hydroxytryptamine 3 serotonin receptor,,BAO_0000223,,Homo sapiens,,Expert,6491,,D,5,CHEMBL617835,,,
3097,1,Binding affinity towards 5-HT3 receptor,,BAO_0000223,,,,Autocuration,6013,,H,4,CHEMBL617836,,,
3098,1,Binding activity radioligand.,,BAO_0000223,,,,Autocuration,12861,,H,4,CHEMBL617837,,,
3099,1,Binding activity against 5-hydroxytryptamine 1A receptor from human brain cortex using [3H]8-OH-DPAT-HT as radioligand.,,BAO_0000019,,,,Autocuration,12861,,H,4,CHEMBL620392,,,
3100,1,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,,BAO_0000223,,,,Autocuration,5104,,H,4,CHEMBL620393,,,
3101,1,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,,BAO_0000223,,,,Autocuration,5105,,H,4,CHEMBL620394,,,
3102,1,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor; NT means Not tested,,BAO_0000223,,,,Autocuration,5104,,H,4,CHEMBL620395,,,
3103,1,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 3 receptor,,BAO_0000019,,,,Autocuration,3935,,U,0,CHEMBL620396,,,
3104,1,Displacement of [3H]-BRC 36694 from 5-hydroxytryptamine 3 receptor in NG108-15 cells,,BAO_0000219,,,,Expert,13657,,H,4,CHEMBL620582,433.0,,
3105,1,"Percent inhibition of [3H]5 binding to 5-hydroxytryptamine 3 receptor was evaluated by injection of compound (75 microCi/kg, 1.32 ug/kg) into the tail vein of mice (in vivo)",,BAO_0000218,,,,Autocuration,10369,In vivo,H,4,CHEMBL620583,,,
3106,1,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),,BAO_0000019,,,,Autocuration,10369,,H,4,CHEMBL620584,,,
3107,1,Compound was evaluated for the binding affinity at 5- HT3 receptor subtype,,BAO_0000224,,,,Autocuration,12918,,H,4,CHEMBL620585,,,
3108,1,Compound was evaluated for the binding affinity at 5- HT3 receptor,,BAO_0000224,,,,Autocuration,12918,,H,4,CHEMBL620586,,,
3109,1,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),,BAO_0000019,,,,Autocuration,10369,,H,4,CHEMBL620587,,,
3110,1,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,,BAO_0000019,,,,Autocuration,773,,H,4,CHEMBL620588,,,
3111,1,5-hydroxytryptamine 3 receptor agonism in mouse,,BAO_0000218,,,,Autocuration,12918,,H,4,CHEMBL620589,,,
3112,1,Binding affinity towards 5-hydroxytryptamine 3 receptor was determined by using [3H]-ICS 205-930 as radioligand in mouse N1E 115 cells,,BAO_0000219,,,,Autocuration,10561,,H,4,CHEMBL620590,,,
3113,1,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,,BAO_0000019,,,,Autocuration,12827,,H,4,CHEMBL617956,,,
3114,1,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,,BAO_0000019,,,,Autocuration,12827,,H,4,CHEMBL617957,,,
3115,1,Binding affinity was evaluated by 5-hydroxytryptamine 3 receptor agonism in the mouse NIE-115 by displacing tropisetron,,BAO_0000224,,,,Autocuration,12918,,H,4,CHEMBL617958,,,
3116,1,Compound was evaluated for binding to 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,,BAO_0000219,,,,Autocuration,273,,H,4,CHEMBL617959,,,
3117,1,Compound was evaluated for binding to Serotonin 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,,BAO_0000219,,,,Autocuration,273,,H,4,CHEMBL617960,,,
3118,1,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,,BAO_0000224,,,,Autocuration,10561,,H,4,CHEMBL617961,,,
3119,1,Ability to displace the radioligand [3H]GR-65630 from 5-hydroxytryptamine 3 receptor expressed in NIE-115 cells,,BAO_0000219,,,,Autocuration,5033,In vitro,H,4,CHEMBL617962,,,
3120,1,In vitro binding affinity at 5-hydroxytryptamine 3 receptor in N1E-115 cells using 3[H]GR-65630 as the radioligand,,BAO_0000219,,,,Autocuration,16429,,H,4,CHEMBL617963,339.0,,
3121,1,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,,BAO_0000019,,,,Autocuration,10322,,H,8,CHEMBL617964,,,
3122,1,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in NG cells 108-15,,BAO_0000219,,,,Autocuration,14331,,H,8,CHEMBL617965,,,
3123,1,Compound was tested for the Binding affinity against N1e-115 neuroblastoma 5-hydroxytryptamine 3 receptor by Radio ligand [3H]GR-65630 binding assay.,,BAO_0000357,,Mus musculus,,Autocuration,13462,,D,9,CHEMBL617966,,,
3124,1,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,BAO_0000019,,,,Autocuration,12861,,H,8,CHEMBL857074,,,
3125,1,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor,,BAO_0000357,,Sus scrofa,,Autocuration,15086,,H,8,CHEMBL617967,,,
3126,1,Binding activity radioligand.,,BAO_0000357,,Sus scrofa,,Autocuration,12861,,H,8,CHEMBL617968,,,
3127,1,Binding affinity to 5-hydroxytryptamine 3 receptor of neuronal in the afferent rabbit vagus,,BAO_0000223,,Oryctolagus cuniculus,,Autocuration,10561,,H,4,CHEMBL617969,,,
3128,1,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,,BAO_0000223,,Oryctolagus cuniculus,,Autocuration,10561,,H,4,CHEMBL617970,,,
3129,1,Potency at neuronal 5-hydroxytryptamine 3 receptors in the rabbit heart,,BAO_0000223,,Oryctolagus cuniculus,,Autocuration,10561,,H,4,CHEMBL617971,,,
3130,1,Potency to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,,BAO_0000019,,Oryctolagus cuniculus,,Autocuration,10561,,H,4,CHEMBL617972,,,
3131,1,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,BAO_0000019,,Oryctolagus cuniculus,,Autocuration,273,,H,4,CHEMBL617973,,,
3132,1,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,BAO_0000019,,Oryctolagus cuniculus,,Autocuration,273,,H,4,CHEMBL617974,,,
3133,1,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),Ileum,BAO_0000221,,Oryctolagus cuniculus,,Autocuration,273,,H,4,CHEMBL617975,,2116.0,
3134,1,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,BAO_0000019,,Oryctolagus cuniculus,,Autocuration,273,,H,4,CHEMBL617976,,,
3135,1,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,BAO_0000019,,Oryctolagus cuniculus,,Autocuration,273,,H,4,CHEMBL617977,,,
3136,1,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,BAO_0000019,,Oryctolagus cuniculus,,Autocuration,273,,H,4,CHEMBL617978,,,
3137,1,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,BAO_0000019,,Oryctolagus cuniculus,,Autocuration,273,,H,4,CHEMBL617979,,,
3138,1,Binding affinity against 5-hydroxytryptamine 3 receptor in CHO cells using [3H]5-HT as radioligand,,BAO_0000219,,Oryctolagus cuniculus,,Autocuration,13047,,H,4,CHEMBL617980,449.0,,
3139,1,In vitro displacement of [3H]-LY 278584 from rat cerebral cortex 5-hydroxytryptamine 3 receptor,,BAO_0000019,,Rattus norvegicus,,Autocuration,1650,,D,7,CHEMBL617981,,,
3140,1,Affinity at 5-hydroxytryptamine 3 receptor from rat frontal cortex using [3H]granisetron as radioligand (For granisetron = Ki(nM)=0.3+/-0.01),,BAO_0000019,,,,Autocuration,16288,,H,8,CHEMBL617982,,,
3141,1,Affinity at 5-hydroxytryptamine 3 receptor (For granisetron = Ki (nM)=0.3+/-0.01),,BAO_0000357,,,,Autocuration,16288,,H,8,CHEMBL617983,,,
3142,1,In vitro displacement of [3H]ICS-205-930 from 5-hydroxytryptamine 3 receptor in cultured NG-108-15 rat glioma cells,,BAO_0000019,,Rattus norvegicus,,Autocuration,10254,,D,7,CHEMBL617984,,,
3143,1,"Binding affinity for 5-hydroxytryptamine 3 receptor in rat cerebral cortex, determined by displacement of [3H]GR-65630",,BAO_0000019,,,,Autocuration,14532,,H,6,CHEMBL617985,,,
3144,1,"5-Hydroxy tryptamine 3 receptor showing agonist activity (in vivo) in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",Heart,BAO_0000218,,,,Autocuration,13392,In vivo,H,6,CHEMBL617986,,948.0,
3145,1,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",Heart,BAO_0000019,,,,Autocuration,13392,,H,6,CHEMBL617987,,948.0,
3146,1,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",Heart,BAO_0000019,,,,Autocuration,13392,,H,6,CHEMBL617988,,948.0,
3147,1,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as change in heart rate",Heart,BAO_0000019,,,,Autocuration,13392,,H,6,CHEMBL617792,,948.0,
3148,1,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptorr in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",Heart,BAO_0000019,,,,Autocuration,13392,,H,6,CHEMBL617793,,948.0,
3149,1,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100(ug/kg), evaluated as percent inhibition of bradycardia",,BAO_0000019,,,,Autocuration,13392,,H,6,CHEMBL617794,,,
3150,1,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",,BAO_0000019,,,,Autocuration,13392,,H,6,CHEMBL617795,,,
3151,1,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",,BAO_0000019,,,,Autocuration,13392,,H,6,CHEMBL617796,,,
3152,1,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60(ug/kg), evaluated as percent inhibition of bradycardia",,BAO_0000019,,,,Autocuration,13392,,H,6,CHEMBL617797,,,
3153,1,Antagonism of 5-HT-induced Von Bezold-Jarisch reflex in rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor antagonism),,BAO_0000218,,Rattus norvegicus,,Autocuration,1089,In vivo,D,7,CHEMBL617798,,,
3154,1,Ability to antagonise the 5-HT- induced Von Bezold-Jarisch reflex in the rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor),,BAO_0000218,,,,Autocuration,1089,In vivo,H,6,CHEMBL617799,,,
3155,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,,Rattus norvegicus,,Autocuration,11454,In vivo,D,7,CHEMBL617800,,,
3156,1,Inhibition of 5-HT-induced bradycardia by 5-hydroxytryptamine 3+,,BAO_0000019,,Rattus norvegicus,,Autocuration,11454,,D,7,CHEMBL617801,,,
3157,1,In vivo inhibitory concentration after 5 minutes against 5-hydroxytryptamine 3 receptor induced bradycardia [bezold-jarisch (B-J) reflex test] in rat by intravenous administration,,BAO_0000218,,Rattus norvegicus,,Autocuration,12205,In vivo,D,7,CHEMBL617802,,,
3158,1,Inhibition of 5-HT (1 ug/mL) induced depolarization in rat vagus nerve (5-hydroxytryptamine 3 receptor antagonism),,BAO_0000019,,Rattus norvegicus,,Autocuration,1089,,D,7,CHEMBL617803,,,
3159,1,Binding affinity towards 5-HT3 receptor in rat was evaluated,,BAO_0000019,,,,Autocuration,5094,,H,6,CHEMBL617804,,,
3160,1,Inhibition of [3H]GR-65630 binding to rat cortical membrane 5-hydroxytryptamine 3 receptor,,BAO_0000019,,Rattus norvegicus,,Autocuration,2622,,D,7,CHEMBL617805,,,
3161,1,Binding affinity was evaluated in vitro by displacement of [3H]zacopride radioligand from 5-hydroxytryptamine 3 receptor,,BAO_0000223,,,,Autocuration,245,,H,6,CHEMBL617806,,,
3162,1,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex.,,BAO_0000019,,,,Autocuration,14788,,H,6,CHEMBL617807,,,
3163,1,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement of [3H]granisetron from rat cerebral cortex,,BAO_0000019,,,,Autocuration,14788,,H,6,CHEMBL617808,,,
3164,1,Binding affinity against 5-hydroxytryptamine 3 receptor in rat cortical membrane using [3H]GR-65630 as radioligand,,BAO_0000249,,,,Autocuration,3020,,H,6,CHEMBL617809,,,
3165,1,Compound was tested for its ability to displace [3H]-Q-ICS 205-930 from 5-hydroxytryptamine 3 receptor in rat cortex homogenates,,BAO_0000019,,,,Autocuration,1742,,H,6,CHEMBL617810,,,
3166,1,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to 5-hydroxytryptamine 3 receptor in rat brain cortical membrane,Brain,BAO_0000249,,,,Autocuration,17394,,H,6,CHEMBL617811,,955.0,
3167,1,Concentration required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine-3 receptor (5-HT 3 receptor)in rat brain cortical membrane,Brain,BAO_0000221,,,,Autocuration,17394,,H,6,CHEMBL617812,,955.0,
3168,1,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine 3 receptor in rat cortical membrane,,BAO_0000249,,,,Autocuration,17394,,H,6,CHEMBL617813,,,
3169,1,In vitro inhibitory concentration against radioligand [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in rat cortical membrane,,BAO_0000249,,,,Autocuration,14286,,H,6,CHEMBL617814,,,
3170,1,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate.,,BAO_0000019,,,,Autocuration,14178,,H,6,CHEMBL617698,,,
3171,1,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; Not active at 10000 nm,,BAO_0000019,,Rattus norvegicus,,Autocuration,14178,,D,7,CHEMBL617699,,,
3172,1,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; not active at 10000 nM,,BAO_0000019,,Rattus norvegicus,,Autocuration,14178,,D,7,CHEMBL617700,,,
3173,1,Inhibition of radiolabeled [3H]-Zacopride ligand binding to 5-hydroxytryptamine 3 receptor,,BAO_0000223,,Rattus norvegicus,,Autocuration,14178,,D,7,CHEMBL617701,,,
3174,1,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,,BAO_0000019,,,,Autocuration,15034,,H,6,CHEMBL617702,,,
3175,1,"Tested for inhibition of binding of [3H]GR-65630 to rat cortical membranes, expressed as IC50",,BAO_0000249,,,,Autocuration,1089,,H,6,CHEMBL617703,,,
3176,1,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 3 receptor,,BAO_0000019,,Rattus norvegicus,,Autocuration,1089,,D,7,CHEMBL617704,,,
3177,1,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,,BAO_0000223,,,,Autocuration,16532,,H,6,CHEMBL617705,,,
3178,1,Inhibition of [3H]BRL-43694 binding to rat 5-hydroxytryptamine 3 receptor,,BAO_0000223,,Rattus norvegicus,,Autocuration,12801,,D,7,CHEMBL617706,,,
3179,1,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells (using [3H]zacopride as radioligand),,BAO_0000219,,,,Autocuration,15194,,H,6,CHEMBL617707,433.0,,
3180,1,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells using [3H]zacopride as radioligand,,BAO_0000219,,,,Autocuration,15194,,H,6,CHEMBL617708,433.0,,
3181,1,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor from rat cortical homogenate using [3H]zacopride as radioligand,,BAO_0000019,,,,Autocuration,15194,,H,6,CHEMBL617709,,,
3182,1,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA= Not active,,BAO_0000019,,,,Autocuration,15194,,H,6,CHEMBL617710,,,
3183,1,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA=Not active,,BAO_0000019,,,,Autocuration,15194,,H,6,CHEMBL882925,,,
3184,1,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; not active,,BAO_0000019,,,,Autocuration,15194,,H,6,CHEMBL617711,,,
3185,1,Antagonist potency to 5-hydroxytryptamine 3 receptor was assayed by antagonism of the 5-HT-evoked reflex bradycardia [Bezold-Jarisch(BJ) reflex] in rats,,BAO_0000019,,,,Autocuration,10610,,H,6,CHEMBL617712,,,
3186,1,Antagonistic activity against 5-hydroxytryptamine 3 receptor as inhibition of 5-HT-induced bradycardia (von Bezold-jarisch reflex) in anesthetized rat,,BAO_0000019,,Rattus norvegicus,,Autocuration,10355,,D,7,CHEMBL617713,,,
3187,1,"Compound was tested as a 5-hydroxytryptamine 3 receptor antagonist in the rat by assessment of the inhibition of the Bezold-Jarisch effect, when administered intravenously",,BAO_0000019,,,,Autocuration,691,,H,6,CHEMBL617714,,,
3188,1,In vivo 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) antagonistic activity expressed as ability to inhibit Bezold-Jarich reflex evoked by 5-HT in rats,,BAO_0000218,,,,Autocuration,10611,,H,6,CHEMBL617715,,,
3189,1,Inhibition dose for 50 percent antagonism for 5-hydroxytryptamine 3 receptor in vivo in rats,,BAO_0000218,,,,Autocuration,12801,In vivo,H,6,CHEMBL617716,,,
3190,1,Inhibition of 5-HT evoked reflex bradycardia in rat.,,BAO_0000218,,,,Autocuration,10609,,H,6,CHEMBL617717,,,
3191,1,5-HT3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,,,,Autocuration,11454,In vivo,H,6,CHEMBL617718,,,
3192,1,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,,,,Autocuration,11454,In vivo,H,6,CHEMBL617719,,,
3193,1,5-hydroxytryptamine 3 receptor antagonistic activity measured by inhibition of 5-HT-induced bradycardia (iv administration 10 ug/kg dose in urethane-anesthetized rats),,BAO_0000218,,,,Autocuration,11454,In vivo,H,6,CHEMBL617720,,,
3194,1,5-hydroxytryptamine 3 receptor antagonistic activity as inhibition of 5-HT-induced bradycardia after iv administration of 100 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,,Rattus norvegicus,,Autocuration,11454,In vivo,D,7,CHEMBL617721,,,
3195,1,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,,,,Autocuration,11454,In vivo,H,6,CHEMBL617722,,,
3196,1,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kgetized rats,,BAO_0000218,,,,Autocuration,11454,In vivo,H,6,CHEMBL617723,,,
3197,1,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 3 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,,,,Autocuration,11454,In vivo,H,6,CHEMBL617724,,,
3198,1,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 10 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,,,,Autocuration,11454,In vivo,H,6,CHEMBL617725,,,
3199,1,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 100 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,,,,Autocuration,11454,In vivo,H,6,CHEMBL617726,,,
3200,1,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 1000 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,,,,Autocuration,11454,In vivo,H,6,CHEMBL617727,,,
3201,1,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 30 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,,,,Autocuration,11454,In vivo,H,6,CHEMBL617728,,,
3202,1,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 300 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,,,,Autocuration,11454,In vivo,H,6,CHEMBL617729,,,
3203,1,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 3ug/kg dose in urethane-anesthetized rats,,BAO_0000218,,,,Autocuration,11454,In vivo,H,6,CHEMBL617730,,,
3204,1,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,,,,Autocuration,11454,In vivo,H,6,CHEMBL617731,,,
3205,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 0.3 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,,,,Autocuration,11454,In vivo,H,6,CHEMBL617732,,,
3206,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 1 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,,,,Autocuration,11454,In vivo,H,6,CHEMBL617733,,,
3207,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 30 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,,,,Autocuration,11454,In vivo,H,6,CHEMBL617734,,,
3208,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 0.05 hour,,BAO_0000218,,,,Autocuration,11454,In vivo,H,6,CHEMBL872874,,,
3209,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 1 hour,,BAO_0000218,,,,Autocuration,11454,In vivo,H,6,CHEMBL617735,,,
3210,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 16 hour,,BAO_0000218,,,,Autocuration,11454,In vivo,H,6,CHEMBL617736,,,
3211,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 3 hour,,BAO_0000218,,,,Autocuration,11454,In vivo,H,6,CHEMBL617737,,,
3212,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 6 hour,,BAO_0000218,,,,Autocuration,11454,In vivo,H,6,CHEMBL617738,,,
3213,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,,,,Autocuration,11454,In vivo,H,6,CHEMBL617739,,,
3214,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 100 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,,,,Autocuration,11454,In vivo,H,6,CHEMBL617740,,,
3215,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,,,,Autocuration,11454,In vivo,H,6,CHEMBL617741,,,
3216,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,,,,Autocuration,11454,In vivo,H,6,CHEMBL617742,,,
3217,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 3 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,,,,Autocuration,11454,In vivo,H,6,CHEMBL617743,,,
3218,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 30 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,,,,Autocuration,11454,In vivo,H,6,CHEMBL617744,,,
3219,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 300 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,,,,Autocuration,11454,In vivo,H,6,CHEMBL617745,,,
3220,1,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.)",,BAO_0000218,,,,Autocuration,670,,H,6,CHEMBL617746,,,
3221,1,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.); Not tested",,BAO_0000218,,,,Autocuration,670,,H,6,CHEMBL617747,,,
3222,1,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 10 ug/Kg,,BAO_0000218,,,,Autocuration,10321,In vivo,H,6,CHEMBL617748,,,
3223,1,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 100 ug/Kg,,BAO_0000218,,,,Autocuration,10321,In vivo,H,6,CHEMBL618909,,,
3224,1,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 2 ug/Kg,,BAO_0000218,,,,Autocuration,10321,In vivo,H,6,CHEMBL618910,,,
3225,1,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 20 ug/Kg,,BAO_0000218,,,,Autocuration,10321,In vivo,H,6,CHEMBL618911,,,
3226,1,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 5 ug/Kg,,BAO_0000218,,,,Autocuration,10321,In vivo,H,6,CHEMBL618912,,,
3227,1,Tested for inhibition of Bezold-Jarisch (B-J) reflex mediated by 5-hydroxytryptamine 3 receptor in rats after intravenous administration (2.0 ug/kg),,BAO_0000218,,,,Autocuration,10322,In vivo,H,6,CHEMBL618913,,,
3228,1,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,,BAO_0000019,,,,Autocuration,15412,,H,6,CHEMBL618914,,,
3229,1,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,,BAO_0000019,,,,Autocuration,15412,,H,6,CHEMBL618915,,,
3230,1,Intrinsic efficacy for rat 5-hydroxytryptamine 3 receptor,,BAO_0000223,,Rattus norvegicus,,Autocuration,15412,,D,7,CHEMBL618916,,,
3231,1,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; PA means partial agonist,,BAO_0000019,,,,Autocuration,15412,,H,6,CHEMBL618917,,,
3232,1,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) of rat cortex and hippocampus tissue,Hippocampus,BAO_0000221,,,,Intermediate,15412,,D,7,CHEMBL618918,,10000000.0,
3233,1,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor of rat cortical membrane,,BAO_0000019,,Rattus norvegicus,,Autocuration,15412,,D,7,CHEMBL618919,,,
3234,1,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 5-hydroxytryptamine 3 receptor,,BAO_0000019,,Rattus norvegicus,,Autocuration,17394,,D,7,CHEMBL618920,,,
3235,1,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 3 receptor,,BAO_0000223,,,,Autocuration,12457,,H,6,CHEMBL618921,,,
3236,1,Affinity was evaluated by inhibition of [3H]GR-65630 binding to NG108-15 cell transfected with cloned rat 5-hydroxytryptamine 3 receptor,,BAO_0000019,,,,Autocuration,12457,,H,6,CHEMBL618922,,,
3237,1,Binding affinity against radioligand [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in neuroblastoma-glioma (NG108-15) cells.,,BAO_0000019,,,,Autocuration,12205,,H,6,CHEMBL618923,,,
3238,1,Binding affinity for 5-hydroxytryptamine 3 receptor was determined by measuring displacement of [3H]GR-65630 from rat brain cortices,,BAO_0000019,,,,Autocuration,14532,,H,6,CHEMBL618924,,,
3239,1,Binding affinity to 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-BRL 43694 as radioligand,,BAO_0000019,,,,Autocuration,1122,,H,6,CHEMBL618925,,,
3240,1,Binding affinity towards 5-HT3 receptor in rat was evaluated,,BAO_0000019,,,,Autocuration,5094,,H,6,CHEMBL618926,,,
3241,1,5-hydroxytryptamine 4 receptor agonist activity as increased response to electrical stimulation in guinea pig ileum,Ileum,BAO_0000221,,Cavia porcellus,,Intermediate,809,,D,9,CHEMBL618927,,2116.0,
3242,1,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum; Not tested,Ileum,BAO_0000221,,Cavia porcellus,,Intermediate,809,,D,9,CHEMBL618928,,2116.0,
3243,1,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum",Ileum,BAO_0000221,,Cavia porcellus,,Intermediate,14290,,D,9,CHEMBL618929,,2116.0,
3244,1,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Inactive up to 10E-5 M",Ileum,BAO_0000221,,Cavia porcellus,,Intermediate,14290,,D,9,CHEMBL618930,,2116.0,
3245,1,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",Ileum,BAO_0000221,,Cavia porcellus,,Intermediate,14290,,D,9,CHEMBL618931,,2116.0,
3246,1,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",Ileum,BAO_0000221,,Cavia porcellus,,Intermediate,14290,,D,9,CHEMBL619594,,2116.0,
3247,1,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not capable of evaluation",Ileum,BAO_0000221,,Cavia porcellus,,Intermediate,14290,,D,9,CHEMBL619595,,2116.0,
3248,1,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum.,Ileum,BAO_0000221,,Cavia porcellus,,Intermediate,13961,,D,9,CHEMBL619596,,2116.0,
3249,1,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum. Activity expressed as percent of the maximum 5-HT response given in brackets.,Ileum,BAO_0000221,,Cavia porcellus,,Intermediate,13961,,D,9,CHEMBL619755,,2116.0,
3250,1,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum,Ileum,BAO_0000221,,Cavia porcellus,,Intermediate,809,,D,9,CHEMBL619756,,2116.0,
3251,1,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not evaluable,Ileum,BAO_0000221,,Cavia porcellus,,Intermediate,809,,D,9,CHEMBL619757,,2116.0,
3252,1,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not tested,Ileum,BAO_0000221,,Cavia porcellus,,Intermediate,809,,D,9,CHEMBL619758,,2116.0,
3253,1,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum",Ileum,BAO_0000221,,Cavia porcellus,,Intermediate,14290,,D,9,CHEMBL619759,,2116.0,
3254,1,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10-5 M",Ileum,BAO_0000221,,Cavia porcellus,,Intermediate,14290,,D,9,CHEMBL619760,,2116.0,
3255,1,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10E-5 M",Ileum,BAO_0000221,,Cavia porcellus,,Intermediate,14290,,D,9,CHEMBL619761,,2116.0,
3256,1,5-hydroxytryptamine 4 receptor antagonist activity as inhibition of 5-HT-induced contractions in guinea pig ileum; Not capable of evaluation.,Ileum,BAO_0000221,,Cavia porcellus,,Intermediate,14290,,D,9,CHEMBL619762,,2116.0,
3257,1,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",Ileum,BAO_0000221,,Cavia porcellus,,Intermediate,14290,,D,9,CHEMBL619763,,2116.0,
3258,1,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",Ileum,BAO_0000221,,Cavia porcellus,,Intermediate,14290,,D,9,CHEMBL617868,,2116.0,
3259,1,Displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor in guinea pig striatum,,BAO_0000357,,Cavia porcellus,,Intermediate,15034,,D,9,CHEMBL617869,,,
3260,1,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,Striatum,BAO_0000249,,Cavia porcellus,,Intermediate,5094,,D,9,CHEMBL882926,,2435.0,
3261,1,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,Striatum,BAO_0000249,,Cavia porcellus,,Intermediate,5094,,D,9,CHEMBL617870,,2435.0,
3262,1,Inhibitory activity against 5-hydroxytryptamine 4 receptor of guinea pig striatum using [3H]GR-113808 as radioligand,Striatum,BAO_0000357,,Cavia porcellus,,Intermediate,5399,,D,9,CHEMBL617871,,2435.0,
3263,1,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea pig striatum,Striatum,BAO_0000357,,Cavia porcellus,,Intermediate,17394,,D,9,CHEMBL617872,,2435.0,
3264,1,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea-pig striatum,Striatum,BAO_0000357,,Cavia porcellus,,Intermediate,17394,,D,9,CHEMBL617873,,2435.0,
3265,1,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to serotonin 5-hydroxytryptamine 4 receptor in guinea-pig striatum,Striatum,BAO_0000357,,Cavia porcellus,,Intermediate,17394,,D,9,CHEMBL617874,,2435.0,
3266,1,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum.,Ileum,BAO_0000221,,Cavia porcellus,,Intermediate,13961,,D,9,CHEMBL619067,,2116.0,
3267,1,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum. 95% confidence limits are in brackets.,Ileum,BAO_0000221,,Cavia porcellus,,Intermediate,13961,,D,9,CHEMBL619068,,2116.0,
3268,1,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,Ileum,BAO_0000221,,Cavia porcellus,,Intermediate,13961,,D,9,CHEMBL619069,,2116.0,
3269,1,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-6 M in guinea pig,,BAO_0000357,,Cavia porcellus,,Intermediate,16946,,D,9,CHEMBL619070,,,
3270,1,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-8 M in guinea pig,,BAO_0000357,,Cavia porcellus,,Intermediate,16946,,D,9,CHEMBL619071,,,
3271,1,Agonistic activity against 5-hydroxytryptamine 4 receptor,,BAO_0000019,,Cavia porcellus,,Intermediate,15034,,D,9,CHEMBL619072,,,
3272,1,Agonistic activity against 5-hydroxytryptamine 4 receptor; not tested,,BAO_0000019,,Cavia porcellus,,Intermediate,15034,,D,9,CHEMBL619073,,,
3273,1,Compound was evaluated for the relative potency with respect to serotonin against 5-hydroxytryptamine 4 receptor,,BAO_0000019,,Cavia porcellus,,Intermediate,12918,,D,9,CHEMBL619074,,,
3274,1,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor,,BAO_0000357,,Cavia porcellus,,Intermediate,16946,,D,9,CHEMBL619075,,,
3275,1,Inhibition of [3H]GR-113808 binding to guinea pig striatum 5-hydroxytryptamine 4 receptor,Striatum,BAO_0000357,,Cavia porcellus,,Intermediate,17394,,D,9,CHEMBL619076,,2435.0,
3276,1,Binding affinity against 5-hydroxytryptamine 4 receptor in guinea pig striatum using [3H]GR-113808 as radioligand,Striatum,BAO_0000357,,Cavia porcellus,,Intermediate,15034,,D,9,CHEMBL619077,,2435.0,
3277,1,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,Striatum,BAO_0000249,,Cavia porcellus,,Intermediate,5094,,D,9,CHEMBL619078,,2435.0,
3278,1,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,Striatum,BAO_0000249,,Cavia porcellus,,Intermediate,5094,,D,9,CHEMBL619079,,2435.0,
3279,1,Tested for affinity against 5-hydroxytryptamine 4 receptor in the myenteric plexus of the guinea pig ileum.,Ileum,BAO_0000221,,Cavia porcellus,,Intermediate,17358,,D,9,CHEMBL619080,,2116.0,
3280,1,Displacement of [3H]-GR113808 from 5-HT4 receptor of guinea pig striatum,,BAO_0000357,,Cavia porcellus,,Expert,12953,,D,9,CHEMBL619081,,,
3281,1,The compound was tested for their binding affinity towards 5-HT4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,,BAO_0000357,,Cavia porcellus,,Intermediate,12953,,D,9,CHEMBL619082,,,
3282,1,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand.,,BAO_0000357,,Cavia porcellus,,Intermediate,12953,,D,9,CHEMBL619083,,,
3283,1,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,,BAO_0000357,,Cavia porcellus,,Intermediate,12953,,D,9,CHEMBL619084,,,
3284,1,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,Ileum,BAO_0000221,,Cavia porcellus,,Intermediate,273,,D,9,CHEMBL859397,,2116.0,
3285,1,5-hydroxytryptamine 4 receptor agonist activity in the guinea pig ileum assay,Ileum,BAO_0000221,,Cavia porcellus,,Intermediate,12918,,D,9,CHEMBL619085,,2116.0,
3286,1,5-hydroxytryptamine 4 receptor agonistic activity was measured by twitch response enhancing activity in electrically stimulated guinea pig ileum preparation,Ileum,BAO_0000221,,Cavia porcellus,,Intermediate,12919,,D,9,CHEMBL619086,,2116.0,
3287,1,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI).,Ileum,BAO_0000221,,Cavia porcellus,,Intermediate,273,,D,9,CHEMBL619087,,2116.0,
3288,1,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,Ileum,BAO_0000221,,Cavia porcellus,,Intermediate,273,,D,9,CHEMBL619088,,2116.0,
3289,1,Ability to antagonize 5-HT-evoked contractions mediated through 5-hydroxytryptamine 4 receptor activation in the guinea pig distal colon LMMP,,BAO_0000357,,Cavia porcellus,,Intermediate,13181,,D,9,CHEMBL619089,,,
3290,1,Binding affinity was determined against 5-hydroxytryptamine 3 receptor,,BAO_0000357,,Cavia porcellus,,Autocuration,13181,,H,8,CHEMBL619090,,,
3291,1,Antagonistic activity against 5-hydroxytryptamine 4 receptor,,BAO_0000019,,Cavia porcellus,,Intermediate,15034,,D,9,CHEMBL619091,,,
3292,1,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-hydroxytryptamine 4 receptor,,BAO_0000357,,Cavia porcellus,,Intermediate,5033,,D,9,CHEMBL619092,,,
3293,1,Binding affinity for 5-hydroxytryptamine 4 receptor by displacement of [3H]GR-113808 from guinea pig brain striatum.,,BAO_0000019,,Cavia porcellus,,Intermediate,1980,,D,9,CHEMBL619093,,,
3294,1,Binding affinity was determined against 5-hydroxytryptamine 2C receptor using cloned rat receptors expressed in 293 cells radiolabeled with [3H]mesulergine,,BAO_0000219,,Cavia porcellus,,Autocuration,13181,,H,8,CHEMBL619094,722.0,,
3295,1,In vitro by displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor on guinea pig striatal membrane,,BAO_0000019,,Cavia porcellus,,Intermediate,14287,,D,9,CHEMBL619095,,,
3296,1,Compound was evaluated for binding affinity against 5-hydroxytryptamine 4 receptor using radioligand binding assay using [3H]GR as radioligand,,BAO_0000357,,Cavia porcellus,,Intermediate,1317,,D,9,CHEMBL857988,,,
3297,1,Compound was evaluated for its ability to displace [3H]GR-113808 binding from 5-hydroxytryptamine 4 receptor in guinea pig striatum.,,BAO_0000357,,Cavia porcellus,,Intermediate,15316,,D,9,CHEMBL619096,,,
3298,1,In vitro binding affinity at 5-hydroxytryptamine 4 receptor in guinea pig striatum using 3[H]GR-113808 as the radioligand,Striatum,BAO_0000357,,Cavia porcellus,,Intermediate,16429,,D,9,CHEMBL619097,,2435.0,
3299,1,The compound was tested for its binding affinity towards 5-hydroxytryptamine 4 receptor in guinea pig hippocampus using [125I]SB-207710.,Hippocampus,BAO_0000221,,Cavia porcellus,,Intermediate,14818,,D,9,CHEMBL619098,,10000000.0,
3300,1,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand,,BAO_0000357,,Cavia porcellus,,Intermediate,15194,,D,9,CHEMBL619751,,,
3301,1,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand.,,BAO_0000357,,Cavia porcellus,,Intermediate,15194,,D,9,CHEMBL619752,,,
3302,1,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,Ileum,BAO_0000221,,Cavia porcellus,,Intermediate,13961,,D,9,CHEMBL875096,,2116.0,
3303,1,Binding affinity towards 5-HT2C receptor by the displacement of [3H]mesulergine] in human recombinant receptors in mammalian cell,,BAO_0000357,,,,Autocuration,5486,,H,8,CHEMBL619004,,,
3304,1,Binding affinity towards human 5-hydroxytryptamine 4 receptor using [3H]5-HT as radioligand,,BAO_0000357,,,,Autocuration,16209,,H,8,CHEMBL619005,,,
3305,1,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 4 receptor,,BAO_0000019,,,,Autocuration,17085,,H,8,CHEMBL619006,,,
3306,1,Compound was evaluated for the binding affinity against human cloned 5-hydroxytryptamine 4 receptor in HeLa cells using [3H]-LSD as the radioligand,,BAO_0000219,,,,Autocuration,4199,,H,8,CHEMBL619007,308.0,,
3307,1,Compound was tested for its binding affinity against 5-hydroxytryptamine 4 receptor,,BAO_0000357,,,,Autocuration,15146,,H,8,CHEMBL619008,,,
3308,1,Compound was tested for its binding affinity for 5-hydroxytryptamine 4 receptor,,BAO_0000357,,,,Autocuration,5213,,H,8,CHEMBL619009,,,
3309,1,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 4 receptor in HeLa cells, using [3H]LSD as radioligand",,BAO_0000219,,,,Autocuration,4829,,H,8,CHEMBL619010,308.0,,
3310,1,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons,,BAO_0000357,,,,Autocuration,17358,,H,8,CHEMBL619011,,,
3311,1,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons; IA means inactive,,BAO_0000357,,,,Autocuration,17358,,H,8,CHEMBL619012,,,
3312,1,Ability to displace [3H]GR-113808 from mouse 5-hydroxytryptamine 4 receptor in COS7 cells,,BAO_0000219,,,,Autocuration,16946,,H,8,CHEMBL619013,,,
3313,1,Tested for ability to stimulate 5-hydroxytryptamine 4 receptors in mouse Coliculi neurons,,BAO_0000357,,,,Autocuration,17358,,H,8,CHEMBL619014,,,
3314,1,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model,Cardiac atrium,BAO_0000019,,,,Autocuration,268,,H,8,CHEMBL857503,,2081.0,
3315,1,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model; compound found inactive at 1 uM,Cardiac atrium,BAO_0000019,,,,Autocuration,268,,H,8,CHEMBL619015,,2081.0,
3316,1,The compound was tested for binding affinity against 5-hydroxytryptamine 4 receptor,,BAO_0000357,,,,Autocuration,15086,,H,8,CHEMBL619016,,,
3317,1,Compound was tested for binding affinity against piglet hippocampus 5-hydroxytryptamine 4 receptor,Hippocampus,BAO_0000221,,,,Autocuration,14875,,H,8,CHEMBL619017,,10000000.0,
3318,1,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]SB 207710 as radioligand,Hippocampus,BAO_0000221,,Sus scrofa,,Autocuration,13267,,H,8,CHEMBL619018,,10000000.0,
3319,1,Binding affinity against 5-hydroxytryptamine 2A receptor using rabbit saphenous vein assay.,,BAO_0000019,,Oryctolagus cuniculus,,Autocuration,13047,,H,8,CHEMBL619019,,,
3320,1,Displacement of [3H]GR-113808 from rat striatum 5-hydroxytryptamine 4 receptor,,BAO_0000357,,Rattus norvegicus,,Expert,1650,,D,9,CHEMBL619020,,,
3321,1,Tested for its agonist potency against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,,BAO_0000019,,,,Autocuration,567,,H,8,CHEMBL619021,,,
3322,1,Tested for affinity towards 5-hydroxytryptamine 4 receptor in relaxation of rat oesophagus,,BAO_0000357,,,,Autocuration,17358,,H,8,CHEMBL619022,,,
3323,1,Tested for the effect on binding at 5-hydroxytryptamine 4 receptor; No activity,,BAO_0000357,,,,Autocuration,188,,H,8,CHEMBL619023,,,
3324,1,lntrinsic activity relative to 5-HT receptor,,BAO_0000019,,,,Autocuration,670,,H,8,CHEMBL619024,,,
3325,1,Compound was evaluated for the agonistic activity towards 5-hydroxytryptamine 4 receptor using the rat tunica muscularis mucosae (TMM) esophagus strip assay,,BAO_0000019,,,,Autocuration,204,,H,8,CHEMBL619025,,,
3326,1,In vitro relaxation of carbachol pre-contracted rat oesophageal TMM.,,BAO_0000019,,,,Expert,1946,,H,8,CHEMBL619026,,,
3327,1,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay,,BAO_0000019,,,,Autocuration,6398,,H,8,CHEMBL619027,,,
3328,1,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay; IN = Inactive,,BAO_0000019,,,,Autocuration,6398,,H,8,CHEMBL619028,,,
3329,1,Efficient 5-hydroxytryptamine 4 agonist in the rat tunica muscularis mucosae,,BAO_0000019,,,,Autocuration,17358,,H,8,CHEMBL619029,,,
3330,1,Tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay of racemate mixture,,BAO_0000019,,,,Autocuration,6398,,H,8,CHEMBL619030,,,
3331,1,Relaxation of carbachol induced contractions of rat tunica muscularis mucosae,,BAO_0000357,,,,Expert,11752,,H,8,CHEMBL619031,,,
3332,1,5-hydroxytryptamine 4 receptor agonist activity was determined by the relaxation of the carbachol-contracted rat esophageal tunica muscularis mucosae,,BAO_0000019,,,,Autocuration,809,,H,8,CHEMBL619032,,,
3333,1,Inhibition of radiolabeled [3H]GR-113808 ligand binding to 5-hydroxytryptamine 4 receptor,,BAO_0000357,,Rattus norvegicus,,Expert,14178,,D,9,CHEMBL619033,,,
3334,1,Tested for its efficacy against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,,BAO_0000357,,,,Autocuration,567,,H,8,CHEMBL619034,,,
3335,1,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae.,,BAO_0000357,,,,Autocuration,1946,,H,8,CHEMBL619035,,,
3336,1,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae; No activity up to 104M concentration,,BAO_0000357,,,,Autocuration,1946,,H,8,CHEMBL619036,,,
3337,1,Binding affinity (Ki+/-SEM) against 5-hydroxytryptamine 4 receptor from cheng Prusoff equation by using [3H]GR-113808 in rat striatum,,BAO_0000019,,Rattus norvegicus,,Expert,13961,,D,9,CHEMBL619037,,,
3338,1,Binding affinity towards 5-HT 4 receptor in rat striatum membranes using [3H]GR-113808 as radioligand,Striatum,BAO_0000249,,,,Autocuration,6238,,H,8,CHEMBL619038,,2435.0,
3339,1,Binding affinity towards 5-HT4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand; Not tested,,BAO_0000249,,,,Autocuration,14290,,H,8,CHEMBL619039,,,
3340,1,Binding affinity towards 5-hydroxytryptamine 4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand,,BAO_0000249,,,,Expert,14290,,H,8,CHEMBL619040,,,
3341,1,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,Striatum,BAO_0000019,,Rattus norvegicus,,Expert,809,,D,9,CHEMBL619041,,2435.0,
3342,1,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,Striatum,BAO_0000019,,,,Autocuration,1578,,H,8,CHEMBL619042,,2435.0,
3343,1,Binding affinity to 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum membrane,Striatum,BAO_0000249,,,,Expert,16709,,H,8,CHEMBL619043,,2435.0,
3344,1,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatum by [3H]GR-113808 displacement.,Striatum,BAO_0000019,,,,Expert,1946,,H,8,CHEMBL619044,,2435.0,
3345,1,In vitro affinity at serotonergic 5-hydroxytryptamine 4 receptor by radioligand binding assay using [3H]GR-113808 in rat striatum membranes.,Striatum,BAO_0000249,,,,Expert,15253,,H,8,CHEMBL619045,,2435.0,
3346,1,In vitro binding affinity to 5-hydroxytryptamine 4 receptor in rat striatum membrane,Striatum,BAO_0000249,,,,Expert,4535,,H,8,CHEMBL619046,,2435.0,
3347,1,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatal membranes by [3H]GR-113808 displacement.,,BAO_0000249,,,,Expert,13961,,H,8,CHEMBL619047,,,
3348,1,Tested for potency against 5-hydroxytryptamine 4 receptor agonist in rat brain,Brain,BAO_0000221,,,,Autocuration,17358,,H,8,CHEMBL619048,,955.0,
3349,1,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat,,BAO_0000019,,,,Autocuration,15847,,H,8,CHEMBL859398,,,
3350,1,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat; ND means not done,,BAO_0000019,,,,Autocuration,15847,,H,8,CHEMBL619049,,,
3351,1,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae,,BAO_0000019,,,,Autocuration,670,,H,8,CHEMBL857886,,,
3352,1,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae; Not tested,,BAO_0000019,,,,Autocuration,670,,H,8,CHEMBL619050,,,
3353,1,Antagonist activity against 5-hydroxytryptamine 4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,,BAO_0000019,,,,Autocuration,1317,,H,8,CHEMBL620591,,,
3354,1,Binding affinity against rat 5-hydroxytryptamine 4 receptor,,BAO_0000357,,Rattus norvegicus,,Expert,12936,,D,9,CHEMBL620592,,,
3355,1,pKi against 5-hydroxytryptamine 4 receptor in rat striatum membrane,Striatum,BAO_0000249,,,,Expert,4535,,H,8,CHEMBL620593,,2435.0,
3356,1,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-5 M.,,BAO_0000019,,Rattus norvegicus,,Expert,14424,,D,9,CHEMBL620594,,,
3357,1,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-6 M.,,BAO_0000019,,,,Expert,14424,,H,8,CHEMBL875079,,,
3358,1,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,,BAO_0000019,,,,Expert,14424,,H,8,CHEMBL620595,,,
3359,1,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-8 M.,,BAO_0000019,,Rattus norvegicus,,Expert,14424,,D,9,CHEMBL620596,,,
3360,1,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-7 M.,,BAO_0000019,,,,Autocuration,14424,,H,8,CHEMBL620597,,,
3361,1,Antagonistic activity evaluated by ability to block serotonin induced relaxation (via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-8 M.,,BAO_0000019,,,,Expert,14424,,H,8,CHEMBL620598,,,
3362,1,Antagonistic activity evaluated by ability to block serotonin induced relaxation via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 0.1 mg/kg (p.o.),,BAO_0000218,,,,Expert,14424,,H,8,CHEMBL620599,,,
3363,1,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,,BAO_0000019,,,,Autocuration,14424,,H,8,CHEMBL620600,,,
3364,1,Estimate from relaxation of carbachol-contracted rat esophageal muscularis mucosae,,BAO_0000019,,Rattus norvegicus,,Autocuration,1980,,H,8,CHEMBL620601,,,
3365,1,Compound was tested for agonistic activity against 5-hydroxytryptamine 4 receptor on guinea colon at a concentration 0.1 uM,,BAO_0000019,,,,Autocuration,4639,,H,8,CHEMBL620602,,,
3366,1,Tested for affinity towards 5-hydroxytryptamine 4 receptor,,BAO_0000357,,,,Autocuration,17358,,H,8,CHEMBL620603,,,
3367,1,Tested for affinity towards 5-hydroxytryptamine 4 receptor.,,BAO_0000357,,,,Autocuration,17358,,H,8,CHEMBL620604,,,
3368,1,Compound was tested for 5-hydroxytryptamine 4 binding affinity,,BAO_0000357,,,,Autocuration,17358,,H,8,CHEMBL620605,,,
3369,1,Compound was tested for its affinity towards 5-hydroxytryptamine 4 receptor,,BAO_0000357,,,,Autocuration,1558,,H,8,CHEMBL620606,,,
3370,1,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,BAO_0000019,,,,Autocuration,17358,,H,8,CHEMBL620607,,,
3371,1,In vitro binding affinity towards 5-HT4 receptor was determined,,BAO_0000357,,,,Autocuration,16117,,H,8,CHEMBL620608,,,
3372,1,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,BAO_0000019,,,,Autocuration,17358,,H,8,CHEMBL620609,,,
3373,1,Tested for agonist activity against 5-hydroxytryptamine 4 receptor,,BAO_0000019,,,,Autocuration,17358,,H,8,CHEMBL620610,,,
3374,1,Tested for selectivity for 5-hydroxytryptamine 4 receptor,,BAO_0000357,,,,Autocuration,17358,,H,8,CHEMBL620611,,,
3375,1,Tested for 5-hydroxytryptamine 4 binding affinity against cisapride,,BAO_0000357,,,,Autocuration,17358,,H,8,CHEMBL620612,,,
3376,1,Tested for 5-hydroxytryptamine 4 binding affinity against renzapride,,BAO_0000357,,,,Autocuration,17358,,H,8,CHEMBL620613,,,
3377,1,Tested for 5-hydroxytryptamine 4 binding affinity against zacopride,,BAO_0000357,,,,Autocuration,17358,,H,8,CHEMBL620614,,,
3378,1,Binding affinity against 5-Hydroxytryptamine 4 receptor,,BAO_0000357,,,,Expert,1274,,H,8,CHEMBL620615,,,
3379,1,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 recognition sites in rat brain membranes,,BAO_0000249,,,,Autocuration,10728,,H,6,CHEMBL857075,,,
3380,1,Compound was evaluated for the displacement of [3H]Q-ICS-205-930 from 5-HT3 recognition sites in rat brain membranes,,BAO_0000249,,,,Autocuration,11695,,H,6,CHEMBL620616,,,
3381,1,Displacement of [3H]Q-ICS-205-930 from 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes,,BAO_0000249,,,,Autocuration,11695,,H,6,CHEMBL619411,,,
3382,1,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor from rat cortex homogenate,,BAO_0000019,,,,Autocuration,12490,,H,6,CHEMBL619412,,,
3383,1,Displacement of [3H]-Q-ICS 205-930 from rat cortex homogenate 5-hydroxytryptamine 3 receptor,,BAO_0000019,,Rattus norvegicus,,Autocuration,11828,,D,7,CHEMBL619413,,,
3384,1,Binding affinity of 5-hydroxytryptamine 3 receptor using [3H]granisetron in rat hippocampus and entorhinal cortex,Hippocampus,BAO_0000221,,,,Autocuration,12253,,H,6,CHEMBL619414,,10000000.0,
3385,1,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,,BAO_0000019,,,,Autocuration,10561,,H,6,CHEMBL619415,,,
3386,1,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]quipazine as radioligand in rat cortex,,BAO_0000019,,,,Autocuration,10561,,H,6,CHEMBL619416,,,
3387,1,Rat 5-hydroxytryptamine 3 receptor (5-HT3) antagonist,,BAO_0000019,,,,Autocuration,14432,,H,6,CHEMBL619417,,,
3388,1,Binding affinity against rat 5-hydroxytryptamine 3 receptor,,BAO_0000223,,Rattus norvegicus,,Autocuration,12936,,D,7,CHEMBL619418,,,
3389,1,Binding affinity against 5-Hydroxytryptamine 3 receptor,,BAO_0000223,,Rattus norvegicus,,Autocuration,1274,,D,7,CHEMBL619419,,,
3390,1,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of racemic [3H]zacopride from rat cortex,,BAO_0000019,,,,Autocuration,1980,,H,6,CHEMBL619420,,,
3391,1,Binding affinity to 5-hydroxytryptamine 3 receptor was determined in rat cerebro cortical membranes using [3H]quipazine.,,BAO_0000249,,,,Autocuration,670,,H,6,CHEMBL619421,,,
3392,1,Displacement of [3H]granisetron from 5-hydroxytryptamine 3 receptor of rat cortex,,BAO_0000019,,Rattus norvegicus,,Autocuration,968,,D,7,CHEMBL619422,,,
3393,1,In vitro by displacement of [3H]LY-278584 from 5-hydroxytryptamine 3 receptor on rat entorhinal cortex,,BAO_0000019,,,,Autocuration,14287,,H,6,CHEMBL619423,,,
3394,1,Tested for its binding affinity by measuring its ability to displace [3H]granisetron from 5-hydroxytryptamine 3 receptor in rat cortex,,BAO_0000019,,,,Autocuration,567,,H,6,CHEMBL875080,,,
3395,1,The binding affinity (pKi) measured against 5-hydroxytryptamine 1A receptor of rat cortex using [3H]8-OH-DPAT as radioligand,,BAO_0000019,,,,Autocuration,13267,,H,6,CHEMBL619424,,,
3396,1,Binding affinity at 5-hydroxytryptamine 3 receptor in rat cortical membrane by [3H]graniestron displacement.,,BAO_0000249,,,,Autocuration,14826,,H,6,CHEMBL619425,,,
3397,1,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand,,BAO_0000223,,,,Autocuration,15194,,H,6,CHEMBL619426,,,
3398,1,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand.,,BAO_0000223,,,,Autocuration,15194,,H,6,CHEMBL619427,,,
3399,1,pKi value for inhibition of [3H]LY-278584 binding to 5-hydroxytryptamine 3 receptor,,BAO_0000223,,Rattus norvegicus,,Autocuration,10394,,D,7,CHEMBL619645,,,
3400,1,"Compound was evaluated for binding affinity on 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding",,BAO_0000249,,,,Expert,13657,,D,9,CHEMBL619646,,,
3401,1,Compound was tested for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat brain using [3H]zacopride as the radioligand.,Brain,BAO_0000221,,,,Autocuration,1879,,H,8,CHEMBL619647,,955.0,
3402,1,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor,,BAO_0000019,,,,Autocuration,1879,,H,8,CHEMBL619648,,,
3403,1,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat CNS.,,BAO_0000019,,,,Autocuration,1879,,H,8,CHEMBL619165,,,
3404,1,Compound was evaluated in vivo for the antagonistic activity towards 5-hydroxytryptamine 3 receptor,,BAO_0000218,,,,Autocuration,204,In vivo,H,8,CHEMBL620719,,,
3405,1,Compound was tested for its binding affinity towards 5-HT-3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,,BAO_0000019,,,,Autocuration,1879,,H,8,CHEMBL872924,,,
3406,1,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor,,BAO_0000357,,,,Autocuration,1879,,H,8,CHEMBL620720,,,
3407,1,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,,BAO_0000019,,,,Autocuration,1879,,H,8,CHEMBL620721,,,
3408,1,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using [125I]DAIZAC as the radioligand.,,BAO_0000019,,,,Autocuration,1879,,H,8,CHEMBL620722,,,
3409,1,"Concentration that inhibits the binding of radioligand, [3H]-ICS 205930, to 5-hydroxytryptamine 3 receptor from rat cortex",,BAO_0000019,,,,Autocuration,10641,,H,6,CHEMBL620723,,,
3410,1,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,,BAO_0000019,,,,Autocuration,773,,H,8,CHEMBL620724,,,
3411,1,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor in rat brain cortical membranes using radioligand [3H]quipazine,,BAO_0000249,,,,Autocuration,11952,,H,6,CHEMBL620725,,,
3412,1,Antagonist activity (100 ug/kg) for the Bezold Jarisch reflex evoked by 30 (ug/Kg) of 5-hydroxytryptamine 3 receptor in ethylurethane anesthetized rats i.v.,,BAO_0000019,,Rattus norvegicus,,Autocuration,14145,,D,9,CHEMBL620726,,,
3413,1,Binding affinity towards 5-hydroxytryptamine 3 receptor,,BAO_0000357,,,,Expert,17066,,H,8,CHEMBL620727,,,
3414,1,Compound was evaluated for 5-hydroxytryptamine 3 receptor binding,,BAO_0000223,,,,Autocuration,6398,,H,4,CHEMBL620728,,,
3415,1,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,,BAO_0000019,,,,Autocuration,10321,,U,0,CHEMBL620729,,,
3416,1,Tested for 5-hydroxytryptamine 3 receptor antagonist activity by inhibiting the 5-HT evoked Bezold-Jarisch reflex,,BAO_0000019,,,,Autocuration,511,,H,4,CHEMBL858288,,,
3417,1,Compound was tested for binding affinity towards 5-hydroxytryptamine 3 receptor,,BAO_0000223,,,,Autocuration,4639,,H,4,CHEMBL620730,,,
3418,1,Binding affinity towards 5-hydroxytryptamine 3 receptor,,BAO_0000223,,,,Autocuration,4639,,H,4,CHEMBL620731,,,
3419,1,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 0.3 uM,,BAO_0000019,,Cavia porcellus,,Autocuration,4639,,H,4,CHEMBL620732,,,
3420,1,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,,BAO_0000019,,Cavia porcellus,,Autocuration,4639,,H,4,CHEMBL618042,,,
3421,1,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 30 uM,,BAO_0000019,,Cavia porcellus,,Autocuration,4639,,H,4,CHEMBL618043,,,
3422,1,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,,BAO_0000223,,,,Autocuration,1558,,H,4,CHEMBL618044,,,
3423,1,Evaluated for the 5-hydroxytryptamine 3 receptor antagonistic activity in Bezold-Jarisch model expressed as inhibition of the reflex bradycardia induced by an intravenous injection,,BAO_0000019,,,,Autocuration,268,,H,4,CHEMBL618045,,,
3424,1,Compound was measured for its binding affinity at 5-hydroxytryptamine 3 receptor at a concentration of 10 uM using [3H]BRL-43694 as radioligand,,BAO_0000223,,,,Autocuration,2474,,H,4,CHEMBL618046,,,
3425,1,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); A: agonist,,BAO_0000019,,,,Autocuration,5067,,H,4,CHEMBL618047,,,
3426,1,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: agonist,,BAO_0000019,,,,Autocuration,5067,,H,4,CHEMBL875084,,,
3427,1,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: antagonist,,BAO_0000019,,,,Autocuration,5067,,H,4,CHEMBL618048,,,
3428,1,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); NA means data not available,,BAO_0000223,,,,Autocuration,5067,,H,4,CHEMBL618049,,,
3429,1,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); PA: Partial agonist,,BAO_0000019,,,,Autocuration,5067,,H,4,CHEMBL619764,,,
3430,1,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; A: agonist,,BAO_0000019,,,,Autocuration,5067,,H,4,CHEMBL619765,,,
3431,1,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; ANT: Antagonist,,BAO_0000019,,,,Autocuration,5067,,H,4,CHEMBL619766,,,
3432,1,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA: not active,,BAO_0000223,,,,Autocuration,5067,,H,4,CHEMBL619767,,,
3433,1,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA means data not available,,BAO_0000223,,,,Autocuration,5067,,H,4,CHEMBL619768,,,
3434,1,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; PA: Partial agonist,,BAO_0000019,,,,Autocuration,5067,,H,4,CHEMBL619769,,,
3435,1,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; na means data not available,,BAO_0000223,,,,Autocuration,5067,,H,4,CHEMBL619770,,,
3436,1,Binding affinity towards 5-hydroxytryptamine 3 receptor,,BAO_0000223,,,,Autocuration,5067,,H,4,CHEMBL619771,,,
3437,1,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor using [3H]-BRL-43694 (1 nM) ligand in NG cells 108-15 was determined,,BAO_0000219,,,,Autocuration,14331,,H,4,CHEMBL619772,,,
3438,1,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor; NA: not active,,BAO_0000223,,,,Autocuration,5067,,H,4,CHEMBL619773,,,
3439,1,Binding affinity for 5-HT3 receptor of NG108-15 cells using [3H]GR-65630,,BAO_0000219,,,,Autocuration,6179,,H,4,CHEMBL619774,433.0,,
3440,1,Binding affinity to 5-HT3 serotonin receptor in NG 108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand.,,BAO_0000019,,,,Autocuration,4265,,H,4,CHEMBL875083,,,
3441,1,Binding affinity to 5-HT3 serotonin receptor in NG108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand,,BAO_0000219,,,,Autocuration,4265,,H,4,CHEMBL620718,433.0,,
3442,1,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,,BAO_0000223,,,,Autocuration,17358,,H,4,CHEMBL618127,,,
3443,1,Compound was tested for selectivity against 5-hydroxytryptamine 3 receptor binding affinity,,BAO_0000223,,,,Autocuration,17358,,H,4,CHEMBL618128,,,
3444,1,Compound was tested for the inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor expressed in NG 108-15 cells,,BAO_0000219,,,,Autocuration,13628,In vitro,H,4,CHEMBL618129,,,
3445,1,In vitro Binding affinity towards 5-hydroxytryptamine 3 receptor was determined,,BAO_0000223,,,,Autocuration,4612,,H,4,CHEMBL618130,,,
3446,1,Tested for 5-hydroxytryptamine 3 receptor antagonist activity,,BAO_0000019,,,,Autocuration,17358,,H,4,CHEMBL618131,,,
3447,1,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 1 uM,,BAO_0000019,,Cavia porcellus,,Autocuration,4639,,H,4,CHEMBL618132,,,
3448,1,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM,,BAO_0000019,,Cavia porcellus,,Autocuration,4639,,H,4,CHEMBL618133,,,
3449,1,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM in the presence of 30 uM MDL 72222,,BAO_0000019,,Cavia porcellus,,Autocuration,4639,,H,4,CHEMBL618134,,,
3450,1,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,,BAO_0000019,,Cavia porcellus,,Autocuration,4639,,H,4,CHEMBL618135,,,
3451,1,Binding affinity for the 5-hydroxytryptamine 3 receptor was evaluated in vitro by examining its ability to displace [3H]-BRL 43694.,,BAO_0000223,,,,Autocuration,511,,H,4,CHEMBL618136,,,
3452,1,Binding affinity towards 5-hydroxytryptamine 3 receptor,,BAO_0000223,,,,Autocuration,1479,,H,4,CHEMBL618137,,,
3453,1,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor using radioligand binding assay,,BAO_0000223,,,,Autocuration,1317,,H,4,CHEMBL618138,,,
3454,1,Tested against 5-hydroxytryptamine 3 receptor in experiment 1,,BAO_0000223,,,,Autocuration,12146,,H,4,CHEMBL618139,,,
3455,1,Tested against 5-hydroxytryptamine 3 receptor in experiment 2,,BAO_0000223,,,,Autocuration,12146,,H,4,CHEMBL618140,,,
3456,1,Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligand,,BAO_0000223,,,,Autocuration,13969,,H,4,CHEMBL618141,,,
3457,1,Binding affinity for 5-hydroxytryptamine 2C receptor,,BAO_0000357,,,,Expert,13392,,H,8,CHEMBL873478,,,
3458,1,Binding affinity towards 5-hydroxytryptamine 3 receptor,,BAO_0000223,,,,Autocuration,13392,,H,6,CHEMBL618142,,,
3459,1,Compound was evaluated for the affinity at 5-hydroxytryptamine 3 receptor,,BAO_0000357,,,,Autocuration,14159,,H,8,CHEMBL618143,,,
3460,1,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,,BAO_0000357,,,,Autocuration,1558,,H,8,CHEMBL618144,,,
3461,1,Inhibition of GR-65630 binding to 5-hydroxytryptamine 3 receptor,,BAO_0000357,,,,Autocuration,16655,,H,8,CHEMBL618145,,,
3462,1,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,,BAO_0000223,,,,Autocuration,13020,,H,4,CHEMBL618146,,,
3463,1,Inhibition of [3H]-BRL 43 694 binding to 5-hydroxytryptamine 3 receptor of central nervous system,,BAO_0000223,,,,Autocuration,13021,,H,4,CHEMBL618147,,,
3464,1,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,,BAO_0000223,,,,Autocuration,13020,,H,4,CHEMBL618148,,,
3465,1,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,,BAO_0000019,,,,Autocuration,10321,,H,8,CHEMBL618149,,,
3466,1,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,,BAO_0000357,,,,Autocuration,15818,,H,8,CHEMBL872927,,,
3467,1,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,,BAO_0000357,,,,Autocuration,15818,,H,8,CHEMBL618150,,,
3468,1,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,,BAO_0000357,,,,Autocuration,17358,,H,8,CHEMBL618151,,,
3469,1,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,,BAO_0000357,,,,Autocuration,2222,,H,8,CHEMBL875094,,,
3470,1,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,,BAO_0000019,,,,Autocuration,10322,,H,8,CHEMBL618152,,,
3471,1,In vitro binding affinity towards 5-hydroxytryptamine 3 receptor was determined,,BAO_0000357,,,,Autocuration,16117,,H,8,CHEMBL618153,,,
3472,1,Inhibitory constant against 5-hydroxytryptamine 3 receptor using [3H]GR-65630 radioligand,,BAO_0000357,,,,Autocuration,17200,,H,8,CHEMBL618888,,,
3473,1,Tested for 5-hydroxytryptamine 3 receptor agonist activity,,BAO_0000019,,,,Autocuration,17358,,H,8,CHEMBL618889,,,
3474,1,The binding affinity towards 5-hydroxytryptamine 3 receptor; No affinity,,BAO_0000357,,,,Autocuration,16700,,H,8,CHEMBL618890,,,
3475,1,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H](R)-zacopride from ondansetron-treated NG-108-15 cell membranes,,BAO_0000019,,,,Autocuration,1980,,H,8,CHEMBL618891,,,
3476,1,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H]-BRL 43694 from NG-108-15 cell membranes,,BAO_0000019,,,,Autocuration,1980,,H,8,CHEMBL619054,,,
3477,1,Binding affinity against the 5-hydroxytryptamine 3 receptor,,BAO_0000223,,,,Autocuration,12409,,H,4,CHEMBL619055,,,
3478,1,Binding affinity against human 5-hydroxytryptamine 3A receptor,,BAO_0000357,,,,Autocuration,4365,,H,8,CHEMBL619056,,,
3479,1,Percent efficacy against 5-hydroxytryptamine 3A receptor,,BAO_0000019,,,,Autocuration,4365,,H,8,CHEMBL619057,,,
3480,1,Binding affinity against human 5-hydroxytryptamine 3A receptor,,BAO_0000357,,,,Autocuration,4365,,H,8,CHEMBL619058,,,
3481,1,Response at rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes,,BAO_0000219,,Rattus norvegicus,,Expert,6769,,D,9,CHEMBL619059,,,
3482,1,Ability to block serotonin (30 uM)-evoked responses at rat 5HT3-alpha receptor expressed in xenopus oocytes,,BAO_0000219,,Rattus norvegicus,,Expert,6769,,D,9,CHEMBL619060,,,
3483,1,Effect on rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes at concentration up to 100 uM,,BAO_0000219,,Rattus norvegicus,,Expert,6769,,D,9,CHEMBL875095,,,
3484,1,5-hydroxytryptamine 4 receptor agonist activity as percent maximum 5-HT effect in response to electrical stimulation in male guinea pig ileum,Ileum,BAO_0000221,,Cavia porcellus,,Intermediate,809,,D,9,CHEMBL619061,,2116.0,
3485,1,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum,Ileum,BAO_0000221,,Cavia porcellus,,Intermediate,809,,D,9,CHEMBL619062,,2116.0,
3486,1,5-hydroxytryptamine 4 receptor agonist activity is expressed as percent of the maximum 5-HT response,,BAO_0000019,,Cavia porcellus,,Intermediate,14290,,D,9,CHEMBL619063,,,
3487,1,Tested for affinity towards 5-hydroxytryptamine 4 receptor in electrically stimulated longitudinal muscle preparation of guinea pig ileum,Ileum,BAO_0000221,,Cavia porcellus,,Intermediate,17358,,D,9,CHEMBL619064,,2116.0,
3488,1,Tested for affinity towards 5-hydroxytryptamine 4 receptor in guinea pig distal colon preparation,,BAO_0000357,,Cavia porcellus,,Intermediate,17358,,D,9,CHEMBL619065,,,
3489,1,Tested for affinity towards 5-hydroxytryptamine 4 receptor in isolated guinea pig ileum longitudinal muscle preparation,Ileum,BAO_0000221,,Cavia porcellus,,Intermediate,17358,,D,9,CHEMBL619066,,2116.0,
3490,1,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,Ileum,BAO_0000221,,,,Autocuration,17386,,H,8,CHEMBL619775,,2116.0,
3491,1,Affinity against 5-hydroxytryptamine 7 receptor,,BAO_0000357,,,,Autocuration,3269,,H,8,CHEMBL619776,,,
3492,1,Ability to displace [3H]5-HT binding from 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,,BAO_0000224,,Cavia porcellus,,Autocuration,7721,,H,4,CHEMBL619777,,,
3493,1,Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,,BAO_0000224,,Cavia porcellus,,Autocuration,7721,,H,4,CHEMBL619778,,,
3494,1,Evaluated for inhibition of 5-hydroxytryptamine receptor on guinea pig ileum at 10 uM; No effect,Ileum,BAO_0000221,,Cavia porcellus,,Autocuration,9117,,H,4,CHEMBL619779,,2116.0,
3495,1,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand, activity is expressed as Kd.",,BAO_0000224,,Cavia porcellus,,Autocuration,7721,,H,4,CHEMBL619780,,,
3496,1,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor using 1 uM LSD as masking ligand, activity is expressed as Kd.",,BAO_0000224,,Cavia porcellus,,Autocuration,7721,,H,4,CHEMBL619166,,,
3497,1,5-HT level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,,BAO_0000019,,Cavia porcellus,,Autocuration,15796,,H,4,CHEMBL619167,,,
3498,1,5-hydroxytryptamine level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,,BAO_0000019,,Cavia porcellus,,Autocuration,15796,,H,4,CHEMBL619168,,,
3499,1,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor in the presence of 10 nM compound in isolated human atrial myocytes,Cardiac atrium,BAO_0000219,,Homo sapiens,,Expert,15650,,D,9,CHEMBL619169,,2081.0,
3500,1,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes,Cardiac atrium,BAO_0000219,,Homo sapiens,,Expert,15650,,D,9,CHEMBL619170,,2081.0,
3501,1,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine",,BAO_0000019,,Homo sapiens,,Autocuration,6866,,D,5,CHEMBL619171,,,
3502,1,",Antagonism of stimulation of 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes",Cardiac atrium,BAO_0000219,,Homo sapiens,,Expert,15650,,D,9,CHEMBL619172,,2081.0,
3503,1,Ability (10 ug/kg) to inhibit binding of [125I]iododexetimide to 5-hydroxytryptamine receptor in mice,,BAO_0000019,,Mus musculus,,Autocuration,10063,,U,0,CHEMBL619173,,,
3504,1,Percent inhibition of radioligand [3H]-LSD binding to 5-HT receptor at 10 uM concentration,,BAO_0000019,,Mus musculus,,Autocuration,12665,,U,0,CHEMBL619174,,,
3505,1,5-hydroxytryptamine receptor binding affinity was determined in rats,,BAO_0000019,,,,Autocuration,7504,,H,4,CHEMBL619175,,,
3506,1,Binding affinity at rat 5-hydroxytryptamine receptor.,,BAO_0000224,,,,Autocuration,7504,,H,4,CHEMBL619176,,,
3507,1,Affinity against 5-hydroxytryptamine receptors in rat fundus model,,BAO_0000019,,,,Autocuration,7038,,H,4,CHEMBL619177,,,
3508,1,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation,,BAO_0000224,,,,Autocuration,7626,,H,4,CHEMBL619178,,,
3509,1,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation; Not determined,,BAO_0000224,,,,Autocuration,7626,,H,4,CHEMBL619179,,,
3510,1,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation,Stomach,BAO_0000019,,,,Autocuration,7185,,H,4,CHEMBL619180,,945.0,
3511,1,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation (resulted in discoloration in the oxygenated muscle bath to give varying results).,Stomach,BAO_0000019,,,,Autocuration,7185,,H,4,CHEMBL619181,,945.0,
3512,1,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,,BAO_0000019,,,,Autocuration,7185,,H,4,CHEMBL619182,,,
3513,1,Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2,,BAO_0000224,,,,Autocuration,6960,,H,4,CHEMBL619183,,,
3514,1,"Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2; Valid pA2, can not be determined because of slope of Schild plot.",,BAO_0000224,,,,Autocuration,6960,,H,4,CHEMBL619184,,,
3515,1,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,Hippocampus,BAO_0000221,,,,Autocuration,12416,,H,8,CHEMBL619185,,10000000.0,
3516,1,Binding affinity for rat 5-hydroxytryptamine transporter.,,BAO_0000357,,,,Expert,15753,,H,8,CHEMBL619186,,,
3517,1,Evaluated for inhibition of specific [3H]5-HT receptor binding in rat cortex.,,BAO_0000019,,,,Autocuration,8062,,H,4,CHEMBL619187,,,
3518,1,Binding affinity at serotonin 5-HT1-type site receptor in rat cortex by displacing [3H]5-HT,,BAO_0000019,,Rattus norvegicus,,Autocuration,9036,,D,5,CHEMBL619188,,,
3519,1,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,,BAO_0000224,,Rattus norvegicus,,Autocuration,15067,,D,5,CHEMBL619189,,,
3520,1,Inhibitory activity against [3H]- 5-hydroxytryptamine reuptake in whole rat brain minus cerebellum,Brain,BAO_0000019,,Rattus norvegicus,,Expert,15753,,D,9,CHEMBL619190,,955.0,
3521,1,Inhibition of [3H]5-HT reuptake in whole rat brain (minus cerebellum) homogenate.,Cerebellum,BAO_0000221,,Rattus norvegicus,,Expert,15753,,D,9,CHEMBL619191,,2037.0,
3522,1,Displacement of [3H]-citalopram from rat forebrain membrane 5-hydroxytryptamine receptor at 10e-7 M,,BAO_0000019,,Rattus norvegicus,,Autocuration,15295,,D,5,CHEMBL619192,,,
3523,1,Percent binding affinity against 5-hydroxytryptamine receptor,,BAO_0000224,,Rattus norvegicus,,Autocuration,6347,,D,5,CHEMBL619193,,,
3524,1,Ability to displace 0.4 nM [3H]paroxetine binding to 5-hydroxytryptamine receptor in rat frontal cortex,,BAO_0000019,,,,Autocuration,6763,,U,0,CHEMBL619194,,,
3525,1,The binding affinity was measured on 5-hydroxytryptamine receptor uptake receptor using [3H]- paroxetine as radioligand.,,BAO_0000224,,Rattus norvegicus,,Autocuration,12092,,D,5,CHEMBL619195,,,
3526,1,Affinity against 5-hydroxytryptamine receptor was determined,,BAO_0000224,,Rattus norvegicus,,Autocuration,1579,,D,5,CHEMBL619196,,,
3527,1,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip,Stomach,BAO_0000019,,Rattus norvegicus,,Autocuration,1579,,D,5,CHEMBL619197,,945.0,
3528,1,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,,BAO_0000219,,Homo sapiens,,Expert,5963,In vitro,D,9,CHEMBL619198,,,
3529,1,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,,BAO_0000219,,Homo sapiens,,Expert,5963,In vitro,D,9,CHEMBL875081,,,
3530,1,Ability to compete with radioactive ligands specific to the Serotonergic 5-HT receptor at 10 uM; NA means compound failed to compete,,BAO_0000357,,,,Autocuration,5030,,H,8,CHEMBL884712,,,
3531,1,Inhibition of 5-hydroxytryptamine reuptake,,BAO_0000357,,,,Expert,15796,,H,8,CHEMBL884710,,,
3532,1,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding",,BAO_0000019,,,,Autocuration,15413,,H,8,CHEMBL619199,,,
3533,1,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 1)",,BAO_0000019,,,,Autocuration,15413,,H,8,CHEMBL619200,,,
3534,1,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 2)",,BAO_0000019,,,,Autocuration,15413,,H,8,CHEMBL619201,,,
3535,1,Tested for 5-hydroxytryptamine receptor uptake,,BAO_0000019,,,,Autocuration,12409,,H,8,CHEMBL619202,,,
3536,1,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,,BAO_0000219,,Homo sapiens,,Expert,16909,,D,9,CHEMBL619203,449.0,,
3537,1,Antagonistic affinity tested against isolated human cloned alpha-1d adrenoceptor subtype,,BAO_0000019,,Homo sapiens,,Expert,16909,,D,9,CHEMBL619204,,,
3538,1,In vitro binding affinity towards 5-hydroxytryptamine receptor 1A receptor by using [3H]8-OH-DPAT in rat hippocampal membranes.,,BAO_0000249,,Homo sapiens,,Autocuration,15629,,H,8,CHEMBL619205,,,
3539,1,Tested in vitro for % inhibition against 5-hydroxytryptamine receptor 1A,,BAO_0000357,,,,Autocuration,15629,,H,8,CHEMBL619206,,,
3540,1,In vitro binding affinity at 5-hydroxytryptamine receptor 1A receptor in rat hippocampal membranes by [3H]8-OH-DPAT displacement.,,BAO_0000249,,,,Expert,15629,,H,8,CHEMBL619207,,,
3541,1,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 0.10 umol/kg,Striatum,BAO_0000019,,,,Autocuration,10034,,H,8,CHEMBL619208,,2435.0,
3542,1,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 10 umol/kg,Striatum,BAO_0000019,,,,Autocuration,10034,,H,8,CHEMBL619209,,2435.0,
3543,1,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 0.32 umol/kg,Striatum,BAO_0000019,,,,Autocuration,10034,,H,8,CHEMBL619210,,2435.0,
3544,1,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 3.2 umol/kg,Striatum,BAO_0000019,,,,Autocuration,10034,,H,8,CHEMBL619211,,2435.0,
3545,1,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 32 umol/kg,Striatum,BAO_0000019,,,,Autocuration,10034,,H,8,CHEMBL619212,,2435.0,
3546,1,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 0.032 umol/kg,Striatum,BAO_0000019,,,,Autocuration,10034,,H,8,CHEMBL620681,,2435.0,
3547,1,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 1.0 umol/kg,Striatum,BAO_0000019,,,,Autocuration,10034,,H,8,CHEMBL620682,,2435.0,
3548,1,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 10 umol/kg,Striatum,BAO_0000019,,,,Autocuration,10034,,H,8,CHEMBL620683,,2435.0,
3549,1,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 100 umol/kg,Striatum,BAO_0000019,,,,Autocuration,10034,,H,8,CHEMBL620684,,2435.0,
3550,1,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 3.2 umol/kg,Striatum,BAO_0000019,,,,Autocuration,10034,,H,8,CHEMBL620685,,2435.0,
3551,1,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 32 umol/kg,Striatum,BAO_0000019,,,,Autocuration,10034,,H,8,CHEMBL620686,,2435.0,
3552,1,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.032 umol/kg,Limbic system,BAO_0000019,,,,Autocuration,10034,,H,8,CHEMBL620687,,349.0,
3553,1,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,Limbic system,BAO_0000019,,,,Autocuration,10034,,H,8,CHEMBL620688,,349.0,
3554,1,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.32 umol/kg,Limbic system,BAO_0000019,,,,Autocuration,10034,,H,8,CHEMBL620689,,349.0,
3555,1,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 1.0 umol/kg,Limbic system,BAO_0000019,,,,Autocuration,10034,,H,8,CHEMBL620690,,349.0,
3556,1,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 10 umol/kg,Limbic system,BAO_0000019,,,,Autocuration,10034,,H,8,CHEMBL620691,,349.0,
3557,1,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 100 umol/kg,Limbic system,BAO_0000019,,,,Autocuration,10034,,H,8,CHEMBL620692,,349.0,
3558,1,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 3.2 umol/kg,Limbic system,BAO_0000019,,,,Autocuration,10034,,H,8,CHEMBL620693,,349.0,
3559,1,Binding affinity against 5-hydroxytryptamine 4 receptor,,BAO_0000357,,,,Expert,1274,,H,8,CHEMBL620694,,,
3560,1,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,BAO_0000019,,,,Autocuration,17358,,H,8,CHEMBL857986,,,
3561,1,Inhibitory activity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand at 10e-5 M concentration,,BAO_0000357,,,,Autocuration,14532,,H,8,CHEMBL620695,,,
3562,1,Binding affinity towards Serotonin 5-hydroxytryptamine 4 receptor,,BAO_0000357,,,,Expert,16989,,H,8,CHEMBL620696,,,
3563,1,Inhibitory constant against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 radioligand,,BAO_0000357,,,,Autocuration,17200,,H,8,CHEMBL620697,,,
3564,1,Binding affinity towards 5-hydroxytryptamine 4 receptor,,BAO_0000357,,,,Autocuration,15779,,H,8,CHEMBL620698,,,
3565,1,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,,BAO_0000357,,,,Autocuration,15779,,H,8,CHEMBL620699,,,
3566,1,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,,BAO_0000357,,,,Autocuration,15779,,H,8,CHEMBL620700,,,
3567,1,Binding affinity was determined against cloned 5-hydroxytryptamine 4A receptor isoform expressed in COS-7 cells,,BAO_0000219,,,,Autocuration,15650,,H,8,CHEMBL620701,643.0,,
3568,1,Binding affinity was determined against cloned 5-hydroxytryptamine 4B receptor isoform expressed in COS-7 cells,,BAO_0000219,,,,Autocuration,15650,,H,8,CHEMBL875082,643.0,,
3569,1,Binding affinity was determined against cloned 5-hydroxytryptamine 4C receptor isoform expressed in COS-7 cells,,BAO_0000219,,,,Autocuration,15650,,H,8,CHEMBL620702,643.0,,
3570,1,Binding affinity was determined against cloned 5-hydroxytryptamine 4D receptor isoform expressed in COS-7 cells,,BAO_0000219,,,,Autocuration,15650,,H,8,CHEMBL620703,643.0,,
3571,1,Binding affinity of compound towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,,BAO_0000219,,,,Autocuration,17046,,H,8,CHEMBL620704,673.0,,
3572,1,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,,BAO_0000219,,,,Expert,17046,,H,8,CHEMBL620705,673.0,,
3573,1,Binding affinity was determined against cloned 5-hydroxytryptamine 4E receptor isoform expressed in C6 glial cells incubated with 0.2 nM [3H]GR-113808,,BAO_0000219,,,,Expert,15650,,H,8,CHEMBL620706,673.0,,
3574,1,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand; Not determined,,BAO_0000219,,,,Expert,17046,,H,8,CHEMBL620707,673.0,,
3575,1,Binding affinity towards 5-hydroxytryptamine 5 receptor,,BAO_0000357,,,,Expert,17066,,H,8,CHEMBL620708,,,
3576,1,Inhibitory constant against human 5-hydroxytryptamine 5A receptor using [3H]LSD radioligand,,BAO_0000357,,,,Autocuration,17200,,H,8,CHEMBL620709,,,
3577,1,Binding affinity against 5-hydroxytryptamine 5A receptor,,BAO_0000357,,Homo sapiens,,Expert,16146,,D,9,CHEMBL620710,,,
3578,1,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 5A receptor stably expressed in CHO cells,,BAO_0000219,,,,Autocuration,15250,,H,8,CHEMBL620711,449.0,,
3579,1,Affinity towards human 5-hydroxytryptamine 5A serotonin receptor,,BAO_0000357,,Homo sapiens,,Expert,6491,,D,9,CHEMBL620712,,,
3580,1,Binding affinity towards human 5-hydroxytryptamine 5A receptor,,BAO_0000357,,Homo sapiens,,Expert,17066,,D,9,CHEMBL620713,,,
3581,1,Binding affinity towards human 5-hydroxytryptamine 5A receptor was evaluated using [3H]-5-CT as radioligand,,BAO_0000357,,Homo sapiens,,Expert,17066,,D,9,CHEMBL620714,,,
3582,1,Binding affinity to cloned human 5-hydroxytryptamine 5A receptor,,BAO_0000357,,Homo sapiens,,Expert,4234,,D,9,CHEMBL620715,,,
3583,1,Binding affinity towards 5-HT5A receptor,,BAO_0000357,,,,Autocuration,6013,,H,8,CHEMBL620716,,,
3584,1,Binding affinity towards human 5-hydroxytryptamine 5A receptor using LSD as radioligand,,BAO_0000357,,,,Expert,17175,,H,8,CHEMBL620717,,,
3585,1,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 5A receptor,,BAO_0000357,,,,Autocuration,15818,,H,8,CHEMBL618072,,,
3586,1,Binding affinity towards cloned human 5-HT5A receptor was determined,,BAO_0000357,,,,Autocuration,6166,,H,8,CHEMBL857987,,,
3587,1,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,BAO_0000219,,,,Autocuration,15779,,H,8,CHEMBL618073,722.0,,
3588,1,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,,BAO_0000219,,,,Autocuration,15779,,H,8,CHEMBL618074,722.0,,
3589,1,Compound was tested for its binding affinity in 5-hydroxytryptamine 5A receptor (using human cloned receptors in HEK 293 and [3H]5-CTas a radioligand ),,BAO_0000219,,,,Autocuration,5213,,H,8,CHEMBL618075,722.0,,
3590,1,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor,,BAO_0000357,,Mus musculus,,Expert,17066,,D,9,CHEMBL618076,,,
3591,1,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [125I]-2-iodo LSD as radioligand,,BAO_0000357,,Mus musculus,,Expert,17066,,D,9,CHEMBL618077,,,
3592,1,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]- LSD as radioligand,,BAO_0000357,,Mus musculus,,Expert,17066,,D,9,CHEMBL618078,,,
3593,1,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]LSD as radioligand,,BAO_0000357,,Mus musculus,,Expert,17066,,D,9,CHEMBL881821,,,
3594,1,Binding affinity towards murine 5-hydroxytryptamine 5A receptor,,BAO_0000357,,Mus musculus,,Expert,17066,,D,9,CHEMBL618079,,,
3595,1,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor using LSD as radioligand,,BAO_0000357,,,,Expert,17175,,H,8,CHEMBL618080,,,
3596,1,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,,BAO_0000219,,,,Autocuration,16190,,H,8,CHEMBL618081,722.0,,
3597,1,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,,BAO_0000219,,,,Autocuration,16190,,H,8,CHEMBL618082,722.0,,
3598,1,Binding affinity towards 5-HT5a receptor,,BAO_0000357,,,,Expert,4820,,H,8,CHEMBL618083,,,
3599,1,Binding affinity towards 5-hydroxytryptamine 5A receptor,,BAO_0000357,,Homo sapiens,,Expert,17066,,D,9,CHEMBL618084,,,
3600,1,Binding affinity for rodent 5-hydroxytryptamine 5A receptor,,BAO_0000357,,,,Expert,17066,,H,8,CHEMBL618085,,,
3601,1,Binding affinity towards 5-hydroxytryptamine 5A receptor using lysergic acid diethylamide (LSD) as radioligand,,BAO_0000357,,,,Expert,17175,,H,8,CHEMBL618086,,,
3602,1,Binding affinities against 5-hydroxytryptamine 5A receptor,,BAO_0000357,,,,Autocuration,16633,,H,8,CHEMBL875092,,,
3603,1,Binding affinities towards 5-hydroxytryptamine 5A receptor,,BAO_0000357,,,,Autocuration,16633,,H,8,CHEMBL618087,,,
3604,1,The binding affinity towards 5-hydroxytryptamine 5A receptor; No affinity,,BAO_0000357,,,,Autocuration,16700,,H,8,CHEMBL872926,,,
3605,1,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.01 uM,,BAO_0000019,,Cavia porcellus,,Autocuration,4639,,H,4,CHEMBL618088,,,
3606,1,Binding affinity towards 5-HT3 receptor by the displacement of [3H]GR-65630] in human recombinant receptors in mammalian cell,,BAO_0000223,,,,Autocuration,5486,,H,4,CHEMBL618089,,,
3607,1,Inhibition of human 5-hydroxytryptamine 6 receptor,,BAO_0000357,,Homo sapiens,,Expert,16146,,D,9,CHEMBL618090,,,
3608,1,Binding affinity towards 5-hydroxytryptamine 6 receptor using [3H]- LSD as radioligand,,BAO_0000357,,Homo sapiens,,Expert,17273,,D,9,CHEMBL618091,,,
3609,1,Inhibition against human 5-hydroxytryptamine 6 receptor,,BAO_0000357,,,,Autocuration,17687,,H,8,CHEMBL618092,,,
3610,1,Affinity towards human 5-hydroxytryptamine 6 serotonin receptor,,BAO_0000357,,Homo sapiens,,Expert,6491,,D,9,CHEMBL618093,,,
3611,1,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells.,,BAO_0000219,,,,Expert,16190,,H,8,CHEMBL618094,308.0,,
3612,1,Binding affinity towards [3H]LSD-labeled human 5-hydroxytryptamine 6 receptor,,BAO_0000357,,Homo sapiens,,Expert,17066,,D,9,CHEMBL618095,,,
3613,1,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,BAO_0000357,,Homo sapiens,,Expert,17066,,D,9,CHEMBL875093,,,
3614,1,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [125I]-2-iodo LSD as radioligand,,BAO_0000357,,Homo sapiens,,Expert,17066,,D,9,CHEMBL618096,,,
3615,1,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [3H]-LSD as radioligand,,BAO_0000357,,Homo sapiens,,Expert,17066,,D,9,CHEMBL618118,,,
3616,1,Binding affinity against 5-hydroxytryptamine 6 receptor,,BAO_0000357,,Homo sapiens,,Expert,3555,,D,9,CHEMBL618119,,,
3617,1,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,BAO_0000357,,,,Expert,5808,,H,8,CHEMBL618120,,,
3618,1,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,BAO_0000357,,,,Autocuration,6013,,H,8,CHEMBL618121,,,
3619,1,"Binding affinity for human 5-hydroxytryptamine 6 receptor expressed in HEK 293 human embryonic kidney cells, [3H]-lysergic acid diethylamide as radioligand",,BAO_0000219,,,,Expert,15818,,H,8,CHEMBL618122,722.0,,
3620,1,Binding affinity towards human 5-hydroxytryptamine 6 receptor using [3H]LSD as radioligand,,BAO_0000357,,,,Autocuration,16209,,H,8,CHEMBL618123,,,
3621,1,Binding affinity against human 5-hydroxytryptamine 6 receptor stably transfected to HEK 293 human embryonic kidney cells using [3H]-lysergic acid diethylamide as radioligand,,BAO_0000219,,,,Expert,3935,,H,8,CHEMBL618124,722.0,,
3622,1,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 6 receptor,,BAO_0000357,,,,Autocuration,15818,,H,8,CHEMBL618125,,,
3623,1,Displacement of [3H]LSD from human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,,BAO_0000219,,Homo sapiens,,Expert,3805,,D,9,CHEMBL618126,722.0,,
3624,1,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD,,BAO_0000019,,,,Expert,16441,,H,8,CHEMBL618236,,,
3625,1,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD; ND is No Data.,,BAO_0000019,,,,Expert,16441,,H,8,CHEMBL618237,,,
3626,1,Ability to displace [3H]LSD from human 5-hydroxytryptamine 6 receptor transiently expressed in COS-7 cells,,BAO_0000219,,,,Expert,6786,,H,8,CHEMBL618238,643.0,,
3627,1,In vitro binding affinity to human 5-hydroxytryptamine 6 receptor,,BAO_0000357,,Homo sapiens,,Expert,4234,,D,9,CHEMBL618239,,,
3628,1,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 6 receptor,,BAO_0000019,,,,Autocuration,17085,,H,8,CHEMBL618240,,,
3629,1,Inhibitory constant against human 5-hydroxytryptamine 6 receptor using [3H]LSD radioligand,,BAO_0000357,,,,Autocuration,17200,,H,8,CHEMBL618241,,,
3630,1,Antagonism assessed in a functional cAMP binding assay using 5-CT to stimulate human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,,BAO_0000219,,,,Autocuration,17451,,H,8,CHEMBL859399,722.0,,
3631,1,The compound was tested for antagonist activity by inhibition of human 5-HT6 stimulated adenylate cyclase,,BAO_0000019,,,,Autocuration,3935,,H,8,CHEMBL618242,,,
3632,1,Ability to displace the radioligand [3H]LSD from human 5-hydroxytryptamine 6 receptor,,BAO_0000357,,,,Autocuration,5033,,H,8,CHEMBL857991,,,
3633,1,Binding affinity against human 5-hydroxytryptamine 6 receptor,,BAO_0000357,,,,Expert,4540,,H,8,CHEMBL619951,,,
3634,1,Binding affinity to human cloned 5-HT6 receptor in HeLa cells using [3H]- LSD as radioligand,,BAO_0000219,,Homo sapiens,,Expert,4540,,D,9,CHEMBL619952,308.0,,
3635,1,Binding affinity to human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]- LSD as radioligand,,BAO_0000219,,Homo sapiens,,Expert,4540,,D,9,CHEMBL619953,308.0,,
3636,1,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells,,BAO_0000219,,,,Autocuration,17296,,H,8,CHEMBL619954,308.0,,
3637,1,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,,BAO_0000219,,,,Autocuration,17296,,H,8,CHEMBL619955,308.0,,
3638,1,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,,BAO_0000219,,,,Autocuration,17296,,H,8,CHEMBL619956,308.0,,
3639,1,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,BAO_0000219,,,,Autocuration,15779,,H,8,CHEMBL619957,449.0,,
3640,1,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,BAO_0000219,,,,Autocuration,15779,,H,8,CHEMBL619958,722.0,,
3641,1,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand; ND means no data.,,BAO_0000219,,,,Autocuration,15779,,H,8,CHEMBL620627,722.0,,
3642,1,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,,BAO_0000219,,,,Autocuration,15779,,H,8,CHEMBL620628,722.0,,
3643,1,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HeLa cells using [3H]LSD as radioligand;ND means no data.,,BAO_0000219,,,,Autocuration,15779,,H,8,CHEMBL620629,308.0,,
3644,1,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,BAO_0000357,,,,Autocuration,6166,,H,8,CHEMBL620630,,,
3645,1,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 6 receptor expressed in HeLa cells using [3H]LSD as radioligand,,BAO_0000219,,,,Autocuration,17451,,H,8,CHEMBL620782,308.0,,
3646,1,Compound was evaluated for its ability to displace [3H]LSD binding from human recombinant 5-hydroxytryptamine 6 receptor,,BAO_0000357,,,,Autocuration,15316,,H,8,CHEMBL620783,,,
3647,1,Binding affinity against human 5-hydroxytryptamine 6 receptor,,BAO_0000357,,,,Expert,4199,,H,8,CHEMBL620784,,,
3648,1,Binding affinity against human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]LSD,,BAO_0000219,,,,Expert,15146,,H,8,CHEMBL620785,308.0,,
3649,1,Compound was tested for its binding affinity in 5-hydroxytryptamine 6 receptor (using human cloned receptors in HeLa and [3H]LSD as a radioligand ),,BAO_0000357,,,,Autocuration,5213,,H,8,CHEMBL857992,,,
3650,1,In vitro binding affinity at human recombinant 5-hydroxytryptamine 6 receptor in mammalian cells using 3[H]LSD as the radioligand,,BAO_0000219,,,,Autocuration,16429,,H,8,CHEMBL620786,,,
3651,1,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]5-LSD.,,BAO_0000219,,,,Autocuration,14818,,H,8,CHEMBL620787,308.0,,
3652,1,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=3",,BAO_0000219,,,,Autocuration,4829,,H,8,CHEMBL620788,308.0,,
3653,1,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=9",,BAO_0000219,,,,Autocuration,4829,,H,8,CHEMBL620789,308.0,,
3654,1,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]LSD as radioligand; n=3",,BAO_0000219,,,,Autocuration,4829,,H,8,CHEMBL620790,308.0,,
3655,1,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 6 receptor stably expressed in CHO cells,,BAO_0000219,,,,Autocuration,15250,,H,8,CHEMBL620791,449.0,,
3656,1,Binding affinity against 5-hydroxytryptamine 6 receptor from CHO cell membranes using [3H]5-HT as the radioligand.,,BAO_0000019,,,,Autocuration,14423,,H,8,CHEMBL620792,,,
3657,1,The compound was tested for binding affinity against 5-hydroxytryptamine 6 receptor,,BAO_0000357,,,,Autocuration,15086,,H,8,CHEMBL620793,,,
3658,1,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor was determined,,BAO_0000357,,,,Autocuration,4342,,H,8,CHEMBL620794,,,
3659,1,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells,,BAO_0000219,,Homo sapiens,,Autocuration,16190,,D,9,CHEMBL620795,308.0,,
3660,1,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,BAO_0000357,,,,Expert,4820,,H,8,CHEMBL620796,,,
3661,1,Percentage of displacement at 5-hydroxytryptamine 6 receptor at 10e-8 M,,BAO_0000357,,,,Autocuration,4639,,H,8,CHEMBL620797,,,
3662,1,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,,BAO_0000019,,Homo sapiens,,Expert,17066,,D,9,CHEMBL620798,,,
3663,1,Inhibition of binding towards 5-hydroxytryptamine 6 receptor at 100 nM concentration,,BAO_0000357,,,,Autocuration,6011,,H,8,CHEMBL620799,,,
3664,1,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,BAO_0000357,,,,Expert,17066,,H,8,CHEMBL620800,,,
3665,1,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor; inactive at 10 uM,,BAO_0000357,,,,Autocuration,17515,,H,8,CHEMBL620801,,,
3666,1,Compound was tested for its binding affinity towards 5-hydroxytryptamine 6 receptor,,BAO_0000357,,,,Autocuration,5014,,H,8,CHEMBL875100,,,
3667,1,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 6 receptor was determined,,BAO_0000357,,,,Autocuration,4373,,H,8,CHEMBL620802,,,
3668,1,Antagonistic activity towards 5-hydroxytryptamine 6 receptor,,BAO_0000019,,,,Expert,17066,,H,8,CHEMBL620803,,,
3669,1,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,,BAO_0000019,,,,Expert,17066,,H,8,CHEMBL620804,,,
3670,1,Binding affinity for 5-hydroxytryptamine 6 receptor was determined,,BAO_0000357,,,,Autocuration,4373,,H,8,CHEMBL620805,,,
3671,1,Evaluated for the binding affinity towards 5-hydroxytryptamine 6 receptor,,BAO_0000357,,,,Autocuration,4687,,H,8,CHEMBL620806,,,
3672,1,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-6 M,,BAO_0000357,,,,Autocuration,16946,,H,8,CHEMBL620807,,,
3673,1,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-8 M,,BAO_0000357,,,,Autocuration,16946,,H,8,CHEMBL620808,,,
3674,1,Binding affinities against 5-hydroxytryptamine 6 receptor,,BAO_0000357,,,,Autocuration,16633,,H,8,CHEMBL620809,,,
3675,1,Binding affinities towards 5-hydroxytryptamine 6 receptor,,BAO_0000357,,,,Autocuration,16633,,H,8,CHEMBL620810,,,
3676,1,Binding affinity towards 5-hydroxytryptamine 6 receptor,,BAO_0000357,,Homo sapiens,,Expert,17066,,D,9,CHEMBL620811,,,
3677,1,The binding affinity towards 5-hydroxytryptamine 6 receptor; No affinity,,BAO_0000357,,,,Autocuration,16700,,H,8,CHEMBL620812,,,
3678,1,Affinity against 5-hydroxytryptamine 6 receptor,,BAO_0000357,,,,Autocuration,3269,,H,8,CHEMBL620813,,,
3679,1,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-CT],,BAO_0000357,,,,Autocuration,5486,,H,8,CHEMBL620814,,,
3680,1,Inhibition of human 5-hydroxytryptamine 7 receptor,,BAO_0000357,,Homo sapiens,,Expert,16146,,D,9,CHEMBL620815,,,
3681,1,Compound was tested for its binding affinity towards human 5-hydroxytryptamine 7 receptor from HEK293 cells using radioligand [3H]LSD,,BAO_0000219,,,,Autocuration,5014,,H,8,CHEMBL620816,722.0,,
3682,1,Compound at 1 uM was tested for the inhibition of radioligand [3H]LSD binding to recombinant human 5-hydroxytryptamine 7 receptor,,BAO_0000357,,,,Autocuration,15463,,H,8,CHEMBL620817,,,
3683,1,In vitro binding affinity against human 5-hydroxytryptamine 7 receptor at a concentration of 100 (nM),,BAO_0000357,,,,Autocuration,3805,,H,8,CHEMBL620818,,,
3684,1,Inhibition (at 1 uM) of radioligand [3H]LSD binding to human 5-hydroxytryptamine 7 receptor on HEK293 cells,,BAO_0000219,,,,Expert,5014,,H,8,CHEMBL620819,722.0,,
3685,1,Affinity towards human 5-hydroxytryptamine 7 serotonin receptor,,BAO_0000357,,Homo sapiens,,Expert,6491,,D,9,CHEMBL620820,,,
3686,1,Binding affinity for 5-hydroxytryptamine 7 receptor human cloned receptors in CHO cells using [3H]5-HT,,BAO_0000219,,,,Autocuration,16190,,H,8,CHEMBL620821,449.0,,
3687,1,Binding affinity towards human 5-hydroxytryptamine 7 receptor,,BAO_0000357,,Homo sapiens,,Expert,17066,,D,9,CHEMBL620822,,,
3688,1,Displacement of [3H]5-HT from human 5-hydroxytryptamine 7 receptor,,BAO_0000357,,Homo sapiens,,Expert,17066,,D,9,CHEMBL620823,,,
3689,1,Binding affinity against 5-hydroxytryptamine 7 receptor,,BAO_0000357,,Homo sapiens,,Expert,3555,,D,9,CHEMBL620824,,,
3690,1,Binding affinity towards human 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-HT radioligand from the cloned receptor expressed in CHO cells,,BAO_0000219,,,,Expert,6588,,H,8,CHEMBL620825,449.0,,
3691,1,Binding affinity towards recombinant human 5-hydroxytryptamine 7 receptor was determined using [3H]LSD as radioligand,,BAO_0000357,,,,Autocuration,15463,,H,8,CHEMBL872930,,,
3692,1,Binding affinity towards 5-hydroxytryptamine 7 receptor,,BAO_0000357,,,,Autocuration,6013,,H,8,CHEMBL620826,,,
3693,1,Binding affinity towards human 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,,BAO_0000357,,,,Autocuration,16209,,H,8,CHEMBL620827,,,
3694,1,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 7 receptor,,BAO_0000357,,,,Autocuration,3935,,H,8,CHEMBL620828,,,
3695,1,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 7 receptor,,BAO_0000357,,,,Autocuration,15818,,H,8,CHEMBL620829,,,
3696,1,Binding affinity towards human 5-hydroxytryptamine 7 receptor on HEK293 cells using radioligand [3H]LSD,,BAO_0000219,,,,Expert,5014,,H,8,CHEMBL620830,722.0,,
3697,1,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD,,BAO_0000019,,,,Expert,16441,,H,8,CHEMBL620831,,,
3698,1,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD; ND is No Data.,,BAO_0000019,,,,Expert,16441,,H,8,CHEMBL620832,,,
3699,1,In vitro binding affinity to human 5-hydroxytryptamine 7 receptor,,BAO_0000357,,Homo sapiens,,Expert,4234,,D,9,CHEMBL621548,,,
3700,1,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor,,BAO_0000019,,,,Autocuration,17085,,H,8,CHEMBL621549,,,
3701,1,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]LSD radioligand,,BAO_0000357,,,,Autocuration,17200,,H,8,CHEMBL621550,,,
3702,1,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]-LSD as radioligand; Not determined,,BAO_0000219,,,,Autocuration,17451,,H,8,CHEMBL621551,449.0,,
3703,1,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor; ND means not determined,,BAO_0000019,,,,Autocuration,17085,,H,8,CHEMBL621552,,,
3704,1,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor,,BAO_0000357,,,,Autocuration,5104,,H,8,CHEMBL857077,,,
3705,1,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor; Not tested,,BAO_0000357,,,,Autocuration,5104,,H,8,CHEMBL618158,,,
3706,1,Ability to displace the radioligand [3H]5-carboxyamidotryptamine ([3H]5-CT) from human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,,BAO_0000219,,Homo sapiens,,Expert,5033,,D,9,CHEMBL618159,643.0,,
3707,1,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-5-CT) from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,,BAO_0000219,,,,Autocuration,5486,,H,8,CHEMBL875101,643.0,,
3708,1,Binding affinity to human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]-5-CT as radioligand,,BAO_0000219,,Homo sapiens,,Expert,4540,,D,9,CHEMBL618160,722.0,,
3709,1,Binding affinity at human cloned 5-hydroxytryptamine 7 receptor.,,BAO_0000357,,,,Expert,6166,,H,8,CHEMBL618161,,,
3710,1,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor was determined in HEK293 cells using [3H]5-CT as radioligand,,BAO_0000219,,,,Expert,17342,,H,8,CHEMBL618162,722.0,,
3711,1,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor was determined using [3H]5-CT as radioligand,,BAO_0000357,,,,Expert,17342,,H,8,CHEMBL618163,,,
3712,1,Binding affinity against 5-hydroxytryptamine 7 human receptors,,BAO_0000357,,,,Autocuration,17296,,H,8,CHEMBL618164,,,
3713,1,Binding affinity to human recombinant 5-hydroxytryptamine 7 receptor in mammalian cells using [3H]5-CT as radioligand,,BAO_0000219,,,,Expert,16429,,H,8,CHEMBL618165,,,
3714,1,Binding affinity toward 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]-5-CT as radioligand.,,BAO_0000219,,,,Autocuration,15779,,H,8,CHEMBL618166,722.0,,
3715,1,Binding affinity towards 5-hydroxytryptamine 7 receptor (a) (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,BAO_0000219,,,,Autocuration,15779,,H,8,CHEMBL857989,722.0,,
3716,1,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,BAO_0000219,,,,Autocuration,15779,,H,8,CHEMBL619888,722.0,,
3717,1,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,BAO_0000219,,,,Autocuration,15779,,H,8,CHEMBL619889,722.0,,
3718,1,Binding affinity towards 5-hydroxytryptamine 7 receptor 7(a) (human cloned receptor in HEK 293 cells using [3H]5-CT as radioligand.,,BAO_0000219,,,,Autocuration,15779,,H,8,CHEMBL619890,722.0,,
3719,1,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]LSD as radioligand,,BAO_0000219,,,,Autocuration,17451,,H,8,CHEMBL619891,449.0,,
3720,1,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand (n=3),,BAO_0000219,,,,Autocuration,4199,,H,8,CHEMBL619892,722.0,,
3721,1,Displacement of [3H]-5-CT from human 5-hydroxytryptamine 7 receptor expressed in HEK-293 cells,,BAO_0000219,,,,Expert,4199,,D,9,CHEMBL619893,722.0,,
3722,1,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand(n=6),,BAO_0000219,,,,Autocuration,4199,,H,8,CHEMBL619894,722.0,,
3723,1,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells,,BAO_0000219,,,,Intermediate,3680,,D,9,CHEMBL619895,722.0,,
3724,1,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor using [3H]5-CT as radioligand,,BAO_0000357,,,,Intermediate,3680,,D,9,CHEMBL619896,,,
3725,1,Compound was evaluated for its ability to displace [3H]5-CT binding from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells.,,BAO_0000219,,,,Autocuration,15316,,H,8,CHEMBL619897,643.0,,
3726,1,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT,,BAO_0000219,,,,Autocuration,15146,,H,8,CHEMBL619898,722.0,,
3727,1,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor in HEK 293 using [3H]5-CT as a radioligand,,BAO_0000219,,,,Expert,5213,,H,8,CHEMBL619899,722.0,,
3728,1,Compound was tested for its binding affinity in 5-hydroxytryptamine 7 receptor (using human cloned receptors in HEK 293 and [3H]5-CT as a radioligand ),,BAO_0000219,,,,Autocuration,5213,,H,8,CHEMBL619900,722.0,,
3729,1,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT,,BAO_0000219,,Homo sapiens,,Expert,14818,,D,9,CHEMBL619901,722.0,,
3730,1,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT. ,,BAO_0000219,,,,Autocuration,14818,,H,8,CHEMBL620580,722.0,,
3731,1,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT.,,BAO_0000219,,,,Autocuration,14818,,H,8,CHEMBL620581,722.0,,
3732,1,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 7 receptor in HEK293 cells, using [3H]5-CT as radioligand",,BAO_0000219,,,,Autocuration,4829,,H,8,CHEMBL620733,722.0,,
3733,1,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]-LSD radioligand; Not determined,,BAO_0000357,,Homo sapiens,,Autocuration,17200,,D,9,CHEMBL620734,,,
3734,1,Binding affinity towards mouse 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,,BAO_0000357,,Mus musculus,,Expert,17066,,D,9,CHEMBL620735,,,
3735,1,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 7 receptor in the endothelium denuded rabbit jugular vein.,,BAO_0000019,,Oryctolagus cuniculus,,Autocuration,14025,,H,8,CHEMBL620736,,,
3736,1,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 7 receptor stably expressed in CHO cells,,BAO_0000219,,,,Autocuration,15250,,H,8,CHEMBL620737,449.0,,
3737,1,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 10000 nM,,BAO_0000219,,,,Autocuration,16372,,H,8,CHEMBL620738,449.0,,
3738,1,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 100 nM,,BAO_0000219,,,,Autocuration,16372,,H,8,CHEMBL620739,449.0,,
3739,1,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 1 nM,,BAO_0000219,,,,Autocuration,16372,,H,8,CHEMBL620740,449.0,,
3740,1,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 10000 nM 5-HT.,,BAO_0000219,,,,Autocuration,16372,,H,8,CHEMBL620741,449.0,,
3741,1,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 100 nM 5-HT.,,BAO_0000219,,,,Autocuration,16372,,H,8,CHEMBL620742,449.0,,
3742,1,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 1 nM 5-HT,,BAO_0000219,,,,Autocuration,16372,,H,8,CHEMBL620743,449.0,,
3743,1,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 10000 nM,,BAO_0000219,,,,Autocuration,16372,,H,8,CHEMBL620744,449.0,,
3744,1,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 100 nM,,BAO_0000219,,,,Autocuration,16372,,H,8,CHEMBL620745,449.0,,
3745,1,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM,,BAO_0000219,,,,Autocuration,16372,,H,8,CHEMBL620746,449.0,,
3746,1,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 10000 nM 5-HT.,,BAO_0000219,,,,Autocuration,16372,,H,8,CHEMBL620747,449.0,,
3747,1,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 100 nM 5-HT.,,BAO_0000219,,,,Autocuration,16372,,H,8,CHEMBL620748,449.0,,
3748,1,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT.,,BAO_0000219,,,,Autocuration,16372,,H,8,CHEMBL620749,449.0,,
3749,1,Binding affinity towards rat 5-hydroxytryptamine 7 receptor,,BAO_0000357,,,,Expert,17066,,H,8,CHEMBL620750,,,
3750,1,Binding affinity towards rat 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,,BAO_0000357,,Rattus norvegicus,,Expert,17066,,D,9,CHEMBL620751,,,
3751,1,Binding affinity to the rat 5-hydroxytryptamine 7 receptor,,BAO_0000357,,,,Expert,17386,,H,8,CHEMBL620752,,,
3752,1,Binding affinity against 5-hydroxytryptamine 7 receptor using from CHO cell membranes [3H]5-HT as the radioligand.,,BAO_0000019,,,,Autocuration,14423,,H,8,CHEMBL872929,,,
3753,1,Binding affinity against Rat 5-hydroxytryptamine 7 receptor using [3H]5-HT,,BAO_0000357,,Rattus norvegicus,,Expert,15874,,D,9,CHEMBL620753,,,
3754,1,Displacement of [3H]5-HT from over-expressed rat 5-hydroxytryptamine 7 receptor,,BAO_0000357,,Rattus norvegicus,,Expert,15874,,D,9,CHEMBL620754,,,
3755,1,Displacement of [3H]5-HT from rat 5-hydroxytryptamine 7 receptor expressed in CHO cells,,BAO_0000219,,Rattus norvegicus,,Expert,16372,,D,9,CHEMBL620755,449.0,,
3756,1,In vitro binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,,BAO_0000357,,,,Autocuration,4622,,H,8,CHEMBL620756,,,
3757,1,The compound was tested for binding affinity against 5-hydroxytryptamine 7 receptor,,BAO_0000357,,,,Autocuration,15086,,H,8,CHEMBL620757,,,
3758,1,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; Not tested",,BAO_0000219,,,,Autocuration,16372,,H,8,CHEMBL620758,449.0,,
3759,1,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; not tested",,BAO_0000219,,,,Autocuration,16372,,H,8,CHEMBL620759,449.0,,
3760,1,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM; not tested,,BAO_0000219,,,,Autocuration,16372,,H,8,CHEMBL620760,449.0,,
3761,1,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT; Not tested,,BAO_0000219,,,,Autocuration,16372,,H,8,CHEMBL620761,449.0,,
3762,1,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,Ileum,BAO_0000221,,,,Autocuration,17386,,H,8,CHEMBL620762,,2116.0,
3763,1,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,Ileum,BAO_0000221,,,,Autocuration,17386,,H,8,CHEMBL620763,,2116.0,
3764,1,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine receptor desensitization,Ileum,BAO_0000221,,,,Autocuration,17386,,H,8,CHEMBL620764,,2116.0,
3765,1,Inhibition of [3H]-5-CT binding to 5-hydroxytryptamine 7 receptor of rat cortical membranes,,BAO_0000249,,Rattus norvegicus,,Expert,5831,,D,9,CHEMBL857990,,,
3766,1,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor was determined,,BAO_0000357,,,,Autocuration,4342,,H,8,CHEMBL620765,,,
3767,1,Binding affinity at rat 5-hydroxytryptamine 7 receptor.,,BAO_0000357,,,,Expert,17319,,H,8,CHEMBL620766,,,
3768,1,Binding affinity towards 5-hydroxytryptamine receptor 7 on rat hypothalamus membranes using [3H]5-CT as radioligand.,Hypothalamus,BAO_0000019,,,,Expert,17342,,H,8,CHEMBL620767,,1898.0,
3769,1,Binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor was determined using [3H]5-HT as radioligand,,BAO_0000357,,,,Autocuration,17342,,H,8,CHEMBL620768,,,
3770,1,Binding affinity against 5-hydroxytryptamine 7 receptor using [3H]-5-CT in rat hypothalamus membranes,Hypothalamus,BAO_0000249,,,,Expert,3680,,H,8,CHEMBL619051,,1898.0,
3771,1,Binding affinity towards 5-hydroxytryptamine 7 receptor,,BAO_0000357,,,,Expert,3680,,H,8,CHEMBL619052,,,
3772,1,Agonistic activity against rat 5-HT7 adenyl cyclase expressed by HEK293 cells,,BAO_0000219,,Rattus norvegicus,,Expert,17319,,D,9,CHEMBL619053,722.0,,
3773,1,Agonistic activity against rat 5-HT7 adenyl cyclase expressed in HEK293 cells; Active,,BAO_0000219,,Rattus norvegicus,,Expert,17319,,D,9,CHEMBL619703,722.0,,
3774,1,Agonistic activity against rat 5-HT7-adenyl cyclase expressed by HEK293 cells; Active,,BAO_0000219,,Rattus norvegicus,,Autocuration,17319,,D,9,CHEMBL619704,722.0,,
3775,1,Binding affinity towards 5-hydroxytryptamine 7 receptor,,BAO_0000357,,,,Expert,4820,,H,8,CHEMBL619851,,,
3776,1,Percentage of displacement at 5-hydroxytryptamine 7 receptor at 10e-8 M,,BAO_0000357,,,,Autocuration,4639,,H,8,CHEMBL619852,,,
3777,1,Inhibition of binding towards 5-hydroxytryptamine 7 receptor at 100 nM concentration,,BAO_0000357,,,,Autocuration,6011,,H,8,CHEMBL619853,,,
3778,1,Binding affinity towards human 5-hydroxytryptamine 7 receptor,,BAO_0000357,,Homo sapiens,,Expert,17066,,D,9,CHEMBL619854,,,
3779,1,Binding affinity of compound towards rodent 5-hydroxytryptamine 7 receptor,,BAO_0000357,,,,Expert,17066,,H,8,CHEMBL619855,,,
3780,1,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor; inactive at 10 uM,,BAO_0000357,,,,Autocuration,17515,,H,8,CHEMBL619856,,,
3781,1,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,,BAO_0000357,,,,Autocuration,4373,,H,8,CHEMBL619857,,,
3782,1,Antagonistic activity towards 5-hydroxytryptamine 7 receptor was evaluated by cAMP assay,,BAO_0000019,,,,Expert,17066,,H,8,CHEMBL619858,,,
3783,1,Binding affinity for 5-hydroxytryptamine 7 receptor was determined,,BAO_0000357,,,,Autocuration,4373,,H,8,CHEMBL619859,,,
3784,1,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,,BAO_0000357,,,,Autocuration,4373,,H,8,CHEMBL619860,,,
3785,1,Evaluated for the binding affinity to 5-hydroxytryptamine 7 receptor,,BAO_0000357,,,,Autocuration,4687,,H,8,CHEMBL619861,,,
3786,1,Non-selective inhibitory activity was determined against 5-hydroxytryptamine 7 receptor,,BAO_0000357,,,,Expert,17342,,H,8,CHEMBL619862,,,
3787,1,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-6 M,,BAO_0000357,,,,Autocuration,16946,,H,8,CHEMBL619863,,,
3788,1,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-8 M,,BAO_0000357,,,,Autocuration,16946,,H,8,CHEMBL619864,,,
3789,1,Binding affinities against 5-hydroxytryptamine 7 receptor,,BAO_0000357,,,,Autocuration,16633,,H,8,CHEMBL872928,,,
3790,1,Binding affinities towards 5-hydroxytryptamine 7 receptor,,BAO_0000357,,,,Autocuration,16633,,H,8,CHEMBL619865,,,
3791,1,Binding affinity towards rodent 5-hydroxytryptamine 7 receptor,,BAO_0000357,,,,Expert,17066,,H,8,CHEMBL619866,,,
3792,1,The binding affinity towards 5-hydroxytryptamine 7 receptor; No affinity,,BAO_0000357,,,,Autocuration,16700,,H,8,CHEMBL619867,,,
3793,1,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,Ileum,BAO_0000221,,,,Autocuration,17386,,H,8,CHEMBL619868,,2116.0,
3794,1,Compound was evaluated for the potency to inhibit oxidation of arachidonic acid by human recombinant 5-Lipoxygenase using a spectrophotometric assay,,BAO_0000019,,,,Autocuration,14080,,H,8,CHEMBL619869,,,
3795,1,Inhibition of oxidation of arachidonic acid by human 5-Lipoxygenase using spectrophotometric assay,,BAO_0000019,,Homo sapiens,,Expert,14080,,D,9,CHEMBL619870,,,
3796,1,In vitro inhibition of human recombinant 5-lipoxygenase enzyme,,BAO_0000357,,,,Autocuration,409,,H,8,CHEMBL619871,,,
3797,1,In vitro inhibition of human recombinant lipoxygenase enzyme,,BAO_0000357,,,,Autocuration,409,,H,8,CHEMBL619872,,,
3798,1,In vitro inhibition of human recombinant lipoxygenase enzyme; No inhibition,,BAO_0000357,,,,Autocuration,409,,H,8,CHEMBL619873,,,
3799,1,Inhibition of 5-lipoxygenase in human whole blood.,Blood,BAO_0000357,,,,Expert,11090,,H,8,CHEMBL619874,,178.0,
3800,1,Inhibition of 5-lipoxygenase in human whole blood.,Blood,BAO_0000357,,,,Expert,11090,,H,8,CHEMBL619875,,178.0,
3801,1,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of 5-HETE,,BAO_0000357,,,,Autocuration,948,,H,8,CHEMBL619876,,,
3802,1,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of leukotriene B4 (LTB4),,BAO_0000357,,,,Autocuration,948,,H,8,CHEMBL619877,,,
3803,1,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human polymorphonuclear leukocytes.,,BAO_0000219,,,,Expert,13622,,H,8,CHEMBL619878,,,
3804,1,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human whole blood,Blood,BAO_0000019,,,,Autocuration,13622,,H,8,CHEMBL619879,,178.0,
3805,1,In vitro inhibition of 5-lipoxygenase from human polymorphs,,BAO_0000357,,,,Autocuration,9637,,H,8,CHEMBL619880,,,
3806,1,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-LPO (5-lipoxygenase),,BAO_0000357,,,,Autocuration,11320,,H,8,CHEMBL619881,,,
3807,1,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-lipoxygenase,,BAO_0000357,,,,Expert,11320,,H,8,CHEMBL619882,,,
3808,1,In vitro inhibitory activity against 5-lipoxygenase in a human whole blood assay,,BAO_0000357,,,,Autocuration,6838,,H,8,CHEMBL619883,,,
3809,1,Inhibition of 5-Lipoxygenase (5-LO) of human whole blood (HWB),Blood,BAO_0000357,,Homo sapiens,,Expert,17667,,D,9,CHEMBL619884,,178.0,
3810,1,In vitro potency against human 5-Lipoxygenase,,BAO_0000357,,,,Autocuration,12703,,H,8,CHEMBL619885,,,
3811,1,Inhibitory activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay,,BAO_0000019,,Homo sapiens,,Expert,14312,,D,9,CHEMBL619886,,,
3812,1,Inhibition activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay; No data,Blood,BAO_0000019,,,,Autocuration,14312,,H,8,CHEMBL619887,,178.0,
3813,1,Inhibition of 5-lipoxygenase activity of compound evaluated as determined by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,,BAO_0000019,,,,Autocuration,5364,,H,8,CHEMBL875097,,,
3814,1,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE,,BAO_0000219,,,,Autocuration,951,,H,8,CHEMBL618001,,,
3815,1,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE; NA means Not active,,BAO_0000219,,,,Autocuration,951,,H,8,CHEMBL618002,,,
3816,1,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4,,BAO_0000219,,,,Autocuration,951,,H,8,CHEMBL618003,,,
3817,1,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4; NA means Not active,,BAO_0000219,,,,Autocuration,951,,H,8,CHEMBL618004,,,
3818,1,Inhibition of human 5-lipoxygenase in human cells,,BAO_0000219,,,,Autocuration,12365,,H,8,CHEMBL618005,,,
3819,1,Inhibition of human neutrophil 5-lipoxygenase,,BAO_0000357,,,,Expert,10603,,H,8,CHEMBL618006,,,
3820,1,Inhibitory activity against 5-lipoxygenase expressed from human polymorphonuclear cells,,BAO_0000019,,,,Autocuration,10501,,H,8,CHEMBL875086,,,
3821,1,Inhibition of 5-lipoxygenase from human whole blood,Blood,BAO_0000357,,,,Expert,12281,,H,8,CHEMBL618007,,178.0,
3822,1,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,,BAO_0000357,,,,Autocuration,2567,,H,8,CHEMBL618008,,,
3823,1,Inhibitory concentration required against 5-lipoxygenase activity in intact cells of human neutrophils,,BAO_0000219,,,,Autocuration,2567,,H,8,CHEMBL618009,,,
3824,1,In vitro inhibition of polymorphonuclear leukocyte derived human 5-lipoxygenase,,BAO_0000357,,,,Expert,10193,,H,8,CHEMBL618010,,,
3825,1,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,BAO_0000357,,,,Autocuration,10193,,H,8,CHEMBL618011,,,
3826,1,Potency to inhibit oxidation of arachidonic acid by recombinant human 5-lipoxygenase,,BAO_0000357,,,,Expert,13623,,H,8,CHEMBL618012,,,
3827,1,Tested against 5-lipoxygenase,,BAO_0000357,,,,Autocuration,12780,,H,8,CHEMBL882927,,,
3828,1,Tested for activity against 5-Lipoxygenase (5-LO),,BAO_0000357,,,,Autocuration,12780,,H,8,CHEMBL618013,,,
3829,1,Tested for activity against 5-lipoxygenase,,BAO_0000357,,,,Autocuration,12780,,H,8,CHEMBL618014,,,
3830,1,Tested for inhibition of 5-HPETE production by human 5-LO,,BAO_0000357,,,,Autocuration,11966,,H,8,CHEMBL618015,,,
3831,1,The 5-lipoxygenase activity by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,,BAO_0000019,,,,Autocuration,5364,,H,8,CHEMBL618016,,,
3832,1,Inhibition of Human 5-lipoxygenase,,BAO_0000357,,,,Expert,13165,,H,8,CHEMBL618017,,,
3833,1,The compound was evaluated for its inhibitory activity against 5-lipoxygenase using granulocytes-type cells,,BAO_0000019,,,,Autocuration,5364,,H,8,CHEMBL618018,,,
3834,1,The compound was tested for inhibitory activity against 5-lipoxygenase in human polymorphonuclear leukocytes[PMNS],,BAO_0000219,,,,Autocuration,11311,,H,8,CHEMBL875087,,,
3835,1,The compound was tested for inhibitory activity against LT synthesis in human polymorphonuclear leukocytes[PMNS],,BAO_0000219,,,,Autocuration,11311,,H,8,CHEMBL618019,,,
3836,1,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50.,,BAO_0000019,,,,Autocuration,14863,,H,8,CHEMBL618020,,,
3837,1,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50; Not tested,,BAO_0000019,,,,Autocuration,14863,,H,8,CHEMBL618021,,,
3838,1,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in human whole blood (HWBL),Blood,BAO_0000357,,,,Autocuration,11087,,H,8,CHEMBL618022,,178.0,
3839,1,The compound was tested in vitro for inhibition against 5-lipoxygenase in intact human neutrophils,,BAO_0000357,,,,Autocuration,455,,H,8,CHEMBL618023,,,
3840,1,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,BAO_0000357,,,,Autocuration,13183,,H,8,CHEMBL618024,,,
3841,1,In vitro inhibitory activity against 5-lipoxygenase in human polymorphonuclear (PMN) cells,,BAO_0000019,,,,Expert,10319,,H,8,CHEMBL873950,,,
3842,1,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,BAO_0000357,,,,Autocuration,10193,,H,8,CHEMBL618025,,,
3843,1,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM,,BAO_0000219,,,,Autocuration,951,,H,8,CHEMBL618026,,,
3844,1,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM; NA means Inactive,,BAO_0000219,,,,Autocuration,951,,H,8,CHEMBL618027,,,
3845,1,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM,,BAO_0000219,,,,Autocuration,951,,H,8,CHEMBL618028,,,
3846,1,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM; NA means Inactive,,BAO_0000219,,,,Autocuration,951,,H,8,CHEMBL618029,,,
3847,1,Inhibitory activity against 5-lipoxygenase at 10 uM concentration,,BAO_0000357,,,,Expert,9859,,H,8,CHEMBL618030,,,
3848,1,Inhibitory activity against 5-lipoxygenase at 1 uM concentration,,BAO_0000357,,,,Expert,9859,,H,8,CHEMBL618031,,,
3849,1,Inhibitory activity against lipoxygenase (LO) at 10 uM concentration,,BAO_0000357,,,,Autocuration,9859,,H,8,CHEMBL618032,,,
3850,1,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,,BAO_0000357,,,,Autocuration,2567,,H,8,CHEMBL618033,,,
3851,1,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 1 uM,,BAO_0000357,,,,Autocuration,10193,,H,8,CHEMBL618034,,,
3852,1,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,BAO_0000357,,,,Autocuration,10193,,H,8,CHEMBL875088,,,
3853,1,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; IA= Inactive,,BAO_0000019,,,,Autocuration,949,,H,8,CHEMBL618035,,,
3854,1,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; value ranges from 70-90,,BAO_0000019,,,,Autocuration,949,,H,8,CHEMBL618036,,,
3855,1,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 0.1 uM,,BAO_0000357,,,,Expert,10603,,H,8,CHEMBL618037,,,
3856,1,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,,BAO_0000357,,,,Expert,10603,,H,8,CHEMBL618038,,,
3857,1,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,,BAO_0000019,,,,Autocuration,10603,,H,8,CHEMBL618761,,,
3858,1,Inhibition of lipoxygenase at the concentration of 0.1 uM,,BAO_0000357,,,,Expert,10603,,H,8,CHEMBL618762,,,
3859,1,Inhibition of lipoxygenase at the concentration of 1 uM,,BAO_0000357,,,,Expert,10603,,H,8,CHEMBL618763,,,
3860,1,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell,,BAO_0000357,,,,Autocuration,10193,,H,8,CHEMBL618764,,,
3861,1,Inhibition of 5-Lipoxygenase (5-LOX),,BAO_0000357,,Homo sapiens,,Expert,14580,,D,9,CHEMBL618765,,,
3862,1,Inhibition of 5-lipoxygenase in mouse macrophages.,,BAO_0000357,,,,Expert,11090,,H,8,CHEMBL618766,,,
3863,1,Inhibition of 5-lipoxygenase in mouse macrophages.,,BAO_0000357,,,,Expert,11090,,H,8,CHEMBL618767,,,
3864,1,Inhibitory activity against lipoxygenase-2 in mice,,BAO_0000357,,,,Autocuration,6339,,H,8,CHEMBL619380,,,
3865,1,Inhibitory activity against murine lipoxygenase-2.,,BAO_0000357,,,,Expert,6339,,H,8,CHEMBL619381,,,
3866,1,Inhibition of 5-lipoxygenase from mouse macrophage,,BAO_0000357,,Mus musculus,,Expert,12281,,D,9,CHEMBL619382,,,
3867,1,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse macrophages,,BAO_0000357,,,,Autocuration,11311,,H,8,CHEMBL619383,,,
3868,1,The compound was tested for the inhibition of Arachidonate 5-lipoxygenase purified from porcine leukocytes.,,BAO_0000019,,Sus scrofa,,Autocuration,11089,,H,8,CHEMBL619384,,,
3869,1,Inhibition of 5-lipoxygenase reaction catalyzed by purified enzyme from porcine leukocytes,,BAO_0000019,,Sus scrofa,,Autocuration,10091,,H,8,CHEMBL619385,,,
3870,1,Inhibitory concentration against 5-lipoxygenase from isolated rabbit granulocytes,,BAO_0000019,,Oryctolagus cuniculus,,Autocuration,14352,,H,8,CHEMBL882928,,,
3871,1,5-lipoxygenase Inhibitory activity against rat polymorphonuclear leucocytes using 5-HETE,,BAO_0000019,,Rattus norvegicus,,Expert,13329,,D,9,CHEMBL619386,,,
3872,1,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE. ",,BAO_0000019,,,,Autocuration,13329,,H,8,CHEMBL619387,,,
3873,1,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",,BAO_0000019,,,,Autocuration,13329,,H,8,CHEMBL619388,,,
3874,1,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4.",,BAO_0000019,,,,Autocuration,13329,,H,8,CHEMBL619389,,,
3875,1,Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay (inhibition of 5-HETE formation),,BAO_0000019,,,,Expert,13329,,H,8,CHEMBL619390,,,
3876,1,"Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay, by ability to inhibit formation of LTB4 AT 10 uM",,BAO_0000019,,,,Expert,13329,,H,8,CHEMBL619391,,,
3877,1,Inhibition of 5-lipoxygenase pathway was evaluated in rat polymorphonuclear assay by compound (50 uM) ability to inhibit formation of 5-HETE,,BAO_0000019,,,,Autocuration,13329,,H,8,CHEMBL619392,,,
3878,1,The effective dose for inhibition of 5-lipoxygenase in rat blood leukocyte (ex vivo),,BAO_0000019,,,,Autocuration,11311,,H,8,CHEMBL619393,,,
3879,1,The effective dose for inhibition of 5-lipoxygenase in rat passive Arthus model after oral administration,,BAO_0000019,,,,Autocuration,11311,,H,8,CHEMBL619394,,,
3880,1,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",,BAO_0000219,,,,Autocuration,105,,H,8,CHEMBL619395,702.0,,
3881,1,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",,BAO_0000219,,,,Autocuration,105,,H,8,CHEMBL619396,702.0,,
3882,1,Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),,BAO_0000357,,,,Autocuration,9138,,H,8,CHEMBL619397,,,
3883,1,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),",,BAO_0000357,,,,Autocuration,9138,,H,8,CHEMBL619398,,,
3884,1,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO), (at a concentration of 0.2 nM ),",,BAO_0000357,,,,Autocuration,9138,,H,8,CHEMBL619399,,,
3885,1,5-LO inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,,BAO_0000357,,,,Autocuration,14427,,H,8,CHEMBL619400,,,
3886,1,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",,BAO_0000019,,,,Autocuration,13329,,H,8,CHEMBL619401,,,
3887,1,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4. ",,BAO_0000019,,,,Autocuration,13329,,H,8,CHEMBL619402,,,
3888,1,Inhibition of 5-lipoxygenase mediated conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cells,,BAO_0000219,,Rattus norvegicus,,Expert,14427,,D,9,CHEMBL619403,663.0,,
3889,1,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,,BAO_0000357,,,,Autocuration,14427,,H,8,CHEMBL619404,,,
3890,1,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography.,,BAO_0000357,,,,Autocuration,14427,,H,8,CHEMBL619405,,,
3891,1,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line,,BAO_0000219,,,,Expert,10293,,H,8,CHEMBL619406,702.0,,
3892,1,Inhibition of 5-Lipoxygenase of rat basophilic leukemia cells,,BAO_0000219,,Rattus norvegicus,,Expert,338,,D,9,CHEMBL619407,702.0,,
3893,1,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase),,BAO_0000357,,,,Autocuration,303,,H,8,CHEMBL619408,,,
3894,1,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) in intact RBL-1 cell line assay,,BAO_0000219,,,,Autocuration,303,,H,8,CHEMBL619409,702.0,,
3895,1,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-lipoxygenase,,BAO_0000219,,,,Expert,9247,,H,8,CHEMBL619410,702.0,,
3896,1,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,,BAO_0000219,,,,Autocuration,9247,,H,8,CHEMBL619753,702.0,,
3897,1,Compound was evaluated in an intact RBL-1 cell line for inhibition of 5-lipoxygenase,,BAO_0000219,,,,Autocuration,137,,H,8,CHEMBL619754,702.0,,
3898,1,Evaluated in vitro for its inhibitory activity against 5-lipoxygenase,,BAO_0000357,,,,Expert,11481,,H,8,CHEMBL619903,,,
3899,1,"Evaluated in vitro for its inhibitory activity against 5-lipoxygenase; N=Inactive, <50% inhibition at 10 uM concentration",,BAO_0000357,,,,Expert,11481,,H,8,CHEMBL619904,,,
3900,1,Inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase in vitro,,BAO_0000357,,,,Expert,9029,,H,8,CHEMBL619905,,,
3901,1,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells,,BAO_0000019,,,,Autocuration,1701,,H,8,CHEMBL619906,,,
3902,1,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 32 uM; Not active,,BAO_0000019,,,,Autocuration,1701,,H,8,CHEMBL619907,,,
3903,1,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 50 uM; Not active,,BAO_0000019,,,,Autocuration,1701,,H,8,CHEMBL619908,,,
3904,1,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells; No data,,BAO_0000019,,,,Autocuration,1701,,H,8,CHEMBL619909,,,
3905,1,Inhibition of 5-lipoxygenase by measuring 5-HETE levels in RBL-1 cell-free supernatant,,BAO_0000219,,,,Expert,13358,,H,8,CHEMBL619910,702.0,,
3906,1,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells,,BAO_0000219,,,,Expert,1175,,H,8,CHEMBL882929,702.0,,
3907,1,Ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells.,,BAO_0000219,,,,Expert,8797,,H,8,CHEMBL619911,702.0,,
3908,1,Compound was tested for its ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells; No data,,BAO_0000019,,,,Autocuration,8797,,H,8,CHEMBL619912,,,
3909,1,Inhibition of rat basophilic leukemia cell 5-lipoxygenase,,BAO_0000357,,Rattus norvegicus,,Expert,577,,D,9,CHEMBL619913,,,
3910,1,In vitro inhibitory activity against RBL-1 5-LO,,BAO_0000219,,,,Expert,9295,,H,8,CHEMBL619914,702.0,,
3911,1,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (insoluble above 45 uM),,BAO_0000219,,,,Autocuration,9295,,H,8,CHEMBL619915,702.0,,
3912,1,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (time dependent),,BAO_0000219,,,,Autocuration,9295,,H,8,CHEMBL619916,702.0,,
3913,1,Compound was tested for its inhibition activity against 5-LO of the whole cell in vitro in rat.,,BAO_0000218,,,,Autocuration,9295,,H,8,CHEMBL619917,,,
3914,1,Compound was tested for its inhibition activity against the 5-LO in isolated enzyme,,BAO_0000357,,,,Autocuration,9295,,H,8,CHEMBL619918,,,
3915,1,Compound was tested for its inhibitory activity against 5-lipoxygenase in rat.,,BAO_0000218,,,,Autocuration,216,,H,8,CHEMBL619919,,,
3916,1,Compound was tested for the inhibition of 5-lipoxygenase (5-LPO) in rat basophilic leukemia (RBL) cells.,,BAO_0000219,,,,Autocuration,11090,,H,8,CHEMBL883710,702.0,,
3917,1,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in rat whole blood.,Blood,BAO_0000019,,,,Autocuration,11090,,H,8,CHEMBL619920,,178.0,
3918,1,Concentration required for 50 % inhibition of arachidonic acid oxidation by rat 5-lipoxygenase,,BAO_0000357,,,,Expert,10091,,H,8,CHEMBL619921,,,
3919,1,Concentration that produces 50% inhibition of A-23187-stimulated radiolabeled 5-HETE and TXB2 synthesis by PMN 5-lipoxygenase.,,BAO_0000019,,,,Autocuration,10274,,H,8,CHEMBL619922,,,
3920,1,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in rat polymorphonuclear leukocytes,,BAO_0000219,,,,Autocuration,13622,,H,8,CHEMBL619923,,,
3921,1,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined,,BAO_0000219,,,,Expert,12118,,H,8,CHEMBL619924,702.0,,
3922,1,In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assay,,BAO_0000357,,,,Expert,12576,,H,8,CHEMBL619925,,,
3923,1,In vitro inhibition of 5-lipoxygenase from RBL-1 cells,,BAO_0000219,,,,Expert,9546,,H,8,CHEMBL619926,702.0,,
3924,1,In vitro inhibition of 5-lipoxygenase in RBL-1 cells,,BAO_0000219,,,,Autocuration,9521,,H,8,CHEMBL619927,702.0,,
3925,1,In vitro inhibition of 5-lipoxygenase pathway in rat basophilic leukemia (RBL-1) cells,,BAO_0000219,,,,Expert,10626,,H,8,CHEMBL619928,702.0,,
3926,1,In vitro inhibition of RBL-1 5-lipoxygenase,,BAO_0000219,,,,Autocuration,9225,,H,8,CHEMBL619929,702.0,,
3927,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.18-0.31,,BAO_0000219,,,,Autocuration,9225,,H,8,CHEMBL875089,702.0,,
3928,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.3-1.6,,BAO_0000219,,,,Autocuration,9225,,H,8,CHEMBL619930,702.0,,
3929,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.4-2.2,,BAO_0000219,,,,Autocuration,9225,,H,8,CHEMBL619931,702.0,,
3930,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.72-1.07,,BAO_0000219,,,,Autocuration,9225,,H,8,CHEMBL619932,702.0,,
3931,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.9-4.0,,BAO_0000219,,,,Autocuration,9225,,H,8,CHEMBL619933,702.0,,
3932,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.5,,BAO_0000219,,,,Autocuration,9225,,H,8,CHEMBL619934,702.0,,
3933,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.7,,BAO_0000219,,,,Autocuration,9225,,H,8,CHEMBL619935,702.0,,
3934,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-2.4,,BAO_0000219,,,,Autocuration,9225,,H,8,CHEMBL619936,702.0,,
3935,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.07-5.54,,BAO_0000219,,,,Autocuration,9225,,H,8,CHEMBL619937,702.0,,
3936,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.1-1.6,,BAO_0000219,,,,Autocuration,9225,,H,8,CHEMBL619938,702.0,,
3937,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.3-2.8,,BAO_0000219,,,,Autocuration,9225,,H,8,CHEMBL619939,702.0,,
3938,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.4-3.2,,BAO_0000219,,,,Autocuration,9225,,H,8,CHEMBL619940,702.0,,
3939,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.7-2.6,,BAO_0000219,,,,Autocuration,9225,,H,8,CHEMBL875090,702.0,,
3940,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-2.8,,BAO_0000219,,,,Autocuration,9225,,H,8,CHEMBL619941,702.0,,
3941,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-5.7,,BAO_0000219,,,,Autocuration,9225,,H,8,CHEMBL619942,702.0,,
3942,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.9-2.4,,BAO_0000219,,,,Autocuration,9225,,H,8,CHEMBL883711,702.0,,
3943,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.3-.8,,BAO_0000219,,,,Autocuration,9225,,H,8,CHEMBL619943,702.0,,
3944,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.46-2.63,,BAO_0000219,,,,Autocuration,9225,,H,8,CHEMBL619944,702.0,,
3945,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.3-3.5,,BAO_0000219,,,,Autocuration,9225,,H,8,CHEMBL619945,702.0,,
3946,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.8-7.1,,BAO_0000219,,,,Autocuration,9225,,H,8,CHEMBL619946,702.0,,
3947,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.0-6.4,,BAO_0000219,,,,Autocuration,9225,,H,8,CHEMBL619947,702.0,,
3948,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.9-11.6,,BAO_0000219,,,,Autocuration,9225,,H,8,CHEMBL619948,702.0,,
3949,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 7.5-11.8,,BAO_0000219,,,,Autocuration,9225,,H,8,CHEMBL619949,702.0,,
3950,1,In vitro inhibitory activity against 5-lipoxygenase from rat basophilic leukemia cells.,,BAO_0000019,,,,Expert,9401,,H,8,CHEMBL619950,,,
3951,1,In vitro inhibitory activity against 5-Lipoxygenase in rat by Peritoneal 5-lipoxygenase assay,,BAO_0000019,,,,Autocuration,10325,,H,8,CHEMBL618050,,,
3952,1,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells.,,BAO_0000219,,,,Expert,1556,,H,8,CHEMBL875091,663.0,,
3953,1,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells; Not tested,,BAO_0000219,,,,Expert,1556,,H,8,CHEMBL618051,663.0,,
3954,1,Inhibition of 5-lipoxygenase from rat basophilic leukemia(RBL-1) cells,,BAO_0000219,,Rattus norvegicus,,Expert,961,,D,9,CHEMBL618052,702.0,,
3955,1,In vitro inhibitory activity against 5-lipoxygenase in an RBL-2H3 cell lysate,,BAO_0000019,,,,Autocuration,6838,,H,8,CHEMBL618053,,,
3956,1,In vitro inhibition of 5-lipoxygenase in rat (peritoneal assay),,BAO_0000019,,,,Expert,10325,,H,8,CHEMBL618054,,,
3957,1,In vitro inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,,BAO_0000219,,Rattus norvegicus,,Expert,9209,,D,9,CHEMBL618055,702.0,,
3958,1,inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cell line.,,BAO_0000219,,,,Expert,11520,,H,8,CHEMBL618056,702.0,,
3959,1,In vitro inhibitory activity against 5-lipoxygenase was determined,,BAO_0000357,,,,Autocuration,137,,H,8,CHEMBL618057,,,
3960,1,In vitro inhibitory concentration against 5-lipoxygenase in RBL-1 cells,,BAO_0000219,,,,Autocuration,4717,,H,8,CHEMBL618058,702.0,,
3961,1,Inhibition of 5-lipoxygenase in intact RBL-1 cell line,,BAO_0000219,,,,Expert,10636,,H,8,CHEMBL618059,702.0,,
3962,1,Inhibitory activity against 5-lipoxygenase catalysis (5-LO) in sonicated rat basophilic leukemia cell lysate,,BAO_0000019,,Rattus norvegicus,,Expert,14312,,D,9,CHEMBL618060,,,
3963,1,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemia cells,,BAO_0000219,,,,Autocuration,1203,,H,8,CHEMBL618061,702.0,,
3964,1,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemic cells,,BAO_0000019,,,,Autocuration,1203,,H,8,CHEMBL618062,,,
3965,1,Inhibition of 5-lipoxygenase catalysis in rat basophilic leukemia (RBL) cells by measuring 5-HETE product formation,,BAO_0000219,,,,Expert,13622,,H,8,CHEMBL618063,702.0,,
3966,1,Inhibition of 5-lipoxygenase from rat peritoneal neutrophils after oral administration,,BAO_0000357,,,,Autocuration,9793,,H,8,CHEMBL618064,,,
3967,1,Inhibition of 5-lipoxygenase of rat basophilic leukemia (RBL) cell cytosolic enzymes,,BAO_0000219,,Rattus norvegicus,,Expert,1143,,D,9,CHEMBL618065,702.0,,
3968,1,Inhibition 5-lipoxygenase mediated LTB4 formation in rat basophilic leukemia (RBL-1) cells,,BAO_0000219,,Rattus norvegicus,,Expert,11854,,D,9,CHEMBL618066,702.0,,
3969,1,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),,BAO_0000219,,,,Autocuration,3595,,H,8,CHEMBL618067,702.0,,
3970,1,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),,BAO_0000219,,,,Autocuration,3595,,H,8,CHEMBL618068,702.0,,
3971,1,Inhibition of 5-lipoxygenase in rat RBL-1 cells,,BAO_0000219,,Rattus norvegicus,,Expert,10501,,D,9,CHEMBL618069,702.0,,
3972,1,Inhibition of 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,BAO_0000219,,,,Expert,12526,,H,8,CHEMBL618070,702.0,,
3973,1,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 32 umol/kg,Limbic system,BAO_0000019,,,,Autocuration,10034,,H,8,CHEMBL618071,,349.0,
3974,1,Compound was tested for its effects on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,Limbic system,BAO_0000019,,,,Autocuration,10034,,H,8,CHEMBL619247,,349.0,
3975,1,Approximate dose levels for a half maximal reduction of 5-HTP levels,,BAO_0000019,,,,Autocuration,10034,,H,8,CHEMBL619248,,,
3976,1,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,Hippocampus,BAO_0000221,,,,Autocuration,10046,,H,8,CHEMBL619249,,10000000.0,
3977,1,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,Hippocampus,BAO_0000221,,,,Autocuration,10046,,H,8,CHEMBL619250,,10000000.0,
3978,1,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,,BAO_0000019,,,,Autocuration,10046,,H,8,CHEMBL619251,,,
3979,1,Inhibitory concentration against human platelet 5-lipoxygenase in dog whole blood,Blood,BAO_0000019,,Canis lupus familiaris,,Autocuration,12079,,H,8,CHEMBL619252,,178.0,
3980,1,Inhibitory concentration against human platelet 5-lipoxygenase in human whole blood,Blood,BAO_0000019,,,,Autocuration,12079,,H,8,CHEMBL619253,,178.0,
3981,1,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat polymorphonuclear leukocytes[PMNS],,BAO_0000219,,,,Autocuration,11311,,H,8,CHEMBL619254,,,
3982,1,Inhibition of 5-lipoxygenase in bovine polymorphonuclear leukocytes,,BAO_0000219,,,,Expert,12338,,H,8,CHEMBL619255,,,
3983,1,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL).,,BAO_0000219,,,,Expert,12143,,H,8,CHEMBL619256,,,
3984,1,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL),,BAO_0000219,,,,Autocuration,12143,,H,8,CHEMBL875418,,,
3985,1,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,,BAO_0000219,,,,Expert,12143,,H,8,CHEMBL619257,,,
3986,1,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,,BAO_0000219,,,,Autocuration,12143,,H,8,CHEMBL619258,,,
3987,1,Inhibition of 5-lipoxygenase in bovine PMNL cell assay.,,BAO_0000357,,,,Expert,12365,,H,8,CHEMBL619259,,,
3988,1,Tested for inhibition of 5-lipoxygenase as inhibition of 5-HETE and LTB4 biosynthesis in bovine PMNL,,BAO_0000357,,,,Expert,13500,,H,8,CHEMBL619260,,,
3989,1,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",Blood,BAO_0000218,,Canis lupus familiaris,,Autocuration,12832,In vivo,H,8,CHEMBL619261,,178.0,
3990,1,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",Blood,BAO_0000218,,Canis lupus familiaris,,Autocuration,12832,In vivo,H,8,CHEMBL619263,,178.0,
3991,1,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",Blood,BAO_0000218,,Canis lupus familiaris,,Autocuration,12832,In vivo,H,8,CHEMBL619264,,178.0,
3992,1,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",Blood,BAO_0000218,,Canis lupus familiaris,,Autocuration,12832,In vivo,H,8,CHEMBL619265,,178.0,
3993,1,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",Blood,BAO_0000218,,Canis lupus familiaris,,Autocuration,12832,In vivo,H,8,CHEMBL619266,,178.0,
3994,1,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",Blood,BAO_0000218,,Canis lupus familiaris,,Autocuration,12832,In vivo,H,8,CHEMBL619902,,178.0,
3995,1,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",Blood,BAO_0000218,,Canis lupus familiaris,,Autocuration,12832,In vivo,H,8,CHEMBL620058,,178.0,
3996,1,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",Blood,BAO_0000218,,Canis lupus familiaris,,Autocuration,12832,In vivo,H,8,CHEMBL620059,,178.0,
3997,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",Blood,BAO_0000218,,Canis lupus familiaris,,Autocuration,12832,In vivo,H,8,CHEMBL620060,,178.0,
3998,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",Blood,BAO_0000218,,Canis lupus familiaris,,Autocuration,12832,In vivo,H,8,CHEMBL620061,,178.0,
3999,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 0.3 mg/kg",Blood,BAO_0000218,,Canis lupus familiaris,,Autocuration,12832,In vivo,H,8,CHEMBL620062,,178.0,
4000,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",Blood,BAO_0000218,,Canis lupus familiaris,,Autocuration,12832,In vivo,H,8,CHEMBL620063,,178.0,
4001,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 3.0 mg/kg",Blood,BAO_0000218,,Canis lupus familiaris,,Autocuration,12832,In vivo,H,8,CHEMBL620064,,178.0,
4002,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",Blood,BAO_0000218,,Canis lupus familiaris,,Autocuration,12832,In vivo,H,8,CHEMBL620065,,178.0,
4003,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 0.3 mg/kg",Blood,BAO_0000218,,Canis lupus familiaris,,Autocuration,12832,In vivo,H,8,CHEMBL620066,,178.0,
4004,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 1.0 mg/kg",Blood,BAO_0000218,,Canis lupus familiaris,,Autocuration,12832,In vivo,H,8,CHEMBL620067,,178.0,
4005,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 3.0 mg/kg",Blood,BAO_0000218,,Canis lupus familiaris,,Autocuration,12832,In vivo,H,8,CHEMBL620068,,178.0,
4006,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",Blood,BAO_0000218,,Canis lupus familiaris,,Autocuration,12832,In vivo,H,8,CHEMBL620069,,178.0,
4007,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 0.3 mg/kg",Blood,BAO_0000218,,Canis lupus familiaris,,Autocuration,12832,In vivo,H,8,CHEMBL620070,,178.0,
4008,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 1.0 mg/kg",Blood,BAO_0000218,,Canis lupus familiaris,,Autocuration,12832,In vivo,H,8,CHEMBL620071,,178.0,
4009,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 3.0 mg/kg",Blood,BAO_0000218,,Canis lupus familiaris,,Autocuration,12832,In vivo,H,8,CHEMBL620072,,178.0,
4010,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",Blood,BAO_0000218,,Canis lupus familiaris,,Autocuration,12832,In vivo,H,8,CHEMBL620036,,178.0,
4011,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 0.3 mg/kg",Blood,BAO_0000218,,Canis lupus familiaris,,Autocuration,12832,In vivo,H,8,CHEMBL857702,,178.0,
4012,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 1.0 mg/kg",Blood,BAO_0000218,,Canis lupus familiaris,,Autocuration,12832,In vivo,H,8,CHEMBL620037,,178.0,
4013,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 3.0 mg/kg",Blood,BAO_0000218,,Canis lupus familiaris,,Autocuration,12832,In vivo,H,8,CHEMBL620038,,178.0,
4014,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",Blood,BAO_0000218,,Canis lupus familiaris,,Autocuration,12832,In vivo,H,8,CHEMBL620039,,178.0,
4015,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 0.3 mg/kg",Blood,BAO_0000218,,Canis lupus familiaris,,Autocuration,12832,In vivo,H,8,CHEMBL620040,,178.0,
4016,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 1.0 mg/kg",Blood,BAO_0000218,,Canis lupus familiaris,,Autocuration,12832,In vivo,H,8,CHEMBL620041,,178.0,
4017,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 3.0 mg/kg",Blood,BAO_0000218,,Canis lupus familiaris,,Autocuration,12832,In vivo,H,8,CHEMBL620042,,178.0,
4018,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",Blood,BAO_0000218,,Canis lupus familiaris,,Autocuration,12832,In vivo,H,8,CHEMBL620043,,178.0,
4019,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 0.3 mg/kg",Blood,BAO_0000218,,Canis lupus familiaris,,Autocuration,12832,In vivo,H,8,CHEMBL620044,,178.0,
4020,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 1.0 mg/kg",Blood,BAO_0000218,,Canis lupus familiaris,,Autocuration,12832,In vivo,H,8,CHEMBL620045,,178.0,
4021,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 3.0 mg/kg",Blood,BAO_0000218,,Canis lupus familiaris,,Autocuration,12832,In vivo,H,8,CHEMBL620046,,178.0,
4022,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",Blood,BAO_0000218,,Canis lupus familiaris,,Autocuration,12832,In vivo,H,8,CHEMBL620047,,178.0,
4023,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 0.3 mg/kg",Blood,BAO_0000218,,Canis lupus familiaris,,Autocuration,12832,In vivo,H,8,CHEMBL620048,,178.0,
4024,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 1.0 mg/kg",Blood,BAO_0000218,,Canis lupus familiaris,,Autocuration,12832,In vivo,H,8,CHEMBL857703,,178.0,
4025,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 3.0 mg/kg",Blood,BAO_0000218,,Canis lupus familiaris,,Autocuration,12832,In vivo,H,8,CHEMBL620049,,178.0,
4026,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",Blood,BAO_0000218,,Canis lupus familiaris,,Autocuration,12832,In vivo,H,8,CHEMBL620050,,178.0,
4027,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",Blood,BAO_0000218,,Canis lupus familiaris,,Autocuration,12832,In vivo,H,8,CHEMBL620051,,178.0,
4028,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",Blood,BAO_0000218,,Canis lupus familiaris,,Autocuration,12832,In vivo,H,8,CHEMBL619213,,178.0,
4029,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",Blood,BAO_0000218,,Canis lupus familiaris,,Autocuration,12832,In vivo,H,8,CHEMBL619214,,178.0,
4030,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",Blood,BAO_0000218,,Canis lupus familiaris,,Autocuration,12832,In vivo,H,8,CHEMBL619804,,178.0,
4031,1,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",Blood,BAO_0000218,,Canis lupus familiaris,,Autocuration,12832,In vivo,H,8,CHEMBL619805,,178.0,
4032,1,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",Blood,BAO_0000218,,Canis lupus familiaris,,Autocuration,12832,In vivo,H,8,CHEMBL619806,,178.0,
4033,1,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",Blood,BAO_0000218,,Canis lupus familiaris,,Autocuration,12832,In vivo,H,8,CHEMBL619807,,178.0,
4034,1,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",Blood,BAO_0000218,,Canis lupus familiaris,,Autocuration,12832,In vivo,H,8,CHEMBL619808,,178.0,
4035,1,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r,,BAO_0000218,,Canis lupus familiaris,,Autocuration,3595,,H,8,CHEMBL619809,,,
4036,1,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r to canine,,BAO_0000218,,Canis lupus familiaris,,Autocuration,3595,,H,8,CHEMBL619810,,,
4037,1,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr,,BAO_0000218,,Canis lupus familiaris,,Autocuration,3595,,H,8,CHEMBL619811,,,
4038,1,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr to canine,,BAO_0000218,,Canis lupus familiaris,,Autocuration,3595,,H,8,CHEMBL620769,,,
4039,1,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr,,BAO_0000218,,Canis lupus familiaris,,Autocuration,3595,,H,8,CHEMBL620770,,,
4040,1,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr to canine,,BAO_0000218,,Canis lupus familiaris,,Autocuration,3595,,H,8,CHEMBL620771,,,
4041,1,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr,,BAO_0000218,,Canis lupus familiaris,,Autocuration,3595,,H,8,CHEMBL620772,,,
4042,1,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr to canine,,BAO_0000218,,Canis lupus familiaris,,Autocuration,3595,,H,8,CHEMBL620773,,,
4043,1,Ability to inhibit 5-lipoxygenase in guinea pig,,BAO_0000357,,Cavia porcellus,,Autocuration,9203,,H,8,CHEMBL620774,,,
4044,1,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-lipoxygenase in vitro (guinea pig PMN),,BAO_0000357,,Cavia porcellus,,Expert,82,,H,8,CHEMBL620775,,,
4045,1,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in guinea pig.,,BAO_0000357,,Cavia porcellus,,Autocuration,11090,,H,8,CHEMBL620776,,,
4046,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 12 h, following intravenous administration at the dose of 1.0 mg/kg",Blood,BAO_0000218,,Cavia porcellus,,Autocuration,12832,,H,8,CHEMBL620777,,178.0,
4047,1,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on 5-hydroxyeicosapentaenoic acid (5-HETE) production,,BAO_0000357,,Cavia porcellus,,Autocuration,1065,,H,8,CHEMBL620778,,,
4048,1,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on LTB4 production,,BAO_0000357,,Cavia porcellus,,Autocuration,1065,,H,8,CHEMBL620779,,,
4049,1,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]-AA to 5-HETE in guinea pig peritoneal polymorphonuclear leukocytes,,BAO_0000019,,Cavia porcellus,,Expert,12832,,H,8,CHEMBL621500,,,
4050,1,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,,BAO_0000019,,Cavia porcellus,,Expert,12832,,H,8,CHEMBL621501,,,
4051,1,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,,BAO_0000019,,Cavia porcellus,,Autocuration,12832,,H,8,CHEMBL618098,,,
4052,1,Inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,,BAO_0000019,,Cavia porcellus,,Autocuration,10504,,H,8,CHEMBL618099,,,
4053,1,Inhibitory activity against 5-lipoxygenase,,BAO_0000357,,Cavia porcellus,,Autocuration,7788,,H,8,CHEMBL618100,,,
4054,1,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte,,BAO_0000357,,Cavia porcellus,,Autocuration,10001,,H,8,CHEMBL618101,,,
4055,1,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant,,BAO_0000357,,Cavia porcellus,,Autocuration,10193,,H,8,CHEMBL618102,,,
4056,1,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase,,BAO_0000357,,Cavia porcellus,,Autocuration,13243,,H,8,CHEMBL618103,,,
4057,1,Inhibitory activity uM,,BAO_0000357,,Cavia porcellus,,Autocuration,13243,,H,8,CHEMBL618104,,,
4058,1,Inhibitory activity against 5-lipoxygenase in guinea pig leukocytes was determined,,BAO_0000219,,Cavia porcellus,,Autocuration,969,,H,8,CHEMBL883712,,,
4059,1,Inhibitory activity against 5-lipoxygenase at 10 uM,,BAO_0000357,,Cavia porcellus,,Autocuration,10001,,H,8,CHEMBL618105,,,
4060,1,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,,BAO_0000357,,Cavia porcellus,,Autocuration,7788,,H,8,CHEMBL618106,,,
4061,1,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte at 30 uM,,BAO_0000357,,Cavia porcellus,,Autocuration,10001,,H,8,CHEMBL618107,,,
4062,1,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,,BAO_0000357,,Cavia porcellus,,Autocuration,10193,,H,8,CHEMBL618108,,,
4063,1,Inhibitory activity uM,,BAO_0000357,,Cavia porcellus,,Autocuration,13243,,H,8,CHEMBL618109,,,
4064,1,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase at 10 uM,,BAO_0000357,,Cavia porcellus,,Autocuration,13243,,H,8,CHEMBL618110,,,
4065,1,Inhibitory activity uM,,BAO_0000357,,Cavia porcellus,,Expert,13243,,H,8,CHEMBL618111,,,
4066,1,Inhibitory activity uM,,BAO_0000019,,Cavia porcellus,,Autocuration,13243,,H,8,CHEMBL618112,,,
4067,1,Percent inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,,BAO_0000019,,Cavia porcellus,,Autocuration,10504,,H,8,CHEMBL618113,,,
4068,1,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,,BAO_0000357,,Cavia porcellus,,Autocuration,7788,,H,8,CHEMBL618114,,,
4069,1,Evaluated for inhibition of the formation and release of 5-lipoxygenase in isolated guinea pig ileum,Ileum,BAO_0000221,,Cavia porcellus,,Expert,10546,,H,8,CHEMBL620871,,2116.0,
4070,1,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,BAO_0000357,,,,Autocuration,13183,,H,8,CHEMBL620872,,,
4071,1,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,BAO_0000357,,,,Autocuration,13183,,H,8,CHEMBL620873,,,
4072,1,Compound was evaluated for in vitro inhibition of recombinant human 5-lipoxygenase (5-LO),,BAO_0000357,,,,Autocuration,2578,,H,8,CHEMBL620874,,,
4073,1,In vitro inhibition of human 5-Lipoxygenase.,,BAO_0000357,,,,Expert,12780,,H,8,CHEMBL620875,,,
4074,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,U,0,CHEMBL620876,,2107.0,
4075,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,U,0,CHEMBL620877,,2107.0,
4076,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,U,0,CHEMBL857854,,2107.0,
4077,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM exposed 100 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,U,0,CHEMBL620878,,2107.0,
4078,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,U,0,CHEMBL620879,,2107.0,
4079,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,U,0,CHEMBL620880,,2107.0,
4080,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,U,0,CHEMBL620881,,2107.0,
4081,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,U,0,CHEMBL620882,,2107.0,
4082,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,U,0,CHEMBL620883,,2107.0,
4083,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,U,0,CHEMBL620884,,2107.0,
4084,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,U,0,CHEMBL620885,,2107.0,
4085,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 27.5 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,U,0,CHEMBL620886,,2107.0,
4086,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,U,0,CHEMBL620887,,2107.0,
4087,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,U,0,CHEMBL618039,,2107.0,
4088,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,U,0,CHEMBL618040,,2107.0,
4089,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to exposed to 3-methylcholanthrene at concentration of 200 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,U,0,CHEMBL618041,,2107.0,
4090,1,"Compound was evaluated for inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,U,0,CHEMBL618216,,2107.0,
4091,1,"Compound was evaluated for inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,U,0,CHEMBL618217,,2107.0,
4092,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 100 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,U,0,CHEMBL618218,,2107.0,
4093,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 200 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,U,0,CHEMBL618219,,2107.0,
4094,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 50 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,U,0,CHEMBL618220,,2107.0,
4095,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 5 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,U,0,CHEMBL618221,,2107.0,
4096,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 50 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,U,0,CHEMBL618222,,2107.0,
4097,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,U,0,CHEMBL618223,,2107.0,
4098,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,U,0,CHEMBL618224,,2107.0,
4099,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 1 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,U,0,CHEMBL618225,,2107.0,
4100,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 20 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,U,0,CHEMBL618226,,2107.0,
4101,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,U,0,CHEMBL618227,,2107.0,
4102,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,U,0,CHEMBL618228,,2107.0,
4103,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,U,0,CHEMBL618229,,2107.0,
4104,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,U,0,CHEMBL618230,,2107.0,
4105,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,U,0,CHEMBL618231,,2107.0,
4106,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,U,0,CHEMBL618232,,2107.0,
4107,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,U,0,CHEMBL618233,,2107.0,
4108,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,U,0,CHEMBL618234,,2107.0,
4109,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,U,0,CHEMBL618235,,2107.0,
4110,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,U,0,CHEMBL618115,,2107.0,
4111,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,U,0,CHEMBL618116,,2107.0,
4112,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,U,0,CHEMBL618117,,2107.0,
4113,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,U,0,CHEMBL619968,,2107.0,
4114,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,U,0,CHEMBL619969,,2107.0,
4115,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,U,0,CHEMBL619970,,2107.0,
4116,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1000 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,U,0,CHEMBL619971,,2107.0,
4117,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1500 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,U,0,CHEMBL619972,,2107.0,
4118,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 27.5 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,U,0,CHEMBL619973,,2107.0,
4119,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 500 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,U,0,CHEMBL619974,,2107.0,
4120,1,Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,U,0,CHEMBL619975,,2107.0,
4121,1,Vmax determined by 7-ethoxycoumarin deethylation in the presence by liver microsomes from rats exposed to 3-methylcholanthrene at concentration of 10 uM,,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,U,0,CHEMBL619976,,,
4122,1,"Compound was evaluated for alpha -rate constant, in liver microsomes from 3-methylcholanthrene-exposed rats",Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,U,0,CHEMBL619977,,2107.0,
4123,1,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats",Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,U,0,CHEMBL619978,,2107.0,
4124,1,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats; competitive inhibition",Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,U,0,CHEMBL619979,,2107.0,
4125,1,"Compound was evaluated for alpha inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,U,0,CHEMBL619980,,2107.0,
4126,1,"Compound was evaluated for alpha inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,U,0,CHEMBL619981,,2107.0,
4127,1,In vitro inhibition of 7226/S myeloma cancer cell line,,BAO_0000219,,Homo sapiens,,Intermediate,10797,,N,1,CHEMBL619982,741.0,,
4128,1,In vitro antitumor activity of compound against 7404 cell line (human liver carcinoma cells),,BAO_0000219,,Homo sapiens,,Intermediate,6881,,N,1,CHEMBL619983,993.0,,
4129,1,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,,BAO_0000219,,Homo sapiens,,Intermediate,3838,,N,1,CHEMBL620031,391.0,,
4130,1,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,,BAO_0000219,,Homo sapiens,,Intermediate,3838,,N,1,CHEMBL620032,391.0,,
4131,1,Net accumulation of the [99mTc]Isonitrile complex was measured in 77A cell lines in the presence of Verapamil.,,BAO_0000219,,Cricetulus griseus,,Expert,12981,,N,1,CHEMBL620033,505.0,,
4132,1,Verapamil index represents the ratio of net uptake in the presense of verapamil over control in 77A cell lines.,,BAO_0000219,,Cricetulus griseus,,Expert,12981,,N,1,CHEMBL620034,505.0,,
4133,1,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 10 ug/mL dose,,BAO_0000219,,Rattus norvegicus,,Intermediate,7653,,N,1,CHEMBL620035,1119.0,,
4134,1,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 2 ug/mL dose,,BAO_0000219,,Rattus norvegicus,,Intermediate,7653,,N,1,CHEMBL618318,1119.0,,
4135,1,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 20 ug/mL dose,,BAO_0000219,,Rattus norvegicus,,Intermediate,7653,,N,1,CHEMBL618319,1119.0,,
4136,1,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 5 ug/mL dose,,BAO_0000219,,Rattus norvegicus,,Intermediate,7653,,N,1,CHEMBL618320,1119.0,,
4137,1,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 50 ug/mL dose,,BAO_0000219,,Rattus norvegicus,,Intermediate,7653,,N,1,CHEMBL618321,1119.0,,
4138,1,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 75 ug/mL dose,,BAO_0000219,,Rattus norvegicus,,Intermediate,7653,,N,1,CHEMBL883118,1119.0,,
4139,1,In vitro antitumor activity against renal 786-0 tumor cell lines,,BAO_0000219,,Homo sapiens,,Intermediate,17229,,N,1,CHEMBL883795,391.0,,
4140,1,Cytotoxic activity against 786-0 Renal cancer cell line,,BAO_0000219,,Homo sapiens,,Intermediate,12858,,N,1,CHEMBL618322,391.0,,
4141,1,Growth inhibitory activity was determined against 786-0 cancer cell line of Renal cancer,,BAO_0000219,,Homo sapiens,,Intermediate,16325,,N,1,CHEMBL618323,391.0,,
4142,1,Growth inhibitory activity was determined against 786-0 cancer cell line of renal cancer,,BAO_0000219,,Homo sapiens,,Intermediate,16325,,N,1,CHEMBL618324,391.0,,
4143,1,In vitro antitumor activity against human renal 786-0 cell line,,BAO_0000219,,Homo sapiens,,Intermediate,5858,,N,1,CHEMBL618325,391.0,,
4144,1,Inhibition of Renal cancer in 786-0 cancer cell lines,,BAO_0000219,,Homo sapiens,,Intermediate,16325,,N,1,CHEMBL875416,391.0,,
4145,1,Inhibition of the growth of renal cancer(786-0) cell line. value in parentheses is percent inhibition at 0.01 uM,,BAO_0000219,,Homo sapiens,,Intermediate,14696,,N,1,CHEMBL618326,391.0,,
4146,1,The compound was tested for its cytotoxic activity against the following renal cancer cell lines 786-0,,BAO_0000219,,Homo sapiens,,Intermediate,3786,,N,1,CHEMBL618327,391.0,,
4147,1,inhibition of the growth of renal cancer(786-0) cell line,,BAO_0000219,,Homo sapiens,,Intermediate,14696,,N,1,CHEMBL619215,391.0,,
4148,1,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),,BAO_0000219,,Homo sapiens,,Intermediate,14769,,N,1,CHEMBL619216,391.0,,
4149,1,Compound was tested for the growth inhibition of 786-0 renal tumor cell line,,BAO_0000219,,Homo sapiens,,Intermediate,15354,,N,1,CHEMBL619217,391.0,,
4150,1,The IC50 value was measured on 786-0 cell line in ovarian tumor,,BAO_0000219,,Homo sapiens,,Intermediate,14255,,N,1,CHEMBL619218,391.0,,
4151,1,The IC50 value was measured on 786-0 cell line in ovarian tumor t,,BAO_0000219,,Homo sapiens,,Intermediate,14255,,N,1,CHEMBL619219,391.0,,
4152,1,The IC50 value was measured on 786-0 cell line in renal tumor type.,,BAO_0000219,,Homo sapiens,,Intermediate,14255,,N,1,CHEMBL619220,391.0,,
4153,1,Inhibition of the growth of renal cancer(786-0) cell line at 0.01 uM,,BAO_0000219,,Homo sapiens,,Intermediate,14696,,N,1,CHEMBL619221,391.0,,
4154,1,Tested for cytotoxic activity against renal cancer 786-0 cell line,,BAO_0000219,,Homo sapiens,,Intermediate,12016,,N,1,CHEMBL619222,391.0,,
4155,1,Compound was tested for growth inhibitory activity against 786-0 cell line,,BAO_0000219,,Homo sapiens,,Intermediate,2597,,N,1,CHEMBL857454,391.0,,
4156,1,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; Inactive(N)= <50% inhibition at 10 uM,,BAO_0000219,,,,Autocuration,12526,,H,8,CHEMBL619223,702.0,,
4157,1,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; N=Inactive,,BAO_0000219,,,,Autocuration,12526,,H,8,CHEMBL619224,702.0,,
4158,1,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,,BAO_0000019,,,,Autocuration,14799,,H,8,CHEMBL619225,,,
4159,1,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),,BAO_0000219,,,,Expert,3595,,H,8,CHEMBL619226,702.0,,
4160,1,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),,BAO_0000219,,,,Expert,3595,,H,8,CHEMBL619227,702.0,,
4161,1,Inhibitory activity against rat basophilic leukemia 5-lipoxygenase,,BAO_0000357,,,,Autocuration,12767,,H,8,CHEMBL619228,,,
4162,1,Inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes,,BAO_0000219,,,,Autocuration,10997,,H,8,CHEMBL619229,,,
4163,1,Inhibitory activity against 5-lipoxygenase of RBL-1 cell line,,BAO_0000219,,,,Autocuration,11388,,H,8,CHEMBL619230,702.0,,
4164,1,Inhibitory activity against RBL broken cell-supematant 5-lipoxygenase was evaluated,,BAO_0000357,,,,Autocuration,167,,H,8,CHEMBL619231,,,
4165,1,"Inhibitory activity against intact rat PMNL, LTB4 5-lipoxygenase was evaluated",,BAO_0000357,,,,Autocuration,167,,H,8,CHEMBL619232,,,
4166,1,Inhibitory activity against rat 5-lipoxygenase by using continuous oxygen consumption assay.,,BAO_0000357,,,,Expert,13744,,H,8,CHEMBL619233,,,
4167,1,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase,,BAO_0000357,,,,Autocuration,1630,,H,8,CHEMBL619234,,,
4168,1,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase (5-LO),,BAO_0000357,,,,Autocuration,1630,,H,8,CHEMBL619235,,,
4169,1,"Inhibitory activity against 5-lipoxygenase in rat neutrophils as inhibition of A 23,187-induced LTB4 production",,BAO_0000019,,Rattus norvegicus,,Expert,969,,D,9,CHEMBL619236,,,
4170,1,Inhibitory concentration against 5-lipoxygenase in rat RBL-1 cells,,BAO_0000219,,,,Autocuration,13621,,H,8,CHEMBL619237,702.0,,
4171,1,Inhibitory concentration to inhibit 5-lipoxygenase in the rat,,BAO_0000357,,,,Autocuration,10089,,H,8,CHEMBL619238,,,
4172,1,In vitro inhibition of rat polymorphonuclear leukocyte 5-lipoxygenase,,BAO_0000357,,,,Expert,10193,,H,8,CHEMBL619239,,,
4173,1,Tested for inhibition of 5-HPETE production by rat 5-LO; value ranges from 16-36 nM,,BAO_0000357,,,,Autocuration,11966,,H,8,CHEMBL619240,,,
4174,1,Tested for inhibition of 5-LO by measuring the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,,BAO_0000019,,,,Autocuration,12251,,H,8,CHEMBL875417,,,
4175,1,Tested for inhibition of 5-Lipoxygenase (ARBL) in calcium-stimulated rat basophilic leukemia cells(RBL-1),,BAO_0000219,,,,Autocuration,211,,H,8,CHEMBL619241,702.0,,
4176,1,Inhibition of 5-lipoxygenase measured by the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,,BAO_0000019,,,,Expert,12251,,H,8,CHEMBL619242,,,
4177,1,Tested for inhibitory activity against 5-lipoxygenase in microsome of RBL-1 cells,,BAO_0000219,,,,Autocuration,12495,,H,8,CHEMBL883796,702.0,,
4178,1,Tested for its inhibitory activity against 5-lipoxygenase,,BAO_0000357,,,,Autocuration,414,,H,8,CHEMBL619243,,,
4179,1,Tested for its inhibitory activity against 5-lipoxygenase; Not determined,,BAO_0000357,,,,Autocuration,414,,H,8,CHEMBL619244,,,
4180,1,"Iin vitro inhibition of 5-lipoxygenase activity in rat basophil leukemia type 1(RBL1) cell homogenates, (reduction of [14C]-5-HETE formation)",,BAO_0000019,,,,Expert,10325,,H,8,CHEMBL619245,,,
4181,1,In vitro test for inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,,BAO_0000019,,,,Expert,11966,,H,8,CHEMBL619246,,,
4182,1,In vitro inhibition of 5-lipoxygenase activity in RBL-1 cells.,,BAO_0000219,,,,Expert,165,,H,8,CHEMBL619984,702.0,,
4183,1,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells; No significant inhibitory activity up to 30 uM,,BAO_0000219,,,,Autocuration,165,,H,8,CHEMBL619985,702.0,,
4184,1,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,,BAO_0000219,,,,Autocuration,165,,H,8,CHEMBL619986,702.0,,
4185,1,In vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,,BAO_0000219,,,,Expert,165,,H,8,CHEMBL619987,702.0,,
4186,1,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse,,BAO_0000218,,,,Autocuration,11311,,H,8,CHEMBL619988,,,
4187,1,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1,,BAO_0000219,,,,Autocuration,11311,,H,8,CHEMBL619989,702.0,,
4188,1,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,,BAO_0000219,,,,Autocuration,11311,,H,8,CHEMBL619990,702.0,,
4189,1,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS],,BAO_0000219,,,,Autocuration,11311,,H,8,CHEMBL619991,,,
4190,1,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vitro),,BAO_0000219,,,,Autocuration,11311,,H,8,CHEMBL619992,,,
4191,1,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vivo),,BAO_0000218,,,,Autocuration,11311,In vivo,H,8,CHEMBL619993,,,
4192,1,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in RBL-2H3 cells,,BAO_0000219,,,,Autocuration,11311,,H,8,CHEMBL619994,663.0,,
4193,1,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in rat RBL-2H3 cells,,BAO_0000219,,,,Autocuration,11311,,H,8,CHEMBL619995,663.0,,
4194,1,The compound was tested for inhibitory activity against 5-lipoxygenase using rat polymorphonuclear leukocytes[PMNS],,BAO_0000019,,,,Autocuration,11311,,H,8,CHEMBL619996,,,
4195,1,The compound was tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase,,BAO_0000019,,,,Autocuration,11732,,H,8,CHEMBL619997,,,
4196,1,Tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase.,,BAO_0000019,,,,Expert,11732,,H,8,CHEMBL619998,,,
4197,1,In vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells,,BAO_0000019,,,,Expert,11087,,H,8,CHEMBL619999,,,
4198,1,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells,,BAO_0000019,,,,Autocuration,11087,,H,8,CHEMBL620000,,,
4199,1,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in homogenized rat basophilic leukemia (RBL-1) cells,,BAO_0000219,,,,Autocuration,11087,,H,8,CHEMBL620001,702.0,,
4200,1,Inhibition of 5-lipoxygenase (5-lo) in intact rat polymorphonuclear leukocyte RPMNL,,BAO_0000357,,Rattus norvegicus,,Expert,11087,,D,9,CHEMBL620002,,,
4201,1,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells,,BAO_0000219,,,,Autocuration,496,,H,8,CHEMBL620003,702.0,,
4202,1,Inhibition of 5-lipoxygenase on rat basophil leukemia cell line lysate (RBL-1 2H3 subline) by measuring 5-HETE production,,BAO_0000219,,,,Expert,13986,,H,8,CHEMBL620004,702.0,,
4203,1,Compound was evaluated for the inhibition of 5-lipoxygenase,,BAO_0000357,,,,Autocuration,11520,,H,8,CHEMBL874063,,,
4204,1,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line at a concentration of 25 uM,,BAO_0000219,,,,Autocuration,10293,,H,8,CHEMBL620005,702.0,,
4205,1,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay,,BAO_0000219,,,,Autocuration,303,,H,8,CHEMBL620006,702.0,,
4206,1,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay; Less than 5% inhibition at 10 uM reported as not active,,BAO_0000219,,,,Autocuration,303,,H,8,CHEMBL620007,702.0,,
4207,1,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 10 uM,,BAO_0000219,,,,Autocuration,9247,,H,8,CHEMBL620008,702.0,,
4208,1,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM,,BAO_0000219,,Rattus norvegicus,,Expert,9247,,D,9,CHEMBL620009,702.0,,
4209,1,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,,BAO_0000219,,,,Autocuration,9247,,H,8,CHEMBL620010,702.0,,
4210,1,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 30 uM,,BAO_0000219,,,,Autocuration,9247,,H,8,CHEMBL620011,702.0,,
4211,1,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 300 uM,,BAO_0000219,,,,Autocuration,9247,,H,8,CHEMBL620677,702.0,,
4212,1,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 33 uM,,BAO_0000219,,,,Autocuration,9247,,H,8,CHEMBL620678,702.0,,
4213,1,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 40 uM,,BAO_0000219,,,,Autocuration,9247,,H,8,CHEMBL620679,702.0,,
4214,1,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 75 uM,,BAO_0000219,,,,Autocuration,9247,,H,8,CHEMBL620680,702.0,,
4215,1,Inhibitory activity against 5-lipoxygenase at 10 uM,,BAO_0000357,,Rattus norvegicus,,Expert,11481,,D,9,CHEMBL620838,,,
4216,1,In vitro inhibition of 5-lipoxygenase; NS means no significant inhibition,,BAO_0000357,,,,Autocuration,105,,H,8,CHEMBL620839,,,
4217,1,In vitro inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase at 10 uM,,BAO_0000357,,,,Expert,9029,,H,8,CHEMBL620840,,,
4218,1,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells at 20 uM,,BAO_0000219,,,,Expert,1175,,H,8,CHEMBL620841,702.0,,
4219,1,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 100 uM,,BAO_0000219,,,,Autocuration,12118,,H,8,CHEMBL620842,702.0,,
4220,1,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 10e-4 M,,BAO_0000219,,,,Autocuration,12118,,H,8,CHEMBL620843,702.0,,
4221,1,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determinedb at 100 uM,,BAO_0000219,,,,Autocuration,12118,,H,8,CHEMBL620844,702.0,,
4222,1,In vitro inhibition of RBL-1 5-lipoxygenase at 20 uM,,BAO_0000219,,,,Autocuration,9225,,H,8,CHEMBL620845,702.0,,
4223,1,In vitro inhibitory activity against 5-Lipoxygenase from rat basophilic leukemia cells at 30 uM concentration,,BAO_0000019,,,,Autocuration,9401,,H,8,CHEMBL620846,,,
4224,1,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,,BAO_0000357,,,,Autocuration,137,,H,8,CHEMBL873951,,,
4225,1,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,,BAO_0000357,,,,Autocuration,137,,H,8,CHEMBL620847,,,
4226,1,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,,BAO_0000219,,,,Autocuration,4717,,H,8,CHEMBL620848,702.0,,
4227,1,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,,BAO_0000219,,,,Autocuration,3595,,H,8,CHEMBL620849,702.0,,
4228,1,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at 40 uM concentration,,BAO_0000219,,,,Autocuration,10501,,H,8,CHEMBL620850,702.0,,
4229,1,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM,,BAO_0000219,,,,Autocuration,10501,,H,8,CHEMBL620851,702.0,,
4230,1,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM.,,BAO_0000219,,,,Autocuration,10501,,H,8,CHEMBL620852,702.0,,
4231,1,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,BAO_0000219,,,,Autocuration,12526,,H,8,CHEMBL875098,702.0,,
4232,1,Inhibition of 5-lipoxygenase of rat basophilic leukemia cells at 30 uM,,BAO_0000219,,Rattus norvegicus,,Expert,14799,,D,9,CHEMBL620853,702.0,,
4233,1,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells at 30 uM concentration; NT=Not tested,,BAO_0000019,,,,Autocuration,14799,,H,8,CHEMBL620854,,,
4234,1,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,,BAO_0000219,,,,Autocuration,3595,,H,8,CHEMBL620855,702.0,,
4235,1,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,,BAO_0000219,,,,Expert,3595,,H,8,CHEMBL839884,702.0,,
4236,1,Inhibitory activity at 10 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,BAO_0000219,,,,Autocuration,12526,,H,8,CHEMBL620856,702.0,,
4237,1,Inhibitory activity at 1 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,BAO_0000219,,,,Autocuration,12526,,H,8,CHEMBL620857,702.0,,
4238,1,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,,BAO_0000019,,,,Autocuration,10193,,H,8,CHEMBL620858,,,
4239,1,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,,BAO_0000019,,,,Autocuration,10193,,H,8,CHEMBL620859,,,
4240,1,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,,BAO_0000019,,,,Autocuration,10193,,H,8,CHEMBL620860,,,
4241,1,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 3 uM,,BAO_0000019,,,,Autocuration,10193,,H,8,CHEMBL620861,,,
4242,1,Percent inhibition of rat neutrophil 5-lipoxygenase (5-LO),,BAO_0000357,,,,Expert,9138,,H,8,CHEMBL620862,,,
4243,1,Percent inhibition of rat neutrophil 5- Lipoxygenase (5-LO) at 100 uM,,BAO_0000357,,,,Autocuration,9138,,H,8,CHEMBL620863,,,
4244,1,Tested in vitro for the inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,,BAO_0000019,,,,Autocuration,11966,,H,8,CHEMBL620864,,,
4245,1,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 100 uM,,BAO_0000219,,,,Autocuration,165,,H,8,CHEMBL620865,702.0,,
4246,1,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 30 uM,,BAO_0000219,,,,Autocuration,165,,H,8,CHEMBL620866,702.0,,
4247,1,The compound was tested for inhibition of 5-lipoxygenase in rat RBL-2H3 cells,,BAO_0000219,,,,Autocuration,11311,,H,8,CHEMBL620867,663.0,,
4248,1,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,,BAO_0000219,,,,Autocuration,11311,,H,8,CHEMBL620868,663.0,,
4249,1,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,,BAO_0000219,,,,Autocuration,11311,,H,8,CHEMBL620869,663.0,,
4250,1,The compound was tested for inhibition of LTB4 synthesis on isolated 5-lipoxygenase,,BAO_0000019,,,,Autocuration,11311,,H,8,CHEMBL873952,,,
4251,1,The compound was tested for inhibition of isolated 5-lipoxygenase,,BAO_0000357,,,,Autocuration,11311,,H,8,CHEMBL875099,,,
4252,1,The compound was tested for inhibition of isolated 5-lipoxygenase translocation into rat RBL-2H3 cells,,BAO_0000219,,,,Autocuration,11311,,H,8,CHEMBL620870,663.0,,
4253,1,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 30 uM,,BAO_0000019,,,,Autocuration,11087,,H,8,CHEMBL618261,,,
4254,1,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 32 uM,,BAO_0000019,,,,Autocuration,11087,,H,8,CHEMBL618262,,,
4255,1,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells measured at a concentration of 30 uM,,BAO_0000019,,,,Autocuration,11087,,H,8,CHEMBL619428,,,
4256,1,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,,BAO_0000019,,,,Autocuration,11087,,H,8,CHEMBL619429,,,
4257,1,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,,BAO_0000019,,,,Autocuration,11087,,H,8,CHEMBL619430,,,
4258,1,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 1.0 uM,,BAO_0000219,,,,Autocuration,496,,H,8,CHEMBL620017,702.0,,
4259,1,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 10 uM,,BAO_0000219,,,,Autocuration,496,,H,8,CHEMBL620018,702.0,,
4260,1,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.1 uM,,BAO_0000219,,,,Autocuration,13986,,H,8,CHEMBL620019,702.0,,
4261,1,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.195 uM,,BAO_0000219,,,,Autocuration,13986,,H,8,CHEMBL620020,702.0,,
4262,1,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.2 at uM,,BAO_0000219,,,,Autocuration,13986,,H,8,CHEMBL620021,702.0,,
4263,1,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.25 uM,,BAO_0000219,,,,Autocuration,13986,,H,8,CHEMBL620022,702.0,,
4264,1,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39,,BAO_0000219,,,,Autocuration,13986,,H,8,CHEMBL620023,702.0,,
4265,1,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39 uM,,BAO_0000219,,,,Autocuration,13986,,H,8,CHEMBL620024,702.0,,
4266,1,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.195 uM,,BAO_0000219,,,,Autocuration,13986,,H,8,CHEMBL620025,702.0,,
4267,1,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.2 uM,,BAO_0000219,,,,Autocuration,13986,,H,8,CHEMBL620026,702.0,,
4268,1,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.39 uM,,BAO_0000219,,,,Autocuration,13986,,H,8,CHEMBL620027,702.0,,
4269,1,Inhibition of 5-lipoxygenase on rat basophil leukemia cell (RBL-2H3) lysate as 5-HETE production at 32 uM,,BAO_0000019,,Rattus norvegicus,,Expert,13986,,D,9,CHEMBL620028,,,
4270,1,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase,,BAO_0000357,,,,Autocuration,10193,,H,8,CHEMBL620029,,,
4271,1,Compound was tested for the percent of inhibition against 5-LO at 10 uM,,BAO_0000357,,,,Autocuration,9295,,H,8,CHEMBL620030,,,
4272,1,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 1 uM concentration,,BAO_0000219,,,,Autocuration,4717,,H,8,CHEMBL875415,702.0,,
4273,1,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,,BAO_0000219,,,,Autocuration,4717,,H,8,CHEMBL618256,702.0,,
4274,1,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line,,BAO_0000219,,,,Autocuration,11854,,H,8,CHEMBL618257,702.0,,
4275,1,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 10 uM,,BAO_0000219,,,,Autocuration,11854,,H,8,CHEMBL618258,702.0,,
4276,1,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 16 uM,,BAO_0000219,,,,Autocuration,11854,,H,8,CHEMBL618259,702.0,,
4277,1,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,,BAO_0000019,,,,Autocuration,10193,,H,8,CHEMBL618260,,,
4278,1,Percent inhibition against RBL-1 5-LO in vitro at 10 uM,,BAO_0000219,,,,Autocuration,9295,,H,8,CHEMBL618215,702.0,,
4279,1,Percent inhibition against RBL-1 5-LO in vitro at 100 uM,,BAO_0000219,,,,Autocuration,9295,,H,8,CHEMBL618390,702.0,,
4280,1,Percent inhibition against RBL-1 5-LO in vitro at 30 uM,,BAO_0000219,,,,Autocuration,9295,,H,8,CHEMBL618391,702.0,,
4281,1,Percent inhibition against RBL-1 5-LO in vitro at 300 uM,,BAO_0000219,,,,Autocuration,9295,,H,8,CHEMBL618392,702.0,,
4282,1,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 20 uM,,BAO_0000219,,,,Autocuration,165,,H,8,CHEMBL618393,702.0,,
4283,1,The compound was tested for inhibition against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] at 10 uM concentration,,BAO_0000219,,,,Autocuration,11311,,H,8,CHEMBL618394,,,
4284,1,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),,BAO_0000219,,Homo sapiens,,Expert,10489,,H,8,CHEMBL618395,702.0,,
4285,1,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),,BAO_0000219,,Rattus norvegicus,,Expert,10489,,D,9,CHEMBL618396,702.0,,
4286,1,Logarithmic value of inhibitory concentration against 5-lipoxygenase in rat basophilic leukemia cells (RBL-1),,BAO_0000219,,Rattus norvegicus,,Expert,10489,,D,9,CHEMBL858253,702.0,,
4287,1,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,,BAO_0000019,,Rattus norvegicus,,Autocuration,14799,,D,9,CHEMBL618397,,,
4288,1,Compound was tested for the percent of inhibition against soybean 15-LO (at 100 uM),,BAO_0000357,,Glycine max,,Autocuration,9295,,H,8,CHEMBL618398,,,
4289,1,"Inhibitory activity against 5-lipoxygenase, by using soybean lipoxygenase spectrophotometric assay",,BAO_0000019,,,,Autocuration,16811,,U,0,CHEMBL618399,,,
4290,1,In vitro inhibition of 5-Lipoxygenase; Inactive.,,BAO_0000357,,,,Expert,168,,H,8,CHEMBL618400,,,
4291,1,Inhibitory concentration against 5-lipoxygenase was determined; No inhibition,,BAO_0000357,,,,Autocuration,6309,,H,8,CHEMBL618401,,,
4292,1,Inhibitory concentration against 5-lipoxygenase; No inhibition,,BAO_0000357,,,,Autocuration,6309,,H,8,CHEMBL618402,,,
4293,1,Evaluated for inhibitory activity against RBL-1 cell 5-lipoxygenase in guinea pig,,BAO_0000219,,,,Autocuration,3092,,H,8,CHEMBL876400,702.0,,
4294,1,Inhibitory activity against 5-lipoxygenase.,,BAO_0000357,,,,Expert,168,,H,8,CHEMBL618403,,,
4295,1,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive,,BAO_0000357,,,,Autocuration,168,,H,8,CHEMBL618404,,,
4296,1,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive at concentrations less than 32 uM,,BAO_0000357,,,,Autocuration,168,,H,8,CHEMBL618405,,,
4297,1,Inhibitory Activity against 5-Lipoxygenase was determined; NA=No significant inhibitory activity up to 300 uM,,BAO_0000357,,,,Autocuration,168,,H,8,CHEMBL618406,,,
4298,1,Inhibitory concentration against arachidonic acid 5-lipoxygenation,,BAO_0000019,,,,Expert,12338,,H,8,CHEMBL618407,,,
4299,1,Tested for the inhibitory activity against 5-lipoxygenase,,BAO_0000357,,,,Autocuration,4501,,H,8,CHEMBL618408,,,
4300,1,Compound was tested for its inhibitory activity against 5-lipoxygenase,,BAO_0000357,,,,Autocuration,1132,,H,8,CHEMBL618409,,,
4301,1,Compound was tested for inhibition of 5-lipoxygenase at 50 uM; NI means no inhibition was observed,,BAO_0000357,,,,Autocuration,2117,,H,8,CHEMBL618410,,,
4302,1,Inhibitory Activity against 5-Lipoxygenase at 30 uM was determined; Weakly active,,BAO_0000357,,,,Autocuration,168,,H,8,CHEMBL618411,,,
4303,1,Inhibitory Activity against 5-Lipoxygenase at concentration 32 uM was determined,,BAO_0000357,,,,Autocuration,168,,H,8,CHEMBL618412,,,
4304,1,Concentration required to inhibit RBL-1 supernatant 5-lipoxygenase,,BAO_0000219,,,,Autocuration,13575,,H,8,CHEMBL618413,702.0,,
4305,1,,,BAO_0000357,,,,Autocuration,11089,,H,8,CHEMBL618414,,,
4306,1,Compound was tested for its binding activity towards 5-lipoxygenase activating protein (FLAP),,BAO_0000357,,,,Autocuration,216,,H,8,CHEMBL618415,,,
4307,1,Inhibition of 5-lipoxygenase activating protein using human leukocyte membrane preparations,,BAO_0000019,,,,Autocuration,13165,,H,8,CHEMBL618416,,,
4308,1,Measuring the affinity of leukotriene synthesis inhibitor for 5-Lipoxygenase activating protein (FLAP) by using [125I]L-691831 as radioligand.,,BAO_0000357,,,,Autocuration,3278,,H,8,CHEMBL876401,,,
4309,1,Measuring the affinity of leukotriene synthesis inhibitor for 5-lipoxygenase activating protein by using [125I]L-691831 as radioligand.,,BAO_0000357,,,,Expert,3278,,H,8,CHEMBL618417,,,
4310,1,Tested for inhibition of leukotriene biosynthesis by binding to 5-lipoxygenase activating protein,,BAO_0000357,,,,Autocuration,11966,,H,8,CHEMBL618418,,,
4311,1,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein",,BAO_0000357,,,,Autocuration,175,,H,8,CHEMBL618419,,,
4312,1,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein (FLAP)",,BAO_0000357,,,,Autocuration,175,,H,8,CHEMBL618420,,,
4313,1,Binding affinity of compound for 5-lipoxygenase activating protein protein by FLAP binding assay,,BAO_0000357,,,,Autocuration,13449,,H,8,CHEMBL618421,,,
4314,1,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane,,BAO_0000019,,,,Autocuration,12014,,H,8,CHEMBL618422,,,
4315,1,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (R metabolically resistant),,BAO_0000019,,,,Autocuration,12014,,H,8,CHEMBL618423,,,
4316,1,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (S substrate),,BAO_0000019,,,,Autocuration,12014,,H,8,CHEMBL618424,,,
4317,1,Inhibition of protein biosynthesis at the level of the peptidyl transferase center of the 50 s ribosomal subunit,,BAO_0000220,,,,Intermediate,99,,S,2,CHEMBL618425,,,
4318,1,The dark toxicity against 543 human galactophore carcinoma cells,,BAO_0000019,,Homo sapiens,,Autocuration,4349,,U,0,CHEMBL618426,,,
4319,1,Tested in vitro for cytotoxicity against 56 human tumor cell lines,,BAO_0000219,,Homo sapiens,,Expert,4071,,N,1,CHEMBL618427,390.0,,
4320,1,Cytotoxic activity against human 5637 cell line at 20 uM expressed as percent growth value,,BAO_0000219,,Homo sapiens,,Expert,17589,,N,1,CHEMBL618428,345.0,,
4321,1,Antitumor activity was evaluated against human bladder carcinoma cell line 5637.,,BAO_0000219,,Homo sapiens,,Intermediate,15002,,N,1,CHEMBL618429,345.0,,
4322,1,"Compound was tested for antiproliferative activity against 5637, human bladder carcinoma cell line",,BAO_0000219,,Homo sapiens,,Intermediate,13958,,N,1,CHEMBL618430,345.0,,
4323,1,Growth inhibition against human 5637 cell lines,,BAO_0000219,,Homo sapiens,,Expert,17589,,N,1,CHEMBL618431,345.0,,
4324,1,Antitumor activity against human bladder carcinoma 5637 cells.,,BAO_0000219,,Homo sapiens,,Expert,16748,,N,1,CHEMBL883799,345.0,,
4325,1,Antitumor activity against human bladder carcinoma 5637 cells,,BAO_0000219,,Homo sapiens,,Intermediate,16747,,N,1,CHEMBL618432,345.0,,
4326,1,Antitumor activity against human bladder carcinoma 5637 cells,,BAO_0000219,,Homo sapiens,,Intermediate,16747,,N,1,CHEMBL618433,345.0,,
4327,1,In vitro inhibition of bovine trypsin(Trp).,,BAO_0000357,,Bos taurus,,Expert,15285,,D,9,CHEMBL618434,,,
4328,1,Transcriptional activation in CV-1 cells expressing retinoic acid gamma receptor,,BAO_0000219,,Cercopithecidae,,Expert,3726,,H,8,CHEMBL618435,407.0,,
4329,1,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-HT1B receptor,,BAO_0000357,,,,Autocuration,5033,,H,8,CHEMBL876402,,,
4330,1,In vitro antagonism of the 5-HT-3 receptor determined by inhibition of 5-HT-induced depolarization of the isolated rat vagus nerve.,,BAO_0000019,,,,Autocuration,11756,,H,6,CHEMBL618436,,,
4331,1,Concentration required to inhibit pressor response to serotonin after 15 min i.v. administration of compound mediated via activation of vascular 5-HT2 receptors in rat,,BAO_0000218,,,,Autocuration,11953,In vivo,U,0,CHEMBL618437,,,
4332,1,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-HT4 receptor,,BAO_0000357,,Cavia porcellus,,Intermediate,5033,,D,9,CHEMBL618438,,,
4333,1,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,,BAO_0000251,,Rattus norvegicus,,Expert,11347,,H,8,CHEMBL883800,,,
4334,1,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,,BAO_0000251,,Rattus norvegicus,,Expert,11347,,H,8,CHEMBL618439,,,
4335,1,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,,BAO_0000019,,,,Intermediate,1229,,U,0,CHEMBL618440,,,
4336,1,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,,BAO_0000019,,,,Intermediate,1229,,U,0,CHEMBL618441,,,
4337,1,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli,,BAO_0000019,,Trypanosoma brucei,,Expert,17588,,H,8,CHEMBL618442,,,
4338,1,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli; NI denotes no inhibition,,BAO_0000019,,Trypanosoma brucei,,Autocuration,17588,,H,8,CHEMBL618443,,,
4339,1,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver,,BAO_0000019,,Ovis aries,,Expert,17588,,H,8,CHEMBL619158,,,
4340,1,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver; NI denotes no inhibition,,BAO_0000019,,Ovis aries,,Autocuration,17588,,H,8,CHEMBL620974,,,
4341,1,log Kd which is the binding affinity against 6-phosphogluconate dehydrogenase,,BAO_0000357,,,,Autocuration,16485,,H,8,CHEMBL620975,,,
4342,1,Average inhibitory concentration against 60 human cell lines was reported,,BAO_0000019,,Homo sapiens,,Intermediate,4337,,U,0,CHEMBL620976,,,
4343,1,Inhibition of proliferation in NCI panel of 60 human tumor cell lines,,BAO_0000019,,Homo sapiens,,Expert,4112,,U,0,CHEMBL620977,,,
4344,1,Cancer specificity was measured from the +/- value under average log LC50 60-cell line,,BAO_0000219,,Homo sapiens,,Intermediate,16160,,N,1,CHEMBL620978,542.0,,
4345,1,Cancer specificity was measured from the +/- value under average log LC50 60-cell line. ,,BAO_0000219,,Homo sapiens,,Intermediate,16160,,N,1,CHEMBL620979,542.0,,
4346,1,In vitro mean growth inhibitory activity against 60-cell panel,,BAO_0000219,,,,Expert,17376,,N,1,CHEMBL620980,542.0,,
4347,1,In vitro mean growth lethal concentration against 60-cell panel,,BAO_0000219,,,,Expert,17376,,N,1,CHEMBL620981,542.0,,
4348,1,In vitro mean growth lethal concentration in colon subpanel against 60-cell panel,,BAO_0000219,,,,Expert,17376,,N,1,CHEMBL620982,542.0,,
4349,1,In vitro mean growth lethal concentration in renal subpanel against 60-cell panel,,BAO_0000219,,,,Expert,17376,,N,1,CHEMBL620983,542.0,,
4350,1,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,,BAO_0000019,,,,Autocuration,3241,,H,4,CHEMBL620984,,,
4351,1,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,,BAO_0000019,,,,Autocuration,3241,,H,4,CHEMBL620985,,,
4352,1,Transcriptional activation in CV-1 expressing retinoid X receptor RXR alpha,,BAO_0000357,,,,Expert,3725,,H,8,CHEMBL620986,,,
4353,1,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase,,BAO_0000218,,Plasmodium falciparum,,Expert,10805,,N,1,CHEMBL620987,,,
4354,1,In vitro inhibition of Plasmodium falciparum 68 neutral proteinase activity by reinvasion of red blood cells,,BAO_0000218,,Plasmodium falciparum,,Expert,10805,,N,1,CHEMBL620988,,,
4355,1,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase.,,BAO_0000218,,Plasmodium falciparum,,Expert,10805,,N,1,CHEMBL620989,,,
4356,1,Substrate affinity for Plasmodium falciparum 68 neutral proteinase.,,BAO_0000218,,Plasmodium falciparum,,Expert,10805,,N,1,CHEMBL620990,,,
4357,1,Reaction velocity for Plasmodium falciparum 68 neutral proteinase.,,BAO_0000218,,Plasmodium falciparum,,Intermediate,10805,,N,1,CHEMBL620991,,,
4358,1,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,,BAO_0000218,,Mus musculus,,Intermediate,10144,,N,1,CHEMBL620992,850.0,,
4359,1,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,,BAO_0000218,,Mus musculus,,Intermediate,10144,,N,1,CHEMBL620993,850.0,,
4360,1,Percent inhibition against 6C3HED lymphosarcoma at dose 200 mg/kg in C3H mice,,BAO_0000218,,Mus musculus,,Intermediate,10144,,N,1,CHEMBL620994,850.0,,
4361,1,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,,BAO_0000218,,Mus musculus,,Intermediate,10144,,N,1,CHEMBL620995,850.0,,
4362,1,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,,BAO_0000218,,Mus musculus,,Intermediate,10144,,N,1,CHEMBL620996,850.0,,
4363,1,Percent inhibition against 6C3HED lymphosarcoma at dose 6 mg/kg in C3H mice,,BAO_0000218,,Mus musculus,,Intermediate,10144,,N,1,CHEMBL875581,850.0,,
4364,1,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 100 mg/kg,,BAO_0000218,,Mus musculus,,Autocuration,10685,In vivo,U,0,CHEMBL620997,,,
4365,1,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 150 mg/kg,,BAO_0000218,,Mus musculus,,Autocuration,10685,In vivo,U,0,CHEMBL620998,,,
4366,1,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 1600 mg/kg (intraperitoneal dosing for 8 days),,BAO_0000218,,Mus musculus,,Autocuration,10685,In vivo,U,0,CHEMBL620999,,,
4367,1,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 200 mg/kg,,BAO_0000218,,Mus musculus,,Autocuration,10685,In vivo,U,0,CHEMBL621000,,,
4368,1,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 225 mg/kg,,BAO_0000218,,Mus musculus,,Autocuration,10685,In vivo,U,0,CHEMBL621001,,,
4369,1,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 270 mg/kg,,BAO_0000218,,Mus musculus,,Autocuration,10685,In vivo,U,0,CHEMBL621002,,,
4370,1,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 275 mg/kg,,BAO_0000218,,Mus musculus,,Autocuration,10685,In vivo,U,0,CHEMBL621003,,,
4371,1,"Antitumor activity in vivo against the 6C3HED lymphosarcoma, dosed for 10 days at 300 mg/kg",,BAO_0000218,,Mus musculus,,Autocuration,10685,In vivo,U,0,CHEMBL621004,,,
4372,1,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (intraperitoneal dosing for 8 days),,BAO_0000218,,Mus musculus,,Autocuration,10685,In vivo,U,0,CHEMBL621005,,,
4373,1,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (ip dosing daily for 8 days),,BAO_0000218,,Mus musculus,,Autocuration,10685,In vivo,U,0,CHEMBL621006,,,
4374,1,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 600 mg/kg,,BAO_0000218,,Mus musculus,,Autocuration,10685,In vivo,U,0,CHEMBL621007,,,
4375,1,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,,BAO_0000218,,Mus musculus,,Autocuration,10144,,U,0,CHEMBL621008,,,
4376,1,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,,BAO_0000218,,Mus musculus,,Autocuration,10144,,U,0,CHEMBL621009,,,
4377,1,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,,BAO_0000218,,Mus musculus,,Autocuration,10144,,U,0,CHEMBL857705,,,
4378,1,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,,BAO_0000218,,Mus musculus,,Autocuration,10144,,U,0,CHEMBL619828,,,
4379,1,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 100 mg/kg dosage administered for 8 days intraperitoneally,,BAO_0000218,,Mus musculus,,Autocuration,10685,,U,0,CHEMBL619829,,,
4380,1,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 10 days intraperitoneally,,BAO_0000218,,Mus musculus,,Autocuration,10685,,U,0,CHEMBL619830,,,
4381,1,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 8 days intraperitoneally,,BAO_0000218,,Mus musculus,,Autocuration,10685,,U,0,CHEMBL619831,,,
4382,1,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 50 mg/kg dosage administered for 8 days intraperitoneally,,BAO_0000218,,Mus musculus,,Autocuration,10685,,U,0,CHEMBL619832,,,
4383,1,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 100 mg/kg dosage administered for 8 days intraperitoneally; 0/10,,BAO_0000218,,Mus musculus,,Autocuration,10685,,U,0,CHEMBL619833,,,
4384,1,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 8 days perorally; 1/10,,BAO_0000218,,Mus musculus,,Autocuration,10685,,U,0,CHEMBL619834,,,
4385,1,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 10 days intraperitoneally; 1/10,,BAO_0000218,,Mus musculus,,Autocuration,10685,,U,0,CHEMBL619835,,,
4386,1,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 50 mg/kg dosage administered for 8 days perorally; 3/10,,BAO_0000218,,Mus musculus,,Autocuration,10685,,U,0,CHEMBL619836,,,
4387,1,"Compound was evaluated for the antitumor activity against 6C3HED lymphosarcoma for ip administration and daily x 8 schedule; Number of toxic deaths over total number of mice per group (T/C), 0/10 at dose of 35 mg/kg",,BAO_0000218,,Mus musculus,,Intermediate,8831,,N,1,CHEMBL619837,850.0,,
4388,1,In vivo antitumor activity against 6C3HED tumor type after intraperitoneal administration of 400 mg/kg,,BAO_0000218,,,,Autocuration,11704,In vivo,U,0,CHEMBL619838,,,
4389,1,In vivo antitumor activity against 6C3HED tumor type was expressed as toxic deaths/total treated mice at 400 mg/kg dose; 2/10,,BAO_0000218,,Mus musculus,,Intermediate,11704,,N,1,CHEMBL619839,,,
4390,1,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line,,BAO_0000218,,Mus musculus,,Intermediate,10685,In vivo,N,1,CHEMBL619840,850.0,,
4391,1,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line; 95-100% inhibition,,BAO_0000218,,Mus musculus,,Intermediate,10685,In vivo,N,1,CHEMBL619841,850.0,,
4392,1,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 150 mg/kg given orally(daily x 8),,BAO_0000218,,Mus musculus,,Expert,11368,,N,1,CHEMBL857704,850.0,,
4393,1,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 200 mg/kg given orally(daily x 8),,BAO_0000218,,Mus musculus,,Intermediate,11368,,N,1,CHEMBL619842,850.0,,
4394,1,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 300 mg/kg given orally (daily x 8),,BAO_0000218,,Mus musculus,,Expert,11368,,N,1,CHEMBL619843,850.0,,
4395,1,"Inhibition of Staphylococcus aureus 7,8-dihydroneopterin aldolase",,BAO_0000019,,Staphylococcus aureus,,Autocuration,17763,,U,0,CHEMBL619844,,,
4396,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at a concentration of 5 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,U,0,CHEMBL857855,,2107.0,
4397,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,U,0,CHEMBL619845,,2107.0,
4398,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 1 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,U,0,CHEMBL619846,,2107.0,
4399,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 20 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,U,0,CHEMBL619847,,2107.0,
4400,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 25 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,U,0,CHEMBL619848,,2107.0,
4401,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 50 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,U,0,CHEMBL620893,,2107.0,
4402,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 5 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,U,0,CHEMBL620894,,2107.0,
4403,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 10 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,U,0,CHEMBL620895,,2107.0,
4404,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,U,0,CHEMBL620896,,2107.0,
4405,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,U,0,CHEMBL620897,,2107.0,
4406,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,U,0,CHEMBL620898,,2107.0,
4407,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,U,0,CHEMBL620899,,2107.0,
4408,1,The apparent total plasma clearance in monkey,Plasma,BAO_0000218,,Cercopithecidae,,Autocuration,347,In vivo,U,0,CHEMBL620900,,1969.0,
4409,1,Compound was evaluated for Hepatic clearance in monkey,,BAO_0000218,,Cercopithecidae,,Autocuration,3341,In vivo,U,0,CHEMBL620901,,,
4410,1,Lower clearance in monkey (i.v.) at 0.5 mpk,,BAO_0000218,,Cercopithecidae,,Autocuration,17853,In vivo,U,0,CHEMBL620902,,,
4411,1,Plasma clearance in rhesus monkey,,BAO_0000218,,Cercopithecidae,,Autocuration,4514,In vivo,U,0,CHEMBL620903,,,
4412,1,Plasma clearance for the compound was measured in monkey after an iv dose of 1 mg/kg,,BAO_0000218,,Cercopithecidae,,Autocuration,6062,In vivo,U,0,CHEMBL620904,,,
4413,1,Plasma clearance of compound was determined in monkey,,BAO_0000218,,Cercopithecidae,,Autocuration,6821,In vivo,U,0,CHEMBL620905,,,
4414,1,Plasma clearance was calculated in rhesus monkey,,BAO_0000218,,Cercopithecidae,,Autocuration,6057,In vivo,U,0,CHEMBL620906,,,
4415,1,Plasma clearance in rhesus monkey,,BAO_0000218,,Cercopithecidae,,Autocuration,5145,In vivo,U,0,CHEMBL875420,,,
4416,1,Plasma clearance in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),,BAO_0000218,,Cercopithecidae,,Autocuration,6641,In vivo,U,0,CHEMBL620907,,,
4417,1,Plasma clearance was evaluated in rhesus,,BAO_0000218,,Cercopithecidae,,Autocuration,5472,In vivo,U,0,CHEMBL620908,,,
4418,1,Plasma clearance value was determined in monkey after a 3 mg/kg of iv dose,,BAO_0000218,,Cercopithecidae,,Autocuration,4257,In vivo,U,0,CHEMBL620909,,,
4419,1,Plasma clearance was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,,BAO_0000218,,Cercopithecidae,,Autocuration,5546,In vivo,U,0,CHEMBL620910,,,
4420,1,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),,BAO_0000218,,Cercopithecidae,,Autocuration,5334,In vivo,U,0,CHEMBL620911,,,
4421,1,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),,BAO_0000218,,Cercopithecidae,,Autocuration,5334,In vivo,U,0,CHEMBL620912,,,
4422,1,Cmax 24 hr after 2 mg/kg oral administration in monkeys,,BAO_0000218,,Cercopithecidae,,Autocuration,17509,In vivo,U,0,CHEMBL620913,,,
4423,1,Cmax in monkey after administration of 1 mg/kg iv,,BAO_0000218,,Cercopithecidae,,Autocuration,6535,In vivo,U,0,CHEMBL620914,,,
4424,1,Cmax was determine after peroral administration at 10 mpk in Rhesus,,BAO_0000218,,Cercopithecidae,,Autocuration,5668,In vivo,U,0,CHEMBL620915,,,
4425,1,Cmax in cynomolgus monkey by iv administration,,BAO_0000218,,Cercopithecidae,,Autocuration,5922,In vivo,U,0,CHEMBL620916,,,
4426,1,Cmax in cynomolgus monkey by po administration,,BAO_0000218,,Cercopithecidae,,Autocuration,5922,In vivo,U,0,CHEMBL620917,,,
4427,1,Cmax value evaluated in monkey,,BAO_0000218,,Cercopithecidae,,Autocuration,6078,In vivo,U,0,CHEMBL620918,,,
4428,1,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,BAO_0000218,,Cercopithecidae,,Autocuration,2661,In vivo,U,0,CHEMBL620919,,,
4429,1,Maximal concentration (Cmax) in rhesus monkey plasma at a dose of 5 mg/kg,Plasma,BAO_0000218,,Cercopithecidae,,Autocuration,3249,In vivo,U,0,CHEMBL620920,,1969.0,
4430,1,Maximal concentration (Cmax) in squirrel monkey plasma at a dose of 5 mg/kg,Plasma,BAO_0000218,,Cercopithecidae,,Autocuration,3249,In vivo,U,0,CHEMBL620921,,1969.0,
4431,1,Maximal plasma concentration in squirrel monkeys,Plasma,BAO_0000218,,Cercopithecidae,,Autocuration,5553,In vivo,U,0,CHEMBL620922,,1969.0,
4432,1,Maximum concentration was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,BAO_0000218,,Cercopithecidae,,Autocuration,1916,In vivo,U,0,CHEMBL620923,,,
4433,1,Maximum plasma concentration (Cmax) in rhesus monkey(in vivo) at a dose of 5 mg/kg,Plasma,BAO_0000218,,Cercopithecidae,,Autocuration,6227,In vivo,U,0,CHEMBL620924,,1969.0,
4434,1,Pharmacokinetic parameter Cmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),,BAO_0000218,,Cercopithecidae,,Autocuration,4809,In vivo,U,0,CHEMBL620925,,,
4435,1,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means Not applicable,,BAO_0000218,,Cercopithecidae,,Autocuration,5355,In vivo,U,0,CHEMBL620926,,,
4436,1,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means not applicable,,BAO_0000218,,Cercopithecidae,,Autocuration,5355,In vivo,U,0,CHEMBL620927,,,
4437,1,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys;NA means not applicable,,BAO_0000218,,Cercopithecidae,,Autocuration,5355,In vivo,U,0,CHEMBL620928,,,
4438,1,The peak concentration (Cmax) value after oral administration in cynomolgus monkeys,,BAO_0000218,,Cercopithecidae,,Autocuration,5355,In vivo,U,0,CHEMBL620929,,,
4439,1,The peak plasma concentration after 5 hr administration (2.5 mg/kg) in monkey was determined,Plasma,BAO_0000218,,Cercopithecidae,,Autocuration,6221,In vivo,U,0,CHEMBL620930,,1969.0,
4440,1,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 0.4 hours,,BAO_0000218,,Cercopithecidae,,Autocuration,167,,U,0,CHEMBL620931,,,
4441,1,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 1.0 hours,,BAO_0000218,,Cercopithecidae,,Autocuration,167,,U,0,CHEMBL620932,,,
4442,1,Absolute bioavailability was evaluated in monkey,,BAO_0000218,,monkey,,Autocuration,4257,In vivo,U,0,CHEMBL620933,,,
4443,1,Bioavailability after oral administration (2.5 mg/kg) in monkey was determined,,BAO_0000218,,monkey,,Autocuration,6221,In vivo,U,0,CHEMBL620934,,,
4444,1,Bioavailability of compound at 3 mg/kg in monkey after i.v. administration,,BAO_0000218,,monkey,,Autocuration,17667,In vivo,U,0,CHEMBL620935,,,
4445,1,Bioavailability of compound was determined in rhesus monkey,,BAO_0000218,,Macaca mulatta,,Autocuration,17267,In vivo,U,0,CHEMBL620936,,,
4446,1,Bioavailability determined after oral administration in marmoset,,BAO_0000218,,marmosets,,Autocuration,4256,In vivo,U,0,CHEMBL620937,,,
4447,1,Oral bioavailability in cynomolgus monkey,,BAO_0000218,,Macaca fascicularis,,Autocuration,4256,In vivo,U,0,CHEMBL620938,,,
4448,1,Bioavailability in monkey (p.o.) at 2.0 mpk,,BAO_0000218,,monkey,,Autocuration,17853,In vivo,U,0,CHEMBL620939,,,
4449,1,Bioavailability was evaluated after oral administration in monkey,,BAO_0000218,,monkey,,Autocuration,16365,In vivo,U,0,CHEMBL620940,,,
4450,1,Bioavailability was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,BAO_0000218,,Macaca fascicularis,,Autocuration,1916,In vivo,U,0,CHEMBL620941,,,
4451,1,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),,BAO_0000218,,Macaca mulatta,,Autocuration,5334,In vivo,U,0,CHEMBL620942,,,
4452,1,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),,BAO_0000218,,Macaca mulatta,,Autocuration,5334,In vivo,U,0,CHEMBL620943,,,
4453,1,Bioavailability of the compound was determined in monkey,,BAO_0000218,,monkey,,Autocuration,17592,In vivo,U,0,CHEMBL620944,,,
4454,1,Bioavailability in squirrel monkey (dose 5 mg/kg),,BAO_0000218,,Saimiri sciureus,,Autocuration,1399,In vivo,U,0,CHEMBL620945,,,
4455,1,Bioavailability was determined in monkey after (po) administration of a dose of 50 (uM/kg),,BAO_0000218,,monkey,,Autocuration,4809,In vivo,U,0,CHEMBL620946,,,
4456,1,Oral bioavailability in monkey,,BAO_0000218,,monkey,,Autocuration,3341,In vivo,U,0,CHEMBL620947,,,
4457,1,Compound was tested for bioavailability in squirrel monkey,,BAO_0000218,,Saimiri sciureus,,Autocuration,64,In vivo,U,0,CHEMBL620948,,,
4458,1,Oral bioavailability in Rhesus monkey,,BAO_0000218,,Macaca mulatta,,Autocuration,5005,In vivo,U,0,CHEMBL620949,,,
4459,1,Oral bioavailability in Rhesus monkey (dose of 0.75 mg/kg i.v. and 1.5 mg/kg p.o.),,BAO_0000218,,Macaca mulatta,,Autocuration,5005,In vivo,U,0,CHEMBL620950,,,
4460,1,Oral bioavailability in cynomolgus monkeys for the compound was determined; Acceptable,,BAO_0000218,,Macaca fascicularis,,Autocuration,5237,In vivo,U,0,CHEMBL620951,,,
4461,1,Oral bioavailability in cynomolgus monkeys was determined; Acceptable,,BAO_0000218,,Macaca fascicularis,,Autocuration,5237,In vivo,U,0,CHEMBL620952,,,
4462,1,Oral bioavailability in monkey (dose 5 mg/kg),,BAO_0000218,,monkey,,Autocuration,5302,In vivo,U,0,CHEMBL875421,,,
4463,1,Oral bioavailability of compound at 5 mg/kg in monkey,,BAO_0000218,,monkey,,Autocuration,17667,In vivo,U,0,CHEMBL620953,,,
4464,1,Pharmacokinetic profile in terms of half life was determined at a dose of 0.5 mg/kg administered intravenously in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6161,In vivo,N,1,CHEMBL873491,,,
4465,1,Pharmacokinetic profile in terms of half life was determined at a dose of 5 mg/kg administered intravenously in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6161,In vivo,N,1,CHEMBL620954,,,
4466,1,Plasma half life determined,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,3854,,N,1,CHEMBL620955,,1969.0,
4467,1,Plasma half life in dog,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,993,,N,1,CHEMBL618097,,1969.0,
4468,1,Plasma half-life in Beagle dogs,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,4514,,N,1,CHEMBL618268,,1969.0,
4469,1,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,5334,In vivo,N,1,CHEMBL618269,,1969.0,
4470,1,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg respectively in Beagle dog (male),Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,5334,In vivo,N,1,CHEMBL618270,,1969.0,
4471,1,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,1466,In vivo,N,1,CHEMBL618271,,,
4472,1,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,1466,In vivo,N,1,CHEMBL873493,,,
4473,1,Tested for the half life period in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5313,,N,1,CHEMBL621031,,,
4474,1,Tested for the half life period in dog at dosage of 10 mpk,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5313,In vivo,N,1,CHEMBL621032,,,
4475,1,The compound was tested for half life in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,3880,,N,1,CHEMBL621033,,,
4476,1,"The compound was tested for time taken to decrease, half of its initial concentration in dog plasma.",Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,3639,,N,1,CHEMBL621034,,1969.0,
4477,1,The half life was determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,3880,,N,1,CHEMBL621035,,,
4478,1,The plasma half-life in dogs,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,3918,,N,1,CHEMBL621036,,1969.0,
4479,1,suboptimal plasma half-life caused a10% prolongation of QTc interval in dogs at a plasma level of 2.5 M,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,16452,,N,1,CHEMBL621037,,1969.0,
4480,1,Half life in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17796,,N,1,CHEMBL619812,,,
4481,1,Pharmacokinetic property (t1/2beta) was measured in dog at the dose of 0.032 mg/kg i.v.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5983,In vivo,N,1,CHEMBL619813,,,
4482,1,tmax upon peroral administration of 10.0 mg/Kg dose in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,1466,In vivo,N,1,CHEMBL873335,,,
4483,1,Volume of distribution in Beagle dogs after intravenous administration at a dose of 10 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,16456,In vivo,N,1,CHEMBL619814,,,
4484,1,Cmax in ferrets after 30 mg/kg oral dose,,BAO_0000218,,Mustela putorius furo,,Expert,6113,In vivo,N,1,CHEMBL619815,,,
4485,1,Emesis in ferrets at 30 mg/kg oral dose,,BAO_0000218,,Mustela putorius furo,,Expert,6113,In vivo,N,1,CHEMBL619816,,,
4486,1,Bioavailability in cynomolgus monkey,,BAO_0000218,,Macaca fascicularis,,Autocuration,17796,In vivo,U,0,CHEMBL619817,,,
4487,1,Volume of distribution in cynomolgus,,BAO_0000218,,Macaca fascicularis,,Intermediate,17796,In vivo,N,1,CHEMBL619818,,,
4488,1,AUC tested in guinea pig when 3 mg/kg dose was given perorally,Plasma,BAO_0000218,,Cavia porcellus,,Autocuration,5308,,U,0,CHEMBL619819,,1969.0,
4489,1,Tested for concentration as Area Under Curve against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,,BAO_0000218,,Cavia porcellus,,Autocuration,4877,,U,0,CHEMBL619820,,,
4490,1,"Tested for the pharmacokinetic parameter in guinea pig, administered orally at 5 mg/kg",,BAO_0000218,,Cavia porcellus,,Autocuration,4876,,U,0,CHEMBL875419,,,
4491,1,AUC in guinea pig after 3mg/kg oral dose,Plasma,BAO_0000218,,Cavia porcellus,,Autocuration,4878,In vivo,U,0,CHEMBL619821,,1969.0,
4492,1,Bioavailability in guinea pig was tested,,BAO_0000218,,Cavia porcellus,,Autocuration,5308,In vivo,U,0,CHEMBL619822,,,
4493,1,Tested for oral bioavailability in guinea pig at 5 mg/kg,,BAO_0000218,,Cavia porcellus,,Autocuration,4877,In vivo,U,0,CHEMBL619823,,,
4494,1,Tested for the oral bioavailability of the compound,,BAO_0000218,,Cavia porcellus,,Autocuration,4876,In vivo,U,0,CHEMBL619824,,,
4495,1,Compound at a dose 5 mg/kg was administered orally to guinea pig and the pharmacokinetic parameter (Cmax) was reported,,BAO_0000218,,Cavia porcellus,,Autocuration,4876,In vivo,U,0,CHEMBL619825,,,
4496,1,Maximum plsma drug concentration in guinea pig when 3 mg/kg dose was given perorally,,BAO_0000218,,Cavia porcellus,,Autocuration,5308,In vivo,U,0,CHEMBL619826,,,
4497,1,Tested for maximum concentration against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,Lung,BAO_0000218,,Cavia porcellus,,Autocuration,4877,In vivo,U,0,CHEMBL619827,,2048.0,
4498,1,Cmax in guinea pig after 3mg/kg oral dose,,BAO_0000218,,Cavia porcellus,,Autocuration,4878,In vivo,U,0,CHEMBL618167,,,
4499,1,Distribution in blood expressed as [18F]- organ uptake in % of injected activity/gram,Blood,BAO_0000019,,Cavia porcellus,,Autocuration,5689,,U,0,CHEMBL618168,,178.0,
4500,1,Distribution in brain expressed as [18F]- organ uptake in % of injected activity/gram,Brain,BAO_0000019,,Cavia porcellus,,Autocuration,5689,,U,0,CHEMBL618169,,955.0,
4501,1,Distribution in heart expressed as [18F]- organ uptake in % of injected activity/gram,,BAO_0000019,,Cavia porcellus,,Autocuration,5689,,U,0,CHEMBL618170,,,
4502,1,Distribution in intestine expressed as [18F]- organ uptake in % of injected activity/gram,Intestine,BAO_0000019,,Cavia porcellus,,Autocuration,5689,,U,0,CHEMBL618171,,160.0,
4503,1,Distribution in kidney expressed as [18F]- organ uptake in % of injected activity/gram,Kidney,BAO_0000019,,Cavia porcellus,,Autocuration,5689,,U,0,CHEMBL618172,,2113.0,
4504,1,Distribution in liver expressed as [18F]- organ uptake in % of injected activity/gram,Liver,BAO_0000019,,Cavia porcellus,,Autocuration,5689,,U,0,CHEMBL618173,,2107.0,
4505,1,Distribution in lung expressed as [18F]- organ uptake in % of injected activity/gram,,BAO_0000019,,Cavia porcellus,,Autocuration,5689,,U,0,CHEMBL618174,,,
4506,1,Distribution in spleen expressed as [18F]- organ uptake in % of injected activity/gram,Spleen,BAO_0000019,,Cavia porcellus,,Autocuration,5689,,U,0,CHEMBL875408,,2106.0,
4507,1,Elimination T1/2 in Guinea pig (PO dose),,BAO_0000218,,Cavia porcellus,,Autocuration,14465,In vivo,U,0,CHEMBL839827,,,
4508,1,Partition coefficient was measured as -log (counts per min ),,BAO_0000019,,Cavia porcellus,,Autocuration,5689,,U,0,CHEMBL618175,,,
4509,1,Biological half life when administered at 0.1 umol/kg intravenously to guinea pig in GR-64349 antagonism,,BAO_0000218,,Cavia porcellus,,Autocuration,611,In vivo,U,0,CHEMBL618176,,,
4510,1,Biological half life when administered at 5 umol/kg intravenously to guinea pig in GR-64349 antagonism,,BAO_0000218,,Cavia porcellus,,Autocuration,611,In vivo,U,0,CHEMBL618177,,,
4511,1,Elimination T1/2 in Guinea pig (PO dose),,BAO_0000218,,Cavia porcellus,,Autocuration,14465,In vivo,U,0,CHEMBL618178,,,
4512,1,"Tested for the half life period of the compound, intravenously",,BAO_0000218,,Cavia porcellus,,Autocuration,4876,In vivo,U,0,CHEMBL618179,,,
4513,1,Half-life was measured,,BAO_0000019,,Cavia porcellus,,Autocuration,5689,,U,0,CHEMBL873489,,,
4514,1,The time required for onset of inotropy after addition of a single dose of delta F75,,BAO_0000019,,Cavia porcellus,,Autocuration,7515,,U,0,CHEMBL618180,,,
4515,1,Bioavailability of compound at 10 mg/kg in guinea pig after i.v. administration,,BAO_0000218,,Cavia porcellus,,Autocuration,17667,In vivo,U,0,CHEMBL618181,,,
4516,1,Bioavailability of compound at 3 mg/kg in guinea pig after i.v. administration,,BAO_0000218,,Cavia porcellus,,Autocuration,17667,In vivo,U,0,CHEMBL618182,,,
4517,1,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,,BAO_0000218,,Cricetulus griseus,,Autocuration,4727,In vivo,U,0,CHEMBL618183,,,
4518,1,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,N,1,CHEMBL618184,,,
4519,1,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,N,1,CHEMBL618185,,,
4520,1,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,N,1,CHEMBL618186,,,
4521,1,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,N,1,CHEMBL618187,,,
4522,1,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hr,,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,N,1,CHEMBL618188,,,
4523,1,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,N,1,CHEMBL875409,,,
4524,1,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,N,1,CHEMBL618189,,,
4525,1,Biodistribution of the injected compound in blood of female BALB/C mice for 0.5 hours,Blood,BAO_0000218,,Mus musculus,,Intermediate,3655,In vivo,N,1,CHEMBL618190,,178.0,
4526,1,Biodistribution of the injected compound in blood of female BALB/C mice for 2.5 hours,Blood,BAO_0000218,,Mus musculus,,Intermediate,3655,In vivo,N,1,CHEMBL618191,,178.0,
4527,1,Biodistribution of the injected compound in blood of female BALB/C mice for 5 hours,Blood,BAO_0000218,,Mus musculus,,Intermediate,3655,In vivo,N,1,CHEMBL618192,,178.0,
4528,1,Biodistribution of the injected compound in bone of female BALB/C mice for 0.5 hours,Bone,BAO_0000218,,Mus musculus,,Intermediate,3655,In vivo,N,1,CHEMBL618193,,10000001.0,
4529,1,Biodistribution of the injected compound in bone of female BALB/C mice for 2.5 hours,Bone,BAO_0000218,,Mus musculus,,Intermediate,3655,In vivo,N,1,CHEMBL618194,,10000001.0,
4530,1,Biodistribution of the injected compound in bone of female BALB/C mice for 5 hours,Bone,BAO_0000218,,Mus musculus,,Intermediate,3655,In vivo,N,1,CHEMBL618195,,10000001.0,
4531,1,Biodistribution of the injected compound in brain of female BALB/C mice for 0.5 hours,Brain,BAO_0000218,,Mus musculus,,Intermediate,3655,In vivo,N,1,CHEMBL618196,,955.0,
4532,1,Biodistribution of the injected compound in brain of female BALB/C mice for 2.5 hours,Brain,BAO_0000218,,Mus musculus,,Intermediate,3655,In vivo,N,1,CHEMBL618197,,955.0,
4533,1,Biodistribution of the injected compound in brain of female BALB/C mice for 5 hours,Brain,BAO_0000218,,Mus musculus,,Intermediate,3655,In vivo,N,1,CHEMBL618198,,955.0,
4534,1,Biodistribution of the injected compound in heart of female BALB/C mice for 0.5 hours,Heart,BAO_0000218,,Mus musculus,,Intermediate,3655,In vivo,N,1,CHEMBL618199,,948.0,
4535,1,Biodistribution of the injected compound in heart of female BALB/C mice for 2.5 hours,Heart,BAO_0000218,,Mus musculus,,Intermediate,3655,In vivo,N,1,CHEMBL618200,,948.0,
4536,1,Biodistribution of the injected compound in heart of female BALB/C mice for 5 hours,Heart,BAO_0000218,,Mus musculus,,Intermediate,3655,In vivo,N,1,CHEMBL618201,,948.0,
4537,1,Biodistribution of the injected compound in intestines of female BALB/C mice for 0.5 hours,Intestine,BAO_0000218,,Mus musculus,,Intermediate,3655,In vivo,N,1,CHEMBL618202,,160.0,
4538,1,Biodistribution of the injected compound in intestines of female BALB/C mice for 2.5 hours,Intestine,BAO_0000218,,Mus musculus,,Intermediate,3655,In vivo,N,1,CHEMBL618203,,160.0,
4539,1,Biodistribution of the injected compound in intestines of female BALB/C mice for 5 hours,Intestine,BAO_0000218,,Mus musculus,,Intermediate,3655,In vivo,N,1,CHEMBL618204,,160.0,
4540,1,Biodistribution of the injected compound in kidneys of female BALB/C mice for 0.5 hours,Kidney,BAO_0000218,,Mus musculus,,Intermediate,3655,In vivo,N,1,CHEMBL618205,,2113.0,
4541,1,Biodistribution of the injected compound in kidneys of female BALB/C mice for 2.5 hours,Kidney,BAO_0000218,,Mus musculus,,Intermediate,3655,In vivo,N,1,CHEMBL618206,,2113.0,
4542,1,Biodistribution of the injected compound in kidneys of female BALB/C mice for 5 hours,Kidney,BAO_0000218,,Mus musculus,,Intermediate,3655,In vivo,N,1,CHEMBL618207,,2113.0,
4543,1,Biodistribution of the injected compound in liver of female BALB/C mice for 0.5 hours,Liver,BAO_0000218,,Mus musculus,,Intermediate,3655,In vivo,N,1,CHEMBL618208,,2107.0,
4544,1,Biodistribution of the injected compound in liver of female BALB/C mice for 2.5 hours,Liver,BAO_0000218,,Mus musculus,,Intermediate,3655,In vivo,N,1,CHEMBL618932,,2107.0,
4545,1,Biodistribution of the injected compound in liver of female BALB/C mice for 5 hours,Liver,BAO_0000218,,Mus musculus,,Intermediate,3655,In vivo,N,1,CHEMBL618933,,2107.0,
4546,1,Biodistribution of the injected compound in lung of female BALB/C mice for 0.5 hours,Lung,BAO_0000218,,Mus musculus,,Intermediate,3655,In vivo,N,1,CHEMBL618934,,2048.0,
4547,1,Biodistribution of the injected compound in lung of female BALB/C mice for 2.5 hours,Lung,BAO_0000218,,Mus musculus,,Intermediate,3655,In vivo,N,1,CHEMBL618935,,2048.0,
4548,1,Biodistribution of the injected compound in lung of female BALB/C mice for 5 hours,Lung,BAO_0000218,,Mus musculus,,Intermediate,3655,In vivo,N,1,CHEMBL618936,,2048.0,
4549,1,Biodistribution of the injected compound in muscle of female BALB/C mice for 0.5 hours,Muscle tissue,BAO_0000218,,Mus musculus,,Intermediate,3655,In vivo,N,1,CHEMBL618937,,2385.0,
4550,1,Biodistribution of the injected compound in muscle of female BALB/C mice for 2.5 hours,Muscle tissue,BAO_0000218,,Mus musculus,,Intermediate,3655,In vivo,N,1,CHEMBL618938,,2385.0,
4551,1,Biodistribution of the injected compound in muscle of female BALB/C mice for 5 hours,Muscle tissue,BAO_0000218,,Mus musculus,,Intermediate,3655,In vivo,N,1,CHEMBL619104,,2385.0,
4552,1,Biodistribution of the injected compound in spleen of female BALB/C mice for 0.5 hours,Spleen,BAO_0000218,,Mus musculus,,Intermediate,3655,In vivo,N,1,CHEMBL619105,,2106.0,
4553,1,Biodistribution of the injected compound in spleen of female BALB/C mice for 2.5 hours,Spleen,BAO_0000218,,Mus musculus,,Intermediate,3655,In vivo,N,1,CHEMBL619106,,2106.0,
4554,1,Biodistribution of the injected compound in spleen of female BALB/C mice for 5 hours,Spleen,BAO_0000218,,Mus musculus,,Intermediate,3655,In vivo,N,1,CHEMBL619107,,2106.0,
4555,1,Biodistribution of the injected compound in stomach of female BALB/C mice for 0.5 hours,Stomach,BAO_0000218,,Mus musculus,,Intermediate,3655,In vivo,N,1,CHEMBL875410,,945.0,
4556,1,Biodistribution of the injected compound in stomach of female BALB/C mice for 2.5 hours,Stomach,BAO_0000218,,Mus musculus,,Intermediate,3655,In vivo,N,1,CHEMBL619108,,945.0,
4557,1,Biodistribution of the injected compound in stomach of female BALB/C mice for 5 hours,Stomach,BAO_0000218,,Mus musculus,,Intermediate,3655,In vivo,N,1,CHEMBL619109,,945.0,
4558,1,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,,BAO_0000218,,Mus musculus,,Intermediate,16597,In vivo,N,1,CHEMBL619110,,,
4559,1,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,,BAO_0000218,,Mus musculus,,Intermediate,16597,In vivo,N,1,CHEMBL619111,,,
4560,1,MRT value at a dose of 10 mg/kg intravenous administration in mice.,,BAO_0000218,,Mus musculus,,Intermediate,16597,In vivo,N,1,CHEMBL619112,,,
4561,1,MRT value at a dose of 10 mg/kg peroral administration in mice.,,BAO_0000218,,Mus musculus,,Intermediate,16597,In vivo,N,1,CHEMBL619113,,,
4562,1,Mean-residence time of compound after intravenous administration in mice at 24 uM/kg,,BAO_0000218,,Mus musculus,,Intermediate,17764,In vivo,N,1,CHEMBL619114,,,
4563,1,Mean-residence time was determined for compound after intraperitoneal administration in mice at 18 uM/kg,,BAO_0000218,,Mus musculus,,Intermediate,17764,In vivo,N,1,CHEMBL619115,,,
4564,1,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C after 96 hr,,BAO_0000219,,Homo sapiens,,Intermediate,3830,,N,1,CHEMBL619116,478.0,,
4565,1,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C for 96 hr,,BAO_0000219,,Homo sapiens,,Intermediate,3829,,N,1,CHEMBL619117,478.0,,
4566,1,Compound was evaluated for cytotoxicity against A2780 cell lines.,,BAO_0000219,,Homo sapiens,,Intermediate,2040,,N,1,CHEMBL619118,478.0,,
4567,1,Potentiation of growth inhibition of A2780 by compound alone in experiment 1,,BAO_0000219,,Homo sapiens,,Intermediate,15684,,N,1,CHEMBL619119,478.0,,
4568,1,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,,BAO_0000219,,Homo sapiens,,Intermediate,15684,,N,1,CHEMBL619120,478.0,,
4569,1,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,,BAO_0000219,,Homo sapiens,,Intermediate,15684,,N,1,CHEMBL619121,478.0,,
4570,1,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,,BAO_0000219,,Homo sapiens,,Intermediate,15684,,N,1,CHEMBL619122,478.0,,
4571,1,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,,BAO_0000219,,Homo sapiens,,Intermediate,15684,,N,1,CHEMBL619123,478.0,,
4572,1,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,,BAO_0000219,,Homo sapiens,,Intermediate,15684,,N,1,CHEMBL619124,478.0,,
4573,1,Compound was evaluated for cytotoxicity against A2780 cell line,,BAO_0000219,,Homo sapiens,,Intermediate,2859,,N,1,CHEMBL619125,478.0,,
4574,1,In vitro inhibitory activity against human tumor cell line A2780,,BAO_0000219,,Homo sapiens,,Intermediate,5618,,N,1,CHEMBL875411,478.0,,
4575,1,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 1,,BAO_0000219,,Homo sapiens,,Intermediate,15684,,N,1,CHEMBL619126,478.0,,
4576,1,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,,BAO_0000219,,Homo sapiens,,Intermediate,15684,,N,1,CHEMBL619127,478.0,,
4577,1,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,,BAO_0000219,,Homo sapiens,,Intermediate,15684,,N,1,CHEMBL619128,478.0,,
4578,1,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,,BAO_0000219,,Homo sapiens,,Intermediate,15684,,N,1,CHEMBL619129,478.0,,
4579,1,The compound was tested for cytotoxic potency against A2780 human tumor cell lines,,BAO_0000219,,Homo sapiens,,Intermediate,2113,,N,1,CHEMBL619130,478.0,,
4580,1,The compound was tested for cytotoxic potency against A2780 human tumor cell lines.,,BAO_0000219,,Homo sapiens,,Intermediate,2113,,N,1,CHEMBL619131,478.0,,
4581,1,cytotoxicity against A2780 cells incubated for 24 hr in MTT assay.,,BAO_0000219,,Homo sapiens,,Intermediate,16745,,N,1,CHEMBL619132,478.0,,
4582,1,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,,BAO_0000218,,Homo sapiens,,Expert,16597,,N,1,CHEMBL619133,478.0,,
4583,1,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,,BAO_0000219,,Homo sapiens,,Intermediate,15684,,N,1,CHEMBL619134,478.0,,
4584,1,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,,BAO_0000219,,Homo sapiens,,Intermediate,15684,,N,1,CHEMBL619135,478.0,,
4585,1,Compound was evaluated for cytotoxicity against A2780 cis cell lines.,,BAO_0000219,,Homo sapiens,,Intermediate,2040,,N,1,CHEMBL619136,478.0,,
4586,1,Relative resistance factor in A2780 cisplatin-resistant line,,BAO_0000219,,Homo sapiens,,Intermediate,2040,,N,1,CHEMBL619137,478.0,,
4587,1,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells,,BAO_0000219,,Homo sapiens,,Intermediate,16165,,N,1,CHEMBL883713,478.0,,
4588,1,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells.,,BAO_0000219,,Homo sapiens,,Intermediate,16165,,N,1,CHEMBL875412,478.0,,
4589,1,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,,BAO_0000218,,Homo sapiens,,Expert,16597,,N,1,CHEMBL619138,478.0,,
4590,1,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,,BAO_0000218,,Homo sapiens,,Expert,16597,,N,1,CHEMBL619262,478.0,,
4591,1,Cytotoxicity against A2780 ovarian carcinoma cells was evaluated using standard sulforhodamine 96h assay test,,BAO_0000219,,Homo sapiens,,Intermediate,3992,,N,1,CHEMBL619139,478.0,,
4592,1,In vitro cytotoxicity was determined against A2780 human ovarian cell line using NCI screen,,BAO_0000219,,Homo sapiens,,Intermediate,10553,,N,1,CHEMBL619140,478.0,,
4593,1,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin,,BAO_0000219,,Homo sapiens,,Intermediate,15608,,N,1,CHEMBL619141,478.0,,
4594,1,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 1,,BAO_0000219,,Homo sapiens,,Intermediate,15608,,N,1,CHEMBL619142,478.0,,
4595,1,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 2,,BAO_0000219,,Homo sapiens,,Intermediate,15608,,N,1,CHEMBL619143,478.0,,
4596,1,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 3,,BAO_0000219,,Homo sapiens,,Intermediate,15608,,N,1,CHEMBL619144,478.0,,
4597,1,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 5,,BAO_0000219,,Homo sapiens,,Intermediate,15608,,N,1,CHEMBL619145,478.0,,
4598,1,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 8,,BAO_0000219,,Homo sapiens,,Intermediate,15608,,N,1,CHEMBL619146,478.0,,
4599,1,Cytotoxic activity in a panel of Human ovarian tumor A2780/CDDP cell line after 96h of drug exposure,,BAO_0000219,,Homo sapiens,,Intermediate,15569,,N,1,CHEMBL619147,478.0,,
4600,1,Antiproliferative effect of compound on A2780/DX cell line,,BAO_0000219,,Homo sapiens,,Intermediate,17420,,N,1,CHEMBL619148,478.0,,
4601,1,Antiproliferative effect of compound on A2780/DX cell line; n.d. indicates not determined,,BAO_0000219,,Homo sapiens,,Intermediate,17420,,N,1,CHEMBL619149,478.0,,
4602,1,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/DX(RI),,BAO_0000219,,Homo sapiens,,Intermediate,15099,,N,1,CHEMBL619150,478.0,,
4603,1,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/Dx(RI),,BAO_0000219,,Homo sapiens,,Intermediate,15099,,N,1,CHEMBL619151,478.0,,
4604,1,Cytotoxicity against ovarian carcinoma A2780/cis tumor cell lines,,BAO_0000219,,Homo sapiens,,Intermediate,17672,,N,1,CHEMBL883794,478.0,,
4605,1,Cytotoxicity against ovarian carcinoma A2780/cis90 tumor cell lines,,BAO_0000219,,Homo sapiens,,Intermediate,17672,,N,1,CHEMBL619152,478.0,,
4606,1,In vitro cytotoxicity against A2780ADR cell line,,BAO_0000219,,Homo sapiens,,Intermediate,17270,,N,1,CHEMBL619153,478.0,,
4607,1,In vitro cytotoxicity against A2780CIS cell line,,BAO_0000219,,Homo sapiens,,Intermediate,17270,,N,1,CHEMBL619154,478.0,,
4608,1,In vitro cytotoxic activity against human tumor cell line A2780CisR after incubation for 96 hours,,BAO_0000219,,Homo sapiens,,Intermediate,5574,,N,1,CHEMBL619155,478.0,,
4609,1,The compound was tested for cytotoxic potency against A2780R human tumor cell lines.,,BAO_0000219,,Homo sapiens,,Intermediate,2113,,N,1,CHEMBL619156,478.0,,
4610,1,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-resistant A2780/R human tumor cell lines",,BAO_0000219,,Homo sapiens,,Intermediate,16913,,N,1,CHEMBL619157,478.0,,
4611,1,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-resistant A2780/R human tumor cell lines",,BAO_0000219,,Homo sapiens,,Intermediate,16913,,N,1,CHEMBL619797,478.0,,
4612,1,Oral bioavailability of compound in rhesus macaques,,BAO_0000218,,Macaca mulatta,,Autocuration,17839,In vivo,U,0,CHEMBL619798,,,
4613,1,Oral bioavailability in monkey,,BAO_0000218,,monkey,,Autocuration,6821,In vivo,U,0,CHEMBL619799,,,
4614,1,Oral bioavailability evaluated in monkey,,BAO_0000218,,monkey,,Autocuration,6078,In vivo,U,0,CHEMBL619800,,,
4615,1,Oral bioavailability in monkey (dose 1 mg/kg p.o.),,BAO_0000218,,monkey,,Autocuration,6535,In vivo,U,0,CHEMBL619801,,,
4616,1,Oral bioavailability in Rhesus monkey,,BAO_0000218,,Macaca mulatta,,Autocuration,4449,In vivo,U,0,CHEMBL619802,,,
4617,1,Oral bioavailability was calculated in rhesus monkey,,BAO_0000218,,Macaca mulatta,,Autocuration,6057,In vivo,U,0,CHEMBL619803,,,
4618,1,Oral bioavailability in cynomolgus monkey,,BAO_0000218,,Macaca fascicularis,,Autocuration,5922,In vivo,U,0,CHEMBL619965,,,
4619,1,Oral bioavailability in monkey,,BAO_0000218,,monkey,,Autocuration,5940,In vivo,U,0,CHEMBL619966,,,
4620,1,Oral bioavailability in monkey,,BAO_0000218,,monkey,,Autocuration,6265,In vivo,U,0,CHEMBL619967,,,
4621,1,Oral bioavailability in monkey (dose 1 mg/kg),,BAO_0000218,,monkey,,Autocuration,6265,In vivo,U,0,CHEMBL620073,,,
4622,1,Oral bioavailability in monkey (dose 5 mg/kg),,BAO_0000218,,monkey,,Autocuration,6265,In vivo,U,0,CHEMBL620074,,,
4623,1,Oral bioavailability in monkey,,BAO_0000218,,monkey,,Autocuration,5940,In vivo,U,0,CHEMBL620075,,,
4624,1,Oral bioavailability in monkey,,BAO_0000218,,monkey,,Autocuration,5940,In vivo,U,0,CHEMBL620076,,,
4625,1,Oral bioavailability in rhesus monkey,,BAO_0000218,,Macaca mulatta,,Autocuration,4514,In vivo,U,0,CHEMBL620077,,,
4626,1,Oral bioavailability in rhesus monkey at a dose of 2 mg/kg by po administration,,BAO_0000218,,Macaca mulatta,,Autocuration,5546,In vivo,U,0,CHEMBL620078,,,
4627,1,Oral bioavailability in squirrel monkey at a dose of 10 mg/kg,,BAO_0000218,,Saimiri sciureus,,Autocuration,5553,In vivo,U,0,CHEMBL620079,,,
4628,1,Oral bioavailability in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),,BAO_0000218,,monkey,,Autocuration,6641,In vivo,U,0,CHEMBL620080,,,
4629,1,Oral bioavailability in Rhesus monkey,,BAO_0000218,,Macaca mulatta,,Autocuration,5472,In vivo,U,0,CHEMBL620081,,,
4630,1,Oral bioavailability in Rhesus monkey (dose 10 mg/kg p.o.),,BAO_0000218,,Macaca mulatta,,Autocuration,5668,In vivo,U,0,CHEMBL620082,,,
4631,1,Oral bioavailability in monkey at 10 mg/kg of the compound,,BAO_0000218,,monkey,,Autocuration,5711,In vivo,U,0,CHEMBL620083,,,
4632,1,Bioavailability in Rhesus monkey,,BAO_0000218,,Macaca mulatta,,Autocuration,5145,In vivo,U,0,CHEMBL620084,,,
4633,1,Glomerular Filtration Rate(GFR) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,BAO_0000218,,Cercopithecidae,,Autocuration,3443,,U,0,CHEMBL620085,,,
4634,1,Glomerular Filtration Rate(GFR)of the compound compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,BAO_0000218,,Cercopithecidae,,Autocuration,3443,,U,0,CHEMBL874595,,,
4635,1,Half life by ''Cr'' assay in rhesus monkey at a dose of 5 mg/kg,,BAO_0000218,,Cercopithecidae,,Autocuration,3249,In vivo,U,0,CHEMBL873352,,,
4636,1,Half life the of compound was determined by ''Cr'' assay in squirrel monkey at a dose of 5 mg/kg,,BAO_0000218,,Cercopithecidae,,Autocuration,3249,In vivo,U,0,CHEMBL620086,,,
4637,1,Mean residence time was determined after intravenous administration in cynomolgus monkeys,,BAO_0000218,,Cercopithecidae,,Autocuration,5355,In vivo,U,0,CHEMBL620087,,,
4638,1,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means Not applicable,,BAO_0000218,,Cercopithecidae,,Autocuration,5355,In vivo,U,0,CHEMBL620088,,,
4639,1,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means not applicable,,BAO_0000218,,Cercopithecidae,,Autocuration,5355,In vivo,U,0,CHEMBL620089,,,
4640,1,Pharmacokinetic parameter MRT was determined in monkey after (iv) administration of a dose of 13 (uM/kg),,BAO_0000218,,Cercopithecidae,,Autocuration,4809,In vivo,U,0,CHEMBL620090,,,
4641,1,Pharmacokinetic parameter MRT was determined in monkey after (po) administration of a dose of 50 (uM/kg),,BAO_0000218,,Cercopithecidae,,Autocuration,4809,In vivo,U,0,CHEMBL620091,,,
4642,1,Metabolism of compound in monkey S9 microsomes ('+''indicates <20% largest observed peak),,BAO_0000251,,Cercopithecidae,,Autocuration,14294,,U,0,CHEMBL620092,,,
4643,1,Metabolism of compound in monkey S9 microsomes ('++''indicates 20-50% largest observed peak),,BAO_0000251,,Cercopithecidae,,Autocuration,14294,,U,0,CHEMBL620093,,,
4644,1,Metabolism of compound in monkey S9 microsomes ('+++'indicates 50-80% largest observed peak),,BAO_0000251,,Cercopithecidae,,Autocuration,14294,,U,0,CHEMBL620094,,,
4645,1,Metabolism of compound in monkey S9 microsomes ('++++' indicates largest observed peak),,BAO_0000251,,Cercopithecidae,,Autocuration,14294,,U,0,CHEMBL620095,,,
4646,1,Plasma clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,BAO_0000218,,Cercopithecidae,,Autocuration,3443,In vivo,U,0,CHEMBL620096,,,
4647,1,Plasma clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,BAO_0000218,,Cercopithecidae,,Autocuration,3443,In vivo,U,0,CHEMBL620097,,,
4648,1,Clearance from plasma(with matabolite-corrected plasma radioactivity-time integral) at 30 min after administration.,,BAO_0000019,,Cercopithecidae,,Autocuration,11271,,U,0,CHEMBL620098,,,
4649,1,Renal clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,BAO_0000218,,Cercopithecidae,,Autocuration,3443,,U,0,CHEMBL620099,,,
4650,1,Renal clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,BAO_0000218,,Cercopithecidae,,Autocuration,3443,,U,0,CHEMBL620100,,,
4651,1,Elimination Half-life of compound was determined in monkey,,BAO_0000019,,Cercopithecidae,,Autocuration,6821,,U,0,CHEMBL620101,,,
4652,1,Half life of compound was determined in rhesus monkey,,BAO_0000019,,Cercopithecidae,,Autocuration,17267,,U,0,CHEMBL620102,,,
4653,1,Half life in monkey plasma,Plasma,BAO_0000366,,Cercopithecidae,,Autocuration,5819,,U,0,CHEMBL620103,,1969.0,
4654,1,Half life in monkey plasma; Not detected,Plasma,BAO_0000366,,Cercopithecidae,,Autocuration,5819,,U,0,CHEMBL620104,,1969.0,
4655,1,Half life period was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,BAO_0000218,,Cercopithecidae,,Autocuration,1916,In vivo,U,0,CHEMBL874596,,,
4656,1,Half-life 24 hr after 2 mg/kg iv administration in monkeys,,BAO_0000218,,Cercopithecidae,,Autocuration,17509,In vivo,U,0,CHEMBL873490,,,
4657,1,Terminal half life of the compound.,,BAO_0000019,,Cercopithecidae,,Autocuration,1399,,U,0,CHEMBL620105,,,
4658,1,Maximum time was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,BAO_0000218,,Cercopithecidae,,Autocuration,1916,In vivo,U,0,CHEMBL620780,,,
4659,1,Pharmacokinetic parameter Tmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),,BAO_0000218,,Cercopithecidae,,Autocuration,4809,In vivo,U,0,CHEMBL620781,,,
4660,1,Unbound plasma was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,,BAO_0000218,,Cercopithecidae,,Autocuration,5546,,U,0,CHEMBL620956,,,
4661,1,Urinary recovery evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Urine,BAO_0000218,,Cercopithecidae,,Autocuration,3443,,U,0,CHEMBL620957,,1088.0,
4662,1,Urinary recovery compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Urine,BAO_0000218,,Cercopithecidae,,Autocuration,3443,,U,0,CHEMBL620958,,1088.0,
4663,1,Volume of distribution was determined in monkey after a 3 mg/kg of iv dose,,BAO_0000218,,Cercopithecidae,,Autocuration,4257,In vivo,U,0,CHEMBL620959,,,
4664,1,Volume distribution after oral administration (2.5 mg/kg) in monkey was determined,,BAO_0000218,,Cercopithecidae,,Autocuration,6221,In vivo,U,0,CHEMBL620960,,,
4665,1,Volume of distribution was evaluated in rhesus,,BAO_0000218,,Cercopithecidae,,Autocuration,5472,In vivo,U,0,CHEMBL620961,,,
4666,1,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,,BAO_0000218,,Cricetulus griseus,,Autocuration,4727,In vivo,U,0,CHEMBL620962,,,
4667,1,Plasma clearance was measured in hamster at the dose of 3 mg/kg by intravenous administration,,BAO_0000218,,Cricetulus griseus,,Autocuration,4727,In vivo,U,0,CHEMBL620963,,,
4668,1,Bioavailability in hamster was determined,,BAO_0000218,,Cricetulus griseus,,Autocuration,4727,In vivo,U,0,CHEMBL620964,,,
4669,1,Bioavailability in hamster at a dose of 3 mg/kg by intravenous administration,,BAO_0000218,,Cricetulus griseus,,Autocuration,4727,In vivo,U,0,CHEMBL620965,,,
4670,1,Bioavailability in hamster at a dose of 3 mg/kg by oral administration,,BAO_0000218,,Cricetulus griseus,,Autocuration,4727,In vivo,U,0,CHEMBL620966,,,
4671,1,Half life of compound was determined in hamster blood,Blood,BAO_0000221,,Cricetulus griseus,,Autocuration,4727,,U,0,CHEMBL620967,,178.0,
4672,1,Michaelis-Menten constant of the compound.,,BAO_0000019,,Sus scrofa,,Autocuration,1452,,U,0,CHEMBL620968,,,
4673,1,Vmax value was measured at 0 uM concentration of silyl ether.,,BAO_0000019,,Sus scrofa,,Autocuration,1452,,U,0,CHEMBL874597,,,
4674,1,Vmax value was measured at 10 uM concentration of silyl ether.,,BAO_0000019,,Sus scrofa,,Autocuration,1452,,U,0,CHEMBL620969,,,
4675,1,Vmax value was measured at 5 uM concentration of silyl ether.,,BAO_0000019,,Sus scrofa,,Autocuration,1452,,U,0,CHEMBL620970,,,
4676,1,Inactivation of human leukocyte (neutrophil) elastase(HLE)(HNE) as rate constant,,BAO_0000357,,Homo sapiens,,Expert,11706,,D,9,CHEMBL620971,,,
4677,1,Area under curve was evaluated against man at a dose of 10 mg/kg after po administration,,BAO_0000218,,Homo sapiens,,Autocuration,1916,,U,0,CHEMBL620972,,,
4678,1,Compound was evaluated for area under the curve expressed as (h*ug/ml),,BAO_0000019,,Homo sapiens,,Autocuration,17791,,U,0,CHEMBL620973,,,
4679,1,Active metabolite of ifosfamide determined in humans; A-Active,,BAO_0000019,,Homo sapiens,,Autocuration,7766,,U,0,CHEMBL618243,,,
4680,1,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis,,BAO_0000019,,Homo sapiens,,Autocuration,6567,,U,0,CHEMBL618244,,,
4681,1,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; -0.5 to 1,,BAO_0000019,,Homo sapiens,,Autocuration,6567,,U,0,CHEMBL618245,,,
4682,1,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; 1-2,,BAO_0000019,,Homo sapiens,,Autocuration,6567,,U,0,CHEMBL618246,,,
4683,1,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; trace,,BAO_0000019,,Homo sapiens,,Autocuration,6567,,U,0,CHEMBL618247,,,
4684,1,Compound was evaluated for oral bioavailability in human,,BAO_0000218,,Homo sapiens,,Autocuration,17791,,U,0,CHEMBL618248,,,
4685,1,Metabolite of ifosfamide determined in urine; NF-Not found,Urine,BAO_0000019,,Homo sapiens,,Autocuration,7766,,U,0,CHEMBL618249,,1088.0,
4686,1,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection (Group A and B),,BAO_0000019,,Homo sapiens,,Autocuration,6852,,U,0,CHEMBL618250,,,
4687,1,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics,,BAO_0000019,,Homo sapiens,,Autocuration,6852,,U,0,CHEMBL874598,,,
4688,1,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics and lactose,,BAO_0000019,,Homo sapiens,,Autocuration,6852,,U,0,CHEMBL618251,,,
4689,1,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics,,BAO_0000019,,Homo sapiens,,Autocuration,6852,,U,0,CHEMBL618252,,,
4690,1,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics and lactose,,BAO_0000019,,Homo sapiens,,Autocuration,6852,,U,0,CHEMBL618253,,,
4691,1,Percent of compound in cirrhotic patients of sterile ascitic fluid (Group C),,BAO_0000019,,Homo sapiens,,Autocuration,6852,,U,0,CHEMBL618254,,,
4692,1,Percent of compound in healthy individuals (Group D),,BAO_0000019,,Homo sapiens,,Autocuration,6852,,U,0,CHEMBL618255,,,
4693,1,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,Liver,BAO_0000251,,Homo sapiens,,Autocuration,4397,,U,0,CHEMBL618983,,2107.0,
4694,1,Binding towards human plasma protein at 10 uM,,BAO_0000019,,Homo sapiens,,Autocuration,17409,,U,0,CHEMBL618984,,,
4695,1,Binding towards human plasma protein at 100 uM,,BAO_0000019,,Homo sapiens,,Autocuration,17409,,U,0,CHEMBL618985,,,
4696,1,Human plasma protein binding activity was determined,,BAO_0000019,,Homo sapiens,,Autocuration,17176,,U,0,CHEMBL618986,,,
4697,1,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),,BAO_0000019,,Homo sapiens,,Autocuration,15444,,U,0,CHEMBL618987,,,
4698,1,Percent binding of compound towards human plasma protein was determined,,BAO_0000019,,Homo sapiens,,Autocuration,17267,,U,0,CHEMBL618988,,,
4699,1,Plasma clearance in human liver microsomes,Liver,BAO_0000251,,Homo sapiens,,Autocuration,5944,In vitro,U,0,CHEMBL618989,,2107.0,
4700,1,In vitro intrinsic clearance in human liver microsome,Liver,BAO_0000251,,Homo sapiens,,Autocuration,5668,In vitro,U,0,CHEMBL618990,,2107.0,
4701,1,In vitro intrinsic clearance in human liver microsome,Liver,BAO_0000251,,Homo sapiens,,Autocuration,5669,In vitro,U,0,CHEMBL618991,,2107.0,
4702,1,In vitro microsome metabolism clearance in human was determined,,BAO_0000251,,Homo sapiens,,Autocuration,5041,In vitro,U,0,CHEMBL876725,,,
4703,1,In vitro microsome metabolism clearance in human was determined; High,,BAO_0000251,,Homo sapiens,,Autocuration,5041,In vitro,U,0,CHEMBL618992,,,
4704,1,In vitro microsome metabolism clearance in human was determined; ND denotes no data,,BAO_0000251,,Homo sapiens,,Autocuration,5041,In vitro,U,0,CHEMBL618993,,,
4705,1,Pharmacokinetic property (clearance) in human liver microsome,Liver,BAO_0000251,,Homo sapiens,,Autocuration,5676,In vitro,U,0,CHEMBL618994,,2107.0,
4706,1,Plasma clearance in human liver microsomes,Liver,BAO_0000251,,Homo sapiens,,Autocuration,5944,In vitro,U,0,CHEMBL618995,,2107.0,
4707,1,In vitro clearance in human liver microsomes,Liver,BAO_0000251,,Homo sapiens,,Autocuration,17538,In vitro,U,0,CHEMBL618996,,2107.0,
4708,1,Intrinsic clearance in human liver microsomes was determined,Liver,BAO_0000251,,Homo sapiens,,Autocuration,6331,In vitro,U,0,CHEMBL618997,,2107.0,
4709,1,Intrinsic clearance in human liver microsomes was determined,Liver,BAO_0000251,,Homo sapiens,,Autocuration,5948,In vitro,U,0,CHEMBL618998,,2107.0,
4710,1,Cmax (Tissue distribution) of compound was determined at a dose of 5 mg/kg in human,,BAO_0000218,,Homo sapiens,,Autocuration,5965,In vivo,U,0,CHEMBL618999,,,
4711,1,Maximum concentration was evaluated against man at a dose of 10 mg/kg after po administration,,BAO_0000218,,Homo sapiens,,Autocuration,1916,In vivo,U,0,CHEMBL620223,,,
4712,1,Cmin (Clearance) of compound was determined at a dose of 5 mg/kg in human,,BAO_0000218,,Homo sapiens,,Autocuration,5965,,U,0,CHEMBL620224,,,
4713,1,Stability in human plasma 2 hr after incubation expressed as percent concentration,,BAO_0000019,,Homo sapiens,,Autocuration,1299,,U,0,CHEMBL620225,,,
4714,1,Stability in human plasma 4 hr after incubation expressed as percent concentration,,BAO_0000019,,Homo sapiens,,Autocuration,1299,,U,0,CHEMBL620226,,,
4715,1,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 3 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Urine,BAO_0000019,,Homo sapiens,,Autocuration,7766,,U,0,CHEMBL620227,,1088.0,
4716,1,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 7 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Urine,BAO_0000019,,Homo sapiens,,Autocuration,7766,,U,0,CHEMBL876726,,1088.0,
4717,1,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 6 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Urine,BAO_0000019,,Homo sapiens,,Autocuration,7766,,U,0,CHEMBL620228,,1088.0,
4718,1,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 8 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Urine,BAO_0000019,,Homo sapiens,,Autocuration,7766,,U,0,CHEMBL620229,,1088.0,
4719,1,Mean-residence time was determined for compound after intraperitoneal administration in mice at 23 uM/kg,,BAO_0000218,,Mus musculus,,Intermediate,17764,In vivo,N,1,CHEMBL620230,,,
4720,1,Mean-residence time was determined for compound after intraperitoneal administration in mice at 25 uM/kg,,BAO_0000218,,Mus musculus,,Intermediate,17764,In vivo,N,1,CHEMBL620231,,,
4721,1,Mean-residence time was determined for compound after intraperitoneal administration in mice at 26 uM/kg,,BAO_0000218,,Mus musculus,,Intermediate,17764,In vivo,N,1,CHEMBL620232,,,
4722,1,Mean-residence time was determined for compound intravenous administration in mice at 23 uM/kg,,BAO_0000218,,Mus musculus,,Intermediate,17764,In vivo,N,1,CHEMBL620233,,,
4723,1,Metabolism of compound in Mouse S9 microsomes ('++++'indicates largest observed peak),,BAO_0000218,,Mus musculus,,Intermediate,14294,,N,1,CHEMBL620234,,,
4724,1,Metabolism of compound in mouse S9 microsomes ('+''indicates <20% largest observed peak),,BAO_0000218,,Mus musculus,,Intermediate,14294,,N,1,CHEMBL620235,,,
4725,1,Metabolism of compound in mouse S9 microsomes ('++++' indicates largest observed peak),,BAO_0000218,,Mus musculus,,Intermediate,14294,,N,1,CHEMBL620236,,,
4726,1,In vitro metabolic potential in mouse liver microsomes,Liver,BAO_0000218,,Mus musculus,,Intermediate,6251,,N,1,CHEMBL620237,,2107.0,
4727,1,Ability of compound to bind to plasma protein was evaluated in HSA cells,,BAO_0000218,,Mus musculus,,Intermediate,17582,,N,1,CHEMBL620238,,,
4728,1,Compound was tested for radioactivity level in mice adrenal glands (Compound is radiolabeled),Adrenal gland,BAO_0000218,,Mus musculus,,Intermediate,17811,,N,1,CHEMBL620239,,2369.0,
4729,1,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.2-4.9% ID/g,Brain,BAO_0000218,,Mus musculus,,Intermediate,17811,,N,1,CHEMBL620240,,955.0,
4730,1,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.6-4.4% ID/g,Brain,BAO_0000218,,Mus musculus,,Intermediate,17811,,N,1,CHEMBL620241,,955.0,
4731,1,Compound was tested for radioactivity level in mice heart (Compound is radiolabeled),,BAO_0000218,,Mus musculus,,Intermediate,17811,,N,1,CHEMBL876727,,,
4732,1,Compound was tested for radioactivity level in mice kidney (Compound is radiolabeled),Kidney,BAO_0000218,,Mus musculus,,Intermediate,17811,,N,1,CHEMBL620242,,2113.0,
4733,1,Compound was tested for radioactivity level in mice lungs (Compound is radiolabeled),,BAO_0000218,,Mus musculus,,Intermediate,17811,,N,1,CHEMBL620243,,,
4734,1,Tested for urinary recovery in mice after subcutaneous administration of 20 mg/Kg,,BAO_0000218,,Mus musculus,,Intermediate,5288,,N,1,CHEMBL620244,,,
4735,1,Compound was evaluated for its potency in CDF1 mice and the serum cholesterol levels were determined,Serum,BAO_0000218,,Mus musculus,,Intermediate,2717,,N,1,CHEMBL620245,,1977.0,
4736,1,Compound was evaluated for its potency in CDF1 mice and the serum metabolite levels were determined,Serum,BAO_0000218,,Mus musculus,,Intermediate,2717,,N,1,CHEMBL620246,,1977.0,
4737,1,Compound was evaluated for its potency in CDF1 mice and the serum triglyceride levels were determined,Serum,BAO_0000218,,Mus musculus,,Intermediate,2717,,N,1,CHEMBL620247,,1977.0,
4738,1,Half life of compound was determined in plasma of mice at 24 mg/Kg,Plasma,BAO_0000218,,Mus musculus,,Intermediate,17753,In vivo,N,1,CHEMBL620248,,1969.0,
4739,1,Half life of compound was determined in plasma of mice at 40 mg/Kg,Plasma,BAO_0000218,,Mus musculus,,Intermediate,17753,In vivo,N,1,CHEMBL873497,,1969.0,
4740,1,Half life of compound was determined in plasma of mice at 5 mg/Kg,Plasma,BAO_0000218,,Mus musculus,,Intermediate,17753,In vivo,N,1,CHEMBL620249,,1969.0,
4741,1,Half life after intraperitoneal administration in mice at 18 uM/kg,,BAO_0000218,,Mus musculus,,Intermediate,17764,In vivo,N,1,CHEMBL620250,,,
4742,1,Half life after intraperitoneal administration in mice at 23 uM/kg,,BAO_0000218,,Mus musculus,,Intermediate,17764,In vivo,N,1,CHEMBL620251,,,
4743,1,Half life after intraperitoneal administration in mice at 25 uM/kg,,BAO_0000218,,Mus musculus,,Intermediate,17764,In vivo,N,1,CHEMBL620252,,,
4744,1,Half life after intraperitoneal administration in mice at 26 uM/kg,,BAO_0000218,,Mus musculus,,Intermediate,17764,In vivo,N,1,CHEMBL620253,,,
4745,1,Half life after intravenous administration in mice at 23 uM/kg,,BAO_0000218,,Mus musculus,,Intermediate,17764,In vivo,N,1,CHEMBL620254,,,
4746,1,Half life after intravenous administration in mice at 24 uM/kg,,BAO_0000218,,Mus musculus,,Intermediate,17764,In vivo,N,1,CHEMBL620255,,,
4747,1,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,,BAO_0000218,,Mus musculus,,Intermediate,16597,In vivo,N,1,CHEMBL620256,,,
4748,1,Maximum time required to reach Cp max was evaluated in mice after intravenous administration; T max Not determined,,BAO_0000218,,Mus musculus,,Intermediate,2675,In vivo,N,1,CHEMBL876728,,,
4749,1,Maximum time required to reach Cp max was evaluated in mice after oral administration,,BAO_0000218,,Mus musculus,,Intermediate,2675,In vivo,N,1,CHEMBL620257,,,
4750,1,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),,BAO_0000218,,Mus musculus,,Intermediate,16597,In vivo,N,1,CHEMBL620258,,,
4751,1,"Compound was evaluated for the pharmacokinetic parameter, Terminal half life period",,BAO_0000218,,Mus musculus,,Intermediate,4890,In vivo,N,1,CHEMBL620259,,,
4752,1,Evaluated for pharmacokinetic parameter half-life in mouse at the dose 20 mg/kg,,BAO_0000218,,Mus musculus,,Intermediate,429,In vivo,N,1,CHEMBL620260,,,
4753,1,Half life of compound in mouse blood following i.v. administration of 10 mg/kg,Blood,BAO_0000218,,Mus musculus,,Intermediate,17837,In vivo,N,1,CHEMBL620261,,178.0,
4754,1,Half life at a dose of 10 mg/kg intravenous administration in mice.,,BAO_0000218,,Mus musculus,,Intermediate,16597,In vivo,N,1,CHEMBL620262,,,
4755,1,Half life at a dose of 10 mg/kg peroral administration in mice.,,BAO_0000218,,Mus musculus,,Intermediate,16597,In vivo,N,1,CHEMBL620263,,,
4756,1,Half life in ob/ob mice,,BAO_0000218,,Mus musculus,,Intermediate,6619,,N,1,CHEMBL620264,,,
4757,1,Half-life at a single subcutaneous administration of 40 mg/kg in mice,,BAO_0000218,,Mus musculus,,Intermediate,4066,In vivo,N,1,CHEMBL620265,,,
4758,1,Half-life was measured in mouse,,BAO_0000218,,Mus musculus,,Intermediate,4239,,N,1,CHEMBL620266,,,
4759,1,In vivo half life period was determined in murine septicemia at dose of 50 mg/kg,,BAO_0000218,,Mus musculus,,Intermediate,5969,In vivo,N,1,CHEMBL620267,,,
4760,1,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation,,BAO_0000218,,Mus musculus,,Intermediate,8999,,N,1,CHEMBL619364,,,
4761,1,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation; 10 % hydrolysis at 60 mins,,BAO_0000218,,Mus musculus,,Intermediate,8999,,N,1,CHEMBL619365,,,
4762,1,T2 in brain of mice at the oral dose of 50 mg/kg,Brain,BAO_0000218,,Mus musculus,,Intermediate,17641,,N,1,CHEMBL619366,,955.0,
4763,1,T2 in kidney of mice at the oral dose of 50 mg/kg,Kidney,BAO_0000218,,Mus musculus,,Intermediate,17641,,N,1,CHEMBL619367,,2113.0,
4764,1,T2 in liver of mice at the oral dose of 50 mg/kg,Liver,BAO_0000218,,Mus musculus,,Intermediate,17641,,N,1,CHEMBL619368,,2107.0,
4765,1,T2 in lungs of mice at the oral dose of 50 mg/kg,Lung,BAO_0000218,,Mus musculus,,Intermediate,17641,,N,1,CHEMBL619369,,2048.0,
4766,1,T2 in spleen of mice at the oral dose of 50 mg/kg,Spleen,BAO_0000218,,Mus musculus,,Intermediate,17641,,N,1,CHEMBL876729,,2106.0,
4767,1,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,,BAO_0000218,,Mus musculus,,Intermediate,16597,In vivo,N,1,CHEMBL619370,,,
4768,1,"Compound was evaluated for the pharmacokinetic parameter, maximum time constant",,BAO_0000218,,Mus musculus,,Intermediate,4890,In vivo,N,1,CHEMBL619371,,,
4769,1,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg,,BAO_0000218,,Mus musculus,,Intermediate,429,In vivo,N,1,CHEMBL619372,,,
4770,1,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg was determined,,BAO_0000218,,Mus musculus,,Intermediate,429,In vivo,N,1,CHEMBL620012,,,
4771,1,In vivo Tmax was determined in murine septicemia at dose of 100 mg/kg,,BAO_0000218,,Mus musculus,,Intermediate,5969,In vivo,N,1,CHEMBL620013,,,
4772,1,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",,BAO_0000219,,Homo sapiens,,Intermediate,16913,,N,1,CHEMBL620014,478.0,,
4773,1,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",,BAO_0000219,,Homo sapiens,,Intermediate,16913,,N,1,CHEMBL620015,478.0,,
4774,1,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-sensitive A2780/S human tumor cell lines",,BAO_0000219,,Homo sapiens,,Intermediate,16913,,N,1,CHEMBL621010,478.0,,
4775,1,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-sensitive A2780/S human tumor cell lines",,BAO_0000219,,Homo sapiens,,Intermediate,16913,,N,1,CHEMBL621011,478.0,,
4776,1,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",,BAO_0000219,,Homo sapiens,,Intermediate,16913,,N,1,CHEMBL621012,478.0,,
4777,1,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",,BAO_0000219,,Homo sapiens,,Intermediate,16913,,N,1,CHEMBL621013,478.0,,
4778,1,In vitro cytotoxicity against A2780TAX cell line,,BAO_0000219,,Homo sapiens,,Intermediate,17270,,N,1,CHEMBL621014,478.0,,
4779,1,In vitro inhibitory activity against human tumor cell line A2780cis,,BAO_0000219,,Homo sapiens,,Intermediate,5618,,N,1,CHEMBL618154,481.0,,
4780,1,Growth inhibition against A2780 cisplatin resistant wild-type ovarian cell lines,,BAO_0000219,,Homo sapiens,,Expert,17777,,N,1,CHEMBL618155,478.0,,
4781,1,Antitumor activity of compound for 96-h exposure in A2780cisR (acquired resistance to cisplatin) human ovarian cell line,,BAO_0000219,,Homo sapiens,,Intermediate,16112,,N,1,CHEMBL618156,481.0,,
4782,1,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),,BAO_0000219,,Homo sapiens,,Intermediate,15748,,N,1,CHEMBL618157,481.0,,
4783,1,Concentration required to inhibit A2780cisR cell growth when compared with control after incubation for 96 h at 37 C,,BAO_0000219,,Homo sapiens,,Intermediate,6633,,N,1,CHEMBL618328,478.0,,
4784,1,Compound was evaluated against human Ovarian carcinoma cell line A2780cisR,,BAO_0000219,,Homo sapiens,,Intermediate,16930,,N,1,CHEMBL618329,478.0,,
4785,1,Cytotoxicity against human ovarian carcinoma A2780cisR cell line,,BAO_0000219,,Homo sapiens,,Intermediate,17496,,N,1,CHEMBL618330,478.0,,
4786,1,In vitro antitumor activity against A2780cisR cell line.,,BAO_0000219,,Homo sapiens,,Expert,12989,,N,1,CHEMBL618331,478.0,,
4787,1,Tested for the cytotoxicity in A2780cisR ovarian cell line (cisR denotes resistance to cisplatin),,BAO_0000219,,Homo sapiens,,Intermediate,4840,,N,1,CHEMBL618332,478.0,,
4788,1,Resistant factor determined between IC50 of resistant line to that of A2780cisR cell line,,BAO_0000219,,Homo sapiens,,Expert,12989,,N,1,CHEMBL618333,478.0,,
4789,1,cytotoxicity against A2780cisR cells incubated for 24 hr in MTT assay,,BAO_0000219,,Homo sapiens,,Intermediate,16745,,N,1,CHEMBL618334,481.0,,
4790,1,Inhibition of A2780 / DDP-S human ovarian carcinoma cell proliferation,,BAO_0000219,,Homo sapiens,,Expert,16597,,N,1,CHEMBL618335,478.0,,
4791,1,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes,,BAO_0000019,,Rattus norvegicus,,Expert,16547,,D,9,CHEMBL618336,,,
4792,1,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),,BAO_0000019,,,,Expert,16547,,H,8,CHEMBL618337,,,
4793,1,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),,BAO_0000019,,Rattus norvegicus,,Expert,16547,,D,9,CHEMBL618338,,,
4794,1,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells uisng [3H]ZM-241385 or [125I]-IABOPX,,BAO_0000219,,Homo sapiens,,Expert,15856,,D,9,CHEMBL618339,722.0,,
4795,1,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells using [3H]ZM-241385 (or) [125 I]IABOPX at 10e-5 M,,BAO_0000219,,Homo sapiens,,Expert,15856,,D,9,CHEMBL618340,722.0,,
4796,1,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes,,BAO_0000019,,Mus musculus,,Expert,16547,,D,9,CHEMBL618341,,,
4797,1,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),,BAO_0000019,,,,Expert,16547,,H,8,CHEMBL618342,,,
4798,1,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),,BAO_0000019,,Mus musculus,,Expert,16547,,D,9,CHEMBL618343,,,
4799,1,Ability to displace the binding of [3H]-MRE 3008-F20 to the ligand binding site of CHO:hA3 (human Adenosine receptor) at concentration of 10 uM,,BAO_0000357,,,,Expert,17402,,H,8,CHEMBL621038,,,
4800,1,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01),,BAO_0000219,,Homo sapiens,,Autocuration,11746,,U,0,CHEMBL621039,574.0,,
4801,1,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01); Not active,,BAO_0000219,,Homo sapiens,,Autocuration,11746,,U,0,CHEMBL621040,574.0,,
4802,1,Compound was evaluated for cytotoxic activity against human melanoma cell line A375,,BAO_0000219,,Homo sapiens,,Intermediate,5455,,N,1,CHEMBL621041,455.0,,
4803,1,In vitro antitumor activity against A375 (melanoma) human tumor cell lines.,,BAO_0000219,,Homo sapiens,,Intermediate,2068,,N,1,CHEMBL621042,455.0,,
4804,1,In vitro antitumor activity against A375cell line extracted form melanoma,,BAO_0000219,,Homo sapiens,,Intermediate,2683,,N,1,CHEMBL621043,455.0,,
4805,1,Inhibition of cell growth in (A375) melan cell line,,BAO_0000219,,Homo sapiens,,Expert,15313,,N,1,CHEMBL621044,455.0,,
4806,1,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines A375,,BAO_0000219,,Homo sapiens,,Intermediate,13739,,N,1,CHEMBL621045,455.0,,
4807,1,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines. A375,,BAO_0000219,,Homo sapiens,,Intermediate,13739,,N,1,CHEMBL621046,455.0,,
4808,1,Compound was tested in vitro for cytotoxicity against A375 cell lines from melanoma.,,BAO_0000219,,Homo sapiens,,Intermediate,14750,,N,1,CHEMBL621047,455.0,,
4809,1,Antiproliferative activity measured against A427 human lung carcinoma,,BAO_0000219,,Homo sapiens,,Intermediate,14777,,N,1,CHEMBL621048,797.0,,
4810,1,Antiproliferative activity measured against A427 human lung carcinoma,,BAO_0000219,,Homo sapiens,,Intermediate,14777,,N,1,CHEMBL883798,797.0,,
4811,1,Cytotoxicity against lung carcinoma A427 tumor cell lines,,BAO_0000219,,Homo sapiens,,Intermediate,17672,,N,1,CHEMBL621049,797.0,,
4812,1,Inhibition of large cell lung carcinoma (A427),,BAO_0000219,,Homo sapiens,,Intermediate,14368,,N,1,CHEMBL621050,797.0,,
4813,1,Inhibition of large cell lung carcinoma (A427) after 48-h treatment,,BAO_0000219,,Homo sapiens,,Intermediate,14368,,N,1,CHEMBL621051,797.0,,
4814,1,Inhibitory activity against A427 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,,BAO_0000219,,Homo sapiens,,Intermediate,13866,,N,1,CHEMBL621052,797.0,,
4815,1,Inhibitory concentration in human lung carcinoma A427 cell line,,BAO_0000219,,Homo sapiens,,Intermediate,2545,,N,1,CHEMBL621053,797.0,,
4816,1,Inhibitory concentration in human lung carcinoma A427/VCR cell line,,BAO_0000219,,Homo sapiens,,Intermediate,2545,,N,1,CHEMBL621054,797.0,,
4817,1,Terminal phase volume of distribution was measured in monkey after an iv dose of 1 mg/kg,,BAO_0000218,,Cercopithecidae,,Autocuration,6062,In vivo,U,0,CHEMBL621055,,,
4818,1,Tested for volume of distribution upon iv administration to african green monkey,,BAO_0000218,,Cercopithecidae,,Autocuration,4578,In vivo,U,0,CHEMBL876398,,,
4819,1,Volume of distribution in monkey,,BAO_0000218,,Cercopithecidae,,Autocuration,17592,In vivo,U,0,CHEMBL621056,,,
4820,1,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,,BAO_0000218,,Macaca mulatta,,Autocuration,5005,In vivo,U,0,CHEMBL621057,,,
4821,1,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,,BAO_0000218,,Macaca mulatta,,Autocuration,5005,In vivo,U,0,CHEMBL621058,,,
4822,1,Pharmacokinetic property(Vdss) in cynomolgus monkey,,BAO_0000218,,Cercopithecidae,,Autocuration,5922,In vivo,U,0,CHEMBL621059,,,
4823,1,The distribution volume after intravenous administration in cynomolgus monkeys,,BAO_0000218,,Cercopithecidae,,Autocuration,5355,In vivo,U,0,CHEMBL621060,,,
4824,1,The distribution volume after oral administration in cynomolgus monkeys; NA means Not applicable,,BAO_0000218,,Cercopithecidae,,Autocuration,5355,In vivo,U,0,CHEMBL621061,,,
4825,1,The distribution volume after oral administration in cynomolgus monkeys; NA means not applicable,,BAO_0000218,,Cercopithecidae,,Autocuration,5355,In vivo,U,0,CHEMBL621062,,,
4826,1,Volume displacement was calculated in rhesus monkey,,BAO_0000218,,Cercopithecidae,,Autocuration,6057,In vivo,U,0,CHEMBL621063,,,
4827,1,Volume of distribution in steady state was determined in rhesus monkey,,BAO_0000218,,Cercopithecidae,,Autocuration,5145,In vivo,U,0,CHEMBL621064,,,
4828,1,Volume of distribution of compound was determined in monkey,,BAO_0000218,,Cercopithecidae,,Autocuration,6821,In vivo,U,0,CHEMBL621065,,,
4829,1,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),,BAO_0000218,,Cercopithecidae,,Autocuration,5334,In vivo,U,0,CHEMBL621066,,,
4830,1,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),,BAO_0000218,,Cercopithecidae,,Autocuration,5334,In vivo,U,0,CHEMBL621067,,,
4831,1,Volumes of distribution in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),,BAO_0000218,,Cercopithecidae,,Autocuration,6641,In vivo,U,0,CHEMBL621068,,,
4832,1,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,BAO_0000218,,Cercopithecidae,,Autocuration,2661,In vivo,U,0,CHEMBL876399,,,
4833,1,Volume distribution in monkey after administration of 1 mg/kg iv,,BAO_0000218,,Cercopithecidae,,Autocuration,6535,In vivo,U,0,CHEMBL621069,,,
4834,1,Volume distribution was determined in monkey after (iv) administration of a dose of 13 (uM/kg),,BAO_0000218,,Cercopithecidae,,Autocuration,4809,In vivo,U,0,CHEMBL621070,,,
4835,1,Volume of distribution was measured in monkey after an iv dose of 1 mg/kg,,BAO_0000218,,Cercopithecidae,,Autocuration,6062,In vivo,U,0,CHEMBL621071,,,
4836,1,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,BAO_0000218,,Cercopithecidae,,Autocuration,3443,In vivo,U,0,CHEMBL621072,,,
4837,1,Oral systemic bioavailability upon iv administration to african green monkey,,BAO_0000218,,Cercopithecidae,,Autocuration,4578,In vivo,U,0,CHEMBL618209,,,
4838,1,Plasma clearance was determined in monkey after (iv) administration of a dose of 13 (uM/kg),,BAO_0000218,,Cercopithecidae,,Autocuration,4809,In vivo,U,0,CHEMBL618210,,,
4839,1,Baboon plasma free fraction. ,,BAO_0000019,,Cercopithecidae,,Autocuration,11271,,U,0,CHEMBL618211,,,
4840,1,Area under the curve was calculated in rhesus monkey after iv administration,,BAO_0000218,,Cercopithecidae,,Autocuration,6057,,U,0,CHEMBL618212,,,
4841,1,Area under the curve was calculated in rhesus monkey after peroral administration,,BAO_0000019,,Cercopithecidae,,Autocuration,6057,,U,0,CHEMBL618213,,,
4842,1,Dose-normalized area under curve in monkey (p.o.) at 2.0 mpk,,BAO_0000019,,Cercopithecidae,,Autocuration,17853,,U,0,CHEMBL618214,,,
4843,1,Half life period in monkey after 5 mg/kg dose,,BAO_0000218,,Cercopithecidae,,Autocuration,5302,In vivo,U,0,CHEMBL873492,,,
4844,1,Half-life was determined in monkey after 3 mg/kg of i.v. dose,,BAO_0000218,,Cercopithecidae,,Autocuration,4257,In vivo,U,0,CHEMBL618272,,,
4845,1,Half-life was determined in monkey after 3 mg/kg of i.v. dose; Not determined,,BAO_0000218,,Cercopithecidae,,Autocuration,4257,In vivo,U,0,CHEMBL618273,,,
4846,1,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,Plasma,BAO_0000218,,Cercopithecidae,,Autocuration,13501,In vivo,U,0,CHEMBL618274,,1969.0,
4847,1,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for half life after administration into monkey at 3 mg/kg,,BAO_0000218,,Cercopithecidae,,Autocuration,5394,In vivo,U,0,CHEMBL618275,,,
4848,1,Compound was evaluated for half-life after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,BAO_0000218,,Cercopithecidae,,Autocuration,2661,In vivo,U,0,CHEMBL618276,,,
4849,1,Compound was evaluated for terminal half life in monkey,,BAO_0000019,,Cercopithecidae,,Autocuration,3341,,U,0,CHEMBL618277,,,
4850,1,Compound was evaluated for the half life period after iv administration in cynomolgus monkey,,BAO_0000218,,Cercopithecidae,,Autocuration,3045,In vivo,U,0,CHEMBL618278,,,
4851,1,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,Plasma,BAO_0000218,,Macaca mulatta,,Autocuration,5005,In vivo,U,0,CHEMBL618279,,1969.0,
4852,1,Half life of compound was determined in squirrel monkey,,BAO_0000019,,Cercopithecidae,,Autocuration,4847,,U,0,CHEMBL618280,,,
4853,1,Half life after iv administration in cynomolgus monkey,,BAO_0000218,,Macaca fascicularis,,Autocuration,4256,In vivo,U,0,CHEMBL618281,,,
4854,1,Half life in monkey plasma after administration of 1 mg/kg iv,Plasma,BAO_0000218,,Cercopithecidae,,Autocuration,6535,In vivo,U,0,CHEMBL618282,,1969.0,
4855,1,Half life was calculated in rhesus monkey,,BAO_0000019,,Cercopithecidae,,Autocuration,6057,,U,0,CHEMBL618283,,,
4856,1,Half life in monkey,,BAO_0000019,,Cercopithecidae,,Autocuration,17592,,U,0,CHEMBL618284,,,
4857,1,Half life in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),,BAO_0000218,,Cercopithecidae,,Autocuration,6641,In vivo,U,0,CHEMBL618285,,,
4858,1,Half life was evaluated in rhesus,,BAO_0000019,,Cercopithecidae,,Autocuration,5472,,U,0,CHEMBL618286,,,
4859,1,Half life period after oral administration (2.5 mg/kg) in monkey was determined,,BAO_0000218,,Cercopithecidae,,Autocuration,6221,In vivo,U,0,CHEMBL618287,,,
4860,1,Half life period was determine after peroral administration at 10 mpk in Rhesus,,BAO_0000218,,Cercopithecidae,,Autocuration,5668,In vivo,U,0,CHEMBL618288,,,
4861,1,Half life period was determined in monkey after (iv) administration of a dose of 13 (uM/kg),,BAO_0000218,,Cercopithecidae,,Autocuration,4809,In vivo,U,0,CHEMBL876393,,,
4862,1,Half life period was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,,BAO_0000218,,Cercopithecidae,,Autocuration,5546,In vivo,U,0,CHEMBL618289,,,
4863,1,Half life period was determined in squirrel monkey after iv administration at a dose of 5 mg/kg,,BAO_0000218,,Cercopithecidae,,Autocuration,5553,In vivo,U,0,CHEMBL618290,,,
4864,1,Half-life was calculated in monkey,,BAO_0000019,,Cercopithecidae,,Autocuration,6078,,U,0,CHEMBL618291,,,
4865,1,Half-life in Squirrel monkey,,BAO_0000019,,Cercopithecidae,,Autocuration,5147,,U,0,CHEMBL618292,,,
4866,1,Half-life in rhesus monkey,,BAO_0000019,,Cercopithecidae,,Autocuration,5145,,U,0,CHEMBL618293,,,
4867,1,Half-life was measured in monkey after an iv dose of 1 mg/kg,,BAO_0000218,,Cercopithecidae,,Autocuration,6062,In vivo,U,0,CHEMBL618294,,,
4868,1,Half-life period after intravenous administration in cynomolgus monkeys,,BAO_0000218,,Cercopithecidae,,Autocuration,5355,In vivo,U,0,CHEMBL618295,,,
4869,1,Half-life period after oral administration in cynomolgus monkeys,,BAO_0000218,,Cercopithecidae,,Autocuration,5355,In vivo,U,0,CHEMBL618296,,,
4870,1,Half-life period after oral administration in cynomolgus monkeys; ND meansn Not determined,,BAO_0000218,,Cercopithecidae,,Autocuration,5355,In vivo,U,0,CHEMBL618297,,,
4871,1,Portion of holoxan excreted in the form of the metabolite from 1500 mL of urine on day 9 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Urine,BAO_0000019,,Homo sapiens,,Autocuration,7766,,U,0,CHEMBL618298,,1088.0,
4872,1,Portion of holoxan excreted in the form of the metabolite from 1600 mL of urine on day 10 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Urine,BAO_0000019,,Homo sapiens,,Autocuration,7766,,U,0,CHEMBL618299,,1088.0,
4873,1,Portion of holoxan excreted in the form of the metabolite from 1700 mL of urine on day 5 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Urine,BAO_0000019,,Homo sapiens,,Autocuration,7766,,U,0,CHEMBL618300,,1088.0,
4874,1,Portion of holoxan excreted in the form of the metabolite from 2310 mL of urine on day 4 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Urine,BAO_0000019,,Homo sapiens,,Autocuration,7766,,U,0,CHEMBL618301,,1088.0,
4875,1,Percent ratio of the enantiomeric form (+)R extracted from the urine of alveolar rhabdomyosarcoma patients was determined,Urine,BAO_0000019,,Homo sapiens,,Autocuration,7766,,U,0,CHEMBL618302,,1088.0,
4876,1,Percent ratio of the enantiomeric form (+)R extracted from the urine of embryonal rhabdomyosarcoma patients was determined,Urine,BAO_0000019,,Homo sapiens,,Autocuration,7766,,U,0,CHEMBL876394,,1088.0,
4877,1,Percent ratio of the enantiomeric form (-)S extracted from the urine of alveolar rhabdomyosarcoma patients was determined,Urine,BAO_0000019,,Homo sapiens,,Autocuration,7766,,U,0,CHEMBL618303,,1088.0,
4878,1,Percent ratio of the enantiomeric form (-)S extracted from the urine of embryonal rhabdomyosarcoma patients was determined,Urine,BAO_0000019,,Homo sapiens,,Autocuration,7766,,U,0,CHEMBL618304,,1088.0,
4879,1,Bioavailability was evaluated in man at a dose of 10 mg/kg after po administration; not determined,,BAO_0000218,,Homo sapiens,,Autocuration,1916,In vivo,U,0,CHEMBL618305,,,
4880,1,Oral bioavailability in human,,BAO_0000218,,Homo sapiens,,Autocuration,16643,In vivo,U,0,CHEMBL618306,,,
4881,1,Compound was tested for human plasma protein binding,,BAO_0000019,,Homo sapiens,,Autocuration,17248,,U,0,CHEMBL618307,,,
4882,1,Compound was tested for human plasma protein binding; Not determined,,BAO_0000019,,Homo sapiens,,Autocuration,17248,,U,0,CHEMBL618308,,,
4883,1,Protein binding activity of compound in human plasma; % Free,,BAO_0000019,,Homo sapiens,,Autocuration,6241,,U,0,CHEMBL618309,,,
4884,1,Unbound fraction (plasma),,BAO_0000019,,Homo sapiens,,Autocuration,17716,,U,0,CHEMBL618310,,,
4885,1,Half life for the hydrolysis of compound in human blood serum,Plasma,BAO_0000366,,Homo sapiens,,Autocuration,17605,,U,0,CHEMBL873353,,1969.0,
4886,1,Half life period in human plasma using phosphate buffer (0.08 M),Plasma,BAO_0000366,,Homo sapiens,,Autocuration,17625,,U,0,CHEMBL618311,,1969.0,
4887,1,Half life period in human plasma using phosphate buffer (0.1 M),Plasma,BAO_0000366,,Homo sapiens,,Autocuration,17625,,U,0,CHEMBL618312,,1969.0,
4888,1,Half-life in human plasma was determined,Plasma,BAO_0000366,,Homo sapiens,,Autocuration,17747,,U,0,CHEMBL618313,,1969.0,
4889,1,Concentration required for 50% toxicity in metastatic lung carcinoma (MV522) cells.,,BAO_0000019,,Homo sapiens,,Autocuration,15613,,U,0,CHEMBL618314,,,
4890,1,Effect of compound on gelation time of human serum induced by dithiothreitol (DTT),,BAO_0000019,,Homo sapiens,,Autocuration,354,,U,0,CHEMBL618315,,,
4891,1,"Rate constant in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",,BAO_0000019,,Homo sapiens,,Autocuration,3741,,U,0,CHEMBL618316,,,
4892,1,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",,BAO_0000019,,Homo sapiens,,Autocuration,3741,,U,0,CHEMBL618317,,,
4893,1,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",,BAO_0000019,,Homo sapiens,,Autocuration,3741,,U,0,CHEMBL620138,,,
4894,1,Partition coefficient (logP),,BAO_0000019,,Homo sapiens,,Autocuration,17599,,U,0,CHEMBL858280,,,
4895,1,In vitro metabolic stability in human was measured as pmol/min/mg/protein,,BAO_0000019,,Homo sapiens,,Autocuration,5486,,U,0,CHEMBL620139,,,
4896,1,In vitro metabolic stability determined after 30 min of incubation in human hepatic microsomes,,BAO_0000251,,Homo sapiens,,Autocuration,5600,,U,0,CHEMBL620140,,,
4897,1,Metabolism of compound in human liver slices (male) ('+''indicates <20% largest observed peak),,BAO_0000019,,Homo sapiens,,Autocuration,14294,,U,0,CHEMBL620141,,,
4898,1,Metabolism of compound in human liver slices (male) ('++''indicates 20-50% largest observed peak),,BAO_0000019,,Homo sapiens,,Autocuration,14294,,U,0,CHEMBL620142,,,
4899,1,Metabolism of compound in human liver slices (male) ('++++' indicates largest observed peak),,BAO_0000019,,Homo sapiens,,Autocuration,14294,,U,0,CHEMBL620143,,,
4900,1,Metabolism of compound in human microsomes ('+''indicates <20% largest observed peak),,BAO_0000251,,Homo sapiens,,Autocuration,14294,,U,0,CHEMBL620144,,,
4901,1,Metabolism of compound in human microsomes ('++++' indicates largest observed peak),,BAO_0000251,,Homo sapiens,,Autocuration,14294,,U,0,CHEMBL620145,,,
4902,1,Metabolism of compound in human microsomes; Trace,,BAO_0000251,,Homo sapiens,,Autocuration,14294,,U,0,CHEMBL620146,,,
4903,1,Percent of compound remaining after 120 min of Metabolization upon incubation with human liver microsomes,Liver,BAO_0000251,,Homo sapiens,,Autocuration,6260,,U,0,CHEMBL620147,,2107.0,
4904,1,Percent metabolized in an in vitro human liver microsomal incubation assay after 60 min,,BAO_0000251,,Homo sapiens,,Autocuration,6187,,U,0,CHEMBL620148,,,
4905,1,In vitro metabolic potential in human liver microsomes,Liver,BAO_0000251,,Homo sapiens,,Autocuration,6251,,U,0,CHEMBL620149,,2107.0,
4906,1,Metabolism by recombinant human NAD(P)H:quinone oxidoreductase (NQO1) was evaluated,,BAO_0000019,,Homo sapiens,,Autocuration,3246,,U,0,CHEMBL876412,,,
4907,1,Tested for human plasma protein binding of the compound; Not tested,,BAO_0000019,,Homo sapiens,,Autocuration,17313,,U,0,CHEMBL619352,,,
4908,1,Compound was tested for percent protein binding (PB) in human,,BAO_0000019,,Homo sapiens,,Autocuration,6227,,U,0,CHEMBL619353,,,
4909,1,Protein binding in human plasma,Plasma,BAO_0000019,,Homo sapiens,,Autocuration,5530,,U,0,CHEMBL619354,,1969.0,
4910,1,Permeability coefficient (B to A) in Caco-2 cell,,BAO_0000019,,Homo sapiens,,Autocuration,6108,,U,0,CHEMBL619355,,,
4911,1,Permeability directional ratio (PB-A/PA-B) in Caco-2 cell,,BAO_0000019,,Homo sapiens,,Autocuration,6108,,U,0,CHEMBL619356,,,
4912,1,Apparent permeability coefficient (Papp) was determined in human Caco-2 cell monolayer (n = 3),,BAO_0000019,,Homo sapiens,,Autocuration,2774,,U,0,CHEMBL619357,,,
4913,1,In vitro rate of absorption observed as Caco-2 permeability in humans,,BAO_0000019,,Homo sapiens,,Autocuration,16643,,U,0,CHEMBL619358,,,
4914,1,Cellular permeability of compound was determined in Caco-2 cells; High,,BAO_0000219,,Homo sapiens,,Autocuration,17582,,U,0,CHEMBL619359,495.0,,
4915,1,Permeability in Caco-2 cells of compound,,BAO_0000219,,Homo sapiens,,Autocuration,6838,,U,0,CHEMBL619360,495.0,,
4916,1,Permeability coefficient (A to B) in Caco-2 cell,,BAO_0000019,,Homo sapiens,,Autocuration,6108,,U,0,CHEMBL619361,,,
4917,1,Permeability coefficient (B to A) in Caco-2 cell,,BAO_0000019,,Homo sapiens,,Autocuration,6108,,U,0,CHEMBL619362,,,
4918,1,Permeability coefficient (Papp) (Caco-2 cell monolayer),,BAO_0000019,,Homo sapiens,,Autocuration,6108,,U,0,CHEMBL619363,,,
4919,1,Compound was measured for binding rate for human serum at a carbapenem concentration of 10 ug/mL,,BAO_0000019,,Homo sapiens,,Autocuration,2146,,U,0,CHEMBL618942,,,
4920,1,Compound was tested for protein binding in human plasma,,BAO_0000019,,Homo sapiens,,Autocuration,4514,,U,0,CHEMBL618943,,,
4921,1,Transcellular permeability of the [(PA-B+PB-A)/2)] compound was determined in Caco-2 cell,,BAO_0000019,,Homo sapiens,,Autocuration,6108,,U,0,CHEMBL618944,,,
4922,1,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 3,Urine,BAO_0000019,,Homo sapiens,,Autocuration,7766,,U,0,CHEMBL618945,,1088.0,
4923,1,In vivo Tmax was determined in murine septicemia at dose of 50 mg/kg,,BAO_0000218,,Mus musculus,,Intermediate,5969,In vivo,N,1,CHEMBL618946,,,
4924,1,Maximum time was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),,BAO_0000218,,Mus musculus,,Intermediate,3277,In vivo,N,1,CHEMBL876413,,,
4925,1,Tested for Tmax value at the dose of 10 mg/kg when administered perorally in mouse,,BAO_0000218,,Mus musculus,,Intermediate,3802,In vivo,N,1,CHEMBL618947,,,
4926,1,Time taken to reach maximum concentration in plasma upon oral administration in mouse,Plasma,BAO_0000218,,Mus musculus,,Intermediate,2862,In vivo,N,1,CHEMBL618948,,1969.0,
4927,1,Time to reach maximum plasma concentration was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,Plasma,BAO_0000218,,Mus musculus,,Intermediate,6348,In vivo,N,1,CHEMBL618949,,1969.0,
4928,1,Tmax after intraperitoneal administration in mice at 23 uM/kg,,BAO_0000218,,Mus musculus,,Intermediate,17764,In vivo,N,1,CHEMBL618950,,,
4929,1,Tmax after oral administration at 30 mg/kg in ICR mouse,,BAO_0000218,,Mus musculus,,Intermediate,5781,In vivo,N,1,CHEMBL618951,,,
4930,1,Tmax after peroral administration in mice at 2.4 uM/kg,,BAO_0000218,,Mus musculus,,Intermediate,17764,In vivo,N,1,CHEMBL618952,,,
4931,1,Tmax at a single subcutaneous administration of 40 mg/kg in mice,,BAO_0000218,,Mus musculus,,Intermediate,4066,In vivo,N,1,CHEMBL618953,,,
4932,1,Tmax in brain of mice at the oral dose of 50 mg/kg,Brain,BAO_0000218,,Mus musculus,,Intermediate,17641,In vivo,N,1,CHEMBL618954,,955.0,
4933,1,Tmax in kidney of mice at the oral dose of 50 mg/kg,Kidney,BAO_0000218,,Mus musculus,,Intermediate,17641,In vivo,N,1,CHEMBL618955,,2113.0,
4934,1,Tmax in liver of mice at the oral dose of 50 mg/kg,Liver,BAO_0000218,,Mus musculus,,Intermediate,17641,In vivo,N,1,CHEMBL618956,,2107.0,
4935,1,Tmax in lungs of mice at the oral dose of 50 mg/kg,Lung,BAO_0000218,,Mus musculus,,Intermediate,17641,In vivo,N,1,CHEMBL618957,,2048.0,
4936,1,Tmax in mice at 18 uM/kg i.p. administration,,BAO_0000218,,Mus musculus,,Intermediate,17764,In vivo,N,1,CHEMBL618958,,,
4937,1,Tmax in mice at 23 uM/kg i.v. administration,,BAO_0000218,,Mus musculus,,Intermediate,17764,In vivo,N,1,CHEMBL618959,,,
4938,1,Tmax in mice at 25 uM/kg i.p. administration,,BAO_0000218,,Mus musculus,,Intermediate,17764,In vivo,N,1,CHEMBL618960,,,
4939,1,Tmax in mice at 26 uM/kg i.p. administration,,BAO_0000218,,Mus musculus,,Intermediate,17764,In vivo,N,1,CHEMBL876723,,,
4940,1,Tmax in spleen of mice at the oral dose of 50 mg/kg,Spleen,BAO_0000218,,Mus musculus,,Intermediate,17641,In vivo,N,1,CHEMBL618961,,2106.0,
4941,1,Tmax value at a dose of 10 mg/kg intravenous administration in mice.,,BAO_0000218,,Mus musculus,,Intermediate,16597,In vivo,N,1,CHEMBL618962,,,
4942,1,Tmax value at a dose of 10 mg/kg peroral administration in mice.,,BAO_0000218,,Mus musculus,,Intermediate,16597,In vivo,N,1,CHEMBL618963,,,
4943,1,Tmax value in IRC mice,,BAO_0000218,,Mus musculus,,Intermediate,5951,,N,1,CHEMBL618964,,,
4944,1,Tmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,,BAO_0000218,,Mus musculus,,Intermediate,5506,In vivo,N,1,CHEMBL618965,,,
4945,1,Tmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,,BAO_0000218,,Mus musculus,,Intermediate,5506,In vivo,N,1,CHEMBL618966,,,
4946,1,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg ( 0-24 hr ),Urine,BAO_0000218,,Mus musculus,,Intermediate,429,,N,1,CHEMBL618967,,1088.0,
4947,1,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg (0-24 hr),Urine,BAO_0000218,,Mus musculus,,Intermediate,429,,N,1,CHEMBL618968,,1088.0,
4948,1,Urinary recovery by disk method using Streptococcus pyogenes (0-24 h),Urine,BAO_0000218,,Mus musculus,,Intermediate,4066,,N,1,CHEMBL618969,,1088.0,
4949,1,The first compartment constitutes the majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,,BAO_0000218,,Mus musculus,,Intermediate,17734,,N,1,CHEMBL618970,,,
4950,1,The second majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,,BAO_0000218,,Mus musculus,,Intermediate,17734,,N,1,CHEMBL618971,,,
4951,1,Terminal phase volume of distribution was measured in mouse after an iv dose of 1 mg/kg,,BAO_0000218,,Mus musculus,,Intermediate,6062,In vivo,N,1,CHEMBL618972,,,
4952,1,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 100 mg/kg,,BAO_0000218,,Mus musculus,,Intermediate,5969,In vivo,N,1,CHEMBL618973,,,
4953,1,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg,,BAO_0000218,,Mus musculus,,Intermediate,5969,In vivo,N,1,CHEMBL618974,,,
4954,1,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,,BAO_0000218,,Mus musculus,,Intermediate,5969,In vivo,N,1,CHEMBL618975,,,
4955,1,Vd in mice,,BAO_0000218,,Mus musculus,,Intermediate,5980,In vivo,N,1,CHEMBL618976,,,
4956,1,Volume of distribution in mouse,,BAO_0000218,,Mus musculus,,Intermediate,17592,In vivo,N,1,CHEMBL618977,,,
4957,1,Volume of distribution was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,BAO_0000218,,Mus musculus,,Intermediate,6348,In vivo,N,1,CHEMBL876724,,,
4958,1,Volume of distribution of compound in plasma was determined at 24 mg/Kg,,BAO_0000218,,Mus musculus,,Intermediate,17753,In vivo,N,1,CHEMBL618978,,,
4959,1,Volume of distribution of compound in plasma was determined at 40 mg/Kg,,BAO_0000218,,Mus musculus,,Intermediate,17753,In vivo,N,1,CHEMBL618979,,,
4960,1,Volume of distribution of compound in plasma was determined at 5 mg/Kg,,BAO_0000218,,Mus musculus,,Intermediate,17753,In vivo,N,1,CHEMBL618980,,,
4961,1,Pharmacokinetic property (vdss) was measured in mouse,,BAO_0000218,,Mus musculus,,Intermediate,4239,In vivo,N,1,CHEMBL618981,,,
4962,1,Value distribution upon iv administration in mouse,,BAO_0000218,,Mus musculus,,Intermediate,2862,In vivo,N,1,CHEMBL618982,,,
4963,1,Volume of distribution after intraperitoneal administration of 100 mg/kg in mice,,BAO_0000218,,Mus musculus,,Intermediate,17734,In vivo,N,1,CHEMBL620150,,,
4964,1,Volume of distribution was evaluated in mice after intravenous administration,,BAO_0000218,,Mus musculus,,Intermediate,2675,In vivo,N,1,CHEMBL620151,,,
4965,1,Volume of distribution was evaluated in mice after oral administration,,BAO_0000218,,Mus musculus,,Intermediate,2675,In vivo,N,1,CHEMBL620152,,,
4966,1,Steady state volume of distribution of compound in mouse blood following i.v. administration of 10 mg/kg,,BAO_0000218,,Mus musculus,,Intermediate,17837,In vivo,N,1,CHEMBL620153,,,
4967,1,Steady state volume of distribution was determined in mice,,BAO_0000218,,Mus musculus,,Intermediate,5727,In vivo,N,1,CHEMBL876395,,,
4968,1,Volume distribution (steady state) of compound was determined in mouse,,BAO_0000218,,Mus musculus,,Intermediate,17852,In vivo,N,1,CHEMBL620154,,,
4969,1,Volume of solubility in solution after intravenous administration in mice at 24 uM/kg,,BAO_0000218,,Mus musculus,,Intermediate,17764,In vivo,N,1,CHEMBL620155,,,
4970,1,Vss value at a dose of 10 mg/kg intravenous administration in mice.,,BAO_0000218,,Mus musculus,,Intermediate,16597,In vivo,N,1,CHEMBL620156,,,
4971,1,Volume of distribution was measured in mouse after an iv dose of 1 mg/kg,,BAO_0000218,,Mus musculus,,Intermediate,6062,In vivo,N,1,CHEMBL620157,,,
4972,1,Biodistribution of compound (oxidized form) in in kidney tissue,Kidney,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,N,1,CHEMBL620158,,2113.0,
4973,1,Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip administration in DMSO solution,Blood,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,N,1,CHEMBL620159,,178.0,
4974,1,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",Blood,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,N,1,CHEMBL620160,,178.0,
4975,1,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Blood,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,N,1,CHEMBL620161,,178.0,
4976,1,Evaluated for the inhibitory concentration required to cause growth inhibition of A427Mer- cell line of lung using the MTT Cytotoxicity Assay,,BAO_0000219,,Homo sapiens,,Intermediate,10708,,N,1,CHEMBL620162,797.0,,
4977,1,Inhibition of A431 human squamous cell carcinoma cell proliferation,,BAO_0000219,,Homo sapiens,,Expert,16597,,N,1,CHEMBL620163,500.0,,
4978,1,Inhibition of cell growth of human epidermoid carcinoma xenograft (A431) model using cell based assay,,BAO_0000219,,Homo sapiens,,Expert,16062,,N,1,CHEMBL620833,500.0,,
4979,1,Inhibition of human epidermoid carcinoma xenograft (A431) tumor growth,,BAO_0000219,,Homo sapiens,,Expert,16062,,N,1,CHEMBL876396,500.0,,
4980,1,Concentration required to inhibit growth of human carcinoma epidermoid (A431) cell line,,BAO_0000219,,Homo sapiens,,Expert,16958,,N,1,CHEMBL620834,500.0,,
4981,1,Inhibition of A431 human carcinoma cell proliferation,,BAO_0000219,,Homo sapiens,,Expert,6700,,N,1,CHEMBL620835,500.0,,
4982,1,In vitro inhibition of A431 (human carcinoma) cell basal growth.,,BAO_0000219,,Homo sapiens,,Expert,17226,,N,1,CHEMBL620836,500.0,,
4983,1,Inhibitory concentration of compound against growth of human A431 cell line; Resistant,,BAO_0000219,,Homo sapiens,,Intermediate,6828,,N,1,CHEMBL620837,500.0,,
4984,1,In vitro cytotoxicity against epidermoid carcinoma cell line,,BAO_0000219,,Homo sapiens,,Intermediate,12314,,N,1,CHEMBL621017,500.0,,
4985,1,"In vivo efficacy following oral administration in nude mouse tumor model, xenograft A431 cells expressing EGF-R",,BAO_0000218,,Homo sapiens,,Expert,13412,,D,9,CHEMBL621018,500.0,,
4986,1,Antiproliferative activity of compound was measured on human tumor cell line A431.,,BAO_0000219,,Homo sapiens,,Intermediate,13299,,N,1,CHEMBL621019,500.0,,
4987,1,Antiproliferative effect of compound on A431 cell line expressing mutant p53,,BAO_0000219,,Homo sapiens,,Intermediate,17420,,N,1,CHEMBL621020,500.0,,
4988,1,Compound was evaluated for cell growth inhibition against A 431 cell line by irradiation in the presence of examined compound,,BAO_0000219,,Homo sapiens,,Intermediate,13678,,N,1,CHEMBL621021,500.0,,
4989,1,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,,BAO_0000219,,,,Expert,14171,,H,8,CHEMBL621022,500.0,,
4990,1,Tested for antiproliferative activity against human A431 cells,,BAO_0000219,,Homo sapiens,,Expert,6333,,N,1,CHEMBL621023,500.0,,
4991,1,Inhibition of epidermal growth factor receptor (EGF-R) autophosphorylation in A431 cells,,BAO_0000219,,Homo sapiens,,Expert,2356,,D,9,CHEMBL621024,500.0,,
4992,1,Concentration needed to inhibit 50% growth of the human A431 (epidermoid carcinoma) cell lines,,BAO_0000219,,Homo sapiens,,Expert,15578,,N,1,CHEMBL621025,500.0,,
4993,1,Inhibition of A431 cell proliferation,,BAO_0000219,,Homo sapiens,,Expert,5126,,N,1,CHEMBL621026,500.0,,
4994,1,Cytotoxic effect on A431 human epidermoid carcinoma cells,,BAO_0000219,,Homo sapiens,,Expert,6844,,N,1,CHEMBL621027,500.0,,
4995,1,Cytotoxic effect on A431 human epidermoid carcinoma cells (No response to 1 mM),,BAO_0000219,,Homo sapiens,,Expert,6844,,N,1,CHEMBL876397,500.0,,
4996,1,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line,,BAO_0000219,,Homo sapiens,,Intermediate,4925,,N,1,CHEMBL883797,500.0,,
4997,1,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line; NT=Not tested,,BAO_0000219,,Homo sapiens,,Intermediate,4925,,N,1,CHEMBL621028,500.0,,
4998,1,In vitro Growth Inhibitory activity against A431 Human vulva cancer cell line,,BAO_0000219,,Homo sapiens,,Intermediate,13978,,N,1,CHEMBL621029,500.0,,
4999,1,In vitro cytotoxicity of compound against human A431 (epidermoid) cancer cell line after 72 hr of drug exposure,,BAO_0000219,,Homo sapiens,,Intermediate,16786,,N,1,CHEMBL621030,500.0,,
5000,1,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells expressing EGF-R,,BAO_0000219,,,,Expert,13412,,H,8,CHEMBL621147,500.0,,
5001,1,In vivo antiproliferative activity against A431 cell line,,BAO_0000218,,Homo sapiens,,Intermediate,17824,,N,1,CHEMBL621148,500.0,,
5002,1,Inhibition of EGF-dependent autophosphorylation of EGF-R in human A431 cells,,BAO_0000219,,Homo sapiens,,Expert,12751,,D,9,CHEMBL621149,500.0,,
5003,1,Inhibition of A431 human epidermoid carcinoma cell proliferation,,BAO_0000219,,Homo sapiens,,Expert,12380,,N,1,CHEMBL621150,500.0,,
5004,1,Inhibition of autophosphorylation of human epidermal growth factor-receptor (EGF-R) expressed in A431 cells,,BAO_0000219,,Homo sapiens,,Expert,4959,,D,9,CHEMBL621151,500.0,,
5005,1,Inhibitory effect on nonphospho-Src after EGF (100 uM) stimulation of A431 cells (control=178),,BAO_0000219,,Homo sapiens,,Intermediate,6333,,N,1,CHEMBL621152,500.0,,
5006,1,Inhibitory effect on phospho-Src (Tyr416) after EGF (100 uM) stimulation of A431 cells (38),,BAO_0000219,,Homo sapiens,,Intermediate,6333,,N,1,CHEMBL621153,500.0,,
5007,1,Inhibitory effect on phospho-Src/nonphospho after EGF (100 uM) stimulation of A431 cells (21),,BAO_0000219,,Homo sapiens,,Intermediate,6333,,N,1,CHEMBL884000,500.0,,
5008,1,Inhibition of EGFR overexpressing A431 cell proliferation,,BAO_0000019,,Homo sapiens,,Expert,5296,,D,9,CHEMBL621154,,,
5009,1,Inhibition of A431 cell proliferation,,BAO_0000219,,Homo sapiens,,Expert,12624,,N,1,CHEMBL621155,500.0,,
5010,1,No inhibition of EGFR phosphorylation in A431 cells 8 hour after washing cells free of the inhibitor,,BAO_0000219,,Homo sapiens,,Expert,14926,,D,9,CHEMBL621156,500.0,,
5011,1,"Partial inhibition of EGFR phosphorylation in A431 cells, 8 hour after washing cells free of the inhibitor",,BAO_0000219,,Homo sapiens,,Expert,14926,,D,9,CHEMBL621157,500.0,,
5012,1,Irreversible inhibition of ATP binding site of EGFR (lack of phosphorylated EGFR) in A431 cells 8 hour after washing cells free of the inhibitor),,BAO_0000219,,,,Expert,14926,,H,8,CHEMBL621158,500.0,,
5013,1,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,,BAO_0000219,,Homo sapiens,,Intermediate,15144,,N,1,CHEMBL621159,500.0,,
5014,1,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,,BAO_0000219,,Homo sapiens,,Intermediate,15144,,N,1,CHEMBL621160,500.0,,
5015,1,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration at 2 uM after 48 h; Did not affect the viability,,BAO_0000219,,Homo sapiens,,Intermediate,5245,,N,1,CHEMBL621161,500.0,,
5016,1,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration in the range of 1-10 uM after 48 h; Did not affect the viability,,BAO_0000219,,Homo sapiens,,Intermediate,5245,,N,1,CHEMBL621162,500.0,,
5017,1,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,,BAO_0000219,,Homo sapiens,,Intermediate,5245,,N,1,CHEMBL621163,500.0,,
5018,1,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 0.01 uM after 48 h; Cell death,,BAO_0000219,,Homo sapiens,,Intermediate,5245,,N,1,CHEMBL621164,500.0,,
5019,1,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 2 uM after 48 h; Cell death,,BAO_0000219,,Homo sapiens,,Intermediate,5245,,N,1,CHEMBL621165,500.0,,
5020,1,Half-life period in cynomolgus monkey,,BAO_0000019,,Cercopithecidae,,Autocuration,5922,,U,0,CHEMBL619159,,,
5021,1,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in monkey plasma",Plasma,BAO_0000366,,Cercopithecidae,,Autocuration,1116,In vitro,U,0,CHEMBL619160,,1969.0,
5022,1,Longer half-life in monkey (i.v.) at 0.5 mpk,,BAO_0000218,,Cercopithecidae,,Autocuration,17853,In vivo,U,0,CHEMBL619161,,,
5023,1,Plasma half life in monkey,Plasma,BAO_0000366,,Cercopithecidae,,Autocuration,993,,U,0,CHEMBL619162,,1969.0,
5024,1,Plasma half-life in rhesus monkey,Plasma,BAO_0000366,,Cercopithecidae,,Autocuration,4514,,U,0,CHEMBL619163,,1969.0,
5025,1,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),Plasma,BAO_0000218,,Cercopithecidae,,Autocuration,5334,In vivo,U,0,CHEMBL619164,,1969.0,
5026,1,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),Plasma,BAO_0000218,,Cercopithecidae,,Autocuration,5334,In vivo,U,0,CHEMBL619320,,1969.0,
5027,1,Tested for half life upon iv administration to african green monkey,,BAO_0000218,,Cercopithecidae,,Autocuration,4578,In vivo,U,0,CHEMBL619321,,,
5028,1,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,BAO_0000218,,Cercopithecidae,,Autocuration,2661,In vivo,U,0,CHEMBL873336,,,
5029,1,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means Not applicable,,BAO_0000218,,Cercopithecidae,,Autocuration,5355,In vivo,U,0,CHEMBL619322,,,
5030,1,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means not applicable,,BAO_0000218,,Cercopithecidae,,Autocuration,5355,In vivo,U,0,CHEMBL619323,,,
5031,1,The time for peak concentration value after oral administration in cynomolgus monkeys,,BAO_0000218,,Cercopithecidae,,Autocuration,5355,In vivo,U,0,CHEMBL619324,,,
5032,1,Percentage of tracer or metabolite (CO2) in baboon plasma at 10 min after injection of the compound,,BAO_0000019,,Cercopithecidae,,Autocuration,11271,,U,0,CHEMBL619325,,,
5033,1,Percentage of tracer or metabolite (CO2) in baboon plasma at 1 min after injection of the compound,,BAO_0000019,,Cercopithecidae,,Autocuration,11271,,U,0,CHEMBL876411,,,
5034,1,Percentage of tracer or metabolite (CO2) in baboon plasma at 30 min after injection of the compound,,BAO_0000019,,Cercopithecidae,,Autocuration,11271,,U,0,CHEMBL619326,,,
5035,1,Percentage of tracer or metabolite (CO2) in baboon plasma at 5 min after injection of the compound,,BAO_0000019,,Cercopithecidae,,Autocuration,11271,,U,0,CHEMBL619327,,,
5036,1,Percentage of tracer or metabolite(EME) in baboon plasma at 10 min after injection of the compound,,BAO_0000019,,Cercopithecidae,,Autocuration,11271,,U,0,CHEMBL619328,,,
5037,1,Percentage of tracer or metabolite(EME) in baboon plasma at 1 min after injection of the compound,,BAO_0000019,,Cercopithecidae,,Autocuration,11271,,U,0,CHEMBL619329,,,
5038,1,Percentage of tracer or metabolite(EME) in baboon plasma at 30 min after injection of the compound,,BAO_0000019,,Cercopithecidae,,Autocuration,11271,,U,0,CHEMBL619330,,,
5039,1,Percentage of tracer or metabolite(EME) in baboon plasma at 5 min after injection of the compound,,BAO_0000019,,Cercopithecidae,,Autocuration,11271,,U,0,CHEMBL619331,,,
5040,1,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 10 min after injection of the compound,,BAO_0000019,,Cercopithecidae,,Autocuration,11271,,U,0,CHEMBL619332,,,
5041,1,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 1 min after injection of the compound,,BAO_0000019,,Cercopithecidae,,Autocuration,11271,,U,0,CHEMBL619333,,,
5042,1,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 30 min after injection of the compound,,BAO_0000019,,Cercopithecidae,,Autocuration,11271,,U,0,CHEMBL619334,,,
5043,1,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 5 min after injection of the compound,,BAO_0000019,,Cercopithecidae,,Autocuration,11271,,U,0,CHEMBL619335,,,
5044,1,Percentage of tracer or metabolite (unchanged) in baboon plasma at 10 min after injection of the compound,,BAO_0000019,,Cercopithecidae,,Autocuration,11271,,U,0,CHEMBL619336,,,
5045,1,Percentage of tracer or metabolite (unchanged) in baboon plasma at 1 min after injection of the compound,,BAO_0000019,,Cercopithecidae,,Autocuration,11271,,U,0,CHEMBL619337,,,
5046,1,Percentage of tracer or metabolite (unchanged) in baboon plasma at 30 min after injection of the compound,,BAO_0000019,,Cercopithecidae,,Autocuration,11271,,U,0,CHEMBL619338,,,
5047,1,Percentage of tracer or metabolite (unchanged) in baboon plasma at 5 min after injection of the compound,,BAO_0000019,,Cercopithecidae,,Autocuration,11271,,U,0,CHEMBL619339,,,
5048,1,Bioavailability in rat (cannulated) (dose 2 mg/kg),,BAO_0000218,,Rattus norvegicus,,Intermediate,5809,In vivo,N,1,CHEMBL619340,,,
5049,1,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,17720,In vivo,N,1,CHEMBL873496,,1969.0,
5050,1,AUC value in rat after IV administration at a dose of 10 mg/kg,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,3546,,N,1,CHEMBL619341,,1969.0,
5051,1,AUC value in rat after oral administration at a dose of 10 mg/kg,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,3546,,N,1,CHEMBL619342,,1969.0,
5052,1,Cmax value in rat after oral administration at a dose of 10 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,3546,In vivo,N,1,CHEMBL619343,,,
5053,1,Bioavailability in rat after oral administration at a dose of 10 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,3546,In vivo,N,1,CHEMBL619344,,,
5054,1,Tmax value in rat after oral administration at a dose of 10 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,3546,In vivo,N,1,CHEMBL619345,,,
5055,1,Vc value in rat after IV administration at a dose of 10 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,3546,,N,1,CHEMBL619346,,,
5056,1,Half life period in rat after IV administration at a dose of 10 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,3546,In vivo,N,1,CHEMBL619347,,,
5057,1,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,,BAO_0000019,,Papio hamadryas,,Autocuration,10625,,U,0,CHEMBL619348,,,
5058,1,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 0.5 min after injection in baboon; (Range = 0.08-0.11),,BAO_0000019,,Papio hamadryas,,Autocuration,10625,,U,0,CHEMBL619349,,,
5059,1,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 1.5 min after injection in baboon; (Range = 0.08-0.11),,BAO_0000019,,Papio hamadryas,,Autocuration,10625,,U,0,CHEMBL619350,,,
5060,1,The amount of unchanged tracer in baboon plasma was determined 1 min after injection of the carbon-11 labeled compound,,BAO_0000019,,Papio hamadryas,,Autocuration,10625,,U,0,CHEMBL619351,,,
5061,1,The amount of unchanged tracer in baboon plasma was determined 10 min after injection of the carbon-11 labeled compound,,BAO_0000019,,Papio hamadryas,,Autocuration,10625,,U,0,CHEMBL875953,,,
5062,1,The amount of unchanged tracer in baboon plasma was determined 30 min after injection of the carbon-11 labeled compound,,BAO_0000019,,Papio hamadryas,,Autocuration,10625,,U,0,CHEMBL621716,,,
5063,1,The amount of unchanged tracer in baboon plasma was determined 60 min after injection of the carbon-11 labeled compound,,BAO_0000019,,Papio hamadryas,,Autocuration,10625,,U,0,CHEMBL621717,,,
5064,1,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,,BAO_0000019,,Papio hamadryas,,Autocuration,10625,,U,0,CHEMBL621718,,,
5065,1,Area under curve after 1 mpk peroral administration to beagles,,BAO_0000019,,beagle,,Autocuration,3510,,U,0,CHEMBL621719,,,
5066,1,Area under curve after 2 mpk peroral administration to beagles,,BAO_0000019,,beagle,,Autocuration,3510,,U,0,CHEMBL621720,,,
5067,1,Cmax value after 1 mpk peroral administration to beagles,,BAO_0000218,,beagle,,Autocuration,3510,In vivo,U,0,CHEMBL621721,,,
5068,1,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 7,Urine,BAO_0000019,,Homo sapiens,,Autocuration,7766,,U,0,CHEMBL621722,,1088.0,
5069,1,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 6,Urine,BAO_0000019,,Homo sapiens,,Autocuration,7766,,U,0,CHEMBL621723,,1088.0,
5070,1,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 8,Urine,BAO_0000019,,Homo sapiens,,Autocuration,7766,,U,0,CHEMBL621724,,1088.0,
5071,1,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1500 mL of urine tested on day 9,Urine,BAO_0000019,,Homo sapiens,,Autocuration,7766,,U,0,CHEMBL623443,,1088.0,
5072,1,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1600 mL of urine tested on day 10,Urine,BAO_0000019,,Homo sapiens,,Autocuration,7766,,U,0,CHEMBL623444,,1088.0,
5073,1,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1700 mL of urine tested on day 5,Urine,BAO_0000019,,Homo sapiens,,Autocuration,7766,,U,0,CHEMBL623445,,1088.0,
5074,1,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 2310 mL of urine tested on day 4,Urine,BAO_0000019,,Homo sapiens,,Autocuration,7766,,U,0,CHEMBL623446,,1088.0,
5075,1,Metabolic stability observed at 30 min after administration in human liver microsomes,Liver,BAO_0000251,,Homo sapiens,,Autocuration,16643,,U,0,CHEMBL623447,,2107.0,
5076,1,Percent recovery of 100 ug/mL compound after administration in cirrhotic patients,,BAO_0000019,,Homo sapiens,,Autocuration,6852,,U,0,CHEMBL623448,,,
5077,1,Percent recovery of 10 ug/mL compound after administration in cirrhotic patients,,BAO_0000019,,Homo sapiens,,Autocuration,6852,,U,0,CHEMBL623449,,,
5078,1,Percent recovery of 500 ug/mL compound after administration in cirrhotic patients,,BAO_0000019,,Homo sapiens,,Autocuration,6852,,U,0,CHEMBL623450,,,
5079,1,"Compound remaining after incubation with 2 mg/mL of human liver microsomes at 37 degrees C for 30 min in a pH 7.4, 0.05 M phosphate buffer",Liver,BAO_0000251,,Homo sapiens,,Autocuration,6567,,U,0,CHEMBL623451,,2107.0,
5080,1,Metabolic stability (% remaining at 30 mins) in human S9.,,BAO_0000019,,Homo sapiens,,Autocuration,6570,,U,0,CHEMBL623452,,,
5081,1,Metabolic stability determined as remaining percent after 30 min of incubation in human isolated liver S9 preparations; N/D= Not determined,,BAO_0000019,,Homo sapiens,,Autocuration,6570,,U,0,CHEMBL623453,,,
5082,1,Percent parent compound remaining after 20 min incubation with human liver microsomes,Liver,BAO_0000251,,Homo sapiens,,Autocuration,5237,,U,0,CHEMBL623454,,2107.0,
5083,1,Percent parent compound remaining after 20 min incubation with human liver microsomes; ND=No data,Liver,BAO_0000251,,Homo sapiens,,Autocuration,5237,,U,0,CHEMBL623455,,2107.0,
5084,1,Percent parent compound remaining after 20 min incubation with human liver microsomes; No data,Liver,BAO_0000251,,Homo sapiens,,Autocuration,5237,,U,0,CHEMBL624371,,2107.0,
5085,1,First pass metabolism and metabolic bioavailability using human hepatic microsomes,,BAO_0000218,,Homo sapiens,,Autocuration,5202,,U,0,CHEMBL624372,,,
5086,1,Percent compound remaining in human plasma after incubation for 60 min at 37 C.,,BAO_0000019,,Homo sapiens,,Autocuration,5481,,U,0,CHEMBL624373,,,
5087,1,Percent remaining in human plasma after incubation for 60 min at 37 C.,,BAO_0000019,,Homo sapiens,,Autocuration,5481,,U,0,CHEMBL624374,,,
5088,1,The percent remaining in human plasma after 30 min was determined,,BAO_0000019,,Homo sapiens,,Autocuration,3956,,U,0,CHEMBL624556,,,
5089,1,Conversion rate of the prodrug in human plasma,Plasma,BAO_0000366,,Homo sapiens,,Autocuration,5074,,U,0,CHEMBL624557,,1969.0,
5090,1,Conversion rate of the prodrug in human plasma; ND means no data,Plasma,BAO_0000366,,Homo sapiens,,Autocuration,5074,,U,0,CHEMBL624558,,1969.0,
5091,1,Half life of compound was determined in human blood,Blood,BAO_0000221,,Homo sapiens,,Autocuration,4727,,U,0,CHEMBL624559,,178.0,
5092,1,Half life of compound was determined in man with once daily dosing,,BAO_0000019,,Homo sapiens,,Autocuration,5965,,U,0,CHEMBL624560,,,
5093,1,Half life in human microsomes,,BAO_0000251,,Homo sapiens,,Autocuration,5732,In vitro,U,0,CHEMBL624561,,,
5094,1,Half life in human plasma,Plasma,BAO_0000366,,Homo sapiens,,Autocuration,5819,,U,0,CHEMBL624562,,1969.0,
5095,1,Half life in human plasma; Not detected,Plasma,BAO_0000366,,Homo sapiens,,Autocuration,5819,,U,0,CHEMBL624563,,1969.0,
5096,1,Half life period was evaluated against man at a dose of 10 mg/kg after po administration,,BAO_0000218,,Homo sapiens,,Autocuration,1916,In vivo,U,0,CHEMBL624564,,,
5097,1,Half-life for oxidative metabolic stability was determined using rat liver microsomes,Liver,BAO_0000251,,Homo sapiens,,Autocuration,6597,In vitro,U,0,CHEMBL624565,,2107.0,
5098,1,Half-life in human plasma,Plasma,BAO_0000366,,Homo sapiens,,Autocuration,5229,,U,0,CHEMBL875152,,1969.0,
5099,1,Half-life of the parent prodrug in plasma,Plasma,BAO_0000366,,Homo sapiens,,Autocuration,5229,,U,0,CHEMBL624566,,1969.0,
5100,1,In vitro half life in human plasma was determined,Plasma,BAO_0000366,,Homo sapiens,,Autocuration,2192,In vitro,U,0,CHEMBL873805,,1969.0,
5101,1,The compound was tested In Vitro for half life in human liver microsomes.,Liver,BAO_0000251,,Homo sapiens,,Autocuration,3032,In vitro,U,0,CHEMBL624567,,2107.0,
5102,1,Maximum time was evaluated against man at a dose of 10 mg/kg after po administration,,BAO_0000218,,Homo sapiens,,Autocuration,1916,In vivo,U,0,CHEMBL624568,,,
5103,1,Observed volume of distribution,,BAO_0000218,,Homo sapiens,,Autocuration,17716,In vivo,U,0,CHEMBL624569,,,
5104,1,Oral bioavailability in human,,BAO_0000218,,Homo sapiens,,Autocuration,15778,In vivo,U,0,CHEMBL624570,,,
5105,1,Tested for human plasma protein binding of the compound,,BAO_0000019,,Homo sapiens,,Autocuration,17313,,U,0,CHEMBL624571,,,
5106,1,"First order rate constant, k was determined in human plasma",,BAO_0000019,,Homo sapiens,,Autocuration,4231,,U,0,CHEMBL624572,,,
5107,1,Observed rate constant in 80% human plasma at 37 degree Centigrade,,BAO_0000019,,Homo sapiens,,Autocuration,4755,,U,0,CHEMBL624573,,,
5108,1,Observed rate constant in 80% human plasma at 37 degree Centigrade,,BAO_0000019,,Homo sapiens,,Autocuration,4755,,U,0,CHEMBL875153,,,
5109,1,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,Liver,BAO_0000251,,Homo sapiens,,Autocuration,16907,,U,0,CHEMBL624574,,2107.0,
5110,1,The compound was tested for the plasma binding in human,,BAO_0000019,,Homo sapiens,,Autocuration,10839,,U,0,CHEMBL624575,,,
5111,1,Plasma protein binding (human),,BAO_0000019,,Homo sapiens,,Autocuration,10839,,U,0,CHEMBL624576,,,
5112,1,Compound was evaluated for half-life in human liver microsomes,Liver,BAO_0000251,,Homo sapiens,,Autocuration,3199,In vitro,U,0,CHEMBL624577,,2107.0,
5113,1,Half life measured in vitro for its stability in human blood,Blood,BAO_0000221,,Homo sapiens,,Autocuration,1345,In vitro,U,0,CHEMBL624578,,178.0,
5114,1,Half life in human serum,Serum,BAO_0000019,,Homo sapiens,,Autocuration,4297,,U,0,CHEMBL622796,,1977.0,
5115,1,Half life in human serum; ND=not determined,Serum,BAO_0000019,,Homo sapiens,,Autocuration,4297,,U,0,CHEMBL622797,,1977.0,
5116,1,Half life were determined in CEM-SS cell extract in decomposition step 1,,BAO_0000019,,Homo sapiens,,Autocuration,4297,,U,0,CHEMBL622798,,,
5117,1,Half life were determined in CEM-SS cell extract in decomposition step 2,,BAO_0000019,,Homo sapiens,,Autocuration,4297,,U,0,CHEMBL622799,,,
5118,1,Half life of the in human plasma,Plasma,BAO_0000366,,Homo sapiens,,Autocuration,4231,,U,0,CHEMBL622800,,1969.0,
5119,1,Half life period in human hepatic S9 fraction was determined,,BAO_0000220,,Homo sapiens,,Autocuration,5633,In vitro,U,0,CHEMBL622801,,,
5120,1,Half life period in human liver microsome was determined,Liver,BAO_0000251,,Homo sapiens,,Autocuration,5633,In vitro,U,0,CHEMBL622802,,2107.0,
5121,1,Half life period was determined; 6-7,,BAO_0000019,,Homo sapiens,,Autocuration,17791,,U,0,CHEMBL622803,,,
5122,1,Half life period was evaluated in human,,BAO_0000019,,Homo sapiens,,Autocuration,17791,,U,0,CHEMBL875154,,,
5123,1,Half life time in human plasma,Plasma,BAO_0000366,,Homo sapiens,,Autocuration,3160,,U,0,CHEMBL622804,,1969.0,
5124,1,"Biodistribution in mice as total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Brain,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,N,1,CHEMBL622805,,955.0,
5125,1,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO sol.",Heart,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,N,1,CHEMBL622611,,948.0,
5126,1,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Heart,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,N,1,CHEMBL622612,,948.0,
5127,1,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after dosing, in DMSO sol.",Kidney,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,N,1,CHEMBL875160,,2113.0,
5128,1,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",Kidney,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,N,1,CHEMBL622613,,2113.0,
5129,1,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Kidney,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,N,1,CHEMBL622614,,2113.0,
5130,1,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after dosing, in DMSO sol.",Liver,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,N,1,CHEMBL622615,,2107.0,
5131,1,Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after ip administration in DMSO solution,Liver,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,N,1,CHEMBL622616,,2107.0,
5132,1,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Liver,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,N,1,CHEMBL622617,,2107.0,
5133,1,Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip administration in DMSO solution,Spleen,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,N,1,CHEMBL622618,,2106.0,
5134,1,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",Spleen,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,N,1,CHEMBL622619,,2106.0,
5135,1,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Spleen,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,N,1,CHEMBL622620,,2106.0,
5136,1,"Biodistribution in mice, total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",Brain,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,N,1,CHEMBL622621,,955.0,
5137,1,Biodistribution of compound (oxidized form) in blood tissue,Blood,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,N,1,CHEMBL622622,,178.0,
5138,1,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",Blood,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,N,1,CHEMBL622623,,178.0,
5139,1,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",Blood,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,N,1,CHEMBL622624,,178.0,
5140,1,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",Blood,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,N,1,CHEMBL622625,,178.0,
5141,1,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Blood,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,N,1,CHEMBL622626,,178.0,
5142,1,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",Blood,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,N,1,CHEMBL622627,,178.0,
5143,1,Biodistribution of compound (oxidized form) in brain tissue of mice,Brain,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,N,1,CHEMBL622628,,955.0,
5144,1,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",Brain,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,N,1,CHEMBL622629,,955.0,
5145,1,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO",Brain,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,N,1,CHEMBL622630,,955.0,
5146,1,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Brain,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,N,1,CHEMBL622631,,955.0,
5147,1,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",Brain,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,N,1,CHEMBL622632,,955.0,
5148,1,"Biodistribution of compound (oxidized form) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO solution",Brain,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,N,1,CHEMBL622633,,955.0,
5149,1,Biodistribution of compound (oxidized form) in heart tissue of mice,Heart,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,N,1,CHEMBL622634,,948.0,
5150,1,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",Heart,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,N,1,CHEMBL622635,,948.0,
5151,1,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",Heart,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,N,1,CHEMBL875161,,948.0,
5152,1,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO",Heart,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,N,1,CHEMBL622636,,948.0,
5153,1,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Heart,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,N,1,CHEMBL623335,,948.0,
5154,1,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",Heart,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,N,1,CHEMBL623336,,948.0,
5155,1,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",Kidney,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,N,1,CHEMBL623337,,2113.0,
5156,1,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",Kidney,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,N,1,CHEMBL623338,,2113.0,
5157,1,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO",Kidney,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,N,1,CHEMBL623339,,2113.0,
5158,1,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Kidney,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,N,1,CHEMBL623524,,2113.0,
5159,1,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",Kidney,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,N,1,CHEMBL623525,,2113.0,
5160,1,Biodistribution of compound (oxidized form) in liver tissue,Liver,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,N,1,CHEMBL623526,,2107.0,
5161,1,"Biodistribution of compound (oxidized form) in liver tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",Liver,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,N,1,CHEMBL623527,,2107.0,
5162,1,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",Liver,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,N,1,CHEMBL623528,,2107.0,
5163,1,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration in the range of 1-10 uM of the compound after 48 h; Cell death,,BAO_0000219,,Homo sapiens,,Intermediate,5245,,N,1,CHEMBL624615,500.0,,
5164,1,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,,BAO_0000219,,Homo sapiens,,Intermediate,5245,,N,1,CHEMBL621672,500.0,,
5165,1,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 10-24 days)",,BAO_0000218,,,,Expert,16289,,N,1,CHEMBL621673,500.0,,
5166,1,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 12-26 days)",,BAO_0000218,,,,Expert,16289,,N,1,CHEMBL621674,500.0,,
5167,1,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,,BAO_0000219,,Homo sapiens,,Expert,16093,,D,9,CHEMBL884002,500.0,,
5168,1,"Concentration required to inhibit the epidermoid A431 cell growth by 50%, P53 status of cell line used was wild-type. ",,BAO_0000219,,Homo sapiens,,Intermediate,16825,,N,1,CHEMBL621850,500.0,,
5169,1,Inhibitory activity against proliferation of human epidermoid carcinoma (A431) cells,,BAO_0000219,,Homo sapiens,,Intermediate,4848,,N,1,CHEMBL621851,500.0,,
5170,1,Inhibition of EGF-dependent autophosphorylation of EGF-R in A431 cells,,BAO_0000219,,Homo sapiens,,Expert,14827,,D,9,CHEMBL621852,500.0,,
5171,1,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture,,BAO_0000219,,Homo sapiens,,Expert,14827,,D,9,CHEMBL621853,500.0,,
5172,1,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 10-24 days)",,BAO_0000218,,,,Expert,16289,,N,1,CHEMBL621854,500.0,,
5173,1,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",,BAO_0000218,,,,Expert,16289,,N,1,CHEMBL621855,500.0,,
5174,1,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",,BAO_0000218,,,,Expert,16289,,N,1,CHEMBL623724,500.0,,
5175,1,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 24",,BAO_0000218,,,,Expert,16289,,N,1,CHEMBL623725,500.0,,
5176,1,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 26",,BAO_0000218,,,,Expert,16289,,N,1,CHEMBL623726,500.0,,
5177,1,"Irreversible inhibition of EGF-R phosphorylation in A431 cells, 8 hr after washing cells free of compound",,BAO_0000219,,Homo sapiens,,Expert,16289,,D,9,CHEMBL623727,500.0,,
5178,1,Irreversible inhibition of formation of phosphorylated EGFR in A431 cells 8 hr after washing cells free of compound,,BAO_0000219,,,,Expert,16289,,H,8,CHEMBL623728,500.0,,
5179,1,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 10-24",,BAO_0000218,,,,Expert,16289,,N,1,CHEMBL623729,500.0,,
5180,1,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",,BAO_0000218,,,,Expert,16289,,N,1,CHEMBL623730,500.0,,
5181,1,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",,BAO_0000218,,,,Expert,16289,,N,1,CHEMBL623731,500.0,,
5182,1,"Ratio of treated and control A431 cell tumor mass in mice at 5 mg/kg peroral dose, days 7-21 administration",,BAO_0000218,,Mus musculus,,Expert,14555,,N,1,CHEMBL623732,500.0,,
5183,1,"Difference in days for treated (T) and control (C) A431 cell tumors to reach 750 mg in mice at 5 mg/kg peroral dose, days 7-21 administration",,BAO_0000218,,Mus musculus,,Expert,14555,,N,1,CHEMBL623733,500.0,,
5184,1,"Net reduction in tumor burden between first and last treatments of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",,BAO_0000218,,Mus musculus,,Expert,14555,,N,1,CHEMBL623734,500.0,,
5185,1,"Weight change of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",,BAO_0000218,,Mus musculus,,Expert,14555,,N,1,CHEMBL623735,500.0,,
5186,1,In vitro antiproliferative effect against A431 human epidermoid carcinoma cells,,BAO_0000219,,Homo sapiens,,Expert,1937,,N,1,CHEMBL623736,500.0,,
5187,1,In vitro tumor cell growth inhibitory activity against Human leiomyosarcoma A431 cell lines,,BAO_0000219,,Homo sapiens,,Intermediate,13739,,N,1,CHEMBL623737,500.0,,
5188,1,Cytotoxicity against A437 cells is the dose giving 50% decrease in the formation of formazan dye,,BAO_0000219,,Homo sapiens,,Intermediate,3558,,N,1,CHEMBL623738,500.0,,
5189,1,Dose giving a 50% decrease in the living cell number (A437 cells),,BAO_0000219,,Homo sapiens,,Intermediate,3558,,N,1,CHEMBL875168,500.0,,
5190,1,In vitro inhibitory concentration against proliferation of A459 cell line.,,BAO_0000219,,Homo sapiens,,Expert,17686,,N,1,CHEMBL623739,646.0,,
5191,1,Inhibitory concentration of compound for cytotoxicity against A459 human lung cells was determined,,BAO_0000219,,Homo sapiens,,Intermediate,5305,,N,1,CHEMBL623740,646.0,,
5192,1,Inhibition of growth of human NSCL non small cell lung carcinoma cell line (A459) after 72 hr of drug exposure,,BAO_0000219,,Homo sapiens,,Intermediate,3614,,N,1,CHEMBL624424,646.0,,
5193,1,In vitro antitumor activity against renal A498 tumor cell lines,,BAO_0000219,,Homo sapiens,,Intermediate,17229,,N,1,CHEMBL624425,624.0,,
5194,1,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors",,BAO_0000219,,Homo sapiens,,Intermediate,15935,,N,1,CHEMBL624426,624.0,,
5195,1,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors in folate deficient medium",,BAO_0000219,,Homo sapiens,,Intermediate,15935,,N,1,CHEMBL624427,624.0,,
5196,1,Cytotoxicity against A498 Tumor cell line in SRB Cell viability test,,BAO_0000219,,Homo sapiens,,Intermediate,15560,,N,1,CHEMBL624428,624.0,,
5197,1,Cytotoxicity concentration against human kidney carcinoma A-498 cell line,,BAO_0000219,,Homo sapiens,,Intermediate,13891,,N,1,CHEMBL624429,624.0,,
5198,1,Cytotoxicity concentration against human kidney carcinoma A-498 cell line; NT =Not tested,,BAO_0000219,,Homo sapiens,,Intermediate,13891,,N,1,CHEMBL624620,624.0,,
5199,1,Cytotoxicity on kidney carcinoma (A-498) cell line,,BAO_0000219,,Homo sapiens,,Intermediate,13788,,N,1,CHEMBL624621,624.0,,
5200,1,Compound was evaluated against Human cell line renal A498,,BAO_0000219,,Homo sapiens,,Intermediate,15403,,N,1,CHEMBL624622,624.0,,
5201,1,Compound was tested for inhibition of A498 human renal cancer cell line,,BAO_0000219,,Homo sapiens,,Intermediate,1009,,N,1,CHEMBL624623,624.0,,
5202,1,Growth inhibitory activity against A498 human cancer cell line,,BAO_0000219,,Homo sapiens,,Intermediate,1043,,N,1,CHEMBL874365,624.0,,
5203,1,In vitro antitumor activity against human renal A498 cell line,,BAO_0000219,,Homo sapiens,,Intermediate,5858,,N,1,CHEMBL624624,624.0,,
5204,1,In vitro cytotoxic activity against renal (A498) cell line,,BAO_0000219,,Homo sapiens,,Intermediate,5958,,N,1,CHEMBL624625,624.0,,
5205,1,In vitro cytotoxic activity against human renal cancer (A498) cell line,,BAO_0000219,,Homo sapiens,,Intermediate,5506,,N,1,CHEMBL624626,624.0,,
5206,1,Tested for cytostatic activity against renal A498 cell line,,BAO_0000219,,Homo sapiens,,Intermediate,12781,,N,1,CHEMBL624627,624.0,,
5207,1,The compound was tested for the concentration to inhibit 50% of renal A498 cell lines.,,BAO_0000219,,Homo sapiens,,Intermediate,14399,,N,1,CHEMBL883157,624.0,,
5208,1,In vitro cytotoxic activity against renal (A498) cell line at a concentration of 10e-5 M,,BAO_0000219,,Homo sapiens,,Expert,5958,,N,1,CHEMBL624628,624.0,,
5209,1,Cmax value after 2 mpk peroral administration to beagles,,BAO_0000218,,beagle,,Autocuration,3510,In vivo,U,0,CHEMBL624629,,,
5210,1,Bioavailability,,BAO_0000218,,Canis lupus familiaris,,Autocuration,3510,In vivo,U,0,CHEMBL623551,,,
5211,1,Bioavailability after 1 mpk peroral administration to beagles,,BAO_0000218,,Canis lupus familiaris,,Autocuration,3510,In vivo,U,0,CHEMBL623552,,,
5212,1,Bioavailability after 2 mpk peroral administration to beagles,,BAO_0000218,,Canis lupus familiaris,,Autocuration,3510,In vivo,U,0,CHEMBL623553,,,
5213,1,Specificity constant of the BSA-catalyzed deprotonation of compound at pH 9,,BAO_0000019,,Bos taurus,,Autocuration,3085,,U,0,CHEMBL623554,,,
5214,1,Specificity constant of the bovine serum albumin catalyzed reaction expressed as (kcat/KM)/kuncat,,BAO_0000019,,Bos taurus,,Autocuration,3085,,U,0,CHEMBL623555,,,
5215,1,Michaelis-Menten kinetics of the bovine serum albumin catalyzed reaction of the compound,,BAO_0000019,,Bos taurus,,Autocuration,3085,,U,0,CHEMBL623556,,,
5216,1,Solubility against bovine alpha-chymotrypsin,,BAO_0000019,,Bos taurus,,Autocuration,9372,,U,0,CHEMBL623557,,,
5217,1,Rate constant of the bovine serum albumin catalyzed reaction of the compound,,BAO_0000019,,Bos taurus,,Autocuration,3085,,U,0,CHEMBL623558,,,
5218,1,Rate constant of the bovine serum albumin catalyzed reaction of the compound,,BAO_0000019,,Bos taurus,,Autocuration,3085,,U,0,CHEMBL623559,,,
5219,1,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards calf spleen (CS-PDE) at a concentration of 20 microg,Spleen,BAO_0000221,,Bos taurus,,Autocuration,1469,,U,0,CHEMBL623560,,2106.0,
5220,1,Half life in culture medium containing 10% of heat inactivated foetal calf serum,,BAO_0000019,,Bos taurus,,Autocuration,4297,,U,0,CHEMBL623561,,,
5221,1,Half life in culture medium containing 10% of heat inactivated foetal calf serum; ND=not determined,,BAO_0000019,,Bos taurus,,Autocuration,4297,,U,0,CHEMBL623562,,,
5222,1,Ability to get deaminated by adenosine deaminase (ADA); Expressed as t1/2,,BAO_0000019,,Bos taurus,,Autocuration,17585,,U,0,CHEMBL623563,,,
5223,1,Enzymatic stability was assessed with bovine spleen phosphodiesterase (BS PDE) exonuclase,Spleen,BAO_0000221,,Bos taurus,,Autocuration,1336,,U,0,CHEMBL623564,,2106.0,
5224,1,Half life in presence of 2 mg/mL BSA at pH 8.8,,BAO_0000019,,Bos taurus,,Autocuration,3085,,U,0,CHEMBL873806,,,
5225,1,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 1,,BAO_0000019,,Bos taurus,,Autocuration,2857,,U,0,CHEMBL623565,,,
5226,1,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2,,BAO_0000019,,Bos taurus,,Autocuration,2857,,U,0,CHEMBL623566,,,
5227,1,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2; Not determined,,BAO_0000019,,Bos taurus,,Autocuration,2857,,U,0,CHEMBL623567,,,
5228,1,Half-life in the culture medium (RPMI 1640+10% fetal calf serum FCS),,BAO_0000019,,Bos taurus,,Autocuration,1540,,U,0,CHEMBL623568,,,
5229,1,AUC (Area Under Plasma concentration-time curve) was after oral administration at 5 mg/kg,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,6316,,N,1,CHEMBL623569,,1969.0,
5230,1,AUC after administration at 100 mg/kg/day in dogs,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,17594,,N,1,CHEMBL623570,,1969.0,
5231,1,AUC in dog at 0-24 hr by peroral administration at 3 mpk,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,4953,,N,1,CHEMBL624254,,1969.0,
5232,1,AUC value after 15 mg/kg iv dose in Dogs,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,16907,,N,1,CHEMBL624255,,1969.0,
5233,1,AUC value after 30 mg/kg po dose in Dogs,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,16907,,N,1,CHEMBL624256,,1969.0,
5234,1,AUC value after administration of 4 mg/Kg oral dose in dog,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,2959,,N,1,CHEMBL624257,,1969.0,
5235,1,AUC0-infinity after single intravenous bolus of 1 mg/kg in dogs,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,17594,,N,1,CHEMBL624258,,1969.0,
5236,1,Area Under Curve for the compound was determined in dogs at 1 mg/kg oral dosing; 25-50 ug min/mL,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5356,,N,1,CHEMBL875277,,,
5237,1,Area under curve (AUC) value in dogs after an intravenous dose of 0.2 mg/Kg in 0.025 M aqueous methanesulfonic acid solution with 5% mannitol at a concentration of 0.2,,BAO_0000218,,Canis lupus familiaris,,Intermediate,16807,,N,1,CHEMBL622667,,,
5238,1,Area under curve by intravenous administration at a dose of 1 uM/kg in dog was determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4527,,N,1,CHEMBL622668,,,
5239,1,Area under curve by oral administration at a dose of 10 uM/kg in dog was determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4527,,N,1,CHEMBL622669,,,
5240,1,Area under curve determined in dogs after intravenous administration of 3 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,15660,,N,1,CHEMBL622670,,,
5241,1,Area under curve determined in dogs after oral administration of 10 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,15660,,N,1,CHEMBL622671,,,
5242,1,Area under curve of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5802,,N,1,CHEMBL622672,,,
5243,1,Area under curve of compound determined in dog after iv administration at a dose of 10 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Expert,3598,,N,1,CHEMBL622673,,,
5244,1,Area under curve of compound from zero time to infinity determined in dog after iv administration at a dose of 10 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Expert,3598,,N,1,CHEMBL622674,,,
5245,1,Area under curve determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),,BAO_0000218,,Canis lupus familiaris,,Intermediate,5944,,N,1,CHEMBL622675,,,
5246,1,Area under curve determined in dog at a dose of 10 mg/kg by oral administration,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5944,,N,1,CHEMBL622676,,,
5247,1,Area under curve determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),,BAO_0000218,,Canis lupus familiaris,,Intermediate,5944,,N,1,CHEMBL622677,,,
5248,1,Area under curve determined in dog at a dose of 5 mg/kg by oral administration,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5944,,N,1,CHEMBL622678,,,
5249,1,Area under curve in dog after administration of 20 mg/kg dose through peroral route,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4186,,N,1,CHEMBL622679,,,
5250,1,Area under curve in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,BAO_0000218,,Canis lupus familiaris,,Intermediate,5007,,N,1,CHEMBL622680,,,
5251,1,Area under curve was determine after peroral administration at 10 mpk in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5668,,N,1,CHEMBL622681,,,
5252,1,Area under curve was determine after peroral administration at 5 mpk in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5668,,N,1,CHEMBL875278,,,
5253,1,Area under curve was determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5006,,N,1,CHEMBL622682,,,
5254,1,Area under curve in dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5006,,N,1,CHEMBL622683,,,
5255,1,Area under curve in dogs at 10 mg/kg dose fo oral administration,,BAO_0000218,,Canis lupus familiaris,,Intermediate,3771,,N,1,CHEMBL622684,,,
5256,1,Area under curve in dogs at 10 mg/kg dose fo oral administration (Evokes hyperglycerolemia),,BAO_0000218,,Canis lupus familiaris,,Intermediate,3771,,N,1,CHEMBL622685,,,
5257,1,Area under curve in dogs at 3 mg/kg dose fo intravenous administration,,BAO_0000218,,Canis lupus familiaris,,Intermediate,3771,,N,1,CHEMBL622686,,,
5258,1,Area under curve was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,BAO_0000218,,Canis lupus familiaris,,Intermediate,1916,,N,1,CHEMBL618344,,,
5259,1,Area under curve value in dog at a dose of 5 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5302,,N,1,CHEMBL875582,,,
5260,1,Area under curve was determined after 0.1 mg/kg iv administration in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5600,,N,1,CHEMBL618345,,,
5261,1,Area under curve was determined after 0.3 mg/kg po administration in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5600,,N,1,CHEMBL618346,,,
5262,1,Area under curve was determined for compound after intravenous administration in dogs at 1.2 uM/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17764,,N,1,CHEMBL618347,,,
5263,1,Area under curve was determined for the compound by intravenous administration of 1.2 mg/kg in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4368,,N,1,CHEMBL618348,,,
5264,1,Tested for half life period at 37 degree Celsius in PBS buffer at 10.5 pH containing human serum esterase,,BAO_0000019,,Homo sapiens,,Autocuration,5318,,U,0,CHEMBL618349,,,
5265,1,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,,BAO_0000019,,Homo sapiens,,Autocuration,5318,,U,0,CHEMBL618350,,,
5266,1,Tested for half life period at 37 degree Celsius in PBS buffer at 8.0 pH containing human serum esterase,,BAO_0000019,,Homo sapiens,,Autocuration,5318,,U,0,CHEMBL618351,,,
5267,1,Tested for half life period at 37 degree Celsius in PBS buffer at 8.8 pH containing human serum esterase,,BAO_0000019,,Homo sapiens,,Autocuration,5318,,U,0,CHEMBL618352,,,
5268,1,Time taken to reduce 50% of the concentration of compound in blood plasma,Blood,BAO_0000221,,Homo sapiens,,Autocuration,14518,,U,0,CHEMBL873494,,178.0,
5269,1,"Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",Plasma,BAO_0000366,,Homo sapiens,,Autocuration,2209,,U,0,CHEMBL618353,,1969.0,
5270,1,Half life in human plasma,Plasma,BAO_0000366,,Homo sapiens,,Autocuration,6787,,U,0,CHEMBL618354,,1969.0,
5271,1,Half life in human plasma was reported,Plasma,BAO_0000366,,Homo sapiens,,Autocuration,4898,,U,0,CHEMBL875583,,1969.0,
5272,1,Half life in human serum,Serum,BAO_0000019,,Homo sapiens,,Autocuration,6072,,U,0,CHEMBL618355,,1977.0,
5273,1,Half life upon exposure to human plasma,Plasma,BAO_0000366,,Homo sapiens,,Autocuration,16907,,U,0,CHEMBL618356,,1969.0,
5274,1,t1/2 in human microsomes,,BAO_0000251,,Homo sapiens,,Autocuration,5656,In vitro,U,0,CHEMBL618357,,,
5275,1,Half life period in 80% human plasma at 37 degree Centigrade,Plasma,BAO_0000366,,Homo sapiens,,Autocuration,4755,,U,0,CHEMBL618358,,1969.0,
5276,1,Half-life for rate of hydrolysis was determined in in human skin homogenate (pH 7.4),Zone of skin,BAO_0000221,,Homo sapiens,,Autocuration,17503,,U,0,CHEMBL618359,,14.0,
5277,1,Half-life measured in in vitro Cathepsin B assay in human plasma,Plasma,BAO_0000366,,Homo sapiens,,Autocuration,12357,In vitro,U,0,CHEMBL618360,,1969.0,
5278,1,Half-life at initial concentration of 5*10e-5 M in CEM cell extract,,BAO_0000019,,Homo sapiens,,Autocuration,3076,,U,0,CHEMBL618361,,,
5279,1,Half-life determined by human liver microsome stability assay at a concentration of 5 uM,Liver,BAO_0000251,,Homo sapiens,,Autocuration,6410,In vitro,U,0,CHEMBL618362,,2107.0,
5280,1,"Half-life in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",Plasma,BAO_0000366,,Homo sapiens,,Autocuration,3741,,U,0,CHEMBL618363,,1969.0,
5281,1,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",Plasma,BAO_0000366,,Homo sapiens,,Autocuration,3741,,U,0,CHEMBL618364,,1969.0,
5282,1,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",Plasma,BAO_0000366,,Homo sapiens,,Autocuration,3741,,U,0,CHEMBL875584,,1969.0,
5283,1,Half-life in the CEM cell extracts,,BAO_0000019,,Homo sapiens,,Autocuration,1540,,U,0,CHEMBL618365,,,
5284,1,Half-life was calculated by Human plasma stability assay at 37 degree Centigrade,Plasma,BAO_0000366,,Homo sapiens,,Autocuration,2905,,U,0,CHEMBL873495,,1969.0,
5285,1,Half-life was calculated by Human plasma stability assay at 37 degree centigrade; Not hydrolyzed,Plasma,BAO_0000366,,Homo sapiens,,Autocuration,2905,,U,0,CHEMBL618366,,1969.0,
5286,1,Half-life was determined,,BAO_0000019,,Homo sapiens,,Autocuration,5523,,U,0,CHEMBL618367,,,
5287,1,Half-life (human blood stability),Blood,BAO_0000221,,Homo sapiens,,Autocuration,1499,,U,0,CHEMBL618368,,178.0,
5288,1,Half-life (human blood stability); no data,Blood,BAO_0000221,,Homo sapiens,,Autocuration,1499,,U,0,CHEMBL618369,,178.0,
5289,1,Half-life in human plasma,Plasma,BAO_0000366,,Homo sapiens,,Autocuration,17065,,U,0,CHEMBL618370,,1969.0,
5290,1,CYP3A4 metabolism half-life (t1/2),,BAO_0000019,,Homo sapiens,,Autocuration,6861,,U,0,CHEMBL618371,,,
5291,1,Half-life was determined; 88% of parent remained after incubation for 120 min (human blood stability),Blood,BAO_0000221,,Homo sapiens,,Autocuration,1499,,U,0,CHEMBL618372,,178.0,
5292,1,In vitro half life in human plasma,Plasma,BAO_0000366,,Homo sapiens,,Autocuration,530,In vitro,U,0,CHEMBL618373,,1969.0,
5293,1,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in human plasma",Plasma,BAO_0000366,,Homo sapiens,,Autocuration,1116,In vitro,U,0,CHEMBL618374,,1969.0,
5294,1,In vitro hydrolysis in human plasma,Plasma,BAO_0000366,,Homo sapiens,,Autocuration,6695,In vitro,U,0,CHEMBL618375,,1969.0,
5295,1,In vitro hydrolysis in human plasma; no data,Plasma,BAO_0000366,,Homo sapiens,,Autocuration,6695,In vitro,U,0,CHEMBL618376,,1969.0,
5296,1,In vitro metabolic stability at 5 uM was determined by incubating with human liver microsomes at 37 degree C,Liver,BAO_0000251,,Homo sapiens,,Autocuration,10,In vitro,U,0,CHEMBL618377,,2107.0,
5297,1,Plasma half life in human,Plasma,BAO_0000366,,Homo sapiens,,Autocuration,993,,U,0,CHEMBL618378,,1969.0,
5298,1,Stability after incubation with human plasma (at 37 degree C),Plasma,BAO_0000366,,Homo sapiens,,Autocuration,15429,,U,0,CHEMBL618379,,1969.0,
5299,1,T1/2 was evaluated in human plasma,Plasma,BAO_0000366,,Homo sapiens,,Autocuration,1675,,U,0,CHEMBL618380,,1969.0,
5300,1,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",Plasma,BAO_0000366,,Homo sapiens,,Autocuration,2209,,U,0,CHEMBL618381,,1969.0,
5301,1,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I); Not determined",Plasma,BAO_0000366,,Homo sapiens,,Autocuration,2209,,U,0,CHEMBL618382,,1969.0,
5302,1,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,,BAO_0000019,,Homo sapiens,,Autocuration,5318,,U,0,CHEMBL618383,,,
5303,1,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase,,BAO_0000019,,Homo sapiens,,Autocuration,2412,In vitro,U,0,CHEMBL618384,,,
5304,1,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase; ND=Not determined,,BAO_0000019,,Homo sapiens,,Autocuration,2412,In vitro,U,0,CHEMBL618385,,,
5305,1,The release rate of the free drug from the substrate in human plasma by human plasma stability assay,Plasma,BAO_0000366,,Homo sapiens,,Autocuration,2906,,U,0,CHEMBL619099,,1969.0,
5306,1,The release rate of the free drug from the substrate in human plasma by human plasma stability assay; Not hydrolyzed,Plasma,BAO_0000366,,Homo sapiens,,Autocuration,2906,,U,0,CHEMBL619100,,1969.0,
5307,1,Time taken for 50% to be consumed by serum PON1 was determined,,BAO_0000019,,Homo sapiens,,Autocuration,5495,,U,0,CHEMBL619101,,,
5308,1,Time taken for 50% to be consumed by serum PON1; NH is Not hydrolysed,,BAO_0000019,,Homo sapiens,,Autocuration,5495,,U,0,CHEMBL619102,,,
5309,1,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,Liver,BAO_0000251,,Homo sapiens,,Autocuration,4397,,U,0,CHEMBL619103,,2107.0,
5310,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 1 hour,,BAO_0000218,,Mus sp.,,Autocuration,2413,,U,0,CHEMBL619268,,,
5311,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 3 hour,,BAO_0000218,,Mus sp.,,Autocuration,2413,,U,0,CHEMBL619269,,,
5312,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 1 hour,,BAO_0000218,,Mus sp.,,Autocuration,2413,,U,0,CHEMBL619270,,,
5313,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 3 hour,,BAO_0000218,,Mus sp.,,Autocuration,2413,,U,0,CHEMBL619271,,,
5314,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 1 hour,,BAO_0000218,,Mus sp.,,Autocuration,2413,,U,0,CHEMBL875585,,,
5315,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 24 hour,,BAO_0000218,,Mus sp.,,Autocuration,2413,,U,0,CHEMBL619272,,,
5316,1,Compound tested for growth inhibition of renal cancer cell line 786-0,,BAO_0000219,,Homo sapiens,,Intermediate,6058,,N,1,CHEMBL619273,391.0,,
5317,1,Compound was tested for 50% growth inhibition against human renal cancer 786-0 cell line,,BAO_0000219,,Homo sapiens,,Intermediate,17708,,N,1,CHEMBL619274,391.0,,
5318,1,Concentration which reduced cell growth to 50 % of level against 786-0 renal cancer line,,BAO_0000219,,Homo sapiens,,Expert,14017,,N,1,CHEMBL619275,391.0,,
5319,1,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-4 concentration",,BAO_0000219,,Homo sapiens,,Intermediate,16818,,N,1,CHEMBL619276,391.0,,
5320,1,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-6 concentration",,BAO_0000219,,Homo sapiens,,Intermediate,16818,,N,1,CHEMBL619277,391.0,,
5321,1,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-8 concentration",,BAO_0000219,,Homo sapiens,,Intermediate,16818,,N,1,CHEMBL619278,391.0,,
5322,1,Tested for cytotoxicity against 786-0 cell lines in renal cancer,,BAO_0000219,,Homo sapiens,,Intermediate,11970,,N,1,CHEMBL619279,391.0,,
5323,1,Tested in vitro for cytotoxicity in 786-0 cell line of Renal cancer,,BAO_0000219,,Homo sapiens,,Intermediate,12400,,N,1,CHEMBL858458,391.0,,
5324,1,Cytotoxic effect on renal cancer line 786-0,,BAO_0000219,,Homo sapiens,,Expert,12888,,N,1,CHEMBL619280,391.0,,
5325,1,In vitro antitumor activity against Renal cancer 786-0 cell lines by 6-day assay,,BAO_0000219,,Homo sapiens,,Intermediate,15300,,N,1,CHEMBL619281,391.0,,
5326,1,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),,BAO_0000219,,Homo sapiens,,Intermediate,14769,,N,1,CHEMBL619282,391.0,,
5327,1,"Cytotoxicity against NCI tumor panel, 786-0 renal cancer cell line",,BAO_0000219,,Homo sapiens,,Intermediate,15895,,N,1,CHEMBL619283,391.0,,
5328,1,Concentration of compound that cause 50% cytotoxicity of 786-0 renal cancer cell line,,BAO_0000219,,Homo sapiens,,Intermediate,17376,,N,1,CHEMBL619284,391.0,,
5329,1,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration that inhibits 50% net cell growth).,,BAO_0000219,,Homo sapiens,,Intermediate,14882,,N,1,CHEMBL619285,391.0,,
5330,1,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration leading to 50% net cell death),,BAO_0000219,,Homo sapiens,,Intermediate,14882,,N,1,CHEMBL619286,391.0,,
5331,1,Growth inhibition of the 786-O Renal cancer cell line for 2-day in vitro assay.,,BAO_0000219,,Homo sapiens,,Intermediate,15176,,N,1,CHEMBL619287,391.0,,
5332,1,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,,BAO_0000219,,Homo sapiens,,Intermediate,12696,,N,1,CHEMBL857455,391.0,,
5333,1,The compound was tested in vitro for cytotoxic activity against 786-O cell line (human perirenal carcinoma),,BAO_0000219,,Homo sapiens,,Intermediate,2496,,N,1,CHEMBL883801,391.0,,
5334,1,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression,,BAO_0000219,,Homo sapiens,,Intermediate,11831,,N,1,CHEMBL619288,972.0,,
5335,1,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression (49% inhibition achieved at 100 micro g/mL),,BAO_0000219,,Homo sapiens,,Intermediate,11831,,N,1,CHEMBL619289,972.0,,
5336,1,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression; <20% inhibition achieved,,BAO_0000219,,Homo sapiens,,Intermediate,11831,,N,1,CHEMBL619290,972.0,,
5337,1,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H1: MSR-33),,BAO_0000219,,Homo sapiens,,Intermediate,11831,,N,1,CHEMBL619291,972.0,,
5338,1,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H2: MSR-26),,BAO_0000219,,Homo sapiens,,Intermediate,11831,,N,1,CHEMBL619292,972.0,,
5339,1,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H3: MSR-28); <20% inhibition achieved,,BAO_0000219,,Homo sapiens,,Intermediate,11831,,N,1,CHEMBL619293,972.0,,
5340,1,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H1: MSR-33),,BAO_0000219,,Homo sapiens,,Intermediate,11831,,N,1,CHEMBL619294,972.0,,
5341,1,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26),,BAO_0000219,,Homo sapiens,,Intermediate,11831,,N,1,CHEMBL619295,972.0,,
5342,1,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26) (less than 20% inhibition achieved),,BAO_0000219,,Homo sapiens,,Intermediate,11831,,N,1,CHEMBL619296,972.0,,
5343,1,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H3: MSR-28); <20% inhibition achieved,,BAO_0000219,,Homo sapiens,,Intermediate,11831,,N,1,CHEMBL619297,972.0,,
5344,1,Growth inhibitory concentration against tumor cells in culture renal cancer 796-0 cell line,,BAO_0000219,,Homo sapiens,,Intermediate,12782,,N,1,CHEMBL619298,391.0,,
5345,1,In vitro anticancer activity against 8 NCI CNS cancer cell lines; inactive,,BAO_0000019,,,,Intermediate,1229,,U,0,CHEMBL619299,,,
5346,1,Inhibition of cell growth in drug resistant 8226 myeloma cell line,,BAO_0000219,,Homo sapiens,,Expert,15313,,N,1,CHEMBL619300,741.0,,
5347,1,Inhibition of cell growth in drug sensitive 8226 myeloma cell line,,BAO_0000219,,Homo sapiens,,Expert,15313,,N,1,CHEMBL619301,741.0,,
5348,1,In vitro inhibition of tumor cell growth in the human myeloma 8226 system.,,BAO_0000219,,Homo sapiens,,Intermediate,11544,,N,1,CHEMBL619302,741.0,,
5349,1,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,,BAO_0000219,,Homo sapiens,,Intermediate,9424,,N,1,CHEMBL619303,741.0,,
5350,1,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,,BAO_0000219,,Homo sapiens,,Intermediate,9424,,N,1,CHEMBL619304,741.0,,
5351,1,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),,BAO_0000219,,Homo sapiens,,Intermediate,9424,,N,1,CHEMBL857706,741.0,,
5352,1,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),,BAO_0000219,,Homo sapiens,,Intermediate,9424,,N,1,CHEMBL619305,741.0,,
5353,1,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),,BAO_0000219,,Homo sapiens,,Intermediate,9424,,N,1,CHEMBL619306,741.0,,
5354,1,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,BAO_0000219,,Homo sapiens,,Intermediate,9424,,N,1,CHEMBL619307,741.0,,
5355,1,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,BAO_0000219,,Homo sapiens,,Intermediate,9424,,N,1,CHEMBL619308,741.0,,
5356,1,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),,BAO_0000219,,Homo sapiens,,Intermediate,9424,,N,1,CHEMBL619309,741.0,,
5357,1,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),,BAO_0000219,,Homo sapiens,,Intermediate,9424,,N,1,CHEMBL619310,741.0,,
5358,1,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),,BAO_0000219,,Homo sapiens,,Intermediate,14769,,N,1,CHEMBL619311,624.0,,
5359,1,Compound was tested for the growth inhibition of A498 renal tumor cell line,,BAO_0000219,,Homo sapiens,,Intermediate,15354,,N,1,CHEMBL619312,624.0,,
5360,1,In vitro cytotoxicity against human tumor A498 cell line (renal cancer),,BAO_0000219,,Homo sapiens,,Intermediate,17445,,N,1,CHEMBL619313,624.0,,
5361,1,In vitro inhibitory concentration against renal cancer cell line A498,,BAO_0000219,,Homo sapiens,,Intermediate,4337,,N,1,CHEMBL619314,624.0,,
5362,1,Cytotoxicity against A 498 tumor cell line,,BAO_0000219,,Homo sapiens,,Intermediate,15277,,N,1,CHEMBL619959,624.0,,
5363,1,In vitro antitumor activity against A498 human cancer cell line,,BAO_0000219,,Homo sapiens,,Intermediate,4812,,N,1,CHEMBL619960,624.0,,
5364,1,In vitro antitumor activity against A498 human cancer cell line (Data from NCI-screening),,BAO_0000219,,Homo sapiens,,Intermediate,4812,,N,1,CHEMBL619961,624.0,,
5365,1,Inhibitory dose required against A498 human tumor cell lines,,BAO_0000219,,Homo sapiens,,Intermediate,4995,,N,1,CHEMBL619962,624.0,,
5366,1,Anticancer activity against one renal cancer (A498 cell line),,BAO_0000219,,Homo sapiens,,Intermediate,5847,,N,1,CHEMBL875586,624.0,,
5367,1,In vitro cytotoxicity against melanoma A498 cell line,,BAO_0000219,,Homo sapiens,,Intermediate,6557,,N,1,CHEMBL619963,624.0,,
5368,1,Compound was tested for growth inhibitory activity against A498 cell line,,BAO_0000219,,Homo sapiens,,Intermediate,2597,,N,1,CHEMBL619964,624.0,,
5369,1,Compound tested for growth inhibition of renal cancer cell line A498,,BAO_0000219,,Homo sapiens,,Intermediate,6058,,N,1,CHEMBL620108,624.0,,
5370,1,Compound was tested for 50% growth inhibition against human renal cancer A498 cell line,,BAO_0000219,,Homo sapiens,,Intermediate,17708,,N,1,CHEMBL620109,624.0,,
5371,1,Growth inhibition of the A498 Renal cancer cell line for 2-day in vitro assay.,,BAO_0000219,,Homo sapiens,,Intermediate,15176,,N,1,CHEMBL620110,624.0,,
5372,1,In vitro antitumor activity against Renal cancer A498 cell lines by 6-day assay,,BAO_0000219,,Homo sapiens,,Intermediate,15300,,N,1,CHEMBL620111,624.0,,
5373,1,Tested for cytotoxicity against A498 cell lines in renal cancer,,BAO_0000219,,Homo sapiens,,Intermediate,11970,,N,1,CHEMBL620112,624.0,,
5374,1,Tested in vitro for cytotoxicity in A498 cell line of Renal cancer,,BAO_0000219,,Homo sapiens,,Intermediate,12400,,N,1,CHEMBL620113,624.0,,
5375,1,Cytotoxic effect on renal cancer lines A498,,BAO_0000219,,Homo sapiens,,Expert,12888,,N,1,CHEMBL620114,624.0,,
5376,1,Antitumor activity was evaluated for reduction of growth of renal cancer (A498) cells at a concentration of 100 uM,,BAO_0000219,,Homo sapiens,,Intermediate,3030,,N,1,CHEMBL620115,624.0,,
5377,1,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),,BAO_0000219,,Homo sapiens,,Intermediate,14769,,N,1,CHEMBL620116,624.0,,
5378,1,Concentration of compound that cause 50% cytotoxicity of A498 renal cancer cell line,,BAO_0000219,,Homo sapiens,,Intermediate,17376,,N,1,CHEMBL620117,624.0,,
5379,1,Growth inhibitory activity against A498-2LM human solid tumor cell line using MTT assay,,BAO_0000219,,Homo sapiens,,Intermediate,16558,,N,1,CHEMBL620118,624.0,,
5380,1,Cytotoxicity against human kidney carcinoma cell lines A4982LM,,BAO_0000219,,Homo sapiens,,Intermediate,5194,,N,1,CHEMBL620119,624.0,,
5381,1,Evaluated for the inhibitory concentration required to cause growth inhibition of A498Rem- renal cell line using the MTT Cytotoxicity Assay,,BAO_0000219,,Homo sapiens,,Intermediate,10708,,N,1,CHEMBL620120,624.0,,
5382,1,Antiproliferative activity in vitro against A549 (human non-small lung carcinoma) cell line.,,BAO_0000219,,Homo sapiens,,Expert,16880,,N,1,CHEMBL620121,646.0,,
5383,1,Antitumor activity against A549 human lung carcinoma cell line,,BAO_0000219,,Homo sapiens,,Intermediate,10196,,N,1,CHEMBL620122,646.0,,
5384,1,Antitumor activity against A549 human lung carcinoma cell line in experiment 1,,BAO_0000219,,Homo sapiens,,Intermediate,10196,,N,1,CHEMBL620123,646.0,,
5385,1,Antitumor activity against A549 human lung carcinoma cell line in experiment 2,,BAO_0000219,,Homo sapiens,,Intermediate,10196,,N,1,CHEMBL620124,646.0,,
5386,1,"Concentration required to inhibit tumor growth in A549, human lung carcinoma (NSCLC) cell line",,BAO_0000219,,Homo sapiens,,Intermediate,12083,,N,1,CHEMBL620125,646.0,,
5387,1,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay,,BAO_0000219,,Homo sapiens,,Expert,16464,,N,1,CHEMBL620126,646.0,,
5388,1,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,BAO_0000219,,Homo sapiens,,Intermediate,16464,,N,1,CHEMBL883027,646.0,,
5389,1,In vitro cytotoxic activity against human lung A549 cell line,,BAO_0000219,,Homo sapiens,,Expert,16470,,N,1,CHEMBL620127,646.0,,
5390,1,In vitro cytotoxic activity against human lung A549 cell line ( standard deviation in parenthesis),,BAO_0000219,,Homo sapiens,,Intermediate,16470,,N,1,CHEMBL620128,646.0,,
5391,1,In vitro cytotoxic activity against human lung A549 cell line),,BAO_0000219,,Homo sapiens,,Intermediate,16470,,N,1,CHEMBL620129,646.0,,
5392,1,In vitro cytotoxic activity against human lung A549 cell line;NT is not tested,,BAO_0000219,,Homo sapiens,,Intermediate,16470,,N,1,CHEMBL620130,646.0,,
5393,1,In vitro cytotoxicity against human non small-cell-lung cell line A549.,,BAO_0000219,,Homo sapiens,,Expert,16582,,N,1,CHEMBL620131,646.0,,
5394,1,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors",,BAO_0000219,,Homo sapiens,,Intermediate,15935,,N,1,CHEMBL620132,646.0,,
5395,1,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors in folate deficient medium",,BAO_0000219,,Homo sapiens,,Intermediate,15935,,N,1,CHEMBL620133,646.0,,
5396,1,Inhibition of A549 human lung carcinoma cell proliferation,,BAO_0000219,,Homo sapiens,,Expert,16597,,N,1,CHEMBL620134,646.0,,
5397,1,Inhibitory activity against A549 lung adenocarcinoma cell line,,BAO_0000219,,Homo sapiens,,Intermediate,17376,,N,1,CHEMBL620135,646.0,,
5398,1,Inhibitory concentration required to reduce A549 tumor cell growth by 50% in MTT assay,,BAO_0000219,,Homo sapiens,,Intermediate,16496,,N,1,CHEMBL620136,646.0,,
5399,1,in vitro anticancer activity against cultured A549 human tumor(lung) cell line,,BAO_0000219,,Homo sapiens,,Intermediate,16152,,N,1,CHEMBL620137,646.0,,
5400,1,in vitro inhibition of tumor cell growth in cultured A549 human tumor cell line,,BAO_0000219,,Homo sapiens,,Intermediate,16152,,N,1,CHEMBL620268,646.0,,
5401,1,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,BAO_0000219,,Homo sapiens,,Intermediate,16464,,N,1,CHEMBL620269,646.0,,
5402,1,Cytotoxicity was evaluated against A549 non-small cell lung carcinoma human cancer cell line,,BAO_0000219,,Homo sapiens,,Intermediate,2288,,N,1,CHEMBL620270,646.0,,
5403,1,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,,BAO_0000219,,Homo sapiens,,Intermediate,17350,,N,1,CHEMBL620271,646.0,,
5404,1,Inhibition of A549 cancer cell proliferation,,BAO_0000219,,Homo sapiens,,Expert,4090,,N,1,CHEMBL620272,646.0,,
5405,1,Inhibition of A549 cancer cell proliferation (Not tested),,BAO_0000219,,Homo sapiens,,Expert,4090,,N,1,CHEMBL620273,646.0,,
5406,1,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,,BAO_0000219,,Homo sapiens,,Intermediate,17350,,N,1,CHEMBL620274,646.0,,
5407,1,In vitro inhibitory concentration required against human lung A549 carcinoma cells proliferation,,BAO_0000219,,Homo sapiens,,Intermediate,4197,,N,1,CHEMBL620275,646.0,,
5408,1,Antiproliferative potency determined as inhibitory concentration against A549 cells,,BAO_0000219,,Homo sapiens,,Intermediate,17072,,N,1,CHEMBL620276,646.0,,
5409,1,Percent assembly of bovine brain tubulin induced by compound at 10 uM versus that caused by 10 uM paclitaxel,,BAO_0000219,,Homo sapiens,,Intermediate,17072,,N,1,CHEMBL620277,646.0,,
5410,1,Cytotoxicity against Renal cell lines A549 was determined,,BAO_0000219,,Homo sapiens,,Intermediate,5194,,N,1,CHEMBL620278,646.0,,
5411,1,Area under curve was determined in dog after a 3 mg/kg of oral dose,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4257,,N,1,CHEMBL620279,,,
5412,1,Area under curve was determined in dog after oral administration at 1 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6123,,N,1,CHEMBL620280,,,
5413,1,Area under curve was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,1337,,N,1,CHEMBL620281,,,
5414,1,Area under curve was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,1337,,N,1,CHEMBL620282,,,
5415,1,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-2 mins),,BAO_0000218,,Canis lupus familiaris,,Intermediate,8833,,N,1,CHEMBL621134,,,
5416,1,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-5 mins),,BAO_0000218,,Canis lupus familiaris,,Intermediate,8833,,N,1,CHEMBL621135,,,
5417,1,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of (0-15 mins),,BAO_0000218,,Canis lupus familiaris,,Intermediate,8833,,N,1,CHEMBL621136,,,
5418,1,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of( 0-120 mins),,BAO_0000218,,Canis lupus familiaris,,Intermediate,8833,,N,1,CHEMBL621137,,,
5419,1,Area under plasma concentration time curve in dog upon oral administration,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,17657,,N,1,CHEMBL621138,,1969.0,
5420,1,Area under plasma concentration time curve was measured in dogs after an oral dose of 10 uM/kg,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,17650,,N,1,CHEMBL875587,,1969.0,
5421,1,Area under the curve for compound was evaluated in dog at a dose of 10 mg/kg.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,1977,,N,1,CHEMBL621139,,,
5422,1,Area under the curve for compound was evaluated in dog at a dose of 20 mg/kg.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,1977,,N,1,CHEMBL621140,,,
5423,1,Area under the curve for the compound was obtained when tested in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,3132,,N,1,CHEMBL621141,,,
5424,1,Area under the curve at a dose of 1 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5473,,N,1,CHEMBL621142,,,
5425,1,Area under the curve at a dose of 1 mg/kg (oral),,BAO_0000218,,Canis lupus familiaris,,Intermediate,5474,,N,1,CHEMBL621143,,,
5426,1,Area under the curve at i.v. dose of 0.2 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5474,,N,1,CHEMBL621144,,,
5427,1,Area under the curve was measured in dog after an iv dose of 1 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6062,,N,1,CHEMBL621145,,,
5428,1,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4709,,N,1,CHEMBL621146,,,
5429,1,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 1 mpk perorally,,BAO_0000218,,Canis lupus familiaris,,Intermediate,2652,,N,1,CHEMBL622567,,,
5430,1,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 5 mpk perorally,,BAO_0000218,,Canis lupus familiaris,,Intermediate,2652,,N,1,CHEMBL622568,,,
5431,1,Compound was evaluated for area under the curve in dog blood.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,2877,,N,1,CHEMBL622569,,,
5432,1,In vivo area under curve was calculated by peroral administration at 1 mg/kg in fasted dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5444,,N,1,CHEMBL622570,,,
5433,1,AUC in dog after oral dose (1 mg/kg),Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,5130,,N,1,CHEMBL622571,,1969.0,
5434,1,Pharmacokinetic (PK) property (AUC) was determined in dog at the single oral dose of 1 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6265,,N,1,CHEMBL622572,,,
5435,1,"Pharmacokinetic data in dogs at dose of 1 mg/kg perorally, and the area under curve (AUC) was reported.",,BAO_0000218,,Canis lupus familiaris,,Intermediate,4657,,N,1,CHEMBL622573,,,
5436,1,Pharmacokinetic parameter AUC after intravenous administration to dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,16367,,N,1,CHEMBL622574,,,
5437,1,Pharmacokinetic parameter AUC after oral administration to dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,16367,,N,1,CHEMBL622575,,,
5438,1,Pharmacokinetic parameter AUC was determined in dog after oral administration of 17b,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9579,,N,1,CHEMBL622576,,,
5439,1,Pharmacokinetic parameter AUC was determined in dog after oral administration of 2b,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9579,,N,1,CHEMBL622577,,,
5440,1,Pharmacokinetic property (AUC) was measured in dog at the dose of 0.032 mg/kg p.o.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5983,,N,1,CHEMBL622578,,,
5441,1,Pharmacokinetic property in dogs after oral administration at 1 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6241,,N,1,CHEMBL622579,,,
5442,1,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog",,BAO_0000218,,Canis lupus familiaris,,Intermediate,5313,,N,1,CHEMBL622580,,,
5443,1,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog at dosage of 10 mpk",,BAO_0000218,,Canis lupus familiaris,,Intermediate,5313,,N,1,CHEMBL622581,,,
5444,1,Oral AUCN in dog ( (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6642,,N,1,CHEMBL622582,,,
5445,1,Oral AUCN in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6642,,N,1,CHEMBL622583,,,
5446,1,Oral AUCN in dog (dosed at 0.5 mpk iv ),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6641,,N,1,CHEMBL622584,,,
5447,1,Oral AUCN in dog (dosed at 0.5 mpk iv ),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6642,,N,1,CHEMBL622585,,,
5448,1,Compound was evaluated for oral bioavailability in dog; 90-100,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17791,,N,1,CHEMBL622586,,,
5449,1,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17655,,N,1,CHEMBL623281,,,
5450,1,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay; Not determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17655,,N,1,CHEMBL623282,,,
5451,1,PAPP (membrane permeability) in dog kidney cell monolayer assay,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6596,,N,1,CHEMBL623283,,,
5452,1,Oral bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,3880,,N,1,CHEMBL623284,,,
5453,1,Bioavailability administered orally at a dose of 10 mg/kg to dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,16367,,N,1,CHEMBL623285,,,
5454,1,Plasma protein binding towards dog plasma at 10 uM,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,17409,,N,1,CHEMBL623463,,1969.0,
5455,1,Plasma protein binding towards dog plasma at 100 uM,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,17409,,N,1,CHEMBL875952,,1969.0,
5456,1,Bioavailability in dog (dose 4 mg/kg p.o.),,BAO_0000218,,Canis lupus familiaris,,Intermediate,2959,In vivo,N,1,CHEMBL621705,,,
5457,1,Bioavailability was determined after oral administration of compound 18 at a dose of 2 mg/kg to dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,13501,In vivo,N,1,CHEMBL621706,,,
5458,1,Bioavailability by oral administration at a dose of 10 uM/kg in dog was determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4527,In vivo,N,1,CHEMBL621707,,,
5459,1,Bioavailability in dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,15145,In vivo,N,1,CHEMBL621708,,,
5460,1,Bioavailability,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4219,In vivo,N,1,CHEMBL621709,,,
5461,1,Oral bioavailability in dog (dose 10 mg/kg),,BAO_0000218,,Canis lupus familiaris,,Intermediate,17538,In vivo,N,1,CHEMBL621710,,,
5462,1,Bioavailability in dog after po administration at a dose of 10 mg/kg; nd is not determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17538,In vivo,N,1,CHEMBL621711,,,
5463,1,Bioavailability in dog (dose 10.0 mg/kg p.o.),,BAO_0000218,,Canis lupus familiaris,,Intermediate,1466,In vivo,N,1,CHEMBL621712,,,
5464,1,Bioavailability was measured in dogs after an oral dose of 10 uM/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17650,In vivo,N,1,CHEMBL621713,,,
5465,1,Bioavailability was obtained by the comparison of AUC of intravenous dosing and AUC of oral dosing in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,3132,In vivo,N,1,CHEMBL621714,,,
5466,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 3 hour,,BAO_0000218,,Mus sp.,,Autocuration,2413,,U,0,CHEMBL621715,,,
5467,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 1 hour,Liver,BAO_0000218,,Mus sp.,,Autocuration,2413,,U,0,CHEMBL623717,,2107.0,
5468,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 24 hour,Liver,BAO_0000218,,Mus sp.,,Autocuration,2413,,U,0,CHEMBL623718,,2107.0,
5469,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 3 hour,Liver,BAO_0000218,,Mus sp.,,Autocuration,2413,,U,0,CHEMBL623719,,2107.0,
5470,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 1 hour,,BAO_0000218,,Mus sp.,,Autocuration,2413,,U,0,CHEMBL623720,,,
5471,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 3 hour,,BAO_0000218,,Mus sp.,,Autocuration,2413,,U,0,CHEMBL623721,,,
5472,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 1 hour,Muscle tissue,BAO_0000218,,Mus sp.,,Autocuration,2413,,U,0,CHEMBL623722,,2385.0,
5473,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 24 hour,Muscle tissue,BAO_0000218,,Mus sp.,,Autocuration,2413,,U,0,CHEMBL623723,,2385.0,
5474,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 3 hour,Muscle tissue,BAO_0000218,,Mus sp.,,Autocuration,2413,,U,0,CHEMBL618543,,2385.0,
5475,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 1 hour,Spleen,BAO_0000218,,Mus sp.,,Autocuration,2413,,U,0,CHEMBL618544,,2106.0,
5476,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 3 hour,Spleen,BAO_0000218,,Mus sp.,,Autocuration,2413,,U,0,CHEMBL875155,,2106.0,
5477,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 1 hour,,BAO_0000218,,Mus sp.,,Autocuration,2413,,U,0,CHEMBL618545,,,
5478,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 24 hour,,BAO_0000218,,Mus sp.,,Autocuration,2413,,U,0,CHEMBL618546,,,
5479,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 3 hour,,BAO_0000218,,Mus sp.,,Autocuration,2413,,U,0,CHEMBL623529,,,
5480,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 24 hour,,BAO_0000218,,Mus sp.,,Autocuration,2413,,U,0,CHEMBL623530,,,
5481,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 3 hour,,BAO_0000218,,Mus sp.,,Autocuration,2413,,U,0,CHEMBL621764,,,
5482,1,Compound (i.v.) was evaluated for elimination rate constants in brainstem of rhesus monkeys (Radiolabeled compound),,BAO_0000019,,Cercopithecidae,,Autocuration,17827,,U,0,CHEMBL621765,,,
5483,1,Compound (i.v.) was evaluated for elimination rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),Cerebellum,BAO_0000019,,Cercopithecidae,,Autocuration,17827,,U,0,CHEMBL621766,,2037.0,
5484,1,Compound (i.v.) was evaluated for elimination rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),Frontal cortex,BAO_0000019,,Cercopithecidae,,Autocuration,17827,,U,0,CHEMBL621767,,1870.0,
5485,1,Compound (i.v.) was evaluated for elimination rate constants in jaw bone of rhesus monkeys; NA = not active (Radiolabeled compound),,BAO_0000019,,Cercopithecidae,,Autocuration,17827,,U,0,CHEMBL621768,,,
5486,1,Compound (i.v.) was evaluated for elimination rate constants in striatum of rhesus monkey (Radiolabeled compound),Striatum,BAO_0000019,,Cercopithecidae,,Autocuration,17827,,U,0,CHEMBL621769,,2435.0,
5487,1,Compound (i.v.) was evaluated for uptake rate constants in brainstem of rhesus monkeys (Radiolabeled compound),,BAO_0000019,,Cercopithecidae,,Autocuration,17827,,U,0,CHEMBL621770,,,
5488,1,Compound (i.v.) was evaluated for uptake rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),Cerebellum,BAO_0000019,,Cercopithecidae,,Autocuration,17827,,U,0,CHEMBL621771,,2037.0,
5489,1,Compound (i.v.) was evaluated for uptake rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),Frontal cortex,BAO_0000019,,Cercopithecidae,,Autocuration,17827,,U,0,CHEMBL621772,,1870.0,
5490,1,Compound (i.v.) was evaluated for uptake rate constants in jaw bone of rhesus monkey (Radiolabeled compound),,BAO_0000019,,Cercopithecidae,,Autocuration,17827,,U,0,CHEMBL621773,,,
5491,1,Compound (i.v.) was evaluated for uptake rate constants in striatum of rhesus monkeys (Radiolabeled compound),Striatum,BAO_0000019,,Cercopithecidae,,Autocuration,17827,,U,0,CHEMBL621774,,2435.0,
5492,1,Compound was evaluated for oral bioavailability in rats,,BAO_0000218,,Cercopithecidae,,Autocuration,17791,,U,0,CHEMBL621775,,,
5493,1,Maximum concentration of compound found in plasma at 5 mg/kg after oral administration,Plasma,BAO_0000218,,Cercopithecidae,,Autocuration,17667,In vivo,U,0,CHEMBL621776,,1969.0,
5494,1,Half life period was evaluated in monkey,,BAO_0000019,,Cercopithecidae,,Autocuration,17791,,U,0,CHEMBL621777,,,
5495,1,Half-life in rhesus monkeys by intravenous administration of dose,,BAO_0000218,,Cercopithecidae,,Autocuration,110,In vivo,U,0,CHEMBL875162,,,
5496,1,AUC (0-6 hr) after oral administration at 30 mg/kg in ICR mouse,Plasma,BAO_0000218,,Mus musculus,,Intermediate,5781,,N,1,CHEMBL621778,,1969.0,
5497,1,AUC after intraperitoneal administration of 100 mg/kg in mice,Plasma,BAO_0000218,,Mus musculus,,Intermediate,17734,,N,1,CHEMBL621779,,1969.0,
5498,1,AUC value was determined after oral administration,Plasma,BAO_0000218,,Mus musculus,,Intermediate,17718,,N,1,CHEMBL622479,,1969.0,
5499,1,Area under curve (AUC) determined at a dose 10 mg/kg administered intraperitoneally to mice,,BAO_0000218,,Mus musculus,,Intermediate,4573,,N,1,CHEMBL622480,,,
5500,1,Area under curve (AUC) was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),,BAO_0000218,,Mus musculus,,Intermediate,3277,,N,1,CHEMBL622481,,,
5501,1,Area under curve by ioral administration in mouse,,BAO_0000218,,Mus musculus,,Intermediate,2862,,N,1,CHEMBL622482,,,
5502,1,Area under curve by iv administration in mouse,,BAO_0000218,,Mus musculus,,Intermediate,2862,,N,1,CHEMBL622483,,,
5503,1,Area under curve at 0-8 hr in IRC mice after peroral administration,,BAO_0000218,,Mus musculus,,Intermediate,5951,,N,1,CHEMBL622484,,,
5504,1,Area under curve when injected i.p. in mice at a dose of 50 mg/kg,,BAO_0000218,,Mus musculus,,Intermediate,17729,,N,1,CHEMBL622641,,,
5505,1,Area under curve when injected intraperitoneally in BALB/C mice at a dose of 20 mg/kg,,BAO_0000218,,Mus musculus,,Intermediate,17728,,N,1,CHEMBL622642,,,
5506,1,Area under curve when injected intravenously in BALB/C mice at a dose of 20 mg/kg,,BAO_0000218,,Mus musculus,,Intermediate,17728,,N,1,CHEMBL622643,,,
5507,1,Area under curve when injected intravenously in mice at a dose of 20 mg/kg,,BAO_0000218,,Mus musculus,,Intermediate,17729,,N,1,CHEMBL622644,,,
5508,1,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,,BAO_0000219,,Homo sapiens,,Intermediate,9424,,N,1,CHEMBL622645,741.0,,
5509,1,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,,BAO_0000219,,Homo sapiens,,Intermediate,9424,,N,1,CHEMBL622646,741.0,,
5510,1,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),,BAO_0000219,,Homo sapiens,,Intermediate,9424,,N,1,CHEMBL621238,741.0,,
5511,1,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),,BAO_0000219,,Homo sapiens,,Intermediate,9424,,N,1,CHEMBL621239,741.0,,
5512,1,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),,BAO_0000219,,Homo sapiens,,Intermediate,9424,,N,1,CHEMBL621240,741.0,,
5513,1,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,BAO_0000219,,Homo sapiens,,Intermediate,9424,,N,1,CHEMBL621241,741.0,,
5514,1,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),,BAO_0000219,,Homo sapiens,,Intermediate,9424,,N,1,CHEMBL621242,741.0,,
5515,1,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),,BAO_0000219,,Homo sapiens,,Intermediate,9424,,N,1,CHEMBL620350,741.0,,
5516,1,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,,BAO_0000219,,Homo sapiens,,Intermediate,9424,,N,1,CHEMBL620351,741.0,,
5517,1,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,,BAO_0000219,,Homo sapiens,,Intermediate,9424,,N,1,CHEMBL620352,741.0,,
5518,1,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),,BAO_0000219,,Homo sapiens,,Intermediate,9424,,N,1,CHEMBL620353,741.0,,
5519,1,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),,BAO_0000219,,Homo sapiens,,Intermediate,9424,,N,1,CHEMBL620354,741.0,,
5520,1,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),,BAO_0000219,,Homo sapiens,,Intermediate,9424,,N,1,CHEMBL620355,741.0,,
5521,1,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,BAO_0000219,,Homo sapiens,,Intermediate,9424,,N,1,CHEMBL620356,741.0,,
5522,1,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),,BAO_0000219,,Homo sapiens,,Intermediate,9424,,N,1,CHEMBL620357,741.0,,
5523,1,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),,BAO_0000219,,Homo sapiens,,Intermediate,9424,,N,1,CHEMBL620358,741.0,,
5524,1,In vitro inhibition of human 8226 myeloma tumor cell line growth.,,BAO_0000219,,Homo sapiens,,Expert,9424,,N,1,CHEMBL620359,741.0,,
5525,1,In vitro inhibition of tumor cell growth in the human myeloma 8226/ADR system.,,BAO_0000219,,Homo sapiens,,Intermediate,11544,,N,1,CHEMBL620360,741.0,,
5526,1,Cytotoxicity of compound against 8226/DOX1V cells,,BAO_0000219,,Homo sapiens,,Intermediate,17378,,N,1,CHEMBL620361,741.0,,
5527,1,Cytotoxicity of compound against 8226/S cells,,BAO_0000219,,Homo sapiens,,Intermediate,17378,,N,1,CHEMBL620362,741.0,,
5528,1,Inhibitory concentration against 8226 myeloma cancer cell line,,BAO_0000219,,Homo sapiens,,Intermediate,17079,,N,1,CHEMBL620363,741.0,,
5529,1,Inhibitory concentration against 8226/Dox40 (Dox-Re) cancer cell line,,BAO_0000219,,Homo sapiens,,Intermediate,17079,,N,1,CHEMBL620364,741.0,,
5530,1,Inhibition of cell growth was studied in human teratocarcinoma (833K).,,BAO_0000219,,Homo sapiens,,Intermediate,13466,,N,1,CHEMBL620365,854.0,,
5531,1,Inhibition of cell growth was studied in human teratocarcinoma (833K); ND ='not determined',,BAO_0000219,,Homo sapiens,,Intermediate,13466,,N,1,CHEMBL620366,854.0,,
5532,1,Tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells,,BAO_0000219,,Homo sapiens,,Expert,2392,,N,1,CHEMBL620367,854.0,,
5533,1,The compound was tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells; No data,,BAO_0000219,,Homo sapiens,,Intermediate,2392,,N,1,CHEMBL620368,854.0,,
5534,1,Inhibitory activity against caspase-1,,BAO_0000019,,,,Autocuration,6608,,U,0,CHEMBL620369,,,
5535,1,Percent inhibition of DAla-DAla Ligase at 10e -3 M of the compound,,BAO_0000357,,Enterococcus faecalis,,Autocuration,10199,,H,8,CHEMBL620370,,,
5536,1,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM) for 72 hr using MTT assay,,BAO_0000219,,Homo sapiens,,Intermediate,17749,,N,1,CHEMBL620371,705.0,,
5537,1,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM,,BAO_0000219,,Homo sapiens,,Intermediate,17749,,N,1,CHEMBL620372,705.0,,
5538,1,In vitro anticancer activity against 9 NCI colon cancer cell lines; inactive,,BAO_0000019,,,,Intermediate,1229,,U,0,CHEMBL876492,,,
5539,1,In vitro anticancer activity against 9 NCI melanoma cell lines; inactive,,BAO_0000019,,,,Intermediate,1229,,U,0,CHEMBL620373,,,
5540,1,In vitro anticancer activity against 9 NCI renal cancer cell lines; inactive,,BAO_0000019,,,,Intermediate,1229,,U,0,CHEMBL620374,,,
5541,1,Inhibitory activity was determined against 9-cis-epoxycarotenoid dioxygenase (NCED) expressed in Escherichia coli in presence of 9''-cis-neo-xanthin,,BAO_0000019,,,,Autocuration,6390,,U,0,CHEMBL620375,,,
5542,1,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,,BAO_0000019,,Streptococcus pyogenes,,Autocuration,16219,,U,0,CHEMBL857902,,,
5543,1,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,,BAO_0000019,,Streptococcus pyogenes,,Autocuration,16219,,U,0,CHEMBL620376,,,
5544,1,Percent inhibition against Cdc25C phosphatase at 50 uM of compound,,BAO_0000357,,,,Autocuration,17043,,H,8,CHEMBL620377,,,
5545,1,Tested for in vitro cytotoxic potency of compound in 9KB assay,,BAO_0000219,,Homo sapiens,,Intermediate,6929,,N,1,CHEMBL620378,324.0,,
5546,1,Tested for in vitro cytotoxic potency of compound in 9KB assay,,BAO_0000219,,Homo sapiens,,Intermediate,6929,,N,1,CHEMBL620379,324.0,,
5547,1,In vitro cytotoxicity of compound was tested against 9KB cells.,,BAO_0000219,,Homo sapiens,,Autocuration,7083,,U,0,CHEMBL620380,,,
5548,1,Cytotoxic concentration against 9L cells was determined on day 3,,BAO_0000219,,Rattus norvegicus,,Intermediate,12446,,N,1,CHEMBL884006,392.0,,
5549,1,Tested in vitro for anticancer activity against 9L cells,,BAO_0000219,,Rattus norvegicus,,Expert,15345,,N,1,CHEMBL620381,392.0,,
5550,1,Tested in vitro for anticancer activity against 9L cells; Not determined,,BAO_0000219,,Rattus norvegicus,,Expert,15345,,N,1,CHEMBL620382,392.0,,
5551,1,In vitro inhibitory activity against human A549 non-small cell lung tumor; Active,,BAO_0000219,,Homo sapiens,,Intermediate,6301,,N,1,CHEMBL620383,646.0,,
5552,1,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; No inhibition,,BAO_0000219,,Homo sapiens,,Intermediate,4833,,N,1,CHEMBL876493,646.0,,
5553,1,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Significant inhibition,,BAO_0000219,,Homo sapiens,,Intermediate,4833,,N,1,CHEMBL620384,646.0,,
5554,1,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Slight inhibition,,BAO_0000219,,Homo sapiens,,Intermediate,4833,,N,1,CHEMBL620385,646.0,,
5555,1,Cytotoxicity against human lung carcinoma A549 cell line,,BAO_0000219,,Homo sapiens,,Expert,13330,,N,1,CHEMBL620386,646.0,,
5556,1,Ability to induce human IL-6 assay in A549 lung carcinoma cell line.,,BAO_0000219,,Homo sapiens,,Expert,17517,,D,9,CHEMBL620387,646.0,,
5557,1,"Ability to induce human IL-6 assay in A549 lung carcinoma cell line; n.r.: not reported, EC50 values not reported in cases were %dex e 35%.",,BAO_0000219,,Homo sapiens,,Expert,17517,,D,9,CHEMBL621404,646.0,,
5558,1,"In vitro growth inhibition of A549, lung carcinoma",,BAO_0000219,,Homo sapiens,,Intermediate,14425,,N,1,CHEMBL621405,646.0,,
5559,1,"In vitro growth inhibition of A549, lung carcinoma.",,BAO_0000219,,Homo sapiens,,Intermediate,14425,,N,1,CHEMBL621406,646.0,,
5560,1,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,,BAO_0000219,,Homo sapiens,,Expert,5228,,N,1,CHEMBL621407,646.0,,
5561,1,Cytotoxic activity against human lung cancer A549 cell line was determined,,BAO_0000219,,Homo sapiens,,Intermediate,5351,,N,1,CHEMBL621408,646.0,,
5562,1,Cytotoxicity against human solid tumor lung carcinoma A549 cell line,,BAO_0000219,,Homo sapiens,,Expert,12198,,N,1,CHEMBL885345,646.0,,
5563,1,Cytotoxicity concentration against human lung carcinoma A-549 cell line,,BAO_0000219,,Homo sapiens,,Intermediate,13891,,N,1,CHEMBL621409,646.0,,
5564,1,Cytotoxicity in A549 (human carcinoma) cell line.,,BAO_0000219,,Homo sapiens,,Expert,5677,,N,1,CHEMBL876034,646.0,,
5565,1,Cytotoxicity on lung carcinoma (A-549) cell line,,BAO_0000219,,Homo sapiens,,Intermediate,13788,,N,1,CHEMBL621410,646.0,,
5566,1,Effective dose against 50% reduction in Human lung carcinoma (A-549) cell number after 3-day incubation.,,BAO_0000219,,Homo sapiens,,Expert,13384,,N,1,CHEMBL621411,646.0,,
5567,1,Effective dose of compound against replication of A549 cell line was evaluated,,BAO_0000219,,Homo sapiens,,Intermediate,6726,,N,1,CHEMBL621412,646.0,,
5568,1,In vitro cytotoxic activity was determined against lung carcinoma (A549) cell line,,BAO_0000219,,Homo sapiens,,Expert,3455,,N,1,CHEMBL621413,646.0,,
5569,1,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line),,BAO_0000219,,Homo sapiens,,Intermediate,5726,,N,1,CHEMBL621414,646.0,,
5570,1,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line); NA is not active,,BAO_0000219,,Homo sapiens,,Intermediate,5726,,N,1,CHEMBL621415,646.0,,
5571,1,The compound was evaluated for antiproliferative activity against A549 cell line,,BAO_0000219,,Homo sapiens,,Intermediate,3936,,N,1,CHEMBL621416,646.0,,
5572,1,The compound was tested for tumor cell growth inhibitory activity against human lung carcinoma (A549) cell line.,,BAO_0000219,,Homo sapiens,,Intermediate,14991,,N,1,CHEMBL621417,646.0,,
5573,1,Concentration required for growth inhibition of human lung carcinoma cell line A549,,BAO_0000219,,Homo sapiens,,Intermediate,5243,,N,1,CHEMBL621418,646.0,,
5574,1,Cytotoxic activity against A549/ATCC non-small cell-lung cancer cell line,,BAO_0000219,,Homo sapiens,,Intermediate,12858,,N,1,CHEMBL621419,646.0,,
5575,1,Growth inhibition against A549 cell line was evaluated,,BAO_0000219,,Homo sapiens,,Intermediate,6776,,N,1,CHEMBL621420,646.0,,
5576,1,Growth inhibitory activity against A549 human solid tumor cell line using MTT assay,,BAO_0000219,,Homo sapiens,,Intermediate,16558,,N,1,CHEMBL875823,646.0,,
5577,1,Inhibition of anchorage independent growth of human tumor cell line A549 K-ras-transformed in soft agar,,BAO_0000219,,Homo sapiens,,Expert,4583,,N,1,CHEMBL621421,646.0,,
5578,1,Inhibitor activity against A549 (Human lung carcinoma)cell line with varying concentration of the drug for 72 hrs,,BAO_0000219,,Homo sapiens,,Intermediate,13514,,N,1,CHEMBL621422,646.0,,
5579,1,Chemosensitivity against DT-diaphorase rich A549 cell lines,,BAO_0000219,,Homo sapiens,,Expert,15166,,N,1,CHEMBL884014,646.0,,
5580,1,Compound tested against A549 lung carcinoma in the sulforhodamine B assay.,,BAO_0000219,,Homo sapiens,,Intermediate,13873,,N,1,CHEMBL621423,646.0,,
5581,1,In vitro cytotoxicity against human A549 (lung cancer) cell line.,,BAO_0000219,,Homo sapiens,,Expert,6447,,N,1,CHEMBL621424,646.0,,
5582,1,In vitro antitumor activity against A549 (lung) human tumor cell lines.,,BAO_0000219,,Homo sapiens,,Intermediate,2068,,N,1,CHEMBL621425,646.0,,
5583,1,In vitro cytotoxic activity against human lung carcinoma A549 cell line,,BAO_0000219,,Homo sapiens,,Expert,1863,,N,1,CHEMBL621426,646.0,,
5584,1,Compound was tested against A549 lung cancer cell line in the sulforhodamine B assay.,,BAO_0000219,,Homo sapiens,,Intermediate,13873,,N,1,CHEMBL621427,646.0,,
5585,1,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,,BAO_0000219,,Homo sapiens,,Intermediate,13873,,N,1,CHEMBL621428,646.0,,
5586,1,Tested against A549 lung carcinoma in the sulforhodamine B assay.,,BAO_0000219,,Homo sapiens,,Expert,13873,,N,1,CHEMBL621429,646.0,,
5587,1,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction),,BAO_0000219,,Homo sapiens,,Intermediate,579,,N,1,CHEMBL621430,646.0,,
5588,1,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction).,,BAO_0000219,,Homo sapiens,,Intermediate,579,,N,1,CHEMBL621431,646.0,,
5589,1,Compound was tested for inhibition of growth of human lung carcinoma cell line A549 up to a conc of 10 uM; NI means no inhibition,,BAO_0000219,,Homo sapiens,,Intermediate,4584,,N,1,CHEMBL621432,646.0,,
5590,1,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line,,BAO_0000219,,Homo sapiens,,Expert,5421,,N,1,CHEMBL621433,646.0,,
5591,1,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,,BAO_0000219,,Homo sapiens,,Intermediate,5421,,N,1,CHEMBL875824,646.0,,
5592,1,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,,BAO_0000219,,Homo sapiens,,Intermediate,5421,,N,1,CHEMBL621434,646.0,,
5593,1,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line; NA=Not assayed,,BAO_0000219,,Homo sapiens,,Intermediate,5421,,N,1,CHEMBL621435,646.0,,
5594,1,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay.,,BAO_0000219,,Homo sapiens,,Intermediate,14188,,N,1,CHEMBL621436,646.0,,
5595,1,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay; UA=Potency was so low that the IC50 was unachievable.,,BAO_0000219,,Homo sapiens,,Intermediate,14188,,N,1,CHEMBL621437,646.0,,
5596,1,Compound was tested for the growth inhibition of A549 lung tumor cell line,,BAO_0000219,,Homo sapiens,,Intermediate,15354,,N,1,CHEMBL621438,646.0,,
5597,1,Growth inhibition of human non-small-lung carcinoma (A549) cell line,,BAO_0000219,,Homo sapiens,,Expert,14253,,N,1,CHEMBL621439,646.0,,
5598,1,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,,BAO_0000219,,Homo sapiens,,Intermediate,13873,,N,1,CHEMBL621440,646.0,,
5599,1,Oral bioavailability in dog (conscious),,BAO_0000218,,Canis lupus familiaris,,Intermediate,3043,In vivo,N,1,CHEMBL621441,,,
5600,1,Compound was evaluated for the oral bioavailability after oral administration in dog.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,3045,In vivo,N,1,CHEMBL621442,,,
5601,1,Compound was tested for percent of oral bioavailability at 10 mg/ml dose in dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,3022,In vivo,N,1,CHEMBL621443,,,
5602,1,Oral bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4453,In vivo,N,1,CHEMBL621444,,,
5603,1,Oral bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,1696,In vivo,N,1,CHEMBL625133,,,
5604,1,Oral bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5045,In vivo,N,1,CHEMBL625134,,,
5605,1,Oral bioavailability in dog (fasted),,BAO_0000218,,Canis lupus familiaris,,Intermediate,5356,In vivo,N,1,CHEMBL625135,,,
5606,1,Oral bioavailability after intravenous administration in dogs at 1.2 uM/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17764,In vivo,N,1,CHEMBL625136,,,
5607,1,Oral bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6448,In vivo,N,1,CHEMBL625137,,,
5608,1,Oral bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,1475,In vivo,N,1,CHEMBL625138,,,
5609,1,Percent bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,3788,In vivo,N,1,CHEMBL625139,,,
5610,1,Percent oral bioavailability of intravenously administered compound (6 mg/kg) was tested in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,3639,In vivo,N,1,CHEMBL872264,,,
5611,1,Oral bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,13397,In vivo,N,1,CHEMBL625140,,,
5612,1,The compound was evaluated for bioavailability in dogs; 34-44,,BAO_0000218,,Canis lupus familiaris,,Intermediate,2137,In vivo,N,1,CHEMBL624436,,,
5613,1,Bioavailability in dog (dose 4 mg/kg p.o.),,BAO_0000218,,Canis lupus familiaris,,Intermediate,2959,In vivo,N,1,CHEMBL624437,,,
5614,1,Oral bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6448,In vivo,N,1,CHEMBL872261,,,
5615,1,8 hour trough Blood level in dog was measured after administration of compound,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6084,,N,1,CHEMBL624438,,,
5616,1,The compound was tested for maximum concentration ( Cmax ) in dog plasma.,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,3639,In vivo,N,1,CHEMBL624439,,1969.0,
5617,1,C24 after oral administration at 5 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6316,,N,1,CHEMBL624440,,,
5618,1,Clearance after oral and iv dosing in dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5238,,N,1,CHEMBL624441,,,
5619,1,Clearance of the drug was measured in the plasma of dog,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,17796,,N,1,CHEMBL624442,,1969.0,
5620,1,Compound was evaluated for Clearance in dogs at a dose of 1 mpk intravenously,,BAO_0000218,,Canis lupus familiaris,,Intermediate,2652,,N,1,CHEMBL624443,,,
5621,1,CL (clearance) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5654,In vivo,N,1,CHEMBL624444,,,
5622,1,Clearance of compound was determined in dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6621,In vivo,N,1,CHEMBL624445,,,
5623,1,Clearance on i.v. administration of 2 mg/kg was measured in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6505,In vivo,N,1,CHEMBL624446,,,
5624,1,Clearance of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5802,In vivo,N,1,CHEMBL624447,,,
5625,1,Plasma clearance in dog was determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17267,In vivo,N,1,CHEMBL624448,,,
5626,1,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4521,In vivo,N,1,CHEMBL624449,,,
5627,1,Plasma clearance in dog after administration of 0.25 mg/kg iv,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6535,In vivo,N,1,CHEMBL624450,,,
5628,1,Plasma clearance in dog after administration of 1 mg/kg iv,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6535,In vivo,N,1,CHEMBL875942,,,
5629,1,Plasma clearance in dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6535,In vivo,N,1,CHEMBL624451,,,
5630,1,Plasma clearance by iv administration in dog at a dose of 0.3 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5542,In vivo,N,1,CHEMBL624452,,,
5631,1,Plasma clearance was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5199,In vivo,N,1,CHEMBL624453,,,
5632,1,Plasma clearance after 15 mg/kg iv dose in Dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,16907,In vivo,N,1,CHEMBL624454,,,
5633,1,Plasma clearance after 30 mg/kg po dose in Dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,16907,In vivo,N,1,CHEMBL624455,,,
5634,1,Plasma administration to dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,16367,In vivo,N,1,CHEMBL624456,,,
5635,1,Plasma clearance was determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5505,In vivo,N,1,CHEMBL624457,,,
5636,1,Systemic clearance after intravenous administration (0.5 mg/kg) was determined in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6215,In vivo,N,1,CHEMBL624458,,,
5637,1,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,1466,In vivo,N,1,CHEMBL624459,,,
5638,1,Intrinsic clearance in human liver microsomes,Liver,BAO_0000251,,Homo sapiens,,Intermediate,5007,In vitro,S,2,CHEMBL624460,,2107.0,
5639,1,Intrinsic clearance in human liver microsomes,Liver,BAO_0000251,,Homo sapiens,,Intermediate,5007,In vitro,S,2,CHEMBL624461,,2107.0,
5640,1,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,16452,In vivo,N,1,CHEMBL875943,,,
5641,1,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,,BAO_0000218,,Canis lupus familiaris,,Intermediate,16452,In vivo,N,1,CHEMBL624462,,,
5642,1,Clearance in dog (dose 1 mg/kg i.v.),,BAO_0000218,,Canis lupus familiaris,,Intermediate,16452,In vivo,N,1,CHEMBL624463,,,
5643,1,Plasma clearance after oral administration (2.5 mg/kg) in dog was determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6221,In vivo,N,1,CHEMBL624464,,,
5644,1,Plasma clearance in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,BAO_0000218,,Canis lupus familiaris,,Intermediate,5007,In vivo,N,1,CHEMBL624465,,,
5645,1,Plasma clearance after peroral administration at 10 mpk in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5668,In vivo,N,1,CHEMBL624466,,,
5646,1,Plasma clearance after peroral administration at 5 mpk in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5668,In vivo,N,1,CHEMBL624467,,,
5647,1,Plasma clearance after peroral administration at 5 mg/kg in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5668,In vivo,N,1,CHEMBL624468,,,
5648,1,Plasma clearance was measured in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,15660,In vivo,N,1,CHEMBL624469,,,
5649,1,Plasma clearance was measured in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,15660,In vivo,N,1,CHEMBL624470,,,
5650,1,Pharmacokinetic property (CLtot) was measured in dog at the dose of 0.032 mg/kg i.v.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5983,In vivo,N,1,CHEMBL624471,,,
5651,1,Total clearance was determined after 0.1 mg/kg iv administration in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5600,In vivo,N,1,CHEMBL624472,,,
5652,1,Clearance of compound after intravenous administration in dogs at 1.2 uM/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17764,In vivo,N,1,CHEMBL622775,,,
5653,1,Clearance after intravenous administration of 0.5 mg/kg in dog was determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6039,In vivo,N,1,CHEMBL622776,,,
5654,1,Clearance after intravenous administration of 1.0 mg/kg in dog was determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6039,In vivo,N,1,CHEMBL622777,,,
5655,1,Clearance after peroral administration of 0.2 mg/kg in dog was determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6039,In vivo,N,1,CHEMBL622778,,,
5656,1,Clearance by intravenous administration of 1.2 mg/kg in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4368,In vivo,N,1,CHEMBL622779,,,
5657,1,Clearance by iv administration in dogs at a dose of 1 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4305,In vivo,N,1,CHEMBL622780,,,
5658,1,Clearance value was evaluated in dog plasma,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,1918,In vivo,N,1,CHEMBL622781,,1969.0,
5659,1,Clearance was evaluated after i.v. administration in dog at a dose of 1 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6005,In vivo,N,1,CHEMBL622782,,,
5660,1,Compound was tested for plasma clearance in dog,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,4839,In vivo,N,1,CHEMBL622783,,1969.0,
5661,1,Pharmacokinetic property (Plasma clearance) was measured in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4239,In vivo,N,1,CHEMBL622784,,,
5662,1,Area under curve when injected perorally in mice at a dose of 50 mg/kg,,BAO_0000218,,Mus musculus,,Intermediate,17729,,N,1,CHEMBL622785,,,
5663,1,Area under curve when injected perorally in BALB/C mice at a dose of 50 mg/kg,,BAO_0000218,,Mus musculus,,Intermediate,17728,,N,1,CHEMBL622786,,,
5664,1,Area under curve value in mouse at a dose of 10 mg/kg,,BAO_0000218,,Mus musculus,,Intermediate,5302,,N,1,CHEMBL622787,,,
5665,1,Area under curve was determined at a dose of 100 mg/kg (i.p.) in Mice,,BAO_0000218,,Mus musculus,,Intermediate,5506,,N,1,CHEMBL875949,,,
5666,1,Area under curve was determined at a dose of 200 mg/kg (i.p.) in Mice,,BAO_0000218,,Mus musculus,,Intermediate,5506,,N,1,CHEMBL622788,,,
5667,1,Area under curve was determined for compound after intraperitoneal administration in mice at 18 uM/kg,,BAO_0000218,,Mus musculus,,Intermediate,17764,,N,1,CHEMBL622789,,,
5668,1,Area under curve was determined for compound after intraperitoneal administration in mice at 23 uM/kg,,BAO_0000218,,Mus musculus,,Intermediate,17764,,N,1,CHEMBL622790,,,
5669,1,Area under curve was determined for compound after intraperitoneal administration in mice at 25 uM/kg,,BAO_0000218,,Mus musculus,,Intermediate,17764,,N,1,CHEMBL622791,,,
5670,1,Area under curve was determined for compound after intraperitoneal administration in mice at 26 uM/kg,,BAO_0000218,,Mus musculus,,Intermediate,17764,,N,1,CHEMBL622792,,,
5671,1,Area under curve was determined for compound after intravenous administration in mice at 24 uM/kg,,BAO_0000218,,Mus musculus,,Intermediate,17764,,N,1,CHEMBL622793,,,
5672,1,Area under curve was determined for the compound at 24 mg/Kg,,BAO_0000218,,Mus musculus,,Intermediate,17753,,N,1,CHEMBL622794,,,
5673,1,Area under curve was determined for the compound at 40 mg/Kg,,BAO_0000218,,Mus musculus,,Intermediate,17753,,N,1,CHEMBL622795,,,
5674,1,Area under curve was determined for the compound at 5 mg/Kg,,BAO_0000218,,Mus musculus,,Intermediate,17753,,N,1,CHEMBL621803,,,
5675,1,Area under the curve for the compound is obtained at dose 25 mg/kg,,BAO_0000218,,Mus musculus,,Intermediate,3132,,N,1,CHEMBL621804,,,
5676,1,Area under the curve for the compound was obtained when tested in mouse,,BAO_0000218,,Mus musculus,,Intermediate,3132,,N,1,CHEMBL621805,,,
5677,1,Area under the curve of compound in mouse blood following i.v. administration of 10 mg/kg,,BAO_0000218,,Mus musculus,,Intermediate,17837,,N,1,CHEMBL621806,,,
5678,1,Area under the curve of compound in mouse blood following p.o. administration of 30 mg/kg,,BAO_0000218,,Mus musculus,,Intermediate,17837,,N,1,CHEMBL621807,,,
5679,1,Area under the curve was measured in mouse after an iv dose of 1 mg/kg,,BAO_0000218,,Mus musculus,,Intermediate,6062,,N,1,CHEMBL621808,,,
5680,1,Area under the curve was determined for the compound at a single subcutaneous administration of 40 mg/kg in mice,,BAO_0000218,,Mus musculus,,Intermediate,4066,,N,1,CHEMBL621809,,,
5681,1,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),,BAO_0000218,,Mus musculus,,Intermediate,16597,,N,1,CHEMBL621810,,,
5682,1,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,,BAO_0000218,,Mus musculus,,Intermediate,14239,,N,1,CHEMBL875164,,,
5683,1,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,,BAO_0000218,,Mus musculus,,Intermediate,14239,,N,1,CHEMBL621811,,,
5684,1,"Compound was evaluated for the pharmacokinetic parameter, area under curve",,BAO_0000218,,Mus musculus,,Intermediate,4890,,N,1,CHEMBL621812,,,
5685,1,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr ),,BAO_0000218,,Mus musculus,,Intermediate,429,,N,1,CHEMBL621813,,,
5686,1,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr),,BAO_0000218,,Mus musculus,,Intermediate,429,,N,1,CHEMBL621814,,,
5687,1,In vivo area under curve (AUC) was determined in murine septicemia at dose of 100 mg/kg,,BAO_0000218,,Mus musculus,,Intermediate,5969,,N,1,CHEMBL621815,,,
5688,1,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg,,BAO_0000218,,Mus musculus,,Intermediate,5969,,N,1,CHEMBL621816,,,
5689,1,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,,BAO_0000218,,Mus musculus,,Intermediate,5969,,N,1,CHEMBL621817,,,
5690,1,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse,,BAO_0000218,,Mus musculus,,Intermediate,6091,,N,1,CHEMBL621818,,,
5691,1,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse;ND=Not determined,,BAO_0000218,,Mus musculus,,Intermediate,6091,,N,1,CHEMBL621819,,,
5692,1,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice,,BAO_0000218,,Mus musculus,,Intermediate,6091,,N,1,CHEMBL621820,,,
5693,1,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice;ND=Not determined,,BAO_0000218,,Mus musculus,,Intermediate,6091,,N,1,CHEMBL621821,,,
5694,1,Pharmacokinetic property (AUC) was determined after ip administration of 32 mg/kg in mice,,BAO_0000218,,Mus musculus,,Intermediate,6178,,N,1,CHEMBL621822,,,
5695,1,Pharmacokinetic property (AUC) was determined after po administration of 32 mg/kg in mice,,BAO_0000218,,Mus musculus,,Intermediate,6178,,N,1,CHEMBL619474,,,
5696,1,"Reduction in area under curve was determined in DIO mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",,BAO_0000218,,Mus musculus,,Intermediate,6619,,N,1,CHEMBL619475,,,
5697,1,"Reduction in area under curve was determined in ob/ob mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",,BAO_0000218,,Mus musculus,,Intermediate,6619,,N,1,CHEMBL619476,,,
5698,1,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered intravenously in mice",,BAO_0000218,,Mus musculus,,Intermediate,3760,,N,1,CHEMBL619477,,,
5699,1,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered perorally in mice",,BAO_0000218,,Mus musculus,,Intermediate,3760,,N,1,CHEMBL619478,,,
5700,1,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered intravenously in mice",,BAO_0000218,,Mus musculus,,Intermediate,3760,,N,1,CHEMBL619479,,,
5701,1,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered perorally in mice",,BAO_0000218,,Mus musculus,,Intermediate,3760,,N,1,CHEMBL619480,,,
5702,1,The area under curve in vivo in mouse blood level after oral administration at dose 50 mk/kg e-1,,BAO_0000218,,Mus musculus,,Intermediate,3192,,N,1,CHEMBL619481,,,
5703,1,The area under curve in vivo in mouse blood level after subcutaneous administration at dose 50 mk/kg e-1,,BAO_0000218,,Mus musculus,,Intermediate,3192,,N,1,CHEMBL619482,,,
5704,1,Area under the curve was evaluated in mice after intravenous administration,,BAO_0000218,,Mus musculus,,Intermediate,2675,,N,1,CHEMBL619483,,,
5705,1,Area under the curve was evaluated in mice after oral administration,,BAO_0000218,,Mus musculus,,Intermediate,2675,,N,1,CHEMBL619484,,,
5706,1,AUC total value at a dose of 10 mg/kg intravenous administration in mice.,Plasma,BAO_0000218,,Mus musculus,,Intermediate,16597,,N,1,CHEMBL619485,,1969.0,
5707,1,AUC total value at a dose of 10 mg/kg peroral administration in mice.,Plasma,BAO_0000218,,Mus musculus,,Intermediate,16597,,N,1,CHEMBL619486,,1969.0,
5708,1,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),,BAO_0000218,,Mus musculus,,Intermediate,16597,,N,1,CHEMBL619487,,,
5709,1,AUMC after intraperitoneal administration of 100 mg/kg in mice,,BAO_0000218,,Mus musculus,,Intermediate,17734,,N,1,CHEMBL619488,,,
5710,1,Biodistribution in blood was determined in mice after iv administration at 15 min Value expressed as percent injected dose per gram,Blood,BAO_0000218,,Mus musculus,,Intermediate,7767,In vivo,N,1,CHEMBL620106,,178.0,
5711,1,The compound was tested in vitro for anticancer activity against 9L cells,,BAO_0000219,,,,Intermediate,15345,,N,1,CHEMBL620107,392.0,,
5712,1,Anti proliferation activity determined; Weak effect,,BAO_0000019,,Rattus norvegicus,,Autocuration,2181,,U,0,CHEMBL620283,,,
5713,1,Inhibition of cell growth by compound at a concentration of 100 uM in 9Ltk+ cells; Completely stopped the process,,BAO_0000219,,Rattus norvegicus,,Autocuration,2181,,U,0,CHEMBL875176,,,
5714,1,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells,,BAO_0000219,,Rattus norvegicus,,Autocuration,2181,,U,0,CHEMBL620284,,,
5715,1,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells; Completely stopped the process,,BAO_0000219,,Rattus norvegicus,,Autocuration,2181,,U,0,CHEMBL623515,,,
5716,1,The cytotoxic activity was in vitro tested by 9PS assay method,,BAO_0000019,,Mus musculus,,Autocuration,10486,,U,0,CHEMBL623516,,,
5717,1,The cytotoxic activity was in vitro tested by 9PS assay method.,,BAO_0000019,,Mus musculus,,Autocuration,10486,,U,0,CHEMBL623517,,,
5718,1,Partition coefficient (logD6.5),,BAO_0000019,,,,Autocuration,15508,,U,0,CHEMBL857878,,,
5719,1,Inhibitory concentration in vitro for cytotoxic activity against A 2780 human ovarian carcinoma cells,,BAO_0000219,,Homo sapiens,,Expert,5242,,N,1,CHEMBL623518,478.0,,
5720,1,Effective concentration against A 375 cell line growth (DFMO concentration is 5.0 mM),,BAO_0000219,,Homo sapiens,,Intermediate,16167,,N,1,CHEMBL624195,455.0,,
5721,1,Inhibitory concentration required against A 431 human epidermoid carcinoma cell line,,BAO_0000219,,Homo sapiens,,Expert,4782,,N,1,CHEMBL624196,500.0,,
5722,1,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,,BAO_0000219,,Homo sapiens,,Expert,16093,,D,9,CHEMBL624197,500.0,,
5723,1,Compound was evaluated for in vitro cytotoxicity against A 498 cancer cell line,,BAO_0000219,,Homo sapiens,,Intermediate,2596,,N,1,CHEMBL624198,624.0,,
5724,1,in vitro cytotoxicity against A 498 cancer cell line,,BAO_0000219,,Homo sapiens,,Intermediate,2596,,N,1,CHEMBL621287,624.0,,
5725,1,In vitro cytotoxic activity against renal (A 498) cancer cell line.,,BAO_0000219,,Homo sapiens,,Intermediate,3239,,N,1,CHEMBL621288,624.0,,
5726,1,Cytotoxic activity against A 498 renal cancer cell lines.,,BAO_0000219,,Homo sapiens,,Intermediate,1847,,N,1,CHEMBL876496,624.0,,
5727,1,In vitro cytotoxicity was determined against A 498 human renal tumor cell line using NCI screen,,BAO_0000219,,Homo sapiens,,Intermediate,10553,,N,1,CHEMBL621289,624.0,,
5728,1,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,,BAO_0000019,,Staphylococcus aureus,,Autocuration,16219,,U,0,CHEMBL621290,,,
5729,1,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,,BAO_0000019,,Staphylococcus aureus,,Autocuration,16219,,U,0,CHEMBL621291,,,
5730,1,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,,BAO_0000019,,Staphylococcus aureus,,Autocuration,16219,,U,0,CHEMBL621292,,,
5731,1,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,,BAO_0000019,,Staphylococcus aureus,,Autocuration,16219,,U,0,CHEMBL621293,,,
5732,1,Inhibitory concentration required against A 549 lung cancer cell line,,BAO_0000219,,Homo sapiens,,Intermediate,4782,,N,1,CHEMBL621294,646.0,,
5733,1,Growth inhibition of A 549 cell line by MTT reduction for 3 days of incubation time,,BAO_0000219,,Homo sapiens,,Intermediate,11805,,N,1,CHEMBL621295,646.0,,
5734,1,Growth inhibition of A 549 cell line by MTT reduction for 7 days of incubation time,,BAO_0000219,,Homo sapiens,,Intermediate,11805,,N,1,CHEMBL884007,646.0,,
5735,1,In vitro cytotoxicity against lung cancer A 549 cell lines,,BAO_0000219,,Homo sapiens,,Intermediate,2007,,N,1,CHEMBL621296,646.0,,
5736,1,Compound was tested for its cytotoxicity against A 549 cell line,,BAO_0000219,,Homo sapiens,,Intermediate,4594,,N,1,CHEMBL621297,646.0,,
5737,1,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.",,BAO_0000219,,Homo sapiens,,Expert,6018,,N,1,CHEMBL839828,646.0,,
5738,1,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.; No data",,BAO_0000219,,Homo sapiens,,Intermediate,6018,,N,1,CHEMBL620397,646.0,,
5739,1,In vitro cytotoxic activity against A 549 (non-small cell lung) using SRB (sulforhodamine B) assay,,BAO_0000219,,Homo sapiens,,Expert,3599,,N,1,CHEMBL620398,646.0,,
5740,1,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,,BAO_0000219,,Homo sapiens,,Intermediate,2551,,N,1,CHEMBL620399,646.0,,
5741,1,In vitro inhibition of A549 (human lung cancer) cell growth.,,BAO_0000219,,Homo sapiens,,Expert,16132,,N,1,CHEMBL620400,646.0,,
5742,1,Cytotoxic related antitumor activity against human cancer cell lines A 549; No data available,,BAO_0000219,,Homo sapiens,,Intermediate,16132,,N,1,CHEMBL620401,646.0,,
5743,1,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,,BAO_0000219,,Homo sapiens,,Expert,2551,,N,1,CHEMBL620402,646.0,,
5744,1,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay; not active (> 100 uM),,BAO_0000219,,Homo sapiens,,Expert,2551,,N,1,CHEMBL620403,646.0,,
5745,1,Tested against A II at (100 ng/kg iv) in Dawley rats (n=2). 24 h,,BAO_0000218,,,,Autocuration,11913,,U,0,CHEMBL620404,,,
5746,1,The duration of action for the % peak inhibition of A II pressor response for dose of 0.1 mg/kg intravenous administration in conscious dogs.,,BAO_0000218,,,,Autocuration,12621,In vivo,H,4,CHEMBL620405,,,
5747,1,The duration of action for the % peak inhibition of A II pressor response for dose of 1.0 mg/kg peroral administration in rhesus monkeys.,,BAO_0000218,,,,Autocuration,12621,In vivo,H,4,CHEMBL620406,,,
5748,1,The duration of action for the % peak inhibition of angiotensin II pressor response for dose of 0.1 mg/kg peroral administration in conscious rats.,,BAO_0000218,,,,Autocuration,12621,In vivo,H,4,CHEMBL620407,,,
5749,1,The compound was evaluated for the % peak inhibition of A II pressor response for dose of 0.3 mg/kg peroral administration in rhesus monkeys.,,BAO_0000218,,,,Autocuration,12621,In vivo,H,4,CHEMBL620408,,,
5750,1,The compound was evaluated for the percentage of inhibition of A II pressor response in rats for peroral administration.,,BAO_0000218,,,,Autocuration,12621,In vivo,H,4,CHEMBL620409,,,
5751,1,Inhibition of A-498 human Renal cell proliferation,,BAO_0000219,,Homo sapiens,,Expert,3600,,N,1,CHEMBL620410,624.0,,
5752,1,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 0.1 uM",,BAO_0000019,,Rattus norvegicus,,Autocuration,1796,,U,0,CHEMBL620411,,,
5753,1,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 1 uM",,BAO_0000019,,Rattus norvegicus,,Autocuration,1796,,U,0,CHEMBL620412,,,
5754,1,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 10 uM",,BAO_0000019,,Rattus norvegicus,,Autocuration,1796,,U,0,CHEMBL876596,,,
5755,1,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay,,BAO_0000219,,Homo sapiens,,Expert,16464,,N,1,CHEMBL620413,622.0,,
5756,1,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,BAO_0000219,,Homo sapiens,,Intermediate,16464,,N,1,CHEMBL620414,622.0,,
5757,1,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,BAO_0000219,,Homo sapiens,,Intermediate,16464,,N,1,CHEMBL620415,622.0,,
5758,1,Concentration required to inhibit growth of human tumor A549 (NSCL) cell line.,,BAO_0000219,,Homo sapiens,,Expert,13617,,N,1,CHEMBL620416,646.0,,
5759,1,Concentration which produces 50% inhibition of growth of human lung carcinoma cell line A549,,BAO_0000219,,Homo sapiens,,Intermediate,4584,,N,1,CHEMBL620417,646.0,,
5760,1,Cytotoxic activity evaluated against A549 tumor cells,,BAO_0000219,,Homo sapiens,,Expert,13799,,N,1,CHEMBL620418,646.0,,
5761,1,Cytotoxic potentiation of Topotecan (TP) by the compound in human lung carcinoma A549 cell line,,BAO_0000219,,Homo sapiens,,Intermediate,16726,,N,1,CHEMBL620419,646.0,,
5762,1,Cytotoxicity against A549 cells when the drug is exposed for a time of 1 hr,,BAO_0000219,,Homo sapiens,,Intermediate,16109,,N,1,CHEMBL620420,646.0,,
5763,1,Cytotoxicity against A549 cells when the drug is exposed for a time of 96 hrs,,BAO_0000219,,Homo sapiens,,Intermediate,16109,,N,1,CHEMBL620421,646.0,,
5764,1,Cytotoxicity against A549 tumor cell line determined by WST-1 assay,,BAO_0000219,,Homo sapiens,,Intermediate,15474,,N,1,CHEMBL620422,646.0,,
5765,1,Cytotoxicity of compound against A549 cell line,,BAO_0000219,,Homo sapiens,,Intermediate,6851,,N,1,CHEMBL620423,646.0,,
5766,1,Cytotoxicity against human lung cell carcinoma A549 cell line,,BAO_0000219,,Homo sapiens,,Expert,17534,,N,1,CHEMBL620424,646.0,,
5767,1,Cytotoxicity against human lung carcinoma A549 cell line using MTT assay,,BAO_0000219,,Homo sapiens,,Intermediate,2621,,N,1,CHEMBL620425,646.0,,
5768,1,Cytotoxicity was evaluated in vitro against A549 (non-small cell lung carcinoma) human tumor cell lines,,BAO_0000219,,Homo sapiens,,Intermediate,830,,N,1,CHEMBL620426,646.0,,
5769,1,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum,,BAO_0000219,,Homo sapiens,,Intermediate,14255,,N,1,CHEMBL620427,646.0,,
5770,1,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum; Not determined,,BAO_0000219,,Homo sapiens,,Intermediate,14255,,N,1,CHEMBL620428,646.0,,
5771,1,In vitro antitumor activity against A549 human NSCLC lung carcinoma cells,,BAO_0000219,,Homo sapiens,,Intermediate,1590,,N,1,CHEMBL620429,646.0,,
5772,1,In vitro concentration required to inhibit the TNF-alpha-induced RANTES production in A549 human lung epithelium cell line,,BAO_0000219,,Homo sapiens,,Expert,6146,,N,1,CHEMBL620430,646.0,,
5773,1,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,,BAO_0000219,,Homo sapiens,,Expert,17427,,N,1,CHEMBL839887,646.0,,
5774,1,In vitro cytotoxicity against parental and drug resistant lung human tumor cell line A549,,BAO_0000219,,Homo sapiens,,Intermediate,5280,,N,1,CHEMBL620431,646.0,,
5775,1,In vitro cytotoxicity of compound against human A549 (non small cell lung) cancer cell line after 72 hr of drug exposure,,BAO_0000219,,Homo sapiens,,Intermediate,16786,,N,1,CHEMBL884010,646.0,,
5776,1,In vitro cytotoxicity against A549 (human lung cancer),,BAO_0000219,,Homo sapiens,,Intermediate,5895,,N,1,CHEMBL620538,646.0,,
5777,1,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,,BAO_0000219,,Homo sapiens,,Expert,14297,,N,1,CHEMBL620539,646.0,,
5778,1,In vivo antiproliferative activity against A549 cell line,,BAO_0000218,,Homo sapiens,,Intermediate,17824,,N,1,CHEMBL623373,646.0,,
5779,1,Inhibition of non-small-cell lung adenocarcinoma (A549),,BAO_0000219,,Homo sapiens,,Intermediate,14368,,N,1,CHEMBL623374,646.0,,
5780,1,Inhibition of non-small-cell lung adenocarcinoma (A549) after 48-h treatment,,BAO_0000219,,Homo sapiens,,Intermediate,14368,,N,1,CHEMBL623375,646.0,,
5781,1,Inhibition of the growth against human non-small-lung carcinoma (A549) cell line after 72 hr exposure,,BAO_0000219,,Homo sapiens,,Intermediate,14254,,N,1,CHEMBL623376,646.0,,
5782,1,Inhibitory activity against A549 cell line using MTT assay(Wild type p53),,BAO_0000219,,Homo sapiens,,Intermediate,15897,,N,1,CHEMBL623377,646.0,,
5783,1,Inhibitory activity against A549 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,,BAO_0000219,,Homo sapiens,,Intermediate,13866,,N,1,CHEMBL623378,646.0,,
5784,1,Inhibitory activity of compound against human A549 lung carcinoma cell line.,,BAO_0000219,,Homo sapiens,,Intermediate,13370,,N,1,CHEMBL623379,646.0,,
5785,1,Inhibitory activity against A549 lung cancer cell line,,BAO_0000219,,Homo sapiens,,Intermediate,4862,,N,1,CHEMBL623380,646.0,,
5786,1,Inhibitory activity against Taxol-resistant A549 lung cancer cell line,,BAO_0000219,,Homo sapiens,,Intermediate,4862,,N,1,CHEMBL623381,646.0,,
5787,1,Inhibitory activity against Taxol-resistant A549 lung cancer cell line; not determined,,BAO_0000219,,Homo sapiens,,Intermediate,4862,,N,1,CHEMBL623382,646.0,,
5788,1,Inhibitory concentration against A549 (lung cancer) cell line,,BAO_0000219,,Homo sapiens,,Intermediate,15970,,N,1,CHEMBL623383,646.0,,
5789,1,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,,BAO_0000219,,Homo sapiens,,Expert,17713,,N,1,CHEMBL623384,646.0,,
5790,1,Tested in vitro for inhibitory effect on the growth of human A-549 cancer cell line,,BAO_0000219,,Homo sapiens,,Intermediate,4833,,N,1,CHEMBL623385,646.0,,
5791,1,Activity against A549 cancer cell line.,,BAO_0000219,,Homo sapiens,,Expert,13736,,N,1,CHEMBL623386,646.0,,
5792,1,The compound was evaluated for cytotoxicity against A549 cell line,,BAO_0000219,,Homo sapiens,,Intermediate,4312,,N,1,CHEMBL884105,646.0,,
5793,1,The compound was examined for its ability to block tumor necrosis factor alpha (TNF alpha) induced IL-8 production in A549 human lung carcinoma cell line using an ELISA,,BAO_0000219,,Homo sapiens,,Intermediate,5421,,N,1,CHEMBL623387,646.0,,
5794,1,The compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,,BAO_0000219,,Homo sapiens,,Intermediate,5421,,N,1,CHEMBL621568,646.0,,
5795,1,Growth inhibitory activity was measured for human A549 tumor cell line.,,BAO_0000219,,Homo sapiens,,Intermediate,14717,,N,1,CHEMBL621569,646.0,,
5796,1,Inhibitory activity against A549 lung cancer cell line,,BAO_0000219,,Homo sapiens,,Intermediate,4634,,N,1,CHEMBL621570,646.0,,
5797,1,Inhibitory activity against A549 cell line; inactive,,BAO_0000219,,Homo sapiens,,Intermediate,1149,,N,1,CHEMBL621571,646.0,,
5798,1,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,,BAO_0000219,,Homo sapiens,,Expert,5421,,N,1,CHEMBL621572,646.0,,
5799,1,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,,BAO_0000219,,Homo sapiens,,Expert,5421,,N,1,CHEMBL621573,646.0,,
5800,1,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,,BAO_0000219,,Homo sapiens,,Intermediate,5421,,N,1,CHEMBL621574,646.0,,
5801,1,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-4 (M/L),,BAO_0000219,,Homo sapiens,,Intermediate,3320,,N,1,CHEMBL621575,646.0,,
5802,1,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-5 (M/L),,BAO_0000219,,Homo sapiens,,Intermediate,3320,,N,1,CHEMBL621576,646.0,,
5803,1,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-6 (M/L),,BAO_0000219,,Homo sapiens,,Intermediate,3320,,N,1,CHEMBL621577,646.0,,
5804,1,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-7 (M/L),,BAO_0000219,,Homo sapiens,,Intermediate,3320,,N,1,CHEMBL621578,646.0,,
5805,1,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-8 (M/L),,BAO_0000219,,Homo sapiens,,Intermediate,3320,,N,1,CHEMBL621579,646.0,,
5806,1,In vitro percent inhibition evaluated against human lung cancer (A549 cell line) at >20 ug/mL,,BAO_0000219,,Homo sapiens,,Intermediate,5726,,N,1,CHEMBL621580,646.0,,
5807,1,Plasma clearance (in vivo) in mongrel dogs was determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17800,In vivo,N,1,CHEMBL621581,,,
5808,1,Plasma clearance was measured in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5985,In vivo,N,1,CHEMBL621582,,,
5809,1,Plasma clearance in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5530,In vivo,N,1,CHEMBL621583,,,
5810,1,Plasma clearance in vivo in dog by intravenous administration at a dose of 1 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5530,In vivo,N,1,CHEMBL621584,,,
5811,1,Tested for plasma clearance in dog,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,4839,In vivo,N,1,CHEMBL621585,,1969.0,
5812,1,The compound was tested for clearance in dog plasma.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,3639,In vivo,N,1,CHEMBL621586,,,
5813,1,"The pharmacokinetic parameter, clearance was reported in dog after intravenous administration",,BAO_0000218,,Canis lupus familiaris,,Intermediate,4838,In vivo,N,1,CHEMBL875835,,,
5814,1,Clearance value of compound was determined after intravenous administration of 1 mg/kg/h in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4137,In vivo,N,1,CHEMBL621587,,,
5815,1,Compound was tested for its ability of plasma clearance when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,5017,In vivo,N,1,CHEMBL621588,,1969.0,
5816,1,In vitro clearance in dog liver microsomes,Liver,BAO_0000218,,Canis lupus familiaris,,Intermediate,17538,In vitro,N,1,CHEMBL621589,,2107.0,
5817,1,Pharmacokinetic profile in terms of clearance was determined at a dose of 0.5 mg/kg administered intravenously in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6161,In vivo,N,1,CHEMBL621590,,,
5818,1,Pharmacokinetic profile in terms of clearance was determined at a dose of 5 mg/kg administered intravenously in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6161,In vivo,N,1,CHEMBL621591,,,
5819,1,Plasma clearance in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,1696,In vivo,N,1,CHEMBL621592,,,
5820,1,Clearance rate in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6762,In vivo,N,1,CHEMBL621593,,,
5821,1,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,5932,In vivo,N,1,CHEMBL621594,,1969.0,
5822,1,Clearance in dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6305,In vivo,N,1,CHEMBL621595,,,
5823,1,Plasma clearance in dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4942,In vivo,N,1,CHEMBL621596,,,
5824,1,Plasma clearance was determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4219,In vivo,N,1,CHEMBL621597,,,
5825,1,Lower clearance in dog (i.v.) at 0.5 mpk,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17853,In vivo,N,1,CHEMBL621598,,,
5826,1,Plasma clearance in Beagle dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4514,In vivo,N,1,CHEMBL621599,,,
5827,1,Plasma clearance (Clp) in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6448,In vivo,N,1,CHEMBL875836,,,
5828,1,Plasma clearance (pharmacokinetic parameter) in dog (in vivo) at a dose of 1 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6227,In vivo,N,1,CHEMBL621600,,,
5829,1,Plasma clearance (pharmacokinetic parameter) in dog was determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6227,In vivo,N,1,CHEMBL621601,,,
5830,1,Plasma clearance for the compound was measured in dog after an iv dose of 1 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6062,In vivo,N,1,CHEMBL618474,,,
5831,1,Plasma clearance of compound was determined in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6821,In vivo,N,1,CHEMBL618475,,,
5832,1,Plasma clearance after intravenous administration of 1 mg/kg in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4709,In vivo,N,1,CHEMBL624524,,,
5833,1,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4521,In vivo,N,1,CHEMBL624525,,,
5834,1,Plasma clearance in dog was determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5374,In vivo,N,1,CHEMBL624526,,,
5835,1,Plasma clearance was calculated in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6057,In vivo,N,1,CHEMBL624527,,,
5836,1,Plasma clearance at the dose of 2 mg/kg in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4727,In vivo,N,1,CHEMBL624528,,,
5837,1,Plasma clearance in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5145,In vivo,N,1,CHEMBL624529,,,
5838,1,Plasma clearance in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17657,In vivo,N,1,CHEMBL624530,,,
5839,1,Plasma clearance in dog; Unable to calculate,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17657,In vivo,N,1,CHEMBL624531,,,
5840,1,Plasma clearance in rhesus monkey,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5145,In vivo,N,1,CHEMBL624532,,,
5841,1,Plasma clearance in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6642,In vivo,N,1,CHEMBL624533,,,
5842,1,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6641,In vivo,N,1,CHEMBL624534,,,
5843,1,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6642,In vivo,N,1,CHEMBL624535,,,
5844,1,Plasma clearance was evaluated in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5472,In vivo,N,1,CHEMBL624536,,,
5845,1,Plasma clearance was evaluated in dog; Not tested,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5472,In vivo,N,1,CHEMBL624537,,,
5846,1,Plasma clearance was evaluated in rhesus,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5472,In vivo,N,1,CHEMBL624538,,,
5847,1,Plasma clearance was evaluated in rhesus; Not tested,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5472,In vivo,N,1,CHEMBL624539,,,
5848,1,Plasma clearance value was determined in dog after a 3 mg/kg of iv dose,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4257,In vivo,N,1,CHEMBL624540,,,
5849,1,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6679,In vivo,N,1,CHEMBL624541,,,
5850,1,Plasma clearance was determined in Beagle dog at a dose of 1 mg/kg by iv administration,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5546,In vivo,N,1,CHEMBL624542,,,
5851,1,Plasma clearance was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6348,In vivo,N,1,CHEMBL624543,,,
5852,1,Clearance value at a dose of 0.2 mg/kg i.v.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5474,In vivo,N,1,CHEMBL624544,,,
5853,1,Cmax (Maximum (Peak) plasma drug concentration) was after oral administration at 5 mg/kg,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,6316,In vivo,N,1,CHEMBL624545,,1969.0,
5854,1,Cmax after oral dose of compound at 3 mg/kg in dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17594,In vivo,N,1,CHEMBL624546,,,
5855,1,Cmax after single intravenous bolus of 1 mg/kg in dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17594,In vivo,N,1,CHEMBL875957,,,
5856,1,Cmax of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5802,In vivo,N,1,CHEMBL624547,,,
5857,1,Cmax in dog after administration of 0.25 mg/kg iv; ND = not determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6535,In vivo,N,1,CHEMBL624548,,,
5858,1,Cmax in dog after administration of 1 mg/kg iv,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6535,In vivo,N,1,CHEMBL624549,,,
5859,1,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in dog,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,1466,In vivo,N,1,CHEMBL624550,,1969.0,
5860,1,Cmax on p.o. administration of 10 mg/kg was measured in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6505,In vivo,N,1,CHEMBL621613,,,
5861,1,Cmax was determine after peroral administration at 10 mpk in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5668,In vivo,N,1,CHEMBL621614,,,
5862,1,Cmax was determine after peroral administration at 5 mpk in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5668,In vivo,N,1,CHEMBL623431,,,
5863,1,Cmax was determine after peroral administration at 5 mg/kg in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5668,In vivo,N,1,CHEMBL623432,,,
5864,1,Cmax after 0.3 mg/kg po administration in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5600,In vivo,N,1,CHEMBL623433,,,
5865,1,Cmax after peroral administration in dogs at 2.4 uM/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17764,In vivo,N,1,CHEMBL623434,,,
5866,1,Cmax in dog after oral administration at 1 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6123,In vivo,N,1,CHEMBL623435,,,
5867,1,Cmax in dog after oral administration at 1 mg/kg; Below the level of quantitation,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6123,In vivo,N,1,CHEMBL623436,,,
5868,1,Cmax upon oral administration in male Beagle dog at 10 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6757,In vivo,N,1,CHEMBL875958,,,
5869,1,Cmax value after 15 mg/kg iv dose in Dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,16907,In vivo,N,1,CHEMBL623437,,,
5870,1,Biodistribution in blood was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Blood,BAO_0000218,,Mus musculus,,Intermediate,7767,In vivo,N,1,CHEMBL623438,,178.0,
5871,1,Biodistribution in blood was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Blood,BAO_0000218,,Mus musculus,,Intermediate,7767,In vivo,N,1,CHEMBL623439,,178.0,
5872,1,Biodistribution in bone was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Bone,BAO_0000218,,Mus musculus,,Intermediate,7767,In vivo,N,1,CHEMBL623440,,10000001.0,
5873,1,Biodistribution in bone was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Bone,BAO_0000218,,Mus musculus,,Intermediate,7767,In vivo,N,1,CHEMBL623441,,10000001.0,
5874,1,Biodistribution in bone was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Bone,BAO_0000218,,Mus musculus,,Intermediate,7767,In vivo,N,1,CHEMBL623442,,10000001.0,
5875,1,Biodistribution in fat and fur was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,BAO_0000218,,Mus musculus,,Intermediate,7767,In vivo,N,1,CHEMBL623469,,,
5876,1,Biodistribution in fat and fur was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,BAO_0000218,,Mus musculus,,Intermediate,7767,In vivo,N,1,CHEMBL623470,,,
5877,1,Biodistribution in fat and fur was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,BAO_0000218,,Mus musculus,,Intermediate,7767,In vivo,N,1,CHEMBL623471,,,
5878,1,Biodistribution in heart was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Heart,BAO_0000218,,Mus musculus,,Intermediate,7767,In vivo,N,1,CHEMBL623472,,948.0,
5879,1,Biodistribution in heart was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Heart,BAO_0000218,,Mus musculus,,Intermediate,7767,In vivo,N,1,CHEMBL623473,,948.0,
5880,1,Biodistribution in heart was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Heart,BAO_0000218,,Mus musculus,,Intermediate,7767,In vivo,N,1,CHEMBL623474,,948.0,
5881,1,Biodistribution in kidney was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Kidney,BAO_0000218,,Mus musculus,,Intermediate,7767,In vivo,N,1,CHEMBL623475,,2113.0,
5882,1,Biodistribution in kidney was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Kidney,BAO_0000218,,Mus musculus,,Intermediate,7767,In vivo,N,1,CHEMBL623476,,2113.0,
5883,1,Biodistribution in kidney was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Kidney,BAO_0000218,,Mus musculus,,Intermediate,7767,In vivo,N,1,CHEMBL623477,,2113.0,
5884,1,Biodistribution in large intestine after iv administration at 1 hr; Value expressed as percent injected dose per gram,Intestine,BAO_0000218,,Mus musculus,,Intermediate,7767,In vivo,N,1,CHEMBL621896,,160.0,
5885,1,Biodistribution in large intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Intestine,BAO_0000218,,Mus musculus,,Intermediate,7767,In vivo,N,1,CHEMBL621897,,160.0,
5886,1,Biodistribution in large intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Intestine,BAO_0000218,,Mus musculus,,Intermediate,7767,In vivo,N,1,CHEMBL621898,,160.0,
5887,1,Biodistribution in liver was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Liver,BAO_0000218,,Mus musculus,,Intermediate,7767,In vivo,N,1,CHEMBL621899,,2107.0,
5888,1,Biodistribution in liver was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Liver,BAO_0000218,,Mus musculus,,Intermediate,7767,In vivo,N,1,CHEMBL621900,,2107.0,
5889,1,Biodistribution in liver was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Liver,BAO_0000218,,Mus musculus,,Intermediate,7767,In vivo,N,1,CHEMBL621901,,2107.0,
5890,1,Biodistribution in lung was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Lung,BAO_0000218,,Mus musculus,,Intermediate,7767,In vivo,N,1,CHEMBL621902,,2048.0,
5891,1,Biodistribution in lung was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Lung,BAO_0000218,,Mus musculus,,Intermediate,7767,In vivo,N,1,CHEMBL621903,,2048.0,
5892,1,Biodistribution in lung was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Lung,BAO_0000218,,Mus musculus,,Intermediate,7767,In vivo,N,1,CHEMBL622587,,2048.0,
5893,1,Biodistribution in muscle was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Muscle tissue,BAO_0000218,,Mus musculus,,Intermediate,7767,In vivo,N,1,CHEMBL620285,,2385.0,
5894,1,Biodistribution in muscle was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Muscle tissue,BAO_0000218,,Mus musculus,,Intermediate,7767,In vivo,N,1,CHEMBL875285,,2385.0,
5895,1,Biodistribution in muscle was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Muscle tissue,BAO_0000218,,Mus musculus,,Intermediate,7767,In vivo,N,1,CHEMBL620286,,2385.0,
5896,1,Biodistribution in pancreatic tissue was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,BAO_0000218,,Mus musculus,,Intermediate,7767,In vivo,N,1,CHEMBL620287,,,
5897,1,Biodistribution in pancreatic tissue was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,BAO_0000218,,Mus musculus,,Intermediate,7767,In vivo,N,1,CHEMBL620288,,,
5898,1,Biodistribution in pancreatic tissue was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,BAO_0000218,,Mus musculus,,Intermediate,7767,In vivo,N,1,CHEMBL620289,,,
5899,1,Biodistribution in small intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Intestine,BAO_0000218,,Mus musculus,,Intermediate,7767,In vivo,N,1,CHEMBL620290,,160.0,
5900,1,Biodistribution in small intestine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Intestine,BAO_0000218,,Mus musculus,,Intermediate,7767,In vivo,N,1,CHEMBL620291,,160.0,
5901,1,Biodistribution in small intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Intestine,BAO_0000218,,Mus musculus,,Intermediate,7767,In vivo,N,1,CHEMBL620292,,160.0,
5902,1,Biodistribution in spleen was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Spleen,BAO_0000218,,Mus musculus,,Intermediate,7767,In vivo,N,1,CHEMBL620293,,2106.0,
5903,1,Biodistribution in spleen was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Spleen,BAO_0000218,,Mus musculus,,Intermediate,7767,In vivo,N,1,CHEMBL620294,,2106.0,
5904,1,Biodistribution in spleen was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Spleen,BAO_0000218,,Mus musculus,,Intermediate,7767,In vivo,N,1,CHEMBL618614,,2106.0,
5905,1,Biodistribution in stomach was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Stomach,BAO_0000218,,Mus musculus,,Intermediate,7767,In vivo,N,1,CHEMBL618615,,945.0,
5906,1,Biodistribution in stomach was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Stomach,BAO_0000218,,Mus musculus,,Intermediate,7767,In vivo,N,1,CHEMBL618616,,945.0,
5907,1,Cytotoxicity against A-172 human tumor cell lines,,BAO_0000219,,Homo sapiens,,Expert,2036,,N,1,CHEMBL618617,622.0,,
5908,1,Compound was evaluated for the in vitro cytotoxicity against A-172 human glioblastoma cell line,,BAO_0000219,,Homo sapiens,,Intermediate,2357,,N,1,CHEMBL618618,622.0,,
5909,1,Antiproliferative activity of compound was tested against rhabdomyosarcoma (A-204) human tumor cells,,BAO_0000219,,Homo sapiens,,Intermediate,1457,,N,1,CHEMBL618619,623.0,,
5910,1,Tested for antiproliferative activity against A-2780 tumoral cell line,,BAO_0000219,,Homo sapiens,,Intermediate,4379,,N,1,CHEMBL618620,478.0,,
5911,1,Inhibitory concentration against melanoma A-375 cell line for cytotoxicity was determined,,BAO_0000219,,Homo sapiens,,Intermediate,1093,,N,1,CHEMBL618621,455.0,,
5912,1,Tested in vitro against A-375 cell line human melanoma,,BAO_0000219,,Homo sapiens,,Intermediate,12152,,N,1,CHEMBL618622,455.0,,
5913,1,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay,,BAO_0000219,,Homo sapiens,,Expert,16464,,N,1,CHEMBL618623,797.0,,
5914,1,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,BAO_0000219,,Homo sapiens,,Intermediate,16464,,N,1,CHEMBL618624,797.0,,
5915,1,In vitro cytotoxicity against human non small-cell-lung cell line A-427.,,BAO_0000219,,Homo sapiens,,Expert,16582,,N,1,CHEMBL618625,797.0,,
5916,1,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,BAO_0000219,,Homo sapiens,,Intermediate,16464,,N,1,CHEMBL618626,797.0,,
5917,1,Antitumor activity on A-427 lung carcinoma cell lines,,BAO_0000219,,Homo sapiens,,Intermediate,10413,,N,1,CHEMBL618627,797.0,,
5918,1,Cytotoxic activity against human A-427 lung tumor cell line,,BAO_0000219,,Homo sapiens,,Intermediate,6418,,N,1,CHEMBL618628,797.0,,
5919,1,In vitro antitumor effects against human A-427 cell lines.,,BAO_0000219,,Homo sapiens,,Expert,17134,,N,1,CHEMBL618629,797.0,,
5920,1,In vitro inhibition of A-427 (human lung cancer) cell growth.,,BAO_0000219,,Homo sapiens,,Expert,16132,,N,1,CHEMBL618630,797.0,,
5921,1,Cytotoxic related antitumor activity against human cancer cell lines A-427; No data available,,BAO_0000219,,Homo sapiens,,Intermediate,16132,,N,1,CHEMBL618631,797.0,,
5922,1,Cytotoxic activity of compound against A-427 lung human tumor cell line,,BAO_0000219,,Homo sapiens,,Intermediate,16780,,N,1,CHEMBL618632,797.0,,
5923,1,Cytotoxicity measured for the growth inhibition of A-431 Human epidermoid carcinoma cell line,,BAO_0000219,,Homo sapiens,,Expert,4085,,N,1,CHEMBL618633,500.0,,
5924,1,Cytotoxic activity was tested against human A-498 (Kidney carcinoma) cell line,,BAO_0000219,,Homo sapiens,,Intermediate,1276,,N,1,CHEMBL619315,624.0,,
5925,1,Cytotoxicity against A-498 cell line in the purdue cell culture screen was determined,,BAO_0000219,,Homo sapiens,,Expert,3498,,N,1,CHEMBL619316,624.0,,
5926,1,Cytotoxicity against human kidney carcinoma A-498cell lines,,BAO_0000219,,Homo sapiens,,Intermediate,1169,,N,1,CHEMBL619317,624.0,,
5927,1,In vitro cytotoxic activity against A-498 (human kidney carcinoma) cell line,,BAO_0000219,,Homo sapiens,,Intermediate,4450,,N,1,CHEMBL619318,624.0,,
5928,1,In vitro cytotoxicity against Renal A-498 human tumors following a 6 day exposure.,,BAO_0000219,,Homo sapiens,,Intermediate,3311,,N,1,CHEMBL619319,624.0,,
5929,1,Antitumor cytotoxic activity against A-498 cell line was determined,,BAO_0000219,,Homo sapiens,,Intermediate,4461,,N,1,CHEMBL619739,624.0,,
5930,1,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure.,,BAO_0000219,,Homo sapiens,,Intermediate,3311,,N,1,CHEMBL619740,624.0,,
5931,1,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure; ND is no data,,BAO_0000219,,Homo sapiens,,Intermediate,3311,,N,1,CHEMBL883158,624.0,,
5932,1,Antiproliferative activity of compound was tested against renal cancer (A-498) human tumor cells,,BAO_0000219,,Homo sapiens,,Intermediate,1457,,N,1,CHEMBL884012,624.0,,
5933,1,In vitro inhibitory activity against A-498 ovarian cancer cell lines,,BAO_0000219,,Homo sapiens,,Intermediate,3664,,N,1,CHEMBL619741,624.0,,
5934,1,"Cytotoxicity against NCI tumor panel, A-498 renal cancer cell line",,BAO_0000219,,Homo sapiens,,Intermediate,15895,,N,1,CHEMBL619742,624.0,,
5935,1,Inhibition of growth lung non-small cell carcinoma A-549 cell line,,BAO_0000219,,Homo sapiens,,Intermediate,11843,,N,1,CHEMBL876610,646.0,,
5936,1,Inhibition of growth of lung non-small cell carcinoma A-549 cell line,,BAO_0000219,,Homo sapiens,,Intermediate,11843,,N,1,CHEMBL619743,646.0,,
5937,1,In vitro antiproliferative activity against human A-549 NSCL cell line,,BAO_0000219,,Homo sapiens,,Intermediate,17705,,N,1,CHEMBL619744,646.0,,
5938,1,In vitro antiproliferative activity against human A-549 NSCL cell line; NS = Not significant,,BAO_0000219,,Homo sapiens,,Intermediate,17705,,N,1,CHEMBL619745,646.0,,
5939,1,Growth inhibition of A-549 human lung adenocarcinoma at 0.01 uM compound concentration in standard MTT assay,,BAO_0000219,,Homo sapiens,,Intermediate,4369,,N,1,CHEMBL619746,646.0,,
5940,1,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay,,BAO_0000219,,Homo sapiens,,Intermediate,4369,,N,1,CHEMBL619747,646.0,,
5941,1,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay; ND means No data,,BAO_0000219,,Homo sapiens,,Intermediate,4369,,N,1,CHEMBL619748,646.0,,
5942,1,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay,,BAO_0000219,,Homo sapiens,,Intermediate,4369,,N,1,CHEMBL619749,646.0,,
5943,1,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay; ND means No data,,BAO_0000219,,Homo sapiens,,Intermediate,4369,,N,1,CHEMBL619750,646.0,,
5944,1,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay,,BAO_0000219,,Homo sapiens,,Intermediate,4369,,N,1,CHEMBL624014,646.0,,
5945,1,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay; ND means No data,,BAO_0000219,,Homo sapiens,,Intermediate,4369,,N,1,CHEMBL624015,646.0,,
5946,1,In vitro effective concentration required to reduce the number of human lung carcinoma (A-549) after 3-day incubation,,BAO_0000219,,Homo sapiens,,Expert,4787,,N,1,CHEMBL885344,646.0,,
5947,1,In vitro effective concentration required to reduce the number of human lung carcinoma cells (A-549) after 3-day incubation,,BAO_0000219,,Homo sapiens,,Intermediate,4787,,N,1,CHEMBL623224,646.0,,
5948,1,Cytotoxic activity against A-549 cell line,,BAO_0000219,,Homo sapiens,,Intermediate,6513,,N,1,CHEMBL623225,646.0,,
5949,1,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 0.01 to 0.03,,BAO_0000219,,Homo sapiens,,Intermediate,6690,,N,1,CHEMBL622698,646.0,,
5950,1,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 10.4 to 118.1,,BAO_0000219,,Homo sapiens,,Intermediate,6690,,N,1,CHEMBL622699,646.0,,
5951,1,"Cytotoxicity in vitro expressed as 50% reduction in cell number after a 3-day incubation, in human lung carcinoma A-549 cell line",,BAO_0000219,,Homo sapiens,,Expert,12263,,N,1,CHEMBL622700,646.0,,
5952,1,Compound was tested for cytotoxic activity against human lung carcinoma (A-549),,BAO_0000219,,Homo sapiens,,Intermediate,1054,,N,1,CHEMBL622701,646.0,,
5953,1,Compound was tested for its cytotoxic activity in MTT assay against A-549 cell line (human lung carcinoma),,BAO_0000219,,Homo sapiens,,Intermediate,1359,,N,1,CHEMBL622702,646.0,,
5954,1,Cytotoxic activity against human lung carcinoma (A-549) cell line,,BAO_0000219,,Homo sapiens,,Intermediate,3547,,N,1,CHEMBL622703,646.0,,
5955,1,Cytotoxic activity towards A-549 cells,,BAO_0000219,,Homo sapiens,,Expert,5771,,N,1,CHEMBL622704,646.0,,
5956,1,"In vitro percent inhibition of A549, lung carcinoma.",,BAO_0000219,,Homo sapiens,,Intermediate,14425,,N,1,CHEMBL622705,646.0,,
5957,1,"In vitro percent inhibition of A549, lung carcinoma",,BAO_0000219,,Homo sapiens,,Intermediate,14425,,N,1,CHEMBL622706,646.0,,
5958,1,"In vitro percent inhibition of A549, lung carcinoma.",,BAO_0000219,,Homo sapiens,,Intermediate,14425,,N,1,CHEMBL622707,646.0,,
5959,1,"In vitro percent inhibition of A549, lung carcinoma.; Range 18-23",,BAO_0000219,,Homo sapiens,,Intermediate,14425,,N,1,CHEMBL622708,646.0,,
5960,1,Percentage inhibition against parental and drug resistant lung human tumor cell line A549 at 10 uM,,BAO_0000219,,Homo sapiens,,Intermediate,5280,,N,1,CHEMBL622709,646.0,,
5961,1,Growth inhibition of the A549/ATCC non-small cell lung cancer cell line for 2-day in vitro assay.,,BAO_0000219,,Homo sapiens,,Intermediate,15176,,N,1,CHEMBL622710,646.0,,
5962,1,In vitro antitumor activity against Non-small cell lung cancer A549/ATCC cell lines by 6-day assay,,BAO_0000219,,Homo sapiens,,Intermediate,15300,,N,1,CHEMBL622711,646.0,,
5963,1,"Antitumor activity against A549 non small cell carcinoma at dose range of 1.56-6.25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,BAO_0000218,,Homo sapiens,,Intermediate,17824,,N,1,CHEMBL622712,646.0,,
5964,1,"Antitumor activity against A549 non small cell carcinoma at dose range of 25-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,BAO_0000218,,Homo sapiens,,Intermediate,17824,,N,1,CHEMBL622713,646.0,,
5965,1,"Antitumor activity against A549 non small cell carcinoma at dose range of 3.12-12.5 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,BAO_0000218,,Homo sapiens,,Intermediate,17824,,N,1,CHEMBL622714,646.0,,
5966,1,"Antitumor activity against A549 non small cell carcinoma at dose range of 6.25-25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,BAO_0000218,,Homo sapiens,,Intermediate,17824,,N,1,CHEMBL622715,646.0,,
5967,1,"Antitumor activity against A549 non small cell carcinoma at dose range of 70-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,BAO_0000218,,Homo sapiens,,Intermediate,17824,,N,1,CHEMBL622716,646.0,,
5968,1,"Antitumor activity against A549 non small cell carcinoma on day 14, 21, 28; activity expressed as maximum tolerated dose; NT = Not tested",,BAO_0000219,,Homo sapiens,,Intermediate,17824,,N,1,CHEMBL622717,646.0,,
5969,1,Optimal dose required to inhibit human non small cell lung A549 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q7dX3),,BAO_0000218,,Homo sapiens,,Intermediate,17528,,N,1,CHEMBL622718,646.0,,
5970,1,Cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration,,BAO_0000219,,Homo sapiens,,Expert,6870,,N,1,CHEMBL622719,646.0,,
5971,1,Compound was evaluated for cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,,BAO_0000219,,Homo sapiens,,Intermediate,6870,,N,1,CHEMBL622720,646.0,,
5972,1,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration,,BAO_0000219,,Homo sapiens,,Intermediate,6870,,N,1,CHEMBL622721,646.0,,
5973,1,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,,BAO_0000219,,Homo sapiens,,Intermediate,6870,,N,1,CHEMBL622722,646.0,,
5974,1,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,,BAO_0000219,,Homo sapiens,,Intermediate,16726,,N,1,CHEMBL876030,646.0,,
5975,1,"Concentration required for 50% inhibition of proliferation of lung cancer cell line, A549 with respect to paclitaxel was tested in vitro after 72 hr of incubation",,BAO_0000219,,Homo sapiens,,Intermediate,6170,,N,1,CHEMBL620206,646.0,,
5976,1,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-4 mol/L,,BAO_0000219,,Homo sapiens,,Expert,6583,,N,1,CHEMBL620207,646.0,,
5977,1,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-5 mol/L,,BAO_0000219,,Homo sapiens,,Expert,6583,,N,1,CHEMBL620208,646.0,,
5978,1,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-6 mol/L,,BAO_0000219,,Homo sapiens,,Expert,6583,,N,1,CHEMBL620209,646.0,,
5979,1,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-7 mol/L,,BAO_0000219,,Homo sapiens,,Expert,6583,,N,1,CHEMBL620210,646.0,,
5980,1,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-8 mol/L,,BAO_0000219,,Homo sapiens,,Expert,6583,,N,1,CHEMBL621639,646.0,,
5981,1,Tested for cytotoxicity against human lung adenocarcinoma A549 cell line,,BAO_0000219,,Homo sapiens,,Intermediate,17321,,N,1,CHEMBL621640,646.0,,
5982,1,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,,BAO_0000219,,Homo sapiens,,Expert,17528,,N,1,CHEMBL621641,646.0,,
5983,1,Cytotoxic effect on non-small-cell lung cancer cell line A549/ATCC,,BAO_0000219,,Homo sapiens,,Expert,12888,,N,1,CHEMBL621642,646.0,,
5984,1,Cytotoxicity of compound in synergy in 94% BCNU (10 uM) against A549 cell line,,BAO_0000219,,Homo sapiens,,Intermediate,4312,,N,1,CHEMBL621643,646.0,,
5985,1,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line,,BAO_0000219,,Homo sapiens,,Intermediate,4312,,N,1,CHEMBL621644,646.0,,
5986,1,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line; No data,,BAO_0000219,,Homo sapiens,,Intermediate,4312,,N,1,CHEMBL621645,646.0,,
5987,1,In vitro antiproliferative activity against A549 cell line,,BAO_0000219,,Mus musculus,,Intermediate,17737,,N,1,CHEMBL621646,646.0,,
5988,1,Synergism with indomethacin in A549 cells,,BAO_0000219,,,,Intermediate,6630,,N,1,CHEMBL621647,646.0,,
5989,1,Synergism with tolmetin in A549 cells,,BAO_0000219,,,,Intermediate,6630,,N,1,CHEMBL621648,646.0,,
5990,1,Synergism with sulindac in A549 cells,,BAO_0000219,,,,Intermediate,6630,,N,1,CHEMBL621649,646.0,,
5991,1,Antagonism of indomethacin in A549 cells,,BAO_0000219,,,,Intermediate,6630,,N,1,CHEMBL621650,646.0,,
5992,1,Antagonism of sulindac in A549 cells,,BAO_0000219,,,,Intermediate,6630,,N,1,CHEMBL621651,646.0,,
5993,1,Antagonism of tolmetin in A549 cells,,BAO_0000219,,,,Intermediate,6630,,N,1,CHEMBL621652,646.0,,
5994,1,Synergism with indomethacin in A549 cells,,BAO_0000219,,,,Intermediate,6630,,N,1,CHEMBL621653,646.0,,
5995,1,Synergism with sulindac in A549 cells,,BAO_0000219,,,,Intermediate,6630,,N,1,CHEMBL621654,646.0,,
5996,1,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tolmetin; Not available,,BAO_0000219,,,,Intermediate,6630,,N,1,CHEMBL621655,646.0,,
5997,1,Cmax value after 30 mg/kg po dose in Dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,16907,In vivo,N,1,CHEMBL621656,,,
5998,1,Cmax value determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),,BAO_0000218,,Canis lupus familiaris,,Intermediate,5944,In vivo,N,1,CHEMBL621657,,,
5999,1,Cmax value determined in dog at a dose of 10 mg/kg by oral administration,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5944,In vivo,N,1,CHEMBL621658,,,
6000,1,Cmax value determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),,BAO_0000218,,Canis lupus familiaris,,Intermediate,5944,In vivo,N,1,CHEMBL621659,,,
6001,1,Cmax value determined in dog at a dose of 5 mg/kg by oral administration,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5944,In vivo,N,1,CHEMBL621660,,,
6002,1,Cmax value after administration of 4 mg/Kg oral dose in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,2959,In vivo,N,1,CHEMBL621661,,,
6003,1,Cmax value in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6241,In vivo,N,1,CHEMBL621662,,,
6004,1,Cmax value in dogs after oral administration at 1 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6241,In vivo,N,1,CHEMBL621663,,,
6005,1,Bioavailability as Cmax in dogs at 5 mg/kg oral dose,,BAO_0000218,,Canis lupus familiaris,,Intermediate,2652,In vivo,N,1,CHEMBL621664,,,
6006,1,Compound was evaluated for maximum observed plasma concentration at dose 27.5 mg/kg DMP323 equiv in dogs,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,1806,In vivo,N,1,CHEMBL621665,,1969.0,
6007,1,Compound was evaluated for maximum observed plasma concentration at dose 7.7 mg/kg DMP323 equiv in dogs,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,1806,In vivo,N,1,CHEMBL621666,,1969.0,
6008,1,Concentration maxima after oral dosing in dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,1021,In vivo,N,1,CHEMBL621667,,,
6009,1,Concentration maxima after oral dosing in dogs; not available,,BAO_0000218,,Canis lupus familiaris,,Intermediate,1021,In vivo,N,1,CHEMBL876738,,,
6010,1,Concentration maxima after oral dosing in dogs; not available,,BAO_0000218,,Canis lupus familiaris,,Intermediate,1021,In vivo,N,1,CHEMBL621668,,,
6011,1,In vivo maximal concentration was calculated at 0.4 mg/kg in dog; Not absorbed,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5444,In vivo,N,1,CHEMBL621669,,,
6012,1,In vivo maximal concentration was calculated at 0.6 mg/kg in dog; Not absorbed,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5444,In vivo,N,1,CHEMBL621670,,,
6013,1,In vivo maximal concentration was calculated at 1 mg/kg in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5444,In vivo,N,1,CHEMBL621671,,,
6014,1,In vivo maximal concentration was calculated at 1 mg/kg in dog; Not absorbed,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5444,In vivo,N,1,CHEMBL622360,,,
6015,1,In vivo maximal concentration was calculated at 1 mg/kg in dog; Poor absorption,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5444,In vivo,N,1,CHEMBL622361,,,
6016,1,Cmax in dog plasma after oral dose (1 mg/kg),Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,5130,In vivo,N,1,CHEMBL622362,,1969.0,
6017,1,Maximal concentration (Cmax) in dog plasma at a dose of 5 mg/kg,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,3249,In vivo,N,1,CHEMBL622363,,1969.0,
6018,1,Maximal plasma concentration at a dose of 1 mg/kg,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,5473,In vivo,N,1,CHEMBL622364,,1969.0,
6019,1,Maximal plasma concentration at a dose of 1 mg/kg (oral),Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,5474,In vivo,N,1,CHEMBL622365,,1969.0,
6020,1,Maximal plasma concentration required for pharmacokinetic data in dogs at dose of 1 mg/kg perorally,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,4657,In vivo,N,1,CHEMBL622533,,1969.0,
6021,1,Maximum concentration of compound in dog was evaluated.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,3031,In vivo,N,1,CHEMBL622534,,,
6022,1,Maximum concentration by oral administration at a dose of 10 uM/kg in dog was determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4527,In vivo,N,1,CHEMBL622535,,,
6023,1,Maximum concentration in dog after administration of 20 mg/kg dose through peroral route,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4186,In vivo,N,1,CHEMBL876739,,,
6024,1,Maximum concentration in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,BAO_0000218,,Canis lupus familiaris,,Intermediate,5007,In vivo,N,1,CHEMBL622536,,,
6025,1,Maximum concentration obtained in dog plasma was determined,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,3132,In vivo,N,1,CHEMBL622537,,1969.0,
6026,1,Maximum concentration was determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5006,In vivo,N,1,CHEMBL622538,,,
6027,1,Maximum concentration at the dose of 2 mg/kg in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4727,In vivo,N,1,CHEMBL627867,,,
6028,1,Maximum concentration was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,BAO_0000218,,Canis lupus familiaris,,Intermediate,1916,In vivo,N,1,CHEMBL627868,,,
6029,1,Maximum concentration was evaluated in dog plasma,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,1918,In vivo,N,1,CHEMBL627869,,1969.0,
6030,1,Maximum concentration was evaluated after 75 min after administration in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,3045,In vivo,N,1,CHEMBL627870,,,
6031,1,Maximum plasma concentration determined in dog after oral administration of 17b,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,9579,In vivo,N,1,CHEMBL627871,,1969.0,
6032,1,Maximum plasma concentration determined in dog after oral administration of 2b,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,9579,In vivo,N,1,CHEMBL627872,,1969.0,
6033,1,Maximum plasma concentration in dog,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,933,In vivo,N,1,CHEMBL627873,,1969.0,
6034,1,Maximum plasma concentration of compound in dog following p.o. administration of 0.5 mg/kg,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,17839,In vivo,N,1,CHEMBL627874,,1969.0,
6035,1,Maximum plasma concentration of compound in dog following p.o. administration of 0.9 mg/kg,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,17839,In vivo,N,1,CHEMBL627875,,1969.0,
6036,1,Maximum plasma concentration of compound in dog following p.o. administration of 0.95 mg/kg,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,17839,In vivo,N,1,CHEMBL627876,,1969.0,
6037,1,Maximum plasma concentration of compound in dog following p.o. administration of 1 mg/kg,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,17839,In vivo,N,1,CHEMBL627877,,1969.0,
6038,1,Maximum plasma concentration of compound was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,6348,In vivo,N,1,CHEMBL627878,,1969.0,
6039,1,Maximum plasma concentration after oral administration to dogs at a dose of 10 mg/kg,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,16367,In vivo,N,1,CHEMBL627879,,1969.0,
6040,1,Maximum plasma concentration in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,1337,In vivo,N,1,CHEMBL875355,,1969.0,
6041,1,Maximum plasma concentration in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,1337,In vivo,N,1,CHEMBL627880,,1969.0,
6042,1,Maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,5199,In vivo,N,1,CHEMBL627881,,1969.0,
6043,1,Maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,17650,In vivo,N,1,CHEMBL627882,,1969.0,
6044,1,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,6679,In vivo,N,1,CHEMBL627883,,1969.0,
6045,1,Maximum plasma concentration was determined as in dogs at 1 mg/kg oral dosing Cmax; 0.05-0.2 ug/mL,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,5356,In vivo,N,1,CHEMBL628526,,1969.0,
6046,1,Maximum plasma concentration was determined in dogs at 1 mg/kg oral dosing; 0.05-0.2 ug/mL,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,5356,In vivo,N,1,CHEMBL628527,,1969.0,
6047,1,Maximum plasma concentration (Cmax) in dog (in vivo) at a dose of 1 mg/kg,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,6227,In vivo,N,1,CHEMBL628528,,1969.0,
6048,1,Maximum plasma concentration (Cmax) in dog at a dose of 0.5 mg/kg,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,6227,In vivo,N,1,CHEMBL628529,,1969.0,
6049,1,Maximum plasma concentration (Cmax) in dog at a dose of 0.7 mg/kg,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,6227,In vivo,N,1,CHEMBL628530,,1969.0,
6050,1,Maximum plasma concentration (Cmax) in dog at a dose of 1 mg/kg,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,6227,In vivo,N,1,CHEMBL625243,,1969.0,
6051,1,Maximum plasma drug concentration of compound determined in dog after iv administration at a dose of 10 mg/kg,Plasma,BAO_0000218,,Canis lupus familiaris,,Expert,3598,In vivo,N,1,CHEMBL625244,,1969.0,
6052,1,Maximum concentration by intravenous administration of 1.2 mg/kg in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4368,In vivo,N,1,CHEMBL625245,,,
6053,1,Pharmacokinetic (PK) property (Cmax) was determined in dog at the single dose of 1 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6265,In vivo,N,1,CHEMBL625246,,,
6054,1,Biodistribution in stomach was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Stomach,BAO_0000218,,Mus musculus,,Intermediate,7767,In vivo,N,1,CHEMBL625247,,945.0,
6055,1,Biodistribution in urine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Urine,BAO_0000218,,Mus musculus,,Intermediate,7767,In vivo,N,1,CHEMBL625248,,1088.0,
6056,1,Biodistribution in urine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram; ND- No data,Urine,BAO_0000218,,Mus musculus,,Intermediate,7767,In vivo,N,1,CHEMBL625249,,1088.0,
6057,1,Biodistribution in urine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram; ND- No data,Urine,BAO_0000218,,Mus musculus,,Intermediate,7767,In vivo,N,1,CHEMBL625250,,1088.0,
6058,1,Compound (0.09% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 120 min; No increase,,BAO_0000218,,Mus musculus,,Intermediate,17811,,N,1,CHEMBL625251,,,
6059,1,Compound (0.31% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 30 min; Low increase,,BAO_0000218,,Mus musculus,,Intermediate,17811,,N,1,CHEMBL875356,,,
6060,1,Compound (i.v.) was tested for maximum activity in mice (Radiolabeled compound),,BAO_0000218,,Mus musculus,,Intermediate,17827,,N,1,CHEMBL625252,,,
6061,1,Compound was evaluated for elimination rate constants in vivo in whole blood of normal mice (Radiolabeled compound),Blood,BAO_0000218,,Mus musculus,,Intermediate,17827,,N,1,CHEMBL625253,,178.0,
6062,1,Compound was evaluated for rate of bone uptake after administration of radiolabeled in mice (Radiolabeled compound),,BAO_0000218,,Mus musculus,,Intermediate,17827,,N,1,CHEMBL625254,,,
6063,1,Compound was evaluated for rate of bone uptake in mice (Radiolabeled compound),,BAO_0000218,,Mus musculus,,Intermediate,17827,,N,1,CHEMBL625255,,,
6064,1,Compound was evaluated for rate of bone uptake in mice; NA - not active (Radiolabeled compound),,BAO_0000218,,Mus musculus,,Intermediate,17827,,N,1,CHEMBL625256,,,
6065,1,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice (Radiolabeled compound),Blood,BAO_0000218,,Mus musculus,,Intermediate,17827,,N,1,CHEMBL625257,,178.0,
6066,1,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice; NA = not active (Radiolabeled compound),Blood,BAO_0000218,,Mus musculus,,Intermediate,17827,,N,1,CHEMBL625258,,178.0,
6067,1,Compound was evaluated for washout rate in mice (Radiolabeled compound),,BAO_0000218,,Mus musculus,,Intermediate,17827,,N,1,CHEMBL625259,,,
6068,1,Compound was evaluated for washout rate in mice after radiolabeled ligand injected,,BAO_0000218,,Mus musculus,,Intermediate,17827,,N,1,CHEMBL625260,,,
6069,1,"Maximum activity (i.v.) after in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",,BAO_0000218,,Mus musculus,,Intermediate,17827,,N,1,CHEMBL625261,,,
6070,1,"Maximum activity in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",,BAO_0000218,,Mus musculus,,Intermediate,17827,,N,1,CHEMBL625262,,,
6071,1,"Residual activity in mice at 120 minutes, expressed as [(ID%-kg)/g] (Radiolabeled compound)",,BAO_0000218,,Mus musculus,,Intermediate,17827,,N,1,CHEMBL622639,,,
6072,1,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice,,BAO_0000218,,Mus musculus,,Intermediate,17257,,N,1,CHEMBL622640,,,
6073,1,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice; Not detected.,,BAO_0000218,,Mus musculus,,Intermediate,17257,,N,1,CHEMBL622812,,,
6074,1,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice,,BAO_0000218,,Mus musculus,,Intermediate,17257,,N,1,CHEMBL622813,,,
6075,1,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice; Not determined,,BAO_0000218,,Mus musculus,,Intermediate,17257,,N,1,CHEMBL622814,,,
6076,1,Time at maximum activity in mice (Radiolabeled compound),,BAO_0000218,,Mus musculus,,Intermediate,17827,,N,1,CHEMBL622815,,,
6077,1,Percent oral bioavailability was determined after administration of compound at 5 mg/kg perorally in mice,,BAO_0000218,,Mus musculus,,Intermediate,3760,,N,1,CHEMBL625342,,,
6078,1,Percent oral bioavailability was determined after administration of compound at 50 mg/kg perorally in mice,,BAO_0000218,,Mus musculus,,Intermediate,3760,,N,1,CHEMBL625343,,,
6079,1,Binding towards mouse plasma protein at 10 uM,,BAO_0000218,,Mus musculus,,Intermediate,17409,,N,1,CHEMBL877591,,,
6080,1,Binding towards mouse plasma protein at 100 uM,,BAO_0000218,,Mus musculus,,Intermediate,17409,,N,1,CHEMBL625344,,,
6081,1,Bioavailability was evaluated in mice after intravenous administration,,BAO_0000218,,Mus musculus,,Intermediate,2675,In vivo,N,1,CHEMBL625345,,,
6082,1,Bioavailability was evaluated in mice after oral administration,,BAO_0000218,,Mus musculus,,Intermediate,2675,In vivo,N,1,CHEMBL625346,,,
6083,1,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse,,BAO_0000218,,Mus musculus,,Intermediate,3132,In vivo,N,1,CHEMBL625347,,,
6084,1,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse at dose 25 mg/kg,,BAO_0000218,,Mus musculus,,Intermediate,3132,In vivo,N,1,CHEMBL625348,,,
6085,1,Bioavailability at a dose of 10 mg/kg peroral administration in mice.,,BAO_0000218,,Mus musculus,,Intermediate,16597,In vivo,N,1,CHEMBL625349,,,
6086,1,Oral bioavailability in mouse,,BAO_0000218,,Mus musculus,,Intermediate,2862,In vivo,N,1,CHEMBL625350,,,
6087,1,Oral bioavailability after intravenous administration in mice at 24 uM/kg,,BAO_0000218,,Mus musculus,,Intermediate,17764,In vivo,N,1,CHEMBL882952,,,
6088,1,Biodistribution of [123I]- labeled compound in mice brain was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,Brain,BAO_0000218,,Mus musculus,,Intermediate,846,In vivo,N,1,CHEMBL625351,,955.0,
6089,1,Biodistribution of [123I]- labeled compound in mice brain was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,Brain,BAO_0000218,,Mus musculus,,Intermediate,846,In vivo,N,1,CHEMBL625352,,955.0,
6090,1,Biodistribution of [123I]- labeled compound in mice brain was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,Brain,BAO_0000218,,Mus musculus,,Intermediate,846,In vivo,N,1,CHEMBL877592,,955.0,
6091,1,Biodistribution of [123I]- labeled compound in mice brain was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,Brain,BAO_0000218,,Mus musculus,,Intermediate,846,In vivo,N,1,CHEMBL625353,,955.0,
6092,1,Biodistribution of [123I]- labeled compound in mice brain was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,Brain,BAO_0000218,,Mus musculus,,Intermediate,846,In vivo,N,1,CHEMBL625354,,955.0,
6093,1,Biodistribution of [123I]- labeled compound in mice brain was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,Brain,BAO_0000218,,Mus musculus,,Intermediate,846,In vivo,N,1,CHEMBL626019,,955.0,
6094,1,Biodistribution of [123I]- labeled compound in mice heart was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,Heart,BAO_0000218,,Mus musculus,,Intermediate,846,In vivo,N,1,CHEMBL626020,,948.0,
6095,1,Biodistribution of [123I]- labeled compound in mice heart was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,Heart,BAO_0000218,,Mus musculus,,Intermediate,846,In vivo,N,1,CHEMBL626021,,948.0,
6096,1,Biodistribution of [123I]- labeled compound in mice heart was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,Heart,BAO_0000218,,Mus musculus,,Intermediate,846,In vivo,N,1,CHEMBL626022,,948.0,
6097,1,Biodistribution of [123I]- labeled compound in mice heart was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,Heart,BAO_0000218,,Mus musculus,,Intermediate,846,In vivo,N,1,CHEMBL626192,,948.0,
6098,1,Cytotoxic activity was tested against human prostate cell line A-549 (lung carcinoma),,BAO_0000219,,Homo sapiens,,Intermediate,1276,,N,1,CHEMBL626193,646.0,,
6099,1,Cytotoxicity against A-549 cell line in the purdue cell culture screen was determined,,BAO_0000219,,Homo sapiens,,Expert,3498,,N,1,CHEMBL626194,646.0,,
6100,1,Cytotoxicity against human lung carcinoma A-549 cell lines,,BAO_0000219,,Homo sapiens,,Intermediate,1169,,N,1,CHEMBL626195,646.0,,
6101,1,In vitro cytotoxic activity against A-549 (human lung carcinoma) cell line,,BAO_0000219,,Homo sapiens,,Intermediate,4450,,N,1,CHEMBL626196,646.0,,
6102,1,In vitro cytotoxicity against human lung carcinoma cell line A-549,,BAO_0000219,,Homo sapiens,,Intermediate,358,,N,1,CHEMBL626197,646.0,,
6103,1,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 3.6*10e-5 M,,BAO_0000219,,Homo sapiens,,Intermediate,358,,N,1,CHEMBL626198,646.0,,
6104,1,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.2*10e-5M,,BAO_0000219,,Homo sapiens,,Intermediate,358,,N,1,CHEMBL626199,646.0,,
6105,1,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.3*10e-5M,,BAO_0000219,,Homo sapiens,,Intermediate,358,,N,1,CHEMBL626200,646.0,,
6106,1,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 5.0*10e-5M,,BAO_0000219,,Homo sapiens,,Intermediate,358,,N,1,CHEMBL626201,646.0,,
6107,1,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 6.1*10e-5 M,,BAO_0000219,,Homo sapiens,,Intermediate,358,,N,1,CHEMBL626202,646.0,,
6108,1,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 7.4*10e-5 M,,BAO_0000219,,Homo sapiens,,Intermediate,358,,N,1,CHEMBL626203,646.0,,
6109,1,In vitro cytotoxicity against A-549 human lung cancer cells,,BAO_0000219,,Homo sapiens,,Intermediate,15167,,N,1,CHEMBL626204,646.0,,
6110,1,In vitro cytotoxicity against human lung carcinoma (A-549) cell line,,BAO_0000219,,Homo sapiens,,Intermediate,4139,,N,1,CHEMBL624701,646.0,,
6111,1,In vitro cytotoxicity in human tumor lung carcinoma A-549 cell lines,,BAO_0000219,,Homo sapiens,,Intermediate,833,,N,1,CHEMBL624702,646.0,,
6112,1,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,,BAO_0000219,,Homo sapiens,,Expert,15718,,N,1,CHEMBL624703,646.0,,
6113,1,Tested in vitro for cytotoxicity against A-549 lung cancer cells,,BAO_0000219,,Homo sapiens,,Intermediate,12373,,N,1,CHEMBL624704,646.0,,
6114,1,The compound was tested for cytotoxicity against A-549 cell in human lung carcinoma,,BAO_0000219,,Homo sapiens,,Intermediate,637,,N,1,CHEMBL624705,646.0,,
6115,1,Cytotoxicity against human lung carcinoma cells (A-549) using SRB assay.,,BAO_0000219,,Homo sapiens,,Expert,14867,,N,1,CHEMBL624706,646.0,,
6116,1,Antitumor cytotoxic activity against A-549 cell line was determined,,BAO_0000219,,Homo sapiens,,Intermediate,4461,,N,1,CHEMBL624707,646.0,,
6117,1,"Tested for the cytotoxicity against the Non-small cell lung cancer cell line A-549, growth inhibition by 50% is reported",,BAO_0000219,,Homo sapiens,,Intermediate,5406,,N,1,CHEMBL624708,646.0,,
6118,1,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,,BAO_0000219,,Homo sapiens,,Intermediate,4457,,N,1,CHEMBL624709,646.0,,
6119,1,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,,BAO_0000219,,Homo sapiens,,Expert,1386,,N,1,CHEMBL884107,646.0,,
6120,1,Antitumoral activity was assayed against A-549 cell line,,BAO_0000219,,Homo sapiens,,Intermediate,3265,,N,1,CHEMBL624710,646.0,,
6121,1,Compound was evaluated for the cytotoxicity against A-549 tumor cell line after 3 days of incubation,,BAO_0000219,,Homo sapiens,,Intermediate,2359,,N,1,CHEMBL624711,646.0,,
6122,1,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,,BAO_0000219,,Homo sapiens,,Intermediate,4457,,N,1,CHEMBL624712,646.0,,
6123,1,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,,BAO_0000219,,Homo sapiens,,Expert,12454,,N,1,CHEMBL624713,646.0,,
6124,1,Compound was tested for inhibition of cell growth of A-549 cells,,BAO_0000219,,Homo sapiens,,Intermediate,1481,,N,1,CHEMBL624714,646.0,,
6125,1,Compound was tested for its inhibitory effect on the growth of A-549 tumor cell line from lung.,,BAO_0000219,,Homo sapiens,,Intermediate,1750,,N,1,CHEMBL624715,646.0,,
6126,1,Concentration required for 50% inhibition of growth in human lung carcinoma cell line was determined,,BAO_0000219,,Homo sapiens,,Intermediate,5065,,N,1,CHEMBL624716,646.0,,
6127,1,In vitro cytotoxicity against A549-human lung carcinoma cells.,,BAO_0000219,,Homo sapiens,,Expert,808,,N,1,CHEMBL619505,646.0,,
6128,1,Cytotoxic activity against cultured cells of A-549 human lung carcinoma.,,BAO_0000219,,Homo sapiens,,Expert,16364,,N,1,CHEMBL619506,646.0,,
6129,1,Cytotoxic activity against A-549 cell lines.,,BAO_0000219,,Homo sapiens,,Intermediate,1847,,N,1,CHEMBL619507,646.0,,
6130,1,Cytotoxicity was measured against neoplastic cultured A-549 cells of human lung carcinoma.,,BAO_0000219,,Homo sapiens,,Expert,1747,,N,1,CHEMBL619508,646.0,,
6131,1,Cytotoxicity against human A549 non small cell lung cell lines,,BAO_0000219,,Homo sapiens,,Intermediate,1003,,N,1,CHEMBL619509,646.0,,
6132,1,Inhibition of cell growth in (A-549) lung cell line,,BAO_0000219,,Homo sapiens,,Expert,15313,,N,1,CHEMBL619510,646.0,,
6133,1,Growth inhibitory effect of compound was measured on A-549 human lung adenocarcinoma cancer cell line,,BAO_0000219,,Homo sapiens,,Intermediate,3122,,N,1,CHEMBL619511,646.0,,
6134,1,In vitro antitumor activity against A-549 tumor cells.,,BAO_0000219,,Homo sapiens,,Intermediate,16049,,N,1,CHEMBL619512,646.0,,
6135,1,In vitro antitumor effects against human A-549 cell lines.,,BAO_0000219,,Homo sapiens,,Expert,17134,,N,1,CHEMBL619513,646.0,,
6136,1,In vitro cytotoxic activity of compound against A-549 cell line,,BAO_0000219,,Homo sapiens,,Intermediate,6406,,N,1,CHEMBL619514,646.0,,
6137,1,In vitro cytotoxicity against human lung carcinoma A-549 cell line,,BAO_0000219,,Homo sapiens,,Intermediate,627,,N,1,CHEMBL619515,646.0,,
6138,1,In vitro cytotoxicity against human non-small cell lung carcinoma A549,,BAO_0000219,,Homo sapiens,,Intermediate,12307,,N,1,CHEMBL619516,646.0,,
6139,1,In vitro cytotoxicity against human A-549 cancer cell line was evaluated,,BAO_0000219,,Homo sapiens,,Intermediate,17861,,N,1,CHEMBL884005,646.0,,
6140,1,In vitro cytotoxicity against the A-549 (human lung carcinoma) neoplastic cell line,,BAO_0000219,,Homo sapiens,,Expert,6682,,N,1,CHEMBL619517,646.0,,
6141,1,Inhibitory concentration of compound against A-549 cell line,,BAO_0000219,,Homo sapiens,,Intermediate,6663,,N,1,CHEMBL619518,646.0,,
6142,1,Tested for the cytostatic activity as inhibitory concentration against A-549 human pulmonary adenocarcinoma cells,,BAO_0000219,,Homo sapiens,,Intermediate,2454,,N,1,CHEMBL619519,646.0,,
6143,1,cytotoxic activity against leukemia (A-549) cancer cell line,,BAO_0000219,,Homo sapiens,,Intermediate,14709,,N,1,CHEMBL876489,646.0,,
6144,1,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,,BAO_0000219,,Homo sapiens,,Expert,15718,,N,1,CHEMBL619520,646.0,,
6145,1,Percent inhibition for cytotoxic activity against lung carcinoma (A-549) cell line,,BAO_0000219,,Homo sapiens,,Intermediate,15718,,N,1,CHEMBL619521,646.0,,
6146,1,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.1(ug/ml),,BAO_0000219,,Homo sapiens,,Intermediate,17130,,N,1,CHEMBL619522,646.0,,
6147,1,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.4(ug/ml),,BAO_0000219,,Homo sapiens,,Intermediate,17130,,N,1,CHEMBL619523,646.0,,
6148,1,Cytotoxic activity of compound against A-549 cell lines at concentration of 1.1 (ug/ml),,BAO_0000219,,Homo sapiens,,Intermediate,17130,,N,1,CHEMBL619524,646.0,,
6149,1,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml),,BAO_0000219,,Homo sapiens,,Intermediate,17130,,N,1,CHEMBL619525,646.0,,
6150,1,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tometin; Not available,,BAO_0000219,,,,Intermediate,6630,,N,1,CHEMBL619526,646.0,,
6151,1,Influence of PARP-1 cellular activity in human lung carcinoma A549 cells on %ADP Polymer formation at a concentration of 25 uM of the compound,,BAO_0000219,,Homo sapiens,,Intermediate,16726,,N,1,CHEMBL619527,646.0,,
6152,1,Cytotoxicity against A549 cells; No cytotoxicity,,BAO_0000219,,Homo sapiens,,Intermediate,17846,,N,1,CHEMBL619528,646.0,,
6153,1,Cytotoxicity against human lung carcinoma (A549) cell lines,,BAO_0000219,,Homo sapiens,,Expert,3415,,N,1,CHEMBL619529,646.0,,
6154,1,Cytotoxicity against human lung carcinoma (A549) cell lines; Not active,,BAO_0000219,,Homo sapiens,,Expert,3415,,N,1,CHEMBL619530,646.0,,
6155,1,In vitro anticancer activity against human lung (A549) cell line,,BAO_0000219,,Homo sapiens,,Intermediate,5609,,N,1,CHEMBL876490,646.0,,
6156,1,Percent growth inhibition at 200 uM PARP inhibitor in A549 cells,,BAO_0000219,,Homo sapiens,,Intermediate,17206,,N,1,CHEMBL619531,646.0,,
6157,1,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..006 uM compound concentration in A549 cells,,BAO_0000219,,Homo sapiens,,Intermediate,17206,,N,1,CHEMBL619532,646.0,,
6158,1,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..03 uM compound concentration in A549 cells,,BAO_0000219,,Homo sapiens,,Intermediate,17206,,N,1,CHEMBL619533,646.0,,
6159,1,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..15 uM compound concentration in A549 cells,,BAO_0000219,,Homo sapiens,,Intermediate,17206,,N,1,CHEMBL619534,646.0,,
6160,1,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..4 uM compound concentration in A549 cells,,BAO_0000219,,Homo sapiens,,Intermediate,17206,,N,1,CHEMBL620164,646.0,,
6161,1,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,,BAO_0000219,,Homo sapiens,,Intermediate,17206,,N,1,CHEMBL620165,646.0,,
6162,1,Inhibition of A549 human lung tumor cell proliferation,,BAO_0000219,,Homo sapiens,,Expert,16295,,N,1,CHEMBL620166,646.0,,
6163,1,"Concentration required to inhibit the lung A549 cell growth by 50%,P53 status of cell line used was wild-type. ",,BAO_0000219,,Homo sapiens,,Intermediate,16825,,N,1,CHEMBL620167,646.0,,
6164,1,In vitro cytotoxicity against human tumor cell line A549,,BAO_0000219,,Homo sapiens,,Expert,3439,,N,1,CHEMBL620168,646.0,,
6165,1,In vitro growth inhibitory activity against A549 human nonsmall cell lung carcinoma cells. ,,BAO_0000219,,Homo sapiens,,Intermediate,10870,,N,1,CHEMBL620338,646.0,,
6166,1,Inhibitory concentration of compound against proliferation of lung carcinoma A549 cell line,,BAO_0000219,,Homo sapiens,,Intermediate,4845,,N,1,CHEMBL620339,646.0,,
6167,1,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells,,BAO_0000219,,Homo sapiens,,Intermediate,5822,,N,1,CHEMBL620340,646.0,,
6168,1,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells,,BAO_0000219,,Homo sapiens,,Intermediate,5822,,N,1,CHEMBL620341,646.0,,
6169,1,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells: Not tested,,BAO_0000219,,Homo sapiens,,Intermediate,5822,,N,1,CHEMBL876491,646.0,,
6170,1,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,,BAO_0000219,,Homo sapiens,,Intermediate,16381,,N,1,CHEMBL620342,646.0,,
6171,1,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,,BAO_0000219,,Homo sapiens,,Intermediate,16381,,N,1,CHEMBL620343,646.0,,
6172,1,% inhibition against A549 cells (lung cancer) at 4 ug/mL,,BAO_0000219,,Homo sapiens,,Intermediate,16381,,N,1,CHEMBL620344,646.0,,
6173,1,In vitro anticancer activity against human lung (A549) cell line,,BAO_0000219,,Homo sapiens,,Intermediate,5609,,N,1,CHEMBL620345,646.0,,
6174,1,Inhibition of proliferation of A549 cells at concentration of 0.1 uM was determined,,BAO_0000219,,Homo sapiens,,Intermediate,4644,,N,1,CHEMBL620346,646.0,,
6175,1,Inhibition of proliferation of A549 cells at concentration of 100 uM was determined,,BAO_0000219,,Homo sapiens,,Intermediate,4644,,N,1,CHEMBL620347,646.0,,
6176,1,Inhibition of proliferation of A549 cells at concentration of 10 uM was determined,,BAO_0000219,,Homo sapiens,,Intermediate,4644,,N,1,CHEMBL620348,646.0,,
6177,1,Inhibition of proliferation of A549 cells at concentration of 1 uM was determined,,BAO_0000219,,Homo sapiens,,Intermediate,4644,,N,1,CHEMBL620349,646.0,,
6178,1,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells at 20 uM,,BAO_0000219,,Homo sapiens,,Intermediate,5822,,N,1,CHEMBL618667,646.0,,
6179,1,Percentage inhibition of human lung carcinoma (A549) cell lines,,BAO_0000219,,Homo sapiens,,Expert,3415,,N,1,CHEMBL618668,646.0,,
6180,1,Influence of PARP-1 cellular activity on NAD+ levels at a concentration of 25 uM of the compound,,BAO_0000219,,Homo sapiens,,Intermediate,16726,,N,1,CHEMBL876031,646.0,,
6181,1,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM); ND denotes not determined",,BAO_0000219,,Homo sapiens,,Intermediate,17206,,N,1,CHEMBL618759,646.0,,
6182,1,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells; ND denotes not determined,,BAO_0000219,,Homo sapiens,,Intermediate,17206,,N,1,CHEMBL618760,646.0,,
6183,1,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells; ND denotes not determined,,BAO_0000219,,Homo sapiens,,Intermediate,17206,,N,1,CHEMBL619000,646.0,,
6184,1,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM)",,BAO_0000219,,Homo sapiens,,Intermediate,17206,,N,1,CHEMBL619001,646.0,,
6185,1,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.006 uM",,BAO_0000219,,Homo sapiens,,Intermediate,17206,,N,1,CHEMBL619002,646.0,,
6186,1,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.03 uM",,BAO_0000219,,Homo sapiens,,Intermediate,17206,,N,1,CHEMBL619003,646.0,,
6187,1,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.15 uM",,BAO_0000219,,Homo sapiens,,Intermediate,17206,,N,1,CHEMBL619597,646.0,,
6188,1,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.4 uM",,BAO_0000219,,Homo sapiens,,Intermediate,17206,,N,1,CHEMBL619598,646.0,,
6189,1,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells,,BAO_0000219,,Homo sapiens,,Intermediate,17206,,N,1,CHEMBL619599,646.0,,
6190,1,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells,,BAO_0000219,,Homo sapiens,,Intermediate,17206,,N,1,CHEMBL619600,646.0,,
6191,1,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,,BAO_0000219,,Homo sapiens,,Intermediate,16726,,N,1,CHEMBL619601,646.0,,
6192,1,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.006 uM compound concentration in A549 cells,,BAO_0000219,,Homo sapiens,,Intermediate,17206,,N,1,CHEMBL619602,646.0,,
6193,1,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.03 uM compound concentration in A549 cells,,BAO_0000219,,Homo sapiens,,Intermediate,17206,,N,1,CHEMBL619603,646.0,,
6194,1,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.15 uM compound concentration in A549 cells,,BAO_0000219,,Homo sapiens,,Intermediate,17206,,N,1,CHEMBL619604,646.0,,
6195,1,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.4 uM compound concentration in A549 cells,,BAO_0000219,,Homo sapiens,,Intermediate,17206,,N,1,CHEMBL619605,646.0,,
6196,1,Pharmacokinetic activity (Cmax) (10 mg/kg) was determined in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6084,In vivo,N,1,CHEMBL619606,,,
6197,1,Pharmacokinetic activity (Cmax) in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6084,In vivo,N,1,CHEMBL876032,,,
6198,1,Pharmacokinetic parameter Cmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),,BAO_0000218,,Canis lupus familiaris,,Intermediate,4809,In vivo,N,1,CHEMBL619607,,,
6199,1,Pharmacokinetic property (Cmax) was measured in dog at the dose of 0.032 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5983,In vivo,N,1,CHEMBL619608,,,
6200,1,Plasma clearance rate by iv administration in dog at a dose of 6 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6251,In vivo,N,1,CHEMBL619609,,,
6201,1,Cmax in dog plasma after 30mg/kg oral dose,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,5932,In vivo,N,1,CHEMBL619610,,1969.0,
6202,1,Tested for the peak blood level in dog,Blood,BAO_0000218,,Canis lupus familiaris,,Intermediate,4273,In vivo,N,1,CHEMBL619611,,178.0,
6203,1,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog",,BAO_0000218,,Canis lupus familiaris,,Intermediate,5313,In vivo,N,1,CHEMBL619612,,,
6204,1,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog at dosage of 10 mpk",,BAO_0000218,,Canis lupus familiaris,,Intermediate,5313,In vivo,N,1,CHEMBL619613,,,
6205,1,The peak blood concentration after 5 hr administration (2.5 mg/kg) in dog was determined,Blood,BAO_0000218,,Canis lupus familiaris,,Intermediate,6221,In vivo,N,1,CHEMBL619614,,178.0,
6206,1,Concentration in the plasma after intravenous administration of 1 mg/kg in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4709,,N,1,CHEMBL619615,,,
6207,1,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Dog at maximum of 0.3 hours,,BAO_0000218,,Canis lupus familiaris,,Intermediate,167,,N,1,CHEMBL619616,,,
6208,1,Final plasma concentration in dogs after oral administration at 1 mg/kg,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,6241,,N,1,CHEMBL619617,,1969.0,
6209,1,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 300 min,,BAO_0000218,,Canis lupus familiaris,,Intermediate,344,,N,1,CHEMBL619618,,,
6210,1,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 30 min,,BAO_0000218,,Canis lupus familiaris,,Intermediate,344,,N,1,CHEMBL876033,,,
6211,1,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 60 min,,BAO_0000218,,Canis lupus familiaris,,Intermediate,344,,N,1,CHEMBL619619,,,
6212,1,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,2189,,N,1,CHEMBL619620,,,
6213,1,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,2189,,N,1,CHEMBL619621,,1088.0,
6214,1,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs; NA is <10% inhibition at 1 uM for binding data,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,2189,,N,1,CHEMBL619622,,1088.0,
6215,1,Percent of radioactive dose in urine and feces excreted in 0-24 hr by dogs; NA is <10% inhibition at 1 uM for binding data,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,2189,,N,1,CHEMBL618874,,1088.0,
6216,1,Absolute bioavailability was evaluated in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4257,In vivo,N,1,CHEMBL618875,,,
6217,1,Bioavailability after oral administration (2.5 mg/kg) in dog was determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6221,In vivo,N,1,CHEMBL618876,,,
6218,1,Bioavailability after peroral administration (1 mg/kg) was determined in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6215,In vivo,N,1,CHEMBL618877,,,
6219,1,Bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17267,In vivo,N,1,CHEMBL618878,,,
6220,1,Bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6621,In vivo,N,1,CHEMBL618879,,,
6221,1,Bioavailability after intravenous administration in dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,3854,In vivo,N,1,CHEMBL618880,,,
6222,1,Bioavailability after peroral administration in dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,3854,In vivo,N,1,CHEMBL618881,,,
6223,1,Bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),,BAO_0000218,,Canis lupus familiaris,,Intermediate,5007,In vivo,N,1,CHEMBL618882,,,
6224,1,Bioavailability in dog (Beagle) (male) (dose 3 mg/kg i.v. and 10 mg/kg p.o.) measured from 1 to 24 hr,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4333,In vivo,N,1,CHEMBL624226,,,
6225,1,Bioavailability in plasma of male Beagle dogs treated with 3 mg/kg (i.v.) and 10 mg/kg (p.o.) measured from 1 to 24 hr; ND indicates not determined,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,4333,In vivo,N,1,CHEMBL624227,,1969.0,
6226,1,Bioavailability,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5006,In vivo,N,1,CHEMBL624228,,,
6227,1,Bioavailability,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5199,In vivo,N,1,CHEMBL624229,,,
6228,1,Bioavailability by intravenous administration of 1.2 mg/kg in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4368,In vivo,N,1,CHEMBL624230,,,
6229,1,Bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,3771,In vivo,N,1,CHEMBL624231,,,
6230,1,Bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4953,In vivo,N,1,CHEMBL624232,,,
6231,1,Bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5064,In vivo,N,1,CHEMBL625127,,,
6232,1,Bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17657,In vivo,N,1,CHEMBL625128,,,
6233,1,Bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17796,In vivo,N,1,CHEMBL621675,,,
6234,1,Bioavailability in dog (p.o.) at 2.0 mpk,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17853,In vivo,N,1,CHEMBL621676,,,
6235,1,Bioavailability in dog (dose 2 mg/kg p.o. and 0.5 mg/kg i.v.),,BAO_0000218,,Canis lupus familiaris,,Intermediate,4521,In vivo,N,1,CHEMBL621677,,,
6236,1,Bioavailability in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4521,In vivo,N,1,CHEMBL621678,,,
6237,1,Bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5006,In vivo,N,1,CHEMBL621679,,,
6238,1,Bioavailability was evaluated after oral administration in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,16365,In vivo,N,1,CHEMBL621680,,,
6239,1,Bioavailability was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,BAO_0000218,,Canis lupus familiaris,,Intermediate,1916,In vivo,N,1,CHEMBL621681,,,
6240,1,Bioavailability was evaluated in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,1918,In vivo,N,1,CHEMBL876740,,,
6241,1,Bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4239,In vivo,N,1,CHEMBL621682,,,
6242,1,Bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6505,In vivo,N,1,CHEMBL621683,,,
6243,1,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),,BAO_0000218,,Canis lupus familiaris,,Intermediate,5334,In vivo,N,1,CHEMBL621684,,,
6244,1,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),,BAO_0000218,,Canis lupus familiaris,,Intermediate,5334,In vivo,N,1,CHEMBL621685,,,
6245,1,Bioavailability was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),,BAO_0000218,,Canis lupus familiaris,,Intermediate,4809,In vivo,N,1,CHEMBL621686,,,
6246,1,Bioavailability was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6348,In vivo,N,1,CHEMBL621687,,,
6247,1,Bioavailability was evaluated in dog after peroral administration at a dose of 1 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6005,In vivo,N,1,CHEMBL621688,,,
6248,1,Bioavailability of compound in dog was determined after peroral administration,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17804,In vivo,N,1,CHEMBL621689,,,
6249,1,Oral bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,3184,In vivo,N,1,CHEMBL621690,,,
6250,1,Compound was evaluated for oral bioavailability at different dose 27.5 mg/kg DMP323 equiv in dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,1806,In vivo,N,1,CHEMBL621691,,,
6251,1,Compound was evaluated for oral bioavailability at different dose 7.7 mg/kg DMP323 equiv in dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,1806,In vivo,N,1,CHEMBL875941,,,
6252,1,Compound was evaluated for oral bioavailability in dogs; 37-38 %,,BAO_0000218,,Canis lupus familiaris,,Intermediate,1806,In vivo,N,1,CHEMBL621692,,,
6253,1,Bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4839,In vivo,N,1,CHEMBL621693,,,
6254,1,Oral bioavailability in dog (1 mg/kg p.o. and 0.2 mg/kg i.v.),,BAO_0000218,,Canis lupus familiaris,,Intermediate,5017,In vivo,N,1,CHEMBL621694,,,
6255,1,Biodistribution of [123I]- labeled compound in mice heart was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,Heart,BAO_0000218,,Mus musculus,,Intermediate,846,In vivo,N,1,CHEMBL621695,,948.0,
6256,1,Biodistribution of [123I]- labeled compound in mice heart was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,Heart,BAO_0000218,,Mus musculus,,Intermediate,846,In vivo,N,1,CHEMBL621696,,948.0,
6257,1,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,Kidney,BAO_0000218,,Mus musculus,,Intermediate,846,In vivo,N,1,CHEMBL621697,,2113.0,
6258,1,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,Kidney,BAO_0000218,,Mus musculus,,Intermediate,846,In vivo,N,1,CHEMBL621698,,2113.0,
6259,1,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,Kidney,BAO_0000218,,Mus musculus,,Intermediate,846,In vivo,N,1,CHEMBL623420,,2113.0,
6260,1,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,Kidney,BAO_0000218,,Mus musculus,,Intermediate,846,In vivo,N,1,CHEMBL623421,,2113.0,
6261,1,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,Kidney,BAO_0000218,,Mus musculus,,Intermediate,846,In vivo,N,1,CHEMBL623422,,2113.0,
6262,1,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,Kidney,BAO_0000218,,Mus musculus,,Intermediate,846,In vivo,N,1,CHEMBL623423,,2113.0,
6263,1,Biodistribution of [123I]- labeled compound in mice liver was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,Liver,BAO_0000218,,Mus musculus,,Intermediate,846,In vivo,N,1,CHEMBL623424,,2107.0,
6264,1,Biodistribution of [123I]- labeled compound in mice liver was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,Liver,BAO_0000218,,Mus musculus,,Intermediate,846,In vivo,N,1,CHEMBL623425,,2107.0,
6265,1,Biodistribution of [123I]- labeled compound in mice liver was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,Liver,BAO_0000218,,Mus musculus,,Intermediate,846,In vivo,N,1,CHEMBL623426,,2107.0,
6266,1,Biodistribution of [123I]- labeled compound in mice liver was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,Liver,BAO_0000218,,Mus musculus,,Intermediate,846,In vivo,N,1,CHEMBL623427,,2107.0,
6267,1,Biodistribution of [123I]- labeled compound in mice liver was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,Liver,BAO_0000218,,Mus musculus,,Intermediate,846,In vivo,N,1,CHEMBL623428,,2107.0,
6268,1,Biodistribution of [123I]- labeled compound in mice liver was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,Liver,BAO_0000218,,Mus musculus,,Intermediate,846,In vivo,N,1,CHEMBL875947,,2107.0,
6269,1,Biodistribution of [123I]- labeled compound in mice lungs was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,Lung,BAO_0000218,,Mus musculus,,Intermediate,846,In vivo,N,1,CHEMBL623429,,2048.0,
6270,1,Biodistribution of [123I]- labeled compound in mice lungs was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,Lung,BAO_0000218,,Mus musculus,,Intermediate,846,In vivo,N,1,CHEMBL623430,,2048.0,
6271,1,Biodistribution of [123I]- labeled compound in mice lungs was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,Lung,BAO_0000218,,Mus musculus,,Intermediate,846,In vivo,N,1,CHEMBL622588,,2048.0,
6272,1,Biodistribution of [123I]- labeled compound in mice lungs was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,Lung,BAO_0000218,,Mus musculus,,Intermediate,846,In vivo,N,1,CHEMBL622589,,2048.0,
6273,1,Biodistribution of [123I]- labeled compound in mice lungs was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,Lung,BAO_0000218,,Mus musculus,,Intermediate,846,In vivo,N,1,CHEMBL622751,,2048.0,
6274,1,Biodistribution of [123I]- labeled compound in mice lungs was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,Lung,BAO_0000218,,Mus musculus,,Intermediate,846,In vivo,N,1,CHEMBL622752,,2048.0,
6275,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 1 hour,,BAO_0000218,,Mus musculus,,Intermediate,6599,,N,1,CHEMBL622753,42.0,,
6276,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 2 hours,,BAO_0000218,,Mus musculus,,Intermediate,6599,,N,1,CHEMBL622647,42.0,,
6277,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 30 minutes,,BAO_0000218,,Mus musculus,,Intermediate,6599,,N,1,CHEMBL875163,42.0,,
6278,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 4 hours,,BAO_0000218,,Mus musculus,,Intermediate,6599,,N,1,CHEMBL622648,42.0,,
6279,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 8 hours,,BAO_0000218,,Mus musculus,,Intermediate,6599,,N,1,CHEMBL622649,42.0,,
6280,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice brain bearing S180 tumor cell line for 1 hour,Brain,BAO_0000218,,Mus musculus,,Intermediate,6599,,N,1,CHEMBL622650,42.0,955.0,
6281,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 2 hours,Brain,BAO_0000218,,Mus musculus,,Intermediate,6599,,N,1,CHEMBL622651,42.0,955.0,
6282,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 30 minutes,Brain,BAO_0000218,,Mus musculus,,Intermediate,6599,,N,1,CHEMBL622652,42.0,955.0,
6283,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 4 hours,Brain,BAO_0000218,,Mus musculus,,Intermediate,6599,,N,1,CHEMBL622653,42.0,955.0,
6284,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 8 hours,Brain,BAO_0000218,,Mus musculus,,Intermediate,6599,,N,1,CHEMBL622654,42.0,955.0,
6285,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 1 hour,Heart,BAO_0000218,,Mus musculus,,Intermediate,6599,,N,1,CHEMBL622655,42.0,948.0,
6286,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 2 hours,Heart,BAO_0000218,,Mus musculus,,Intermediate,6599,,N,1,CHEMBL622656,42.0,948.0,
6287,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 30 minutes,Heart,BAO_0000218,,Mus musculus,,Intermediate,6599,,N,1,CHEMBL622657,42.0,948.0,
6288,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 4 hours,Heart,BAO_0000218,,Mus musculus,,Intermediate,6599,,N,1,CHEMBL622658,42.0,948.0,
6289,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 8 hours,Heart,BAO_0000218,,Mus musculus,,Intermediate,6599,,N,1,CHEMBL622659,42.0,948.0,
6290,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 1 hour,Kidney,BAO_0000218,,Mus musculus,,Intermediate,6599,,N,1,CHEMBL624630,42.0,2113.0,
6291,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 2 hours,Kidney,BAO_0000218,,Mus musculus,,Intermediate,6599,,N,1,CHEMBL624631,42.0,2113.0,
6292,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 30 minutes,Kidney,BAO_0000218,,Mus musculus,,Intermediate,6599,,N,1,CHEMBL624632,42.0,2113.0,
6293,1,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml) on,,BAO_0000219,,Homo sapiens,,Intermediate,17130,,N,1,CHEMBL624633,646.0,,
6294,1,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml)on,,BAO_0000219,,Homo sapiens,,Intermediate,17130,,N,1,CHEMBL624634,646.0,,
6295,1,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml),,BAO_0000219,,Homo sapiens,,Intermediate,17130,,N,1,CHEMBL624635,646.0,,
6296,1,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml)),,BAO_0000219,,Homo sapiens,,Intermediate,17130,,N,1,CHEMBL624636,646.0,,
6297,1,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,,BAO_0000219,,Homo sapiens,,Expert,3263,,N,1,CHEMBL857055,646.0,,
6298,1,In vitro rate of inhibition of A-549 tumor cell growth at 10E-4 mol/L,,BAO_0000219,,Homo sapiens,,Expert,6663,,N,1,CHEMBL624637,646.0,,
6299,1,In vitro rate of inhibition of A-549 tumor cell growth at 10E-5 mol/L,,BAO_0000219,,Homo sapiens,,Expert,6663,,N,1,CHEMBL624638,646.0,,
6300,1,In vitro rate of inhibition of A-549 tumor cell growth at 10E-6 mol/L,,BAO_0000219,,Homo sapiens,,Expert,6663,,N,1,CHEMBL874366,646.0,,
6301,1,In vitro rate of inhibition of A-549 tumor cell growth at 10E-7 mol/L,,BAO_0000219,,Homo sapiens,,Expert,6663,,N,1,CHEMBL624639,646.0,,
6302,1,In vitro rate of inhibition of A-549 tumor cell growth at 10E-8 mol/L,,BAO_0000219,,Homo sapiens,,Expert,6663,,N,1,CHEMBL624640,646.0,,
6303,1,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.0625 uM,,BAO_0000219,,Homo sapiens,,Intermediate,6663,,N,1,CHEMBL624641,646.0,,
6304,1,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.125 uM,,BAO_0000219,,Homo sapiens,,Intermediate,6663,,N,1,CHEMBL624642,646.0,,
6305,1,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.25 uM,,BAO_0000219,,Homo sapiens,,Intermediate,6663,,N,1,CHEMBL624643,646.0,,
6306,1,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.5 uM,,BAO_0000219,,Homo sapiens,,Intermediate,6663,,N,1,CHEMBL624644,646.0,,
6307,1,Rate of inhibition of A-549 tumor cell growth at a concentration of 1 uM,,BAO_0000219,,Homo sapiens,,Intermediate,6663,,N,1,CHEMBL624645,646.0,,
6308,1,The compound was evaluated for its cytotoxic potency against A-549 cell line,,BAO_0000219,,Homo sapiens,,Intermediate,3983,,N,1,CHEMBL619445,646.0,,
6309,1,Cytotoxic concentration required to inhibit 50% cell growth in A-549 lung carcinoma cell lines,,BAO_0000219,,Homo sapiens,,Expert,11141,,N,1,CHEMBL839886,646.0,,
6310,1,Cytotoxic activity of compound against A-549 tumor cell line.,,BAO_0000219,,Homo sapiens,,Intermediate,5076,,N,1,CHEMBL619446,646.0,,
6311,1,In vitro cytotoxicity against Lung A-549 human tumors following a 6 day exposure.,,BAO_0000219,,Homo sapiens,,Intermediate,3311,,N,1,CHEMBL619447,646.0,,
6312,1,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure.,,BAO_0000219,,Homo sapiens,,Intermediate,3311,,N,1,CHEMBL619448,646.0,,
6313,1,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure; ND is no data,,BAO_0000219,,Homo sapiens,,Intermediate,3311,,N,1,CHEMBL619449,646.0,,
6314,1,Cytotoxic activity of compound against A-549 tumor cell line at conc. of 20 ug/mL,,BAO_0000219,,Homo sapiens,,Intermediate,5076,,N,1,CHEMBL619450,646.0,,
6315,1,Compound was tested for cytotoxic activity against A-549 human lung carcinoma (ATCC:CCL-185),,BAO_0000219,,Homo sapiens,,Intermediate,4150,,N,1,CHEMBL619451,646.0,,
6316,1,In vitro inhibitory concentration against cell culture of A-549 human lung carcinoma,,BAO_0000219,,Homo sapiens,,Expert,2150,,N,1,CHEMBL619452,646.0,,
6317,1,Concentration for in vitro cytotoxicity against A-549 human lung tumor cells,,BAO_0000219,,Homo sapiens,,Intermediate,4644,,N,1,CHEMBL619453,646.0,,
6318,1,Dose required for in vitro cytotoxic activity against A-549 lung carcinoma cells at concentration of 10 ug/ml; NA is no cytotoxicity,,BAO_0000219,,Homo sapiens,,Intermediate,263,,N,1,CHEMBL874367,646.0,,
6319,1,Cytotoxic concentration against A-549 tumor cells.,,BAO_0000219,,Homo sapiens,,Intermediate,11333,,N,1,CHEMBL619454,646.0,,
6320,1,Cytotoxic concentration against A-549 tumor cells; Inactive at 10 ug/mL.,,BAO_0000219,,Homo sapiens,,Intermediate,11333,,N,1,CHEMBL619455,646.0,,
6321,1,"Cytotoxicity against NCI tumor panel, A-549/ATCC non small-cell lung cancer cell line",,BAO_0000219,,Homo sapiens,,Intermediate,15895,,N,1,CHEMBL619456,646.0,,
6322,1,Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Acinetobacter baumannii 118A,,BAO_0000218,,Acinetobacter baumannii,,Expert,16677,,N,1,CHEMBL619457,,,
6323,1,Activity against Acinetobacter calcoaceticus (AC54),,BAO_0000218,,Acinetobacter calcoaceticus,,Intermediate,10624,,N,1,CHEMBL619458,,,
6324,1,In vitro antifungal activity against Aspergillus flavus CM74,,BAO_0000218,,Aspergillus flavus,,Expert,16717,,N,1,CHEMBL619459,,,
6325,1,In vitro antifungal activity against Aspergillus flavus CM74,,BAO_0000218,,Aspergillus flavus,,Expert,16717,,N,1,CHEMBL619460,,,
6326,1,Inhibitory activity tested against Aspergillus fumigatus at 256 ug/mL concentration,,BAO_0000218,,Aspergillus fumigatus,,Intermediate,5513,,N,1,CHEMBL619461,,,
6327,1,In vitro minimum fungicidal concentration required to inhibit Aspergillus fumigatus(MFC),,BAO_0000218,,Aspergillus fumigatus,,Intermediate,15962,,N,1,CHEMBL619462,,,
6328,1,Antimicrobial activity against Aspergillus fumigatus (MIC),,BAO_0000218,,Aspergillus fumigatus,,Intermediate,15962,,N,1,CHEMBL620388,,,
6329,1,Antimicrobial activity against Aspergillus fumigatus (MIC),,BAO_0000218,,Aspergillus fumigatus,,Intermediate,15962,,N,1,CHEMBL620389,,,
6330,1,In vitro antimicrobial activity against Aspergillus fumigatus (MIC),,BAO_0000218,,Aspergillus fumigatus,,Intermediate,15962,,N,1,CHEMBL620390,,,
6331,1,In vitro antifungal activity against Aspergillus fumigatus 48238E,,BAO_0000218,,Aspergillus fumigatus,,Expert,16717,,N,1,CHEMBL620391,,,
6332,1,In vitro antifungal activity against Aspergillus fumigatus 48238E,,BAO_0000218,,Aspergillus fumigatus,,Expert,16717,,N,1,CHEMBL621073,,,
6333,1,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces naeslundii 631,,BAO_0000218,,Actinomyces naeslundii,,Intermediate,8117,,N,1,CHEMBL621074,,,
6334,1,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces viscosus M-100,,BAO_0000218,,Actinomyces viscosus,,Intermediate,8117,,N,1,CHEMBL621075,,,
6335,1,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),,BAO_0000218,,Acanthocheilonema viteae,,Intermediate,15472,,N,1,CHEMBL619554,,,
6336,1,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),,BAO_0000218,,Acanthocheilonema viteae,,Intermediate,15472,,N,1,CHEMBL619555,,,
6337,1,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527,,BAO_0000218,,Aggregatibacter actinomycetemcomitans,,Intermediate,16443,,N,1,CHEMBL619556,,,
6338,1,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2,,BAO_0000218,,Aggregatibacter actinomycetemcomitans,,Intermediate,16443,,N,1,CHEMBL619557,,,
6339,1,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2; ND is Not Determined,,BAO_0000218,,Aggregatibacter actinomycetemcomitans,,Intermediate,16443,,N,1,CHEMBL619558,,,
6340,1,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,,BAO_0000219,,Homo sapiens,,Intermediate,17206,,N,1,CHEMBL619559,646.0,,
6341,1,Percent ADP-ribose polymer formation at 25 uM compound concentration in A549 cells,,BAO_0000219,,Homo sapiens,,Intermediate,17206,,N,1,CHEMBL619560,646.0,,
6342,1,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,,BAO_0000219,,Homo sapiens,,Intermediate,16381,,N,1,CHEMBL619561,646.0,,
6343,1,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,,BAO_0000219,,Homo sapiens,,Intermediate,16381,,N,1,CHEMBL619562,646.0,,
6344,1,% inhibition against A549 cells (lung cancer) at 4 ug/mL,,BAO_0000219,,Homo sapiens,,Intermediate,16381,,N,1,CHEMBL619563,646.0,,
6345,1,GI values against A549 cells (lung cancer),,BAO_0000219,,Homo sapiens,,Intermediate,16381,,N,1,CHEMBL857457,646.0,,
6346,1,Effect on NAD+ depletion (% remaining versus vehicle control) 25 uM compound concentration in A549 cells,,BAO_0000219,,Homo sapiens,,Intermediate,17206,,N,1,CHEMBL619564,646.0,,
6347,1,Inhibitory activity against A549 human adenocarcinoma,,BAO_0000219,,Homo sapiens,,Intermediate,16325,,N,1,CHEMBL619565,646.0,,
6348,1,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 200 mg/kg,,BAO_0000218,,Homo sapiens,,Intermediate,10708,,N,1,CHEMBL619566,646.0,,
6349,1,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 100 mg/kg,,BAO_0000218,,Homo sapiens,,Intermediate,10708,,N,1,CHEMBL619567,646.0,,
6350,1,Inhibitory activity against A549 lung adenocarcinoma cell line,,BAO_0000219,,Homo sapiens,,Intermediate,17376,,N,1,CHEMBL619568,646.0,,
6351,1,Inhibitory activity against A549 lung adenocarcinoma cell line; not determined,,BAO_0000219,,Homo sapiens,,Intermediate,17376,,N,1,CHEMBL619569,646.0,,
6352,1,Cytotoxicity against human A549 lung cells,,BAO_0000219,,Homo sapiens,,Intermediate,17488,,N,1,CHEMBL619570,646.0,,
6353,1,In vivo percent inhibitory activity of intraperitoneally administered compound (50 mg/kg/day) against mice infected with A549 tumor,,BAO_0000218,,Homo sapiens,,Intermediate,17404,,N,1,CHEMBL619571,646.0,,
6354,1,Growth inhibition of A549 (human lung carcinoma) cell line.,,BAO_0000219,,Homo sapiens,,Expert,10958,,N,1,CHEMBL619572,646.0,,
6355,1,Effective dose required for inhibitory activity against A549 human tumor cell line.,,BAO_0000219,,Homo sapiens,,Expert,17099,,N,1,CHEMBL619573,646.0,,
6356,1,Effective dose required for inhibitory activity against A549 human tumor cell line; Not active,,BAO_0000219,,Homo sapiens,,Intermediate,17099,,N,1,CHEMBL619574,646.0,,
6357,1,Cytotoxicity was evaluated against A549 tumor cell lines; Inactive,,BAO_0000219,,Homo sapiens,,Intermediate,4096,,N,1,CHEMBL619575,646.0,,
6358,1,Cytotoxicity evaluated against A549 tumor cell lines; significant activity,,BAO_0000219,,Homo sapiens,,Expert,4096,,N,1,CHEMBL619576,646.0,,
6359,1,Cytotoxicity was evaluated against A549 tumor cell lines; Slightly active,,BAO_0000219,,Homo sapiens,,Intermediate,4096,,N,1,CHEMBL619577,646.0,,
6360,1,In vitro inhibitory activity against A549 tumor cell culture,,BAO_0000219,,Homo sapiens,,Intermediate,2525,,N,1,CHEMBL619578,646.0,,
6361,1,In vitro inhibitory activity against A549 tumor cell culture; IA= Inactive,,BAO_0000219,,Homo sapiens,,Intermediate,2525,,N,1,CHEMBL884009,646.0,,
6362,1,Activity against human lung cancer with mutated beta-tubulin (A549-T2415),,BAO_0000219,,Homo sapiens,,Intermediate,5302,,N,1,CHEMBL619579,646.0,,
6363,1,Growth inhibitory activity was determined against A549/ATCC cancer cell line of non-small cell lung cancer,,BAO_0000219,,Homo sapiens,,Intermediate,16325,,N,1,CHEMBL619580,646.0,,
6364,1,Inhibition of growth of A549/ATCC nonsmall cell lung cancer cell line,,BAO_0000219,,Homo sapiens,,Intermediate,16939,,N,1,CHEMBL619581,646.0,,
6365,1,In vitro antitumor activity against NSCL A549/ATCC tumor cell lines,,BAO_0000219,,Homo sapiens,,Intermediate,17229,,N,1,CHEMBL619582,646.0,,
6366,1,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells,,BAO_0000219,,Homo sapiens,,Intermediate,17380,,N,1,CHEMBL619583,646.0,,
6367,1,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells; No data,,BAO_0000219,,Homo sapiens,,Intermediate,17380,,N,1,CHEMBL876502,646.0,,
6368,1,In vitro cytotoxicity against human Non-small cell lung cancer A549/ATCC cell line.,,BAO_0000219,,Homo sapiens,,Intermediate,1903,,N,1,CHEMBL619584,646.0,,
6369,1,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,,BAO_0000219,,Homo sapiens,,Intermediate,3838,,N,1,CHEMBL619585,646.0,,
6370,1,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,,BAO_0000219,,Homo sapiens,,Intermediate,14696,,N,1,CHEMBL619586,646.0,,
6371,1,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,,BAO_0000219,,Homo sapiens,,Intermediate,3838,,N,1,CHEMBL619587,646.0,,
6372,1,Tested for in vitro cytotoxicity against non-small cell lung cancer cell line A549/ATCC,,BAO_0000219,,Homo sapiens,,Intermediate,1522,,N,1,CHEMBL619588,646.0,,
6373,1,Tested in vitro for cytotoxicity in A549/ATCC cell lines,,BAO_0000219,,Homo sapiens,,Intermediate,12400,,N,1,CHEMBL619589,646.0,,
6374,1,inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,,BAO_0000219,,Homo sapiens,,Intermediate,14696,,N,1,CHEMBL619590,646.0,,
6375,1,Compound was evaluated for in vitro activity against A549/ATCC lung cancer cell lines (Human tumor cells ),,BAO_0000219,,Homo sapiens,,Intermediate,14769,,N,1,CHEMBL619591,646.0,,
6376,1,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line at 0.01 uM,,BAO_0000219,,Homo sapiens,,Intermediate,14696,,N,1,CHEMBL619592,646.0,,
6377,1,Compound was evaluated for cytotoxic activity against non-small lung cancer A549/ATCC cell lines.,,BAO_0000219,,Homo sapiens,,Intermediate,1888,,N,1,CHEMBL619593,646.0,,
6378,1,Tested for cytotoxic activity against non-small cell lung cancer A549/ATCC cell line,,BAO_0000219,,Homo sapiens,,Intermediate,12016,,N,1,CHEMBL620217,646.0,,
6379,1,Compound tested for growth inhibition of non-small cell lung cancer cell line A549/ATCC,,BAO_0000219,,Homo sapiens,,Intermediate,6058,,N,1,CHEMBL620218,646.0,,
6380,1,Compound was tested for 50% growth inhibition against human non-small cell lung cancer A549/ATCC cell line,,BAO_0000219,,Homo sapiens,,Intermediate,17708,,N,1,CHEMBL620219,646.0,,
6381,1,Antitumor activity against A549/ATCC cell line,,BAO_0000219,,Homo sapiens,,Intermediate,12301,,N,1,CHEMBL620220,646.0,,
6382,1,Tested for cytotoxicity against A549/ATCC cell lines in non-small-cell lung cancer,,BAO_0000219,,Homo sapiens,,Intermediate,11970,,N,1,CHEMBL625141,646.0,,
6383,1,In vitro cytotoxicity against A549/ATCC cell line.,,BAO_0000219,,Homo sapiens,,Expert,11818,,N,1,CHEMBL625142,646.0,,
6384,1,Tested in vitro for cytotoxicity in A549/ATCC cell line of Non-Small Cell Lung Cancer,,BAO_0000219,,Homo sapiens,,Intermediate,12400,,N,1,CHEMBL625143,646.0,,
6385,1,In vitro inhibition of Non-Small Cell Lung Cancer A549/ATCC cell lines,,BAO_0000219,,Homo sapiens,,Intermediate,3381,,N,1,CHEMBL625144,646.0,,
6386,1,Concentration of compound that cause 50% cytotoxicity of A549/ATCC non small cell lung cancer cell line,,BAO_0000219,,Homo sapiens,,Intermediate,17376,,N,1,CHEMBL622474,646.0,,
6387,1,Evaluated for the inhibitory concentration required to cause growth inhibition of A549Rem- cell line of lung using the MTT Cytotoxicity Assay,,BAO_0000219,,Homo sapiens,,Intermediate,10708,,N,1,CHEMBL884104,646.0,,
6388,1,Cytotoxicity was evaluated against A649 human mammary carcinoma cells,,BAO_0000219,,Homo sapiens,,Autocuration,2964,,U,0,CHEMBL622475,,,
6389,1,Compound was tested for oral bioavailability in dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5005,In vivo,U,0,CHEMBL622476,,,
6390,1,Compound was tested for orally bioavailable in dogs with a half life of 0.7 hr,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6229,In vivo,N,1,CHEMBL875831,,,
6391,1,Compound was tested for orally bioavailable in dogs with a half life of 1.2h,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6229,In vivo,N,1,CHEMBL622477,,,
6392,1,Oral bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5374,In vivo,N,1,CHEMBL622478,,,
6393,1,Compound was tested for the oral bioavailability in dog; No availability,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5374,In vivo,N,1,CHEMBL623172,,,
6394,1,Oral bioavailability in dog (dose 5 mg/kg),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6265,In vivo,N,1,CHEMBL623173,,,
6395,1,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5654,In vivo,N,1,CHEMBL623174,,,
6396,1,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5654,In vivo,N,1,CHEMBL623175,,,
6397,1,Oral bioavailability in Beagle dogs after Per oral administration at dose of 50(mg/kg),,BAO_0000218,,Canis lupus familiaris,,Intermediate,16456,In vivo,N,1,CHEMBL623340,,,
6398,1,Oral bioavailability in dog (dose 5 mg/kg),,BAO_0000218,,Canis lupus familiaris,,Intermediate,5302,In vivo,N,1,CHEMBL623341,,,
6399,1,Oral bioavailability in dog (p.o. dosing of 0.05 M citric acid/0.05 M hydrochloric acid solution),,BAO_0000218,,Canis lupus familiaris,,Intermediate,3624,In vivo,N,1,CHEMBL623342,,,
6400,1,Oral bioavailability of active FTIs in dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,16452,In vivo,N,1,CHEMBL623343,,,
6401,1,Oral bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),,BAO_0000218,,Canis lupus familiaris,,Intermediate,5802,In vivo,N,1,CHEMBL623344,,,
6402,1,Oral bioavailability of compound determined in dog after iv administration at a dose of 10 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Expert,3598,In vivo,N,1,CHEMBL623345,,,
6403,1,Oral bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17839,In vivo,N,1,CHEMBL875832,,,
6404,1,Oral bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6762,In vivo,N,1,CHEMBL623346,,,
6405,1,Oral bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6821,In vivo,N,1,CHEMBL623347,,,
6406,1,Oral bioavailability of compound was determined in dog; Not tested,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6821,In vivo,N,1,CHEMBL623348,,,
6407,1,Oral bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5210,In vivo,N,1,CHEMBL623349,,,
6408,1,Oral bioavailability (10 mg/kg) was determined in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6227,In vivo,N,1,CHEMBL623350,,,
6409,1,Oral bioavailability,,BAO_0000218,,Canis lupus familiaris,,Intermediate,761,In vivo,N,1,CHEMBL623351,,,
6410,1,Oral bioavailability in dog (dosed as neat powder in hard gelatin capsule),,BAO_0000218,,Canis lupus familiaris,,Intermediate,761,In vivo,N,1,CHEMBL623352,,,
6411,1,Oral bioavailability administered in solution in rats,,BAO_0000218,,Canis lupus familiaris,,Intermediate,761,In vivo,N,1,CHEMBL623353,,,
6412,1,Oral bioavailability after 30 mg/kg po dose in Dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,16907,In vivo,N,1,CHEMBL875833,,,
6413,1,Oral bioavailability at a dose of 1 mg/kg in dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5474,In vivo,N,1,CHEMBL623354,,,
6414,1,Oral bioavailability in dog (dose 1 mg/kg p.o.),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6535,In vivo,N,1,CHEMBL623355,,,
6415,1,Oral bioavailability in Dog; ND = not determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6535,In vivo,N,1,CHEMBL623356,,,
6416,1,Oral bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,3352,In vivo,N,1,CHEMBL623357,,,
6417,1,Oral bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6168,In vivo,N,1,CHEMBL623358,,,
6418,1,Oral bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5988,In vivo,N,1,CHEMBL623359,,,
6419,1,Oral bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4942,In vivo,N,1,CHEMBL623360,,,
6420,1,Oral bioavailability in dogs; No data,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4942,In vivo,N,1,CHEMBL623361,,,
6421,1,Oral bioavailability measured in dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,14541,In vivo,N,1,CHEMBL623362,,,
6422,1,Oral bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4449,In vivo,N,1,CHEMBL623363,,,
6423,1,Oral bioavailability was calculated in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6057,In vivo,N,1,CHEMBL623364,,,
6424,1,Oral bioavailability after 0.3 mg/kg po administration in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5600,In vivo,N,1,CHEMBL875834,,,
6425,1,Oral bioavailability in dog (i.v. dosing),,BAO_0000218,,Canis lupus familiaris,,Intermediate,5542,In vivo,N,1,CHEMBL623365,,,
6426,1,Oral bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5542,In vivo,N,1,CHEMBL623366,,,
6427,1,Oral bioavailability in Beagle dog at a dose of 2 mg/kg by po administration,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5546,In vivo,N,1,CHEMBL623367,,,
6428,1,Oral bioavailability in Beagle dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4514,In vivo,N,1,CHEMBL623368,,,
6429,1,Oral bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,3624,In vivo,N,1,CHEMBL623369,,,
6430,1,Oral bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,3854,In vivo,N,1,CHEMBL623370,,,
6431,1,Oral bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5836,In vivo,N,1,CHEMBL623371,,,
6432,1,Oral bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5940,In vivo,N,1,CHEMBL623372,,,
6433,1,Oral bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6168,In vivo,N,1,CHEMBL621351,,,
6434,1,Oral bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6227,In vivo,N,1,CHEMBL621352,,,
6435,1,Oral bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6251,In vivo,N,1,CHEMBL621353,,,
6436,1,Oral bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6448,In vivo,N,1,CHEMBL621354,,,
6437,1,Oral bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6647,In vivo,N,1,CHEMBL621355,,,
6438,1,Oral bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5940,In vivo,N,1,CHEMBL621356,,,
6439,1,Oral bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,933,In vivo,N,1,CHEMBL621357,,,
6440,1,Oral bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5210,In vivo,N,1,CHEMBL621358,,,
6441,1,Oral bioavailability in dog (dosed as a mixture of five compounds at 0.5 mg/kg each via i.v. only),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6642,In vivo,N,1,CHEMBL621359,,,
6442,1,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6641,In vivo,N,1,CHEMBL621360,,,
6443,1,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6642,In vivo,N,1,CHEMBL621361,,,
6444,1,Oral bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5472,In vivo,N,1,CHEMBL621362,,,
6445,1,Oral bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5985,In vivo,N,1,CHEMBL621363,,,
6446,1,Oral bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,15660,In vivo,N,1,CHEMBL621364,,,
6447,1,Oral bioavailability in dog (dose 0.2 mg/kg i.v.),,BAO_0000218,,Canis lupus familiaris,,Intermediate,5530,In vivo,N,1,CHEMBL621166,,,
6448,1,Oral bioavailability in dog (dose 1 mg/kg i.v.),,BAO_0000218,,Canis lupus familiaris,,Intermediate,5530,In vivo,N,1,CHEMBL621167,,,
6449,1,Oral bioavailability (F) in dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6305,In vivo,N,1,CHEMBL621168,,,
6450,1,Oral bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5210,In vivo,N,1,CHEMBL621169,,,
6451,1,Bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5238,In vivo,N,1,CHEMBL875950,,,
6452,1,Oral bioavailability in dog (dose 10 mg/kg),,BAO_0000218,,Canis lupus familiaris,,Intermediate,5668,In vivo,N,1,CHEMBL621170,,,
6453,1,Oral bioavailability after peroral administration at 5 mpk in Dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5668,In vivo,N,1,CHEMBL621171,,,
6454,1,Oral bioavailability in dog (dose 5 mg/kg),,BAO_0000218,,Canis lupus familiaris,,Intermediate,5668,In vivo,N,1,CHEMBL621172,,,
6455,1,Oral bioavailability in dog (dose 10 mg/kg),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6084,In vivo,N,1,CHEMBL621173,,,
6456,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 4 hours,Kidney,BAO_0000218,,Mus musculus,,Intermediate,6599,,N,1,CHEMBL621174,42.0,2113.0,
6457,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 8 hours,Kidney,BAO_0000218,,Mus musculus,,Intermediate,6599,,N,1,CHEMBL621175,42.0,2113.0,
6458,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 1 hour,Liver,BAO_0000218,,Mus musculus,,Intermediate,6599,,N,1,CHEMBL621176,42.0,2107.0,
6459,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 2 hours,Liver,BAO_0000218,,Mus musculus,,Intermediate,6599,,N,1,CHEMBL621177,42.0,2107.0,
6460,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 30 minutes,Liver,BAO_0000218,,Mus musculus,,Intermediate,6599,,N,1,CHEMBL621178,42.0,2107.0,
6461,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 4 hours,Liver,BAO_0000218,,Mus musculus,,Intermediate,6599,,N,1,CHEMBL621179,42.0,2107.0,
6462,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 8 hours,Liver,BAO_0000218,,Mus musculus,,Intermediate,6599,,N,1,CHEMBL621180,42.0,2107.0,
6463,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 1 hour,Lung,BAO_0000218,,Mus musculus,,Intermediate,6599,,N,1,CHEMBL875951,42.0,2048.0,
6464,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 2 hours,Lung,BAO_0000218,,Mus musculus,,Intermediate,6599,,N,1,CHEMBL621181,42.0,2048.0,
6465,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 30 minutes,Lung,BAO_0000218,,Mus musculus,,Intermediate,6599,,N,1,CHEMBL621182,42.0,2048.0,
6466,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 4 hours,Lung,BAO_0000218,,Mus musculus,,Intermediate,6599,,N,1,CHEMBL621183,42.0,2048.0,
6467,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 8 hours,Lung,BAO_0000218,,Mus musculus,,Intermediate,6599,,N,1,CHEMBL621184,42.0,2048.0,
6468,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 1 hour,,BAO_0000218,,Mus musculus,,Intermediate,6599,,N,1,CHEMBL621185,42.0,,
6469,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice muscle bearing S180 tumor cell line for 2 hours,,BAO_0000218,,Mus musculus,,Intermediate,6599,,N,1,CHEMBL621186,42.0,,
6470,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 30 minutes,,BAO_0000218,,Mus musculus,,Intermediate,6599,,N,1,CHEMBL621187,42.0,,
6471,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 4 hours,,BAO_0000218,,Mus musculus,,Intermediate,6599,,N,1,CHEMBL621188,42.0,,
6472,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 8 hours,,BAO_0000218,,Mus musculus,,Intermediate,6599,,N,1,CHEMBL621189,42.0,,
6473,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice spleen bearing S180 tumor cell line for 1 hour,Spleen,BAO_0000218,,Mus musculus,,Intermediate,6599,,N,1,CHEMBL621190,42.0,2106.0,
6474,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 2 hours,Spleen,BAO_0000218,,Mus musculus,,Intermediate,6599,,N,1,CHEMBL618520,42.0,2106.0,
6475,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 30 minutes,Spleen,BAO_0000218,,Mus musculus,,Intermediate,6599,,N,1,CHEMBL621739,42.0,2106.0,
6476,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 4 hours,Spleen,BAO_0000218,,Mus musculus,,Intermediate,6599,,N,1,CHEMBL621740,42.0,2106.0,
6477,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 8 hours,Spleen,BAO_0000218,,Mus musculus,,Intermediate,6599,,N,1,CHEMBL621741,42.0,2106.0,
6478,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 1 hour,,BAO_0000218,,Mus musculus,,Intermediate,6599,,N,1,CHEMBL621742,42.0,,
6479,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 2 hours,,BAO_0000218,,Mus musculus,,Intermediate,6599,,N,1,CHEMBL621743,42.0,,
6480,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 30 minutes,,BAO_0000218,,Mus musculus,,Intermediate,6599,,N,1,CHEMBL621744,42.0,,
6481,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 4 hours,,BAO_0000218,,Mus musculus,,Intermediate,6599,,N,1,CHEMBL621745,42.0,,
6482,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 8 hours,,BAO_0000218,,Mus musculus,,Intermediate,6599,,N,1,CHEMBL621746,42.0,,
6483,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 1 hour,,BAO_0000218,,Mus musculus,,Intermediate,6599,,N,1,CHEMBL621747,42.0,,
6484,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 2 hours,,BAO_0000218,,Mus musculus,,Intermediate,6599,,N,1,CHEMBL621748,42.0,,
6485,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 30 minutes,,BAO_0000218,,Mus musculus,,Intermediate,6599,,N,1,CHEMBL621749,42.0,,
6486,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 4 hours,,BAO_0000218,,Mus musculus,,Intermediate,6599,,N,1,CHEMBL621750,42.0,,
6487,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 8 hours,,BAO_0000218,,Mus musculus,,Intermediate,6599,,N,1,CHEMBL621751,42.0,,
6488,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 1 hour,Heart,BAO_0000218,,Mus musculus,,Intermediate,6599,,N,1,CHEMBL621752,42.0,948.0,
6489,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 2 hours,Heart,BAO_0000218,,Mus musculus,,Intermediate,6599,,N,1,CHEMBL621753,42.0,948.0,
6490,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 30 minutes,Heart,BAO_0000218,,Mus musculus,,Intermediate,6599,,N,1,CHEMBL875955,42.0,948.0,
6491,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 4 hours,Heart,BAO_0000218,,Mus musculus,,Intermediate,6599,,N,1,CHEMBL621754,42.0,948.0,
6492,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 8 hours,Heart,BAO_0000218,,Mus musculus,,Intermediate,6599,,N,1,CHEMBL621755,42.0,948.0,
6493,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 1 hour,Liver,BAO_0000218,,Mus musculus,,Intermediate,6599,,N,1,CHEMBL621756,42.0,2107.0,
6494,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 2 hours,Liver,BAO_0000218,,Mus musculus,,Intermediate,6599,,N,1,CHEMBL624199,42.0,2107.0,
6495,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 30 minutes,Liver,BAO_0000218,,Mus musculus,,Intermediate,6599,,N,1,CHEMBL624200,42.0,2107.0,
6496,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 4 hours,Liver,BAO_0000218,,Mus musculus,,Intermediate,6599,,N,1,CHEMBL624375,42.0,2107.0,
6497,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 8 hours,Liver,BAO_0000218,,Mus musculus,,Intermediate,6599,,N,1,CHEMBL624376,42.0,2107.0,
6498,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 1 hour,Lung,BAO_0000218,,Mus musculus,,Intermediate,6599,,N,1,CHEMBL624377,42.0,2048.0,
6499,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/lung bearing S180 tumor cell line for 2 hours,Lung,BAO_0000218,,Mus musculus,,Intermediate,6599,,N,1,CHEMBL624378,42.0,2048.0,
6500,1,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,BAO_0000218,,aeinetobacter anitrotap,,Intermediate,12269,,N,1,CHEMBL857901,,,
6501,1,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,BAO_0000218,,Acinetobacter calcoaceticus subsp. anitratus,,Intermediate,12269,,N,1,CHEMBL875274,,,
6502,1,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,BAO_0000218,,Acinetobacter calcoaceticus subsp. anitratus,,Intermediate,12269,,N,1,CHEMBL624379,,,
6503,1,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,BAO_0000218,,aeinetobacter anitrotap,,Intermediate,12269,,N,1,CHEMBL624380,,,
6504,1,Activity against Acinetobacter calcoaceticus (AC54),,BAO_0000218,,Acinetobacter calcoaceticus,,Intermediate,10624,,N,1,CHEMBL624381,,,
6505,1,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates no prolonged biological activity,,BAO_0000218,,Anolis carolinensis,,Intermediate,17216,,N,1,CHEMBL624382,,,
6506,1,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates prolonged biological activity,,BAO_0000218,,Anolis carolinensis,,Intermediate,17216,,N,1,CHEMBL624383,,,
6507,1,Chlorohexidine coefficient for Actinomyces naeslundii 631,,BAO_0000218,,Actinomyces naeslundii,,Intermediate,9560,,N,1,CHEMBL624384,,,
6508,1,Chlorohexidine coefficient for Actinomyces naeslundii B74,,BAO_0000218,,Actinomyces naeslundii,,Intermediate,9560,,N,1,CHEMBL624385,,,
6509,1,Chlorohexidine coefficient for Actinomyces naeslundii N/3,,BAO_0000218,,Actinomyces naeslundii,,Intermediate,9560,,N,1,CHEMBL624386,,,
6510,1,Chlorohexidine coefficient for Actinomyces naeslundii N/9,,BAO_0000218,,Actinomyces naeslundii,,Intermediate,9560,,N,1,CHEMBL624387,,,
6511,1,Plaque bactericidal index against Actinomyces naeslundii 631,,BAO_0000218,,Actinomyces naeslundii,,Intermediate,9560,,N,1,CHEMBL624388,,,
6512,1,Plaque bactericidal index against Actinomyces naeslundii N/9,,BAO_0000218,,Actinomyces naeslundii,,Intermediate,9560,,N,1,CHEMBL624389,,,
6513,1,Plaque bactericidal index against Actinomyces naeslundii B74,,BAO_0000218,,Actinomyces naeslundii,,Intermediate,9560,,N,1,CHEMBL624390,,,
6514,1,Plaque bactericidal index against Actinomyces naeslundii N/3,,BAO_0000218,,Actinomyces naeslundii,,Intermediate,9560,,N,1,CHEMBL875275,,,
6515,1,Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay,,BAO_0000218,,Artemia salina,,Intermediate,114,,N,1,CHEMBL624391,,,
6516,1,"Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay; highest level tested, showed <100% activity",,BAO_0000218,,Artemia salina,,Intermediate,114,,N,1,CHEMBL623636,,,
6517,1,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 0 uM,,BAO_0000218,,Ascaris suum,,Intermediate,10841,,N,1,CHEMBL623637,,,
6518,1,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 10 uM,,BAO_0000218,,Ascaris suum,,Intermediate,10841,,N,1,CHEMBL623638,,,
6519,1,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 200 uM,,BAO_0000218,,Ascaris suum,,Intermediate,10841,,N,1,CHEMBL623639,,,
6520,1,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 25 uM,,BAO_0000218,,Ascaris suum,,Intermediate,10841,,N,1,CHEMBL623640,,,
6521,1,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 3 uM,,BAO_0000218,,Ascaris suum,,Intermediate,10841,,N,1,CHEMBL623641,,,
6522,1,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 50 uM.,,BAO_0000218,,Ascaris suum,,Intermediate,10841,,N,1,CHEMBL623642,,,
6523,1,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 0 uM,,BAO_0000218,,Ascaris suum,,Intermediate,10841,,N,1,CHEMBL623643,,,
6524,1,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 10 uM,,BAO_0000218,,Ascaris suum,,Intermediate,10841,,N,1,CHEMBL623644,,,
6525,1,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 200 uM,,BAO_0000218,,Ascaris suum,,Intermediate,10841,,N,1,CHEMBL623645,,,
6526,1,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 25 uM,,BAO_0000218,,Ascaris suum,,Intermediate,10841,,N,1,CHEMBL623646,,,
6527,1,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 3 uM,,BAO_0000218,,Ascaris suum,,Intermediate,10841,,N,1,CHEMBL623647,,,
6528,1,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 50 uM,,BAO_0000218,,Ascaris suum,,Intermediate,10841,,N,1,CHEMBL623648,,,
6529,1,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,,BAO_0000218,,Actinomyces viscosus,,Intermediate,8117,,N,1,CHEMBL623649,,,
6530,1,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,,BAO_0000218,,Actinomyces viscosus,,Intermediate,8117,,N,1,CHEMBL623650,,,
6531,1,Chlorohexidine coefficient for Actinomyces viscosus 8A06,,BAO_0000218,,Actinomyces viscosus,,Intermediate,9560,,N,1,CHEMBL623651,,,
6532,1,Chlorohexidine coefficient for Actinomyces viscosus M-100,,BAO_0000218,,Actinomyces viscosus,,Expert,9560,,N,1,CHEMBL623652,,,
6533,1,Chlorohexidine coefficient for Actinomyces viscosus M-626,,BAO_0000218,,Actinomyces viscosus,,Intermediate,9560,,N,1,CHEMBL623653,,,
6534,1,Chlorohexidine coefficient for Actinomyces viscosus T14V,,BAO_0000218,,Actinomyces viscosus,,Intermediate,9560,,N,1,CHEMBL623654,,,
6535,1,Plaque bactericidal index against Actinomyces viscosus 8A06,,BAO_0000218,,Actinomyces viscosus,,Intermediate,9560,,N,1,CHEMBL623655,,,
6536,1,Plaque bactericidal index against Actinomyces viscosus M-100,,BAO_0000218,,Actinomyces viscosus,,Intermediate,9560,,N,1,CHEMBL623656,,,
6537,1,Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient,,BAO_0000218,,Actinomyces viscosus,,Expert,9560,,N,1,CHEMBL623657,,,
6538,1,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; d=Not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",,BAO_0000218,,Actinomyces viscosus,,Intermediate,9560,,N,1,CHEMBL623658,,,
6539,1,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",,BAO_0000218,,Actinomyces viscosus,,Intermediate,9560,,N,1,CHEMBL623659,,,
6540,1,Plaque bactericidal index against Actinomyces viscosus 626,,BAO_0000218,,Actinomyces viscosus,,Intermediate,9560,,N,1,CHEMBL623660,,,
6541,1,Plaque bactericidal index against Actinomyces viscosus T14V,,BAO_0000218,,Actinomyces viscosus,,Intermediate,9560,,N,1,CHEMBL623661,,,
6542,1,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 1.56 mg/kg/day(5 days) dose,,BAO_0000218,,Acanthocheilonema viteae,,Intermediate,10986,,N,1,CHEMBL875281,,,
6543,1,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 100 mg/kg/day(5 days) dose,,BAO_0000218,,Acanthocheilonema viteae,,Intermediate,10986,,N,1,CHEMBL623662,,,
6544,1,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 12.5 mg/kg/day(5 days) dose,,BAO_0000218,,Acanthocheilonema viteae,,Intermediate,10986,,N,1,CHEMBL623663,,,
6545,1,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 200 mg/kg/day(5 days) dose,,BAO_0000218,,Acanthocheilonema viteae,,Intermediate,10986,,N,1,CHEMBL623664,,,
6546,1,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 25 mg/kg/day(5 days) dose,,BAO_0000218,,Acanthocheilonema viteae,,Intermediate,10986,,N,1,CHEMBL623665,,,
6547,1,Evaluated for the inhibitory concentration required to cause growth inhibition of A673Mer+ sarcoma cell line using the MTT Cytotoxicity Assay,,BAO_0000219,,Homo sapiens,,Intermediate,10708,,N,1,CHEMBL621856,165.0,,
6548,1,Evaluated for the inhibitory concentration required to cause growth inhibition of A704Rem- renal cell line using the MTT Cytotoxicity Assay,,BAO_0000219,,Homo sapiens,,Intermediate,10708,,N,1,CHEMBL620432,645.0,,
6549,1,Tested for inhibition of ET-1 induced phosphoinositide (PI) turnover in A7r5 smooth muscle cells,,BAO_0000219,,Rattus norvegicus,,Autocuration,416,,U,0,CHEMBL620433,,,
6550,1,Inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,,BAO_0000219,,Mus musculus,,Intermediate,14354,,N,1,CHEMBL620434,625.0,,
6551,1,Percent inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,,BAO_0000219,,Mus musculus,,Intermediate,14354,,N,1,CHEMBL620435,625.0,,
6552,1,Cytotoxicity against Beta- tubulin mutant expressing A9-PTX10 cell line of humans was tested,,BAO_0000219,,Homo sapiens,,Intermediate,5116,,N,1,CHEMBL620436,625.0,,
6553,1,Percentage inhibition at higher concentration (100 nM) against Beta- tubulin mutant expressing A9-PTX10 cell line,,BAO_0000219,,Homo sapiens,,Intermediate,5116,,N,1,CHEMBL876597,625.0,,
6554,1,Inhibition of human ovarian carcinoma (A90) FGF-R overexpressing cell proliferation,,BAO_0000219,,Homo sapiens,,Expert,15694,,N,1,CHEMBL620437,874.0,,
6555,1,"Tested for stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells, activity expressed as EC50 mM.",,BAO_0000219,,Mus musculus,,Expert,13038,,N,1,CHEMBL620438,625.0,,
6556,1,Stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells.,,BAO_0000219,,Mus musculus,,Expert,13038,,N,1,CHEMBL620439,625.0,,
6557,1,Increase in phosphoinositide (PI) metabolism in A9L-m1 cells at 100 uM.,,BAO_0000219,,Mus musculus,,Expert,10923,,N,1,CHEMBL619657,625.0,,
6558,1,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; - = Not determined,,BAO_0000219,,Mus musculus,,Intermediate,10923,,N,1,CHEMBL619658,625.0,,
6559,1,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; i = inactive,,BAO_0000219,,Mus musculus,,Intermediate,10923,,N,1,CHEMBL619659,625.0,,
6560,1,"Increase in phosphoinositide (PI) metabolism in A9L-cholinergic receptor, muscarinic 3 expressing cells was measured at 100 uMolar",,BAO_0000019,,,,Expert,10923,,H,8,CHEMBL619660,,,
6561,1,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; - = Not determined,,BAO_0000219,,Mus musculus,,Intermediate,10923,,N,1,CHEMBL619661,625.0,,
6562,1,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; i = inactive,,BAO_0000219,,Mus musculus,,Intermediate,10923,,N,1,CHEMBL619662,625.0,,
6563,1,Ability to inhibit growth of AA-6 cells (a mutant cell line resistant to 8-azaadenine and lacks adenine phosphoryltransferase) was determined,,BAO_0000219,,Cricetulus griseus,,Intermediate,8158,,N,1,CHEMBL619663,975.0,,
6564,1,Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied after 5 hrs of Incubation.,,BAO_0000219,,Homo sapiens,,Autocuration,15494,,U,0,CHEMBL619664,,,
6565,1,"Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied, after 5 hrs of Incubation.",,BAO_0000219,,Homo sapiens,,Autocuration,15494,,U,0,CHEMBL619665,,,
6566,1,Anti -HIV activity was measured against AA5/HIV-1(IIIB),,BAO_0000219,,Homo sapiens,,Intermediate,12348,,N,1,CHEMBL883244,974.0,,
6567,1,Cytotoxicity was measured against AA5/HIV-1(IIIB),,BAO_0000219,,Homo sapiens,,Intermediate,12348,,N,1,CHEMBL884011,974.0,,
6568,1,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in AA5 EBV-infected B-cell,,BAO_0000219,,Homo sapiens,,Intermediate,2726,,N,1,CHEMBL619666,974.0,,
6569,1,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in U937 monocytic cell,,BAO_0000219,,Homo sapiens,,Intermediate,2726,,N,1,CHEMBL619667,379.0,,
6570,1,Hypersensitivity factor obtained from in vitro cytotoxicities against Chinese hamster ovary derived AA8 / UV4 cell lines,,BAO_0000219,,Cricetulus griseus,,Intermediate,10747,,N,1,CHEMBL619668,274.0,,
6571,1,"Inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",,BAO_0000219,,Cricetulus griseus,,Expert,11005,,N,1,CHEMBL619669,185.0,,
6572,1,Average intracellular compound concentration when the hypoxic SER=1.6,,BAO_0000219,,Cricetulus griseus,,Intermediate,12687,,N,1,CHEMBL876608,185.0,,
6573,1,Average intracellular compound concentration when the hypoxic SER=1.6.,,BAO_0000219,,Cricetulus griseus,,Intermediate,12687,,N,1,CHEMBL619670,185.0,,
6574,1,Average intracellular compound concentration where the hypoxia sensitizer enhancement ratio (SER)=1.6,,BAO_0000219,,Cricetulus griseus,,Intermediate,12687,,N,1,CHEMBL619671,185.0,,
6575,1,Average intracellular compound concentration where the sensitizer enhancement ratio (SER)=1.6 under hypoxia,,BAO_0000219,,Cricetulus griseus,,Intermediate,12687,,N,1,CHEMBL619672,185.0,,
6576,1,Compound concentration at which sensitizer enhancement ratio =1.6 under hypoxia.,,BAO_0000219,,Cricetulus griseus,,Intermediate,12687,,N,1,CHEMBL619673,185.0,,
6577,1,"Compound was tested for the concentration required to reduce cell survival under hypoxic conditions, using the cell line AA8 in the clonogenic assay.",,BAO_0000219,,Cricetulus griseus,,Intermediate,13436,,N,1,CHEMBL619674,185.0,,
6578,1,"Concentration needed to reduce cell survival to 10% of control values, using 1 hour exposure of plateau phase AA8 cells at 10e6 cells/ml",,BAO_0000219,,Cricetulus griseus,,Intermediate,13435,,N,1,CHEMBL619675,185.0,,
6579,1,Activity to reduce the surviving fraction to 10% (CT10) was used as an inverse measure of cytotoxic potency in aerobic conditions,,BAO_0000219,,Cricetulus griseus,,Intermediate,13302,,N,1,CHEMBL619676,185.0,,
6580,1,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,,BAO_0000219,,Cricetulus griseus,,Intermediate,12687,,N,1,CHEMBL619677,185.0,,
6581,1,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,,BAO_0000219,,Cricetulus griseus,,Intermediate,12687,,N,1,CHEMBL619678,185.0,,
6582,1,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition.,,BAO_0000219,,Cricetulus griseus,,Intermediate,12687,,N,1,CHEMBL619679,185.0,,
6583,1,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay,,BAO_0000219,,Cricetulus griseus,,Expert,12878,,N,1,CHEMBL619680,185.0,,
6584,1,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay. Inactive at the solubility limit,,BAO_0000219,,Cricetulus griseus,,Intermediate,12878,,N,1,CHEMBL621457,185.0,,
6585,1,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% controls in clonogenic assay,,BAO_0000219,,Cricetulus griseus,,Expert,14367,,N,1,CHEMBL876609,185.0,,
6586,1,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% of controls in clonogenic assay,,BAO_0000219,,Cricetulus griseus,,Intermediate,14367,,N,1,CHEMBL621458,185.0,,
6587,1,Aerobic cytotoxicity was assessed in a growth inhibition assay using log phase cultures of the chinese hamster ovary fibroblast line AA8,,BAO_0000219,,hampster,,Expert,12398,,N,1,CHEMBL621459,185.0,,
6588,1,Aerobic growth inhibition in Chinese hamster cell line AA8,,BAO_0000219,,Cricetulus griseus,,Expert,12878,,N,1,CHEMBL621460,185.0,,
6589,1,Cytotoxicity against AA8 cell and IC50 values were determined as drug concentration required to inhibit cell protein to 50%.,,BAO_0000219,,Cricetulus griseus,,Expert,13820,,N,1,CHEMBL621461,185.0,,
6590,1,Inhibition of growth under aerobic conditions in AA8 cells,,BAO_0000219,,Cricetulus griseus,,Expert,13436,,N,1,CHEMBL621462,185.0,,
6591,1,Oral bioavailability in dog (dose 10 mg/kg),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6084,In vivo,N,1,CHEMBL621463,,,
6592,1,Oral bioavailability in dog at 10 mg/kg of the compound,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5711,In vivo,N,1,CHEMBL621464,,,
6593,1,Oral bioavailability in dog (dose 5 uM/kg),,BAO_0000218,,Canis lupus familiaris,,Intermediate,4353,In vivo,N,1,CHEMBL621465,,,
6594,1,Oral bioavailability in dog (dose 5 uM/kg),,BAO_0000218,,Canis lupus familiaris,,Intermediate,4353,In vivo,N,1,CHEMBL621466,,,
6595,1,Oral bioavailability in dog (mongrel),,BAO_0000218,,Canis lupus familiaris,,Intermediate,17800,In vivo,N,1,CHEMBL621467,,,
6596,1,Oral bioavailability in dog (dose 10 mg/kg),,BAO_0000218,,Canis lupus familiaris,,Intermediate,3994,In vivo,N,1,CHEMBL621468,,,
6597,1,Oral bioavailability in dog (dose 10 mg/kg),,BAO_0000218,,Canis lupus familiaris,,Intermediate,3994,In vivo,N,1,CHEMBL876734,,,
6598,1,Bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5145,In vivo,N,1,CHEMBL618476,,,
6599,1,Bioavailability in dog (dose 1 mg/kg i.v.),,BAO_0000218,,Canis lupus familiaris,,Intermediate,16452,In vivo,N,1,CHEMBL618477,,,
6600,1,Pharmacokinetic data for dose given to dogs intravenously (oral PK study in parentheses),,BAO_0000218,,Canis lupus familiaris,,Intermediate,16452,In vivo,N,1,CHEMBL618478,,,
6601,1,Pharmacokinetic property (F) was measured in dog at the dose of 0.032 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5983,In vivo,N,1,CHEMBL618479,,,
6602,1,Bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4273,In vivo,N,1,CHEMBL618480,,,
6603,1,Bioavailability in dog (dose 3-10 mg/kg),,BAO_0000218,,Canis lupus familiaris,,Intermediate,12500,In vivo,N,1,CHEMBL618481,,,
6604,1,The compound was tested for bioavailability of compound in plasma of dog; Complete,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,12500,In vivo,N,1,CHEMBL618482,,1969.0,
6605,1,Oral bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,3639,In vivo,N,1,CHEMBL618483,,,
6606,1,Oral bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,3880,In vivo,N,1,CHEMBL618484,,,
6607,1,Bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4838,In vivo,N,1,CHEMBL618485,,,
6608,1,oral bioavailability was measured in dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,15600,In vivo,N,1,CHEMBL618486,,,
6609,1,Compound was tested for plasma protein binding in dog; Not determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17248,,N,1,CHEMBL618487,,,
6610,1,Compound was tested for plasma protein binding of dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17248,,N,1,CHEMBL618488,,,
6611,1,Compound was tested for plasma protein binding of dog; Not determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17248,,N,1,CHEMBL876735,,,
6612,1,Concentration in dogs after oral administration at dose of 1 mg/kg after 180 min.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17443,,N,1,CHEMBL618489,,,
6613,1,Apparent terminal elimination half-life in dog after administration of 20 mg/kg dose through peroral route,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4186,In vivo,N,1,CHEMBL618490,,,
6614,1,Half life was determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,3749,,N,1,CHEMBL618491,,,
6615,1,Half life by ''Cr'' assay in dog at a dose of 5 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,3249,In vivo,N,1,CHEMBL618492,,,
6616,1,Half life was evaluated in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,3022,,N,1,CHEMBL873354,,,
6617,1,Half life was determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,3749,,N,1,CHEMBL618493,,,
6618,1,Biodistribution of compound was measured in bile at 2 hr post-injection in canine deep vein thrombosis model (DVT),,BAO_0000218,,Canis lupus familiaris,,Intermediate,2517,In vivo,N,1,CHEMBL618494,,,
6619,1,Biodistribution of compound was measured in heart at 2 hr post-injection in canine deep vein thrombosis model (DVT),Heart,BAO_0000218,,Canis lupus familiaris,,Intermediate,2517,In vivo,N,1,CHEMBL618495,,948.0,
6620,1,Biodistribution of compound was measured in kidney at 2 hr post-injection in canine deep vein thrombosis model (DVT),Kidney,BAO_0000218,,Canis lupus familiaris,,Intermediate,2517,In vivo,N,1,CHEMBL618496,,2113.0,
6621,1,Biodistribution of compound was measured in liver at 2 hr post-injection in canine deep vein thrombosis model (DVT),Liver,BAO_0000218,,Canis lupus familiaris,,Intermediate,2517,In vivo,N,1,CHEMBL618497,,2107.0,
6622,1,Biodistribution of compound was measured in lung at 2 hr post-injection in canine deep vein thrombosis model (DVT),Lung,BAO_0000218,,Canis lupus familiaris,,Intermediate,2517,In vivo,N,1,CHEMBL618498,,2048.0,
6623,1,Biodistribution of compound was measured in spleen at 2 hr post-injection in canine deep vein thrombosis model (DVT),Spleen,BAO_0000218,,Canis lupus familiaris,,Intermediate,2517,In vivo,N,1,CHEMBL618499,,2106.0,
6624,1,LogP in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,3639,,N,1,CHEMBL876736,,,
6625,1,Partition coefficient (logP),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6227,,N,1,CHEMBL618500,,,
6626,1,Partition coefficient in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6227,,N,1,CHEMBL857831,,,
6627,1,Mean-residence time of compound after intravenous administration in dogs at 1.2 uM/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17764,In vivo,N,1,CHEMBL618501,,,
6628,1,Pharmacokinetic parameter MRT was determined in Beagle dogs after (po) administration of a dose of 28 (uM/kg),,BAO_0000218,,Canis lupus familiaris,,Intermediate,4809,In vivo,N,1,CHEMBL618502,,,
6629,1,In vitro metabolic stability determined after 30 min of incubation in dog hepatic microsomes,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5600,,N,1,CHEMBL618503,,,
6630,1,Metabolism of compound in dog S9 microsomes ('++''indicates 20-50% largest observed peak),,BAO_0000218,,Canis lupus familiaris,,Intermediate,14294,,N,1,CHEMBL618504,,,
6631,1,Metabolism of compound in dog S9 microsomes ('++++' indicates largest observed peak),,BAO_0000218,,Canis lupus familiaris,,Intermediate,14294,,N,1,CHEMBL618505,,,
6632,1,Metabolism of compound in dog S9 microsomes; Trace,,BAO_0000218,,Canis lupus familiaris,,Intermediate,14294,,N,1,CHEMBL618506,,,
6633,1,In vitro metabolic potential in dog liver microsomes,Liver,BAO_0000218,,Canis lupus familiaris,,Intermediate,6251,,N,1,CHEMBL618507,,2107.0,
6634,1,Oral bioavailability of perorally administered compound (10 mg/kg) was tested in dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,3748,In vivo,N,1,CHEMBL876737,,,
6635,1,Oral bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,2713,In vivo,N,1,CHEMBL618508,,,
6636,1,Oral bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6512,In vivo,N,1,CHEMBL618509,,,
6637,1,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6679,In vivo,N,1,CHEMBL618510,,,
6638,1,The compound was tested for bioavailability in dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,3749,In vivo,N,1,CHEMBL618511,,,
6639,1,The compound was tested for oral bioavailability in dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,3749,In vivo,N,1,CHEMBL618512,,,
6640,1,Oral bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6742,In vivo,N,1,CHEMBL618513,,,
6641,1,Compound was tested for percent protein binding (PB) in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6227,,N,1,CHEMBL618514,,,
6642,1,Apparent permeability coefficient (Papp) for apical to basolateral flux was determined in MadinDarby Canine Kidney cells,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6874,,N,1,CHEMBL620052,,,
6643,1,Compound was evaluated for plasma clearance.,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,2877,In vivo,N,1,CHEMBL620053,,1969.0,
6644,1,The compound was tested for plasma clearance in dog,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,12500,In vivo,N,1,CHEMBL620054,,1969.0,
6645,1,The compound was tested for plasma clearance in dog at dose of 3-10 mgkg,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,12500,In vivo,N,1,CHEMBL620055,,1969.0,
6646,1,Plasma protein binding was determined after intravenous administration of 1 mg/kg in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4709,,N,1,CHEMBL620056,,,
6647,1,In vitro relative rate of metabolism was determined in dog liver microsomes,Liver,BAO_0000218,,Canis lupus familiaris,,Intermediate,5542,,N,1,CHEMBL620057,,2107.0,
6648,1,Relative bioavailability after oral dose of compound at 3 mg/kg in dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17594,In vivo,N,1,CHEMBL618939,,,
6649,1,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,,BAO_0000218,,Canis lupus familiaris,,Intermediate,2652,In vivo,N,1,CHEMBL618940,,,
6650,1,Half life after intravenous administration in dogs at 1.2 uM/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17764,In vivo,N,1,CHEMBL618941,,,
6651,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 30 minutes,Lung,BAO_0000218,,Mus musculus,,Intermediate,6599,,N,1,CHEMBL624473,42.0,2048.0,
6652,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 4 hours,Lung,BAO_0000218,,Mus musculus,,Intermediate,6599,,N,1,CHEMBL624474,42.0,2048.0,
6653,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 8 hours,Lung,BAO_0000218,,Mus musculus,,Intermediate,6599,,N,1,CHEMBL624475,42.0,2048.0,
6654,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 1 hour,,BAO_0000218,,Mus musculus,,Intermediate,6599,,N,1,CHEMBL624476,42.0,,
6655,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 2 hours,,BAO_0000218,,Mus musculus,,Intermediate,6599,,N,1,CHEMBL623478,42.0,,
6656,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 30 minutes,,BAO_0000218,,Mus musculus,,Intermediate,6599,,N,1,CHEMBL623479,42.0,,
6657,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 4 hours,,BAO_0000218,,Mus musculus,,Intermediate,6599,,N,1,CHEMBL623480,42.0,,
6658,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 8 hours,,BAO_0000218,,Mus musculus,,Intermediate,6599,,N,1,CHEMBL623481,42.0,,
6659,1,C2 in brain of mice at the oral dose of 50 mg/kg,Brain,BAO_0000218,,Mus musculus,,Intermediate,17641,,N,1,CHEMBL623482,,955.0,
6660,1,C2 in kidney of mice at the oral dose of 50 mg/kg,Kidney,BAO_0000218,,Mus musculus,,Intermediate,17641,,N,1,CHEMBL623483,,2113.0,
6661,1,C2 in liver of mice at the oral dose of 50 mg/kg,Liver,BAO_0000218,,Mus musculus,,Intermediate,17641,,N,1,CHEMBL623484,,2107.0,
6662,1,C2 in lungs of mice at the oral dose of 50 mg/kg,Lung,BAO_0000218,,Mus musculus,,Intermediate,17641,,N,1,CHEMBL623485,,2048.0,
6663,1,C2 in spleen of mice at the oral dose of 50 mg/kg,Spleen,BAO_0000218,,Mus musculus,,Intermediate,17641,,N,1,CHEMBL623486,,2106.0,
6664,1,Plasma clearance in mouse,,BAO_0000218,,Mus musculus,,Intermediate,17852,In vivo,N,1,CHEMBL623487,,,
6665,1,Clearance of compound after intravenous administration in mice at 24 uM/kg,,BAO_0000218,,Mus musculus,,Intermediate,17764,In vivo,N,1,CHEMBL623488,,,
6666,1,Clearance from mouse blood following i.v. administration of 10 mg/kg,,BAO_0000218,,Mus musculus,,Intermediate,17837,In vivo,N,1,CHEMBL623489,,,
6667,1,Clearance was evaluated in mice after intravenous administration,,BAO_0000218,,Mus musculus,,Intermediate,2675,In vivo,N,1,CHEMBL875157,,,
6668,1,Clearance was evaluated in mice after oral administration,,BAO_0000218,,Mus musculus,,Intermediate,2675,In vivo,N,1,CHEMBL623490,,,
6669,1,Pharmacokinetic property (Plasma clearance) was measured in mouse,,BAO_0000218,,Mus musculus,,Intermediate,4239,In vivo,N,1,CHEMBL623491,,,
6670,1,Plasma clearance of compound was determined at 40 mg/Kg,,BAO_0000218,,Mus musculus,,Intermediate,17753,In vivo,N,1,CHEMBL623492,,,
6671,1,Plasma clearance of at 24 mg/Kg,,BAO_0000218,,Mus musculus,,Intermediate,17753,In vivo,N,1,CHEMBL623493,,,
6672,1,Plasma clearance at 24 mg/Kg,,BAO_0000218,,Mus musculus,,Intermediate,17753,In vivo,N,1,CHEMBL623494,,,
6673,1,Plasma clearance at 5 mg/Kg,,BAO_0000218,,Mus musculus,,Intermediate,17753,In vivo,N,1,CHEMBL623495,,,
6674,1,Plasma clearance in mice,,BAO_0000218,,Mus musculus,,Intermediate,5727,In vivo,N,1,CHEMBL623496,,,
6675,1,Plasma clearance value upon iv administration in mouse,,BAO_0000218,,Mus musculus,,Intermediate,2862,In vivo,N,1,CHEMBL623497,,,
6676,1,Total plasma clearance in mice,Plasma,BAO_0000218,,Mus musculus,,Intermediate,5980,In vivo,N,1,CHEMBL623498,,1969.0,
6677,1,Clearance in mouse,,BAO_0000218,,Mus musculus,,Intermediate,17592,In vivo,N,1,CHEMBL623499,,,
6678,1,Clearance value was determined,,BAO_0000218,,Mus musculus,,Intermediate,17718,In vivo,N,1,CHEMBL623500,,,
6679,1,Plasma clearance at a dose of 10 mg/kg intravenous administration in mice.,,BAO_0000218,,Mus musculus,,Intermediate,16597,In vivo,N,1,CHEMBL623501,,,
6680,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Intermediate,17384,,U,0,CHEMBL875158,,,
6681,1,Plasma clearance for the compound was measured in mouse after an iv dose of 1 mg/kg,,BAO_0000218,,Mus musculus,,Intermediate,6062,In vivo,N,1,CHEMBL623502,,,
6682,1,Plasma clearance rate after intraperitoneal administration of 100 mg/kg in mice,,BAO_0000218,,Mus musculus,,Intermediate,17734,In vivo,N,1,CHEMBL623503,,,
6683,1,Plasma clearance was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,BAO_0000218,,Mus musculus,,Intermediate,6348,In vivo,N,1,CHEMBL623504,,,
6684,1,In vivo total clearance was determined in murine septicemia at dose of 100 mg/kg,,BAO_0000218,,Mus musculus,,Intermediate,5969,In vivo,N,1,CHEMBL623505,,,
6685,1,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg,,BAO_0000218,,Mus musculus,,Intermediate,5969,In vivo,N,1,CHEMBL623506,,,
6686,1,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,,BAO_0000218,,Mus musculus,,Intermediate,5969,In vivo,N,1,CHEMBL623507,,,
6687,1,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for Cmax,,BAO_0000218,,Mus musculus,,Intermediate,16597,In vivo,N,1,CHEMBL623508,,,
6688,1,Cmax after oral administration at 30 mg/kg in ICR mouse,,BAO_0000218,,Mus musculus,,Intermediate,5781,In vivo,N,1,CHEMBL623509,,,
6689,1,Cmax after peroral administration in mice at 2.4 uM/kg,,BAO_0000218,,Mus musculus,,Intermediate,17764,In vivo,N,1,CHEMBL875159,,,
6690,1,Cmax in brain of mice at the oral dose of 50 mg/kg,Brain,BAO_0000218,,Mus musculus,,Intermediate,17641,In vivo,N,1,CHEMBL623510,,955.0,
6691,1,Cmax in kidney of mice at the oral dose of 50 mg/kg,Kidney,BAO_0000218,,Mus musculus,,Intermediate,17641,In vivo,N,1,CHEMBL623511,,2113.0,
6692,1,Cmax in liver of mice at the oral dose of 50 mg/kg,Liver,BAO_0000218,,Mus musculus,,Intermediate,17641,In vivo,N,1,CHEMBL623512,,2107.0,
6693,1,Cmax in lungs of mice at the oral dose of 50 mg/kg,Lung,BAO_0000218,,Mus musculus,,Intermediate,17641,In vivo,N,1,CHEMBL623513,,2048.0,
6694,1,Cmax in mice at 18 uM/kg i.p. administration,,BAO_0000218,,Mus musculus,,Intermediate,17764,In vivo,N,1,CHEMBL623514,,,
6695,1,Cmax in mice at 23 uM/kg i.v. administration,,BAO_0000218,,Mus musculus,,Intermediate,17764,In vivo,N,1,CHEMBL622609,,,
6696,1,Cmax in mice at 24 uM/kg i.p. administration,,BAO_0000218,,Mus musculus,,Intermediate,17764,In vivo,N,1,CHEMBL622610,,,
6697,1,Cmax in mice at 25 uM/kg i.p. administration,,BAO_0000218,,Mus musculus,,Intermediate,17764,In vivo,N,1,CHEMBL621823,,,
6698,1,Cmax in mice at 26 uM/kg i.p. administration,,BAO_0000218,,Mus musculus,,Intermediate,17764,In vivo,N,1,CHEMBL621824,,,
6699,1,Cmax in spleen of mice at the oral dose of 50 mg/kg,Spleen,BAO_0000218,,Mus musculus,,Intermediate,17641,In vivo,N,1,CHEMBL621825,,2106.0,
6700,1,Cmax value at a dose of 10 mg/kg intravenous administration in mice.,,BAO_0000218,,Mus musculus,,Intermediate,16597,In vivo,N,1,CHEMBL621826,,,
6701,1,Cmax value at a dose of 10 mg/kg peroral administration in mice.,,BAO_0000218,,Mus musculus,,Intermediate,16597,In vivo,N,1,CHEMBL621827,,,
6702,1,Cmax value was determined,,BAO_0000218,,Mus musculus,,Intermediate,5727,In vivo,N,1,CHEMBL621828,,,
6703,1,Cmax value in IRC mice,,BAO_0000218,,Mus musculus,,Intermediate,5951,In vivo,N,1,CHEMBL621829,,,
6704,1,Cmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,,BAO_0000218,,Mus musculus,,Intermediate,5506,In vivo,N,1,CHEMBL621830,,,
6705,1,Cmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,,BAO_0000218,,Mus musculus,,Intermediate,5506,In vivo,N,1,CHEMBL621831,,,
6706,1,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,Plasma,BAO_0000218,,Mus musculus,,Intermediate,14239,In vivo,N,1,CHEMBL621832,,1969.0,
6707,1,"Compound was evaluated for the pharmacokinetic parameter, maximum plasma concentration",Plasma,BAO_0000218,,Mus musculus,,Intermediate,4890,In vivo,N,1,CHEMBL624579,,1969.0,
6708,1,Evaluated for pharmacokinetic parameter Cmax in mouse at the dose 20 mg/kg,,BAO_0000218,,Mus musculus,,Intermediate,429,In vivo,N,1,CHEMBL624580,,,
6709,1,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 50 mg/kg/day(5 days) dose,,BAO_0000218,,Acanthocheilonema viteae,,Intermediate,10986,,N,1,CHEMBL624581,,,
6710,1,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 6.25 mg/kg/day(5 days) dose,,BAO_0000218,,Acanthocheilonema viteae,,Intermediate,10986,,N,1,CHEMBL624582,,,
6711,1,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 75 mg/kg/day(5 days) dose,,BAO_0000218,,Acanthocheilonema viteae,,Intermediate,10986,,N,1,CHEMBL624583,,,
6712,1,Inhibitory activity against human tumor cell line A0375 melanoma.,,BAO_0000219,,Homo sapiens,,Intermediate,13227,,N,1,CHEMBL624584,455.0,,
6713,1,Displacement of [3H]N6-PIA binding from A1 receptor in whole rat brain membranes,,BAO_0000249,,Rattus norvegicus,,Expert,4481,,D,9,CHEMBL624585,,,
6714,1,Forskolin-induced cAMP production at human A1 adenosine receptor,,BAO_0000019,,Homo sapiens,,Expert,16931,,D,9,CHEMBL875165,,,
6715,1,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1; change of less than 5% of allosteric enhancement.,,BAO_0000219,,,,Autocuration,3850,,H,8,CHEMBL619490,449.0,,
6716,1,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,,BAO_0000219,,,,Autocuration,3850,,H,8,CHEMBL619491,449.0,,
6717,1,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM,,BAO_0000219,,,,Expert,3850,,H,8,CHEMBL619492,449.0,,
6718,1,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration,,BAO_0000219,,,,Expert,3850,,H,8,CHEMBL619493,449.0,,
6719,1,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; An increase of cAmp content of cells,,BAO_0000219,,,,Autocuration,3850,,H,8,CHEMBL619494,449.0,,
6720,1,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement,,BAO_0000219,,,,Autocuration,3850,,H,8,CHEMBL619495,449.0,,
6721,1,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement.,,BAO_0000219,,,,Autocuration,3850,,H,8,CHEMBL619496,449.0,,
6722,1,Percent response to 10 uM PD-81723 on CHO cells expressing human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,,BAO_0000219,,Homo sapiens,,Expert,3850,,D,9,CHEMBL619497,449.0,,
6723,1,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM,,BAO_0000219,,,,Autocuration,3850,,H,8,CHEMBL619498,449.0,,
6724,1,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; change of less than 5% of allosteric enhancement.,,BAO_0000219,,,,Autocuration,3850,,H,8,CHEMBL619499,449.0,,
6725,1,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration,,BAO_0000219,,,,Expert,3850,,H,8,CHEMBL619500,449.0,,
6726,1,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration; change of less than 5% of allosteric enhancement.,,BAO_0000219,,,,Autocuration,3850,,H,8,CHEMBL619501,449.0,,
6727,1,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; An increase of cAmp content of cells,,BAO_0000219,,,,Expert,3850,,H,8,CHEMBL619502,449.0,,
6728,1,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM,,BAO_0000219,,,,Autocuration,3850,,H,8,CHEMBL619503,449.0,,
6729,1,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,,BAO_0000219,,,,Autocuration,3850,,H,8,CHEMBL619504,449.0,,
6730,1,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; change of less than 5% of allosteric enhancement.,,BAO_0000219,,,,Autocuration,3850,,H,8,CHEMBL621298,449.0,,
6731,1,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration,,BAO_0000219,,,,Expert,3850,,H,8,CHEMBL621299,449.0,,
6732,1,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; An increase of cAmp content of cells,,BAO_0000219,,,,Autocuration,3850,,H,8,CHEMBL621300,449.0,,
6733,1,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; change of less than 5% of allosteric enhancement.,,BAO_0000219,,,,Autocuration,3850,,H,8,CHEMBL621301,449.0,,
6734,1,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,,BAO_0000219,,,,Expert,3850,,H,8,CHEMBL621302,449.0,,
6735,1,Ability to inhibit [125I]ET1 binding to vascular smooth muscle (vsm)- A10 cells,,BAO_0000219,,Oryctolagus cuniculus,,Intermediate,12680,,N,1,CHEMBL621303,164.0,,
6736,1,In vitro potassium channel opening activity in A10 (smooth muscle) cells,,BAO_0000219,,Rattus norvegicus,,Autocuration,1313,,U,0,CHEMBL621304,164.0,,
6737,1,In vitro potassium channel opening activity in A10 (smooth muscle) cells; Inactive,,BAO_0000219,,Rattus norvegicus,,Autocuration,1313,,U,0,CHEMBL621305,164.0,,
6738,1,Effect on membrane potential of mitochondria in A10 smooth muscle cells from rats,,BAO_0000219,,Rattus norvegicus,,Intermediate,17567,,N,1,CHEMBL621306,164.0,,
6739,1,Effect on membrane potential of mitochondria of A10 smooth muscle cells in rats,,BAO_0000219,,Rattus norvegicus,,Intermediate,17567,,N,1,CHEMBL618444,164.0,,
6740,1,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.001 uM,,BAO_0000219,,Rattus norvegicus,,Intermediate,11819,,N,1,CHEMBL618445,164.0,,
6741,1,Compound was tested for aerobic growth inhibition against AA8 cells after 4 hr of exposure,,BAO_0000219,,Cricetulus griseus,,Intermediate,13436,,N,1,CHEMBL618446,185.0,,
6742,1,Concentration required to reduce AA8 cell numbers to 50% of controls in a growth inhibition microassay,,BAO_0000219,,Cricetulus griseus,,Intermediate,12687,,N,1,CHEMBL618447,185.0,,
6743,1,Concentration of the drug to inhibit chinese hamster ovary derived cell (AA8) growth in culture,,BAO_0000219,,Cricetulus griseus,,Intermediate,12651,,N,1,CHEMBL618448,185.0,,
6744,1,Cytotoxicity in a growth inhibition assay against aerobic cultures of AA8 cells was determined,,BAO_0000219,,Cricetulus griseus,,Intermediate,13300,,N,1,CHEMBL618449,185.0,,
6745,1,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,,BAO_0000219,,Cricetulus griseus,,Intermediate,15296,,N,1,CHEMBL618637,185.0,,
6746,1,"Cytotoxicity in chinese hamster ovary tumor cell line-AA8, by growth inhibition assay.",,BAO_0000219,,Cricetulus griseus,,Intermediate,15328,,N,1,CHEMBL618638,185.0,,
6747,1,Growth inhibition activity was measured in repair proficient AA8 cells under aerobic conditions (4 hours drug exposure),,BAO_0000219,,Cricetulus griseus,,Intermediate,13302,,N,1,CHEMBL618639,185.0,,
6748,1,"Growth inhibition of aerobic AA8 cells, after 18 hours exposure",,BAO_0000219,,Cricetulus griseus,,Expert,14367,,N,1,CHEMBL618640,185.0,,
6749,1,In vitro cellular toxicity against chinese hamster AA8 cell line after 4 hr of compound exposure,,BAO_0000219,,Cricetulus griseus,,Expert,17002,,N,1,CHEMBL618641,185.0,,
6750,1,Inhibitory activity against AA8 cell growth in aerobic condition after 4 hr of exposure,,BAO_0000219,,Cricetulus griseus,,Intermediate,13436,,N,1,CHEMBL618642,185.0,,
6751,1,Inhibitory activity against aerobic growth of AA8 cells.,,BAO_0000219,,Cricetulus griseus,,Intermediate,13435,,N,1,CHEMBL618643,185.0,,
6752,1,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,,BAO_0000219,,Cricetulus griseus,,Intermediate,10503,,N,1,CHEMBL884013,185.0,,
6753,1,In vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,,BAO_0000219,,Cricetulus griseus,,Expert,10503,,N,1,CHEMBL622723,185.0,,
6754,1,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,,BAO_0000219,,Cricetulus griseus,,Intermediate,10503,,N,1,CHEMBL622724,185.0,,
6755,1,Tested for growth inhibition against AA8 tumor cell line(chinese hamster ovary).,,BAO_0000219,,Cricetulus griseus,,Expert,15090,,N,1,CHEMBL622725,185.0,,
6756,1,Cytotoxicity against AA8 cell line,,BAO_0000219,,Cricetulus griseus,,Expert,10368,,N,1,CHEMBL622726,185.0,,
6757,1,Hypersensitivity factor(HF) was determined as ratio of IC50(AA8) to IC50(UV4),,BAO_0000219,,Cricetulus griseus,,Intermediate,12651,,N,1,CHEMBL622727,185.0,,
6758,1,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),,BAO_0000219,,Cricetulus griseus,,Intermediate,12687,,N,1,CHEMBL622728,185.0,,
6759,1,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),,BAO_0000219,,Cricetulus griseus,,Intermediate,12687,,N,1,CHEMBL622729,185.0,,
6760,1,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),,BAO_0000219,,Cricetulus griseus,,Intermediate,12687,,N,1,CHEMBL622730,185.0,,
6761,1,Compound was evaluated for cytotoxicity against CHO AA8 cell lines for 4 hr at pH-7.4,,BAO_0000219,,Cricetulus griseus,,Intermediate,1890,,N,1,CHEMBL622731,185.0,,
6762,1,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,,BAO_0000219,,Cricetulus griseus,,Intermediate,10747,,N,1,CHEMBL622732,185.0,,
6763,1,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,,BAO_0000219,,Cricetulus griseus,,Intermediate,10747,,N,1,CHEMBL622733,185.0,,
6764,1,Maximum tolerated dose (MTD) in C3H/HeN mice (single ip dose),,BAO_0000218,,Cricetulus griseus,,Autocuration,11616,,U,0,CHEMBL622734,,,
6765,1,Concentration required to increase radiation sensitivity by 1.3 when AA8 cells are exposed to drug for 30 min before and during irradiation under hypoxic condition.,,BAO_0000219,,Cricetulus griseus,,Expert,11616,,N,1,CHEMBL622735,185.0,,
6766,1,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under anoxic conditions,,BAO_0000219,,Cricetulus griseus,,Autocuration,3471,,U,0,CHEMBL618746,185.0,,
6767,1,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under anoxic conditions,,BAO_0000219,,Cricetulus griseus,,Autocuration,3471,,U,0,CHEMBL618747,185.0,,
6768,1,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under anoxic conditions,,BAO_0000219,,Cricetulus griseus,,Autocuration,3471,,U,0,CHEMBL620540,185.0,,
6769,1,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under aerobic conditions,,BAO_0000219,,Cricetulus griseus,,Autocuration,3471,,U,0,CHEMBL620541,185.0,,
6770,1,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under aerobic conditions,,BAO_0000219,,Cricetulus griseus,,Autocuration,3471,,U,0,CHEMBL620542,185.0,,
6771,1,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under aerobic conditions,,BAO_0000219,,Cricetulus griseus,,Autocuration,3471,,U,0,CHEMBL620543,185.0,,
6772,1,Ratio of oxygen dependence of cytotoxicities of AA8 cells in aerobic condition to anoxic condition,,BAO_0000219,,Cricetulus griseus,,Autocuration,3471,,U,0,CHEMBL618832,185.0,,
6773,1,Concentration required to reduce AA8 cell survival by 10%,,BAO_0000219,,Cricetulus griseus,,Expert,11616,,N,1,CHEMBL618833,185.0,,
6774,1,"Concentration required to reduce cell survival to 10% of controls under hypoxic conditions, using the AA8 (chinese hamster) aerobic cells",,BAO_0000219,,Cricetulus griseus,,Autocuration,2656,,U,0,CHEMBL618834,185.0,,
6775,1,Tested for the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,,BAO_0000219,,Cricetulus griseus,,Autocuration,10518,,U,0,CHEMBL618835,185.0,,
6776,1,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,,BAO_0000219,,Cricetulus griseus,,Autocuration,10518,,U,0,CHEMBL618836,185.0,,
6777,1,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 0.8-1.5,,BAO_0000219,,Cricetulus griseus,,Autocuration,10518,,U,0,CHEMBL618837,185.0,,
6778,1,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 1-2,,BAO_0000219,,Cricetulus griseus,,Autocuration,10518,,U,0,CHEMBL618838,185.0,,
6779,1,Ability to reduce cell density of AA8 cells to 50% after 4 hr of exposure to air,,BAO_0000219,,Cricetulus griseus,,Autocuration,16156,,U,0,CHEMBL618839,185.0,,
6780,1,Aerobic cytotoxic activity was evaluated by the growth inhibition of AA8 (chinese hamster) aerobic cells,,BAO_0000219,,Cricetulus griseus,,Autocuration,2656,,U,0,CHEMBL618840,185.0,,
6781,1,"Compound was evaluated for the inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",,BAO_0000019,,Cricetulus griseus,,Autocuration,11005,,U,0,CHEMBL618841,,,
6782,1,Concentration for 50% inhibition of AA8 cells growth under aerobic conditions after 18 hours exposure,,BAO_0000219,,Cricetulus griseus,,Autocuration,11942,,U,0,CHEMBL618842,185.0,,
6783,1,Concentration required for 50% inhibition of growth of AA8 cells following 4 hr drug exposure,,BAO_0000219,,Cricetulus griseus,,Autocuration,2128,,U,0,CHEMBL618843,185.0,,
6784,1,Half life period after 15 mg/kg iv dose in Dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,16907,In vivo,N,1,CHEMBL618844,,,
6785,1,Half life period after 30 mg/kg po dose in Dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,16907,In vivo,N,1,CHEMBL618845,,,
6786,1,Half life was measured after oral 2b administration (tested in 6 dogs),,BAO_0000218,,Canis lupus familiaris,,Intermediate,9579,In vivo,N,1,CHEMBL618846,,,
6787,1,Half life was measured in dog after oral 17b administration,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9579,In vivo,N,1,CHEMBL618847,,,
6788,1,Pharmacokinetic parameter T max determined in dog after oral administration of 17b,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9579,In vivo,N,1,CHEMBL618848,,,
6789,1,Pharmacokinetic parameter T max determined in dog after oral administration of 2b,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9579,In vivo,N,1,CHEMBL618849,,,
6790,1,Tmax value after 15 mg/kg iv dose in Dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,16907,In vivo,N,1,CHEMBL618850,,,
6791,1,Tmax value after 30 mg/kg po dose in Dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,16907,In vivo,N,1,CHEMBL618851,,,
6792,1,Compound was evaluated for its half life when administered intravenously in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,3184,In vivo,N,1,CHEMBL873815,,,
6793,1,Compound was tested for plasma half life when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,5017,In vivo,N,1,CHEMBL618852,,1969.0,
6794,1,Elimination Half-life of compound was determined in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6821,,N,1,CHEMBL618853,,,
6795,1,Half life of compound in dog following oral administration,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17839,In vivo,N,1,CHEMBL618854,,,
6796,1,Half life of compound was determined in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17267,,N,1,CHEMBL618855,,,
6797,1,Half life of compound was determined in dog blood,Blood,BAO_0000218,,Canis lupus familiaris,,Intermediate,4727,,N,1,CHEMBL618856,,178.0,
6798,1,Half life after oral and iv dosing in dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5238,In vivo,N,1,CHEMBL875827,,,
6799,1,Half life in dogs in hours,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4942,,N,1,CHEMBL618857,,,
6800,1,Half life on i.v. administration of 2 mg/kg was measured in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6505,In vivo,N,1,CHEMBL618858,,,
6801,1,t1/2 in dog after oral dose (1 mg/kg),,BAO_0000218,,Canis lupus familiaris,,Intermediate,5130,In vivo,N,1,CHEMBL618859,,,
6802,1,Half life was evaluated in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,1475,,N,1,CHEMBL618860,,,
6803,1,Half life period of compound was determined after intravenous administration at 2 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17804,In vivo,N,1,CHEMBL618861,,,
6804,1,Half life period of compound was determined after peroral administration at 2 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17804,In vivo,N,1,CHEMBL622539,,,
6805,1,Half life period (10 mg/kg) was determined in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6084,In vivo,N,1,CHEMBL622540,,,
6806,1,Half life period (10 mg/kg) was determined in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6084,In vivo,N,1,CHEMBL873803,,,
6807,1,Half life period by iv administration in dog at a dose of 0.3 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5542,In vivo,N,1,CHEMBL873804,,,
6808,1,Half life period by po administration in dog at a dose of 0.3 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5542,In vivo,N,1,CHEMBL624311,,,
6809,1,Half life period in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6084,,N,1,CHEMBL624312,,,
6810,1,Half life period in dogs after oral administration at 1 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6241,In vivo,N,1,CHEMBL624313,,,
6811,1,Half life period was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,BAO_0000218,,Canis lupus familiaris,,Intermediate,1916,In vivo,N,1,CHEMBL624314,,,
6812,1,Half-life of compound was determined in dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6621,,N,1,CHEMBL624315,,,
6813,1,Half-life in dog plasma,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,1696,,N,1,CHEMBL624316,,1969.0,
6814,1,Half-life in mongrel dogs was determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17800,,N,1,CHEMBL624317,,,
6815,1,Half-life in dog upon oral administration,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17657,In vivo,N,1,CHEMBL624318,,,
6816,1,Half-life in dog upon oral administration; Unable to calculate,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17657,In vivo,N,1,CHEMBL624319,,,
6817,1,Half-life was measured in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4239,,N,1,CHEMBL624496,,,
6818,1,Half-life was measured in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5985,,N,1,CHEMBL624497,,,
6819,1,Half-recovery time (T1/2) of the vascular resistance decrease at ED30 in anesthetized dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9932,,N,1,CHEMBL624498,,,
6820,1,Oral half life was determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5199,In vivo,N,1,CHEMBL624499,,,
6821,1,Plasma elimination half-life (08 h) was determined in canine following intravenous (iv) administration (1 mg/kg).,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,5199,In vivo,N,1,CHEMBL624500,,1969.0,
6822,1,Plasma half life was evaluated,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,1475,,N,1,CHEMBL624501,,1969.0,
6823,1,Plasma half life was evaluated in Dog,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,1475,,N,1,CHEMBL623666,,1969.0,
6824,1,Plasma half life was evaluated in dog,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,1475,,N,1,CHEMBL623667,,1969.0,
6825,1,T1/2 (Half-life) was after oral administration at 5 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6316,In vivo,N,1,CHEMBL623668,,,
6826,1,Tested for the half life value in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4883,,N,1,CHEMBL623669,,,
6827,1,Maximum time at the dose of 2 mg/kg in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4727,In vivo,N,1,CHEMBL623670,,,
6828,1,Maximum time was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,BAO_0000218,,Canis lupus familiaris,,Intermediate,1916,In vivo,N,1,CHEMBL623671,,,
6829,1,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,Blood,BAO_0000218,,Canis lupus familiaris,,Intermediate,1337,In vivo,N,1,CHEMBL875945,,178.0,
6830,1,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,Blood,BAO_0000218,,Canis lupus familiaris,,Intermediate,1337,In vivo,N,1,CHEMBL623672,,178.0,
6831,1,Pharmacokinetic (PK) property (Tmax) was determined in dog at the single dose of 1 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6265,In vivo,N,1,CHEMBL623673,,,
6832,1,Pharmacokinetic parameter Tmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),,BAO_0000218,,Canis lupus familiaris,,Intermediate,4809,In vivo,N,1,CHEMBL623674,,,
6833,1,Pharmacokinetic property (Tmax) was measured in dog at the dose of 0.032 mg/kg p.o.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5983,In vivo,N,1,CHEMBL623675,,,
6834,1,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog",,BAO_0000218,,Canis lupus familiaris,,Intermediate,5313,,N,1,CHEMBL872526,,,
6835,1,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog at dosage of 10 mpk",,BAO_0000218,,Canis lupus familiaris,,Intermediate,5313,In vivo,N,1,CHEMBL623676,,,
6836,1,Time for maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,17650,In vivo,N,1,CHEMBL623677,,1969.0,
6837,1,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,5199,In vivo,N,1,CHEMBL623678,,1969.0,
6838,1,Time taken for maximum plasma concentration in dog,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,933,,N,1,CHEMBL623679,,1969.0,
6839,1,Time to reach Cmax after oral administration to dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,16367,In vivo,N,1,CHEMBL623680,,,
6840,1,Time to reach maximum plasma concentration was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,6348,In vivo,N,1,CHEMBL623681,,1969.0,
6841,1,Tmax (time to reach maximum concentration) was after oral administration at 5 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6316,In vivo,N,1,CHEMBL623682,,,
6842,1,Tmax after peroral administration (1 mg/kg) was determined in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6215,In vivo,N,1,CHEMBL623683,,,
6843,1,Tmax of compound determined in dog after iv administration at a dose of 10 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Expert,3598,In vivo,N,1,CHEMBL623684,,,
6844,1,Tmax by oral administration at a dose of 10 uM/kg in dog was determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4527,In vivo,N,1,CHEMBL622745,,,
6845,1,Tmax after peroral administration in dogs at 2.4 uM/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17764,In vivo,N,1,CHEMBL622746,,,
6846,1,In vivo Cmax in mice at dose of 100 mg/kg,,BAO_0000218,,Mus musculus,,Intermediate,5969,In vivo,N,1,CHEMBL622747,,,
6847,1,In vivo Cmax in mice at dose of 50 mg/kg,,BAO_0000218,,Mus musculus,,Intermediate,5969,In vivo,N,1,CHEMBL622748,,,
6848,1,Maximal concentration determined at a dose 10 mg/kg administered intraperitoneally to mice,,BAO_0000218,,Mus musculus,,Intermediate,4573,In vivo,N,1,CHEMBL622749,,,
6849,1,Maximum plasma concentration was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),Plasma,BAO_0000218,,Mus musculus,,Intermediate,3277,In vivo,N,1,CHEMBL622750,,1969.0,
6850,1,Maximum concentration in plasma was determined after intraperitoneal administration of 100 mg/kg in mice,Plasma,BAO_0000218,,Mus musculus,,Intermediate,17734,In vivo,N,1,CHEMBL623411,,1969.0,
6851,1,Maximum concentration obtained in mouse plasma was determined,Plasma,BAO_0000218,,Mus musculus,,Intermediate,3132,In vivo,N,1,CHEMBL875946,,1969.0,
6852,1,Maximum concentration obtained in mouse plasma was determined at dose 25 mg/kg,Plasma,BAO_0000218,,Mus musculus,,Intermediate,3132,In vivo,N,1,CHEMBL623412,,1969.0,
6853,1,Maximum plasma concentration of compound was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,Plasma,BAO_0000218,,Mus musculus,,Intermediate,6348,In vivo,N,1,CHEMBL623413,,1969.0,
6854,1,Maximum plasma concentration when injected i.p. in mice at a dose of 50 mg/kg,Plasma,BAO_0000218,,Mus musculus,,Intermediate,17729,In vivo,N,1,CHEMBL623414,,1969.0,
6855,1,Maximum plasma concentration when injected intravenously in mice at a dose of 20 mg/kg,Plasma,BAO_0000218,,Mus musculus,,Intermediate,17729,In vivo,N,1,CHEMBL623415,,1969.0,
6856,1,Maximum plasma concentration when injected perorally in mice at a dose of 50 mg/kg,Plasma,BAO_0000218,,Mus musculus,,Intermediate,17729,In vivo,N,1,CHEMBL623416,,1969.0,
6857,1,Maximal plasma concentration in BALB/C mice after 20 mg/kg intraperitoneal dose,Plasma,BAO_0000218,,Mus musculus,,Intermediate,17728,In vivo,N,1,CHEMBL623417,,1969.0,
6858,1,Maximal plasma concentration in BALB/C mice after 20 mg/kg intravenous dose,Plasma,BAO_0000218,,Mus musculus,,Intermediate,17728,In vivo,N,1,CHEMBL623418,,1969.0,
6859,1,Maximal plasma concentration in BALB/C mice after 50 mg/kg oral dose,Plasma,BAO_0000218,,Mus musculus,,Intermediate,17728,In vivo,N,1,CHEMBL623419,,1969.0,
6860,1,Peak concentration at a single subcutaneous administration of 40 mg/kg in mice,,BAO_0000218,,Mus musculus,,Intermediate,4066,In vivo,N,1,CHEMBL622816,,,
6861,1,Pharmacokinetic property (C(max)) was determined after ip administration of 32 mg/kg in mice,,BAO_0000218,,Mus musculus,,Intermediate,6178,In vivo,N,1,CHEMBL623313,,,
6862,1,Pharmacokinetic property (C(max)) was determined after po administration of 32 mg/kg in mice,,BAO_0000218,,Mus musculus,,Intermediate,6178,In vivo,N,1,CHEMBL623314,,,
6863,1,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg intravenously in mice,,BAO_0000218,,Mus musculus,,Intermediate,3760,In vivo,N,1,CHEMBL876788,,,
6864,1,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg perorally in mice,,BAO_0000218,,Mus musculus,,Intermediate,3760,In vivo,N,1,CHEMBL623315,,,
6865,1,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg intravenously in mice,,BAO_0000218,,Mus musculus,,Intermediate,3760,In vivo,N,1,CHEMBL623316,,,
6866,1,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg perorally in mice,,BAO_0000218,,Mus musculus,,Intermediate,3760,In vivo,N,1,CHEMBL623317,,,
6868,1,Cmax in male mice after 2 mg/kg oral dose,,BAO_0000218,,Mus musculus,,Intermediate,5961,In vivo,N,1,CHEMBL623319,,,
6869,1,Plasma concentration of 5-FU in HT-3 (human cervical cancer) xenograft mice at 1.38 mg/kg oral dose co-administered with 135 mg/kg Capecitabine,,BAO_0000218,,Mus musculus,,Intermediate,6137,In vivo,N,1,CHEMBL623320,,,
6870,1,Tested for Cmax value at the dose of 10 mg/kg when administered perorally in mouse,,BAO_0000218,,Mus musculus,,Intermediate,3802,In vivo,N,1,CHEMBL623321,,,
6871,1,Concentration in plasma (systemic) following oral dose in mouse at 0.25 hr,,BAO_0000218,,Mus musculus,,Intermediate,3535,,N,1,CHEMBL623322,,,
6872,1,Concentration in plasma (systemic) following oral dose in mouse at 1 hr,,BAO_0000218,,Mus musculus,,Intermediate,3535,,N,1,CHEMBL623323,,,
6873,1,Concentration in plasma (systemic) following oral dose in mouse at 24 hr,,BAO_0000218,,Mus musculus,,Intermediate,3535,,N,1,CHEMBL623324,,,
6874,1,Concentration in plasma (systemic) following oral dose in mouse at 2 hr,,BAO_0000218,,Mus musculus,,Intermediate,3535,,N,1,CHEMBL623325,,,
6875,1,Concentration in plasma (systemic) following oral dose in mouse at 4 hr,,BAO_0000218,,Mus musculus,,Intermediate,3535,,N,1,CHEMBL623326,,,
6876,1,Concentration in plasma (systemic) following oral dose in mouse at 6 hr,,BAO_0000218,,Mus musculus,,Intermediate,3535,,N,1,CHEMBL623327,,,
6877,1,Maximum concentration in plasma upon oral administration in mouse,Plasma,BAO_0000218,,Mus musculus,,Intermediate,2862,,N,1,CHEMBL623328,,1969.0,
6878,1,Maximum plasma concentration was evaluated in mice after oral administration,Plasma,BAO_0000218,,Mus musculus,,Intermediate,2675,,N,1,CHEMBL623329,,1969.0,
6879,1,Maximum plasma concentration was evaluated in mice after intravenous administration; Cp max Not determined,Plasma,BAO_0000218,,Mus musculus,,Intermediate,2675,In vivo,N,1,CHEMBL623330,,1969.0,
6880,1,Dose at which the compound induced fecal excretion in mice,,BAO_0000218,,Mus musculus,,Intermediate,5399,,N,1,CHEMBL876789,,,
6893,1,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.01 uM,,BAO_0000219,,Rattus norvegicus,,Expert,11819,,N,1,CHEMBL623333,164.0,,
6894,1,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.1 uM,,BAO_0000219,,Rattus norvegicus,,Expert,11819,,N,1,CHEMBL623334,164.0,,
6895,1,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 1.0 uM,,BAO_0000219,,Rattus norvegicus,,Expert,11819,,N,1,CHEMBL627536,164.0,,
6896,1,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 10.0 uM,,BAO_0000219,,Rattus norvegicus,,Expert,11819,,N,1,CHEMBL627537,164.0,,
6897,1,In vitro [14C]- creatine uptake (1 mM) was determined in rat A10 smooth muscle cells at a concentration of (1 mM),,BAO_0000219,,Rattus norvegicus,,Intermediate,16361,,N,1,CHEMBL627538,164.0,,
6898,1,Cytotoxicity was evaluated against A121 ovarian carcinoma human cancer cell line,,BAO_0000219,,Homo sapiens,,Intermediate,2288,,N,1,CHEMBL884106,393.0,,
6899,1,Anticancer activity against human ovarian carcinoma A121 cells,,BAO_0000219,,Homo sapiens,,Intermediate,10404,,N,1,CHEMBL625294,393.0,,
6900,1,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 16.6 mM,,BAO_0000219,,Homo sapiens,,Intermediate,14790,,N,1,CHEMBL625295,393.0,,
6901,1,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 83 mM,,BAO_0000219,,Homo sapiens,,Intermediate,14790,,N,1,CHEMBL625296,393.0,,
6902,1,Growth inhibition of human ovarian carcinoma (A121) cell line,,BAO_0000219,,Homo sapiens,,Expert,14253,,N,1,CHEMBL625297,393.0,,
6903,1,Concentration required to inhibit growth of human tumor A121 (ovarian) cell line.,,BAO_0000219,,Homo sapiens,,Expert,13617,,N,1,CHEMBL625298,393.0,,
6904,1,Cytotoxicity against human A121 ovarian cells,,BAO_0000219,,Homo sapiens,,Intermediate,1003,,N,1,CHEMBL625960,393.0,,
6905,1,Cytotoxicity was evaluated in vitro against A121 (ovarian carcinoma) human tumor cell lines,,BAO_0000219,,Homo sapiens,,Intermediate,830,,N,1,CHEMBL625961,393.0,,
6906,1,In vitro cytotoxicity against human ovarian carcinoma A21,,BAO_0000219,,Homo sapiens,,Intermediate,12307,,N,1,CHEMBL625962,393.0,,
6907,1,Inhibition of the growth against human Ovarian Carcinoma (A121) cell line after 72 hr exposure,,BAO_0000219,,Homo sapiens,,Intermediate,14254,,N,1,CHEMBL624717,393.0,,
6908,1,Inhibitory activity of compound against human A121 ovarian cell line.,,BAO_0000219,,Homo sapiens,,Intermediate,13370,,N,1,CHEMBL624718,393.0,,
6909,1,Dose at which compound exhibits cytotoxicity in the A121 ovarian carcinoma cell line.,,BAO_0000219,,Homo sapiens,,Intermediate,14790,,N,1,CHEMBL624719,393.0,,
6910,1,Inhibition of growth of human ovarian tumor cell line (A121) after 72 hr of drug exposure,,BAO_0000219,,Homo sapiens,,Intermediate,3614,,N,1,CHEMBL624720,393.0,,
6911,1,Compound was evaluated for in vitro antiproliferative activity against A172 human CNS cancer cell line,,BAO_0000219,,Homo sapiens,,Intermediate,2664,,N,1,CHEMBL624721,622.0,,
6912,1,In vitro cytotoxicity against A172 human tumor cell lines.,,BAO_0000219,,Homo sapiens,,Expert,2037,,N,1,CHEMBL624722,622.0,,
6913,1,Growth inhibition time for A172 Human Glioma cell growth at concentration 5 uM,,BAO_0000219,,Homo sapiens,,Intermediate,14539,,N,1,CHEMBL877597,622.0,,
6914,1,Compound was evaluated for cytotoxicity against human glioblastoma (A172) cell line,,BAO_0000219,,Homo sapiens,,Intermediate,2836,,N,1,CHEMBL624723,622.0,,
6915,1,Evaluated for the inhibitory concentration required to cause growth inhibition of A172Mer- cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay,,BAO_0000219,,Homo sapiens,,Intermediate,10708,,N,1,CHEMBL624724,622.0,,
6916,1,Association constant against A2 adenosine receptor,,BAO_0000224,,Canis lupus familiaris,,Autocuration,8975,,H,4,CHEMBL624725,,,
6917,1,In vitro effective dose that causes 50% inhibition of growth of A2 cell line - amelanotic melanoma,,BAO_0000219,,fish,,Intermediate,7645,,N,1,CHEMBL624726,1085.0,,
6918,1,Ratio of Ki for adenosine A2 and A1 receptor binding,,BAO_0000224,,Rattus norvegicus,,Autocuration,11377,,D,5,CHEMBL857535,,,
6919,1,In vitro cytotoxicity against A204 human rhabdomyosarcoma cancer cell line,,BAO_0000219,,Homo sapiens,,Expert,13528,,N,1,CHEMBL624727,623.0,,
6920,1,In vitro antitumor activity against A204 rhabdomyosarcoma tumor cell line was determined,,BAO_0000219,,Homo sapiens,,Expert,10160,,N,1,CHEMBL624728,623.0,,
6921,1,The compound was tested in vitro for antiproliferative activity against A2058 tumor cell lines,,BAO_0000219,,Homo sapiens,,Intermediate,15144,,N,1,CHEMBL624729,404.0,,
6922,1,Growth inhibition against Human squamous cell line(A 253),,BAO_0000219,,Homo sapiens,,Intermediate,13160,,N,1,CHEMBL624730,973.0,,
6923,1,Growth inhibition of human squamous carcinoma cell lines following continuous (120 hours) exposure to MTX and compound A253 cell line,,BAO_0000219,,Homo sapiens,,Intermediate,12898,,N,1,CHEMBL624731,973.0,,
6924,1,The compound was tested for Growth inhibition of the human squamous cell carcinoma A253 cells,,BAO_0000219,,Homo sapiens,,Intermediate,13069,,N,1,CHEMBL624732,973.0,,
6925,1,Growth inhibition of A253 cell lines.,,BAO_0000219,,Homo sapiens,,Intermediate,15984,,N,1,CHEMBL883245,973.0,,
6926,1,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h),,BAO_0000219,,Homo sapiens,,Intermediate,15564,,N,1,CHEMBL624733,973.0,,
6927,1,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,,BAO_0000219,,Homo sapiens,,Intermediate,15564,,N,1,CHEMBL624734,973.0,,
6928,1,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,,BAO_0000219,,Homo sapiens,,Intermediate,15564,,N,1,CHEMBL624735,973.0,,
6929,1,In vitro cytotoxicity causing 50% growth inhibition was determined against A270 (human ovarian cancer)cell line,,BAO_0000219,,Homo sapiens,,Intermediate,4720,,N,1,CHEMBL621780,478.0,,
6930,1,Antitumor activity of compound for 96-h exposure in A2780 human ovarian cell line,,BAO_0000219,,Homo sapiens,,Intermediate,16112,,N,1,CHEMBL877598,478.0,,
6931,1,Cytotoxic activity against A2780 human ovarian carcinoma cell line,,BAO_0000219,,Homo sapiens,,Expert,16597,,N,1,CHEMBL621781,478.0,,
6932,1,Cytotoxicity against human cancer cell lines A2780 (ovarian),,BAO_0000219,,Homo sapiens,,Intermediate,16378,,N,1,CHEMBL621782,478.0,,
6933,1,Growth and colony formation inhibition of A2780 ovarian cancer cell lines,,BAO_0000219,,Homo sapiens,,Expert,16085,,N,1,CHEMBL621783,478.0,,
6934,1,Inhibition of cell growth in human ovarian carcinoma cell line (A2780) using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay,,BAO_0000219,,Homo sapiens,,Intermediate,16317,,N,1,CHEMBL621784,478.0,,
6935,1,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),,BAO_0000219,,Homo sapiens,,Intermediate,15748,,N,1,CHEMBL621785,478.0,,
6936,1,Inhibition of A2780 / DDP-R human ovarian carcinoma cell proliferation,,BAO_0000219,,Homo sapiens,,Expert,16597,,N,1,CHEMBL621968,478.0,,
6937,1,Inhibition of A2780 / TAX-R human ovarian carcinoma cell proliferation,,BAO_0000219,,Homo sapiens,,Expert,16597,,N,1,CHEMBL621969,478.0,,
6938,1,Inhibition of A2780 / TAX-S human ovarian carcinoma cell proliferation,,BAO_0000219,,Homo sapiens,,Expert,16597,,N,1,CHEMBL621970,478.0,,
6939,1,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 2,,BAO_0000219,,Homo sapiens,,Intermediate,15608,,N,1,CHEMBL621971,478.0,,
6940,1,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 3,,BAO_0000219,,Homo sapiens,,Intermediate,15608,,N,1,CHEMBL621972,478.0,,
6941,1,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 5,,BAO_0000219,,Homo sapiens,,Intermediate,15608,,N,1,CHEMBL884108,478.0,,
6942,1,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,,BAO_0000019,,Cricetulus griseus,,Autocuration,15296,,U,0,CHEMBL623826,,,
6943,1,Evaluated for cytotoxicity under aerobic conditions against AA8 cells using microassay,,BAO_0000219,,Cricetulus griseus,,Autocuration,10251,,U,0,CHEMBL623827,185.0,,
6944,1,Evaluated for growth inhibition of AA8 cells under aerobic conditions,,BAO_0000219,,Cricetulus griseus,,Autocuration,10251,,U,0,CHEMBL623828,185.0,,
6945,1,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions,,BAO_0000219,,Cricetulus griseus,,Autocuration,10251,,U,0,CHEMBL623829,185.0,,
6946,1,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions (air/N2),,BAO_0000219,,Cricetulus griseus,,Autocuration,10251,,U,0,CHEMBL623830,185.0,,
6947,1,Growth inhibition against CHO-derived cell line AA8,,BAO_0000019,,Cricetulus griseus,,Autocuration,11858,,U,0,CHEMBL623831,,,
6948,1,Growth inhibition against CHO-derived cell line AA8 (Non toxic at solubility limit) [RB6145 used as positive control],,BAO_0000219,,Cricetulus griseus,,Autocuration,11858,,U,0,CHEMBL623832,185.0,,
6949,1,Growth inhibition in CHO subline AA8 cells exposed for 18 hr under aerobic(air) conditions,,BAO_0000219,,hampster,,Expert,11616,,N,1,CHEMBL623833,185.0,,
6950,1,Growth inhibitory activity against CHO subline AA8 cells exposed for 18 hr under aerobic conditions,,BAO_0000219,,Cricetulus griseus,,Expert,11616,,N,1,CHEMBL623834,185.0,,
6951,1,Tested for the concentration of the drug to reduce cell numbers to 50 percent of controls against AA8 cells in the microassay,,BAO_0000219,,Cricetulus griseus,,Autocuration,10518,,U,0,CHEMBL623835,185.0,,
6952,1,Growth inhibition of aerobic chinese hamster ovary fibroblast AA8 cell line using an exposure time of 18 hours,,BAO_0000219,,Cricetulus griseus,,Autocuration,11396,,U,0,CHEMBL623836,185.0,,
6953,1,IC50 (air/N2) ratio of the drug to reduce cell numbers to 50 percent of controls using AA8 cells in the microassay,,BAO_0000219,,Cricetulus griseus,,Autocuration,10518,,U,0,CHEMBL623837,185.0,,
6954,1,In vitro therapeutic index as ratio of CT10 and C1.3 calculated for AA8 cells.,,BAO_0000219,,Cricetulus griseus,,Expert,11616,,N,1,CHEMBL623838,185.0,,
6955,1,compound was evaluated for association constant (Ka) of isolated serum protein AAG,,BAO_0000019,,,,Autocuration,14837,,H,8,CHEMBL623839,,,
6956,1,Number of binding sites (n) of isolated serum protein AAG,,BAO_0000019,,,,Autocuration,14837,,H,8,CHEMBL623840,,,
6957,1,Association constant for binding to AATT duplex,,BAO_0000225,,,,Intermediate,16037,,M,3,CHEMBL623841,,,
6958,1,Inhibition of ABAE human fibroblast cell proliferation,,BAO_0000219,,Homo sapiens,,Expert,16597,,N,1,CHEMBL623842,416.0,,
6959,1,"Compound was evaluated for the antitumor activity against AC755 breast carcinoma for ip administration and daily x 10 schedule; Number of toxic deaths over total number of mice per group (T/C), 1/7 at dose of 25 mg/kg",,BAO_0000218,,Mus musculus,,Intermediate,8831,,N,1,CHEMBL623843,1064.0,,
6960,1,Percent change in total cholesterol(TC) versus (T0)- at which drug intervention begins at a dose of 25 mg/kg in the chronic cholesterol-fed rabbit model,,BAO_0000218,,Oryctolagus cuniculus,,Expert,13419,,D,9,CHEMBL618669,,,
6961,1,Oral bioactivity expressed as %inhibition after 4 hours of drug administration (dose 25 mg/kg) in rabbit bioassay,,BAO_0000218,,Oryctolagus cuniculus,,Expert,13419,In vivo,D,9,CHEMBL618670,,,
6962,1,Inhibitory activity against angiotensin-converting enzyme (ACE).,,BAO_0000357,,,,Autocuration,15778,,H,8,CHEMBL618671,,,
6963,1,oral activity against angiotensin -converting enzyme ( ACE) and neutral endopeptidase in mouse.,,BAO_0000357,,,,Autocuration,15778,,H,8,CHEMBL618672,,,
6964,1,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells,,BAO_0000219,,Homo sapiens,,Intermediate,12988,,N,1,CHEMBL618673,978.0,,
6965,1,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells in the presence of PMA(phorbol 12-myristate 13-acetate),,BAO_0000219,,Homo sapiens,,Intermediate,12988,,N,1,CHEMBL618674,978.0,,
6966,1,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2,,BAO_0000219,,Human immunodeficiency virus 1,,Autocuration,12988,,U,0,CHEMBL618675,998.0,,
6967,1,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2 in the presence of PMA(phorbol 12-myristate 13-acetate),,BAO_0000219,,Human immunodeficiency virus 1,,Autocuration,12988,,U,0,CHEMBL618676,998.0,,
6968,1,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2i n the presence of PMA(phorbol 12-myristate 13-acetate),,BAO_0000219,,Human immunodeficiency virus 1,,Autocuration,12988,,U,0,CHEMBL618677,998.0,,
6969,1,Inhibition of growth of renal cancer ACHN cell line,,BAO_0000219,,Homo sapiens,,Intermediate,11843,,N,1,CHEMBL618678,626.0,,
6970,1,Inhibition of growth of ACHN renal cancer cell line,,BAO_0000219,,Homo sapiens,,Intermediate,16939,,N,1,CHEMBL618679,626.0,,
6971,1,Inhibitory concentration required against ACHN renal cancer cell line,,BAO_0000219,,Homo sapiens,,Intermediate,4782,,N,1,CHEMBL618680,626.0,,
6972,1,Concentration required to inhibit growth of human renal (ACHN) cell line,,BAO_0000219,,Homo sapiens,,Expert,6310,,N,1,CHEMBL618681,626.0,,
6973,1,Concentration required to inhibit growth of human renal (ACHN) cell line; nt = not tested,,BAO_0000219,,Homo sapiens,,Intermediate,6310,,N,1,CHEMBL618682,626.0,,
6974,1,Cytotoxic activity against ACHN Renal cancer cell line,,BAO_0000219,,Homo sapiens,,Intermediate,12858,,N,1,CHEMBL618683,626.0,,
6975,1,Cytotoxicity evaluation against ACHN renal cancer cells,,BAO_0000219,,Homo sapiens,,Intermediate,17380,,N,1,CHEMBL618684,626.0,,
6976,1,In vitro antitumor activity against human renal ACHN cell line,,BAO_0000219,,Homo sapiens,,Intermediate,5858,,N,1,CHEMBL618685,626.0,,
6977,1,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,,BAO_0000219,,Homo sapiens,,Intermediate,3838,,N,1,CHEMBL876499,626.0,,
6978,1,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,,BAO_0000219,,Homo sapiens,,Intermediate,3838,,N,1,CHEMBL618686,626.0,,
6979,1,"Tested for the cytotoxicity against the Renal cancer cell line ACHN, growth inhibition by 50% is reported",,BAO_0000219,,Homo sapiens,,Intermediate,5406,,N,1,CHEMBL618687,626.0,,
6980,1,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,,BAO_0000219,,Homo sapiens,,Intermediate,4071,,N,1,CHEMBL618688,626.0,,
6981,1,Tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,,BAO_0000219,,Homo sapiens,,Expert,4071,,N,1,CHEMBL618689,626.0,,
6982,1,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal); Not determined,,BAO_0000219,,Homo sapiens,,Intermediate,4071,,N,1,CHEMBL618690,626.0,,
6983,1,Antitumor activity was evaluated against human renal adenocarcinoma cell line ACHN.,,BAO_0000219,,Homo sapiens,,Intermediate,15002,,N,1,CHEMBL618691,626.0,,
6984,1,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),,BAO_0000219,,Homo sapiens,,Intermediate,14769,,N,1,CHEMBL619373,626.0,,
6985,1,"Compound was tested for antiproliferative activity against ACHN, human renal adenocarcinoma",,BAO_0000219,,Homo sapiens,,Intermediate,13958,,N,1,CHEMBL884008,626.0,,
6986,1,Compound was tested for its effect on the proliferation of ACHN human kidney adenocarcinoma,,BAO_0000219,,Homo sapiens,,Intermediate,1665,,N,1,CHEMBL619374,626.0,,
6987,1,Compound was tested for the growth inhibition of ACHN renal tumor cell line,,BAO_0000219,,Homo sapiens,,Intermediate,15354,,N,1,CHEMBL619375,626.0,,
6988,1,Compound was tested for the growth inhibition of ACHN renal tumor cell line; ND=Not determined,,BAO_0000219,,Homo sapiens,,Intermediate,15354,,N,1,CHEMBL619376,626.0,,
6989,1,In vitro Growth Inhibitory activity against ACHN Human kidney cancer cell line,,BAO_0000219,,Homo sapiens,,Intermediate,13978,,N,1,CHEMBL619377,626.0,,
6990,1,In vitro cytotoxicity against human renal adenocarcinoma (ACHN) tumor cell line,,BAO_0000219,,Homo sapiens,,Intermediate,6798,,N,1,CHEMBL619378,626.0,,
6991,1,Tmax value after administration of 4 mg/Kg oral dose in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,2959,In vivo,N,1,CHEMBL872527,,,
6992,1,"Time to peak response on lowering of vascular resistance, in dogs when administered intravenously",,BAO_0000218,,Canis lupus familiaris,,Intermediate,9932,,N,1,CHEMBL876500,,,
6993,1,Unbound plasma was determined in Beagle dog at a dose of 1 mg/kg by iv administration,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5546,,N,1,CHEMBL619379,,,
6994,1,Volume distribution after 15 mg/kg iv dose in Dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,16907,In vivo,N,1,CHEMBL619538,,,
6995,1,Volume distribution after 30 mg/kg po dose in Dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,16907,In vivo,N,1,CHEMBL619539,,,
6996,1,Volume of distribution was determined in dog after a 3 mg/kg of iv dose,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4257,In vivo,N,1,CHEMBL619540,,,
6997,1,Volume of distribution was determined by iv administration in dogs at a dose of 1 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4305,In vivo,N,1,CHEMBL619541,,,
6998,1,Volume of distribution was evaluated in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5472,In vivo,N,1,CHEMBL619542,,,
6999,1,Terminal phase volume of distribution was measured in dog after an iv dose of 1 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6062,In vivo,N,1,CHEMBL619543,,,
7000,1,Apparent volume of the central plasma compartment (Vc) of compound determined in dog after iv administration at a dose of 10 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Expert,3598,,N,1,CHEMBL619544,,,
7001,1,The compound was tested for volume of distribution in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,12500,In vivo,N,1,CHEMBL619545,,,
7002,1,The compound was tested for volume of distribution in dog at dose of 3-10 mgkg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,12500,In vivo,N,1,CHEMBL619546,,,
7003,1,Vd (1 mg/kg) was determined in dog (in vivo),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6227,In vivo,N,1,CHEMBL619547,,,
7004,1,Vd in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6227,In vivo,N,1,CHEMBL619548,,,
7005,1,Volume distribution was determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4219,In vivo,N,1,CHEMBL619549,,,
7006,1,Volume of distribution in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,1696,In vivo,N,1,CHEMBL619550,,,
7007,1,Volume of distribution by as 4 fold increase by iv administration in dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5542,In vivo,N,1,CHEMBL876501,,,
7008,1,Volume of distribution was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5199,In vivo,N,1,CHEMBL619551,,,
7009,1,Volume of distribution was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6348,In vivo,N,1,CHEMBL619552,,,
7010,1,Volume distribution at the dose of 2 mg/kg in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4727,In vivo,N,1,CHEMBL619553,,,
7011,1,Steady state volume of distribution was determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,16367,In vivo,N,1,CHEMBL618722,,,
7012,1,Bioavailability as Vdss in dogs at 1 mg/kg intravenous dose,,BAO_0000218,,Canis lupus familiaris,,Intermediate,2652,In vivo,N,1,CHEMBL618723,,,
7013,1,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,16452,In vivo,N,1,CHEMBL618724,,,
7014,1,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,,BAO_0000218,,Canis lupus familiaris,,Intermediate,16452,In vivo,N,1,CHEMBL618725,,,
7015,1,Bioavailability in dog (dose 1 mg/kg i.v.),,BAO_0000218,,Canis lupus familiaris,,Intermediate,16452,In vivo,N,1,CHEMBL618726,,,
7016,1,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),,BAO_0000218,,Canis lupus familiaris,,Intermediate,5334,In vivo,N,1,CHEMBL618727,,,
7017,1,Pharmacokinetic property (vdss) was measured in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4239,In vivo,N,1,CHEMBL624233,,,
7018,1,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4709,In vivo,N,1,CHEMBL624234,,,
7019,1,Vdss was determined after iv 0.1 mg/kg administration in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5600,In vivo,N,1,CHEMBL624235,,,
7020,1,Volume displacement was calculated in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6057,In vivo,N,1,CHEMBL624236,,,
7021,1,Volume distribution (Vdss) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5654,In vivo,N,1,CHEMBL624237,,,
7022,1,Volume distribution constant was determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5505,In vivo,N,1,CHEMBL624238,,,
7023,1,Volume distribution at a dose of 1 uM/kg in dog was determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4527,In vivo,N,1,CHEMBL624239,,,
7024,1,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4521,In vivo,N,1,CHEMBL875829,,,
7025,1,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4521,In vivo,N,1,CHEMBL624240,,,
7026,1,Volume distribution (Vdss) was measured in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,15660,In vivo,N,1,CHEMBL624241,,,
7027,1,Volume distribution (Vdss) was measured in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,15660,In vivo,N,1,CHEMBL624242,,,
7028,1,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6679,In vivo,N,1,CHEMBL624243,,,
7029,1,Volume of distribution in steady state was determined in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5145,In vivo,N,1,CHEMBL624244,,,
7030,1,Volume of distribution of compound was determined in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6821,In vivo,N,1,CHEMBL624245,,,
7031,1,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4137,In vivo,N,1,CHEMBL624246,,,
7032,1,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),,BAO_0000218,,Canis lupus familiaris,,Intermediate,5334,In vivo,N,1,CHEMBL624247,,,
7033,1,Volume of distribution (Vdss) was measured in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,15660,In vivo,N,1,CHEMBL624248,,,
7034,1,Volumes of distribution in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6642,In vivo,N,1,CHEMBL624249,,,
7035,1,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6641,In vivo,N,1,CHEMBL624250,,,
7036,1,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6642,In vivo,N,1,CHEMBL624251,,,
7037,1,Maximum rate of depolarization of the upstroke of the action potential,,BAO_0000218,,Canis lupus familiaris,,Intermediate,11659,,N,1,CHEMBL624252,,,
7038,1,Steady state volume distribution in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6448,In vivo,N,1,CHEMBL624253,,,
7039,1,Steady state volume of distribution at a dose of 0.2 mg/kg i.v.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5474,In vivo,N,1,CHEMBL624950,,,
7040,1,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,1466,In vivo,N,1,CHEMBL624951,,,
7041,1,Volume distribution in dog after administration of 0.25 mg/kg iv; ND = not determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6535,In vivo,N,1,CHEMBL875830,,,
7042,1,Volume distribution in dog after administration of 1 mg/kg iv,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6535,In vivo,N,1,CHEMBL624952,,,
7043,1,Volume of solubility in solution after intravenous administration in dogs at 1.2 uM/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17764,In vivo,N,1,CHEMBL624953,,,
7044,1,Vss after intravenous administration (0.5 mg/kg) was determined in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6215,In vivo,N,1,CHEMBL624954,,,
7045,1,Vss on i.v. administration of 2 mg/kg was measured in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6505,In vivo,N,1,CHEMBL624955,,,
7046,1,Vss was determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,3639,,N,1,CHEMBL624956,,,
7047,1,Vss in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,3639,,N,1,CHEMBL625129,,,
7048,1,Volume of distribution was measured in dog after an iv dose of 1 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6062,In vivo,N,1,CHEMBL625130,,,
7049,1,Volume distribution in dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4942,In vivo,N,1,CHEMBL625131,,,
7050,1,Volume of distribution in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17796,In vivo,N,1,CHEMBL625132,,,
7051,1,Tested for the oral bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4883,In vivo,N,1,CHEMBL872263,,,
7060,1,Bioavailability of compound in mouse blood following p.o. administration of 30 mg/kg,,BAO_0000218,,Mus musculus,,Intermediate,17837,In vivo,N,1,CHEMBL624336,,,
7061,1,Bioavailability after i.p. administration of 50 mg/kg of dose in mice,,BAO_0000218,,Mus musculus,,Intermediate,17729,In vivo,N,1,CHEMBL624337,,,
7062,1,Bioavailability after peroral administration of 50 mg/kg of dose in mice,,BAO_0000218,,Mus musculus,,Intermediate,17729,In vivo,N,1,CHEMBL624338,,,
7063,1,Bioavailability was measured in mouse,,BAO_0000218,,Mus musculus,,Intermediate,4239,In vivo,N,1,CHEMBL624339,,,
7064,1,Bioavailability in mouse,,BAO_0000218,,Mus musculus,,Intermediate,17592,In vivo,N,1,CHEMBL624340,,,
7065,1,Bioavailability was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,BAO_0000218,,Mus musculus,,Intermediate,6348,In vivo,N,1,CHEMBL624341,,,
7066,1,Bioavailability in mouse,,BAO_0000218,,Mus musculus,,Intermediate,2801,In vivo,N,1,CHEMBL624342,,,
7067,1,Compound was evaluated for its bioavailability in mice at a dose of 1 mg/kg,,BAO_0000218,,Mus musculus,,Intermediate,2801,In vivo,N,1,CHEMBL624343,,,
7068,1,Oral bioavailability in mouse,,BAO_0000218,,Mus musculus,,Intermediate,17718,In vivo,N,1,CHEMBL624344,,,
7069,1,Oral availability at 50 mg/kg po in male mice,,BAO_0000218,,Mus musculus,,Intermediate,5727,In vivo,N,1,CHEMBL624345,,,
7070,1,Oral bioavailability in mouse (dose 10 mg/kg),,BAO_0000218,,Mus musculus,,Intermediate,5302,In vivo,N,1,CHEMBL624346,,,
7071,1,Oral bioavailability of compound determined in mouse after iv administration at a dose of 10 mg/kg,,BAO_0000218,,Mus musculus,,Expert,3598,In vivo,N,1,CHEMBL624347,,,
7072,1,"Bioavailability in male mice, 2mg/kg oral and 1 mg/kg intravenous dose",,BAO_0000218,,Mus musculus,,Intermediate,5961,In vivo,N,1,CHEMBL624348,,,
7074,1,Oral bioavailability in mouse,,BAO_0000218,,Mus musculus,,Intermediate,6091,In vivo,N,1,CHEMBL622754,,,
7075,1,Oral bioavailability in vivo in mice;ND=Not determined,,BAO_0000218,,Mus musculus,,Intermediate,6091,In vivo,N,1,CHEMBL622755,,,
7076,1,Oral bioavailability in mouse at 10 mg/kg of the compound,,BAO_0000218,,Mus musculus,,Intermediate,5711,In vivo,N,1,CHEMBL622756,,,
7077,1,Bioavailability in mouse (BALB/C) (dose 50 mg/kg i.p.),,BAO_0000218,,Mus musculus,,Intermediate,17728,In vivo,N,1,CHEMBL622757,,,
7078,1,Bioavailability in mouse (BALB/C) (dose 20 mg/kg i.v.),,BAO_0000218,,Mus musculus,,Intermediate,17728,In vivo,N,1,CHEMBL622758,,,
7079,1,Tested for bioavailability of the compound,,BAO_0000218,,Mus musculus,,Intermediate,3802,In vivo,N,1,CHEMBL622759,,,
7080,1,Tested for half life at the dose of 10 mg/kg when administered intravenously,,BAO_0000218,,Mus musculus,,Intermediate,3802,In vivo,N,1,CHEMBL622760,,,
7081,1,The plasma half life of compound was determined on EDTA prepared by mouse plasma. ,Plasma,BAO_0000218,,Mus musculus,,Intermediate,14029,,N,1,CHEMBL622761,,1969.0,
7082,1,The plasma half life of compound was determined on heparin prepared by human plasma. ,Plasma,BAO_0000218,,Mus musculus,,Intermediate,14029,,N,1,CHEMBL622762,,1969.0,
7083,1,The plasma half life of compound was determined on heparin prepared by human plasma; Not degraded,Plasma,BAO_0000218,,Mus musculus,,Intermediate,14029,,N,1,CHEMBL622763,,1969.0,
7084,1,The plasma half life of compound was determined on heparin prepared by mouse plasma. ,Plasma,BAO_0000218,,Mus musculus,,Intermediate,14029,,N,1,CHEMBL622764,,1969.0,
7085,1,The plasma half life of compound was determined on heparin prepared by mouse plasma; Not degraded,Plasma,BAO_0000218,,Mus musculus,,Intermediate,14029,,N,1,CHEMBL622765,,1969.0,
7086,1,Inhibitory concentration of compound was determined after intravenous administration in mice after 6 hours of exposure at 40 mg/Kg,,BAO_0000218,,Mus musculus,,Intermediate,17753,,N,1,CHEMBL622766,,,
7087,1,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 24 mg/Kg,,BAO_0000218,,Mus musculus,,Intermediate,17753,,N,1,CHEMBL622767,,,
7088,1,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 5 mg/Kg,,BAO_0000218,,Mus musculus,,Intermediate,17753,,N,1,CHEMBL622768,,,
7089,1,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Blood,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,N,1,CHEMBL875948,,178.0,
7090,1,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,Blood,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,N,1,CHEMBL622769,,178.0,
7091,1,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Blood,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,N,1,CHEMBL622770,,178.0,
7092,1,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Blood,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,N,1,CHEMBL622771,,178.0,
7093,1,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Blood,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,N,1,CHEMBL622772,,178.0,
7094,1,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Blood,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,N,1,CHEMBL622773,,178.0,
7095,1,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Blood,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,N,1,CHEMBL622774,,178.0,
7096,1,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Bone,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,N,1,CHEMBL621725,,10000001.0,
7097,1,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,Bone,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,N,1,CHEMBL621726,,10000001.0,
7098,1,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 8,,BAO_0000219,,Homo sapiens,,Intermediate,15608,,N,1,CHEMBL621727,478.0,,
7099,1,In vitro cytotoxicity against human ovarian carcinoma cell line A2780 using sulforhodamine B (SRB) assay,,BAO_0000219,,Homo sapiens,,Expert,3290,,N,1,CHEMBL622413,478.0,,
7100,1,Compound was evaluated for cytotoxicity against A2780 cell line,,BAO_0000219,,Homo sapiens,,Intermediate,2859,,N,1,CHEMBL622414,478.0,,
7101,1,Inhibition of A2780 cell clonogenic assay,,BAO_0000219,,Homo sapiens,,Expert,15688,,N,1,CHEMBL622415,478.0,,
7102,1,Cytotoxic effect on ovarian cancer cell line (A2780),,BAO_0000219,,Homo sapiens,,Expert,5642,,N,1,CHEMBL884001,478.0,,
7103,1,Concentration required to inhibit A2780 cell growth when compared with control after incubation for 96 hr at 37 C,,BAO_0000219,,Homo sapiens,,Intermediate,6633,,N,1,CHEMBL622416,478.0,,
7104,1,"MDR-reversing activity was measured by vincristine accumulation in the multidrug resistant 2780AD, a subline of A2780 ovarian carcinoma cells at 10 mg/mL",,BAO_0000219,,Homo sapiens,,Intermediate,3906,,N,1,CHEMBL622417,478.0,,
7105,1,50% growth inhibition of A2780 (Human ovarian carcinoma) cell line compared with untreated control cells,,BAO_0000219,,Homo sapiens,,Expert,6788,,N,1,CHEMBL622590,478.0,,
7106,1,Antiproliferative activity against human A2780 cells,,BAO_0000219,,Homo sapiens,,Expert,17582,,N,1,CHEMBL622591,478.0,,
7107,1,Inhibition of human A2780 cell proliferation,,BAO_0000219,,Homo sapiens,,Expert,17764,,N,1,CHEMBL622592,478.0,,
7108,1,Antiproliferative effect against human A2780 cell line was determined in a whole cell 72 hr cytotoxicity assay,,BAO_0000219,,Homo sapiens,,Expert,17764,,N,1,CHEMBL622593,478.0,,
7109,1,Inhibition of human A2780 cell proliferation (No data),,BAO_0000219,,Homo sapiens,,Expert,17764,,N,1,CHEMBL622594,478.0,,
7110,1,Cell cytotoxicity was determined against human ovarian cancer (A2780) cell line,,BAO_0000219,,Homo sapiens,,Intermediate,2815,,N,1,CHEMBL622595,478.0,,
7111,1,Compound was evaluated against human Ovarian carcinoma cell line A2780,,BAO_0000219,,Homo sapiens,,Intermediate,16930,,N,1,CHEMBL622596,478.0,,
7112,1,Growth inhibition against A2780 wild-type ovarian cell lines,,BAO_0000219,,Homo sapiens,,Expert,17777,,N,1,CHEMBL622597,478.0,,
7113,1,Compound was evaluated for growth inhibition against A2780 wild-type ovarian cell lines; No data,,BAO_0000219,,Homo sapiens,,Intermediate,17777,,N,1,CHEMBL622598,478.0,,
7114,1,Inhibition of tubulin polymerization in human ovarian cancer cell lines,,BAO_0000019,,Homo sapiens,,Autocuration,16936,,D,5,CHEMBL622599,,,
7115,1,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,,BAO_0000219,,Homo sapiens,,Intermediate,13759,,N,1,CHEMBL622600,478.0,,
7116,1,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,,BAO_0000219,,Homo sapiens,,Intermediate,13759,,N,1,CHEMBL622601,478.0,,
7117,1,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,,BAO_0000219,,Homo sapiens,,Intermediate,13759,,N,1,CHEMBL622602,478.0,,
7118,1,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,,BAO_0000219,,Homo sapiens,,Intermediate,13759,,N,1,CHEMBL622603,478.0,,
7119,1,Compound was tested for inhibitory activity against A2780 human ovarian carcinoma cell line; activity expressed in Mean IC50 values,,BAO_0000219,,Homo sapiens,,Intermediate,15292,,N,1,CHEMBL622604,478.0,,
7120,1,Compound was tested for inhibitory activity against A2780cisR human ovarian carcinoma cell line; activity expressed in Mean IC50 values,,BAO_0000219,,Homo sapiens,,Intermediate,15292,,N,1,CHEMBL622605,478.0,,
7121,1,In vitro inhibition of human ovarian cell line A2780,,BAO_0000219,,Homo sapiens,,Expert,15069,,N,1,CHEMBL622606,478.0,,
7122,1,"In vitro inhibition of human ovarian cell line, resistant to cisplatin (A2780cisR).",,BAO_0000219,,Homo sapiens,,Expert,15069,,N,1,CHEMBL619463,478.0,,
7123,1,Concentration of compound to inhibit the growth of human A2780 ovarian carcinoma cells(in vitro),,BAO_0000219,,Homo sapiens,,Intermediate,14073,,N,1,CHEMBL619464,478.0,,
7124,1,Concentration required to inhibit A2780-cell growth by 50%,,BAO_0000219,,Homo sapiens,,Expert,14553,,N,1,CHEMBL619465,478.0,,
7125,1,Concentration required to inhibit the cell growth by 50 % after 96 hr A2780 leukemic cells.,,BAO_0000219,,Homo sapiens,,Expert,13040,,N,1,CHEMBL619466,478.0,,
7126,1,Cytotoxic effect on human ovarian (A2780) cancer cell line,,BAO_0000219,,Homo sapiens,,Expert,6891,,N,1,CHEMBL619467,478.0,,
7127,1,Cytotoxic activity in a panel of Human ovarian tumor A2780 cell line after 96h of drug exposure,,BAO_0000219,,Homo sapiens,,Intermediate,15569,,N,1,CHEMBL619468,478.0,,
7128,1,Cytotoxic potency required to inhibit A2780 cell growth by 50% after cell drug contact for 96 hrs,,BAO_0000219,,Homo sapiens,,Expert,14190,,N,1,CHEMBL619469,478.0,,
7129,1,Cytotoxicity measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,,BAO_0000219,,Homo sapiens,,Expert,15014,,N,1,CHEMBL619470,478.0,,
7130,1,Cytotoxicity activity of the compound was measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,,BAO_0000219,,Homo sapiens,,Intermediate,15014,,N,1,CHEMBL619471,478.0,,
7131,1,Cytotoxicity against human ovarian carcinoma A2780 cell line,,BAO_0000219,,Homo sapiens,,Intermediate,17496,,N,1,CHEMBL619472,478.0,,
7132,1,"Cytotoxicity against A2780-C25, oxaliplatin-resistant Ovarian carcinoma cell line",,BAO_0000219,,Homo sapiens,,Intermediate,13617,,N,1,CHEMBL619473,478.0,,
7133,1,"Cytotoxicity against A2780-CP3, cisplatin-resistant Ovarian carcinoma cell line",,BAO_0000219,,Homo sapiens,,Intermediate,13617,,N,1,CHEMBL874368,478.0,,
7134,1,"Cytotoxicity against A2780-DX5, Doxorubicin-resistant Ovarian carcinoma cell line",,BAO_0000219,,Homo sapiens,,Intermediate,13617,,N,1,CHEMBL884003,478.0,,
7135,1,"Cytotoxicity against A2780-WT, human ovarian carcinoma cell line",,BAO_0000219,,Homo sapiens,,Intermediate,13617,,N,1,CHEMBL622690,478.0,,
7136,1,Cytotoxicity against ovarian carcinoma A2780 tumor cell lines,,BAO_0000219,,Homo sapiens,,Intermediate,17672,,N,1,CHEMBL622691,478.0,,
7137,1,Dose of required to inhibit growth of cisplatin resistant human ovarian carcinoma (A2780 cisR) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,,BAO_0000219,,Homo sapiens,,Intermediate,4544,,N,1,CHEMBL622692,478.0,,
7138,1,Dose of required to inhibit growth of human ovarian carcinoma (A2780) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,,BAO_0000219,,Homo sapiens,,Intermediate,4544,,N,1,CHEMBL623406,478.0,,
7139,1,"Growth inhibition in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant) using the 96 hour exposure sulforhodamine B (SRB) growth delay assay",,BAO_0000219,,Homo sapiens,,Intermediate,16317,,N,1,CHEMBL884004,478.0,,
7140,1,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780,,BAO_0000219,,Homo sapiens,,Intermediate,15099,,N,1,CHEMBL623407,478.0,,
7141,1,In vitro Growth Inhibitory activity against A2780 Human ovarian cancer cell line,,BAO_0000219,,Homo sapiens,,Intermediate,13978,,N,1,CHEMBL623408,478.0,,
7142,1,In vitro antitumor activity against A2780 cell line.,,BAO_0000219,,Homo sapiens,,Expert,12989,,N,1,CHEMBL623409,478.0,,
7143,1,In vitro cytotoxic activity against human tumor cell line A2780 after incubation for 96 hours,,BAO_0000219,,Homo sapiens,,Intermediate,5574,,N,1,CHEMBL623410,478.0,,
7144,1,In vitro cytotoxicity against A2780 human ovarian cancer cell line,,BAO_0000219,,Homo sapiens,,Expert,13528,,N,1,CHEMBL623576,478.0,,
7145,1,Inhibitory activity against kidney A-CHN tumor cell growth in culture,,BAO_0000219,,Homo sapiens,,Intermediate,12782,,N,1,CHEMBL623577,626.0,,
7146,1,The IC50 value was measured on ACHN cell line in renal tumor type.,,BAO_0000219,,Homo sapiens,,Intermediate,14255,,N,1,CHEMBL623578,626.0,,
7147,1,Concentration required for killing 50% of cells of renal ACHN cell lines was determined in vitro,,BAO_0000219,,Homo sapiens,,Intermediate,16364,,N,1,CHEMBL623579,626.0,,
7148,1,In vitro lethal concentration against most sensitive ACHN cell line,,BAO_0000219,,Homo sapiens,,Expert,17376,,N,1,CHEMBL623580,626.0,,
7149,1,Tested for cytotoxic activity against renal cancer ACHN cell line,,BAO_0000219,,Homo sapiens,,Intermediate,12016,,N,1,CHEMBL623581,626.0,,
7150,1,Compound tested for growth inhibition of renal cancer cell line ACHN,,BAO_0000219,,Homo sapiens,,Intermediate,6058,,N,1,CHEMBL857456,626.0,,
7151,1,Compound was tested for 50% growth inhibition against human renal cancer ACHN cell line,,BAO_0000219,,Homo sapiens,,Intermediate,17708,,N,1,CHEMBL623582,626.0,,
7152,1,Growth inhibition of the ACHN Renal cancer cell line for 2-day in vitro assay.,,BAO_0000219,,Homo sapiens,,Intermediate,15176,,N,1,CHEMBL623583,626.0,,
7153,1,In vitro anticancer activity against ACHN renal cancer cell line,,BAO_0000219,,Homo sapiens,,Intermediate,2806,,N,1,CHEMBL623584,626.0,,
7154,1,In vitro antitumor activity against Renal cancer ACHN cell lines by 6-day assay,,BAO_0000219,,Homo sapiens,,Intermediate,15300,,N,1,CHEMBL623585,626.0,,
7155,1,Percent selectivity was evaluated in renal ACHN cell lines,,BAO_0000219,,Homo sapiens,,Intermediate,16364,,N,1,CHEMBL623586,626.0,,
7156,1,In vitro inhibitory activity against renal ACHN cancer cell line,,BAO_0000219,,Homo sapiens,,Intermediate,13859,,N,1,CHEMBL623587,626.0,,
7157,1,Tested for cytotoxicity against ACHN cell lines in renal cancer,,BAO_0000219,,Homo sapiens,,Intermediate,11970,,N,1,CHEMBL875279,626.0,,
7158,1,Tested for the in vitro cytotoxicity against ACHN renal cancer cell line,,BAO_0000219,,Homo sapiens,,Intermediate,2450,,N,1,CHEMBL623588,626.0,,
7159,1,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,,BAO_0000219,,Homo sapiens,,Intermediate,12696,,N,1,CHEMBL623589,626.0,,
7160,1,Tested in vitro for cytotoxicity in ACHN cell line of Renal cancer,,BAO_0000219,,Homo sapiens,,Intermediate,12400,,N,1,CHEMBL623590,626.0,,
7161,1,Cytotoxic effect on renal cancer line ACHN,,BAO_0000219,,Homo sapiens,,Expert,12888,,N,1,CHEMBL623591,626.0,,
7162,1,In vitro anti-cancer activity against ACHN(Renal) human tumor cell line,,BAO_0000219,,Homo sapiens,,Intermediate,3156,,N,1,CHEMBL623592,626.0,,
7163,1,In vitro inhibition of Renal Cancer ACHN cell lines,,BAO_0000219,,Homo sapiens,,Intermediate,3381,,N,1,CHEMBL623593,626.0,,
7164,1,Antitumor activity against human renal adenocarcinoma ACHN cells,,BAO_0000219,,Homo sapiens,,Intermediate,16747,,N,1,CHEMBL623594,626.0,,
7165,1,Antitumor activity against human renal adenocarcinoma ACHN cells.,,BAO_0000219,,Homo sapiens,,Expert,16748,,N,1,CHEMBL621833,626.0,,
7166,1,Inhibitory concentration required to decrease cell viability in cell growth culture against kidney cells ACHN,,BAO_0000219,,Homo sapiens,,Intermediate,12062,,N,1,CHEMBL621834,626.0,,
7167,1,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),,BAO_0000219,,Homo sapiens,,Intermediate,14769,,N,1,CHEMBL621835,626.0,,
7168,1,"Cytotoxicity against NCI tumor panel, ACHN renal cancer cell line",,BAO_0000219,,Homo sapiens,,Intermediate,15895,,N,1,CHEMBL621836,626.0,,
7169,1,Concentration of compound that cause 50% cytotoxicity of ACHN renal cancer cell line,,BAO_0000219,,Homo sapiens,,Intermediate,17376,,N,1,CHEMBL621837,626.0,,
7170,1,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration that inhibits 50% net cell growth).,,BAO_0000219,,Homo sapiens,,Intermediate,14882,,N,1,CHEMBL875280,626.0,,
7171,1,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration leading to 50% net cell death).,,BAO_0000219,,Homo sapiens,,Intermediate,14882,,N,1,CHEMBL621838,626.0,,
7172,1,Cytotoxicity was tested against renal cancer ACHN tumor cell lines.,,BAO_0000219,,Homo sapiens,,Intermediate,15661,,N,1,CHEMBL621839,626.0,,
7173,1,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,,BAO_0000019,,,,Autocuration,9680,,U,0,CHEMBL621840,,,
7174,1,Compound tested for relative response using 1 uM ACh as agonist against AChM1 receptor.,,BAO_0000019,,,,Autocuration,14579,,H,8,CHEMBL621841,,,
7175,1,Antiviral activity against AD169 strain of cytomegalovirus (CMV) in HEL (human erythroleukemia) cells.,,BAO_0000218,,Cytomegalovirus,,Expert,17290,,N,1,CHEMBL622979,468.0,,
7176,1,Antiviral activity against AD169 strain of cytomegalovirus (CMV); ND=No data,,BAO_0000218,,Cytomegalovirus,,Intermediate,17290,,N,1,CHEMBL876595,,,
7177,1,Compound was evaluated for its inhibitory activity against calf intestinal Adenosine deaminase (ADA),,BAO_0000357,,,,Autocuration,15891,,H,8,CHEMBL620221,,,
7178,1,Evaluated for the inhibition of calf intestinal Adenosine deaminase (ADA),,BAO_0000357,,,,Autocuration,15890,,H,8,CHEMBL620222,,,
7179,1,Inhibitory activity against ovarian tumor cell line ADDP after 72 hr continuous exposure to compound,,BAO_0000219,,Bos taurus,,Intermediate,3801,,N,1,CHEMBL620506,979.0,,
7180,1,Tumor growth inhibition activity after subcutaneous transplanted tumor in ADJ-PC6 plasmacytoma cells,,BAO_0000219,,Mus musculus,,Intermediate,9222,,N,1,CHEMBL620507,980.0,,
7181,1,Tumor growth inhibition activity after subcutaneously transplanted tumor in ADJ-PC6 plasmacytoma cells,,BAO_0000219,,Mus musculus,,Intermediate,9222,,N,1,CHEMBL620508,980.0,,
7182,1,"Compound was tested for dose producing 90% reduction in tumor weight, in ADJ/PC6 mouse plasma cell tumor",,BAO_0000219,,Mus musculus,,Intermediate,7257,,N,1,CHEMBL620509,980.0,,
7183,1,Compound was tested for inhibition against ADJ/PC6 mouse plasma cell tumor at the dose of 320 mg/Kg,,BAO_0000219,,Mus musculus,,Intermediate,7257,,N,1,CHEMBL620510,980.0,,
7184,1,Compound was tested for dose required to kill 50 % of ADJ/PC6 mouse plasma cell tumor in a group,,BAO_0000219,,Mus musculus,,Intermediate,7257,,N,1,CHEMBL620511,980.0,,
7185,1,In vitro incorporation of the [3H]thymidine into the ADJ/PC6 Plasmacytoma cells,,BAO_0000219,,Mus musculus,,Intermediate,8084,,N,1,CHEMBL620512,980.0,,
7186,1,Tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma,,BAO_0000019,,Mus musculus,,Autocuration,14943,,U,0,CHEMBL620513,,,
7187,1,The compound was tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma; Not determined,,BAO_0000019,,Mus musculus,,Autocuration,14943,,U,0,CHEMBL620514,,,
7188,1,Tested for cytotoxicity against ADJ/PC6 plasmacytoma,,BAO_0000019,,Mus musculus,,Autocuration,14943,,U,0,CHEMBL620515,,,
7189,1,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),,BAO_0000218,,Bacillus subtilis,,Autocuration,10524,In vivo,U,0,CHEMBL620516,,,
7190,1,AUC value in dog after IV administration at a dose of 5 mg/kg,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,3546,,N,1,CHEMBL620517,,1969.0,
7191,1,AUC value in dog after oral administration at a dose of 5 mg/kg,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,3546,,N,1,CHEMBL620518,,1969.0,
7192,1,Cmax value in dog after oral administration at a dose of 5 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,3546,In vivo,N,1,CHEMBL620519,,,
7193,1,Bioavailability in dog after oral administration at a dose of 5 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,3546,In vivo,N,1,CHEMBL621386,,,
7194,1,Tmax value in dog after oral administration at a dose of 5 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,3546,In vivo,N,1,CHEMBL621387,,,
7195,1,Compound was evaluated for its clearance when administered intravenously in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,3184,In vivo,N,1,CHEMBL621388,,,
7196,1,Plasma clearance in Beagle dogs after intravenous administration at a dose of 10 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,16456,In vivo,N,1,CHEMBL621389,,,
7197,1,Plasma clearance was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),,BAO_0000218,,Canis lupus familiaris,,Intermediate,4809,In vivo,N,1,CHEMBL621390,,,
7198,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Intermediate,4219,,U,0,CHEMBL621391,,,
7199,1,Half life in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,3748,,N,1,CHEMBL621392,,,
7200,1,Time taken for EC90 was determined when tested in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,3132,,N,1,CHEMBL621393,,,
7201,1,Half life (iv) was determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4219,,N,1,CHEMBL621394,,,
7202,1,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,Liver,BAO_0000218,,Canis lupus familiaris,,Intermediate,16907,,N,1,CHEMBL621395,,2107.0,
7203,1,Area under the curve was calculated in dog after iv administration,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6057,,N,1,CHEMBL621396,,,
7204,1,Area under the curve was calculated in dog after peroral administration,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6057,,N,1,CHEMBL621397,,,
7205,1,Dose-normalized area under curve in dog (p.o.) at 2.0 mpk,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17853,,N,1,CHEMBL621398,,,
7206,1,pKa was evaluated in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,3639,,N,1,CHEMBL618818,,,
7207,1,Compound was evaluated for pronounced GH response at 100 mg (n=6)(area under concentration curve was determined from 0-8 hr following morning and evening dosing with 25 mg of the compound,,BAO_0000218,,Canis lupus familiaris,,Intermediate,14541,,N,1,CHEMBL618819,,,
7208,1,Alpha-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,16456,In vivo,N,1,CHEMBL618820,,,
7209,1,Beta-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,16456,In vivo,N,1,CHEMBL873810,,,
7210,1,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,,BAO_0000218,,Canis lupus familiaris,,Intermediate,2652,In vivo,N,1,CHEMBL876606,,,
7211,1,Compound was evaluated for the half-life (t 1/2) in hours,,BAO_0000218,,Canis lupus familiaris,,Intermediate,3624,,N,1,CHEMBL618821,,,
7212,1,Half life to reach the blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,Blood,BAO_0000218,,Canis lupus familiaris,,Intermediate,1337,In vivo,N,1,CHEMBL618822,,178.0,
7213,1,Half life to reach the blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,Blood,BAO_0000218,,Canis lupus familiaris,,Intermediate,1337,In vivo,N,1,CHEMBL618823,,178.0,
7214,1,Half life after intravenous administration of 1 mg/kg in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4709,In vivo,N,1,CHEMBL618824,,,
7215,1,Half life was measured in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,15660,,N,1,CHEMBL618825,,,
7216,1,Half life period in dog after 5 mg/kg dose,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5302,In vivo,N,1,CHEMBL618826,,,
7217,1,Half life period was evaluated in dog; 4-4.8,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17791,,N,1,CHEMBL618827,,,
7218,1,Half life was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6348,In vivo,N,1,CHEMBL618828,,,
7219,1,Half-life was determined in dog after a3 mg/kg of iv dose,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4257,In vivo,N,1,CHEMBL618829,,,
7220,1,Half-life was determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,3771,,N,1,CHEMBL618830,,,
7221,1,Half life in dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6305,,N,1,CHEMBL618831,,,
7222,1,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 2 mg/kg tp dog,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,13501,In vivo,N,1,CHEMBL619489,,1969.0,
7223,1,Apparent half-life after single intravenous bolus of 1 mg/kg in dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17594,In vivo,N,1,CHEMBL619649,,,
7224,1,Compound was evaluated for the half life period after iv administration in Beagle dog.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,3045,In vivo,N,1,CHEMBL876607,,,
7225,1,Compound was evaluated for the half life period after oral administration in conscious dog.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,3043,In vivo,N,1,CHEMBL619650,,,
7226,1,Compound was tested for half life in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4839,,N,1,CHEMBL619651,,,
7227,1,Compound was tested for its half life in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4839,,N,1,CHEMBL619652,,,
7228,1,Half life of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5802,In vivo,N,1,CHEMBL619653,,,
7229,1,Half life of compound in dog was determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17839,,N,1,CHEMBL619654,,,
7230,1,Half life (iv) was determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4219,In vivo,N,1,CHEMBL619655,,,
7231,1,Half life following administration of 70 nM in canine whole blood (dose exceeding platelet binding capacity),Blood,BAO_0000218,,Canis lupus familiaris,,Intermediate,13966,,N,1,CHEMBL619656,,178.0,
7232,1,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,3994,In vivo,N,1,CHEMBL873812,,1969.0,
7233,1,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,3994,In vivo,N,1,CHEMBL621365,,1969.0,
7234,1,Half life in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4453,,N,1,CHEMBL621366,,,
7235,1,Half life in dog plasma,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,6535,,N,1,CHEMBL621367,,1969.0,
7236,1,Half life in dog plasma after administration of 0.25 mg/kg iv,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,6535,In vivo,N,1,CHEMBL621368,,1969.0,
7237,1,Half life in dog plasma after administration of 1 mg/kg iv,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,6535,In vivo,N,1,CHEMBL621369,,1969.0,
7238,1,Half life in dog plasma was determined at dose 10 mg/kg,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,3132,In vivo,N,1,CHEMBL621370,,1969.0,
7239,1,Half life in dog was determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5374,,N,1,CHEMBL621371,,,
7240,1,Half life in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,BAO_0000218,,Canis lupus familiaris,,Intermediate,5007,In vivo,N,1,CHEMBL621372,,,
7241,1,Half life upon exposure to human plasma,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,16907,,N,1,CHEMBL621373,,1969.0,
7242,1,Half life was calculated in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6057,,N,1,CHEMBL621374,,,
7243,1,Half life was determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5006,,N,1,CHEMBL621375,,,
7244,1,Half life was determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5473,,N,1,CHEMBL621376,,,
7245,1,Half life by intravenous administration of 1.2 mg/kg in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4368,In vivo,N,1,CHEMBL619624,,,
7246,1,Half life in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6448,,N,1,CHEMBL875840,,,
7247,1,Half life in dog after intra venous administration of the compound,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4353,,N,1,CHEMBL619625,,,
7248,1,Half life in dog after intra venous administration of the compound; ND means Not determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4353,,N,1,CHEMBL619626,,,
7249,1,Half life in dog after po administration of the compound,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4353,In vivo,N,1,CHEMBL619627,,,
7250,1,Half life in dog after po administration of the compound; ND means Not determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4353,In vivo,N,1,CHEMBL873817,,,
7251,1,Half life in dog at the single oral dose of 1 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6265,In vivo,N,1,CHEMBL619628,,,
7252,1,Half life in dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5006,,N,1,CHEMBL619629,,,
7253,1,Half life in dogs at 1 mg/kg oral dosing; 35-100 min,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5356,In vivo,N,1,CHEMBL619630,,,
7254,1,Half life in rat,,BAO_0000218,,Canis lupus familiaris,,Intermediate,405,,N,1,CHEMBL619631,,,
7255,1,Half life in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6642,In vivo,N,1,CHEMBL619632,,,
7256,1,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Bone,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,N,1,CHEMBL619633,,10000001.0,
7257,1,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Bone,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,N,1,CHEMBL875841,,10000001.0,
7258,1,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Bone,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,N,1,CHEMBL619634,,10000001.0,
7259,1,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Bone,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,N,1,CHEMBL619635,,10000001.0,
7260,1,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Bone,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,N,1,CHEMBL619636,,10000001.0,
7261,1,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Gut,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,N,1,CHEMBL619637,,10000004.0,
7262,1,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,Gut,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,N,1,CHEMBL619638,,10000004.0,
7263,1,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Gut,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,N,1,CHEMBL619639,,10000004.0,
7264,1,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Gut,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,N,1,CHEMBL619640,,10000004.0,
7265,1,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Gut,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,N,1,CHEMBL619641,,10000004.0,
7266,1,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Gut,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,N,1,CHEMBL619642,,10000004.0,
7267,1,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Gut,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,N,1,CHEMBL619643,,10000004.0,
7268,1,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Heart,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,N,1,CHEMBL619644,,948.0,
7269,1,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,Heart,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,N,1,CHEMBL621112,,948.0,
7270,1,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Heart,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,N,1,CHEMBL621113,,948.0,
7271,1,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Heart,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,N,1,CHEMBL621114,,948.0,
7272,1,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Heart,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,N,1,CHEMBL621115,,948.0,
7273,1,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Heart,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,N,1,CHEMBL621116,,948.0,
7274,1,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Heart,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,N,1,CHEMBL621117,,948.0,
7275,1,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Kidney,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,N,1,CHEMBL621118,,2113.0,
7276,1,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,Kidney,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,N,1,CHEMBL621119,,2113.0,
7277,1,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Kidney,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,N,1,CHEMBL621120,,2113.0,
7278,1,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Kidney,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,N,1,CHEMBL621757,,2113.0,
7279,1,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Kidney,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,N,1,CHEMBL621758,,2113.0,
7280,1,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Kidney,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,N,1,CHEMBL621759,,2113.0,
7281,1,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Kidney,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,N,1,CHEMBL621760,,2113.0,
7282,1,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Liver,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,N,1,CHEMBL621761,,2107.0,
7283,1,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,Liver,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,N,1,CHEMBL621762,,2107.0,
7284,1,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Liver,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,N,1,CHEMBL621763,,2107.0,
7285,1,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Liver,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,N,1,CHEMBL624502,,2107.0,
7286,1,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Liver,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,N,1,CHEMBL624503,,2107.0,
7287,1,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Liver,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,N,1,CHEMBL624504,,2107.0,
7288,1,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Liver,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,N,1,CHEMBL624505,,2107.0,
7289,1,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Lung,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,N,1,CHEMBL624506,,2048.0,
7290,1,In vitro cytotoxicity against A2780 (human ovarian cancer),,BAO_0000219,,Homo sapiens,,Intermediate,5895,,N,1,CHEMBL624507,478.0,,
7291,1,In vitro cytotoxicity against the paclitaxel sensitive human breast carcinoma cell line A2780,,BAO_0000219,,Homo sapiens,,Intermediate,6338,,N,1,CHEMBL624508,478.0,,
7292,1,In vitro cytotoxicity against. ovarian carcinoma cell line A2780.,,BAO_0000219,,Homo sapiens,,Intermediate,15163,,N,1,CHEMBL624509,478.0,,
7293,1,In vitro cytotoxicity against. ovarian carcinoma cell line A2780cisR (cisplatin resistant counter part of A2780).,,BAO_0000219,,Homo sapiens,,Intermediate,15163,,N,1,CHEMBL624510,478.0,,
7294,1,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cell line,,BAO_0000219,,Homo sapiens,,Expert,15000,,N,1,CHEMBL875956,478.0,,
7295,1,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cisplatin resistant cell line,,BAO_0000219,,Homo sapiens,,Expert,15000,,N,1,CHEMBL839885,478.0,,
7296,1,In vitro cytotoxicity against A2780 ovarian cells using the sulforhodamine B(SRB) assay.,,BAO_0000219,,Homo sapiens,,Expert,14729,,N,1,CHEMBL624511,478.0,,
7297,1,In vitro cytotoxicity against A2780 cell line,,BAO_0000219,,Homo sapiens,,Intermediate,17270,,N,1,CHEMBL624512,478.0,,
7298,1,In vitro growth inhibitory activity against A2780 human ovarium carcinoma cell line was determined,,BAO_0000219,,Homo sapiens,,Intermediate,5685,,N,1,CHEMBL624513,478.0,,
7299,1,In vitro inhibitory activity against human ovarian cancer A2780 cell line,,BAO_0000219,,Homo sapiens,,Intermediate,3563,,N,1,CHEMBL624514,478.0,,
7300,1,In vivo cytotoxic concentration of compound against A2780 cell line after 72 hr exposure,,BAO_0000218,,Homo sapiens,,Intermediate,17753,,N,1,CHEMBL618547,478.0,,
7301,1,"Inhibition of cell growth in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant)using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay",,BAO_0000219,,Homo sapiens,,Intermediate,16317,,N,1,CHEMBL618548,478.0,,
7302,1,Inhibition of tubulin polymerization in analogy of ca.,,BAO_0000219,,Homo sapiens,,Intermediate,16936,,N,1,CHEMBL618549,478.0,,
7303,1,Inhibitory activity against ovarian tumor cell line A2780 after 72 hr continuous exposure to compound,,BAO_0000219,,Homo sapiens,,Intermediate,3801,,N,1,CHEMBL618550,478.0,,
7304,1,Cytotoxic effect in ovarian cancer cell line (A2780),,BAO_0000219,,Homo sapiens,,Expert,6181,,N,1,CHEMBL618551,478.0,,
7305,1,Tested for cytotoxicity against Ovarian carcinoma parental type A2780 cell line expressing MDR-1 (-) gene,,BAO_0000219,,Homo sapiens,,Intermediate,5318,,N,1,CHEMBL618552,478.0,,
7306,1,Tested for the cytotoxicity in A2780 ovarian cell line,,BAO_0000219,,Homo sapiens,,Intermediate,4840,,N,1,CHEMBL618553,478.0,,
7307,1,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),,BAO_0000219,,Homo sapiens,,Intermediate,15748,,N,1,CHEMBL618554,478.0,,
7308,1,The compound was tested for cytotoxic activity against A2780/Cs cell line(human ovarian carcinoma,,BAO_0000219,,Homo sapiens,,Intermediate,15748,,N,1,CHEMBL618555,478.0,,
7309,1,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma,,BAO_0000219,,,,Intermediate,15748,,N,1,CHEMBL618556,481.0,,
7310,1,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),,BAO_0000219,,,,Intermediate,15748,,N,1,CHEMBL618557,481.0,,
7311,1,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ); ND means no data,,BAO_0000219,,,,Intermediate,15748,,N,1,CHEMBL618558,481.0,,
7312,1,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma),,BAO_0000219,,,,Intermediate,15748,,N,1,CHEMBL618559,481.0,,
7313,1,In vivo log of cells killed after administration of compound in A2780 cell line,,BAO_0000218,,Homo sapiens,,Intermediate,17753,,N,1,CHEMBL618560,478.0,,
7314,1,Compound was tested in vivo for maximum tolerated dose after i.v. administration twice a day for 5 days in A2780 cell line,,BAO_0000218,,Homo sapiens,,Intermediate,17753,In vivo,N,1,CHEMBL618561,478.0,,
7315,1,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.;NA means not active,,BAO_0000219,,Homo sapiens,,Intermediate,16936,,N,1,CHEMBL618562,478.0,,
7316,1,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines (at 5 uM );NA means not active,,BAO_0000219,,Homo sapiens,,Intermediate,16936,,N,1,CHEMBL618563,478.0,,
7317,1,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines; ND means no data,,BAO_0000219,,Homo sapiens,,Intermediate,16936,,N,1,CHEMBL618564,478.0,,
7318,1,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines. (at 5 uM ); ND means no data,,BAO_0000219,,Homo sapiens,,Intermediate,16936,,N,1,CHEMBL618565,478.0,,
7319,1,Optimal dose required to inhibit human ovarian A2780 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q4dX2),,BAO_0000218,,Homo sapiens,,Intermediate,17528,,N,1,CHEMBL618566,478.0,,
7320,1,Resistance factor was determined as IC50 cisplatin-resistant/parent for human A2780 ovarian cell line,,BAO_0000219,,Homo sapiens,,Intermediate,6633,,N,1,CHEMBL618567,478.0,,
7321,1,Resistance index is IC50 ratio of A2780 cell line and A2780cisR cell line,,BAO_0000219,,Homo sapiens,,Expert,15000,,N,1,CHEMBL618568,478.0,,
7322,1,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,,BAO_0000219,,Homo sapiens,,Expert,17528,,N,1,CHEMBL618569,478.0,,
7323,1,Compound was tested for Tubulin polymerization inhibition by using human ovarian cancer cell lines.,,BAO_0000219,,Homo sapiens,,Intermediate,16936,,N,1,CHEMBL621857,478.0,,
7324,1,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.,,BAO_0000219,,Homo sapiens,,Intermediate,16936,,N,1,CHEMBL621858,478.0,,
7325,1,Percent of Tubulin polymerization inhibition by using human ovarian cancer cell lines at a concentration of 5 uM,,BAO_0000219,,Homo sapiens,,Intermediate,16936,,N,1,CHEMBL621859,478.0,,
7326,1,"Colchicine Binding Inhibition ( CBI ) by using human ovarian cancer cell lines at 5 uM, (values are mean of 9 over 4 concentrations +/- SD)",,BAO_0000219,,Homo sapiens,,Intermediate,16936,,N,1,CHEMBL621860,478.0,,
7327,1,Compound tested for colchicine Binding Inhibition by using human ovarian cancer cell line (at 5 uM ),,BAO_0000219,,Homo sapiens,,Intermediate,16936,,N,1,CHEMBL621861,478.0,,
7328,1,"Tested for colchicine binding inhibition, using human ovarian cancer cell lines (at 5 uM )",,BAO_0000219,,Homo sapiens,,Expert,16936,,N,1,CHEMBL621862,478.0,,
7329,1,Compound tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),,BAO_0000219,,Homo sapiens,,Intermediate,16936,,N,1,CHEMBL621863,478.0,,
7330,1,Compound was tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),,BAO_0000219,,Homo sapiens,,Intermediate,16936,,N,1,CHEMBL621864,478.0,,
7331,1,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell line (at 5 uM ),,BAO_0000219,,Homo sapiens,,Intermediate,16936,,N,1,CHEMBL621865,478.0,,
7332,1,In vitro antiproliferative activity against A2780 cell line,,BAO_0000219,,Mus musculus,,Intermediate,17737,,N,1,CHEMBL621866,478.0,,
7333,1,Maximum tolerated dose in A2780 tumor in mice after intraperitoneal administration daily for 8 days,,BAO_0000219,,Mus musculus,,Expert,17764,,N,1,CHEMBL621867,478.0,,
7334,1,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C after 96 hr,,BAO_0000219,,Homo sapiens,,Intermediate,3830,,N,1,CHEMBL621868,478.0,,
7335,1,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C for 96 hr,,BAO_0000219,,Homo sapiens,,Intermediate,3829,,N,1,CHEMBL875282,478.0,,
7336,1,Vc value in dog after IV administration at a dose of 5 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,3546,,N,1,CHEMBL621869,,,
7337,1,Half life period in dog after IV administration at a dose of 5 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,3546,In vivo,N,1,CHEMBL621870,,,
7338,1,Area under curve was determine after peroral administration at 10 mpk in Rhesus,,BAO_0000019,,Cercopithecidae,,Autocuration,5668,,U,0,CHEMBL621871,,,
7339,1,AUC (area under curve) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Plasma,BAO_0000218,,Cercopithecidae,,Autocuration,3443,,U,0,CHEMBL621243,,1969.0,
7340,1,AUC (area under curve) compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Plasma,BAO_0000218,,Cercopithecidae,,Autocuration,3443,,U,0,CHEMBL621244,,1969.0,
7341,1,Area under curve determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,,BAO_0000218,,Macaca fascicularis,,Autocuration,4256,In vivo,U,0,CHEMBL621245,,,
7342,1,Area under curve determined after peroral administration at a dose of 10 mg/kg in cynomolgus monkey,,BAO_0000218,,Macaca fascicularis,,Autocuration,4256,In vivo,U,0,CHEMBL621246,,,
7343,1,Area under curve determined after peroral administration at a dose of 3 mg/kg in cynomolgus monkey,,BAO_0000218,,Macaca fascicularis,,Autocuration,4256,In vivo,U,0,CHEMBL621247,,,
7344,1,Oral Bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Autocuration,4256,In vivo,U,0,CHEMBL618386,,,
7345,1,Area under curve was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,BAO_0000218,,Cercopithecidae,,Autocuration,1916,,U,0,CHEMBL618387,,,
7346,1,Area under curve value in monkey at a dose of 5 mg/kg,,BAO_0000218,,Cercopithecidae,,Autocuration,5302,,U,0,CHEMBL618388,,,
7347,1,Area under curve was determined in monkey after a 3 mg/kg of oral dose,,BAO_0000218,,Cercopithecidae,,Autocuration,4257,,U,0,CHEMBL618389,,,
7348,1,Area under curve was determined using trapezoidal rule after intravenous administration in cynomolgus monkeys,,BAO_0000019,,Cercopithecidae,,Autocuration,5355,,U,0,CHEMBL618574,,,
7349,1,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys,,BAO_0000019,,Cercopithecidae,,Autocuration,5355,,U,0,CHEMBL618575,,,
7350,1,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys; ND means Not determined,,BAO_0000019,,Cercopithecidae,,Autocuration,5355,,U,0,CHEMBL618576,,,
7351,1,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in monkey,,BAO_0000218,,Cercopithecidae,,Autocuration,6078,,U,0,CHEMBL618577,,,
7352,1,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in monkey,,BAO_0000218,,Cercopithecidae,,Autocuration,6078,,U,0,CHEMBL876487,,,
7353,1,Area under the curve was measured in monkey after an iv dose of 1 mg/kg,,BAO_0000218,,Cercopithecidae,,Autocuration,6062,,U,0,CHEMBL618578,,,
7354,1,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,BAO_0000218,,Cercopithecidae,,Autocuration,2661,,U,0,CHEMBL618579,,,
7355,1,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,BAO_0000019,,Cercopithecidae,,Autocuration,2661,,U,0,CHEMBL618580,,,
7356,1,Pharmacokinetic parameter Cmax was measured after administration into monkey at 3 mg/kg,,BAO_0000218,,Cercopithecidae,,Autocuration,5394,,U,0,CHEMBL618581,,,
7357,1,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in cynomolgus monkeys (0 to 24 hr) p.o.,,BAO_0000218,,Cercopithecidae,,Autocuration,4397,,U,0,CHEMBL618582,,,
7358,1,Area under curve value 24 hr after 2 mg/kg iv administration in monkeys,,BAO_0000218,,Cercopithecidae,,Autocuration,17509,,U,0,CHEMBL618583,,,
7359,1,Area under curve value 24 hr after 2 mg/kg oral administration in monkeys,,BAO_0000218,,Cercopithecidae,,Autocuration,17509,,U,0,CHEMBL618584,,,
7360,1,Oral AUCN in monkey (dosed at 0.5 mpk iv ),,BAO_0000218,,Cercopithecidae,,Autocuration,6641,In vivo,U,0,CHEMBL618585,,,
7361,1,Bioavailability was reported in cynomolgus monkeys (ratio of AUC in oral administration to that of intravenous administration),,BAO_0000218,,Cercopithecidae,,Autocuration,5355,,U,0,CHEMBL618586,,,
7362,1,Half life compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,BAO_0000218,,Cercopithecidae,,Autocuration,3443,In vivo,U,0,CHEMBL618587,,,
7363,1,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,BAO_0000218,,Cercopithecidae,,Autocuration,3443,In vivo,U,0,CHEMBL618588,,,
7364,1,Binding towards monkey plasma protein at 10 uM,,BAO_0000019,,Cercopithecidae,,Autocuration,17409,,U,0,CHEMBL618589,,,
7365,1,Binding towards monkey plasma protein at 100 uM,,BAO_0000019,,Cercopithecidae,,Autocuration,17409,,U,0,CHEMBL618590,,,
7366,1,Apparent bioavailability in squirrel monkey was determined,,BAO_0000218,,Cercopithecidae,,Autocuration,1052,In vivo,U,0,CHEMBL872262,,,
7367,1,Bioavailability was determined after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,,BAO_0000218,,Cercopithecidae,,Autocuration,13501,In vivo,U,0,CHEMBL618591,,,
7368,1,Bioavailability in monkey (dose 2 mg/kg),,BAO_0000218,,monkey,,Autocuration,17509,In vivo,U,0,CHEMBL618592,,,
7369,1,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for bioavailability after administration into monkey at 3 mg/kg,,BAO_0000218,,Cercopithecidae,,Autocuration,5394,In vivo,U,0,CHEMBL876488,,,
7370,1,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,BAO_0000218,,Cercopithecidae,,Autocuration,2661,In vivo,U,0,CHEMBL618593,,,
7371,1,Bioavailability in monkey (i.d. dosing),,BAO_0000218,,monkey,,Autocuration,11219,In vivo,U,0,CHEMBL618594,,,
7372,1,Oral bioavailability after 5 mg/kg in cynomolgus monkey was determined,,BAO_0000218,,Cercopithecidae,,Autocuration,3045,In vivo,U,0,CHEMBL618595,,,
7373,1,Clearance of the drug was measured in cynomolgus,,BAO_0000019,,Cercopithecidae,,Autocuration,17796,,U,0,CHEMBL621469,,,
7374,1,Clearance was estimated in two squirrel monkeys after iv administration at 5 mg/kg,,BAO_0000218,,Cercopithecidae,,Autocuration,1399,In vivo,U,0,CHEMBL621470,,,
7375,1,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,BAO_0000218,,Cercopithecidae,,Autocuration,2661,In vivo,U,0,CHEMBL621471,,,
7376,1,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,Plasma,BAO_0000218,,Macaca mulatta,,Autocuration,5005,In vivo,U,0,CHEMBL621472,,1969.0,
7377,1,Plasma clearance in rhesus monkey was determined,,BAO_0000218,,Cercopithecidae,,Autocuration,17267,In vivo,U,0,CHEMBL621473,,,
7378,1,Plasma clearance in monkey after administration of 1 mg/kg iv,,BAO_0000218,,Cercopithecidae,,Autocuration,6535,In vivo,U,0,CHEMBL621474,,,
7379,1,Plasma clearance in cynomolgus monkey,,BAO_0000218,,Cercopithecidae,,Autocuration,5922,In vivo,U,0,CHEMBL621475,,,
7380,1,Plasma clearance after oral administration (2.5 mg/kg) in monkey was determined,,BAO_0000218,,Cercopithecidae,,Autocuration,6221,In vivo,U,0,CHEMBL621476,,,
7381,1,Plasma clearance after peroral administration at 10 mpk in Rhesus,,BAO_0000218,,Cercopithecidae,,Autocuration,5668,In vivo,U,0,CHEMBL624290,,,
7382,1,The total clearance was determined after intravenous administration in cynomolgus monkeys,,BAO_0000218,,Cercopithecidae,,Autocuration,5355,In vivo,U,0,CHEMBL624291,,,
7383,1,The total clearance was determined after oral administration in cynomolgus monkeys; NA means Not applicable,,BAO_0000218,,Cercopithecidae,,Autocuration,5355,In vivo,U,0,CHEMBL624292,,,
7384,1,The total clearance was determined after oral administration in cynomolgus monkeys; NA means not applicable,,BAO_0000218,,Cercopithecidae,,Autocuration,5355,In vivo,U,0,CHEMBL624293,,,
7385,1,Tested for Clearance upon iv administration to african green monkey,,BAO_0000218,,Cercopithecidae,,Autocuration,4578,In vivo,U,0,CHEMBL624294,,,
7386,1,Clearance in monkey,,BAO_0000218,,Cercopithecidae,,Autocuration,17592,In vivo,U,0,CHEMBL624295,,,
7387,1,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6641,In vivo,N,1,CHEMBL624296,,,
7388,1,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6642,In vivo,N,1,CHEMBL624297,,,
7389,1,Half life was evaluated after intravenous administration to dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,16367,In vivo,N,1,CHEMBL624298,,,
7390,1,Half life was evaluated in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5472,,N,1,CHEMBL624299,,,
7391,1,Half life was evaluated in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5474,,N,1,CHEMBL624300,,,
7392,1,Half life period (t1/2) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5654,In vivo,N,1,CHEMBL624301,,,
7393,1,Half life period after intravenous administration (1 mg/kg) was determined in dog (in vivo),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6227,In vivo,N,1,CHEMBL624302,,,
7394,1,Half life period after intravenous administration in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6227,In vivo,N,1,CHEMBL876026,,,
7395,1,Half life period after oral administration (2.5 mg/kg) in dog was determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6221,In vivo,N,1,CHEMBL624303,,,
7396,1,Half life period at a dose of 1 uM/kg in dog was determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4527,,N,1,CHEMBL624304,,,
7397,1,Half life period was determine after peroral administration at 10 mpk in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5668,In vivo,N,1,CHEMBL624305,,,
7398,1,Half life period was determine after peroral administration at 5 mpk in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5668,In vivo,N,1,CHEMBL624306,,,
7399,1,Half life period was determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,3854,,N,1,CHEMBL624307,,,
7400,1,Half life period was determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5505,,N,1,CHEMBL624308,,,
7401,1,Half life period by iv administration in dog at a dose of 6 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6251,In vivo,N,1,CHEMBL624309,,,
7402,1,Half life period was evaluated in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,1918,,N,1,CHEMBL624310,,,
7403,1,Half life period was determined in Beagle dog at a dose of 1 mg/kg by iv administration,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5546,In vivo,N,1,CHEMBL625003,,,
7404,1,Half life period was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),,BAO_0000218,,Canis lupus familiaris,,Intermediate,4809,In vivo,N,1,CHEMBL625004,,,
7405,1,Half life time after intravenous administration (0.5 mg/kg) was determined in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6215,In vivo,N,1,CHEMBL625005,,,
7406,1,Half-life period by oral administration at a dose of 10 uM/kg in dog was determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4527,In vivo,N,1,CHEMBL873813,,,
7407,1,Half-life after oral dose of compound at 3 mg/kg in dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17594,In vivo,N,1,CHEMBL625006,,,
7408,1,Half-life of compound in dog following p.o. administration of 0.5 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17839,In vivo,N,1,CHEMBL625007,,,
7409,1,Half-life of compound in dog following p.o. administration of 0.9 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17839,In vivo,N,1,CHEMBL876027,,,
7410,1,Half-life of compound in dog following p.o. administration of 0.95 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17839,In vivo,N,1,CHEMBL625008,,,
7411,1,Half-life of compound in dog following p.o. administration of 1 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17839,In vivo,N,1,CHEMBL625009,,,
7412,1,Half-life of compound in plasma of dog was determined,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,5210,,N,1,CHEMBL625010,,1969.0,
7413,1,Half-life of compound was determined in dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5210,,N,1,CHEMBL625011,,,
7414,1,Half-life after administration of 4 mg/Kg oral dose in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,2959,In vivo,N,1,CHEMBL621553,,,
7415,1,Half-life after intravenous administration of 1 mg/kg/h in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4137,In vivo,N,1,CHEMBL621554,,,
7416,1,Half-life in Dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5064,,N,1,CHEMBL621555,,,
7417,1,Half-life in Dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5147,,N,1,CHEMBL621556,,,
7418,1,Half-life in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5145,,N,1,CHEMBL621557,,,
7419,1,Half-life in dog after oral administration at 1 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6123,In vivo,N,1,CHEMBL621558,,,
7420,1,Half-life in dog after oral administration at 1 mg/kg; nd is not determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6123,In vivo,N,1,CHEMBL621559,,,
7421,1,Half-life in dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4333,,N,1,CHEMBL621560,,,
7422,1,Half-life in dogs; ND indicates not determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4333,,N,1,CHEMBL876028,,,
7423,1,Half-life in plasma of dog,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,12500,,N,1,CHEMBL621561,,1969.0,
7424,1,Half-life in plasma of dog at dose of 3-10 mgkg,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,12500,,N,1,CHEMBL621562,,1969.0,
7425,1,Half-life was evaluated after i.v. administration in dog at a dose of 1 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6005,In vivo,N,1,CHEMBL621563,,,
7426,1,Half-life was measured in dog after an iv dose of 1 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6062,In vivo,N,1,CHEMBL621564,,,
7427,1,Half-life was measured in dogs after an oral dose of 10 uM/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17650,In vivo,N,1,CHEMBL621565,,,
7428,1,Half-life in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5530,In vivo,N,1,CHEMBL621566,,,
7429,1,Half-life in vivo in dog by intravenous administration at a dose of 1 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5530,In vivo,N,1,CHEMBL621567,,,
7430,1,Half-life of the compound after 0.3 mg/kg po administration in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5600,In vivo,N,1,CHEMBL622978,,,
7431,1,Half-life period after intravenous administration of 0.5 mg/kg in dog was determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6039,In vivo,N,1,CHEMBL873814,,,
7432,1,Half-life period after intravenous administration of 1.0 mg/kg in dog was determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6039,In vivo,N,1,CHEMBL623219,,,
7433,1,Half-life period after peroral administration of 0.2 mg/kg in dog was determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6039,In vivo,N,1,CHEMBL624477,,,
7434,1,t1/2 in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6227,,N,1,CHEMBL624478,,,
7435,1,Half-life period measured in dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,14541,,N,1,CHEMBL624479,,,
7436,1,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4521,In vivo,N,1,CHEMBL624480,,,
7437,1,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4521,In vivo,N,1,CHEMBL623595,,,
7438,1,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6679,In vivo,N,1,CHEMBL623596,,,
7439,1,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in dog plasma",Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,1116,In vitro,N,1,CHEMBL623597,,1969.0,
7440,1,In vivo half life period was calculated at 1 mg/kg in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5444,In vivo,N,1,CHEMBL623598,,,
7441,1,In vivo half life period was calculated at 1 mg/kg in dog; ND=Not determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5444,In vivo,N,1,CHEMBL623599,,,
7442,1,Longer half-life in dog (i.v.) at 0.5 mpk,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17853,In vivo,N,1,CHEMBL623600,,,
7443,1,Oral bioavailability in dog (dose 5 uM/kg),,BAO_0000218,,Canis lupus familiaris,,Intermediate,4353,In vivo,N,1,CHEMBL623601,,,
7444,1,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,16452,In vivo,N,1,CHEMBL623602,,,
7445,1,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,,BAO_0000218,,Canis lupus familiaris,,Intermediate,16452,In vivo,N,1,CHEMBL623603,,,
7446,1,Bioavailability in dog (dose 1 mg/kg i.v.),,BAO_0000218,,Canis lupus familiaris,,Intermediate,16452,In vivo,N,1,CHEMBL623604,,,
7447,1,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,Lung,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,N,1,CHEMBL623605,,2048.0,
7448,1,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Lung,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,N,1,CHEMBL623606,,2048.0,
7449,1,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Lung,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,N,1,CHEMBL623607,,2048.0,
7450,1,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Lung,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,N,1,CHEMBL623608,,2048.0,
7451,1,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Lung,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,N,1,CHEMBL623609,,2048.0,
7452,1,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Lung,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,N,1,CHEMBL623610,,2048.0,
7453,1,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Muscle tissue,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,N,1,CHEMBL623611,,2385.0,
7454,1,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,Muscle tissue,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,N,1,CHEMBL623612,,2385.0,
7455,1,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Muscle tissue,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,N,1,CHEMBL623613,,2385.0,
7456,1,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Muscle tissue,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,N,1,CHEMBL623614,,2385.0,
7457,1,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Muscle tissue,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,N,1,CHEMBL623615,,2385.0,
7458,1,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Muscle tissue,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,N,1,CHEMBL623616,,2385.0,
7459,1,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Muscle tissue,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,N,1,CHEMBL623617,,2385.0,
7460,1,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Zone of skin,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,N,1,CHEMBL875944,,14.0,
7461,1,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,Zone of skin,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,N,1,CHEMBL623618,,14.0,
7462,1,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Zone of skin,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,N,1,CHEMBL623619,,14.0,
7463,1,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Zone of skin,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,N,1,CHEMBL623620,,14.0,
7464,1,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Zone of skin,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,N,1,CHEMBL623621,,14.0,
7465,1,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Zone of skin,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,N,1,CHEMBL623622,,14.0,
7466,1,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Zone of skin,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,N,1,CHEMBL623623,,14.0,
7467,1,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Spleen,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,N,1,CHEMBL623624,,2106.0,
7468,1,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,Spleen,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,N,1,CHEMBL618521,,2106.0,
7469,1,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Spleen,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,N,1,CHEMBL618522,,2106.0,
7470,1,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Spleen,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,N,1,CHEMBL618523,,2106.0,
7471,1,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Spleen,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,N,1,CHEMBL618524,,2106.0,
7472,1,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Spleen,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,N,1,CHEMBL618525,,2106.0,
7473,1,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Spleen,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,N,1,CHEMBL624586,,2106.0,
7474,1,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Stomach,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,N,1,CHEMBL624587,,945.0,
7475,1,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,Stomach,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,N,1,CHEMBL624588,,945.0,
7476,1,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Stomach,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,N,1,CHEMBL624589,,945.0,
7477,1,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Stomach,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,N,1,CHEMBL624590,,945.0,
7478,1,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Stomach,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,N,1,CHEMBL624591,,945.0,
7479,1,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Stomach,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,N,1,CHEMBL624592,,945.0,
7480,1,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Stomach,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,N,1,CHEMBL624593,,945.0,
7481,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4689,In vivo,N,1,CHEMBL624594,,,
7482,1,Tested for the bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4950,In vivo,N,1,CHEMBL624595,,,
7483,1,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),,BAO_0000218,,Rattus norvegicus,,Intermediate,5328,In vivo,N,1,CHEMBL624596,,,
7484,1,Bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,406,In vivo,N,1,CHEMBL624597,,,
7485,1,Bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,12500,In vivo,N,1,CHEMBL624598,,,
7486,1,Bioavailability in rat (dose 3-10 mg/kg),,BAO_0000218,,Rattus norvegicus,,Intermediate,12500,In vivo,N,1,CHEMBL624599,,,
7487,1,Bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5247,In vivo,N,1,CHEMBL875166,,,
7488,1,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,4186,In vivo,N,1,CHEMBL624600,,1969.0,
7489,1,Apparent terminal elimination half-life in rat plasma after administration of 50 mg/kg dose through subcutaneous route,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,4186,In vivo,N,1,CHEMBL624601,,1969.0,
7490,1,Half life after oral administration was determined in rats at 6 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,6647,In vivo,N,1,CHEMBL624602,,,
7491,1,Half life was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,6484,,N,1,CHEMBL624603,,,
7492,1,Half life the of compound was determined by ''Cr'' assay in rat at a dose of 10 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,3249,In vivo,N,1,CHEMBL624604,,,
7493,1,Plasma half life in rat at oral dose 2.8 mg/mk body weight,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,6281,In vivo,N,1,CHEMBL624605,,1969.0,
7494,1,Half life in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,3307,,N,1,CHEMBL624606,,,
7495,1,Half-lives were estimated from the elimination phase of the blood conc-time curve after oral administration,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,12058,In vivo,N,1,CHEMBL624607,,178.0,
7496,1,Hill coefficient of the compound,,BAO_0000218,,Rattus norvegicus,,Intermediate,8833,,N,1,CHEMBL624608,,,
7497,1,Compound was tested for percent hydrolysis in whole blood after a time interval of 0.5 min,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,3193,,N,1,CHEMBL624609,,178.0,
7498,1,Compound was tested for percent hydrolysis in whole blood after a time interval of 180.0 min,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,3193,,N,1,CHEMBL624610,,178.0,
7499,1,Compound was tested for percent hydrolysis in whole blood after a time interval of 2.0 min,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,3193,,N,1,CHEMBL624611,,178.0,
7500,1,Compound was tested for percent hydrolysis in whole blood after a time interval of 5.0 min,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,3193,,N,1,CHEMBL624612,,178.0,
7501,1,Compound was tested for percent hydrolysis in whole blood after a time interval of 60.0 min,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,3193,,N,1,CHEMBL875167,,178.0,
7502,1,Compound was tested for percent hydrolysis in whole blood after a time interval of 7.0 min,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,3193,,N,1,CHEMBL624613,,178.0,
7503,1,"Compound was tested for percent hydrolysis in whole blood, after a time interval of 15.0 min",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,3193,,N,1,CHEMBL624614,,178.0,
7504,1,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,,BAO_0000218,,Rattus norvegicus,,Intermediate,5960,,N,1,CHEMBL624392,,,
7505,1,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/organ,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,N,1,CHEMBL624393,,955.0,
7506,1,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/organ,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,N,1,CHEMBL624394,,955.0,
7507,1,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/organ,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,N,1,CHEMBL624395,,955.0,
7508,1,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/organ,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,N,1,CHEMBL624396,,955.0,
7509,1,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/organ,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,N,1,CHEMBL624397,,955.0,
7510,1,Biodistribution of [123I]-label in rat thyroid was reported at 0.33 hr post injection. Value shown is %ID/organ,Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,N,1,CHEMBL624398,,2046.0,
7511,1,Biodistribution of [123I]-label in rat thyroid was reported at 1 hr post injection. Value shown is %ID/organ,Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,N,1,CHEMBL624399,,2046.0,
7512,1,Biodistribution of [123I]-label in rat thyroid was reported at 2 hr post injection. Value shown is %ID/organ,Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,N,1,CHEMBL624400,,2046.0,
7513,1,Biodistribution of [123I]-label in rat thyroid was reported at 24 hr post injection. Value shown is %ID/organ,Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,N,1,CHEMBL624401,,2046.0,
7514,1,Biodistribution of [123I]-label in rat thyroid was reported at 4 hr post injection. Value shown is %ID/organ,Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,N,1,CHEMBL624402,,2046.0,
7515,1,Biodistribution in normal rat blood in the presence of 0.005 M Gd/0.01 M lig at 2 hr,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL624403,,178.0,
7516,1,Biodistribution in normal rat blood in the presence of 0.01 M Gd/0.05 M lig,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL624404,,178.0,
7517,1,Biodistribution in normal rat blood in the presence of NAC Gd 0.01 M lig at 2 hr,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL624405,,178.0,
7518,1,Biodistribution in normal rat bone in the presence of 0.005 M Gd/0.01 M lig at 2 hr,Bone,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL624406,,10000001.0,
7519,1,Biodistribution in normal rat bone in the presence of 0.01 M Gd/0.05 M lig,Bone,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL624407,,10000001.0,
7520,1,Biodistribution in normal rat bone in the presence of NAC Gd 0.01 M lig at 2 hr,Bone,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL624408,,10000001.0,
7521,1,Biodistribution in normal rat heart in the presence of 0.005 M Gd/0.01 M lig at 2 hr,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL618644,,948.0,
7522,1,Biodistribution in normal rat heart in the presence of 0.01 M Gd/0.05 M lig,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL618645,,948.0,
7523,1,Biodistribution in normal rat heart in the presence of NAC Gd 0.01 M lig at 2 hr,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL618646,,948.0,
7524,1,Biodistribution in normal rat kidney in the presence of 0.005 M Gd/0.01 M lig at 2 hr,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL618647,,2113.0,
7525,1,Biodistribution in normal rat kidney in the presence of 0.01 M Gd/0.05 M lig,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL618648,,2113.0,
7526,1,Biodistribution in normal rat kidney in the presence of NAC Gd 0.01 M lig at 2 hr,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL618649,,2113.0,
7527,1,Biodistribution in normal rat liver in the presence of 0.005 M Gd/0.01 M lig at 2 hr,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL618650,,2107.0,
7528,1,Biodistribution in normal rat liver in the presence of 0.01 M Gd/0.05 M lig,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL618651,,2107.0,
7529,1,Biodistribution in normal rat liver in the presence of NAC Gd 0.01 M lig at 2 hr,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL876497,,2107.0,
7530,1,Biodistribution in normal rat lung in the presence of 0.005 M Gd/0.01 M lig at 2 hr,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL618652,,2048.0,
7531,1,Biodistribution in normal rat lung in the presence of 0.01 M Gd/0.05 M lig,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL618653,,2048.0,
7532,1,Biodistribution in normal rat lung in the presence of NAC Gd 0.01 M lig at 2 hr,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL618654,,2048.0,
7533,1,Recovery rate from urine and bile was determined after iv administration at 20 mg/kg in rats; Not tested,,BAO_0000218,,Rattus norvegicus,,Intermediate,6351,,N,1,CHEMBL618655,,,
7534,1,Compound was tested for solubility in water,,BAO_0000218,,Rattus norvegicus,,Intermediate,1465,,N,1,CHEMBL618656,,,
7535,1,Solubility in phosphate buffered saline (1% DMSO) at pH 6.5 (24 hr equilibration),,BAO_0000100,,,,Intermediate,5182,,U,0,CHEMBL618657,,,
7536,1,Solubility was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,17847,,N,1,CHEMBL618658,,,
7537,1,solubility in water (ug/mL) at 37 degree C.,,BAO_0000218,,Rattus norvegicus,,Intermediate,15339,,N,1,CHEMBL618659,,,
7538,1,First pass metabolism and metabolic bioavailability using rat hepatic microsomes,,BAO_0000218,,Rattus norvegicus,,Intermediate,5202,,N,1,CHEMBL618660,,,
7539,1,In vitro stability relative to (+)-AJ76 in rat hepatocyte assay,,BAO_0000218,,Rattus norvegicus,,Intermediate,1088,,N,1,CHEMBL618661,,,
7540,1,Half life in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,3169,,N,1,CHEMBL873807,,,
7541,1,Half life in Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5353,,N,1,CHEMBL618662,,,
7542,1,Half life period after 3 mg/kg iv administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,2864,In vivo,N,1,CHEMBL618663,,,
7543,1,Half life period after 3 mg/kg iv administration in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,2864,In vivo,N,1,CHEMBL618664,,,
7544,1,Half life period after 3 mg/kg iv administration in the rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,2864,In vivo,N,1,CHEMBL618665,,,
7545,1,Half life period in female Sprague-Dawley rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,6362,,N,1,CHEMBL876498,,,
7546,1,Half life period in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6249,,N,1,CHEMBL618666,,,
7547,1,Half-life in rats was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,3169,,N,1,CHEMBL620440,,,
7548,1,Half-life in rats with metabolic oxidation,,BAO_0000218,,Rattus norvegicus,,Intermediate,3169,,N,1,CHEMBL620441,,,
7549,1,Half-life in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,3169,,N,1,CHEMBL620442,,,
7550,1,T 1/2 at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,17260,In vivo,N,1,CHEMBL620443,,,
7551,1,T 1/2 at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,17260,In vivo,N,1,CHEMBL620444,,,
7552,1,T max at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,17260,In vivo,N,1,CHEMBL620445,,,
7553,1,T max at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,17260,In vivo,N,1,CHEMBL620446,,,
7554,1,Biological half-life measured in plasma of rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,2879,,N,1,CHEMBL620447,,1969.0,
7555,1,Biological half-life measured in plasma of rat; 22-25,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,2879,,N,1,CHEMBL621129,,1969.0,
7556,1,Biological half-life measured in plasma of rat; 9-16,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,2879,,N,1,CHEMBL621130,,1969.0,
7557,1,Compound was evaluated for its half life when administered intravenously in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,3184,In vivo,N,1,CHEMBL873808,,,
7558,1,Compound was evaluated for pharmacokinetic parameter percent bioavailability at 8 h,,BAO_0000218,,Rattus norvegicus,,Intermediate,4891,In vivo,N,1,CHEMBL876598,,,
7559,1,Evaluated for pharmacokinetic parameter half-life in rat at the dose 50 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,429,In vivo,N,1,CHEMBL621131,,,
7560,1,Half life (T1/2) after oral administration in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5656,In vivo,N,1,CHEMBL621132,,,
7561,1,Half life of compound after iv administration of 20 mg/kg dose in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4413,In vivo,N,1,CHEMBL621133,,,
7562,1,Half life of compound determined in rat after iv administration at a dose of 10 mg/kg,,BAO_0000218,,Rattus norvegicus,,Expert,3598,In vivo,N,1,CHEMBL621312,,,
7563,1,Half life of compound was determined in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,17267,,N,1,CHEMBL621313,,,
7564,1,Half life of compound was determined in rat blood,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,4727,,N,1,CHEMBL621314,,178.0,
7565,1,Half life at 1 mg/kg was determined in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,17651,In vivo,N,1,CHEMBL621315,,,
7566,1,Half life at 10 mg/kg was determined in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,17651,In vivo,N,1,CHEMBL621316,,,
7567,1,Half life in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,401,,N,1,CHEMBL621317,,,
7568,1,Half life in rats in hours,,BAO_0000218,,Rattus norvegicus,,Intermediate,4942,,N,1,CHEMBL621318,,,
7569,1,Half life following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,17735,In vivo,N,1,CHEMBL621319,,,
7570,1,Half life was calculated at a single intravenous administration of 20 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6056,In vivo,N,1,CHEMBL621377,,,
7571,1,Half life was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,5213,,N,1,CHEMBL621378,,,
7572,1,Half life after i.v. administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,6616,In vivo,N,1,CHEMBL876599,,,
7573,1,Half life in rat after intravenous administration at a concentration 0.5 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,5937,In vivo,N,1,CHEMBL621379,,,
7574,1,Half life in rat plasma,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,5819,,N,1,CHEMBL621380,,1969.0,
7575,1,Half life in rat plasma; Not detected,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,5819,,N,1,CHEMBL621381,,1969.0,
7576,1,Half life in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,6803,,N,1,CHEMBL618515,,,
7577,1,Half life period of compound was determined after peroral administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,17804,In vivo,N,1,CHEMBL618516,,,
7578,1,Half life period of compound was determined at a dose of 3 mg/kg by intravenous administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,17804,In vivo,N,1,CHEMBL618517,,,
7579,1,Half life period in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5948,,N,1,CHEMBL618518,,,
7580,1,Half life period was evaluated against Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,1916,In vivo,N,1,CHEMBL618519,,,
7581,1,Half life period was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,1916,In vivo,N,1,CHEMBL618698,,,
7582,1,Half life period was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration; Not available,,BAO_0000218,,Rattus norvegicus,,Intermediate,1916,In vivo,N,1,CHEMBL618862,,,
7583,1,Half life period was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,4890,In vivo,N,1,CHEMBL618863,,,
7584,1,Half life period was determined for compound after intravenous administration in rats at 24 uM/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,17764,In vivo,N,1,CHEMBL618864,,,
7585,1,Half life time in rat the dose of 2 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,4727,In vivo,N,1,CHEMBL618865,,,
7586,1,Half-life 24 hr after 10 mg/kg iv administration in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,17509,In vivo,N,1,CHEMBL618866,,,
7587,1,Half-life 24 hr after 2 mg/kg iv administration in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,17509,In vivo,N,1,CHEMBL618867,,,
7588,1,Half-life consistent with the observed metabolic steady state in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,6597,,N,1,CHEMBL875828,,,
7589,1,Half-life following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,17735,In vivo,N,1,CHEMBL618868,,,
7590,1,Half-life for oxidative metabolic stability was determined using male human,,BAO_0000218,,Rattus norvegicus,,Intermediate,6597,,N,1,CHEMBL618869,,,
7591,1,"Half-life in fischer rats at 5 mg/kg dose, administered intravenously",,BAO_0000218,,Rattus norvegicus,,Intermediate,17670,In vivo,N,1,CHEMBL618870,,,
7592,1,Half-life in rat plasma,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,1696,,N,1,CHEMBL618871,,1969.0,
7593,1,Half-life in rat plasma was determined,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,1742,,N,1,CHEMBL618872,,1969.0,
7594,1,Half-life in rats was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,17800,,N,1,CHEMBL873816,,,
7595,1,Area under curve of acid 2a was determined by HPLC at a dosage of 54.5 mg/kg administered intragastrically by gavage method in dog,,BAO_0000218,,,,Autocuration,12923,,U,0,CHEMBL618873,,,
7596,1,Area under curve after oral dose of 0.1 mg//kg,,BAO_0000019,,,,Autocuration,11954,,U,0,CHEMBL621602,,,
7597,1,Area under curve after oral dose of 0.3 mg/kg,,BAO_0000218,,,,Autocuration,11954,,U,0,CHEMBL621603,,,
7598,1,Area under curve after oral dose of 1 mg/kg,,BAO_0000218,,,,Autocuration,11954,,U,0,CHEMBL621604,,,
7599,1,Area under curve after oral dose of 10 mg/kg,,BAO_0000218,,,,Autocuration,11954,,U,0,CHEMBL621605,,,
7600,1,Area under curve after oral dose of 23.4 mg/kg,,BAO_0000218,,,,Autocuration,11954,,U,0,CHEMBL621606,,,
7601,1,Area under curve after oral dose of 3 mg/kg,,BAO_0000218,,,,Autocuration,11954,,U,0,CHEMBL621607,,,
7602,1,Area under curve after oral dose of 3.87 mg/kg,,BAO_0000218,,,,Autocuration,11954,,U,0,CHEMBL621608,,,
7603,1,Area under curve was determined,,BAO_0000019,,,,Autocuration,5237,,U,0,CHEMBL621609,,,
7604,1,Area under curve at a dose of 10 mg/kg,,BAO_0000218,,,,Autocuration,4026,,U,0,CHEMBL621610,,,
7605,1,Area under curve was determined; ND=No data,,BAO_0000218,,Rattus norvegicus,,Intermediate,5237,,N,1,CHEMBL621611,,,
7606,1,Area under curve was evaluated in rat brain when administered intraperitoneally at a dose of 10 mg/kg for 4 or 6 hours,,BAO_0000218,,Rattus norvegicus,,Intermediate,14793,,N,1,CHEMBL621612,,,
7607,1,Area under curve was evaluated in rat brain when administered intraperitoneally at a dose of 10 mg/kg for infinite hours,,BAO_0000218,,Rattus norvegicus,,Intermediate,14793,,N,1,CHEMBL622308,,,
7608,1,Area under curve was evaluated in rat brain when administered intravenously at a dose of 10 mg/kg for 4 or 6 hours,,BAO_0000218,,Rattus norvegicus,,Intermediate,14793,,N,1,CHEMBL622309,,,
7609,1,Area under curve was evaluated in rat brain when administered intravenously at a dose of 10 mg/kg for infinite hours,,BAO_0000218,,Rattus norvegicus,,Intermediate,14793,,N,1,CHEMBL622310,,,
7610,1,Area under curve was evaluated in rat brain when administered perorally at a dose of 100 mg/kg for 4 or 6 hours,,BAO_0000218,,Rattus norvegicus,,Intermediate,14793,,N,1,CHEMBL622311,,,
7611,1,Area under curve was evaluated in rat brain when administered perorally at a dose of 100 mg/kg for infinite hours; Not calculated,,BAO_0000218,,Rattus norvegicus,,Intermediate,14793,,N,1,CHEMBL622312,,,
7612,1,Area under curve was evaluated in rat brain when administered perorally at a dose of 10 mg/kg for 4 or 6 hours,,BAO_0000218,,Rattus norvegicus,,Intermediate,14793,,N,1,CHEMBL622931,,,
7613,1,Area under curve was evaluated in rat brain when administered perorally at a dose of 10 mg/kg for infinite hours; Not calculated,,BAO_0000218,,Rattus norvegicus,,Intermediate,14793,,N,1,CHEMBL622932,,,
7614,1,Area under curve was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg for 4 or 6 hours,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14793,,N,1,CHEMBL622736,,1969.0,
7615,1,Area under curve was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg for infinite hours,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14793,,N,1,CHEMBL622737,,1969.0,
7616,1,Area under curve was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg for 4 or 6 hours,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14793,,N,1,CHEMBL622738,,1969.0,
7617,1,Area under curve was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg for infinite hours,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14793,,N,1,CHEMBL622739,,1969.0,
7618,1,Area under curve was evaluated in rat plasma when administered perorally at a dose of 100 mg/kg for 4 or 6 hours,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14793,,N,1,CHEMBL622740,,1969.0,
7619,1,Area under curve was evaluated in rat plasma when administered perorally at a dose of 100 mg/kg for infinite hours,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14793,,N,1,CHEMBL622741,,1969.0,
7620,1,Area under curve was evaluated in rat plasma when administered perorally at a dose of 10 mg/kg for 4 or 6 hours,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14793,,N,1,CHEMBL622742,,1969.0,
7621,1,Area under curve was evaluated in rat plasma when administered perorally at a dose of 10 mg/kg for infinite hours,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14793,,N,1,CHEMBL622743,,1969.0,
7622,1,AUC in mice,Plasma,BAO_0000218,,Mus musculus,,Intermediate,11637,,N,1,CHEMBL622744,,1969.0,
7623,1,Area under curve was measured from the graph obtained from concentration Vs time,,BAO_0000019,,,,Autocuration,11149,,U,0,CHEMBL624134,,,
7624,1,Area under curve value of compound per hour after oral administration,,BAO_0000019,,,,Autocuration,10016,,U,0,CHEMBL624135,,,
7625,1,Area under curve was determined after oral administration in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,17796,,N,1,CHEMBL624136,,,
7626,1,Area under curve was determined after oral administration in rats; No data,,BAO_0000218,,Rattus norvegicus,,Intermediate,17796,,N,1,CHEMBL624137,,,
7627,1,Area under curve was determined after oral administration in rats;No data,,BAO_0000218,,Rattus norvegicus,,Intermediate,17796,,N,1,CHEMBL624320,,,
7628,1,Area under curve was determined by HPLC at a dosage of 2.27 mg/kg administered intravenously by bolus method in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,12923,,N,1,CHEMBL624321,,,
7629,1,Area under curve was determined for the compound after iv dose of 4.74 mg/kg in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,15372,,N,1,CHEMBL624322,,,
7630,1,Area under curve was determined for the compound after iv dose of 5.06 in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,15372,,N,1,CHEMBL624323,,,
7631,1,Area under curve was determined for the compound after iv dose of 5.10 mg/kg in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,15372,,N,1,CHEMBL624324,,,
7632,1,Area under curve was determined for the compound after po dose of 5.01 mg/kg in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,15372,,N,1,CHEMBL624325,,,
7633,1,Area under curve was determined for the compound after po dose of 5.03 mg/kg in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,15372,,N,1,CHEMBL624326,,,
7634,1,Area under curve was determined for the compound after po dose of 5.22 mg/kg in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,15372,,N,1,CHEMBL624327,,,
7635,1,Area under curve was determined for the compound after po dose of 5.46 mg/kg in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,15372,,N,1,CHEMBL624328,,,
7636,1,Area under curve was determined in Dogs after peroral administration,,BAO_0000218,,Canis lupus familiaris,,Intermediate,14169,,N,1,CHEMBL627848,,,
7637,1,Area under curve was determined in Rats after peroral administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,14169,,N,1,CHEMBL627849,,,
7638,1,Area under curve was determined in carotid blood of rat when administered intradermally,,BAO_0000218,,Rattus norvegicus,,Intermediate,14258,,N,1,CHEMBL627850,,,
7639,1,Area under curve was determined in portal blood of rat when administered intradermally,,BAO_0000218,,Rattus norvegicus,,Intermediate,14258,,N,1,CHEMBL627851,,,
7640,1,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg,,BAO_0000218,,Mus musculus,,Intermediate,15011,,N,1,CHEMBL627852,,,
7641,1,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg,,BAO_0000218,,Mus musculus,,Intermediate,15011,,N,1,CHEMBL627853,,,
7642,1,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (micronized sample),,BAO_0000218,,Mus musculus,,Intermediate,15011,,N,1,CHEMBL627854,,,
7643,1,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg,,BAO_0000218,,Mus musculus,,Intermediate,15011,,N,1,CHEMBL627855,,,
7644,1,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg (run time 7 hr),,BAO_0000218,,Mus musculus,,Intermediate,15011,,N,1,CHEMBL627856,,,
7645,1,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg,,BAO_0000218,,Mus musculus,,Intermediate,15011,,N,1,CHEMBL875339,,,
7646,1,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (Run time = 7 hr),,BAO_0000218,,Mus musculus,,Intermediate,15011,,N,1,CHEMBL627857,,,
7647,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 65 mins after i.v. administration,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,11195,In vivo,N,1,CHEMBL627858,,2106.0,
7648,1,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in blood; Expressed as percent dose/organ,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,10130,,N,1,CHEMBL627859,,178.0,
7649,1,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in brain; Expressed as percent dose/organ,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,10130,,N,1,CHEMBL627860,,955.0,
7650,1,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in heart; Expressed as percent dose/organ,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,10130,,N,1,CHEMBL627019,,948.0,
7651,1,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in liver; Expressed as percent dose/organ,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,10130,,N,1,CHEMBL627020,,2107.0,
7652,1,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in lung; Expressed as percent dose/organ,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,10130,,N,1,CHEMBL627021,,2048.0,
7653,1,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in muscle; Expressed as percent dose/organ,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,10130,,N,1,CHEMBL627022,,2385.0,
7654,1,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in skin; Expressed as percent dose/organ,,BAO_0000218,,Rattus norvegicus,,Intermediate,10130,,N,1,CHEMBL627023,,,
7655,1,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in spleen; Expressed as percent dose/organ,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,10130,,N,1,CHEMBL627024,,2106.0,
7656,1,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in thyroid; Expressed as percent dose/organ,Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,10130,,N,1,CHEMBL627025,,2046.0,
7657,1,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in kidney; Expressed as percent dose/organ,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,10130,,N,1,CHEMBL627026,,2113.0,
7658,1,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in blood; Expressed as percent dose/organ,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,10130,,N,1,CHEMBL627027,,178.0,
7659,1,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in brain; Expressed as percent dose/organ,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,10130,,N,1,CHEMBL627028,,955.0,
7660,1,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in heart; Expressed as percent dose/organ,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,10130,,N,1,CHEMBL627029,,948.0,
7661,1,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in kidney; Expressed as percent dose/organ,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,10130,,N,1,CHEMBL627030,,2113.0,
7662,1,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in liver; Expressed as percent dose/organ,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,10130,,N,1,CHEMBL627031,,2107.0,
7663,1,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in lung; Expressed as percent dose/organ,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,10130,,N,1,CHEMBL627032,,2048.0,
7664,1,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in muscle; Expressed as percent dose/organ,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,10130,,N,1,CHEMBL627033,,2385.0,
7665,1,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in skin; Expressed as percent dose/organ,,BAO_0000218,,Rattus norvegicus,,Intermediate,10130,,N,1,CHEMBL627034,,,
7666,1,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in spleen; Expressed as percent dose/organ,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,10130,,N,1,CHEMBL627035,,2106.0,
7667,1,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in thyroid; Expressed as percent dose/organ,Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,10130,,N,1,CHEMBL627036,,2046.0,
7668,1,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in blood; Expressed as percent dose/organ,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,10130,,N,1,CHEMBL875340,,178.0,
7669,1,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in heart; Expressed as percent dose/organ,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,10130,,N,1,CHEMBL627037,,948.0,
7670,1,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in kidney; Expressed as percent dose/organ,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,10130,,N,1,CHEMBL627038,,2113.0,
7671,1,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in liver; Expressed as percent dose/organ,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,10130,,N,1,CHEMBL627039,,2107.0,
7672,1,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in muscle; Expressed as percent dose/organ,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,10130,,N,1,CHEMBL627040,,2385.0,
7673,1,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in spleen; Expressed as percent dose/organ,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,10130,,N,1,CHEMBL624663,,2106.0,
7674,1,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in thyroid; Expressed as percent dose/organ,Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,10130,,N,1,CHEMBL625963,,2046.0,
7675,1,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in brain; Expressed as percent dose/organ,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,10130,,N,1,CHEMBL876799,,955.0,
7676,1,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in lung; Expressed as percent dose/organ,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,10130,,N,1,CHEMBL626133,,2048.0,
7677,1,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in skin; Expressed as percent dose/organ,,BAO_0000218,,Rattus norvegicus,,Intermediate,10130,,N,1,CHEMBL626134,,,
7678,1,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,6295,,N,1,CHEMBL626135,,,
7679,1,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,6296,,N,1,CHEMBL626136,,,
7680,1,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg; Below detection limit,,BAO_0000218,,Rattus norvegicus,,Intermediate,6296,,N,1,CHEMBL626137,,,
7681,1,In vivo concentration in rat plasma exposure at 8 hour after oral administration 50 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,6295,,N,1,CHEMBL626138,,,
7682,1,In vivo concentration in rat plasma exposure at 8 hour after oral administration 50 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,6296,,N,1,CHEMBL626139,,,
7683,1,C max at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,17260,In vivo,N,1,CHEMBL626140,,,
7684,1,C max at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,17260,In vivo,N,1,CHEMBL626141,,,
7685,1,C24h in rat p.o. at 20 mg/kg concentration,,BAO_0000218,,Rattus norvegicus,,Intermediate,17686,,N,1,CHEMBL626142,,,
7686,1,Biodistribution in normal rat muscle in the presence of 0.005 M Gd/0.01 M lig at 2 hr,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL627930,,2385.0,
7687,1,Biodistribution in normal rat muscle in the presence of 0.01 M Gd/0.05 M lig,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL627931,,2385.0,
7688,1,Biodistribution in normal rat muscle in the presence of NAC Gd 0.01 M lig at 2 hr,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL627932,,2385.0,
7689,1,Biodistribution in normal rat spleen in the presence of 0.005 M Gd/0.01 M lig at 2 hr,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL627933,,2106.0,
7690,1,Biodistribution in normal rat spleen in the presence of 0.01 M Gd/0.05 M lig,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL627934,,2106.0,
7691,1,Biodistribution in normal rat spleen in the presence of NAC Gd 0.01 M lig at 2 hr,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL627935,,2106.0,
7692,1,Biodistribution in rat blood in the presence of 0.001 M/0.008 M GdDTPA-AEP,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL627936,,178.0,
7693,1,Biodistribution in rat blood in the presence of 0.01 M GdDTPA-BDP,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL627937,,178.0,
7694,1,Biodistribution in rat blood in the presence of 0.01 M/0.01 M GdDTPA-AEP,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL627938,,178.0,
7695,1,Biodistribution in rat blood in the presence of 0.05 M Gd/0.15 M lig,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL627939,,178.0,
7696,1,Biodistribution in rat blood in the presence of 0.05 M GdDTPA-BDP,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL627940,,178.0,
7697,1,Biodistribution in rat blood in the presence of 0.05 M/0.05 M GdDTPA-AEP,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL627941,,178.0,
7698,1,Biodistribution in rat blood in the presence of 0.05 M/0.08 M GdDTPA-HPDP,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL876800,,178.0,
7699,1,Biodistribution in rat blood in the presence of 0.10 M GdDTPA-BDP,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL627942,,178.0,
7700,1,Biodistribution in rat blood in the presence of 0.10 M/0.11 M GdDTPA-AEP,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL627943,,178.0,
7701,1,Biodistribution in rat blood in the presence of 50 Gd/kg at 15 min,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL627944,,178.0,
7702,1,Biodistribution in rat blood in the presence of 50 Gd/kg at 2 hr,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL627945,,178.0,
7703,1,Biodistribution in rat blood in the presence of 50 Gd/kg at 6 hr,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL628584,,178.0,
7704,1,Biodistribution in rat blood in the presence of GdDTPA at 15 min,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL628585,,178.0,
7705,1,Biodistribution in rat blood in the presence of GdDTPA at 1 hr,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL628586,,178.0,
7706,1,Biodistribution in rat blood in the presence of GdDTPA at 30 min,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL628587,,178.0,
7707,1,Biodistribution in rat blood in the presence of GdDTPA at 4 hr,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL628588,,178.0,
7708,1,Biodistribution in rat blood in the presence of GdDTPA-BDP at 15 min,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL628589,,178.0,
7709,1,Biodistribution in rat blood in the presence of GdDTPA-BDP at 30 min,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL625304,,178.0,
7710,1,Biodistribution in rat blood in the presence of GdDTPA-BDP at 4 hr,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL625305,,178.0,
7711,1,Biodistribution in rat blood in the presence of GdDTPA-BDPat 1 hr,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL625306,,178.0,
7712,1,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 15 min,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL625307,,178.0,
7713,1,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 30 min,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL625308,,178.0,
7714,1,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 4 hr,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL627740,,178.0,
7715,1,Biodistribution in rat blood in the presence of GdDTPA-HPDPat 1 hr,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL627741,,178.0,
7716,1,Biodistribution in rat blood in the presence of NAC Gd/0.01 M GdDTPA-HPDP,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL627742,,178.0,
7717,1,Biodistribution in rat blood in the presence of NCA Gd/0.01 M lip,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL627743,,178.0,
7718,1,Biodistribution in rat blood in the presence of NCAGd/0.01 M lig,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL627744,,178.0,
7719,1,Biodistribution in rat bone in the presence of 0.01 M GdDTPA-BDP,Bone,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL627745,,10000001.0,
7720,1,Biodistribution in rat bone in the presence of 0.01 M/0.01 M GdDTPA-AEP,Bone,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL627746,,10000001.0,
7721,1,Biodistribution in rat bone in the presence of 0.01 M/0.08 M GdDTPA-AEP,Bone,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL627747,,10000001.0,
7722,1,Biodistribution in rat bone in the presence of 0.05 M Gd/0.15 M lig,Bone,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL876810,,10000001.0,
7723,1,Biodistribution in rat bone in the presence of 0.05 M GdDTPA-BDP,Bone,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL627748,,10000001.0,
7724,1,Biodistribution in rat bone in the presence of 0.05 M/0.05 M GdDTPA-AEP,Bone,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL627749,,10000001.0,
7725,1,Biodistribution in rat bone in the presence of 0.05 M/0.08 M GdDTPA-HPDP,Bone,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL627750,,10000001.0,
7726,1,Biodistribution in rat bone in the presence of 0.10 M GdDTPA-BDP,Bone,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL618728,,10000001.0,
7727,1,Biodistribution in rat bone in the presence of 0.10 M/0.11 M GdDTPA-AEP,Bone,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL618729,,10000001.0,
7728,1,Biodistribution in rat bone in the presence of GdDTPA at 15 min,Bone,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL618730,,10000001.0,
7729,1,Biodistribution in rat bone in the presence of GdDTPA at 1 hr,Bone,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL618731,,10000001.0,
7730,1,Biodistribution in rat bone in the presence of GdDTPA at 30 min,Bone,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL618732,,10000001.0,
7731,1,Biodistribution in rat bone in the presence of GdDTPA at 4 hr,Bone,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL618733,,10000001.0,
7732,1,Biodistribution in rat bone in the presence of GdDTPA-BDP at 15 min,Bone,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL618734,,10000001.0,
7733,1,Biodistribution in rat bone in the presence of GdDTPA-BDP at 1 hr,Bone,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL618735,,10000001.0,
7734,1,Biodistribution in rat bone in the presence of GdDTPA-BDP at 30 min,Bone,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL876602,,10000001.0,
7735,1,Biodistribution in rat bone in the presence of GdDTPA-BDP at 4 hr,Bone,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL618736,,10000001.0,
7736,1,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 15 min,Bone,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL618737,,10000001.0,
7737,1,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 1 hr,Bone,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL618738,,10000001.0,
7738,1,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 30 min,Bone,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL618739,,10000001.0,
7739,1,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 4 hr,Bone,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL618740,,10000001.0,
7740,1,Biodistribution in rat bone in the presence of NAC Gd/0.01 M GdDTPA-HPDP,Bone,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL618741,,10000001.0,
7741,1,Biodistribution in rat bone in the presence of NCA Gd/0.01 M lip,Bone,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL618742,,10000001.0,
7742,1,Biodistribution in rat bone in the presence of NCAGd/0.01 M lig,Bone,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL618743,,10000001.0,
7743,1,Half-life from rat plasma at a single oral dose of 25 mg/kg,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,17752,In vivo,N,1,CHEMBL618744,,1969.0,
7744,1,Half-life in male rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5610,,N,1,CHEMBL618745,,,
7745,1,Half-life in rat after peroral administration at 10 mg/kg concentration,,BAO_0000218,,Rattus norvegicus,,Intermediate,5939,In vivo,N,1,CHEMBL620479,,,
7746,1,Half-life in rat after peroral administration at 5 mg/kg concentration,,BAO_0000218,,Rattus norvegicus,,Intermediate,5939,In vivo,N,1,CHEMBL620480,,,
7747,1,Half-life in rat at a dose of 3 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,17771,In vivo,N,1,CHEMBL620481,,,
7748,1,Half-life was evaluated in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,1974,,N,1,CHEMBL620482,,,
7749,1,Half-life was measured in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4239,,N,1,CHEMBL876603,,,
7750,1,Half-life period for the compound was determined in rats at 50 mg/kg dose,,BAO_0000218,,Rattus norvegicus,,Intermediate,6681,In vivo,N,1,CHEMBL620483,,,
7751,1,Half-life period in rats after intravenous administration at 5 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,17752,In vivo,N,1,CHEMBL620484,,,
7752,1,Half-life period in rat at 10 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,6046,In vivo,N,1,CHEMBL620485,,,
7753,1,"Half-life period was determined in rats at 10 mg/kg, p.o. dose",,BAO_0000218,,Rattus norvegicus,,Intermediate,6685,In vivo,N,1,CHEMBL620486,,,
7754,1,"Half-life period was determined in rats at 20 mg/kg, i.p. dose",,BAO_0000218,,Rattus norvegicus,,Intermediate,6685,In vivo,N,1,CHEMBL620487,,,
7755,1,"Half-life period was determined in rats at 2 mg/kg, i.v. dose",,BAO_0000218,,Rattus norvegicus,,Intermediate,6685,In vivo,N,1,CHEMBL620488,,,
7756,1,Half-life time in rat the dose of 2 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,4727,In vivo,N,1,CHEMBL620489,,,
7757,1,Half-life was estimated from the elimination phase of the oral [C] vs time curves in 4 rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,1088,In vivo,N,1,CHEMBL620490,,,
7758,1,In vivo activity against Staphylococcus aureus when administered orally for 1 hr in rat at a dose of 15 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,5610,In vivo,N,1,CHEMBL620491,,,
7759,1,"In vivo half life of compound in rat plasma after a oral dose of 10 mg/kg (in water, N=4)",Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,3032,In vivo,N,1,CHEMBL876604,,1969.0,
7760,1,Oral half life was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,5199,In vivo,N,1,CHEMBL620492,,,
7761,1,"Pharmacokinetic Parameter, half life period measured in Female Wistar Rats at 100 mg/kg by po administration",,BAO_0000218,,Rattus norvegicus,,Intermediate,14941,In vivo,N,1,CHEMBL620493,,,
7762,1,Pharmacokinetic property (t1/2) in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4408,In vivo,N,1,CHEMBL620494,,,
7763,1,Plasma elimination half-life was determined,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,2552,,N,1,CHEMBL620495,,1969.0,
7764,1,Plasma elimination half-life was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,5199,In vivo,N,1,CHEMBL620496,,1969.0,
7765,1,Plasma half life was observed after intravenous administration in rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,15662,In vivo,N,1,CHEMBL620497,,1969.0,
7766,1,Plasma half-life was determined,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,1465,,N,1,CHEMBL620498,,1969.0,
7767,1,Plasma half-life following oral administration in Fisher rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,1446,In vivo,N,1,CHEMBL620499,,1969.0,
7768,1,Plasma half-life in rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,6824,,N,1,CHEMBL620500,,1969.0,
7769,1,Plasmatic Half-life after intravenous administration to rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,17533,In vivo,N,1,CHEMBL873809,,1969.0,
7770,1,T1/2 (half life) of compound after 2 hr iv infusion of 8.4 mg/kg in three rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5979,In vivo,N,1,CHEMBL620501,,,
7771,1,Terminal half life after intravenous administration (1 mg/kg) in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4689,In vivo,N,1,CHEMBL620502,,,
7772,1,Terminal half life in Rat at a oral dose of 5 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,4689,In vivo,N,1,CHEMBL620503,,,
7773,1,Terminal phase half-life was evaluated in vivo in rat at a dose of 5 mg/kg by intra venous administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,2463,In vivo,N,1,CHEMBL620504,,,
7774,1,Tested for half life value after intravenous administration at dose of 0.2 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4883,In vivo,N,1,CHEMBL876605,,,
7775,1,Tested for half life value after oral administration at dosage of 4 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4883,In vivo,N,1,CHEMBL620505,,,
7776,1,plasma half life was observed after intravenous administration in rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,15662,In vivo,N,1,CHEMBL873811,,1969.0,
7777,1,Half life of compound determined in rat after iv administration at a dose of 10 mg/kg,,BAO_0000218,,Rattus norvegicus,,Expert,3598,In vivo,N,1,CHEMBL624016,,,
7778,1,Half life of compound determined in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4576,,N,1,CHEMBL624017,,,
7779,1,Mean residence time determined in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4576,,N,1,CHEMBL624018,,,
7780,1,Plasma half life determined in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4576,,N,1,CHEMBL624019,,,
7781,1,Compound was evaluated for Tmax in brain after intravenous administration in male rats,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,4910,In vivo,N,1,CHEMBL624020,,955.0,
7782,1,Compound was evaluated for pharmacokinetic parameter maximum time period,,BAO_0000218,,Rattus norvegicus,,Intermediate,4891,In vivo,N,1,CHEMBL624201,,,
7783,1,Evaluated for pharmacokinetic parameter tmax in rat at the dose 50 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,429,In vivo,N,1,CHEMBL872528,,,
7784,1,In vivo Tmax was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5974,In vivo,N,1,CHEMBL624202,,,
7785,1,In vivo Tmax was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5974,In vivo,N,1,CHEMBL624203,,,
7786,1,In vivo Tmax was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5974,In vivo,N,1,CHEMBL624350,,,
7787,1,In vivo Tmax was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5974,In vivo,N,1,CHEMBL621320,,,
7788,1,In vivo maximum time required for clearance of compound after oral (po) administration at a dose of 10 mg/kg was measured in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,17582,In vivo,N,1,CHEMBL621321,,,
7789,1,Maximum time (Tmax) required to reach Cmax in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,4026,,N,1,CHEMBL621322,,,
7790,1,Maximum time constant was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,4890,In vivo,N,1,CHEMBL621323,,,
7791,1,Maximum time of clearance of compound in rats after peroral administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,6571,In vivo,N,1,CHEMBL621324,,,
7792,1,Maximum time at the dose of 2 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4727,,N,1,CHEMBL621325,,,
7793,1,Maximum time to achieve peak plasma concentration was determined in rat at 1 mg/kg,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,17651,In vivo,N,1,CHEMBL875837,,1969.0,
7794,1,Maximum time to achieve peak plasma concentration was determined in rat at 10 mg/kg,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,17651,In vivo,N,1,CHEMBL621326,,1969.0,
7795,1,Tmax in Guinea pig (PO dose),,BAO_0000218,,Rattus norvegicus,,Intermediate,14465,In vivo,N,1,CHEMBL621327,,,
7796,1,"Pharmacokinetic Parameter, Tmax is the time at which maximum concentration (Cmax) is reached in Female Wistar Rats at 100 mg/kg by po administration",,BAO_0000218,,Rattus norvegicus,,Intermediate,14941,In vivo,N,1,CHEMBL621328,,,
7797,1,Pharmacokinetic parameter (Tmax) in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5960,In vivo,N,1,CHEMBL621329,,,
7798,1,Pharmacokinetic parameter (Tmax) was estimated,,BAO_0000218,,Rattus norvegicus,,Intermediate,5022,In vivo,N,1,CHEMBL621330,,,
7799,1,Pharmacokinetic property (Tmax) in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4408,In vivo,N,1,CHEMBL621331,,,
7800,1,Pharmacokinetic property (Tmax) was measured in rat at the dose of 0.32 mg/kg p.o.,,BAO_0000218,,Rattus norvegicus,,Intermediate,5983,In vivo,N,1,CHEMBL621332,,,
7801,1,T max in Rat at a oral dose of 5 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,4689,In vivo,N,1,CHEMBL621333,,,
7802,1,T max was determined at 10 mg/kg po dose in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,2792,In vivo,N,1,CHEMBL621334,,,
7803,1,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (run time 7 hr),,BAO_0000218,,Mus musculus,,Intermediate,15011,,N,1,CHEMBL621335,,,
7804,1,Area under curve was evaluated after intravenous injection of 1 mg/kg of compound in dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,14180,,N,1,CHEMBL621336,,,
7805,1,Area under curve was evaluated after intravenous injection of 1 mg/kg of compound in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,14180,,N,1,CHEMBL621337,,,
7806,1,Area under curve was measured after i.v. administration into Beagle dog.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,14599,,N,1,CHEMBL621338,,,
7807,1,Area under curve was measured after iv administration into Beagle dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,14599,,N,1,CHEMBL875838,,,
7808,1,Area under curve was measured after po administration into Beagle dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,14599,,N,1,CHEMBL621339,,,
7809,1,Area under curve was measured after po administration into Beagle dog.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,14599,,N,1,CHEMBL621340,,,
7810,1,Area under curve was measured at peroral dose of 3 mg/kg,,BAO_0000218,,,,Autocuration,15675,,U,0,CHEMBL621341,,,
7811,1,Area under curve was measured by using concentration Vs time,,BAO_0000019,,,,Autocuration,12706,,U,0,CHEMBL621342,,,
7812,1,Area under curve was measured by using concentration Vs time; not tested,,BAO_0000019,,,,Autocuration,12706,,U,0,CHEMBL621343,,,
7813,1,Area under curve(AUC) was measured in mice after oral administration (50 mg/kg),,BAO_0000218,,Mus musculus,,Intermediate,9750,,N,1,CHEMBL621344,,,
7814,1,Area under curve(AUC) was measured in mice after oral administration.,,BAO_0000218,,Mus musculus,,Intermediate,9750,,N,1,CHEMBL621345,,,
7815,1,Area under curve(AUC) value of the compound,,BAO_0000019,,,,Autocuration,14691,,U,0,CHEMBL621346,,,
7816,1,Area under curve(AUC) value of the compound in dogs at 0.5 mg/kg dose upon oral administration,,BAO_0000218,,,,Autocuration,14691,,U,0,CHEMBL621347,,,
7817,1,Area under curve(AUC) value of the compound in dogs at 1 mg/kg dose upon oral administration,,BAO_0000218,,Canis lupus familiaris,,Intermediate,14691,,N,1,CHEMBL621348,,,
7818,1,Area under curve(carotid artery) was determined by the availability in blood,Blood,BAO_0000019,,,,Autocuration,2939,,U,0,CHEMBL621349,,178.0,
7819,1,Area under curve(carotid artery) was determined by the availability in blood; ND means no data,Blood,BAO_0000019,,,,Autocuration,2939,,U,0,CHEMBL621350,,178.0,
7820,1,Area under curve(carotid artery) was determined by the availability in blood; No data,Blood,BAO_0000019,,,,Autocuration,2939,,U,0,CHEMBL875839,,178.0,
7821,1,Area under curve(portal vein) was determined by the availability in blood,Blood,BAO_0000019,,,,Autocuration,2939,,U,0,CHEMBL620211,,178.0,
7822,1,Area under curve(portal vein) was determined by the availability in blood; ND means no data,Blood,BAO_0000019,,,,Autocuration,2939,,U,0,CHEMBL620212,,178.0,
7823,1,Area under curve(portal vein) was determined by the availability in blood; No data,Blood,BAO_0000019,,,,Autocuration,2939,,U,0,CHEMBL620213,,178.0,
7824,1,"Area under plasma concentration vs time curve observed in Rhesus monkeys after, iv administration of single 30 mg/kg dose",Plasma,BAO_0000218,,Macaca mulatta,,Intermediate,9552,,N,1,CHEMBL620214,,1969.0,
7825,1,"Area under plasma concentration vs time curve observed in Rhesus monkeys after, iv administration of single 30 mg/kg dose",Plasma,BAO_0000218,,Macaca mulatta,,Intermediate,9552,,N,1,CHEMBL620215,,1969.0,
7826,1,Area under plasma concentration vs time curve observed in Rhesus monkeys after oral administration of single 30 mg/kg dose,Plasma,BAO_0000218,,Macaca mulatta,,Intermediate,9552,,N,1,CHEMBL620216,,1969.0,
7827,1,"Area under plasma concentration vs time curve observed in female mongrel dogs after, iv administration of single 15 mg/kg dose",Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,9552,,N,1,CHEMBL620888,,1969.0,
7828,1,"Area under plasma concentration vs time curve observed in female mongrel dogs after, oral administration of single 15 mg/kg dose",Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,9552,,N,1,CHEMBL620889,,1969.0,
7829,1,Area under plasma concentration vs time curve observed in rats for 0-3 h,Plasma,BAO_0000019,,,,Autocuration,9552,,U,0,CHEMBL620890,,1969.0,
7830,1,Area under plasma time curve determined in male rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,11911,,N,1,CHEMBL620891,,1969.0,
7831,1,Area under the MAP curve measured over 5 min.,,BAO_0000019,,,,Autocuration,16618,,U,0,CHEMBL620892,,,
7832,1,Area under the concentration time curve (AUC) taken for 0-24 hr was measured when administered through iv route in mice,,BAO_0000218,,Mus musculus,,Intermediate,14387,,N,1,CHEMBL621079,,,
7833,1,Area under the concentration time curve (AUC) taken for 0-24 hr was measured when administered through oral route in mice,,BAO_0000218,,Mus musculus,,Intermediate,14387,,N,1,CHEMBL621080,,,
7834,1,Area under the concentration vs time curve in dog at 10 mg/kg oral dose,,BAO_0000218,,Canis lupus familiaris,,Intermediate,12836,,N,1,CHEMBL621081,,,
7835,1,Area under the concentration vs time curve in hamster at 10 mg/kg oral dose,,BAO_0000218,,Cricetinae,,Intermediate,12836,,N,1,CHEMBL621082,,,
7836,1,Area under the concentration vs time curve in rat at 10 mg/kg oral dose,,BAO_0000218,,Rattus norvegicus,,Intermediate,12836,,N,1,CHEMBL621083,,,
7837,1,Area under the concentration-time curve from time zero to infinity after intravenous administration of 2.5 mg/kg in dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,14339,,N,1,CHEMBL621084,,,
7838,1,Area under the concentration-time curve from time zero to infinity in oral (5 mg/kg) fasted dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,14339,,N,1,CHEMBL621085,,,
7839,1,Area under the concentration-time curve from time zero to infinity in oral (5 mg/kg) fed dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,14339,,N,1,CHEMBL621086,,,
7840,1,Area under the concentration/ time determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),,BAO_0000218,,Canis lupus familiaris,,Intermediate,10524,,N,1,CHEMBL621087,,,
7841,1,Area under the concentration/ time in plasma after oral administration in dog (25 mg/kg),,BAO_0000218,,Canis lupus familiaris,,Intermediate,9994,,N,1,CHEMBL622607,,,
7842,1,Serum AUC in marmosets (IV dose),,BAO_0000218,,Canis lupus familiaris,,Intermediate,11325,,N,1,CHEMBL622608,,,
7843,1,Area under the curve after intravenous administration at a dose of 10 umol/kg,,BAO_0000019,,,,Autocuration,12536,,U,0,CHEMBL624481,,,
7844,1,Area under the curve after intravenous administration at a dose of 2 umol/kg,,BAO_0000019,,,,Autocuration,12536,,U,0,CHEMBL624482,,,
7845,1,Area under the curve after intravenous administration at a dose of 4 umol/kg,,BAO_0000019,,,,Autocuration,12536,,U,0,CHEMBL624483,,,
7846,1,Area under the curve after intravenous administration at a dose of 40 umol/kg,,BAO_0000019,,,,Autocuration,12536,,U,0,CHEMBL624484,,,
7847,1,Area under the curve after intravenous administration at a dose of 5 umol/kg,,BAO_0000019,,,,Autocuration,12536,,U,0,CHEMBL624485,,,
7848,1,Area under the curve for fumarate salt was evaluated in F344 Rats.,,BAO_0000218,,Rattus norvegicus,,Intermediate,15556,,N,1,CHEMBL624486,,,
7849,1,Area under the curve for the compound was calculated.,,BAO_0000019,,,,Autocuration,2809,,U,0,CHEMBL624487,,,
7850,1,Area under the curve in concentration/ time,,BAO_0000019,,,,Autocuration,9511,,U,0,CHEMBL624488,,,
7851,1,Area under the curve administered intraintestinal in rats.,,BAO_0000218,,Rattus norvegicus,,Intermediate,12818,,N,1,CHEMBL624489,,,
7852,1,Area under the curve administered intravenously in rats.,,BAO_0000218,,Rattus norvegicus,,Intermediate,12818,,N,1,CHEMBL625184,,,
7853,1,Area under the curve during intravenous administration,,BAO_0000019,,,,Autocuration,15118,,U,0,CHEMBL625185,,,
7854,1,Area under the curve during intravenous administration; Not determined,,BAO_0000019,,,,Autocuration,15118,,U,0,CHEMBL875954,,,
7855,1,Area under the curve during systemic administration,,BAO_0000019,,,,Autocuration,15118,,U,0,CHEMBL625186,,,
7856,1,Area under the curve during systemic administration; Not determined,,BAO_0000019,,,,Autocuration,15118,,U,0,CHEMBL625187,,,
7857,1,Area under the curve was calculated for the compound.,,BAO_0000019,,,,Autocuration,2632,,U,0,CHEMBL625188,,,
7858,1,Area under the curve was determined after intravenous administration of 1.8 mg/kg in male Beagle dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,14346,,N,1,CHEMBL625189,,,
7859,1,Area under the curve was determined after intravenous administration of 10 mg/kg in male Beagle dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,14346,,N,1,CHEMBL625190,,,
7860,1,Area under the curve was determined after intravenous administration of 2.5 mg/kg in male Dawley rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,14346,,N,1,CHEMBL621733,,,
7861,1,Area under the curve was determined after intravenous administration of 2.6 mg/kg in male Dawley rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,14346,,N,1,CHEMBL621734,,,
7862,1,C6h was measured as concentration obtained after 6 hr of oral administration in air pouch exudate after oral administration to male F344 rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,11149,,N,1,CHEMBL621735,,,
7863,1,Clearance of the drug was measured in the plasma of rat; No data,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,17796,,N,1,CHEMBL621736,,1969.0,
7864,1,The pharmacokinetic parameter plasma clearance in vivo in rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,5247,,N,1,CHEMBL621737,,1969.0,
7865,1,Plasma clearance at the dose of 2 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4727,,N,1,CHEMBL621738,,,
7866,1,CL (clearance) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,5654,In vivo,N,1,CHEMBL622806,,,
7867,1,CL (clearance) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,5654,In vivo,N,1,CHEMBL623519,,,
7868,1,CL at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,17260,In vivo,N,1,CHEMBL623520,,,
7869,1,Clearance measured after intravenous bolus administration of 50 mg/kg of compound to rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,17065,In vivo,N,1,CHEMBL623521,,,
7870,1,Clearance in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,17671,In vivo,N,1,CHEMBL623522,,,
7871,1,Clearance rate in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6672,In vivo,N,1,CHEMBL623523,,,
7872,1,Clearance rate in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6673,In vivo,N,1,CHEMBL623690,,,
7873,1,Clearance (Cl) of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5978,In vivo,N,1,CHEMBL623691,,,
7874,1,Clearance (Cl) of compound (9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5978,In vivo,N,1,CHEMBL623692,,,
7875,1,Clearance (Cl) of compound (9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5978,In vivo,N,1,CHEMBL623693,,,
7876,1,Clearance (Cl) of compound (9.92 mg/kg) after iv administration was determined in Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5978,In vivo,N,1,CHEMBL623694,,,
7877,1,Clearance of compound after iv administration of 20 mg/kg dose in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4413,In vivo,N,1,CHEMBL623695,,,
7878,1,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female wistar rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,2661,In vivo,N,1,CHEMBL623696,,,
7879,1,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to male wistar rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,2661,In vivo,N,1,CHEMBL623697,,,
7880,1,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,Plasma,BAO_0000218,,Macaca mulatta,,Intermediate,5005,In vivo,U,0,CHEMBL623698,,1969.0,
7881,1,Compound was tested for its plasma clearance rate in Sprague Dawley rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,5005,In vivo,U,0,CHEMBL623699,,1969.0,
7882,1,Mean (%CV) PK parameters for CL(mL/min/kg).,,BAO_0000218,,Rattus norvegicus,,Intermediate,15765,In vivo,N,1,CHEMBL623700,,,
7883,1,Pharmacokinetic studies were carried out to determine the clearance after administration at 20 mg/kg intravenously in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,3747,In vivo,N,1,CHEMBL623701,,,
7884,1,Pharmacokinetic parameter plasma clearance was determined at when a dose of 1 mg/kg is administered,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,16366,In vivo,N,1,CHEMBL623702,,1969.0,
7885,1,Plasma Clearance measured at steady-state following iv infusion at 0.6 mg/kg/h in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,4199,In vivo,N,1,CHEMBL623703,,,
7886,1,Plasma clearance in rat was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,17267,In vivo,N,1,CHEMBL623704,,,
7887,1,Plasma clearance in rat after administration of 2 mg/kg iv,,BAO_0000218,,Rattus norvegicus,,Intermediate,6535,In vivo,N,1,CHEMBL623705,,,
7888,1,Plasma clearance in rat after administration of 2 mg/kg iv,,BAO_0000218,,Rattus norvegicus,,Intermediate,6535,In vivo,N,1,CHEMBL623706,,,
7889,1,Plasma clearance was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,5041,In vivo,N,1,CHEMBL623707,,,
7890,1,Plasma clearance in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5960,In vivo,N,1,CHEMBL623708,,,
7891,1,Plasma clearance in rat after intravenous administration at a concentration 0.5 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,5937,In vivo,N,1,CHEMBL623709,,,
7892,1,Plasma clearance in rat by iv administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,5871,In vivo,N,1,CHEMBL623710,,,
7893,1,Plasma clearance in rat by iv administration at a dose of 3 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,5874,In vivo,N,1,CHEMBL623711,,,
7894,1,Plasma clearance in rat p.o.,,BAO_0000218,,Rattus norvegicus,,Intermediate,6504,In vivo,N,1,CHEMBL623712,,,
7895,1,Plasma clearance in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,6803,In vivo,N,1,CHEMBL623713,,,
7896,1,Plasma clearance was determined; ND denotes no data,,BAO_0000218,,Rattus norvegicus,,Intermediate,5041,In vivo,N,1,CHEMBL623714,,,
7897,1,Plasma clearance was determined; ND denotes not determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,5041,In vivo,N,1,CHEMBL623715,,,
7898,1,Plasma clearance was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,1916,In vivo,N,1,CHEMBL623716,,,
7899,1,Plasma clearance was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,,BAO_0000218,,Rattus norvegicus,,Intermediate,5199,In vivo,N,1,CHEMBL622980,,,
7900,1,Plasma administration to rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,16367,In vivo,N,1,CHEMBL622981,,,
7901,1,Plasma clearance of the compound in female Sprague-Dawley rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,6362,In vivo,N,1,CHEMBL622982,,,
7902,1,Plasma clearance was observed after intravenous administration in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,15662,In vivo,N,1,CHEMBL622983,,,
7903,1,Systemic clearance after intravenous administration (5.0 mg/kg) was determined in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6215,In vivo,N,1,CHEMBL622984,,,
7904,1,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,1466,In vivo,N,1,CHEMBL622985,,,
7905,1,plasma clearance was observed after intravenous administration in rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,15662,In vivo,N,1,CHEMBL623631,,1969.0,
7906,1,In vivo CL/F determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,4723,In vivo,N,1,CHEMBL623632,,,
7907,1,Pharmacokinetic parameter plasma clearance was determined at 2 mg/kg i.v. dose in rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,2792,In vivo,N,1,CHEMBL623633,,1969.0,
7908,1,Pharmacokinetic parameter plasma clearance was determined at 5 mg/kg i.v. dose in rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,2792,In vivo,N,1,CHEMBL623634,,1969.0,
7909,1,Compound was tested for the lower blood clearance in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5213,In vivo,N,1,CHEMBL623635,,,
7910,1,Evaluated for the low clearance in rat (in vivo),,BAO_0000218,,Rattus norvegicus,,Intermediate,4687,In vivo,N,1,CHEMBL621195,,,
7911,1,Pharmacokinetic property (CLb)of the compound was determined in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,3371,In vivo,N,1,CHEMBL621196,,,
7912,1,Rapid clearance after intravenous administration in rat was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,4690,In vivo,N,1,CHEMBL875287,,,
7913,1,Clearance measured in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5702,In vivo,N,1,CHEMBL621197,,,
7914,1,Compound was evaluated for plasma clearance in rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,740,In vivo,N,1,CHEMBL621198,,1969.0,
7915,1,Low plasma clearance was calculated in rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,4853,In vivo,N,1,CHEMBL621199,,1969.0,
7916,1,Pharmacokinetic property (Clp) in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5789,In vivo,N,1,CHEMBL621200,,,
7917,1,Plasma clearance in dog at a dose of 1 uM/kg in rat was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,4527,In vivo,N,1,CHEMBL621201,,,
7918,1,Plasma clearance in rat at a dose of 10 uM/kg in rat was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,4527,In vivo,N,1,CHEMBL621202,,,
7919,1,Plasma clearance after IV dosing at 0.5 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6518,In vivo,N,1,CHEMBL621203,,,
7920,1,Plasma clearance after IV dosing at 1 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6518,In vivo,N,1,CHEMBL621204,,,
7921,1,Biodistribution in rat heart in the presence of 0.01 M Gd/0.01 M GdDTPA-AEP,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL621205,,948.0,
7922,1,Biodistribution in rat heart in the presence of 0.01 M GdDTPA-BDP,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL621206,,948.0,
7923,1,Biodistribution in rat heart in the presence of 0.01 M/0.08 M GdDTPA-AEP,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL621207,,948.0,
7924,1,Biodistribution in rat heart in the presence of 0.05 M /0.05 M GdDTPA-AEP,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL621208,,948.0,
7925,1,Biodistribution in rat heart in the presence of 0.05 M Gd/0.15 M lig,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL621209,,948.0,
7926,1,Biodistribution in rat heart in the presence of 0.05 M GdDTPA-BDP,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL876484,,948.0,
7927,1,Biodistribution in rat heart in the presence of 0.05 M/0.08 M GdDTPA-HPDP,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL621210,,948.0,
7928,1,Biodistribution in rat heart in the presence of 0.10 M GdDTPA-BDP,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL621211,,948.0,
7929,1,Biodistribution in rat heart in the presence of 0.10 M/0.11 M GdDTPA-AEP,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL621212,,948.0,
7930,1,Biodistribution in rat heart in the presence of GdDTPA at 15 min,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL621213,,948.0,
7931,1,Biodistribution in rat heart in the presence of GdDTPA at 1 hr,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL621214,,948.0,
7932,1,Biodistribution in rat heart in the presence of GdDTPA at 30 min,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL621215,,948.0,
7933,1,Biodistribution in rat heart in the presence of GdDTPA at 4 hr,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL621216,,948.0,
7934,1,Biodistribution in rat heart in the presence of GdDTPA-BDP at 1 hr,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL621217,,948.0,
7935,1,Biodistribution in rat heart in the presence of GdDTPA-BDP at 30 min,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL621218,,948.0,
7936,1,Biodistribution in rat heart in the presence of GdDTPA-BDP at 4 hr,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL621219,,948.0,
7937,1,Biodistribution in rat heart in the presence of GdDTPA-BDPat 15 min,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL621220,,948.0,
7938,1,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 1 hr,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL621221,,948.0,
7939,1,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 30 min,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL621222,,948.0,
7940,1,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 4 hr,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL621223,,948.0,
7941,1,Biodistribution in rat heart in the presence of GdDTPA-HPDPat 15 min,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL876485,,948.0,
7942,1,Biodistribution in rat heart in the presence of NAC Gd/0.01 M GdDTPA-HPDP,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL621224,,948.0,
7943,1,Biodistribution in rat heart in the presence of NCA Gd/0.01 M lip,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL621225,,948.0,
7944,1,Biodistribution in rat heart in the presence of NCAGd/0.01 M lig,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL621226,,948.0,
7945,1,Biodistribution in rat kidney in the presence of 0.01 M GdDTPA-BDP,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL621227,,2113.0,
7946,1,Biodistribution in rat kidney in the presence of 0.01 M/0.01 M GdDTPA-AEP,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL621228,,2113.0,
7947,1,Biodistribution in rat kidney in the presence of 0.01 M/0.08 M GdDTPA-AEP,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL621229,,2113.0,
7948,1,Biodistribution in rat kidney in the presence of 0.05 M Gd/0.15 M lig,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL621230,,2113.0,
7949,1,Biodistribution in rat kidney in the presence of 0.05 M GdDTPA-BDP; ND=No data,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL621231,,2113.0,
7950,1,Biodistribution in rat kidney in the presence of 0.05 M/0.05 M GdDTPA-AEP,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL621232,,2113.0,
7951,1,Biodistribution in rat kidney in the presence of 0.05 M/0.08 M GdDTPA-HPDP,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL621233,,2113.0,
7952,1,Biodistribution in rat kidney in the presence of 0.10 M GdDTPA-BDP,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL621234,,2113.0,
7953,1,Biodistribution in rat kidney in the presence of 0.10 M/0.11 M GdDTPA-AEP; ND=No data,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL621235,,2113.0,
7954,1,Biodistribution in rat kidney in the presence of NAC Gd/0.01 M GdDTPA-HPDP,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL621236,,2113.0,
7955,1,Biodistribution in rat kidney in the presence of NCA Gd/0.01 M lip,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL621237,,2113.0,
7956,1,Biodistribution in rat kidney in the presence of NCAGd/0.01 M lig,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL876486,,2113.0,
7957,1,Biodistribution in rat l. intestine in the presence of 0.01 M carrier at 1 hr,Intestine,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL622436,,160.0,
7958,1,Biodistribution in rat l. intestine in the presence of 50 Gd/kg at 2 hr,Intestine,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL622437,,160.0,
7959,1,Biodistribution in rat l. intestine in the presence of 50 Gd/kg at 6 hr,Intestine,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL622438,,160.0,
7960,1,Biodistribution in rat liver by in the presence 50 Gd/kg at 15 min,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL622439,,2107.0,
7961,1,Biodistribution in rat liver by in the presence of 0.05 M Gd/0.15 M lig,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL622440,,2107.0,
7962,1,Biodistribution in rat liver by in the presence of NCAGd/0.01 M lig,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL622441,,2107.0,
7963,1,Biodistribution in rat liver in the presence of 0.001 M/0.008 M GdDTPA-AEP,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL622442,,2107.0,
7964,1,Biodistribution in rat liver in the presence of 0.01 M GdDTPA-BDP,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL622443,,2107.0,
7965,1,Biodistribution in rat liver in the presence of 0.01 M/0.01 M GdDTPA-AEP,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL622444,,2107.0,
7966,1,Biodistribution in rat liver in the presence of 0.05 M GdDTPA-BDP,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL622445,,2107.0,
7967,1,Biodistribution in rat liver in the presence of 0.05 M/0.05 M GdDTPA-AEP,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL622446,,2107.0,
7968,1,Biodistribution in rat liver in the presence of 0.05 M/0.08 M GdDTPA-HPDP,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL622447,,2107.0,
7969,1,Biodistribution in rat liver in the presence of 0.10 M GdDTPA-BDP,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL622448,,2107.0,
7970,1,Biodistribution in rat liver in the presence of 0.10 M/0.11 M GdDTPA-AEP; ND=No data,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL622449,,2107.0,
7971,1,Biodistribution in rat liver in the presence of 50 Gd/kg at 2 hr,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL622450,,2107.0,
7972,1,Biodistribution in rat liver in the presence of 50 Gd/kg at at 6 hr,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL622451,,2107.0,
7973,1,Biodistribution in rat liver in the presence of GdDTPA at 15 min,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL622452,,2107.0,
7974,1,Biodistribution in rat liver in the presence of GdDTPA at 1 hr,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL622453,,2107.0,
7975,1,Biodistribution in rat liver in the presence of GdDTPA at 30 min,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL622454,,2107.0,
7976,1,Biodistribution in rat liver in the presence of GdDTPA at 4 hr,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL622455,,2107.0,
7977,1,Biodistribution in rat liver in the presence of GdDTPA-BDP at 15 min,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL876024,,2107.0,
7978,1,T max was determined at 3 mg/kg po dose in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,2792,In vivo,N,1,CHEMBL622456,,,
7979,1,"The Tmax value in female wistar rat at 100 mg/kg, p.o. dose",,BAO_0000218,,Rattus norvegicus,,Intermediate,15078,In vivo,N,1,CHEMBL622457,,,
7980,1,"The Tmax value in male wistar rat at 100 mg/kg, p.o. dose",,BAO_0000218,,Rattus norvegicus,,Intermediate,15078,In vivo,N,1,CHEMBL622458,,,
7981,1,The time to reach maximum concentration of compound was measured at the dose of 100 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,15022,,N,1,CHEMBL622459,,,
7982,1,The time to reach maximum concentration of compound was measured at the dose of 300 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,15022,,N,1,CHEMBL873343,,,
7983,1,The time to reach maximum concentration of compound was measured at the dose of 30 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,15022,,N,1,CHEMBL622460,,,
7984,1,Time for maximum plasma concentration determined in rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,4576,,N,1,CHEMBL622461,,1969.0,
7985,1,Time for maximum plasma concentration reached by compound was determined in rats at 50 mg/kg dose,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,6681,In vivo,N,1,CHEMBL622462,,1969.0,
7986,1,Time of maximum concentration of the drug when administered orally a dose of 10 mg/kg to a fasting rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,16365,In vivo,N,1,CHEMBL622463,,,
7987,1,Time of maximum concentration of the drug when administered orally a dose of 1 mg/kg to a fasting rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,16365,In vivo,N,1,CHEMBL622464,,,
7988,1,Time of maximum concentration of the drug when administered orally a dose of 30 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,16365,In vivo,N,1,CHEMBL622465,,,
7989,1,Time of maximum concentration of the drug when administered orally a dose of 3 mg/kg to a fasting rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,16365,In vivo,N,1,CHEMBL622466,,,
7990,1,Time of maximum concentration of the drug when administered orally at dose of 3 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,16365,In vivo,N,1,CHEMBL622467,,,
7991,1,Time of maximum plasma concentration in rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,6824,,N,1,CHEMBL622468,,1969.0,
7992,1,"Time required by compound for reaching maximum plasma concentration was determined in rats at 10 mg/kg, p.o. dose",Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,6685,,N,1,CHEMBL876025,,1969.0,
7993,1,"Time required by compound for reaching maximum plasma concentration was determined in rats at 20 mg/kg, i.p. dose",Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,6685,,N,1,CHEMBL622469,,1969.0,
7994,1,"Time required by compound for reaching maximum plasma concentration was determined in rats at 2 mg/kg, i.v. dose; n/a: not applicable",Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,6685,,N,1,CHEMBL622470,,1969.0,
7995,1,Time required to reach maximum concentration (Cmax) after oral administration in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,15662,In vivo,N,1,CHEMBL622471,,,
7996,1,Time required to reach maximum concentration in rat plasma,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,1742,,N,1,CHEMBL622472,,1969.0,
7997,1,Time taken by the compound to achieve maximum concentration in rat plasma at 30 mg/Kg upon oral administration.,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,2774,In vivo,N,1,CHEMBL622473,,1969.0,
7998,1,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in female Sprague-Dawley rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,5199,In vivo,N,1,CHEMBL624282,,1969.0,
7999,1,Time taken for maximum plasma concentration for the compound in solution form (formulation) was determined in rats at peroral dose of 5 mg/kg,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,12873,In vivo,N,1,CHEMBL624283,,1969.0,
8000,1,Time taken for maximum plasma concentration for the compound in suspension form (formulation) was determined in rats at peroral dose of 5 mg/kg,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,12873,In vivo,N,1,CHEMBL624284,,1969.0,
8001,1,Time taken to reach maximum concentration in plasma was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,1916,In vivo,N,1,CHEMBL624285,,1969.0,
8002,1,Time to reach Cmax after oral administration to rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,16367,In vivo,N,1,CHEMBL624286,,,
8003,1,Time to reach Cmax when a dose of 1 mg/kg is administered orally,,BAO_0000218,,Rattus norvegicus,,Intermediate,16366,In vivo,N,1,CHEMBL624287,,,
8004,1,Time to reach maximum concentration following oral administration of 200 mg/kg in rat; value ranges from 2-4,,BAO_0000218,,Rattus norvegicus,,Intermediate,216,,N,1,CHEMBL624288,,,
8005,1,Time to reach maximum plasma concentration was evaluated at an intravenous dose of 3 mg/kg; Not applicable,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,6410,In vivo,N,1,CHEMBL624289,,1969.0,
8006,1,Time to reach maximum plasma concentration was evaluated at an oral dose of 30 mg/kg,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,6410,In vivo,N,1,CHEMBL873344,,1969.0,
8007,1,Tmax after peroral administration (10 mg/kg) was determined in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6215,In vivo,N,1,CHEMBL619623,,,
8008,1,Tmax of compound determined in rat after iv administration at a dose of 10 mg/kg,,BAO_0000218,,Rattus norvegicus,,Expert,3598,In vivo,N,1,CHEMBL621399,,,
8009,1,Tmax by oral administration at a dose of 100 uM/kg in rat was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,4527,In vivo,N,1,CHEMBL621400,,,
8010,1,"Tmax in fischer rats at 5 mg/kg dose, administered intravenously",,BAO_0000218,,Rattus norvegicus,,Intermediate,17670,In vivo,N,1,CHEMBL621401,,,
8011,1,Tmax was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,1465,,N,1,CHEMBL621402,,,
8012,1,Tmax was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,2552,,N,1,CHEMBL621403,,,
8013,1,Tmax after oral administration in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5656,In vivo,N,1,CHEMBL621121,,,
8014,1,Tmax after peroral administration in rats at 2.4 uM/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,17764,In vivo,N,1,CHEMBL872525,,,
8015,1,Tmax in male rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5610,,N,1,CHEMBL621122,,,
8016,1,Tmax in rat at 10 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,6046,In vivo,N,1,CHEMBL621123,,,
8017,1,Tmax in rat by po administration at a dose of 40 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,5874,In vivo,N,1,CHEMBL621124,,,
8018,1,Tmax in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,17596,,N,1,CHEMBL621125,,,
8019,1,Tmax was measured in rats after peroral administration at 5 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,17804,In vivo,N,1,CHEMBL621126,,,
8020,1,Tmax value after oral dose at a dose of 10 mg/kg in rats.,,BAO_0000218,,Rattus norvegicus,,Intermediate,1908,In vivo,N,1,CHEMBL621127,,,
8021,1,Tmax value after administration of 20 mg/Kg oral dose in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,2959,In vivo,N,1,CHEMBL621128,,,
8022,1,Tmax value at a dose of 10 mg/kg in male SD rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,6757,In vivo,N,1,CHEMBL618263,,,
8023,1,Tmax value at a dose of 100 mg/kg in male SD rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,6757,In vivo,N,1,CHEMBL618264,,,
8024,1,Tmax value at a dose of 50 mg/kg in male SD rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,6757,In vivo,N,1,CHEMBL618265,,,
8025,1,Total concentration in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,4186,In vivo,N,1,CHEMBL618266,,1969.0,
8026,1,time required to reach maximum concentration (Cmax) after oral administration in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,15662,In vivo,N,1,CHEMBL618267,,,
8027,1,Evaluated for pharmacokinetic parameter urine recovery in rat at the dose 50 mg/kg ( 0-24 hr ),Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,429,,N,1,CHEMBL618450,,1088.0,
8028,1,Evaluated for pharmacokinetic parameter urine recovery in rat at the dose 50 mg/kg (0-24 hr),Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,429,,N,1,CHEMBL618451,,1088.0,
8029,1,Unbound plasma was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,5546,,N,1,CHEMBL618452,,,
8030,1,Amount of urine output was measured in rat at a dose of 1 mg/kg/po,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,3173,,N,1,CHEMBL618453,,1088.0,
8031,1,Amount of urine output was measured in rat at a dose of 10 mg/kg/po,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,3173,,N,1,CHEMBL618454,,1088.0,
8032,1,Amount of urine output was measured in rat at a dose of 10 mg/kg/po; NT-Not tested,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,3173,,N,1,CHEMBL618455,,1088.0,
8033,1,Volume of distribution was determined in rat after a 3 mg/kg of iv dose,,BAO_0000218,,Rattus norvegicus,,Intermediate,4257,In vivo,N,1,CHEMBL618456,,,
8034,1,Compound distribution in rat tissues was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,6011,In vivo,N,1,CHEMBL618457,,,
8035,1,Volume of distribution was evaluated in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5472,In vivo,N,1,CHEMBL618458,,,
8036,1,Area under the curve was determined after intravenous administration of 2.7 mg/kg in male Dawley rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,14346,,N,1,CHEMBL618459,,,
8037,1,Area under the curve was determined after intravenous administration of 2.8 mg/kg in male Dawley rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,14346,,N,1,CHEMBL876733,,,
8038,1,Area under the curve was determined after intravenous administration of 4.9 mg/kg in male Beagle dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,14346,,N,1,CHEMBL618460,,,
8039,1,Area under the curve was determined after intravenous administration of 5.1 mg/kg in male Dawley rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,14346,,N,1,CHEMBL618461,,,
8040,1,Area under the curve was determined after oral administration (300 uM/Kg),,BAO_0000019,,,,Autocuration,15469,,U,0,CHEMBL618462,,,
8041,1,Area under the curve was determined after peroral administration of 5.0 mg/kg in male Dawley rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,14346,,N,1,CHEMBL618463,,,
8042,1,Area under the curve was determined after peroral administration of 5.1 mg/kg in mal Dawley rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,14346,,N,1,CHEMBL618464,,,
8043,1,Area under the curve was determined after peroral administration of 5.1 mg/kg in male Dawley rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,14346,,N,1,CHEMBL618465,,,
8044,1,Area under the curve was determined after peroral administration of 5.2 mg/kg in mal Dawley rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,14346,,N,1,CHEMBL618466,,,
8045,1,Area under the curve was determined after peroral administration of 5.2 mg/kg in male Dawley rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,14346,,N,1,CHEMBL618467,,,
8046,1,Area under the curve was determined for the compound after iv dose of 4.97 mg/kg in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,15372,,N,1,CHEMBL618468,,,
8047,1,Area under the plasma concentration was determined in fasted Beagle dogs after peroral administration of 100 mg/kg,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,12935,,N,1,CHEMBL618469,,1969.0,
8048,1,Area under the plasma concentration was determined in fasted Beagle dogs after peroral administration of 20 mg/kg,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,12935,,N,1,CHEMBL618470,,1969.0,
8049,1,Plasma drug AUC in rat (PO dose),,BAO_0000218,,,,Autocuration,14813,,U,0,CHEMBL618471,,,
8050,1,Area under the tumor growth curve (AUC) in the B-6 Melanoma Model in C57/b1 mice at the dose of 1 mg/kg.,,BAO_0000218,,Mus musculus,,Intermediate,15792,,N,1,CHEMBL618472,,,
8051,1,Area under was determined at a dose of 30 mg/kg,,BAO_0000218,,,,Autocuration,3579,,U,0,CHEMBL618473,,,
8052,1,Average area under curve for compound at 1 mg/kg dose intravenous administration to Ferret,,BAO_0000218,,Mustela putorius furo,,Intermediate,12487,,N,1,CHEMBL621699,,,
8053,1,Average area under curve for the compound at 10 mg/kg dose after intraduodenal administration to rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,12487,,N,1,CHEMBL621700,,,
8054,1,Average area under curve for the compound at 1 mg/kg dose after intravenous administration to rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,12487,,N,1,CHEMBL621701,,,
8055,1,Average area under curve at 10 mg/kg dose after intraduodenal administration to Ferret,,BAO_0000218,,Mustela putorius furo,,Intermediate,12487,,N,1,CHEMBL621702,,,
8056,1,Average area under curve at 10 mg/kg intraduodenal administration to salt depleted dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,12487,,N,1,CHEMBL621703,,,
8057,1,Average area under curve at 1 mg/kg intravenous administration to salt depleted dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,12487,,N,1,CHEMBL621704,,,
8058,1,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 1.0(pmol/g/h)",,BAO_0000218,,Rattus norvegicus,,Intermediate,12902,,N,1,CHEMBL624259,,,
8059,1,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 2.0(pmol/g/h)",,BAO_0000218,,Rattus norvegicus,,Intermediate,12902,,N,1,CHEMBL624260,,,
8060,1,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 4.0(pmol/g/h)",,BAO_0000218,,Rattus norvegicus,,Intermediate,12902,,N,1,CHEMBL624430,,,
8061,1,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 5.0(pmol/g/h)",,BAO_0000218,,Rattus norvegicus,,Intermediate,12902,,N,1,CHEMBL624431,,,
8062,1,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 54.0(pmol/g/h)",,BAO_0000218,,Rattus norvegicus,,Intermediate,12902,,N,1,CHEMBL624432,,,
8063,1,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 10.0(pmol/g/h)",,BAO_0000218,,Rattus norvegicus,,Intermediate,12902,,N,1,CHEMBL624433,,,
8064,1,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 20.0(pmol/g/h)",,BAO_0000218,,Rattus norvegicus,,Intermediate,12902,,N,1,CHEMBL624434,,,
8065,1,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 40.0(pmol/g/h)",,BAO_0000218,,Rattus norvegicus,,Intermediate,12902,,N,1,CHEMBL624435,,,
8066,1,Bioavailability in mouse brain after intravenous administration of 105.1 mg/kg of dose,,BAO_0000218,,Mus musculus,,Intermediate,12745,,N,1,CHEMBL618570,,,
8067,1,Bioavailability in mouse brain after intravenous administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),,BAO_0000218,,Mus musculus,,Intermediate,12745,,N,1,CHEMBL618571,,,
8068,1,Bioavailability in mouse brain after oral administration of 100 mg/kg of dose,,BAO_0000218,,Mus musculus,,Intermediate,12745,,N,1,CHEMBL618572,,,
8069,1,Bioavailability in mouse brain after oral administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),,BAO_0000218,,Mus musculus,,Intermediate,12745,,N,1,CHEMBL618573,,,
8070,1,Bioavailability in mouse serum after intravenous administration of 105.1 mg/kg of dose,,BAO_0000218,,Mus musculus,,Intermediate,12745,,N,1,CHEMBL619267,,,
8071,1,Bioavailability in mouse serum after intravenous administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),,BAO_0000218,,Mus musculus,,Intermediate,12745,,N,1,CHEMBL619431,,,
8072,1,Bioavailability in mouse serum after oral administration of 100 mg/kg of dose,,BAO_0000218,,Mus musculus,,Intermediate,12745,,N,1,CHEMBL619432,,,
8073,1,Bioavailability in mouse serum after oral administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),,BAO_0000218,,Mus musculus,,Intermediate,12745,,N,1,CHEMBL619433,,,
8074,1,AUC in mice after oral dose (50 mg/kg),Plasma,BAO_0000218,,,,Autocuration,13298,,U,0,CHEMBL619434,,1969.0,
8075,1,Blood level after oral administration in mice (50 mg/kg) was determined by bioassay procedure and represent total activity present in the serum,Serum,BAO_0000218,,Mus musculus,,Intermediate,12226,,N,1,CHEMBL619435,,1977.0,
8076,1,AUC (0-4 hr) ug/ml/h,Plasma,BAO_0000019,,,,Autocuration,12634,,U,0,CHEMBL619436,,1969.0,
8077,1,Compound at a dose of 10 mg/kg was orally administered to rats and Area under curve was reported,,BAO_0000218,,Rattus norvegicus,,Intermediate,14810,,N,1,CHEMBL619437,,,
8078,1,Compound evaluated for AUC = Area under the nucleoside serum or brain concentration versus time curve after iv administration,,BAO_0000218,,,,Autocuration,13889,,U,0,CHEMBL619438,,,
8079,1,Compound was evaluated for Area under curve in mice,,BAO_0000218,,Mus musculus,,Intermediate,10018,,N,1,CHEMBL619439,,,
8080,1,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,,BAO_0000218,,Rattus norvegicus,,Intermediate,8758,,N,1,CHEMBL619440,,,
8081,1,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,,BAO_0000218,,,,Autocuration,8758,,U,0,CHEMBL619441,,,
8082,1,Compound was evaluated for area under curve doses in rat at 50 mg/kg po,,BAO_0000218,,Rattus norvegicus,,Intermediate,8758,,N,1,CHEMBL619442,,,
8083,1,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 0.5 mpk on day 1,,BAO_0000019,,,,Autocuration,2249,,U,0,CHEMBL875156,,,
8084,1,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 0.5 mpk on day 4,,BAO_0000019,,,,Autocuration,2249,,U,0,CHEMBL619443,,,
8085,1,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 1.0 mpk on day 1,,BAO_0000019,,,,Autocuration,2249,,U,0,CHEMBL619444,,,
8086,1,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 1.0 mpk on day 4,,BAO_0000019,,,,Autocuration,2249,,U,0,CHEMBL623464,,,
8087,1,Compound was evaluated for area under curve when administered through oral route in mouse,,BAO_0000218,,Mus musculus,,Intermediate,15115,,N,1,CHEMBL623465,,,
8088,1,Plasma clearance after oral administration at a dose of 2 mg/kg in rat; no data,,BAO_0000218,,Rattus norvegicus,,Intermediate,6518,In vivo,N,1,CHEMBL623466,,,
8089,1,Plasma clearance after oral administration at a dose of 4 mg/kg in rat; no data,,BAO_0000218,,Rattus norvegicus,,Intermediate,6518,In vivo,N,1,CHEMBL623467,,,
8090,1,Plasma clearance in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6249,In vivo,N,1,CHEMBL623468,,,
8091,1,Plasma clearance was evaluated in vivo in rat at a dose of 5 mg/kg by intra venous administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,2463,In vivo,N,1,CHEMBL622660,,,
8092,1,Plasma clearance rate in Sprague-Dawley rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,4969,In vivo,N,1,CHEMBL622661,,,
8093,1,CLtot at a dose of 4 mg/kg in Rat Plasma after iv administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,17720,In vivo,N,1,CHEMBL622662,,,
8094,1,Pharmacokinetic property (total body clearance) in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,3457,In vivo,N,1,CHEMBL622663,,,
8095,1,Pharmacokinetic property (CLtot)of the compound was measured in rat at the dose of 0.32 mg/kg i.v.,,BAO_0000218,,Rattus norvegicus,,Intermediate,5983,In vivo,N,1,CHEMBL622664,,,
8096,1,In vivo concentration in rat liver exposure 0-8 hour after oral administration 50 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,6295,,N,1,CHEMBL622665,,,
8097,1,In vivo concentration in rat liver exposure 0-8 hour after oral administration 50 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,6296,,N,1,CHEMBL622666,,,
8098,1,Cl in rat i.v. at 2 mg/kg concentration,,BAO_0000218,,Rattus norvegicus,,Intermediate,17686,In vivo,N,1,CHEMBL621615,,,
8099,1,Clearance of compound after intravenous administration in rats at 24 uM/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,17764,In vivo,N,1,CHEMBL621616,,,
8100,1,Clearance was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,5503,In vivo,N,1,CHEMBL621617,,,
8101,1,Clearance by intravenous administration of 3.4 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4368,In vivo,N,1,CHEMBL621618,,,
8102,1,Clearance was evaluated after i.v. administration in rat at a dose of 1 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,6005,In vivo,N,1,CHEMBL621619,,,
8103,1,Clearance rate after i.v. administration in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,5031,In vivo,N,1,CHEMBL621620,,,
8104,1,Clearance was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,4890,In vivo,N,1,CHEMBL621786,,,
8105,1,Clearance was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5182,In vivo,N,1,CHEMBL621787,,,
8106,1,Clearance (Cl) of compound after 2 h iv infusion of 8.4 mg/kg in three rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5979,In vivo,N,1,CHEMBL621788,,,
8107,1,Clearance (Cl) after oral administration in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5656,In vivo,N,1,CHEMBL621789,,,
8108,1,Compound clearance in rats was measured after intravenous administration at 3 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,17804,In vivo,N,1,CHEMBL621790,,,
8109,1,Compound was tested for plasma clearance in rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,4839,In vivo,N,1,CHEMBL621791,,1969.0,
8110,1,In vitro microsome metabolism clearance in rat was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,5041,In vitro,N,1,CHEMBL621792,,,
8111,1,In vitro microsome metabolism clearance in rat was determined; ND denotes no data,,BAO_0000218,,Rattus norvegicus,,Intermediate,5041,In vitro,N,1,CHEMBL621793,,,
8112,1,In vivo Clearance (Cl) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5974,In vivo,N,1,CHEMBL621794,,,
8113,1,In vivo plasma clearance was determined,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,5496,In vivo,N,1,CHEMBL621795,,1969.0,
8114,1,Pharmacokinetic property (Clearance) for the compound (5 mg/kg iv) was determined in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,5739,In vivo,N,1,CHEMBL621796,,,
8115,1,Pharmacokinetic property (Clearance) in rat hepatocyte i.v.,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,5676,In vivo,N,1,CHEMBL621797,401.0,2107.0,
8116,1,Pharmacokinetic property (Plasma clearance) was measured in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4239,In vivo,N,1,CHEMBL621798,,,
8117,1,Pharmacokinetic property (clearance) in rat i.v.,,BAO_0000218,,Rattus norvegicus,,Intermediate,5676,In vivo,N,1,CHEMBL621799,,,
8118,1,"Plasma Clearance was evaluated in rats, iv",,BAO_0000218,,Rattus norvegicus,,Intermediate,1918,In vivo,N,1,CHEMBL621800,,,
8119,1,Plasma clearance (in vivo) in rats was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,17800,In vivo,N,1,CHEMBL621801,,,
8120,1,Plasma clearance for the compound was calculated at a single intravenous administration of 20 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6056,In vivo,N,1,CHEMBL621802,,,
8121,1,Plasma clearance was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,5496,In vivo,N,1,CHEMBL618596,,,
8122,1,Plasma clearance in rat after peroral administration at 10 mg/kg concentration,,BAO_0000218,,Rattus norvegicus,,Intermediate,5939,In vivo,N,1,CHEMBL618597,,,
8123,1,Plasma clearance in rat after peroral administration at 5 mg/kg concentration,,BAO_0000218,,Rattus norvegicus,,Intermediate,5939,In vivo,N,1,CHEMBL618598,,,
8124,1,Plasma clearance in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,17752,In vivo,N,1,CHEMBL618599,,,
8125,1,Plasma clearance rate determined in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4576,In vivo,N,1,CHEMBL618600,,,
8126,1,Plasma clearance was determined in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6011,In vivo,N,1,CHEMBL618601,,,
8127,1,Plasma clearance was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,5510,In vivo,N,1,CHEMBL618602,,,
8128,1,Plasma clearance value in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5948,In vivo,N,1,CHEMBL618603,,,
8129,1,Clearance rate constant using isolated perfused rat liver (IPRL) assay,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,6125,Ex vivo,N,1,CHEMBL618604,,2107.0,
8130,1,Clearance in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4839,In vivo,N,1,CHEMBL618605,,,
8131,1,Total body clearance in rat i.v. at 2 mg/kg concentration,,BAO_0000218,,Rattus norvegicus,,Intermediate,17686,In vivo,N,1,CHEMBL618606,,,
8132,1,Clearance of compound in rats after intravenous administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,6571,In vivo,N,1,CHEMBL618607,,,
8133,1,Clearance after iv administration to rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,3364,In vivo,N,1,CHEMBL618608,,,
8134,1,Clearance at an iv dose of 12 mg/Kg and po dose of 23 mg/Kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,13569,In vivo,N,1,CHEMBL618609,,,
8135,1,Clearance at an iv dose of 14 mg/Kg and po dose of 15 mg/Kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,13569,In vivo,N,1,CHEMBL618610,,,
8136,1,Clearance at an iv dose of 15 mg/Kg and po dose of 30 mg/Kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,13569,In vivo,N,1,CHEMBL618611,,,
8137,1,Clearance at an iv dose of 15 mg/Kg and po dose of 30.2 mg/Kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,13569,In vivo,N,1,CHEMBL618612,,,
8138,1,Clearance at an iv dose of 15.6 mg/Kg and po dose of 31.2 mg/Kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,13569,In vivo,N,1,CHEMBL618613,,,
8139,1,Clearance at an iv dose of 15.7 mg/Kg and po dose of 31.4 mg/Kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,13569,In vivo,N,1,CHEMBL621076,,,
8140,1,Clearance at an iv dose of 16 mg/Kg and po dose of 35 mg/Kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,13569,In vivo,N,1,CHEMBL621077,,,
8141,1,"Clearance in fischer rats at 5 mg/kg dose, administered intravenously",,BAO_0000218,,Rattus norvegicus,,Intermediate,17670,In vivo,N,1,CHEMBL621078,,,
8142,1,Clearance in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5970,In vivo,N,1,CHEMBL621251,,,
8143,1,Clearance in rat after oral administration at 10 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,6495,In vivo,N,1,CHEMBL621252,,,
8144,1,Clearance in rat.,,BAO_0000218,,Rattus norvegicus,,Intermediate,4590,In vivo,N,1,CHEMBL621253,,,
8145,1,Clearance rate following an oral dose of 20 mg/kg in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,6193,In vivo,N,1,CHEMBL621254,,,
8146,1,Compound was evaluated for the rate of clearance in rat upon intravenous administration.,,BAO_0000218,,Rattus norvegicus,,Intermediate,2832,In vivo,N,1,CHEMBL621255,,,
8147,1,Compound was tested for plasma clearance in rats after 5 mg/kg of intravenous dosing,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,1052,In vivo,N,1,CHEMBL621256,,1969.0,
8148,1,Biodistribution in rat liver in the presence of GdDTPA-BDP at 1 hr,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL621257,,2107.0,
8149,1,Biodistribution in rat liver in the presence of GdDTPA-BDP at 30 min,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL621258,,2107.0,
8150,1,Biodistribution in rat liver in the presence of GdDTPA-BDP at 4 hr,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL621259,,2107.0,
8151,1,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 15 min,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL621260,,2107.0,
8152,1,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 1 hr,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL876494,,2107.0,
8153,1,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 30 min,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL621261,,2107.0,
8154,1,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 4 hr,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL621262,,2107.0,
8155,1,Biodistribution in rat liver in the presence of NAC Gd/0.01 M GdDTPA-HPDP,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL621263,,2107.0,
8156,1,Biodistribution in rat liver in the presence of NCA Gd/0.01 M lip,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL621264,,2107.0,
8157,1,Biodistribution in rat muscle in the presence of 0.01 M GdDTPA-BDP,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL621265,,2385.0,
8158,1,Biodistribution in rat muscle in the presence of 0.05 M Gd/0.15 M lig,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL621266,,2385.0,
8159,1,Biodistribution in rat muscle in the presence of 0.05 M GdDTPA-BDP,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL621267,,2385.0,
8160,1,Biodistribution in rat muscle in the presence of 0.10 M GdDTPA-BDP,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL621268,,2385.0,
8161,1,Biodistribution in rat muscle in the presence of GdDTPA-BDP at 1 hr,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL621269,,2385.0,
8162,1,Biodistribution in rat muscle in the presence of GdDTPA-BDP at 4 hr,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL621270,,2385.0,
8163,1,Biodistribution in rat muscle in the presence of GdDTPA-BDPat 15 min,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL621271,,2385.0,
8164,1,Biodistribution in rat muscle in the presence of GdDTPA-BDPat 30 min,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL621272,,2385.0,
8165,1,Biodistribution in rat muscle in the presence of GdDTPA-HPDP at 1 hr,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL621273,,2385.0,
8166,1,Biodistribution in rat muscle in the presence of GdDTPA-HPDP at 4 hr,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL621274,,2385.0,
8167,1,Biodistribution in rat muscle in the presence of GdDTPA-HPDPat 15 min,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL876495,,2385.0,
8168,1,Biodistribution in rat muscle in the presence of GdDTPA-HPDPat 30 min,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL621275,,2385.0,
8169,1,Biodistribution in rat muscle in the presence of NCA Gd/0.01 M lip,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL621276,,2385.0,
8170,1,Biodistribution in rat muscle in the presence of NCAGd/0.01 M lig,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL621277,,2385.0,
8171,1,Biodistribution in rat s. intestine in the presence of 50 Gd/kg at 2 hr,Intestine,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL621278,,160.0,
8172,1,Biodistribution in rat s. intestine in the presence of 50 Gd/kg at 6 hr,Intestine,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL621279,,160.0,
8173,1,Biodistribution in rat s. intestine in the presence of NCA (No carrier added),Intestine,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL621280,,160.0,
8174,1,Biodistribution in rat spleen in the presence of 0.01 M GdDTPA-BDP,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL621281,,2106.0,
8175,1,Biodistribution in rat spleen in the presence of 0.05 M Gd/0.15 M lig; ND=No data,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL621282,,2106.0,
8176,1,Biodistribution in rat spleen in the presence of 0.05 M GdDTPA-BDP; ND=No data,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL621283,,2106.0,
8177,1,Biodistribution in rat spleen in the presence of 0.10 M GdDTPA-BDP,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL621284,,2106.0,
8178,1,Biodistribution in rat spleen in the presence of 50 Gd/kg at 15 min,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL621285,,2106.0,
8179,1,Biodistribution in rat spleen in the presence of 50 Gd/kg at 2 hr,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL621286,,2106.0,
8180,1,Biodistribution in rat spleen in the presence of 50 Gd/kg at 6 hr,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL623220,,2106.0,
8181,1,Biodistribution in rat spleen in the presence of NCA Gd/0.01 M lip,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL623221,,2106.0,
8182,1,Biodistribution in rat spleen in the presence of NCAGd/0.01 M lig,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL876029,,2106.0,
8183,1,Biodistribution in rat stomach in the presence of 50 Gd/kg at 15 min,Stomach,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL623222,,945.0,
8184,1,Biodistribution in rat stomach in the presence of 50 Gd/kg at 2 hr,Stomach,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL623223,,945.0,
8185,1,Biodistribution in rat stomach in the presence of 50 Gd/kg at 6 h; ND=No data,Stomach,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,N,1,CHEMBL621445,,945.0,
8186,1,Biodistribution of [123I]-label in rat blood was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,N,1,CHEMBL621446,,178.0,
8187,1,Biodistribution of [123I]-label in rat blood was reported at 1 hr post injection. Value shown is %ID/g of tissue,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,N,1,CHEMBL621447,,178.0,
8188,1,Biodistribution of [123I]-label in rat blood was reported at 2 hr post injection. Value shown is %ID/g of tissue,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,N,1,CHEMBL619681,,178.0,
8189,1,Biodistribution of [123I]-label in rat blood was reported at 24 hr post injection. Value shown is %ID/g of tissue,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,N,1,CHEMBL619682,,178.0,
8190,1,Biodistribution of [123I]-label in rat blood was reported at 4 hr post injection. Value shown is %ID/g of tissue,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,N,1,CHEMBL619683,,178.0,
8191,1,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,N,1,CHEMBL619684,,955.0,
8192,1,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/g of tissue,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,N,1,CHEMBL619685,,955.0,
8193,1,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/g of tissue,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,N,1,CHEMBL619686,,955.0,
8194,1,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/g of tissue,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,N,1,CHEMBL619687,,955.0,
8195,1,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/g of tissue,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,N,1,CHEMBL619688,,955.0,
8196,1,Biodistribution of [123I]-label in rat heart was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,N,1,CHEMBL619689,,948.0,
8197,1,Biodistribution of [123I]-label in rat heart was reported at 1 hr post injection. Value shown is %ID/g of tissue,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,N,1,CHEMBL619690,,948.0,
8198,1,Biodistribution of [123I]-label in rat heart was reported at 2 hr post injection. Value shown is %ID/g of tissue,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,N,1,CHEMBL619691,,948.0,
8199,1,Terminal phase volume of distribution was measured in rat after an iv dose of 1 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,6062,In vivo,N,1,CHEMBL619692,,,
8200,1,Apparent volume of the central plasma compartment (Vc) of compound determined in rat after iv administration at a dose of 10 mg/kg,,BAO_0000218,,Rattus norvegicus,,Expert,3598,,N,1,CHEMBL619693,,,
8201,1,Vc value after IV dose at a dose of 5 mg/kg in rats.,,BAO_0000218,,Rattus norvegicus,,Intermediate,1908,In vivo,N,1,CHEMBL619694,,,
8202,1,Apparent volume of distribution at 10 mg/kg in rat upon intravenous administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,17596,In vivo,N,1,CHEMBL619695,,,
8203,1,Compound was evaluated for pharmacokinetic parameter volume of distribution,,BAO_0000218,,Rattus norvegicus,,Intermediate,4891,In vivo,N,1,CHEMBL619696,,,
8204,1,Compound was evaluated for volume of distribution in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,740,In vivo,N,1,CHEMBL619697,,,
8205,1,Steady state volume distribution was determined; steady state(ss),,BAO_0000218,,Rattus norvegicus,,Intermediate,16366,In vivo,N,1,CHEMBL619698,,,
8206,1,Steady state volume of distribution after iv administration to rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,3364,In vivo,N,1,CHEMBL619699,,,
8207,1,Steady state volume of distribution dosing at 3 mg/kg iv,,BAO_0000218,,Rattus norvegicus,,Intermediate,2552,In vivo,N,1,CHEMBL619700,,,
8208,1,The compound was evaluated for volume of distribution in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,406,In vivo,N,1,CHEMBL619701,,,
8209,1,The compound was tested for volume of distribution in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,12500,In vivo,N,1,CHEMBL619702,,,
8210,1,The compound was tested for volume of distribution in rat at dose of 3-10 mgkg,,BAO_0000218,,Rattus norvegicus,,Intermediate,12500,In vivo,N,1,CHEMBL620335,,,
8211,1,Volume distribution (VD) after oral administration in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5656,In vivo,N,1,CHEMBL620336,,,
8212,1,Volume distribution of compound in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,17671,In vivo,N,1,CHEMBL620337,,,
8213,1,Volume distribution in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,1094,In vivo,N,1,CHEMBL620520,,,
8214,1,Volume distribution in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5833,In vivo,N,1,CHEMBL620521,,,
8215,1,Volume distribution in rat after peroral administration at 10 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,5939,In vivo,N,1,CHEMBL875825,,,
8216,1,Volume distribution in rat after peroral administration at 5 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,5939,In vivo,N,1,CHEMBL620522,,,
8217,1,Volume distribution was evaluated after i.v. administration in rat at a dose of 1 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,6005,In vivo,N,1,CHEMBL620523,,,
8218,1,Volume of distribution in rat.,,BAO_0000218,,Rattus norvegicus,,Intermediate,1696,In vivo,N,1,CHEMBL620524,,,
8219,1,Volume of distribution in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6672,In vivo,N,1,CHEMBL620525,,,
8220,1,Volume of distribution in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6673,In vivo,N,1,CHEMBL620526,,,
8221,1,Volume of distribution in rat by iv administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,5871,In vivo,N,1,CHEMBL620527,,,
8222,1,Volume of distribution in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,6803,In vivo,N,1,CHEMBL620528,,,
8223,1,Volume of distribution was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,,BAO_0000218,,Rattus norvegicus,,Intermediate,5199,In vivo,N,1,CHEMBL620529,,,
8224,1,Volume distribution at the dose of 2 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4727,,N,1,CHEMBL620530,,,
8225,1,Steady state volume of distribution was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,16367,In vivo,N,1,CHEMBL620531,,,
8226,1,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,,BAO_0000218,,Macaca mulatta,,Intermediate,5005,In vivo,U,0,CHEMBL620532,,,
8227,1,Compound was tested for its plasma volume distribution in Sprague Dawley rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,5005,In vivo,U,0,CHEMBL620533,,,
8228,1,Compound was tested for its plasma volume distribution in Sprague Dawley rats; ND is not determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,5005,In vivo,U,0,CHEMBL620534,,,
8229,1,Mean (%CV) PK parameters for Vdss(mL/kg).,,BAO_0000218,,Rattus norvegicus,,Intermediate,15765,In vivo,N,1,CHEMBL620535,,,
8230,1,Pharmacokinetic parameter Vdss was determined at 2 mg/kg i.v. dose in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,2792,In vivo,N,1,CHEMBL875826,,,
8231,1,Pharmacokinetic parameter Vdss was determined at 5 mg/kg i.v. dose in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,2792,In vivo,N,1,CHEMBL620536,,,
8232,1,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5334,In vivo,N,1,CHEMBL620537,,,
8233,1,Pharmacokinetic parameter volume of distribution was reported in Sprague-Dawley rat; ND=Not determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,5334,In vivo,N,1,CHEMBL618526,,,
8234,1,Pharmacokinetic property (Vdss) for the compound (5 mg/kg iv) was determined in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,5739,In vivo,N,1,CHEMBL618527,,,
8235,1,Pharmacokinetic property (Vdss) in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5789,In vivo,N,1,CHEMBL618528,,,
8236,1,Pharmacokinetic property (vdss) was measured in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4239,In vivo,N,1,CHEMBL618529,,,
8237,1,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4709,In vivo,N,1,CHEMBL618530,,,
8238,1,Volume of distribution in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6642,In vivo,N,1,CHEMBL618531,,,
8239,1,The pharmacokinetic parameter volume of distribution in vivo in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,5247,In vivo,N,1,CHEMBL618532,,,
8240,1,Vdss at a dose of 4 mg/kg in Rat Plasma after iv administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,17720,In vivo,N,1,CHEMBL618533,,,
8241,1,Vdss in rat i.v. at 2 mg/kg concentration,,BAO_0000218,,Rattus norvegicus,,Intermediate,17686,In vivo,N,1,CHEMBL618534,,,
8242,1,Volume distribution after intravenous administration (1 mg/kg) in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4689,In vivo,N,1,CHEMBL618535,,,
8243,1,Volume distribution of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,5654,In vivo,N,1,CHEMBL618536,,,
8244,1,Volume distribution of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,5654,In vivo,N,1,CHEMBL618537,,,
8245,1,Volume distribution at a dose of 10 uM/kg in rat was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,4527,In vivo,N,1,CHEMBL618538,,,
8246,1,Volume distribution in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,4521,In vivo,N,1,CHEMBL618539,,,
8247,1,Volume distribution was calculated in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6057,In vivo,N,1,CHEMBL618540,,,
8248,1,Volume distribution was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,5510,In vivo,N,1,CHEMBL618541,,,
8249,1,Volume of distribution after intravenous administration was evaluated in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,2938,In vivo,N,1,CHEMBL618542,,,
8250,1,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,6679,In vivo,N,1,CHEMBL622544,,,
8251,1,"Volume of distribution at steady state was determined in rats at 10 mg/kg, p.o. dose; n/a: not applicable",,BAO_0000218,,Rattus norvegicus,,Intermediate,6685,In vivo,N,1,CHEMBL622545,,,
8252,1,"Volume of distribution at steady state was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",,BAO_0000218,,Rattus norvegicus,,Intermediate,6685,In vivo,N,1,CHEMBL622546,,,
8253,1,"Volume of distribution at steady state was determined in rats at 2 mg/kg, i.v. dose",,BAO_0000218,,Rattus norvegicus,,Intermediate,6685,In vivo,N,1,CHEMBL622547,,,
8254,1,Volume of distribution in steady state was determined in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5145,In vivo,N,1,CHEMBL622548,,,
8255,1,Volume of distribution in steady state was determined in rats at the dose of 1.0 mpk by i.v. administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,6467,In vivo,N,1,CHEMBL622549,,,
8256,1,Volume of distribution in steady state was determined in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,6467,In vivo,N,1,CHEMBL622550,,,
8257,1,Compound was evaluated for area under curve when administered through oral route to mouse,,BAO_0000218,,Mus musculus,,Intermediate,15115,,N,1,CHEMBL622551,,,
8258,1,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,,BAO_0000218,,Rattus norvegicus,,Intermediate,8758,,N,1,CHEMBL622552,,,
8259,1,Compound was evaluated for area under curve doses in rat at 50 mg/kg po,,BAO_0000218,,Rattus norvegicus,,Intermediate,8758,,N,1,CHEMBL622553,,,
8260,1,Compound was evaluated for its bioavailability after oral administration (100 mg) to Beagle dogs,,BAO_0000218,,,,Autocuration,8267,In vivo,U,0,CHEMBL622554,,,
8261,1,Compound was evaluated for its bioavailability after oral administration (200 mg) to Beagle dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,8267,,N,1,CHEMBL622555,,,
8262,1,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,,BAO_0000218,,Mus musculus,,Intermediate,14239,,N,1,CHEMBL622556,,,
8263,1,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,,BAO_0000218,,Mus musculus,,Intermediate,14239,,N,1,CHEMBL622557,,,
8264,1,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration using Area under the time-concentration curve after 40 mg/kg intramuscular administration to mice,Blood,BAO_0000218,,Mus musculus,,Intermediate,10754,,N,1,CHEMBL622558,,178.0,
8265,1,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration using Area under the time-concentration curve after 40 mg/kg peroral administration to mice,Blood,BAO_0000218,,Mus musculus,,Intermediate,10754,,N,1,CHEMBL622559,,178.0,
8266,1,Compound was evaluated in vivo in for its concentration using Area under the time-concentration curve after 40 mg/kg peroral administration to dogs.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,10754,,N,1,CHEMBL622560,,,
8267,1,Compound was tested for area under concentration -time curve from time 0 to time infinity in three male Wistar rats at a single 5 mg/kg oral gavage dose,,BAO_0000218,,Rattus norvegicus,,Intermediate,14681,,N,1,CHEMBL622561,,,
8268,1,Compound was tested for area under concentration -time curve from time 0 to time infinity in three male Wistar rats at a single 5 mg/kg oral gavage dose. ,,BAO_0000218,,Rattus norvegicus,,Intermediate,14681,,N,1,CHEMBL622562,,,
8269,1,Compound was tested for area under concentration -time curve from time 0 to time of last detectable concentration in three male Wistar rats at a single 5 mg/kg oral gavage dose,,BAO_0000218,,Rattus norvegicus,,Intermediate,14681,,N,1,CHEMBL622563,,,
8270,1,Concentration of compound in Central nervous system,,BAO_0000019,,,,Autocuration,13118,,U,0,CHEMBL622564,,,
8271,1,Concentration of compound in Central nervous system; Not detectable,,BAO_0000019,,,,Autocuration,13118,,U,0,CHEMBL622565,,,
8272,1,"Concentration of diester in the blood, following oral administration in mice",,BAO_0000218,,Mus musculus,,Intermediate,13318,,N,1,CHEMBL622566,,,
8273,1,"Concentration of monoester in the blood, following oral administration in mice",,BAO_0000218,,Mus musculus,,Intermediate,13318,,N,1,CHEMBL624515,,,
8274,1,Concentration of the 9-[2-(Phosphonomethoxy)ethoxy]adenine in the blood following oral administration in mice,,BAO_0000218,,Mus musculus,,Intermediate,13318,,N,1,CHEMBL624516,,,
8275,1,Evaluated for Pharmacokinetic property: Area under the curve,,BAO_0000019,,,,Autocuration,15692,,U,0,CHEMBL624517,,,
8276,1,In vivo antitumor efficacy expressed as plasma area under the curve 0.4 hr after a peroral dose of 25 mg/kg in nude mice,,BAO_0000218,,Mus musculus,,Intermediate,14839,,N,1,CHEMBL624518,,,
8277,1,In vivo antitumor efficacy expressed as plasma area under the curve 0.4 hr after iv dose of 25 mg/kg in nude mice,,BAO_0000218,,Macaca fascicularis,,Intermediate,14839,,N,1,CHEMBL624519,,,
8278,1,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after iv dose of 5 mg/kg expressed as Area under the curve,,BAO_0000218,,Macaca fascicularis,,Intermediate,14839,,N,1,CHEMBL624520,,,
8279,1,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after peroral dose of 10 mg/kg expressed as Area under the curve,,BAO_0000218,,Macaca fascicularis,,Intermediate,14839,,N,1,CHEMBL624521,,,
8280,1,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after peroral dose of 5 mg/kg expressed as Area under the curve,,BAO_0000218,,Macaca fascicularis,,Intermediate,14839,,N,1,CHEMBL624522,,,
8281,1,In vivo antitumor efficacy in cynomolgus monkeys 0-8 hours after peroral dose of 25 mg/kg expressed as Area under the curve,,BAO_0000218,,Macaca fascicularis,,Intermediate,14839,,N,1,CHEMBL624523,,,
8282,1,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 10 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",,BAO_0000218,,Macaca fascicularis,,Intermediate,14839,,N,1,CHEMBL624409,,,
8283,1,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-8 hr)",,BAO_0000218,,Macaca fascicularis,,Intermediate,14839,,N,1,CHEMBL624410,,,
8284,1,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",,BAO_0000218,,Macaca fascicularis,,Intermediate,14839,,N,1,CHEMBL624411,,,
8285,1,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as the micronised free base in corn oil, iv and the total drug exposure was determined. (0-8 hr)",,BAO_0000218,,Macaca fascicularis,,Intermediate,14839,,N,1,CHEMBL623531,,,
8286,1,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as the micronised free base in corn oil, perorally and the total drug exposure was determined (0-8 hr)",,BAO_0000218,,Macaca fascicularis,,Intermediate,14839,,N,1,CHEMBL623532,,,
8287,1,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, intravenously and the total drug exposure was determined (0-8 hr)",,BAO_0000218,,Macaca fascicularis,,Intermediate,14839,,N,1,CHEMBL623533,,,
8288,1,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",,BAO_0000218,,Macaca fascicularis,,Intermediate,14839,,N,1,CHEMBL623534,,,
8289,1,In vivo antitumor efficacy in nude mice 0-24 hr after intravenous dose of 25 mg/kg expressed as Area under the curve,,BAO_0000218,,Mus musculus,,Intermediate,14839,,N,1,CHEMBL623535,,,
8290,1,In vivo antitumor efficacy in nude mice 0-24 hr after iperoral dose of 25 mg/kg expressed as Area under the curve,,BAO_0000218,,Mus musculus,,Intermediate,14839,,N,1,CHEMBL623536,,,
8291,1,In vivo antitumor efficacy in nude mice 0-24 hr after iv dose of 25 mg/kg expressed as Area under the curve,,BAO_0000218,,Mus musculus,,Intermediate,14839,,N,1,CHEMBL623537,,,
8292,1,In vivo antitumor efficacy in nude mice 0-24 hr after peroral dose of 25 mg/kg expressed as Area under the curve,,BAO_0000218,,Mus musculus,,Intermediate,14839,,N,1,CHEMBL623538,,,
8293,1,In vivo antitumor efficacy in nude mice after peroral dose of 10 mg/kg expressed as Area under the curve,,BAO_0000218,,Mus musculus,,Intermediate,14839,,N,1,CHEMBL623539,,,
8294,1,In vivo antitumor efficacy in nude mice after peroral dose of 25 mg/kg expressed as Area under the curve,,BAO_0000218,,Mus musculus,,Intermediate,14839,,N,1,CHEMBL623540,,,
8295,1,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined.",,BAO_0000218,,Mus musculus,,Intermediate,14839,,N,1,CHEMBL623541,,,
8296,1,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-24hr)",,BAO_0000218,,Mus musculus,,Intermediate,14839,,N,1,CHEMBL623542,,,
8297,1,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-4 hr)",,BAO_0000218,,Mus musculus,,Intermediate,14839,,N,1,CHEMBL623543,,,
8298,1,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined",,BAO_0000218,,Mus musculus,,Intermediate,14839,,N,1,CHEMBL623544,,,
8299,1,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-24hr)",,BAO_0000218,,Mus musculus,,Intermediate,14839,,N,1,CHEMBL623545,,,
8300,1,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-4 hr)",,BAO_0000218,,Mus musculus,,Intermediate,14839,,N,1,CHEMBL623546,,,
8301,1,Evaluated for plasma clearance after iv administration of 5 mg/kg to male Sprague-Dawley rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,5408,In vivo,N,1,CHEMBL623547,,1969.0,
8302,1,High i.v. clearance in Dawley rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,6827,In vivo,N,1,CHEMBL623548,,,
8303,1,In vitro clearance in rat liver microsomes,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,17538,In vitro,N,1,CHEMBL623549,,2107.0,
8304,1,Intrinsic clearance in rat liver microsomes was determined,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,6331,In vitro,N,1,CHEMBL623550,,2107.0,
8305,1,Intrinsic clearance in rat hepatocytes was determined,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,5948,In vitro,N,1,CHEMBL875276,401.0,2107.0,
8306,1,Plasma Clearance was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,4026,In vivo,N,1,CHEMBL621872,,,
8307,1,Plasma clearance after intravenous administration of 0.4 mg/kg of dose in rats was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,6647,In vivo,N,1,CHEMBL621873,,,
8308,1,Plasma clearance in rat.,,BAO_0000218,,Rattus norvegicus,,Intermediate,1696,In vivo,N,1,CHEMBL621874,,,
8309,1,Plasma clearance in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,6597,In vivo,N,1,CHEMBL621875,,,
8310,1,Plasma clearance was estimated from the AUC after 5 mg/kg intravenous dosing in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,347,In vivo,N,1,CHEMBL621876,,,
8311,1,Plasma clearance was evaluated after 10 uM/kg of intra arterial administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,16423,In vivo,N,1,CHEMBL621877,,,
8312,1,Plasma clearance was measured in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,2879,In vivo,N,1,CHEMBL621878,,,
8313,1,Clearance after iv administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,4883,In vivo,N,1,CHEMBL621879,,,
8314,1,"Tested for the plasma clearance in Dawley rat at a dose of 1 mg/kg intravenous, 2 mg/kg orally",Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,5328,In vivo,N,1,CHEMBL621880,,1969.0,
8315,1,The clearance rate in mature male rat at a intravenous dose of 3 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,5160,In vivo,N,1,CHEMBL621881,,,
8316,1,Total body clearance was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,17582,In vivo,N,1,CHEMBL621882,,,
8317,1,Total clearance at 1 mg/kg was determined in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,17651,In vivo,N,1,CHEMBL875283,,,
8318,1,Total clearance at 10 mg/kg was determined in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,17651,In vivo,N,1,CHEMBL621883,,,
8319,1,Clearance in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6596,In vivo,N,1,CHEMBL621884,,,
8320,1,Plasma clearance rate determined in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,4796,In vivo,N,1,CHEMBL621885,,,
8321,1,Clearance of compound in rat was evaluated,,BAO_0000218,,Rattus norvegicus,,Intermediate,6850,In vivo,N,1,CHEMBL621886,,,
8322,1,Plasma concentration in rats after 7 hr at 30mg/kg oral dose,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,5932,In vivo,N,1,CHEMBL621887,,1969.0,
8323,1,Pharmacokinetic property (blood clearance) in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,3371,In vivo,N,1,CHEMBL621888,,,
8324,1,Plasma clearance in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,2083,In vivo,N,1,CHEMBL621889,,,
8325,1,Plasma clearance in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,4942,In vivo,N,1,CHEMBL621890,,,
8326,1,Intrinsic clearance of compound against NADPH-fortified rat liver microsomes,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,6838,In vitro,N,1,CHEMBL621891,,2107.0,
8327,1,Clearance in Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5353,In vivo,N,1,CHEMBL621892,,,
8328,1,Clearance rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6641,In vivo,N,1,CHEMBL621893,,,
8329,1,Clearance rat (dosed at 0.5 mpk IV and 2.0 mpk po.),,BAO_0000218,,Rattus norvegicus,,Intermediate,6641,In vivo,N,1,CHEMBL621894,,,
8330,1,Clearance rat; Not determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,6641,In vivo,N,1,CHEMBL621895,,,
8331,1,Clearance rate was determined in rat at a dose of 1 mpk i.v.,,BAO_0000218,,Rattus norvegicus,,Intermediate,6444,In vivo,N,1,CHEMBL875284,,,
8332,1,Clearance rate was determined in rat at a dose of 1 mpk i.v.; ND means not determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,6444,In vivo,N,1,CHEMBL618699,,,
8333,1,Clearance rate was determined in rat at a dose of 1 mpk i.v.; ND=not determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,6444,In vivo,N,1,CHEMBL618700,,,
8334,1,Clearance was determined by iv administration (1.5 mg/kg) in fasted male Sprague-Dawley rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,6211,In vivo,N,1,CHEMBL618701,,,
8335,1,"Clearance in plasma calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv",Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,12873,In vivo,N,1,CHEMBL876600,,1969.0,
8336,1,Clearance of compound in rat after 1 mg/kg i.v. administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,6570,In vivo,N,1,CHEMBL618702,,,
8337,1,Compound was evaluated for Hepatic clearance in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,3341,In vivo,N,1,CHEMBL618703,,,
8338,1,In vivo clearance after 5 mg/kg dose,,BAO_0000218,,Rattus norvegicus,,Intermediate,4891,In vivo,N,1,CHEMBL618704,,,
8339,1,Compound was tested for plasma clearance in rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,1094,In vivo,N,1,CHEMBL618705,,1969.0,
8340,1,Hepatic clearance after intravenous administration was evaluated in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,2938,In vivo,N,1,CHEMBL618706,,,
8341,1,Lower clearance in rat (i.v.) at 0.5 mpk,,BAO_0000218,,Rattus norvegicus,,Intermediate,17853,In vivo,N,1,CHEMBL618707,,,
8342,1,Pharmacokinetic parameter expressed as plasma clearance in rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,6049,In vivo,N,1,CHEMBL618708,,1969.0,
8343,1,Pharmacokinetic property (Clp) in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5789,In vivo,N,1,CHEMBL618709,,,
8344,1,Plasma clearance in Sprague-Dawley rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,4514,In vivo,N,1,CHEMBL618710,,,
8345,1,Plasma clearance (Clp) in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6448,In vivo,N,1,CHEMBL618711,,,
8346,1,Plasma clearance for the compound was measured in rat after an iv dose of 1 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,6062,In vivo,N,1,CHEMBL618712,,,
8347,1,Plasma clearance in fasted male Sprague dawely rats on administration of 0.5 mg/Kg i.v. of the compound,,BAO_0000218,,Rattus norvegicus,,Intermediate,5710,In vivo,N,1,CHEMBL618713,,,
8348,1,Plasma clearance after intravenous administration of 1 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4709,In vivo,N,1,CHEMBL618714,,,
8349,1,Plasma clearance in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,4521,In vivo,N,1,CHEMBL618715,,,
8350,1,Plasma clearance in rat was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,1742,In vivo,N,1,CHEMBL618716,,,
8351,1,Plasma clearance measured in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6057,In vivo,N,1,CHEMBL876601,,,
8352,1,Plasma clearance was calculated in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6057,In vivo,N,1,CHEMBL618717,,,
8353,1,Plasma clearance in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5145,In vivo,N,1,CHEMBL618718,,,
8354,1,Plasma clearance in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5833,In vivo,N,1,CHEMBL618719,,,
8355,1,Plasma clearance in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6453,In vivo,N,1,CHEMBL618720,,,
8356,1,Plasma clearance in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6640,In vivo,N,1,CHEMBL618721,,,
8357,1,Plasma clearance in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,6305,In vivo,N,1,CHEMBL621477,,,
8358,1,Plasma clearance in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6642,In vivo,N,1,CHEMBL621478,,,
8359,1,Plasma clearance was evaluated in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5472,In vivo,N,1,CHEMBL621479,,,
8360,1,Plasma clearance was evaluated in rat; Not tested,,BAO_0000218,,Rattus norvegicus,,Intermediate,5472,In vivo,N,1,CHEMBL621480,,,
8361,1,Plasma clearance rate was determined for the compound in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5144,In vivo,N,1,CHEMBL621481,,,
8362,1,"Plasma clearance rate was determined in rats at 10mg/kg, p.o. dose; n/a: not applicable",,BAO_0000218,,Rattus norvegicus,,Intermediate,6685,In vivo,N,1,CHEMBL621482,,,
8363,1,"Plasma clearance rate was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",,BAO_0000218,,Rattus norvegicus,,Intermediate,6685,In vivo,N,1,CHEMBL621483,,,
8364,1,"Plasma clearance rate was determined in rats at 2 mg/kg, i.v. dose",,BAO_0000218,,Rattus norvegicus,,Intermediate,6685,In vivo,N,1,CHEMBL621484,,,
8365,1,Biodistribution of [123I]-label in rat heart was reported at 24 hr post injection. Value shown is %ID/g of tissue,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,N,1,CHEMBL621485,,948.0,
8366,1,Biodistribution of [123I]-label in rat heart was reported at 4 hr post injection. Value shown is %ID/g of tissue,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,N,1,CHEMBL621486,,948.0,
8367,1,Biodistribution of [123I]-label in rat intestine was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,Intestine,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,N,1,CHEMBL621487,,160.0,
8368,1,Biodistribution of [123I]-label in rat intestine was reported at 1 hr post injection. Value shown is %ID/g of tissue,Intestine,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,N,1,CHEMBL621488,,160.0,
8369,1,Biodistribution of [123I]-label in rat intestine was reported at 2 hr post injection. Value shown is %ID/g of tissue,Intestine,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,N,1,CHEMBL621489,,160.0,
8370,1,Biodistribution of [123I]-label in rat intestine was reported at 24 hr post injection. Value shown is %ID/g of tissue,Intestine,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,N,1,CHEMBL621490,,160.0,
8371,1,Biodistribution of [123I]-label in rat intestine was reported at 4 hr post injection. Value shown is %ID/g of tissue,Intestine,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,N,1,CHEMBL621491,,160.0,
8372,1,Biodistribution of [123I]-label in rat kidneys was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,N,1,CHEMBL621492,,2113.0,
8373,1,Biodistribution of [123I]-label in rat kidneys was reported at 1 h post injection. Value shown is %ID/g of tissue,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,N,1,CHEMBL621493,,2113.0,
8374,1,Biodistribution of [123I]-label in rat kidneys was reported at 2 hr post injection. Value shown is %ID/g of tissue,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,N,1,CHEMBL621494,,2113.0,
8375,1,Biodistribution of [123I]-label in rat kidneys was reported at 24 hr post injection. Value shown is %ID/g of tissue,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,N,1,CHEMBL621495,,2113.0,
8376,1,Biodistribution of [123I]-label in rat kidneys was reported at 4 hr post injection. Value shown is %ID/g of tissue,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,N,1,CHEMBL621496,,2113.0,
8377,1,Biodistribution of [123I]-label in rat liver was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,N,1,CHEMBL621497,,2107.0,
8378,1,Biodistribution of [123I]-label in rat liver was reported at 1 hr post injection. Value shown is %ID/g of tissue,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,N,1,CHEMBL621498,,2107.0,
8379,1,Biodistribution of [123I]-label in rat liver was reported at 2 hr post injection. Value shown is %ID/g of tissue,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,N,1,CHEMBL621499,,2107.0,
8380,1,Biodistribution of [123I]-label in rat liver was reported at 24 h post injection. Value shown is %ID/g of tissue,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,N,1,CHEMBL618634,,2107.0,
8381,1,Biodistribution of [123I]-label in rat liver was reported at 4 hr post injection. Value shown is %ID/g of tissue,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,N,1,CHEMBL618635,,2107.0,
8382,1,Biodistribution of [123I]-label in rat lung was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,N,1,CHEMBL618636,,2048.0,
8383,1,Biodistribution of [123I]-label in rat lung was reported at 1 hr post injection. Value shown is %ID/g of tissue,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,N,1,CHEMBL619737,,2048.0,
8384,1,Biodistribution of [123I]-label in rat lung was reported at 2 hr post injection. Value shown is %ID/g of tissue,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,N,1,CHEMBL619738,,2048.0,
8385,1,Biodistribution of [123I]-label in rat lung was reported at 24 hr post injection. Value shown is %ID/g of tissue,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,N,1,CHEMBL624329,,2048.0,
8386,1,Biodistribution of [123I]-label in rat lung was reported at 4 hr post injection. Value shown is %ID/g of tissue,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,N,1,CHEMBL624330,,2048.0,
8387,1,Biodistribution of [123I]-label in rat muscle was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,N,1,CHEMBL624331,,2385.0,
8388,1,Biodistribution of [123I]-label in rat muscle was reported at 1 hr post injection. Value shown is %ID/g of tissue,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,N,1,CHEMBL624332,,2385.0,
8389,1,Biodistribution of [123I]-label in rat muscle was reported at 2 hr post injection. Value shown is %ID/g of tissue,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,N,1,CHEMBL624333,,2385.0,
8390,1,Biodistribution of [123I]-label in rat muscle was reported at 24 hr post injection. Value shown is %ID/g of tissue,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,N,1,CHEMBL624334,,2385.0,
8391,1,Biodistribution of [123I]-label in rat muscle was reported at 4 hr post injection. Value shown is %ID/g of tissue,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,N,1,CHEMBL624335,,2385.0,
8392,1,Biodistribution of [123I]-label in rat spleen was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,N,1,CHEMBL620016,,2106.0,
8393,1,Biodistribution of [123I]-label in rat spleen was reported at 1 hr post injection. Value shown is %ID/g of tissue,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,N,1,CHEMBL620169,,2106.0,
8394,1,Biodistribution of [123I]-label in rat spleen was reported at 2 hr post injection. Value shown is %ID/g of tissue,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,N,1,CHEMBL620170,,2106.0,
8395,1,Biodistribution of [123I]-label in rat spleen was reported at 24 h post injection. Value shown is %ID/g of tissue,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,N,1,CHEMBL620171,,2106.0,
8396,1,Biodistribution of [123I]-label in rat spleen was reported at 4 hr post injection. Value shown is %ID/g of tissue,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,N,1,CHEMBL620172,,2106.0,
8397,1,Biodistribution of [123I]-label in rat stomach was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,Stomach,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,N,1,CHEMBL620173,,945.0,
8398,1,Biodistribution of [123I]-label in rat stomach was reported at 1 h post injection. Value shown is %ID/g of tissue,Stomach,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,N,1,CHEMBL620174,,945.0,
8399,1,Biodistribution of [123I]-label in rat stomach was reported at 2 hr post injection. Value shown is %ID/g of tissue,Stomach,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,N,1,CHEMBL620175,,945.0,
8400,1,Biodistribution of [123I]-label in rat stomach was reported at 24 hr post injection. Value shown is %ID/g of tissue,Stomach,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,N,1,CHEMBL620176,,945.0,
8401,1,Biodistribution of [123I]-label in rat stomach was reported at 4 hr post injection. Value shown is %ID/g of tissue,Stomach,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,N,1,CHEMBL620177,,945.0,
8402,1,Distribution of [123I]-label in rat brain (cerebellum) was reported at 20 min post injection. Value shown is %ID/g of tissue,Cerebellum,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,,N,1,CHEMBL620178,,2037.0,
8403,1,Distribution of [123I]-label in rat brain (cerebellum) was reported at 60 min post injection. Value shown is %ID/g of tissue,Cerebellum,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,,N,1,CHEMBL620179,,2037.0,
8404,1,Distribution of [123I]-label in rat brain (diencephalon) was reported at 20 min post injection. Value shown is %ID/g of tissue,,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,,N,1,CHEMBL620180,,,
8405,1,Volume of distribution of compound in rat after 1 mg/kg i.v. administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,6570,In vivo,N,1,CHEMBL620181,,,
8406,1,Volume of distribution of compound in rats after intravenous administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,6571,In vivo,N,1,CHEMBL620182,,,
8407,1,Volume of distribution in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6453,In vivo,N,1,CHEMBL620183,,,
8408,1,Volume of distribution was determined in rat at a dose of 1 mpk i.v.,,BAO_0000218,,Rattus norvegicus,,Intermediate,6444,In vivo,N,1,CHEMBL620184,,,
8409,1,Volume of distribution was determined in rat at a dose of 1 mpk i.v.; ND means not determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,6444,In vivo,N,1,CHEMBL620185,,,
8410,1,Volume of distribution was determined in rat at a dose of 1 mpk i.v.; ND=not determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,6444,In vivo,N,1,CHEMBL620186,,,
8411,1,Volume of distribution was determined in Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5353,In vivo,N,1,CHEMBL620187,,,
8412,1,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5334,In vivo,N,1,CHEMBL620188,,,
8413,1,Volume of distribution was reported in Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5334,In vivo,N,1,CHEMBL620189,,,
8414,1,Volumes of distribution in rat after peroral administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,6641,In vivo,N,1,CHEMBL620190,,,
8415,1,Volumes of distribution in rat after po administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,6641,In vivo,N,1,CHEMBL620191,,,
8416,1,Volumes of distribution in rat after po administration; Not determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,6641,In vivo,N,1,CHEMBL620192,,,
8417,1,Pharmacokinetic property (Volume) in rat i.v.,,BAO_0000218,,Rattus norvegicus,,Intermediate,5676,In vivo,N,1,CHEMBL620193,,,
8418,1,Apparent volume of distribution when 3 mg/Kg dose was administered intravenously,,BAO_0000218,,Rattus norvegicus,,Intermediate,6410,In vivo,N,1,CHEMBL620194,,,
8419,1,"Volume distribution in fischer rats at 5 mg/kg dose, administered intravenously",,BAO_0000218,,Rattus norvegicus,,Intermediate,17670,In vivo,N,1,CHEMBL876730,,,
8420,1,Volume distribution in rat after oral administration at 10 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,6495,In vivo,N,1,CHEMBL620195,,,
8421,1,Evaluated for Volume of distribution after iv administration of 5 mg/kg to male Sprague-Dawley rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,5408,In vivo,N,1,CHEMBL620196,,,
8422,1,Tested for volume of distribution after intravenous administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,4883,In vivo,N,1,CHEMBL620197,,,
8423,1,Volume of distribution after oral administration of 6 mg/kg of dose in rats was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,6647,In vivo,N,1,CHEMBL620198,,,
8424,1,Volume of distribution in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,6495,In vivo,N,1,CHEMBL620199,,,
8425,1,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female wistar rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,2661,In vivo,N,1,CHEMBL620200,,,
8426,1,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to male wistar rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,2661,In vivo,N,1,CHEMBL620201,,,
8427,1,In vivo Volume distribution (Vss) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5974,In vivo,N,1,CHEMBL620202,,,
8428,1,In vivo Volume distribution (Vss) was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5974,In vivo,N,1,CHEMBL620203,,,
8429,1,In vivo Volume distribution (Vss) was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat;no value,,BAO_0000218,,Rattus norvegicus,,Intermediate,5974,In vivo,N,1,CHEMBL620204,,,
8430,1,In vivo Volume distribution (Vss) was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5974,In vivo,N,1,CHEMBL620205,,,
8431,1,Pharmacokinetic parameter (Vss) in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5960,In vivo,N,1,CHEMBL624664,,,
8432,1,Pharmacokinetic property (Volume) in rat i.v.,,BAO_0000218,,Rattus norvegicus,,Intermediate,5676,In vivo,N,1,CHEMBL624665,,,
8433,1,Pharmacokinetic property (Vss) in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5948,,N,1,CHEMBL624666,,,
8434,1,Steady state volume distribution (Vss) of compound after 2 hr iv infusion of 8.4 mg/kg in three rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5979,In vivo,N,1,CHEMBL624667,,,
8435,1,Steady state volume distribution (Vss) of compound after iv administration was determined in Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5978,In vivo,N,1,CHEMBL624668,,,
8436,1,Steady state volume distribution (Vss) of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5978,In vivo,N,1,CHEMBL624669,,,
8437,1,Steady state volume distribution (Vss) of compound(9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5978,In vivo,N,1,CHEMBL624670,,,
8438,1,Steady state volume distribution (Vss) of compound(9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5978,In vivo,N,1,CHEMBL624671,,,
8439,1,Steady state volume distribution in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6448,In vivo,N,1,CHEMBL624672,,,
8440,1,"Steady state volume of distribution calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv.",Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,12873,In vivo,N,1,CHEMBL624673,,1969.0,
8441,1,Steady state volume of distribution determined in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4576,In vivo,N,1,CHEMBL624674,,,
8442,1,Steady-state volume of distribution was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,17582,In vivo,N,1,CHEMBL624675,,,
8443,1,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,1466,In vivo,N,1,CHEMBL621728,,,
8444,1,Volume at steady state distribution by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,5182,,N,1,CHEMBL621729,,,
8445,1,Volume at steady state distribution by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat was determined; NC means not calculated,,BAO_0000218,,Rattus norvegicus,,Intermediate,5182,,N,1,CHEMBL621730,,,
8446,1,Volume distribution in rat after administration of 2 mg/kg iv,,BAO_0000218,,Rattus norvegicus,,Intermediate,6535,In vivo,N,1,CHEMBL621731,,,
8447,1,Volume distribution in rat after administration of 2 mg/kg iv,,BAO_0000218,,Rattus norvegicus,,Intermediate,6535,In vivo,N,1,CHEMBL621732,,,
8448,1,Volume in steady state distribution value was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,5041,In vivo,N,1,CHEMBL621908,,,
8449,1,Volume in steady state distribution value was determined; ND denotes no data,,BAO_0000218,,Rattus norvegicus,,Intermediate,5041,In vivo,N,1,CHEMBL875347,,,
8450,1,Volume in steady state distribution value was determined; ND denotes not determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,5041,In vivo,N,1,CHEMBL621909,,,
8451,1,Volume of distribution at a steady state measured after intravenous bolus administration of 50 mg/kg of compound to rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,17065,In vivo,N,1,CHEMBL621910,,,
8452,1,Volume of distribution at steady state was evaluated in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,6597,In vivo,N,1,CHEMBL621911,,,
8453,1,Volume of distribution at steady state was observed after intravenous administration in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,15662,In vivo,N,1,CHEMBL621912,,,
8454,1,Volume of distribution in steady state was determined in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6485,In vivo,N,1,CHEMBL621913,,,
8455,1,Volume of distribution in steady state was determined in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,17655,In vivo,N,1,CHEMBL621914,,,
8456,1,Volume of distribution after i.v. administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,6616,In vivo,N,1,CHEMBL621915,,,
8457,1,Volume of distribution was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,1916,In vivo,N,1,CHEMBL621916,,,
8458,1,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",Liver,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,N,1,CHEMBL621917,,2107.0,
8459,1,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Liver,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,N,1,CHEMBL621918,,2107.0,
8460,1,Biodistribution of compound (oxidized form) in spleen tissue,Spleen,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,N,1,CHEMBL621919,,2106.0,
8461,1,"Biodistribution of compound (oxidized form) in spleen tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",Spleen,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,N,1,CHEMBL621920,,2106.0,
8462,1,"Biodistribution of compound (oxidized form) in spleen tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",Spleen,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,N,1,CHEMBL621921,,2106.0,
8463,1,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO",Spleen,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,N,1,CHEMBL622401,,2106.0,
8464,1,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Spleen,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,N,1,CHEMBL875348,,2106.0,
8465,1,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",Spleen,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,N,1,CHEMBL622402,,2106.0,
8466,1,Biodistribution of compound (total concentration of both oxidized and reduced forms) in blood,Blood,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,N,1,CHEMBL622403,,178.0,
8467,1,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",Blood,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,N,1,CHEMBL622404,,178.0,
8468,1,Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues,Brain,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,N,1,CHEMBL622405,,955.0,
8469,1,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO",Brain,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,N,1,CHEMBL622406,,955.0,
8470,1,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",Brain,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,N,1,CHEMBL622407,,955.0,
8471,1,Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues,Heart,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,N,1,CHEMBL622408,,948.0,
8472,1,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO",Heart,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,N,1,CHEMBL622409,,948.0,
8473,1,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO",Heart,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,N,1,CHEMBL622410,,948.0,
8474,1,Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney,Kidney,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,N,1,CHEMBL622411,,2113.0,
8475,1,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney tissues, animals were sacrificed 60 minutes after dosing in DMSO",Kidney,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,N,1,CHEMBL627864,,2113.0,
8476,1,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO",Kidney,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,N,1,CHEMBL627865,,2113.0,
8477,1,Biodistribution of compound (total concentration of both oxidized and reduced forms) in liver,Liver,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,N,1,CHEMBL627866,,2107.0,
8478,1,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",Liver,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,N,1,CHEMBL627751,,2107.0,
8479,1,Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen,Spleen,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,N,1,CHEMBL627752,,2106.0,
8480,1,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen tissues, animals were sacrificed 60 minutes after dosing in DMSO",Spleen,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,N,1,CHEMBL627753,,2106.0,
8481,1,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO",Spleen,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,N,1,CHEMBL627754,,2106.0,
8482,1,Cellular uptake kinetics of Porphycenes saturation cell level (cs) in SSK2 murine fibrosarcoma cells,,BAO_0000218,,Mus musculus,,Intermediate,12467,,N,1,CHEMBL627755,,,
8483,1,Biodistribution of radioactivity in normal mice (ICR) brain after 1 hour of intravenous injection of [125I]-16(IMPY),Brain,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,N,1,CHEMBL627756,,955.0,
8484,1,Biodistribution of radioactivity in normal mice (ICR) brain after 2 hours of intravenous injection of [125I]-16(IMPY),Brain,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,N,1,CHEMBL627757,,955.0,
8485,1,Biodistribution of radioactivity in normal mice (ICR) brain after 2 minutes of intravenous injection of [125I]-16(IMPY),Brain,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,N,1,CHEMBL627758,,955.0,
8486,1,Biodistribution of radioactivity in normal mice (ICR) brain after 24 hours of intravenous injection of [125I]-16(IMPY),Brain,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,N,1,CHEMBL627759,,955.0,
8487,1,Biodistribution of radioactivity in normal mice (ICR) brain after 30 minutes of intravenous injection of [125I]-16(IMPY),Brain,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,N,1,CHEMBL627760,,955.0,
8488,1,Biodistribution of radioactivity in normal mice (ICR) brain after 6 hours of intravenous injection of [125I]-16(IMPY),Brain,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,N,1,CHEMBL627761,,955.0,
8489,1,Biodistribution of radioactivity in normal mice (ICR) heart after 1 hour of intravenous injection of [125I]-16(IMPY),Heart,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,N,1,CHEMBL876811,,948.0,
8490,1,Biodistribution of radioactivity in normal mice (ICR) heart after 2 hours of intravenous injection of [125I]-16(IMPY),Heart,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,N,1,CHEMBL627762,,948.0,
8491,1,Biodistribution of radioactivity in normal mice (ICR) heart after 2 minutes of intravenous injection of [125I]-16(IMPY),Heart,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,N,1,CHEMBL627763,,948.0,
8492,1,Biodistribution of radioactivity in normal mice (ICR) heart after 24 hours of intravenous injection of [125I]-16(IMPY),Heart,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,N,1,CHEMBL627764,,948.0,
8493,1,Biodistribution of radioactivity in normal mice (ICR) heart after 30 minutes of intravenous injection of [125I]-16(IMPY),Heart,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,N,1,CHEMBL627765,,948.0,
8494,1,Biodistribution of radioactivity in normal mice (ICR) heart after 6 hours of intravenous injection of [125I]-16(IMPY),Heart,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,N,1,CHEMBL627766,,948.0,
8495,1,Biodistribution of radioactivity in normal mice (ICR) kidney after 1 hour of intravenous injection of [125I]-16(IMPY),Kidney,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,N,1,CHEMBL627767,,2113.0,
8496,1,Biodistribution of radioactivity in normal mice (ICR) kidney after 2 hours of intravenous injection of [125I]-16(IMPY),Kidney,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,N,1,CHEMBL627768,,2113.0,
8497,1,Biodistribution of radioactivity in normal mice (ICR) kidney after 2 minutes of intravenous injection of [125I]-16(IMPY),Kidney,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,N,1,CHEMBL628422,,2113.0,
8498,1,Biodistribution of radioactivity in normal mice (ICR) kidney after 24 hours of intravenous injection of [125I]-16(IMPY),Kidney,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,N,1,CHEMBL628423,,2113.0,
8499,1,Plasma clearance value at intravenous dose of 1 mg/kg (2 mg/kg po (cassette dosing) in Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5089,In vivo,N,1,CHEMBL628424,,,
8500,1,Plasma clearance value at intravenous dose of 1 mg/kg (2 mg/kg po (cassette dosing)) in Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5089,In vivo,N,1,CHEMBL628425,,,
8501,1,Plasma clearance value was determined in rat after a 3 mg/kg of iv dose,,BAO_0000218,,Rattus norvegicus,,Intermediate,4257,In vivo,N,1,CHEMBL628426,,,
8502,1,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,6679,In vivo,N,1,CHEMBL628427,,,
8503,1,Plasma clearance was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,5546,In vivo,N,1,CHEMBL626938,,,
8504,1,Plasma clearance was evaluated at 1 mg/kg of iv administration in Sprague-Dawley rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,6141,In vivo,N,1,CHEMBL626939,,,
8505,1,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5334,In vivo,N,1,CHEMBL626940,,,
8506,1,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5334,In vivo,N,1,CHEMBL626941,,,
8507,1,Plasma clearance was reported in Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5334,In vivo,N,1,CHEMBL626942,,,
8508,1,Plasma clearance after intravenous administration (1 mg/kg) in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4689,In vivo,N,1,CHEMBL876812,,,
8509,1,Plasma clearance of compound in rats was evaluated,,BAO_0000218,,Rattus norvegicus,,Intermediate,6848,In vivo,N,1,CHEMBL626943,,,
8510,1,Plasma clearance of compound in rats was evaluated; ND indicates not determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,6848,In vivo,N,1,CHEMBL626944,,,
8511,1,Plasma clearance in rats at the dose of 1.0 mpk by i.v. administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,6467,In vivo,N,1,CHEMBL626945,,,
8512,1,Plasma clearance in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,6467,In vivo,N,1,CHEMBL626946,,,
8513,1,Plasma clearance rate in Sprague-Dawley rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,4956,In vivo,N,1,CHEMBL626856,,,
8514,1,Plasma clearance was determined in rat after intravenous administration (0.5 mg/kg),,BAO_0000218,,Rattus norvegicus,,Intermediate,5529,In vivo,N,1,CHEMBL626857,,,
8515,1,The compound was evaluated for plasma clearance in rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,406,In vivo,N,1,CHEMBL626858,,1969.0,
8516,1,Total plasma clearance in rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,17655,In vivo,N,1,CHEMBL627018,,1969.0,
8517,1,Absorption behavior was judged by the peak blood concentration determined after oral dose of 30 mg/kg in rats.,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,3293,In vivo,N,1,CHEMBL625331,,178.0,
8518,1,Blood level after a 10 mg/kg oral dose in rat expressed as Cmax was determined,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,4075,In vivo,N,1,CHEMBL625332,,178.0,
8519,1,C max was determined at 10 mg/kg po dose in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,2792,In vivo,N,1,CHEMBL877590,,,
8520,1,C max was determined at 3 mg/kg po dose in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,2792,In vivo,N,1,CHEMBL625333,,,
8521,1,Cmax after repeated oral dose of compound at 1 mg/kg in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,17594,In vivo,N,1,CHEMBL625334,,,
8522,1,Cmax after single intravenous bolus of 1 mg/kg in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,17594,In vivo,N,1,CHEMBL625335,,,
8523,1,Cmax of compound at 5 mg/kg after po administration was determined in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4762,In vivo,N,1,CHEMBL625336,,,
8524,1,Cmax 24 hr after 10 mg/kg oral administration in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,17509,In vivo,N,1,CHEMBL625337,,,
8525,1,Cmax 24 hr after 2 mg/kg oral administration in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,17509,In vivo,N,1,CHEMBL625338,,,
8526,1,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,1466,In vivo,N,1,CHEMBL625339,,1969.0,
8527,1,Cmax in rat after administration of 2 mg/kg iv,,BAO_0000218,,Rattus norvegicus,,Intermediate,6535,In vivo,N,1,CHEMBL625340,,,
8528,1,Cmax in rat after administration of 2 mg/kg iv,,BAO_0000218,,Rattus norvegicus,,Intermediate,6535,In vivo,N,1,CHEMBL625341,,,
8529,1,Cmax in rats determined 6 hours after oral dosing of 20 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,3169,In vivo,N,1,CHEMBL622687,,,
8530,1,Cmax wa determined in rat plasma at 30 mg/kg after po administration,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,6515,In vivo,N,1,CHEMBL622688,,1969.0,
8531,1,Cmax was calculated as maximum concentration reached in the blood after oral administration to male F344 rats,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,11149,In vivo,N,1,CHEMBL622689,,178.0,
8532,1,Cmax was calculated as maximum concentration reached in the blood in air pouch exudate after oral administration to male F344 rats,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,11149,In vivo,N,1,CHEMBL620295,,178.0,
8533,1,Cmax after 10 mg/kg oral administration in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,17858,In vivo,N,1,CHEMBL620296,,,
8534,1,Cmax after IV dosing at 0.5 mg/kg in rat; no data,,BAO_0000218,,Rattus norvegicus,,Intermediate,6518,In vivo,N,1,CHEMBL620297,,,
8535,1,Cmax after IV dosing at 1 mg/kg in rat; no data,,BAO_0000218,,Rattus norvegicus,,Intermediate,6518,In vivo,N,1,CHEMBL620298,,,
8536,1,Cmax after oral administration at 20 mpk in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,4426,In vivo,N,1,CHEMBL620299,,,
8537,1,Cmax after oral administration at 20 mpk in rats; Not performed.,,BAO_0000218,,Rattus norvegicus,,Intermediate,4426,In vivo,N,1,CHEMBL620300,,,
8538,1,Cmax after oral administration at 20 mpk in rats d; Not performed.,,BAO_0000218,,Rattus norvegicus,,Intermediate,4426,In vivo,N,1,CHEMBL620301,,,
8539,1,Cmax after oral administration in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5656,In vivo,N,1,CHEMBL620302,,,
8540,1,Cmax after oral administration at a dose of 2 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6518,In vivo,N,1,CHEMBL620303,,,
8541,1,Cmax after oral administration at a dose of 4 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6518,In vivo,N,1,CHEMBL620304,,,
8542,1,Cmax in rats after 20 mg/kg oral dose,,BAO_0000218,,Rattus norvegicus,,Intermediate,6113,In vivo,N,1,CHEMBL620305,,,
8543,1,Cmax after peroral administration in rats at 2.4 uM/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,17764,In vivo,N,1,CHEMBL620306,,,
8544,1,Cmax at the dose of 2 mg/Kg administered perorally in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,4756,In vivo,N,1,CHEMBL620307,,,
8545,1,Cmax at the dose of 5 mg/Kg administered perorally in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,4756,In vivo,N,1,CHEMBL620308,,,
8546,1,Cmax by administering at 20 mg/kg p.o. in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,6402,In vivo,N,1,CHEMBL620309,,,
8547,1,Cmax in male rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5610,In vivo,N,1,CHEMBL620310,,,
8548,1,Cmax in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5207,In vivo,N,1,CHEMBL620311,,,
8549,1,Cmax in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6011,In vivo,N,1,CHEMBL620312,,,
8550,1,Cmax in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6504,In vivo,N,1,CHEMBL620313,,,
8551,1,Cmax in rat at 10 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,6046,In vivo,N,1,CHEMBL620314,,,
8552,1,Cmax in rat at the dose of 1 mg/kg i.v.,,BAO_0000218,,Rattus norvegicus,,Intermediate,6504,In vivo,N,1,CHEMBL620315,,,
8553,1,Cmax in rat by po administration at a dose of 40 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,5874,In vivo,N,1,CHEMBL620316,,,
8554,1,Cmax in rat p.o. at 20 mg/kg concentration,,BAO_0000218,,Rattus norvegicus,,Intermediate,17686,In vivo,N,1,CHEMBL620317,,,
8555,1,Cmax in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,5836,In vivo,N,1,CHEMBL620318,,,
8556,1,Cmax in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,17596,In vivo,N,1,CHEMBL620319,,,
8557,1,Cmax was evaluated after 20 uM/kg of peroral administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,16423,In vivo,N,1,CHEMBL620320,,,
8558,1,Cmax was measured in rats after peroral administration at 3 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,17804,In vivo,N,1,CHEMBL620321,,,
8559,1,Cmax value after oral dose at a dose of 10 mg/kg in rats.,,BAO_0000218,,Rattus norvegicus,,Intermediate,1908,In vivo,N,1,CHEMBL620322,,,
8560,1,Distribution of [123I]-label in rat brain (diencephalon) was reported at 60 min post injection. Value shown is %ID/g of tissue,,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,,N,1,CHEMBL620323,,,
8561,1,Distribution of [123I]-label in rat brain (frontal cortex) was reported at 20 min post injection. Value shown is %ID/g of tissue,Frontal cortex,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,,N,1,CHEMBL620324,,1870.0,
8562,1,Distribution of [123I]-label in rat brain (frontal cortex) was reported at 60 min post injection. Value shown is %ID/g of tissue,Frontal cortex,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,,N,1,CHEMBL620325,,1870.0,
8563,1,Distribution of [123I]-label in rat brain (hippocampus) was reported at 20 min post injection. Value shown is %ID/g of tissue,Hippocampus,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,,N,1,CHEMBL620326,,10000000.0,
8564,1,Distribution of [123I]-label in rat brain (hippocampus) was reported at 60 min post injection. Value shown is %ID/g of tissue,Hippocampus,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,,N,1,CHEMBL620327,,10000000.0,
8565,1,Distribution of [123I]-label in rat brain (medulla pons) was reported at 20 min post injection. Value shown is %ID/g of tissue,,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,,N,1,CHEMBL620328,,,
8566,1,Distribution of [123I]-label in rat brain (medulla pons) was reported at 60 min post injection. Value shown is %ID/g of tissue,,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,,N,1,CHEMBL620329,,,
8567,1,Distribution of [123I]-label in rat brain (midbrain) was reported at 20 min post injection. Value shown is %ID/g of tissue,Midbrain,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,,N,1,CHEMBL620330,,1891.0,
8568,1,Distribution of [123I]-label in rat brain (midbrain) was reported at 60 min post injection. Value shown is %ID/g of tissue,Midbrain,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,,N,1,CHEMBL875286,,1891.0,
8569,1,Distribution of [123I]-label in rat brain (posterior cortex) was reported at 20 min post injection. Value shown is %ID/g of tissue,,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,,N,1,CHEMBL620331,,,
8570,1,Distribution of [123I]-label in rat brain (posterior cortex) was reported at 60 min post injection. Value shown is %ID/g of tissue,,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,,N,1,CHEMBL620332,,,
8571,1,Distribution of [123I]-label in rat brain (striatum) was reported at 20 min post injection. Value shown is %ID/g of tissue,Striatum,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,,N,1,CHEMBL620333,,2435.0,
8572,1,Distribution of [123I]-label in rat brain (striatum) was reported at 60 min post injection. Value shown is %ID/g of tissue,Striatum,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,,N,1,CHEMBL620334,,2435.0,
8573,1,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL621015,,178.0,
8574,1,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL621016,,178.0,
8575,1,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL621191,,178.0,
8576,1,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL621192,,178.0,
8577,1,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL621193,,178.0,
8578,1,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL621194,,178.0,
8579,1,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL624204,,178.0,
8580,1,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL624205,,178.0,
8581,1,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL624206,,178.0,
8582,1,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL624207,,178.0,
8583,1,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL624208,,178.0,
8584,1,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL624209,,178.0,
8585,1,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL624210,,178.0,
8586,1,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL624211,,178.0,
8587,1,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL624212,,178.0,
8588,1,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL624213,,178.0,
8589,1,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL876611,,178.0,
8590,1,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL624214,,178.0,
8591,1,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL624215,,178.0,
8592,1,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL624216,,178.0,
8593,1,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL624217,,178.0,
8594,1,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL624218,,178.0,
8595,1,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL624219,,178.0,
8596,1,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL624220,,178.0,
8597,1,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL624221,,178.0,
8598,1,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL624222,,,
8599,1,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL624223,,,
8600,1,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL624224,,,
8601,1,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL624225,,,
8602,1,Volume of solubility in solution after intravenous administration in rats at 24 uM/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,17764,In vivo,N,1,CHEMBL622420,,,
8603,1,Volume of steady state distribution after i.v. administration in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,5031,In vivo,N,1,CHEMBL622421,,,
8604,1,Vss after intravenous administration (5.0 mg/kg) was determined in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6215,In vivo,N,1,CHEMBL622422,,,
8605,1,Vss in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,17671,In vivo,N,1,CHEMBL622423,,,
8606,1,Vss was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,17752,In vivo,N,1,CHEMBL622424,,,
8607,1,Vss in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6596,In vivo,N,1,CHEMBL622425,,,
8608,1,Vss was evaluated after 10 uM/kg of intra arterial administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,16423,In vivo,N,1,CHEMBL876612,,,
8609,1,volume of distribution at steady state was observed after intravenous administration in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,15662,In vivo,N,1,CHEMBL622426,,,
8610,1,Volume of distribution was measured in rat after an iv dose of 1 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,6062,In vivo,N,1,CHEMBL622427,,,
8611,1,Pharmacokinetic (PK) parameter Vz in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5874,In vivo,N,1,CHEMBL622428,,,
8612,1,Volume distribution in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,4942,In vivo,N,1,CHEMBL622429,,,
8613,1,Volume of distribution in rat; No data,,BAO_0000218,,Rattus norvegicus,,Intermediate,17796,In vivo,N,1,CHEMBL622430,,,
8614,1,Volume of distribution was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,4890,In vivo,N,1,CHEMBL622431,,,
8615,1,% absorption predicted from in vitro rat ileum transport studies,Ileum,BAO_0000218,,Rattus norvegicus,,Intermediate,15765,,N,1,CHEMBL622432,,2116.0,
8616,1,Bioavailability at an iv dose of 12 mg/Kg and po dose of 23 mg/Kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,13569,In vivo,N,1,CHEMBL622433,,,
8617,1,Bioavailability at an iv dose of 14 mg/Kg and po dose of 15 mg/Kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,13569,In vivo,N,1,CHEMBL622434,,,
8618,1,Bioavailability at an iv dose of 14 mg/Kg and po dose of 28 mg/Kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,13569,In vivo,N,1,CHEMBL622435,,,
8619,1,Bioavailability (dose 15 mg/kg i.v. and 30 mg/kg p.o.),,BAO_0000218,,Rattus norvegicus,,Intermediate,13569,In vivo,N,1,CHEMBL618748,,,
8620,1,Bioavailability at an iv dose of 15 mg/Kg and po dose of 30.2 mg/Kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,13569,In vivo,N,1,CHEMBL618749,,,
8621,1,Bioavailability at an iv dose of 15.6 mg/Kg and po dose of 31.2 mg/Kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,13569,In vivo,N,1,CHEMBL618750,,,
8622,1,Bioavailability at an iv dose of 15.7 mg/Kg and po dose of 31.4 mg/Kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,13569,In vivo,N,1,CHEMBL618751,,,
8623,1,Bioavailability at an iv dose of 16 mg/Kg and po dose of 35 mg/Kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,13569,In vivo,N,1,CHEMBL618752,,,
8624,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4576,In vivo,N,1,CHEMBL618753,,,
8625,1,Oral bioavailability estimated by measurement of the circulating plasma levels of BMS-183920 after intravenous and oral dosing to rats for 4 determinations,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,750,In vivo,N,1,CHEMBL618754,,1969.0,
8626,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,750,In vivo,N,1,CHEMBL618755,,,
8627,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4590,In vivo,N,1,CHEMBL618756,,,
8628,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,1716,In vivo,N,1,CHEMBL618757,,,
8629,1,Bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,1974,In vivo,N,1,CHEMBL618758,,,
8630,1,Oral bioavailability in rat (dose 30 mg/kg),,BAO_0000218,,Rattus norvegicus,,Intermediate,4502,In vivo,N,1,CHEMBL621088,,,
8631,1,Pharmacokinetic property (cLogP) in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,3371,,N,1,CHEMBL621089,,,
8632,1,Hyperglycemic activity and change in blood glucose concentration was reported 2 hours after administration of 100 mg/Kg perorally,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,9099,,N,1,CHEMBL621090,,178.0,
8633,1,Hyperglycemic activity and change in blood glucose concentration was reported 4 hours after administration of 100 mg/Kg perorally,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,9099,,N,1,CHEMBL621091,,178.0,
8634,1,Clearance in rat.,,BAO_0000218,,Rattus norvegicus,,Intermediate,4590,In vivo,N,1,CHEMBL876731,,,
8635,1,Compound was evaluated for its clearance when administered intravenously in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,3184,In vivo,N,1,CHEMBL621092,,,
8636,1,Plasma clearance in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,16456,In vivo,N,1,CHEMBL621093,,,
8637,1,Blood: Brain distribution ratio is determined in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4199,,N,1,CHEMBL621094,,,
8638,1,Blood: Brain distribution ratio is determined in rat; NQ: non quantifable,,BAO_0000218,,Rattus norvegicus,,Intermediate,4199,,N,1,CHEMBL621095,,,
8639,1,Blood: Brain distribution ratio is determined in rat; NQ:non quantifable,,BAO_0000218,,Rattus norvegicus,,Intermediate,4199,,N,1,CHEMBL621096,,,
8640,1,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,In vivo,N,1,CHEMBL621097,,2113.0,
8641,1,Percent dose excreted in 0-48 hours administered ip to male rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,7449,,N,1,CHEMBL621098,,,
8642,1,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 120 minutes after an intravenous injection is given (average of 3 rats),Cerebellum,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,,N,1,CHEMBL621099,,2037.0,
8643,1,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 2 minutes after an intravenous injection is given (average of 3 rats),Cerebellum,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,,N,1,CHEMBL621100,,2037.0,
8644,1,Uptake of radioligand [125I]-FIDA1 by cerebellum in rat after 30 minutes after an intravenous injection is given (average of 2 rats),Cerebellum,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,,N,1,CHEMBL621101,,2037.0,
8645,1,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 30 minutes after an intravenous injection is given (average of 3 rats),Cerebellum,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,,N,1,CHEMBL621102,,2037.0,
8646,1,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 60 minutes after an intravenous injection is given (average of 3 rats),Cerebellum,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,,N,1,CHEMBL876732,,2037.0,
8647,1,Uptake of radioligand [125I]-FIDA1 by cortex in rat after 120 minutes after an intravenous injection is given (average of 3 rats),,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,,N,1,CHEMBL621103,,,
8648,1,Uptake of radioligand [125I]FIDA1 by cortex in rat after 2 minutes after an intravenous injection is given (average of 3 rats),,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,,N,1,CHEMBL621104,,,
8649,1,Uptake of radioligand [125I]FIDA1 by cortex in rat after 30 minutes after an intravenous injection is given (average of 2 rats),,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,,N,1,CHEMBL621105,,,
8650,1,Uptake of radioligand [125I]-FIDA1 by cortex in rat after 30 minutes after an intravenous injection is given (average of 3 rats),,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,,N,1,CHEMBL621106,,,
8651,1,Uptake of radioligand [125I]FIDA1 by cortex in rat after 60 minutes after an intravenous injection is given (average of 3 rats),,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,,N,1,CHEMBL621107,,,
8652,1,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 120 minutes after an intravenous injection is given (average of 3 rats),,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,,N,1,CHEMBL621108,,,
8653,1,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 2 minutes after an intravenous injection is given (average of 3 rats),,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,,N,1,CHEMBL621109,,,
8654,1,Biodistribution of radioactivity in normal mice (ICR) kidney after 30 minutes of intravenous injection of [125I]-16(IMPY),Kidney,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,N,1,CHEMBL621110,,2113.0,
8655,1,Biodistribution of radioactivity in normal mice (ICR) kidney after 6 hours of intravenous injection of [125I]-16(IMPY),Kidney,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,N,1,CHEMBL621111,,2113.0,
8656,1,Biodistribution of radioactivity in normal mice (ICR) liver after 1 hour of intravenous injection of [125I]-16(IMPY),Liver,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,N,1,CHEMBL622541,,2107.0,
8657,1,Biodistribution of radioactivity in normal mice (ICR) liver after 2 hours of intravenous injection of [125I]-16(IMPY),Liver,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,N,1,CHEMBL622542,,2107.0,
8658,1,Biodistribution of radioactivity in normal mice (ICR) liver after 2 minutes of intravenous injection of [125I]-16(IMPY),Liver,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,N,1,CHEMBL622543,,2107.0,
8659,1,Biodistribution of radioactivity in normal mice (ICR) liver after 24 hours of intravenous injection of [125I]-16(IMPY),Liver,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,N,1,CHEMBL624412,,2107.0,
8660,1,Biodistribution of radioactivity in normal mice (ICR) liver after 30 minutes of intravenous injection of [125I]-16(IMPY),Liver,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,N,1,CHEMBL624413,,2107.0,
8661,1,Biodistribution of radioactivity in normal mice (ICR) liver after 6 hours of intravenous injection of [125I]-16(IMPY),Liver,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,N,1,CHEMBL624414,,2107.0,
8662,1,Biodistribution of radioactivity in normal mice (ICR) lung after 1 hour of intravenous injection of [125I]-16(IMPY),Lung,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,N,1,CHEMBL624415,,2048.0,
8663,1,Biodistribution of radioactivity in normal mice (ICR) lung after 2 hours of intravenous injection of [125I]-16(IMPY),Lung,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,N,1,CHEMBL624416,,2048.0,
8664,1,Biodistribution of radioactivity in normal mice (ICR) lung after 2 minutes of intravenous injection of [125I]-16(IMPY),Lung,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,N,1,CHEMBL624417,,2048.0,
8665,1,Biodistribution of radioactivity in normal mice (ICR) lung after 24 hours of intravenous injection of [125I]-16(IMPY),Lung,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,N,1,CHEMBL624418,,2048.0,
8666,1,Biodistribution of radioactivity in normal mice (ICR) lung after 30 minutes of intravenous injection of [125I]-16(IMPY),Lung,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,N,1,CHEMBL624419,,2048.0,
8667,1,Biodistribution of radioactivity in normal mice (ICR) lung after 6 hours of intravenous injection of [125I]-16(IMPY),Lung,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,N,1,CHEMBL624420,,2048.0,
8668,1,Biodistribution of radioactivity in normal mice (ICR) muscle after 1 hr of intravenous injection of [125I]-16(IMPY),Muscle tissue,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,N,1,CHEMBL624421,,2385.0,
8669,1,Biodistribution of radioactivity in normal mice (ICR) muscle after 2 hours of intravenous injection of [125I]-16(IMPY),Muscle tissue,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,N,1,CHEMBL624422,,2385.0,
8670,1,Biodistribution of radioactivity in normal mice (ICR) muscle after 2 minutes of intravenous injection of [125I]-16(IMPY),Muscle tissue,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,N,1,CHEMBL624423,,2385.0,
8671,1,Biodistribution of radioactivity in normal mice (ICR) muscle after 24 hours of intravenous injection of [125I]-16(IMPY),Muscle tissue,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,N,1,CHEMBL625123,,2385.0,
8672,1,Biodistribution of radioactivity in normal mice (ICR) muscle after 30 minutes of intravenous injection of [125I]-16(IMPY),Muscle tissue,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,N,1,CHEMBL625124,,2385.0,
8673,1,Biodistribution of radioactivity in normal mice (ICR) muscle after 6 hours of intravenous injection of [125I]-16(IMPY),Muscle tissue,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,N,1,CHEMBL625125,,2385.0,
8674,1,Biodistribution of radioactivity in normal mice (ICR) skin after 1 hour of intravenous injection of [125I]-16(IMPY),Zone of skin,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,N,1,CHEMBL625126,,14.0,
8675,1,Biodistribution of radioactivity in normal mice (ICR) skin after 2 hours of intravenous injection of [125I]-16(IMPY),Zone of skin,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,N,1,CHEMBL626947,,14.0,
8676,1,Biodistribution of radioactivity in normal mice (ICR) skin after 2 minutes of intravenous injection of [125I]-16(IMPY),Zone of skin,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,N,1,CHEMBL626948,,14.0,
8677,1,Biodistribution of radioactivity in normal mice (ICR) skin after 24 hours of intravenous injection of [125I]-16(IMPY),Zone of skin,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,N,1,CHEMBL626949,,14.0,
8678,1,Biodistribution of radioactivity in normal mice (ICR) skin after 30 minutes of intravenous injection of [125I]-16(IMPY),Zone of skin,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,N,1,CHEMBL626950,,14.0,
8679,1,Biodistribution of radioactivity in normal mice (ICR) skin after 6 hours of intravenous injection of [125I]-16(IMPY),Zone of skin,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,N,1,CHEMBL626951,,14.0,
8680,1,Biodistribution of radioactivity in normal mice (ICR) spleen after 1 hour of intravenous injection of [125I]-16(IMPY),Spleen,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,N,1,CHEMBL626952,,2106.0,
8681,1,Biodistribution of radioactivity in normal mice (ICR) spleen after 2 hours of intravenous injection of [125I]-16(IMPY),Spleen,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,N,1,CHEMBL626953,,2106.0,
8682,1,Biodistribution of radioactivity in normal mice (ICR) spleen after 2 minutes of intravenous injection of [125I]-16(IMPY),Spleen,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,N,1,CHEMBL626954,,2106.0,
8683,1,Biodistribution of radioactivity in normal mice (ICR) spleen after 24 hours of intravenous injection of [125I]-16(IMPY),Spleen,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,N,1,CHEMBL626955,,2106.0,
8684,1,Biodistribution of radioactivity in normal mice (ICR) spleen after 30 minutes of intravenous injection of [125I]-16(IMPY),Spleen,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,N,1,CHEMBL626956,,2106.0,
8685,1,Biodistribution of radioactivity in normal mice (ICR) spleen after 6 hours of intravenous injection of [125I]-16(IMPY),Spleen,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,N,1,CHEMBL626957,,2106.0,
8686,1,Biodistribution of radioactivity in normal mice blood after 1 hour of intravenous injection of [125I]-16(IMPY),Blood,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,N,1,CHEMBL626958,,178.0,
8687,1,Biodistribution of radioactivity in normal mice blood after 2 hours of intravenous injection of [125I]-16(IMPY),Blood,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,N,1,CHEMBL626959,,178.0,
8688,1,Biodistribution of radioactivity in normal mice blood after 2 minutes of intravenous injection of [125I]-16(IMPY),Blood,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,N,1,CHEMBL626960,,178.0,
8689,1,Biodistribution of radioactivity in normal mice blood after 24 hours of intravenous injection of [125I]-16(IMPY),Blood,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,N,1,CHEMBL626961,,178.0,
8690,1,Biodistribution of radioactivity in normal mice blood after 30 minutes of intravenous injection of [125I]-16(IMPY),Blood,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,N,1,CHEMBL627589,,178.0,
8691,1,Biodistribution of radioactivity in normal mice blood after 6 hours of intravenous injection of [125I]-16(IMPY),Blood,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,N,1,CHEMBL627590,,178.0,
8692,1,Time taken for EC90 was determined when tested in mouse,,BAO_0000218,,Mus musculus,,Intermediate,3132,,N,1,CHEMBL627591,,,
8693,1,Time taken for EC90 was determined when tested in mouse at dose 25 mg/kg,,BAO_0000218,,Mus musculus,,Intermediate,3132,,N,1,CHEMBL627592,,,
8694,1,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),,BAO_0000218,,Mus musculus,,Intermediate,16597,In vivo,N,1,CHEMBL627593,,,
8695,1,Half life in mice,,BAO_0000218,,Mus musculus,,Intermediate,5727,,N,1,CHEMBL627594,,,
8696,1,Half life period in mouse after 10 mg/Kg dose,,BAO_0000218,,Mus musculus,,Intermediate,5302,In vivo,N,1,CHEMBL876813,,,
8697,1,Half life period in mouse after 10 mg/kg dose,,BAO_0000218,,Mus musculus,,Intermediate,5302,In vivo,N,1,CHEMBL627595,,,
8698,1,Half life was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,BAO_0000218,,Mus musculus,,Intermediate,6348,In vivo,N,1,CHEMBL627596,,,
8699,1,Cmax value at 5 mg/kg po was determined in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5964,In vivo,N,1,CHEMBL627597,,,
8700,1,Cmax value evaluated in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6078,In vivo,N,1,CHEMBL627598,,,
8701,1,Cmax value was calculated by applying at a dose of 10 mg/Kg ip in rat brain,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,5206,In vivo,N,1,CHEMBL627599,,955.0,
8702,1,Cmax value after administration of 20 mg/Kg oral dose in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,2959,In vivo,N,1,CHEMBL627600,,,
8703,1,Cmax value at 1 mg/kg po in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5964,In vivo,N,1,CHEMBL627601,,,
8704,1,Cmax value at 5 mg/kg po in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5964,In vivo,N,1,CHEMBL627776,,,
8705,1,Cmax value at a dose of 10 mg/kg in male SD rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,6757,In vivo,N,1,CHEMBL627777,,,
8706,1,Cmax value at a dose of 100 mg/kg in male SD rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,6757,In vivo,N,1,CHEMBL627778,,,
8707,1,Cmax value at a dose of 50 mg/kg in male SD rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,6757,In vivo,N,1,CHEMBL627779,,,
8708,1,Cmax value in rats at 10 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,17617,In vivo,N,1,CHEMBL876814,,,
8709,1,Cmax value was evaluated in rats at a dose of 20 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,1445,In vivo,N,1,CHEMBL627780,,,
8710,1,Cmax value was determined after peroral administration of 20 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6082,In vivo,N,1,CHEMBL627781,,,
8711,1,Cmax value was determined between 15 and 30 minutes post administration in fisher rats; value ranges from 200-500,,BAO_0000218,,Rattus norvegicus,,Intermediate,1446,In vivo,N,1,CHEMBL627782,,,
8712,1,Compound was evaluated for its pharmacokinetic parameter maximum plasma concentration (Cmax) after oral administration to rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,5407,In vivo,N,1,CHEMBL627783,,1969.0,
8713,1,Compound was evaluated for maximal plasma concentration in rat upon 5 mg/kg upon oral administration,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,2690,In vivo,N,1,CHEMBL627784,,1969.0,
8714,1,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female wistar rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,2661,In vivo,N,1,CHEMBL627785,,,
8715,1,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to male wistar rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,2661,In vivo,N,1,CHEMBL627786,,,
8716,1,Compound was evaluated for pharmacokinetic parameter maximum plasma concentration,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,4891,In vivo,N,1,CHEMBL627787,,1969.0,
8717,1,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 0.5 hr,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,2807,In vivo,N,1,CHEMBL627788,,1969.0,
8718,1,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 1 hr,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,2807,In vivo,N,1,CHEMBL626579,,1969.0,
8719,1,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 2 hr,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,2807,In vivo,N,1,CHEMBL626580,,1969.0,
8720,1,Compound was evaluated for the pharmacokinetic property in rats after an oral dose of 10 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,3634,In vivo,N,1,CHEMBL876815,,,
8721,1,Compound was tested for plasma concentration in rats when administered at 20 mg/kg in 1% methocel at 1 hr,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,1881,In vivo,N,1,CHEMBL626581,,1969.0,
8722,1,Compound was tested for plasma concentration in rats when administered at 20 mg/kg in 1% methocel at 2 hr,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,1881,In vivo,N,1,CHEMBL626582,,1969.0,
8723,1,Evaluated for pharmacokinetic parameter Cmax in rat at the dose 50 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,429,In vivo,N,1,CHEMBL626583,,,
8724,1,In vivo Cmax was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5974,In vivo,N,1,CHEMBL626205,,,
8725,1,In vivo Cmax was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5974,In vivo,N,1,CHEMBL626206,,,
8726,1,In vivo Cmax was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5974,In vivo,N,1,CHEMBL626207,,,
8727,1,In vivo Cmax was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5974,In vivo,N,1,CHEMBL623882,,,
8728,1,Maximal concentration in male Sprague-Dawley rats after 5 mg/kg intravenous dose,,BAO_0000218,,Rattus norvegicus,,Intermediate,17582,In vivo,N,1,CHEMBL623883,,,
8729,1,Maximal concentration in male Sprague-Dawley rats after 10 mg/kg oral dose,,BAO_0000218,,Rattus norvegicus,,Intermediate,17582,In vivo,N,1,CHEMBL623884,,,
8730,1,"In vivo maximum concentration of compound in rat plasma after a oral dose of 10 mg/kg (in water, N=4)",Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,3032,In vivo,N,1,CHEMBL623885,,1969.0,
8731,1,In vivo maximum concentration in rat plasma exposure after oral administration 50 mg/kg,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,6295,In vivo,N,1,CHEMBL623886,,1969.0,
8732,1,Maximal concentration in rat was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,6619,In vivo,N,1,CHEMBL623887,,,
8733,1,Maximal concentration after i.v. administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,6616,In vivo,N,1,CHEMBL623888,,,
8734,1,Maximal concentration (Cmax) in the rat plasma at a dose of 10 mg/kg,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,3249,In vivo,N,1,CHEMBL623889,,1969.0,
8735,1,Maximal plasma concentration in rat after oral administration at 50 mg/kg,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,17791,In vivo,N,1,CHEMBL623890,,1969.0,
8736,1,Cmax in rat plasma after oral dose (50 mg/Kg),Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,17791,In vivo,N,1,CHEMBL623891,,1969.0,
8737,1,Maximal plasma concentration was determined.,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,1360,In vivo,N,1,CHEMBL623892,,1969.0,
8738,1,Maximal plasma drug concentration was determined,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,2552,In vivo,N,1,CHEMBL623893,,1969.0,
8739,1,Maximal concentration in rats after peroral administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,6571,In vivo,N,1,CHEMBL877616,,,
8740,1,Maximum concentration in rat after 2 mg/kg peroral administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,6570,In vivo,N,1,CHEMBL623894,,,
8741,1,Maximum concentration in rat plasma after 5 mg/kg oral gavage,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,6567,In vivo,N,1,CHEMBL623895,,1969.0,
8742,1,Maximum concentration of compound in rat was evaluated.,,BAO_0000218,,Rattus norvegicus,,Intermediate,3031,In vivo,N,1,CHEMBL623896,,,
8743,1,Maximum concentration at 0.5 hr by peroral administration at a dose of 20 mg/kg in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,3436,In vivo,N,1,CHEMBL623897,,,
8744,1,Maximum concentration at 2 hr by peroral administration at a dose of 20 mg/kg in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,3436,In vivo,N,1,CHEMBL623898,,,
8745,1,Maximum concentration at 4 hr after administration of 5 mg/kg dose peroral in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,2083,In vivo,N,1,CHEMBL623899,,,
8746,1,Maximum concentration at 4 hr by peroral administration at a dose of 20 mg/kg in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,3436,In vivo,N,1,CHEMBL623900,,,
8747,1,Maximum concentration by oral administration at a dose of 100 uM/kg in rat was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,4527,In vivo,N,1,CHEMBL623901,,,
8748,1,Maximum concentration was evaluated in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,1974,In vivo,N,1,CHEMBL623902,,,
8749,1,Maximum concentration in CSF at 30 min following 24 mg/kg subcutaneous dose in rats,Cerebrospinal fluid,BAO_0000218,,Rattus norvegicus,,Intermediate,3307,In vivo,N,1,CHEMBL623903,,1359.0,
8750,1,Maximum concentration in plasma at 30 min following 24 mg/kg subcutaneous dose in rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,3307,In vivo,N,1,CHEMBL623904,,1969.0,
8751,1,Maximum concentration in plasma was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,1916,In vivo,N,1,CHEMBL877617,,1969.0,
8752,1,Maximum concentration in portal vein was determined at a concentration of 10 mg/kg in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,1500,In vivo,N,1,CHEMBL623905,,,
8753,1,Maximum concentration in portal vein was determined at a concentration of 20 mg/kg in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,1500,In vivo,N,1,CHEMBL623906,,,
8754,1,Maximum concentration in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,4186,In vivo,N,1,CHEMBL623907,,1969.0,
8755,1,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL623908,,,
8756,1,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 30 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL623909,,,
8757,1,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL623910,,,
8758,1,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL623911,,,
8759,1,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL623912,,,
8760,1,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL624616,,,
8761,1,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL624617,,,
8762,1,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL624618,,,
8763,1,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL624619,,,
8764,1,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL624794,,,
8765,1,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL624795,,,
8766,1,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL623921,,,
8767,1,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL623922,,,
8768,1,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL623923,,,
8769,1,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL623924,,,
8770,1,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL623925,,,
8771,1,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL623926,,,
8772,1,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL623927,,,
8773,1,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL623928,,,
8774,1,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL623929,,,
8775,1,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL623930,,,
8776,1,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL623931,,955.0,
8777,1,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL622165,,955.0,
8778,1,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL621249,,955.0,
8779,1,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL621250,,955.0,
8780,1,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL621448,,955.0,
8781,1,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL621449,,955.0,
8782,1,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL621450,,955.0,
8783,1,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL621451,,955.0,
8784,1,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL621452,,955.0,
8785,1,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL621453,,955.0,
8786,1,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL621454,,955.0,
8787,1,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL621455,,955.0,
8788,1,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL621456,,955.0,
8789,1,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL625145,,955.0,
8790,1,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL875847,,955.0,
8791,1,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL625146,,955.0,
8792,1,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL625147,,955.0,
8793,1,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL625148,,955.0,
8794,1,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL625149,,955.0,
8795,1,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL625150,,955.0,
8796,1,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL625151,,955.0,
8797,1,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL625152,,955.0,
8798,1,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL625153,,955.0,
8799,1,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL625154,,955.0,
8800,1,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL625155,,955.0,
8801,1,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 30 minutes after an intravenous injection is given (average of 2 rats),,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,,N,1,CHEMBL625156,,,
8802,1,Uptake of radioligand [125I]-FIDA1 by hippo-campus in rat after 60 minutes after an intravenous injection is given (average of 3 rats),,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,,N,1,CHEMBL624354,,,
8803,1,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 120 minutes after an intravenous injection is given (average of 3 rats),Hippocampus,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,,N,1,CHEMBL624355,,10000000.0,
8804,1,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 2 minutes after an intravenous injection is given (average of 3 rats),Hippocampus,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,,N,1,CHEMBL624356,,10000000.0,
8805,1,Uptake of radioligand [125I]-FIDA1 by hippocampus in rat after 30 minutes after an intravenous injection is given (average of 3 rats),Hippocampus,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,,N,1,CHEMBL624357,,10000000.0,
8806,1,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 60 minutes after an intravenous injection is given (average of 3 rats),Hippocampus,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,,N,1,CHEMBL624358,,10000000.0,
8807,1,Uptake of radioligand [125I]FIDA1 by striatum in rat after 120 minutes after an intravenous injection is given (average of 3 rats),Striatum,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,,N,1,CHEMBL624359,,2435.0,
8808,1,Uptake of radioligand [125I]FIDA1 by striatum in rat after 2 minutes after an intravenous injection is given (average of 3 rats),Striatum,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,,N,1,CHEMBL624360,,2435.0,
8809,1,Uptake of radioligand [125I]FIDA1 by striatum in rat after 30 minutes after an intravenous injection is given (average of 2 rats),Striatum,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,,N,1,CHEMBL624361,,2435.0,
8810,1,Uptake of radioligand [125I]FIDA1 by striatum in rat after 30 minutes after an intravenous injection is given (average of 3 rats),Striatum,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,,N,1,CHEMBL624362,,2435.0,
8811,1,Uptake of radioligand [125I]FIDA1 by striatum in rat after 60 minutes after an intravenous injection is given (average of 3 rats),Striatum,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,,N,1,CHEMBL624363,,2435.0,
8812,1,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 120 minutes after an intravenous injection is given (average of 3 rats),Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,In vivo,N,1,CHEMBL624364,,178.0,
8813,1,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 2 minutes after an intravenous injection is given (average of 3 rats),Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,In vivo,N,1,CHEMBL624365,,178.0,
8814,1,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 30 minutes after an intravenous injection is given (average of 3 rats),Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,In vivo,N,1,CHEMBL624366,,178.0,
8815,1,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 60 minutes after an intravenous injection is given (average of 3 rats),Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,In vivo,N,1,CHEMBL624367,,178.0,
8816,1,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 120 minutes after an intravenous injection is given (average of 3 rats),Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,In vivo,N,1,CHEMBL624368,,955.0,
8817,1,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 2 minutes after an intravenous injection is given (average of 3 rats),Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,In vivo,N,1,CHEMBL624369,,955.0,
8818,1,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 30 minutes after an intravenous injection is given (average of 2 rats),Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,In vivo,N,1,CHEMBL624370,,955.0,
8819,1,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 30 minutes after an intravenous injection is given (average of 3 rats),Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,In vivo,N,1,CHEMBL625069,,955.0,
8820,1,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 60 minutes after an intravenous injection is given (average of 3 rats),Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,In vivo,N,1,CHEMBL625070,,955.0,
8821,1,Biodistribution of radioligand [125I]-FIDA1 in heart of rat after 120 minutes after an intravenous injection is given (average of 3 rats),Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,In vivo,N,1,CHEMBL626051,,948.0,
8822,1,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 2 minutes after an intravenous injection is given (average of 3 rats),Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,In vivo,N,1,CHEMBL626052,,948.0,
8823,1,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 30 minutes after an intravenous injection is given (average of 2 rats),Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,In vivo,N,1,CHEMBL626053,,948.0,
8824,1,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 30 minutes after an intravenous injection is given (average of 3 rats),Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,In vivo,N,1,CHEMBL626054,,948.0,
8825,1,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 60 minutes after an intravenous injection is given (average of 3 rats),Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,In vivo,N,1,CHEMBL626055,,948.0,
8826,1,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 120 minutes after an intravenous injection is given (average of 3 rats),Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,In vivo,N,1,CHEMBL626056,,2113.0,
8827,1,Biodistribution of radioligand [125I]-FIDA1 in kidney of rat after 2 minutes after an intravenous injection is given (average of 3 rats),Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,In vivo,N,1,CHEMBL626057,,2113.0,
8828,1,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 30 minutes after an intravenous injection is given (average of 3 rats),Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,In vivo,N,1,CHEMBL625193,,2113.0,
8829,1,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 60 minutes after an intravenous injection is given (average of 3 rats),Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,In vivo,N,1,CHEMBL625194,,2113.0,
8830,1,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 120 minutes after an intravenous injection is given (average of 3 rats),Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,In vivo,N,1,CHEMBL625195,,2107.0,
8831,1,Biodistribution of radioligand [125I]-FIDA1 in liver of rat after 2 minutes after an intravenous injection is given (average of 3 rats),Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,In vivo,N,1,CHEMBL625196,,2107.0,
8832,1,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 30 minutes after an intravenous injection is given (average of 2 rats),Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,In vivo,N,1,CHEMBL625197,,2107.0,
8833,1,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 30 minutes after an intravenous injection is given (average of 3 rats),Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,In vivo,N,1,CHEMBL625198,,2107.0,
8834,1,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 60 minutes after an intravenous injection is given (average of 3 rats),Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,In vivo,N,1,CHEMBL627929,,2107.0,
8835,1,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 120 minutes after an intravenous injection is given (average of 3 rats),Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,In vivo,N,1,CHEMBL627074,,2048.0,
8836,1,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 2 minutes after an intravenous injection is given (average of 3 rats),Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,In vivo,N,1,CHEMBL627075,,2048.0,
8837,1,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 30 minutes after an intravenous injection is given (average of 2 rats),Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,In vivo,N,1,CHEMBL627076,,2048.0,
8838,1,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 30 minutes after an intravenous injection is given (average of 3 rats),Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,In vivo,N,1,CHEMBL627077,,2048.0,
8839,1,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 60 minutes after an intravenous injection is given (average of 3 rats),Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,In vivo,N,1,CHEMBL627078,,2048.0,
8840,1,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 120 minutes after an intravenous injection is given (average of 2 rats),Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,In vivo,N,1,CHEMBL627079,,2385.0,
8841,1,Half life (t1/2) determined at a dose 10 mg/kg administered intraperitoneally to mice,,BAO_0000218,,Mus musculus,,Intermediate,4573,In vivo,N,1,CHEMBL873824,,,
8842,1,Half life in mouse plasma was determined at dose 25 mg/kg,Plasma,BAO_0000218,,Mus musculus,,Intermediate,3132,In vivo,N,1,CHEMBL627080,,1969.0,
8843,1,Half life was determined,,BAO_0000218,,Mus musculus,,Intermediate,17718,,N,1,CHEMBL627081,,,
8844,1,Half life in BALB/C mice at the dose of 20 mg/kg by i.v. administration,,BAO_0000218,,Mus musculus,,Intermediate,17728,In vivo,N,1,CHEMBL627082,,,
8845,1,Half-life in male mice after 1 mg/kg intravenous dose,,BAO_0000218,,Mus musculus,,Intermediate,5961,In vivo,N,1,CHEMBL627083,,,
8847,1,Half life in mice plasma,Plasma,BAO_0000218,,Mus musculus,,Intermediate,17731,,N,1,CHEMBL627085,,1969.0,
8848,1,Half life in mouse,,BAO_0000218,,Mus musculus,,Intermediate,17592,,N,1,CHEMBL627086,,,
8849,1,Half life in mouse plasma at dose 25 mg/kg,Plasma,BAO_0000218,,Mus musculus,,Intermediate,3132,In vivo,N,1,CHEMBL627087,,1969.0,
8850,1,Half life when injected i.p. in mice at a dose of 50 mg/kg was determined,,BAO_0000218,,Mus musculus,,Intermediate,17729,In vivo,N,1,CHEMBL627088,,,
8851,1,Half life when injected intravenously in mice at a dose of 20 mg/kg was determined,,BAO_0000218,,Mus musculus,,Intermediate,17729,In vivo,N,1,CHEMBL627089,,,
8852,1,Half life when injected perorally in mice at a dose of 50 mg/kg was determined,,BAO_0000218,,Mus musculus,,Intermediate,17729,In vivo,N,1,CHEMBL627090,,,
8853,1,Half life was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),,BAO_0000218,,Mus musculus,,Intermediate,3277,In vivo,N,1,CHEMBL627091,,,
8854,1,"Half life was evaluated at 5 mg/kg of compound dose, administered perorally in mice",,BAO_0000218,,Mus musculus,,Intermediate,3760,In vivo,N,1,CHEMBL627092,,,
8855,1,"Half life was evaluated at 50 mg/kg of compound dose, administered perorally in mice",,BAO_0000218,,Mus musculus,,Intermediate,3760,In vivo,N,1,CHEMBL876785,,,
8856,1,Half-life by iv administration in mouse,,BAO_0000218,,Mus musculus,,Intermediate,2862,In vivo,N,1,CHEMBL627093,,,
8857,1,Half-life by oral administration in mouse,,BAO_0000218,,Mus musculus,,Intermediate,2862,In vivo,N,1,CHEMBL627094,,,
8858,1,Half-life in mice,,BAO_0000218,,Mus musculus,,Intermediate,5980,,N,1,CHEMBL627095,,,
8859,1,Half-life using mouse brain homogenate,Brain,BAO_0000218,,Mus musculus,,Intermediate,6159,,N,1,CHEMBL627096,,955.0,
8860,1,Half-life was measured in mice,,BAO_0000218,,Mus musculus,,Intermediate,6254,,N,1,CHEMBL627097,,,
8861,1,Half-life was measured in mouse after an iv dose of 1 mg/kg,,BAO_0000218,,Mus musculus,,Intermediate,6062,In vivo,N,1,CHEMBL627098,,,
8862,1,Half-life period was determined in mouse blood,Blood,BAO_0000218,,Mus musculus,,Intermediate,1574,,N,1,CHEMBL627099,,178.0,
8863,1,"Half-times of inhibition of PEP in in an ex vivo enzyme studies, using mice brain",Brain,BAO_0000218,,Mus musculus,,Intermediate,56,,N,1,CHEMBL627100,,955.0,
8864,1,Plasma half life in mouse,Plasma,BAO_0000218,,Mus musculus,,Intermediate,993,,N,1,CHEMBL627101,,1969.0,
8865,1,Stability of the peptide in the presence of mouse serum,,BAO_0000218,,Mus musculus,,Intermediate,6652,,N,1,CHEMBL627102,,,
8866,1,Terminal half life of compound was determined in mouse,,BAO_0000218,,Mus musculus,,Intermediate,17852,,N,1,CHEMBL627103,,,
8867,1,Terminal half life was evaluated in mice after intravenous administration,,BAO_0000218,,Mus musculus,,Intermediate,2675,In vivo,N,1,CHEMBL627104,,,
8868,1,Terminal half life was evaluated in mice after oral administration,,BAO_0000218,,Mus musculus,,Intermediate,2675,In vivo,N,1,CHEMBL627105,,,
8869,1,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 5.,,BAO_0000218,,Mus musculus,,Intermediate,499,,N,1,CHEMBL876786,,,
8870,1,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 7.,,BAO_0000218,,Mus musculus,,Intermediate,499,,N,1,CHEMBL873825,,,
8871,1,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 7; ND means no data,,BAO_0000218,,Mus musculus,,Intermediate,499,,N,1,CHEMBL627106,,,
8872,1,half life period is evaluated by administering intravenously at 25 mg/kg in mice,,BAO_0000218,,Mus musculus,,Intermediate,14239,In vivo,N,1,CHEMBL626336,,,
8873,1,"Half life beta(2,4,6,8h) value was determined at a dose of 200 mg/kg (i.p.) in Mice",,BAO_0000218,,Mus musculus,,Intermediate,5506,In vivo,N,1,CHEMBL877462,,,
8874,1,"Half life beta(2,4,6,8h) value was determined at a dose of 200 mg/kg (i.p.) in Mice; NC: not calculable",,BAO_0000218,,Mus musculus,,Intermediate,5506,In vivo,N,1,CHEMBL626337,,,
8875,1,Half life after intraperitoneal administration of 100 mg/kg in mice,,BAO_0000218,,Mus musculus,,Intermediate,17734,,N,1,CHEMBL626338,,,
8876,1,Half life in BALB/C mice at the dose of 20 mg/kg by i.p. administration,,BAO_0000218,,Mus musculus,,Intermediate,17728,In vivo,N,1,CHEMBL626339,,,
8877,1,Half life in BALB/C mice at the dose of 20 mg/kg by i.v. administration,,BAO_0000218,,Mus musculus,,Intermediate,17728,In vivo,N,1,CHEMBL626340,,,
8878,1,Half life in BALB/C mice at the dose of 20 mg/kg by p.o. administration,,BAO_0000218,,Mus musculus,,Intermediate,17728,In vivo,N,1,CHEMBL625377,,,
8879,1,Half life in BALB/C mice at the dose of 50 mg/kg by i.p. administration,,BAO_0000218,,Mus musculus,,Intermediate,17728,In vivo,N,1,CHEMBL625378,,,
8880,1,Half life in BALB/C mice at the dose of 50 mg/kg by p.o. administration,,BAO_0000218,,Mus musculus,,Intermediate,17728,In vivo,N,1,CHEMBL625379,,,
8881,1,Metabolism of compound in mini pig S9 microsomes ('+''indicates <20% largest observed peak),,BAO_0000251,,Sus scrofa,,Autocuration,14294,,U,0,CHEMBL625380,,,
8882,1,Metabolism of compound in mini pig S9 microsomes ('++++' indicates largest observed peak),,BAO_0000251,,Sus scrofa,,Autocuration,14294,,U,0,CHEMBL625381,,,
8883,1,Stability to porcine renal DHP-I,,BAO_0000019,,Sus scrofa,,Autocuration,6056,,U,0,CHEMBL625382,,,
8884,1,Compound was tested for its half-life period at an intravenous dose of 30 ug/kg,,BAO_0000218,,Sus scrofa,,Autocuration,1317,In vivo,U,0,CHEMBL873828,,,
8885,1,Compound was tested for its half-life period at an intravenous dose of 3 ug/kg,,BAO_0000218,,Sus scrofa,,Autocuration,1317,In vivo,U,0,CHEMBL625383,,,
8886,1,Half-life of the parent prodrug in porcine esterase solution,,BAO_0000019,,Sus scrofa,,Autocuration,5229,,U,0,CHEMBL625384,,,
8887,1,"First order rate constant, k was determined in in pig liver Esterase",,BAO_0000019,,Sus scrofa,,Autocuration,4231,,U,0,CHEMBL625385,,,
8888,1,Half life of the in pig liver Esterase,Liver,BAO_0000221,,Sus scrofa,,Autocuration,4231,,U,0,CHEMBL625386,,2107.0,
8889,1,Tested for half life period at 37 degree Celsius in PBS buffer at 11.8 pH containing porcine liver esterase,Liver,BAO_0000221,,Sus scrofa,,Autocuration,5318,,U,0,CHEMBL623571,,2107.0,
8890,1,Tested for half life period at 37 degree Celsius in PBS buffer at 7.3 pH containing porcine liver esterase,Liver,BAO_0000221,,Sus scrofa,,Autocuration,5318,,U,0,CHEMBL623572,,2107.0,
8891,1,Tested for half life period at 37 degree Celsius in PBS buffer at 7.3 pH in containing porcine liver esterase,Liver,BAO_0000221,,Sus scrofa,,Autocuration,5318,,U,0,CHEMBL623573,,2107.0,
8892,1,Compound was evaluated for esterase half-life (t 1/2) period using Pig Liver Esterase (PLE) assay,Liver,BAO_0000221,,Sus scrofa,,Autocuration,3305,,U,0,CHEMBL623574,,2107.0,
8893,1,Compound was evaluated for esterase half-life (t 1/2) period using Pig Liver Esterase (PLE) assay; ND is not determined,Liver,BAO_0000221,,Sus scrofa,,Autocuration,3305,,U,0,CHEMBL623575,,2107.0,
8894,1,Half-life in the presence of pig liver esterase(PLE) was evaluated.,Liver,BAO_0000221,,Sus scrofa,,Autocuration,2842,,U,0,CHEMBL623749,,2107.0,
8895,1,Half-life in the presence of pig liver esterase(PLE) was evaluated; Stable,Liver,BAO_0000221,,Sus scrofa,,Autocuration,2842,,U,0,CHEMBL623750,,2107.0,
8896,1,Half-life in vitro in pig liver,Liver,BAO_0000221,,Sus scrofa,,Autocuration,889,In vitro,U,0,CHEMBL623751,,2107.0,
8897,1,Half-life time was determined for esterase-catalyzed hydrolysis of the phenol ester bond in porcine liver esterase,Liver,BAO_0000221,,Sus scrofa,,Autocuration,1904,,U,0,CHEMBL623752,,2107.0,
8898,1,Maximum concentration in rat plasma after administration of 50 mg/kg dose through subcutaneous route,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,4186,In vivo,N,1,CHEMBL623753,,1969.0,
8899,1,Maximum concentration in rat plasma at 30 mg/Kg upon oral administration.,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,2774,In vivo,N,1,CHEMBL623754,,1969.0,
8900,1,Maximum concentration in rat plasma was determined,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,1742,In vivo,N,1,CHEMBL623755,,1969.0,
8901,1,Maximum concentration in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,3169,In vivo,N,1,CHEMBL623756,,,
8902,1,Maximum concentration in rats at 1-2 hours,,BAO_0000218,,Rattus norvegicus,,Intermediate,3169,In vivo,N,1,CHEMBL623757,,,
8903,1,Maximum concentration in rats at 1 hr was determined when dosed at 20 mg/Kg perorally,,BAO_0000218,,Rattus norvegicus,,Intermediate,2081,In vivo,N,1,CHEMBL623758,,,
8904,1,Maximum concentration in whole brain at 30 min following 24 mg/kg subcutaneous dose in rats,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,3307,In vivo,N,1,CHEMBL623759,,955.0,
8905,1,Maximum concentration at the dose of 2 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4727,In vivo,N,1,CHEMBL623760,,,
8906,1,Maximum concentration was evaluated in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,6597,In vivo,N,1,CHEMBL623761,,,
8907,1,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 10 mg/kg to a fasting rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,16365,In vivo,N,1,CHEMBL623762,,1969.0,
8908,1,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 1 mg/kg to a fasting rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,16365,In vivo,N,1,CHEMBL877594,,1969.0,
8909,1,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 30 mg/kg,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,16365,In vivo,N,1,CHEMBL623763,,1969.0,
8910,1,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 3 mg/kg,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,16365,In vivo,N,1,CHEMBL623764,,1969.0,
8911,1,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 3 mg/kg to a fasting rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,16365,In vivo,N,1,CHEMBL623765,,1969.0,
8912,1,Maximum concentration value was evaluated for high sustained blood levels in rat after 1 hr of administration,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,2591,In vivo,N,1,CHEMBL623766,,178.0,
8913,1,Maximum concentration value was evaluated for high sustained blood levels in rat after 2 hr of administration,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,2591,In vivo,N,1,CHEMBL623767,,178.0,
8914,1,Maximum concentration value was evaluated for high sustained blood levels in rat after 30 min of administration,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,2591,In vivo,N,1,CHEMBL623768,,178.0,
8915,1,Maximum plasma concentration (Cmax) of compound (19.2 mg/kg) after po administration was determined Sprague-Dawley rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,5978,In vivo,N,1,CHEMBL623769,,1969.0,
8916,1,Maximum plasma concentration (Cmax) of compound (19.76 mg/kg) after po administration was determined Sprague-Dawley rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,5978,In vivo,N,1,CHEMBL623770,,1969.0,
8917,1,Maximum plasma concentration (Cmax) of compound (20.73 mg/kg) after po administration was determined Sprague-Dawley rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,5978,In vivo,N,1,CHEMBL623771,,1969.0,
8918,1,Maximum plasma concentration (Cmax) of compound (25 mg/kg) after po administration was determined Sprague-Dawley rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,5978,In vivo,N,1,CHEMBL623772,,1969.0,
8919,1,Maximum plasma concentration (Cmax) of compound (9.83 mg/kg) after iv administration was determined Sprague-Dawley rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,5978,In vivo,N,1,CHEMBL623773,,1969.0,
8920,1,Maximum plasma concentration (Cmax) of compound (9.84 mg/kg) after iv administration was determined Sprague-Dawley rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,5978,In vivo,N,1,CHEMBL623774,,1969.0,
8921,1,Maximum plasma concentration (Cmax) of compound (9.92 mg/kg) after iv administration was determined Sprague-Dawley rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,5978,In vivo,N,1,CHEMBL623775,,1969.0,
8922,1,Cmax in rat (PO dose),,BAO_0000218,,Rattus norvegicus,,Intermediate,14465,In vivo,N,1,CHEMBL623776,,,
8923,1,Maximum plasma concentration determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,4723,In vivo,N,1,CHEMBL622191,,1969.0,
8924,1,Maximum plasma concentration determined after 3 mg/kg oral administration in potassium oxonate treated rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,4723,In vivo,N,1,CHEMBL622192,,1969.0,
8925,1,Maximum plasma concentration determined in rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,4576,In vivo,N,1,CHEMBL622193,,1969.0,
8926,1,Maximum plasma concentration for the compound in solution form (formulation) was determined in rats at peroral dose of 5 mg/kg,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,12873,In vivo,N,1,CHEMBL622194,,1969.0,
8927,1,Maximum plasma concentration for the compound in suspension form (formulation) was determined in rats at peroral dose of 5 mg/kg,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,12873,In vivo,N,1,CHEMBL622195,,1969.0,
8928,1,Maximum plasma concentration in rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,6824,In vivo,N,1,CHEMBL622196,,1969.0,
8929,1,Maximum plasma concentration measured after intravenous bolus administration of 50 mg/kg of compound to rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,17065,In vivo,N,1,CHEMBL622197,,1969.0,
8930,1,Maximum plasma concentration of compound present in rats at the dose of 37 mg/kg in 15 min,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,2932,In vivo,N,1,CHEMBL622198,,1969.0,
8931,1,Maximum plasma concentration of compound present in rats at the dose of 38 mg/kg in 15 min,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,2932,In vivo,N,1,CHEMBL622199,,1969.0,
8932,1,Maximum plasma concentration of compound was measured in rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,2879,In vivo,N,1,CHEMBL622200,,1969.0,
8933,1,Maximum plasma concentration after 20 mg/kg oral administration in rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,2864,In vivo,N,1,CHEMBL622201,,1969.0,
8934,1,Maximum plasma concentration after oral administration to rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,16367,In vivo,N,1,CHEMBL623990,,1969.0,
8935,1,Maximum plasma concentration at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,17717,In vivo,N,1,CHEMBL623991,,1969.0,
8936,1,"Maximum plasma concentration at a concentration of 3 mg/kg in rats, intravenously",Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,17717,In vivo,N,1,CHEMBL623992,,1969.0,
8937,1,Maximum plasma concentration at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,17717,In vivo,N,1,CHEMBL623993,,1969.0,
8938,1,Maximum plasma concentration at a concentration of 60 mg/kg perorally in rats along with control,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,17717,In vivo,N,1,CHEMBL623994,,1969.0,
8939,1,Maximum plasma concentration at a dose of 100 mg/kg in Rat Plasma after iv administration,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,17720,In vivo,N,1,CHEMBL623995,,1969.0,
8940,1,Maximum plasma concentration at a dose of 4 mg/kg in Rat Plasma after iv administration,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,17720,In vivo,N,1,CHEMBL623996,,1969.0,
8941,1,Maximum plasma concentration at a dose of 50 mg/kg in Rat Plasma after iv administration,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,17720,In vivo,N,1,CHEMBL623997,,1969.0,
8942,1,Maximum plasma concentration dosed orally in rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,4516,In vivo,N,1,CHEMBL623998,,1969.0,
8943,1,Maximum plasma concentration dosed orally in rats after 6 hours,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,4516,In vivo,N,1,CHEMBL623999,,1969.0,
8944,1,Maximum plasma concentration dosed orally in rats after 6 hours; ND is not detected,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,4516,In vivo,N,1,CHEMBL624000,,1969.0,
8945,1,Maximum plasma concentration at a 1 mg/kg oral dose in female Sprague-Dawley rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,5199,In vivo,N,1,CHEMBL624001,,1969.0,
8946,1,Maximum plasma concentration in rat after po administration,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,17538,In vivo,N,1,CHEMBL624002,,1969.0,
8947,1,"Maximum plasma concentration in rats at 10 mg/kg, p.o. dose",Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,6685,In vivo,N,1,CHEMBL624003,,1969.0,
8948,1,"Maximum plasma concentration in rats at 20mg/kg, i.p. dose",Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,6685,In vivo,N,1,CHEMBL624004,,1969.0,
8949,1,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL624005,,948.0,
8950,1,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL624006,,948.0,
8951,1,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL624007,,948.0,
8952,1,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL624008,,948.0,
8953,1,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL624009,,948.0,
8954,1,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL874387,,948.0,
8955,1,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL624010,,948.0,
8956,1,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL624011,,948.0,
8957,1,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL624012,,948.0,
8958,1,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL624013,,948.0,
8959,1,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL624736,,948.0,
8960,1,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL624737,,948.0,
8961,1,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL624738,,948.0,
8962,1,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL624739,,948.0,
8963,1,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL624740,,948.0,
8964,1,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL624896,,948.0,
8965,1,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL624897,,948.0,
8966,1,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL624108,,948.0,
8967,1,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL624109,,948.0,
8968,1,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL624110,,948.0,
8969,1,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL624111,,948.0,
8970,1,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL624112,,948.0,
8971,1,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL624113,,948.0,
8972,1,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL619709,,948.0,
8973,1,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL619710,,948.0,
8974,1,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL619711,,2113.0,
8975,1,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL619712,,2113.0,
8976,1,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL619713,,2113.0,
8977,1,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL619714,,2113.0,
8978,1,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL619715,,2113.0,
8979,1,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL619716,,2113.0,
8980,1,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL619717,,2113.0,
8981,1,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL619718,,2113.0,
8982,1,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL619719,,2113.0,
8983,1,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL875329,,2113.0,
8984,1,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL619720,,2113.0,
8985,1,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL619721,,2113.0,
8986,1,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL619722,,2113.0,
8987,1,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL619723,,2113.0,
8988,1,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL619724,,2113.0,
8989,1,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL619725,,2113.0,
8990,1,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL619726,,2113.0,
8991,1,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL619727,,2113.0,
8992,1,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL619728,,2113.0,
8993,1,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL619729,,2113.0,
8994,1,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 120 minutes after an intravenous injection is given (average of 3 rats),Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,In vivo,N,1,CHEMBL619730,,2385.0,
8995,1,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 2 minutes after an intravenous injection is given (average of 3 rats),Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,In vivo,N,1,CHEMBL619731,,2385.0,
8996,1,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 30 minutes after an intravenous injection is given (average of 2 rats),Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,In vivo,N,1,CHEMBL619732,,2385.0,
8997,1,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 30 minutes after an intravenous injection is given (average of 3 rats),Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,In vivo,N,1,CHEMBL619733,,2385.0,
8998,1,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 60 minutes after an intravenous injection is given (average of 3 rats),Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,In vivo,N,1,CHEMBL619734,,2385.0,
8999,1,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 120 minutes after an intravenous injection is given (average of 3 rats),Zone of skin,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,In vivo,N,1,CHEMBL619735,,14.0,
9000,1,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 2 minutes after an intravenous injection is given (average of 3 rats),Zone of skin,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,In vivo,N,1,CHEMBL875330,,14.0,
9001,1,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 30 minutes after an intravenous injection is given (average of 2 rats),Zone of skin,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,In vivo,N,1,CHEMBL628465,,14.0,
9002,1,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 30 minutes after an intravenous injection is given (average of 3 rats),Zone of skin,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,In vivo,N,1,CHEMBL628466,,14.0,
9003,1,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 60 minutes after an intravenous injection is given (average of 3 rats),Zone of skin,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,In vivo,N,1,CHEMBL628467,,14.0,
9004,1,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 120 minutes after an intravenous injection is given (average of 3 rats),Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,In vivo,N,1,CHEMBL628468,,2106.0,
9005,1,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 2 minutes after an intravenous injection is given (average of 3 rats),Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,In vivo,N,1,CHEMBL628469,,2106.0,
9006,1,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 30 minutes after an intravenous injection is given (average of 2 rats),Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,In vivo,N,1,CHEMBL628470,,2106.0,
9007,1,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 30 minutes after an intravenous injection is given (average of 3 rats),Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,In vivo,N,1,CHEMBL628471,,2106.0,
9008,1,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 60 minutes after an intravenous injection is given (average of 3 rats),Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,In vivo,N,1,CHEMBL628472,,2106.0,
9009,1,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 120 minutes after an intravenous injection is given (average of 3 rats),Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,In vivo,N,1,CHEMBL625191,,2046.0,
9010,1,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 2 minutes after an intravenous injection is given (average of 3 rats),Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,In vivo,N,1,CHEMBL625192,,2046.0,
9011,1,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 30 minutes after an intravenous injection is given (average of 2 rats),Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,In vivo,N,1,CHEMBL875337,,2046.0,
9012,1,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 30 minutes after an intravenous injection is given (average of 3 rats),Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,In vivo,N,1,CHEMBL626341,,2046.0,
9013,1,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 60 minutes after an intravenous injection is given (average of 3 rats),Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,In vivo,N,1,CHEMBL626342,,2046.0,
9014,1,Biodistribution of radioligand [125I]-FIDA1 in liver of rat after 2 minutes after an intravenous injection is given (average of 3 rats),Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,In vivo,N,1,CHEMBL621943,,2107.0,
9015,1,Half life in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,3748,,N,1,CHEMBL621944,,,
9016,1,Mean percent inhibition of joint damage reduction in fasted rats at 35 mg/kg administered orally twice daily,,BAO_0000218,,Rattus norvegicus,,Intermediate,15765,,N,1,CHEMBL621945,,,
9017,1,Compound was evaluated for rate of clearance by using IPRL (Isolated Perfused Rat Liver),,BAO_0000218,,Rattus norvegicus,,Intermediate,4871,,N,1,CHEMBL621946,,,
9018,1,Compound was evaluated for rate of clearance by using IPRL (Isolated Perfused Rat Liver); ND=Not determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,4871,,N,1,CHEMBL621947,,,
9019,1,Compound was evaluated for rate of clearance in IPRL (Isolated Perfused Rat Liver),,BAO_0000218,,Rattus norvegicus,,Intermediate,4872,,N,1,CHEMBL621948,,,
9020,1,Compound was evaluated for rate of clearance in IPRL (Isolated Perfused Rat Liver); ND=Not determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,4872,,N,1,CHEMBL621949,,,
9021,1,Rate constant (k) of clearance from isolated perfused rat liver (IPRL),,BAO_0000218,,Rattus norvegicus,,Intermediate,5413,,N,1,CHEMBL621950,,,
9022,1,Tested for rate of clearance from isolated perfused rat liver (IPRL) and expressed in terms of rate constant (k); not determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,5413,,N,1,CHEMBL621951,,,
9023,1,Maximal blood concentration after oral administration of a 30 uM/kg dose of compound,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,15272,In vivo,N,1,CHEMBL621952,,178.0,
9024,1,Stability (%) in rat liver microsomes,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,4689,,N,1,CHEMBL621953,,2107.0,
9025,1,Area under curve was calculated after intravenous administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,6057,,N,1,CHEMBL621954,,,
9026,1,Area under the curve was calculated after iv administration in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6057,,N,1,CHEMBL621955,,,
9027,1,Area under the curve was calculated in rat after peroral administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,6057,,N,1,CHEMBL621956,,,
9028,1,Dose-normalized AUC was determined by po administration (10 mg/kg) in fasted male Sprague-Dawley rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,6211,,N,1,CHEMBL621957,,,
9029,1,Dose-normalized AUC measured in fasted male Sprague dawely rats when the compound was administered at a peroral dose of 2 mg/Kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,5710,,N,1,CHEMBL621958,,,
9030,1,Dose-normalized AUC measured in fasted male Sprague dawely rats when the compound was administered at a peroral of 2 mg/Kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,5710,,N,1,CHEMBL621959,,,
9031,1,Dose-normalized area under curve in rat (i.v.) at 0.5 mpk,,BAO_0000218,,Rattus norvegicus,,Intermediate,17853,,N,1,CHEMBL621960,,,
9032,1,Dose-normalized area under curve in rat (p.o.) at 2.0 mpk,,BAO_0000218,,Rattus norvegicus,,Intermediate,17853,,N,1,CHEMBL621961,,,
9033,1,p value of the compound,,BAO_0000218,,Rattus norvegicus,,Intermediate,15765,,N,1,CHEMBL621962,,,
9034,1,p value of the compound,,BAO_0000218,,Rattus norvegicus,,Intermediate,15765,,N,1,CHEMBL876787,,,
9035,1,p value of the compound,,BAO_0000218,,Rattus norvegicus,,Intermediate,15765,,N,1,CHEMBL621963,,,
9036,1,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (10 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),Stomach,BAO_0000218,,Rattus norvegicus,,Intermediate,6175,,N,1,CHEMBL622637,,945.0,
9037,1,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (20 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),Stomach,BAO_0000218,,Rattus norvegicus,,Intermediate,6175,,N,1,CHEMBL622638,,945.0,
9038,1,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),Stomach,BAO_0000218,,Rattus norvegicus,,Intermediate,6175,,N,1,CHEMBL626561,,945.0,
9039,1,Negative log of minimum effective dose (moles per kilogram) in rabbits (hypnotic),,BAO_0000019,,Oryctolagus cuniculus,,Autocuration,7991,,U,0,CHEMBL626562,,,
9040,1,Evaluated for pharmacokinetic parameter area under curve in rabbit at the dose 20 mg/kg ( 0-4 hr ),,BAO_0000218,,Oryctolagus cuniculus,,Autocuration,429,,U,0,CHEMBL626563,,,
9041,1,Evaluated for pharmacokinetic parameter area under curve in rabbit at the dose 20 mg/kg (0-4 hr ),,BAO_0000218,,Oryctolagus cuniculus,,Autocuration,429,,U,0,CHEMBL626564,,,
9042,1,Clearance was measured at the concentration of 1.11 mg/kg in rabbit blood sample,,BAO_0000218,,Oryctolagus cuniculus,,Autocuration,6253,In vivo,U,0,CHEMBL626565,,,
9043,1,Clearance was measured at the concentration of 2.0 mg/kg in rabbit blood sample,,BAO_0000218,,Oryctolagus cuniculus,,Autocuration,6253,In vivo,U,0,CHEMBL626566,,,
9044,1,Clearance rate in rabbits,,BAO_0000218,,Oryctolagus cuniculus,,Autocuration,3615,In vivo,U,0,CHEMBL626567,,,
9045,1,Plasma clearance was determined in rabbit at a dose of 5 mg/kg/h administered i.v.,,BAO_0000218,,Oryctolagus cuniculus,,Autocuration,4059,In vivo,U,0,CHEMBL626568,,,
9046,1,Clearance in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,,BAO_0000218,,Oryctolagus cuniculus,,Autocuration,5124,In vivo,U,0,CHEMBL626569,,,
9047,1,Clearance in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,,BAO_0000218,,Oryctolagus cuniculus,,Autocuration,5124,In vivo,U,0,CHEMBL626570,,,
9048,1,Clearance in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,,BAO_0000218,,Oryctolagus cuniculus,,Autocuration,5124,In vivo,U,0,CHEMBL626571,,,
9049,1,Evaluated for pharmacokinetic parameter Cmax in rabbit at the dose 20 mg/kg,,BAO_0000218,,Oryctolagus cuniculus,,Autocuration,429,In vivo,U,0,CHEMBL626572,,,
9050,1,Maximum plasma concentration was determined in rabbit at a dose of 5 mg/kg/h administered i.v.,Plasma,BAO_0000218,,Oryctolagus cuniculus,,Autocuration,4059,In vivo,U,0,CHEMBL626573,,1969.0,
9051,1,Oxidation by dutch rabbit liver microsomes in presence of NADPH/O2,Liver,BAO_0000251,,Oryctolagus cuniculus,,Autocuration,9659,,U,0,CHEMBL626574,,2107.0,
9052,1,Oxidation by dutch rabbit liver microsomes in presence of cumene hydroperoxide,Liver,BAO_0000251,,Oryctolagus cuniculus,,Autocuration,9659,,U,0,CHEMBL626575,,2107.0,
9053,1,Dose at which bioavailability of intravenously administered compound was tested in rabbit,,BAO_0000218,,Oryctolagus cuniculus,,Autocuration,3639,,U,0,CHEMBL626576,,,
9054,1,Dose at which bioavailability of perorally administered compound was tested in rabbit,,BAO_0000218,,Oryctolagus cuniculus,,Autocuration,3639,,U,0,CHEMBL626577,,,
9055,1,The compound was tested for its bioavailability in rabbit (by oral dosage).,,BAO_0000218,,Oryctolagus cuniculus,,Autocuration,3639,In vivo,U,0,CHEMBL626578,,,
9056,1,Mean retention time in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,,BAO_0000218,,Oryctolagus cuniculus,,Autocuration,5124,In vivo,U,0,CHEMBL625263,,,
9057,1,Mean retention time in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,,BAO_0000218,,Oryctolagus cuniculus,,Autocuration,5124,In vivo,U,0,CHEMBL625264,,,
9058,1,Mean retention time in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,,BAO_0000218,,Oryctolagus cuniculus,,Autocuration,5124,In vivo,U,0,CHEMBL625265,,,
9059,1,Metabolism of compound in rabbit S9 microsomes ('+''indicates <20% largest observed peak),,BAO_0000251,,Oryctolagus cuniculus,,Autocuration,14294,,U,0,CHEMBL625266,,,
9060,1,Metabolism of compound in rabbit S9 microsomes ('++++' indicates largest observed peak),,BAO_0000251,,Oryctolagus cuniculus,,Autocuration,14294,,U,0,CHEMBL876796,,,
9061,1,Evaluated for pharmacokinetic parameter half-life in rabbit at the dose 20 mg/kg,,BAO_0000218,,Oryctolagus cuniculus,,Autocuration,429,In vivo,U,0,CHEMBL625267,,,
9062,1,Plasma half-life in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,Plasma,BAO_0000218,,Oryctolagus cuniculus,,Autocuration,5124,In vivo,U,0,CHEMBL625268,,1969.0,
9063,1,Plasma half-life in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,Plasma,BAO_0000218,,Oryctolagus cuniculus,,Autocuration,5124,In vivo,U,0,CHEMBL625269,,1969.0,
9064,1,Plasma half-life in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,Plasma,BAO_0000218,,Oryctolagus cuniculus,,Autocuration,5124,In vivo,U,0,CHEMBL624689,,1969.0,
9065,1,Evaluated for pharmacokinetic parameter tmax in rabbit at the dose 20 mg/kg,,BAO_0000218,,Oryctolagus cuniculus,,Autocuration,429,In vivo,U,0,CHEMBL624690,,,
9066,1,Evaluated for pharmacokinetic parameter urine recovery in rabbit at the dose 20 mg/kg ( 0-24 hr ),Urine,BAO_0000218,,Oryctolagus cuniculus,,Autocuration,429,,U,0,CHEMBL624691,,1088.0,
9067,1,Evaluated for pharmacokinetic parameter urine recovery in rabbit at the dose 20 mg/kg (0-24 hr),Urine,BAO_0000218,,Oryctolagus cuniculus,,Autocuration,429,,U,0,CHEMBL624692,,1088.0,
9068,1,The compound was evaluated for volume of distribution in rabbit at a dose of 5 mg/kg/h administered i.v.,,BAO_0000218,,Oryctolagus cuniculus,,Autocuration,4059,In vivo,U,0,CHEMBL624693,,,
9069,1,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,,BAO_0000218,,Oryctolagus cuniculus,,Autocuration,4137,In vivo,U,0,CHEMBL624694,,,
9070,1,In vitro Biological half-life in crude homogenate of rabbit renal cortex,,BAO_0000221,,Oryctolagus cuniculus,,Autocuration,11672,In vitro,U,0,CHEMBL877596,,,
9071,1,Time within which only 10% of the drug was degraded,,BAO_0000019,,Oryctolagus cuniculus,,Autocuration,12886,,U,0,CHEMBL624695,,,
9072,1,Half life period in rabbit liver homogenate,Liver,BAO_0000221,,Oryctolagus cuniculus,,Autocuration,3853,,U,0,CHEMBL624696,,2107.0,
9073,1,Half life value in rabbits,,BAO_0000019,,Oryctolagus cuniculus,,Autocuration,3615,,U,0,CHEMBL624697,,,
9074,1,Half-life was measured at the concentration of 1.11 mg/kg in rabbit blood sample,Blood,BAO_0000218,,Oryctolagus cuniculus,,Autocuration,6253,In vivo,U,0,CHEMBL624698,,178.0,
9075,1,Half-life was measured at the concentration of 2.0 mg/kg in rabbit blood sample,Blood,BAO_0000218,,Oryctolagus cuniculus,,Autocuration,6253,In vivo,U,0,CHEMBL624699,,178.0,
9076,1,Half-life period in rabbits following intravenous administration at 2 mg/kg,,BAO_0000218,,Oryctolagus cuniculus,,Autocuration,6077,In vivo,U,0,CHEMBL624700,,,
9077,1,AUC 0-8 hr value in rats at 10 mg/kg,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,17617,,N,1,CHEMBL622903,,1969.0,
9078,1,AUC after administration at 2000 mg/kg/day in rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,17594,,N,1,CHEMBL622904,,1969.0,
9079,1,AUC of compound for a 2 mpk po dose of the sodium salt in rats.,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,6149,,N,1,CHEMBL622905,,1969.0,
9080,1,AUC at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,17260,,N,1,CHEMBL622906,,1969.0,
9081,1,AUC at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,17260,,N,1,CHEMBL622907,,1969.0,
9082,1,AUC in rat after oral administration at 10.5 mg/kg dose,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,6644,,N,1,CHEMBL622908,,1969.0,
9083,1,AUC in rat after oral administration at 11.2 mg/kg dose,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,6644,,N,1,CHEMBL622909,,1969.0,
9084,1,AUC in rat after oral administration at 9.7 mg/kg dose,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,6644,,N,1,CHEMBL622910,,1969.0,
9085,1,AUC in rat brain after oral administration at 10 mg/kg,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,6495,,N,1,CHEMBL622911,,955.0,
9086,1,AUC in rat p.o.,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,6504,,N,1,CHEMBL622912,,1969.0,
9087,1,AUC in rat p.o. at 20 mg/kg concentration,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,17686,,N,1,CHEMBL622913,,1969.0,
9088,1,AUC in rat plasma after oral administration at 10 mg/kg,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,6495,,N,1,CHEMBL622914,,1969.0,
9089,1,AUC in rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,216,,N,1,CHEMBL622915,,1969.0,
9090,1,AUC value after IV dose at a dose of 5 mg/kg in rats.,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,1908,,N,1,CHEMBL622916,,1969.0,
9091,1,AUC value after oral dose at a dose of 10 mg/kg in rats.,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,1908,,N,1,CHEMBL622917,,1969.0,
9092,1,"Maximum plasma concentration in rats at 2 mg/kg, i.v. dose; n/a: not applicable",Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,6685,In vivo,N,1,CHEMBL622918,,1969.0,
9093,1,Maximum plasma concentration in rats when a oral dose of 200 mg/kg was given,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,216,In vivo,N,1,CHEMBL622919,,1969.0,
9094,1,Maximum plasma concentration was evaluated in rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,6049,In vivo,N,1,CHEMBL622920,,1969.0,
9095,1,Maximum plasma concentration was evaluated in vivo in rat at a dose of 5 mg/kg by oral administration,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,2463,In vivo,N,1,CHEMBL622921,,1969.0,
9096,1,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,6679,In vivo,N,1,CHEMBL622922,,1969.0,
9097,1,Maximum plasma concentration reached by compound was determined in rats at 50 mg/kg dose,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,6681,In vivo,N,1,CHEMBL622923,,1969.0,
9098,1,Maximum plasma concentration was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,4890,In vivo,N,1,CHEMBL877604,,1969.0,
9099,1,Maximum plasma concentration was evaluated in rats at an intravenous dose of 3 mg/kg,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,6410,In vivo,N,1,CHEMBL622924,,1969.0,
9100,1,Maximum plasma concentration was evaluated in rats at an oral dose of 30 mg/kg,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,6410,In vivo,N,1,CHEMBL622925,,1969.0,
9101,1,Maximum plasma concentration was measured when a dose of 1 mg/kg is administered orally,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,16366,In vivo,N,1,CHEMBL622926,,1969.0,
9102,1,Maximum plasma concentration (Cmax) in rat (in vivo) at a dose of 10 mg/kg,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,6227,In vivo,N,1,CHEMBL623625,,1969.0,
9103,1,Maximum plasma drug concentration of compound determined in rat after iv administration at a dose of 10 mg/kg,Plasma,BAO_0000218,,Rattus norvegicus,,Expert,3598,In vivo,N,1,CHEMBL623626,,1969.0,
9104,1,Maximum plasma drug concentration was determined,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,1465,In vivo,N,1,CHEMBL623627,,1969.0,
9105,1,Maximum concentration by intravenous administration of 3.4 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4368,In vivo,N,1,CHEMBL623628,,,
9106,1,Mean peak plasma concentration was observed after intravenous administration in rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,15662,In vivo,N,1,CHEMBL623629,,1969.0,
9107,1,Mean peak plasma concentration was observed after oral administration in rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,15662,In vivo,N,1,CHEMBL623630,,1969.0,
9108,1,Peak concentration (Cmax) at a dose of 10 mg/kg in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,5355,In vivo,N,1,CHEMBL623804,,,
9109,1,Peak concentration (Cmax) at a dose of 20 mg/kg in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,5355,In vivo,N,1,CHEMBL623805,,,
9110,1,Peak oral plasma concentration was determined in rats by oral administration,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,1567,In vivo,N,1,CHEMBL623806,,1969.0,
9111,1,Peak plasma concentration (Cmax) was determined,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,4026,In vivo,N,1,CHEMBL623807,,1969.0,
9112,1,Peak plasma concentration (Cmax) following an oral dose of 20 mg/kg in rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,6193,In vivo,N,1,CHEMBL623808,,1969.0,
9113,1,Peak plasma concentration (Cmax) in rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,4026,In vivo,N,1,CHEMBL623809,,1969.0,
9114,1,Peak plasma concentration at 1 mg/kg peroral administration,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,6485,In vivo,N,1,CHEMBL623810,,1969.0,
9115,1,Peak plasma concentration in rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,17655,In vivo,N,1,CHEMBL623811,,1969.0,
9116,1,"Pharmacokinetic Parameter, Cmax is observed maximum plasma concentration in Female Wistar Rats at 100 mg/kg by po administration",Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14941,In vivo,N,1,CHEMBL623812,,1969.0,
9117,1,Pharmacokinetic parameter Cmax was measured after administration into rat at 10 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,5394,In vivo,N,1,CHEMBL877605,,,
9118,1,Pharmacokinetic property (Cmax) in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4408,In vivo,N,1,CHEMBL623813,,,
9119,1,Pharmacokinetic property (Cmax) was measured in rat at the dose of 0.32 mg/kg p.o.,,BAO_0000218,,Rattus norvegicus,,Intermediate,5983,In vivo,N,1,CHEMBL623814,,,
9120,1,Cmax in rat after 3mg/kg oral dose,,BAO_0000218,,Rattus norvegicus,,Intermediate,4878,In vivo,N,1,CHEMBL623815,,,
9121,1,Clearance in Sprague-Dawley rats after 2mg/kg oral dose,,BAO_0000218,,Rattus norvegicus,,Intermediate,5862,In vivo,N,1,CHEMBL623816,,,
9122,1,Cmax in rats after 20 mg/kg oral dose,,BAO_0000218,,Rattus norvegicus,,Intermediate,4517,In vivo,N,1,CHEMBL623145,,,
9123,1,Cmax in rat plasma after 30mg/kg oral dose,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,5932,In vivo,N,1,CHEMBL623146,,1969.0,
9124,1,Plasma concentration after oral administration of 100 mg/kg to rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,5436,In vivo,N,1,CHEMBL623147,,1969.0,
9125,1,Tested for concentration in brain after intravenous administration (4.7 mg/kg) to male rats,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,4910,In vivo,N,1,CHEMBL623042,,955.0,
9126,1,Tested for the Cmax in rat at 10 mg/kg per orally,,BAO_0000218,,Rattus norvegicus,,Intermediate,4950,In vivo,N,1,CHEMBL623043,,,
9127,1,"The Cmax value in female wistar rat at 100 mg/kg, p.o. dose",,BAO_0000218,,Rattus norvegicus,,Intermediate,15078,In vivo,N,1,CHEMBL623044,,,
9128,1,"The Cmax value in male wistar rat at 100 mg/kg, p.o. dose",,BAO_0000218,,Rattus norvegicus,,Intermediate,15078,In vivo,N,1,CHEMBL623045,,,
9129,1,Bioavailability as oral Cmax in rats at 30 mins,,BAO_0000218,,Rattus norvegicus,,Intermediate,3360,In vivo,N,1,CHEMBL623046,,,
9130,1,Bioavailability as oral Cmax in rats at 6hr,,BAO_0000218,,Rattus norvegicus,,Intermediate,3360,In vivo,N,1,CHEMBL623226,,,
9131,1,The maximum concentration of compound was measured at the dose of 100 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,15022,In vivo,N,1,CHEMBL623227,,,
9132,1,The maximum concentration of compound was measured at the dose of 300 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,15022,In vivo,N,1,CHEMBL623228,,,
9133,1,The maximum concentration of compound was measured at the dose of 30 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,15022,In vivo,N,1,CHEMBL623229,,,
9134,1,The maximum plasma levels for the compounds were determined by LC-MS.,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,5160,In vivo,N,1,CHEMBL623230,,1969.0,
9135,1,mean peak plasma concentration was observed after intravenous administration in rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,15662,In vivo,N,1,CHEMBL623231,,1969.0,
9136,1,mean peak plasma concentration was observed after oral administration in rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,15662,In vivo,N,1,CHEMBL623232,,1969.0,
9137,1,Concentration in the plasma after intravenous administration of 1 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4709,,N,1,CHEMBL623233,,,
9138,1,Concentration in plasma (portal) following oral dose in rats at 0.25 hr,,BAO_0000218,,Rattus norvegicus,,Intermediate,3535,,N,1,CHEMBL623234,,,
9139,1,Concentration in plasma (portal) following oral dose in rats at 1 hr,,BAO_0000218,,Rattus norvegicus,,Intermediate,3535,,N,1,CHEMBL623235,,,
9140,1,Concentration in plasma (portal) following oral dose in rats at 2 hr,,BAO_0000218,,Rattus norvegicus,,Intermediate,3535,,N,1,CHEMBL623236,,,
9141,1,Concentration in plasma (systemic) following oral dose in rats at 0.25 hr,,BAO_0000218,,Rattus norvegicus,,Intermediate,3535,,N,1,CHEMBL623237,,,
9142,1,Concentration in plasma (systemic) following oral dose in rats at 1 hr,,BAO_0000218,,Rattus norvegicus,,Intermediate,3535,,N,1,CHEMBL623238,,,
9143,1,Concentration in plasma (systemic) following oral dose in rats at 2 hr,,BAO_0000218,,Rattus norvegicus,,Intermediate,3535,,N,1,CHEMBL623239,,,
9144,1,Compound was evaluated for the plasma concentration in rats versus time curves (AUC) in vivo,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,5005,In vivo,U,0,CHEMBL623240,,1969.0,
9145,1,"Concentration (30 mg/kg, p.o.) in rat hypothalamus after 2 hours",Hypothalamus,BAO_0000218,,Rattus norvegicus,,Intermediate,6326,,N,1,CHEMBL623241,,1898.0,
9146,1,"Concentration (30 mg/kg, p.o.) in rat hypothalamus after 6 hours",Hypothalamus,BAO_0000218,,Rattus norvegicus,,Intermediate,6326,,N,1,CHEMBL623242,,1898.0,
9147,1,"Concentration (30 mg/kg, p.o.) in rat plasma after 2 hours",,BAO_0000218,,Rattus norvegicus,,Intermediate,6326,,N,1,CHEMBL874394,,,
9148,1,"Concentration (30 mg/kg, p.o.) in rat plasma after 6 hours",,BAO_0000218,,Rattus norvegicus,,Intermediate,6326,,N,1,CHEMBL623243,,,
9149,1,Kidney concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,17411,,N,1,CHEMBL623244,,,
9150,1,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL623245,,2113.0,
9151,1,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL623246,,2113.0,
9152,1,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL623247,,2113.0,
9153,1,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL623248,,2113.0,
9154,1,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL623249,,2113.0,
9155,1,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL625072,,2107.0,
9156,1,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL625073,,2107.0,
9157,1,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL625074,,2107.0,
9158,1,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL625075,,2107.0,
9159,1,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 120 min.,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL625076,,2107.0,
9160,1,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL625077,,2107.0,
9161,1,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL625078,,2107.0,
9162,1,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL874395,,2107.0,
9163,1,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL625079,,2107.0,
9164,1,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL625080,,2107.0,
9165,1,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL625081,,2107.0,
9166,1,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL625082,,2107.0,
9167,1,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL625083,,2107.0,
9168,1,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL625084,,2107.0,
9169,1,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL625085,,2107.0,
9170,1,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL625086,,2107.0,
9171,1,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL625087,,2107.0,
9172,1,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL625088,,2107.0,
9173,1,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL622205,,2107.0,
9174,1,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL622206,,2107.0,
9175,1,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL622207,,2107.0,
9176,1,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL622366,,2107.0,
9177,1,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL622367,,2107.0,
9178,1,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL875331,,2107.0,
9179,1,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL622368,,2107.0,
9180,1,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL622369,,2048.0,
9181,1,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL622370,,2048.0,
9182,1,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL622371,,2048.0,
9183,1,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL622372,,2048.0,
9184,1,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL622373,,2048.0,
9185,1,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL622374,,2048.0,
9186,1,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL622375,,2048.0,
9187,1,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL622376,,2048.0,
9188,1,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL622377,,2048.0,
9189,1,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL622378,,2048.0,
9190,1,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL622379,,2048.0,
9191,1,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL622380,,2048.0,
9192,1,Radioactivity distribution in lung of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL622381,,2048.0,
9193,1,Radioactivity distribution in lung of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL622382,,2048.0,
9194,1,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 120 min,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL622383,,2048.0,
9195,1,pH of the gastric juice (Control value = 1.44+/-0.01) of stomach content of pylorus ligated rats was measured ( 5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),Stomach,BAO_0000218,,Rattus norvegicus,,Intermediate,6175,,N,1,CHEMBL875332,,945.0,
9196,1,pH of the gastric juice (Control value = 1.44+/-0.01) of stomach content of pylorus ligated rats was measured (10 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),Stomach,BAO_0000218,,Rattus norvegicus,,Intermediate,6175,,N,1,CHEMBL622384,,945.0,
9197,1,pH of the gastric juice (control value = 1.39+/-0.02) of stomach content of pylorus ligated rats was measured (2.5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),Stomach,BAO_0000218,,Rattus norvegicus,,Intermediate,6175,,N,1,CHEMBL622385,,945.0,
9198,1,pH of the gastric juice (control value = 1.39+/-0.02) of stomach content of pylorus ligated rats was measured (5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),Stomach,BAO_0000218,,Rattus norvegicus,,Intermediate,6175,,N,1,CHEMBL622386,,945.0,
9199,1,The compound was tested for the plasma binding in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,10839,,N,1,CHEMBL622387,,,
9200,1,"Plasma concentration after intravenous aministration at 1hr, (1 mg/kg, n=3)",,BAO_0000218,,Rattus norvegicus,,Intermediate,16459,,N,1,CHEMBL622388,,,
9201,1,"Plasma concentration after intravenous aministration at 30 min. (1 mg/kg, n=3)",,BAO_0000218,,Rattus norvegicus,,Intermediate,16459,,N,1,CHEMBL622389,,,
9202,1,"Plasma concentration after intravenous aministration at 60 min. (1 mg/kg, n=3)",,BAO_0000218,,Rattus norvegicus,,Intermediate,16459,,N,1,CHEMBL622390,,,
9203,1,Plasma concentration after oral aministration at 1 hr. (10 mg/kg),,BAO_0000218,,Rattus norvegicus,,Intermediate,16459,,N,1,CHEMBL622391,,,
9204,1,Plasma concentration after oral aministration at 2 hr. (10 mg/kg),,BAO_0000218,,Rattus norvegicus,,Intermediate,16459,,N,1,CHEMBL622392,,,
9205,1,Plasma concentration after oral aministration at 4 hr. (10 mg/kg),,BAO_0000218,,Rattus norvegicus,,Intermediate,16459,,N,1,CHEMBL622393,,,
9206,1,Plasma level at 2 hr after administration of the compound,,BAO_0000218,,Rattus norvegicus,,Intermediate,3278,,N,1,CHEMBL622394,,,
9207,1,plasma level at 2 hr after administration of the compound,,BAO_0000218,,Rattus norvegicus,,Intermediate,3278,,N,1,CHEMBL622395,,,
9208,1,Stability in rat serum measured as % recovery at 1 min,Serum,BAO_0000218,,Rattus norvegicus,,Intermediate,4684,,N,1,CHEMBL622396,,1977.0,
9209,1,Stability in rat serum measured as % recovery at 10 min,Serum,BAO_0000218,,Rattus norvegicus,,Intermediate,4684,,N,1,CHEMBL624894,,1977.0,
9210,1,Stability in rat serum measured as % recovery at 10 mins,Serum,BAO_0000218,,Rattus norvegicus,,Intermediate,4684,,N,1,CHEMBL624895,,1977.0,
9211,1,Stability in rat serum measured as % recovery at 2 hr,Serum,BAO_0000218,,Rattus norvegicus,,Intermediate,4684,,N,1,CHEMBL624058,,1977.0,
9212,1,Stability in rat serum measured as % recovery at 3 min,Serum,BAO_0000218,,Rattus norvegicus,,Intermediate,4684,,N,1,CHEMBL624059,,1977.0,
9213,1,Stability in rat serum measured as % recovery at 3 mins,Serum,BAO_0000218,,Rattus norvegicus,,Intermediate,4684,,N,1,CHEMBL624060,,1977.0,
9214,1,Stability in rat serum measured as % recovery at 5 min,Serum,BAO_0000218,,Rattus norvegicus,,Intermediate,4684,,N,1,CHEMBL624061,,1977.0,
9215,1,Stability in rat serum measured as % recovery at 5 mins,Serum,BAO_0000218,,Rattus norvegicus,,Intermediate,4684,,N,1,CHEMBL624062,,1977.0,
9216,1,Alpha-elimination half-life in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,16456,In vivo,N,1,CHEMBL624063,,,
9217,1,Beta-elimination half-life in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,16456,In vivo,N,1,CHEMBL624064,,,
9218,1,Half life in plasma was determined against ovariectomized rats; t 1/2 (h) is short in plasma,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,723,,N,1,CHEMBL624065,,1969.0,
9219,1,Half life in plasma was determined against ovariectomized rats; t1/2 is longer in plasma.,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,723,,N,1,CHEMBL624066,,1969.0,
9220,1,Half life tested in mature male rat at a dose of 30 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,5160,In vivo,N,1,CHEMBL877490,,,
9221,1,Half life after intravenous administration of 1 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4709,In vivo,N,1,CHEMBL874442,,,
9222,1,Half life period after administration (30 mg/kg) in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5633,In vivo,N,1,CHEMBL626890,,,
9223,1,Half life period in rat after 5 mg/Kg dose,,BAO_0000218,,Rattus norvegicus,,Intermediate,5302,In vivo,N,1,CHEMBL626891,,,
9224,1,Half life period in rat after 5 mg/kg dose,,BAO_0000218,,Rattus norvegicus,,Intermediate,5302,In vivo,N,1,CHEMBL626892,,,
9225,1,Half life period was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,17791,,N,1,CHEMBL626893,,,
9226,1,Half life period was evaluated in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,17791,,N,1,CHEMBL626894,,,
9227,1,Half life period was evaluated in rat; 0.5-1.0,,BAO_0000218,,Rattus norvegicus,,Intermediate,17791,,N,1,CHEMBL626895,,,
9228,1,Half life period was evaluated in rat; 5.9-7.5,,BAO_0000218,,Rattus norvegicus,,Intermediate,17791,,N,1,CHEMBL626896,,,
9229,1,Half-life in rat plasma,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14512,,N,1,CHEMBL626897,,1969.0,
9230,1,Half-life time in rat was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,6230,,N,1,CHEMBL626898,,,
9231,1,Terminal half-life after iv administration to rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,3364,In vivo,N,1,CHEMBL626899,,,
9232,1,Tested for iv terminal half-life dosed as a solution in male Han Wistar rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,6874,In vivo,N,1,CHEMBL626900,,,
9233,1,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 0.5 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,857,,N,1,CHEMBL626901,,,
9234,1,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 0.5 umol/kg (iv),,BAO_0000218,,Rattus norvegicus,,Intermediate,858,In vivo,N,1,CHEMBL626902,,,
9235,1,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 5 umol/kg (iv),,BAO_0000218,,Rattus norvegicus,,Intermediate,858,In vivo,N,1,CHEMBL626903,,,
9236,1,Time for peak concentration (tmax) at a dose of 10 mg/kg in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,5355,In vivo,N,1,CHEMBL874443,,,
9237,1,Time for peak concentration (tmax) at a dose of 20 mg/kg in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,5355,In vivo,N,1,CHEMBL626904,,,
9238,1,Half life in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,6305,,N,1,CHEMBL626905,,,
9239,1,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 4 mg/kg to rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,13501,In vivo,N,1,CHEMBL873830,,1969.0,
9240,1,Apparent half-life after single intravenous bolus of 1 mg/kg in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,17594,In vivo,N,1,CHEMBL626906,,,
9241,1,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,4186,In vivo,N,1,CHEMBL631076,,1969.0,
9242,1,Biological half-life was measured in plasma of rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,2932,,N,1,CHEMBL631077,,1969.0,
9243,1,Circulatory half life measured after intravenous bolus administration of 50 mg/kg of compound to rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,17065,In vivo,N,1,CHEMBL631078,,,
9244,1,Compound demonstarted an oral bioavailability of 6% with the half-life time as given in rats.,,BAO_0000218,,Rattus norvegicus,,Intermediate,15765,In vivo,N,1,CHEMBL631079,,,
9245,1,Compound was evaluated for half life (t1/2) upon intravenous administration of 1 mg/Kg in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,2713,In vivo,N,1,CHEMBL631080,,,
9246,1,Compound was evaluated for half life after treatment with iv dose of 1 mgkg to female wistar rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,2661,In vivo,N,1,CHEMBL631081,,,
9247,1,Compound was evaluated for half life after treatment with iv dose of 1 mgkg to male wistar rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,2661,In vivo,N,1,CHEMBL631239,,,
9248,1,Compound was evaluated for plasma half life in rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,740,,N,1,CHEMBL631240,,1969.0,
9249,1,AUC value at a dose of 5 mg/kg (p.o.) in rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,6597,,N,1,CHEMBL631241,,1969.0,
9250,1,AUC value after administration of 20 mg/Kg oral dose in rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,2959,,N,1,CHEMBL631242,,1969.0,
9251,1,AUC0-24 after repeated oral dose of compound at 1 mg/kg in rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,17594,,N,1,CHEMBL631243,,1969.0,
9252,1,AUC0-96 after administration at 50 mg/kg,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,17596,,N,1,CHEMBL874444,,1969.0,
9253,1,AUC0-infinity after single intravenous bolus of 1 mg/kg in rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,17594,,N,1,CHEMBL631244,,1969.0,
9254,1,"Absorption behavior was judged by the area under the curve, determined after oral dose of 30 mg/kg in rats.",,BAO_0000218,,Rattus norvegicus,,Intermediate,3293,,N,1,CHEMBL631245,,,
9255,1,Area under curve (0-24 hr) at a dose of 10 mg/kg in male SD rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,6757,,N,1,CHEMBL627162,,,
9256,1,Area under curve (0-24 hr) at a dose of 100 mg/kg in male SD rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,6757,,N,1,CHEMBL627163,,,
9257,1,Area under curve (0-24 hr) at a dose of 50 mg/kg in male SD rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,6757,,N,1,CHEMBL627164,,,
9258,1,Area under curve (AUC) at a dose 1 mg/kg was determined in rat kidney,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,5979,,N,1,CHEMBL627165,,2113.0,
9259,1,Area under curve (AUC) at a dose 1 mg/kg was determined in rat liver,,BAO_0000218,,Rattus norvegicus,,Intermediate,5979,,N,1,CHEMBL627166,,,
9260,1,Area under curve (AUC) at a dose 1 mg/kg was determined in rat lung,,BAO_0000218,,Rattus norvegicus,,Intermediate,5979,,N,1,CHEMBL627167,,,
9261,1,Area under curve (AUC) at a dose of 30 mg/kg in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,4026,,N,1,CHEMBL627822,,,
9262,1,Area under curve (AUC) was calculated using trapezoidal rule at a dose of 20 mg/kg in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,5355,,N,1,CHEMBL627823,,,
9263,1,Area under curve (AUC) was calculated using trapezoidal rule. at a dose of 10 mg/kg in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,5355,,N,1,CHEMBL627824,,,
9264,1,Area under curve (AUC) was calculated using trapezoidal rule at a dose of 20 mg/kg in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,5355,,N,1,CHEMBL627825,,,
9265,1,Area under curve (AUC0-24 h) after administration (30 mg/kg) in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5633,,N,1,CHEMBL627826,,,
9266,1,Area under curve (Pharmacokinetic property) was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,1716,,N,1,CHEMBL627827,,,
9267,1,Area under curve (Pharmacokinetic property) of the compound; Not determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,1716,,N,1,CHEMBL627828,,,
9268,1,Area under curve after intravenous administration (1 mg/kg) in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4689,,N,1,CHEMBL627829,,,
9269,1,Area under curve by intravenous administration at a dose of 10 uM/kg in rat was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,4527,,N,1,CHEMBL627830,,,
9270,1,Area under curve by oral administration at a dose of 100 uM/kg in rat was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,4527,,N,1,CHEMBL627831,,,
9271,1,Area under curve in male SD rats was observed after oral administration in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,15662,,N,1,CHEMBL627832,,,
9272,1,Area under curve of compound after iv administration of 20 mg/kg dose in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4413,,N,1,CHEMBL627833,,,
9273,1,Area under curve of compound determined in rat after iv administration at a dose of 10 mg/kg,,BAO_0000218,,Rattus norvegicus,,Expert,3598,,N,1,CHEMBL627834,,,
9274,1,Area under curve of compound from zero time to infinity determined in rat after iv administration at a dose of 10 mg/kg,,BAO_0000218,,Rattus norvegicus,,Expert,3598,,N,1,CHEMBL628004,,,
9275,1,Area under curve at 5 mg/kg po was determined in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5964,,N,1,CHEMBL628005,,,
9276,1,Area under curve in Rat at a oral dose of 5 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,4689,,N,1,CHEMBL628006,,,
9277,1,Area under curve in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,,BAO_0000218,,Rattus norvegicus,,Intermediate,4186,,N,1,CHEMBL628007,,,
9278,1,Area under curve was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,5510,,N,1,CHEMBL625676,,,
9279,1,Area under curve after 10 mg/kg oral administration in rat at 0-24 hr,,BAO_0000218,,Rattus norvegicus,,Intermediate,17858,,N,1,CHEMBL631309,,,
9280,1,Area under curve after intravenous administration at 3 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,17804,,N,1,CHEMBL631310,,,
9281,1,Area under curve after peroral administration at 10 mg/kg in rat for 0-6 h,,BAO_0000218,,Rattus norvegicus,,Intermediate,6106,,N,1,CHEMBL631311,,,
9282,1,Area under curve at 4 hr in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5964,,N,1,CHEMBL631312,,,
9283,1,Area under curve at a dose of 30 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,4026,,N,1,CHEMBL631313,,,
9284,1,Area under curve at the dose of 2 mg/Kg administered perorally in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,4756,,N,1,CHEMBL631314,,,
9285,1,Area under curve at the dose of 5 mg/Kg administered perorally in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,4756,,N,1,CHEMBL631315,,,
9286,1,Area under curve for a 2-mpk po dose in SD rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,5862,,N,1,CHEMBL631316,,,
9287,1,Area under curve in SD rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,5862,,N,1,CHEMBL631317,,,
9288,1,Area under curve in rat after oral administration at 13 mg/kg dose,,BAO_0000218,,Rattus norvegicus,,Intermediate,6644,,N,1,CHEMBL874471,,,
9289,1,Area under curve in rat by po administration at 0-24 hr,,BAO_0000218,,Rattus norvegicus,,Intermediate,5871,,N,1,CHEMBL631318,,,
9290,1,Area under curve in rat plasma,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,5919,,N,1,CHEMBL631319,,1969.0,
9291,1,Area under curve in rat plasma for 0-4 hr after peroral administration at 10 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,5939,,N,1,CHEMBL631320,,,
9292,1,Area under curve in rat plasma for 0-4 hr after peroral administration at 5 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,5939,,N,1,CHEMBL631321,,,
9293,1,Area under curve was evaluated in rat at 3 mg/kg dose administered intravenously,,BAO_0000218,,Rattus norvegicus,,Intermediate,10,,N,1,CHEMBL631322,,,
9294,1,Area under curve was measured from the graph obtained from concentration Vs time after oral administration to male F344 rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,11149,,N,1,CHEMBL631323,,,
9295,1,Area under curve value in rat at a dose of 5 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,5302,,N,1,CHEMBL631324,,,
9296,1,Area under curve was determined after oral administration in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,17796,,N,1,CHEMBL631325,,,
9297,1,Area under curve was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,4890,,N,1,CHEMBL631326,,,
9298,1,Area under curve was determined after peroral administration in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6011,,N,1,CHEMBL631327,,,
9299,1,Area under curve was determined at a dose 30 mpk administered orally.,,BAO_0000218,,Rattus norvegicus,,Intermediate,5375,,N,1,CHEMBL631328,,,
9300,1,Area under curve was determined for compound after intravenous administration in rats at 24 uM/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,17764,,N,1,CHEMBL631329,,,
9301,1,Area under curve was determined for the compound by intravenous administration of 3.4 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4368,,N,1,CHEMBL627217,,,
9302,1,Area under curve was determined in male rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5610,,N,1,CHEMBL626352,,,
9303,1,Area under curve was determined in rat after PO administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,5833,,N,1,CHEMBL626353,,,
9304,1,Area under curve was determined in rat after a 3 mg/kg of oral dose,,BAO_0000218,,Rattus norvegicus,,Intermediate,4257,,N,1,CHEMBL626354,,,
9305,1,Area under curve was determined in rat after oral administration at a concentration 1 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,5937,,N,1,CHEMBL626355,,,
9306,1,Area under curve was determined in rat after oral administration at a concentration 30 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,5932,,N,1,CHEMBL626356,,,
9307,1,Area under curve was determined in rat after oral administration at a concentration 30 mg/kg; NA= Not active,,BAO_0000218,,Rattus norvegicus,,Intermediate,5932,,N,1,CHEMBL626357,,,
9308,1,Liver concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,17411,,N,1,CHEMBL626358,,,
9309,1,Lung concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,17411,,N,1,CHEMBL626359,,,
9310,1,Peak plasma concentration in rat at a dose of 3 mg/kg,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,17771,,N,1,CHEMBL626360,,1969.0,
9311,1,Plasma concentration at 2 hr in rats was evaluated.,,BAO_0000218,,Rattus norvegicus,,Intermediate,1628,,N,1,CHEMBL626361,,,
9312,1,Plasma concentration at 2 hr in rats was evaluated; Not available,,BAO_0000218,,Rattus norvegicus,,Intermediate,1628,,N,1,CHEMBL626362,,,
9313,1,Serum concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,17411,,N,1,CHEMBL626363,,,
9314,1,Tested for concentration in brain after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,4910,,N,1,CHEMBL626970,,,
9315,1,Tested for concentration in brain after 2 hrs of intravenous administration (5 mg/kg) to male rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,4910,,N,1,CHEMBL626971,,,
9316,1,Tested for plasma concentration after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,4910,,N,1,CHEMBL626972,,1969.0,
9317,1,Tested for plasma concentration after 2 hrs of intravenous administration (5 mg/kg) to male rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,4910,,N,1,CHEMBL626973,,1969.0,
9318,1,Tested for plasma concentration in the after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,4910,,N,1,CHEMBL626974,,1969.0,
9319,1,Tested for plasma concentration in the after 2 hrs of intravenous administration (5 mg/kg) to male rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,4910,,N,1,CHEMBL874592,,1969.0,
9320,1,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C,,BAO_0000218,,Rattus norvegicus,,Intermediate,5510,,N,1,CHEMBL626975,,,
9321,1,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Converted to an unknown compound,,BAO_0000218,,Rattus norvegicus,,Intermediate,5510,,N,1,CHEMBL626976,,,
9322,1,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Not determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,5510,,N,1,CHEMBL626977,,,
9323,1,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Not tested,,BAO_0000218,,Rattus norvegicus,,Intermediate,5510,,N,1,CHEMBL626978,,,
9324,1,PK study was carried to determine the relative absorption ranking in rat.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16427,,N,1,CHEMBL626979,,,
9325,1,Maximum plasma concentration in Rat at a oral dose of 5 mg/kg,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,4689,In vivo,N,1,CHEMBL626980,,1969.0,
9326,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.57-0.75 % dose/g",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,11450,,N,1,CHEMBL626981,,178.0,
9327,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.06-0.63 % dose/g",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,11450,,N,1,CHEMBL626982,,178.0,
9328,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.40-0.55 % dose/g",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,11450,,N,1,CHEMBL626983,,178.0,
9329,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.28-0.37% dose/g",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,11450,,N,1,CHEMBL622522,,178.0,
9330,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.56-0.74 % dose/g",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,11450,,N,1,CHEMBL622523,,178.0,
9331,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from % dose/g",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,11450,,N,1,CHEMBL622524,,178.0,
9332,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.20-2.85 % dose/g",Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,11450,,N,1,CHEMBL622525,,955.0,
9333,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.16-1.76 % dose/g",Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,11450,,N,1,CHEMBL622526,,955.0,
9334,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.96-3.72 % dose/g",Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,11450,,N,1,CHEMBL619849,,955.0,
9335,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 2.57-3.59 % dose/g",Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,11450,,N,1,CHEMBL619850,,955.0,
9336,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.36-1.53 % dose/g",Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,11450,,N,1,CHEMBL623864,,955.0,
9337,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.81-1.08 % dose/g",Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,11450,,N,1,CHEMBL623865,,955.0,
9338,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.84-0.98 % dose/g",Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,11450,,N,1,CHEMBL623866,,948.0,
9339,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.06-0.53 % dose/g",Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,11450,,N,1,CHEMBL623867,,948.0,
9340,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.22-1.48 % dose/g",Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,11450,,N,1,CHEMBL877615,,948.0,
9341,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.85-1.13 % dose/g",Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,11450,,N,1,CHEMBL623868,,948.0,
9342,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.55-0.63 % dose/g",Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,11450,,N,1,CHEMBL623869,,948.0,
9343,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.33-0.42 % dose/g",Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,11450,,N,1,CHEMBL623870,,948.0,
9344,1,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL623871,,2048.0,
9345,1,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL623872,,2048.0,
9346,1,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL622129,,2048.0,
9347,1,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL622130,,2048.0,
9348,1,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL622131,,2048.0,
9349,1,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL622132,,2048.0,
9350,1,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL622133,,2048.0,
9351,1,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL622134,,2048.0,
9352,1,Radioactivity distribution in lungs of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL622135,,2048.0,
9353,1,Radioactivity distribution in lungs of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL622136,,2048.0,
9354,1,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL622137,,2385.0,
9355,1,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL622138,,2385.0,
9356,1,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL623017,,2385.0,
9357,1,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL623018,,2385.0,
9358,1,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL623019,,2385.0,
9359,1,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL623020,,2385.0,
9360,1,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min.,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL623021,,2385.0,
9361,1,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL623022,,2385.0,
9362,1,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL623023,,2385.0,
9363,1,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL623024,,2385.0,
9364,1,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL623025,,2385.0,
9365,1,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL620545,,2385.0,
9366,1,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL620546,,2385.0,
9367,1,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL620547,,2385.0,
9368,1,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL620548,,2385.0,
9369,1,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL620549,,2385.0,
9370,1,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL620550,,2385.0,
9371,1,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL620551,,2385.0,
9372,1,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL620552,,2385.0,
9373,1,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL620553,,2385.0,
9374,1,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL620554,,2385.0,
9375,1,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL875845,,2385.0,
9376,1,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL620555,,2385.0,
9377,1,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL620556,,2385.0,
9378,1,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL620557,,2385.0,
9379,1,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL620558,,,
9380,1,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL620559,,,
9381,1,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL622939,,,
9382,1,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL622940,,,
9383,1,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL622941,,,
9384,1,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL622942,,,
9385,1,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL622943,,,
9386,1,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL622944,,,
9387,1,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL622945,,,
9388,1,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL622946,,,
9389,1,Compound was evaluated for terminal half life in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,3341,,N,1,CHEMBL622947,,,
9390,1,Compound was evaluated in vivo in rat for the plasma half-life at a iv dose of 3 mg/kg and oral dose of 10 mg/kg and experiment by using concentration vs time curve,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,3634,In vivo,N,1,CHEMBL622948,,1969.0,
9391,1,Compound was evaluated in vivo in rat for the plasma half-life at a oral dose of 20 mg/kg experiment by using concentration vs time curve,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,3634,In vivo,N,1,CHEMBL622949,,1969.0,
9392,1,Compound was tested for its half life in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4839,,N,1,CHEMBL622950,,,
9393,1,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,Plasma,BAO_0000218,,Macaca mulatta,,Intermediate,5005,In vivo,U,0,CHEMBL622951,,1969.0,
9394,1,Compound was tested for its plasma half life in Sprague Dawley rats,Plasma,BAO_0000366,,Rattus norvegicus,,Intermediate,5005,,U,0,CHEMBL622952,,1969.0,
9395,1,Compound was tested for its plasma half life in Sprague Dawley rats; ND is not determined,Plasma,BAO_0000366,,Rattus norvegicus,,Intermediate,5005,,U,0,CHEMBL622953,,1969.0,
9396,1,Compound was tested for plasma half-life period in rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,1094,,N,1,CHEMBL873818,,1969.0,
9397,1,Elimination half life after i.v. administration of compound in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,5031,In vivo,N,1,CHEMBL622954,,,
9398,1,Elimination half-life after IV dosing at 0.5 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6518,In vivo,N,1,CHEMBL622955,,,
9399,1,Elimination half-life after IV dosing at 1 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6518,In vivo,N,1,CHEMBL875229,,,
9400,1,Elimination half-life after oral administration at a dose of 2 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6518,In vivo,N,1,CHEMBL622956,,,
9401,1,Elimination half-life after oral administration at a dose of 4 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6518,In vivo,N,1,CHEMBL622957,,,
9402,1,Evaluated for half-life after iv administration of 1 mg/kg to male Sprague-Dawley rats in brain; not determined,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,5408,In vivo,N,1,CHEMBL622958,,955.0,
9403,1,Evaluated for half-life after iv administration of 1 mg/kg to male Sprague-Dawley rats in plasma,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,5408,In vivo,N,1,CHEMBL622959,,1969.0,
9404,1,Evaluated for half-life after iv administration of 5 mg/kg to male Sprague-Dawley rats in brain,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,5408,In vivo,N,1,CHEMBL622960,,955.0,
9405,1,Evaluated for half-life after iv administration of 5 mg/kg to male Sprague-Dawley rats in plasma,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,5408,In vivo,N,1,CHEMBL622961,,1969.0,
9406,1,Evaluated for the half life in rat (in vivo),,BAO_0000218,,Rattus norvegicus,,Intermediate,4687,In vivo,N,1,CHEMBL622962,,,
9407,1,Hafl life in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6640,,N,1,CHEMBL622963,,,
9408,1,Hafl life rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6640,,N,1,CHEMBL622964,,,
9409,1,Hafl life rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6641,,N,1,CHEMBL622965,,,
9410,1,Hafl life rat; Not determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,6640,,N,1,CHEMBL622966,,,
9411,1,Hafl life rat; Not determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,6641,,N,1,CHEMBL622967,,,
9412,1,Half life in kidney was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,17411,In vivo,N,1,CHEMBL622968,,2113.0,
9413,1,Half life in liver was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,17411,In vivo,N,1,CHEMBL622969,,2107.0,
9414,1,Half life in lung was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,17411,In vivo,N,1,CHEMBL875327,,2048.0,
9415,1,Half life in rat after 1 mg/kg i.v. administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,6570,In vivo,N,1,CHEMBL628638,,,
9416,1,Half life in rat after 2 mg/kg peroral administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,6570,In vivo,N,1,CHEMBL628639,,,
9417,1,Half life in serum was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,17411,In vivo,N,1,CHEMBL625840,,,
9418,1,Half life of 10 mg/kg oral dose determined in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,4722,In vivo,N,1,CHEMBL625841,,,
9419,1,Half life of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5978,In vivo,N,1,CHEMBL625842,,,
9420,1,Half life of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5978,In vivo,N,1,CHEMBL625843,,,
9421,1,Half life of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5978,In vivo,N,1,CHEMBL625844,,,
9422,1,Half life of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5978,In vivo,N,1,CHEMBL873822,,,
9423,1,Half life of compound (9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5978,In vivo,N,1,CHEMBL625845,,,
9424,1,Half life of compound (9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5978,In vivo,N,1,CHEMBL627059,,,
9425,1,Half life of compound (9.84 mg/kg) after po administration was determined in Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5978,In vivo,N,1,CHEMBL627060,,,
9426,1,Half life of compound (9.92 mg/kg) after iv administration was determined in Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5978,In vivo,N,1,CHEMBL627061,,,
9427,1,Half life of compound at 5 mg/kg after po administration was determined in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4762,In vivo,N,1,CHEMBL627709,,,
9428,1,Half life of compound determined after intravenous administration to rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5327,In vivo,N,1,CHEMBL627710,,,
9429,1,Half life of compound was determined in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4847,,N,1,CHEMBL627711,,,
9430,1,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,17720,In vivo,N,1,CHEMBL627712,,1969.0,
9431,1,Half life determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,4723,In vivo,N,1,CHEMBL627713,,,
9432,1,Half life determined after 3 mg/kg oral administration in potassium oxonate treated rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,4723,In vivo,N,1,CHEMBL627714,,,
9433,1,Half life determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,,BAO_0000218,,Macaca fascicularis,,Intermediate,4256,In vivo,U,0,CHEMBL627889,,,
9434,1,Half life determined in rat by intravenous administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,4256,In vivo,U,0,CHEMBL627890,,,
9435,1,Half life determined in rats after iv administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,4722,In vivo,N,1,CHEMBL627891,,,
9436,1,Half life in rat plasma after administration of 2 mg/kg iv,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,6535,In vivo,N,1,CHEMBL627892,,1969.0,
9437,1,Half life in rat plasma after administration of 2 mg/kg iv,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,6535,In vivo,N,1,CHEMBL627893,,1969.0,
9438,1,Half life in rat plasma was determined,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,1435,,N,1,CHEMBL627894,,1969.0,
9439,1,Half life in rat plasma was determined; NA means not applicable,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,1435,,N,1,CHEMBL627895,,1969.0,
9440,1,Half life in rat was tested,,BAO_0000218,,Rattus norvegicus,,Intermediate,5206,,N,1,CHEMBL627896,,,
9441,1,Half life measured in rat plasma,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,6080,,N,1,CHEMBL627897,,1969.0,
9442,1,Half life recorded in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,4449,,N,1,CHEMBL627898,,,
9443,1,Half life was calculated,,BAO_0000218,,Rattus norvegicus,,Intermediate,6057,,N,1,CHEMBL627899,,,
9444,1,Half life was calculated in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6057,,N,1,CHEMBL873823,,,
9445,1,Half life was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,3747,,N,1,CHEMBL627900,,,
9446,1,Half life after 10 mg/kg oral administration in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,17858,In vivo,N,1,CHEMBL627901,,,
9447,1,Half life after administering orally a dose of 10 mg/kg to a fasting rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,16365,In vivo,N,1,CHEMBL627902,,,
9448,1,Half life after administering orally a dose of 30 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,16365,In vivo,N,1,CHEMBL627903,,,
9449,1,Area under the curve (Concentration) was determined for the compound as AUC with limits 0-8 after i.v. administration in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,5031,,N,1,CHEMBL627904,,,
9450,1,Area under the curve determined under pharmacokinetic behavior of the 10 mg/kg oral dose of compound for 0-6 hours,,BAO_0000218,,Rattus norvegicus,,Intermediate,4722,,N,1,CHEMBL627905,,,
9451,1,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6078,,N,1,CHEMBL627906,,,
9452,1,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6078,,N,1,CHEMBL627907,,,
9453,1,Area under the curve for the compound calculated from 0-6 hr after oral administration at a dose of 10 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,6078,,N,1,CHEMBL876783,,,
9454,1,Area under the curve for the compound calculated from 0-6 hr after oral administration at a dose of 10 mg/kg; activity was not determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,6078,,N,1,CHEMBL627908,,,
9455,1,Area under the curve measured after intravenous bolus administration of 50 mg/kg of compound to rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,17065,,N,1,CHEMBL627909,,,
9456,1,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,1353,,N,1,CHEMBL627910,,,
9457,1,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-1),,BAO_0000218,,Rattus norvegicus,,Intermediate,1353,,N,1,CHEMBL627911,,,
9458,1,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-2),,BAO_0000218,,Rattus norvegicus,,Intermediate,1353,,N,1,CHEMBL627912,,,
9459,1,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-5),,BAO_0000218,,Rattus norvegicus,,Intermediate,1353,,N,1,CHEMBL627913,,,
9460,1,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(5-10),,BAO_0000218,,Rattus norvegicus,,Intermediate,1353,,N,1,CHEMBL627914,,,
9461,1,Area under the curve was evaluated after 10 uM/kg of intra arterial administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,16423,,N,1,CHEMBL627915,,,
9462,1,Area under the curve was evaluated after 20 uM/kg of peroral administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,16423,,N,1,CHEMBL627916,,,
9463,1,Area under the curve was measured in rat after an iv dose of 1 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,6062,,N,1,CHEMBL627917,,,
9464,1,Area under the curve was calculated for the compound at a single intravenous administration of 20 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6056,,N,1,CHEMBL627918,,,
9465,1,Area under the curve was determined by administering the compound at a dose of 1 mg/kg intravenously in male wistar rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5182,,N,1,CHEMBL627919,,,
9466,1,Area under the curve was evaluated at an intravenous dose of 3 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,6410,,N,1,CHEMBL627920,,,
9467,1,Area under the curve was evaluated at an oral dose of 30 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,6410,,N,1,CHEMBL627921,,,
9468,1,Area under the effect time curves from time 0-24 hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,4723,,N,1,CHEMBL627922,,,
9469,1,Area under the effect time curves from time 0-24 hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,4723,,N,1,CHEMBL876784,,,
9470,1,Area under the effect time curves from time 0-6 hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,4723,,N,1,CHEMBL627923,,,
9471,1,Area under the effect time curves from time 0-6 hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,4723,,N,1,CHEMBL626208,,,
9472,1,Area under the effect time curves from time 0-infinity hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,4723,,N,1,CHEMBL626209,,,
9473,1,Area under the effect time curves from time 0-infinity hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,4723,,N,1,CHEMBL626210,,,
9474,1,Area under the plasma concentration curve was evaluated in vivo in rat at a dose of 5 mg/kg by oral administration,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,2463,,N,1,CHEMBL627994,,1969.0,
9475,1,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4709,,N,1,CHEMBL627995,,,
9476,1,Blood level after a 10 mg/kg oral dose in rat expressed as AUC was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,4075,,N,1,CHEMBL627996,,,
9477,1,Compound at a dose 10 mg/kg was administered orally to rat and the pharmacokinetic parameter area under curve (AUC) was measured,,BAO_0000218,,Rattus norvegicus,,Intermediate,5394,,N,1,CHEMBL627997,,,
9478,1,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female wistar rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,2661,,N,1,CHEMBL627998,,,
9479,1,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to male wistar rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,2661,,N,1,CHEMBL628640,,,
9480,1,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female wistar rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,2661,,N,1,CHEMBL628641,,,
9481,1,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to male wistar rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,2661,,N,1,CHEMBL628642,,,
9482,1,Compound was evaluated for area under the curve expressed as (h*ug/ml),,BAO_0000218,,Rattus norvegicus,,Intermediate,17791,,N,1,CHEMBL628643,,,
9483,1,Compound was tested for area under curve in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,2591,,N,1,CHEMBL628644,,,
9484,1,Concentration in rat plasma after 5 mg/kg oral gavage for 8 hours,,BAO_0000218,,Rattus norvegicus,,Intermediate,6567,,N,1,CHEMBL628645,,,
9485,1,Dose-normalized AUC was determined by po administration (10 mg/kg) in fasted male Sprague-Dawley rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,6211,,N,1,CHEMBL628646,,,
9486,1,Dose-normalized AUC was determined in rat after peroral administration (2 mg/kg),,BAO_0000218,,Rattus norvegicus,,Intermediate,5529,,N,1,CHEMBL628647,,,
9487,1,Evaluated for AUC after iv administration of 1 mg/kg to male Sprague-Dawley rats in brain; not determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,5408,,N,1,CHEMBL628648,,,
9488,1,Evaluated for AUC after iv administration of 1 mg/kg to male Sprague-Dawley rats in plasma,,BAO_0000218,,Rattus norvegicus,,Intermediate,5408,,N,1,CHEMBL625358,,,
9489,1,Evaluated for AUC after iv administration of 5 mg/kg to male Sprague-Dawley rats in brain,,BAO_0000218,,Rattus norvegicus,,Intermediate,5408,,N,1,CHEMBL625359,,,
9490,1,Evaluated for AUC after iv administration of 5 mg/kg to male Sprague-Dawley rats in plasma,,BAO_0000218,,Rattus norvegicus,,Intermediate,5408,,N,1,CHEMBL625360,,,
9491,1,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg ( 0-8 hr ),,BAO_0000218,,Rattus norvegicus,,Intermediate,429,,N,1,CHEMBL625361,,,
9492,1,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg (0-8 hr ),,BAO_0000218,,Rattus norvegicus,,Intermediate,429,,N,1,CHEMBL625362,,,
9493,1,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg (0-8 hr),,BAO_0000218,,Rattus norvegicus,,Intermediate,429,,N,1,CHEMBL625363,,,
9494,1,Hepatic portal AUC was determined by pharmacokinetic study conducted in portal vein cannulated rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,4796,,N,1,CHEMBL625364,,,
9495,1,In vivo Area under curve (AUC) was determined after intravenous administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5974,,N,1,CHEMBL625365,,,
9496,1,In vivo Area under curve (AUC) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5974,,N,1,CHEMBL625366,,,
9497,1,In vivo Area under curve (AUC) was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5974,,N,1,CHEMBL625367,,,
9498,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.98-2.56 % dose/g",Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,11450,,N,1,CHEMBL625368,,2113.0,
9499,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.15-1.43 % dose/g",Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,11450,,N,1,CHEMBL625369,,2113.0,
9500,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 3.43-4.52 % dose/g",Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,11450,,N,1,CHEMBL625370,,2113.0,
9501,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 2.12-3.14 % dose/g",Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,11450,,N,1,CHEMBL625371,,2113.0,
9502,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.40-1.60 % dose/g",Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,11450,,N,1,CHEMBL625372,,2113.0,
9503,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.74-0.85 % dose/g",Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,11450,,N,1,CHEMBL625373,,2113.0,
9504,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.31-1.45 % dose/g",Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,11450,,N,1,CHEMBL625374,,2107.0,
9505,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.08-0.90 % dose/g",Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,11450,,N,1,CHEMBL877593,,2107.0,
9506,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.02-2.78 % dose/g",Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,11450,,N,1,CHEMBL625375,,2107.0,
9507,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 1.64-2.38 % dose/g",Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,11450,,N,1,CHEMBL625376,,2107.0,
9508,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.95-1.07 % dose/g",Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,11450,,N,1,CHEMBL621973,,2107.0,
9509,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.61-0.81 % dose/g",Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,11450,,N,1,CHEMBL621974,,2107.0,
9510,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 5.01-7.13 % dose/g",Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,11450,,N,1,CHEMBL621975,,2048.0,
9511,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.51-3.71 % dose/g",Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,11450,,N,1,CHEMBL622166,,2048.0,
9512,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 10.84-13.77 % dose/g",Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,11450,,N,1,CHEMBL622167,,2048.0,
9513,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 5.92-8.51% dose/g",Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,11450,,N,1,CHEMBL622168,,2048.0,
9514,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 3.37-3.94 % dose/g",Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,11450,,N,1,CHEMBL622169,,2048.0,
9515,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 1.87-2.12 % dose/g",Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,11450,,N,1,CHEMBL622170,,2048.0,
9516,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 37.97-75.23 % dose/g",Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,11450,,N,1,CHEMBL622171,,2046.0,
9517,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 5.03-36.88 % dose/g",Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,11450,,N,1,CHEMBL622172,,2046.0,
9518,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 13.20-17.31 % dose/g",Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,11450,,N,1,CHEMBL622173,,2046.0,
9519,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 7.87-16.51 % dose/g",Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,11450,,N,1,CHEMBL622174,,2046.0,
9520,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 81.37-166.09 % dose/g",Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,11450,,N,1,CHEMBL622175,,2046.0,
9521,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 31.90-39.98 % dose/g",Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,11450,,N,1,CHEMBL622176,,2046.0,
9522,1,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.41-0.83 % dose/g",Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,11450,,N,1,CHEMBL622177,,2046.0,
9523,1,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.05-0.38 % dose/g",Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,11450,,N,1,CHEMBL622178,,2046.0,
9524,1,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.16-0.20 % dose/g",Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,11450,,N,1,CHEMBL622179,,2046.0,
9525,1,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.08-0.17 % dose/g",Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,11450,,N,1,CHEMBL622180,,2046.0,
9526,1,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL622181,,,
9527,1,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL622182,,,
9528,1,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL622183,,,
9529,1,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL622184,,,
9530,1,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL622185,,,
9531,1,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL622186,,,
9532,1,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL622187,,,
9533,1,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL625002,,,
9534,1,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min,,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL622090,,,
9535,1,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL622091,,,
9536,1,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL622092,,,
9537,1,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL622093,,,
9538,1,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL622094,,,
9539,1,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL622095,,,
9540,1,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL622264,,,
9541,1,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL622265,,2106.0,
9542,1,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL622266,,2106.0,
9543,1,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL622267,,2106.0,
9544,1,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL622268,,2106.0,
9545,1,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL622269,,2106.0,
9546,1,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL625071,,2106.0,
9547,1,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL621621,,2106.0,
9548,1,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL621622,,2106.0,
9549,1,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL621623,,2106.0,
9550,1,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL621624,,2106.0,
9551,1,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL621625,,2106.0,
9552,1,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL621626,,2106.0,
9553,1,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL621627,,2106.0,
9554,1,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL621628,,2106.0,
9555,1,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL875328,,2106.0,
9556,1,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL621629,,2106.0,
9557,1,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL621630,,2106.0,
9558,1,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL621631,,2106.0,
9559,1,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL621632,,2106.0,
9560,1,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL621633,,2106.0,
9561,1,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL621634,,2106.0,
9562,1,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL621635,,2106.0,
9563,1,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL621636,,2106.0,
9564,1,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL621637,,2106.0,
9565,1,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL621638,,2106.0,
9566,1,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL618883,,,
9567,1,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL618884,,,
9568,1,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL628627,,,
9569,1,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL628628,,,
9570,1,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL628629,,,
9571,1,Half life after administering orally a dose of 3 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,16365,In vivo,N,1,CHEMBL628630,,,
9572,1,Half life after administering orally a dose of 3 mg/kg to a fasting rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,16365,In vivo,N,1,CHEMBL628631,,,
9573,1,Half life after administering intravenously a dose of 1 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,16365,In vivo,N,1,CHEMBL628632,,,
9574,1,Half life after oral dosing in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,526,In vivo,N,1,CHEMBL628633,,,
9575,1,Half life after the administered orally a dose of 1 mg/kg to a fasting rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,16365,In vivo,N,1,CHEMBL628634,,,
9576,1,Half life by intravenous administration of 3.4 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4368,In vivo,N,1,CHEMBL627789,,,
9577,1,Half life in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,3371,,N,1,CHEMBL627790,,,
9578,1,Half life in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6448,,N,1,CHEMBL627791,,,
9579,1,Half life in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6453,,N,1,CHEMBL627792,,,
9580,1,Half life in rat after intravenous administration of the compound,,BAO_0000218,,Rattus norvegicus,,Intermediate,4353,In vivo,N,1,CHEMBL627793,,,
9581,1,Half life in rat after intravenous administration of the compound; nf:unable to estimate plasma elimination half life,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,4353,In vivo,N,1,CHEMBL627794,,1969.0,
9582,1,Half life in rat after po administration of the compound,,BAO_0000218,,Rattus norvegicus,,Intermediate,4353,In vivo,N,1,CHEMBL627795,,,
9583,1,Half life in rat after po administration of the compound; ND means Not determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,4353,In vivo,N,1,CHEMBL627796,,,
9584,1,Half life in rat after po administration of the compound; nf: unable to estimate plasma elimination half life,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,4353,In vivo,N,1,CHEMBL875335,,1969.0,
9585,1,Half life in rat after po administration of the compound; nf:unable to estimate plasma elimination half life,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,4353,In vivo,N,1,CHEMBL627797,,1969.0,
9586,1,Half life in rat i.v.,,BAO_0000218,,Rattus norvegicus,,Intermediate,5789,In vivo,N,1,CHEMBL627798,,,
9587,1,Half life in rat i.v. at 2 mg/kg concentration,,BAO_0000218,,Rattus norvegicus,,Intermediate,17686,In vivo,N,1,CHEMBL627799,,,
9588,1,Half life in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,6495,,N,1,CHEMBL627800,,,
9589,1,Half life in rats after intravenous administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,484,In vivo,N,1,CHEMBL627801,,,
9590,1,Half life in rats at the dose of 1.0 mpk by i.v. administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,6467,In vivo,N,1,CHEMBL627802,,,
9591,1,Half life in rat,,BAO_0000218,,Rattus norvegicus,,Expert,6642,,N,1,CHEMBL627803,,,
9592,1,Half life was evaluated after intravenous administration to rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,16367,In vivo,N,1,CHEMBL873820,,,
9593,1,Half life was evaluated by addition of 2 mM of 2-mercaptoethanol for inactivation of semicarbazide-sensitive amine oxidase (SSAO),,BAO_0000218,,Rattus norvegicus,,Intermediate,1369,,N,1,CHEMBL627804,,,
9594,1,Half life was evaluated in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5472,,N,1,CHEMBL627805,,,
9595,1,Half life was evaluated in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6049,,N,1,CHEMBL627806,,,
9596,1,Half life was evaluated in rat; Not tested,,BAO_0000218,,Rattus norvegicus,,Intermediate,5472,,N,1,CHEMBL627107,,,
9597,1,Half life was evaluated when a dose of 1 mg/kg was administered intravenously to rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,16366,In vivo,N,1,CHEMBL627108,,,
9598,1,Half life was measured as time taken to reach the half of the initial dose in air pouch exudate after oral administration to male F344 rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,11149,In vivo,N,1,CHEMBL627109,,,
9599,1,Half life was measured as time taken to reach the half of the initial dose in the blood after oral administration to male F344 rats,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,11149,In vivo,N,1,CHEMBL627110,,178.0,
9600,1,Half life was measured in monkey at dose of 10 mg/kg by po administration,,BAO_0000218,,Primates,,Intermediate,2891,In vivo,U,0,CHEMBL627111,,,
9601,1,Half life was measured in monkey at dose of 10 mg/kg by po administration,,BAO_0000218,,Primates,,Intermediate,2891,In vivo,U,0,CHEMBL627112,,,
9602,1,Half life was measured in rat at dose of 30 mg/kg by iv administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,2891,In vivo,U,0,CHEMBL627113,,,
9603,1,Half life was measured in rat at dose of 30 mg/kg by po administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,2891,In vivo,U,0,CHEMBL627114,,,
9604,1,Half life (t1/2) was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,4026,,N,1,CHEMBL627115,,,
9605,1,Half life period at a dose of 10 uM/kg in rat was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,4527,,N,1,CHEMBL627116,,,
9606,1,Half life period by oral administration at a dose of 100 uM/kg in rat was determined; ND is not determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,4527,In vivo,N,1,CHEMBL627117,,,
9607,1,Half life period was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,5503,,N,1,CHEMBL627118,,,
9608,1,Half life period after intravenous administration at 20 mpk in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,4426,In vivo,N,1,CHEMBL627119,,,
9609,1,Half life period after intravenous administration at 20 mpk in rats; Not performed.,,BAO_0000218,,Rattus norvegicus,,Intermediate,4426,In vivo,N,1,CHEMBL627120,,,
9610,1,Half life period after intravenous administration in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6109,In vivo,N,1,CHEMBL626922,,,
9611,1,Half life period as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,5654,In vivo,N,1,CHEMBL626923,,,
9612,1,Half life period as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,5654,In vivo,N,1,CHEMBL626924,,,
9613,1,Half life period in 80% rat plasma at 37 degree Centigrade,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,4755,,N,1,CHEMBL626925,,1969.0,
9614,1,Half life period in SD rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,5862,,N,1,CHEMBL626926,,,
9615,1,Half life period in human plasma at 25 degree Celsius temperature (pH 7.4),Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,1515,,N,1,CHEMBL626927,,1969.0,
9616,1,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4),Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,1515,,N,1,CHEMBL626928,,1969.0,
9617,1,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,1515,,N,1,CHEMBL626929,,1969.0,
9618,1,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,1515,,N,1,CHEMBL626930,,1969.0,
9619,1,Half life period in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5960,,N,1,CHEMBL626931,,,
9620,1,Half life period in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6103,,N,1,CHEMBL626932,,,
9621,1,Half life period in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6317,,N,1,CHEMBL626933,,,
9622,1,Half life period in rat after oral administration at 10.5 mg/kg dose,,BAO_0000218,,Rattus norvegicus,,Intermediate,6644,In vivo,N,1,CHEMBL873826,,,
9623,1,Half life period in rat after oral administration at 11.2 mg/kg dose,,BAO_0000218,,Rattus norvegicus,,Intermediate,6644,In vivo,N,1,CHEMBL626934,,,
9624,1,Half life period in rat after oral administration at 13 mg/kg dose,,BAO_0000218,,Rattus norvegicus,,Intermediate,6644,In vivo,N,1,CHEMBL626935,,,
9625,1,Half life period in rat after oral administration at 9.7 mg/kg dose,,BAO_0000218,,Rattus norvegicus,,Intermediate,6644,In vivo,N,1,CHEMBL626936,,,
9626,1,In vivo Area under curve (AUC) was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5974,,N,1,CHEMBL626937,,,
9627,1,In vivo area under curve in rat plasma exposure after oral administration 50 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,6295,,N,1,CHEMBL625906,,,
9628,1,In vivo area under curve in rat plasma exposure after oral administration 50 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,6296,,N,1,CHEMBL625907,,,
9629,1,PK study was carried to determine AUC (area under curve) value in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,16427,,N,1,CHEMBL625908,,,
9630,1,Pharmacokinetic parameter AUC after intravenous administration to rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,16367,,N,1,CHEMBL625909,,,
9631,1,Pharmacokinetic parameter AUC after oral administration to rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,16367,,N,1,CHEMBL625910,,,
9632,1,Pharmacokinetic parameter AUC was evaluated intravenous administration of 3 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,16365,,N,1,CHEMBL625911,,,
9633,1,Pharmacokinetic parameter AUC was evaluated when a dose of 10 mg/kg is administered orally to a fasting rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,16365,,N,1,CHEMBL625912,,,
9634,1,Pharmacokinetic parameter AUC was evaluated when a dose of 1 mg/kg is administered orally to a fasting rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,16365,,N,1,CHEMBL626538,,,
9635,1,Pharmacokinetic parameter AUC was evaluated when a dose of 30 mg/kg is administered orally,,BAO_0000218,,Rattus norvegicus,,Intermediate,16365,,N,1,CHEMBL876794,,,
9636,1,Pharmacokinetic parameter AUC was evaluated when a dose of 3 mg/kg is administered orally,,BAO_0000218,,Rattus norvegicus,,Intermediate,16365,,N,1,CHEMBL626539,,,
9637,1,Pharmacokinetic parameter AUC was evaluated when a dose of 3 mg/kg is administered orally to a fasting rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,16365,,N,1,CHEMBL626540,,,
9638,1,Pharmacokinetic parameter area under curve (AUC) was measured after administration into monkey at 3 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,5394,,N,1,CHEMBL626541,,,
9639,1,Pharmacokinetic parameter area under curve (AUC) was measured after administration into rat at 10 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,5394,,N,1,CHEMBL626542,,,
9640,1,Pharmacokinetic parameter area under curve was determined at 10 mg/kg po dose in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,2792,,N,1,CHEMBL626543,,,
9641,1,Pharmacokinetic parameter area under curve was determined at 2 mg/kg i.v. dose in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,2792,,N,1,CHEMBL626544,,,
9642,1,Pharmacokinetic parameter area under curve was determined at 3 mg/kg po dose in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,2792,,N,1,CHEMBL626545,,,
9643,1,Pharmacokinetic parameter area under curve was determined at 5 mg/kg i.v. dose in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,2792,,N,1,CHEMBL626546,,,
9644,1,Pharmacokinetic parameter area under curve was reported,,BAO_0000218,,Rattus norvegicus,,Intermediate,5334,,N,1,CHEMBL626547,,,
9645,1,Pharmacokinetic property (AUC) in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4408,,N,1,CHEMBL626548,,,
9646,1,Pharmacokinetic property (AUC) was measured in rat at the dose of 0.32 mg/kg p.o.,,BAO_0000218,,Rattus norvegicus,,Intermediate,5983,,N,1,CHEMBL626549,,,
9647,1,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in rat (0 to 6 hr) p.o.,,BAO_0000218,,Rattus norvegicus,,Intermediate,4397,,N,1,CHEMBL626550,,,
9648,1,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in rat (0 to 6 hr) p.o.; Not tested,,BAO_0000218,,Rattus norvegicus,,Intermediate,4397,,N,1,CHEMBL626551,,,
9649,1,Pharmacokinetic property was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,5491,,N,1,CHEMBL623777,,,
9650,1,Pharmacokinetic property when administered intravenously in rat at 2 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,5491,,N,1,CHEMBL623778,,,
9651,1,Pharmacokinetic property when administered intravenously in rat at 2 mg/kg; Not tested,,BAO_0000218,,Rattus norvegicus,,Intermediate,5491,,N,1,CHEMBL623779,,,
9652,1,Pharmacokinetic property( plasma concentration) was determined upon 10 mg/kg in 1% methylcellulose peroral administration in rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,4199,,N,1,CHEMBL623780,,1969.0,
9653,1,Pharmacokinetic property( plasma concentration) was determined upon 2 mg/kg in 1% methylcellulose peroral administration in rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,4199,,N,1,CHEMBL622015,,1969.0,
9654,1,Pharmacokinetic property( plasma concentration) was determined upon 3 mg/kg in 1% methylcellulose peroral administration in rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,4199,,N,1,CHEMBL622016,,1969.0,
9655,1,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 0.25 h",,BAO_0000218,,Rattus norvegicus,,Intermediate,5173,,N,1,CHEMBL622017,,,
9656,1,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 0.5 h",,BAO_0000218,,Rattus norvegicus,,Intermediate,5173,,N,1,CHEMBL622018,,,
9657,1,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 1 h",,BAO_0000218,,Rattus norvegicus,,Intermediate,5173,,N,1,CHEMBL622019,,,
9658,1,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 2 h",,BAO_0000218,,Rattus norvegicus,,Intermediate,5173,,N,1,CHEMBL622020,,,
9659,1,Pharmacokinetic parameter AUC was determined when a dose of 1 mg/kg was administered intravenously,,BAO_0000218,,Rattus norvegicus,,Intermediate,16366,,N,1,CHEMBL622021,,,
9660,1,Pharmacokinetic parameter AUC was determined when a dose of 1 mg/kg was administered orally,,BAO_0000218,,Rattus norvegicus,,Intermediate,16366,,N,1,CHEMBL622022,,,
9661,1,Plasma concentration expressed as area under curve after intravenous administration was determined in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5327,,N,1,CHEMBL622023,,,
9662,1,Plasma concentration for the compound was determined in rats at 50 mg/kg dose,,BAO_0000218,,Rattus norvegicus,,Intermediate,6681,,N,1,CHEMBL622024,,,
9663,1,Plasma concentration was calculated in rats at a peroral dose of 5 mg/kg of solution (formulation of compound),,BAO_0000218,,Rattus norvegicus,,Intermediate,12873,,N,1,CHEMBL622693,,,
9664,1,Plasma concentration was calculated in rats at a peroral dose of 5 mg/kg of suspension (formulation of compound),,BAO_0000218,,Rattus norvegicus,,Intermediate,12873,,N,1,CHEMBL622694,,,
9665,1,"Plasma concentration was determined in rats at 10 mg/kg, p.o. dose",,BAO_0000218,,Rattus norvegicus,,Intermediate,6685,,N,1,CHEMBL622695,,,
9666,1,"Plasma concentration was determined in rats at 20 mg/kg, i.p. dose",,BAO_0000218,,Rattus norvegicus,,Intermediate,6685,,N,1,CHEMBL622696,,,
9667,1,"Plasma concentration was determined in rats at 2 mg/kg, i.v. dose",,BAO_0000218,,Rattus norvegicus,,Intermediate,6685,,N,1,CHEMBL622697,,,
9668,1,"Reduction in area under curve was determined in fa/fa Zucker rats by oral glucose tolerance test following a single i.p. dose (20 mg/kg, 30 min pre-treatment)",,BAO_0000218,,Rattus norvegicus,,Intermediate,6619,,N,1,CHEMBL622874,,,
9669,1,"Reduction in area under curve was determined in fa/fa Zucker rats by oral glucose tolerance test following a single i.p. dose (30 mg/kg, 30 min pre-treatment)",,BAO_0000218,,Rattus norvegicus,,Intermediate,6619,,N,1,CHEMBL622875,,,
9670,1,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg; Not significant,,BAO_0000218,,Rattus norvegicus,,Intermediate,10363,,N,1,CHEMBL622876,,,
9671,1,Systemic AUC was determined by pharmacokinetic study conducted in portal vein cannulated rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,4796,,N,1,CHEMBL622877,,,
9672,1,Tested for concentration in brain after intravenous administration (4.7 mg/kg) to male rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,4910,,N,1,CHEMBL622878,,,
9673,1,Tested for plasma concentration after intravenous administration (4.7 mg/kg) to male rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,4910,,N,1,CHEMBL622879,,1969.0,
9674,1,Tested for the pharmacokinetic parameter in rat and expressed as area under curve,,BAO_0000218,,Rattus norvegicus,,Intermediate,4839,,N,1,CHEMBL877602,,,
9675,1,"The AUC(0-infinitive) value in female wistar rat at 100 mg/kg, p.o. dose",,BAO_0000218,,Rattus norvegicus,,Intermediate,15078,,N,1,CHEMBL622880,,,
9676,1,"The AUC(0-infinitive) value in male wistar rat at 100 mg/kg, p.o. dose",,BAO_0000218,,Rattus norvegicus,,Intermediate,15078,,N,1,CHEMBL622881,,,
9677,1,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose",,BAO_0000218,,Rattus norvegicus,,Intermediate,15078,,N,1,CHEMBL622882,,,
9678,1,"The AUC(0-t)value in male wistar rat at 100 mg/kg, p.o. dose",,BAO_0000218,,Rattus norvegicus,,Intermediate,15078,,N,1,CHEMBL622883,,,
9679,1,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.16-2.39% dose/g",Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,11450,,N,1,CHEMBL622884,,2046.0,
9680,1,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.99-1.40 % dose/g",Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,11450,,N,1,CHEMBL622885,,2046.0,
9681,1,Antidiuretic activity expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,,BAO_0000218,,Rattus norvegicus,,Intermediate,8151,,N,1,CHEMBL622886,,,
9682,1,Antidiuretic activity expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,8151,,N,1,CHEMBL622887,,,
9683,1,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,8151,,N,1,CHEMBL622888,,1088.0,
9684,1,"Biodistribution in Sprague-Dawley rat blood 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,In vivo,N,1,CHEMBL622889,,178.0,
9685,1,"Biodistribution in Sprague-Dawley rat blood 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,In vivo,N,1,CHEMBL622890,,178.0,
9686,1,"Biodistribution in Sprague-Dawley rat blood 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,In vivo,N,1,CHEMBL622891,,178.0,
9687,1,"Biodistribution in Sprague-Dawley rat blood 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,In vivo,N,1,CHEMBL877603,,178.0,
9688,1,"Biodistribution in Sprague-Dawley rat brain 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,In vivo,N,1,CHEMBL622892,,955.0,
9689,1,"Biodistribution in Sprague-Dawley rat brain 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,In vivo,N,1,CHEMBL622893,,955.0,
9690,1,"Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,In vivo,N,1,CHEMBL622894,,955.0,
9691,1,"Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,In vivo,N,1,CHEMBL622895,,955.0,
9692,1,Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration.,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,In vivo,N,1,CHEMBL622896,,955.0,
9693,1,"Biodistribution in Sprague-Dawley rat heart 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,In vivo,N,1,CHEMBL622897,,948.0,
9694,1,"Biodistribution in Sprague-Dawley rat heart 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,In vivo,N,1,CHEMBL622898,,948.0,
9695,1,"Biodistribution in Sprague-Dawley rat heart 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,In vivo,N,1,CHEMBL622899,,948.0,
9696,1,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,In vivo,N,1,CHEMBL622900,,2113.0,
9697,1,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,In vivo,N,1,CHEMBL624114,,2113.0,
9698,1,"Biodistribution in Sprague-Dawley rat kidneys(2) 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,In vivo,N,1,CHEMBL624115,,2113.0,
9699,1,"Biodistribution in Sprague-Dawley rat kidneys(2) 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,In vivo,N,1,CHEMBL624116,,2113.0,
9700,1,"Biodistribution in Sprague-Dawley rat liver 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,In vivo,N,1,CHEMBL624117,,2107.0,
9701,1,"Biodistribution in Sprague-Dawley rat liver 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,In vivo,N,1,CHEMBL624118,,2107.0,
9702,1,"Biodistribution in Sprague-Dawley rat liver 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,In vivo,N,1,CHEMBL624119,,2107.0,
9703,1,"Biodistribution in Sprague-Dawley rat liver 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,In vivo,N,1,CHEMBL624120,,2107.0,
9704,1,"Biodistribution in Sprague-Dawley rat lungs(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,In vivo,N,1,CHEMBL624121,,2048.0,
9705,1,"Biodistribution in Sprague-Dawley rat lungs(2) 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,In vivo,N,1,CHEMBL624122,,2048.0,
9706,1,"Biodistribution in Sprague-Dawley rat lungs(2) 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,In vivo,N,1,CHEMBL624123,,2048.0,
9707,1,"Biodistribution in Sprague-Dawley rat lungs(2) 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,In vivo,N,1,CHEMBL624124,,2048.0,
9708,1,"Biodistribution in Sprague-Dawley rat muscle 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,In vivo,N,1,CHEMBL624125,,2385.0,
9709,1,"Biodistribution in Sprague-Dawley rat muscle 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,In vivo,N,1,CHEMBL624126,,2385.0,
9710,1,"Biodistribution in Sprague-Dawley rat muscle 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,In vivo,N,1,CHEMBL624127,,2385.0,
9711,1,"Biodistribution in Sprague-Dawley rat muscle 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,In vivo,N,1,CHEMBL624128,,2385.0,
9712,1,"Biodistribution in Sprague-Dawley rat skin 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Zone of skin,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,In vivo,N,1,CHEMBL624129,,14.0,
9713,1,"Biodistribution in Sprague-Dawley rat skin 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Zone of skin,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,In vivo,N,1,CHEMBL624130,,14.0,
9714,1,"Biodistribution in Sprague-Dawley rat skin 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Zone of skin,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,In vivo,N,1,CHEMBL622340,,14.0,
9715,1,"Biodistribution in Sprague-Dawley rat skin 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Zone of skin,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,In vivo,N,1,CHEMBL622341,,14.0,
9716,1,"Biodistribution in Sprague-Dawley rat small intestine 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intestine,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,In vivo,N,1,CHEMBL622342,,160.0,
9717,1,"Biodistribution in Sprague-Dawley rat small intestine 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intestine,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,In vivo,N,1,CHEMBL622343,,160.0,
9718,1,"Biodistribution in Sprague-Dawley rat small intestine 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intestine,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,In vivo,N,1,CHEMBL622344,,160.0,
9719,1,"Biodistribution in Sprague-Dawley rat small intestine 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intestine,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,In vivo,N,1,CHEMBL622345,,160.0,
9720,1,"Biodistribution in Sprague-Dawley rat spleen 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,In vivo,N,1,CHEMBL622346,,2106.0,
9721,1,"Biodistribution in Sprague-Dawley rat spleen 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,In vivo,N,1,CHEMBL622347,,2106.0,
9722,1,"Biodistribution in Sprague-Dawley rat spleen 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,In vivo,N,1,CHEMBL622348,,2106.0,
9723,1,"Biodistribution in Sprague-Dawley rat spleen 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,In vivo,N,1,CHEMBL622349,,2106.0,
9724,1,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL622350,,,
9725,1,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL622351,,,
9726,1,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL622352,,,
9727,1,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL622353,,,
9728,1,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL622354,,,
9729,1,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL622355,,,
9730,1,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL622356,,,
9731,1,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL622357,,,
9732,1,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL622358,,,
9733,1,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL622359,,,
9734,1,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL874393,,,
9735,1,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL622872,,,
9736,1,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL622873,,,
9737,1,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL623047,,,
9738,1,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL623048,,,
9739,1,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL623049,,,
9740,1,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL623050,,,
9741,1,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL623051,,,
9742,1,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL623052,,,
9743,1,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL626343,,,
9744,1,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL626344,,,
9745,1,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL626345,,,
9746,1,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL626346,,,
9747,1,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL626347,,,
9748,1,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL626348,,,
9749,1,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,N,1,CHEMBL626349,,,
9750,1,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL626350,,,
9751,1,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL626351,,,
9752,1,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL627650,,,
9753,1,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL627651,,,
9754,1,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL627652,,,
9755,1,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,N,1,CHEMBL627653,,,
9756,1,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr blocked time interval,,BAO_0000218,,Rattus norvegicus,,Intermediate,13091,,N,1,CHEMBL627654,,,
9757,1,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr low time interval,,BAO_0000218,,Rattus norvegicus,,Intermediate,13091,,N,1,CHEMBL627835,,,
9758,1,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr time interval,,BAO_0000218,,Rattus norvegicus,,Intermediate,13091,,N,1,CHEMBL627836,,,
9759,1,Tissue biodistribution into estrogen-primed immature female rat blood at 3 hr time interval,,BAO_0000218,,Rattus norvegicus,,Intermediate,13091,,N,1,CHEMBL627837,,,
9760,1,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr blocked time interval,,BAO_0000218,,Rattus norvegicus,,Intermediate,13091,,N,1,CHEMBL627838,,,
9761,1,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr low time interval,,BAO_0000218,,Rattus norvegicus,,Intermediate,13091,,N,1,CHEMBL875338,,,
9762,1,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr time interval,,BAO_0000218,,Rattus norvegicus,,Intermediate,13091,,N,1,CHEMBL627839,,,
9763,1,Tissue biodistribution into estrogen-primed immature female rat bone at 3 hr time interval,,BAO_0000218,,Rattus norvegicus,,Intermediate,13091,,N,1,CHEMBL627840,,,
9764,1,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr blocked time interval,,BAO_0000218,,Rattus norvegicus,,Intermediate,13091,,N,1,CHEMBL627841,,,
9765,1,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr low time interval,,BAO_0000218,,Rattus norvegicus,,Intermediate,13091,,N,1,CHEMBL627842,,,
9766,1,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr time interval,,BAO_0000218,,Rattus norvegicus,,Intermediate,13091,,N,1,CHEMBL627843,,,
9767,1,Tissue biodistribution into estrogen-primed immature female rat brain at 3 hr time interval,,BAO_0000218,,Rattus norvegicus,,Intermediate,13091,,N,1,CHEMBL627844,,,
9768,1,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr blocked time interval,,BAO_0000218,,Rattus norvegicus,,Intermediate,13091,,N,1,CHEMBL627845,,,
9769,1,Half life period in rat by iv administration at a dose of 3 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,5874,In vivo,N,1,CHEMBL627846,,,
9770,1,Half life period in rat plasma at 25 degree Centigrade temperature (pH 7.4),Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,1515,,N,1,CHEMBL627847,,1969.0,
9771,1,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4),Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,1515,,N,1,CHEMBL873821,,1969.0,
9772,1,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,1515,,N,1,CHEMBL626079,,1969.0,
9773,1,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,1515,,N,1,CHEMBL626080,,1969.0,
9774,1,Half life period was evaluated in rat plasma,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,5491,,N,1,CHEMBL626081,,1969.0,
9775,1,Half life period was evaluated in rat plasma; Not tested,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,5491,,N,1,CHEMBL875344,,1969.0,
9776,1,Half life period was evaluated in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,1918,,N,1,CHEMBL626082,,,
9777,1,"Half life period was evaluated in rats, iv",,BAO_0000218,,Rattus norvegicus,,Intermediate,1918,In vivo,N,1,CHEMBL626250,,,
9778,1,Half life period after intravenous administration at 5 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6113,In vivo,N,1,CHEMBL626251,,,
9779,1,Half life period was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,5546,In vivo,N,1,CHEMBL626252,,,
9780,1,Half life period was determined in rat after iv administration at a dose of 5 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,5553,In vivo,N,1,CHEMBL626253,,,
9781,1,Half life stability of compound was evaluated in rat plasma,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,4188,,N,1,CHEMBL626254,,1969.0,
9782,1,Half life time after intravenous administration (5.0 mg/kg) was determined in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6215,In vivo,N,1,CHEMBL626255,,,
9783,1,Half life time was evaluated at 1 mg/kg of iv administration in Sprague-Dawley rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,6141,In vivo,N,1,CHEMBL626256,,,
9784,1,Half life was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5182,In vivo,N,1,CHEMBL626257,,,
9785,1,Half life was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat; NC means not calculated,,BAO_0000218,,Rattus norvegicus,,Intermediate,5182,In vivo,N,1,CHEMBL626258,,,
9786,1,Half life was measured in fasted male administration of compound 0.5 mg/Kg i.v.,,BAO_0000218,,Rattus norvegicus,,Intermediate,5710,In vivo,N,1,CHEMBL626259,,,
9787,1,Half in rat i.v.,,BAO_0000218,,Rattus norvegicus,,Intermediate,5789,In vivo,N,1,CHEMBL626260,,,
9788,1,Half period in rat after intravenous administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,6011,In vivo,N,1,CHEMBL875345,,,
9789,1,Half-life after repeated oral dose of compound at 1 mg/kg in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,17594,In vivo,N,1,CHEMBL626261,,,
9790,1,Half-life measured in in vitro Cathepsin B assay in rat liver,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,12357,In vitro,N,1,CHEMBL626262,,2107.0,
9791,1,Half-life of compound was determined in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,5210,,N,1,CHEMBL626263,,,
9792,1,Half-life at 10 mg/kg in rat upon intravenous administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,17596,In vivo,N,1,CHEMBL625270,,,
9793,1,Half-life determined in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6672,,N,1,CHEMBL625271,,,
9794,1,Half-life determined in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6673,,N,1,CHEMBL625272,,,
9795,1,Half-life in brain after intravenous administration (4.7 mg/kg) to male rats,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,4910,In vivo,N,1,CHEMBL625273,,955.0,
9796,1,"Half-life in chemical and enzymatic hydrolysis, in 80% rat plasma",Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,3741,,N,1,CHEMBL625274,,1969.0,
9797,1,Half-life in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,17671,In vivo,N,1,CHEMBL625275,,,
9798,1,Half-life in plasma after intravenous administration (4.7 mg/kg) to male rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,4910,In vivo,N,1,CHEMBL625276,,1969.0,
9799,1,Half-life in rat plasma,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,17537,,N,1,CHEMBL625277,,1969.0,
9800,1,Half-life in rat plasma was determined,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,4965,,N,1,CHEMBL625278,,1969.0,
9801,1,Half-life in rat plasma; Not tested,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,17537,,N,1,CHEMBL625279,,1969.0,
9802,1,Half-life in rat serum,Serum,BAO_0000218,,Rattus norvegicus,,Intermediate,6124,,N,1,CHEMBL625280,,1977.0,
9803,1,Half-life in rat serum; na is not available,Serum,BAO_0000218,,Rattus norvegicus,,Intermediate,6124,,N,1,CHEMBL876797,,1977.0,
9804,1,Half-life was calculated in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6078,,N,1,CHEMBL625281,,,
9805,1,Half-life was calculated in rat plasma,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,17668,,N,1,CHEMBL873827,,1969.0,
9806,1,Half-life was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,3185,,N,1,CHEMBL625282,,,
9807,1,Half-life was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,4883,,N,1,CHEMBL625283,,,
9808,1,Half-life after administration of 20 mg/Kg oral dose in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,2959,In vivo,N,1,CHEMBL625284,,,
9809,1,Half-life after administration of 3.2 mg/kg intravenously in male rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4029,In vivo,N,1,CHEMBL625285,,,
9810,1,Half-life after intravenous administration in female rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4029,In vivo,N,1,CHEMBL625286,,,
9811,1,Half-life after intravenous administration in male rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4029,In vivo,N,1,CHEMBL625287,,,
9812,1,Half-life after intravenous dose in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6180,In vivo,N,1,CHEMBL625288,,,
9813,1,Half-life in a rat liver homogenate preparation,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,1557,,N,1,CHEMBL625289,,2107.0,
9814,1,Half-life in plasma of rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,12500,,N,1,CHEMBL625290,,1969.0,
9815,1,Half-life in plasma of rat at dose of 3-10 mgkg,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,12500,,N,1,CHEMBL876798,,1969.0,
9816,1,Half-life in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5064,,N,1,CHEMBL625291,,,
9817,1,Half-life in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5145,,N,1,CHEMBL625292,,,
9818,1,Half-life in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5147,,N,1,CHEMBL625293,,,
9819,1,Half-life in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5833,,N,1,CHEMBL622832,,,
9820,1,Half-life in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6596,,N,1,CHEMBL622833,,,
9821,1,Half-life in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,17655,,N,1,CHEMBL622834,,,
9822,1,Half-life in rat after oral administration at 10 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,6495,In vivo,N,1,CHEMBL622835,,,
9823,1,Half-life in rat after po administration at a dose of 10 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,17538,In vivo,N,1,CHEMBL622836,,,
9824,1,Half-life in rat after po administration at a dose of 10 mg/kg; nd is not determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,17538,In vivo,N,1,CHEMBL622837,,,
9825,1,Half-life in rat at 3 mg/kg dose administered intravenously,,BAO_0000218,,Rattus norvegicus,,Intermediate,10,In vivo,N,1,CHEMBL622838,,,
9826,1,Half-life in rat brain homogenate,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,17669,,N,1,CHEMBL622839,,955.0,
9827,1,Half-life in rat plasma,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,17065,,N,1,CHEMBL622840,,1969.0,
9828,1,Half-life in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,4333,,N,1,CHEMBL622841,,,
9829,1,Half-life in Dawley rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,6827,,N,1,CHEMBL622842,,,
9830,1,Half-life in vitro in rat plasma,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,889,In vitro,N,1,CHEMBL622843,,1969.0,
9831,1,Half-life in vitro in rat plasma; No detectable degradation over 2 hr; no detectable degradation over 2 hours,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,889,In vitro,N,1,CHEMBL622844,,1969.0,
9832,1,"The area under concentration-time curve(AUC) was determined at 20 mg/kg of compound dose, administered intravenously in rat",,BAO_0000218,,Rattus norvegicus,,Intermediate,3747,,N,1,CHEMBL622845,,,
9833,1,The area under the curve of compound was measured at the dose of 100 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,15022,,N,1,CHEMBL622846,,,
9834,1,The area under the curve of compound was measured at the dose of 300 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,15022,,N,1,CHEMBL622847,,,
9835,1,The area under the curve of compound was measured at the dose of 30 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,15022,,N,1,CHEMBL622848,,,
9836,1,Bioavailability as oral AUC in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,3360,In vivo,N,1,CHEMBL622849,,,
9837,1,The plasma concentration versus time curve (AUC) was determined,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,5334,,N,1,CHEMBL622850,,1969.0,
9838,1,Total concentration in kidney was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,17411,,N,1,CHEMBL876807,,,
9839,1,Total concentration in liver was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,17411,,N,1,CHEMBL622851,,,
9840,1,Total concentration in lung was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,17411,,N,1,CHEMBL622852,,,
9841,1,Total concentration in rat after 1 mg/kg i.v. administration in 24 hours,,BAO_0000218,,Rattus norvegicus,,Intermediate,6570,,N,1,CHEMBL622853,,,
9842,1,Total concentration in rat after 2 mg/kg peroral administration in 24 hours,,BAO_0000218,,Rattus norvegicus,,Intermediate,6570,,N,1,CHEMBL622854,,,
9843,1,Total concentration in serum was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,17411,,N,1,CHEMBL622855,,,
9844,1,"Pharmacokinetic Parameter, AUC (0-infinity) is the area under the plasma concentration versus time curve extrapolated to infinity in Female Wistar Rats at 100 mg/kg by po administration",Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14941,,N,1,CHEMBL622856,,1969.0,
9845,1,"Pharmacokinetic Parameter, AUC (0-t) is the area under the plasma concentration versus time curve in Female Wistar Rats at 100 mg/kg by po administration",Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14941,,N,1,CHEMBL622857,,1969.0,
9846,1,AUC in rat after po administration at a dose of 10 mg/kg,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,17538,,N,1,CHEMBL622858,,1969.0,
9847,1,Area under the plasma concentration-time curve in rats after oral administration at 25 mg/kg,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,17752,,N,1,CHEMBL622859,,1969.0,
9848,1,Area under curve value 24 hr after 10 mg/kg iv administration in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,17509,,N,1,CHEMBL622860,,,
9849,1,Area under curve value 24 hr after 10 mg/kg oral administration in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,17509,,N,1,CHEMBL622861,,,
9850,1,Area under curve value 24 hr after 2 mg/kg iv administration in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,17509,,N,1,CHEMBL622862,,,
9851,1,Area under curve value 24 hr after 2 mg/kg oral administration in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,17509,,N,1,CHEMBL622863,,,
9852,1,Area under curve value 6 hr after po administration in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,17509,,N,1,CHEMBL623817,,,
9853,1,Area under the curve at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,,BAO_0000218,,Rattus norvegicus,,Intermediate,17717,,N,1,CHEMBL623818,,,
9854,1,"Area under the curve at a concentration of 3 mg/kg in rats, intravenously",,BAO_0000218,,Rattus norvegicus,,Intermediate,17717,,N,1,CHEMBL623819,,,
9855,1,Area under the curve at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,,BAO_0000218,,Rattus norvegicus,,Intermediate,17717,,N,1,CHEMBL623820,,,
9856,1,Area under the curve at a concentration of 60 mg/kg perorally in rats along with control,,BAO_0000218,,Rattus norvegicus,,Intermediate,17717,,N,1,CHEMBL623821,,,
9857,1,AUC normalized for dose (AUCN) in rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,6642,,N,1,CHEMBL623822,,1969.0,
9858,1,Area under curve in rat after p.o. administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,6640,,N,1,CHEMBL623823,,,
9859,1,Area under curve in rat after p.o. administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,6641,,N,1,CHEMBL623824,,,
9860,1,Area under curve in rat after p.o. administration; Not determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,6641,,N,1,CHEMBL623825,,,
9861,1,Area under curve in rat after peroral administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,6641,,N,1,CHEMBL622070,,,
9862,1,Area under curve (carotid artery) value of the compound,,BAO_0000218,,Rattus norvegicus,,Intermediate,3603,,N,1,CHEMBL622071,,,
9863,1,Bioavailability expressed as the area under curve of rat carotid artery,,BAO_0000218,,Rattus norvegicus,,Intermediate,3550,,N,1,CHEMBL622072,,,
9864,1,Area under curve in male SD rats was observed after intravenous administration in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,15662,,N,1,CHEMBL622073,,,
9865,1,Area under curve of the compound was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,17720,,N,1,CHEMBL622074,,,
9866,1,Compound was evaluated for its pharmacokinetic parameter maximum area under curve AUCmax,,BAO_0000218,,Rattus norvegicus,,Intermediate,5407,,N,1,CHEMBL622075,,,
9867,1,Area under the plasma concentration-time curve in rats after oral administration at 20 mg/kg,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,17752,,N,1,CHEMBL622076,,1969.0,
9868,1,Area under the plasma concentration-time curve in rats following oral administration at 20 mg/kg,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,17752,,N,1,CHEMBL622077,,1969.0,
9869,1,Area under curve (portal vein) value of the compound,,BAO_0000218,,Rattus norvegicus,,Intermediate,3603,,N,1,CHEMBL622078,,,
9870,1,Bioavailability expressed as the area under curve of rat portal vein,,BAO_0000218,,Rattus norvegicus,,Intermediate,3550,,N,1,CHEMBL622079,,,
9871,1,Area Under plasma concentration time curve in rat upon peroral administration,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,17655,,N,1,CHEMBL622080,,1969.0,
9872,1,In vivo area under curve was determined for the compound after i.v. administration at a dose of 5 mg/kg in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,17582,,N,1,CHEMBL877612,,,
9873,1,In vivo area under curve was determined for the compound after oral (po) administration at a dose of 10 mg/kg in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,17582,,N,1,CHEMBL622081,,,
9874,1,Compound was evaluated for oral bioavailability in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,17791,,N,1,CHEMBL622082,,,
9875,1,Compound was evaluated for oral bioavailability in rats after iv administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,17791,,N,1,CHEMBL622083,,,
9876,1,Compound was evaluated for oral bioavailability in rats; 30-80,,BAO_0000218,,Rattus norvegicus,,Intermediate,17791,,N,1,CHEMBL622084,,,
9877,1,Compound was evaluated for oral bioavailability in rats; 50-60,,BAO_0000218,,Rattus norvegicus,,Intermediate,17791,,N,1,CHEMBL622085,,,
9878,1,Compound was evaluated for oral bioavailability in rats; no data,,BAO_0000218,,Rattus norvegicus,,Intermediate,17791,,N,1,CHEMBL622086,,,
9879,1,Compound was evaluated for oral bioavailability in rats; peptide,,BAO_0000218,,Rattus norvegicus,,Intermediate,17791,,N,1,CHEMBL622087,,,
9880,1,"Distribution of radioactivity in blood of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.03-0.03",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,7768,,N,1,CHEMBL622088,,178.0,
9881,1,"Distribution of radioactivity in blood of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range-0.9-1.03",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,7768,,N,1,CHEMBL622089,,178.0,
9882,1,"Distribution of radioactivity in blood of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range = 0.88-1.15",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,7768,,N,1,CHEMBL623685,,178.0,
9883,1,"Distribution of radioactivity in blood of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range = 0.71-0.87",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,7768,,N,1,CHEMBL623686,,178.0,
9884,1,"Biodistribution in Sprague-Dawley rat stomach 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Stomach,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,In vivo,N,1,CHEMBL623687,,945.0,
9885,1,"Biodistribution in Sprague-Dawley rat stomach 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Stomach,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,In vivo,N,1,CHEMBL623688,,945.0,
9886,1,"Biodistribution in Sprague-Dawley rat stomach 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Stomach,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,In vivo,N,1,CHEMBL623689,,945.0,
9887,1,"Biodistribution in Sprague-Dawley rat stomach 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Stomach,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,In vivo,N,1,CHEMBL622485,,945.0,
9888,1,"Biodistribution in Sprague-Dawley rat thyroid 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,In vivo,N,1,CHEMBL622486,,2046.0,
9889,1,"Biodistribution in Sprague-Dawley rat thyroid 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,In vivo,N,1,CHEMBL877613,,2046.0,
9890,1,"Biodistribution in Sprague-Dawley rat thyroid 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,In vivo,N,1,CHEMBL622487,,2046.0,
9891,1,"Biodistribution in Sprague-Dawley rat thyroid 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,In vivo,N,1,CHEMBL622488,,2046.0,
9892,1,"Biodistribution in Sprague-Dawley rats heart 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,In vivo,N,1,CHEMBL622489,,948.0,
9893,1,Compound was evaluated for percent dimer tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,6899,,N,1,CHEMBL622490,,1088.0,
9894,1,Compound was evaluated for percent dimer tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine; na - not available,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,6899,,N,1,CHEMBL622491,,1088.0,
9895,1,Compound was evaluated for percent dose tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in liver,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,6899,,N,1,CHEMBL622492,,2107.0,
9896,1,Compound was evaluated for percent thiol tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,6899,,N,1,CHEMBL622493,,1088.0,
9897,1,Compound was evaluated for percent thiol tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine; na - not available,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,6899,,N,1,CHEMBL622494,,1088.0,
9898,1,"Compound was evaluated for the biodistribution in Sprague-Dawley rats in muscle 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,,N,1,CHEMBL622495,,2385.0,
9899,1,Compound was evaluated for tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in rat kidney,,BAO_0000218,,Rattus norvegicus,,Intermediate,6899,,N,1,CHEMBL622496,,,
9900,1,Compound was evaluated for tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,6899,,N,1,CHEMBL622497,,1088.0,
9901,1,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,2189,,N,1,CHEMBL622498,,,
9902,1,Percent of radioactive dose in urine and feces excreted in 0-24 hr by rats,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,2189,,N,1,CHEMBL624918,,1088.0,
9903,1,Percent of radioactive dose in urine and feces excreted in 0-24 hr by rats; NA is <10% inhibition at 1 uM for binding data,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,2189,,N,1,CHEMBL624919,,1088.0,
9904,1,Biodistribution of compound in rat blood after 5 min of administration,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,10839,In vivo,N,1,CHEMBL624920,,178.0,
9905,1,Biodistribution of compound in rat blood after 5 min of administration.,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,10839,In vivo,N,1,CHEMBL624921,,178.0,
9906,1,Biodistribution of compound in rat brain after 5 min of administration,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,10839,In vivo,N,1,CHEMBL624922,,955.0,
9907,1,Biodistribution of compound in rat heart after 5 min of administration,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,10839,In vivo,N,1,CHEMBL624923,,948.0,
9908,1,Biodistribution of compound in rat heart after 5 min of administration.,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,10839,In vivo,N,1,CHEMBL624924,,948.0,
9909,1,Biodistribution of compound in rat kidney after 5 min of administration,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,10839,In vivo,N,1,CHEMBL624925,,2113.0,
9910,1,Biodistribution of compound in rat kidney after 5 min of administration.,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,10839,In vivo,N,1,CHEMBL624926,,2113.0,
9911,1,Biodistribution of compound in rat liver after 5 min of administration,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,10839,In vivo,N,1,CHEMBL624927,,2107.0,
9912,1,Biodistribution of compound in rat liver after 5 min of administration.,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,10839,In vivo,N,1,CHEMBL874402,,2107.0,
9913,1,Biodistribution of compound in rat lung after 5 min of administration,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,10839,In vivo,N,1,CHEMBL624928,,2048.0,
9914,1,Biodistribution of compound in rat lung after 5 min of administration.,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,10839,In vivo,N,1,CHEMBL624929,,2048.0,
9915,1,Biodistribution of compound in rat muscle after 5 min of administration,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,10839,In vivo,N,1,CHEMBL624930,,2385.0,
9916,1,Biodistribution of compound in rat muscle after 5 min of administration.,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,10839,In vivo,N,1,CHEMBL624931,,2385.0,
9917,1,In vivo heart distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,4043,,N,1,CHEMBL624932,,948.0,
9918,1,In vivo heart distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,4043,,N,1,CHEMBL624933,,948.0,
9919,1,In vivo liver distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,4043,,N,1,CHEMBL624934,,2107.0,
9920,1,In vivo liver distribution of total doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,4043,,N,1,CHEMBL624935,,2107.0,
9921,1,In vivo plasma distribution of free doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,BAO_0000218,,Rattus norvegicus,,Intermediate,4043,,N,1,CHEMBL624936,,,
9922,1,In vivo plasma distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,BAO_0000218,,Rattus norvegicus,,Intermediate,4043,,N,1,CHEMBL624937,,,
9923,1,In vivo spleen distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,4043,,N,1,CHEMBL624938,,2106.0,
9924,1,In vivo spleen distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,4043,,N,1,CHEMBL624939,,2106.0,
9925,1,In vivo tumor distribution of free doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,BAO_0000218,,Rattus norvegicus,,Intermediate,4043,,N,1,CHEMBL624940,,,
9926,1,In vivo tumor distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,BAO_0000218,,Rattus norvegicus,,Intermediate,4043,,N,1,CHEMBL874403,,,
9927,1,Compound was tested for the duration that the plasma drug concentrations remained above the IC95,,BAO_0000218,,Rattus norvegicus,,Intermediate,1446,,N,1,CHEMBL624941,,,
9928,1,Dose required to lower urine osmolality to 300 mOsm/kg in rat,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,9971,,N,1,CHEMBL624942,,1088.0,
9929,1,Dose required to lower urine osmolality to 300 mOsm/kg in rat; NT=Not tested,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,9971,,N,1,CHEMBL624943,,1088.0,
9930,1,% Bioavailability after 1 day of the drug administration in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,5765,In vivo,N,1,CHEMBL624944,,,
9931,1,% Bioavailability after 4 day of the drug administration in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,5765,In vivo,N,1,CHEMBL624945,,,
9932,1,Absolute bioavailability was evaluated in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4257,In vivo,N,1,CHEMBL624946,,,
9933,1,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr low time interval,,BAO_0000218,,Rattus norvegicus,,Intermediate,13091,,N,1,CHEMBL624947,,,
9934,1,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr time interval,,BAO_0000218,,Rattus norvegicus,,Intermediate,13091,,N,1,CHEMBL624948,,,
9935,1,Tissue biodistribution into estrogen-primed immature female rat fat at 3 hr time interval,,BAO_0000218,,Rattus norvegicus,,Intermediate,13091,,N,1,CHEMBL624949,,,
9936,1,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr blocked time interval,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,13091,,N,1,CHEMBL622025,,2113.0,
9937,1,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr low time interval,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,13091,,N,1,CHEMBL622026,,2113.0,
9938,1,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr time interval,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,13091,,N,1,CHEMBL622027,,2113.0,
9939,1,Tissue biodistribution into estrogen-primed immature female rat kidney at 3 hr time interval,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,13091,,N,1,CHEMBL622028,,2113.0,
9940,1,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr blocked time interval,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,13091,,N,1,CHEMBL622029,,2107.0,
9941,1,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr low time interval,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,13091,,N,1,CHEMBL622208,,2107.0,
9942,1,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr time interval,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,13091,,N,1,CHEMBL622209,,2107.0,
9943,1,Tissue biodistribution into estrogen-primed immature female rat liver at 3 hr time interval,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,13091,,N,1,CHEMBL622210,,2107.0,
9944,1,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr blocked time interval,,BAO_0000218,,Rattus norvegicus,,Intermediate,13091,,N,1,CHEMBL622211,,,
9945,1,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr low time interval,,BAO_0000218,,Rattus norvegicus,,Intermediate,13091,,N,1,CHEMBL622212,,,
9946,1,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr time interval,,BAO_0000218,,Rattus norvegicus,,Intermediate,13091,,N,1,CHEMBL622213,,,
9947,1,Tissue biodistribution into estrogen-primed immature female rat lung at 3 hr time interval,,BAO_0000218,,Rattus norvegicus,,Intermediate,13091,,N,1,CHEMBL874404,,,
9948,1,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr blocked time interval,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,13091,,N,1,CHEMBL620452,,2385.0,
9949,1,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr low time interval,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,13091,,N,1,CHEMBL620453,,2385.0,
9950,1,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr time interval,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,13091,,N,1,CHEMBL620454,,2385.0,
9951,1,Tissue biodistribution into estrogen-primed immature female rat muscle at 3 hr time interval,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,13091,,N,1,CHEMBL624067,,2385.0,
9952,1,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr blocked time interval,,BAO_0000218,,Rattus norvegicus,,Intermediate,13091,,N,1,CHEMBL624068,,,
9953,1,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr low time interval,Female gonad,BAO_0000218,,Rattus norvegicus,,Intermediate,13091,,N,1,CHEMBL624069,,992.0,
9954,1,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr time interval,Female gonad,BAO_0000218,,Rattus norvegicus,,Intermediate,13091,,N,1,CHEMBL624070,,992.0,
9955,1,Tissue biodistribution into estrogen-primed immature female rat ovaries at 3 hr time interval,Female gonad,BAO_0000218,,Rattus norvegicus,,Intermediate,13091,,N,1,CHEMBL624071,,992.0,
9956,1,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr blocked time interval,Uterus,BAO_0000218,,Rattus norvegicus,,Intermediate,13091,,N,1,CHEMBL624072,,995.0,
9957,1,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr low time interval,Uterus,BAO_0000218,,Rattus norvegicus,,Intermediate,13091,,N,1,CHEMBL624073,,995.0,
9958,1,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr time interval,Uterus,BAO_0000218,,Rattus norvegicus,,Intermediate,13091,,N,1,CHEMBL624788,,995.0,
9959,1,Tissue biodistribution into estrogen-primed immature female rat uterus at 3 hr time interval,Uterus,BAO_0000218,,Rattus norvegicus,,Intermediate,13091,,N,1,CHEMBL624789,,995.0,
9960,1,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr blocked time interval,,BAO_0000218,,Rattus norvegicus,,Intermediate,13091,,N,1,CHEMBL624790,,,
9961,1,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr low time interval,,BAO_0000218,,Rattus norvegicus,,Intermediate,13091,,N,1,CHEMBL624791,,,
9962,1,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr time interval,,BAO_0000218,,Rattus norvegicus,,Intermediate,13091,,N,1,CHEMBL624792,,,
9963,1,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 3 hr time interval,,BAO_0000218,,Rattus norvegicus,,Intermediate,13091,,N,1,CHEMBL624793,,,
9964,1,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr blocked time interval,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,13091,,N,1,CHEMBL877491,,2385.0,
9965,1,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr low time interval,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,13091,,N,1,CHEMBL624957,,2385.0,
9966,1,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr time interval,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,13091,,N,1,CHEMBL624958,,2385.0,
9967,1,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 3 hr time interval,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,13091,,N,1,CHEMBL624959,,2385.0,
9968,1,Dissociation constant was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,,N,1,CHEMBL624960,,,
9969,1,"Pharmacokinetic Parameter, Kel is elimination rate constant in Female Wistar Rats at 100 mg/kg by po administration",,BAO_0000218,,Rattus norvegicus,,Intermediate,14941,,N,1,CHEMBL624961,,,
9970,1,"The Kel value in female wistar rat at 100 mg/kg, p.o. dose",,BAO_0000218,,Rattus norvegicus,,Intermediate,15078,,N,1,CHEMBL624962,,,
9971,1,"The Kel value in male wistar rat at 100 mg/kg, p.o. dose",,BAO_0000218,,Rattus norvegicus,,Intermediate,15078,,N,1,CHEMBL624963,,,
9972,1,Observed rate constant in 80% rat plasma at 37 degree Centigrade,,BAO_0000218,,Rattus norvegicus,,Intermediate,4755,,N,1,CHEMBL624964,,,
9973,1,LogP value was evaluated in the in situ rat gut perfusion assay,,BAO_0000218,,Rattus norvegicus,,Intermediate,589,,N,1,CHEMBL624965,,,
9974,1,In vivo retention time was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,17582,In vivo,N,1,CHEMBL624966,,,
9975,1,Mean residence time (Pharmacokinetic property) after i.v. administration in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,5031,In vivo,N,1,CHEMBL624967,,,
9976,1,Mean-residence time of compound after intravenous administration in rats at 24 uM/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,17764,In vivo,N,1,CHEMBL624968,,,
9977,1,Mean residence time at a dose of 4 mg/kg in Rat Plasma after iv administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,17720,,N,1,CHEMBL624969,,,
9978,1,Streptococcal cell wall-washed arthritis model in rats at 10.0 mg/kg peroral dose,,BAO_0000218,,Rattus norvegicus,,Expert,2862,,N,1,CHEMBL624970,,,
9979,1,Half-life was evaluated after 10 uM/kg of intra arterial administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,16423,,N,1,CHEMBL624971,,,
9980,1,Half-life was evaluated after 20 uM/kg of peroral administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,16423,In vivo,N,1,CHEMBL624972,,,
9981,1,Half-life was evaluated after i.v. administration in rat at a dose of 1 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,6005,In vivo,N,1,CHEMBL624973,,,
9982,1,Half-life was evaluated in plasma of rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,2938,,N,1,CHEMBL624974,,1969.0,
9983,1,Half-life was evaluated in rats at an intravenous dose of 3 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,6410,In vivo,N,1,CHEMBL624975,,,
9984,1,Half-life was evaluated in rats at an oral dose of 30 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,6410,In vivo,N,1,CHEMBL877492,,,
9985,1,Half-life was measured in rat after an iv dose of 1 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,6062,In vivo,N,1,CHEMBL624976,,,
9986,1,Half-life period of compound in rats after peroral administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,6571,In vivo,N,1,CHEMBL624977,,,
9987,1,Half-life period of compound was measured in rat plasma.,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,3136,,N,1,CHEMBL626848,,1969.0,
9988,1,Half-life period of compound was measured in rat plasma; ND is not determined,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,3136,,N,1,CHEMBL626849,,1969.0,
9989,1,Half-life period of compound was measured in rat plasma; not determined,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,3136,,N,1,CHEMBL626850,,1969.0,
9990,1,Half-life period in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,4521,In vivo,N,1,CHEMBL626851,,,
9991,1,Half-life period in rat by iv administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,5871,In vivo,N,1,CHEMBL626852,,,
9992,1,Half-life period in rats following intravenous administration at 2 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,6077,In vivo,N,1,CHEMBL626853,,,
9993,1,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,6679,In vivo,N,1,CHEMBL626854,,,
9994,1,Half-life period was determined for the compound in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5144,,N,1,CHEMBL627486,,,
9995,1,"Half-life period was evaluated in rat, after administering 1 mg/kg intravenously",,BAO_0000218,,Rattus norvegicus,,Intermediate,4498,In vivo,N,1,CHEMBL627487,,,
9996,1,"Half-life period was evaluated in rat, after administering 10 mg/kg orally",,BAO_0000218,,Rattus norvegicus,,Intermediate,4498,In vivo,N,1,CHEMBL627488,,,
9997,1,Half-life value after IV dose at a dose of 5 mg/kg in rats.,,BAO_0000218,,Rattus norvegicus,,Intermediate,1908,In vivo,N,1,CHEMBL627489,,,
9998,1,Half-life was determined by iv administration (1.5 mg/kg) in fasted male Sprague-Dawley rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,6211,In vivo,N,1,CHEMBL627490,,,
9999,1,Half-life was determined in rat after intravenous administration (0.5 mg/kg),,BAO_0000218,,Rattus norvegicus,,Intermediate,5529,In vivo,N,1,CHEMBL873829,,,
10000,1,Half-life was determined in rat at a dose of 1 mpk i.v.,,BAO_0000218,,Rattus norvegicus,,Intermediate,6444,In vivo,N,1,CHEMBL627655,,,
10001,1,Half-life was determined in rat at a dose of 1 mpk i.v.; ND means not determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,6444,In vivo,N,1,CHEMBL625994,,,
10002,1,Half-life was determined in rat at a dose of 1 mpk i.v.; ND=not determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,6444,In vivo,N,1,CHEMBL625995,,,
10003,1,Half-life in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5207,,N,1,CHEMBL625996,,,
10004,1,In vitro half life in rat plasma,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,530,In vitro,N,1,CHEMBL625850,,1969.0,
10005,1,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in rat plasma",Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,1116,In vitro,N,1,CHEMBL625851,,1969.0,
10006,1,In vitro half life in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,3219,In vitro,N,1,CHEMBL625852,,,
10007,1,In vivo half life period after intravenous administration in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6109,In vivo,N,1,CHEMBL625853,,,
10008,1,In vivo half-life period for compound after i.v. administration at a dose of 5 mg/kg was measured in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,17582,In vivo,N,1,CHEMBL625854,,,
10009,1,In vivo half-life period for compound after oral (po) administration at a dose of 10 mg/kg was measured in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,17582,In vivo,N,1,CHEMBL874450,,,
10010,1,In vivo t1/2 was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5974,In vivo,N,1,CHEMBL625855,,,
10011,1,In vivo t1/2 was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5974,In vivo,N,1,CHEMBL625856,,,
10012,1,In vivo t1/2 was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5974,In vivo,N,1,CHEMBL625857,,,
10013,1,In vivo t1/2 was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5974,In vivo,N,1,CHEMBL873831,,,
10014,1,Longer half-life in rat (i.v.) at 0.5 mpk,,BAO_0000218,,Rattus norvegicus,,Intermediate,17853,In vivo,N,1,CHEMBL625858,,,
10015,1,Longer half-life in rat (p.o.) at 2.0 mpk,,BAO_0000218,,Rattus norvegicus,,Intermediate,17853,In vivo,N,1,CHEMBL625859,,,
10016,1,Pharmacokinetic property (half life) in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,3457,,N,1,CHEMBL625860,,,
10017,1,Pharmacokinetic parameter half-life was determined at 10 mg/kg po dose in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,2792,In vivo,N,1,CHEMBL625861,,,
10018,1,Pharmacokinetic parameter half-life was determined at 2 mg/kg i.v. dose in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,2792,In vivo,N,1,CHEMBL625862,,,
10019,1,Pharmacokinetic parameter half-life was determined at 3 mg/kg po dose in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,2792,In vivo,N,1,CHEMBL625863,,,
10020,1,Pharmacokinetic parameter half-life was determined at 5 mg/kg i.v. dose in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,2792,In vivo,N,1,CHEMBL625864,,,
10021,1,Pharmacokinetic property (t1/2) for the compound (5 mg/kg iv) was determined in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,5739,In vivo,N,1,CHEMBL625865,,,
10022,1,Pharmacokinetic half time was determined intravenously in rats.,,BAO_0000218,,Rattus norvegicus,,Intermediate,15765,In vivo,N,1,CHEMBL625866,,,
10023,1,Plasma half life in rat after 5 mg/kg oral gavage; 6-8 hours,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,6567,In vivo,N,1,CHEMBL625867,,1969.0,
10024,1,Plasma half life of hydrolysis of the compound,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,2448,,N,1,CHEMBL625868,,1969.0,
10025,1,Plasma half life was reported after a intravenous dose of 1 mg/kg in Dawley rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,5423,In vivo,N,1,CHEMBL625869,,1969.0,
10026,1,Plasma half life period was calculated in rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,4853,,N,1,CHEMBL874451,,1969.0,
10027,1,Plasma half-life in Sprague-Dawley rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,4514,,N,1,CHEMBL625870,,1969.0,
10028,1,Plasma half-life in Sprague-Dawley rats; Not determined,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,4514,,N,1,CHEMBL625871,,1969.0,
10029,1,Plasma half-life in rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,1500,,N,1,CHEMBL625872,,1969.0,
10030,1,Plasma half-life in rats; <MQL,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,1500,,N,1,CHEMBL625873,,1969.0,
10031,1,Plasma half-life period (0-8 h) was determined,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,5334,,N,1,CHEMBL625874,,1969.0,
10032,1,Plasma half-life period (0-8 h) was determined in Sprague-Dawley rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,5334,,N,1,CHEMBL625875,,1969.0,
10033,1,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,5334,In vivo,N,1,CHEMBL625876,,1969.0,
10034,1,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,5334,In vivo,N,1,CHEMBL631258,,1969.0,
10035,1,Plasma half-life was determined in Sprague-Dawley rats after 0-8 h administration of the compound,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,4956,,N,1,CHEMBL631259,,1969.0,
10036,1,Plasma half-life was determined in Sprague-Dawley rats after 0-8 hr administration of the compound; Not determined,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,4956,,N,1,CHEMBL631260,,1969.0,
10037,1,"Distribution of radioactivity in blood of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range = 0.68-1.03",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,7768,,N,1,CHEMBL631261,,178.0,
10038,1,"Distribution of radioactivity in blood of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.45-0.48",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,7768,,N,1,CHEMBL631262,,178.0,
10039,1,"Distribution of radioactivity in blood of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range-0.81-1",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,7768,,N,1,CHEMBL631263,,178.0,
10040,1,"Distribution of radioactivity in brain tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.007-0.008",,BAO_0000218,,Rattus norvegicus,,Intermediate,7768,,N,1,CHEMBL631264,,,
10041,1,"Distribution of radioactivity in brain tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.18-0.22",,BAO_0000218,,Rattus norvegicus,,Intermediate,7768,,N,1,CHEMBL631265,,,
10042,1,"Distribution of radioactivity in brain tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.77-0.97",,BAO_0000218,,Rattus norvegicus,,Intermediate,7768,,N,1,CHEMBL631266,,,
10043,1,"Distribution of radioactivity in brain tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.08-0.13",,BAO_0000218,,Rattus norvegicus,,Intermediate,7768,,N,1,CHEMBL631267,,,
10044,1,"Distribution of radioactivity in brain tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.25-0.37",,BAO_0000218,,Rattus norvegicus,,Intermediate,7768,,N,1,CHEMBL631268,,,
10045,1,"Distribution of radioactivity in brain tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.03-0.04",,BAO_0000218,,Rattus norvegicus,,Intermediate,7768,,N,1,CHEMBL631269,,,
10046,1,"Distribution of radioactivity in brain tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.74-0.94",,BAO_0000218,,Rattus norvegicus,,Intermediate,7768,,N,1,CHEMBL631270,,,
10047,1,"Distribution of radioactivity in heart tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.02",Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,7768,,N,1,CHEMBL631271,,948.0,
10048,1,"Distribution of radioactivity in heart tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.5-0.63",Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,7768,,N,1,CHEMBL631272,,948.0,
10049,1,"Distribution of radioactivity in heart tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.35-1.55",Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,7768,,N,1,CHEMBL631273,,948.0,
10050,1,"Distribution of radioactivity in heart tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.24-0.38",Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,7768,,N,1,CHEMBL631274,,948.0,
10051,1,"Distribution of radioactivity in heart tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.55-0.82",Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,7768,,N,1,CHEMBL631275,,948.0,
10052,1,"Distribution of radioactivity in heart tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.16-0.2",Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,7768,,N,1,CHEMBL626984,,948.0,
10053,1,"Distribution of radioactivity in heart tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.13-1.29",Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,7768,,N,1,CHEMBL626985,,948.0,
10054,1,"Distribution of radioactivity in liver tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.02",Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,7768,,N,1,CHEMBL626986,,2107.0,
10055,1,"Distribution of radioactivity in liver tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.71-0.93",Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,7768,,N,1,CHEMBL626987,,2107.0,
10056,1,"Distribution of radioactivity in liver tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 2.91-3.53",Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,7768,,N,1,CHEMBL626988,,2107.0,
10057,1,"Distribution of radioactivity in liver tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.42-0.62",Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,7768,,N,1,CHEMBL626989,,2107.0,
10058,1,"Distribution of radioactivity in liver tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.97-1.41",Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,7768,,N,1,CHEMBL626990,,2107.0,
10059,1,"Distribution of radioactivity in liver tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.19-0.23",Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,7768,,N,1,CHEMBL626991,,2107.0,
10060,1,"Distribution of radioactivity in liver tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 2.49-2.82",Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,7768,,N,1,CHEMBL626992,,2107.0,
10061,1,"Distribution of radioactivity in lung tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.03",Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,7768,,N,1,CHEMBL626993,,2048.0,
10062,1,"Distribution of radioactivity in lung tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.66-0.77",Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,7768,,N,1,CHEMBL874593,,2048.0,
10063,1,"Distribution of radioactivity in lung tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.17-1.42",Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,7768,,N,1,CHEMBL626994,,2048.0,
10064,1,"Distribution of radioactivity in lung tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.47-0.58",Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,7768,,N,1,CHEMBL626995,,2048.0,
10065,1,"Distribution of radioactivity in lung tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.65-0.87",Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,7768,,N,1,CHEMBL626190,,2048.0,
10066,1,"Distribution of radioactivity in lung tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.28-0.31",Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,7768,,N,1,CHEMBL626191,,2048.0,
10067,1,"Distribution of radioactivity in lung tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.98-1.22",Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,7768,,N,1,CHEMBL626364,,2048.0,
10068,1,"Distribution of radioactivity in thyroid tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 406-499",Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,7768,,N,1,CHEMBL626365,,2046.0,
10069,1,"Distribution of radioactivity in thyroid tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 53.0-96",Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,7768,,N,1,CHEMBL626366,,2046.0,
10070,1,"Distribution of radioactivity in thyroid tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 6.65-8.0.8",Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,7768,,N,1,CHEMBL626367,,2046.0,
10071,1,"Distribution of radioactivity in thyroid tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 92-159",Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,7768,,N,1,CHEMBL626368,,2046.0,
10072,1,"Distribution of radioactivity in thyroid tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 18.74-30.84",Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,7768,,N,1,CHEMBL626369,,2046.0,
10073,1,"Distribution of radioactivity in thyroid tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 156-207",Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,7768,,N,1,CHEMBL626370,,2046.0,
10074,1,"Bioavailability (F) was evaluated in rat, after administering 1 mg/kg intravenously",,BAO_0000218,,Rattus norvegicus,,Intermediate,4498,In vivo,N,1,CHEMBL626371,,,
10075,1,"Bioavailability (F) was evaluated in rat, after administering 10 mg/kg orally",,BAO_0000218,,Rattus norvegicus,,Intermediate,4498,In vivo,N,1,CHEMBL626372,,,
10076,1,Bioavailability after a dose of 10 mg/kg p.o.,,BAO_0000218,,Rattus norvegicus,,Intermediate,3603,In vivo,N,1,CHEMBL626373,,,
10077,1,Bioavailability after peroral administration (10 mg/kg) was determined in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6215,In vivo,N,1,CHEMBL626374,,,
10078,1,Bioavailability in fasted male administration of 2 mg/Kg of compound p.o.,,BAO_0000218,,Rattus norvegicus,,Intermediate,5710,In vivo,N,1,CHEMBL626375,,,
10079,1,Oral bioavailability in rat (Sprague-Dawley) (fasted male) (dose 2 mg/kg),,BAO_0000218,,Rattus norvegicus,,Intermediate,5710,In vivo,N,1,CHEMBL626376,,,
10080,1,Bioavailability in rat po was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,5676,In vivo,N,1,CHEMBL626377,,,
10081,1,Bioavailability of compound at 10 mg/kg in rat after oral administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,17667,In vivo,N,1,CHEMBL626378,,,
10082,1,Bioavailability of compound at 3 mg/kg in rat after i.v. administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,17667,In vivo,N,1,CHEMBL626379,,,
10083,1,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),,BAO_0000218,,Rattus norvegicus,,Intermediate,6848,In vivo,N,1,CHEMBL626380,,,
10084,1,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),,BAO_0000218,,Rattus norvegicus,,Intermediate,6848,In vivo,N,1,CHEMBL626381,,,
10085,1,Bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,17267,In vivo,N,1,CHEMBL626382,,,
10086,1,Bioavailability in rat (Sprague-Dawley) (female),,BAO_0000218,,Rattus norvegicus,,Intermediate,6362,In vivo,N,1,CHEMBL626383,,,
10087,1,Bioavailability in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,17671,In vivo,N,1,CHEMBL874652,,,
10088,1,Bioavailability in rat (Sprague-Dawley) (male) (dose 10-20 mg/kg),,BAO_0000218,,Rattus norvegicus,,Intermediate,17671,In vivo,N,1,CHEMBL626384,,,
10089,1,Bioavailability in rat (Sprague-Dawley) (male) (dose 1 mg/kg i.v. and 3 mg/kg p.o.) measured from 0.3 to 6 hr,,BAO_0000218,,Rattus norvegicus,,Intermediate,4333,In vivo,N,1,CHEMBL626385,,,
10090,1,Bioavailability in rat at an oral dose of 2 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,6077,In vivo,N,1,CHEMBL626386,,,
10091,1,Bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,3278,In vivo,N,1,CHEMBL626387,,,
10092,1,Bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5964,In vivo,N,1,CHEMBL626388,,,
10093,1,Bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4884,In vivo,N,1,CHEMBL626389,,,
10094,1,Bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4905,In vivo,N,1,CHEMBL626390,,,
10095,1,Bioavailability in rat was reported at the dose of 6 mg/kg in 25% PEG-300,,BAO_0000218,,Rattus norvegicus,,Intermediate,4884,In vivo,N,1,CHEMBL626391,,,
10096,1,Bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6850,In vivo,N,1,CHEMBL626392,,,
10097,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,2864,In vivo,N,1,CHEMBL626393,,,
10098,1,Bioavailability was determined in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5780,In vivo,N,1,CHEMBL623026,,,
10099,1,Bioavailability,,BAO_0000218,,Rattus norvegicus,,Intermediate,1465,In vivo,N,1,CHEMBL623027,,,
10100,1,Bioavailability,,BAO_0000218,,Rattus norvegicus,,Intermediate,5199,In vivo,N,1,CHEMBL623028,,,
10101,1,Bioavailability in rat after 1 day dosing,,BAO_0000218,,Rattus norvegicus,,Intermediate,5765,In vivo,N,1,CHEMBL623029,,,
10102,1,Bioavailability in rat after 4 day dosing,,BAO_0000218,,Rattus norvegicus,,Intermediate,5765,In vivo,N,1,CHEMBL623030,,,
10103,1,Bioavailability after IV dosing at 0.5 mg/kg in rat; no data,,BAO_0000218,,Rattus norvegicus,,Intermediate,6518,In vivo,N,1,CHEMBL623031,,,
10104,1,Bioavailability after IV dosing at 1 mg/kg in rat; no data,,BAO_0000218,,Rattus norvegicus,,Intermediate,6518,In vivo,N,1,CHEMBL623032,,,
10105,1,Bioavailability after oral administration at a dose of 2 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6518,In vivo,N,1,CHEMBL623033,,,
10106,1,Bioavailability after oral administration at a dose of 4 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6518,In vivo,N,1,CHEMBL623034,,,
10107,1,Bioavailability at 4 hr after administration of 5 mg/kg dose peroral in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,2083,In vivo,N,1,CHEMBL623035,,,
10108,1,Bioavailability at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,17260,In vivo,N,1,CHEMBL623036,,,
10109,1,Bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v. and 2 mg/kg p.o.),,BAO_0000218,,Rattus norvegicus,,Intermediate,4956,In vivo,N,1,CHEMBL623037,,,
10110,1,Bioavailability by intravenous administration of 3.4 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4368,In vivo,N,1,CHEMBL623038,,,
10111,1,Bioavailability from rat plasma at a single oral dose of 25 mg/kg,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,17752,In vivo,N,1,CHEMBL874385,,1969.0,
10112,1,Bioavailability in rat (Fisher) (fasted),,BAO_0000218,,Rattus norvegicus,,Intermediate,1446,In vivo,N,1,CHEMBL623039,,,
10113,1,Bioavailability in monkey after po administration of 10 mg/kg dose,,BAO_0000218,,Primates,,Intermediate,2891,In vivo,U,0,CHEMBL623040,,,
10114,1,Oral bioavailability in monkey (dose 10 mg/kg),,BAO_0000218,,Primates,,Intermediate,2891,In vivo,U,0,CHEMBL623041,,,
10115,1,Bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6672,In vivo,N,1,CHEMBL623741,,,
10116,1,Bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6673,In vivo,N,1,CHEMBL623742,,,
10117,1,Bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,17655,In vivo,N,1,CHEMBL623743,,,
10118,1,Bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,17796,In vivo,N,1,CHEMBL623744,,,
10119,1,Bioavailability in rat (dose 2.0 mg/kg p.o.),,BAO_0000218,,Rattus norvegicus,,Intermediate,17853,In vivo,N,1,CHEMBL623745,,,
10120,1,Bioavailability in rat (dose 5 mg/kg p.o. and 1 mg/kg i.v.),,BAO_0000218,,Rattus norvegicus,,Intermediate,4521,In vivo,N,1,CHEMBL623746,,,
10121,1,Oral bioavailability in rat (dose 5 mg/kg p.o.),,BAO_0000218,,Rattus norvegicus,,Intermediate,4940,In vivo,N,1,CHEMBL623747,,,
10122,1,Bioavailability in rat after po administration of 30 mg/kg dose,,BAO_0000218,,Rattus norvegicus,,Intermediate,2891,In vivo,U,0,CHEMBL623748,,,
10123,1,Bioavailability in rat after po administration of 30 mg/kg dose,,BAO_0000218,,Rattus norvegicus,,Intermediate,2891,In vivo,U,0,CHEMBL623916,,,
10124,1,Bioavailability in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,4521,In vivo,N,1,CHEMBL623917,,,
10125,1,Bioavailability in rat (dose 2 mg/kg i.v.),,BAO_0000218,,Rattus norvegicus,,Intermediate,17686,In vivo,N,1,CHEMBL623918,,,
10126,1,Bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,17796,In vivo,N,1,CHEMBL874386,,,
10127,1,Bioavailability in rat; Only traces detected in rat plasma,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,17796,In vivo,N,1,CHEMBL623919,,1969.0,
10128,1,Bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5064,In vivo,N,1,CHEMBL623920,,,
10129,1,Bioavailability upon oral administration of compound,,BAO_0000218,,Rattus norvegicus,,Intermediate,5147,In vivo,N,1,CHEMBL623148,,,
10130,1,Oral bioavailability in rat (Sprague-Dawley) (dose 15 mg/kg),,BAO_0000218,,Rattus norvegicus,,Intermediate,1916,In vivo,N,1,CHEMBL623149,,,
10131,1,Bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6049,In vivo,N,1,CHEMBL623150,,,
10132,1,"Bioavailability was evaluated in rats at a dose of 20 mg/kg, under fasting state",,BAO_0000218,,Rattus norvegicus,,Intermediate,1445,In vivo,N,1,CHEMBL623151,,,
10133,1,"Bioavailability was evaluated in rats at a dose of 20 mg/kg, under fed state",,BAO_0000218,,Rattus norvegicus,,Intermediate,1445,In vivo,N,1,CHEMBL623152,,,
10134,1,Streptococcal cell wall-washed arthritis model in rats at 3.0 mg/kg peroral dose,,BAO_0000218,,Rattus norvegicus,,Expert,2862,,N,1,CHEMBL623153,,,
10135,1,Streptococcal cell wall-washed arthritis model in rats at 30.0 mg/kg peroral dose,,BAO_0000218,,Rattus norvegicus,,Expert,2862,,N,1,CHEMBL623154,,,
10136,1,In vitro and metabolic stability was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,4194,,N,1,CHEMBL623155,,,
10137,1,In vitro metabolic stability in rat hepatocytes,,BAO_0000218,,Rattus norvegicus,,Intermediate,4194,,N,1,CHEMBL623156,,,
10138,1,In vitro metabolic stability in rat was measured as pmol/min/mg/protein,,BAO_0000218,,Rattus norvegicus,,Intermediate,5486,,N,1,CHEMBL623157,,,
10139,1,Metabolic rate for compound was observed in rat hepatocytes,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,17582,In vitro,N,1,CHEMBL623158,401.0,2107.0,
10140,1,In vitro metabolic stability determined after 30 min of incubation in rat hepatic microsomes,,BAO_0000218,,Rattus norvegicus,,Intermediate,5600,,N,1,CHEMBL623159,,,
10141,1,Metabolism of compound in rat S9 microsomes ('+''indicates <20% largest observed peak),,BAO_0000218,,Rattus norvegicus,,Intermediate,14294,,N,1,CHEMBL874390,,,
10142,1,Metabolism of compound in rat S9 microsomes ('++++' indicates largest observed peak),,BAO_0000218,,Rattus norvegicus,,Intermediate,14294,,N,1,CHEMBL623160,,,
10143,1,Metabolism of compound in rat S9 microsomes; Trace,,BAO_0000218,,Rattus norvegicus,,Intermediate,14294,,N,1,CHEMBL623161,,,
10144,1,Metabolism was measured as percent loss at 4 hr in rat hepatocytes,,BAO_0000218,,Rattus norvegicus,,Intermediate,17847,,N,1,CHEMBL623162,,,
10145,1,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex 5-HIAA,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,N,1,CHEMBL623163,,,
10146,1,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex 5-HT,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,N,1,CHEMBL623164,,,
10147,1,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex DA,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,N,1,CHEMBL623165,,,
10148,1,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex DOPAC,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,N,1,CHEMBL623166,,,
10149,1,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex HVA,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,N,1,CHEMBL624983,,,
10150,1,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex NE,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,N,1,CHEMBL624984,,,
10151,1,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Hippocampus 5-HIAA,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,N,1,CHEMBL624985,,,
10152,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus 5-HT,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,N,1,CHEMBL622970,,,
10153,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DA; below level of detection,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,N,1,CHEMBL622971,,,
10154,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DA; below the levels of detection,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,N,1,CHEMBL622972,,,
10155,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DOPAC; below level of detection,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,N,1,CHEMBL622973,,,
10156,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DOPAC; below the levels of detection,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,N,1,CHEMBL622974,,,
10157,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus HVA; below level of detection,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,N,1,CHEMBL622975,,,
10158,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus HVA; below the levels of detection,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,N,1,CHEMBL622976,,,
10159,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus NE,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,N,1,CHEMBL622977,,,
10160,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex 5-HIAA,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,N,1,CHEMBL624351,,,
10161,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex 5-HT,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,N,1,CHEMBL624352,,,
10162,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DA,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,N,1,CHEMBL624353,,,
10163,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DOPAC,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,N,1,CHEMBL622397,,,
10164,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex HVA,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,N,1,CHEMBL622398,,,
10165,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex NE,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,N,1,CHEMBL622399,,,
10166,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DA,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,N,1,CHEMBL622400,,,
10167,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus 5-HIAA,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,N,1,CHEMBL628428,,,
10168,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus 5-HT,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,N,1,CHEMBL628590,,,
10169,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DA; below level of detection,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,N,1,CHEMBL628591,,,
10170,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DA; below the levels of detection,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,N,1,CHEMBL628592,,,
10171,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DOPAC; below level of detection,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,N,1,CHEMBL628593,,,
10172,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DOPAC; below the levels of detection,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,N,1,CHEMBL875333,,,
10173,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus HVA; below level of detection,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,N,1,CHEMBL628594,,,
10174,1,Plasma half-life was determined in Sprague-Dawley rats after 0-8 hr of administration,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,4969,,N,1,CHEMBL628595,,1969.0,
10175,1,Stability in rat plasma was determined,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,6737,,N,1,CHEMBL628596,,1969.0,
10176,1,Stability in rat plasma was determined; ND= no data,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,6737,,N,1,CHEMBL628597,,1969.0,
10177,1,Tested for plasma half life period in rat (0-8 hr),Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,5089,,N,1,CHEMBL628598,,1969.0,
10178,1,Tested for plasma half life period in rat (0-8 hr); Not determined,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,5089,,N,1,CHEMBL628599,,1969.0,
10179,1,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,1466,In vivo,N,1,CHEMBL628600,,,
10180,1,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,1466,In vivo,N,1,CHEMBL628601,,,
10181,1,Tested for the half life in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4950,,N,1,CHEMBL628602,,,
10182,1,Tested in vitro for the time for half reactivation against rat small intestinal glucoamylase,,BAO_0000218,,Rattus norvegicus,,Intermediate,2412,In vitro,N,1,CHEMBL628603,,,
10183,1,Tested in vitro for the time for half reactivation against rat small intestinal glucoamylase; ND=Not determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,2412,In vitro,N,1,CHEMBL628604,,,
10184,1,Tested in vitro for the time for half reactivation against rat small intestinal isomaltase,,BAO_0000218,,Rattus norvegicus,,Intermediate,2412,In vitro,N,1,CHEMBL628605,,,
10185,1,Tested in vitro for the time for half reactivation against rat small intestinal isomaltase; ND=Not determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,2412,In vitro,N,1,CHEMBL628606,,,
10186,1,Tested in vitro for the time for half reactivation against rat small intestinal sucrase,,BAO_0000218,,Rattus norvegicus,,Intermediate,2412,In vitro,N,1,CHEMBL628607,,,
10187,1,The biological half life the compound was measured at the dose of 100 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,15022,,N,1,CHEMBL628608,,,
10188,1,The biological half life the compound was measured at the dose of 30 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,15022,,N,1,CHEMBL628609,,,
10189,1,The compound was evaluated for plasma half life period in rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,406,,N,1,CHEMBL628610,,1969.0,
10190,1,"The half life value in female wistar rat at 100 mg/kg, p.o. dose",,BAO_0000218,,Rattus norvegicus,,Intermediate,15078,In vivo,N,1,CHEMBL873819,,,
10191,1,"The half life value in male wistar rat at 100 mg/kg, p.o. dose",,BAO_0000218,,Rattus norvegicus,,Intermediate,15078,In vivo,N,1,CHEMBL628611,,,
10192,1,The pharmacokinetic parameter half-life period in vivo in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,5247,In vivo,N,1,CHEMBL628612,,,
10193,1,"The pharmacokinetic property, Half-life was determined",,BAO_0000218,,Rattus norvegicus,,Intermediate,5041,In vivo,N,1,CHEMBL628613,,,
10194,1,"The pharmacokinetic property, Half-life in rat in vivo",,BAO_0000218,,Rattus norvegicus,,Intermediate,5041,In vivo,N,1,CHEMBL628614,,,
10195,1,"The pharmacokinetic property, Half-life was determined; ND denotes no data",,BAO_0000218,,Rattus norvegicus,,Intermediate,5041,In vivo,N,1,CHEMBL628615,,,
10196,1,"The pharmacokinetic property, Half-life was determined; ND denotes not determined",,BAO_0000218,,Rattus norvegicus,,Intermediate,5041,In vivo,N,1,CHEMBL628616,,,
10197,1,The plasma half life period in rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,3918,,N,1,CHEMBL627924,,1969.0,
10198,1,The release rate of the free drug from the substrate in rat liver lysosomal preparation by rat liver lysosomal assay,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,2906,,N,1,CHEMBL627925,,2107.0,
10199,1,half life in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,6467,In vivo,N,1,CHEMBL627926,,,
10200,1,t1/2 (apparent elimination)of the compound was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,5510,,N,1,CHEMBL627927,,,
10201,1,t1/2 value in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,3788,,N,1,CHEMBL627928,,,
10202,1,Half life in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,17796,,N,1,CHEMBL627539,,,
10203,1,"Half life period calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv",Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,12873,In vivo,N,1,CHEMBL876790,,1969.0,
10204,1,Pharmacokinetic property (t1/2beta) was measured in rat at the dose of 0.32 mg/kg i.v.,,BAO_0000218,,Rattus norvegicus,,Intermediate,5983,In vivo,N,1,CHEMBL858186,,,
10205,1,Half-life period in fasted rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,15765,,N,1,CHEMBL627540,,,
10206,1,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female wistar rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,2661,In vivo,N,1,CHEMBL627541,,,
10207,1,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to male wistar rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,2661,In vivo,N,1,CHEMBL627715,,,
10208,1,Evaluated for pharmacokinetic parameter tmax in rat at the dose 50 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,429,In vivo,N,1,CHEMBL627716,,,
10209,1,Maximum time required to achieve Cmax was determined in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,17655,,N,1,CHEMBL627717,,,
10210,1,Time calculated to reach Cmax at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,,BAO_0000218,,Rattus norvegicus,,Intermediate,17717,In vivo,N,1,CHEMBL627718,,,
10211,1,Time calculated to reach Cmax at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,,BAO_0000218,,Rattus norvegicus,,Intermediate,17717,In vivo,N,1,CHEMBL627719,,,
10212,1,Time calculated to reach Cmax at a concentration of 60 mg/kg perorally in rats along with control,,BAO_0000218,,Rattus norvegicus,,Intermediate,17717,In vivo,N,1,CHEMBL627720,,,
10213,1,Time to reach maximum concentration in rat after 2 mg/kg peroral administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,6570,In vivo,N,1,CHEMBL627721,,,
10214,1,Time to reach maximum concentration in rat after 2 mg/kg peroral administration; 4-6,,BAO_0000218,,Rattus norvegicus,,Intermediate,6570,In vivo,N,1,CHEMBL627722,,,
10215,1,Tmax of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5978,In vivo,N,1,CHEMBL627723,,,
10216,1,Tmax of compound (19.76 mg/kg) after po administration was determined in Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5978,In vivo,N,1,CHEMBL626058,,,
10217,1,Tmax of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5978,In vivo,N,1,CHEMBL626059,,,
10218,1,Tmax of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5978,In vivo,N,1,CHEMBL626060,,,
10219,1,Tmax at a dose of 4 mg/kg in Rat Plasma after iv administration,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,17720,In vivo,N,1,CHEMBL626061,,1969.0,
10220,1,Tmax determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,4723,In vivo,N,1,CHEMBL876791,,,
10221,1,Tmax determined after 3 mg/kg oral administration in potassium oxonate treated rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,4723,In vivo,N,1,CHEMBL626062,,,
10222,1,Tmax at the dose of 2 mg/Kg administered perorally in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,4756,In vivo,N,1,CHEMBL626063,,,
10223,1,Tmax at the dose of 5 mg/Kg administered perorally in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,4756,In vivo,N,1,CHEMBL626064,,,
10224,1,tmax at a dose of 100 mg/kg in Rat Plasma after iv administration,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,17720,In vivo,N,1,CHEMBL626065,,1969.0,
10225,1,tmax at a dose of 50 mg/kg in Rat Plasma after iv administration,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,17720,In vivo,N,1,CHEMBL626066,,1969.0,
10226,1,tmax upon peroral administration of 10.0 mg/Kg dose in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,1466,In vivo,N,1,CHEMBL626067,,,
10227,1,Percent total excretion of 3-(thiomethyl)acetaminophen glucuronide,,BAO_0000218,,Rattus norvegicus,,Intermediate,7449,,N,1,CHEMBL626068,,,
10228,1,Percent total excretion of 3-(thiomethyl)acetaminophen sulfate,,BAO_0000218,,Rattus norvegicus,,Intermediate,7449,,N,1,CHEMBL626069,,,
10229,1,Percent total excretion of 3-methoxyacetaminophen glucuronide,,BAO_0000218,,Rattus norvegicus,,Intermediate,7449,,N,1,CHEMBL626070,,,
10230,1,Percent total excretion of N-methoxyacetaminophen glucuronide,,BAO_0000218,,Rattus norvegicus,,Intermediate,7449,,N,1,CHEMBL626071,,,
10231,1,Percent total excretion of N-methoxyacetaminophen sulfate,,BAO_0000218,,Rattus norvegicus,,Intermediate,7449,,N,1,CHEMBL626072,,,
10232,1,Percent total excretion of acetaminophen,,BAO_0000218,,Rattus norvegicus,,Intermediate,7449,,N,1,CHEMBL626073,,,
10233,1,"Distribution of radioactivity in thyroid tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 6.19-7.22",Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,7768,,N,1,CHEMBL626741,,2046.0,
10234,1,"Percent instability was measured by Rat S9 liver slice metabolism assay, in vitro",,BAO_0000218,,Rattus norvegicus,,Intermediate,17655,,N,1,CHEMBL626742,,,
10235,1,Plasma clearance following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,17735,,N,1,CHEMBL626743,,,
10236,1,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,,BAO_0000218,,Rattus norvegicus,,Intermediate,5960,,N,1,CHEMBL876792,,,
10237,1,Volume of distribution following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,17735,,N,1,CHEMBL626744,,,
10238,1,Compound was tested for antidiuretic activity in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,7116,,N,1,CHEMBL626745,,,
10239,1,AUC in rat after 3mg/kg oral dose,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,4878,In vivo,N,1,CHEMBL626746,,1969.0,
10240,1,Ratio in brain to that of rat plasma for 2 hr after peroral administration at 10 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,5939,,N,1,CHEMBL626747,,,
10241,1,Ratio in brain to that of rat plasma for 2 hr after peroral administration at 5 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,5939,,N,1,CHEMBL626748,,,
10242,1,Bioavailability administered orally at a dose of 10 mg/kg to rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,16367,,N,1,CHEMBL626749,,,
10243,1,Oral Bioavailability was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,16366,,N,1,CHEMBL626750,,,
10244,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4426,,N,1,CHEMBL626751,,,
10245,1,Oral bioavailability in rat; Not performed.,,BAO_0000218,,Rattus norvegicus,,Intermediate,4426,,N,1,CHEMBL626913,,,
10246,1,Bioavailability,,BAO_0000218,,Rattus norvegicus,,Intermediate,5041,,N,1,CHEMBL626914,,,
10247,1,Bioavailability was determined; ND denotes no data,,BAO_0000218,,Rattus norvegicus,,Intermediate,5041,,N,1,CHEMBL626915,,,
10248,1,Biliary excretion when administered intravenously at a dose of 2.5 mg/kg in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,1500,,N,1,CHEMBL626916,,,
10249,1,Biliary excretion when administered intravenously at a dose of 5 mg/kg in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,1500,,N,1,CHEMBL626917,,,
10250,1,Binding towards rat plasma protein at 10 uM,,BAO_0000218,,Rattus norvegicus,,Intermediate,17409,,N,1,CHEMBL626918,,,
10251,1,Binding towards rat plasma protein at 100 uM,,BAO_0000218,,Rattus norvegicus,,Intermediate,17409,,N,1,CHEMBL626919,,,
10252,1,Bioavailability in rat (dose 20 mg/kg p.o.),,BAO_0000218,,Rattus norvegicus,,Intermediate,2959,In vivo,N,1,CHEMBL626920,,,
10253,1,Bioavailability was determined after oral administration of compound 18 at a dose of 4 mg/kg to rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,13501,In vivo,N,1,CHEMBL621976,,,
10254,1,Bioavailability in rat after 5 mg/kg oral gavage,,BAO_0000218,,Rattus norvegicus,,Intermediate,6567,In vivo,N,1,CHEMBL877599,,,
10255,1,Bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6571,In vivo,N,1,CHEMBL621977,,,
10256,1,Bioavailability in rat (dose 1 mg/kg i.v.),,BAO_0000218,,Rattus norvegicus,,Intermediate,6715,In vivo,N,1,CHEMBL621978,,,
10257,1,Bioavailability in rat (dose 3 mg/kg p.o.),,BAO_0000218,,Rattus norvegicus,,Intermediate,6715,In vivo,N,1,CHEMBL621979,,,
10258,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,2932,In vivo,N,1,CHEMBL621980,,,
10259,1,Bioavailability of the compound in rats after administration of 30 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,4171,In vivo,N,1,CHEMBL621981,,,
10260,1,Bioavailability after administration of 10 mg/kg in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,17509,In vivo,N,1,CHEMBL621982,,,
10261,1,Bioavailability after administration of 2 mg/kg in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,17509,In vivo,N,1,CHEMBL882953,,,
10262,1,Bioavailability by oral administration at a dose of 100 uM/kg in rat was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,4527,In vivo,N,1,CHEMBL621983,,,
10263,1,Bioavailability in dogs was determined; high,,BAO_0000218,,Rattus norvegicus,,Intermediate,4026,In vivo,N,1,CHEMBL621984,,,
10264,1,Bioavailability in monkey after intravenous administration at 1 mpk,,BAO_0000218,,Rattus norvegicus,,Intermediate,6659,In vivo,N,1,CHEMBL621985,,,
10265,1,Bioavailability in monkey after peroral administration at 10 mpk,,BAO_0000218,,Rattus norvegicus,,Intermediate,6659,In vivo,N,1,CHEMBL621986,,,
10266,1,Bioavailability in rat after intravenous administration at 1 mpk,,BAO_0000218,,Rattus norvegicus,,Intermediate,6659,In vivo,N,1,CHEMBL621987,,,
10267,1,Bioavailability in rat after intravenous administration at 2 mpk,,BAO_0000218,,Rattus norvegicus,,Intermediate,6659,In vivo,N,1,CHEMBL877600,,,
10268,1,Bioavailability in rat after peroral administration at 30 mpk,,BAO_0000218,,Rattus norvegicus,,Intermediate,6659,In vivo,N,1,CHEMBL621988,,,
10269,1,Bioavailability in rat after peroral administration at at 100 mpk,,BAO_0000218,,Rattus norvegicus,,Intermediate,6659,In vivo,N,1,CHEMBL621989,,,
10270,1,Bioavailability in rats was evaluated,,BAO_0000218,,Rattus norvegicus,,Intermediate,6597,In vivo,N,1,CHEMBL621990,,,
10271,1,Bioavailability was calculated after an intravenous dose of 0.3 mg/Kg in rats after 6 hr,,BAO_0000218,,Rattus norvegicus,,Intermediate,1202,In vivo,N,1,CHEMBL621991,,,
10272,1,Bioavailability was calculated after an intravenous dose of 1 mg/Kg in rats after 6 hr,,BAO_0000218,,Rattus norvegicus,,Intermediate,1202,In vivo,N,1,CHEMBL621992,,,
10273,1,Bioavailability was calculated after peroral dose of 3.0 mg/Kg in rats after 4 hr,,BAO_0000218,,Rattus norvegicus,,Intermediate,1202,In vivo,N,1,CHEMBL621993,,,
10274,1,Bioavailability was calculated after peroral dose of 3.0 mg/Kg in rats after 6 hr,,BAO_0000218,,Rattus norvegicus,,Intermediate,1202,In vivo,N,1,CHEMBL621994,,,
10275,1,Bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5207,In vivo,N,1,CHEMBL621995,,,
10276,1,Bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5970,In vivo,N,1,CHEMBL621996,,,
10277,1,Oral bioavailability in rat (dose 10 mg/kg),,BAO_0000218,,Rattus norvegicus,,Intermediate,17538,In vivo,N,1,CHEMBL621997,,,
10278,1,Bioavailability in rat after po administration at a dose of 10 mg/kg; nd is not determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,17538,In vivo,N,1,CHEMBL621998,,,
10279,1,Bioavailability upon peroral administration of 10.0 mg/Kg dose in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,1466,In vivo,N,1,CHEMBL621999,,,
10280,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,2879,In vivo,N,1,CHEMBL622000,,,
10281,1,Bioavailability was measured in rat after oral administration; 2-4,,BAO_0000218,,Rattus norvegicus,,Intermediate,2879,In vivo,N,1,CHEMBL622001,,,
10282,1,Bioavailability was measured in rat after oral administration; 3-7,,BAO_0000218,,Rattus norvegicus,,Intermediate,2879,In vivo,N,1,CHEMBL622002,,,
10283,1,Bioavailability in rat (intraduodenal administration),,BAO_0000218,,Rattus norvegicus,,Intermediate,3777,In vivo,N,1,CHEMBL622003,,,
10284,1,Bioavailability in rat (intraduodenal administration),,BAO_0000218,,Rattus norvegicus,,Intermediate,3777,In vivo,N,1,CHEMBL877601,,,
10285,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,3777,In vivo,N,1,CHEMBL624871,,,
10286,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,3777,In vivo,N,1,CHEMBL622004,,,
10287,1,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg p.o.),,BAO_0000218,,Rattus norvegicus,,Intermediate,5423,In vivo,N,1,CHEMBL882954,,,
10288,1,Bioavailability was evaluated when a dose of 3 mg/kg was administered orally,,BAO_0000218,,Rattus norvegicus,,Intermediate,16365,In vivo,N,1,CHEMBL622005,,,
10289,1,Bioavailability was evaluated when a dose of 3 mg/kg was administered orally to a fasting rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,16365,In vivo,N,1,CHEMBL622006,,,
10290,1,Bioavailability was measured in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4239,In vivo,N,1,CHEMBL622007,,,
10291,1,Bioavailability was reported,,BAO_0000218,,Rattus norvegicus,,Intermediate,5438,In vivo,N,1,CHEMBL622008,,,
10292,1,Bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),,BAO_0000218,,Rattus norvegicus,,Intermediate,5334,In vivo,N,1,CHEMBL622009,,,
10293,1,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),,BAO_0000218,,Rattus norvegicus,,Intermediate,5334,In vivo,N,1,CHEMBL622010,,,
10294,1,Bioavailability was determined upon 10 mg/kg in 1% methylcellulose peroral administration in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,4199,In vivo,N,1,CHEMBL622011,,,
10295,1,Bioavailability in rat (dose 2 mg/kg in 1% methylcellulose p.o.),,BAO_0000218,,Rattus norvegicus,,Intermediate,4199,In vivo,N,1,CHEMBL622012,,,
10296,1,Bioavailability in rat (dose 3 mg/kg in 1% methylcellulose ),,BAO_0000218,,Rattus norvegicus,,Intermediate,4199,In vivo,N,1,CHEMBL622013,,,
10297,1,Bioavailability was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,4890,In vivo,N,1,CHEMBL622014,,,
10298,1,Bioavailability was determined at 3 mg/kg po dose in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,2792,In vivo,N,1,CHEMBL624749,,,
10299,1,Oral bioavailability in rat (dose 2 mg/kg),,BAO_0000218,,Rattus norvegicus,,Intermediate,5529,In vivo,N,1,CHEMBL624750,,,
10300,1,"Bioavailability was determined in rats at 10 mg/kg, p.o. dose",,BAO_0000218,,Rattus norvegicus,,Intermediate,6685,In vivo,N,1,CHEMBL624751,,,
10301,1,"Bioavailability was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",,BAO_0000218,,Rattus norvegicus,,Intermediate,6685,In vivo,N,1,CHEMBL624752,,,
10302,1,"Bioavailability was determined in rats at 2 mg/kg, i.v. dose; n/a: not applicable",,BAO_0000218,,Rattus norvegicus,,Intermediate,6685,In vivo,N,1,CHEMBL624753,,,
10303,1,Bioavailability was evaluated in rat after peroral administration at a dose of 1 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,6005,In vivo,N,1,CHEMBL624754,,,
10304,1,Bioavailability was evaluated in rats at an intravenous dose of 3 mg/kg; Not applicable,,BAO_0000218,,Rattus norvegicus,,Intermediate,6410,In vivo,N,1,CHEMBL624755,,,
10305,1,Bioavailability was evaluated in rats at an oral dose of 30 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,6410,In vivo,N,1,CHEMBL624756,,,
10306,1,Bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6103,In vivo,N,1,CHEMBL624757,,,
10307,1,Bioavailability was evaluated in rats at an intravenous dose of 3 mg/kg; Not applicable,,BAO_0000218,,Rattus norvegicus,,Intermediate,6410,In vivo,N,1,CHEMBL624758,,,
10308,1,Bioavailability was evaluated in rats at an oral dose of 30 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,6410,In vivo,N,1,CHEMBL622270,,,
10309,1,Bioavailability in rat (Sprague-Dawley),,BAO_0000218,,Rattus norvegicus,,Intermediate,5353,In vivo,N,1,CHEMBL622271,,,
10310,1,Bioavailability in rat at the dose of 2 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,4727,In vivo,N,1,CHEMBL622272,,,
10311,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,17804,In vivo,N,1,CHEMBL622273,,,
10312,1,Bioavailability in rat (cannulated) (dose 2 mg/kg),,BAO_0000218,,Rattus norvegicus,,Intermediate,5809,In vivo,N,1,CHEMBL622274,,,
10313,1,Bioavailability value of compound in rats was determined after peroral administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,17804,In vivo,N,1,CHEMBL622275,,,
10314,1,Oral bioavailability in rat (dose 20 mg/kg),,BAO_0000218,,Rattus norvegicus,,Intermediate,3634,In vivo,N,1,CHEMBL622276,,,
10315,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,3341,In vivo,N,1,CHEMBL622277,,,
10316,1,Oral bioavailability in rat (dose 5 mg/kg),,BAO_0000218,,Rattus norvegicus,,Intermediate,2690,In vivo,N,1,CHEMBL622278,,,
10317,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,3184,In vivo,N,1,CHEMBL622279,,,
10318,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,740,In vivo,N,1,CHEMBL622280,,,
10319,1,Compound was evaluated for oral bioavailability in rats; 15-27 %,,BAO_0000218,,Rattus norvegicus,,Intermediate,1806,In vivo,N,1,CHEMBL624083,,,
10320,1,Compound was evaluated for pharmacokinetic parameter percent bioavailability at 18 h,,BAO_0000218,,Rattus norvegicus,,Intermediate,4891,In vivo,N,1,CHEMBL624084,,,
10321,1,Compound was evaluated for pharmacokinetic property in rats after an oral dose of 10 mg/kg and the value was reported as oral bioavailability (F),,BAO_0000218,,Rattus norvegicus,,Intermediate,3634,In vivo,N,1,CHEMBL624085,,,
10322,1,Compound was tested for bioavailability in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,64,In vivo,N,1,CHEMBL624086,,,
10323,1,Bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4839,In vivo,N,1,CHEMBL624087,,,
10324,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,1094,In vivo,N,1,CHEMBL624088,,,
10325,1,Compound was tested for oral bioavailability in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po.,,BAO_0000218,,Macaca mulatta,,Intermediate,5005,In vivo,U,0,CHEMBL624089,,,
10326,1,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v. and 2 mg/kg p.o.),,BAO_0000218,,Rattus norvegicus,,Intermediate,5005,In vivo,U,0,CHEMBL624090,,,
10327,1,Evaluated for the bioavailability in rat (in vivo),,BAO_0000218,,Rattus norvegicus,,Intermediate,4687,In vivo,N,1,CHEMBL624091,,,
10328,1,F value of compound in rats was determined after peroral administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,17804,In vivo,N,1,CHEMBL624092,,,
10329,1,In vivo Oral bioavailability (F)was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5974,In vivo,N,1,CHEMBL624093,,,
10330,1,In vivo Oral bioavailability (F)was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5974,In vivo,N,1,CHEMBL624094,,,
10331,1,In vivo Oral bioavailability (F)was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5974,In vivo,N,1,CHEMBL624095,,,
10332,1,In vivo Oral bioavailability (F)was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5974,In vivo,N,1,CHEMBL624096,,,
10333,1,"In vivo percent of absolute bioavailability obtained from blood plasma levels analyzed by means of GC/MS (dose 5 uM/kg i.v. and 40 uM/kg, p.o.)",,BAO_0000218,,Rattus norvegicus,,Intermediate,1088,In vivo,N,1,CHEMBL624097,,,
10334,1,Maximum fall in carotid flow in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,1742,In vivo,N,1,CHEMBL624098,,,
10335,1,Oral Bioavailability after intravenous administration (1 mg/kg) in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4689,In vivo,N,1,CHEMBL874392,,,
10336,1,Oral bioavailability in rat (dose 5 mg/kg),,BAO_0000218,,Rattus norvegicus,,Intermediate,2463,In vivo,N,1,CHEMBL624099,,,
10337,1,Oral bioavailability (F%) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,5654,In vivo,N,1,CHEMBL624100,,,
10338,1,Oral bioavailability (F%) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,5654,In vivo,N,1,CHEMBL624101,,,
10339,1,Oral bioavailability in rat (male Wistar),,BAO_0000218,,Rattus norvegicus,,Intermediate,6874,In vivo,N,1,CHEMBL624102,,,
10340,1,Oral bioavailability after administration (30 mg/kg) in rat; good,,BAO_0000218,,Rattus norvegicus,,Intermediate,5633,In vivo,N,1,CHEMBL624103,,,
10341,1,Oral bioavailability at the dose of 2 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5496,In vivo,N,1,CHEMBL624104,,,
10342,1,Oral bioavailability determined in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,2358,In vivo,N,1,CHEMBL624105,,,
10343,1,Oral bioavailability in rat (Sprague-Dawley) (male) (dose 50 mg/kg p.o.),,BAO_0000218,,Rattus norvegicus,,Intermediate,16456,In vivo,N,1,CHEMBL624106,,,
10344,1,Oral bioavailability in rat (dose single 10 mg/kg),,BAO_0000218,,Rattus norvegicus,,Intermediate,5302,In vivo,N,1,CHEMBL624107,,,
10345,1,Oral bioavailability in rat (dose single 10 mg/kg),,BAO_0000218,,Rattus norvegicus,,Intermediate,5302,In vivo,N,1,CHEMBL623943,,,
10346,1,Oral bioavailability in rat (dose 5 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,5302,In vivo,N,1,CHEMBL623944,,,
10347,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus HVA; below the levels of detection,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,N,1,CHEMBL623945,,,
10348,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus NE,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,N,1,CHEMBL623946,,,
10349,1,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex 5-HIAA,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,N,1,CHEMBL623947,,,
10350,1,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex 5-HT,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,N,1,CHEMBL623948,,,
10351,1,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex DA,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,N,1,CHEMBL623949,,,
10352,1,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex DOPAC,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,N,1,CHEMBL623950,,,
10353,1,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex HVA,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,N,1,CHEMBL874398,,,
10354,1,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex NE,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,N,1,CHEMBL623951,,,
10355,1,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus 5-HIAA,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,N,1,CHEMBL623952,,,
10356,1,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus 5-HT,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,N,1,CHEMBL623953,,,
10357,1,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DA; below level of detection,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,N,1,CHEMBL623954,,,
10358,1,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DA; below the levels of detection,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,N,1,CHEMBL623955,,,
10359,1,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DOPAC; below level of detection,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,N,1,CHEMBL623956,,,
10360,1,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DOPAC; below the levels of detection,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,N,1,CHEMBL627807,,,
10361,1,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus HVA; below level of detection,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,N,1,CHEMBL627808,,,
10362,1,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus HVA; below the levels of detection,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,N,1,CHEMBL627809,,,
10363,1,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus NE,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,N,1,CHEMBL627810,,,
10364,1,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex 5-HIAA",,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,N,1,CHEMBL627811,,,
10365,1,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex 5-HT",,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,N,1,CHEMBL627812,,,
10366,1,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex DA",,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,N,1,CHEMBL627813,,,
10367,1,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex DOPAC",,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,N,1,CHEMBL627814,,,
10368,1,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex HVA",,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,N,1,CHEMBL875336,,,
10369,1,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex NE",,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,N,1,CHEMBL627815,,,
10370,1,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus 5-HIAA",,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,N,1,CHEMBL627816,,,
10371,1,"Momoamine and metabolic levels observed at 3 h postdrug against, at a dose of 20 mg/kg Hippocampus 5-HT",,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,N,1,CHEMBL627817,,,
10372,1,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus DA; below the levels of detection",,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,N,1,CHEMBL627818,,,
10373,1,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus DOPAC; below the levels of detection",,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,N,1,CHEMBL627819,,,
10374,1,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus HVA; below the levels of detection",,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,N,1,CHEMBL627820,,,
10375,1,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus NE",,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,N,1,CHEMBL627821,,,
10376,1,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex 5-HIAA,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,N,1,CHEMBL628464,,,
10377,1,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex 5-HT,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,N,1,CHEMBL626239,,,
10378,1,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex DA,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,N,1,CHEMBL626240,,,
10379,1,Momoamine and metabolic levels observed at 3 h postdrug against at a dose of 20 mg/kg Frontal cortex DOPAC,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,N,1,CHEMBL626241,,,
10380,1,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex HVA,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,N,1,CHEMBL626242,,,
10381,1,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex NE,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,N,1,CHEMBL626243,,,
10382,1,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus 5-HIAA,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,N,1,CHEMBL626244,,,
10383,1,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus 5-HT; below level of detection,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,N,1,CHEMBL626907,,,
10384,1,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus DA; below level of detection,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,N,1,CHEMBL626908,,,
10385,1,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus DOPAC; below level of detection,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,N,1,CHEMBL626909,,,
10386,1,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus HVA; below level of detection,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,N,1,CHEMBL626910,,,
10387,1,Percent total excretion of acetaminophen cysteine conjugate,,BAO_0000218,,Rattus norvegicus,,Intermediate,7449,,N,1,CHEMBL875342,,,
10388,1,Percent total excretion of acetaminophen glucuronide,,BAO_0000218,,Rattus norvegicus,,Intermediate,7449,,N,1,CHEMBL626911,,,
10389,1,Percent total excretion of acetaminophen sulfate,,BAO_0000218,,Rattus norvegicus,,Intermediate,7449,,N,1,CHEMBL626912,,,
10390,1,Percent total excretion of acetaminophen-mercapturic acid,,BAO_0000218,,Rattus norvegicus,,Intermediate,7449,,N,1,CHEMBL627065,,,
10391,1,Amount of urine output was measured in rat at a dose of 10 mg/kg administered orally,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,3172,,N,1,CHEMBL627066,,1088.0,
10392,1,Volume of distribution in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,16456,In vivo,N,1,CHEMBL627067,,,
10393,1,Biodistribution of compound in rat muscle after 5 min of administration,Muscle tissue,BAO_0000218,,ratrat,,Autocuration,10839,In vivo,U,0,CHEMBL627068,,2385.0,
10394,1,Biodistribution of compound in rat muscle after 5 min of administration.,Muscle tissue,BAO_0000218,,ratrat,,Autocuration,10839,In vivo,U,0,CHEMBL627069,,2385.0,
10395,1,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),,BAO_0000218,,Ovis aries,,Autocuration,5334,In vivo,U,0,CHEMBL627070,,,
10396,1,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),,BAO_0000218,,Ovis aries,,Autocuration,5334,In vivo,U,0,CHEMBL627071,,,
10397,1,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),,BAO_0000218,,Ovis aries,,Autocuration,5334,In vivo,U,0,CHEMBL627072,,,
10398,1,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),,BAO_0000218,,Ovis aries,,Autocuration,5334,In vivo,U,0,CHEMBL627073,,,
10399,1,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),,BAO_0000218,,Ovis aries,,Autocuration,5334,In vivo,U,0,CHEMBL625387,,,
10400,1,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),,BAO_0000218,,Ovis aries,,Autocuration,5334,In vivo,U,0,CHEMBL625388,,,
10401,1,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),Plasma,BAO_0000218,,Ovis aries,,Autocuration,5334,In vivo,U,0,CHEMBL625389,,1969.0,
10402,1,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),Plasma,BAO_0000218,,Ovis aries,,Autocuration,5334,In vivo,U,0,CHEMBL875343,,1969.0,
10403,1,Biological half life period of compound was measured against snake venom phosphodiesterase (SVPDE),,BAO_0000218,,Serpentes,,Intermediate,1735,,N,1,CHEMBL876795,,,
10404,1,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards snake venom (SV-PDE) at a concentration of 4 microg,,BAO_0000218,,Serpentes,,Intermediate,1469,,N,1,CHEMBL626552,,,
10405,1,Enzymatic stability was assessed with snake venom phosphodiesterase (SV PDE) exonuclase,,BAO_0000218,,Serpentes,,Intermediate,1336,,N,1,CHEMBL626553,,,
10406,1,The human biological plasma half life of the compound,Plasma,BAO_0000366,,Homo sapiens,,Autocuration,12403,,U,0,CHEMBL626554,,1969.0,
10407,1,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,8151,,N,1,CHEMBL626555,,1088.0,
10408,1,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 120 min after iv administration compound,,BAO_0000218,,Rattus norvegicus,,Intermediate,8004,,N,1,CHEMBL626556,,,
10409,1,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 15 after iv administration of compound,,BAO_0000218,,Rattus norvegicus,,Intermediate,8004,,N,1,CHEMBL626557,,,
10410,1,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 240 min after iv administration compound,,BAO_0000218,,Rattus norvegicus,,Intermediate,8004,,N,1,CHEMBL626558,,,
10411,1,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 30 min after iv administration of compound,,BAO_0000218,,Rattus norvegicus,,Intermediate,8004,,N,1,CHEMBL626559,,,
10412,1,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 5 min after iv administration of compound,,BAO_0000218,,Rattus norvegicus,,Intermediate,8004,,N,1,CHEMBL626560,,,
10413,1,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 60 min after iv administration of compound,,BAO_0000218,,Rattus norvegicus,,Intermediate,8004,,N,1,CHEMBL876803,,,
10414,1,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 120 min after iv administration compound,,BAO_0000218,,Rattus norvegicus,,Intermediate,8004,,N,1,CHEMBL627964,,,
10415,1,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 15 min after iv administration of compound,,BAO_0000218,,Rattus norvegicus,,Intermediate,8004,,N,1,CHEMBL627965,,,
10416,1,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 240 min after iv administration compound,,BAO_0000218,,Rattus norvegicus,,Intermediate,8004,,N,1,CHEMBL627966,,,
10417,1,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 30 min after iv administration of compound,,BAO_0000218,,Rattus norvegicus,,Intermediate,8004,,N,1,CHEMBL627967,,,
10418,1,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 5 min after iv administration of compound,,BAO_0000218,,Rattus norvegicus,,Intermediate,8004,,N,1,CHEMBL627968,,,
10419,1,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 60 min after iv administration of compound,,BAO_0000218,,Rattus norvegicus,,Intermediate,8004,,N,1,CHEMBL627969,,,
10420,1,Distribution of Se-75 activity in Liver of female Sprague-Dawley Rat 5 min after iv administration of compound,,BAO_0000218,,Rattus norvegicus,,Intermediate,8004,,N,1,CHEMBL627970,,,
10421,1,Distribution of Se-75 activity in blood of female Sprague-Dawley Rat 120 min after iv administration of compound,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8004,,N,1,CHEMBL627971,,178.0,
10422,1,Distribution of Se-75 activity in blood of female Sprague-Dawley Rat 240 min after iv administration of compound,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8004,,N,1,CHEMBL627972,,178.0,
10423,1,Dissociation constant against binding to human cyclophilin A,,BAO_0000357,,Homo sapiens,,Expert,15917,,D,9,CHEMBL856029,,,
10424,1,Michaelis-Menten constant for inhibitory activity against bovine liver glyoxalase II,,BAO_0000019,,Bos taurus,,Expert,12396,,H,8,CHEMBL627973,,,
10425,1,-Log C was determined by performing the electroshock minimum test,,BAO_0000019,,,,Autocuration,7065,,U,0,CHEMBL627974,,,
10426,1,-Log C was determined by performing the foot shock test,,BAO_0000019,,,,Autocuration,7065,,U,0,CHEMBL627975,,,
10427,1,-Log C was determined by performing the incl screen test,,BAO_0000019,,,,Autocuration,7065,,U,0,CHEMBL627976,,,
10428,1,-Log C was determined by performing the maximum electroshock test,,BAO_0000019,,,,Autocuration,7065,,U,0,CHEMBL627977,,,
10429,1,-Log C was determined by performing the pentylenetetrazole test,,BAO_0000019,,,,Autocuration,7065,,U,0,CHEMBL627978,,,
10430,1,Tested for experimental arotinoid inhibitory dose,,BAO_0000019,,,,Autocuration,12415,,U,0,CHEMBL627979,,,
10431,1,Negative log transformed activity,,BAO_0000019,,,,Autocuration,10256,,U,0,CHEMBL876804,,,
10432,1,"Negative log of Langmuir's alpha constant (-log alpha), which is inversely proportional to the effective binding constant (protein binding)",,BAO_0000019,,,,Autocuration,7991,,U,0,CHEMBL627980,,,
10433,1,Dissociation constant was evaluated on guinea pig bladder at M3 muscarinic receptor,,BAO_0000218,,Cavia porcellus,,Intermediate,14342,,N,1,CHEMBL627981,,,
10434,1,Dissociation constant was evaluated on guinea pig heart (force) at M2 muscarinic receptor,,BAO_0000218,,Cavia porcellus,,Intermediate,14342,,N,1,CHEMBL627982,,,
10435,1,Dissociation constant was evaluated on guinea pig heart (rate) at M2 muscarinic receptor,,BAO_0000218,,Cavia porcellus,,Intermediate,14342,,N,1,CHEMBL627983,,,
10436,1,Dissociation constant was evaluated on guinea pig ileum at M3 muscarinic receptor,Ileum,BAO_0000218,,Cavia porcellus,,Intermediate,14342,,N,1,CHEMBL627984,,2116.0,
10437,1,Solubility in water was determined; values expressed as -log,,BAO_0000100,,,,Autocuration,6047,,U,0,CHEMBL627985,,,
10438,1,Ratio of Kcat to that of Km was determined,,BAO_0000019,,,,Autocuration,17269,,U,0,CHEMBL627986,,,
10439,1,Observed first order rate constant,,BAO_0000019,,,,Autocuration,10026,,U,0,CHEMBL627987,,,
10440,1,Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours,,BAO_0000019,,,,Autocuration,14583,,U,0,CHEMBL627988,,,
10441,1,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female wistar rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,2661,In vivo,N,1,CHEMBL627989,,,
10442,1,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to male wistar rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,2661,In vivo,N,1,CHEMBL627990,,,
10443,1,Oral Bioavailability after administration of 10 mg/kg in male rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4029,In vivo,N,1,CHEMBL876805,,,
10444,1,Oral bioavailability in rat (dose 10 mg/kg i.v. and 50 mg/kg p.o.),,BAO_0000218,,Rattus norvegicus,,Intermediate,17735,In vivo,N,1,CHEMBL627991,,,
10445,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4576,In vivo,N,1,CHEMBL627992,,,
10446,1,Oral bioavailability after oral (po) administration at a dose of 10 mg/kg was measured in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,17582,In vivo,N,1,CHEMBL627993,,,
10447,1,Oral bioavailability at 1 mg/kg was determined in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,17651,In vivo,N,1,CHEMBL622817,,,
10448,1,Oral bioavailability at 10 mg/kg was determined in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,17651,In vivo,N,1,CHEMBL622818,,,
10449,1,"Oral bioavailability in fischer rats at 30 mg/kg dose, administered perorally",,BAO_0000218,,Rattus norvegicus,,Intermediate,17670,In vivo,N,1,CHEMBL622819,,,
10450,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5045,In vivo,N,1,CHEMBL872267,,,
10451,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,1696,In vivo,N,1,CHEMBL622820,,,
10452,1,Oral bioavailability after intravenous administration in rats at 24 uM/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,17764,In vivo,N,1,CHEMBL622821,,,
10453,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6448,In vivo,N,1,CHEMBL622822,,,
10454,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6596,In vivo,N,1,CHEMBL622823,,,
10455,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,17547,In vivo,N,1,CHEMBL622824,,,
10456,1,Oral bioavailability in rat at a dose of 3 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,17771,In vivo,N,1,CHEMBL622825,,,
10457,1,Oral bioavailability in rat after oral administration at 10 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,6495,In vivo,N,1,CHEMBL622901,,,
10458,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4558,In vivo,N,1,CHEMBL622902,,,
10459,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,17596,In vivo,N,1,CHEMBL621844,,,
10460,1,Oral bioavailability in Dawley rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,6827,In vivo,N,1,CHEMBL621845,,,
10461,1,Oral bioavailability,,BAO_0000218,,Rattus norvegicus,,Intermediate,4026,In vivo,N,1,CHEMBL621846,,,
10462,1,Oral bioavailability in rat (dose 30 mg/kg),,BAO_0000218,,Rattus norvegicus,,Intermediate,10,In vivo,N,1,CHEMBL621847,,,
10463,1,Bioavailability in rat at a concentration of 15 mg/kg perorally in rat along with 100 mg/kg 11,,BAO_0000218,,Rattus norvegicus,,Intermediate,17717,In vivo,N,1,CHEMBL877609,,,
10464,1,Bioavailability in rat (dose 3 mg/kg i.v.),,BAO_0000218,,Rattus norvegicus,,Intermediate,17717,In vivo,N,1,CHEMBL621848,,,
10465,1,Bioavailability in rat at a concentration of 60 mg/kg perorally in rat along with 100 mg/kg 11,,BAO_0000218,,Rattus norvegicus,,Intermediate,17717,In vivo,N,1,CHEMBL621849,,,
10466,1,Oral bioavailability in rat (dose 60 mg/kg p.o.),,BAO_0000218,,Rattus norvegicus,,Intermediate,17717,In vivo,N,1,CHEMBL622030,,,
10467,1,Percent oral bioavailability determined in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,4796,In vivo,N,1,CHEMBL622031,,,
10468,1,Tested for percent bioavailability after oral administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,4883,In vivo,N,1,CHEMBL622032,,,
10469,1,The compound was evaluated for bioavailability in rats; 32-51,,BAO_0000218,,Rattus norvegicus,,Intermediate,2137,In vivo,N,1,CHEMBL622033,,,
10470,1,Bioavailability in rat (dose 20 mg/kg p.o.),,BAO_0000218,,Rattus norvegicus,,Intermediate,2959,In vivo,N,1,CHEMBL622034,,,
10471,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,1361,In vivo,N,1,CHEMBL622035,,,
10472,1,Bioavailability percent in rat at the dose of 2 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,4727,In vivo,N,1,CHEMBL882966,,,
10473,1,Bioavailability was evaluated after 20 uM/kg of peroral administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,16423,In vivo,N,1,CHEMBL622036,,,
10474,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5206,In vivo,N,1,CHEMBL622037,,,
10475,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6448,In vivo,N,1,CHEMBL622038,,,
10476,1,Bioavailability in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,17723,In vivo,N,1,CHEMBL622039,,,
10477,1,Biodistribution of radiolabeled compound in rat blood after 24 hr postinjection activity expressed as %ID/Organ,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,17738,In vivo,N,1,CHEMBL622040,,178.0,
10478,1,Biodistribution of radiolabeled compound in rat blood after 24 hr activity expressed as %ID/Organ,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,17738,In vivo,N,1,CHEMBL622041,,178.0,
10479,1,Biodistribution of radiolabeled compound in rat blood after 2 hr activity expressed as %ID/Organ,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,17738,In vivo,N,1,CHEMBL622042,,178.0,
10480,1,Biodistribution of radiolabeled compound in rat blood after 30 min activity expressed as %ID/Organ,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,17738,In vivo,N,1,CHEMBL622043,,178.0,
10481,1,Biodistribution of radiolabeled compound in rat blood after 5 min activity expressed as %ID/Organ,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,17738,In vivo,N,1,CHEMBL622044,,178.0,
10482,1,Biodistribution of radiolabeled compound in rat bone after 24 hr activity expressed as %ID/Organ,Bone,BAO_0000218,,Rattus norvegicus,,Intermediate,17738,In vivo,N,1,CHEMBL622045,,10000001.0,
10483,1,Biodistribution of radiolabeled compound in rat bone after 2 hr activity expressed as %ID/Organ,Bone,BAO_0000218,,Rattus norvegicus,,Intermediate,17738,In vivo,N,1,CHEMBL622046,,10000001.0,
10484,1,Biodistribution of radiolabeled compound in rat bone after 30 min activity expressed as %ID/Organ,Bone,BAO_0000218,,Rattus norvegicus,,Intermediate,17738,In vivo,N,1,CHEMBL622047,,10000001.0,
10485,1,Biodistribution of radiolabeled compound in rat bone after 5 min activity expressed as %ID/Organ,Bone,BAO_0000218,,Rattus norvegicus,,Intermediate,17738,In vivo,N,1,CHEMBL877610,,10000001.0,
10486,1,Biodistribution of radiolabeled compound in rat brain after 24 hr activity expressed as %ID/Organ,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,17738,In vivo,N,1,CHEMBL622048,,955.0,
10487,1,Biodistribution of radiolabeled compound in rat brain after 2 hr activity expressed as %ID/Organ,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,17738,In vivo,N,1,CHEMBL622049,,955.0,
10488,1,Biodistribution of radiolabeled compound in rat brain after 30 min activity expressed as %ID/Organ,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,17738,In vivo,N,1,CHEMBL622050,,955.0,
10489,1,Biodistribution of radiolabeled compound in rat brain after 5 min activity expressed as %ID/Organ,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,17738,In vivo,N,1,CHEMBL622051,,955.0,
10490,1,Biodistribution of radiolabeled compound in rat fat after 24 hr activity expressed as %ID/Organ,,BAO_0000218,,Rattus norvegicus,,Intermediate,17738,In vivo,N,1,CHEMBL622052,,,
10491,1,Biodistribution of radiolabeled compound in rat fat after 2 hr activity expressed as %ID/Organ,,BAO_0000218,,Rattus norvegicus,,Intermediate,17738,In vivo,N,1,CHEMBL622053,,,
10492,1,Biodistribution of radiolabeled compound in rat fat after 30 min activity expressed as %ID/Organ,,BAO_0000218,,Rattus norvegicus,,Intermediate,17738,In vivo,N,1,CHEMBL622054,,,
10493,1,Biodistribution of radiolabeled compound in rat fat after 5 min activity expressed as %ID/Organ,,BAO_0000218,,Rattus norvegicus,,Intermediate,17738,In vivo,N,1,CHEMBL622055,,,
10494,1,Oral bioavailability in rats was determined; High,,BAO_0000218,,Rattus norvegicus,,Intermediate,5237,In vivo,N,1,CHEMBL622056,,,
10495,1,Oral bioavailability in the rat was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,5503,In vivo,N,1,CHEMBL622057,,,
10496,1,Oral bioavailability measured by the ratio of intravenous to oral area under concentration.,,BAO_0000218,,Rattus norvegicus,,Intermediate,15765,In vivo,N,1,CHEMBL628008,,,
10497,1,Oral bioavailability in rat (dose 10 mg/kg p.o. and 3 mg/kg i.v.),,BAO_0000218,,Rattus norvegicus,,Intermediate,15660,In vivo,N,1,CHEMBL622058,,,
10498,1,Oral bioavailability of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5978,In vivo,N,1,CHEMBL622059,,,
10499,1,Oral bioavailability of compound (19.76 mg/kg) after po administration was determined in Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5978,In vivo,N,1,CHEMBL622060,,,
10500,1,Oral bioavailability of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5978,In vivo,N,1,CHEMBL622061,,,
10501,1,Oral bioavailability of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5978,In vivo,N,1,CHEMBL622062,,,
10502,1,Oral bioavailability of compound at a dose of 20 mg/kg was determined after oral administration in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5656,In vivo,N,1,CHEMBL622063,,,
10503,1,Oral bioavailability of compound determined in rat after iv administration at a dose of 10 mg/kg,,BAO_0000218,,Rattus norvegicus,,Expert,3598,In vivo,N,1,CHEMBL877611,,,
10504,1,Oral bioavailability of compound in Sprague Dawley rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,4216,In vivo,N,1,CHEMBL622064,,,
10505,1,Oral bioavailability of compound in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,17839,In vivo,N,1,CHEMBL622065,,,
10506,1,Oral bioavailability in rat (dose 2 mg/kg),,BAO_0000218,,Rattus norvegicus,,Intermediate,6570,In vivo,N,1,CHEMBL622066,,,
10507,1,Oral bioavailability of compound in rat was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,5334,In vivo,N,1,CHEMBL622067,,,
10508,1,Oral bioavailability of compound in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,6886,In vivo,N,1,CHEMBL622068,,,
10509,1,Oral bioavailability of compound was determined in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,5210,In vivo,N,1,CHEMBL622069,,,
10510,1,Oral bioavailability at a dose of 30 mg/kg in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,4170,In vivo,N,1,CHEMBL624796,,,
10511,1,Oral bioavailability in rat (dose 10 mg/kg),,BAO_0000218,,Rattus norvegicus,,Intermediate,6028,In vivo,N,1,CHEMBL624797,,,
10512,1,Oral bioavailability in rat (dose 10 mg/kg),,BAO_0000218,,Rattus norvegicus,,Intermediate,6028,In vivo,N,1,CHEMBL623053,,,
10513,1,Oral bioavailability evaluated in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6078,In vivo,N,1,CHEMBL623054,,,
10514,1,Oral bioavailability in fasted rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6168,In vivo,N,1,CHEMBL623055,,,
10515,1,Oral bioavailability in fed rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6168,In vivo,N,1,CHEMBL623056,,,
10516,1,Oral bioavailability in rat (mature male) (dose 30 mg/kg),,BAO_0000218,,Rattus norvegicus,,Intermediate,5160,In vivo,N,1,CHEMBL623057,,,
10517,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6057,In vivo,N,1,CHEMBL623058,,,
10518,1,Oral bioavailability in rat (dose 10 mg/kg p.o.),,BAO_0000218,,Rattus norvegicus,,Intermediate,6535,In vivo,N,1,CHEMBL623059,,,
10519,1,Oral bioavailability in rat after administration of 10 mg/kg po,,BAO_0000218,,Rattus norvegicus,,Intermediate,6535,In vivo,N,1,CHEMBL623060,,,
10520,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4194,In vivo,N,1,CHEMBL623061,,,
10521,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6230,In vivo,N,1,CHEMBL623062,,,
10522,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6619,In vivo,N,1,CHEMBL623063,,,
10523,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,17607,In vivo,N,1,CHEMBL623064,,,
10524,1,Oral bioavailability in ratrs,,BAO_0000218,,Rattus norvegicus,,Intermediate,4942,In vivo,N,1,CHEMBL623065,,,
10525,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4942,In vivo,N,1,CHEMBL623066,,,
10526,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6646,In vivo,N,1,CHEMBL623067,,,
10527,1,Oral bioavailability in rats was determined; High,,BAO_0000218,,Rattus norvegicus,,Intermediate,5237,In vivo,N,1,CHEMBL623068,,,
10528,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6646,In vivo,N,1,CHEMBL623069,,,
10529,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4449,In vivo,N,1,CHEMBL623070,,,
10530,1,Oral bioavailability was calculated in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6057,In vivo,N,1,CHEMBL623071,,,
10531,1,Oral bioavailability,,BAO_0000218,,Rattus norvegicus,,Intermediate,2552,In vivo,N,1,CHEMBL623072,,,
10532,1,Oral bioavailability,,BAO_0000218,,Rattus norvegicus,,Intermediate,5496,In vivo,N,1,CHEMBL623073,,,
10533,1,Oral bioavailability,,BAO_0000218,,Rattus norvegicus,,Intermediate,6484,In vivo,N,1,CHEMBL623074,,,
10534,1,Oral bioavailability,,BAO_0000218,,Rattus norvegicus,,Intermediate,6485,In vivo,N,1,CHEMBL623075,,,
10535,1,Oral bioavailability after i.v. administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,6616,In vivo,N,1,CHEMBL623076,,,
10536,1,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),,BAO_0000218,,Rattus norvegicus,,Intermediate,4969,In vivo,N,1,CHEMBL623077,,,
10537,1,Oral bioavailability in rat (Sprague-Dawley),,BAO_0000218,,Rattus norvegicus,,Intermediate,5862,In vivo,N,1,CHEMBL623078,,,
10538,1,Oral bioavailability in Sprague-Dawley rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,4514,In vivo,N,1,CHEMBL623079,,,
10539,1,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),,BAO_0000218,,Rattus norvegicus,,Intermediate,4514,In vivo,N,1,CHEMBL623080,,,
10540,1,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),,BAO_0000218,,Rattus norvegicus,,Intermediate,4514,In vivo,N,1,CHEMBL623081,,,
10541,1,Oral bioavailability in Sprague-Dawley rats at a dose of 2 mg/kg by po administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,5546,In vivo,N,1,CHEMBL623082,,,
10542,1,Oral bioavailability in fasted rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6168,In vivo,N,1,CHEMBL874400,,,
10543,1,Oral bioavailability in fed rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6168,In vivo,N,1,CHEMBL623083,,,
10544,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,3624,In vivo,N,1,CHEMBL623084,,,
10545,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5213,In vivo,N,1,CHEMBL623085,,,
10546,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5496,In vivo,N,1,CHEMBL623086,,,
10547,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5553,In vivo,N,1,CHEMBL623087,,,
10548,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5833,In vivo,N,1,CHEMBL623088,,,
10549,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5836,In vivo,N,1,CHEMBL623089,,,
10550,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5865,In vivo,N,1,CHEMBL623090,,,
10551,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5960,In vivo,N,1,CHEMBL623091,,,
10552,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6249,In vivo,N,1,CHEMBL623092,,,
10553,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6448,In vivo,N,1,CHEMBL623093,,,
10554,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6453,In vivo,N,1,CHEMBL874401,,,
10555,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6640,In vivo,N,1,CHEMBL623094,,,
10556,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,17607,In vivo,N,1,CHEMBL623095,,,
10557,1,Oral bioavailability in rat after peroral administration at 10 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,5939,In vivo,N,1,CHEMBL623096,,,
10558,1,Oral bioavailability in rat after peroral administration at 5 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,5939,In vivo,N,1,CHEMBL624913,,,
10559,1,Oral bioavailability in rat (dose 2.8 mg/kg p.o.),,BAO_0000218,,Rattus norvegicus,,Intermediate,6281,In vivo,N,1,CHEMBL624914,,,
10560,1,Oral bioavailability in rat by po administration at a dose of 40 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,5874,In vivo,N,1,CHEMBL624915,,,
10561,1,Oral bioavailability in rat; Not measured,,BAO_0000218,,Rattus norvegicus,,Intermediate,5213,In vivo,N,1,CHEMBL624916,,,
10562,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4964,In vivo,N,1,CHEMBL624917,,,
10563,1,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus NE,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,N,1,CHEMBL625157,,,
10564,1,In vitro metabolic potential in rat liver microsomes,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,6251,,N,1,CHEMBL625158,,2107.0,
10565,1,"Oral availability was tested for plasma levels at a dose of 40 mg/kg, after 6 hr of in fed fisher rats.",,BAO_0000218,,Rattus norvegicus,,Intermediate,1568,In vivo,N,1,CHEMBL625159,,,
10566,1,"In vivo percentage mean absolute bioavailability of compound in rat after an oral dose of 10 mg/kg (in water, N=4)",,BAO_0000218,,Rattus norvegicus,,Intermediate,3032,In vivo,N,1,CHEMBL625160,,,
10567,1,Oral bioavailability of intravenously administered compound (3 mg/kg) was tested in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,3748,In vivo,N,1,CHEMBL625161,,,
10568,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,401,In vivo,N,1,CHEMBL625162,,,
10569,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6512,In vivo,N,1,CHEMBL625163,,,
10570,1,Oral bioavailability in rats at 10 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,17617,In vivo,N,1,CHEMBL625164,,,
10571,1,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,6679,In vivo,N,1,CHEMBL625165,,,
10572,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6742,In vivo,N,1,CHEMBL625166,,,
10573,1,Tested for effective permeability across the rat intestinal membrane using mass balance analysis,,BAO_0000218,,Rattus norvegicus,,Intermediate,589,,N,1,CHEMBL625167,,,
10574,1,Tested for effective permeability across the rat intestinal membrane using mass balance analysis at 0.01 mM concentration,,BAO_0000218,,Rattus norvegicus,,Intermediate,589,,N,1,CHEMBL625168,,,
10575,1,Plasma clearance of the compound,,BAO_0000218,,Rattus norvegicus,,Intermediate,3185,In vivo,N,1,CHEMBL625169,,,
10576,1,Plasma clearance at 10 mg/kg in rat upon intravenous administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,17596,In vivo,N,1,CHEMBL626264,,,
10577,1,Plasma clearance upon intravenous administration of 1 mg/Kg in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,2713,In vivo,N,1,CHEMBL626265,,,
10578,1,The compound was tested for plasma clearance in rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,12500,In vivo,N,1,CHEMBL626266,,1969.0,
10579,1,The compound was tested for plasma clearance in rat at dose of 3-10 mgkg,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,12500,In vivo,N,1,CHEMBL626267,,1969.0,
10580,1,Plasma concentration upon oral administration of 1 mg/Kg in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,2713,,N,1,CHEMBL626268,,,
10581,1,Peak plasma level between 0.5 and 1.0 hour in Dawley rats; value ranges from 1021-2551,,BAO_0000218,,Rattus norvegicus,,Intermediate,1446,,N,1,CHEMBL626269,,,
10582,1,Plasma level after intravenous administration in rat model of FeCl3-induced carotid thrombosis,,BAO_0000218,,Rattus norvegicus,,Intermediate,6227,,N,1,CHEMBL626270,,,
10583,1,Plasma protein binding was determined after intravenous administration of 1 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4709,,N,1,CHEMBL626271,,,
10584,1,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1",,BAO_0000218,,Rattus norvegicus,,Intermediate,5510,,N,1,CHEMBL626272,,,
10585,1,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not determined",,BAO_0000218,,Rattus norvegicus,,Intermediate,5510,,N,1,CHEMBL626273,,,
10586,1,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not determined",,BAO_0000218,,Rattus norvegicus,,Intermediate,5510,,N,1,CHEMBL875346,,,
10587,1,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not stable",,BAO_0000218,,Rattus norvegicus,,Intermediate,5510,,N,1,CHEMBL626274,,,
10588,1,Compound was tested for protein binding in rat plasma,,BAO_0000218,,Rattus norvegicus,,Intermediate,4514,,N,1,CHEMBL626275,,,
10589,1,Compound was evaluated for absorption of radioligand following oral administration to bile duct cannulated rat. ,,BAO_0000218,,Rattus norvegicus,,Intermediate,2713,,N,1,CHEMBL624646,,,
10590,1,Compound was evaluated for absorption of radioligand upon oral administration to bile duct cannulated rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,2713,,N,1,CHEMBL624647,,,
10591,1,In vitro metabolism in rat liver microsomes was evaluated to determine diminishing of glucuronidation rate,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,5340,,N,1,CHEMBL624648,,2107.0,
10592,1,Area under curve ratio was determined (po/iv) in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,12058,,N,1,CHEMBL624649,,,
10593,1,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 15 mins after i.v. administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,11195,,N,1,CHEMBL624650,,,
10594,1,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 2 mins after i.v. administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,11195,,N,1,CHEMBL624651,,,
10595,1,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 65 mins after i.v. administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,11195,,N,1,CHEMBL624652,,,
10596,1,Compound was tested for brain/plasma ratio after oral administration at 10 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,6495,,N,1,CHEMBL624653,,,
10597,1,Ratio of AUCbrain to AUCplasma,,BAO_0000218,,Rattus norvegicus,,Intermediate,6078,,N,1,CHEMBL624654,,,
10598,1,Ratio of brain to plasma,,BAO_0000218,,Rattus norvegicus,,Intermediate,5656,,N,1,CHEMBL624655,,,
10599,1,Ratio of the AUC values of brain and plasma after intravenous administration (4.7 mg/kg) to male rats was evaluated,,BAO_0000218,,Rattus norvegicus,,Intermediate,4910,,N,1,CHEMBL624656,,,
10600,1,Ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats was evaluated,,BAO_0000218,,Rattus norvegicus,,Intermediate,4910,,N,1,CHEMBL624657,,,
10601,1,Ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats was evaluated,,BAO_0000218,,Rattus norvegicus,,Intermediate,4910,,N,1,CHEMBL624658,,,
10602,1,Selectivity ratio for biodistribution in brain and blood of rats after 15 minutes; Expressed as percent dose/gram ratio,,BAO_0000218,,Rattus norvegicus,,Intermediate,10130,,N,1,CHEMBL624659,,,
10603,1,Selectivity ratio for biodistribution in brain and blood of rats after 2 minutes; Expressed as percent dose/gram ratio,,BAO_0000218,,Rattus norvegicus,,Intermediate,10130,,N,1,CHEMBL624660,,,
10604,1,Selectivity ratio for biodistribution in brain and blood of rats after 60 minutes; Expressed as percent dose/gram ratio,,BAO_0000218,,Rattus norvegicus,,Intermediate,10130,,N,1,CHEMBL624661,,,
10605,1,Steady state brain :blood ratio was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,5213,,N,1,CHEMBL624662,,,
10606,1,Tested for ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,4910,,N,1,CHEMBL625199,,,
10607,1,Tested for ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats; ND = not determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,4910,,N,1,CHEMBL625200,,,
10608,1,Tested for ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,4910,,N,1,CHEMBL625201,,,
10609,1,Tested for ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats; ND = not determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,4910,,N,1,CHEMBL625202,,,
10610,1,Percentage recovery after 3h incubation with rat hapatocytes was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,2083,,N,1,CHEMBL625203,,,
10611,1,Percentage recovery in rat hepatic microsomal fractions under oxidative conditions after 1 hour,,BAO_0000218,,Rattus norvegicus,,Intermediate,2082,,N,1,CHEMBL625204,,,
10612,1,Percentage recovery in rhesus monkey hepatic microsomal fractions under oxidative conditions after 1 hour,,BAO_0000218,,Rattus norvegicus,,Intermediate,2082,,N,1,CHEMBL625205,,,
10613,1,Recovery rate from urine and bile was determined after iv administration at 20 mg/kg in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,6351,,N,1,CHEMBL625206,,,
10614,1,"Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours; not measured, No site available for protein conjugation.",,BAO_0000019,,,,Autocuration,14583,,U,0,CHEMBL625207,,,
10615,1,Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours; not measured.,,BAO_0000019,,,,Autocuration,14583,,U,0,CHEMBL625208,,,
10616,1,In vivo absorption in Caco-2 cell line monolayers was determined,,BAO_0000218,,Homo sapiens,,Intermediate,4608,,N,1,CHEMBL625209,495.0,,
10617,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,13668,,U,0,CHEMBL625210,,,
10618,1,Area under curve was determine after peroral administration at 10 mpk in Rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5669,,N,1,CHEMBL625211,,,
10619,1,Area under curve was determine after peroral administration at 10 mpk in Rhesus,,BAO_0000218,,Macaca mulatta,,Intermediate,5669,,N,1,CHEMBL625212,,,
10620,1,Area under curve was determine after peroral administration at 160 mpk in Rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5669,,N,1,CHEMBL625213,,,
10621,1,Area under curve was determine after peroral administration at 20 mpk in Rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5669,,N,1,CHEMBL625214,,,
10622,1,Area under curve was determine after peroral administration at 50 mpk in Rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5669,,N,1,CHEMBL874542,,,
10623,1,Calculated partition coefficient (clogP) (AlogP),,BAO_0000100,,,,Autocuration,6472,,U,0,CHEMBL625215,,,
10624,1,Activated partial thromboplastin time measured,,BAO_0000019,,,,Autocuration,15106,,U,0,CHEMBL625216,,,
10625,1,Compound was evaluated for the aqueous solubility (AS) in mg/mL (Measured in 0.2 M phosphate buffer of pH 7.4),,BAO_0000100,,,,Autocuration,15207,,U,0,CHEMBL625217,,,
10626,1,Compound was evaluated for the aqueous solubility (AS) in mg/mL (Measured in 0.2 M phosphate buffer of pH 7.4); ND=Not determined (AS mg/mL),,BAO_0000100,,,,Autocuration,15207,,U,0,CHEMBL625218,,,
10627,1,AUC (Area under curve) was determined after intravenous administration at a dose 1 mg/kg in dog,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,13941,,N,1,CHEMBL622864,,1969.0,
10628,1,AUC (Area under curve) was determined after intravenous administration at a dose 2 mg/kg in rat.,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,13941,,N,1,CHEMBL622865,,1969.0,
10629,1,AUC (Area under curve) was determined after peroral administration at a dose 10 mg/kg in rat.,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,13941,,N,1,CHEMBL622866,,1969.0,
10630,1,AUC (Area under curve) was determined after peroral administration at a dose 5 mg/kg in dog,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,13941,,N,1,CHEMBL622867,,1969.0,
10631,1,AUC (ng h/mL) value after oral administration of 10 mg/kg in guinea pig.,Plasma,BAO_0000218,,Cavia porcellus,,Intermediate,15240,,N,1,CHEMBL876808,,1969.0,
10632,1,AUC in brain,Brain,BAO_0000019,,,,Autocuration,10655,,U,0,CHEMBL627725,,955.0,
10633,1,AUC in serum,Serum,BAO_0000019,,,,Autocuration,10655,,U,0,CHEMBL627726,,1977.0,
10634,1,AUC was determined,Plasma,BAO_0000019,,,,Autocuration,6504,,U,0,CHEMBL627727,,1969.0,
10635,1,AUC of the compound.,Plasma,BAO_0000019,,,,Autocuration,10615,,U,0,CHEMBL627728,,1969.0,
10636,1,AUC value (0-4 hr),Plasma,BAO_0000019,,,,Autocuration,10353,,U,0,CHEMBL627729,,1969.0,
10637,1,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 150 uMol/kg,",Plasma,BAO_0000019,,,,Autocuration,14907,,U,0,CHEMBL627730,,1969.0,
10638,1,AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 300 uMol/kg,Plasma,BAO_0000019,,,,Autocuration,14907,,U,0,CHEMBL627731,,1969.0,
10639,1,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 300 uMol/kg,",Plasma,BAO_0000019,,,,Autocuration,14907,,U,0,CHEMBL627732,,1969.0,
10640,1,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 700 uMol/kg,",Plasma,BAO_0000019,,,,Autocuration,14907,,U,0,CHEMBL627733,,1969.0,
10641,1,AUC(area under curve) was determined after intravenous administration in rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,16359,,N,1,CHEMBL627734,,1969.0,
10642,1,AUC(area under curve) was determined after oral administration in rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,16359,,N,1,CHEMBL627735,,1969.0,
10643,1,AUC(ng h/mL)values after oral administration of 10 mg/kg in guinea pig.,Plasma,BAO_0000218,,Cavia porcellus,,Intermediate,15240,,N,1,CHEMBL627736,,1969.0,
10644,1,AUC(ng h/mL)values after oral administration of 10 mg/kg in rat.,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,15240,,N,1,CHEMBL876809,,1969.0,
10645,1,Area Under Curve after oral dosing of 100 uM/Kg,,BAO_0000019,,,,Autocuration,15469,,U,0,CHEMBL627737,,,
10646,1,Area Under Curve after oral dosing of 30 uM/Kg,,BAO_0000019,,,,Autocuration,15469,,U,0,CHEMBL627738,,,
10647,1,Area Under Curve was measured by ploting the graph between concentration verses time,,BAO_0000019,,,,Autocuration,13520,,U,0,CHEMBL627739,,,
10648,1,Area under concentration-time curve of compound was determined in dog at 25 mg/kg orally,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17025,,N,1,CHEMBL626143,,,
10649,1,Area under concentration-time curve of compound was determined in monkey at 25 mg/kg orally,,BAO_0000218,,Simiiformes,,Autocuration,17025,,U,0,CHEMBL626144,,,
10650,1,Area under concentration-time curve of compound was determined in rabbit at 25 mg/kg orally,,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,17025,,N,1,CHEMBL626145,,,
10651,1,Area under concentration-time curve of compound was determined in rat at 25 mg/kg orally,,BAO_0000218,,Rattus norvegicus,,Intermediate,17025,,N,1,CHEMBL626146,,,
10652,1,Area under curve (AUC) is the drug concentrations in blood samples of rats with arterial catheters at 5 min and 12 hr plotted against time,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,12032,,N,1,CHEMBL626147,,178.0,
10653,1,Area under curve (AUC) was determined,,BAO_0000019,,,,Autocuration,10291,,U,0,CHEMBL626148,,,
10654,1,Area under curve (AUC) following ip administration at 1 mg/kg,,BAO_0000218,,,,Autocuration,5767,,U,0,CHEMBL626149,,,
10655,1,Area under curve (AUC) was determined; ND is Not determined,,BAO_0000019,,,,Autocuration,1434,,U,0,CHEMBL626150,,,
10656,1,Area under curve (AUC) was determined in dogs fed after intravenous administration of 25 mg/kg of the compound,,BAO_0000218,,Canis lupus familiaris,,Intermediate,14925,,N,1,CHEMBL626151,,,
10657,1,Area under curve (AUC) was determined in dogs fed after oral administration of 25 mg/kg of the compound,,BAO_0000218,,Canis lupus familiaris,,Intermediate,14925,,N,1,CHEMBL626152,,,
10658,1,Area under curve (AUC) was determined in fasted dogs after oral administration of 25 mg/kg of the compound,,BAO_0000218,,Canis lupus familiaris,,Intermediate,14925,,N,1,CHEMBL626153,,,
10659,1,Area under curve (AUR) was determined,,BAO_0000019,,,,Autocuration,1434,,U,0,CHEMBL626154,,,
10660,1,Area under curve at 1 uM/dg administered intravenously,,BAO_0000019,,,,Autocuration,11883,,U,0,CHEMBL626155,,,
10661,1,Area under curve at 10 uM/dg administered perorally,,BAO_0000019,,,,Autocuration,11883,,U,0,CHEMBL626156,,,
10662,1,Area under curve at 2 uM/dg administered intravenously,,BAO_0000019,,,,Autocuration,11883,,U,0,CHEMBL626157,,,
10663,1,Area under curve at 20 uM/dg administered perorally,,BAO_0000019,,,,Autocuration,11883,,U,0,CHEMBL626158,,,
10664,1,Area under curve at a peroral dose of 3 mg/kg in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,15233,,N,1,CHEMBL626159,,,
10665,1,Area under curve at a peroral dose of 3 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,15233,,N,1,CHEMBL626160,,,
10666,1,Area under curve at an iv dose of 1 mg/kg in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,15233,,N,1,CHEMBL626161,,,
10667,1,Area under curve at an iv dose of 1 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,15233,,N,1,CHEMBL626162,,,
10668,1,Area under curve gives the effective duration for the angiotensin II antagonist effect of the compound.,,BAO_0000019,,,,Autocuration,12978,,U,0,CHEMBL626163,,,
10669,1,Area under curve gives the effective duration for the angiotensin II antagonist effect.,,BAO_0000019,,,,Autocuration,12978,,U,0,CHEMBL626164,,,
10670,1,Area under curve measured as conc vs time after intravenous administration to mice.,,BAO_0000218,,Mus musculus,,Intermediate,11355,,N,1,CHEMBL626165,,,
10671,1,Area under curve measured as conc vs time after peroral administration to mice.,,BAO_0000218,,Mus musculus,,Intermediate,11355,,N,1,CHEMBL626166,,,
10672,1,Area under curve of acid 2a was determined by HPLC at a dosage of 2.27 mg/kg administered intravenously by bolus method in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,12923,,N,1,CHEMBL626167,,,
10673,1,Area under curve of acid 2a was determined by HPLC at a dosage of 5.45 mg/kg administered intragastrically by capsule method in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,12923,,N,1,CHEMBL626168,,,
10674,1,Area under curve of acid 2a was determined by HPLC at a dosage of 5.45 mg/kg administered intragastrically by gavage method in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,12923,,N,1,CHEMBL877463,,,
10675,1,Area under curve of acid 2a was determined by HPLC at a dosage of 54.5 mg/kg administered intragastrically by capsule method in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,12923,,N,1,CHEMBL626169,,,
10676,1,Biodistribution of radiolabeled compound in rat heart after 24 hr activity expressed as %ID/Organ,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,17738,In vivo,N,1,CHEMBL626170,,948.0,
10677,1,Biodistribution of radiolabeled compound in rat heart after 2 hr activity expressed as %ID/Organ,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,17738,In vivo,N,1,CHEMBL626171,,948.0,
10678,1,Biodistribution of radiolabeled compound in rat heart after 30 min activity expressed as %ID/Organ,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,17738,In vivo,N,1,CHEMBL626172,,948.0,
10679,1,Biodistribution of radiolabeled compound in rat heart after 5 min activity expressed as %ID/Organ,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,17738,In vivo,N,1,CHEMBL626173,,948.0,
10680,1,Biodistribution of radiolabeled compound in rat kidney after 24 hr postinjection activity expressed as %ID/Organ,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,17738,In vivo,N,1,CHEMBL626174,,2113.0,
10681,1,Biodistribution of radiolabeled compound in rat kidney after 24 hr activity expressed as %ID/Organ,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,17738,In vivo,N,1,CHEMBL626175,,2113.0,
10682,1,Biodistribution of radiolabeled compound in rat kidney after 2 hr activity expressed as %ID/Organ,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,17738,In vivo,N,1,CHEMBL626176,,2113.0,
10683,1,Biodistribution of radiolabeled compound in rat kidney after 30 min activity expressed as %ID/Organ,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,17738,In vivo,N,1,CHEMBL626177,,2113.0,
10684,1,Biodistribution of radiolabeled compound in rat kidney after 5 min activity expressed as %ID/Organ,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,17738,In vivo,N,1,CHEMBL622499,,2113.0,
10685,1,Biodistribution of radiolabeled compound in rat liver after 24 hr postinjection activity expressed as %ID/Organ,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,17738,In vivo,N,1,CHEMBL622500,,2107.0,
10686,1,Biodistribution of radiolabeled compound in rat liver after 24 hr activity expressed as %ID/Organ,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,17738,In vivo,N,1,CHEMBL622501,,2107.0,
10687,1,Biodistribution of radiolabeled compound in rat liver after 2 hr activity expressed as %ID/Organ,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,17738,In vivo,N,1,CHEMBL622502,,2107.0,
10688,1,Biodistribution of radiolabeled compound in rat liver after 30 min activity expressed as %ID/Organ,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,17738,In vivo,N,1,CHEMBL622503,,2107.0,
10689,1,Biodistribution of radiolabeled compound in rat liver after 5 min activity expressed as %ID/Organ,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,17738,In vivo,N,1,CHEMBL877614,,2107.0,
10690,1,Biodistribution of radiolabeled compound in rat lung after 24 hr activity expressed as %ID/Organ,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,17738,In vivo,N,1,CHEMBL624839,,2048.0,
10691,1,Biodistribution of radiolabeled compound in rat lung after 2 hr activity expressed as %ID/Organ,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,17738,In vivo,N,1,CHEMBL624840,,2048.0,
10692,1,Biodistribution of radiolabeled compound in rat lung after 30 min activity expressed as %ID/Organ,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,17738,In vivo,N,1,CHEMBL624841,,2048.0,
10693,1,Biodistribution of radiolabeled compound in rat lung after 5 min activity expressed as %ID/Organ,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,17738,In vivo,N,1,CHEMBL624842,,2048.0,
10694,1,Biodistribution of radiolabeled compound in rat muscle after 24 hr activity expressed as %ID/Organ,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,17738,In vivo,N,1,CHEMBL624843,,2385.0,
10695,1,Biodistribution of radiolabeled compound in rat muscle after 2 hr activity expressed as %ID/Organ,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,17738,In vivo,N,1,CHEMBL624844,,2385.0,
10696,1,Biodistribution of radiolabeled compound in rat muscle after 30 min activity expressed as %ID/Organ,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,17738,In vivo,N,1,CHEMBL624845,,2385.0,
10697,1,Biodistribution of radiolabeled compound in rat muscle after 5 min activity expressed as %ID/Organ,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,17738,In vivo,N,1,CHEMBL621904,,2385.0,
10698,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 15 mins after i.v. administration,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,11195,In vivo,N,1,CHEMBL621905,,178.0,
10699,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 2 mins after i.v. administration,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,11195,In vivo,N,1,CHEMBL874382,,178.0,
10700,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 65 mins after i.v. administration,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,11195,In vivo,N,1,CHEMBL621906,,178.0,
10701,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 15 mins after i.v. administration,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,11195,In vivo,N,1,CHEMBL621907,,955.0,
10702,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 2 mins after i.v. administration,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,11195,In vivo,N,1,CHEMBL622096,,955.0,
10703,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 65 mins after i.v. administration,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,11195,In vivo,N,1,CHEMBL622097,,955.0,
10704,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 15 mins after i.v. administration,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,11195,In vivo,N,1,CHEMBL622098,,948.0,
10705,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 2 mins after i.v. administration,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,11195,In vivo,N,1,CHEMBL622099,,948.0,
10706,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 65 mins after i.v. administration,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,11195,In vivo,N,1,CHEMBL622100,,948.0,
10707,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 15 mins after i.v. administration,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,11195,In vivo,N,1,CHEMBL622101,,2113.0,
10708,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 2 mins after i.v. administration,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,11195,In vivo,N,1,CHEMBL622102,,2113.0,
10709,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 65 mins after i.v. administration,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,11195,In vivo,N,1,CHEMBL622103,,2113.0,
10710,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 15 mins after i.v. administration,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,11195,In vivo,N,1,CHEMBL622104,,2107.0,
10711,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 2 mins after i.v. administration,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,11195,In vivo,N,1,CHEMBL622105,,2107.0,
10712,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 65 mins after i.v. administration,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,11195,In vivo,N,1,CHEMBL622106,,2107.0,
10713,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 15 mins after i.v. administration,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,11195,In vivo,N,1,CHEMBL622107,,2048.0,
10714,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 2 mins after i.v. administration,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,11195,In vivo,N,1,CHEMBL622108,,2048.0,
10715,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 65 mins after i.v. administration,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,11195,In vivo,N,1,CHEMBL622109,,2048.0,
10716,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 15 mins after i.v. administration,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,11195,In vivo,N,1,CHEMBL622110,,2385.0,
10717,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 2 mins after i.v. administration,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,11195,In vivo,N,1,CHEMBL622111,,2385.0,
10718,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 65 mins after i.v. administration,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,11195,In vivo,N,1,CHEMBL874383,,2385.0,
10719,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 15 mins after i.v. administration,Zone of skin,BAO_0000218,,Rattus norvegicus,,Intermediate,11195,In vivo,N,1,CHEMBL622112,,14.0,
10720,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 2 mins after i.v. administration,Zone of skin,BAO_0000218,,Rattus norvegicus,,Intermediate,11195,In vivo,N,1,CHEMBL622113,,14.0,
10721,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 65 mins after i.v. administration,Zone of skin,BAO_0000218,,Rattus norvegicus,,Intermediate,11195,In vivo,N,1,CHEMBL622114,,14.0,
10722,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 15 mins after i.v. administration,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,11195,In vivo,N,1,CHEMBL622115,,2106.0,
10723,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 2 mins after i.v. administration,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,11195,In vivo,N,1,CHEMBL622116,,2106.0,
10724,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6193,In vivo,N,1,CHEMBL622117,,,
10725,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6803,In vivo,N,1,CHEMBL622118,,,
10726,1,Oral bioavailability in rats at 6 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,6647,In vivo,N,1,CHEMBL622119,,,
10727,1,Oral bioavailability in rat (dose 6 mg/kg),,BAO_0000218,,Rattus norvegicus,,Intermediate,6647,In vivo,N,1,CHEMBL622120,,,
10728,1,Oral bioavailability in rats at 6 mg/kg dose; Not tested,,BAO_0000218,,Rattus norvegicus,,Intermediate,6647,In vivo,N,1,CHEMBL622121,,,
10729,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6640,In vivo,N,1,CHEMBL622122,,,
10730,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6641,In vivo,N,1,CHEMBL622123,,,
10731,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6641,In vivo,N,1,CHEMBL622124,,,
10732,1,Bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6642,In vivo,N,1,CHEMBL622125,,,
10733,1,Oral bioavailability,,BAO_0000218,,Rattus norvegicus,,Intermediate,5472,In vivo,N,1,CHEMBL622126,,,
10734,1,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),,BAO_0000218,,Rattus norvegicus,,Intermediate,6141,In vivo,N,1,CHEMBL620455,,,
10735,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4390,In vivo,N,1,CHEMBL620456,,,
10736,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5472,In vivo,N,1,CHEMBL620457,,,
10737,1,Oral bioavailability was evaluated; Not tested,,BAO_0000218,,Rattus norvegicus,,Intermediate,5472,In vivo,N,1,CHEMBL620458,,,
10738,1,Oral bioavailability,,BAO_0000218,,Rattus norvegicus,,Intermediate,5438,In vivo,N,1,CHEMBL620459,,,
10739,1,Oral bioavailability in rat by oral dosing,,BAO_0000218,,Rattus norvegicus,,Intermediate,4883,In vivo,N,1,CHEMBL620460,,,
10740,1,Oral bioavailability in rat (dose 10 mg/kg p.o.),,BAO_0000218,,Rattus norvegicus,,Intermediate,1908,In vivo,N,1,CHEMBL620461,,,
10741,1,Oral bioavailability in rat (Sprague-Dawley),,BAO_0000218,,Rattus norvegicus,,Intermediate,4853,In vivo,N,1,CHEMBL620462,,,
10742,1,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),,BAO_0000218,,Rattus norvegicus,,Intermediate,4853,In vivo,N,1,CHEMBL620463,,,
10743,1,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),,BAO_0000218,,Rattus norvegicus,,Intermediate,4853,In vivo,N,1,CHEMBL620464,,,
10744,1,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),,BAO_0000218,,Rattus norvegicus,,Intermediate,4853,In vivo,N,1,CHEMBL620465,,,
10745,1,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg p.o.),,BAO_0000218,,Rattus norvegicus,,Intermediate,4853,In vivo,N,1,CHEMBL620466,,,
10746,1,Oral bioavailability was calculated in Spragun Dawley rat at oral dosage of 1 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,4853,In vivo,N,1,CHEMBL620467,,,
10747,1,Oral bioavailability was calculated in Spragun Dawley rat at oral dosage of 2 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,4853,In vivo,N,1,CHEMBL620468,,,
10748,1,Oral bioavailability was calculated in rats using an average of the intravenous AUC at peroral dose of 5 mgkg in solution form,,BAO_0000218,,Rattus norvegicus,,Intermediate,12873,In vivo,N,1,CHEMBL620469,,,
10749,1,Oral bioavailability was calculated in rats using an average of the intravenous AUC at peroral dose of 5 mgkg in suspension form,,BAO_0000218,,Rattus norvegicus,,Intermediate,12873,In vivo,N,1,CHEMBL620470,,,
10750,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,3169,In vivo,N,1,CHEMBL620471,,,
10751,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6305,In vivo,N,1,CHEMBL620472,,,
10752,1,Oral bioavailability of compound at 5 mg/kg after po administration was determined in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4762,In vivo,N,1,CHEMBL620473,,,
10753,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,17847,In vivo,N,1,CHEMBL620474,,,
10754,1,Oral bioavailability in rat (Sprague-Dawley) (fasted male) (dose 10 mg/kg),,BAO_0000218,,Rattus norvegicus,,Intermediate,6211,In vivo,N,1,CHEMBL620475,,,
10755,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6011,In vivo,N,1,CHEMBL620476,,,
10756,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6317,In vivo,N,1,CHEMBL620477,,,
10757,1,Oral bioavailability in rat after oral administration at 10.5 mg/kg dose,,BAO_0000218,,Rattus norvegicus,,Intermediate,6644,In vivo,N,1,CHEMBL620478,,,
10758,1,Oral bioavailability in rat after oral administration at 11.2 mg/kg dose,,BAO_0000218,,Rattus norvegicus,,Intermediate,6644,In vivo,N,1,CHEMBL618768,,,
10759,1,Oral bioavailability in rat after oral administration at 13 mg/kg dose,,BAO_0000218,,Rattus norvegicus,,Intermediate,6644,In vivo,N,1,CHEMBL618769,,,
10760,1,Oral bioavailability in rat after oral administration at 9.7 mg/kg dose,,BAO_0000218,,Rattus norvegicus,,Intermediate,6644,In vivo,N,1,CHEMBL618770,,,
10761,1,Oral bioavailability (dose 20 mg/kg p.o.),,BAO_0000218,,Rattus norvegicus,,Intermediate,6113,In vivo,N,1,CHEMBL618771,,,
10762,1,Oral bioavailability was determined in rat after oral administration at a concentration 1 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,5937,In vivo,N,1,CHEMBL618772,,,
10763,1,Oral bioavailability in rat at 10 mg/kg of the compound,,BAO_0000218,,Rattus norvegicus,,Intermediate,5711,In vivo,N,1,CHEMBL618773,,,
10764,1,Bioavailability in rat at a concentration of 15 mg/kg perorally in rat along with 100 mg/kg 11,,BAO_0000218,,Rattus norvegicus,,Intermediate,17717,In vivo,N,1,CHEMBL875842,,,
10765,1,Bioavailability in rat (dose 3 mg/kg i.v.),,BAO_0000218,,Rattus norvegicus,,Intermediate,17717,In vivo,N,1,CHEMBL618774,,,
10766,1,Bioavailability in rat at a concentration of 60 mg/kg perorally in rat along with 100 mg/kg 11,,BAO_0000218,,Rattus norvegicus,,Intermediate,17717,In vivo,N,1,CHEMBL618775,,,
10767,1,Oral bioavailability in rat (dose 60 mg/kg p.o.),,BAO_0000218,,Rattus norvegicus,,Intermediate,17717,In vivo,N,1,CHEMBL618776,,,
10768,1,Percent bioavailability (F) in rats after iv administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,4722,In vivo,N,1,CHEMBL618777,,,
10769,1,Percent bioavailability (F) in rats after oral dose of 10 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,4722,In vivo,N,1,CHEMBL618778,,,
10770,1,Bioavailability in rat (dose 5 uM/kg p.o.),,BAO_0000218,,Rattus norvegicus,,Intermediate,4353,In vivo,N,1,CHEMBL618779,,,
10771,1,Oral bioavailability,,BAO_0000218,,Rattus norvegicus,,Intermediate,15662,In vivo,N,1,CHEMBL618780,,,
10772,1,Bioavailability in rat (dose 2 mg/kg p.o.),,BAO_0000218,,Rattus norvegicus,,Intermediate,4756,In vivo,N,1,CHEMBL618781,,,
10773,1,Percent bioavailability at the dose of 5 mg/Kg administered perorally in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,4756,In vivo,N,1,CHEMBL618782,,,
10774,1,Oral bioavailability in rat (dose 20 mg/kg),,BAO_0000218,,Rattus norvegicus,,Intermediate,3436,In vivo,N,1,CHEMBL618783,,,
10775,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,17800,In vivo,N,1,CHEMBL618784,,,
10776,1,Percent oral bioavailability evaluated in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,15762,In vivo,N,1,CHEMBL618785,,,
10777,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5089,In vivo,N,1,CHEMBL618786,,,
10778,1,Percent oral bioavailability in rat; Not determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,5089,In vivo,N,1,CHEMBL618787,,,
10779,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,3185,In vivo,N,1,CHEMBL618788,,,
10780,1,Bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5145,In vivo,N,1,CHEMBL618789,,,
10781,1,Pharmacokinetic property (oral bioavailability) in rat (dose given as a solution),,BAO_0000218,,Rattus norvegicus,,Intermediate,3457,In vivo,N,1,CHEMBL618790,,,
10782,1,Pharmacokinetic property (oral bioavailability) in rat (dose given as a suspension),,BAO_0000218,,Rattus norvegicus,,Intermediate,3457,In vivo,N,1,CHEMBL618791,,,
10783,1,Pharmacokinetic property (F) was measured in rat at the dose of 0.32 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,5983,In vivo,N,1,CHEMBL875843,,,
10784,1,Oral bioavailability in rat (dose 20 mg/kg p.o.),,BAO_0000218,,Rattus norvegicus,,Intermediate,5739,In vivo,N,1,CHEMBL618792,,,
10785,1,Cmax at a dose of 30 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,3579,In vivo,N,1,CHEMBL623395,,,
10786,1,Cmax in monkeys at a dose of 1 mg/kg,,BAO_0000218,,Simiiformes,,Autocuration,17788,In vivo,U,0,CHEMBL623396,,,
10787,1,Cmax in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,14956,In vivo,N,1,CHEMBL623397,,,
10788,1,Cmax in rats at a dose of 1 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,17788,In vivo,N,1,CHEMBL623398,,,
10789,1,Cmax was measured in mice after an oral dose of 50 mg/kg.,,BAO_0000218,,Mus musculus,,Intermediate,9750,In vivo,N,1,CHEMBL623399,,,
10790,1,"Cmax value at a dose of 12.7 uM/kg, po",,BAO_0000218,,,,Autocuration,12767,In vivo,U,0,CHEMBL623400,,,
10791,1,"Cmax value at a dose of 6.3 uM/kg, iv",,BAO_0000218,,,,Autocuration,12767,In vivo,U,0,CHEMBL623401,,,
10792,1,"Cmax value at a dose of 7.1 uM/kg, iv",,BAO_0000218,,,,Autocuration,12767,In vivo,U,0,CHEMBL623402,,,
10793,1,Cmax value of compound was determined after 1 hr,,BAO_0000218,,,,Autocuration,12703,In vivo,U,0,CHEMBL623403,,,
10794,1,Cmax value of the compound,,BAO_0000218,,,,Autocuration,15778,In vivo,U,0,CHEMBL623404,,,
10795,1,Cmax value administered intraintestinal in rats.,,BAO_0000218,,Rattus norvegicus,,Intermediate,12818,In vivo,N,1,CHEMBL625997,,,
10796,1,Cmax value administered perorally was determined in rat; Not determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,14964,In vivo,N,1,CHEMBL625998,,,
10797,1,Cmax value at the dose of 2.3 mg/kg,,BAO_0000218,,,,Autocuration,15808,In vivo,U,0,CHEMBL625999,,,
10798,1,Cmax value at the dose of 5 mg/kg,,BAO_0000218,,,,Autocuration,15808,In vivo,U,0,CHEMBL626000,,,
10799,1,Cmax value in the period of 8 hr after dosing. ,,BAO_0000218,,,,Autocuration,15778,In vivo,U,0,CHEMBL626001,,,
10800,1,Cmax value at a oral dose of 20 mg/kg; Not tested,,BAO_0000218,,,,Autocuration,3715,In vivo,U,0,CHEMBL626002,,,
10801,1,Cmax value at a oral dose of 20 mg/kg,,BAO_0000218,,,,Autocuration,3715,In vivo,U,0,CHEMBL626003,,,
10802,1,Cmax value was determined between 15 and 30 minutes post administration in fisher rats; value ranges from 200-500,,BAO_0000218,,Rattus norvegicus,,Intermediate,1446,In vivo,N,1,CHEMBL626004,,,
10803,1,Cmax(ng /mL)values after oral administration of 10 mg/kg in guinea pig.,,BAO_0000218,,Cavia porcellus,,Intermediate,15240,In vivo,N,1,CHEMBL626005,,,
10804,1,Cmax(ng /mL)values after oral administration of 10 mg/kg in rat.,,BAO_0000218,,Rattus norvegicus,,Intermediate,15240,In vivo,N,1,CHEMBL626006,,,
10805,1,Compound at a dose of 10 mg/kg was orally administered to rats and maximum plasma concentration was reported,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14810,In vivo,N,1,CHEMBL626007,,1969.0,
10806,1,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,Plasma,BAO_0000218,,Mus musculus,,Intermediate,14239,In vivo,N,1,CHEMBL626008,,1969.0,
10807,1,Compound was evaluated for maximum plasma concentration levels in dogs for the orally delivered compound in 0.05 M citric acid,Liver,BAO_0000218,,Canis lupus familiaris,,Intermediate,12555,In vivo,N,1,CHEMBL626009,,2107.0,
10808,1,Compound was evaluated in vivo for its concentration after a peroral administration 40 mg/kg in dogs.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,10754,In vivo,N,1,CHEMBL626010,,,
10809,1,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a intramuscular administration 40 mg/kg in mice,Blood,BAO_0000218,,Mus musculus,,Intermediate,10754,In vivo,N,1,CHEMBL626011,,178.0,
10810,1,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a peroral administration 40 mg/kg in mice,Blood,BAO_0000218,,Mus musculus,,Intermediate,10754,In vivo,N,1,CHEMBL626012,,178.0,
10811,1,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a peroral administration of 40 mg/kg in mice,Blood,BAO_0000218,,Mus musculus,,Intermediate,10754,In vivo,N,1,CHEMBL626013,,178.0,
10812,1,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after an intramuscular administration of 40 mg/kg in mice,Blood,BAO_0000218,,Mus musculus,,Intermediate,10754,In vivo,N,1,CHEMBL626014,,178.0,
10813,1,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after an intramuscular administration of 40 mg/kg in mice.,Blood,BAO_0000218,,Mus musculus,,Intermediate,10754,In vivo,N,1,CHEMBL877496,,178.0,
10814,1,Compound was tested Growth Hormone(GH) release after 0.5 mg/kg administration (Po) in Beagle dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,14600,In vivo,N,1,CHEMBL626015,,,
10815,1,Compound was tested Growth Hormone(GH) release after 10 mg/kg administration (Po) in Beagle dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,14600,In vivo,N,1,CHEMBL626016,,,
10816,1,Compound was tested Growth Hormone(GH) release after 2.5 mg/kg administration (Po) in Beagle dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,14600,In vivo,N,1,CHEMBL626017,,,
10817,1,Bioavailability as maximal plasma concentration in dogs,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,13543,In vivo,N,1,CHEMBL626018,,1969.0,
10818,1,Bioavailability as maximal plasma concentration in dogs,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,13543,In vivo,N,1,CHEMBL626692,,1969.0,
10819,1,Bioavailability as maximal plasma concentration in rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,13543,In vivo,N,1,CHEMBL626693,,1969.0,
10820,1,Bioavailability as maximal plasma concentration in rats,Plasma,BAO_0000218,,Rattus norvegicus,,Autocuration,13543,In vivo,U,0,CHEMBL626694,,1969.0,
10821,1,Compound was tested for maximum blood concentration after 0.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,Blood,BAO_0000218,,Canis lupus familiaris,,Intermediate,14600,In vivo,N,1,CHEMBL626695,,178.0,
10822,1,Compound was tested for maximum blood concentration after 10 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,Blood,BAO_0000218,,Canis lupus familiaris,,Intermediate,14600,In vivo,N,1,CHEMBL626696,,178.0,
10823,1,Compound was tested for maximum blood concentration after 2.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,Blood,BAO_0000218,,Canis lupus familiaris,,Intermediate,14600,In vivo,N,1,CHEMBL626697,,178.0,
10824,1,Compound was tested for maximum concentration in blood after 0.5 mg/kg administration (Po) in Beagle dogs; nd = Not Detectable,Blood,BAO_0000218,,Canis lupus familiaris,,Intermediate,14600,In vivo,N,1,CHEMBL626859,,178.0,
10825,1,Compound was tested for maximum concentration in blood after 10 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,Blood,BAO_0000218,,Canis lupus familiaris,,Intermediate,14600,In vivo,N,1,CHEMBL626860,,178.0,
10826,1,Compound was tested for maximum concentration in blood after 2.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,Blood,BAO_0000218,,Canis lupus familiaris,,Intermediate,14600,In vivo,N,1,CHEMBL626861,,178.0,
10827,1,Compound was tested for maximum observed concentration in three male Wistar rats at a single 5 mg/kg oral gavage dose,,BAO_0000218,,Rattus norvegicus,,Intermediate,14681,In vivo,N,1,CHEMBL626296,,,
10828,1,Compound was tested for the max. conc. when administered perorally(po) 30 mg/kg,,BAO_0000218,,,,Autocuration,15905,In vivo,U,0,CHEMBL626297,,,
10829,1,Compound was tested for the max. plasma conc. when administered intraperitoneally (ip) 30 mg/kg.,Plasma,BAO_0000218,,,,Autocuration,15905,In vivo,U,0,CHEMBL626298,,1969.0,
10830,1,"Drug plasma level in rat was determined on the last day of dosing at 1,2,4.8 and 24 hr and ED50 was evaluated",Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,13304,In vivo,N,1,CHEMBL626299,,1969.0,
10831,1,Effect of ip administration of compound on plasma concentration of allo-pregnanolone (AP) in rats after 30 min.,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,15137,In vivo,N,1,CHEMBL626300,,1969.0,
10832,1,Effect of ip administration of compound on plasma concentration of allotetrahydrodeoxy corticosterone(THDOC) in rats after 30 min.,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,15137,In vivo,N,1,CHEMBL626301,,1969.0,
10833,1,Effect of ip administration of compound on plasma concentration of corticosterone (CTS) in rats after 30 min.,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,15137,In vivo,N,1,CHEMBL626962,,1969.0,
10834,1,Effect of ip administration of compound on plasma concentration of pregnenolone (PRE) in rats after 30 min.,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,15137,In vivo,N,1,CHEMBL626963,,1969.0,
10835,1,Effect of ip administration of compound on plasma concentration of progesterone (PRO) in rats after 30 min.,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,15137,In vivo,N,1,CHEMBL626964,,1969.0,
10836,1,In vivo antitumor efficacy expressed as maximum plasma concentration 0.4 hr after a peroral dose of 25 mg/kg in cynomolgus monkeys,Plasma,BAO_0000218,,Macaca fascicularis,,Intermediate,14839,In vivo,N,1,CHEMBL626965,,1969.0,
10837,1,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,Plasma,BAO_0000218,,Mus musculus,,Intermediate,14839,In vivo,N,1,CHEMBL626966,,1969.0,
10838,1,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,Plasma,BAO_0000218,,Mus musculus,,Intermediate,14839,In vivo,N,1,CHEMBL626967,,1969.0,
10839,1,In vivo antitumor efficacy expressed as maximum plasma concentration after a peroral dose of 10 mg/kg in cynomolgus monkeys,Plasma,BAO_0000218,,Macaca fascicularis,,Intermediate,14839,In vivo,N,1,CHEMBL626968,,1969.0,
10840,1,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.89-1.24,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL626969,,948.0,
10841,1,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.24-2.58,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL627126,,948.0,
10842,1,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.24-0.28,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL631276,,948.0,
10843,1,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.52-0.62,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL631277,,948.0,
10844,1,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.68-0.84,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL631278,,948.0,
10845,1,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.75-1.03,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL874457,,948.0,
10846,1,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.96-2.46,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL631279,,948.0,
10847,1,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.36-0.42,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL631280,,948.0,
10848,1,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.58-0.82,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL631281,,948.0,
10849,1,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.24-1.46,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL631968,,948.0,
10850,1,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 2.36-3.96,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL631969,,948.0,
10851,1,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.24-0.29,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL631970,,948.0,
10852,1,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.39-0.74,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL631971,,948.0,
10853,1,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.79-0.85,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL631972,,948.0,
10854,1,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.64-0.86,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL630435,,948.0,
10855,1,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.68-2.23,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL630436,,948.0,
10856,1,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.19-0.23,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL630437,,948.0,
10857,1,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.22-0.29,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL630438,,948.0,
10858,1,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.58-0.75,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL630439,,948.0,
10859,1,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.42-1.82,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL630440,,2113.0,
10860,1,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.24-3.12,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL630441,,2113.0,
10861,1,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.62-0.92,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL630442,,2113.0,
10862,1,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.12-2.04,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL625234,,2113.0,
10863,1,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.59-2.03,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL625235,,2113.0,
10864,1,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.14-1.4,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL625236,,2113.0,
10865,1,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.56-1.83,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL625237,,2113.0,
10866,1,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.58-0.73,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL626125,,2113.0,
10867,1,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 1.67-2.11,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL626126,,2113.0,
10868,1,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.64-3.43,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL626127,,2113.0,
10869,1,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 3.18-4.74,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL626128,,2113.0,
10870,1,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.62-1.13,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL626129,,2113.0,
10871,1,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.73-2.64,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL626130,,2113.0,
10872,1,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 13.02-19.07,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL626131,,2113.0,
10873,1,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.89-1.19,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL626132,,2113.0,
10874,1,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.17-1.48,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL626752,,2113.0,
10875,1,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.48-0.72,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL626753,,2113.0,
10876,1,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.49-0.57,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL626754,,2113.0,
10877,1,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.99-1.24,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL626755,,2113.0,
10878,1,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.23-1.78,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL626756,,2107.0,
10879,1,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.43-2.92,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL626757,,2107.0,
10880,1,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.81-1.18,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL626758,,2107.0,
10881,1,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.37-1.74,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL626759,,2107.0,
10882,1,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 4.01-4.81,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL626760,,2107.0,
10883,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,N,1,CHEMBL626394,,,
10884,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,N,1,CHEMBL626395,,,
10885,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration (0-6 hr),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,N,1,CHEMBL626396,,,
10886,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,N,1,CHEMBL626397,,,
10887,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,N,1,CHEMBL626398,,,
10888,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,N,1,CHEMBL626399,,,
10889,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,N,1,CHEMBL874653,,,
10890,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,N,1,CHEMBL626400,,,
10891,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration (0-5 hr),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,N,1,CHEMBL626401,,,
10892,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,N,1,CHEMBL626402,,,
10893,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,N,1,CHEMBL626403,,,
10894,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,N,1,CHEMBL626404,,,
10895,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,N,1,CHEMBL626405,,,
10896,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,N,1,CHEMBL625529,,,
10897,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration (0-5 hr),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,N,1,CHEMBL625530,,,
10898,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,N,1,CHEMBL625531,,,
10899,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,N,1,CHEMBL625532,,,
10900,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,N,1,CHEMBL625533,,,
10901,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,N,1,CHEMBL875474,,,
10902,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,N,1,CHEMBL625534,,,
10903,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration (0-5 hr),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,N,1,CHEMBL625535,,,
10904,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0 - 5 hr),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,N,1,CHEMBL625536,,,
10905,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,N,1,CHEMBL625537,,,
10906,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,N,1,CHEMBL625538,,,
10907,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,N,1,CHEMBL625539,,,
10908,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,N,1,CHEMBL625540,,,
10909,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,N,1,CHEMBL625541,,,
10910,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,N,1,CHEMBL625542,,,
10911,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,N,1,CHEMBL625543,,,
10912,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,N,1,CHEMBL625544,,,
10913,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.312 mg/kg after ip administration,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,N,1,CHEMBL625545,,,
10914,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,N,1,CHEMBL625546,,,
10915,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.625 mg/kg after ip administration,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,N,1,CHEMBL625547,,,
10916,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,N,1,CHEMBL625548,,,
10917,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,N,1,CHEMBL625549,,,
10918,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 10 mg/kg after ip administration (0-6 hr),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,N,1,CHEMBL625550,,,
10919,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,N,1,CHEMBL625551,,,
10920,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,N,1,CHEMBL875475,,,
10921,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,N,1,CHEMBL625552,,,
10922,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration (0-6 hr),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,N,1,CHEMBL625553,,,
10923,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,N,1,CHEMBL625554,,,
10924,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,N,1,CHEMBL625555,,,
10925,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,N,1,CHEMBL625556,,,
10926,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,N,1,CHEMBL624986,,,
10927,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration (0-6 hr),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,N,1,CHEMBL624987,,,
10928,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,N,1,CHEMBL624988,,,
10929,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; -2/-14,Artery,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,N,1,CHEMBL624989,,1637.0,
10930,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; -4/-4,Artery,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,N,1,CHEMBL624990,,1637.0,
10931,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; 4/7,Artery,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,N,1,CHEMBL874391,,1637.0,
10932,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3/10 range; -3/0/4,Artery,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,N,1,CHEMBL624991,,1637.0,
10933,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; -6/0,Artery,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,N,1,CHEMBL624992,,1637.0,
10934,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 10/31,Artery,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,N,1,CHEMBL624993,,1637.0,
10935,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 11/-19,Artery,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,N,1,CHEMBL624994,,1637.0,
10936,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 14/6,Artery,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,N,1,CHEMBL624995,,1637.0,
10937,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 19/25,Artery,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,N,1,CHEMBL624996,,1637.0,
10938,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 19/3,Artery,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,N,1,CHEMBL624997,,1637.0,
10939,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 2/16,Artery,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,N,1,CHEMBL624998,,1637.0,
10940,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 6/2,Artery,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,N,1,CHEMBL624999,,1637.0,
10941,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 7/26,Artery,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,N,1,CHEMBL882955,,1637.0,
10942,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 8/49,Artery,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,N,1,CHEMBL625000,,1637.0,
10943,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 8/8,Artery,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,N,1,CHEMBL625001,,1637.0,
10944,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 9/-18,Artery,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,N,1,CHEMBL625089,,1637.0,
10945,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/60 range; 13/23,Artery,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,N,1,CHEMBL625090,,1637.0,
10946,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 3 range,Artery,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,N,1,CHEMBL625091,,1637.0,
10947,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 3/10 range; -7/-11,Artery,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,N,1,CHEMBL625092,,1637.0,
10948,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 1/3 dose range; 6/-7,Artery,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,N,1,CHEMBL625093,,1637.0,
10949,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 10/30 dose range; -13/19,Artery,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,N,1,CHEMBL625094,,1637.0,
10950,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 3/10 dose range; 30/47,Artery,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,N,1,CHEMBL625095,,1637.0,
10951,1,Compound was evaluated for its bioavailability in the dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,2249,In vivo,N,1,CHEMBL625096,,,
10952,1,Compound was evaluated for its bioavailability in the rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,2249,In vivo,N,1,CHEMBL625097,,,
10953,1,Compound was evaluated for oral bioavailability,,BAO_0000218,,,,Autocuration,17515,In vivo,U,0,CHEMBL882956,,,
10954,1,Compound was evaluated for percentage of Oral bioavailability in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,14541,In vivo,N,1,CHEMBL625098,,,
10955,1,Bioavailability in guinea pig,,BAO_0000218,,Cavia porcellus,,Autocuration,12797,In vivo,U,0,CHEMBL625099,,,
10956,1,Compound was evaluated for the oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,12797,In vivo,N,1,CHEMBL625100,,,
10957,1,Compound was evaluated for the oral bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,12797,In vivo,N,1,CHEMBL625101,,,
10958,1,Compound was evaluated for the oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,12797,In vivo,N,1,CHEMBL874396,,,
10959,1,Bioavailability in dog (dosed i.v.),,BAO_0000218,,Canis lupus familiaris,,Autocuration,11727,In vivo,U,0,CHEMBL625102,,,
10960,1,Compound was tested for in vivo bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,13249,In vivo,N,1,CHEMBL625103,,,
10961,1,Compound was tested for in vivo bioavailability in hamsters,,BAO_0000218,,Cricetinae,,Intermediate,13249,In vivo,N,1,CHEMBL625104,,,
10962,1,Compound was tested for in vivo bioavailability in monkey,,BAO_0000218,,Simiiformes,,Autocuration,13249,In vivo,U,0,CHEMBL625105,,,
10963,1,Compound was tested for in vivo bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,13249,In vivo,N,1,CHEMBL625106,,,
10964,1,Oral bioavailability in mouse,,BAO_0000218,,Mus musculus,,Autocuration,9552,In vivo,U,0,CHEMBL625107,,,
10965,1,Compound was tested for percent of oral bioavailability in mice; 56-74,,BAO_0000218,,Mus musculus,,Intermediate,9552,In vivo,N,1,CHEMBL625108,,,
10966,1,Oral bioavailability in mouse (nude) (dose of 25 mg/kg),,BAO_0000218,,Mus musculus,,Autocuration,14839,In vivo,U,0,CHEMBL625109,,,
10967,1,Bioavailability in cynomolgus monkey (dose 25 mg/kg i.v.),,BAO_0000218,,Macaca fascicularis,,Autocuration,14839,In vivo,U,0,CHEMBL625110,,,
10968,1,Bioavailability in cynomolgus monkey (dose 5 mg/kg i.v.),,BAO_0000218,,Macaca fascicularis,,Autocuration,14839,In vivo,U,0,CHEMBL625111,,,
10969,1,Oral bioavailability in mouse (nude) (dose 25 mg/kg i.v.),,BAO_0000218,,Mus musculus,,Intermediate,14839,In vivo,N,1,CHEMBL625112,,,
10970,1,Oral bioavailability in nude mice,,BAO_0000218,,Mus musculus,,Intermediate,14839,In vivo,N,1,CHEMBL875334,,,
10971,1,Bioavailability in monkey (i.d. dosing),,BAO_0000218,,Primates,,Autocuration,11219,In vivo,U,0,CHEMBL628617,,,
10972,1,Bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Autocuration,9552,In vivo,U,0,CHEMBL628618,,,
10973,1,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 10%,,BAO_0000218,,,,Autocuration,11732,In vivo,U,0,CHEMBL628619,,,
10974,1,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 20%,,BAO_0000218,,,,Autocuration,11732,In vivo,U,0,CHEMBL628620,,,
10975,1,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 10 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",,BAO_0000218,,Macaca fascicularis,,Intermediate,14839,In vivo,N,1,CHEMBL628621,,,
10976,1,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",,BAO_0000218,,Macaca fascicularis,,Intermediate,14839,In vivo,N,1,CHEMBL628622,,,
10977,1,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",,BAO_0000218,,Macaca fascicularis,,Intermediate,14839,In vivo,N,1,CHEMBL628623,,,
10978,1,Maximal plasma concentration in cynomolgus monkeys after 10 mg/kg oral dose,Plasma,BAO_0000218,,Macaca fascicularis,,Intermediate,14839,In vivo,N,1,CHEMBL628624,,1969.0,
10979,1,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,Plasma,BAO_0000218,,Mus musculus,,Intermediate,14839,In vivo,N,1,CHEMBL628625,,1969.0,
10980,1,Maximal plasma concentration in cynomolgus monkeys after 5 mg/kg oral dose,Plasma,BAO_0000218,,Macaca fascicularis,,Intermediate,14839,In vivo,N,1,CHEMBL628626,,1969.0,
10981,1,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,Plasma,BAO_0000218,,Mus musculus,,Intermediate,14839,In vivo,N,1,CHEMBL627041,,1969.0,
10982,1,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,Plasma,BAO_0000218,,Mus musculus,,Intermediate,14839,In vivo,N,1,CHEMBL627042,,1969.0,
10983,1,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,Plasma,BAO_0000218,,Mus musculus,,Intermediate,14839,In vivo,N,1,CHEMBL627043,,1969.0,
10984,1,In vivo evaluation of maximum plasma concentration at a dose of 10 mg/kg,Plasma,BAO_0000218,,,,Autocuration,13932,In vivo,U,0,CHEMBL627044,,1969.0,
10985,1,Cmax in mouse plasma,Plasma,BAO_0000218,,Mus musculus,,Intermediate,11637,In vivo,N,1,CHEMBL627045,,1969.0,
10986,1,Max plasma concentration was measured by 40 mg/kg dose of peroral administration.,Plasma,BAO_0000218,,,,Autocuration,11637,In vivo,U,0,CHEMBL627046,,1969.0,
10987,1,Maximal plasma concentration in rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,13960,In vivo,N,1,CHEMBL627047,,1969.0,
10988,1,Maximal plasma level when administered 1 mg/kg perorally (po) in rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,15905,In vivo,N,1,CHEMBL627048,,1969.0,
10989,1,Maximum concentration at an intraduodenal dose of 5.2 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,14062,In vivo,N,1,CHEMBL627049,,,
10990,1,Maximum concentration at an intraduodenal dose of 6.6 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,14062,In vivo,N,1,CHEMBL627050,,,
10991,1,Maximum concentration at an intravenous dose of 5.5 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,14062,In vivo,N,1,CHEMBL627051,,,
10992,1,Maximum concentration at an intravenous dose of 6.5 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,14062,In vivo,N,1,CHEMBL627052,,,
10993,1,Maximum concentration at an peroral dose of 6.2 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,14062,In vivo,N,1,CHEMBL627053,,,
10994,1,Maximum concentration at an peroral dose of 6.3 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,14062,In vivo,N,1,CHEMBL627054,,,
10995,1,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered intravenously to nude mice at a dose of 25 mg/kg,,BAO_0000218,,Mus musculus,,Intermediate,15011,In vivo,N,1,CHEMBL627055,,,
10996,1,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg,,BAO_0000218,,Mus musculus,,Intermediate,15011,In vivo,N,1,CHEMBL627056,,,
10997,1,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg (micronized sample),,BAO_0000218,,Mus musculus,,Intermediate,15011,In vivo,N,1,CHEMBL627057,,,
10998,1,Maximum concentration (Cmax) using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. compound was administered intravenously to nude mice at a dose of 25 mg/kg,,BAO_0000218,,Mus musculus,,Intermediate,15011,In vivo,N,1,CHEMBL627058,,,
10999,1,Maximum concentration (Cmax) using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg,,BAO_0000218,,Mus musculus,,Intermediate,15011,In vivo,N,1,CHEMBL626211,,,
11000,1,Maximum Concentration of the compound.,,BAO_0000218,,,,Autocuration,10291,In vivo,U,0,CHEMBL626212,,,
11001,1,Maximum Concentration was measured after iv administration into Beagle dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,14599,In vivo,N,1,CHEMBL626213,,,
11002,1,Maximum Concentration was measured after iv administration into Beagle dog.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,14599,In vivo,N,1,CHEMBL626214,,,
11003,1,Maximum Concentration was measured after po administration into Beagle dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,14599,In vivo,N,1,CHEMBL626215,,,
11004,1,Maximum Concentration was measured after po administration into Beagle dog.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,14599,In vivo,N,1,CHEMBL626216,,,
11005,1,Maximum blood level reached after an dose of 10.6 uM/kg intravenously,Blood,BAO_0000218,,,,Autocuration,12767,In vivo,U,0,CHEMBL626217,,178.0,
11006,1,Maximum blood level reached after an iv dose of 12.2 uM/kg,Blood,BAO_0000218,,,,Autocuration,12767,In vivo,U,0,CHEMBL626218,,178.0,
11007,1,Maximum blood level reached after an oral dose 14.7 uM/kg oral route,Blood,BAO_0000218,,,,Autocuration,12767,In vivo,U,0,CHEMBL626219,,178.0,
11008,1,Maximum blood level reached after an oral dose of 14.7 uM/kg intravenous route,Blood,BAO_0000218,,,,Autocuration,12767,In vivo,U,0,CHEMBL626220,,178.0,
11009,1,Maximum blood level reached after an oral dose of 5.0 mg/kg,Blood,BAO_0000218,,,,Autocuration,12767,In vivo,U,0,CHEMBL626221,,178.0,
11010,1,Maximum blood level reached at dose of 10.6 uM/kg orally,Blood,BAO_0000218,,,,Autocuration,12767,In vivo,U,0,CHEMBL626222,,178.0,
11011,1,Maximum concentration (Cmax) in guinea pigs at 2 mg/kg after oral administration,,BAO_0000218,,Cavia porcellus,,Intermediate,14706,In vivo,N,1,CHEMBL626223,,,
11012,1,Maximum concentration (Cmax) in guinea pigs at 3 mg/kg after oral administration,,BAO_0000218,,Cavia porcellus,,Intermediate,14706,In vivo,N,1,CHEMBL626224,,,
11013,1,Maximum concentration achieved in rat brain when administered intraperitoneally at a dose of 10 mg/kg,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,14793,In vivo,N,1,CHEMBL626225,,955.0,
11014,1,Maximum concentration achieved in rat brain when administered intravenously at a dose of 10 mg/kg,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,14793,In vivo,N,1,CHEMBL626226,,955.0,
11015,1,Maximum concentration achieved in rat brain when administered perorally at a dose of 100 mg/kg,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,14793,In vivo,N,1,CHEMBL626227,,955.0,
11016,1,Maximum concentration achieved in rat brain when administered perorally at a dose of 10 mg/kg,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,14793,In vivo,N,1,CHEMBL626228,,955.0,
11017,1,Maximum concentration achieved in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,14793,In vivo,N,1,CHEMBL626229,,,
11018,1,Maximum concentration achieved in rat plasma when administered intravenously at a dose of 10 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,14793,In vivo,N,1,CHEMBL626921,,,
11019,1,Maximum concentration achieved in rat plasma when administered perorally at a dose of 100 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,14793,In vivo,N,1,CHEMBL876793,,,
11020,1,Maximum concentration achieved in rat plasma when administered perorally at a dose of 10 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,14793,In vivo,N,1,CHEMBL625309,,,
11021,1,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),,BAO_0000218,,Bacillus subtilis,,Intermediate,10524,In vivo,N,1,CHEMBL625310,,,
11022,1,Maximum concentration determined in monkeys dosed intravenously with 30 mg/kg,,BAO_0000218,,Simiiformes,,Autocuration,11871,In vivo,U,0,CHEMBL625311,,,
11023,1,Maximum concentration determined in rats dosed intravenously with 20 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11871,In vivo,N,1,CHEMBL625312,,,
11024,1,Maximum concentration for the bioavailability at a dose of 20 mg/kg administered orally,,BAO_0000218,,,,Autocuration,3437,In vivo,U,0,CHEMBL625313,,,
11025,1,Maximum concentration in male CD-1 mice after sc administration of 20 mg/kg,,BAO_0000218,,Mus musculus,,Intermediate,12038,In vivo,N,1,CHEMBL625314,,,
11026,1,Maximum concentration in male rats after iv administration of 20 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,12038,In vivo,N,1,CHEMBL625315,,,
11027,1,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.06-1.29,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL625316,,2107.0,
11028,1,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.77-2.08,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL625317,,2107.0,
11029,1,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.54-0.89,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL625318,,2107.0,
11030,1,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 1.57-1.66,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL625319,,2107.0,
11031,1,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.06-2.71,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL625320,,2107.0,
11032,1,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 2.98-3.22,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL625321,,2107.0,
11033,1,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.73-1.45,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL625322,,2107.0,
11034,1,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.03-1.31,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL876801,,2107.0,
11035,1,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 6.76-10.44,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL625323,,2107.0,
11036,1,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.47-1.17,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL625324,,2107.0,
11037,1,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.12-1.44,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL625325,,2107.0,
11038,1,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.38-0.57,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL625326,,2107.0,
11039,1,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.75-1.14,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL625327,,2107.0,
11040,1,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 1.36-1.74,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL625328,,2107.0,
11041,1,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.05-1.5,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL625329,,2048.0,
11042,1,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 3.10-3.77,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL625330,,2048.0,
11043,1,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.4-0.54,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL627774,,2048.0,
11044,1,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.58-0.86,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL627775,,2048.0,
11045,1,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.77-0.86,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL627949,,2048.0,
11046,1,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.86-1.13,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL627950,,2048.0,
11047,1,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 2.26-2.89,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL627951,,2048.0,
11048,1,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.54-0.7,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL627952,,2048.0,
11049,1,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.6-0.66,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL627953,,2048.0,
11050,1,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.35-1.74,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL627954,,2048.0,
11051,1,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 3.62-7.08,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL627955,,2048.0,
11052,1,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.47-0.56,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL627956,,2048.0,
11053,1,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.54-1.07,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL876802,,2048.0,
11054,1,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.76-0.91,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL627957,,2048.0,
11055,1,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.61-0.86,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL627958,,2048.0,
11056,1,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 2.11-3.79,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL627959,,2048.0,
11057,1,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.3-0.36,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL627960,,2048.0,
11058,1,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.36-0.44,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL627961,,2048.0,
11059,1,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.5-0.65,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL627962,,2048.0,
11060,1,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,,BAO_0000218,,Rattus norvegicus,,Intermediate,9796,,N,1,CHEMBL627963,,,
11061,1,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,,BAO_0000218,,Rattus norvegicus,,Intermediate,9796,,N,1,CHEMBL624759,,,
11062,1,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,,BAO_0000218,,Rattus norvegicus,,Intermediate,9796,,N,1,CHEMBL624760,,,
11063,1,Distribution of radiolabeled compound in intestinal contents of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,,BAO_0000218,,Rattus norvegicus,,Intermediate,9796,,N,1,CHEMBL624761,,,
11064,1,Distribution of radiolabeled compound in intestinal contents of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,,BAO_0000218,,Rattus norvegicus,,Intermediate,9796,,N,1,CHEMBL877607,,,
11065,1,Distribution of radiolabeled compound in liver of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,9796,,N,1,CHEMBL624762,,2107.0,
11066,1,Distribution of radiolabeled compound in liver of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,9796,,N,1,CHEMBL624763,,2107.0,
11067,1,Distribution of radiolabeled compound in liver of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,9796,,N,1,CHEMBL624764,,2107.0,
11068,1,Distribution of radiolabeled compound in liver of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,9796,,N,1,CHEMBL624765,,2107.0,
11069,1,Distribution of radiolabeled compound in liver of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,9796,,N,1,CHEMBL624766,,2107.0,
11070,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,N,1,CHEMBL624767,,,
11071,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,N,1,CHEMBL624768,,,
11072,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration (0-6 hr),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,N,1,CHEMBL624769,,,
11073,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,N,1,CHEMBL624770,,,
11074,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,N,1,CHEMBL624771,,,
11075,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,N,1,CHEMBL624772,,,
11076,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,N,1,CHEMBL624773,,,
11077,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,N,1,CHEMBL624774,,,
11078,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration (0-5 hr),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,N,1,CHEMBL624775,,,
11079,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,N,1,CHEMBL624776,,,
11080,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,N,1,CHEMBL624777,,,
11081,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,N,1,CHEMBL624778,,,
11082,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,N,1,CHEMBL624779,,,
11083,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,N,1,CHEMBL624780,,,
11084,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,N,1,CHEMBL624781,,,
11085,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,N,1,CHEMBL877608,,,
11086,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration (0-5 hr),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,N,1,CHEMBL624782,,,
11087,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,N,1,CHEMBL624783,,,
11088,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,N,1,CHEMBL624784,,,
11089,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,N,1,CHEMBL624785,,,
11090,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration (0-5 hr),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,N,1,CHEMBL624786,,,
11091,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,N,1,CHEMBL624787,,,
11092,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,N,1,CHEMBL628676,,,
11093,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,N,1,CHEMBL621842,,,
11094,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,N,1,CHEMBL621843,,,
11095,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,N,1,CHEMBL623873,,,
11096,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,N,1,CHEMBL623874,,,
11097,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,N,1,CHEMBL623875,,,
11098,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,N,1,CHEMBL623876,,,
11099,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.312 mg/kg after ip administration,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,N,1,CHEMBL623877,,,
11100,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,N,1,CHEMBL623878,,,
11101,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.625 mg/kg after ip administration,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,N,1,CHEMBL623879,,,
11102,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,N,1,CHEMBL623880,,,
11103,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,N,1,CHEMBL623881,,,
11104,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 10 mg/kg after ip administration (0-6 hr),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,N,1,CHEMBL623957,,,
11105,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,N,1,CHEMBL623958,,,
11106,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,N,1,CHEMBL623959,,,
11107,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,N,1,CHEMBL623960,,,
11108,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration (0-6 hr),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,N,1,CHEMBL623961,,,
11109,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,N,1,CHEMBL623962,,,
11110,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,N,1,CHEMBL624676,,,
11111,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,N,1,CHEMBL624677,,,
11112,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,N,1,CHEMBL624678,,,
11113,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration (0-6 hr),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,N,1,CHEMBL624679,,,
11114,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,N,1,CHEMBL624680,,,
11115,1,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 27%,,BAO_0000218,,,,Autocuration,11732,In vivo,U,0,CHEMBL624849,,,
11116,1,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 4%,,BAO_0000218,,,,Autocuration,11732,In vivo,U,0,CHEMBL624850,,,
11117,1,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 54%,,BAO_0000218,,,,Autocuration,11732,In vivo,U,0,CHEMBL874399,,,
11118,1,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 72%,,BAO_0000218,,,,Autocuration,11732,In vivo,U,0,CHEMBL624851,,,
11119,1,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 76%,,BAO_0000218,,,,Autocuration,11732,In vivo,U,0,CHEMBL624852,,,
11120,1,Oral bioavailability in rat (dose 10 mg/kg),,BAO_0000218,,Rattus norvegicus,,Autocuration,13359,In vivo,U,0,CHEMBL624853,,,
11121,1,Oral bioavailability in rat (Sprague-Dawley),,BAO_0000218,,Rattus norvegicus,,Autocuration,16618,In vivo,U,0,CHEMBL624854,,,
11122,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Autocuration,13960,In vivo,U,0,CHEMBL624855,,,
11123,1,Oral bioavailability in rats was determined in vivo,,BAO_0000218,,Rattus norvegicus,,Autocuration,13917,In vivo,U,0,CHEMBL624856,,,
11124,1,Oral bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Autocuration,14266,In vivo,U,0,CHEMBL882957,,,
11125,1,Oral bioavailability of compound in monkey,,BAO_0000218,,Simiiformes,,Autocuration,12359,In vivo,U,0,CHEMBL624857,,,
11126,1,Oral bioavailability of compound in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,12359,In vivo,N,1,CHEMBL622202,,,
11127,1,Bioavailability in rat of PMEA prodrug,,BAO_0000218,,Rattus norvegicus,,Autocuration,12359,In vivo,U,0,CHEMBL622203,,,
11128,1,Oral bioavailability of compound was evaluated relative to that of PMEA in rat; Not determined due to lack of solubility,,BAO_0000218,,Rattus norvegicus,,Intermediate,12359,In vivo,N,1,CHEMBL625522,,,
11129,1,Serum conc at 3 hours following 25 mg/kg dose,,BAO_0000218,,Macaca mulatta,,Autocuration,10791,In vivo,U,0,CHEMBL622868,,,
11130,1,Urine conc 0-5 hours following 25 mg/kg dose,Urine,BAO_0000218,,Macaca mulatta,,Autocuration,10791,In vivo,U,0,CHEMBL622869,,1088.0,
11131,1,Urine conc 0-24 hours following 25 mg/kg dose,Urine,BAO_0000218,,Macaca mulatta,,Autocuration,10791,In vivo,U,0,CHEMBL622870,,1088.0,
11132,1,Oral bioavailability in African green monkeys; 20-25,,BAO_0000218,,Chlorocebus aethiops,,Autocuration,138,In vivo,U,0,CHEMBL622871,,,
11133,1,Oral bioavailability in cynomolgus monkey.,,BAO_0000218,,Macaca fascicularis,,Intermediate,14521,In vivo,N,1,CHEMBL620560,,,
11134,1,Oral bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Autocuration,13953,In vivo,U,0,CHEMBL620561,,,
11135,1,Oral bioavailability in dog at 10 mg/kg oral dose,,BAO_0000218,,Canis lupus familiaris,,Intermediate,12836,In vivo,N,1,CHEMBL620562,,,
11136,1,Oral bioavailability in hamster at 10 mg/kg oral dose,,BAO_0000218,,Cricetinae,,Intermediate,12836,In vivo,N,1,CHEMBL620563,,,
11137,1,Oral bioavailability in rat at 10 mg/kg oral dose,,BAO_0000218,,Rattus norvegicus,,Intermediate,12836,In vivo,N,1,CHEMBL620564,,,
11138,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Autocuration,14521,In vivo,U,0,CHEMBL872265,,,
11139,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Autocuration,13953,In vivo,U,0,CHEMBL620565,,,
11140,1,Oral bioavailability,,BAO_0000218,,Eutheria,,Autocuration,6799,In vivo,U,0,CHEMBL620566,,,
11141,1,Oral bioavailability was determined; range 49-102%,,BAO_0000218,,,,Autocuration,11311,In vivo,U,0,CHEMBL620567,,,
11142,1,Oral bioavailability was determined in dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4013,In vivo,N,1,CHEMBL620568,,,
11143,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Autocuration,4013,In vivo,U,0,CHEMBL620569,,,
11144,1,Oral bioavailability,,BAO_0000218,,Eutheria,,Autocuration,17591,In vivo,U,0,CHEMBL620570,,,
11145,1,Oral bioavailability was determined; Not orally available,,BAO_0000218,,,,Autocuration,17591,In vivo,U,0,CHEMBL620571,,,
11146,1,Percent bioavailability was administered by using 0.4% Methyl cellulose (MC) as vehicle to nude mice at a dose of 25 mg/kg (micronized sample),,BAO_0000218,,Mus musculus,,Intermediate,15011,In vivo,N,1,CHEMBL620572,,,
11147,1,Bioavailability in mouse (nude) (dose 0.4% Methylcellulose (MC) as vehicle 25 mg/kg),,BAO_0000218,,Mus musculus,,Autocuration,15011,In vivo,U,0,CHEMBL620573,,,
11148,1,Bioavailability in mouse (nude) using 20% aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle 25 mg/kg,,BAO_0000218,,Mus musculus,,Autocuration,15011,In vivo,U,0,CHEMBL620574,,,
11149,1,Oral bioavailability in Rhesus monkey,,BAO_0000218,,Macaca mulatta,,Autocuration,9552,In vivo,U,0,CHEMBL620575,,,
11150,1,Oral bioavailability in dog (female mongrel),,BAO_0000218,,Canis lupus familiaris,,Autocuration,9552,In vivo,U,0,CHEMBL620576,,,
11151,1,Percent oral bioavailability of perorally administered compound (30 mg/kg) was tested,,BAO_0000218,,,,Autocuration,3639,In vivo,U,0,CHEMBL875846,,,
11152,1,Oral bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Autocuration,13397,In vivo,U,0,CHEMBL620577,,,
11153,1,Percentage Bioavailability was evaluated.,,BAO_0000218,,,,Autocuration,3031,In vivo,U,0,CHEMBL620578,,,
11154,1,Bioavailability in rat administered i.d.,,BAO_0000218,,Rattus norvegicus,,Autocuration,12818,In vivo,U,0,CHEMBL620579,,,
11155,1,Bioavailability,,BAO_0000218,,Eutheria,,Autocuration,4847,In vivo,U,0,CHEMBL621248,,,
11156,1,Bioavailability in dog (male Beagle) i.v. administration,,BAO_0000218,,Canis lupus familiaris,,Autocuration,12421,In vivo,U,0,CHEMBL625390,,,
11157,1,"Bioavailability in rat (dose 20 mg/kg p.o. in 1% methocel, and 5 mg/kg i.v. in PEG400)",,BAO_0000218,,Rattus norvegicus,,Autocuration,11966,In vivo,U,0,CHEMBL625391,,,
11158,1,Bioavailability in monkey (dose 10 mg/kg i.d. or 0.3 mg/kg i.v.),,BAO_0000218,,Primates,,Autocuration,11218,In vivo,U,0,CHEMBL872266,,,
11159,1,Oral bioavailability in rat (Sprague-Dawley) (male),,BAO_0000218,,Rattus norvegicus,,Autocuration,13129,In vivo,U,0,CHEMBL625392,,,
11160,1,The oral bioavailability was measured on rats after oral administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,12350,In vivo,N,1,CHEMBL625393,,,
11161,1,Bioavailability was evaluated in rat at an intravenous dose of 3 mg/kg and peroral dose of 5 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,2231,In vivo,N,1,CHEMBL625394,,,
11162,1,Bioavailability was evaluated in rhesus monkey at an intravenous dose of 1 mg/kg and peroral dose of 1 mg/kg,,BAO_0000218,,Macaca mulatta,,Intermediate,2231,In vivo,N,1,CHEMBL625395,,,
11163,1,Bioavailability in rat (dose 10 mg/kg i.d.),,BAO_0000218,,Rattus norvegicus,,Autocuration,12187,In vivo,U,0,CHEMBL625396,,,
11164,1,Bioavailability in dog (male Beagle) i.v. administration,,BAO_0000218,,Canis lupus familiaris,,Autocuration,12421,In vivo,U,0,CHEMBL625397,,,
11165,1,Biodistribution in CD-1 mice was determined after 1 minute in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),,BAO_0000218,,Mus musculus,,Intermediate,13256,In vivo,N,1,CHEMBL625398,,,
11166,1,Biodistribution in CD-1 mice was determined after 1 minute in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),Blood,BAO_0000218,,Mus musculus,,Intermediate,13256,In vivo,N,1,CHEMBL625399,,178.0,
11167,1,Biodistribution in CD-1 mice was determined after 1 minute in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),Cerebellum,BAO_0000218,,Mus musculus,,Intermediate,13256,In vivo,N,1,CHEMBL626074,,2037.0,
11168,1,Biodistribution in CD-1 mice was determined after 1 minute in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),,BAO_0000218,,Mus musculus,,Intermediate,13256,In vivo,N,1,CHEMBL626075,,,
11169,1,Maximum concentration in plasma (Cmax) was evaluated in rat at an intravenous dose of 3 mg/kg and peroral dose of 5 mg/kg,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,2231,In vivo,N,1,CHEMBL626076,,1969.0,
11170,1,Maximum concentration in plasma (Cmax) was evaluated in rhesus monkey at an intravenous dose of 1 mg/kg and peroral dose of 1 mg/kg,Plasma,BAO_0000218,,Macaca mulatta,,Intermediate,2231,In vivo,N,1,CHEMBL626077,,1969.0,
11171,1,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 1 mg/kg in rat (normalized to a 1 mg/kg dose),Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,12178,In vivo,N,1,CHEMBL626078,,178.0,
11172,1,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 2.5 mg/kg in rat (normalized to a 1 mg/kg dose),Blood,BAO_0000218,,,,Autocuration,12178,In vivo,U,0,CHEMBL625846,,178.0,
11173,1,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 5.0 mg/kg GP (normalized to a 1 mg/kg dose),Blood,BAO_0000218,,,,Autocuration,12178,In vivo,U,0,CHEMBL625847,,178.0,
11174,1,Maximum concentration observed in rats at an oral dose of 50 mg/kg,,BAO_0000218,,Rattus norvegicus,,Expert,15633,In vivo,N,1,CHEMBL625848,,,
11175,1,Maximum concentration of compound in plasma administered orally to rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14258,In vivo,N,1,CHEMBL625849,,1969.0,
11176,1,"Maximum concentration (10 mg/kg, orally) in plasma of dogs",Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,14224,In vivo,N,1,CHEMBL626023,,1969.0,
11177,1,"Maximum concentration (10 mg/kg, perorally) in plasma of dogs",Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,14224,In vivo,N,1,CHEMBL626024,,1969.0,
11178,1,"Maximum concentration (5 mg/kg, intravenously) in plasma of dogs",Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,14224,In vivo,N,1,CHEMBL626025,,1969.0,
11179,1,Maximum concentration after 10 mg/kg by oral administration,,BAO_0000218,,,,Autocuration,5566,In vivo,U,0,CHEMBL626026,,,
11180,1,Maximum concentration at a dose of 1.5 mg/kg,,BAO_0000218,,,,Autocuration,16935,In vivo,U,0,CHEMBL626027,,,
11181,1,Maximum concentration at a dose of 2.0 mg/kg,,BAO_0000218,,,,Autocuration,16935,In vivo,U,0,CHEMBL626028,,,
11182,1,Maximum concentration in dog plasma,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,14224,In vivo,N,1,CHEMBL626029,,1969.0,
11183,1,Maximum concentration in plasma after administration of 10 umol/kg dose perorally,Plasma,BAO_0000218,,,,Autocuration,12536,In vivo,U,0,CHEMBL626030,,1969.0,
11184,1,Maximum concentration in plasma after administration of 2 umol/kg dose intravenously,Plasma,BAO_0000218,,,,Autocuration,12536,In vivo,U,0,CHEMBL626031,,1969.0,
11185,1,Maximum concentration in plasma after administration of 4 umol/kg dose intravenously,Plasma,BAO_0000218,,,,Autocuration,12536,In vivo,U,0,CHEMBL626032,,1969.0,
11186,1,Maximum concentration in plasma after administration of 40 umol/kg dose perorally,Plasma,BAO_0000218,,,,Autocuration,12536,In vivo,U,0,CHEMBL626033,,1969.0,
11187,1,Maximum concentration in plasma after administration of 5 umol/kg dose intravenously,Plasma,BAO_0000218,,,,Autocuration,12536,In vivo,U,0,CHEMBL626034,,1969.0,
11188,1,Maximum concentration in plasma after oral administration in dog (25 mg/kg),Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,9994,In vivo,N,1,CHEMBL626035,,1969.0,
11189,1,Maximum concentration in plasma at Tmax,Plasma,BAO_0000218,,,,Autocuration,1434,In vivo,U,0,CHEMBL626036,,1969.0,
11190,1,Maximum concentration in plasma recorded 0-6 hr post dose in dog at 10 mg/kg oral dose,Plasma,BAO_0000218,,Canis lupus familiaris,,Expert,12836,In vivo,N,1,CHEMBL626037,,1969.0,
11191,1,Maximum concentration in plasma recorded in the period 0-6 hr post dose in hamster at 10 mg/kg oral dose,Plasma,BAO_0000218,,Cricetinae,,Intermediate,12836,In vivo,N,1,CHEMBL626038,,1969.0,
11192,1,Maximum concentration in plasma recorded in the period 0-6 hr post dose in rat at 10 mg/kg oral dose,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,12836,In vivo,N,1,CHEMBL626039,,1969.0,
11193,1,Maximum concentration in plasma was determined by oral administration to rats at 20 mg/kg,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,12545,In vivo,N,1,CHEMBL626040,,1969.0,
11194,1,Maximum concentration present in the rabbit plasma following peroral administration of 10 mg/kg,Plasma,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,13856,In vivo,N,1,CHEMBL626041,,1969.0,
11195,1,Maximum concentration was calculated,,BAO_0000218,,,,Autocuration,3550,In vivo,U,0,CHEMBL626042,,,
11196,1,Maximum concentration was calculated.,,BAO_0000218,,,,Autocuration,2632,In vivo,U,0,CHEMBL626043,,,
11197,1,Maximum concentration at a peroral dose of 10 mg/kg,,BAO_0000218,,,,Autocuration,5566,In vivo,U,0,CHEMBL626044,,,
11198,1,Maximum concentration of the drug at 10 uM/dg administered perorally,,BAO_0000218,,,,Autocuration,11883,In vivo,U,0,CHEMBL626045,,,
11199,1,Maximum concentration of the drug at 2 uM/dg administered intravenously,,BAO_0000218,,,,Autocuration,11883,In vivo,U,0,CHEMBL626046,,,
11200,1,"Maximum concentration of the unchanged compound in dog plasma, recorded in the period 0-6 hr post dose.",Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,14122,In vivo,N,1,CHEMBL626047,,1969.0,
11201,1,"Maximum concentration of the unchanged compound in hamster plasma, recorded in the period 0-6 hr post dose.",Plasma,BAO_0000218,,Cricetinae,,Intermediate,14122,In vivo,N,1,CHEMBL626048,,1969.0,
11202,1,"Maximum concentration of the unchanged compound in rat plasma, recorded in the period 0-6 hr post dose.",Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14122,In vivo,N,1,CHEMBL626049,,1969.0,
11203,1,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in anesthetized rat at 60 mg/kg oral dose,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,12542,In vivo,N,1,CHEMBL626050,,1969.0,
11204,1,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in dog at 5 mg/kg oral dose,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,12542,In vivo,N,1,CHEMBL874541,,1969.0,
11205,1,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in hamster at 40 mg/kg oral dose,Plasma,BAO_0000218,,Cricetinae,,Intermediate,12542,In vivo,N,1,CHEMBL622826,,1969.0,
11206,1,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose to hamster at 40 mg/kg oral dose,Plasma,BAO_0000218,,Cricetinae,,Intermediate,12542,In vivo,N,1,CHEMBL622827,,1969.0,
11207,1,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in anesthetized rat at 25 mg/kg oral dose,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,12542,In vivo,N,1,CHEMBL622828,,1969.0,
11208,1,Maximum concentration of unchanged drug in rat plasma in the period 0-24 hr after dosing,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14080,In vivo,N,1,CHEMBL622829,,1969.0,
11209,1,Maximum concentration reached following intravenous administration in male rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,11911,In vivo,N,1,CHEMBL876806,,,
11210,1,Maximum concentration was determined in an aqueous sodium hydroxide solution adjusted to pH 10 at 10 mg/kg dosage administered perorally in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,13204,In vivo,N,1,CHEMBL622830,,,
11211,1,Maximum concentration was determined in an aqueous sodium hydroxide solution adjusted to pH 10 at 5 mg/kg dosage administered perorally in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,13204,In vivo,N,1,CHEMBL622831,,,
11212,1,Maximum concentration was measured after peroral administration of 10 mg/kg of drug in male Beagle dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,14346,In vivo,N,1,CHEMBL626794,,,
11213,1,Maximum concentration was measured after peroral administration of 5.0 mg/kg of drug in male Dawley rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,14346,In vivo,N,1,CHEMBL626795,,,
11214,1,Maximum concentration was measured after peroral administration of 5.1 mg/kg of drug in male Dawley rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,14346,In vivo,N,1,CHEMBL626796,,,
11215,1,Maximum concentration was measured after peroral administration of 5.2 mg/kg of drug in male Dawley rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,14346,In vivo,N,1,CHEMBL626797,,,
11216,1,Maximum drug concentration is determined after oral dosing in rats.,,BAO_0000218,,Rattus norvegicus,,Intermediate,14127,In vivo,N,1,CHEMBL626798,,,
11217,1,Maximum observed concentration in oral (5 mg/kg) fasted dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,14339,In vivo,N,1,CHEMBL626799,,,
11218,1,Maximum observed concentration in oral (5 mg/kg) fed dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,14339,In vivo,N,1,CHEMBL626800,,,
11219,1,Maximum plasma concentration,Plasma,BAO_0000218,,,,Autocuration,13494,In vivo,U,0,CHEMBL626801,,1969.0,
11220,1,Maximum plasma concentration (Cmax) was determined in rats after intraduodenal administration of the drug,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14925,In vivo,N,1,CHEMBL876816,,1969.0,
11221,1,Maximum plasma concentration following oral administration of 26.3 mg/kg in rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14474,In vivo,N,1,CHEMBL626802,,1969.0,
11222,1,Maximum plasma concentration following oral administration of 3.8 mg/kg in Beagle dog,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,14474,In vivo,N,1,CHEMBL626803,,1969.0,
11223,1,Maximum plasma concentration following oral administration of 30 umol/kg,Plasma,BAO_0000218,,,,Autocuration,13917,In vivo,U,0,CHEMBL626804,,1969.0,
11224,1,Distribution of radiolabeled compound in plasma of rat 1 hr after ip administration of dose,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,9796,,N,1,CHEMBL626805,,1969.0,
11225,1,Distribution of radiolabeled compound in plasma of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,9796,,N,1,CHEMBL626309,,1969.0,
11226,1,Distribution of radiolabeled compound in plasma of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,9796,,N,1,CHEMBL626310,,1969.0,
11227,1,Distribution of radiolabeled compound in plasma of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,9796,,N,1,CHEMBL626311,,1969.0,
11228,1,Distribution of radiolabeled compound in plasma of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,9796,,N,1,CHEMBL626312,,1969.0,
11229,1,Distribution of radiolabeled compound in uterus of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,Uterus,BAO_0000218,,Rattus norvegicus,,Intermediate,9796,,N,1,CHEMBL626313,,995.0,
11230,1,Distribution of radiolabeled compound in uterus of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,Uterus,BAO_0000218,,Rattus norvegicus,,Intermediate,9796,,N,1,CHEMBL626314,,995.0,
11231,1,Distribution of radiolabeled compound in uterus of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,Uterus,BAO_0000218,,Rattus norvegicus,,Intermediate,9796,,N,1,CHEMBL626315,,995.0,
11232,1,Distribution of radiolabeled compound in uterus of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,Uterus,BAO_0000218,,Rattus norvegicus,,Intermediate,9796,,N,1,CHEMBL626316,,995.0,
11233,1,Distribution of radiolabeled compound in uterus of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,Uterus,BAO_0000218,,Rattus norvegicus,,Intermediate,9796,,N,1,CHEMBL626317,,995.0,
11234,1,Distribution of rat erythrocytes for tube 2 on rate of aging in 2 mL of cell suspension; Minus (-),,BAO_0000218,,Rattus norvegicus,,Intermediate,8363,,N,1,CHEMBL626318,,,
11235,1,Distribution of rat erythrocytes for tube 2 on rate of aging in 2 mL of cell suspension; Plus (+),,BAO_0000218,,Rattus norvegicus,,Intermediate,8363,,N,1,CHEMBL626319,,,
11236,1,Distribution of rat erythrocytes for tube 3 on rate of aging in 2 mL of cell suspension; Minus (-),,BAO_0000218,,Rattus norvegicus,,Intermediate,8363,,N,1,CHEMBL626320,,,
11237,1,Distribution of rat erythrocytes for tube 3 on rate of aging in 2 mL of cell suspension; Plus (+),,BAO_0000218,,Rattus norvegicus,,Intermediate,8363,,N,1,CHEMBL875053,,,
11238,1,Distribution of rat erythrocytes for tube 4 on rate of aging in 2 mL of cell suspension; Minus (-),,BAO_0000218,,Rattus norvegicus,,Intermediate,8363,,N,1,CHEMBL626321,,,
11239,1,Distribution of rat erythrocytes for tube 4 on rate of aging in 2 mL of cell suspension; Plus (+),,BAO_0000218,,Rattus norvegicus,,Intermediate,8363,,N,1,CHEMBL626322,,,
11240,1,Distribution of rat erythrocytes for tube 5 on rate of aging in 2 mL of cell suspension; Minus (-),,BAO_0000218,,Rattus norvegicus,,Intermediate,8363,,N,1,CHEMBL626323,,,
11241,1,Distribution of rat erythrocytes for tube 5 on rate of aging in 2 mL of cell suspension; Plus (+),,BAO_0000218,,Rattus norvegicus,,Intermediate,8363,,N,1,CHEMBL626324,,,
11242,1,Distribution of rat erythrocytes for tube 6 on rate of aging in 2 mL of cell suspension; Minus (-),,BAO_0000218,,Rattus norvegicus,,Intermediate,8363,,N,1,CHEMBL626325,,,
11243,1,Distribution of rat erythrocytes for tube 6 on rate of aging in 2 mL of cell suspension; Plus (+),,BAO_0000218,,Rattus norvegicus,,Intermediate,8363,,N,1,CHEMBL626326,,,
11244,1,Distribution of rat erythrocytes for tube 7 on rate of aging in 2 mL of cell suspension; Plus (+),,BAO_0000218,,Rattus norvegicus,,Intermediate,8363,,N,1,CHEMBL626327,,,
11245,1,Distribution of rat erythrocytes for tube 1 on rate of aging in 2 mL of cell suspension; Minus (-),,BAO_0000218,,Rattus norvegicus,,Intermediate,8363,,N,1,CHEMBL626328,,,
11246,1,"Distribution in blood of rat 5 min after intravenous administration, injected dose/gm",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL626329,,178.0,
11247,1,"Distribution in blood of rat, 15 min after intravenous administration, injected dose/gm",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL626330,,178.0,
11248,1,"Distribution in blood of rat, 1 hr after intravenous administration, injected dose/gm",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL626331,,178.0,
11249,1,"Distribution in blood of rat, 2 hr after intravenous administration, injected dose/gm",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL626332,,178.0,
11250,1,"Distribution in blood of rat, 30 min after intravenous administration, injected dose/gm",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL626333,,178.0,
11251,1,"Distribution in blood of rat, 4 hr after intravenous administration, injected dose/gm",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL626334,,178.0,
11252,1,"Distribution in blood of rat, 6 hr after intravenous administration, injected dose/gm",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL626335,,178.0,
11253,1,"Distribution in blood of rat, 8 hr after intravenous administration, injected dose/gm",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL624798,,178.0,
11254,1,"Distribution in brain of rat, 15 min after intravenous administered, injected dose/gm",Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL624799,,955.0,
11255,1,"Distribution in brain of rat, 1 hr after intravenous administered, injected dose/gm",Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL624800,,955.0,
11256,1,"Distribution in brain of rat, 2 hr after intravenous administered, injected dose/gm",Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL624801,,955.0,
11257,1,"Distribution in brain of rat, 30 min after intravenous administered, injected dose/gm",Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL624802,,955.0,
11258,1,"Distribution in brain of rat, 4 hr after intravenous administered, injected dose/gm",Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL624803,,955.0,
11259,1,"Distribution in brain of rat, 5 min after intravenous administered, injected dose/gm",Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL624804,,955.0,
11260,1,"Distribution in brain of rat, 6 hr after intravenous administered, injected dose/gm",Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL624805,,955.0,
11261,1,"Distribution in brain of rat, 8 hr after intravenous administered, injected dose/gm",Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL624806,,955.0,
11262,1,"Distribution in rat fat 15 min after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL624807,,,
11263,1,"Distribution in rat fat 1 hr after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL624808,,,
11264,1,"Distribution in rat fat 2 hr after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL624809,,,
11265,1,"Distribution in rat fat 30 min after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL624810,,,
11266,1,"Distribution in rat fat 4 hr after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL877618,,,
11267,1,"Distribution in rat fat 5 min after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL624811,,,
11268,1,"Distribution in rat fat 6 hr after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL624812,,,
11269,1,"Distribution in rat fat 8 hr after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL624813,,,
11270,1,"Distribution in rat heart 15 min after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL624814,,,
11271,1,"Distribution in rat heart 1 hr after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL624815,,,
11272,1,"Distribution in rat heart 2 hr after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL624816,,,
11273,1,"Distribution in rat heart 30 min after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL624817,,,
11274,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,N,1,CHEMBL624818,,,
11275,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,N,1,CHEMBL624819,,,
11276,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration (0-6 hr),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,N,1,CHEMBL624820,,,
11277,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,N,1,CHEMBL624821,,,
11278,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,N,1,CHEMBL624822,,,
11279,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,N,1,CHEMBL624823,,,
11280,1,Observed diffusion coefficient in organic solvent for Escherichia coli,,BAO_0000218,,Escherichia coli,,Intermediate,15599,,N,1,CHEMBL624824,,,
11281,1,"Concentration of compound in blood of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,9614,,N,1,CHEMBL624825,,178.0,
11282,1,"Concentration of compound in blood of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,9614,,N,1,CHEMBL624826,,178.0,
11283,1,"Concentration of compound in left atrium of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",Cardiac atrium,BAO_0000218,,Rattus norvegicus,,Intermediate,9614,,N,1,CHEMBL876817,,2081.0,
11284,1,"Concentration of compound in left atrium of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",Cardiac atrium,BAO_0000218,,Rattus norvegicus,,Intermediate,9614,,N,1,CHEMBL624827,,2081.0,
11285,1,"Concentration of compound in left ventricle of of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",,BAO_0000218,,Rattus norvegicus,,Intermediate,9614,,N,1,CHEMBL624828,,,
11286,1,"Concentration of compound in left ventricle of of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",,BAO_0000218,,Rattus norvegicus,,Intermediate,9614,,N,1,CHEMBL624829,,,
11287,1,"Concentration of compound in liver of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,9614,,N,1,CHEMBL624830,,2107.0,
11288,1,"Concentration of compound in liver of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,9614,,N,1,CHEMBL624831,,2107.0,
11289,1,"Concentration of compound in right atrium of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",Cardiac atrium,BAO_0000218,,Rattus norvegicus,,Intermediate,9614,,N,1,CHEMBL624832,,2081.0,
11290,1,"Concentration of compound in right atrium of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",Cardiac atrium,BAO_0000218,,Rattus norvegicus,,Intermediate,9614,,N,1,CHEMBL624833,,2081.0,
11291,1,"Concentration of compound in right ventricle of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",,BAO_0000218,,Rattus norvegicus,,Intermediate,9614,,N,1,CHEMBL624834,,,
11292,1,"Concentration of compound in right ventricle of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",,BAO_0000218,,Rattus norvegicus,,Intermediate,9614,,N,1,CHEMBL624835,,,
11293,1,"Concentration of compound in spleen of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,9614,,N,1,CHEMBL624836,,2106.0,
11294,1,"Concentration of compound in spleen of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,9614,,N,1,CHEMBL624837,,2106.0,
11295,1,Distribution of radioactivity of radiolabeled compound in blood of female rats 30 minutes after intravenous administration,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,9071,,N,1,CHEMBL624838,,178.0,
11296,1,Distribution of radioactivity of radiolabeled compound in blood of female rats 5 minutes after intravenous administration,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,9071,,N,1,CHEMBL622188,,178.0,
11297,1,Distribution of radioactivity of radiolabeled compound in heart of female rats 30 minutes after intravenous administration,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,9071,,N,1,CHEMBL622189,,948.0,
11298,1,Distribution of radioactivity of radiolabeled compound in heart of female rats 30 minutes after intravenous administration at,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,9071,,N,1,CHEMBL622190,,948.0,
11299,1,Distribution of radioactivity of radiolabeled compound in heart of female rats 5 minutes after intravenous administration,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,9071,,N,1,CHEMBL625170,,948.0,
11300,1,Distribution of radioactivity of radiolabeled compound in kidney of female rats 30 minutes after intravenous administration,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,9071,,N,1,CHEMBL625171,,2113.0,
11301,1,Distribution of radioactivity of radiolabeled compound in kidney of female rats 30 minutes after intravenous administration,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,9071,,N,1,CHEMBL625172,,2113.0,
11302,1,Distribution of radioactivity of radiolabeled compound in kidney of female rats 5 minutes after intravenous administration,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,9071,,N,1,CHEMBL625173,,2113.0,
11303,1,Distribution of radioactivity of radiolabeled compound in liver of female rats 30 minutes after intravenous administration,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,9071,,N,1,CHEMBL625174,,2107.0,
11304,1,Distribution of radioactivity of radiolabeled compound in liver of female rats 5 minutes after intravenous administration,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,9071,,N,1,CHEMBL625175,,2107.0,
11305,1,Distribution of radioactivity of radiolabeled compound in liver of female rats 5 minutes after intravenous administration at,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,9071,,N,1,CHEMBL625176,,2107.0,
11306,1,Distribution of radioactivity of radiolabeled compound in lung of female rats 30 minutes after intravenous administration,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,9071,,N,1,CHEMBL625177,,2048.0,
11307,1,Distribution of radioactivity of radiolabeled compound in lung of female rats 5 minutes after intravenous administration,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,9071,,N,1,CHEMBL625178,,2048.0,
11308,1,Distribution of radioactivity of radiolabeled compound in lung of female rats 5 minutes after intravenous administration at,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,9071,,N,1,CHEMBL625179,,2048.0,
11309,1,Distribution of radioactivity of radiolabeled compound in lung of female rats 30 minutes after intravenous administration,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,9071,,N,1,CHEMBL625180,,2048.0,
11310,1,"Original dose appeared in the bile as unchanged compound, which was eliminated at a fairly constant rate over the first 4 hr following the iv administration",,BAO_0000218,,,,Autocuration,10677,,U,0,CHEMBL625181,,,
11311,1,Percentage of dose recovered after 0-6 hr in the urine of mice was measured.,Urine,BAO_0000218,,Mus musculus,,Intermediate,9750,,N,1,CHEMBL625182,,1088.0,
11312,1,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat blood as Percent of injected dose per gram in the organ,,BAO_0000218,,Rattus norvegicus,,Intermediate,8319,,N,1,CHEMBL625183,,,
11313,1,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose in the total organ,,BAO_0000218,,Rattus norvegicus,,Intermediate,8319,,N,1,CHEMBL875848,,,
11314,1,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose per gram in the organ,,BAO_0000218,,Rattus norvegicus,,Intermediate,8319,,N,1,CHEMBL622260,,,
11315,1,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose in the total organ,,BAO_0000218,,Rattus norvegicus,,Intermediate,8319,,N,1,CHEMBL622261,,,
11316,1,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose per gram in the organ,,BAO_0000218,,Rattus norvegicus,,Intermediate,8319,,N,1,CHEMBL622262,,,
11317,1,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose in the total organ,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,8319,,N,1,CHEMBL622263,,2113.0,
11318,1,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,8319,,N,1,CHEMBL622418,,2113.0,
11319,1,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose in the total organ,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8319,,N,1,CHEMBL622419,,2107.0,
11320,1,Biodistribution in CD-1 mice was determined after 1 minute in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),,BAO_0000218,,Mus musculus,,Intermediate,13256,In vivo,N,1,CHEMBL623388,,,
11321,1,Biodistribution in CD-1 mice was determined after 1 minute in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),Liver,BAO_0000218,,Mus musculus,,Intermediate,13256,In vivo,N,1,CHEMBL623389,,2107.0,
11322,1,Biodistribution in CD-1 mice was determined after 1 minute in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),,BAO_0000218,,Mus musculus,,Intermediate,13256,In vivo,N,1,CHEMBL623390,,,
11323,1,Biodistribution in CD-1 mice was determined after 120 minutes in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),,BAO_0000218,,Mus musculus,,Intermediate,13256,In vivo,N,1,CHEMBL623391,,,
11324,1,Biodistribution in CD-1 mice was determined after 120 minutes in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),Blood,BAO_0000218,,Mus musculus,,Intermediate,13256,In vivo,N,1,CHEMBL623392,,178.0,
11325,1,Biodistribution in CD-1 mice was determined after 120 minutes in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),Cerebellum,BAO_0000218,,Mus musculus,,Intermediate,13256,In vivo,N,1,CHEMBL623393,,2037.0,
11326,1,Biodistribution in CD-1 mice was determined after 120 minutes in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),,BAO_0000218,,Mus musculus,,Intermediate,13256,In vivo,N,1,CHEMBL623394,,,
11327,1,Biodistribution in CD-1 mice was determined after 120 minutes in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),,BAO_0000218,,Mus musculus,,Intermediate,13256,In vivo,N,1,CHEMBL618885,,,
11328,1,Biodistribution in CD-1 mice was determined after 120 minutes in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),Liver,BAO_0000218,,Mus musculus,,Intermediate,13256,In vivo,N,1,CHEMBL618886,,2107.0,
11329,1,Biodistribution in CD-1 mice was determined after 120 minutes in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),,BAO_0000218,,Mus musculus,,Intermediate,13256,In vivo,N,1,CHEMBL618887,,,
11330,1,Biodistribution in CD-1 mice was determined after 30 minutes in Striatum (expressed as percent injected dose per gram normalized to a 25 g mouse),,BAO_0000218,,Mus musculus,,Intermediate,13256,In vivo,N,1,CHEMBL619535,,,
11331,1,Biodistribution in CD-1 mice was determined after 30 minutes in blood (expressed as percent injected dose per gram normalized to a 25 g mouse),Blood,BAO_0000218,,Mus musculus,,Intermediate,13256,In vivo,N,1,CHEMBL619536,,178.0,
11332,1,Biodistribution in CD-1 mice was determined after 30 minutes in cerebellum (expressed as percent injected dose per gram normalized to a 25 g mouse),Cerebellum,BAO_0000218,,Mus musculus,,Intermediate,13256,In vivo,N,1,CHEMBL619537,,2037.0,
11333,1,Biodistribution in CD-1 mice was determined after 30 minutes in cortex (expressed as percent injected dose per gram normalized to a 25 g mouse),,BAO_0000218,,Mus musculus,,Intermediate,13256,In vivo,N,1,CHEMBL619705,,,
11334,1,Biodistribution in CD-1 mice was determined after 30 minutes in femur (expressed as percent injected dose per gram normalized to a 25 g mouse),,BAO_0000218,,Mus musculus,,Intermediate,13256,In vivo,N,1,CHEMBL619706,,,
11335,1,Biodistribution in CD-1 mice was determined after 30 minutes in liver (expressed as percent injected dose per gram normalized to a 25 g mouse),Liver,BAO_0000218,,Mus musculus,,Intermediate,13256,In vivo,N,1,CHEMBL619707,,2107.0,
11336,1,Biodistribution in CD-1 mice was determined after 30 minutes in lung (expressed as percent injected dose per gram normalized to a 25 g mouse),,BAO_0000218,,Mus musculus,,Intermediate,13256,In vivo,N,1,CHEMBL619708,,,
11337,1,Biodistribution in CD-1 mice was determined after 5 minute in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),,BAO_0000218,,Mus musculus,,Intermediate,13256,In vivo,N,1,CHEMBL625219,,,
11338,1,Biodistribution in CD-1 mice was determined after 5 minute in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),Blood,BAO_0000218,,Mus musculus,,Intermediate,13256,In vivo,N,1,CHEMBL625220,,178.0,
11339,1,Biodistribution in CD-1 mice was determined after 5 minute in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),Cerebellum,BAO_0000218,,Mus musculus,,Intermediate,13256,In vivo,N,1,CHEMBL625221,,2037.0,
11340,1,Biodistribution in CD-1 mice was determined after 5 minute in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),,BAO_0000218,,Mus musculus,,Intermediate,13256,In vivo,N,1,CHEMBL625222,,,
11341,1,Biodistribution in CD-1 mice was determined after 5 minute in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),,BAO_0000218,,Mus musculus,,Intermediate,13256,In vivo,N,1,CHEMBL625223,,,
11342,1,Biodistribution in CD-1 mice was determined after 5 minute in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),Liver,BAO_0000218,,Mus musculus,,Intermediate,13256,In vivo,N,1,CHEMBL625224,,2107.0,
11343,1,Biodistribution in CD-1 mice was determined after 5 minute in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),,BAO_0000218,,Mus musculus,,Intermediate,13256,In vivo,N,1,CHEMBL625225,,,
11344,1,Biodistribution in Rat blood after 24 hours of iv administration,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8829,In vivo,N,1,CHEMBL625226,,178.0,
11345,1,Biodistribution in Rat blood after 24 hours of iv administration; per g of tissue,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8829,In vivo,N,1,CHEMBL625227,,178.0,
11346,1,Biodistribution in Rat blood after 30 minutes of iv administration,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8829,In vivo,N,1,CHEMBL625228,,178.0,
11347,1,Biodistribution in Rat blood after 30 minutes of iv administration; per g of tissue,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8829,In vivo,N,1,CHEMBL875354,,178.0,
11348,1,Biodistribution in Rat blood after 5 minutes of iv administration,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8829,In vivo,N,1,CHEMBL625229,,178.0,
11349,1,Biodistribution in Rat blood after 5 minutes of iv administration; per g of tissue,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8829,In vivo,N,1,CHEMBL625230,,178.0,
11350,1,Biodistribution in Rat heart after 24 hours of iv administration,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,8829,In vivo,N,1,CHEMBL625231,,948.0,
11351,1,Biodistribution in Rat heart after 24 hours of iv administration; per g of tissue,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,8829,In vivo,N,1,CHEMBL625900,,948.0,
11352,1,Biodistribution in Rat heart after 30 minutes of iv administration,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,8829,In vivo,N,1,CHEMBL625901,,948.0,
11353,1,Biodistribution in Rat heart after 30 minutes of iv administration; per g of tissue,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,8829,In vivo,N,1,CHEMBL625902,,948.0,
11354,1,Biodistribution in Rat heart after 5 minutes of iv administration,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,8829,In vivo,N,1,CHEMBL625903,,948.0,
11355,1,Biodistribution in Rat heart after 5 minutes of iv administration; per g of tissue,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,8829,In vivo,N,1,CHEMBL625904,,948.0,
11356,1,Biodistribution in Rat liver after 24 hours of iv administration,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8829,In vivo,N,1,CHEMBL625905,,2107.0,
11357,1,Biodistribution in Rat liver after 24 hours of iv administration; per g of tissue,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8829,In vivo,N,1,CHEMBL627861,,2107.0,
11358,1,Biodistribution in Rat liver after 30 minutes of iv administration,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8829,In vivo,N,1,CHEMBL627862,,2107.0,
11359,1,Biodistribution in Rat liver after 30 minutes of iv administration; per g of tissue,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8829,In vivo,N,1,CHEMBL627863,,2107.0,
11360,1,Biodistribution in Rat liver after 30 minutes of iv administration,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8829,In vivo,N,1,CHEMBL627769,,2107.0,
11361,1,Maximum plasma concentration in Beagle dogs at oral dose of 20 mg/kg and an intravenous dose of 5 mg/kg was administered,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,13249,In vivo,N,1,CHEMBL627770,,1969.0,
11362,1,Cmax in cynomolgus monkey (PO dose),,BAO_0000218,,Macaca fascicularis,,Intermediate,13622,In vivo,N,1,CHEMBL627771,,,
11363,1,Cmax in rat (PO dose),,BAO_0000218,,Rattus norvegicus,,Intermediate,13622,In vivo,N,1,CHEMBL627772,,,
11364,1,Cmax in rat (PO dose),,BAO_0000218,,Rattus norvegicus,,Intermediate,13622,In vivo,N,1,CHEMBL627773,,,
11365,1,Maximum plasma concentration in rats after an oral dose of 5 mg/kg,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,13494,In vivo,N,1,CHEMBL621922,,1969.0,
11366,1,Cmax in rat plasma after oral dose (10 mg/kg),Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,12170,In vivo,N,1,CHEMBL621923,,1969.0,
11367,1,Cmax in plasma after oral dose (10 mg/kg),Plasma,BAO_0000218,,,,Autocuration,12170,In vivo,U,0,CHEMBL621924,,1969.0,
11368,1,Maximum plasma concentration of compound was determined in dog at 25 mg/kg orally,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,17025,In vivo,N,1,CHEMBL621925,,1969.0,
11369,1,Maximum plasma concentration of compound was determined in monkey at 25 mg/kg orally,Plasma,BAO_0000218,,Simiiformes,,Autocuration,17025,In vivo,U,0,CHEMBL621926,,1969.0,
11370,1,Maximum plasma concentration of compound was determined in rabbit at 25 mg/kg orally,Plasma,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,17025,In vivo,N,1,CHEMBL621927,,1969.0,
11371,1,Maximum plasma concentration of compound was determined in rat at 25 mg/kg orally,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,17025,In vivo,N,1,CHEMBL621928,,1969.0,
11372,1,Maximum plasma concentration after p.o. (10 mpk) administration in rats.,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14187,In vivo,N,1,CHEMBL621929,,1969.0,
11373,1,Maximum plasma concentration (Cmax) after p.o. administration of 200 mg/kg in mice,Plasma,BAO_0000218,,Mus musculus,,Intermediate,14816,In vivo,N,1,CHEMBL621930,,1969.0,
11374,1,Maximum plasma concentration after oral dosing in rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,17820,In vivo,N,1,CHEMBL621931,,1969.0,
11375,1,Maximum plasma concentration evaluated in 100% PEG solution at a dose of 20 mg/kg orally,Plasma,BAO_0000218,,,,Autocuration,14380,In vivo,U,0,CHEMBL621932,,1969.0,
11376,1,Maximum plasma concentration evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,Plasma,BAO_0000218,,,,Autocuration,14380,In vivo,U,0,CHEMBL621933,,1969.0,
11377,1,Maximum plasma concentration in dogs at 0.5 mg/kg dose upon oral administration,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,14691,In vivo,N,1,CHEMBL621934,,1969.0,
11378,1,Maximum plasma concentration in dogs at 1 mg/kg dose upon oral administration,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,14691,In vivo,N,1,CHEMBL621935,,1969.0,
11379,1,Maximum plasma concentration in rat upon oral administration of 40 mg/kg,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,13375,In vivo,N,1,CHEMBL621936,,1969.0,
11380,1,Maximum plasma concentration was determined,Plasma,BAO_0000218,,,,Autocuration,6236,In vivo,U,0,CHEMBL621937,,1969.0,
11381,1,Maximum plasma concentration was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,Plasma,BAO_0000218,,,,Autocuration,14380,In vivo,U,0,CHEMBL621938,,1969.0,
11382,1,Maximum plasma concentration was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,Plasma,BAO_0000218,,,,Autocuration,14380,In vivo,U,0,CHEMBL621939,,1969.0,
11383,1,Maximum plasma concentration was evaluated in 10% of PEG suspension at a dose of 20 mg/kg orally,Plasma,BAO_0000218,,,,Autocuration,14380,In vivo,U,0,CHEMBL621940,,1969.0,
11384,1,Maximum plasma concentration was evaluated in 100% of PEG solution at a dose of 20 mg/kg orally,Plasma,BAO_0000218,,,,Autocuration,14380,In vivo,U,0,CHEMBL621941,,1969.0,
11385,1,Maximum plasma concentration was evaluated in DMA:H2O solution at a dose of 20 mg/kg orally,Plasma,BAO_0000218,,,,Autocuration,14380,In vivo,U,0,CHEMBL621942,,1969.0,
11386,1,Maximum plasma concentration was evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,Plasma,BAO_0000218,,,,Autocuration,14380,In vivo,U,0,CHEMBL626178,,1969.0,
11387,1,Maximum plasma concentration was evaluated in Hp-beta-CD solution at a dose of 20 mg/kg orally,Plasma,BAO_0000218,,,,Autocuration,14380,In vivo,U,0,CHEMBL626179,,1969.0,
11388,1,Maximum plasma concentration was evaluated in saline solution at a dose of 20 mg/kg orally,Plasma,BAO_0000218,,,,Autocuration,14380,In vivo,U,0,CHEMBL626180,,1969.0,
11389,1,Plasma Cmax in rat (PO dose),Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,13622,In vivo,N,1,CHEMBL626181,,1969.0,
11390,1,Maximum serum concentration after po dose of 5.22 mg/kg in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,15372,In vivo,N,1,CHEMBL626182,,,
11391,1,Maximum serum concentration after po dose of 5.46 mg/kg in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,15372,In vivo,N,1,CHEMBL626183,,,
11392,1,Maximum serum concentration was determined for the compound after po dose of 5.01 mg/kg in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,15372,In vivo,N,1,CHEMBL626184,,,
11393,1,Maximum serum concentration was determined for the compound after po dose of 5.03 mg/kg in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,15372,In vivo,N,1,CHEMBL626185,,,
11394,1,Maximum plasma concentration (Cmax) was determined in dogs fed after oral administration of 25 mg/kg of the compound.,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,14925,In vivo,N,1,CHEMBL626186,,1969.0,
11395,1,Maximum plasma concentration (Cmax) was determined in fasted dogs after oral administration of 25 mg/kg of the compound.,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,14925,In vivo,N,1,CHEMBL877589,,1969.0,
11396,1,Maximum concentration of the drug at 1 uM/dg administered intravenously,,BAO_0000218,,,,Autocuration,11883,In vivo,U,0,CHEMBL626187,,,
11397,1,Maximum concentration of the drug at 20 uM/dg administered perorally,,BAO_0000218,,,,Autocuration,11883,In vivo,U,0,CHEMBL626188,,,
11398,1,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg,,BAO_0000218,,,,Autocuration,13391,In vivo,U,0,CHEMBL626189,,,
11399,1,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg; b = No compound detectable in blood above the detection limit of 0.1 uM,Blood,BAO_0000218,,,,Autocuration,13391,In vivo,U,0,CHEMBL626855,,178.0,
11400,1,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg; b denotes No compound detectable in blood above the detection limit of 0.1 uM,Blood,BAO_0000218,,,,Autocuration,13391,In vivo,U,0,CHEMBL623781,,178.0,
11401,1,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg;b = No compound detectable in blood above the detection limit of 0.1 uM,Blood,BAO_0000218,,,,Autocuration,13391,In vivo,U,0,CHEMBL623782,,178.0,
11402,1,Oral absorption expressed as peak plasma conc (Cmax) after oral dosing of 50 mg/kg in rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,16360,In vivo,N,1,CHEMBL623783,,1969.0,
11403,1,Cmax in dog plasma after 1mg/kg oral dose,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,3673,In vivo,N,1,CHEMBL623784,,1969.0,
11404,1,Bioavailability as maximal plasma concentration in dogs after 2.5 mg/kg oral dose,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,14431,In vivo,N,1,CHEMBL623785,,1969.0,
11405,1,Bioavailability as maximal plasma concentration in rats after 10 mg/kg oral dose,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14431,In vivo,N,1,CHEMBL623786,,1969.0,
11406,1,Oral maximum concentration in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,14964,In vivo,N,1,CHEMBL623787,,,
11407,1,Oral maximum concentration in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,14964,In vivo,N,1,CHEMBL623788,,,
11408,1,Oral plasma concentration in mice at 100 mg/kg dosage within 4-hr time frame.,Plasma,BAO_0000218,,Mus musculus,,Intermediate,14209,In vivo,N,1,CHEMBL623789,,1969.0,
11409,1,Peak concentration in blood after intravenous administration to mice,Blood,BAO_0000218,,Mus musculus,,Intermediate,11355,In vivo,N,1,CHEMBL623790,,178.0,
11410,1,Peak concentration in blood after peroral administration to mice,Blood,BAO_0000218,,Mus musculus,,Intermediate,11355,In vivo,N,1,CHEMBL623791,,178.0,
11411,1,Peak concentration in rat plasma was determined,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,11966,In vivo,N,1,CHEMBL623792,,1969.0,
11412,1,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of monkey after oral administration of 0.05 mmol/kg,Plasma,BAO_0000218,,Simiiformes,,Autocuration,8918,In vivo,U,0,CHEMBL623793,,1969.0,
11413,1,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of mouse after oral administration of 0.05 mmol/kg,Plasma,BAO_0000218,,Mus musculus,,Intermediate,8918,In vivo,N,1,CHEMBL623794,,1969.0,
11414,1,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of rat after oral administration of 0.05 mmol/kg,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,8918,In vivo,N,1,CHEMBL623795,,1969.0,
11415,1,"Distribution in rat heart 4 hr after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL623796,,,
11416,1,"Distribution in rat heart 5 min after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL623797,,,
11417,1,"Distribution in rat heart 6 hr after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL623798,,,
11418,1,"Distribution in rat heart 8 hr after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL623799,,,
11419,1,"Distribution in rat intestine 15 min after intravenous administration, injected dose/gm",Intestine,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL624490,,160.0,
11420,1,"Distribution in rat intestine 1 hr after intravenous administration, injected dose/gm",Intestine,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL624491,,160.0,
11421,1,"Distribution in rat intestine 2 hr after intravenous administration, injected dose/gm",Intestine,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL624492,,160.0,
11422,1,"Distribution in rat intestine 30 min after intravenous administration, injected dose/gm",Intestine,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL624493,,160.0,
11423,1,"Distribution in rat intestine 4 hr after intravenous administration, injected dose/gm",Intestine,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL877595,,160.0,
11424,1,"Distribution in rat intestine 5 min after intravenous administration, injected dose/gm",Intestine,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL624494,,160.0,
11425,1,"Distribution in rat intestine 6 hr after intravenous administration, injected dose/gm",Intestine,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL624495,,160.0,
11426,1,"Distribution in rat intestine 8 hr after intravenous administration, injected dose/gm",Intestine,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL624681,,160.0,
11427,1,"Distribution in rat kidney, 15 min after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL624682,,,
11428,1,"Distribution in rat kidney, 1 hr after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL624683,,,
11429,1,"Distribution in rat kidney, 2 hr after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL624684,,,
11430,1,"Distribution in rat kidney, 30 min after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL624685,,,
11431,1,"Distribution in rat kidney, 4 hr after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL624686,,,
11432,1,"Distribution in rat kidney, 5 min after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL624687,,,
11433,1,"Distribution in rat kidney, 6 hr after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL624688,,,
11434,1,"Distribution in rat kidney, 8 hr after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL627161,,,
11435,1,"Distribution in rat liver 15 min after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL622127,,,
11436,1,"Distribution in rat liver 1 hr after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL622128,,,
11437,1,"Distribution in rat liver 2 hr after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL874384,,,
11438,1,"Distribution in rat liver 30 min after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL624898,,,
11439,1,"Distribution in rat liver 4 hr after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL624899,,,
11440,1,"Distribution in rat liver 5 min after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL624900,,,
11441,1,"Distribution in rat liver 6 hr after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL624901,,,
11442,1,"Distribution in rat liver 8 hr after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL624902,,,
11443,1,"Distribution in rat lungs 15 min after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL624903,,,
11444,1,"Distribution in rat lungs 1 hr after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL624904,,,
11445,1,"Distribution in rat lungs 2 hr after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL624905,,,
11446,1,"Distribution in rat lungs 30 min after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL624906,,,
11447,1,"Distribution in rat lungs 4 hr after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL624907,,,
11448,1,"Distribution in rat lungs 5 min after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL624908,,,
11449,1,"Distribution in rat lungs 6 hr after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL624909,,,
11450,1,"Distribution in rat lungs 8 hr after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL624910,,,
11451,1,"Distribution in rat muscle 15 min after intravenous administration, injected dose/gm",Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL624911,,2385.0,
11452,1,"Distribution in rat muscle 1 hr after intravenous administration, injected dose/gm",Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL874388,,2385.0,
11453,1,"Distribution in rat muscle 2 hr after intravenous administration, injected dose/gm",Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL624912,,2385.0,
11454,1,"Distribution in rat muscle 30 min after intravenous administration, injected dose/gm",Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL622930,,2385.0,
11455,1,"Distribution in rat muscle 4 hr after intravenous administration, injected dose/gm",Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL623121,,2385.0,
11456,1,"Distribution in rat muscle 5 min after intravenous administration, injected dose/gm",Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL623122,,2385.0,
11457,1,"Distribution in rat muscle 6 hr after intravenous administration, injected dose/gm",Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL623123,,2385.0,
11458,1,"Distribution in rat muscle 8 hr after intravenous administration, injected dose/gm",Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL623124,,2385.0,
11459,1,"Distribution in rat pancreas 15 min after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL623125,,,
11460,1,"Distribution in rat pancreas 1 hr after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL623126,,,
11461,1,"Distribution in rat pancreas 2 hr after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL623127,,,
11462,1,"Distribution in rat pancreas 30 min after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL623128,,,
11463,1,"Distribution in rat pancreas 4 hr after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL623129,,,
11464,1,"Distribution in rat pancreas 5 min after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL623130,,,
11465,1,"Distribution in rat pancreas 6 hr after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL623131,,,
11466,1,"Distribution in rat pancreas 8 hr after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL623132,,,
11467,1,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose per gram in the organ,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8319,,N,1,CHEMBL623133,,2107.0,
11468,1,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat lung as Percent of injected dose per gram in the organ,,BAO_0000218,,Rattus norvegicus,,Intermediate,8319,,N,1,CHEMBL623134,,,
11469,1,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat blood as Percent of injected dose per gram in the organ,,BAO_0000218,,Rattus norvegicus,,Intermediate,8319,,N,1,CHEMBL874389,,,
11470,1,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose in the total organ,,BAO_0000218,,Rattus norvegicus,,Intermediate,8319,,N,1,CHEMBL623135,,,
11471,1,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose per gram in the organ,,BAO_0000218,,Rattus norvegicus,,Intermediate,8319,,N,1,CHEMBL623136,,,
11472,1,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose in the total organ,,BAO_0000218,,Rattus norvegicus,,Intermediate,8319,,N,1,CHEMBL623137,,,
11473,1,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose per gram in the organ,,BAO_0000218,,Rattus norvegicus,,Intermediate,8319,,N,1,CHEMBL623138,,,
11474,1,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose in the total organ,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,8319,,N,1,CHEMBL623139,,2113.0,
11475,1,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,8319,,N,1,CHEMBL623140,,2113.0,
11476,1,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose in the total organ,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8319,,N,1,CHEMBL623141,,2107.0,
11477,1,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose per gram in the organ,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8319,,N,1,CHEMBL623142,,2107.0,
11478,1,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat lung as Percent of injected dose per gram in the organ,,BAO_0000218,,Rattus norvegicus,,Intermediate,8319,,N,1,CHEMBL623143,,,
11479,1,The total amount of penciclovir recovered in the urine over a 48-h period was determined by HPLC using a C18 reversed-phase column in mouse.,Urine,BAO_0000218,,Mus musculus,,Intermediate,14571,,N,1,CHEMBL623144,,1088.0,
11480,1,The total amount of penciclovir recovered in the urine over a 48-h period was determined by HPLC using a C18 reversed-phase column in rat.,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,14571,,N,1,CHEMBL623405,,1088.0,
11481,1,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat blood as Percent of injected dose per gram in the organ,,BAO_0000218,,Rattus norvegicus,,Intermediate,8319,,N,1,CHEMBL624074,,,
11482,1,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose in the total organ,,BAO_0000218,,Rattus norvegicus,,Intermediate,8319,,N,1,CHEMBL624075,,,
11483,1,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose per gram in the organ,,BAO_0000218,,Rattus norvegicus,,Intermediate,8319,,N,1,CHEMBL624076,,,
11484,1,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose in the total organ,,BAO_0000218,,Rattus norvegicus,,Intermediate,8319,,N,1,CHEMBL624077,,,
11485,1,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose per gram in the organ,,BAO_0000218,,Rattus norvegicus,,Intermediate,8319,,N,1,CHEMBL624078,,,
11486,1,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose in the total organ,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,8319,,N,1,CHEMBL624079,,2113.0,
11487,1,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,8319,,N,1,CHEMBL624261,,2113.0,
11488,1,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose in the total organ,,BAO_0000218,,Rattus norvegicus,,Intermediate,8319,,N,1,CHEMBL624262,,,
11489,1,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose per gram in the organ,,BAO_0000218,,Rattus norvegicus,,Intermediate,8319,,N,1,CHEMBL624263,,,
11490,1,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat lung as Percent of injected dose per gram in the organ,,BAO_0000218,,Rattus norvegicus,,Intermediate,8319,,N,1,CHEMBL624264,,,
11491,1,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat blood as Percent of injected dose per gram in the organ,,BAO_0000218,,Rattus norvegicus,,Intermediate,8319,,N,1,CHEMBL624265,,,
11492,1,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose in the total organ,,BAO_0000218,,Rattus norvegicus,,Intermediate,8319,,N,1,CHEMBL624266,,,
11493,1,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose per gram in the organ,,BAO_0000218,,Rattus norvegicus,,Intermediate,8319,,N,1,CHEMBL624267,,,
11494,1,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose in the total organ,,BAO_0000218,,Rattus norvegicus,,Intermediate,8319,,N,1,CHEMBL624268,,,
11495,1,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose per gram in the organ,,BAO_0000218,,Rattus norvegicus,,Intermediate,8319,,N,1,CHEMBL875227,,,
11496,1,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose in the total organ,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,8319,,N,1,CHEMBL624269,,2113.0,
11497,1,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,8319,,N,1,CHEMBL624270,,2113.0,
11498,1,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose in the total organ,,BAO_0000218,,Rattus norvegicus,,Intermediate,8319,,N,1,CHEMBL624271,,,
11499,1,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose per gram in the organ,,BAO_0000218,,Rattus norvegicus,,Intermediate,8319,,N,1,CHEMBL624272,,,
11500,1,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat lung as Percent of injected dose per gram in the organ,,BAO_0000218,,Rattus norvegicus,,Intermediate,8319,,N,1,CHEMBL624273,,,
11501,1,Urinary excretion in rat after 0-4 hours of oral administration at 50 mg/kg,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12064,,N,1,CHEMBL624274,,1088.0,
11502,1,Urinary excretion in rat after 4-8 hours of oral administration at 50 mg/kg,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12064,,N,1,CHEMBL624275,,1088.0,
11503,1,Urinary excretion in rat after 8-24 hours of oral administration at 50 mg/kg,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12064,,N,1,CHEMBL624276,,1088.0,
11504,1,Urinary recovery expressed as percentage dose in male rats after iv administration of 20 mg/kg,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12038,,N,1,CHEMBL624277,,1088.0,
11505,1,% dose converted to 2-amino-5-chlorophenyl sulfate,,BAO_0000019,,,,Autocuration,14314,,U,0,CHEMBL624278,,,
11506,1,% dose converted to 4-(S-amino-N-{[(4-chlorophenyl)amino]carbonyl}sulfonimidoyl)benzoic acid (compound 41),,BAO_0000019,,,,Autocuration,14314,,U,0,CHEMBL624279,,,
11507,1,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 0-24 hr",Feces,BAO_0000218,,Rattus norvegicus,,Intermediate,11488,,N,1,CHEMBL624280,,1988.0,
11508,1,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 24-48 hr",Feces,BAO_0000218,,Rattus norvegicus,,Intermediate,11488,,N,1,CHEMBL624281,,1988.0,
11509,1,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 0-24 hr",Feces,BAO_0000218,,Rattus norvegicus,,Intermediate,11488,,N,1,CHEMBL622933,,1988.0,
11510,1,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 24-48 hr",Feces,BAO_0000218,,Rattus norvegicus,,Intermediate,11488,,N,1,CHEMBL622934,,1988.0,
11511,1,Biodistribution in Rat liver after 30 minutes of iv administration; per g of tissue,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8829,In vivo,N,1,CHEMBL622935,,2107.0,
11512,1,Biodistribution in Rat liver after 5 minutes of iv administration,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8829,In vivo,N,1,CHEMBL622936,,2107.0,
11513,1,Biodistribution in Rat liver after 5 minutes of iv administration; per g of tissue,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8829,In vivo,N,1,CHEMBL875228,,2107.0,
11514,1,Biodistribution in Rat lung after 24 hours of iv administration,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8829,In vivo,N,1,CHEMBL622937,,2048.0,
11515,1,Biodistribution in Rat lung after 24 hours of iv administration; per g of tissue,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8829,In vivo,N,1,CHEMBL622938,,2048.0,
11516,1,Biodistribution in Rat lung after 30 minutes of iv administration,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8829,In vivo,N,1,CHEMBL619736,,2048.0,
11517,1,Biodistribution in Rat lung after 30 minutes of iv administration; per g of tissue,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8829,In vivo,N,1,CHEMBL625117,,2048.0,
11518,1,Biodistribution in Rat lung after 5 minutes of iv administration,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8829,In vivo,N,1,CHEMBL625118,,2048.0,
11519,1,Biodistribution in Rat lung after 5 minutes of iv administration; per g of tissue,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8829,In vivo,N,1,CHEMBL625119,,2048.0,
11520,1,"Biodistribution in rat cerebellum, expressed as percent I.D./g tissue",Cerebellum,BAO_0000218,,Rattus norvegicus,,Intermediate,14972,In vivo,N,1,CHEMBL625120,,2037.0,
11521,1,"Biodistribution in rat superior coliculus, expressed as percent I.D./g tissue",,BAO_0000218,,Rattus norvegicus,,Intermediate,14972,In vivo,N,1,CHEMBL625121,,,
11522,1,"Biodistribution in rat thalamus, expressed as percent I.D./g tissue",Thalamus,BAO_0000218,,Rattus norvegicus,,Intermediate,14972,In vivo,N,1,CHEMBL625122,,10000006.0,
11523,1,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 2 min,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,14608,In vivo,N,1,CHEMBL622204,,178.0,
11524,1,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 30 min,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,14608,In vivo,N,1,CHEMBL877503,,178.0,
11525,1,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 60 min,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,14608,In vivo,N,1,CHEMBL627127,,178.0,
11526,1,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 2 min,Hippocampus,BAO_0000218,,,,Autocuration,14608,In vivo,U,0,CHEMBL627128,,10000000.0,
11527,1,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 30 min,Hippocampus,BAO_0000218,,,,Autocuration,14608,In vivo,U,0,CHEMBL627129,,10000000.0,
11528,1,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 60 min,Hippocampus,BAO_0000218,,,,Autocuration,14608,In vivo,U,0,CHEMBL627130,,10000000.0,
11529,1,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 2 min,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,14608,In vivo,N,1,CHEMBL627131,,955.0,
11530,1,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 30 min,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,14608,In vivo,N,1,CHEMBL627132,,955.0,
11531,1,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 60 min,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,14608,In vivo,N,1,CHEMBL627133,,955.0,
11532,1,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 2 min,Cerebellum,BAO_0000218,,Rattus norvegicus,,Intermediate,14608,In vivo,N,1,CHEMBL627134,,2037.0,
11533,1,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 30 min,Cerebellum,BAO_0000218,,Rattus norvegicus,,Intermediate,14608,In vivo,N,1,CHEMBL627135,,2037.0,
11534,1,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 60 min,Cerebellum,BAO_0000218,,Rattus norvegicus,,Intermediate,14608,In vivo,N,1,CHEMBL627136,,2037.0,
11535,1,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 2 min,,BAO_0000218,,Rattus norvegicus,,Intermediate,14608,In vivo,N,1,CHEMBL628435,,,
11536,1,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 30 min,,BAO_0000218,,Rattus norvegicus,,Intermediate,14608,In vivo,N,1,CHEMBL628436,,,
11537,1,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 60 min,,BAO_0000218,,Rattus norvegicus,,Intermediate,14608,In vivo,N,1,CHEMBL628437,,,
11538,1,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 2 min,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,14608,In vivo,N,1,CHEMBL628438,,948.0,
11539,1,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 30 min,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,14608,In vivo,N,1,CHEMBL628439,,948.0,
11540,1,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 60 min,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,14608,In vivo,N,1,CHEMBL628440,,948.0,
11541,1,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 2 min,Hippocampus,BAO_0000218,,Rattus norvegicus,,Intermediate,14608,In vivo,N,1,CHEMBL628441,,10000000.0,
11542,1,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 30 min,Hippocampus,BAO_0000218,,Rattus norvegicus,,Intermediate,14608,In vivo,N,1,CHEMBL628442,,10000000.0,
11543,1,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 60 min,Hippocampus,BAO_0000218,,Rattus norvegicus,,Intermediate,14608,In vivo,N,1,CHEMBL628443,,10000000.0,
11544,1,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 2 min,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,14608,In vivo,N,1,CHEMBL628444,,2113.0,
11545,1,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 30 min,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,14608,In vivo,N,1,CHEMBL628445,,2113.0,
11546,1,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 60 min,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,14608,In vivo,N,1,CHEMBL877504,,2113.0,
11547,1,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 2 min,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,14608,In vivo,N,1,CHEMBL628446,,2107.0,
11548,1,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 30 min,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,14608,In vivo,N,1,CHEMBL626874,,2107.0,
11549,1,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 60 min,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,14608,In vivo,N,1,CHEMBL626875,,2107.0,
11550,1,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 2 min,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,14608,In vivo,N,1,CHEMBL626876,,2048.0,
11551,1,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 30 min,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,14608,In vivo,N,1,CHEMBL626877,,2048.0,
11552,1,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 60 min,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,14608,In vivo,N,1,CHEMBL626878,,2048.0,
11553,1,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 2 min,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,14608,In vivo,N,1,CHEMBL626879,,2385.0,
11554,1,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of monkey after oral administration of 0.05 mmol/kg,Plasma,BAO_0000218,,Simiiformes,,Autocuration,8918,In vivo,U,0,CHEMBL626880,,1969.0,
11555,1,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of mouse after oral administration of 0.05 mmol/kg,Plasma,BAO_0000218,,Mus musculus,,Intermediate,8918,In vivo,N,1,CHEMBL626881,,1969.0,
11556,1,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of rat after oral administration of 0.05 mmol/kg,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,8918,In vivo,N,1,CHEMBL626882,,1969.0,
11557,1,Peak plasma concentration was measured in dogs,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,14470,In vivo,N,1,CHEMBL626883,,1969.0,
11558,1,Pharmacokinetic Parameter (Cmax) was evaluated at 10 mg/kg (p.o.) in Wistar rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,14393,In vivo,N,1,CHEMBL626884,,,
11559,1,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given intravenously at dose 15 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,14886,In vivo,N,1,CHEMBL626885,,,
11560,1,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given peroral at dose 30 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,14886,In vivo,N,1,CHEMBL626886,,,
11561,1,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given peroral at dose 80 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,14886,In vivo,N,1,CHEMBL626887,,,
11562,1,Pharmacokinetic parameter (Cmax) was evaluated at 10 mg/kg (p.o.) in Wistar rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,14393,In vivo,N,1,CHEMBL626888,,,
11563,1,Pharmacokinetic parameter Cmax determined after intravenous administration of 15 mg/kg to dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,13465,In vivo,N,1,CHEMBL626889,,,
11564,1,Pharmacokinetic parameter Cmax determined after intravenous administration of 25 mg/kg to monkey,,BAO_0000218,,Simiiformes,,Autocuration,13465,In vivo,U,0,CHEMBL626761,,,
11565,1,Pharmacokinetic parameter Cmax determined after intravenous administration of 30 mg/kg abd antacid (CaCO3 dosed orally 10 min prior to and 60 min postdosing) to dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,13465,In vivo,N,1,CHEMBL626762,,,
11566,1,Pharmacokinetic parameter Cmax determined after intravenous administration of 30 mg/kg to dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,13465,In vivo,N,1,CHEMBL626763,,,
11567,1,Pharmacokinetic parameter Cmax determined after intravenous administration of 50 mg/kg to rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,13465,In vivo,N,1,CHEMBL626764,,,
11568,1,Pharmacokinetic parameter Cmax determined after intravenous administration of 60 mg/kg to rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,13465,In vivo,N,1,CHEMBL626765,,,
11569,1,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,13465,In vivo,N,1,CHEMBL626766,,,
11570,1,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,13465,In vivo,N,1,CHEMBL626767,,,
11571,1,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to rat; No levels,,BAO_0000218,,Rattus norvegicus,,Intermediate,13465,In vivo,N,1,CHEMBL626768,,,
11572,1,Pharmacokinetic parameter Cmax determined after peroral administration of 15 mg/kg to dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,13465,In vivo,N,1,CHEMBL626769,,,
11573,1,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,13465,In vivo,N,1,CHEMBL874463,,,
11574,1,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to monkey,,BAO_0000218,,Simiiformes,,Autocuration,13465,In vivo,U,0,CHEMBL626770,,,
11575,1,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to monkey; No levels,,BAO_0000218,,Simiiformes,,Autocuration,13465,In vivo,U,0,CHEMBL626771,,,
11576,1,Pharmacokinetic parameter Cmax determined after peroral administration of 50 mg/kg to rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,13465,In vivo,N,1,CHEMBL626772,,,
11577,1,Pharmacokinetic parameter Cmax for the compound was evaluated in nude cynomolgus monkeys after oral administration. ,,BAO_0000218,,Macaca fascicularis,,Intermediate,14731,In vivo,N,1,CHEMBL626773,,,
11578,1,Pharmacokinetic parameter Cmax for the compound was evaluated in nude mice after oral administration. ,,BAO_0000218,,Mus musculus,,Intermediate,14731,In vivo,N,1,CHEMBL626774,,,
11579,1,Pharmacokinetic parameter Cmax has been determined in fed Beagle dogs at a dose of 375 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,13376,In vivo,N,1,CHEMBL626775,,,
11580,1,Pharmacokinetic parameter Cmax has been determined in fed Beagle dogs at a dose of 500 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,13376,In vivo,N,1,CHEMBL626776,,,
11581,1,Maximum concentration (Cmax) in rat when administered orally,,BAO_0000218,,Rattus norvegicus,,Intermediate,14443,In vivo,N,1,CHEMBL626777,,,
11582,1,Maximal concentration in monkey plasma after 25 mg/kg oral dose,Plasma,BAO_0000218,,Simiiformes,,Autocuration,13465,In vivo,U,0,CHEMBL626778,,1969.0,
11583,1,"Mean Cmax in rats after 5 mg/kg oral dose, range (0.17-0.20)",,BAO_0000218,,Rattus norvegicus,,Autocuration,16359,In vivo,U,0,CHEMBL626779,,,
11584,1,"Mean Cmax in rats after 5 mg/kg oral dose, range (0.4-0.8)",,BAO_0000218,,Rattus norvegicus,,Autocuration,16359,In vivo,U,0,CHEMBL626780,,,
11585,1,Cmax in rat plasma after single 5 mg/kg oral cassette gavage dose,Plasma,BAO_0000218,,,,Autocuration,15618,In vivo,U,0,CHEMBL626781,,1969.0,
11586,1,Pharmacokinetic profile Cmax was evaluated in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,14554,In vivo,N,1,CHEMBL632164,,,
11587,1,Pharmacokinetic property(Cmax- maximum concentration) after oral administration in dog (25 mg/kg),,BAO_0000218,,Canis lupus familiaris,,Intermediate,11537,In vivo,N,1,CHEMBL632165,,,
11588,1,Pharmacokinetic property(Cmax- maximum concentration) after oral administration in mice (50 mg/kg),,BAO_0000218,,Mus musculus,,Intermediate,11537,In vivo,N,1,CHEMBL632166,,,
11589,1,Pharmacokinetic property(Cmax- maximum concentration) after oral administration to dog (25 mg/kg),,BAO_0000218,,Canis lupus familiaris,,Intermediate,11537,In vivo,N,1,CHEMBL632167,,,
11590,1,Pharmacokinetic property(Cmax- maximum concentration) after oral administration to mice (50 mg/kg),,BAO_0000218,,Mus musculus,,Intermediate,11537,In vivo,N,1,CHEMBL632168,,,
11591,1,Cmax in rat plasma,Plasma,BAO_0000218,,Rattus norvegicus,,Autocuration,2021,In vivo,U,0,CHEMBL632169,,1969.0,
11592,1,Cmax in dog plasma after 30mg/kg oral dose,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,5932,In vivo,N,1,CHEMBL632170,,1969.0,
11593,1,Cmax in rat plasma after 30mg/kg oral dose,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,5932,In vivo,N,1,CHEMBL632171,,1969.0,
11594,1,Plasma level in rats at 30 mg/kg,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,17320,In vivo,N,1,CHEMBL632172,,1969.0,
11595,1,Tested for maximum plasma concentration in mice,Plasma,BAO_0000218,,Mus musculus,,Intermediate,15831,In vivo,N,1,CHEMBL632173,,1969.0,
11596,1,"The Cmax value in female wistar rat at 100 mg/kg, p.o. dose",,BAO_0000218,,Rattus norvegicus,,Intermediate,15078,In vivo,N,1,CHEMBL632174,,,
11597,1,The Cmax values in female wistar rats.,,BAO_0000218,,Rattus norvegicus,,Intermediate,14941,In vivo,N,1,CHEMBL632175,,,
11598,1,The Peak plasma concentration was measured in dogs after oral administration of 1 mg/kg dose,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,15343,In vivo,N,1,CHEMBL632176,,1969.0,
11599,1,The Peak plasma concentration was measured in rats after oral administration of 1 mg/kg dose,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,15343,In vivo,N,1,CHEMBL632177,,1969.0,
11600,1,The compound tested for maximum observed plasma concentration in rats and is expressed in microgram/mL.,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14856,In vivo,N,1,CHEMBL632178,,1969.0,
11601,1,The compound was tested for Cmax value pharmacokinetic parameter in the male Sprague-Dawley rat.,,BAO_0000218,,Rattus norvegicus,,Intermediate,13129,In vivo,N,1,CHEMBL632179,,,
11602,1,The compound was tested for maximum blood level reached in rats at 15.9 uM/kg after peroral administration.,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,13098,In vivo,N,1,CHEMBL632180,,178.0,
11603,1,The compound was tested for maximum blood level reached in rats at 15.9 uM/Kg after intravenous administration.,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,13098,In vivo,N,1,CHEMBL632181,,178.0,
11604,1,The compound was tested for maximum blood level reached in rats at 15.9 uM/Kg after peroral administration.,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,13098,In vivo,N,1,CHEMBL632182,,178.0,
11605,1,The maximum concentration observed (Cmax) in the blood sample at indicated time point (tmax) at a dose 50 mg/Kg administered orally in mice.,Blood,BAO_0000218,,Mus musculus,,Autocuration,15478,In vivo,U,0,CHEMBL632183,,178.0,
11606,1,The maximum concentration of the compound was measured in dog at dose 5 mg/kg after peroral administration.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,15341,In vivo,N,1,CHEMBL632184,,,
11607,1,The maximum concentration of the compound was measured in rat at dose 1 mg/kg after peroral administration.,,BAO_0000218,,Rattus norvegicus,,Intermediate,15341,In vivo,N,1,CHEMBL874470,,,
11608,1,"Distribution in rat skin 15 min after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL631302,,,
11609,1,"Distribution in rat skin 1 hr after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL631303,,,
11610,1,"Distribution in rat skin 2 hr after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL631304,,,
11611,1,"Distribution in rat skin 30 min after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL631305,,,
11612,1,"Distribution in rat skin 4 hr after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL631306,,,
11613,1,"Distribution in rat skin 5 min after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL631307,,,
11614,1,"Distribution in rat skin 6 hr after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL631308,,,
11615,1,"Distribution in rat skin 8 hr after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL625557,,,
11616,1,"Distribution in rat spleen 15 min after intravenous administration, injected dose/gm",Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL625558,,2106.0,
11617,1,"Distribution in rat spleen 1 hr after intravenous administration, injected dose/gm",Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL625559,,2106.0,
11618,1,"Distribution in rat spleen 2 hr after intravenous administration, injected dose/gm",Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL625560,,2106.0,
11619,1,"Distribution in rat spleen 30 min after intravenous administration, injected dose/gm",Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL625561,,2106.0,
11620,1,"Distribution in rat spleen 4 hr after intravenous administration, injected dose/gm",Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL625562,,2106.0,
11621,1,"Distribution in rat spleen 5 min after intravenous administration, injected dose/gm",Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL875320,,2106.0,
11622,1,"Distribution in rat spleen 6 hr after intravenous administration, injected dose/gm",Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL625563,,2106.0,
11623,1,"Distribution in rat spleen 8 hr after intravenous administration, injected dose/gm",Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL625564,,2106.0,
11624,1,"Distribution in rat uterus 15 min after intravenous administration, injected dose/gm",Uterus,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL625565,,995.0,
11625,1,"Distribution in rat uterus 1 hr after intravenous administration, injected dose/gm",Uterus,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL625566,,995.0,
11626,1,"Distribution in rat uterus 2 hr after intravenous administration, injected dose/gm",Uterus,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL625567,,995.0,
11627,1,"Distribution in rat uterus 30 min after intravenous administration, injected dose/gm",Uterus,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL625568,,995.0,
11628,1,"Distribution in rat uterus 4 hr after intravenous administration, injected dose/gm",Uterus,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL628217,,995.0,
11629,1,"Distribution in rat uterus 5 min after intravenous administration, injected dose/gm",Uterus,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL628218,,995.0,
11630,1,"Distribution in rat uterus 6 hr after intravenous administration, injected dose/gm",Uterus,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL628219,,995.0,
11631,1,"Distribution in rat uterus 8 hr after intravenous administration, injected dose/gm",Uterus,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,N,1,CHEMBL628220,,995.0,
11632,1,Distribution in the blood after 120 min of intravenous administration,,BAO_0000019,,,,Autocuration,8926,,U,0,CHEMBL628221,,,
11633,1,Distribution in the blood after 15 min of intravenous administration,,BAO_0000019,,,,Autocuration,8926,,U,0,CHEMBL628222,,,
11634,1,Distribution in the blood after 30 min of intravenous administration,,BAO_0000019,,,,Autocuration,8926,,U,0,CHEMBL628223,,,
11635,1,Distribution in the blood after 5 min of intravenous administration,,BAO_0000019,,,,Autocuration,8926,,U,0,CHEMBL628224,,,
11636,1,Distribution in the blood after 60 min of intravenous administration,,BAO_0000019,,,,Autocuration,8926,,U,0,CHEMBL628225,,,
11637,1,Distribution in the blood after 90 min of intravenous administration,,BAO_0000019,,,,Autocuration,8926,,U,0,CHEMBL628226,,,
11638,1,Distribution in the bone after 120 min of intravenous administration,,BAO_0000019,,,,Autocuration,8926,,U,0,CHEMBL628227,,,
11639,1,Distribution in the bone after 15 min of intravenous administration,,BAO_0000019,,,,Autocuration,8926,,U,0,CHEMBL875481,,,
11640,1,Distribution in the bone after 30 min of intravenous administration,,BAO_0000019,,,,Autocuration,8926,,U,0,CHEMBL628228,,,
11641,1,Distribution in the bone after 5 min of intravenous administration,,BAO_0000019,,,,Autocuration,8926,,U,0,CHEMBL628229,,,
11642,1,Distribution in the bone after 60 min of intravenous administration,,BAO_0000019,,,,Autocuration,8926,,U,0,CHEMBL628230,,,
11643,1,Distribution in the bone after 90 min of intravenous administration,,BAO_0000019,,,,Autocuration,8926,,U,0,CHEMBL628231,,,
11644,1,Distribution in the heart after 120 min of intravenous administration,,BAO_0000019,,,,Autocuration,8926,,U,0,CHEMBL628232,,,
11645,1,Distribution in the heart after 15 min of intravenous administration,,BAO_0000019,,,,Autocuration,8926,,U,0,CHEMBL628233,,,
11646,1,Distribution in the heart after 30 min of intravenous administration,,BAO_0000019,,,,Autocuration,8926,,U,0,CHEMBL628234,,,
11647,1,Distribution in the heart after 5 min of intravenous administration,,BAO_0000019,,,,Autocuration,8926,,U,0,CHEMBL628235,,,
11648,1,Distribution in the heart after 60 min of intravenous administration,,BAO_0000019,,,,Autocuration,8926,,U,0,CHEMBL628236,,,
11649,1,Distribution in the heart after 90 min of intravenous administration,,BAO_0000019,,,,Autocuration,8926,,U,0,CHEMBL628237,,,
11650,1,Distribution in the kidneys after 120 min of intravenous administration,,BAO_0000019,,,,Autocuration,8926,,U,0,CHEMBL628238,,,
11651,1,Distribution in the kidneys after 15 min of intravenous administration,,BAO_0000019,,,,Autocuration,8926,,U,0,CHEMBL628239,,,
11652,1,Distribution in the kidneys after 30 min of intravenous administration,,BAO_0000019,,,,Autocuration,8926,,U,0,CHEMBL628240,,,
11653,1,Distribution in the kidneys after 5 min of intravenous administration,,BAO_0000019,,,,Autocuration,8926,,U,0,CHEMBL628241,,,
11654,1,Distribution in the kidneys after 60 min of intravenous administration,,BAO_0000019,,,,Autocuration,8926,,U,0,CHEMBL628242,,,
11655,1,Distribution in the kidneys after 90 min of intravenous administration,,BAO_0000019,,,,Autocuration,8926,,U,0,CHEMBL875482,,,
11656,1,Distribution in the liver after 120 min of intravenous administration,,BAO_0000019,,,,Autocuration,8926,,U,0,CHEMBL628243,,,
11657,1,Distribution in the liver after 15 min of intravenous administration,,BAO_0000019,,,,Autocuration,8926,,U,0,CHEMBL628244,,,
11658,1,Distribution in the liver after 30 min of intravenous administration,,BAO_0000019,,,,Autocuration,8926,,U,0,CHEMBL628245,,,
11659,1,Distribution in the liver after 5 min of intravenous administration,,BAO_0000019,,,,Autocuration,8926,,U,0,CHEMBL628246,,,
11660,1,Distribution in the liver after 60 min of intravenous administration,,BAO_0000019,,,,Autocuration,8926,,U,0,CHEMBL628247,,,
11661,1,Distribution in the liver after 90 min of intravenous administration,,BAO_0000019,,,,Autocuration,8926,,U,0,CHEMBL628248,,,
11662,1,Distribution in the lung after 120 min of intravenous administration,,BAO_0000019,,,,Autocuration,8926,,U,0,CHEMBL628249,,,
11663,1,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in solution, iv and the total drug exposure was determined. (0-24hr)",,BAO_0000218,,Mus musculus,,Intermediate,14839,,N,1,CHEMBL625452,,,
11664,1,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in solution, perorally and the total drug exposure was determined (0-24hr)",,BAO_0000218,,Mus musculus,,Intermediate,14839,,N,1,CHEMBL625453,,,
11665,1,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, micronized free base in 20% HPbetaCD, iv and the total drug exposure was determined. (0-24hr)",,BAO_0000218,,Mus musculus,,Intermediate,14839,,N,1,CHEMBL625454,,,
11666,1,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, micronized free base in 20% HPbetaCD, perorally and the total drug exposure was determined (0-24hr)",,BAO_0000218,,Mus musculus,,Intermediate,14839,,N,1,CHEMBL623844,,,
11667,1,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 1 mg/kg (normalized to a 1 mg/kg dose) in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,12178,,N,1,CHEMBL623845,,,
11668,1,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 2.5 mg/kg (normalized to a 1 mg/kg dose) in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,12178,,N,1,CHEMBL623846,,,
11669,1,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 5.0 mg/kg (normalized to a 1 mg/kg dose) GP,,BAO_0000218,,,,Autocuration,12178,,U,0,CHEMBL623847,,,
11670,1,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using HPLC assay,,BAO_0000218,,Macaca fascicularis,,Intermediate,12186,,N,1,CHEMBL623848,,,
11671,1,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,,BAO_0000218,,Macaca fascicularis,,Intermediate,12186,,N,1,CHEMBL623849,,,
11672,1,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using HPLC assay,,BAO_0000218,,Macaca fascicularis,,Intermediate,12186,,N,1,CHEMBL623850,,,
11673,1,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,,BAO_0000218,,Macaca fascicularis,,Intermediate,12186,,N,1,CHEMBL623851,,,
11674,1,Integrated area under the plasma drug level-time curve was determined in portal circulation after intraduodenal dose of 10 mg/kg in monkey,,BAO_0000218,,Simiiformes,,Autocuration,12187,,U,0,CHEMBL623852,,,
11675,1,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret,,BAO_0000218,,Mustela putorius furo,,Intermediate,12187,,N,1,CHEMBL624551,,,
11676,1,"Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret, determined by renin inhibition assay",,BAO_0000218,,Mustela putorius furo,,Intermediate,12187,,N,1,CHEMBL624552,,,
11677,1,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey,,BAO_0000218,,Simiiformes,,Autocuration,12187,,U,0,CHEMBL624553,,,
11678,1,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey determined by renin inhibition assay,,BAO_0000218,,Simiiformes,,Autocuration,12187,,U,0,CHEMBL624554,,,
11679,1,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,12187,,N,1,CHEMBL624555,,,
11680,1,"Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",,BAO_0000218,,Rattus norvegicus,,Intermediate,12187,,N,1,CHEMBL624741,,,
11681,1,"Intravenous integrated area under the concentration vs time curve, for compound in dog plasma",,BAO_0000218,,Canis lupus familiaris,,Intermediate,14122,,N,1,CHEMBL624742,,,
11682,1,"Intravenous integrated area under the concentration vs time curve, for compound in hamster plasma",,BAO_0000218,,Cricetinae,,Intermediate,14122,,N,1,CHEMBL624743,,,
11683,1,"Intravenous integrated area under the concentration vs time curve, for compound in rat plasma",,BAO_0000218,,Rattus norvegicus,,Intermediate,14122,,N,1,CHEMBL877606,,,
11684,1,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg,,BAO_0000218,,,,Autocuration,13391,,U,0,CHEMBL624744,,,
11685,1,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg; b = No compound detectable in blood above the detection limit of 0.1 uM,Blood,BAO_0000218,,,,Autocuration,13391,,U,0,CHEMBL624745,,178.0,
11686,1,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg; b denotes No compound detectable in blood above the detection limit of 0.1 uM,Blood,BAO_0000218,,,,Autocuration,13391,,U,0,CHEMBL624746,,178.0,
11687,1,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg;b = No compound detectable in blood above the detection limit of 0.1 uM,Blood,BAO_0000218,,,,Autocuration,13391,,U,0,CHEMBL624747,,178.0,
11688,1,Oral absorption expressed as Area under curve was determined,,BAO_0000019,,,,Autocuration,16360,,U,0,CHEMBL624748,,,
11689,1,Oral absorption kinetics (AUC) was determined after administration of compound orally at 1 mg/kg in dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,3673,,N,1,CHEMBL622504,,,
11690,1,"Oral integrated area under the concentration vs time curve, for compound in dog plasma",,BAO_0000218,,Canis lupus familiaris,,Intermediate,14122,,N,1,CHEMBL622505,,,
11691,1,"Oral integrated area under the concentration vs time curve, for compound in hamster plasma",,BAO_0000218,,Cricetinae,,Intermediate,14122,,N,1,CHEMBL622506,,,
11692,1,"Oral integrated area under the concentration vs time curve, for compound in hamster plasma",,BAO_0000218,,Cricetinae,,Intermediate,14122,,N,1,CHEMBL622507,,,
11693,1,"Oral integrated area under the concentration vs time curve, for compound in rat plasma",,BAO_0000218,,Rattus norvegicus,,Intermediate,14122,,N,1,CHEMBL622508,,,
11694,1,Pharmacokinetic parameter AUC in mice following a single dose intravenous administration of the compound,,BAO_0000019,,,,Autocuration,13889,,U,0,CHEMBL622509,,,
11695,1,Pharmacokinetic Parameter [Area under curve (AUC)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,14393,,N,1,CHEMBL622510,,,
11696,1,Pharmacokinetic parameter (AUC) was determined after administering 1 mg/kg of compound intravenously in rat no.3 belonging to phenotype EM (extensive metabolizer),,BAO_0000218,,Rattus norvegicus,,Intermediate,17279,,N,1,CHEMBL622511,,,
11697,1,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered intravenously at 0.5 mg/kg concentration,,BAO_0000218,,Macaca fascicularis,,Intermediate,14548,,N,1,CHEMBL622512,,,
11698,1,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered intravenously at 1 mg/kg concentration,,BAO_0000218,,Macaca fascicularis,,Intermediate,14548,,N,1,CHEMBL622513,,,
11699,1,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered po at 5 mg/kg concentration,,BAO_0000218,,Macaca fascicularis,,Intermediate,14548,,N,1,CHEMBL622514,,,
11700,1,Pharmacokinetic parameter AUC calculated in dog when the compound was administered intravenously at 2 mg/kg concentration,,BAO_0000218,,Canis lupus familiaris,,Intermediate,14548,,N,1,CHEMBL622515,,,
11701,1,Pharmacokinetic parameter AUC calculated in dog when the compound was administered po at 5 mg/kg concentration,,BAO_0000218,,Canis lupus familiaris,,Intermediate,14548,,N,1,CHEMBL622516,,,
11702,1,Pharmacokinetic parameter AUC calculated in rat when the compound was administered intravenously at 5 mg/kg concentration,,BAO_0000218,,Rattus norvegicus,,Intermediate,14548,,N,1,CHEMBL622517,,,
11703,1,Pharmacokinetic parameter AUC calculated in rat when the compound was administered po at 12 mg/kg concentration,,BAO_0000218,,Rattus norvegicus,,Intermediate,14548,,N,1,CHEMBL622518,,,
11704,1,Pharmacokinetic parameter AUC calculated in rat when the compound was administered po at 20 mg/kg concentration,,BAO_0000218,,Rattus norvegicus,,Intermediate,14548,,N,1,CHEMBL622519,,,
11705,1,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 30 min,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,14608,In vivo,N,1,CHEMBL622520,,2385.0,
11706,1,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 60 min,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,14608,In vivo,N,1,CHEMBL622521,,2385.0,
11707,1,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 2 min,Zone of skin,BAO_0000218,,Mus musculus,,Intermediate,14608,In vivo,N,1,CHEMBL625113,,14.0,
11708,1,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 30 min,Zone of skin,BAO_0000218,,Rattus norvegicus,,Intermediate,14608,In vivo,N,1,CHEMBL625114,,14.0,
11709,1,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 60 min,Zone of skin,BAO_0000218,,Rattus norvegicus,,Intermediate,14608,In vivo,N,1,CHEMBL874397,,14.0,
11710,1,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 2 min,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,14608,In vivo,N,1,CHEMBL625115,,2106.0,
11711,1,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 30 min,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,14608,In vivo,N,1,CHEMBL625116,,2106.0,
11712,1,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 60 min,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,14608,In vivo,N,1,CHEMBL623932,,2106.0,
11713,1,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 2 min,Striatum,BAO_0000218,,Rattus norvegicus,,Intermediate,14608,In vivo,N,1,CHEMBL623933,,2435.0,
11714,1,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 30 min,Striatum,BAO_0000218,,Rattus norvegicus,,Intermediate,14608,In vivo,N,1,CHEMBL623934,,2435.0,
11715,1,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 60 min,Striatum,BAO_0000218,,Rattus norvegicus,,Intermediate,14608,In vivo,N,1,CHEMBL623935,,2435.0,
11716,1,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 2 min,Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,14608,In vivo,N,1,CHEMBL623936,,2046.0,
11717,1,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 30 min,Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,14608,In vivo,N,1,CHEMBL623937,,2046.0,
11718,1,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 60 min,Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,14608,In vivo,N,1,CHEMBL623938,,2046.0,
11719,1,In vivo biodistribution in mice blood bearing intracerebral GL261 gliomas at the dose of 30 ug/day,,BAO_0000218,,Mus musculus,,Intermediate,15383,,N,1,CHEMBL623939,,,
11720,1,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 10 ug/g,,BAO_0000218,,Mus musculus,,Intermediate,15383,,N,1,CHEMBL623940,,,
11721,1,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 20 ug/g,,BAO_0000218,,Mus musculus,,Intermediate,15383,,N,1,CHEMBL623941,,,
11722,1,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,BAO_0000218,,Mus musculus,,Intermediate,15383,,N,1,CHEMBL627216,,,
11723,1,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,BAO_0000218,,Mus musculus,,Intermediate,15383,,N,1,CHEMBL623942,,,
11724,1,In vivo biodistribution in mice brain bearing intracerebral GL261 gliomas at the dose of 30 ug/day,Brain,BAO_0000218,,Mus musculus,,Intermediate,15383,,N,1,CHEMBL618793,,955.0,
11725,1,In vivo biodistribution in mice brain bearing subcutaneous B16 melanomas at the dose of 30 ug/g,Brain,BAO_0000218,,Mus musculus,,Intermediate,15383,,N,1,CHEMBL618794,,955.0,
11726,1,In vivo biodistribution in mice brain bearing subcutaneous B16 melanomas at the dose of 40 ug/g,Brain,BAO_0000218,,Mus musculus,,Intermediate,15383,,N,1,CHEMBL618795,,955.0,
11727,1,In vivo biodistribution in mice eyes bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,BAO_0000218,,Mus musculus,,Intermediate,15383,,N,1,CHEMBL618796,,,
11728,1,In vivo biodistribution in mice eyes bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,BAO_0000218,,Mus musculus,,Intermediate,15383,,N,1,CHEMBL618797,,,
11729,1,In vivo biodistribution in mice kidney bearing intracerebral GL261 gliomas at the dose of 10 microg of boron/g/day,Kidney,BAO_0000218,,Mus musculus,,Intermediate,15383,,N,1,CHEMBL618798,,2113.0,
11730,1,In vivo biodistribution in mice kidney bearing intracerebral GL261 gliomas at the dose of 30 ug/day,Kidney,BAO_0000218,,Mus musculus,,Intermediate,15383,,N,1,CHEMBL618799,,2113.0,
11731,1,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 10 ug/g,Kidney,BAO_0000218,,Mus musculus,,Intermediate,15383,,N,1,CHEMBL618800,,2113.0,
11732,1,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 20 ug/g,Kidney,BAO_0000218,,Mus musculus,,Intermediate,15383,,N,1,CHEMBL618801,,2113.0,
11733,1,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 30 ug/g,Kidney,BAO_0000218,,Mus musculus,,Intermediate,15383,,N,1,CHEMBL618802,,2113.0,
11734,1,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 40 ug/g,Kidney,BAO_0000218,,Mus musculus,,Intermediate,15383,,N,1,CHEMBL618803,,2113.0,
11735,1,In vivo biodistribution in mice liver bearing intracerebral GL261 gliomas at the dose of 10 microg of boron/g/day,Liver,BAO_0000218,,Mus musculus,,Intermediate,15383,,N,1,CHEMBL618804,,2107.0,
11736,1,In vivo biodistribution in mice liver bearing intracerebral GL261 gliomas at the dose of 30 ug/day,Liver,BAO_0000218,,Mus musculus,,Intermediate,15383,,N,1,CHEMBL618805,,2107.0,
11737,1,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 10 ug/g,Liver,BAO_0000218,,Mus musculus,,Intermediate,15383,,N,1,CHEMBL618806,,2107.0,
11738,1,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 20 ug/g,Liver,BAO_0000218,,Mus musculus,,Intermediate,15383,,N,1,CHEMBL618807,,2107.0,
11739,1,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 30 ug/g,Liver,BAO_0000218,,Mus musculus,,Intermediate,15383,,N,1,CHEMBL618808,,2107.0,
11740,1,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 40 ug/g,Liver,BAO_0000218,,Mus musculus,,Intermediate,15383,,N,1,CHEMBL618809,,2107.0,
11741,1,In vivo biodistribution in mice muscle bearing intracerebral GL261 gliomas at the dose of 30 ug/day,Muscle tissue,BAO_0000218,,Mus musculus,,Intermediate,15383,,N,1,CHEMBL618810,,2385.0,
11742,1,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 10 ug/g,Muscle tissue,BAO_0000218,,Mus musculus,,Intermediate,15383,,N,1,CHEMBL618811,,2385.0,
11743,1,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 20 ug/g,Muscle tissue,BAO_0000218,,Mus musculus,,Intermediate,15383,,N,1,CHEMBL875844,,2385.0,
11744,1,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 30 ug/g,Muscle tissue,BAO_0000218,,Mus musculus,,Intermediate,15383,,N,1,CHEMBL618812,,2385.0,
11745,1,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 40 ug/g,Muscle tissue,BAO_0000218,,Mus musculus,,Intermediate,15383,,N,1,CHEMBL618813,,2385.0,
11746,1,In vivo biodistribution in mice skin bearing intracerebral GL261 gliomas at the dose of 30 ug/day,,BAO_0000218,,Mus musculus,,Intermediate,15383,,N,1,CHEMBL618814,,,
11747,1,In vivo biodistribution in mice skin bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,BAO_0000218,,Mus musculus,,Intermediate,15383,,N,1,CHEMBL618815,,,
11748,1,In vivo biodistribution in mice skin bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,BAO_0000218,,Mus musculus,,Intermediate,15383,,N,1,CHEMBL618816,,,
11749,1,In vivo biodistribution in mice skin by pump bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,BAO_0000218,,Mus musculus,,Intermediate,15383,,N,1,CHEMBL618817,,,
11750,1,In vivo biodistribution in mice skin by pump bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,BAO_0000218,,Mus musculus,,Intermediate,15383,,N,1,CHEMBL620544,,,
11751,1,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after intraperitoneal administration.,,BAO_0000218,,Rattus norvegicus,,Intermediate,15341,In vivo,N,1,CHEMBL626230,,,
11752,1,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after intravenous administration.,,BAO_0000218,,Rattus norvegicus,,Intermediate,15341,In vivo,N,1,CHEMBL626231,,,
11753,1,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after peroral administration.,,BAO_0000218,,Rattus norvegicus,,Intermediate,15341,In vivo,N,1,CHEMBL626232,,,
11754,1,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on dog.,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,14906,In vivo,N,1,CHEMBL626233,,1969.0,
11755,1,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14906,In vivo,N,1,CHEMBL626234,,1969.0,
11756,1,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on rat.,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14906,In vivo,N,1,CHEMBL875341,,1969.0,
11757,1,The maximum plasma concentration (100 mg/kg) administered orally in human,Plasma,BAO_0000218,,Homo sapiens,,Intermediate,14215,In vivo,N,1,CHEMBL626235,,1969.0,
11758,1,The maximum plasma concentration (12.5 mg/kg) administered intravenously in marmoset,Plasma,BAO_0000218,,Callithrix,,Autocuration,14215,In vivo,U,0,CHEMBL626236,,1969.0,
11759,1,The maximum plasma concentration (12.5 mg/kg) administered intravenously in monkey,Plasma,BAO_0000218,,Simiiformes,,Autocuration,14215,In vivo,U,0,CHEMBL626237,,1969.0,
11760,1,The maximum plasma concentration (15 mg/kg) administered intravenously in dog,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,14215,In vivo,N,1,CHEMBL626238,,1969.0,
11761,1,The maximum plasma concentration (200 mg/kg) administered orally in human,Plasma,BAO_0000218,,Homo sapiens,,Intermediate,14215,In vivo,N,1,CHEMBL622412,,1969.0,
11762,1,The maximum plasma concentration (25 mg/kg) administered intravenously in rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14215,In vivo,N,1,CHEMBL623114,,1969.0,
11763,1,The maximum plasma concentration (25 mg/kg) administered orally in marmoset,Plasma,BAO_0000218,,Callithrix,,Autocuration,14215,In vivo,U,0,CHEMBL623115,,1969.0,
11764,1,The maximum plasma concentration (25 mg/kg) administered orally in monkey,Plasma,BAO_0000218,,Simiiformes,,Autocuration,14215,In vivo,U,0,CHEMBL623116,,1969.0,
11765,1,The maximum plasma concentration (30 mg/kg) administered orally in dog,Plasma,BAO_0000218,,Canis lupus familiaris,,Autocuration,14215,In vivo,U,0,CHEMBL623117,,1969.0,
11766,1,The maximum plasma concentration (400 mg/kg) administered orally in human,Plasma,BAO_0000218,,Homo sapiens,,Intermediate,14215,In vivo,N,1,CHEMBL623118,,1969.0,
11767,1,The maximum plasma concentration (50 mg/kg) administered orally in fasted rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14215,In vivo,N,1,CHEMBL623119,,1969.0,
11768,1,The maximum plasma concentration (50 mg/kg) administered orally in rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14215,In vivo,N,1,CHEMBL623120,,1969.0,
11769,1,The maximum plasma concentration (800 mg/kg) administered orally in human,Plasma,BAO_0000218,,Homo sapiens,,Intermediate,14215,In vivo,N,1,CHEMBL623286,,1969.0,
11770,1,The maximum plasma concentration was measured on rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14067,In vivo,N,1,CHEMBL623287,,1969.0,
11771,1,The maximum plasma concentration was measured on rats after oral administration,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,12350,In vivo,N,1,CHEMBL623288,,1969.0,
11772,1,Plasma drug Cmax in rat (PO dose),Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14813,In vivo,N,1,CHEMBL623289,,1969.0,
11773,1,Time taken to reach maximum concentration after administration of 2 umol/kg dose intravenously,,BAO_0000218,,,,Autocuration,12536,In vivo,U,0,CHEMBL623290,,,
11774,1,maximum Plasma concentration in Dog was determined after Peroral administration,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,14169,In vivo,N,1,CHEMBL623291,,1969.0,
11775,1,maximum Plasma concentration in Rats was determined after Peroral administration,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14169,In vivo,N,1,CHEMBL623292,,1969.0,
11776,1,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in dog,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,15604,In vivo,N,1,CHEMBL623293,,1969.0,
11777,1,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in monkey,Plasma,BAO_0000218,,Simiiformes,,Autocuration,15604,In vivo,U,0,CHEMBL623294,,1969.0,
11778,1,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,15604,In vivo,N,1,CHEMBL623295,,1969.0,
11779,1,maximum concentration was measured when administered through oral route in mice,,BAO_0000218,,Mus musculus,,Intermediate,14387,In vivo,N,1,CHEMBL623296,,,
11780,1,Compound was evaluated for Cmax/Tmax when administered through oral route in mouse; Value is 0.93/1,,BAO_0000218,,Mus musculus,,Intermediate,15115,,N,1,CHEMBL875349,,,
11781,1,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 0.34/1,,BAO_0000019,,Simiiformes,,Autocuration,15115,,U,0,CHEMBL623297,,,
11782,1,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 0.81/1.6,,BAO_0000019,,Simiiformes,,Autocuration,15115,,U,0,CHEMBL623298,,,
11783,1,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 1.1/1.3,,BAO_0000019,,Simiiformes,,Autocuration,15115,,U,0,CHEMBL623299,,,
11784,1,Pharmacokinetic parameter was evaluated in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,16359,,N,1,CHEMBL623300,,,
11785,1,Plasma concentration at time-0 was measured in mice at 100 mg/kg after intraperitoneal administration with 90% DMSO as vehicle,,BAO_0000218,,Mus musculus,,Intermediate,12829,,N,1,CHEMBL623301,,,
11786,1,Plasma concentration at time-0 was measured in mice at 100 mg/kg after intraperitoneal administration with saline(pH=11.4) as vehicle,,BAO_0000218,,Mus musculus,,Intermediate,12829,,N,1,CHEMBL623302,,,
11787,1,Plasma concentration at time-0 was measured in mice at 120 mg/kg after intraperitoneal administration with 90% DMSO as vehicle,,BAO_0000218,,Mus musculus,,Intermediate,12829,,N,1,CHEMBL623303,,,
11788,1,Plasma concentration at time-0 was measured in mice at 40 mg/kg after intravenous administration with saline(pH=11.4) as vehicle,,BAO_0000218,,Mus musculus,,Intermediate,12829,,N,1,CHEMBL623304,,,
11789,1,Plasma concentration at time-0 was measured in mice at 40 mg/kg after intravenous administration with 90% DMSO as vehicle,,BAO_0000218,,Mus musculus,,Intermediate,12829,,N,1,CHEMBL623305,,,
11790,1,Effect of ip administration of compound on plasma concentration of allo-pregnanolone (AP) in rats(Cerebral Cortex) after 30 min.,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,15137,,N,1,CHEMBL623306,,1969.0,
11791,1,Effect of ip administration of compound on plasma concentration of allotetrahydrodeoxy corticosterone(THDOC) in rats(Cerebral Cortex) after 30 min.,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,15137,,N,1,CHEMBL623307,,1969.0,
11792,1,Effect of ip administration of compound on plasma concentration of pregnenolone (PRE) in rats(Cerebral Cortex) after 30 min.,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,15137,,N,1,CHEMBL623308,,1969.0,
11793,1,Effect of ip administration of compound on plasma concentration of progesterone (PRO) in rats(Cerebral Cortex) after 30 min.,Plasma,BAO_0000218,,Mus musculus,,Intermediate,15137,,N,1,CHEMBL623309,,1969.0,
11794,1,Plasma Concentration after 120 min of oral administration to mice,,BAO_0000218,,Mus musculus,,Intermediate,13509,,N,1,CHEMBL623310,,,
11795,1,Plasma Concentration after 30 min of oral administration to mice,,BAO_0000218,,Mus musculus,,Intermediate,13509,,N,1,CHEMBL623311,,,
11796,1,Plasma Concentration after 60 min of oral administration to mice,,BAO_0000218,,Macaca fascicularis,,Intermediate,13509,,N,1,CHEMBL623312,,,
11797,1,Plasma Concentration after 60 min of oral administration to mice; Not determined,,BAO_0000218,,Mus musculus,,Intermediate,13509,,N,1,CHEMBL875350,,,
11798,1,Plasma Concentration after 90 min of oral administration to mice,,BAO_0000218,,Mus musculus,,Intermediate,13509,,N,1,CHEMBL628635,,,
11799,1,Plasma concentration level in rat after 1 hour of oral administration at 50 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,12064,,N,1,CHEMBL628636,,,
11800,1,Plasma concentration level in rat after 15 hours of oral administration at 50 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,12064,,N,1,CHEMBL628637,,,
11801,1,Plasma concentration level in rat after 4 hours of oral administration at 50 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,12064,,N,1,CHEMBL628058,,,
11802,1,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 0-1 hr time,,BAO_0000218,,Rattus norvegicus,,Intermediate,10677,,N,1,CHEMBL628059,,,
11803,1,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 1-2 hr time,,BAO_0000218,,Rattus norvegicus,,Intermediate,10677,,N,1,CHEMBL628060,,,
11804,1,Distribution in the lung after 15 min of intravenous administration,,BAO_0000019,,,,Autocuration,8926,,U,0,CHEMBL628061,,,
11805,1,Distribution in the lung after 30 min of intravenous administration,,BAO_0000019,,,,Autocuration,8926,,U,0,CHEMBL628062,,,
11806,1,Distribution in the lung after 5 min of intravenous administration,,BAO_0000019,,,,Autocuration,8926,,U,0,CHEMBL628063,,,
11807,1,Distribution in the lung after 60 min of intravenous administration,,BAO_0000019,,,,Autocuration,8926,,U,0,CHEMBL628064,,,
11808,1,Distribution in the lung after 90 min of intravenous administration,,BAO_0000019,,,,Autocuration,8926,,U,0,CHEMBL628065,,,
11809,1,Distribution in the muscle after 120 min of intravenous administration,Muscle tissue,BAO_0000019,,,,Autocuration,8926,,U,0,CHEMBL628066,,2385.0,
11810,1,Distribution in the muscle after 15 min of intravenous administration,Muscle tissue,BAO_0000019,,,,Autocuration,8926,,U,0,CHEMBL628067,,2385.0,
11811,1,Distribution in the muscle after 30 min of intravenous administration,Muscle tissue,BAO_0000218,,Mus musculus,,Intermediate,8926,,N,1,CHEMBL874646,,2385.0,
11812,1,Distribution in the muscle after 5 min of intravenous administration,Muscle tissue,BAO_0000019,,,,Autocuration,8926,,U,0,CHEMBL628068,,2385.0,
11813,1,Distribution in the muscle after 60 min of intravenous administration,Muscle tissue,BAO_0000019,,,,Autocuration,8926,,U,0,CHEMBL628069,,2385.0,
11814,1,Distribution in the muscle after 90 min of intravenous administration,Muscle tissue,BAO_0000019,,,,Autocuration,8926,,U,0,CHEMBL628070,,2385.0,
11815,1,Distribution in the spleen after 120 min of intravenous administration,Spleen,BAO_0000019,,,,Autocuration,8926,,U,0,CHEMBL628071,,2106.0,
11816,1,Distribution in the spleen after 15 min of intravenous administration,Spleen,BAO_0000019,,,,Autocuration,8926,,U,0,CHEMBL628072,,2106.0,
11817,1,Distribution in the spleen after 30 min of intravenous administration,Spleen,BAO_0000019,,,,Autocuration,8926,,U,0,CHEMBL628073,,2106.0,
11818,1,Distribution in the spleen after 5 min of intravenous administration,Spleen,BAO_0000019,,,,Autocuration,8926,,U,0,CHEMBL628074,,2106.0,
11819,1,Distribution in the spleen after 60 min of intravenous administration,Spleen,BAO_0000019,,,,Autocuration,8926,,U,0,CHEMBL628075,,2106.0,
11820,1,Distribution in the spleen after 90 min of intravenous administration,Spleen,BAO_0000019,,,,Autocuration,8926,,U,0,CHEMBL628076,,2106.0,
11821,1,Evaluated for distribution at 0.5 hr after intravenous administration in adrenal cortex of female Sprague Dawley rats,Adrenal cortex,BAO_0000218,,Rattus norvegicus,,Intermediate,7570,,N,1,CHEMBL628077,,1235.0,
11822,1,Evaluated for distribution at 0.5 hr after intravenous administration in blood of female Sprague Dawley rats,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,7570,,N,1,CHEMBL628078,,178.0,
11823,1,Evaluated for distribution at 0.5 hr after intravenous administration in liver of female Sprague Dawley rats,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,7570,,N,1,CHEMBL628079,,2107.0,
11824,1,Evaluated for distribution at 0.5 hr after intravenous administration in ovary of female Sprague Dawley rats,Female gonad,BAO_0000218,,Rattus norvegicus,,Intermediate,7570,,N,1,CHEMBL628080,,992.0,
11825,1,Evaluated for distribution at 0.5 hr after intravenous administration in thyroid of female Sprague Dawley rats,Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,7570,,N,1,CHEMBL628081,,2046.0,
11826,1,Evaluated for distribution at 24 hours after intravenous administration in adrenal cortex of female Sprague Dawley rats,Adrenal cortex,BAO_0000218,,Rattus norvegicus,,Intermediate,7570,,N,1,CHEMBL628082,,1235.0,
11827,1,Evaluated for distribution at 24 hours after intravenous administration in blood of female Sprague Dawley rats,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,7570,,N,1,CHEMBL874647,,178.0,
11828,1,Evaluated for distribution at 24 hours after intravenous administration in liver of female Sprague Dawley rats,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,7570,,N,1,CHEMBL626406,,2107.0,
11829,1,Evaluated for distribution at 24 hours after intravenous administration in ovary of female Sprague Dawley rats,Female gonad,BAO_0000218,,Rattus norvegicus,,Intermediate,7570,,N,1,CHEMBL626407,,992.0,
11830,1,Evaluated for distribution at 24 hours after intravenous administration in thyroid of female Sprague Dawley rats,Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,7570,,N,1,CHEMBL626408,,2046.0,
11831,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.07-0.09",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL626409,,178.0,
11832,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.10-0.13",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL626410,,178.0,
11833,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.18-0.24",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL626411,,178.0,
11834,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.19-0.24",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL626412,,178.0,
11835,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.22-0.32",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL626413,,178.0,
11836,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.25-0.32",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL626414,,178.0,
11837,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.10-0.14",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL626415,,178.0,
11838,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.25-0.34",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL626416,,178.0,
11839,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.27-0.33",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL627062,,178.0,
11840,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.32-0.46",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL627063,,178.0,
11841,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.40-0.45",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL627064,,178.0,
11842,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.44-0.52",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL627227,,178.0,
11843,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.08-0.09",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL627228,,178.0,
11844,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.12-0.14",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL627229,,178.0,
11845,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.13-0.15",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL625792,,178.0,
11846,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.15-0.20",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL625793,,178.0,
11847,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.15-0.23",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL625794,,178.0,
11848,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.16-0.21",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL625795,,178.0,
11849,1,Pharmacokinetic parameter AUC for the compound after intravenous administration into BALB/c Mice in plasma samples.,,BAO_0000218,,Mus musculus,,Intermediate,13792,,N,1,CHEMBL625796,,,
11850,1,Pharmacokinetic parameter AUC has been determined in fed Beagle dogs at a dose of 375 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,13376,,N,1,CHEMBL625797,,,
11851,1,Pharmacokinetic parameter AUC has been determined in fed Beagle dogs at a dose of 500 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,13376,,N,1,CHEMBL625798,,,
11852,1,Pharmacokinetic parameter AUC evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,,BAO_0000218,,,,Autocuration,14380,,U,0,CHEMBL875613,,,
11853,1,Pharmacokinetic parameter AUC was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,,BAO_0000218,,,,Autocuration,14380,,U,0,CHEMBL625799,,,
11854,1,Pharmacokinetic parameter AUC was evaluated in 10% PEG suspension at a dose of 20 mg/kg orally,,BAO_0000218,,,,Autocuration,14380,,U,0,CHEMBL625800,,,
11855,1,Pharmacokinetic parameter AUC was evaluated in 100% PEG solution at a dose of 20 mg/kg orally,,BAO_0000218,,,,Autocuration,14380,,U,0,CHEMBL625801,,,
11856,1,Pharmacokinetic parameter AUC was evaluated in DMA:H2O solution at a dose of 20 mg/kg orally,,BAO_0000218,,,,Autocuration,14380,,U,0,CHEMBL625802,,,
11857,1,Pharmacokinetic parameter AUC was evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,,BAO_0000218,,,,Autocuration,14380,,U,0,CHEMBL625803,,,
11858,1,Pharmacokinetic parameter AUC was evaluated in Hp-beta-CD solution,,BAO_0000019,,,,Autocuration,14380,,U,0,CHEMBL625804,,,
11859,1,Pharmacokinetic parameter AUC was evaluated in saline solution at a dose of 20 mg/kg orally,,BAO_0000218,,,,Autocuration,14380,,U,0,CHEMBL622530,,,
11860,1,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice brain; AUC (mM.h); not detected,,BAO_0000218,,Mus musculus,,Intermediate,13701,,N,1,CHEMBL622531,,,
11861,1,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),,BAO_0000218,,Mus musculus,,Intermediate,13701,,N,1,CHEMBL622532,,,
11862,1,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),,BAO_0000218,,Mus musculus,,Intermediate,13701,,N,1,CHEMBL623176,,,
11863,1,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice brain; AUC (mM.h),,BAO_0000218,,Mus musculus,,Intermediate,13701,,N,1,CHEMBL623177,,,
11864,1,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),,BAO_0000218,,Mus musculus,,Intermediate,13701,,N,1,CHEMBL623178,,,
11865,1,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration using FMAddA as substrate in mice brain; AUC 0-r (mM.h); not detected,,BAO_0000218,,Mus musculus,,Intermediate,13701,,N,1,CHEMBL623179,,,
11866,1,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice brain; AUC (mM.h),,BAO_0000218,,Mus musculus,,Intermediate,13701,,N,1,CHEMBL623180,,,
11867,1,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),,BAO_0000218,,Mus musculus,,Intermediate,13701,,N,1,CHEMBL623181,,,
11868,1,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),,BAO_0000218,,Mus musculus,,Intermediate,13701,,N,1,CHEMBL624131,,,
11869,1,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration using 2`-F-ara-ddI as substrate in mice serum; AUC (mM.h),,BAO_0000218,,Mus musculus,,Intermediate,13701,,N,1,CHEMBL624132,,,
11870,1,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by oral administration in mice serum; AUC 0-r (mM.h),,BAO_0000218,,Mus musculus,,Intermediate,13701,,N,1,CHEMBL624133,,,
11871,1,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h).,,BAO_0000218,,Mus musculus,,Intermediate,13701,,N,1,CHEMBL624846,,,
11872,1,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by oral administration in mice serum.; AUC 0-r (mM.h),,BAO_0000218,,Mus musculus,,Intermediate,13701,,N,1,CHEMBL624847,,,
11873,1,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),,BAO_0000218,,Mus musculus,,Intermediate,13701,,N,1,CHEMBL624848,,,
11874,1,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),,BAO_0000218,,Mus musculus,,Intermediate,13701,,N,1,CHEMBL625012,,,
11875,1,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),,BAO_0000218,,Mus musculus,,Intermediate,13701,,N,1,CHEMBL625013,,,
11876,1,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice brain; AUC 0-r (mM.h); not detected,,BAO_0000218,,Mus musculus,,Intermediate,13701,,N,1,CHEMBL625014,,,
11877,1,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum; AUC (mM.h),,BAO_0000218,,Mus musculus,,Intermediate,13701,,N,1,CHEMBL625015,,,
11878,1,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum; AUC 0-r (mM.h),,BAO_0000218,,Mus musculus,,Intermediate,13701,,N,1,CHEMBL625016,,,
11879,1,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral in mice brain; AUC (mM.h); not detected,,BAO_0000218,,Mus musculus,,Intermediate,13701,,N,1,CHEMBL625017,,,
11880,1,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),,BAO_0000218,,Mus musculus,,Intermediate,13701,,N,1,CHEMBL625018,,,
11881,1,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration mice serum.; AUC 0-r (mM.h),,BAO_0000218,,Mus musculus,,Intermediate,13701,,N,1,CHEMBL625019,,,
11882,1,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice brain.; AUC 0-r (mM.h),,BAO_0000218,,Mus musculus,,Intermediate,13701,,N,1,CHEMBL625020,,,
11883,1,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum.,,BAO_0000218,,Mus musculus,,Intermediate,13701,,N,1,CHEMBL625021,,,
11884,1,Pharmacokinetic parameter [area under curve (AUC)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,14393,,N,1,CHEMBL625022,,,
11885,1,Pharmacokinetic parameter area under the curve (0-24 hr) for the compound was evaluated in nude mice after oral administration. ,,BAO_0000218,,Mus musculus,,Intermediate,14731,,N,1,CHEMBL625023,,,
11886,1,Pharmacokinetic parameter area under the curve (0-48 h) for the compound was evaluated in nude cynomolgus monkeys after oral administration,,BAO_0000218,,Macaca fascicularis,,Intermediate,14731,,N,1,CHEMBL625024,,,
11887,1,Pharmacokinetic parameter area under the curve (0-48 h) for the compound was evaluated in nude cynomolgus monkeys after oral administration. ,,BAO_0000218,,Macaca fascicularis,,Intermediate,14731,,N,1,CHEMBL627626,,,
11888,1,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in brain,Brain,BAO_0000218,,,,Autocuration,13758,,U,0,CHEMBL627627,,955.0,
11889,1,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in serum,Serum,BAO_0000218,,,,Autocuration,13758,,U,0,CHEMBL627628,,1977.0,
11890,1,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in brain,Brain,BAO_0000218,,,,Autocuration,13758,,U,0,CHEMBL627629,,955.0,
11891,1,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in serum,Serum,BAO_0000218,,,,Autocuration,13758,,U,0,CHEMBL627630,,1977.0,
11892,1,Pharmacokinetic parameter was evaluated which is represented as AUC when administered 5 mg/Kg orally; range (0.19-0.35),,BAO_0000019,,,,Autocuration,16359,,U,0,CHEMBL627631,,,
11893,1,Pharmacokinetic parameter was evaluated which is represented as AUC when administered 5 mg/kg intravenously; range (2.1-2.3),,BAO_0000218,,,,Autocuration,16359,,U,0,CHEMBL629515,,,
11894,1,In vivo biodistribution in mice spleen bearing intracerebral GL261 gliomas at the dose of 30 ug/day,Spleen,BAO_0000218,,Mus musculus,,Intermediate,15383,,N,1,CHEMBL629516,,2106.0,
11895,1,In vivo biodistribution in mice spleen bearing subcutaneous B16 melanomas at the dose of 30 ug/g,Spleen,BAO_0000218,,Mus musculus,,Intermediate,15383,,N,1,CHEMBL629517,,2106.0,
11896,1,In vivo biodistribution in mice spleen bearing subcutaneous B16 melanomas at the dose of 40 ug/g,Spleen,BAO_0000218,,Mus musculus,,Intermediate,15383,,N,1,CHEMBL629518,,2106.0,
11897,1,In vivo biodistribution in mice tumor bearing intracerebral GL261 gliomas at the dose of 30 ug/day,,BAO_0000218,,Mus musculus,,Intermediate,15383,,N,1,CHEMBL877499,,,
11898,1,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 20 ug/g,,BAO_0000218,,Mus musculus,,Intermediate,15383,,N,1,CHEMBL629519,,,
11899,1,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,BAO_0000218,,Mus musculus,,Intermediate,15383,,N,1,CHEMBL629520,,,
11900,1,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,BAO_0000218,,Mus musculus,,Intermediate,15383,,N,1,CHEMBL629521,,,
11901,1,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Heart (H) and Blood (B),,BAO_0000218,,Mus musculus,,Intermediate,14439,,N,1,CHEMBL629522,,,
11902,1,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Heart (H) and Lung (L),,BAO_0000218,,Mus musculus,,Intermediate,14439,,N,1,CHEMBL629523,,,
11903,1,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Tumor (T) and Muscle (M),,BAO_0000218,,Mus musculus,,Intermediate,14439,,N,1,CHEMBL629524,,,
11904,1,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Tumor (T) and blood (B),,BAO_0000218,,Mus musculus,,Intermediate,14439,,N,1,CHEMBL629525,,,
11905,1,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Heart (H) and Blood (B),,BAO_0000218,,Mus musculus,,Intermediate,14439,,N,1,CHEMBL629526,,,
11906,1,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Heart (H) and Lung (L),,BAO_0000218,,Mus musculus,,Intermediate,14439,,N,1,CHEMBL629527,,,
11907,1,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Tumor (T) and Muscle (M),,BAO_0000218,,Mus musculus,,Intermediate,14439,,N,1,CHEMBL629528,,,
11908,1,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Tumor (T) and blood (B),,BAO_0000218,,Mus musculus,,Intermediate,14439,,N,1,CHEMBL629529,,,
11909,1,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Heart (H) and Blood (B),,BAO_0000218,,Mus musculus,,Intermediate,14439,,N,1,CHEMBL629530,,,
11910,1,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Heart (H) and Lung (L),,BAO_0000218,,Mus musculus,,Intermediate,14439,,N,1,CHEMBL629531,,,
11911,1,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Tumor (T) and Muscle (M),,BAO_0000218,,Mus musculus,,Intermediate,14439,,N,1,CHEMBL628656,,,
11912,1,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Tumor (T) and blood (B),,BAO_0000218,,Mus musculus,,Intermediate,14439,,N,1,CHEMBL628657,,,
11913,1,"Biodistribution in abdominal Dawley rat after 30min, expressed as percent injected dose/g",,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,N,1,CHEMBL628658,,,
11914,1,"Biodistribution in abdominal of mature female Dawley rat after 10min, expressed as percent injected dose/g",,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,N,1,CHEMBL628659,,,
11915,1,"Biodistribution in abdominal of mature female Dawley rat after 15min, expressed as percent injected dose/g",,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,N,1,CHEMBL877500,,,
11916,1,"Biodistribution in abdominal of mature female Dawley rat after 1h, expressed as percent injected dose/g",,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,N,1,CHEMBL628660,,,
11917,1,"Biodistribution in abdominal of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,N,1,CHEMBL628661,,,
11918,1,"Biodistribution in abdominal of mature female Dawley rat after 30min, expressed as percent injected dose/g",,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,N,1,CHEMBL628662,,,
11919,1,"Biodistribution in abdominal of mature female Dawley rat after 45min, expressed as percent injected dose/g",,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,N,1,CHEMBL628663,,,
11920,1,"Biodistribution in abdominal of mature female Dawley rat after 5min, expressed as percent injected dose/g",,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,N,1,CHEMBL628664,,,
11921,1,"Biodistribution in blood of mature female Dawley rat after 10min, expressed as percent injected dose/g",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,N,1,CHEMBL628665,,178.0,
11922,1,"Biodistribution in blood of mature female Dawley rat after 15min, expressed as percent injected dose/g",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,N,1,CHEMBL628666,,178.0,
11923,1,"Biodistribution in blood of mature female Dawley rat after 1h, expressed as percent injected dose/g",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,N,1,CHEMBL628667,,178.0,
11924,1,"Biodistribution in blood of mature female Dawley rat after 3 h, expressed as percent injected dose/g",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,N,1,CHEMBL628668,,178.0,
11925,1,"Biodistribution in blood of mature female Dawley rat after 30min, expressed as percent injected dose/g",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,N,1,CHEMBL628669,,178.0,
11926,1,"Biodistribution in blood of mature female Dawley rat after 45min, expressed as percent injected dose/g",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,N,1,CHEMBL628670,,178.0,
11927,1,"Biodistribution in blood of mature female Dawley rat after 5min, expressed as percent injected dose/g",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,N,1,CHEMBL628671,,178.0,
11928,1,"Biodistribution in bone of mature female Dawley rat after 10min, expressed as percent injected dose/g",Bone,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,N,1,CHEMBL628672,,10000001.0,
11929,1,"Biodistribution in bone of mature female Dawley rat after 1h, expressed as percent injected dose/g",Bone,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,N,1,CHEMBL630300,,10000001.0,
11930,1,"Biodistribution in bone of mature female Dawley rat after 3 h, expressed as percent injected dose/g",Bone,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,N,1,CHEMBL629787,,10000001.0,
11931,1,"Biodistribution in bone of mature female Dawley rat after 30min, expressed as percent injected dose/g",Bone,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,N,1,CHEMBL629788,,10000001.0,
11932,1,"Biodistribution in brain of mature female Dawley rat after 10min, expressed as percent injected dose/g",Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,N,1,CHEMBL629789,,955.0,
11933,1,"Biodistribution in brain of mature female Dawley rat after 15min, expressed as percent injected dose/g",Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,N,1,CHEMBL629790,,955.0,
11934,1,"Biodistribution in brain of mature female Dawley rat after 1h, expressed as percent injected dose/g",Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,N,1,CHEMBL629791,,955.0,
11935,1,"Biodistribution in brain of mature female Dawley rat after 3 h, expressed as percent injected dose/g",Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,N,1,CHEMBL629792,,955.0,
11936,1,"Biodistribution in brain of mature female Dawley rat after 30min, expressed as percent injected dose/g",Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,N,1,CHEMBL629793,,955.0,
11937,1,"Biodistribution in brain of mature female Dawley rat after 45min, expressed as percent injected dose/g",Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,N,1,CHEMBL629794,,955.0,
11938,1,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 2-3 hr time,,BAO_0000218,,Rattus norvegicus,,Intermediate,10677,,N,1,CHEMBL874459,,,
11939,1,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 3-4 hr time,,BAO_0000218,,Rattus norvegicus,,Intermediate,10677,,N,1,CHEMBL629795,,,
11940,1,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 4-5 hr time,,BAO_0000218,,Rattus norvegicus,,Intermediate,10677,,N,1,CHEMBL629796,,,
11941,1,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 5-6 hr time,,BAO_0000218,,Rattus norvegicus,,Intermediate,10677,,N,1,CHEMBL629797,,,
11942,1,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 6-24 h time,,BAO_0000218,,Rattus norvegicus,,Intermediate,10677,,N,1,CHEMBL629798,,,
11943,1,Biodistribution studied in the adrenals of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,Adrenal gland,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,N,1,CHEMBL629799,,2369.0,
11944,1,Biodistribution studied in the adrenals of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,Adrenal gland,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,N,1,CHEMBL629800,,2369.0,
11945,1,Biodistribution studied in the adrenals of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,Adrenal gland,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,N,1,CHEMBL629801,,2369.0,
11946,1,Biodistribution studied in the adrenals of immature Fischer female rats at 5 hour,Adrenal gland,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,N,1,CHEMBL629802,,2369.0,
11947,1,Biodistribution studied in the adrenals of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,Adrenal gland,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,N,1,CHEMBL629803,,2369.0,
11948,1,Biodistribution studied in the blood of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,N,1,CHEMBL629804,,178.0,
11949,1,Biodistribution studied in the blood of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,N,1,CHEMBL629805,,178.0,
11950,1,Biodistribution studied in the blood of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,N,1,CHEMBL629806,,178.0,
11951,1,Biodistribution studied in the blood of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,N,1,CHEMBL629807,,178.0,
11952,1,Biodistribution studied in the blood of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,N,1,CHEMBL629808,,178.0,
11953,1,Biodistribution studied in the brain of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,N,1,CHEMBL629809,,955.0,
11954,1,Biodistribution studied in the brain of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,N,1,CHEMBL629810,,955.0,
11955,1,Biodistribution studied in the brain of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,N,1,CHEMBL629811,,955.0,
11956,1,Biodistribution studied in the brain of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,N,1,CHEMBL629812,,955.0,
11957,1,Biodistribution studied in the brain of immature Fischer female rats at 5 hou; activity is expressed as inductive dose / gram,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,N,1,CHEMBL629813,,955.0,
11958,1,Biodistribution studied in the brain of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,N,1,CHEMBL874460,,955.0,
11959,1,Biodistribution studied in the fat of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,N,1,CHEMBL629814,,,
11960,1,Biodistribution studied in the fat of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,N,1,CHEMBL629815,,,
11961,1,Biodistribution studied in the fat of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,N,1,CHEMBL629816,,,
11962,1,Biodistribution studied in the fat of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,N,1,CHEMBL629817,,,
11963,1,Biodistribution studied in the kidneys of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,N,1,CHEMBL626643,,2113.0,
11964,1,Biodistribution studied in the kidneys of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,N,1,CHEMBL626644,,2113.0,
11965,1,Biodistribution studied in the kidneys of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,N,1,CHEMBL626806,,2113.0,
11966,1,Biodistribution studied in the kidneys of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,N,1,CHEMBL626807,,2113.0,
11967,1,Biodistribution studied in the liver of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,N,1,CHEMBL627261,,2107.0,
11968,1,Biodistribution studied in the liver of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,N,1,CHEMBL627262,,2107.0,
11969,1,Biodistribution studied in the liver of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,N,1,CHEMBL627263,,2107.0,
11970,1,Biodistribution studied in the liver of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,N,1,CHEMBL627264,,2107.0,
11971,1,Biodistribution studied in the lungs of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,N,1,CHEMBL627265,,2048.0,
11972,1,Biodistribution studied in the lungs of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,N,1,CHEMBL627266,,2048.0,
11973,1,Biodistribution studied in the lungs of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,N,1,CHEMBL627267,,2048.0,
11974,1,Biodistribution studied in the lungs of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,N,1,CHEMBL627268,,2048.0,
11975,1,Biodistribution studied in the muscle of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,N,1,CHEMBL627269,,2385.0,
11976,1,Biodistribution studied in the muscle of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,N,1,CHEMBL627270,,2385.0,
11977,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 0.95-1.44",,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL627271,,,
11978,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 1.39-2.43",,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL627946,,,
11979,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.47-2.96",,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL875472,,,
11980,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.67-3.69",,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL627947,,,
11981,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.67-4.31",,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL627948,,,
11982,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 3.17-4.70",,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL628113,,,
11983,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration.; dose/g, range 2.20-2.97",,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL628114,,,
11984,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 0.90-1.46",,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL628115,,,
11985,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.72-3.52",,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL628116,,,
11986,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.78-3.62",,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL628117,,,
11987,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.82-3.86",,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL628118,,,
11988,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 3.80-5.74",,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL628119,,,
11989,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 1.05-1.57",,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL628120,,,
11990,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 1.93-3.58",,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL628121,,,
11991,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 2.88-4.32",,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL628122,,,
11992,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3-3.70",,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL627297,,,
11993,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3.21-3.92",,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL627298,,,
11994,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3.51-5.44",,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL627299,,,
11995,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 0.24-0.31",,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL627300,,,
11996,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 10.5-14.4",,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL627301,,,
11997,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 6.28-7.41",,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL627302,,,
11998,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 6.47-10.2",,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL627303,,,
11999,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 7.21-7.95",,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL627304,,,
12000,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 8.28-10.72",,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL627305,,,
12001,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 1.04-2.56",,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL627306,,,
12002,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 10.7-16.9",,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL623982,,,
12003,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 11.7-14.6",,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL623983,,,
12004,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 14.4-20.1",,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL623984,,,
12005,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 4.78-9.72",,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL623985,,,
12006,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 9.87-11.9",,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL623986,,,
12007,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 0.17-0.25",,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL623987,,,
12008,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 3.33-4.68",,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL623988,,,
12009,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 4.59-8.81",,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL623989,,,
12010,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 4.62-5.60",,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL622215,,,
12011,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 5.02-6.57",,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL622216,,,
12012,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 5.67-8.41",,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL877481,,,
12013,1,Pharmacokinetic parameter was evaluated which is represented as AUC when administered orally a dose of 5 mg/kg; range (4.2-8.8),,BAO_0000218,,,,Autocuration,16359,,U,0,CHEMBL622217,,,
12014,1,Pharmacokinetic parameters was measured at 55 mg/kg dose by oral administration in mice serum.; AUC 0-r (mM.h),,BAO_0000218,,Mus musculus,,Intermediate,13701,,N,1,CHEMBL622218,,,
12015,1,Pharmacokinetic profile AUC was evaluated in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,14554,,N,1,CHEMBL622219,,,
12016,1,Pharmacokinetic property (Area under curve),,BAO_0000019,,,,Autocuration,6241,,U,0,CHEMBL622220,,,
12017,1,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration in dog (25 mg/kg).",,BAO_0000218,,Canis lupus familiaris,,Intermediate,11537,,N,1,CHEMBL622221,,,
12018,1,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration in mice (50 mg/kg).",,BAO_0000218,,Mus musculus,,Intermediate,11537,,N,1,CHEMBL622222,,,
12019,1,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration to dog (25 mg/kg).",,BAO_0000218,,Canis lupus familiaris,,Intermediate,11537,,N,1,CHEMBL622223,,,
12020,1,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration to mice (50 mg/kg).",,BAO_0000218,,Mus musculus,,Intermediate,11537,,N,1,CHEMBL622224,,,
12021,1,Plasma concentration (AUC) was determined,,BAO_0000019,,,,Autocuration,13118,,U,0,CHEMBL622225,,,
12022,1,Plasma concentration (AUC) was determined; Not detectable,,BAO_0000019,,,,Autocuration,13118,,U,0,CHEMBL622226,,,
12023,1,Prolongation of time to collapse in guinea pig treated with aerosolized histamine was measured in vivo as area under curve (AUC),,BAO_0000218,,Cavia porcellus,,Intermediate,9562,,N,1,CHEMBL624154,,,
12024,1,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,10363,,N,1,CHEMBL624155,,,
12025,1,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg; Not significant,,BAO_0000218,,Rattus norvegicus,,Intermediate,10363,,N,1,CHEMBL624156,,,
12026,1,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 60 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,10363,,N,1,CHEMBL624157,,,
12027,1,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 7.5 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,10363,,N,1,CHEMBL624158,,,
12028,1,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 1,,BAO_0000218,,Rattus norvegicus,,Intermediate,12504,,N,1,CHEMBL624159,,,
12029,1,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 2,,BAO_0000218,,Rattus norvegicus,,Intermediate,12504,,N,1,CHEMBL624160,,,
12030,1,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 3,,BAO_0000218,,Rattus norvegicus,,Intermediate,12504,,N,1,CHEMBL624161,,,
12031,1,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 4,,BAO_0000218,,Rattus norvegicus,,Intermediate,12504,,N,1,CHEMBL624162,,,
12032,1,Tested for pharmacokinetic parameter in fasted Beagle dogs (Area Under Curve value) iv administration.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,13317,,N,1,CHEMBL624163,,,
12033,1,"The AUC(0-infinitive) value in female wistar rat at 100 mg/kg, p.o. dose",,BAO_0000218,,Rattus norvegicus,,Intermediate,15078,,N,1,CHEMBL624164,,,
12034,1,The AUC(0-infinity) values in female wistar rats.,,BAO_0000218,,Rattus norvegicus,,Intermediate,14941,,N,1,CHEMBL624165,,,
12035,1,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose",,BAO_0000218,,Rattus norvegicus,,Intermediate,15078,,N,1,CHEMBL624166,,,
12036,1,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose in mice",,BAO_0000218,,Rattus norvegicus,,Intermediate,15078,,N,1,CHEMBL624167,,,
12037,1,The AUC(0-t)values in female wistar rats.,,BAO_0000218,,Rattus norvegicus,,Intermediate,14941,,N,1,CHEMBL624168,,,
12038,1,The Area under the concentration time curve of compound was measured on rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,14067,,N,1,CHEMBL624169,,,
12039,1,The area under curve (100 mg/kg) administered orally in humans,,BAO_0000218,,Homo sapiens,,Intermediate,14215,,N,1,CHEMBL624170,,,
12040,1,The area under curve (12.5 mg/kg) administered intravenously in marmoset,,BAO_0000218,,Callithrix,,Autocuration,14215,,U,0,CHEMBL624171,,,
12041,1,The area under curve (12.5 mg/kg) administered intravenously in monkey,,BAO_0000218,,Simiiformes,,Autocuration,14215,,U,0,CHEMBL624172,,,
12042,1,The area under curve (15 mg/kg) administered intravenously in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,14215,,N,1,CHEMBL624173,,,
12043,1,The area under curve (200 mg/kg) administered orally in humans,,BAO_0000218,,Homo sapiens,,Intermediate,14215,,N,1,CHEMBL877488,,,
12044,1,The area under curve (25 mg/kg) administered intravenously in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,14215,,N,1,CHEMBL624174,,,
12045,1,The area under curve (25 mg/kg) administered orally in marmoset,,BAO_0000218,,Callithrix,,Autocuration,14215,,U,0,CHEMBL624175,,,
12046,1,The area under curve (25 mg/kg) administered orally in monkey,,BAO_0000218,,Simiiformes,,Autocuration,14215,,U,0,CHEMBL624176,,,
12047,1,The area under curve (30 mg/kg) administered orally in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,14215,,N,1,CHEMBL624177,,,
12048,1,The area under curve (400 mg/kg) administered orally in humans,,BAO_0000218,,Homo sapiens,,Intermediate,14215,,N,1,CHEMBL624178,,,
12049,1,The area under curve (50 mg/kg) administered orally in fasted rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,14215,,N,1,CHEMBL624179,,,
12050,1,The area under curve (50 mg/kg) administered orally in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,14215,,N,1,CHEMBL627689,,,
12051,1,The area under curve (800 mg/kg) administered orally in humans,,BAO_0000218,,Homo sapiens,,Intermediate,14215,,N,1,CHEMBL627690,,,
12052,1,The compound was evaluated for area under the curve,,BAO_0000019,,,,Autocuration,11324,,U,0,CHEMBL627691,,,
12053,1,The compound was evaluated for area under the curve in marmosets,,BAO_0000019,,Callithrix,,Autocuration,11324,,U,0,CHEMBL627692,,,
12054,1,The compound was evaluated for area under the curve in marmosets,,BAO_0000019,,Callithrix,,Autocuration,11324,,U,0,CHEMBL627693,,,
12055,1,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,13875,,N,1,CHEMBL627694,,,
12056,1,The compound was tested for the area of the change in MABP versus time curve at dose 10 mg/kg (po) in conscious spontaneously hypertensive rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,13875,,N,1,CHEMBL627695,,,
12057,1,The compound was tested for the area of the change in MABP versus time curve at dose 10 mg/kg (po),,BAO_0000218,,,,Autocuration,13875,,U,0,CHEMBL627696,,,
12058,1,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,13875,,N,1,CHEMBL627697,,,
12059,1,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,13875,,N,1,CHEMBL627698,,,
12060,1,The compound was tested for the area of the change in MABP versus time curve at dose 5 mg/kg (po) in conscious spontaneously hypertensive rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,13875,,N,1,CHEMBL627699,,,
12061,1,Total absorption was estimated by area under curve (AUC) after intravenous administration in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,13807,,N,1,CHEMBL627700,,,
12062,1,Total drug exposure is determined after oral dosing in rats.,,BAO_0000218,,Rattus norvegicus,,Intermediate,14127,,N,1,CHEMBL627701,,,
12063,1,Total drug exposure (5 mg/kg) when administered intravenously,,BAO_0000218,,,,Autocuration,15116,,U,0,CHEMBL627702,,,
12064,1,Total drug exposure (5 mg/kg) when administered orally,,BAO_0000218,,,,Autocuration,15116,,U,0,CHEMBL627703,,,
12065,1,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.01 mg/kg) in monkey,,BAO_0000218,,Simiiformes,,Autocuration,15604,,U,0,CHEMBL626873,,,
12066,1,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.05 mg/kg) in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,15604,,N,1,CHEMBL629583,,,
12067,1,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.1 mg/kg) in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,15604,,N,1,CHEMBL629584,,,
12068,1,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,15604,,N,1,CHEMBL629585,,,
12069,1,"Biodistribution in brain of mature female Dawley rat after 5min, expressed as percent injected dose/g",Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,N,1,CHEMBL629586,,955.0,
12070,1,"Biodistribution in brain of mature female Dawley rat after 30min, expressed as percent injected dose/g",Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,N,1,CHEMBL629587,,955.0,
12071,1,"Biodistribution in fat of mature female Dawley rat after 10min, expressed as percent injected dose/g",,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,N,1,CHEMBL629588,,,
12072,1,"Biodistribution in fat of mature female Dawley rat after 15min, expressed as percent injected dose/g",,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,N,1,CHEMBL629589,,,
12073,1,"Biodistribution in fat of mature female Dawley rat after 1h, expressed as percent injected dose/g",,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,N,1,CHEMBL629590,,,
12074,1,"Biodistribution in fat of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,N,1,CHEMBL629591,,,
12075,1,"Biodistribution in fat of mature female Dawley rat after 30min, expressed as percent injected dose/g",,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,N,1,CHEMBL629592,,,
12076,1,"Biodistribution in fat of mature female Dawley rat after 45min, expressed as percent injected dose/g",,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,N,1,CHEMBL629593,,,
12077,1,"Biodistribution in fat of mature female Dawley rat after 5min, expressed as percent injected dose/g",,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,N,1,CHEMBL629594,,,
12078,1,"Biodistribution in heart of mature female Dawley rat after 10min, expressed as percent injected dose/g",Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,N,1,CHEMBL629595,,948.0,
12079,1,"Biodistribution in heart of mature female Dawley rat after 15min, expressed as percent injected dose/g",Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,N,1,CHEMBL630290,,948.0,
12080,1,"Biodistribution in heart of mature female Dawley rat after 1h, expressed as percent injected dose/g",Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,N,1,CHEMBL627137,,948.0,
12081,1,"Biodistribution in heart of mature female Dawley rat after 3 h, expressed as percent injected dose/g",Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,N,1,CHEMBL627138,,948.0,
12082,1,"Biodistribution in heart of mature female Dawley rat after 30min, expressed as percent injected dose/g",Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,N,1,CHEMBL627139,,948.0,
12083,1,"Biodistribution in heart of mature female Dawley rat after 45min, expressed as percent injected dose/g",Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,N,1,CHEMBL627140,,948.0,
12084,1,"Biodistribution in heart of mature female Dawley rat after 5min, expressed as percent injected dose/g",Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,N,1,CHEMBL627141,,948.0,
12085,1,"Biodistribution in kidney of mature female Dawley rat after 10min, expressed as percent injected dose/g",Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,N,1,CHEMBL627142,,2113.0,
12086,1,"Biodistribution in kidney of mature female Dawley rat after 15min, expressed as percent injected dose/g",Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,N,1,CHEMBL627143,,2113.0,
12087,1,"Biodistribution in kidney of mature female Dawley rat after 1h, expressed as percent injected dose/g",Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,N,1,CHEMBL874449,,2113.0,
12088,1,"Biodistribution in kidney of mature female Dawley rat after 3 h, expressed as percent injected dose/g",Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,N,1,CHEMBL627144,,2113.0,
12089,1,"Biodistribution in kidney of mature female Dawley rat after 30min, expressed as percent injected dose/g",Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,N,1,CHEMBL627145,,2113.0,
12090,1,"Biodistribution in kidney of mature female Dawley rat after 45min, expressed as percent injected dose/g",Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,N,1,CHEMBL627146,,2113.0,
12091,1,"Biodistribution in kidney of mature female Dawley rat after 5min, expressed as percent injected dose/g",Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,N,1,CHEMBL627147,,2113.0,
12092,1,"Biodistribution in liver of mature female Dawley rat after 10min, expressed as percent injected dose/g",Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,N,1,CHEMBL627148,,2107.0,
12093,1,"Biodistribution in lung of mature female Dawley rat after 10min, expressed as percent injected dose/g",Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,N,1,CHEMBL627149,,2048.0,
12094,1,"Biodistribution in lung of mature female Dawley rat after 15min, expressed as percent injected dose/g",Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,N,1,CHEMBL632160,,2048.0,
12095,1,"Biodistribution in lung of mature female Dawley rat after 1h, expressed as percent injected dose/g",Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,N,1,CHEMBL632161,,2048.0,
12096,1,"Biodistribution in lung of mature female Dawley rat after 3 h, expressed as percent injected dose/g",Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,N,1,CHEMBL632162,,2048.0,
12097,1,"Biodistribution in lung of mature female Dawley rat after 30min, expressed as percent injected dose/g",Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,N,1,CHEMBL632163,,2048.0,
12098,1,"Biodistribution in lung of mature female Dawley rat after 45min, expressed as percent injected dose/g",Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,N,1,CHEMBL874469,,2048.0,
12099,1,"Biodistribution in lung of mature female Dawley rat after 5min, expressed as percent injected dose/g",Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,N,1,CHEMBL627182,,2048.0,
12100,1,"Biodistribution in muscle of mature female Dawley rat after 10min, expressed as percent injected dose/g",Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,N,1,CHEMBL627183,,2385.0,
12101,1,"Biodistribution in muscle of mature female Dawley rat after 15min, expressed as percent injected dose/g",Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,N,1,CHEMBL627184,,2385.0,
12102,1,"Biodistribution in muscle of mature female Dawley rat after 1h, expressed as percent injected dose/g",Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,N,1,CHEMBL627185,,2385.0,
12103,1,"Biodistribution in muscle of mature female Dawley rat after 3 h, expressed as percent injected dose/g",Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,N,1,CHEMBL627186,,2385.0,
12104,1,"Biodistribution in muscle of mature female Dawley rat after 30min, expressed as percent injected dose/g",Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,N,1,CHEMBL627187,,2385.0,
12105,1,"Biodistribution in muscle of mature female Dawley rat after 45min, expressed as percent injected dose/g",Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,N,1,CHEMBL627188,,2385.0,
12106,1,"Biodistribution in muscle of mature female Dawley rat after 5min, expressed as percent injected dose/g",Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,N,1,CHEMBL627189,,2385.0,
12107,1,"Biodistribution inl ilver of mature female Dawley rat after 30min, expressed as percent injected dose/g",,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,N,1,CHEMBL627190,,,
12108,1,"Biodistribution inl iver of mature female Dawley rat after 15min, expressed as percent injected dose/g",Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,N,1,CHEMBL627191,,2107.0,
12109,1,"Biodistribution inl iver of mature female Dawley rat after 3 h, expressed as percent injected dose/g",Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,N,1,CHEMBL627192,,2107.0,
12110,1,"Biodistribution inl iver of mature female Dawley rat after 5min, expressed as percent injected dose/g",Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,N,1,CHEMBL627193,,2107.0,
12111,1,Biodistribution studied in the muscle of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,N,1,CHEMBL874590,,2385.0,
12112,1,Biodistribution studied in the muscle of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,N,1,CHEMBL627194,,2385.0,
12113,1,Biodistribution studied in the muscle of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,N,1,CHEMBL627195,,2385.0,
12114,1,Biodistribution studied in the ovaries of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,Female gonad,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,N,1,CHEMBL627196,,992.0,
12115,1,Biodistribution studied in the ovaries of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,Female gonad,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,N,1,CHEMBL627197,,992.0,
12116,1,Biodistribution studied in the ovaries of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,Female gonad,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,N,1,CHEMBL627198,,992.0,
12117,1,Biodistribution studied in the ovaries of immature Fischer female rats at 5 hour,Female gonad,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,N,1,CHEMBL627199,,992.0,
12118,1,Biodistribution studied in the ovaries of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,Female gonad,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,N,1,CHEMBL627200,,992.0,
12119,1,Biodistribution studied in the plasma of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,N,1,CHEMBL627201,,1969.0,
12120,1,Biodistribution studied in the plasma of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,N,1,CHEMBL627202,,1969.0,
12121,1,Biodistribution studied in the plasma of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,N,1,CHEMBL627203,,1969.0,
12122,1,Biodistribution studied in the plasma of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,N,1,CHEMBL627204,,1969.0,
12123,1,Biodistribution studied in the spleen of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,N,1,CHEMBL627205,,2106.0,
12124,1,Biodistribution studied in the spleen of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,N,1,CHEMBL627206,,2106.0,
12125,1,Biodistribution studied in the spleen of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,N,1,CHEMBL627207,,2106.0,
12126,1,Biodistribution studied in the spleen of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,N,1,CHEMBL627208,,2106.0,
12127,1,Biodistribution studied in the thyroid of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,N,1,CHEMBL627209,,2046.0,
12128,1,Biodistribution studied in the thyroid of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,N,1,CHEMBL627210,,2046.0,
12129,1,Biodistribution studied in the thyroid of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,N,1,CHEMBL627211,,2046.0,
12130,1,Biodistribution studied in the thyroid of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,N,1,CHEMBL627212,,2046.0,
12131,1,Biodistribution studied in the uterus of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,Uterus,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,N,1,CHEMBL627213,,995.0,
12132,1,Biodistribution studied in the uterus of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,Uterus,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,N,1,CHEMBL626599,,995.0,
12133,1,Biodistribution studied in the uterus of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,Uterus,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,N,1,CHEMBL626600,,995.0,
12134,1,Biodistribution studied in the uterus of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,Uterus,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,N,1,CHEMBL626601,,995.0,
12135,1,C(f=2) is the concentration at which the half life (t1/2) in the time course of inhibition of BChE by DFP increased by twofold in the presence of compound,,BAO_0000019,,,,Autocuration,8081,,U,0,CHEMBL627484,,,
12136,1,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg),Plasma,BAO_0000218,,Macaca fascicularis,,Intermediate,17248,,N,1,CHEMBL627485,,1969.0,
12137,1,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg); Not applicable,Plasma,BAO_0000218,,Macaca fascicularis,,Intermediate,17248,,N,1,CHEMBL628147,,1969.0,
12138,1,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg); Not determined,Plasma,BAO_0000218,,Macaca fascicularis,,Intermediate,17248,,N,1,CHEMBL628148,,1969.0,
12139,1,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg),Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,17248,,N,1,CHEMBL628149,,1969.0,
12140,1,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg) in experiment 1,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,17248,,N,1,CHEMBL628150,,1969.0,
12141,1,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg) in experiment 2,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,17248,,N,1,CHEMBL628318,,1969.0,
12142,1,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg); Not applicable,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,17248,,N,1,CHEMBL628319,,1969.0,
12143,1,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 )",,BAO_0000218,,Canis lupus familiaris,,Intermediate,15592,,N,1,CHEMBL875609,,,
12144,1,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 10,,BAO_0000019,,,,Autocuration,7040,,U,0,CHEMBL628320,,,
12145,1,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 10.5,,BAO_0000019,,,,Autocuration,7040,,U,0,CHEMBL628321,,,
12146,1,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 6.8,,BAO_0000019,,,,Autocuration,7040,,U,0,CHEMBL628322,,,
12147,1,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 7.2,,BAO_0000019,,,,Autocuration,7040,,U,0,CHEMBL628323,,,
12148,1,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 7.6,,BAO_0000019,,,,Autocuration,7040,,U,0,CHEMBL628324,,,
12149,1,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 8.2,,BAO_0000019,,,,Autocuration,7040,,U,0,CHEMBL628325,,,
12150,1,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 9.6,,BAO_0000019,,,,Autocuration,7040,,U,0,CHEMBL628326,,,
12151,1,"Concentration of compound in adrenal medulla of dog 2, after administering intravenously",Adrenal medulla,BAO_0000218,,Canis lupus familiaris,,Intermediate,9614,,N,1,CHEMBL628327,,1236.0,
12152,1,"Concentration of compound in adrenal medulla of dog1, after administering intravenously",Adrenal medulla,BAO_0000218,,Canis lupus familiaris,,Intermediate,9614,,N,1,CHEMBL628328,,1236.0,
12153,1,"Concentration of compound in blood of dog 1, after administering intravenously",Blood,BAO_0000218,,Canis lupus familiaris,,Intermediate,9614,,N,1,CHEMBL628329,,178.0,
12154,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration.; dose/g, range 0.23-0.29",Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL628330,,2107.0,
12155,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.22-0.30",Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL628331,,2107.0,
12156,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.55-0.71",Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL628332,,2107.0,
12157,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.57-0.72",Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL628333,,2107.0,
12158,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 1.51-2.23",Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL628334,,2107.0,
12159,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 2.30-3.12",Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL628335,,2107.0,
12160,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 0.93-1.20",Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL628336,,2107.0,
12161,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.04-2.56",Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL628337,,2107.0,
12162,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.06-1.70",Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL628338,,2107.0,
12163,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.26-2.45",Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL875610,,2107.0,
12164,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 3.12-4.56",Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL628339,,2107.0,
12165,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 4.12-6.30",Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL628340,,2107.0,
12166,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.14-0.19",Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL628341,,2107.0,
12167,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.15-0.19",Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL622214,,2107.0,
12168,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.24-0.30",Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL623167,,2107.0,
12169,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.44-0.54",Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL623168,,2107.0,
12170,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.73-1.19",Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL623169,,2107.0,
12171,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 1.08-2.31",Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL623170,,2107.0,
12172,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration.; dose/g, range 0.34-0.47",Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL627224,,2048.0,
12173,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.83-1.21",Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL875634,,2048.0,
12174,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.91-1.74",Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL627225,,2048.0,
12175,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.99-1.23",Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL627226,,2048.0,
12176,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 1.07-1.30",Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL626083,,2048.0,
12177,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 1.12-1.39",Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL626084,,2048.0,
12178,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.51-0.66",Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL626085,,2048.0,
12179,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.95-1.49",Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL626086,,2048.0,
12180,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.96-1.35",Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL626087,,2048.0,
12181,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.18-1.44",Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL626088,,2048.0,
12182,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.20-1.52",Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL626089,,2048.0,
12183,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.41-2.17",Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL626090,,2048.0,
12184,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.28-0.33",Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL626091,,2048.0,
12185,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.81-1.13",Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL626092,,2048.0,
12186,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.83-2.11",Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL626093,,2048.0,
12187,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.94-1.36",Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL626094,,2048.0,
12188,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.97-1.54",Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL626095,,2048.0,
12189,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 1.07-1.26",Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL626096,,2048.0,
12190,1,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in monkey,,BAO_0000218,,Simiiformes,,Autocuration,15604,,U,0,CHEMBL626097,,,
12191,1,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,15604,,N,1,CHEMBL626098,,,
12192,1,compound was evaluated for area under the plasma concentration vs. time curve at different dose 27.5 mg/kg DMP323 equiv,Plasma,BAO_0000218,,,,Autocuration,1806,,U,0,CHEMBL626099,,1969.0,
12193,1,compound was evaluated for area under the plasma concentration vs. time curve at different dose 7.7 mg/kg DMP323 equiv,Plasma,BAO_0000218,,,,Autocuration,1806,,U,0,CHEMBL626100,,1969.0,
12194,1,AUC 0-inf in dog,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,17237,,N,1,CHEMBL626101,,1969.0,
12195,1,AUC 0-inf in guinea pig,Plasma,BAO_0000218,,Cavia porcellus,,Intermediate,17237,,N,1,CHEMBL626102,,1969.0,
12196,1,AUC 0-t in dog,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,17237,,N,1,CHEMBL626103,,1969.0,
12197,1,AUC 0-t in guinea pig,Plasma,BAO_0000218,,Cavia porcellus,,Intermediate,17237,,N,1,CHEMBL628391,,1969.0,
12198,1,The compound was tested for brain to plasma partition in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,15194,,N,1,CHEMBL628392,,,
12199,1,The compound was tested for brain to plasma partition in rat.,,BAO_0000218,,Rattus norvegicus,,Intermediate,15194,,N,1,CHEMBL628393,,,
12200,1,Area under curve was determined for 0-6 hr duration using dihydralazine as reference drug for the peak blood pressure,Blood,BAO_0000019,,,,Autocuration,8787,,U,0,CHEMBL628394,,178.0,
12201,1,Area under concentration-time curve of compound was determined in dog at 5 mg/kg intravenously admn.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17025,,N,1,CHEMBL628395,,,
12202,1,Area under concentration-time curve of compound was determined in monkey at 5 mg/kg intravenously admn.,,BAO_0000218,,Simiiformes,,Autocuration,17025,,U,0,CHEMBL628396,,,
12203,1,Area under concentration-time curve of compound was determined in rabbit at 5 mg/kg intravenously admn.,,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,17025,,N,1,CHEMBL628397,,,
12204,1,Area under concentration-time curve of compound was determined in rat at 5 mg/kg intravenously admn.,,BAO_0000218,,Rattus norvegicus,,Intermediate,17025,,N,1,CHEMBL628398,,,
12205,1,Area under curve obtained at a dose of 10 mg/kg when administered orally to rhesus monkey,,BAO_0000218,,Macaca mulatta,,Intermediate,4236,,N,1,CHEMBL628399,,,
12206,1,The Plasma area under the compound concentration -time curve was measured in dogs after oral administration of 1 mg/kg dose,,BAO_0000218,,Canis lupus familiaris,,Intermediate,15343,,N,1,CHEMBL628400,,,
12207,1,The Plasma area under the compound concentration -time curve was measured in rats after oral administration of 1 mg/kg dose,,BAO_0000218,,Rattus norvegicus,,Intermediate,15343,,N,1,CHEMBL874907,,,
12208,1,Area under curve of the compound was determined,,BAO_0000019,,,,Autocuration,17720,,U,0,CHEMBL628401,,,
12209,1,AUC in monkeys at a dose of 1 mg/kg,Plasma,BAO_0000218,,Simiiformes,,Autocuration,17788,,U,0,CHEMBL628402,,1969.0,
12210,1,AUC in rats at a dose of 1 mg/kg,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,17788,,N,1,CHEMBL628403,,1969.0,
12211,1,Compound was evaluated for the overall absorbance loss at pH of 2,,BAO_0000019,,,,Autocuration,8778,,U,0,CHEMBL628404,,,
12212,1,Compound was evaluated for the overall absorbance loss at pH of 4,,BAO_0000019,,,,Autocuration,8778,,U,0,CHEMBL628405,,,
12213,1,Compound was evaluated for the overall absorbance loss at pH of 7,,BAO_0000019,,,,Autocuration,8778,,U,0,CHEMBL628406,,,
12214,1,Compound was evaluated for its absorption in the rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,2249,,N,1,CHEMBL628407,,,
12215,1,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight per mole of pro drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,8881,,N,1,CHEMBL628408,,1088.0,
12216,1,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight.,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,8881,,N,1,CHEMBL629171,,1088.0,
12217,1,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight per mole of pro drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,8881,,N,1,CHEMBL629172,,1088.0,
12218,1,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of per moiety tranexamic acid,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,8881,,N,1,CHEMBL629173,,1088.0,
12219,1,In vitro percent permeability into rat ileum,,BAO_0000218,,Rattus norvegicus,,Intermediate,15286,,N,1,CHEMBL629174,,,
12220,1,In vitro percent permeability into rat ileum; Range is 10-17,,BAO_0000218,,Rattus norvegicus,,Intermediate,15286,,N,1,CHEMBL629175,,,
12221,1,In vitro percent permeability into rat ileum; Range is 10-18,,BAO_0000218,,Rattus norvegicus,,Intermediate,15286,,N,1,CHEMBL629176,,,
12222,1,In vitro percent permeability into rat ileum; Range is 10-19,,BAO_0000218,,Rattus norvegicus,,Intermediate,15286,,N,1,CHEMBL629177,,,
12223,1,In vitro percent permeability into rat ileum; Range is 12-15,,BAO_0000218,,Rattus norvegicus,,Intermediate,15286,,N,1,CHEMBL629178,,,
12224,1,In vitro percent permeability into rat ileum; Range is 13-19,,BAO_0000218,,Rattus norvegicus,,Intermediate,15286,,N,1,CHEMBL631869,,,
12225,1,In vitro percent permeability into rat ileum; Range is 14-17,,BAO_0000218,,Rattus norvegicus,,Intermediate,15286,,N,1,CHEMBL631870,,,
12226,1,In vitro percent permeability into rat ileum; Range is 15-18,,BAO_0000218,,Rattus norvegicus,,Intermediate,15286,,N,1,CHEMBL631871,,,
12227,1,In vitro percent permeability into rat ileum; Range is 2-5,,BAO_0000218,,Rattus norvegicus,,Intermediate,15286,,N,1,CHEMBL631872,,,
12228,1,In vitro percent permeability into rat ileum; Range is 23-42,Ileum,BAO_0000221,,,,Autocuration,15286,,U,0,CHEMBL875775,,2116.0,
12229,1,In vitro percent permeability into rat ileum; Range is 28-36,,BAO_0000218,,Rattus norvegicus,,Intermediate,15286,,N,1,CHEMBL631873,,,
12230,1,In vitro percent permeability into rat ileum; Range is 29-35,,BAO_0000218,,Rattus norvegicus,,Intermediate,15286,,N,1,CHEMBL631874,,,
12231,1,In vitro percent permeability into rat ileum; Range is 46-66,,BAO_0000218,,Rattus norvegicus,,Intermediate,15286,,N,1,CHEMBL631875,,,
12232,1,In vitro percent permeability into rat ileum; Range is 50-68,,BAO_0000218,,Rattus norvegicus,,Intermediate,15286,,N,1,CHEMBL631876,,,
12233,1,In vitro percent permeability into rat ileum; Range is 78-81,,BAO_0000218,,Rattus norvegicus,,Intermediate,15286,,N,1,CHEMBL631877,,,
12234,1,In vitro percent permeability into rat ileum; insol indicates not soluble in aqueous buffer,,BAO_0000218,,Rattus norvegicus,,Intermediate,15286,,N,1,CHEMBL631878,,,
12235,1,In vitro percent permeability into rat ileum; nd indicates not detected,,BAO_0000218,,Rattus norvegicus,,Intermediate,15286,,N,1,CHEMBL631879,,,
12236,1,In vitro percent permeability into rat ileum; nt indicates not detected,,BAO_0000218,,Rattus norvegicus,,Intermediate,15286,,N,1,CHEMBL631880,,,
12237,1,In vitro percent permeability into rat ileum; nt indicates not tested,,BAO_0000218,,Rattus norvegicus,,Intermediate,15286,,N,1,CHEMBL631881,,,
12238,1,Compound was tested for oral absorption in bile-duct cannulated rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,13770,,N,1,CHEMBL631882,,,
12239,1,Compound was tested for oral absorption in bile-duct cannulated rats.,,BAO_0000218,,Rattus norvegicus,,Intermediate,13770,,N,1,CHEMBL630749,,,
12240,1,Oral absorption using Caco-2 cell monolayers.,,BAO_0000218,,Homo sapiens,,Intermediate,5202,,N,1,CHEMBL630750,,,
12241,1,Percent of the drug absorbed after administration to humans was determined,,BAO_0000218,,Homo sapiens,,Intermediate,14920,,N,1,CHEMBL630253,,,
12242,1,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 120 minutes.,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14103,,N,1,CHEMBL630254,,1969.0,
12243,1,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 15 minutes.,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14103,,N,1,CHEMBL630255,,1969.0,
12244,1,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 180 minutes.,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14103,,N,1,CHEMBL630256,,1969.0,
12245,1,"Biodistribution inl liver of mature female Dawley rat after 1h, expressed as percent injected dose/g",Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,N,1,CHEMBL875781,,2107.0,
12246,1,"Biodistribution inl liver of mature female Dawley rat after 30min, expressed as percent injected dose/g",Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,N,1,CHEMBL630257,,2107.0,
12247,1,"Biodistribution inl liver of mature female Dawley rat after 45min, expressed as percent injected dose/g",Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,N,1,CHEMBL630258,,2107.0,
12248,1,"Distribution of radioactivity in rat blood after 2 minutes of iv administration at the dose of 10.05-0.07 gram of tissue, expressed as percent injected dose per gram of tissue",,BAO_0000218,,Rattus norvegicus,,Intermediate,15807,,N,1,CHEMBL630259,,,
12249,1,"Distribution of radioactivity in rat striatum after 5 minutes of iv administration at the dose of 1.89-3.73 g of tissue, expressed as percent injected dose per gram of tissue",Striatum,BAO_0000218,,Rattus norvegicus,,Intermediate,15807,,N,1,CHEMBL630260,,2435.0,
12250,1,"Distribution of radioactivity in rat striatum after 5 minutes of iv administration at the dose of 3.44-4.80 g of tissue, expressed as percent injected dose per gram of tissue",Striatum,BAO_0000218,,Rattus norvegicus,,Intermediate,15807,,N,1,CHEMBL630261,,2435.0,
12251,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat and 5-alpha-DHT was reported,,BAO_0000218,,Rattus norvegicus,,Intermediate,14950,,N,1,CHEMBL630262,,,
12252,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat blood at 1 hour time,,BAO_0000218,,Rattus norvegicus,,Intermediate,14950,,N,1,CHEMBL630263,,,
12253,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat blood at 2 hours time,,BAO_0000218,,Rattus norvegicus,,Intermediate,14950,,N,1,CHEMBL630264,,,
12254,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat fat at 0.5 hours time,,BAO_0000218,,Rattus norvegicus,,Intermediate,14950,,N,1,CHEMBL630265,,,
12255,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat fat at 4 hours time,,BAO_0000218,,Rattus norvegicus,,Intermediate,14950,,N,1,CHEMBL630266,,,
12256,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat kidney at 0.5 hours time,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,14950,,N,1,CHEMBL630267,,2113.0,
12257,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat kidney at 4 hours time,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,14950,,N,1,CHEMBL630268,,2113.0,
12258,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat liver at 1 hour time,,BAO_0000218,,Rattus norvegicus,,Intermediate,14950,,N,1,CHEMBL630269,,,
12259,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat liver at 2 hours time,,BAO_0000218,,Rattus norvegicus,,Intermediate,14950,,N,1,CHEMBL630270,,,
12260,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat lung at 1 hour time,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,14950,,N,1,CHEMBL630141,,2048.0,
12261,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat lung at 2 hours time,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,14950,,N,1,CHEMBL630142,,2048.0,
12262,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat muscle at 0.5 hours time,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,14950,,N,1,CHEMBL630143,,2385.0,
12263,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat muscle at 4 hours time,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,14950,,N,1,CHEMBL630144,,2385.0,
12264,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate at 0.5 hours time,Prostate gland,BAO_0000218,,Rattus norvegicus,,Intermediate,14950,,N,1,CHEMBL630145,,2367.0,
12265,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate at 4 hours time,Prostate gland,BAO_0000218,,Rattus norvegicus,,Intermediate,14950,,N,1,CHEMBL630146,,2367.0,
12266,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood,,BAO_0000218,,Rattus norvegicus,,Intermediate,14950,,N,1,CHEMBL630147,,,
12267,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood at 1 hours time,,BAO_0000218,,Rattus norvegicus,,Intermediate,14950,,N,1,CHEMBL630148,,,
12268,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood at 2 hours time,,BAO_0000218,,Rattus norvegicus,,Intermediate,14950,,N,1,CHEMBL630149,,,
12269,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat spleen at 1 hour time,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,14950,,N,1,CHEMBL630150,,2106.0,
12270,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat spleen at 2 hours time,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,14950,,N,1,CHEMBL630151,,2106.0,
12271,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat thyroid at 0.5 hours time,Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,14950,,N,1,CHEMBL632031,,2046.0,
12272,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat thyroid at 4 hours time,Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,14950,,N,1,CHEMBL632032,,2046.0,
12273,1,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat fat at 1 hour time,,BAO_0000218,,Rattus norvegicus,,Intermediate,14950,,N,1,CHEMBL632033,,,
12274,1,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat kidney at 1 hour time,,BAO_0000218,,Rattus norvegicus,,Intermediate,14950,,N,1,CHEMBL632034,,,
12275,1,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat muscle at 1 hour time,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,14950,,N,1,CHEMBL632035,,2385.0,
12276,1,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat prostrateat 1 hour time,,BAO_0000218,,Rattus norvegicus,,Intermediate,14950,,N,1,CHEMBL632036,,,
12277,1,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat thyroid at 1 hour time,Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,14950,,N,1,CHEMBL632037,,2046.0,
12278,1,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 10 minutes,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8631,,N,1,CHEMBL632038,,178.0,
12279,1,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 15 minutes,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8631,,N,1,CHEMBL632039,,178.0,
12280,1,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 20 minutes,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8631,,N,1,CHEMBL632040,,178.0,
12281,1,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 30 minutes,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8631,,N,1,CHEMBL632041,,178.0,
12282,1,"Concentration of compound in blood of dog 2, after administering intravenously",Blood,BAO_0000218,,Canis lupus familiaris,,Intermediate,9614,,N,1,CHEMBL632042,,178.0,
12283,1,"Concentration of compound in left ventricle of dog 1, after administering intravenously",,BAO_0000218,,Canis lupus familiaris,,Intermediate,9614,,N,1,CHEMBL632043,,,
12284,1,"Concentration of compound in left ventricle of dog 2, after administering intravenously",,BAO_0000218,,Canis lupus familiaris,,Intermediate,9614,,N,1,CHEMBL632044,,,
12285,1,"Concentration of compound in liver of dog 1, after administering intravenously",Liver,BAO_0000218,,Canis lupus familiaris,,Intermediate,9614,,N,1,CHEMBL632045,,2107.0,
12286,1,"Concentration of compound in liver of dog 2, after administering intravenously",Liver,BAO_0000218,,Canis lupus familiaris,,Intermediate,9614,,N,1,CHEMBL632046,,2107.0,
12287,1,"Concentration of compound in lung of dog 1, after administering intravenously",Lung,BAO_0000218,,Canis lupus familiaris,,Intermediate,9614,,N,1,CHEMBL632047,,2048.0,
12288,1,"Concentration of compound in lung of dog 2, after administering intravenously",Lung,BAO_0000218,,Canis lupus familiaris,,Intermediate,9614,,N,1,CHEMBL632048,,2048.0,
12289,1,"Concentration of compound in muscle of dog 1, after administering intravenously",Muscle tissue,BAO_0000218,,Canis lupus familiaris,,Intermediate,9614,,N,1,CHEMBL632049,,2385.0,
12290,1,"Concentration of compound in muscle of dog 2, after administering intravenously",Muscle tissue,BAO_0000218,,Canis lupus familiaris,,Intermediate,9614,,N,1,CHEMBL876418,,2385.0,
12291,1,"Concentration of compound in spleen of dog 1,after administering intravenously",Spleen,BAO_0000218,,Canis lupus familiaris,,Intermediate,9614,,N,1,CHEMBL632050,,2106.0,
12292,1,"Concentration of compound in spleen of dog 2, after administering intravenously",Spleen,BAO_0000218,,Canis lupus familiaris,,Intermediate,9614,,N,1,CHEMBL632051,,2106.0,
12293,1,Concentration of liberated compound in serum after 120 min at the dose of 50 mg/kg (po).,,BAO_0000218,,,,Autocuration,10353,,U,0,CHEMBL632052,,,
12294,1,Concentration of liberated compound in serum after 240 min at the dose of 50 mg/kg (po).,,BAO_0000218,,,,Autocuration,10353,,U,0,CHEMBL632053,,,
12295,1,Concentration of liberated compound in serum after 30 min at the dose of 50 mg/kg (po).,,BAO_0000218,,,,Autocuration,10353,,U,0,CHEMBL632054,,,
12296,1,Concentration of liberated compound in serum after 30 min at the dose of 50 mg/kg (po).,,BAO_0000218,,,,Autocuration,10353,,U,0,CHEMBL632055,,,
12297,1,Concentration of liberated compound in serum after 60 min at the dose of 50 mg/kg (po).,,BAO_0000218,,,,Autocuration,10353,,U,0,CHEMBL631181,,,
12298,1,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous after 1.5 hr,,BAO_0000218,,,,Autocuration,9196,,U,0,CHEMBL631182,,,
12299,1,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,,BAO_0000218,,,,Autocuration,9196,,U,0,CHEMBL631183,,,
12300,1,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,,BAO_0000218,,,,Autocuration,9196,,U,0,CHEMBL631184,,,
12301,1,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,,BAO_0000218,,,,Autocuration,9196,,U,0,CHEMBL629774,,,
12302,1,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,,BAO_0000218,,,,Autocuration,9196,,U,0,CHEMBL629775,,,
12303,1,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,,BAO_0000218,,,,Autocuration,9196,,U,0,CHEMBL876549,,,
12304,1,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,,BAO_0000218,,,,Autocuration,9196,,U,0,CHEMBL628172,,,
12305,1,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,,BAO_0000218,,,,Autocuration,9196,,U,0,CHEMBL628173,,,
12306,1,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous after 1.5 hr,,BAO_0000218,,,,Autocuration,9196,,U,0,CHEMBL628174,,,
12307,1,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage a after 4.0 hr,,BAO_0000218,,,,Autocuration,9196,,U,0,CHEMBL628175,,,
12308,1,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,,BAO_0000218,,,,Autocuration,9196,,U,0,CHEMBL628176,,,
12309,1,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,,BAO_0000218,,,,Autocuration,9196,,U,0,CHEMBL628177,,,
12310,1,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,,BAO_0000218,,,,Autocuration,9196,,U,0,CHEMBL628178,,,
12311,1,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,,BAO_0000218,,,,Autocuration,9196,,U,0,CHEMBL628179,,,
12312,1,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg i intravenous dosage after 1.0 hr; insufficient gastric juice produced,,BAO_0000218,,,,Autocuration,9196,,U,0,CHEMBL628180,,,
12313,1,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage a after 2.5 hr,,BAO_0000218,,,,Autocuration,9196,,U,0,CHEMBL628181,,,
12314,1,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,,BAO_0000218,,,,Autocuration,9196,,U,0,CHEMBL628182,,,
12315,1,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,,BAO_0000218,,,,Autocuration,9196,,U,0,CHEMBL628183,,,
12316,1,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr; ND means not determined,,BAO_0000218,,,,Autocuration,9196,,U,0,CHEMBL628184,,,
12317,1,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,,BAO_0000218,,,,Autocuration,9196,,U,0,CHEMBL628185,,,
12318,1,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,,BAO_0000218,,,,Autocuration,9196,,U,0,CHEMBL875617,,,
12319,1,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr; ND means not determined,,BAO_0000218,,,,Autocuration,9196,,U,0,CHEMBL628186,,,
12320,1,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,,BAO_0000218,,,,Autocuration,9196,,U,0,CHEMBL628187,,,
12321,1,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,,BAO_0000218,,,,Autocuration,9196,,U,0,CHEMBL628188,,,
12322,1,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr,,BAO_0000218,,,,Autocuration,9196,,U,0,CHEMBL628189,,,
12323,1,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr; ND means not determined,,BAO_0000218,,,,Autocuration,9196,,U,0,CHEMBL628190,,,
12324,1,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,,BAO_0000218,,,,Autocuration,9196,,U,0,CHEMBL628191,,,
12325,1,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr; ND means not determined,,BAO_0000218,,,,Autocuration,9196,,U,0,CHEMBL626513,,,
12326,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 19-24",Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL626514,,2046.0,
12327,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 26-40",Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL626515,,2046.0,
12328,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 29-44",Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL626516,,2046.0,
12329,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 32-42",Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL626517,,2046.0,
12330,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 33-60",Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL626518,,2046.0,
12331,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 4-7",Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL626519,,2046.0,
12332,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 13-18",Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL626520,,2046.0,
12333,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 16-32",Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL626521,,2046.0,
12334,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 22-25",Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL626522,,2046.0,
12335,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 26-49",Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL626523,,2046.0,
12336,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 29-36",Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL626524,,2046.0,
12337,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 5-8",Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL626688,,2046.0,
12338,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 26-42",Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL626689,,2046.0,
12339,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 30-53",Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL626690,,2046.0,
12340,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 32-43",Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL626691,,2046.0,
12341,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 35-53",Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL627319,,2046.0,
12342,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 5-12",Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL624052,,2046.0,
12343,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 55-102",Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,N,1,CHEMBL624053,,2046.0,
12344,1,In vivo distribution of the drug in plasma was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,8085,,N,1,CHEMBL624054,,,
12345,1,In vivo distribution of the drug in plasma was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,8085,,N,1,CHEMBL624055,,,
12346,1,In vivo distribution of the drug in plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,8085,,N,1,CHEMBL624056,,,
12347,1,In vivo distribution of the drug in uterus was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,Uterus,BAO_0000218,,Rattus norvegicus,,Intermediate,8085,,N,1,CHEMBL624057,,995.0,
12348,1,In vivo distribution of the drug in uterus was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,Uterus,BAO_0000218,,Rattus norvegicus,,Intermediate,8085,,N,1,CHEMBL622281,,995.0,
12349,1,In vivo distribution of the drug in uterus was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,Uterus,BAO_0000218,,Rattus norvegicus,,Intermediate,8085,,N,1,CHEMBL622282,,995.0,
12350,1,In vivo distribution of the drug in uterus/plasma was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,Uterus,BAO_0000218,,Rattus norvegicus,,Intermediate,8085,,N,1,CHEMBL622283,,995.0,
12351,1,In vivo distribution of the drug in uterus/plasma was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,Uterus,BAO_0000218,,Rattus norvegicus,,Intermediate,8085,,N,1,CHEMBL622284,,995.0,
12352,1,In vivo distribution of the drug in uterus/plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,Uterus,BAO_0000218,,Rattus norvegicus,,Intermediate,8085,,N,1,CHEMBL622285,,995.0,
12353,1,In vivo distribution of the drug in uterus/plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,Uterus,BAO_0000218,,Rattus norvegicus,,Intermediate,8085,,N,1,CHEMBL622286,,995.0,
12354,1,Distribution coefficient (D %) between octanol and buffer of pH 7.4,,BAO_0000100,,,,Autocuration,7657,,U,0,CHEMBL622287,,,
12355,1,Partition coefficient (logD7.4),,BAO_0000218,,Mus musculus,,Intermediate,8935,,N,1,CHEMBL622288,,,
12356,1,"Percentage of radioactivity in P1 subregion in mouse brain that contains nuclei and cell debris, after Jugular Vein Injection",,BAO_0000218,,Mus musculus,,Intermediate,13792,,N,1,CHEMBL622289,,,
12357,1,"Percentage of radioactivity in P2 subregion in mouse brain that contains myelin fragments, synaptosomes (pinched-nerve endings), and mitochondria after Jugular Vein Injection",Brain,BAO_0000218,,Mus musculus,,Intermediate,13792,,N,1,CHEMBL622290,,955.0,
12358,1,Percentage of radioactivity in P3 subregion in mouse brain that contains microsomal fraction after Jugular Vein Injection,,BAO_0000218,,Mus musculus,,Intermediate,13792,,N,1,CHEMBL622291,,,
12359,1,Percentage of radioactivity in S3 which is the soluble fraction in mouse brain after Jugular Vein Injection,Brain,BAO_0000218,,Mus musculus,,Intermediate,13792,,N,1,CHEMBL622292,,955.0,
12360,1,"Percentage of total protein recovered in P1 subregion in mouse brain that contains nuclei and cell debris, after Jugular Vein Injection",,BAO_0000218,,Mus musculus,,Intermediate,13792,,N,1,CHEMBL622293,,,
12361,1,"Percentage of total protein recovered in P2 subregion in mouse brain that contains myelin fragments, synaptosomes (pinched-nerve endings), and mitochondria after Jugular Vein Injection",Brain,BAO_0000218,,Mus musculus,,Intermediate,13792,,N,1,CHEMBL622294,,955.0,
12362,1,Percentage of total protein recovered in P3 subregion in mouse brain that contains microsomal fraction after Jugular Vein Injection,,BAO_0000218,,Mus musculus,,Intermediate,13792,,N,1,CHEMBL622295,,,
12363,1,Percentage of total protein recovered in S3 which is the soluble fraction in mouse brain after Jugular Vein Injection,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,13792,,N,1,CHEMBL622296,,955.0,
12364,1,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 2 minutes.,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14103,,N,1,CHEMBL874409,,1969.0,
12365,1,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 240 minutes.,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14103,,N,1,CHEMBL622297,,1969.0,
12366,1,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 30 minutes.,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14103,,N,1,CHEMBL622298,,1969.0,
12367,1,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 45 minutes.,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14103,,N,1,CHEMBL622299,,1969.0,
12368,1,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 5 minutes.,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14103,,N,1,CHEMBL622300,,1969.0,
12369,1,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 60 minutes.,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14103,,N,1,CHEMBL622301,,1969.0,
12370,1,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 90 minutes.,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14103,,N,1,CHEMBL622302,,1969.0,
12371,1,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 120 minutes.,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14103,,N,1,CHEMBL622303,,1969.0,
12372,1,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 15 minutes.,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14103,,N,1,CHEMBL622304,,1969.0,
12373,1,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 15 minutes;nd=not determined,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14103,,N,1,CHEMBL622305,,1969.0,
12374,1,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 180 minutes.,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14103,,N,1,CHEMBL622306,,1969.0,
12375,1,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 2 minutes;nd=not determined,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14103,,N,1,CHEMBL626864,,1969.0,
12376,1,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 240 minutes.,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14103,,N,1,CHEMBL626865,,1969.0,
12377,1,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 240 minutes;nd=not determined,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14103,,N,1,CHEMBL626866,,1969.0,
12378,1,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 30 minutes.,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14103,,N,1,CHEMBL626867,,1969.0,
12379,1,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 45 minutes.,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14103,,N,1,CHEMBL626868,,1969.0,
12380,1,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 45 minutes;nd=not determined,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14103,,N,1,CHEMBL626869,,1969.0,
12381,1,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 5 minutes.,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14103,,N,1,CHEMBL626870,,1969.0,
12382,1,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 5 minutes;nd=not determined,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14103,,N,1,CHEMBL626871,,1969.0,
12383,1,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 60 minutes.,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14103,,N,1,CHEMBL626872,,1969.0,
12384,1,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 90 minutes.,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14103,,N,1,CHEMBL632185,,1969.0,
12385,1,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 90 minutes;nd=not determined,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14103,,N,1,CHEMBL632186,,1969.0,
12386,1,Amount of acetic acid produced by the compound,,BAO_0000019,,,,Autocuration,12904,,U,0,CHEMBL629310,,,
12387,1,Apparent first-order rate of solvolysis for the bipinnatin-A(A4) was determined,,BAO_0000019,,,,Autocuration,12904,,U,0,CHEMBL629311,,,
12388,1,Log of (Cbrain/Cblood) in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,9663,,N,1,CHEMBL629312,,,
12389,1,Compound in absence of MPM cell homogenate at pH 3 to isolate compound 4 (ng),,BAO_0000221,,,,Autocuration,7652,,U,0,CHEMBL629313,,,
12390,1,Compound in absence of MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),,BAO_0000221,,,,Autocuration,7652,,U,0,CHEMBL629314,,,
12391,1,Compound in absence of MPM cell homogenate at pH 7 to isolate compound 4 (ng),,BAO_0000221,,,,Autocuration,7652,,U,0,CHEMBL629315,,,
12392,1,Compound in presence of MPM cells and in absence of inactivator at pH 8 to isolate compound 4 (ng),,BAO_0000219,,,,Autocuration,7652,,U,0,CHEMBL629316,,,
12393,1,Compound treated in absence of MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),,BAO_0000221,,,,Autocuration,7652,,U,0,CHEMBL629317,,,
12394,1,Compound treated with MPM cell homogenate at pH 3 to isolate compound 4 (ng),,BAO_0000019,,,,Autocuration,7652,,U,0,CHEMBL629318,,,
12395,1,Compound treated with MPM cell homogenate at pH 3.5 to isolate compound 4 (ng),,BAO_0000019,,,,Autocuration,7652,,U,0,CHEMBL877497,,,
12396,1,Compound treated with MPM cell homogenate at pH 4 to isolate compound 4 (ng),,BAO_0000019,,,,Autocuration,7652,,U,0,CHEMBL629319,,,
12397,1,Compound treated with MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),,BAO_0000019,,,,Autocuration,7652,,U,0,CHEMBL629320,,,
12398,1,Compound treated with MPM cell homogenate at pH 5 to isolate compound 4 (ng),,BAO_0000019,,,,Autocuration,7652,,U,0,CHEMBL629496,,,
12399,1,Compound treated with MPM cell homogenate at pH 5.5 to isolate compound 4 (ng),,BAO_0000019,,,,Autocuration,7652,,U,0,CHEMBL629497,,,
12400,1,Compound treated with MPM cell homogenate at pH 6 to isolate compound 4 (ng),,BAO_0000019,,,,Autocuration,7652,,U,0,CHEMBL629498,,,
12401,1,Compound treated with MPM cell homogenate at pH 6.5 to isolate compound 4 (ng),,BAO_0000019,,,,Autocuration,7652,,U,0,CHEMBL629499,,,
12402,1,Compound treated with MPM cell homogenate at pH 7 to isolate compound 4 (ng),,BAO_0000019,,,,Autocuration,7652,,U,0,CHEMBL629500,,,
12403,1,Compound treated with MPM cell homogenate at pH 7.5 to isolate compound 4 (ng),,BAO_0000019,,,,Autocuration,7652,,U,0,CHEMBL629501,,,
12404,1,Compound treated with MPM cell homogenate at pH 8 to isolate compound 4 (ng),,BAO_0000019,,,,Autocuration,7652,,U,0,CHEMBL629502,,,
12405,1,Compound was evaluated for its urinary recovery after oral administration (100 mg) to Beagle dogs,,BAO_0000218,,,,Autocuration,8267,In vivo,U,0,CHEMBL629503,,,
12406,1,Compound was evaluated for its urinary recovery after oral administration (200 mg) to Beagle dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,8267,,N,1,CHEMBL629504,,,
12407,1,Compound was evaluated for the rate of degradation by Carboxypeptidase A.,,BAO_0000019,,,,Autocuration,14479,,U,0,CHEMBL629505,,,
12408,1,Compound was evaluated for total body clearance,,BAO_0000019,,,,Autocuration,17515,,U,0,CHEMBL629506,,,
12409,1,Compound was evaluated for volume of distribution at steady state,,BAO_0000019,,,,Autocuration,17515,,U,0,CHEMBL629507,,,
12410,1,Compound was tested for hydrolysis by acetylcholinesterase and the kinetic constant KOH- was reported.,,BAO_0000019,,,,Autocuration,8142,,U,0,CHEMBL877498,,,
12411,1,Percentage of the diamine which is monoprotonated at pH 7.4,,BAO_0000019,,,,Autocuration,14849,,U,0,CHEMBL629508,,,
12412,1,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells,,BAO_0000019,,,,Autocuration,7653,,U,0,CHEMBL629509,,,
12413,1,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 5 minutes,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8631,,N,1,CHEMBL629510,,178.0,
12414,1,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8631,,N,1,CHEMBL629511,,178.0,
12415,1,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8631,,N,1,CHEMBL629512,,178.0,
12416,1,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8631,,N,1,CHEMBL629513,,178.0,
12417,1,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 30 minutes,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8631,,N,1,CHEMBL629514,,178.0,
12418,1,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8631,,N,1,CHEMBL628447,,178.0,
12419,1,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 10 minutes,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8631,,N,1,CHEMBL628448,,178.0,
12420,1,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 15 minutes,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8631,,N,1,CHEMBL628449,,178.0,
12421,1,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 20 minutes,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8631,,N,1,CHEMBL631119,,178.0,
12422,1,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 30 minutes,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8631,,N,1,CHEMBL631120,,178.0,
12423,1,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 5 minutes,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8631,,N,1,CHEMBL631121,,178.0,
12424,1,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 min,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8631,,N,1,CHEMBL874458,,178.0,
12425,1,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8631,,N,1,CHEMBL631122,,178.0,
12426,1,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8631,,N,1,CHEMBL631123,,178.0,
12427,1,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8631,,N,1,CHEMBL631124,,178.0,
12428,1,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8631,,N,1,CHEMBL631125,,178.0,
12429,1,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8631,,N,1,CHEMBL631290,,178.0,
12430,1,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8631,,N,1,CHEMBL631291,,178.0,
12431,1,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8631,,N,1,CHEMBL631292,,178.0,
12432,1,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8631,,N,1,CHEMBL631293,,178.0,
12433,1,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8631,,N,1,CHEMBL631294,,178.0,
12434,1,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8631,,N,1,CHEMBL631295,,178.0,
12435,1,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 30 minutes,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8631,,N,1,CHEMBL631296,,178.0,
12436,1,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8631,,N,1,CHEMBL631297,,178.0,
12437,1,Maximum biodistribution (Bmax) was determined.,,BAO_0000218,,,,Autocuration,10263,,U,0,CHEMBL631298,,,
12438,1,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 1.5625 (mg/kg) intravenous dose in 6 mice,,BAO_0000218,,Mus musculus,,Intermediate,12364,,N,1,CHEMBL631299,,,
12439,1,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 10 (mg/kg) intravenous dose in 6 mice,,BAO_0000218,,Mus musculus,,Intermediate,12364,,N,1,CHEMBL631300,,,
12440,1,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 3.125 (mg/kg) intravenous dose in 6 mice,,BAO_0000218,,Mus musculus,,Intermediate,12364,,N,1,CHEMBL631301,,,
12441,1,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 6.25 (mg/kg) intravenous dose in 6 mice,,BAO_0000218,,Mus musculus,,Intermediate,12364,,N,1,CHEMBL630291,,,
12442,1,Brain concentration after 0.25 hr at a dose of 10 mg/kg when administered intraperitoneally,,BAO_0000218,,,,Autocuration,14793,,U,0,CHEMBL630292,,,
12443,1,Brain concentration after 0.25 h at a dose of 10 mg/kg when administered intravenously,,BAO_0000218,,,,Autocuration,14793,,U,0,CHEMBL630293,,,
12444,1,Brain concentration after 0.5 h at a dose of 100 mg/kg when administered perorally,,BAO_0000218,,,,Autocuration,14793,,U,0,CHEMBL630294,,,
12445,1,Brain concentration after 0.5 h at a dose of 10 mg/kg when administered intraperitoneally,,BAO_0000218,,,,Autocuration,14793,,U,0,CHEMBL630295,,,
12446,1,Brain concentration after 0.5 hr at a dose of 10 mg/kg when administered intravenously,,BAO_0000218,,,,Autocuration,14793,,U,0,CHEMBL630296,,,
12447,1,Brain concentration after 0.5 hr at a dose of 10 mg/kg when administered perorally,,BAO_0000218,,,,Autocuration,14793,,U,0,CHEMBL626782,,,
12448,1,Brain concentration after 1 hr at a dose of 100 mg/kg when administered perorally,,BAO_0000218,,,,Autocuration,14793,,U,0,CHEMBL626783,,,
12449,1,Brain concentration after 1 hr at a dose of 10 mg/kg when administered intraperitoneally,,BAO_0000218,,,,Autocuration,14793,,U,0,CHEMBL626784,,,
12450,1,Brain concentration after 1 hr at a dose of 10 mg/kg when administered intravenously,,BAO_0000218,,,,Autocuration,14793,,U,0,CHEMBL626785,,,
12451,1,Brain concentration after 1 hr at a dose of 10 mg/kg when administered perorally,,BAO_0000218,,,,Autocuration,14793,,U,0,CHEMBL626786,,,
12452,1,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,,BAO_0000218,,,,Autocuration,9196,,U,0,CHEMBL626787,,,
12453,1,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr; ND means not determined,,BAO_0000218,,,,Autocuration,9196,,U,0,CHEMBL626788,,,
12454,1,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,,BAO_0000218,,,,Autocuration,9196,,U,0,CHEMBL625927,,,
12455,1,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8374,,N,1,CHEMBL625928,,178.0,
12456,1,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8374,,N,1,CHEMBL625929,,178.0,
12457,1,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected.,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8374,,N,1,CHEMBL625930,,178.0,
12458,1,"Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound, Compound was found to be in trace amount.",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8374,,N,1,CHEMBL625931,,178.0,
12459,1,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound; ND is Not Detected.,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8374,,N,1,CHEMBL627230,,178.0,
12460,1,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8374,,N,1,CHEMBL627231,,178.0,
12461,1,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8374,,N,1,CHEMBL627232,,178.0,
12462,1,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected.,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8374,,N,1,CHEMBL627233,,178.0,
12463,1,Concentration 5a detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8374,,N,1,CHEMBL875470,,178.0,
12464,1,Concentration 5a detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8374,,N,1,CHEMBL627234,,178.0,
12465,1,Concentration 5b detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8374,,N,1,CHEMBL627235,,178.0,
12466,1,Concentration 5b detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8374,,N,1,CHEMBL627236,,178.0,
12467,1,Concentration 5c detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8374,,N,1,CHEMBL627237,,178.0,
12468,1,Concentration 5c detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8374,,N,1,CHEMBL627238,,178.0,
12469,1,Concentration 5d detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8374,,N,1,CHEMBL627239,,178.0,
12470,1,Concentration 5d detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8374,,N,1,CHEMBL627240,,178.0,
12471,1,Concentration 5e detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8374,,N,1,CHEMBL627241,,178.0,
12472,1,Concentration 5e detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8374,,N,1,CHEMBL627242,,178.0,
12473,1,Concentration 5f detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound; ND is Not Detected,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8374,,N,1,CHEMBL627243,,178.0,
12474,1,Concentration 5f detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8374,,N,1,CHEMBL627244,,178.0,
12475,1,Concentration 6a detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8374,,N,1,CHEMBL627245,,178.0,
12476,1,Concentration 6a detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8374,,N,1,CHEMBL627246,,178.0,
12477,1,Concentration 6c detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8374,,N,1,CHEMBL627247,,178.0,
12478,1,Concentration 6c detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8374,,N,1,CHEMBL627248,,178.0,
12479,1,Concentration 6d detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8374,,N,1,CHEMBL627249,,178.0,
12480,1,Concentration 6d detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8374,,N,1,CHEMBL625569,,178.0,
12481,1,Concentration 6e detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8374,,N,1,CHEMBL625570,,178.0,
12482,1,Concentration 6e detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8374,,N,1,CHEMBL625571,,178.0,
12483,1,Concentration 6f detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8374,,N,1,CHEMBL625572,,178.0,
12484,1,Concentration 6f detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8374,,N,1,CHEMBL625573,,178.0,
12485,1,Concentration detected in blood of rat 1 hr after an oral dose of 200 mg/kg,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8374,,N,1,CHEMBL625574,,178.0,
12486,1,Concentration detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8374,,N,1,CHEMBL626245,,178.0,
12487,1,Concentration detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8374,,N,1,CHEMBL626246,,178.0,
12488,1,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,,BAO_0000218,,,,Autocuration,9196,,U,0,CHEMBL626247,,,
12489,1,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,,BAO_0000218,,,,Autocuration,9196,,U,0,CHEMBL626248,,,
12490,1,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.5 hr,,BAO_0000218,,,,Autocuration,9196,,U,0,CHEMBL626249,,,
12491,1,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,,BAO_0000218,,,,Autocuration,9196,,U,0,CHEMBL626420,,,
12492,1,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,,BAO_0000218,,,,Autocuration,9196,,U,0,CHEMBL626421,,,
12493,1,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,,BAO_0000218,,,,Autocuration,9196,,U,0,CHEMBL626422,,,
12494,1,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,,BAO_0000218,,,,Autocuration,9196,,U,0,CHEMBL626423,,,
12495,1,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,,BAO_0000218,,,,Autocuration,9196,,U,0,CHEMBL626424,,,
12496,1,Volume of distribution in Beagles dog at a dose of 1 mg/kg given intravenously,,BAO_0000218,,Canis lupus familiaris,,Intermediate,12023,,N,1,CHEMBL626425,,,
12497,1,Volume of distribution in CD rat at a dose of 5 mg/kg given intravenously,,BAO_0000218,,Rattus norvegicus,,Intermediate,12023,,N,1,CHEMBL875476,,,
12498,1,Volume of distribution in Cynomolgus monkey at a dose of 5 mg/kg given intravenously,,BAO_0000218,,Macaca fascicularis,,Intermediate,12023,,N,1,CHEMBL626426,,,
12499,1,Distribution coefficient and iron(III) complex was measured at an aqueous phase buffered at pH 7.4 and octanol,,BAO_0000100,,,,Autocuration,10580,,U,0,CHEMBL626427,,,
12500,1,Distribution coefficient was measured at an aqueous phase buffered at pH 7.4 and octanol,,BAO_0000100,,,,Autocuration,10580,,U,0,CHEMBL626428,,,
12501,1,Iron clearance was stimulated by the compound was expressed as % distribution of excreted Fe in bile by subcutaneous dose of 150 umol/kg,,BAO_0000019,,,,Autocuration,16032,,U,0,CHEMBL626429,,,
12502,1,Iron clearance was stimulated by the compound was expressed as % distribution of excreted Fe in urine by subcutaneous dose of 150 umol/kg,Urine,BAO_0000019,,,,Autocuration,16032,,U,0,CHEMBL625025,,1088.0,
12503,1,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL625026,,178.0,
12504,1,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL625027,,178.0,
12505,1,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL874410,,178.0,
12506,1,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL625028,,178.0,
12507,1,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL625029,,178.0,
12508,1,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL625030,,178.0,
12509,1,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL625031,,178.0,
12510,1,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL625032,,178.0,
12511,1,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL625033,,178.0,
12512,1,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL625034,,178.0,
12513,1,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL624872,,948.0,
12514,1,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL624873,,948.0,
12515,1,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL624874,,948.0,
12516,1,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL624875,,948.0,
12517,1,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL624876,,948.0,
12518,1,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL624877,,948.0,
12519,1,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL624878,,948.0,
12520,1,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL624879,,948.0,
12521,1,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL624880,,948.0,
12522,1,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 10 min (radiolabeled with [125I]-,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL624881,,948.0,
12523,1,"Concentration was measured in heart tissue of unfasted Fischer 344 rats, administered intravenous, after 5 minute (radiolabeled with [125I]-",Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL624882,,948.0,
12524,1,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL624883,,2113.0,
12525,1,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL624884,,2113.0,
12526,1,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL624885,,2113.0,
12527,1,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL624886,,2113.0,
12528,1,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL624887,,2113.0,
12529,1,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL624888,,2113.0,
12530,1,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL624889,,2113.0,
12531,1,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL624890,,2113.0,
12532,1,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL621964,,2113.0,
12533,1,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL621965,,2113.0,
12534,1,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL621966,,2107.0,
12535,1,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL621967,,2107.0,
12536,1,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL622164,,2107.0,
12537,1,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid insoluble (nucleic acids),,BAO_0000019,,,,Autocuration,7653,,U,0,CHEMBL623097,,,
12538,1,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid insoluble (protein),,BAO_0000019,,,,Autocuration,7653,,U,0,CHEMBL623098,,,
12539,1,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid soluble,,BAO_0000019,,,,Autocuration,7653,,U,0,CHEMBL623099,,,
12540,1,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; total uptake,,BAO_0000019,,,,Autocuration,7653,,U,0,CHEMBL623100,,,
12541,1,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated Number of new tumors observed",,BAO_0000218,,Rattus norvegicus,,Intermediate,9104,,N,1,CHEMBL628673,,,
12542,1,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated complete percent remission indicates tumor not palpable.",,BAO_0000218,,Rattus norvegicus,,Intermediate,9104,,N,1,CHEMBL628674,,,
12543,1,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated number of tumors at the beginning of the test.",,BAO_0000218,,Rattus norvegicus,,Intermediate,9104,,N,1,CHEMBL628675,,,
12544,1,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated of percent static tumors indicates size of tumor 51-150% of the initial size",,BAO_0000218,,Rattus norvegicus,,Intermediate,9104,,N,1,CHEMBL627644,,,
12545,1,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated partial percent remission indicates reduction of initial tumor size <=50%.",,BAO_0000218,,Rattus norvegicus,,Intermediate,9104,,N,1,CHEMBL627645,,,
12546,1,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent progress in tumor size indicates >150% of the initial size",,BAO_0000218,,Rattus norvegicus,,Intermediate,9104,,N,1,CHEMBL627646,,,
12547,1,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent static tumors indicates size of tumor 51-150% of the initial size",,BAO_0000218,,Rattus norvegicus,,Intermediate,9104,,N,1,CHEMBL627647,,,
12548,1,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent tumor area measured as the average on the 28th day of therapy.",,BAO_0000218,,Rattus norvegicus,,Intermediate,9104,,N,1,CHEMBL627648,,,
12549,1,Free level in rat plasma,,BAO_0000218,,Rattus norvegicus,,Intermediate,12902,,N,1,CHEMBL627649,,,
12550,1,Level reaching in blood plasma of rat or human was determined,,BAO_0000019,,,,Autocuration,6614,,U,0,CHEMBL628313,,,
12551,1,Log (Cbrain/Cblood) in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,9663,,N,1,CHEMBL628314,,,
12552,1,Mean percentage of compound transport through P-glycoprotein; expressed as p-glycoprotein affinity,,BAO_0000019,,,,Autocuration,17658,,U,0,CHEMBL628315,,,
12553,1,Mean percentage of compound transport through membrane; expressed as membrane transport,,BAO_0000019,,,,Autocuration,17658,,U,0,CHEMBL628316,,,
12554,1,Metabolic breakdown to the o-sulfate of p-chloroaniline (2-amino-5-chlorophenyl sulfate) by giving 100 mg/kg oral doses of the compound,,BAO_0000218,,,,Autocuration,14314,,U,0,CHEMBL628317,,,
12555,1,Michaelis-Menten constant was measured in the inactivation of HPK; Km x 10 e5,,BAO_0000019,,,,Autocuration,7385,,U,0,CHEMBL628473,,,
12556,1,"Michaelis-Menten constant was measured in the inactivation of HPK; Km x 10 e5, ND=Not determined",,BAO_0000019,,,,Autocuration,7385,,U,0,CHEMBL628474,,,
12557,1,Michaelis-Menten constant was measured in the inactivation of trypsin; Km x 10 e5,,BAO_0000019,,,,Autocuration,7385,,U,0,CHEMBL628475,,,
12558,1,Net water uptake by a carrier mediated transport (%cm) mechanism,,BAO_0000019,,,,Autocuration,1329,,U,0,CHEMBL628476,,,
12559,1,Peak concentration was determined in portal circulation after intraduodenal dose of 10 mg/kg in monkey,,BAO_0000218,,Simiiformes,,Autocuration,12187,,U,0,CHEMBL628477,,,
12560,1,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret,,BAO_0000218,,Mustela putorius furo,,Intermediate,12187,,N,1,CHEMBL628478,,,
12561,1,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret, determined by renin inhibition assay",,BAO_0000218,,Mustela putorius furo,,Intermediate,12187,,N,1,CHEMBL628479,,,
12562,1,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey,,BAO_0000218,,Simiiformes,,Autocuration,12187,,U,0,CHEMBL628480,,,
12563,1,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey, determined by renin inhibition assay",,BAO_0000218,,Simiiformes,,Autocuration,12187,,U,0,CHEMBL628481,,,
12564,1,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,12187,,N,1,CHEMBL628482,,,
12565,1,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",,BAO_0000218,,Rattus norvegicus,,Intermediate,12187,,N,1,CHEMBL628483,,,
12566,1,"Peak plasma concentration at a dose of 10 mg/kg, ip route in rat suspended in carboxymethyl cellulose (CMC);ND is defined as no-data.",Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,9278,,N,1,CHEMBL628484,,1969.0,
12567,1,"Peak plasma concentration at a dose of 100 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,9278,,N,1,CHEMBL628485,,1969.0,
12568,1,"Peak plasma concentration at a dose of 20 mg/kg, oral route in monkey (Macaca fascicularis) suspended in carboxymethyl cellulose (CMC);Range is between (5.5-6)",Plasma,BAO_0000218,,Macaca fascicularis,,Intermediate,9278,,N,1,CHEMBL628486,,1969.0,
12569,1,"Peak plasma concentration at a dose of 200 mg/kg, oral route in human",Plasma,BAO_0000218,,Homo sapiens,,Intermediate,9278,,N,1,CHEMBL628487,,1969.0,
12570,1,"Peak plasma concentration at a dose of 25 mg/kg, ip route in rat suspended in carboxymethyl cellulose (CMC);ND is defined as no-data.",Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,9278,,N,1,CHEMBL628488,,1969.0,
12571,1,"Peak plasma concentration at a dose of 25 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,9278,,N,1,CHEMBL628489,,1969.0,
12572,1,"Peak plasma concentration at a dose of 50 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,9278,,N,1,CHEMBL628490,,1969.0,
12573,1,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using HPLC assay,,BAO_0000218,,Macaca fascicularis,,Intermediate,12186,,N,1,CHEMBL628491,,,
12574,1,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using HPLC assay,,BAO_0000218,,Macaca fascicularis,,Intermediate,12186,,N,1,CHEMBL877507,,,
12575,1,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,,BAO_0000218,,,,Autocuration,12186,,U,0,CHEMBL628492,,,
12576,1,% metabolized in monkey S-9 after 2 hours (10 ug/mL),,BAO_0000019,,Simiiformes,,Autocuration,12041,,U,0,CHEMBL628493,,,
12577,1,% metabolized in monkey S-9 after 2 hours (1 ug/ml),,BAO_0000019,,Simiiformes,,Autocuration,12041,,U,0,CHEMBL628494,,,
12578,1,% metabolized in monkey S-9 after 2 hours (10 ug/ml),,BAO_0000019,,Simiiformes,,Autocuration,12041,,U,0,CHEMBL628495,,,
12579,1,Permeability in Caco-2 assay at 10E-6,,BAO_0000218,,Homo sapiens,,Intermediate,6737,,N,1,CHEMBL628496,,,
12580,1,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in brain,Brain,BAO_0000218,,,,Autocuration,13758,,U,0,CHEMBL628497,,955.0,
12581,1,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in brain,Brain,BAO_0000218,,,,Autocuration,13758,,U,0,CHEMBL628498,,955.0,
12582,1,Plasma protein binding was determined,,BAO_0000019,,,,Autocuration,5676,,U,0,CHEMBL628499,,,
12583,1,Brain concentration after 2 hr at a dose of 100 mg/kg when administered perorally,,BAO_0000218,,,,Autocuration,14793,,U,0,CHEMBL627656,,,
12584,1,Brain concentration after 2 hr at a dose of 10 mg/kg when administered intraperitoneally,,BAO_0000218,,,,Autocuration,14793,,U,0,CHEMBL627657,,,
12585,1,Brain concentration after 2 hr at a dose of 10 mg/kg when administered intravenously,,BAO_0000218,,,,Autocuration,14793,,U,0,CHEMBL626808,,,
12586,1,Brain concentration after 2 hr at a dose of 10 mg/kg when administered perorally,,BAO_0000218,,,,Autocuration,14793,,U,0,CHEMBL626809,,,
12587,1,Brain concentration after 4 hr at a dose of 100 mg/kg when administered perorally,,BAO_0000218,,,,Autocuration,14793,,U,0,CHEMBL626810,,,
12588,1,Brain concentration after 4 hr at a dose of 10 mg/kg when administered intraperitoneally,,BAO_0000218,,,,Autocuration,14793,,U,0,CHEMBL626811,,,
12589,1,Brain concentration after 4 hr at a dose of 10 mg/kg when administered intravenously,,BAO_0000218,,,,Autocuration,14793,,U,0,CHEMBL874465,,,
12590,1,Brain concentration after 4 hr at a dose of 10 mg/kg when administered perorally,,BAO_0000218,,,,Autocuration,14793,,U,0,CHEMBL626812,,,
12591,1,Brain concentration after 6 hr at a dose of 100 mg/kg when administered perorally,,BAO_0000218,,,,Autocuration,14793,,U,0,CHEMBL626813,,,
12592,1,Brain concentration after 6 hr at a dose of 10 mg/kg when administered perorally,,BAO_0000218,,,,Autocuration,14793,,U,0,CHEMBL626814,,,
12593,1,Bullaticin index relates the IC50 values by normalizing to the value of bullatacin for easy comparison.,,BAO_0000019,,,,Autocuration,14000,,U,0,CHEMBL626815,,,
12594,1,Partition coefficient (logP),,BAO_0000019,,,,Autocuration,5948,,U,0,CHEMBL628566,,,
12595,1,Calculated partition coefficient (clogP) (CLOGP3 V3.4),,BAO_0000100,,,,Autocuration,13824,,U,0,CHEMBL628567,,,
12596,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,10778,,U,0,CHEMBL628568,,,
12597,1,C max in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17237,In vivo,N,1,CHEMBL628569,,,
12598,1,C max in guinea pig,,BAO_0000218,,Cavia porcellus,,Intermediate,17237,In vivo,N,1,CHEMBL628570,,,
12599,1,C max value was evaluated,,BAO_0000218,,,,Autocuration,2809,In vivo,U,0,CHEMBL628571,,,
12600,1,Cmax value after oral dose of 0.1 mg//kg,,BAO_0000218,,,,Autocuration,11954,In vivo,U,0,CHEMBL628572,,,
12601,1,Cmax value after oral dose of 0.3 mg/kg,,BAO_0000218,,,,Autocuration,11954,In vivo,U,0,CHEMBL628573,,,
12602,1,Cmax value after oral dose of 1 mg/kg,,BAO_0000218,,,,Autocuration,11954,In vivo,U,0,CHEMBL628574,,,
12603,1,Cmax value after oral dose of 10 mg/kg,,BAO_0000218,,,,Autocuration,11954,In vivo,U,0,CHEMBL628575,,,
12604,1,Cmax value after oral dose of 23.4 mg/kg,,BAO_0000218,,,,Autocuration,11954,In vivo,U,0,CHEMBL628576,,,
12605,1,Cmax value after oral dose of 3 mg/kg,,BAO_0000218,,,,Autocuration,11954,In vivo,U,0,CHEMBL628577,,,
12606,1,Cmax value after oral dose of 3.87 mg/kg,,BAO_0000218,,,,Autocuration,11954,In vivo,U,0,CHEMBL628578,,,
12607,1,Cmax value in female Beagle dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,12768,In vivo,N,1,CHEMBL874466,,,
12608,1,Cmax value in male rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,12768,In vivo,N,1,CHEMBL628579,,,
12609,1,Cmax value in rat plasma when administered 20 mg/kg perorally,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,12780,In vivo,N,1,CHEMBL628580,,1969.0,
12610,1,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,15592,In vivo,N,1,CHEMBL628581,,1969.0,
12611,1,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,15592,In vivo,N,1,CHEMBL628582,,1969.0,
12612,1,Peak concentration of compound at Time = 0 was determined in dog at 5 mg/kg intravenously admn.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17025,,N,1,CHEMBL628583,,,
12613,1,Peak concentration of compound at Time = 0 was determined in monkey at 5 mg/kg intravenously admn.,,BAO_0000218,,Simiiformes,,Autocuration,17025,,U,0,CHEMBL625782,,,
12614,1,Peak concentration of compound at Time = 0 was determined in rabbit at 5 mg/kg intravenously admn.,,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,17025,,N,1,CHEMBL625783,,,
12615,1,Peak concentration of compound at Time = 0 was determined in rat at 5 mg/kg intravenously admn.,,BAO_0000218,,Rattus norvegicus,,Intermediate,17025,,N,1,CHEMBL625784,,,
12616,1,Total plasma concentration at 24 hr at a dose of 10 mg/kg when administered orally to rhesus monkey,Plasma,BAO_0000218,,Macaca mulatta,,Intermediate,4236,,N,1,CHEMBL625785,,1969.0,
12617,1,C5min (nM) value was determined in rats after intravenous dose of 5 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,15791,,N,1,CHEMBL625786,,,
12618,1,C6h was measured as concentration obtained after 6 hr of oral administration in air pouch exudate,,BAO_0000019,,,,Autocuration,11149,,U,0,CHEMBL874467,,,
12619,1,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 )",,BAO_0000218,,Canis lupus familiaris,,Intermediate,15592,,N,1,CHEMBL625787,,,
12620,1,cytotoxicity against HIV protease enzyme.,,BAO_0000218,,Human immunodeficiency virus,,Intermediate,15778,,N,1,CHEMBL625964,,,
12621,1,Apparent clearance in mice after intravenous administration of 105.1 mg/kg of dose,,BAO_0000218,,Mus musculus,,Intermediate,12745,,N,1,CHEMBL625965,,,
12622,1,Apparent clearance in mice after oral administration of 100 mg/kg of dose,,BAO_0000218,,Mus musculus,,Intermediate,12745,,N,1,CHEMBL625966,,,
12623,1,The plasma clearance in dog.,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,13941,In vivo,N,1,CHEMBL625967,,1969.0,
12624,1,The plasma clearance in rat.,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,13941,In vivo,N,1,CHEMBL625968,,1969.0,
12625,1,Clearance from plasma in male Sprague-Dawley rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,16449,In vivo,N,1,CHEMBL625969,,1969.0,
12626,1,Clearance from plasma in male cynomolgus monkeys,Plasma,BAO_0000218,,Macaca fascicularis,,Intermediate,16449,In vivo,N,1,CHEMBL625970,,1969.0,
12627,1,"Clearance of compound (5 mg/kg, intravenously), in dog plasma",Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,14224,In vivo,N,1,CHEMBL625971,,1969.0,
12628,1,Clearance of compound in dog plasma,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,14224,In vivo,N,1,CHEMBL625972,,1969.0,
12629,1,Clearance of compound in human plasma,Plasma,BAO_0000218,,Homo sapiens,,Intermediate,14224,In vivo,N,1,CHEMBL625973,,1969.0,
12630,1,Clearance of compound when administered intravenously as a mixture (five-in-one dose) to a single dog.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,14317,In vivo,N,1,CHEMBL625974,,,
12631,1,Clearance of compound when administered intravenously as an individual dose to a single dog.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,14317,In vivo,N,1,CHEMBL625975,,,
12632,1,"Clearance (10 mg/kg, intravenously) in dog plasma",Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,14224,In vivo,N,1,CHEMBL625976,,1969.0,
12633,1,Clearance value in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17237,In vivo,N,1,CHEMBL625977,,,
12634,1,Clearance value in guinea pig,,BAO_0000218,,Cavia porcellus,,Intermediate,17237,In vivo,N,1,CHEMBL625978,,,
12635,1,Clearance values in rats after iv administration.,,BAO_0000218,,Rattus norvegicus,,Intermediate,14187,In vivo,N,1,CHEMBL874468,,,
12636,1,Compound was tested for plasma clearance on administered orally as aqueous solutions at 1 mpk and by iv at 0.2 mpk,Plasma,BAO_0000218,,,,Autocuration,4806,In vivo,U,0,CHEMBL625421,,1969.0,
12637,1,In vivo clearance (5 mg/kg) was determined in rabbits,,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,15025,In vivo,N,1,CHEMBL625422,,,
12638,1,Plasma Clearance rate was determined for the compound in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,13197,In vivo,N,1,CHEMBL625423,,,
12639,1,Plasma Clearance rate was determined for the compound in squirrel monkeys,,BAO_0000218,,Saimiri,,Autocuration,13197,In vivo,U,0,CHEMBL625424,,,
12640,1,Plasma clearance in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,13960,In vivo,N,1,CHEMBL625425,,,
12641,1,Plasma clearance of the compound,,BAO_0000218,,,,Autocuration,17820,In vivo,U,0,CHEMBL625426,,,
12642,1,Plasma clearance in guinea pigs at 2 mg/kg after iv administration,,BAO_0000218,,Cavia porcellus,,Intermediate,14706,In vivo,N,1,CHEMBL625427,,,
12643,1,Plasma clearance in guinea pigs at 3 mg/kg after iv administration,,BAO_0000218,,Cavia porcellus,,Intermediate,14706,In vivo,N,1,CHEMBL625428,,,
12644,1,Plasma clearance was determined,,BAO_0000218,,,,Autocuration,6504,In vivo,U,0,CHEMBL625429,,,
12645,1,Plasma clearance rate (CL) was determined in dogs after intravenous administration of 25 mg/kg of the compound.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,14925,In vivo,N,1,CHEMBL625430,,,
12646,1,Plasma clearance rate was determined for the compound in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,13197,In vivo,N,1,CHEMBL625431,,,
12647,1,Plasma clearance rate was determined for the compound in squirrel monkeys,,BAO_0000218,,Saimiri,,Autocuration,13197,In vivo,U,0,CHEMBL627307,,,
12648,1,Slow clearance (CL) was determined,,BAO_0000218,,,,Autocuration,3437,In vivo,U,0,CHEMBL627308,,,
12649,1,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,,BAO_0000218,,,,Autocuration,9196,,U,0,CHEMBL627309,,,
12650,1,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr; insufficient gastric juice produced,,BAO_0000218,,,,Autocuration,9196,,U,0,CHEMBL627310,,,
12651,1,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr,,BAO_0000218,,,,Autocuration,9196,,U,0,CHEMBL627311,,,
12652,1,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,,BAO_0000218,,,,Autocuration,9196,,U,0,CHEMBL627312,,,
12653,1,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr,,BAO_0000218,,,,Autocuration,9196,,U,0,CHEMBL627313,,,
12654,1,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,,BAO_0000218,,,,Autocuration,9196,,U,0,CHEMBL627314,,,
12655,1,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,,BAO_0000218,,,,Autocuration,9196,,U,0,CHEMBL627315,,,
12656,1,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,,BAO_0000218,,,,Autocuration,9196,,U,0,CHEMBL627316,,,
12657,1,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,,BAO_0000218,,,,Autocuration,9196,,U,0,CHEMBL627317,,,
12658,1,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,,BAO_0000218,,,,Autocuration,9196,,U,0,CHEMBL627318,,,
12659,1,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.5 hr,,BAO_0000218,,,,Autocuration,9196,,U,0,CHEMBL627999,,,
12660,1,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,,BAO_0000218,,,,Autocuration,9196,,U,0,CHEMBL628000,,,
12661,1,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,,BAO_0000218,,,,Autocuration,9196,,U,0,CHEMBL628001,,,
12662,1,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,,BAO_0000218,,,,Autocuration,9196,,U,0,CHEMBL628002,,,
12663,1,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,,BAO_0000218,,,,Autocuration,9196,,U,0,CHEMBL625610,,,
12664,1,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,,BAO_0000218,,,,Autocuration,9196,,U,0,CHEMBL625611,,,
12665,1,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr,,BAO_0000218,,,,Autocuration,9196,,U,0,CHEMBL625612,,,
12666,1,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr,,BAO_0000218,,,,Autocuration,9196,,U,0,CHEMBL625613,,,
12667,1,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,,BAO_0000218,,,,Autocuration,9196,,U,0,CHEMBL875479,,,
12668,1,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,,BAO_0000218,,,,Autocuration,9196,,U,0,CHEMBL625614,,,
12669,1,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,,BAO_0000218,,,,Autocuration,9196,,U,0,CHEMBL625615,,,
12670,1,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr,,BAO_0000218,,,,Autocuration,9196,,U,0,CHEMBL626302,,,
12671,1,Cumulative concentration 6b and compound 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8374,,N,1,CHEMBL626303,,178.0,
12672,1,Cumulative concentration 6b and compound 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8374,,N,1,CHEMBL627420,,178.0,
12673,1,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 1 hour relative to initial concentration of 1 uM,,BAO_0000218,,Rattus norvegicus,,Intermediate,13477,,N,1,CHEMBL627421,,,
12674,1,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 24 hour relative to initial concentration of 1 uM,,BAO_0000218,,Rattus norvegicus,,Intermediate,13477,,N,1,CHEMBL625695,,,
12675,1,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 4 hour relative to initial concentration of 1 uM,,BAO_0000218,,Rattus norvegicus,,Intermediate,13477,,N,1,CHEMBL625696,,,
12676,1,Distribution of compound in mice brain was measured after 1 hr,Brain,BAO_0000218,,Mus musculus,,Intermediate,10009,,N,1,CHEMBL875606,,955.0,
12677,1,Distribution of compound in mice brain was measured after 24 hr r,Brain,BAO_0000218,,Mus musculus,,Intermediate,10009,,N,1,CHEMBL625697,,955.0,
12678,1,Distribution of compound in mice brain was measured after 2 hr,Brain,BAO_0000218,,Mus musculus,,Intermediate,10009,,N,1,CHEMBL625698,,955.0,
12679,1,Distribution of compound in mice brain was measured after 3 hr,Brain,BAO_0000218,,Mus musculus,,Intermediate,10009,,N,1,CHEMBL625699,,955.0,
12680,1,Distribution of compound in mice brain was measured after 6 hr,Brain,BAO_0000218,,Mus musculus,,Intermediate,10009,,N,1,CHEMBL625700,,955.0,
12681,1,Distribution of compound in mice liver was measured after 1 hr,,BAO_0000218,,Mus musculus,,Intermediate,10009,,N,1,CHEMBL625701,,,
12682,1,Distribution of compound in mice liver was measured after 24 hr; b=Undetected,,BAO_0000218,,Mus musculus,,Intermediate,10009,,N,1,CHEMBL625702,,,
12683,1,Distribution of compound in mice liver was measured after 2 hr,,BAO_0000218,,Mus musculus,,Intermediate,10009,,N,1,CHEMBL625703,,,
12684,1,Distribution of compound in mice liver was measured after 3 hr,,BAO_0000218,,Mus musculus,,Intermediate,10009,,N,1,CHEMBL625704,,,
12685,1,Distribution of compound in mice liver was measured after 6 hr,,BAO_0000218,,Mus musculus,,Intermediate,10009,,N,1,CHEMBL625705,,,
12686,1,Distribution in dog adrenal medulla 30 min after administration.,Adrenal medulla,BAO_0000218,,Canis lupus familiaris,,Intermediate,8170,,N,1,CHEMBL625706,,1236.0,
12687,1,Distribution in dog adrenal medulla 72 hours after administration.,Adrenal medulla,BAO_0000218,,Canis lupus familiaris,,Intermediate,8170,,N,1,CHEMBL625707,,1236.0,
12688,1,Distribution in female dog Ovary 24 hours after administration.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,8170,,N,1,CHEMBL625708,,,
12689,1,Distribution in female dog Ovary 72 hours after administration.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,8170,,N,1,CHEMBL625709,,,
12690,1,Distribution in female dog adipose 24 hours after administration.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,8170,,N,1,CHEMBL624180,,,
12691,1,Distribution in female dog adipose 72 hours after administration.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,8170,,N,1,CHEMBL624181,,,
12692,1,Distribution in female dog adrenal cortex 72 hours after administration.,Adrenal cortex,BAO_0000218,,Canis lupus familiaris,,Intermediate,8170,,N,1,CHEMBL624182,,1235.0,
12693,1,Distribution in female dog adrenal cortex 72 hours after administration.,Adrenal cortex,BAO_0000218,,Canis lupus familiaris,,Intermediate,8170,,N,1,CHEMBL624183,,1235.0,
12694,1,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL624184,,2107.0,
12695,1,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL877489,,2107.0,
12696,1,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL624185,,2107.0,
12697,1,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL624186,,2107.0,
12698,1,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL624187,,2107.0,
12699,1,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL624188,,2107.0,
12700,1,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL624189,,2048.0,
12701,1,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL624190,,2048.0,
12702,1,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL624191,,2048.0,
12703,1,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL624192,,2048.0,
12704,1,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL624193,,2048.0,
12705,1,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL624194,,2048.0,
12706,1,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL624891,,2048.0,
12707,1,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL624892,,2048.0,
12708,1,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL624893,,2048.0,
12709,1,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL627632,,2048.0,
12710,1,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL627633,,,
12711,1,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL627634,,,
12712,1,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL627635,,,
12713,1,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL627636,,,
12714,1,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL626816,,,
12715,1,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL626817,,,
12716,1,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL626818,,,
12717,1,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL626819,,,
12718,1,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL626820,,,
12719,1,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL626821,,,
12720,1,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL626822,,2046.0,
12721,1,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL626823,,2046.0,
12722,1,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL626824,,2046.0,
12723,1,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL626825,,2046.0,
12724,1,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL626826,,2046.0,
12725,1,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL626827,,2046.0,
12726,1,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL626828,,2046.0,
12727,1,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL626829,,2046.0,
12728,1,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL626830,,2046.0,
12729,1,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL627150,,,
12730,1,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL627151,,,
12731,1,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL627152,,,
12732,1,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL627153,,,
12733,1,Rate of acetate production by the compound was determined,,BAO_0000019,,,,Autocuration,12904,,U,0,CHEMBL627154,,,
12734,1,Rate of acetate production by the compound was determined; Not determined,,BAO_0000019,,,,Autocuration,12904,,U,0,CHEMBL627155,,,
12735,1,Rate of hydrolysis of nitrocefin by compound was evaluated in water,,BAO_0000019,,,,Autocuration,3730,,U,0,CHEMBL627156,,,
12736,1,Reductive elimination of leaving group was determined at pH 7.4; expressed as loss of parent,,BAO_0000019,,,,Autocuration,3627,,U,0,CHEMBL627157,,,
12737,1,Relative concentration of compound (70 mg/Kg) in brain compared to concentration in plasma (160 ug/mL) at the time of tissue collection from rabbit; relative concentration,,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,13799,,N,1,CHEMBL627158,,,
12738,1,Relative concentration of compound (70 mg/Kg) in lung compared to concentration in plasma (160 ug/mL) at the time of tissue collection from rabbit; relative concentration,Plasma,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,13799,,N,1,CHEMBL627159,,1969.0,
12739,1,Relative concentration of compound in brain compared to concentration in plasma (0.4 ug/mL) at the time of tissue collection from mice; relative concentration,,BAO_0000218,,Mus musculus,,Intermediate,13799,,N,1,CHEMBL627160,,,
12740,1,Relative concentration of compound in brain compared to concentration in plasma (3.5 ug/mL) at the time of tissue collection from mice; relative concentration,,BAO_0000218,,Rattus norvegicus,,Intermediate,13799,,N,1,CHEMBL628540,,,
12741,1,Relative concentration of compound in lung compared to concentration in plasma (0.4 ug/mL) at the time of tissue collection from mice; relative concentration,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,13799,,N,1,CHEMBL628541,,1969.0,
12742,1,Relative concentration of compound in lung compared to concentration in plasma (3.5 ug/mL) at the time of tissue collection from mice; relative concentration,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,13799,,N,1,CHEMBL628542,,1969.0,
12743,1,Solubility after at a pH 1.2,,BAO_0000100,,,,Autocuration,6629,,U,0,CHEMBL628543,,,
12744,1,Solubility after at pH 1.2,,BAO_0000100,,,,Autocuration,6629,,U,0,CHEMBL628544,,,
12745,1,Solubility after injection of water,,BAO_0000100,,,,Autocuration,6629,,U,0,CHEMBL628545,,,
12746,1,Statistical significance of IC 50 values; Expressed as R value,,BAO_0000019,,,,Autocuration,14000,,U,0,CHEMBL628546,,,
12747,1,Systemic availability with respect to methyldopa was determined,,BAO_0000019,,,,Autocuration,8267,,U,0,CHEMBL874455,,,
12748,1,Tissue distribution of the in rat brain relative to plasma concentration of 1 ug/kg; relative concentration,,BAO_0000218,,Rattus norvegicus,,Intermediate,13799,,N,1,CHEMBL628547,,,
12749,1,Tissue distribution of the in rat lung relative to plasma concentration of 1 ug/kg; relative concentration,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,13799,,N,1,CHEMBL628548,,1969.0,
12750,1,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit 1 lung, and radioactivity content in feces was estimated",Feces,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,7132,,N,1,CHEMBL628549,,1988.0,
12751,1,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit 1 liver, and radioactivity content in feces was estimated",Feces,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,7132,,N,1,CHEMBL628550,,1988.0,
12752,1,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit3, and radioactivity content in feces was estimated at total hours",Feces,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,7132,,N,1,CHEMBL628551,,1988.0,
12753,1,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit1, and radioactivity content in urine was estimated at 0-2 hr",Urine,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,7132,,N,1,CHEMBL628552,,1088.0,
12754,1,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 0-24 hr",Urine,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,7132,,N,1,CHEMBL628553,,1088.0,
12755,1,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 0-48 hr",Urine,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,7132,,N,1,CHEMBL628554,,1088.0,
12756,1,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 24-48 h",Urine,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,7132,,N,1,CHEMBL628555,,1088.0,
12757,1,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 48-72 h",Urine,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,7132,,N,1,CHEMBL628556,,1088.0,
12758,1,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit kidney, and radioactivity content in feces was estimated",Kidney,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,7132,,N,1,CHEMBL628557,,2113.0,
12759,1,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated",Feces,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,7132,,N,1,CHEMBL628558,,1988.0,
12760,1,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 1 lung, and radioactivity content in feces was estimated at",Feces,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,7132,,N,1,CHEMBL628559,,1988.0,
12761,1,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit1plasma, and radioactivity content in feces was estimated",Feces,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,7132,,N,1,CHEMBL628560,,1988.0,
12762,1,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at total hours",Urine,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,7132,,N,1,CHEMBL874456,,1088.0,
12763,1,"200 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit4, and radioactivity content in feces was estimated at 0-48 hr",Feces,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,7132,,N,1,CHEMBL628561,,1988.0,
12764,1,"200 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit4, and radioactivity content in feces was estimated at total hours",Feces,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,7132,,N,1,CHEMBL628562,,1988.0,
12765,1,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit2, and radioactivity content in urine was estimated at 0-4 hr",Urine,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,7132,,N,1,CHEMBL628563,,1088.0,
12766,1,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at",Urine,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,7132,,N,1,CHEMBL628564,,1088.0,
12767,1,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at 24-48 h",Urine,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,7132,,N,1,CHEMBL628565,,1088.0,
12768,1,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at 48-72 h",Urine,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,7132,,N,1,CHEMBL631248,,1088.0,
12769,1,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at total hours",Urine,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,7132,,N,1,CHEMBL631249,,1088.0,
12770,1,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 kidney, and radioactivity content in feces was estimated",Kidney,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,7132,,N,1,CHEMBL627214,,2113.0,
12771,1,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 liver, and radioactivity content in feces was estimated",Feces,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,7132,,N,1,CHEMBL874591,,1988.0,
12772,1,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 lung, and radioactivity content in feces was estimated",Feces,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,7132,,N,1,CHEMBL627215,,1988.0,
12773,1,200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 plasma and radioactivity content in feces was estimated,Feces,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,7132,,N,1,CHEMBL625471,,1988.0,
12774,1,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 1,,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,7132,,N,1,CHEMBL625472,,,
12775,1,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 3 by Gas-liquid chromatographic analysis,,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,7132,,N,1,CHEMBL625473,,,
12776,1,Tested for pharmacokinetic parameter in fasted Beagle dogs (Clearance value of the compound) iv administration.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,13317,In vivo,N,1,CHEMBL625474,,,
12777,1,The clearance was measured in dog at dose 5 mg/kg after intravenous administration.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,15341,In vivo,N,1,CHEMBL625475,,,
12778,1,The clearance was measured in rat at dose 12 mg/kg after intravenous administration.,,BAO_0000218,,Rattus norvegicus,,Intermediate,15341,In vivo,N,1,CHEMBL625476,,,
12779,1,The clearance was measured in rat at dose 1 mg/kg after intravenous administration.,,BAO_0000218,,Rattus norvegicus,,Intermediate,15341,In vivo,N,1,CHEMBL625477,,,
12780,1,The clearance was measured in rat at dose 30 mg/kg after intravenous administration.,,BAO_0000218,,Rattus norvegicus,,Intermediate,15341,In vivo,N,1,CHEMBL625478,,,
12781,1,The compound was evaluated for clearance value in rat isolated esophageal tunica muscularis mucose,esophageal tunica muscularis mucosae,BAO_0000218,,Rattus norvegicus,,Intermediate,12801,In vitro,N,1,CHEMBL625479,,,
12782,1,The compound was evaluated for the value in rat isolated esophageal tunica muscularis mucose,esophageal tunica muscularis mucosae,BAO_0000218,,Rattus norvegicus,,Intermediate,12801,In vitro,N,1,CHEMBL625480,,,
12783,1,The compound was tested for systemic plasma clearance(CL) in rats and is expressed in mL/min/kg.,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14856,In vivo,N,1,CHEMBL625481,,1969.0,
12784,1,Total body clearance at an intravenous dose of 5.2 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,14062,In vivo,N,1,CHEMBL625482,,,
12785,1,Total body clearance at an intravenous dose of 5.5 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,14062,In vivo,N,1,CHEMBL625483,,,
12786,1,Total body clearance at an intravenous dose of 6.3 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,14062,In vivo,N,1,CHEMBL625484,,,
12787,1,Total body clearance at an intravenous dose of 6.5 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,14062,In vivo,N,1,CHEMBL625485,,,
12788,1,Total plasma clearance value was obtained after intravenous administration of 1.8 mg/kg of drug in male Beagle dogs,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,14346,In vivo,N,1,CHEMBL625486,,1969.0,
12789,1,Total plasma clearance value was obtained after intravenous administration of 2.5 mg/kg of drug in male Dawley rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14346,In vivo,N,1,CHEMBL625487,,1969.0,
12790,1,Total plasma clearance value was obtained after intravenous administration of 2.6 mg/kg of drug in male Dawley rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14346,In vivo,N,1,CHEMBL625488,,1969.0,
12791,1,Total plasma clearance value was obtained after intravenous administration of 2.7 mg/kg of drug in male Dawley rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14346,In vivo,N,1,CHEMBL625489,,1969.0,
12792,1,Total plasma clearance value was obtained after intravenous administration of 2.8 mg/kg of drug in male Dawley rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14346,In vivo,N,1,CHEMBL625490,,1969.0,
12793,1,Total plasma clearance value was obtained after intravenous administration of 4.9 mg/kg of drug in male Beagle dogs,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,14346,In vivo,N,1,CHEMBL625491,,1969.0,
12794,1,Total plasma clearance value was obtained after intravenous administration of 5.1 mg/kg of drug in male Dawley rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14346,In vivo,N,1,CHEMBL625492,,1969.0,
12795,1,plasma clearance in human,Plasma,BAO_0000218,,Homo sapiens,,Intermediate,15711,In vivo,N,1,CHEMBL625493,,1969.0,
12796,1,Pharmacokinetic parameter (CL/F ) was evaluated in Spargue-Dawley rat when given intravenously at dose 15 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,14886,In vivo,N,1,CHEMBL625494,,,
12797,1,Pharmacokinetic parameter (CL/F ) was evaluated in Spargue-Dawley rat when given peroral at dose 30 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,14886,In vivo,N,1,CHEMBL625495,,,
12798,1,Pharmacokinetic parameter (CL/F) was evaluated in Spargue-Dawley rat when given peroral at dose 80 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,14886,In vivo,N,1,CHEMBL625496,,,
12799,1,1-Octanol/water partition coefficient measured at 7.4,,BAO_0000100,,,,Autocuration,4115,,U,0,CHEMBL625497,,,
12800,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,13733,,U,0,CHEMBL625498,,,
12801,1,Partition coefficient (logP),,BAO_0000019,,,,Autocuration,12102,,U,0,CHEMBL625499,,,
12802,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,12676,,U,0,CHEMBL625500,,,
12803,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,13733,,U,0,CHEMBL625501,,,
12804,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,13740,,U,0,CHEMBL625502,,,
12805,1,Calculated partition coefficient (clogP) (relative to BAY K 8644),,BAO_0000100,,,,Autocuration,12766,,U,0,CHEMBL625503,,,
12806,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,2764,,U,0,CHEMBL625504,,,
12807,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,12355,,U,0,CHEMBL625505,,,
12808,1,Calculated partition coefficient of the compound,,BAO_0000100,,,,Autocuration,11314,,U,0,CHEMBL625506,,,
12809,1,Partition coefficient (logP),,BAO_0000019,,,,Autocuration,12706,,U,0,CHEMBL625507,,,
12810,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,12645,,U,0,CHEMBL625508,,,
12811,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,13668,,U,0,CHEMBL625509,,,
12812,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,12819,,U,0,CHEMBL625510,,,
12813,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,13668,,U,0,CHEMBL883125,,,
12814,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,13017,,U,0,CHEMBL625511,,,
12815,1,Partition coefficient of the compound,,BAO_0000019,,,,Autocuration,2448,,U,0,CHEMBL874650,,,
12816,1,Partition coefficient of the compound,,BAO_0000019,,,,Autocuration,11526,,U,0,CHEMBL625512,,,
12817,1,Partition coefficient of compound was determined,,BAO_0000019,,,,Autocuration,12426,,U,0,CHEMBL625513,,,
12818,1,Partition coefficient was determined,,BAO_0000019,,,,Autocuration,2448,,U,0,CHEMBL625514,,,
12819,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,12001,,U,0,CHEMBL625515,,,
12820,1,partition coefficient of compound was determined,,BAO_0000100,,,,Autocuration,12426,,U,0,CHEMBL625516,,,
12821,1,The total body administered intravenously in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,13204,In vivo,N,1,CHEMBL625517,,,
12822,1,The total body administered intravenously in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,13204,In vivo,N,1,CHEMBL625518,,,
12823,1,Time taken for the administration to female NIH mice weighing 25-30 g.,,BAO_0000218,,Mus musculus,,Intermediate,13889,,N,1,CHEMBL625519,,,
12824,1,Time taken for the administration,,BAO_0000019,,,,Autocuration,13889,,U,0,CHEMBL625520,,,
12825,1,Total clearance of compound was determined in dog at 5 mg/kg intravenously admn.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17025,In vivo,N,1,CHEMBL874651,,,
12826,1,Total clearance of compound was determined in monkey at 5 mg/kg intravenously admn.,,BAO_0000218,,Simiiformes,,Autocuration,17025,In vivo,U,0,CHEMBL625521,,,
12827,1,Total clearance of compound was determined in rabbit at 5 mg/kg intravenously admn.,,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,17025,In vivo,N,1,CHEMBL623171,,,
12828,1,Total clearance of compound was determined in rat at 5 mg/kg intravenously admn.,,BAO_0000218,,Rattus norvegicus,,Intermediate,17025,In vivo,N,1,CHEMBL623853,,,
12829,1,Plasma clearance for the compound was determined.,,BAO_0000019,,,,Autocuration,15067,,U,0,CHEMBL623854,,,
12830,1,CLog P value of the compound,,BAO_0000100,,,,Autocuration,3091,,U,0,CHEMBL874405,,,
12831,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,15592,,U,0,CHEMBL623855,,,
12832,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,14738,,U,0,CHEMBL623856,,,
12833,1,ClogP value of the compound; nd ='no data',,BAO_0000100,,,,Autocuration,14738,,U,0,CHEMBL623857,,,
12834,1,ClogP value of the compound; nd ='not determined',,BAO_0000100,,,,Autocuration,14738,,U,0,CHEMBL623858,,,
12835,1,CLog P was determined,,BAO_0000100,,,,Autocuration,6076,,U,0,CHEMBL623859,,,
12836,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,17840,,U,0,CHEMBL839829,,,
12837,1,CLogP was calculated,,BAO_0000019,,,,Autocuration,13589,,U,0,CHEMBL623860,,,
12838,1,CLogP value was determined,,BAO_0000019,,,,Autocuration,17655,,U,0,CHEMBL623861,,,
12839,1,CLogP value was evaluated using http://esc.syrres.com/interkow/kowdemo.htm.,,BAO_0000019,,,,Autocuration,5867,,U,0,CHEMBL623862,,,
12840,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,5867,,U,0,CHEMBL874406,,,
12841,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,10783,,U,0,CHEMBL623863,,,
12842,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,14849,,U,0,CHEMBL624021,,,
12843,1,Distribution in female dog adrenal medulla 24 hours after administration.,Adrenal medulla,BAO_0000218,,Canis lupus familiaris,,Intermediate,8170,,N,1,CHEMBL624022,,1236.0,
12844,1,Distribution in female dog adrenal medulla 72 hours after administration.,Adrenal medulla,BAO_0000218,,Canis lupus familiaris,,Intermediate,8170,,N,1,CHEMBL624023,,1236.0,
12845,1,Distribution in female dog bile 24 hours after administration.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,8170,,N,1,CHEMBL624024,,,
12846,1,Distribution in female dog bile 72 hr after administration.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,8170,,N,1,CHEMBL624025,,,
12847,1,Distribution in female dog blood 24 hours after administration.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,8170,,N,1,CHEMBL624026,,,
12848,1,Distribution in female dog blood 72 hours after administration.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,8170,,N,1,CHEMBL624027,,,
12849,1,Distribution in female dog heart 24 hours after administration.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,8170,,N,1,CHEMBL624028,,,
12850,1,Distribution in female dog heart 72 hours after administration.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,8170,,N,1,CHEMBL624029,,,
12851,1,Distribution in female dog kidney 24 hours after administration.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,8170,,N,1,CHEMBL624030,,,
12852,1,Distribution in female dog kidney 72 hours after administration.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,8170,,N,1,CHEMBL624031,,,
12853,1,Distribution in female dog large intestine 24 hours after administration.,Intestine,BAO_0000218,,Canis lupus familiaris,,Intermediate,8170,,N,1,CHEMBL624032,,160.0,
12854,1,Distribution in female dog large intestine 72 hours after administration.,Intestine,BAO_0000218,,Canis lupus familiaris,,Intermediate,8170,,N,1,CHEMBL874407,,160.0,
12855,1,Distribution in female dog liver 24 hours after administration.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,8170,,N,1,CHEMBL624033,,,
12856,1,Distribution in female dog liver 72 hours after administration.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,8170,,N,1,CHEMBL624034,,,
12857,1,Distribution in female dog lung 24 hours after administration.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,8170,,N,1,CHEMBL624035,,,
12858,1,Distribution in female dog lung 72 hours after administration.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,8170,,N,1,CHEMBL624036,,,
12859,1,Distribution in female dog muscle 24 hours after administration.,Muscle tissue,BAO_0000218,,Canis lupus familiaris,,Intermediate,8170,,N,1,CHEMBL624037,,2385.0,
12860,1,Distribution in female dog muscle 72 hours after administration.,Muscle tissue,BAO_0000218,,Canis lupus familiaris,,Intermediate,8170,,N,1,CHEMBL624038,,2385.0,
12861,1,Distribution in female dog pancreas 24 hours after administration.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,8170,,N,1,CHEMBL624039,,,
12862,1,Distribution in female dog pancreas 72 hours after administration.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,8170,,N,1,CHEMBL624040,,,
12863,1,Distribution in female dog small intestine 24 hours after administration.,Intestine,BAO_0000218,,Canis lupus familiaris,,Intermediate,8170,,N,1,CHEMBL624041,,160.0,
12864,1,Distribution in female dog small intestine 72 hours after administration.,Intestine,BAO_0000218,,Canis lupus familiaris,,Intermediate,8170,,N,1,CHEMBL624042,,160.0,
12865,1,Distribution in female dog spleen 24 hours after administration.,Spleen,BAO_0000218,,Canis lupus familiaris,,Intermediate,8170,,N,1,CHEMBL624043,,2106.0,
12866,1,Distribution in female dog spleen 72 hours after administration.,Spleen,BAO_0000218,,Canis lupus familiaris,,Intermediate,8170,,N,1,CHEMBL624044,,2106.0,
12867,1,Distribution in female dog stomach 24 hours after administration.,Stomach,BAO_0000218,,Canis lupus familiaris,,Intermediate,8170,,N,1,CHEMBL624045,,945.0,
12868,1,Distribution in female dog stomach 72 hours after administration.,Stomach,BAO_0000218,,Canis lupus familiaris,,Intermediate,8170,,N,1,CHEMBL624046,,945.0,
12869,1,Distribution in female dog thyroid 24 hours after administration.,Thyroid gland,BAO_0000218,,Canis lupus familiaris,,Intermediate,8170,,N,1,CHEMBL624047,,2046.0,
12870,1,Distribution in female dog thyroid 72 hours after administration.,Thyroid gland,BAO_0000218,,Canis lupus familiaris,,Intermediate,8170,,N,1,CHEMBL624048,,2046.0,
12871,1,Distribution in female dog urine 24 hours after administration.,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,8170,,N,1,CHEMBL874408,,1088.0,
12872,1,Distribution in female dog urine 72 hr after administration.,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,8170,,N,1,CHEMBL624049,,1088.0,
12873,1,Mean plasma concentration measured 1 h following an oral dose of 30 mg/kg,Plasma,BAO_0000218,,,,Autocuration,14283,,U,0,CHEMBL624050,,1969.0,
12874,1,Plasma concentration at 7 hr after intravenous dosing,,BAO_0000019,,,,Autocuration,5623,,U,0,CHEMBL624051,,,
12875,1,Plasma concentration of 3 mg/kg iv after 0.25 hr in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,13477,,N,1,CHEMBL623278,,,
12876,1,Plasma concentration of 3 mg/kg iv after 0.5 hr in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,13477,,N,1,CHEMBL623279,,,
12877,1,Plasma concentration of 3 mg/kg iv after 1 hr in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,13477,,N,1,CHEMBL623280,,,
12878,1,Plasma concentration of 3 mg/kg iv after 2 hr in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,13477,,N,1,CHEMBL623963,,,
12879,1,Plasma concentration of 3 mg/kg iv after 4 hr in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,13477,,N,1,CHEMBL623964,,,
12880,1,Plasma concentration of 3 mg/kg iv after 6 hr in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,13477,,N,1,CHEMBL623965,,,
12881,1,Plasma concentration of 3 mg/kg po after 0.083 hr in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,13477,,N,1,CHEMBL623966,,,
12882,1,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.083 h,,BAO_0000218,,Rattus norvegicus,,Intermediate,13477,,N,1,CHEMBL874415,,,
12883,1,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.25 hr,,BAO_0000218,,Rattus norvegicus,,Intermediate,13477,,N,1,CHEMBL623967,,,
12884,1,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.5 hr,,BAO_0000218,,Rattus norvegicus,,Intermediate,13477,,N,1,CHEMBL623968,,,
12885,1,Plasma concentration after 3 mg/kg peroral dosing in rat at 1 hr,,BAO_0000218,,Rattus norvegicus,,Intermediate,13477,,N,1,CHEMBL623969,,,
12886,1,Plasma concentration after 3 mg/kg peroral dosing in rat at 2 hr,,BAO_0000218,,Rattus norvegicus,,Intermediate,13477,,N,1,CHEMBL628409,,,
12887,1,Plasma concentration after 3 mg/kg peroral dosing in rat at 4 hr,,BAO_0000218,,Rattus norvegicus,,Intermediate,13477,,N,1,CHEMBL628410,,,
12888,1,Plasma concentration after 3 mg/kg peroral dosing in rat at 6 hr,,BAO_0000218,,Rattus norvegicus,,Intermediate,13477,,N,1,CHEMBL628411,,,
12889,1,Plasma concentration after 3 mg/kg peroral dosing in rat at 8 hr,,BAO_0000218,,Rattus norvegicus,,Intermediate,13477,,N,1,CHEMBL628412,,,
12890,1,Tested for the highest concentration at which toxicity was not observed or the concentration which provided the highest number of net grain counts,,BAO_0000019,,,,Autocuration,12553,,U,0,CHEMBL628413,,,
12891,1,The concentration in plasmat; Not determined,Plasma,BAO_0000019,,,,Autocuration,14548,,U,0,CHEMBL628414,,1969.0,
12892,1,Tissue level at 10 mg/kg/po in wistar rats in blood,,BAO_0000218,,Rattus norvegicus,,Intermediate,14393,,N,1,CHEMBL628415,,,
12893,1,Tissue level at 10 mg/kg/po in wistar rats in brown fat,,BAO_0000218,,Rattus norvegicus,,Intermediate,14393,,N,1,CHEMBL628416,,,
12894,1,Tissue level at 10 mg/kg/po in wistar rats in heart,,BAO_0000218,,Rattus norvegicus,,Intermediate,14393,,N,1,CHEMBL628417,,,
12895,1,Tissue level at 10 mg/kg/po in wistar rats in liver,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,14393,,N,1,CHEMBL874908,,2107.0,
12896,1,Tissue level at 10 mg/kg/po in wistar rats in plasma,,BAO_0000218,,Rattus norvegicus,,Intermediate,14393,,N,1,CHEMBL628418,,,
12897,1,Tissue level at 10 mg/kg/po in wistar rats in skeletal muscle,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,14393,,N,1,CHEMBL628419,,2385.0,
12898,1,Tissue level at 10 mg/kg/po in wistar rats in subcutaneous fat,,BAO_0000218,,Rattus norvegicus,,Intermediate,14393,,N,1,CHEMBL628420,,,
12899,1,Water solubility at 37 degree C.,,BAO_0000019,,,,Autocuration,1629,,U,0,CHEMBL628421,,,
12900,1,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 13.5 hr,,BAO_0000100,,,,Autocuration,8194,,U,0,CHEMBL626726,,,
12901,1,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,,BAO_0000100,,,,Autocuration,8194,,U,0,CHEMBL626727,,,
12902,1,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL626728,,178.0,
12903,1,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL626729,,178.0,
12904,1,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL626730,,178.0,
12905,1,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL626731,,178.0,
12906,1,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL626732,,178.0,
12907,1,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL626733,,948.0,
12908,1,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL626734,,948.0,
12909,1,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL626735,,948.0,
12910,1,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL874909,,948.0,
12911,1,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL626736,,948.0,
12912,1,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL626737,,2113.0,
12913,1,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL630999,,2113.0,
12914,1,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL631000,,2113.0,
12915,1,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL631001,,2113.0,
12916,1,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL631002,,2113.0,
12917,1,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL631003,,2107.0,
12918,1,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL631004,,2107.0,
12919,1,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL631005,,2107.0,
12920,1,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL631006,,2107.0,
12921,1,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL631007,,2107.0,
12922,1,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL631008,,2048.0,
12923,1,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL631009,,2048.0,
12924,1,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL631010,,2048.0,
12925,1,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL631011,,2048.0,
12926,1,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL631012,,2048.0,
12927,1,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL630271,,2046.0,
12928,1,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL630272,,2046.0,
12929,1,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL630273,,2046.0,
12930,1,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL630274,,2046.0,
12931,1,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL630275,,2046.0,
12932,1,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 15 minutes (radiolabeled with [125I]-,,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL875782,,,
12933,1,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 2 minutes (radiolabeled with [125I]-,,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL630276,,,
12934,1,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 30 minutes (radiolabeled with [125I]-,,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL630277,,,
12935,1,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 5 minutes (radiolabeled with [125I]-,,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL630278,,,
12936,1,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 60 minutes (radiolabeled with [125I]-,,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,N,1,CHEMBL630279,,,
12937,1,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 10 mg/Kg,,BAO_0000019,,,,Autocuration,8151,,U,0,CHEMBL630280,,,
12938,1,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,,BAO_0000019,,,,Autocuration,8151,,U,0,CHEMBL630281,,,
12939,1,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 4 by Gas-liquid chromatographic analysis,,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,7132,,N,1,CHEMBL630282,,,
12940,1,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 2,,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,7132,,N,1,CHEMBL630283,,,
12941,1,Alkylating activity (0.1 mM) was determined at pH 7.4; expressed as OD (540n m)/mM of drug),,BAO_0000019,,,,Autocuration,5797,,U,0,CHEMBL630284,,,
12942,1,Alkylating activity was determined,,BAO_0000019,,,,Autocuration,7849,,U,0,CHEMBL630285,,,
12943,1,Amount of metabolites in the microsomal medium after 90 min incubation of BTCP (500 uM),,BAO_0000251,,,,Autocuration,14220,,U,0,CHEMBL630286,,,
12944,1,"Formation of metabolite by rabbit liver microsomal preparation in absence of NADPH, at 2 hours",,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,8650,,N,1,CHEMBL630069,,,
12945,1,"Formation of metabolite by rabbit liver microsomal preparation in presence of Co-O2 (90:10),at 2 hour",,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,8650,,N,1,CHEMBL630070,,,
12946,1,"Formation of metabolite by rabbit liver microsomal preparation in presence of N2,at 2 hour",,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,8650,,N,1,CHEMBL630071,,,
12947,1,"Formation of metabolite by rabbit liver microsomal preparation in presence of NADPH, at 2 hours",,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,8650,,N,1,CHEMBL630072,,,
12948,1,"Formation of metabolite by rabbit liver microsomal preparation in presence of SKF525A,at 2 hour",,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,8650,,N,1,CHEMBL875110,,,
12949,1,Compound was tested for antidiuretic activity in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,7116,,N,1,CHEMBL630073,,,
12950,1,Compound was tested for inactivation kinetic values,,BAO_0000019,,,,Autocuration,14131,,U,0,CHEMBL630074,,,
12951,1,Compound was evaluated for the average apparent volume of distribution when administered through intravenous route,,BAO_0000218,,,,Autocuration,7415,In vivo,U,0,CHEMBL630075,,,
12952,1,Dissociation rate calculated from the first-order equation using the t1/2 value,,BAO_0000019,,,,Autocuration,13178,,U,0,CHEMBL630076,,,
12953,1,Compound was evaluated for pKa by titration of the compounds in 1:2 methyl alcohol and water,,BAO_0000100,,,,Autocuration,8815,,U,0,CHEMBL630077,,,
12954,1,Aqueous solubility was measured,,BAO_0000100,,,,Autocuration,1450,,U,0,CHEMBL630078,,,
12955,1,Aqueous solubility was measured at a pH 4,,BAO_0000100,,,,Autocuration,1450,,U,0,CHEMBL630079,,,
12956,1,Aqueous solubility (pH 7),,BAO_0000100,,,,Autocuration,1450,,U,0,CHEMBL630080,,,
12957,1,Aqueous solubility was measured at a pH 9,,BAO_0000100,,,,Autocuration,1450,,U,0,CHEMBL630081,,,
12958,1,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents",,BAO_0000019,,,,Autocuration,12711,,U,0,CHEMBL630082,,,
12959,1,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents.",,BAO_0000019,,,,Autocuration,12711,,U,0,CHEMBL630083,,,
12960,1,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents.",,BAO_0000019,,,,Autocuration,12711,,U,0,CHEMBL630084,,,
12961,1,Aqueous solubility of the compound,,BAO_0000100,,,,Autocuration,15032,,U,0,CHEMBL629198,,,
12962,1,Aqueous solubility at 37 degree Celsius at pH 7.38,,BAO_0000100,,,,Autocuration,9964,,U,0,CHEMBL629199,,,
12963,1,Aqueous solubility in pH 7.4 phosphate buffer,,BAO_0000100,,,,Autocuration,14962,,U,0,CHEMBL629200,,,
12964,1,Mean arterial pressure response following 10 mg/kg intraduodenal administration to salt depleted dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,12487,,N,1,CHEMBL629201,,,
12965,1,Mean arterial pressure response following 1 mg/kg intravenous administration to salt depleted dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,12487,,N,1,CHEMBL629202,,,
12966,1,Percentage of aspirin formed during hydrolysis in 10% human plasma at pH 7.4 at 37 degrees celsius,,BAO_0000218,,Homo sapiens,,Intermediate,10026,,N,1,CHEMBL875111,,,
12967,1,Percentage of aspirin formed during hydrolysis in undiluted human plasma at pH 7.4 at 37 degrees celsius,,BAO_0000218,,Homo sapiens,,Intermediate,10026,,N,1,CHEMBL629203,,,
12968,1,The percentage of aspirin formed during hydrolysis in 100% human plasma at pH 7.4 at 37 degrees celsius,,BAO_0000218,,Homo sapiens,,Intermediate,10026,,N,1,CHEMBL629204,,,
12969,1,The percentage of aspirin formed during hydrolysis in 20% human plasma at pH 7.4 at 37 degrees celsius,,BAO_0000218,,Homo sapiens,,Intermediate,10026,,N,1,CHEMBL629205,,,
12970,1,The percentage of aspirin formed during hydrolysis in 60% human plasma at pH 7.4 at 37 degrees celsius,,BAO_0000218,,Homo sapiens,,Intermediate,10026,,N,1,CHEMBL629206,,,
12971,1,The percentage of aspirin formed during hydrolysis in 80% human plasma at pH 7.4 at 37 degrees celsius,,BAO_0000019,,,,Autocuration,10026,,U,0,CHEMBL631185,,,
12972,1,Compound was evaluated for the average bile flow rat in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,7415,,N,1,CHEMBL631186,,,
12973,1,"Effect of compound on cartilage in surgically induced osteoarthritis (OA) model in rabbit at 15 mg/kg, value are relative to activity of RS-130830 (7.9+/-1.5) at 25 mg/kg",,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,17025,,N,1,CHEMBL631187,,,
12974,1,"Effect of compound on cartilage in surgically induced osteoarthritis (OA) model in rabbit at 25 mg/kg, value are relative to activity of RS-130830 (7.9+/-1.5) at 25 mg/kg",,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,17025,,N,1,CHEMBL631188,,,
12975,1,Average half life period was determined,,BAO_0000019,,,,Autocuration,10184,,U,0,CHEMBL876419,,,
12976,1,Average half life period was determined,,BAO_0000019,,,,Autocuration,10184,,U,0,CHEMBL631189,,,
12977,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 0.8 mg/kg per day.,,BAO_0000218,,Human herpesvirus 1,,Intermediate,8613,,N,1,CHEMBL631190,,,
12978,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 0.8 mg/kg per day.,,BAO_0000218,,Human herpesvirus 1,,Intermediate,8613,,N,1,CHEMBL631191,,,
12979,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day.,,BAO_0000218,,Human herpesvirus 1,,Intermediate,8613,,N,1,CHEMBL631192,,,
12980,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 3.1 mg/kg per day.,,BAO_0000218,,Human herpesvirus 1,,Intermediate,8613,,N,1,CHEMBL632400,,,
12981,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day.,,BAO_0000218,,Human herpesvirus 1,,Intermediate,8613,,N,1,CHEMBL630564,,,
12982,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day.,,BAO_0000218,,Human herpesvirus 1,,Intermediate,8613,,N,1,CHEMBL630565,,,
12983,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.02 mg/kg per day.,,BAO_0000218,,Human herpesvirus 1,,Intermediate,8613,,N,1,CHEMBL630566,,,
12984,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.06 mg/kg per day.,,BAO_0000218,,Human herpesvirus 1,,Intermediate,8613,,N,1,CHEMBL631229,,,
12985,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.25 mg/kg per day.,,BAO_0000218,,Human herpesvirus 1,,Intermediate,8613,,N,1,CHEMBL631230,,,
12986,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,6030,,U,0,CHEMBL876428,,,
12987,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,6147,,U,0,CHEMBL631231,,,
12988,1,Calculated partition coefficient (clogP) (MacLogP),,BAO_0000100,,,,Autocuration,14556,,U,0,CHEMBL631232,,,
12989,1,Hydrophilicity was determined,,BAO_0000019,,,,Autocuration,768,,U,0,CHEMBL631233,,,
12990,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,14452,,U,0,CHEMBL631234,,,
12991,1,Increased absorption was determined,,BAO_0000019,,,,Autocuration,5237,,U,0,CHEMBL883126,,,
12992,1,Lipophilicity value was evaluated,,BAO_0000100,,,,Autocuration,14378,,U,0,CHEMBL631235,,,
12993,1,Log P value of the compound.,,BAO_0000100,,,,Autocuration,14418,,U,0,CHEMBL631236,,,
12994,1,Partition coefficient of compound was determined,,BAO_0000019,,,,Autocuration,5249,,U,0,CHEMBL631237,,,
12995,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,14621,,U,0,CHEMBL631238,,,
12996,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,12542,,U,0,CHEMBL876429,,,
12997,1,Partition coefficient was measured by medchem software; Not calculated,,BAO_0000019,,,,Autocuration,12542,,U,0,CHEMBL631414,,,
12998,1,Partition coefficient was measured by octanol-water using standard shake-flask method,,BAO_0000100,,,,Autocuration,12542,,U,0,CHEMBL631415,,,
12999,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,15462,,U,0,CHEMBL631416,,,
13000,1,Partition coefficient (logP),,BAO_0000019,,,,Autocuration,14884,,U,0,CHEMBL631417,,,
13001,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,16526,,U,0,CHEMBL631418,,,
13002,1,The Octanol/Water partition coefficient CLogP,,BAO_0000100,,,,Autocuration,13693,,U,0,CHEMBL631419,,,
13003,1,The pharmacokinetic parameter C Log p was reported,,BAO_0000019,,,,Autocuration,13693,,U,0,CHEMBL631420,,,
13004,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,13779,,U,0,CHEMBL631421,,,
13005,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,14772,,U,0,CHEMBL631422,,,
13006,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,14393,,U,0,CHEMBL631423,,,
13007,1,Clearance rate in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14793,In vivo,N,1,CHEMBL876430,,1969.0,
13008,1,Clearance rate in rat plasma when administered intravenously at a dose of 10 mg/kg,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14793,In vivo,N,1,CHEMBL631424,,1969.0,
13009,1,Compound was administered intravenously in dog to evaluate plasma clearance values,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,13744,In vivo,N,1,CHEMBL631425,,1969.0,
13010,1,Compound was administered intravenously in monkey to evaluate plasma clearance values,Plasma,BAO_0000218,,Simiiformes,,Autocuration,13744,In vivo,U,0,CHEMBL631426,,1969.0,
13011,1,Compound was administered intravenously in mouse to evaluate plasma clearance values,Plasma,BAO_0000218,,Mus musculus,,Intermediate,13744,In vivo,N,1,CHEMBL631427,,1969.0,
13012,1,Compound was evaluated in vivo for plasma clearance in dog after intravenous dose at 2 mg/Kg,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,13207,In vivo,N,1,CHEMBL631428,,1969.0,
13013,1,Intrinsic clearance in Rhesus liver microsome,Liver,BAO_0000218,,Macaca mulatta,,Intermediate,5669,In vitro,N,1,CHEMBL631429,,2107.0,
13014,1,Intrinsic clearance in dog liver microsome,Liver,BAO_0000218,,Canis lupus familiaris,,Intermediate,5669,In vitro,N,1,CHEMBL631430,,2107.0,
13015,1,Intrinsic clearance in rat liver microsome,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,5669,In vitro,N,1,CHEMBL631431,,2107.0,
13016,1,Low plasma clearance was calculated in rhesus monkey,Plasma,BAO_0000218,,Macaca mulatta,,Intermediate,4853,In vivo,N,1,CHEMBL631432,,1969.0,
13017,1,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,16452,In vivo,N,1,CHEMBL631433,,,
13018,1,Plasma clearance after intravenous dose of 0.3 mg/kg,,BAO_0000218,,,,Autocuration,11954,In vivo,U,0,CHEMBL631434,,,
13019,1,Plasma clearance after intravenous dose of 1 mg/kg,,BAO_0000218,,,,Autocuration,11954,In vivo,U,0,CHEMBL631435,,,
13020,1,Plasma clearance after intravenous dose of 3 mg/kg,,BAO_0000218,,,,Autocuration,11954,In vivo,U,0,CHEMBL631436,,,
13021,1,Plasma clearance after intravenous dose of 3.87 mg/kg,,BAO_0000218,,,,Autocuration,11954,In vivo,U,0,CHEMBL631437,,,
13022,1,Plasma clearance after peroral administration at 10 mpk in Rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5669,In vivo,N,1,CHEMBL631438,,,
13023,1,Plasma clearance after peroral administration at 10 mpk in Rhesus,,BAO_0000218,,Macaca mulatta,,Intermediate,5669,In vivo,N,1,CHEMBL876431,,,
13024,1,Plasma clearance after peroral administration at 10 mpk in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5669,In vivo,N,1,CHEMBL631439,,,
13025,1,Totla clearance of compound reported after 5 mg/kg i.v. dose in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,13662,In vivo,N,1,CHEMBL631440,,,
13026,1,Compound was evaluated for physico-chemical property of Critical micellar concentration (CMC),,BAO_0000019,,,,Autocuration,8272,,U,0,CHEMBL631441,,,
13027,1,Critical Micellar concentration was determined,,BAO_0000019,,,,Autocuration,13410,,U,0,CHEMBL631442,,,
13028,1,Critical Micellar concentration of the compound. was determined,,BAO_0000019,,,,Autocuration,13410,,U,0,CHEMBL626525,,,
13029,1,Critical micelle concentration determined from the plots of the fluorescence intensity as a function of compound concentration,,BAO_0000019,,,,Autocuration,12628,,U,0,CHEMBL627168,,,
13030,1,Critical micellar concentration was measured in water by the dye solubilization method,,BAO_0000019,,,,Autocuration,9675,,U,0,CHEMBL875618,,,
13031,1,Hydrolysis turn over determined from the plots of the fluorescence assay quantified by HPLC,,BAO_0000019,,,,Autocuration,12628,,U,0,CHEMBL626612,,,
13032,1,CMR value (relative to BAY K 8644),,BAO_0000019,,,,Autocuration,12766,,U,0,CHEMBL626613,,,
13033,1,Carbamoylating activity was determined,,BAO_0000019,,,,Autocuration,7849,,U,0,CHEMBL626614,,,
13034,1,Hypotension peak is percentage change from predose baseline pressure observed after intraduodenal dose of 10 mg/kg in monkey,,BAO_0000218,,Simiiformes,,Autocuration,12187,,U,0,CHEMBL626615,,,
13035,1,Compound was evaluated for induced thermal stabilization for compound: DNA ratio of 1:10 at 0.1 to 0.2 degrees Centigrade.,,BAO_0000019,,,,Autocuration,2040,,U,0,CHEMBL626616,,,
13036,1,Compound was evaluated for induced thermal stabilization for compound: DNA ratio of 1:5 at 0.1 to 0.2 degrees Centigrade.,,BAO_0000019,,,,Autocuration,2040,,U,0,CHEMBL626617,,,
13037,1,Clearance from dog plasma after intravenous injection of 1 mg/kg of compound,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,14180,In vivo,N,1,CHEMBL626618,,1969.0,
13038,1,Clearance from rat plasma after intravenous injection of 1 mg/kg of compound,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14180,In vivo,N,1,CHEMBL626619,,1969.0,
13039,1,"Clearance rate at 0.46 mg/kg, iv, in dogs",,BAO_0000218,,Canis lupus familiaris,,Intermediate,14474,In vivo,N,1,CHEMBL626620,,,
13040,1,"Clearance rate at 5.5 mg/kg, iv, in rat",,BAO_0000218,,Rattus norvegicus,,Intermediate,14474,In vivo,N,1,CHEMBL626621,,,
13041,1,Pharmacokinetic parameter Cl calculated in cynomolgus monkey when the compound was administered intravenously at 1 mg/kg concentration,,BAO_0000218,,Macaca fascicularis,,Intermediate,14548,In vivo,N,1,CHEMBL626622,,,
13042,1,Pharmacokinetic parameter Cl calculated in cynomolgus monkey when the compound was administered intravenously at 0.5 mg/kg concentration,,BAO_0000218,,Macaca fascicularis,,Intermediate,14548,In vivo,N,1,CHEMBL626623,,,
13043,1,Pharmacokinetic parameter Cl calculated in dog when the compound was administered intravenously at 2 mg/kg concentration,,BAO_0000218,,Canis lupus familiaris,,Intermediate,14548,In vivo,N,1,CHEMBL626624,,,
13044,1,Pharmacokinetic parameter Cl calculated in rat when the compound was administered intravenously at 5 mg/kg concentration,,BAO_0000218,,Rattus norvegicus,,Intermediate,14548,In vivo,N,1,CHEMBL626625,,,
13045,1,Clearance rate constant using isolated perfused rat liver (IPRL) assay,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,6125,Ex vivo,N,1,CHEMBL626626,,2107.0,
13046,1,Tested for the total clearance of the compound,,BAO_0000218,,,,Autocuration,6874,In vivo,U,0,CHEMBL626627,,,
13047,1,The clearance was measured in dogs after intravenous administration of 1 mg/kg dose,,BAO_0000218,,Canis lupus familiaris,,Intermediate,15343,In vivo,N,1,CHEMBL626628,,,
13048,1,Total body clearance was determined,,BAO_0000218,,,,Autocuration,6236,In vivo,U,0,CHEMBL626629,,,
13049,1,Mean Chlorine excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL626630,,,
13050,1,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL626631,,,
13051,1,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Centigrade after 8.0 hr,,BAO_0000100,,,,Autocuration,8194,,U,0,CHEMBL626632,,,
13052,1,Solubility of 150 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,,BAO_0000100,,,,Autocuration,8194,,U,0,CHEMBL626633,,,
13053,1,Solubility of 150 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 8.0 hr,,BAO_0000100,,,,Autocuration,8194,,U,0,CHEMBL626634,,,
13054,1,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 13.5 hr,,BAO_0000100,,,,Autocuration,8194,,U,0,CHEMBL626635,,,
13055,1,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,,BAO_0000100,,,,Autocuration,8194,,U,0,CHEMBL626636,,,
13056,1,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Centigrade after 8.0 hr,,BAO_0000100,,,,Autocuration,8194,,U,0,CHEMBL626637,,,
13057,1,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 10.9 uM/Kg/day),,BAO_0000218,,Pneumocystis carinii,,Intermediate,13273,,N,1,CHEMBL626638,,,
13058,1,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 2.3 uM/Kg/day,,BAO_0000218,,Pneumocystis carinii,,Intermediate,13273,,N,1,CHEMBL626639,,,
13059,1,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 23.3 uM/Kg/day,,BAO_0000218,,Pneumocystis carinii,,Intermediate,13273,,N,1,CHEMBL626640,,,
13060,1,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 4.8 uM/Kg/day,,BAO_0000218,,Pneumocystis carinii,,Intermediate,13273,,N,1,CHEMBL626641,,,
13061,1,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 9.2 uM/Kg/day,,BAO_0000218,,Pneumocystis carinii,,Intermediate,13273,,N,1,CHEMBL627272,,,
13062,1,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted uM/Kg/day,,BAO_0000218,,Pneumocystis carinii,,Intermediate,13273,,N,1,CHEMBL627273,,,
13063,1,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 0.027 (uM/kg/day),,BAO_0000218,,Pneumocystis carinii,,Intermediate,13273,,N,1,CHEMBL627441,,,
13064,1,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 0.27 (uM/kg/day),,BAO_0000218,,Pneumocystis carinii,,Intermediate,13273,,N,1,CHEMBL628355,,,
13065,1,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 13.3 (uM/kg/day),,BAO_0000218,,Pneumocystis carinii,,Intermediate,13273,,N,1,CHEMBL628356,,,
13066,1,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 2.7 (uM/kg/day),,BAO_0000218,,Pneumocystis carinii,,Intermediate,13273,,N,1,CHEMBL628357,,,
13067,1,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 22.1 (uM/kg/day),,BAO_0000218,,Pneumocystis carinii,,Intermediate,13273,,N,1,CHEMBL628358,,,
13068,1,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 66.3 (uM/kg/day),,BAO_0000218,,Pneumocystis carinii,,Intermediate,13273,,N,1,CHEMBL622307,,,
13069,1,Conversion rate by hydrolysis of compound in plasma after 2 hr at a pH of 1.0,,BAO_0000019,,,,Autocuration,13118,,U,0,CHEMBL622527,,,
13070,1,Conversion rate by hydrolysis of compound in plasma after 2 hr at a pH of 1.0; Not detectable,,BAO_0000019,,,,Autocuration,13118,,U,0,CHEMBL622528,,,
13071,1,Conversion rate by hydrolysis of compound in plasma after 4 hr at a pH of 7.4,,BAO_0000019,,,,Autocuration,13118,,U,0,CHEMBL622529,,,
13072,1,Conversion rate by hydrolysis of compound in plasma after 4 hr at a pH of 7.4; Not detectable,,BAO_0000019,,,,Autocuration,13118,,U,0,CHEMBL622992,,,
13073,1,Conversion rate by hydrolysis of compound in plasma after 6 hr. ,,BAO_0000019,,,,Autocuration,13118,,U,0,CHEMBL622993,,,
13074,1,Conversion rate by hydrolysis of compound in plasma after 6 h; Not detectable,,BAO_0000019,,,,Autocuration,13118,,U,0,CHEMBL622994,,,
13075,1,"In vitro rate constant, correlation coefficient for the conversion to progesterone in rat liver homogenate",,BAO_0000218,,Rattus norvegicus,,Intermediate,10633,,N,1,CHEMBL622995,,,
13076,1,"In vitro rate constant, correlation coefficient for the conversion to progesterone in whole rat blood.",,BAO_0000218,,Rattus norvegicus,,Intermediate,10633,,N,1,CHEMBL622996,,,
13077,1,"In vitro rate constant, correlation coefficient for the disappearance in rat liver homogenate",,BAO_0000218,,Rattus norvegicus,,Intermediate,10633,,N,1,CHEMBL622997,,,
13078,1,"In vitro rate constant, correlation coefficient for the disappearance in rat brain homogenate",,BAO_0000218,,Rattus norvegicus,,Intermediate,10633,,N,1,CHEMBL622998,,,
13079,1,Cp max following ip administration at 1 mg/kg,,BAO_0000218,,,,Autocuration,5767,,U,0,CHEMBL622999,,,
13080,1,Maximum concentration in plasma was reported at 0.5 hour,Plasma,BAO_0000218,,,,Autocuration,3302,In vivo,U,0,CHEMBL623000,,1969.0,
13081,1,Maximum concentration in plasma was reported at 2 hour,Plasma,BAO_0000218,,,,Autocuration,3302,In vivo,U,0,CHEMBL623001,,1969.0,
13082,1,Cellular uptake kinetics of Porphycenes saturation cell level (cs) in SSK3 murine fibrosarcoma cells,,BAO_0000218,,Mus musculus,,Intermediate,12467,,N,1,CHEMBL623002,,,
13083,1,Aqueous solubility in 25 mM N-glycyl-glycine and 10 mM MgSO4 (pH 7.8),,BAO_0000100,,,,Autocuration,11778,,U,0,CHEMBL623003,,,
13084,1,Steady state concentration was evaluated,,BAO_0000019,,,,Autocuration,4321,,U,0,CHEMBL623004,,,
13085,1,Partition coefficient (logP),,BAO_0000019,,,,Autocuration,14884,,U,0,CHEMBL623005,,,
13086,1,Partition coefficient (logD7.4),,BAO_0000019,,,,Autocuration,15234,,U,0,CHEMBL623006,,,
13087,1,Biodistribution of {18]Fluoro-CGP 12388 (60 minutes post injection) in liver of male wistar rats,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,N,1,CHEMBL623007,,2107.0,
13088,1,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in bone of male wistar rats,Bone,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,N,1,CHEMBL623008,,10000001.0,
13089,1,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in cerebellum of male wistar rats,Cerebellum,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,N,1,CHEMBL876654,,2037.0,
13090,1,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in cortex of male wistar rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,N,1,CHEMBL623009,,,
13091,1,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in fat of male wistar rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,N,1,CHEMBL623010,,,
13092,1,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in heart of male wistar rats,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,N,1,CHEMBL623011,,948.0,
13093,1,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in intestine of male wistar rats,Intestine,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,N,1,CHEMBL623012,,160.0,
13094,1,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg,,BAO_0000019,,,,Autocuration,8151,,U,0,CHEMBL623013,,,
13095,1,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli euivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,,BAO_0000019,,,,Autocuration,8151,,U,0,CHEMBL623014,,,
13096,1,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 10 mg/Kg,Urine,BAO_0000019,,,,Autocuration,8151,,U,0,CHEMBL623015,,1088.0,
13097,1,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,Urine,BAO_0000019,,,,Autocuration,8151,,U,0,CHEMBL623016,,1088.0,
13098,1,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 25 mg/Kg,Urine,BAO_0000019,,,,Autocuration,8151,,U,0,CHEMBL624858,,1088.0,
13099,1,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 10 mg/Kg.,,BAO_0000218,,Rattus norvegicus,,Intermediate,8151,,N,1,CHEMBL624859,,,
13100,1,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,8151,,N,1,CHEMBL624860,,,
13101,1,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,,BAO_0000218,,Rattus norvegicus,,Intermediate,8151,,N,1,CHEMBL624861,,,
13102,1,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,8151,,N,1,CHEMBL624862,,,
13103,1,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg.,,BAO_0000218,,Rattus norvegicus,,Intermediate,8151,,N,1,CHEMBL624863,,,
13104,1,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli euivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,,BAO_0000218,,Rattus norvegicus,,Intermediate,8151,,N,1,CHEMBL876655,,,
13105,1,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,N,1,CHEMBL624864,,,
13106,1,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 0-99,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,N,1,CHEMBL624865,,,
13107,1,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,N,1,CHEMBL624866,,,
13108,1,Salidiuretic activity in dog following i.v. dosing at 5 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Expert,6996,,N,1,CHEMBL624867,,,
13109,1,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 400-599,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,N,1,CHEMBL624868,,,
13110,1,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600- 799,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,N,1,CHEMBL628450,,,
13111,1,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600-799,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,N,1,CHEMBL628451,,,
13112,1,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 800-899,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,N,1,CHEMBL628452,,,
13113,1,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,N,1,CHEMBL628453,,,
13114,1,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; act above 5 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,N,1,CHEMBL628454,,,
13115,1,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,N,1,CHEMBL628455,,,
13116,1,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 0-99,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,N,1,CHEMBL628456,,,
13117,1,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,N,1,CHEMBL628457,,,
13118,1,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-299,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,N,1,CHEMBL877505,,,
13119,1,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 250-399,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,N,1,CHEMBL628458,,,
13120,1,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 400-599,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,N,1,CHEMBL628459,,,
13121,1,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600-799,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,N,1,CHEMBL628460,,,
13122,1,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 800-899,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,N,1,CHEMBL628461,,,
13123,1,"Evaluated for salidiuretic activity measured as sodium ion excretion in Rat, administered orally at a dose of 16.5 mg/kg",,BAO_0000218,,,,Autocuration,6996,,U,0,CHEMBL628462,,,
13124,1,Compound administered orally at a dose of 1 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,N,1,CHEMBL628463,,,
13125,1,"Evaluated for salidiuretic activity measured as sodium ion excretion in Rat, administered orally at a dose of 50 mg/kg",,BAO_0000218,,Rattus norvegicus,,Expert,6996,,N,1,CHEMBL625666,,,
13126,1,Compound administered orally at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,,BAO_0000218,,,,Autocuration,6996,,U,0,CHEMBL625667,,,
13127,1,Compound administered orally at a dose of 81 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,,BAO_0000218,,Rattus norvegicus,,Expert,6996,,N,1,CHEMBL625668,,,
13128,1,Compound administered orally was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,N,1,CHEMBL625669,,,
13129,1,Compound was tested for diuretic activity in potassium content of the 3-h sample was measured by flame photometry,,BAO_0000019,,,,Autocuration,7114,,U,0,CHEMBL625670,,,
13130,1,Compound was tested for diuretic activity in potassium content of the 3-h sample was measured by flame photometry in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,7114,,N,1,CHEMBL625671,,,
13131,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 1 mg/kg per day.,,BAO_0000218,,Human herpesvirus 1,,Intermediate,8613,,N,1,CHEMBL625672,,,
13132,1,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 0.8 mg/kg administered subcutaneously,,BAO_0000218,,Human herpesvirus 1,,Intermediate,8613,,N,1,CHEMBL625673,,,
13133,1,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 0.8 mg/kg administered subcutaneously.,,BAO_0000218,,Human herpesvirus 1,,Intermediate,8613,,N,1,CHEMBL625674,,,
13134,1,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously,,BAO_0000218,,Human herpesvirus 1,,Intermediate,8613,,N,1,CHEMBL625675,,,
13135,1,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously.,,BAO_0000218,,Human herpesvirus 1,,Intermediate,8613,,N,1,CHEMBL627637,,,
13136,1,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered orally.,,BAO_0000218,,Human herpesvirus 1,,Intermediate,8613,,N,1,CHEMBL627638,,,
13137,1,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered subcutaneously,,BAO_0000218,,Human herpesvirus 1,,Intermediate,8613,,N,1,CHEMBL627639,,,
13138,1,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered subcutaneously.,,BAO_0000218,,Human herpesvirus 1,,Intermediate,8613,,N,1,CHEMBL627640,,,
13139,1,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered orally.,,BAO_0000218,,Human herpesvirus 1,,Intermediate,8613,,N,1,CHEMBL627641,,,
13140,1,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 50 mg/kg administered orally.,,BAO_0000218,,Human herpesvirus 1,,Intermediate,8613,,N,1,CHEMBL627642,,,
13141,1,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 50 mg/kg administered orally.,,BAO_0000218,,Human herpesvirus 1,,Intermediate,8613,,N,1,CHEMBL877506,,,
13142,1,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously.,,BAO_0000218,,Mus musculus,,Intermediate,8613,,N,1,CHEMBL627275,,,
13143,1,"Average area under curve value dosed at 0.3 mg/kg, iv in ferrets.",,BAO_0000218,,Mustela putorius furo,,Intermediate,11219,,N,1,CHEMBL627643,,,
13144,1,"Average area under curve value dosed at 10 mg/kg, id in ferrets.",,BAO_0000218,,Mustela putorius furo,,Intermediate,11219,,N,1,CHEMBL631246,,,
13145,1,"Average area under curve value dosed at 10 mg/kg, id in ferrets.",,BAO_0000218,,Mustela putorius furo,,Intermediate,11219,,N,1,CHEMBL631247,,,
13146,1,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from portal blood).,,BAO_0000218,,Mustela putorius furo,,Intermediate,11219,,N,1,CHEMBL629532,,,
13147,1,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from arterial blood).,,BAO_0000218,,Mustela putorius furo,,Intermediate,11219,,N,1,CHEMBL629533,,,
13148,1,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from portal blood).,,BAO_0000218,,Mustela putorius furo,,Intermediate,11219,,N,1,CHEMBL629534,,,
13149,1,Average peak plasma drug concentration after iv dose of 0.3 mg/kg in ferrets.,,BAO_0000218,,Mustela putorius furo,,Intermediate,11219,,N,1,CHEMBL629535,,,
13150,1,Pharmacokinetic parameter :drug bound to plasma was reported,,BAO_0000019,,,,Autocuration,14837,,U,0,CHEMBL625932,,,
13151,1,compound was evaluated for drug bound in plasma,,BAO_0000019,,,,Autocuration,14837,,U,0,CHEMBL625933,,,
13152,1,The Brain concentration compared to plasma concentration in rats after oral administration of 1 mg/kg dose,,BAO_0000218,,Rattus norvegicus,,Intermediate,15343,,N,1,CHEMBL625934,,,
13153,1,Bioavailability,,BAO_0000218,,Eutheria,,Autocuration,13761,,U,0,CHEMBL625935,,,
13154,1,Compound at a dose of 10 mg/kg was orally administered to rats and Bioavailability was reported,,BAO_0000218,,Rattus norvegicus,,Intermediate,14810,,N,1,CHEMBL625936,,,
13155,1,Compound at a dose of 10 mg/kg was orally administered to rats and Bioavailability was reported; Not tested,,BAO_0000218,,Rattus norvegicus,,Intermediate,14810,,N,1,CHEMBL625937,,,
13156,1,Oral bioavailability in Beagle dogs at oral dose of 20 mg/kg and an intravenous dose of 5 mg/kg was administered,,BAO_0000218,,Canis lupus familiaris,,Intermediate,13249,,N,1,CHEMBL625938,,,
13157,1,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-1 hr after the treatment.,Bile,BAO_0000218,,Rattus norvegicus,,Intermediate,9267,,N,1,CHEMBL625939,,1970.0,
13158,1,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-2 hr after the treatment.,Bile,BAO_0000218,,Rattus norvegicus,,Intermediate,9267,,N,1,CHEMBL625940,,1970.0,
13159,1,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-3 hr after the treatment.,Bile,BAO_0000218,,Rattus norvegicus,,Intermediate,9267,,N,1,CHEMBL874464,,1970.0,
13160,1,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-4 hr after the treatment.,Bile,BAO_0000218,,Rattus norvegicus,,Intermediate,9267,,N,1,CHEMBL625941,,1970.0,
13161,1,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-5 hr after the treatment.,Bile,BAO_0000218,,Rattus norvegicus,,Intermediate,9267,,N,1,CHEMBL625942,,1970.0,
13162,1,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-6 hr after the treatment.,Bile,BAO_0000218,,Rattus norvegicus,,Intermediate,9267,,N,1,CHEMBL625943,,1970.0,
13163,1,In vitro protein binding in human serum at 5 ug/ml,Serum,BAO_0000218,,Homo sapiens,,Intermediate,15549,,N,1,CHEMBL625944,,1977.0,
13164,1,Serum protein binding ability was measured,,BAO_0000019,,,,Autocuration,10929,,U,0,CHEMBL625945,,,
13165,1,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),,BAO_0000019,,,,Autocuration,15444,,U,0,CHEMBL625946,,,
13166,1,Oral bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Autocuration,12860,In vivo,U,0,CHEMBL625947,,,
13167,1,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,,BAO_0000218,,Rattus norvegicus,,Intermediate,12170,In vivo,N,1,CHEMBL625948,,,
13168,1,Absolute oral bioavailability at an iv dose of 14 mg/kg,,BAO_0000218,,,,Autocuration,15173,In vivo,U,0,CHEMBL625949,,,
13169,1,Absolute oral bioavailability at an iv dose of 15.2 mg/kg,,BAO_0000218,,,,Autocuration,15173,In vivo,U,0,CHEMBL625950,,,
13170,1,Oral bioavailability (dose 15 mg/kg i.v.),,BAO_0000218,,Eutheria,,Autocuration,15173,In vivo,U,0,CHEMBL625951,,,
13171,1,Absolute oral bioavailability at an peroral dose of 15 mg/kg orally.,,BAO_0000218,,,,Autocuration,15173,In vivo,U,0,CHEMBL625952,,,
13172,1,Absolute oral bioavailability at an peroral dose of 30 mg/kg orally,,BAO_0000218,,,,Autocuration,15173,In vivo,U,0,CHEMBL625953,,,
13173,1,Absolute oral bioavailability at an peroral dose of 30.2 mg/kg orally.,,BAO_0000218,,,,Autocuration,15173,In vivo,U,0,CHEMBL625954,,,
13174,1,Absolute oral bioavailability at an peroral dose of 30.3 mg/kg orally.,,BAO_0000218,,,,Autocuration,15173,In vivo,U,0,CHEMBL882959,,,
13175,1,Apparent bioavailability in dogs at 15 mg/kg in an iv vs po dosing regimen,,BAO_0000218,,Canis lupus familiaris,,Intermediate,11767,In vivo,N,1,CHEMBL625955,,,
13176,1,Bioavailability in ferret,,BAO_0000218,,Mustela putorius furo,,Autocuration,11219,In vivo,U,0,CHEMBL625956,,,
13177,1,Bioavailability after intraduodenal administration at a dose 10 mg/kg in cynomolgus monkeys using renin inhibition assay,,BAO_0000218,,Macaca fascicularis,,Intermediate,12186,In vivo,N,1,CHEMBL625957,,,
13178,1,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL625958,,,
13179,1,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL625959,,,
13180,1,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL626642,,,
13181,1,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL631330,,,
13182,1,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL631331,,,
13183,1,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL631332,,,
13184,1,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL631333,,,
13185,1,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL632018,,,
13186,1,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL632019,,,
13187,1,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL632020,,,
13188,1,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL632021,,,
13189,1,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL632022,,,
13190,1,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL632023,,,
13191,1,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL632024,,,
13192,1,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL874472,,,
13193,1,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL632025,,,
13194,1,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL632026,,,
13195,1,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL632027,,,
13196,1,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL632028,,,
13197,1,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL626430,,,
13198,1,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL626431,,,
13199,1,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL626432,,,
13200,1,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL626433,,,
13201,1,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL626434,,,
13202,1,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL627280,,,
13203,1,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL627281,,,
13204,1,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL627282,,,
13205,1,Total body clearance was measured at given dose,,BAO_0000019,,,,Autocuration,7199,,U,0,CHEMBL627283,,,
13206,1,Total body clearance was measured at given dose.,,BAO_0000218,,,,Autocuration,7199,,U,0,CHEMBL627284,,,
13207,1,Metabolic clearance from the body in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,7095,,N,1,CHEMBL627285,,,
13208,1,Renal clearance from the body,,BAO_0000218,,,,Autocuration,7095,In vivo,U,0,CHEMBL627286,,,
13209,1,Renal clearance from the body in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,7095,In vivo,N,1,CHEMBL875477,,,
13210,1,Tested for pharmacokinetic parameter to calculate the total body clearance at a dosage of 12 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,12528,In vivo,N,1,CHEMBL627287,,,
13211,1,Tested for pharmacokinetic parameter to calculate the total body clearance at a dosage of 2.5 mg/kg in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,12528,In vivo,N,1,CHEMBL627288,,,
13212,1,Total clearance from the body in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,7095,,N,1,CHEMBL627289,,,
13213,1,Clearance into cortex from rat plasma or PBS,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14223,In vivo,N,1,CHEMBL627290,,1969.0,
13214,1,Clearance at an iv dose of 15 mg/Kg and po dose of 120 mg/Kg,,BAO_0000218,,,,Autocuration,13569,In vivo,U,0,CHEMBL627291,,,
13215,1,Clearance at an iv dose of 15 mg/Kg and po dose of 240 mg/Kg,,BAO_0000218,,,,Autocuration,13569,In vivo,U,0,CHEMBL627292,,,
13216,1,Clearance at an iv dose of 15 mg/Kg and po dose of 29.1 mg/Kg,,BAO_0000218,,,,Autocuration,13569,In vivo,U,0,CHEMBL627293,,,
13217,1,Clearance at an iv dose of 15 mg/Kg and po dose of 30 mg/Kg,,BAO_0000218,,,,Autocuration,13569,In vivo,U,0,CHEMBL627294,,,
13218,1,Clearance at an iv dose of 15 mg/Kg and po dose of 60 mg/Kg,,BAO_0000218,,,,Autocuration,13569,In vivo,U,0,CHEMBL875478,,,
13219,1,Clearance was determined,,BAO_0000218,,,,Autocuration,13979,In vivo,U,0,CHEMBL627295,,,
13220,1,Clearance was measured in mouse after administration of compound 20 mg/kg intravenously,,BAO_0000218,,Mus musculus,,Intermediate,14315,In vivo,N,1,CHEMBL627296,,,
13221,1,Clearance was measured in rabbit after administration of compound 20 mg/kg intravenously,,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,14315,In vivo,N,1,CHEMBL626119,,,
13222,1,Clearance was measured in rat after administration of compound 20 mg/kg intravenously,,BAO_0000218,,Rattus norvegicus,,Intermediate,14315,In vivo,N,1,CHEMBL626120,,,
13223,1,Clearance in rat after iv dose (100 ug/kg),,BAO_0000218,,Rattus norvegicus,,Intermediate,12174,In vivo,N,1,CHEMBL626121,,,
13224,1,Clearance in guinea pig,,BAO_0000218,,Cavia porcellus,,Autocuration,12797,In vivo,U,0,CHEMBL626122,,,
13225,1,Compound was evaluated for clearance in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,12797,In vivo,N,1,CHEMBL626123,,,
13226,1,Compound was evaluated for the clearance in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,12797,In vivo,N,1,CHEMBL623456,,,
13227,1,Compound was evaluated for the clearance in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,12797,In vivo,N,1,CHEMBL623457,,,
13228,1,Compound was tested in vivo for clearance after iv administration in the rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,11500,In vivo,N,1,CHEMBL623458,,,
13229,1,IV clearance determined at an iv dose of 14 mg/kg,,BAO_0000218,,,,Autocuration,15173,In vivo,U,0,CHEMBL623459,,,
13230,1,IV clearance determined at an iv dose of 15.2 mg/kg,,BAO_0000218,,,,Autocuration,15173,In vivo,U,0,CHEMBL875484,,,
13231,1,IV clearance determined at an iv dose of 15 mg/kg,,BAO_0000218,,,,Autocuration,15173,In vivo,U,0,CHEMBL623460,,,
13232,1,IV clearance determined at an peroral dose of 30 mg/kg.,,BAO_0000218,,,,Autocuration,15173,In vivo,U,0,CHEMBL623461,,,
13233,1,IV clearance determined at an peroral dose of 30.2 mg/kg.,,BAO_0000218,,,,Autocuration,15173,In vivo,U,0,CHEMBL623462,,,
13234,1,IV clearance determined at an peroral dose of 30.3 mg/kg.,,BAO_0000218,,,,Autocuration,15173,In vivo,U,0,CHEMBL627386,,,
13235,1,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in kidney of male wistar rats,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,N,1,CHEMBL627387,,2113.0,
13236,1,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in liver of male wistar rats,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,N,1,CHEMBL627388,,2107.0,
13237,1,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in lung of male wistar rats,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,N,1,CHEMBL627389,,2048.0,
13238,1,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in muscle of male wistar rats,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,N,1,CHEMBL627390,,2385.0,
13239,1,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in plasma of male wistar rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,N,1,CHEMBL627391,,1969.0,
13240,1,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in red blood cells of male wistar rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,N,1,CHEMBL627392,,,
13241,1,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in spleen of male wistar rats,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,N,1,CHEMBL627393,,2106.0,
13242,1,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in trachea of male wistar rats,Trachea,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,N,1,CHEMBL627394,,3126.0,
13243,1,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in bone of male wistar rats,Bone,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,N,1,CHEMBL627395,,10000001.0,
13244,1,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in cerebellum of male wistar rats,Cerebellum,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,N,1,CHEMBL875485,,2037.0,
13245,1,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in cortex of male wistar rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,N,1,CHEMBL627396,,,
13246,1,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in fat of male wistar rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,N,1,CHEMBL627397,,,
13247,1,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in heart of male wistar rats,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,N,1,CHEMBL627398,,948.0,
13248,1,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in intestine bone of male wistar rats,Bone,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,N,1,CHEMBL627399,,10000001.0,
13249,1,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in kidney of male wistar rats,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,N,1,CHEMBL627400,,2113.0,
13250,1,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in liver of male wistar rats,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,N,1,CHEMBL627401,,2107.0,
13251,1,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in lung of male wistar rats,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,N,1,CHEMBL627402,,2048.0,
13252,1,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in muscle of male wistar rats,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,N,1,CHEMBL627403,,2385.0,
13253,1,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in plasma of male wistar rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,N,1,CHEMBL627404,,1969.0,
13254,1,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in red blood cells of male wistar rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,N,1,CHEMBL623101,,,
13255,1,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in spleen of male wistar rats,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,N,1,CHEMBL877480,,2106.0,
13256,1,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in trachea of male wistar rats,Trachea,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,N,1,CHEMBL623102,,3126.0,
13257,1,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in bone of male wistar rats,Bone,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,N,1,CHEMBL623103,,10000001.0,
13258,1,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in cerebellum of male wistar rats,Cerebellum,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,N,1,CHEMBL623104,,2037.0,
13259,1,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in cortex of male wistar rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,N,1,CHEMBL623105,,,
13260,1,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in fat of male wistar rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,N,1,CHEMBL623106,,,
13261,1,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in heart of male wistar rats,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,N,1,CHEMBL623107,,948.0,
13262,1,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in intestine of male wistar rats,Intestine,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,N,1,CHEMBL623108,,160.0,
13263,1,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in kidney of male wistar rats,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,N,1,CHEMBL623109,,2113.0,
13264,1,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in liver of male wistar rats,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,N,1,CHEMBL623110,,2107.0,
13265,1,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in lung of male wistar rats,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,N,1,CHEMBL623111,,2048.0,
13266,1,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in muscle of male wistar rats,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,N,1,CHEMBL625060,,2385.0,
13267,1,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in plasma of male wistar rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,N,1,CHEMBL625061,,1969.0,
13268,1,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in red blood cells of male wistar rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,N,1,CHEMBL625062,,,
13269,1,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in spleen of male wistar rats,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,N,1,CHEMBL625063,,2106.0,
13270,1,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in trachea of male wistar rats,Trachea,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,N,1,CHEMBL625064,,3126.0,
13271,1,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in bone of male wistar rats,Bone,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,N,1,CHEMBL625065,,10000001.0,
13272,1,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in cerebellum of male wistar rats,Cerebellum,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,N,1,CHEMBL625066,,2037.0,
13273,1,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in cortex of male wistar rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,N,1,CHEMBL625067,,,
13274,1,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in fat of male wistar rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,N,1,CHEMBL625068,,,
13275,1,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in heart of male wistar rats,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,N,1,CHEMBL622159,,948.0,
13276,1,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in intestine of male wistar rats,Intestine,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,N,1,CHEMBL622160,,160.0,
13277,1,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in kidney of male wistar rats,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,N,1,CHEMBL622161,,2113.0,
13278,1,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in lung of male wistar rats,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,N,1,CHEMBL622162,,2048.0,
13279,1,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in muscle of male wistar rats,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,N,1,CHEMBL622163,,2385.0,
13280,1,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in plasma of male wistar rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,N,1,CHEMBL622313,,1969.0,
13281,1,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in red blood cells of male wistar rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,N,1,CHEMBL622314,,,
13282,1,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in spleen of male wistar rats,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,N,1,CHEMBL622315,,2106.0,
13283,1,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in trachea of male wistar rats,Trachea,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,N,1,CHEMBL622316,,3126.0,
13284,1,Normal diffusion coefficient in water for Escherichia coli,,BAO_0000218,,Escherichia coli,,Intermediate,15599,,N,1,CHEMBL877486,,,
13285,1,Average max percent decrease in RVR (renal vascular resistance) was determined,,BAO_0000019,,,,Autocuration,8204,,U,0,CHEMBL622317,,,
13286,1,Average max percent decrease in RVR (renal vascular resistance) was determined.,,BAO_0000019,,,,Autocuration,8204,,U,0,CHEMBL622318,,,
13287,1,In vitro stability to pepsin promoting hydrolysis after 1 hr incubation time,,BAO_0000019,,,,Autocuration,6154,,U,0,CHEMBL622319,,,
13288,1,In vitro stability to pepsin promoting hydrolysis after 2 hr incubation time,,BAO_0000019,,,,Autocuration,6154,,U,0,CHEMBL622320,,,
13289,1,In vitro stability to pepsin promoting hydrolysis after 64h incubation time,,BAO_0000019,,,,Autocuration,6154,,U,0,CHEMBL622321,,,
13290,1,In vitro stability to pepsin promoting hydrolysis after 84 hr incubation time,,BAO_0000019,,,,Autocuration,6154,,U,0,CHEMBL622322,,,
13291,1,Compound was tested for diuretic activity in sodium content of the 3-h sample was measured by flame photometry,,BAO_0000019,,,,Autocuration,7114,,U,0,CHEMBL622323,,,
13292,1,Compound was tested for diuretic activity in sodium content of the 3-h sample was measured by flame photometry in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,7114,,N,1,CHEMBL622324,,,
13293,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 0.03mg/kg, po",Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,8133,,N,1,CHEMBL622325,,1088.0,
13294,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,8133,,N,1,CHEMBL622326,,1088.0,
13295,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 10.0 mg/kg, po",Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,8133,,N,1,CHEMBL877487,,1088.0,
13296,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 1 mg/kg, po",Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,8133,,N,1,CHEMBL622327,,1088.0,
13297,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 3.0 mg/kg, po",Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,8133,,N,1,CHEMBL622328,,1088.0,
13298,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 30 mg/kg, po",Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,8133,,N,1,CHEMBL622329,,1088.0,
13299,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,8133,,N,1,CHEMBL622330,,1088.0,
13300,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 0.3mg/kg, po",Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,8133,,N,1,CHEMBL622331,,1088.0,
13301,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,8133,,N,1,CHEMBL622332,,1088.0,
13302,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 3 mg/kg, po",Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,8133,,N,1,CHEMBL622333,,1088.0,
13303,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",Urine,BAO_0000218,,Simiiformes,,Autocuration,8133,,U,0,CHEMBL627658,,1088.0,
13304,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 10mg/kg, po",Urine,BAO_0000218,,Simiiformes,,Autocuration,8133,,U,0,CHEMBL630428,,1088.0,
13305,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",Urine,BAO_0000218,,Simiiformes,,Autocuration,8133,,U,0,CHEMBL630429,,1088.0,
13306,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 30 mg/kg, po",Urine,BAO_0000218,,Simiiformes,,Autocuration,8133,,U,0,CHEMBL630430,,1088.0,
13307,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 3 mg/kg, po",Urine,BAO_0000218,,Simiiformes,,Autocuration,8133,,U,0,CHEMBL630431,,1088.0,
13308,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,8133,,N,1,CHEMBL630432,,1088.0,
13309,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 0.3mg/kg, po",Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,8133,,N,1,CHEMBL630433,,1088.0,
13310,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 1.0mg/kg, po",Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,8133,,N,1,CHEMBL630434,,1088.0,
13311,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 10.0mg/kg, po",Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,8133,,N,1,CHEMBL629372,,1088.0,
13312,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 100.0mg/kg, po",Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,8133,,N,1,CHEMBL629553,,1088.0,
13313,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 2.1 mg/kg, po",Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,8133,,N,1,CHEMBL629554,,1088.0,
13314,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 20.8mg/kg, po",Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,8133,,N,1,CHEMBL874447,,1088.0,
13315,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 207.6mg/kg, po",Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,8133,,N,1,CHEMBL629555,,1088.0,
13316,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 3.0mg/kg, po",Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,8133,,N,1,CHEMBL629556,,1088.0,
13317,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded rats at 30.0 mg/kg, po",Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,8133,,N,1,CHEMBL629557,,1088.0,
13318,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 6.9mg/kg, po",Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,8133,,N,1,CHEMBL629558,,1088.0,
13319,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 69.2mg/kg, po",Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,8133,,N,1,CHEMBL629559,,1088.0,
13320,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 691.9mg/kg, po",Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,8133,,N,1,CHEMBL629560,,1088.0,
13321,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.03mg/kg, po",Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,8133,,N,1,CHEMBL629561,,1088.0,
13322,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,8133,,N,1,CHEMBL629562,,1088.0,
13323,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.3mg/kg, po",Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,8133,,N,1,CHEMBL629563,,1088.0,
13324,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,8133,,N,1,CHEMBL629564,,1088.0,
13325,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 10.0mg/kg, po",Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,8133,,N,1,CHEMBL629565,,1088.0,
13326,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,8133,,N,1,CHEMBL629566,,1088.0,
13327,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded dogs at 1 mg/kg, po",Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,8133,,N,1,CHEMBL629567,,1088.0,
13328,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 3.0mg/kg, po",Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,8133,,N,1,CHEMBL629568,,1088.0,
13329,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 30mg/kg, po",Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,8133,,N,1,CHEMBL629569,,1088.0,
13330,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 3mg/kg, po",Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,8133,,N,1,CHEMBL629570,,1088.0,
13331,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",Urine,BAO_0000218,,Simiiformes,,Autocuration,8133,,U,0,CHEMBL629571,,1088.0,
13332,1,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,,BAO_0000218,,Rattus norvegicus,,Autocuration,12170,In vivo,U,0,CHEMBL629572,,,
13333,1,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,,BAO_0000218,,Rattus norvegicus,,Autocuration,12170,In vivo,U,0,CHEMBL629573,,,
13334,1,Bioavailability (dose 20 mg/kg),,BAO_0000218,,Eutheria,,Autocuration,4985,In vivo,U,0,CHEMBL629574,,,
13335,1,Bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Autocuration,15145,In vivo,U,0,CHEMBL629575,,,
13336,1,Bioavailability in rat (Sprague-Dawley) (male),,BAO_0000218,,Rattus norvegicus,,Autocuration,14080,In vivo,U,0,CHEMBL874448,,,
13337,1,Bioavailability in monkey (dose 10 mg/kg i.d.),,BAO_0000218,,Primates,,Autocuration,11219,In vivo,U,0,CHEMBL629576,,,
13338,1,Bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Autocuration,15145,In vivo,U,0,CHEMBL629577,,,
13339,1,Bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Autocuration,15145,In vivo,U,0,CHEMBL629578,,,
13340,1,Bioavailability in dog (dose 3.0 mg/kg p.o.),,BAO_0000218,,Canis lupus familiaris,,Autocuration,1202,In vivo,U,0,CHEMBL629579,,,
13341,1,Bioavailability in dog (dose of 1.0 mg/kg i.v.) 0.5 hr,,BAO_0000218,,Canis lupus familiaris,,Autocuration,1202,In vivo,U,0,CHEMBL882958,,,
13342,1,Bioavailability was calculated after peroral dose of 10 mg/Kg in chimp,,BAO_0000218,,Pan troglodytes,,Intermediate,1202,In vivo,N,1,CHEMBL629580,,,
13343,1,Bioavailability,,BAO_0000218,,Eutheria,,Autocuration,4026,In vivo,U,0,CHEMBL629581,,,
13344,1,Bioavailability in squirrel monkey,,BAO_0000218,,Saimiri,,Autocuration,1492,In vivo,U,0,CHEMBL629582,,,
13345,1,Bioavailability was evaluated in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,12793,In vivo,N,1,CHEMBL628522,,,
13346,1,Bioavailability was evaluated in hamster,,BAO_0000218,,Cricetinae,,Intermediate,12793,In vivo,N,1,CHEMBL625432,,,
13347,1,Bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Autocuration,12793,In vivo,U,0,CHEMBL625433,,,
13348,1,Bioavailability was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14793,In vivo,N,1,CHEMBL625434,,1969.0,
13349,1,Bioavailability was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg; <Tr>,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14793,In vivo,N,1,CHEMBL625435,,1969.0,
13350,1,Bioavailability in rat (dose 10 mg/kg p.o.),,BAO_0000218,,Rattus norvegicus,,Autocuration,14793,In vivo,U,0,CHEMBL625436,,,
13351,1,Bioavailability was measured in cynomolgus monkeys.,,BAO_0000218,,Macaca fascicularis,,Intermediate,14731,In vivo,N,1,CHEMBL874588,,,
13352,1,Bioavailability was measured in nude mice.,,BAO_0000218,,Mus musculus,,Intermediate,14731,In vivo,N,1,CHEMBL625437,,,
13353,1,Bioavailability in ferret (dose 10 mg/kg i.d.),,BAO_0000218,,Mustela putorius furo,,Autocuration,12187,In vivo,U,0,CHEMBL625438,,,
13354,1,Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 0.3 mg/kg intravenous dose),,BAO_0000218,,Simiiformes,,Autocuration,12187,In vivo,U,0,CHEMBL625439,,,
13355,1,"Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 0.3 mg/kg intravenous dose), determined by renin inhibition assay",,BAO_0000218,,Simiiformes,,Autocuration,12187,In vivo,U,0,CHEMBL625440,,,
13356,1,Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 1 mg/kg intravenous dose),,BAO_0000218,,Simiiformes,,Autocuration,12187,In vivo,U,0,CHEMBL625441,,,
13357,1,Bioavailability in rat (dose 10 mg/kg i.d.),,BAO_0000218,,Rattus norvegicus,,Autocuration,12187,In vivo,U,0,CHEMBL625442,,,
13358,1,"Bioavailability was determined after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",,BAO_0000218,,Rattus norvegicus,,Intermediate,12187,In vivo,N,1,CHEMBL625443,,,
13359,1,Bioavailability was determined; extremely poor,,BAO_0000218,,,,Autocuration,17431,In vivo,U,0,CHEMBL625444,,,
13360,1,% bioavailability in mice after oral administration of prodrug,,BAO_0000218,,Mus musculus,,Intermediate,13318,In vivo,N,1,CHEMBL625445,,,
13361,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose 10/30 range (low/high); -21/-5,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,N,1,CHEMBL625446,,,
13362,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -2/6,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,N,1,CHEMBL882960,,,
13363,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -4/-14,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,N,1,CHEMBL625447,,,
13364,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -5/-12,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,N,1,CHEMBL625448,,,
13365,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3/10 range (low/high); -1/-7/-11,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,N,1,CHEMBL625449,,,
13366,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high),,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,N,1,CHEMBL874589,,,
13367,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -1/-9,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,N,1,CHEMBL625450,,,
13368,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -11/-28,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,N,1,CHEMBL625451,,,
13369,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -13/-29,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,N,1,CHEMBL626584,,,
13370,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -13/30,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,N,1,CHEMBL626585,,,
13371,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -16/-18,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,N,1,CHEMBL626586,,,
13372,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -16/-35,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,N,1,CHEMBL626587,,,
13373,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -19/-50,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,N,1,CHEMBL626588,,,
13374,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -21/-29,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,N,1,CHEMBL626589,,,
13375,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -24/-56,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,N,1,CHEMBL626590,,,
13376,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -25/-33,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,N,1,CHEMBL626591,,,
13377,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -3/-13,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,N,1,CHEMBL627181,,,
13378,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -5/-47,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,N,1,CHEMBL628083,,,
13379,1,IV clearance determined at an peroral dose of 15 mg/kg.,,BAO_0000218,,,,Autocuration,15173,In vivo,U,0,CHEMBL628084,,,
13380,1,Mouse oral clearance was measured against Hymenolepiasis nana.,,BAO_0000218,,Hymenolepis nana,,Expert,7732,In vivo,N,1,CHEMBL628085,,,
13381,1,Mouse oral clearance was measured against Nematospiroides dubius,,BAO_0000218,,Heligmosomoides polygyrus,,Expert,7732,In vivo,N,1,CHEMBL628086,,,
13382,1,Mouse oral clearance was measured against N. dubius; NT is Not Tested,,BAO_0000218,,,,Autocuration,7732,In vivo,U,0,CHEMBL628087,,,
13383,1,Mouse oral clearance was measured against N. nana; NT is Not Tested,,BAO_0000218,,Mus musculus,,Intermediate,7732,In vivo,N,1,CHEMBL628088,,,
13384,1,Mouse oral clearance was measured against N. nana; NT is Not Tested,,BAO_0000218,,,,Autocuration,7732,In vivo,U,0,CHEMBL628089,,,
13385,1,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 10 J/cm e2 ultraviolet-A radiation,,BAO_0000218,,,,Autocuration,8328,In vivo,U,0,CHEMBL628090,,,
13386,1,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 6 J/cm e2 ultraviolet-A radiation,,BAO_0000218,,,,Autocuration,8328,In vivo,U,0,CHEMBL628091,,,
13387,1,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 8 J/cm e2 ultraviolet-A radiation,,BAO_0000218,,,,Autocuration,8328,In vivo,U,0,CHEMBL628092,,,
13388,1,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 9 J/cm e2 ultraviolet-A radiation,,BAO_0000218,,,,Autocuration,8328,In vivo,U,0,CHEMBL628093,,,
13389,1,Percentage of clearance of psoriatic lesions by the compound at dose of 10 J/cm e2 ultraviolet-A radiation,,BAO_0000218,,,,Autocuration,8328,In vivo,U,0,CHEMBL875607,,,
13390,1,Percentage of clearance of psoriatic lesions by the compound at dose of 4 J/cm e2 ultraviolet-A radiation,,BAO_0000218,,,,Autocuration,8328,In vivo,U,0,CHEMBL625710,,,
13391,1,Percentage of clearance of psoriatic lesions by the compound at dose of 6 J/cm e2 ultraviolet-A radiation,,BAO_0000218,,,,Autocuration,8328,In vivo,U,0,CHEMBL625711,,,
13392,1,Percentage of clearance of psoriatic lesions by the compound at dose of 8 J/cm e2 ultraviolet-A radiation,,BAO_0000218,,,,Autocuration,8328,In vivo,U,0,CHEMBL625712,,,
13393,1,Percentage of clearance of psoriatic lesions by the compound at dose of 9 J/cm e2 ultraviolet-A radiation,,BAO_0000218,,,,Autocuration,8328,In vivo,U,0,CHEMBL625713,,,
13394,1,Pharmacokinetic parameter clearance was determined in fed Beagle dogs after iv administration of 1.5 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,13376,In vivo,N,1,CHEMBL625714,,,
13395,1,Plasma clearance after intravenous administration dosing (30 mg/kg) in Rhesus monkey,,BAO_0000218,,Macaca mulatta,,Intermediate,13477,In vivo,N,1,CHEMBL625715,,,
13396,1,Plasma clearance after intravenous administration dosing (30 mg/kg) in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,13477,In vivo,N,1,CHEMBL625716,,,
13397,1,Plasma clearance after intravenous administration iv dosing of 3 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,13477,In vivo,N,1,CHEMBL625717,,,
13398,1,Plasma clearance was determined for the compound in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,13313,In vivo,N,1,CHEMBL625718,,,
13399,1,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 1,,BAO_0000218,,Rattus norvegicus,,Intermediate,12504,In vivo,N,1,CHEMBL625719,,,
13400,1,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 2,,BAO_0000218,,Rattus norvegicus,,Intermediate,12504,In vivo,N,1,CHEMBL625720,,,
13401,1,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 3,,BAO_0000218,,Rattus norvegicus,,Intermediate,12504,In vivo,N,1,CHEMBL625721,,,
13402,1,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 4,,BAO_0000218,,Rattus norvegicus,,Intermediate,12504,In vivo,N,1,CHEMBL625722,,,
13403,1,The compound was tested for systemic clearance pharmacokinetic parameter in the male Sprague-Dawley rat.,,BAO_0000218,,Rattus norvegicus,,Intermediate,13129,In vivo,N,1,CHEMBL625723,,,
13404,1,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.0125 concentration of diet.,,BAO_0000218,,Heligmosomoides polygyrus,,Intermediate,7732,In vivo,N,1,CHEMBL625724,,,
13405,1,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.025 concentration of diet.,,BAO_0000218,,Heligmosomoides polygyrus,,Intermediate,7732,In vivo,N,1,CHEMBL625725,,,
13406,1,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.05 concentration of diet.,,BAO_0000218,,Heligmosomoides polygyrus,,Intermediate,7732,In vivo,N,1,CHEMBL625726,,,
13407,1,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.1 concentration of diet.,,BAO_0000218,,Heligmosomoides polygyrus,,Intermediate,7732,In vivo,N,1,CHEMBL875608,,,
13408,1,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.2 concentration of diet.,,BAO_0000218,,Heligmosomoides polygyrus,,Intermediate,7732,In vivo,N,1,CHEMBL625727,,,
13409,1,Urinary clearance was determined in rat at 100 mg/kg os dosage;ND is defined as no-data.,Urine,BAO_0000218,,Rattus norvegicus,,Autocuration,9278,In vivo,U,0,CHEMBL625728,,1088.0,
13410,1,Total clearance was determined in rat at 10 mg/kg intraperitoneal dosage,,BAO_0000218,,Rattus norvegicus,,Autocuration,9278,In vivo,U,0,CHEMBL625729,,,
13411,1,Total clearance was determined in rat at 25 mg/kg os dosage;ND is defined as no-data.,,BAO_0000218,,Rattus norvegicus,,Autocuration,9278,In vivo,U,0,CHEMBL625730,,,
13412,1,Urinary clearance was determined in rat at 10 mg/kg intraperitoneal dosage,Urine,BAO_0000218,,Rattus norvegicus,,Autocuration,9278,In vivo,U,0,CHEMBL625731,,1088.0,
13413,1,Urinary clearance was determined in rat at 25 mg/kg os dosage,Urine,BAO_0000218,,Rattus norvegicus,,Autocuration,9278,In vivo,U,0,CHEMBL626417,,1088.0,
13414,1,Urinary clearance was determined at 100 mg/kg oral dosage in human,Urine,BAO_0000218,,Homo sapiens,,Intermediate,9278,In vivo,N,1,CHEMBL626418,,1088.0,
13415,1,Urinary clearance was determined at 20 mg/kg oral dosage in dog(beagle);ND is defined as no-data.,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,9278,In vivo,N,1,CHEMBL626419,,1088.0,
13416,1,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,5932,In vivo,N,1,CHEMBL626592,,1969.0,
13417,1,Plasma concentration in rats after 7 hr at 30mg/kg oral dose,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,5932,In vivo,N,1,CHEMBL626593,,1969.0,
13418,1,Clearance was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5182,In vivo,N,1,CHEMBL626594,,,
13419,1,Clearance rate in dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,10499,In vivo,N,1,CHEMBL625035,,,
13420,1,Compound was measured for intrinsic clearance,,BAO_0000019,,,,Autocuration,6051,In vitro,U,0,CHEMBL625036,,,
13421,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,17508,,U,0,CHEMBL625037,,,
13422,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,6228,,U,0,CHEMBL625038,,,
13423,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,6231,,U,0,CHEMBL625039,,,
13424,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,17740,,U,0,CHEMBL625040,,,
13425,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,6495,,U,0,CHEMBL625041,,,
13426,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,2171,,U,0,CHEMBL625042,,,
13427,1,Partition coefficient of the compound,,BAO_0000019,,,,Autocuration,3255,,U,0,CHEMBL874411,,,
13428,1,Permeability,,BAO_0000019,,,,Autocuration,6821,,U,0,CHEMBL625043,,,
13429,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,2685,,U,0,CHEMBL625044,,,
13430,1,Partition coefficient (logD),,BAO_0000019,,,,Autocuration,17584,,U,0,CHEMBL625045,,,
13431,1,Calculated partition coefficient (clogP) (CLOGP3 V3.4),,BAO_0000100,,,,Autocuration,13824,,U,0,CHEMBL625046,,,
13432,1,Calculated partition coefficient (clogP) (CLOGP3 V3.4),,BAO_0000100,,,,Autocuration,13824,,U,0,CHEMBL625047,,,
13433,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,16479,,U,0,CHEMBL625048,,,
13434,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,11997,,U,0,CHEMBL625049,,,
13435,1,Calculated logarithm of partition coefficient (P) was determined,,BAO_0000100,,,,Autocuration,2988,,U,0,CHEMBL625050,,,
13436,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,931,,U,0,CHEMBL625051,,,
13437,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,4381,,U,0,CHEMBL874412,,,
13438,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,4397,,U,0,CHEMBL625052,,,
13439,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,5889,,U,0,CHEMBL625053,,,
13440,1,In vitro stability to pepsin promoting hydrolysis after 8 hr incubation time,,BAO_0000019,,,,Autocuration,6154,,U,0,CHEMBL623250,,,
13441,1,In vitro stability to trypsin promoting hydrolysis after 1 hr incubation time,,BAO_0000019,,,,Autocuration,6154,,U,0,CHEMBL623251,,,
13442,1,In vitro stability to trypsin promoting hydrolysis after 2 hr incubation time,,BAO_0000019,,,,Autocuration,6154,,U,0,CHEMBL623252,,,
13443,1,In vitro stability to trypsin promoting hydrolysis after 64h incubation time,,BAO_0000019,,,,Autocuration,6154,,U,0,CHEMBL623253,,,
13444,1,In vitro stability to trypsin promoting hydrolysis after 84 hr incubation time,,BAO_0000019,,,,Autocuration,6154,,U,0,CHEMBL623254,,,
13445,1,In vitro stability to trypsin promoting hydrolysis after 8 hr incubation time,,BAO_0000019,,,,Autocuration,6154,,U,0,CHEMBL623255,,,
13446,1,Percent degradation of compound at a pH of 1 over a 18 hr period,,BAO_0000019,,,,Autocuration,6887,,U,0,CHEMBL626831,,,
13447,1,Percent degradation of compound at pH of 1 over an 18 hr period,,BAO_0000019,,,,Autocuration,6887,,U,0,CHEMBL877494,,,
13448,1,Delta Logarithm of Partition Coefficient value was determined.,,BAO_0000019,,,,Autocuration,14116,,U,0,CHEMBL626832,,,
13449,1,Delta logPoct-cyc,,BAO_0000019,,,,Autocuration,11137,,U,0,CHEMBL626833,,,
13450,1,Lipophilicity estimated on reversed phase TLC,,BAO_0000100,,,,Autocuration,7230,,U,0,CHEMBL626834,,,
13451,1,Delta Tm value ( Tmdrug-DNA )-TmDNA ) was obtained for the covalently cross-linked compound in the absence of formaldehyde using calf thymus DNA.,,BAO_0000019,,,,Autocuration,15741,,U,0,CHEMBL626835,,,
13452,1,Delta logPoct-cyc,,BAO_0000019,,,,Autocuration,9663,,U,0,CHEMBL626836,,,
13453,1,Change in logarithm of partition coefficient of the compound,,BAO_0000100,,,,Autocuration,9663,,U,0,CHEMBL626837,,,
13454,1,Delta logD (pH 6.5),,BAO_0000019,,,,Autocuration,13807,,U,0,CHEMBL626838,,,
13455,1,"Partition coefficient by standard shake-flask techniquesat 37 C, using octanol and cyclohexane",,BAO_0000100,,,,Autocuration,13807,,U,0,CHEMBL626839,,,
13456,1,Oxygen pressure at which hemoglobin is 50% oxygenated; negative sign indicates that P50 of modified Hb is lower than that of unmodified Hb,,BAO_0000019,,,,Autocuration,17425,,U,0,CHEMBL626840,,,
13457,1,Deoxyribose-damaging property as a measure of hydroxyl-radical formation (uM of malondialdehyde/mmol of deoxyribose released by 75 uM test compound),,BAO_0000019,,,,Autocuration,12143,,U,0,CHEMBL626841,,,
13458,1,Peak depolarizations produced by injections of 100 micro M Ins p3 isomers in nine cells,,BAO_0000219,,,,Autocuration,12608,,U,0,CHEMBL626842,,,
13459,1,Peak depolarizations produced by injections of 100 micro M Ins p3 isomers in six cells,,BAO_0000219,,,,Autocuration,12608,,U,0,CHEMBL626843,,,
13460,1,Amount of deuterium retained was reported after normal workup in beta-naphthoflavone-treated male rats with the substrate rac 7-D,,BAO_0000218,,Rattus norvegicus,,Intermediate,8649,,N,1,CHEMBL626844,,,
13461,1,Amount of deuterium retained was reported after normal workup in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,8649,,N,1,CHEMBL877495,,,
13462,1,Amount of deuterium retained was reported after reincubation followed by normal workup in phenobarbital treated male rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,8649,,N,1,CHEMBL626845,,,
13463,1,Amount of deuterium retained was reported after reincubation followed by normal workup in phenobarbital treated male rats with rac 8-D,,BAO_0000218,,Rattus norvegicus,,Intermediate,8649,,N,1,CHEMBL626846,,,
13464,1,Compound incubated with microsomal preparations from beta-naphthoflavone-treated male rats with the substrate rac 7-D and the amount of deuterium retained was reported after reincubation followed by normal workup,,BAO_0000218,,Rattus norvegicus,,Intermediate,8649,,N,1,CHEMBL626847,,,
13465,1,Compound incubated with microsomal preparations from beta-naphthoflavone-treated male rats with the substrate rac 7-D and the amount of deuterium retained was reported after reincubation followed by normal workup,,BAO_0000218,,Rattus norvegicus,,Intermediate,8649,,N,1,CHEMBL628677,,,
13466,1,Compound incubated with microsomal preparations from phenobarbital treated male rats with the substrate rac 8-D and the amount of deuterium retained was reported after normal workup,,BAO_0000218,,Rattus norvegicus,,Intermediate,8649,,N,1,CHEMBL628678,,,
13467,1,Compound was subjected to electrochemical oxidation,,BAO_0000019,,,,Autocuration,9659,,U,0,CHEMBL628679,,,
13468,1,Compound was subjected to photochemical oxidation,,BAO_0000019,,,,Autocuration,9659,,U,0,CHEMBL628680,,,
13469,1,Oxidation of compound by Chloroperoxidase in presence of ethylperoxide,,BAO_0000019,,,,Autocuration,9659,,U,0,CHEMBL628681,,,
13470,1,Oxidation of compound by horseradish peroxidase in presence of hydroperoxide,,BAO_0000019,,,,Autocuration,9659,,U,0,CHEMBL628682,,,
13471,1,Oxidation of compound by methemoglobin in presence of hydroperoxide,,BAO_0000019,,,,Autocuration,9659,,U,0,CHEMBL628683,,,
13472,1,Percent diffusion through fuzzy rat skin after 48 h of incubation,,BAO_0000218,,Rattus norvegicus,,Intermediate,9607,,N,1,CHEMBL628684,,,
13473,1,Dissociation constant (pKa),,BAO_0000100,,,,Autocuration,7057,,U,0,CHEMBL877501,,,
13474,1,Dissociation constant value of the compound; ND means not determined.,,BAO_0000100,,,,Autocuration,7057,,U,0,CHEMBL628685,,,
13475,1,% distribution of the radioiron in blood of rat followed by intravenous injection of chelating agent,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,7911,,N,1,CHEMBL628686,,178.0,
13476,1,% distribution of the radioiron in blood of rats followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,7911,,N,1,CHEMBL628687,,178.0,
13477,1,% distribution of the radioiron in rat kidney followed by intravenous injection of chelating agent,,BAO_0000218,,Rattus norvegicus,,Intermediate,7911,,N,1,CHEMBL628688,,,
13478,1,% distribution of the radioiron in rat kidney followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,,BAO_0000218,,Rattus norvegicus,,Intermediate,7911,,N,1,CHEMBL628689,,,
13479,1,% distribution of the radioiron in rat liver followed by intravenous injection of chelating agent,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,7911,,N,1,CHEMBL628690,,2107.0,
13480,1,% distribution of the radioiron in rat liver followed by intravenous injection of transferrin preincubated with 10 mg of chelating agent,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,7911,,N,1,CHEMBL629363,,2107.0,
13481,1,% distribution of the radioiron in rat spleen followed by intravenous injection of chelating agent,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,7911,,N,1,CHEMBL629364,,2106.0,
13482,1,% distribution of the radioiron in rat spleen followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,7911,,N,1,CHEMBL629365,,2106.0,
13483,1,% excretion of ferritin determined in faces of rat followed by intravenous injection of chelating agent,,BAO_0000218,,Rattus norvegicus,,Intermediate,7911,,N,1,CHEMBL629366,,,
13484,1,% excretion of ferritin determined in urine of rat followed by intravenous injection of chelating agent,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,7911,,N,1,CHEMBL629367,,1088.0,
13485,1,% excretion of radioiron determined in feces of rat followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,Feces,BAO_0000218,,Rattus norvegicus,,Intermediate,7911,,N,1,CHEMBL629368,,1988.0,
13486,1,% excretion of radioiron determined in urine of rat followed by intravenous injection of transferrin preincubated with 10 mg of chelating agent,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,7911,,N,1,CHEMBL877502,,1088.0,
13487,1,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into cerebellum,Cerebellum,BAO_0000218,,Mus musculus,,Intermediate,13792,,N,1,CHEMBL629369,,2037.0,
13488,1,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into cortex,Brain,BAO_0000218,,Mus musculus,,Intermediate,13792,,N,1,CHEMBL629370,,955.0,
13489,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded monkey at 10 mg/kg, po",Urine,BAO_0000218,,Simiiformes,,Autocuration,8133,,U,0,CHEMBL629371,,1088.0,
13490,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",Urine,BAO_0000218,,Simiiformes,,Autocuration,8133,,U,0,CHEMBL626276,,1088.0,
13491,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 30mg/kg, po",Urine,BAO_0000218,,Simiiformes,,Autocuration,8133,,U,0,CHEMBL626277,,1088.0,
13492,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 3mg/kg, po",Urine,BAO_0000218,,Simiiformes,,Autocuration,8133,,U,0,CHEMBL631250,,1088.0,
13493,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,8133,,N,1,CHEMBL631251,,1088.0,
13494,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 0.3mg/kg, po",Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,8133,,N,1,CHEMBL631252,,1088.0,
13495,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 1.0 mg/kg, po",Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,8133,,N,1,CHEMBL631253,,1088.0,
13496,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 10.0mg/kg, po",Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,8133,,N,1,CHEMBL631254,,1088.0,
13497,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 100.0 mg/kg, po",Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,8133,,N,1,CHEMBL631255,,1088.0,
13498,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 2.1 mg/kg, po",Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,8133,,N,1,CHEMBL631256,,1088.0,
13499,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 20.8mg/kg, po",Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,8133,,N,1,CHEMBL631257,,1088.0,
13500,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 207.6 mg/kg, po",Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,8133,,N,1,CHEMBL628009,,1088.0,
13501,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 3.0mg/kg, po",Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,8133,,N,1,CHEMBL628010,,1088.0,
13502,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 30.0mg/kg, po",Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,8133,,N,1,CHEMBL628011,,1088.0,
13503,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 6.9 mg/kg, po",Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,8133,,N,1,CHEMBL628012,,1088.0,
13504,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 69.2mg/kg, po",Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,8133,,N,1,CHEMBL628013,,1088.0,
13505,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 691.9mg/kg, po",Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,8133,,N,1,CHEMBL628014,,1088.0,
13506,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 0.03 mg/kg, po",Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,8133,,N,1,CHEMBL628015,,1088.0,
13507,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,8133,,N,1,CHEMBL628016,,1088.0,
13508,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 0.3 mg/kg, po",Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,8133,,N,1,CHEMBL874461,,1088.0,
13509,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,8133,,N,1,CHEMBL628017,,1088.0,
13510,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 10.0mg/kg, po",Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,8133,,N,1,CHEMBL628018,,1088.0,
13511,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,8133,,N,1,CHEMBL628019,,1088.0,
13512,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 1 mg/kg, po",Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,8133,,N,1,CHEMBL628020,,1088.0,
13513,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 30 mg/kg, po",Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,8133,,N,1,CHEMBL628021,,1088.0,
13514,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 3mg/kg, po",Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,8133,,N,1,CHEMBL628022,,1088.0,
13515,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 3.0mg/kg, po",Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,8133,,N,1,CHEMBL628023,,1088.0,
13516,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",Urine,BAO_0000218,,Simiiformes,,Autocuration,8133,,U,0,CHEMBL628024,,1088.0,
13517,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 10mg/kg, po",Urine,BAO_0000218,,Simiiformes,,Autocuration,8133,,U,0,CHEMBL628025,,1088.0,
13518,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",Urine,BAO_0000218,,Simiiformes,,Autocuration,8133,,U,0,CHEMBL628026,,1088.0,
13519,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 30mg/kg, po",Urine,BAO_0000218,,Simiiformes,,Autocuration,8133,,U,0,CHEMBL628027,,1088.0,
13520,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 3mg/kg, po",Urine,BAO_0000218,,Simiiformes,,Autocuration,8133,,U,0,CHEMBL628028,,1088.0,
13521,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,8133,,N,1,CHEMBL628029,,1088.0,
13522,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 0.3 mg/kg, po",Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,8133,,N,1,CHEMBL628030,,1088.0,
13523,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 1.0mg/kg, po",Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,8133,,N,1,CHEMBL628031,,1088.0,
13524,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 10.0 mg/kg, po",Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,8133,,N,1,CHEMBL628032,,1088.0,
13525,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 100.0 mg/kg, po",Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,8133,,N,1,CHEMBL628033,,1088.0,
13526,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 2.08 mg/kg, po",Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,8133,,N,1,CHEMBL628034,,1088.0,
13527,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 207.6mg/kg, po",Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,8133,,N,1,CHEMBL628035,,1088.0,
13528,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 3.0 mg/kg, po",Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,8133,,N,1,CHEMBL628036,,1088.0,
13529,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 30.0mg/kg, po",Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,8133,,N,1,CHEMBL874462,,1088.0,
13530,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -8/-38,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,N,1,CHEMBL628037,,,
13531,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); 13/-25,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,N,1,CHEMBL628123,,,
13532,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); 27/-15,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,N,1,CHEMBL628124,,,
13533,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -2/-19,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,N,1,CHEMBL628125,,,
13534,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/60 range (low/high); -3/-4,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,N,1,CHEMBL628126,,,
13535,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3 range (low/high),,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,N,1,CHEMBL628127,,,
13536,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3/10 range (low/high); -9/24,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,N,1,CHEMBL628128,,,
13537,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3/10 range (low/high); 3/-1,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,N,1,CHEMBL628129,,,
13538,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/030 range (low/high); 12/23,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,N,1,CHEMBL628130,,,
13539,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 1/3,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,N,1,CHEMBL628131,,,
13540,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 6/16,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,N,1,CHEMBL628132,,,
13541,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 7/14,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,N,1,CHEMBL628133,,,
13542,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3/10 range (low/high); 4/4/23,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,N,1,CHEMBL628134,,,
13543,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 10/14,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,N,1,CHEMBL628135,,,
13544,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 11/15,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,N,1,CHEMBL628136,,,
13545,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 11/44,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,N,1,CHEMBL628137,,,
13546,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 14/28,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,N,1,CHEMBL628138,,,
13547,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 15-28,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,N,1,CHEMBL628139,,,
13548,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 2/3,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,N,1,CHEMBL628140,,,
13549,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 26/32,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,N,1,CHEMBL628141,,,
13550,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 5/1,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,N,1,CHEMBL628142,,,
13551,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 5/12,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,N,1,CHEMBL628143,,,
13552,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 6/7,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,N,1,CHEMBL628144,,,
13553,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 7/6,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,N,1,CHEMBL628145,,,
13554,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 8/12,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,N,1,CHEMBL628146,,,
13555,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 8/27,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,N,1,CHEMBL625355,,,
13556,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 9/14,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,N,1,CHEMBL625356,,,
13557,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 9/16,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,N,1,CHEMBL625357,,,
13558,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/60 range (low/high); 12/23,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,N,1,CHEMBL625527,,,
13559,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3 range (low/high),,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,N,1,CHEMBL875473,,,
13560,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3/10 range (low/high); 10/22,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,N,1,CHEMBL625528,,,
13561,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3/10 range (low/high); 4/12,,BAO_0000218,,Rattus norvegicus,,Intermediate,9025,In vivo,N,1,CHEMBL626304,,,
13562,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a 10/30 dose range; 11/-11,Artery,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,N,1,CHEMBL624138,,1637.0,
13563,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,6448,,U,0,CHEMBL624139,,,
13564,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,17221,,U,0,CHEMBL624140,,,
13565,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,6545,,U,0,CHEMBL624141,,,
13566,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,577,,U,0,CHEMBL624142,,,
13567,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,6285,,U,0,CHEMBL624143,,,
13568,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,6500,,U,0,CHEMBL624144,,,
13569,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,6716,,U,0,CHEMBL624145,,,
13570,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,13658,,U,0,CHEMBL624146,,,
13571,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,6549,,U,0,CHEMBL624147,,,
13572,1,Calculated partition coefficient (clogP) (MacLogP),,BAO_0000100,,,,Autocuration,14685,,U,0,CHEMBL883123,,,
13573,1,Partition coefficient (logP),,BAO_0000019,,,,Autocuration,6893,,U,0,CHEMBL624148,,,
13574,1,Kinetic parameter was determined,,BAO_0000019,,,,Autocuration,3687,,U,0,CHEMBL874416,,,
13575,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,4207,,U,0,CHEMBL624149,,,
13576,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,4626,,U,0,CHEMBL624150,,,
13577,1,Lipophilicity was determined,,BAO_0000100,,,,Autocuration,1021,,U,0,CHEMBL624151,,,
13578,1,Lipophilicity was determined,,BAO_0000100,,,,Autocuration,3777,,U,0,CHEMBL624152,,,
13579,1,Lipophilicity was determined,,BAO_0000100,,,,Autocuration,17533,,U,0,CHEMBL622139,,,
13580,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,6524,,U,0,CHEMBL622140,,,
13581,1,Lipophilicity was determined,,BAO_0000100,,,,Autocuration,17533,,U,0,CHEMBL622141,,,
13582,1,Lipophilicity in octanol-water,,BAO_0000100,,,,Autocuration,6480,,U,0,CHEMBL622142,,,
13583,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,17606,,U,0,CHEMBL622143,,,
13584,1,Octanol-water partition coefficient was determined,,BAO_0000100,,,,Autocuration,6863,,U,0,CHEMBL622144,,,
13585,1,Partition coefficient (logP),,BAO_0000019,,,,Autocuration,1356,,U,0,CHEMBL877473,,,
13586,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,3326,,U,0,CHEMBL622145,,,
13587,1,Partition coefficient was determined; ND means not determined,,BAO_0000019,,,,Autocuration,1356,,U,0,CHEMBL622146,,,
13588,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,12984,,U,0,CHEMBL622147,,,
13589,1,Partition coefficient of the compound,,BAO_0000019,,,,Autocuration,17363,,U,0,CHEMBL622148,,,
13590,1,Permeability was determined,,BAO_0000019,,,,Autocuration,6827,,U,0,CHEMBL883124,,,
13591,1,The compound was evaluated for the partition coefficient,,BAO_0000100,,,,Autocuration,261,,U,0,CHEMBL622149,,,
13592,1,Partition coefficient (logP),,BAO_0000019,,,,Autocuration,2685,,U,0,CHEMBL622150,,,
13593,1,The lipophilicity was reported,,BAO_0000100,,,,Autocuration,414,,U,0,CHEMBL622151,,,
13594,1,logarithm of the octanol-water partition coefficient for the compound,,BAO_0000100,,,,Autocuration,15769,,U,0,CHEMBL622152,,,
13595,1,Clogp value was determined,,BAO_0000019,,,,Autocuration,17248,,U,0,CHEMBL622153,,,
13596,1,Clp at a dose of 1.5 mg/kg,,BAO_0000218,,,,Autocuration,16935,In vivo,U,0,CHEMBL877474,,,
13597,1,Clp at a dose of 2.0 mg/kg,,BAO_0000218,,,,Autocuration,16935,In vivo,U,0,CHEMBL622154,,,
13598,1,"Clp, plasma clearance at a dose of 10 mg/kg",Plasma,BAO_0000218,,,,Autocuration,14832,In vivo,U,0,CHEMBL622155,,1969.0,
13599,1,"Clp, plasma clearance at a dose of 50 mg/kg",Plasma,BAO_0000218,,,,Autocuration,14832,In vivo,U,0,CHEMBL622156,,1969.0,
13600,1,Compound was tested for plasma clearance in rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,2399,In vivo,N,1,CHEMBL622157,,1969.0,
13601,1,Compound was tested for plasma clearance in rat; Not determined,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,2399,In vivo,N,1,CHEMBL622158,,1969.0,
13602,1,Plasma clearance (pharmacokinetic parameter) in rat (in vivo) at a dose of 10 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,6227,In vivo,N,1,CHEMBL622807,,,
13603,1,Plasma clearance (pharmacokinetic parameter) in rhesus (in vivo) at a dose of 5 mg/kg,,BAO_0000218,,Macaca mulatta,,Intermediate,6227,In vivo,N,1,CHEMBL622808,,,
13604,1,Plasma clearance by iv administration at a dose 0.003 ug/mL,,BAO_0000218,,,,Autocuration,5623,In vivo,U,0,CHEMBL622809,,,
13605,1,Plasma clearance determined,,BAO_0000218,,,,Autocuration,4854,In vivo,U,0,CHEMBL622810,,,
13606,1,Plasma clearance after iv administration at 3 mg/kg in hamster,,BAO_0000218,,Cricetinae,,Intermediate,4493,In vivo,N,1,CHEMBL876653,,,
13607,1,Plasma clearance after iv administration at 4 mg/kg in hamster,,BAO_0000218,,Cricetinae,,Intermediate,4493,In vivo,N,1,CHEMBL622811,,,
13608,1,Rate of clearance in rat was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,14956,In vivo,N,1,CHEMBL622986,,,
13609,1,Total plasma clearance Clp was determined for the compound after iv dose of 5.06 mg/kg in rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,15372,In vivo,N,1,CHEMBL622987,,1969.0,
13610,1,Total plasma clearance after iv dose of 5.10 mg/kg in rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,15372,In vivo,N,1,CHEMBL622988,,1969.0,
13611,1,Total plasma clearance was determined for the compound after iv dose of 4.74 mg/kg in rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,15372,In vivo,N,1,CHEMBL622989,,1969.0,
13612,1,Total plasma clearance was determined for the compound after iv dose of 4.97 mg/kg in rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,15372,In vivo,N,1,CHEMBL622990,,1969.0,
13613,1,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.01 mg/kg) in monkey,Plasma,BAO_0000218,,Simiiformes,,Autocuration,15604,In vivo,U,0,CHEMBL622991,,1969.0,
13614,1,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.05 mg/kg) in rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,15604,In vivo,N,1,CHEMBL622227,,1969.0,
13615,1,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.1 mg/kg) in dog,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,15604,In vivo,N,1,CHEMBL622228,,1969.0,
13616,1,Clpl value in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,14964,In vivo,N,1,CHEMBL622229,,,
13617,1,Cmax (ng /mL) value after oral administration of 10 mg/kg in guinea pig.,,BAO_0000218,,Cavia porcellus,,Intermediate,15240,In vivo,N,1,CHEMBL622230,,,
13618,1,Cmax after an oral dose of 10 uM/Kg in male Sprague-Dawley rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,16449,In vivo,N,1,CHEMBL622231,,,
13619,1,Cmax after an oral dose of 10 uM/Kg in male cynomolgus monkeys,,BAO_0000218,,Macaca fascicularis,,Intermediate,16449,In vivo,N,1,CHEMBL622232,,,
13620,1,Cmax in minutes at a iv dose of 1.0(pmol/g/h).,,BAO_0000218,,,,Autocuration,12902,In vivo,U,0,CHEMBL622233,,,
13621,1,Cmax in minutes at a iv dose of 2.0(pmol/g/h).,,BAO_0000218,,,,Autocuration,12902,In vivo,U,0,CHEMBL622234,,,
13622,1,Cmax in minutes at a iv dose of 4.0(pmol/g/h).,,BAO_0000218,,,,Autocuration,12902,In vivo,U,0,CHEMBL622235,,,
13623,1,Cmax in minutes at a iv dose of 5.0(pmol/g/h).,,BAO_0000218,,,,Autocuration,12902,In vivo,U,0,CHEMBL622236,,,
13624,1,Cmax in minutes at a iv dose of 54.0(pmol/g/h).,,BAO_0000218,,,,Autocuration,12902,In vivo,U,0,CHEMBL622237,,,
13625,1,Cmax in minutes at a po dose of 10.0(pmol/g/h).,,BAO_0000218,,,,Autocuration,12902,In vivo,U,0,CHEMBL877482,,,
13626,1,Cmax in minutes at a po dose of 20.0(pmol/g/h).,,BAO_0000218,,,,Autocuration,12902,In vivo,U,0,CHEMBL622238,,,
13627,1,Cmax in minutes at a po dose of 40.0(pmol/g/h).,,BAO_0000218,,,,Autocuration,12902,In vivo,U,0,CHEMBL622239,,,
13628,1,Cmax was calculated as maximum concentration reached in the blood,Blood,BAO_0000218,,,,Autocuration,11149,In vivo,U,0,CHEMBL622240,,178.0,
13629,1,Cmax was calculated as maximum concentration reached in the blood in air pouch exudate,Blood,BAO_0000218,,,,Autocuration,11149,In vivo,U,0,CHEMBL622241,,178.0,
13630,1,Cmax was determine after peroral administration at 10 mpk in Rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5669,In vivo,N,1,CHEMBL631013,,,
13631,1,Cmax was determine after peroral administration at 10 mpk in Rhesus,,BAO_0000218,,Macaca mulatta,,Intermediate,5669,In vivo,N,1,CHEMBL631014,,,
13632,1,Cmax was determine after peroral administration at 10 mpk in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5669,In vivo,N,1,CHEMBL631015,,,
13633,1,Cmax was determine after peroral administration at 160 mpk in Rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5669,In vivo,N,1,CHEMBL631016,,,
13634,1,Cmax was determine after peroral administration at 20 mpk in Rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5669,In vivo,N,1,CHEMBL631017,,,
13635,1,Cmax was determine after peroral administration at 50 mpk in Rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5669,In vivo,N,1,CHEMBL631018,,,
13636,1,Cmax was determined,,BAO_0000218,,,,Autocuration,4236,In vivo,U,0,CHEMBL631019,,,
13637,1,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into hippocampus,Brain,BAO_0000218,,Mus musculus,,Intermediate,13792,,N,1,CHEMBL875761,,955.0,
13638,1,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into hypothalamus,Brain,BAO_0000218,,Mus musculus,,Intermediate,13792,,N,1,CHEMBL631020,,955.0,
13639,1,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into pons and medulla,Brain,BAO_0000218,,Mus musculus,,Intermediate,13792,,N,1,CHEMBL631669,,955.0,
13640,1,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into rest of the brain,Brain,BAO_0000218,,Mus musculus,,Intermediate,13792,,N,1,CHEMBL631670,,955.0,
13641,1,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into striatum,Striatum,BAO_0000218,,Mus musculus,,Intermediate,13792,,N,1,CHEMBL631671,,2435.0,
13642,1,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.31-0.4,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL631672,,178.0,
13643,1,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.97-1.12,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL631673,,178.0,
13644,1,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.35-0.37,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL631856,,178.0,
13645,1,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.72-1.03,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL631857,,178.0,
13646,1,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.95-1.06,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL631858,,178.0,
13647,1,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.35-0.4,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL631859,,178.0,
13648,1,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.73-0.85,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL631860,,178.0,
13649,1,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.65-0.83,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL631861,,178.0,
13650,1,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.69-0.84,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL631862,,178.0,
13651,1,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.28-0.46,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL631863,,178.0,
13652,1,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.38-1.5,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL631864,,178.0,
13653,1,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.34-0.48,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL631865,,178.0,
13654,1,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.58-1.17,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL631866,,178.0,
13655,1,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.0-1.24,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL629360,,178.0,
13656,1,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.28-0.37,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL629361,,178.0,
13657,1,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.54-0.63,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL629362,,178.0,
13658,1,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.25-0.32,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL630740,,178.0,
13659,1,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.49-0.58,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL630741,,178.0,
13660,1,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.58-0.77,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL630742,,178.0,
13661,1,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.20-0.25,,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL630743,,,
13662,1,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.05-1.25,,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL630744,,,
13663,1,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.03-0.03,,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL630745,,,
13664,1,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.03-0.06,,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL630746,,,
13665,1,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.34-0.5,,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL630747,,,
13666,1,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.17-0.20,,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL630748,,,
13667,1,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.81-1.26,,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL632056,,,
13668,1,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.03-0.06,,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL632057,,,
13669,1,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.18-0.36,,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL632058,,,
13670,1,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.28-0.37,,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL632059,,,
13671,1,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.97-2.17,,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL632060,,,
13672,1,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.02-0.03,,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL632061,,,
13673,1,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.05-0.07,,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL629207,,,
13674,1,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.35-0.72,,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL629208,,,
13675,1,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.15-0.19,,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL629209,,,
13676,1,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.76-1.42,,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL629210,,,
13677,1,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.02-0.03,,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL629211,,,
13678,1,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.03-0.06,,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL629212,,,
13679,1,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.05-0.06,,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,N,1,CHEMBL629213,,,
13680,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 6.9mg/kg, po",Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,8133,,N,1,CHEMBL629214,,1088.0,
13681,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 69.2 mg/kg, po",Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,8133,,N,1,CHEMBL629215,,1088.0,
13682,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 691.9 mg/kg, po",Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,8133,,N,1,CHEMBL635154,,1088.0,
13683,1,Oral diuretic activity measured by Na+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,N,1,CHEMBL629216,,,
13684,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,N,1,CHEMBL629217,,,
13685,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,N,1,CHEMBL629218,,,
13686,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration (0-5 hr),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,N,1,CHEMBL629219,,,
13687,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,N,1,CHEMBL629220,,,
13688,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,N,1,CHEMBL629221,,,
13689,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,N,1,CHEMBL631127,,,
13690,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,N,1,CHEMBL631128,,,
13691,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,N,1,CHEMBL631129,,,
13692,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration (0-5 hr),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,N,1,CHEMBL631130,,,
13693,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,N,1,CHEMBL631131,,,
13694,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,N,1,CHEMBL631132,,,
13695,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,N,1,CHEMBL631133,,,
13696,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,N,1,CHEMBL631134,,,
13697,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,N,1,CHEMBL875120,,,
13698,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration (0-5 hr),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,N,1,CHEMBL631135,,,
13699,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0 - 5 hr),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,N,1,CHEMBL631136,,,
13700,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,N,1,CHEMBL631137,,,
13701,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,N,1,CHEMBL631138,,,
13702,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,N,1,CHEMBL631139,,,
13703,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,N,1,CHEMBL631140,,,
13704,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration (0-5 hr),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,N,1,CHEMBL631141,,,
13705,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,N,1,CHEMBL631142,,,
13706,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,N,1,CHEMBL631143,,,
13707,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,N,1,CHEMBL631144,,,
13708,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.312 mg/kg after ip administration,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,N,1,CHEMBL631145,,,
13709,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,N,1,CHEMBL631146,,,
13710,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.625 mg/kg after ip administration,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,N,1,CHEMBL631147,,,
13711,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,N,1,CHEMBL631148,,,
13712,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,N,1,CHEMBL631149,,,
13713,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 10 mg/kg after ip administration (0-6 hr),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,N,1,CHEMBL631150,,,
13714,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,N,1,CHEMBL631151,,,
13715,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,N,1,CHEMBL631152,,,
13716,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,N,1,CHEMBL631443,,,
13717,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration (0-6 hr),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,N,1,CHEMBL631444,,,
13718,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,N,1,CHEMBL631445,,,
13719,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,N,1,CHEMBL631446,,,
13720,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg g after ip administration (0-6 hr),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,N,1,CHEMBL631447,,,
13721,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,N,1,CHEMBL631448,,,
13722,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,N,1,CHEMBL631449,,,
13723,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration (0-6 hr),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,N,1,CHEMBL631450,,,
13724,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,N,1,CHEMBL629724,,,
13725,1,"Biodistribution in mice skin, after 24 hr of intravenous aadministration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",Zone of skin,BAO_0000218,,Mus musculus,,Intermediate,9716,In vivo,N,1,CHEMBL629725,,14.0,
13726,1,"Biodistribution in mice skin, after 48 hr of intravenous administration of 1-2 ug ofcompound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",Zone of skin,BAO_0000218,,Mus musculus,,Intermediate,9716,In vivo,N,1,CHEMBL629726,,14.0,
13727,1,"Biodistribution in mice spleen, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",Spleen,BAO_0000218,,Mus musculus,,Intermediate,9716,In vivo,N,1,CHEMBL629727,,2106.0,
13728,1,"Biodistribution in mice spleen, after 1 hr of intravenous aadministration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",Spleen,BAO_0000218,,Mus musculus,,Intermediate,9716,In vivo,N,1,CHEMBL630404,,2106.0,
13729,1,"Biodistribution in mice spleen, after 24 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",Spleen,BAO_0000218,,Mus musculus,,Intermediate,9716,In vivo,N,1,CHEMBL630405,,2106.0,
13730,1,"Biodistribution in mice spleen, after 48 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",Spleen,BAO_0000218,,Mus musculus,,Intermediate,9716,In vivo,N,1,CHEMBL630406,,2106.0,
13731,1,"Biodistribution in mice stomach, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",Stomach,BAO_0000218,,Mus musculus,,Intermediate,9716,In vivo,N,1,CHEMBL630407,,945.0,
13732,1,"Biodistribution in mice stomach, after 1 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",Stomach,BAO_0000218,,Mus musculus,,Intermediate,9716,In vivo,N,1,CHEMBL630573,,945.0,
13733,1,"Biodistribution in mice stomach, after 24 hr of intravenous administration of 1-2 ug of ofcompound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",Stomach,BAO_0000218,,Mus musculus,,Intermediate,9716,In vivo,N,1,CHEMBL630574,,945.0,
13734,1,"Biodistribution in mice stomach, after 48 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",Stomach,BAO_0000218,,Mus musculus,,Intermediate,9716,In vivo,N,1,CHEMBL630575,,945.0,
13735,1,"Biodistribution in mice tail, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,BAO_0000218,,Mus musculus,,Intermediate,9716,In vivo,N,1,CHEMBL630576,,,
13736,1,"Biodistribution in mice tail, after 1 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,BAO_0000218,,Mus musculus,,Intermediate,9716,In vivo,N,1,CHEMBL630577,,,
13737,1,"Biodistribution in mice tail, after 24 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,BAO_0000218,,Mus musculus,,Intermediate,9716,In vivo,N,1,CHEMBL630578,,,
13738,1,"Biodistribution in mice tail, after 48 hr of intravenous administration of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,BAO_0000218,,Mus musculus,,Intermediate,9716,In vivo,N,1,CHEMBL630579,,,
13739,1,Percent of injected 238-Plutonium(IV) in mice kidney at 24 hr (orally administered),Kidney,BAO_0000218,,Mus musculus,,Intermediate,12192,,N,1,CHEMBL630580,,2113.0,
13740,1,Percent of injected 238-Plutonium(IV) in mice kidneys at 24 h,Kidney,BAO_0000218,,Mus musculus,,Intermediate,12192,,N,1,CHEMBL630581,,2113.0,
13741,1,Percent of injected 238-Plutonium(IV) in mice kidneys at 24 hr (orally administered),Kidney,BAO_0000218,,Mus musculus,,Intermediate,12192,,N,1,CHEMBL630582,,2113.0,
13742,1,Percent of injected 238-Plutonium(IV) in mice liver at 24 h,,BAO_0000218,,Mus musculus,,Intermediate,12192,,N,1,CHEMBL630583,,,
13743,1,Percent of injected 238-Plutonium(IV) in mice liver at 24 hr (orally administered),,BAO_0000218,,Mus musculus,,Intermediate,12192,,N,1,CHEMBL630584,,,
13744,1,Percent of injected 238-Plutonium(IV) in mice skeleton at 24 h,,BAO_0000218,,Mus musculus,,Intermediate,12192,,N,1,CHEMBL630585,,,
13745,1,Percent of injected 238-Plutonium(IV) in mice skeleton at 24 hr (orally administered),,BAO_0000218,,Mus musculus,,Intermediate,12192,,N,1,CHEMBL630586,,,
13746,1,Percent of injected 238-Plutonium(IV) in mice soft tissue at 24 h,,BAO_0000218,,Mus musculus,,Intermediate,12192,,N,1,CHEMBL630587,,,
13747,1,Percent of injected 238-Plutonium(IV) in mice soft tissue at 24 hr (orally administered),,BAO_0000218,,Mus musculus,,Intermediate,12192,,N,1,CHEMBL630588,,,
13748,1,Percent of injected 238-Plutonium(IV) in mice whole body at 24 h,,BAO_0000218,,Mus musculus,,Intermediate,12192,,N,1,CHEMBL630589,,,
13749,1,Percent of injected 238-Plutonium(IV) in mice whole body at 24 hr (orally administered),,BAO_0000218,,Mus musculus,,Intermediate,12192,,N,1,CHEMBL630590,,,
13750,1,Removal of 238-Plutonium(IV) in feces at 24 h,Feces,BAO_0000019,,,,Autocuration,12192,,U,0,CHEMBL630591,,1988.0,
13751,1,Removal of 238-Plutonium(IV) in feces at 24 hr (orally administered),Feces,BAO_0000019,,,,Autocuration,12192,,U,0,CHEMBL630592,,1988.0,
13752,1,Removal of 238-Plutonium(IV) in gastrointestinal (GI) contents at 24 h,,BAO_0000019,,,,Autocuration,12192,,U,0,CHEMBL630593,,,
13753,1,Removal of 238-Plutonium(IV) in gastrointestinal (GI) contents at 24 hr (orally administered),,BAO_0000019,,,,Autocuration,12192,,U,0,CHEMBL630594,,,
13754,1,Removal of 238-Plutonium(IV) in urine 0-4 h (orally administered),Urine,BAO_0000019,,,,Autocuration,12192,,U,0,CHEMBL630595,,1088.0,
13755,1,Removal of 238-Plutonium(IV) in urine 4-24 hr (orally administered),Urine,BAO_0000019,,,,Autocuration,12192,,U,0,CHEMBL630596,,1088.0,
13756,1,Removal of 238-Plutonium(IV) in urine after 0-24 h,Urine,BAO_0000019,,,,Autocuration,12192,,U,0,CHEMBL630597,,1088.0,
13757,1,Removal of 238-Plutonium(IV) in urine after 0-24 hr (orally administered),Urine,BAO_0000019,,,,Autocuration,12192,,U,0,CHEMBL630598,,1088.0,
13758,1,Removal of 238-Plutonium(IV) in urine after 0-4 h,Urine,BAO_0000019,,,,Autocuration,12192,,U,0,CHEMBL630599,,1088.0,
13759,1,Removal of 238-Plutonium(IV) in urine after 0-4 hr (orally administered),Urine,BAO_0000019,,,,Autocuration,12192,,U,0,CHEMBL630600,,1088.0,
13760,1,Removal of 238-Plutonium(IV) in urine after 4-24 h,Urine,BAO_0000019,,,,Autocuration,12192,,U,0,CHEMBL630601,,1088.0,
13761,1,Removal of 238-Plutonium(IV) in urine after 4-24 hr (orally administered),Urine,BAO_0000019,,,,Autocuration,12192,,U,0,CHEMBL630602,,1088.0,
13762,1,Removal of 238-Plutonium(IV) in urine at 0-4 hr (orally administered),Urine,BAO_0000019,,,,Autocuration,12192,,U,0,CHEMBL630603,,1088.0,
13763,1,Removal of 238-Plutonium(IV) in urine at 4-24 hr (orally administered),Urine,BAO_0000019,,,,Autocuration,12192,,U,0,CHEMBL630604,,1088.0,
13764,1,Biodistribution in blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL624869,,178.0,
13765,1,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL624870,,178.0,
13766,1,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL623189,,178.0,
13767,1,Biodistribution in blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL623190,,178.0,
13768,1,Biodistribution in blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL623191,,178.0,
13769,1,Biodistribution in fat of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL623192,,,
13770,1,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL623193,,,
13771,1,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL623194,,,
13772,1,Biodistribution in fat of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL623195,,,
13773,1,Biodistribution in fat of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL623196,,,
13774,1,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 15 microCi of the drug and 15 micro g of estradiol,,BAO_0000218,,Rattus norvegicus,,Intermediate,11836,,N,1,CHEMBL623197,,,
13775,1,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,,BAO_0000218,,Rattus norvegicus,,Intermediate,11836,,N,1,CHEMBL623198,,,
13776,1,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 50 microCi of the drug and 15 ug of estradiol,,BAO_0000218,,Rattus norvegicus,,Intermediate,11836,,N,1,CHEMBL623199,,,
13777,1,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 100 microCi of drug in 10%ethanol saline,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,11836,,N,1,CHEMBL623200,,2385.0,
13778,1,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 120 microCi of drug in 10%ethanol saline,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,11836,,N,1,CHEMBL623201,,2385.0,
13779,1,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 15 microCi of drug in 10%ethanol saline,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,11836,,N,1,CHEMBL623202,,2385.0,
13780,1,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 50 microCi of drug in 10%ethanol saline,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,11836,,N,1,CHEMBL623203,,2385.0,
13781,1,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 100 microCi of drug in 10%ethanol saline,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,11836,,N,1,CHEMBL623204,,2385.0,
13782,1,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 100 microCi of the drug and 15 ug of estradiol,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,11836,,N,1,CHEMBL623205,,2385.0,
13783,1,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 120 microCi of drug in 10%ethanol saline,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,11836,,N,1,CHEMBL623206,,2385.0,
13784,1,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 120 microCi of the drug and 15 micro g of estradiol,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,11836,,N,1,CHEMBL623207,,2385.0,
13785,1,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 15 microCi of the drug and 15 ug of estradiol,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,11836,,N,1,CHEMBL623208,,2385.0,
13786,1,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,11836,,N,1,CHEMBL623209,,2385.0,
13787,1,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 50 microCi of the drug and 15 ug of estradiol,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,11836,,N,1,CHEMBL623210,,2385.0,
13788,1,Tested in vivo for the biodistribution in rat fat at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,,BAO_0000218,,Rattus norvegicus,,Intermediate,11836,,N,1,CHEMBL623211,,,
13789,1,Tested in vivo for the biodistribution in rat uterus at 1 hour after intravenous dose of 120 microCi of drug in 10%ethanol saline,Uterus,BAO_0000218,,Rattus norvegicus,,Intermediate,11836,,N,1,CHEMBL623212,,995.0,
13790,1,Tested in vitro for intrinsic activity relative to quinpirole,,BAO_0000019,,,,Autocuration,12640,,U,0,CHEMBL623213,,,
13791,1,"Relative ion enhancement, determined in pulsed ultrafiltration",,BAO_0000019,,,,Autocuration,14218,,U,0,CHEMBL623214,,,
13792,1,% ionization at the pH 7.4 at 37 degree Centigrade,,BAO_0000019,,,,Autocuration,11296,,U,0,CHEMBL623215,,,
13793,1,Percentage ionization was measured,,BAO_0000019,,,,Autocuration,10929,,U,0,CHEMBL623216,,,
13794,1,Association constant of binding of compound with calf thymus DNA was determined by using equilibrium dialysis.,,BAO_0000218,,Bos taurus,,Intermediate,13841,,N,1,CHEMBL623217,,,
13795,1,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 Pseudo-first-order rate constant,,BAO_0000019,,,,Autocuration,10431,,U,0,CHEMBL623218,,,
13796,1,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 phosphate buffer Pseudo-first-order rate constant,,BAO_0000019,,,,Autocuration,10431,,U,0,CHEMBL623913,,,
13797,1,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 phosphate buffer pseudo-first-order rate constant 0.1 mM EDTA,,BAO_0000019,,,,Autocuration,10431,,U,0,CHEMBL623914,,,
13798,1,Compound was evaluated for the partition coefficient in octanol/water,,BAO_0000100,,,,Autocuration,8826,,U,0,CHEMBL623915,,,
13799,1,Compound was evaluated for the partition coefficient in octanol/water (1-octanol / 10 mM phosphate buffer at pH 7.4),,BAO_0000100,,,,Autocuration,8826,,U,0,CHEMBL624080,,,
13800,1,Equilibrium constant measured by the pulse radiolysis at pH 7,,BAO_0000019,,,,Autocuration,9884,,U,0,CHEMBL624081,,,
13801,1,In vitro hydrolytic rate constant determined in human blood,,BAO_0000218,,Homo sapiens,,Intermediate,9827,,N,1,CHEMBL624082,,,
13802,1,In vitro oxidation of compound to its pyridinium salt (3) in presence of human plasma,,BAO_0000218,,Homo sapiens,,Intermediate,10009,,N,1,CHEMBL625054,,,
13803,1,In vitro oxidation of compound to its pyridinium salt (3) in presence of hydrogen peroxide,,BAO_0000019,,,,Autocuration,10009,,U,0,CHEMBL877485,,,
13804,1,In vitro oxidation of compound to its pyridinium salt (3) in presence of mouse brain homogenate,,BAO_0000218,,Mus musculus,,Intermediate,10009,,N,1,CHEMBL625055,,,
13805,1,In vitro oxidation of compound to its pyridinium salt (3) in presence of mouse liver homogenate,,BAO_0000218,,Mus musculus,,Intermediate,10009,,N,1,CHEMBL625056,,,
13806,1,In vitro oxidation of compound in presence of human plasma,,BAO_0000218,,Homo sapiens,,Intermediate,10009,,N,1,CHEMBL625057,,,
13807,1,In vitro oxidation of compound in presence of hydrogen peroxide,,BAO_0000019,,,,Autocuration,10009,,U,0,CHEMBL625058,,,
13808,1,In vitro oxidation of compound in presence of mouse brain homogenate,,BAO_0000218,,Mus musculus,,Intermediate,10009,,N,1,CHEMBL625059,,,
13809,1,In vitro oxidation of compound in presence of mouse liver homogenate,,BAO_0000218,,Mus musculus,,Intermediate,10009,,N,1,CHEMBL629536,,,
13810,1,Mean potassium excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL629537,,,
13811,1,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL629538,,,
13812,1,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL629539,,,
13813,1,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL874445,,,
13814,1,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL629540,,,
13815,1,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL629541,,,
13816,1,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL629542,,,
13817,1,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL630243,,,
13818,1,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL630244,,,
13819,1,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL630245,,,
13820,1,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL630246,,,
13821,1,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL630247,,,
13822,1,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL630248,,,
13823,1,Biodistribution in rat blood at 240 minutes after dose administration.,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,N,1,CHEMBL630249,,178.0,
13824,1,Biodistribution in rat blood at 30 minutes after dose administration.,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,N,1,CHEMBL630250,,178.0,
13825,1,Biodistribution in rat blood at 360 minutes after dose administration.,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,N,1,CHEMBL630251,,178.0,
13826,1,Biodistribution in rat blood at 3 hr after dose administration.,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,N,1,CHEMBL630252,,178.0,
13827,1,Biodistribution in rat blood at 60 minutes after dose administration.,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,N,1,CHEMBL630408,,178.0,
13828,1,Biodistribution in rat cerebellum at 120 minutes after dose administration.,Cerebellum,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,N,1,CHEMBL630409,,2037.0,
13829,1,Biodistribution in rat cerebellum at 1440 minutes after dose administration.,Cerebellum,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,N,1,CHEMBL874446,,2037.0,
13830,1,Biodistribution in rat cerebellum at 15 minutes after dose administration.,Cerebellum,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,N,1,CHEMBL630410,,2037.0,
13831,1,Biodistribution in rat cerebellum at 240 minutes after dose administration.,Cerebellum,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,N,1,CHEMBL630411,,2037.0,
13832,1,Biodistribution in rat cerebellum at 30 minutes after dose administration.,Cerebellum,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,N,1,CHEMBL630412,,2037.0,
13833,1,Biodistribution in rat cerebellum at 360 minutes after dose administration.,Cerebellum,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,N,1,CHEMBL630413,,2037.0,
13834,1,Biodistribution in rat cerebellum at 3 hr after dose administration.,Cerebellum,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,N,1,CHEMBL630414,,2037.0,
13835,1,Biodistribution in rat cerebellum at 60 minutes after dose administration.,Cerebellum,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,N,1,CHEMBL630415,,2037.0,
13836,1,Biodistribution in rat cortex at 120 minutes after dose administration.,,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,N,1,CHEMBL630416,,,
13837,1,Biodistribution in rat cortex at 1440 minutes after dose administration.,,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,N,1,CHEMBL630417,,,
13838,1,Biodistribution in rat cortex at 15 minutes after dose administration.,,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,N,1,CHEMBL630418,,,
13839,1,Biodistribution in rat cortex at 240 minutes after dose administration.,,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,N,1,CHEMBL630419,,,
13840,1,Biodistribution in rat cortex at 30 minutes after dose administration.,,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,N,1,CHEMBL630420,,,
13841,1,Biodistribution in rat cortex at 360 minutes after dose administration.,,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,N,1,CHEMBL630421,,,
13842,1,Biodistribution in rat cortex at 3 hr after dose administration.,,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,N,1,CHEMBL630422,,,
13843,1,Biodistribution in rat cortex at 60 minutes after dose administration.,,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,N,1,CHEMBL630423,,,
13844,1,Biodistribution in rat heart at 120 minutes after dose administration.,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,N,1,CHEMBL630424,,948.0,
13845,1,Biodistribution in rat heart at 15 minutes after dose administration.,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,N,1,CHEMBL630425,,948.0,
13846,1,Biodistribution in rat heart at 240 minutes after dose administration.,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,N,1,CHEMBL629462,,948.0,
13847,1,Biodistribution in rat heart at 30 minutes after dose administration.,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,N,1,CHEMBL630426,,948.0,
13848,1,Biodistribution in rat heart at 360 minutes after dose administration.,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,N,1,CHEMBL630427,,948.0,
13849,1,Biodistribution in rat heart at 3 hr after dose administration.,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,N,1,CHEMBL625877,,948.0,
13850,1,Biodistribution in rat heart at 60 minutes after dose administration.,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,N,1,CHEMBL625878,,948.0,
13851,1,Biodistribution in rat hippocampus at 1440 minutes after dose administration.,Hippocampus,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,N,1,CHEMBL625879,,10000000.0,
13852,1,Biodistribution in rat hippocampus at 240 minutes after dose administration.,Hippocampus,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,N,1,CHEMBL625880,,10000000.0,
13853,1,Biodistribution in rat hippocampus at 30 minutes after dose administration.,Hippocampus,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,N,1,CHEMBL625881,,10000000.0,
13854,1,Biodistribution in rat hippocampus at 360 minutes after dose administration.,Hippocampus,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,N,1,CHEMBL625882,,10000000.0,
13855,1,Biodistribution in rat hippocampus at 15 minutes after dose administration.,Hippocampus,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,N,1,CHEMBL625883,,10000000.0,
13856,1,Biodistribution in rat kidney at 120 minutes after dose administration.,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,N,1,CHEMBL625884,,2113.0,
13857,1,Biodistribution in rat kidney at 1440 minutes after dose administration.,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,N,1,CHEMBL625885,,2113.0,
13858,1,Biodistribution in rat kidney at 15 minutes after dose administration.,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,N,1,CHEMBL628649,,2113.0,
13859,1,Biodistribution in rat kidney at 240 minutes after dose administration.,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,N,1,CHEMBL628650,,2113.0,
13860,1,Biodistribution in rat kidney at 30 minutes after dose administration.,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,N,1,CHEMBL628651,,2113.0,
13861,1,Biodistribution in rat kidney at 360 minutes after dose administration.,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,N,1,CHEMBL628652,,2113.0,
13862,1,Biodistribution in rat kidney at 60 minutes after dose administration.,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,N,1,CHEMBL628653,,2113.0,
13863,1,Biodistribution in rat liver at 120 minutes after dose administration.,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,N,1,CHEMBL628654,,2107.0,
13864,1,Biodistribution in rat liver at 1440 minutes after dose administration.,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,N,1,CHEMBL628655,,2107.0,
13865,1,Biodistribution in rat liver at 15 minutes after dose administration.,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,N,1,CHEMBL625238,,2107.0,
13866,1,Biodistribution in rat liver at 240 minutes after dose administration.,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,N,1,CHEMBL625239,,2107.0,
13867,1,Biodistribution in rat liver at 30 minutes after dose administration.,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,N,1,CHEMBL625240,,2107.0,
13868,1,Biodistribution in rat liver at 360 minutes after dose administration.,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,N,1,CHEMBL625241,,2107.0,
13869,1,Biodistribution in rat liver at 60 minutes after dose administration.,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,N,1,CHEMBL625242,,2107.0,
13870,1,Biodistribution in rat lung at 120 minutes after dose administration.,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,N,1,CHEMBL874587,,2048.0,
13871,1,Biodistribution in rat lung at 1440 minutes after dose administration.,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,N,1,CHEMBL625405,,2048.0,
13872,1,Biodistribution in rat lung at 15 minutes after dose administration.,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,N,1,CHEMBL625406,,2048.0,
13873,1,Biodistribution in rat lung at 240 minutes after dose administration.,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,N,1,CHEMBL625407,,2048.0,
13874,1,Biodistribution in rat lung at 30 minutes after dose administration.,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,N,1,CHEMBL625408,,2048.0,
13875,1,Biodistribution in rat lung at 360 minutes after dose administration.,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,N,1,CHEMBL625409,,2048.0,
13876,1,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of calcium deficient buffer,Thoracic aorta,BAO_0000218,,Rattus norvegicus,,Intermediate,12361,,N,1,CHEMBL625410,,1515.0,
13877,1,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of nifedipine,Thoracic aorta,BAO_0000218,,Rattus norvegicus,,Intermediate,12361,,N,1,CHEMBL625411,,1515.0,
13878,1,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of verapamil,Thoracic aorta,BAO_0000218,,Rattus norvegicus,,Intermediate,12361,,N,1,CHEMBL625412,,1515.0,
13879,1,Percent of maximal contractile response to compound in rat thoracic aorta strips presence of PBZ and CIR,Thoracic aorta,BAO_0000218,,Rattus norvegicus,,Intermediate,12361,,N,1,CHEMBL625413,,1515.0,
13880,1,Percent of maximal contractile response to compound in rat thoracic aorta strips v,Thoracic aorta,BAO_0000218,,Rattus norvegicus,,Intermediate,12361,,N,1,CHEMBL625414,,1515.0,
13881,1,Percent of maximal contractile response to compound with phenoxybenzamine pretreatment on rat thoracic aorta strips,Thoracic aorta,BAO_0000218,,Rattus norvegicus,,Intermediate,12361,,N,1,CHEMBL625415,,1515.0,
13882,1,Percent of maximal contractile response to compound without phenoxybenzamine pretreatment on rat thoracic aorta strips,Thoracic aorta,BAO_0000218,,Rattus norvegicus,,Intermediate,12361,,N,1,CHEMBL625416,,1515.0,
13883,1,% of the total radioactive dose of compound present in the 0-24 hour urine after a single 5 mg/kg dose administered intravenously in rats,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12712,,N,1,CHEMBL625417,,1088.0,
13884,1,Compound at the dose 10 mg/kg administered intraperitoneally was evaluated for the excretion rate in rats in 7 days through feces,Feces,BAO_0000218,,Rattus norvegicus,,Intermediate,7415,,N,1,CHEMBL625418,,1988.0,
13885,1,Compound at the dose 10 mg/kg administered intraperitoneally was evaluated for the excretion rate in rats in 7 days through urine,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,7415,,N,1,CHEMBL625419,,1088.0,
13886,1,Compound was evaluated for the biliary excretion in the anesthetized rats in 6 hours after intravenous doses 1 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,7415,,N,1,CHEMBL625420,,,
13887,1,Compound was evaluated for the biliary excretion in the anesthetized rats in 6 hours after intravenous doses 10 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,7415,,N,1,CHEMBL626996,,,
13888,1,"Compound was evaluated for the cumulative excretion rate in rats at the dose 10 mg/kg, intraperitoneally for 18 days through feces",Feces,BAO_0000218,,Rattus norvegicus,,Intermediate,7415,,N,1,CHEMBL626997,,1988.0,
13889,1,"Compound was evaluated for the cumulative excretion rate in rats at the dose 10 mg/kg, intraperitoneally for 18 days through urine",Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,7415,,N,1,CHEMBL626998,,1088.0,
13890,1,"Compound was evaluated for the in rats after the dose of 5 mg/kg intravenously, at the dose 4 hour biliary excretion",,BAO_0000218,,Rattus norvegicus,,Intermediate,7415,,N,1,CHEMBL626999,,,
13891,1,faecal levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-30h,,BAO_0000218,,Mus musculus,,Intermediate,8050,,N,1,CHEMBL627000,,,
13892,1,fecal levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-30h,,BAO_0000218,,Mus musculus,,Intermediate,8050,,N,1,CHEMBL627001,,,
13893,1,fecal levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-30h,,BAO_0000218,,Mus musculus,,Intermediate,8050,,N,1,CHEMBL627002,,,
13894,1,fecal levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-30h,,BAO_0000218,,Mus musculus,,Intermediate,8050,,N,1,CHEMBL627003,,,
13895,1,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-24 hr,Urine,BAO_0000218,,Mus musculus,,Intermediate,8050,,N,1,CHEMBL627004,,1088.0,
13896,1,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-6 hr,Urine,BAO_0000218,,Mus musculus,,Intermediate,8050,,N,1,CHEMBL627005,,1088.0,
13897,1,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 24-30 hr,Urine,BAO_0000218,,Mus musculus,,Intermediate,8050,,N,1,CHEMBL874594,,1088.0,
13898,1,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-24 hr,Urine,BAO_0000218,,Mus musculus,,Intermediate,8050,,N,1,CHEMBL627006,,1088.0,
13899,1,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-6 hr,Urine,BAO_0000218,,Mus musculus,,Intermediate,8050,,N,1,CHEMBL627007,,1088.0,
13900,1,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 24-30 hr,Urine,BAO_0000218,,Mus musculus,,Intermediate,8050,,N,1,CHEMBL627884,,1088.0,
13901,1,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-24 hr,Urine,BAO_0000218,,Mus musculus,,Intermediate,8050,,N,1,CHEMBL627885,,1088.0,
13902,1,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-6 hr,Urine,BAO_0000218,,Mus musculus,,Intermediate,8050,,N,1,CHEMBL627886,,1088.0,
13903,1,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 24-30 hr,Urine,BAO_0000218,,Mus musculus,,Intermediate,8050,,N,1,CHEMBL627887,,1088.0,
13904,1,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-24 hr,Urine,BAO_0000218,,Mus musculus,,Intermediate,8050,,N,1,CHEMBL627888,,1088.0,
13905,1,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-6 hr,Urine,BAO_0000218,,Mus musculus,,Intermediate,8050,,N,1,CHEMBL628057,,1088.0,
13906,1,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 24-30 hr,Urine,BAO_0000218,,Mus musculus,,Intermediate,8050,,N,1,CHEMBL627405,,1088.0,
13907,1,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,N,1,CHEMBL627406,,1088.0,
13908,1,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,N,1,CHEMBL627407,,1088.0,
13909,1,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,N,1,CHEMBL627408,,1088.0,
13910,1,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,N,1,CHEMBL627409,,1088.0,
13911,1,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,N,1,CHEMBL875486,,1088.0,
13912,1,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,N,1,CHEMBL627410,,1088.0,
13913,1,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,N,1,CHEMBL627411,,1088.0,
13914,1,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,N,1,CHEMBL627412,,1088.0,
13915,1,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,N,1,CHEMBL627413,,1088.0,
13916,1,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,N,1,CHEMBL627414,,1088.0,
13917,1,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 10.1 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,N,1,CHEMBL627415,,1088.0,
13918,1,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 102 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,N,1,CHEMBL627416,,1088.0,
13919,1,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 3.40 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,N,1,CHEMBL627417,,1088.0,
13920,1,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 3.76 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,N,1,CHEMBL627418,,1088.0,
13921,1,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 34.1 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,N,1,CHEMBL627419,,1088.0,
13922,1,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 50.8 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,N,1,CHEMBL627320,,1088.0,
13923,1,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 68.1 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,N,1,CHEMBL627321,,1088.0,
13924,1,Biodistribution in kidney of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL627322,,2113.0,
13925,1,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL627323,,2113.0,
13926,1,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL627491,,2113.0,
13927,1,Biodistribution in kidney of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL627492,,2113.0,
13928,1,Biodistribution in kidney of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL627493,,2113.0,
13929,1,Biodistribution in liver of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL627494,,2107.0,
13930,1,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL627495,,2107.0,
13931,1,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL627496,,2107.0,
13932,1,Biodistribution in liver of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL627497,,2107.0,
13933,1,Biodistribution in liver of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL627498,,2107.0,
13934,1,Biodistribution in lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL627499,,2048.0,
13935,1,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL627500,,2048.0,
13936,1,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL627501,,2048.0,
13937,1,Biodistribution in lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL625616,,2048.0,
13938,1,Biodistribution in lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL625617,,2048.0,
13939,1,Biodistribution in muscle of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL625618,,2385.0,
13940,1,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL625619,,2385.0,
13941,1,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL625620,,2385.0,
13942,1,Biodistribution in muscle of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL625621,,2385.0,
13943,1,Biodistribution in muscle of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL625622,,2385.0,
13944,1,Biodistribution in spleen of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL625788,,2106.0,
13945,1,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL625789,,2106.0,
13946,1,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL625790,,2106.0,
13947,1,Biodistribution in spleen of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL625791,,2106.0,
13948,1,Biodistribution in spleen of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL622334,,2106.0,
13949,1,Biodistribution in thyroid of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL622335,,2046.0,
13950,1,Biodistribution in thyroid of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL622336,,2046.0,
13951,1,Biodistribution in thyroid of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL622337,,2046.0,
13952,1,Biodistribution in thyroid of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL622338,,2046.0,
13953,1,Biodistribution in thyroid of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL622339,,2046.0,
13954,1,Biodistribution in uterus / blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL624153,,,
13955,1,Biodistribution in uterus / blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL628430,,,
13956,1,Biodistribution in uterus / blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL628431,,,
13957,1,Biodistribution in uterus / blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL628432,,,
13958,1,Biodistribution in uterus / blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL628433,,,
13959,1,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL628434,,2106.0,
13960,1,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL626789,,2106.0,
13961,1,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2)",Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL626790,,2106.0,
13962,1,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL626791,,2106.0,
13963,1,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL626792,,2106.0,
13964,1,"Biodistribution in uterus / spleen, muscle, lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL626793,,2106.0,
13965,1,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL627436,,,
13966,1,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL627437,,,
13967,1,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL627438,,,
13968,1,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL627439,,,
13969,1,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL627440,,,
13970,1,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL627602,,,
13971,1,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL627603,,,
13972,1,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL627604,,,
13973,1,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL627605,,,
13974,1,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL627606,,,
13975,1,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL627607,,,
13976,1,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL627608,,,
13977,1,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL627609,,,
13978,1,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL627610,,,
13979,1,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL627611,,,
13980,1,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL627612,,,
13981,1,Octanol:water partition coefficient is evaluated,,BAO_0000100,,,,Autocuration,8362,,U,0,CHEMBL627613,,,
13982,1,Partition coefficient in 1-octanol/water system,,BAO_0000100,,,,Autocuration,8257,,U,0,CHEMBL627614,,,
13983,1,Partition coefficient in 1-octanol/water system measured using radio active compounds,,BAO_0000100,,,,Autocuration,8257,,U,0,CHEMBL627615,,,
13984,1,Partition coefficient in octanol/water system was determined,,BAO_0000100,,,,Autocuration,9468,,U,0,CHEMBL627616,,,
13985,1,Partition coefficient in octanol/water system was determined using [14C]-labeled compounds.,,BAO_0000100,,,,Autocuration,9468,,U,0,CHEMBL627617,,,
13986,1,Pseudo-first-order rate constant at pH 10 and 35 degrees Centigrade,,BAO_0000019,,,,Autocuration,10568,,U,0,CHEMBL627618,,,
13987,1,"Pseudo-first-order rate constant at pH 10, micro=0.5, 35 degrees Centigrade",,BAO_0000019,,,,Autocuration,10568,,U,0,CHEMBL627619,,,
13988,1,Pseudo-first-order rate constant of the compound,,BAO_0000019,,,,Autocuration,15359,,U,0,CHEMBL627620,,,
13989,1,Pseudo-first-order rate constant with 1-min time point,,BAO_0000019,,,,Autocuration,15359,,U,0,CHEMBL627621,,,
13990,1,Pseudo-first-order rate constant without 1-min time point,,BAO_0000019,,,,Autocuration,15359,,U,0,CHEMBL627622,,,
13991,1,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 0.5 mM EDTA,,BAO_0000019,,,,Autocuration,10431,,U,0,CHEMBL627623,,,
13992,1,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 50 mM EDTA,,BAO_0000019,,,,Autocuration,10431,,U,0,CHEMBL627624,,,
13993,1,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 70 mM EDTA,,BAO_0000019,,,,Autocuration,10431,,U,0,CHEMBL627625,,,
13994,1,Rate constants determined using 31P NMR Kinetics experiments at 37 degrees Centigrade,,BAO_0000019,,,,Autocuration,15704,,U,0,CHEMBL628523,,,
13995,1,The alkaline hydrolysis second order rate constant(K OH) of the compound,,BAO_0000019,,,,Autocuration,15287,,U,0,CHEMBL628524,,,
13996,1,The efflux rate constant of the compound,,BAO_0000019,,,,Autocuration,7516,,U,0,CHEMBL628525,,,
13997,1,The reaction rate constant (K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,,BAO_0000019,,,,Autocuration,12973,,U,0,CHEMBL625732,,,
13998,1,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,,BAO_0000019,,,,Autocuration,12973,,U,0,CHEMBL625733,,,
13999,1,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,,BAO_0000019,,,,Autocuration,12973,,U,0,CHEMBL625734,,,
14000,1,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine; ND= not determined,,BAO_0000019,,,,Autocuration,12973,,U,0,CHEMBL625913,,,
14001,1,Association constant was evaluated towards synthetic peptidoglycan analogue Ac2-Lys-D-Ala-D-Ala,,BAO_0000019,,,,Autocuration,8696,,U,0,CHEMBL625914,,,
14002,1,Equilibrium association (binding) constant interacting with Unilamellar Vesicles of electroneutral DMPC in PBSbuffer at pH 7.4 and 37 C,,BAO_0000019,,,,Autocuration,15052,,U,0,CHEMBL625915,,,
14003,1,Equilibrium association (binding) constant interacting with Unilamellar Vesicles of negatively charged DMPG in PBS buffer at pH 7.4 and 37 C,,BAO_0000019,,,,Autocuration,15052,,U,0,CHEMBL625916,,,
14004,1,Evaluated for the mustard reactivity by determining rate constant for hydrolysis of mustard in aqueous acetone (K H),,BAO_0000019,,,,Autocuration,10503,,U,0,CHEMBL625917,,,
14005,1,"Effective biomolecular rate constant at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",,BAO_0000019,,,,Autocuration,8354,,U,0,CHEMBL625918,,,
14006,1,"Effective biomolecular rate constant at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",,BAO_0000019,,,,Autocuration,8354,,U,0,CHEMBL625919,,,
14007,1,"Effective biomolecular rate constant at the concentration 0.790 mM [HOX] in the conditions of 25degreeC,pH 7.6",,BAO_0000019,,,,Autocuration,8354,,U,0,CHEMBL625920,,,
14008,1,"Effective biomolecular rate constant at the concentration 1.00 mM [HOX] in the conditions of 25degreeC,pH 7.6",,BAO_0000019,,,,Autocuration,8354,,U,0,CHEMBL874453,,,
14009,1,"Effective biomolecular rate constant in the conditions of 25degreeC,pH 7.6",,BAO_0000019,,,,Autocuration,8354,,U,0,CHEMBL625921,,,
14010,1,Evaluated for the mustard reactivity by determining rate constant for alkylation of 4-(4-nitrobenzyl)pyridine using NBP alkylation assay,,BAO_0000019,,,,Autocuration,10503,,U,0,CHEMBL625922,,,
14011,1,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",,BAO_0000019,,,,Autocuration,8354,,U,0,CHEMBL625923,,,
14012,1,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",,BAO_0000019,,,,Autocuration,8354,,U,0,CHEMBL625924,,,
14013,1,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.790 mM [HOX] in the conditions of 25degreeC,pH 7.6",,BAO_0000019,,,,Autocuration,8354,,U,0,CHEMBL625925,,,
14014,1,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 1.00 mM [HOX] in the conditions of 25degreeC,pH 7.6",,BAO_0000019,,,,Autocuration,8354,,U,0,CHEMBL625926,,,
14015,1,Biodistribution in rat lung at 60 minutes after dose administration.,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,N,1,CHEMBL627704,,2048.0,
14016,1,Biodistribution in rat pons/medulla at 120 minutes after dose administration.,,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,N,1,CHEMBL627705,,,
14017,1,Biodistribution in rat pons/medulla at 15 minutes after dose administration.,,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,N,1,CHEMBL627706,,,
14018,1,Biodistribution in rat pons/medulla at 240 minutes after dose administration.,,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,N,1,CHEMBL627707,,,
14019,1,Biodistribution in rat pons/medulla at 30 minutes after dose administration.,,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,N,1,CHEMBL627708,,,
14020,1,Biodistribution in rat pons/medulla at 360 minutes after dose administration.,,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,N,1,CHEMBL628361,,,
14021,1,Biodistribution in rat pons/medulla at 60 minutes after dose administration.,,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,N,1,CHEMBL628362,,,
14022,1,Biodistribution in rat striatum at 120 minutes after dose administration.,Striatum,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,N,1,CHEMBL628363,,2435.0,
14023,1,Biodistribution in rat striatum at 1440 minutes after dose administration.,Striatum,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,N,1,CHEMBL628364,,2435.0,
14024,1,Biodistribution in rat striatum at 15 minutes after dose administration.,Striatum,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,N,1,CHEMBL628365,,2435.0,
14025,1,Biodistribution in rat striatum at 240 minutes after dose administration.,Striatum,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,N,1,CHEMBL874454,,2435.0,
14026,1,Biodistribution in rat striatum at 30 minutes after dose administration.,Striatum,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,N,1,CHEMBL628531,,2435.0,
14027,1,Biodistribution in rat striatum at 360 minutes after dose administration.,Striatum,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,N,1,CHEMBL628532,,2435.0,
14028,1,Biodistribution in rat striatum at 3 hr after dose administration.,Striatum,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,N,1,CHEMBL628533,,2435.0,
14029,1,Biodistribution in rat striatum at 60 minutes after dose administration.,Striatum,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,N,1,CHEMBL628534,,2435.0,
14030,1,Biodistribution in rat thyroid at 120 minutes after dose administration.,Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,N,1,CHEMBL628535,,2046.0,
14031,1,Biodistribution in rat thyroid at 1440 minutes after dose administration.,Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,N,1,CHEMBL628536,,2046.0,
14032,1,Biodistribution in rat thyroid at 15 minutes after dose administration.,Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,N,1,CHEMBL628537,,2046.0,
14033,1,Biodistribution in rat thyroid at 240 minutes after dose administration.,Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,N,1,CHEMBL628538,,2046.0,
14034,1,Biodistribution in rat thyroid at 30 minutes after dose administration.,Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,N,1,CHEMBL628539,,2046.0,
14035,1,Biodistribution in rat thyroid at 360 minutes after dose administration.,Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,N,1,CHEMBL630297,,2046.0,
14036,1,Biodistribution in rat thyroid at 60 minutes after dose administration.,Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,N,1,CHEMBL630298,,2046.0,
14037,1,Biodistribution in rest of brain of rat 120 minutes after dose administration.,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,N,1,CHEMBL630299,,955.0,
14038,1,Biodistribution in rest of brain of rat at 1440 minutes after dose administration.,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,N,1,CHEMBL628094,,955.0,
14039,1,Biodistribution in rest of brain of rat at 15 minutes after dose administration.,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,N,1,CHEMBL628095,,955.0,
14040,1,Biodistribution in rest of brain of rat at 240 minutes after dose administration.,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,N,1,CHEMBL874648,,955.0,
14041,1,Biodistribution in rest of brain of rat at 30 minutes after dose administration.,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,N,1,CHEMBL628096,,955.0,
14042,1,Biodistribution in rest of brain of rat at 360 minutes after dose administration.,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,N,1,CHEMBL628097,,955.0,
14043,1,Biodistribution in rest of brain of rat at 60 minutes after dose administration.,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,N,1,CHEMBL628098,,955.0,
14044,1,"Mean rate constant for the hydrolysis of compound in buffers at pH 6.5, at 37 degrees Celsius in incubation mixture - d(A)-d(T) (10:1)",,BAO_0000019,,,,Autocuration,13331,,U,0,CHEMBL628099,,,
14045,1,"Mean rate constant for the hydrolysis of compound in buffers at pH 6.5, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (10:1)",,BAO_0000019,,,,Autocuration,13331,,U,0,CHEMBL628100,,,
14046,1,Mean rate constant for the hydrolysis of compound in buffers at pH 7.4 at 37 degrees Centigrade in incubation mixture - d(A)-d(T) (10:!),,BAO_0000019,,,,Autocuration,13331,,U,0,CHEMBL628101,,,
14047,1,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - 5'-GMP/5'-CMP (1:1)",,BAO_0000019,,,,Autocuration,13331,,U,0,CHEMBL628102,,,
14048,1,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(A)-d(T) (1:1)",,BAO_0000019,,,,Autocuration,13331,,U,0,CHEMBL628103,,,
14049,1,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (10:1)",,BAO_0000019,,,,Autocuration,13331,,U,0,CHEMBL628104,,,
14050,1,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (1:1)",,BAO_0000019,,,,Autocuration,13331,,U,0,CHEMBL628105,,,
14051,1,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(T) (10:1)",,BAO_0000019,,,,Autocuration,13331,,U,0,CHEMBL628106,,,
14052,1,Mean urine volume excretion in conscious rats at a dose of 0.3 mg/kg given orally,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,10086,,N,1,CHEMBL628107,,1088.0,
14053,1,Mean urine volume excretion in conscious rats at a dose of 0.3 mg/kg given orally,Urine,BAO_0000218,,,,Autocuration,10086,,U,0,CHEMBL628108,,1088.0,
14054,1,Mean urine volume excretion in conscious rats at a dose of 1.0 mg/kg given orally,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,10086,,N,1,CHEMBL628109,,1088.0,
14055,1,Mean urine volume excretion in conscious rats at a dose of 1.0 mg/kg given orally,Urine,BAO_0000218,,,,Autocuration,10086,,U,0,CHEMBL625299,,1088.0,
14056,1,Mean urine volume excretion in conscious rats at a dose of 10 mg/kg given orally,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,10086,,N,1,CHEMBL625300,,1088.0,
14057,1,Mean urine volume excretion in conscious rats at a dose of 100 mg/kg given orally,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,10086,,N,1,CHEMBL625301,,1088.0,
14058,1,Mean urine volume excretion in conscious rats at a dose of 3.0 mg/kg given orally,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,10086,,N,1,CHEMBL625302,,1088.0,
14059,1,Mean urine volume excretion in conscious rats at a dose of 30 mg/kg given orally,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,10086,,N,1,CHEMBL874649,,1088.0,
14060,1,In vitro metabolic stability of the test compound was evaluated after incubation in the presence of freshly isolated rat hepatocytes,,BAO_0000218,,Rattus norvegicus,,Intermediate,13248,,N,1,CHEMBL625303,,,
14061,1,In vitro metabolic stability of the test compound was evaluated after incubation in the presence of freshly isolated rat hepatocytes; NA= Not tested,,BAO_0000218,,Rattus norvegicus,,Intermediate,13248,,N,1,CHEMBL625463,,,
14062,1,In vitro metabolism in human liver microsomes,Liver,BAO_0000218,,Homo sapiens,,Intermediate,14527,,N,1,CHEMBL625464,,2107.0,
14063,1,Metabolism (NADH oxidation) by recombinant human NAD(P)H: quinone oxidoreductase (NQO1) is evaluated.,,BAO_0000218,,Homo sapiens,,Intermediate,3008,,N,1,CHEMBL625465,,,
14064,1,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 9.06 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,N,1,CHEMBL625466,,1088.0,
14065,1,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 9.6 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,N,1,CHEMBL625467,,1088.0,
14066,1,Total electrolytic excretion of chlorine in urine of rats after intravenous administration of 7.94 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL625468,,1088.0,
14067,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 0 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL625469,,1088.0,
14068,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 1.01 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL625470,,1088.0,
14069,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 1.13 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL632418,,1088.0,
14070,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 10.1 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL627250,,1088.0,
14071,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 102 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL627251,,1088.0,
14072,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 105 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL627252,,1088.0,
14073,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 11.3 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL627253,,1088.0,
14074,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 113 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL627254,,1088.0,
14075,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 19.5 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL875471,,1088.0,
14076,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 195 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL627255,,1088.0,
14077,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 21.7 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL627256,,1088.0,
14078,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 217 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL627257,,1088.0,
14079,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 23.9 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL627258,,1088.0,
14080,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 239 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL627259,,1088.0,
14081,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 24.9 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL627260,,1088.0,
14082,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 249 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL623256,,1088.0,
14083,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 25.9 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL874413,,1088.0,
14084,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 259 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL623257,,1088.0,
14085,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 26.5 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL623258,,1088.0,
14086,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 265 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL623259,,1088.0,
14087,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 27 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL623260,,1088.0,
14088,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 27.9 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL623261,,1088.0,
14089,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 270 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL623262,,1088.0,
14090,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 279 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL623263,,1088.0,
14091,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.2 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL623264,,1088.0,
14092,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.22 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL623265,,1088.0,
14093,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.9 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL623266,,1088.0,
14094,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 282 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL623267,,1088.0,
14095,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 289 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL623268,,1088.0,
14096,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 3.40 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL623269,,1088.0,
14097,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 3.76 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL623270,,1088.0,
14098,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 30.2 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL623271,,1088.0,
14099,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 302 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL623272,,1088.0,
14100,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 31.6 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL623273,,1088.0,
14101,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 316 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL623274,,1088.0,
14102,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 32.4 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL874414,,1088.0,
14103,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 324 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL623275,,1088.0,
14104,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.0 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL629150,,1088.0,
14105,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.1 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL623276,,1088.0,
14106,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.8 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL623277,,1088.0,
14107,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 341 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL623112,,1088.0,
14108,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 348 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL623113,,1088.0,
14109,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 37.6 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL623800,,1088.0,
14110,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 58.4 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL623801,,1088.0,
14111,1,"Biodistribution in uterus / spleen, muscle, lungs of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL623802,,2106.0,
14112,1,Biodistribution in uterus of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Uterus,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL623803,,995.0,
14113,1,Biodistribution in uterus of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Uterus,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL623970,,995.0,
14114,1,Biodistribution in uterus of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Uterus,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL623971,,995.0,
14115,1,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 10 min post injection (Average of three to five animals),Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,14045,In vivo,N,1,CHEMBL623972,,178.0,
14116,1,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 30 min post injection (Average of three to five animals),Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,14045,In vivo,N,1,CHEMBL623973,,178.0,
14117,1,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 5 min post injection (Average of three to five animals),Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,14045,In vivo,N,1,CHEMBL623974,,178.0,
14118,1,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 60 min post injection (Average of three to five animals),Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,14045,In vivo,N,1,CHEMBL623975,,178.0,
14119,1,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 10 min post injection (Average of three to five animals),Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,14045,In vivo,N,1,CHEMBL623976,,955.0,
14120,1,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 30 min post injection (Average of three to five animals),Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,14045,In vivo,N,1,CHEMBL623977,,955.0,
14121,1,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 5 min post injection (Average of three to five animals),Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,14045,In vivo,N,1,CHEMBL623978,,955.0,
14122,1,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 60 min post injection (Average of three to five animals),Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,14045,In vivo,N,1,CHEMBL623979,,955.0,
14123,1,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 10 min post injection (Average of three to five animals),,BAO_0000218,,Rattus norvegicus,,Intermediate,14045,In vivo,N,1,CHEMBL623980,,,
14124,1,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 30 min post injection (Average of three to five animals),,BAO_0000218,,Rattus norvegicus,,Intermediate,14045,In vivo,N,1,CHEMBL623981,,,
14125,1,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 5 min post injection (Average of three to five animals),,BAO_0000218,,Rattus norvegicus,,Intermediate,14045,In vivo,N,1,CHEMBL626278,,,
14126,1,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 60 min post injection (Average of three to five animals),,BAO_0000218,,Rattus norvegicus,,Intermediate,14045,In vivo,N,1,CHEMBL626279,,,
14127,1,Biodistribution in mice bladder plus excreted urine was determined,,BAO_0000218,,Mus musculus,,Intermediate,14045,In vivo,N,1,CHEMBL626280,,,
14128,1,"Percentage biodistribution in mouse blood, 10 minutes post injection",,BAO_0000218,,Mus musculus,,Intermediate,14045,,N,1,CHEMBL626281,,,
14129,1,"Percentage biodistribution in mouse blood, 30 minutes post injection",,BAO_0000218,,Mus musculus,,Intermediate,14045,,N,1,CHEMBL626282,,,
14130,1,"Percentage biodistribution in mouse blood, 5 minutes post injection",,BAO_0000218,,Mus musculus,,Intermediate,14045,,N,1,CHEMBL626283,,,
14131,1,"Percentage biodistribution in mouse blood, 60 minutes post injection",,BAO_0000218,,Mus musculus,,Intermediate,14045,,N,1,CHEMBL626284,,,
14132,1,"Percentage biodistribution in mouse brain, 10 minutes post injection",Brain,BAO_0000218,,Mus musculus,,Intermediate,14045,,N,1,CHEMBL626285,,955.0,
14133,1,"Percentage biodistribution in mouse brain, 30 minutes post injection",Brain,BAO_0000218,,Mus musculus,,Intermediate,14045,,N,1,CHEMBL626286,,955.0,
14134,1,"Percentage biodistribution in mouse brain, 5 minutes post injection",Brain,BAO_0000218,,Mus musculus,,Intermediate,14045,,N,1,CHEMBL626287,,955.0,
14135,1,"Percentage biodistribution in mouse brain, 60 minutes post injection",Brain,BAO_0000218,,Mus musculus,,Intermediate,14045,,N,1,CHEMBL626288,,955.0,
14136,1,"Percentage biodistribution in mouse heart, 10 minutes post injection",,BAO_0000218,,Mus musculus,,Intermediate,14045,,N,1,CHEMBL626289,,,
14137,1,"Percentage biodistribution in mouse heart, 30 minutes post injection",,BAO_0000218,,Mus musculus,,Intermediate,14045,,N,1,CHEMBL626290,,,
14138,1,"Percentage biodistribution in mouse heart, 5 minutes post injection",,BAO_0000218,,Mus musculus,,Intermediate,14045,,N,1,CHEMBL626291,,,
14139,1,"Percentage biodistribution in mouse heart, 60 minutes post injection",,BAO_0000218,,Mus musculus,,Intermediate,14045,,N,1,CHEMBL839888,,,
14140,1,"Percentage biodistribution in mouse intestine, 10 minutes post injection",Intestine,BAO_0000218,,Mus musculus,,Intermediate,14045,,N,1,CHEMBL626292,,160.0,
14141,1,"Percentage biodistribution in mouse intestine, 30 minutes post injection",Intestine,BAO_0000218,,Mus musculus,,Intermediate,14045,,N,1,CHEMBL626293,,160.0,
14142,1,"Percentage biodistribution in mouse intestine, 5 minutes post injection",Intestine,BAO_0000218,,Mus musculus,,Intermediate,14045,,N,1,CHEMBL626294,,160.0,
14143,1,"Percentage biodistribution in mouse intestine, 60 minutes post injection",Intestine,BAO_0000218,,Mus musculus,,Intermediate,14045,,N,1,CHEMBL626295,,160.0,
14144,1,"Percentage biodistribution in mouse liver, 10 minutes post injection",Liver,BAO_0000218,,Mus musculus,,Intermediate,14045,,N,1,CHEMBL627659,,2107.0,
14145,1,"Percentage biodistribution in mouse liver, 30 minutes of post injection",Liver,BAO_0000218,,Mus musculus,,Intermediate,14045,,N,1,CHEMBL627660,,2107.0,
14146,1,"Percentage biodistribution in mouse liver, 5 minutes post injection",Liver,BAO_0000218,,Mus musculus,,Intermediate,14045,,N,1,CHEMBL627661,,2107.0,
14147,1,Biodistribution in mice liver at 60 minutes of post injection,Liver,BAO_0000218,,Mus musculus,,Intermediate,14045,In vivo,N,1,CHEMBL627662,,2107.0,
14148,1,Biodistribution in mice lungs at 10 min of post injection,Lung,BAO_0000218,,Mus musculus,,Intermediate,14045,In vivo,N,1,CHEMBL627663,,2048.0,
14149,1,"Percentage biodistribution in mouse lung, 30 minutes post injection",,BAO_0000218,,Mus musculus,,Intermediate,14045,,N,1,CHEMBL627664,,,
14150,1,"Percentage biodistribution in mousee lung, 5 minutes post injection",,BAO_0000218,,Mus musculus,,Intermediate,14045,,N,1,CHEMBL627665,,,
14151,1,Biodistribution in mice lungs at 60 min of post injection,Lung,BAO_0000218,,Mus musculus,,Intermediate,14045,In vivo,N,1,CHEMBL627666,,2048.0,
14152,1,Percentage biodistribution in mouse spleen,Spleen,BAO_0000218,,Mus musculus,,Intermediate,14045,,N,1,CHEMBL627667,,2106.0,
14153,1,Percentage biodistribution in mouse stomach,Stomach,BAO_0000218,,Mus musculus,,Intermediate,14045,,N,1,CHEMBL627668,,945.0,
14154,1,Mean biodistribution and elimination data in urine was reported 24 h after administering compound intravenously in tumor-bearing female BALB-C mice.,Urine,BAO_0000218,,Mus musculus,,Intermediate,11745,,N,1,CHEMBL627669,,1088.0,
14155,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in bladder,Urinary bladder,BAO_0000218,,,,Autocuration,13257,In vivo,U,0,CHEMBL627670,,1255.0,
14156,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in blood,Blood,BAO_0000218,,,,Autocuration,13257,In vivo,U,0,CHEMBL627671,,178.0,
14157,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in bone,Bone element,BAO_0000218,,,,Autocuration,13257,In vivo,U,0,CHEMBL627672,,1474.0,
14158,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in fat,,BAO_0000218,,,,Autocuration,13257,In vivo,U,0,CHEMBL627673,,,
14159,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in kidney,Kidney,BAO_0000218,,,,Autocuration,13257,In vivo,U,0,CHEMBL627674,,2113.0,
14160,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in liver,Liver,BAO_0000218,,,,Autocuration,13257,In vivo,U,0,CHEMBL627675,,2107.0,
14161,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in lung,Lung,BAO_0000218,,,,Autocuration,13257,In vivo,U,0,CHEMBL627676,,2048.0,
14162,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in muscle,Muscle tissue,BAO_0000218,,,,Autocuration,13257,In vivo,U,0,CHEMBL627677,,2385.0,
14163,1,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator in the conditions of 25degreeC,pH 7.6",,BAO_0000019,,,,Autocuration,8354,,U,0,CHEMBL627678,,,
14164,1,Affinity for protein binding expressed as association constant in fresh rat serum,Serum,BAO_0000218,,Rattus norvegicus,,Intermediate,7095,,N,1,CHEMBL627679,,1977.0,
14165,1,Kinetic constant (Kcat) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation,,BAO_0000019,,,,Autocuration,12185,,U,0,CHEMBL627680,,,
14166,1,Kinetic constant (Kcat) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation; Inactive,,BAO_0000019,,,,Autocuration,12185,,U,0,CHEMBL627681,,,
14167,1,Inactivation constant (Kinact) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation,,BAO_0000019,,,,Autocuration,12185,,U,0,CHEMBL627682,,,
14168,1,Inactivation constant (Kinact) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation; Inactive,,BAO_0000019,,,,Autocuration,12185,,U,0,CHEMBL627683,,,
14169,1,The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 2.4,,BAO_0000019,,,,Autocuration,12686,,U,0,CHEMBL627684,,,
14170,1,"The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 2.4; Significant cyclization occurred during nitro reduction, precluding isolation of the pure amine and determination of rate constants",,BAO_0000019,,,,Autocuration,12686,,U,0,CHEMBL874441,,,
14171,1,The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 6.8; No cyclization detected over 4 h,,BAO_0000019,,,,Autocuration,12686,,U,0,CHEMBL627685,,,
14172,1,"The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 6.8; Significant cyclization occurred during nitro reduction, precluding isolation of the pure amine and determination of rate constants",,BAO_0000019,,,,Autocuration,12686,,U,0,CHEMBL627686,,,
14173,1,Apparent rate constant Koff for inactivation of dTMP synthase.,,BAO_0000019,,,,Autocuration,8057,,U,0,CHEMBL627687,,,
14174,1,The irreversible inhibitor activity by second order rate equation.,,BAO_0000019,,,,Autocuration,15778,,U,0,CHEMBL627688,,,
14175,1,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at 1 mg/kg concentration,,BAO_0000218,,Rattus norvegicus,,Intermediate,12375,,N,1,CHEMBL628038,,,
14176,1,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at 5 mg/kg concentration,,BAO_0000218,,Rattus norvegicus,,Intermediate,12375,,N,1,CHEMBL628039,,,
14177,1,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at vehicle concentration,,BAO_0000218,,Rattus norvegicus,,Intermediate,12375,,N,1,CHEMBL628040,,,
14178,1,Dissociation rate calculated from the first-order equation using t1/2 value,,BAO_0000019,,,,Autocuration,13588,,U,0,CHEMBL628041,,,
14179,1,The compound was tested for Binding constant against DNA,,BAO_0000019,,,,Autocuration,15039,,U,0,CHEMBL630226,,,
14180,1,First order rate constant for cyclization of the compound,,BAO_0000019,,,,Autocuration,9500,,U,0,CHEMBL628042,,,
14181,1,First order rate constant of compound was determined in 50 mM phosphate buffer (pH 7.4) at 24 degree celsius,,BAO_0000019,,,,Autocuration,10014,,U,0,CHEMBL625232,,,
14182,1,First order rate constant of compound was determined in 50 mM phosphate buffer (pH 7.4) at 37 degree celsius,,BAO_0000019,,,,Autocuration,10014,,U,0,CHEMBL625233,,,
14183,1,Hydrolysis rate constant was determined,,BAO_0000019,,,,Autocuration,568,,U,0,CHEMBL625979,,,
14184,1,Observed first order rate constant,,BAO_0000019,,,,Autocuration,10026,,U,0,CHEMBL625980,,,
14185,1,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,,BAO_0000019,,,,Autocuration,10281,,U,0,CHEMBL625981,,,
14186,1,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,,BAO_0000019,,,,Autocuration,10281,,U,0,CHEMBL625982,,,
14187,1,Second-order rate constant for attack on PNPA at 25 degree Centigrade,,BAO_0000019,,,,Autocuration,9680,,U,0,CHEMBL625983,,,
14188,1,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,BAO_0000019,,,,Autocuration,13028,,U,0,CHEMBL625984,,,
14189,1,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,BAO_0000019,,,,Autocuration,13028,,U,0,CHEMBL625985,,,
14190,1,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,BAO_0000019,,,,Autocuration,13028,,U,0,CHEMBL625986,,,
14191,1,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,BAO_0000019,,,,Autocuration,13028,,U,0,CHEMBL625987,,,
14192,1,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,BAO_0000019,,,,Autocuration,13028,,U,0,CHEMBL625988,,,
14193,1,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,,BAO_0000019,,,,Autocuration,13028,,U,0,CHEMBL625989,,,
14194,1,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,,BAO_0000019,,,,Autocuration,13028,,U,0,CHEMBL625990,,,
14195,1,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,BAO_0000019,,,,Autocuration,13028,,U,0,CHEMBL625991,,,
14196,1,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,BAO_0000019,,,,Autocuration,13028,,U,0,CHEMBL625992,,,
14197,1,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,BAO_0000019,,,,Autocuration,13028,,U,0,CHEMBL625993,,,
14198,1,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,BAO_0000019,,,,Autocuration,13028,,U,0,CHEMBL631973,,,
14199,1,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,BAO_0000019,,,,Autocuration,13028,,U,0,CHEMBL632143,,,
14200,1,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,BAO_0000019,,,,Autocuration,13028,,U,0,CHEMBL632144,,,
14201,1,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,BAO_0000019,,,,Autocuration,13028,,U,0,CHEMBL632145,,,
14202,1,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,BAO_0000019,,,,Autocuration,13028,,U,0,CHEMBL632146,,,
14203,1,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,,BAO_0000019,,,,Autocuration,13028,,U,0,CHEMBL632147,,,
14204,1,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,,BAO_0000019,,,,Autocuration,13028,,U,0,CHEMBL632148,,,
14205,1,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,BAO_0000019,,,,Autocuration,13028,,U,0,CHEMBL632149,,,
14206,1,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,BAO_0000019,,,,Autocuration,13028,,U,0,CHEMBL632150,,,
14207,1,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,BAO_0000019,,,,Autocuration,13028,,U,0,CHEMBL632151,,,
14208,1,Metabolism (NADH oxidation) by recombinant human NAD(P)H: quinone oxidoreductase (NQO1) is evaluated; not detected,,BAO_0000218,,Homo sapiens,,Intermediate,3008,,N,1,CHEMBL632152,,,
14209,1,Metabolism after 30 min of incubation with human liver microsomes in the absence of cofactor NADH (2.0 mM) at a concentration of 25 uM,,BAO_0000218,,Homo sapiens,,Intermediate,4509,,N,1,CHEMBL632153,,,
14210,1,Metabolism after 30 min of incubation with human liver microsomes in the presence of cofactor NADH (2.0 mM) at a concentration of 25 uM,,BAO_0000218,,Homo sapiens,,Intermediate,4509,,N,1,CHEMBL632154,,,
14211,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day; Tested mice 10,,BAO_0000218,,Human herpesvirus 1,,Intermediate,8613,,N,1,CHEMBL632155,,,
14212,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day; Total mice tested 10,,BAO_0000218,,Human herpesvirus 1,,Intermediate,8613,,N,1,CHEMBL632156,,,
14213,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 3.1 mg/kg per day; Tested mice 10,,BAO_0000218,,Human herpesvirus 1,,Intermediate,8613,,N,1,CHEMBL632157,,,
14214,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day; Tested mice 10,,BAO_0000218,,Human herpesvirus 1,,Intermediate,8613,,N,1,CHEMBL632158,,,
14215,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day; Total mice tested 10,,BAO_0000218,,Human herpesvirus 1,,Intermediate,8613,,N,1,CHEMBL632159,,,
14216,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at dose 0.8 mg/kg per day; Tested mice 10,,BAO_0000218,,Human herpesvirus 1,,Intermediate,8613,,N,1,CHEMBL626305,,,
14217,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at dose 3.1 mg/kg per day; Total mice tested 10,,BAO_0000218,,Human herpesvirus 1,,Intermediate,8613,,N,1,CHEMBL626306,,,
14218,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.02 mg/kg per day; Tested mice 10,,BAO_0000218,,Human herpesvirus 1,,Intermediate,8613,,N,1,CHEMBL626307,,,
14219,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.06 mg/kg per day; Tested mice 10,,BAO_0000218,,Human herpesvirus 1,,Intermediate,8613,,N,1,CHEMBL626308,,,
14220,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.25 mg/kg per day; Tested mice 10,,BAO_0000218,,Human herpesvirus 1,,Intermediate,8613,,N,1,CHEMBL626479,,,
14221,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 1 mg/kg per day; Tested mice 10,,BAO_0000218,,Human herpesvirus 1,,Intermediate,8613,,N,1,CHEMBL626480,,,
14222,1,Calculated partition coefficient (clogP) (MlogP),,BAO_0000100,,,,Autocuration,6021,,U,0,CHEMBL626481,,,
14223,1,Equipotent potent ratio relative to carbachol (nicotinic activity),,BAO_0000019,,,,Autocuration,9348,,U,0,CHEMBL626482,,,
14224,1,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 ); NA denotes not available",,BAO_0000218,,Canis lupus familiaris,,Intermediate,15592,,N,1,CHEMBL626483,,,
14225,1,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 );NA denotes not available",,BAO_0000218,,Canis lupus familiaris,,Intermediate,15592,,N,1,CHEMBL626484,,,
14226,1,Solubility at pH 7.4 in micro g/mL;NA denotes available,,BAO_0000100,,,,Autocuration,15592,,U,0,CHEMBL626485,,,
14227,1,Solubility at pH 7.4 in micro g/mL;NA denotes not available,,BAO_0000100,,,,Autocuration,15592,,U,0,CHEMBL626486,,,
14228,1,Solubility at pH 7.4 in ug/mL;NA denotes not available,,BAO_0000100,,,,Autocuration,15592,,U,0,CHEMBL626487,,,
14229,1,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,15592,In vivo,N,1,CHEMBL626488,,1969.0,
14230,1,Affinity for protein binding expressed as association constant in fresh rat serum; ND is Not Determined.,Serum,BAO_0000218,,Rattus norvegicus,,Intermediate,7095,,N,1,CHEMBL626489,,1977.0,
14231,1,Area under the MAP curve measured over 5 min; ND means Not determined,,BAO_0000019,,,,Autocuration,16618,,U,0,CHEMBL626490,,,
14232,1,Lipophilicity expressed as the negative logarithm of the equilibrium constant; ND denotes no data.,,BAO_0000100,,,,Autocuration,16835,,U,0,CHEMBL626491,,,
14233,1,The apparent partition coefficient(D) in cyclohexane-0.05 M phosphate buffer (pH 7.4) at 21 degree celsius; not determined,,BAO_0000100,,,,Autocuration,15284,,U,0,CHEMBL626492,,,
14234,1,Half-life was measured in the presence of NADPH at 20 uM; No inhibition,,BAO_0000019,,,,Autocuration,15750,,U,0,CHEMBL626493,,,
14235,1,Half life after oral administration to Sprague-Dawley rats; NT is Not tested,,BAO_0000218,,Rattus norvegicus,,Intermediate,16618,In vivo,N,1,CHEMBL626494,,,
14236,1,Half life after oral tested,,BAO_0000218,,,,Autocuration,16618,In vivo,U,0,CHEMBL626495,,,
14237,1,Half life was determined in plasma of rat; NT indicates not tested,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,15812,,N,1,CHEMBL626496,,1969.0,
14238,1,Oral bioavailability after oral administration to Sprague-Dawley rats; NT is Not tested,,BAO_0000218,,Rattus norvegicus,,Intermediate,16618,In vivo,N,1,CHEMBL626497,,,
14239,1,Oral bioavailability after oral tested,,BAO_0000218,,,,Autocuration,16618,In vivo,U,0,CHEMBL626498,,,
14240,1,The bioavailability in rats at 15.9 uM/Kg after intravenous administration; NT=Not tested (F),,BAO_0000218,,Rattus norvegicus,,Intermediate,13098,,N,1,CHEMBL626499,,,
14241,1,The compound was tested for volume of distribution in rat at 15.9 uM/Kg after peroral administration; NT=Not tested (Vd L/Kg),,BAO_0000218,,Rattus norvegicus,,Intermediate,13098,,N,1,CHEMBL626500,,,
14242,1,half life was determined in plasma of rat; NT indicates not tested,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,15812,,N,1,CHEMBL626501,,1969.0,
14243,1,half life was determined in plasma of rat; NT means not tested,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,15812,,N,1,CHEMBL626502,,1969.0,
14244,1,Mean sodium excretion in rats (Control/Drug treatment value); Value 0.41/2.32,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL626503,,,
14245,1,Mean sodium excretion in rats (Control/Drug treatment value); inactive,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL626504,,,
14246,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.17/0.43,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL626505,,,
14247,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.2/0.38,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL626506,,,
14248,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.26/0.23,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL626507,,,
14249,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.28/0.26,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL626508,,,
14250,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.31/0.35,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL626509,,,
14251,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.35/2.88,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL875480,,,
14252,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.29,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL626510,,,
14253,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.47,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL626511,,,
14254,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.49,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL626512,,,
14255,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.38/0.23,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL628208,,,
14256,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.39/0.22,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL628209,,,
14257,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/0.48,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL628210,,,
14258,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/1.49,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL628211,,,
14259,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/2.06,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL628212,,,
14260,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.42/0.65,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL628213,,,
14261,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 65.2 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL628214,,1088.0,
14262,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 71.6 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL628215,,1088.0,
14263,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 71.8 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL628216,,1088.0,
14264,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 74.8 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL626595,,1088.0,
14265,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 77.5 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL626596,,1088.0,
14266,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 79.4 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL626597,,1088.0,
14267,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 80.9 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL626598,,1088.0,
14268,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 83.8 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL622242,,1088.0,
14269,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 84.5 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL622243,,1088.0,
14270,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 84.7 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL622244,,1088.0,
14271,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 86.7 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL622245,,1088.0,
14272,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 86.9 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL622246,,1088.0,
14273,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 9.06 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL622247,,1088.0,
14274,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 90.6 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL622248,,1088.0,
14275,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 94.9 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL877483,,1088.0,
14276,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 97.1 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL622249,,1088.0,
14277,1,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,N,1,CHEMBL622250,,1088.0,
14278,1,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,N,1,CHEMBL622251,,1088.0,
14279,1,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,N,1,CHEMBL622252,,1088.0,
14280,1,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,N,1,CHEMBL622253,,1088.0,
14281,1,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,N,1,CHEMBL622254,,1088.0,
14282,1,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,N,1,CHEMBL622255,,1088.0,
14283,1,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,N,1,CHEMBL622256,,1088.0,
14284,1,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,N,1,CHEMBL622257,,1088.0,
14285,1,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,N,1,CHEMBL622258,,1088.0,
14286,1,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,N,1,CHEMBL622259,,1088.0,
14287,1,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 10.1 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,N,1,CHEMBL622927,,1088.0,
14288,1,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 3.40 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,N,1,CHEMBL622928,,1088.0,
14289,1,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 3.76 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,N,1,CHEMBL622929,,1088.0,
14290,1,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 9.06 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,N,1,CHEMBL623182,,1088.0,
14291,1,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 9.6 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,N,1,CHEMBL623183,,1088.0,
14292,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 0 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL623184,,1088.0,
14293,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 1.01 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL623185,,1088.0,
14294,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 1.13 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL877484,,1088.0,
14295,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 10.1 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL627274,,1088.0,
14296,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 102 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL623186,,1088.0,
14297,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 105 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL623187,,1088.0,
14298,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 11.3 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL623188,,1088.0,
14299,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 113 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL628055,,1088.0,
14300,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 19.5 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL628056,,1088.0,
14301,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 195 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL628200,,1088.0,
14302,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 21.7 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL628201,,1088.0,
14303,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 217 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL628202,,1088.0,
14304,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 23.9 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL628203,,1088.0,
14305,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 239 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL628204,,1088.0,
14306,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 24.9 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL628205,,1088.0,
14307,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 249 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL628206,,1088.0,
14308,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d),Prostate gland,BAO_0000218,,,,Autocuration,13257,In vivo,U,0,CHEMBL628207,,2367.0,
14309,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d)/biood,Prostate gland,BAO_0000218,,,,Autocuration,13257,In vivo,U,0,CHEMBL627220,,2367.0,
14310,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d)/muscle,Muscle tissue,BAO_0000218,,,,Autocuration,13257,In vivo,U,0,CHEMBL627221,,2385.0,
14311,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v),Prostate gland,BAO_0000218,,,,Autocuration,13257,In vivo,U,0,CHEMBL627222,,2367.0,
14312,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v)/blood,,BAO_0000218,,,,Autocuration,13257,In vivo,U,0,CHEMBL627223,,,
14313,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v)/muscle,Muscle tissue,BAO_0000218,,,,Autocuration,13257,In vivo,U,0,CHEMBL632062,,2385.0,
14314,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in spleen,Spleen,BAO_0000218,,,,Autocuration,13257,In vivo,U,0,CHEMBL632063,,2106.0,
14315,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in bladder,Urinary bladder,BAO_0000218,,,,Autocuration,13257,In vivo,U,0,CHEMBL632064,,1255.0,
14316,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in blood,Blood,BAO_0000218,,,,Autocuration,13257,In vivo,U,0,CHEMBL632065,,178.0,
14317,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in bone,Bone element,BAO_0000218,,,,Autocuration,13257,In vivo,U,0,CHEMBL632066,,1474.0,
14318,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in fat,,BAO_0000218,,,,Autocuration,13257,In vivo,U,0,CHEMBL632067,,,
14319,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in kidney,Kidney,BAO_0000218,,,,Autocuration,13257,In vivo,U,0,CHEMBL629188,,2113.0,
14320,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in liver,Liver,BAO_0000218,,,,Autocuration,13257,In vivo,U,0,CHEMBL629189,,2107.0,
14321,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in lung,Lung,BAO_0000218,,,,Autocuration,13257,In vivo,U,0,CHEMBL629190,,2048.0,
14322,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in muscle,Muscle tissue,BAO_0000218,,,,Autocuration,13257,In vivo,U,0,CHEMBL629191,,2385.0,
14323,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (d),Prostate gland,BAO_0000218,,,,Autocuration,13257,In vivo,U,0,CHEMBL629192,,2367.0,
14324,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (d)/muscle,Muscle tissue,BAO_0000218,,,,Autocuration,13257,In vivo,U,0,CHEMBL629193,,2385.0,
14325,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v),Prostate gland,BAO_0000218,,,,Autocuration,13257,In vivo,U,0,CHEMBL629194,,2367.0,
14326,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v)/blood,,BAO_0000218,,,,Autocuration,13257,In vivo,U,0,CHEMBL629195,,,
14327,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v)/muscle,Muscle tissue,BAO_0000218,,,,Autocuration,13257,In vivo,U,0,CHEMBL629373,,2385.0,
14328,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in spleen,Spleen,BAO_0000218,,,,Autocuration,13257,In vivo,U,0,CHEMBL629374,,2106.0,
14329,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked)i n prostate (d)/biood,Prostate gland,BAO_0000218,,,,Autocuration,13257,In vivo,U,0,CHEMBL629375,,2367.0,
14330,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in bladder,Urinary bladder,BAO_0000218,,,,Autocuration,13257,In vivo,U,0,CHEMBL629376,,1255.0,
14331,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in blood,Blood,BAO_0000218,,,,Autocuration,13257,In vivo,U,0,CHEMBL629377,,178.0,
14332,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in bone,Bone element,BAO_0000218,,,,Autocuration,13257,In vivo,U,0,CHEMBL629378,,1474.0,
14333,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in fat,,BAO_0000218,,,,Autocuration,13257,In vivo,U,0,CHEMBL629379,,,
14334,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in kidney,Kidney,BAO_0000218,,,,Autocuration,13257,In vivo,U,0,CHEMBL629151,,2113.0,
14335,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in liver,Liver,BAO_0000218,,,,Autocuration,13257,In vivo,U,0,CHEMBL629152,,2107.0,
14336,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in lung,Lung,BAO_0000218,,,,Autocuration,13257,In vivo,U,0,CHEMBL629153,,2048.0,
14337,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in muscle,Muscle tissue,BAO_0000218,,,,Autocuration,13257,In vivo,U,0,CHEMBL629154,,2385.0,
14338,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d),Prostate gland,BAO_0000218,,,,Autocuration,13257,In vivo,U,0,CHEMBL629155,,2367.0,
14339,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d)/biood,Prostate gland,BAO_0000218,,,,Autocuration,13257,In vivo,U,0,CHEMBL629156,,2367.0,
14340,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d)/muscle,Muscle tissue,BAO_0000218,,,,Autocuration,13257,In vivo,U,0,CHEMBL629157,,2385.0,
14341,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v),Prostate gland,BAO_0000218,,,,Autocuration,13257,In vivo,U,0,CHEMBL629158,,2367.0,
14342,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v)/blood,,BAO_0000218,,,,Autocuration,13257,In vivo,U,0,CHEMBL629159,,,
14343,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v)/muscle,Muscle tissue,BAO_0000218,,,,Autocuration,13257,In vivo,U,0,CHEMBL629160,,2385.0,
14344,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in spleen,Spleen,BAO_0000218,,,,Autocuration,13257,In vivo,U,0,CHEMBL629161,,2106.0,
14345,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in bladder,Urinary bladder,BAO_0000218,,,,Autocuration,13257,In vivo,U,0,CHEMBL629162,,1255.0,
14346,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in blood,Blood,BAO_0000218,,,,Autocuration,13257,In vivo,U,0,CHEMBL629163,,178.0,
14347,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in bone,Bone element,BAO_0000218,,,,Autocuration,13257,In vivo,U,0,CHEMBL629164,,1474.0,
14348,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in fat,,BAO_0000218,,,,Autocuration,13257,In vivo,U,0,CHEMBL629165,,,
14349,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in liver,Liver,BAO_0000218,,,,Autocuration,13257,In vivo,U,0,CHEMBL629166,,2107.0,
14350,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in lung,Lung,BAO_0000218,,,,Autocuration,13257,In vivo,U,0,CHEMBL629167,,2048.0,
14351,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in muscle,Muscle tissue,BAO_0000218,,,,Autocuration,13257,In vivo,U,0,CHEMBL629168,,2385.0,
14352,1,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 100 uM,,BAO_0000019,,,,Autocuration,2193,,U,0,CHEMBL629169,,,
14353,1,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 100 uM; no inhibition is observed at this concentration,,BAO_0000019,,,,Autocuration,2193,,U,0,CHEMBL629170,,,
14354,1,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 10 uM,,BAO_0000019,,,,Autocuration,2193,,U,0,CHEMBL631153,,,
14355,1,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 10 uM; too active and complete inhibition is observed,,BAO_0000019,,,,Autocuration,2193,,U,0,CHEMBL875121,,,
14356,1,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 1 uM,,BAO_0000019,,,,Autocuration,2193,,U,0,CHEMBL631154,,,
14357,1,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 1 uM; too active and complete inhibition is observed,,BAO_0000019,,,,Autocuration,2193,,U,0,CHEMBL631155,,,
14358,1,Hydrolysis rate constant was determined,,BAO_0000019,,,,Autocuration,568,,U,0,CHEMBL631156,,,
14359,1,"K2, The intrinsic biomolecular reactivation rate constant on VX at 25 degree Centigrade",,BAO_0000019,,,,Autocuration,9680,,U,0,CHEMBL631157,,,
14360,1,"K2, The intrinsic biomolecular reactivation rate constant on paraxon at 25 degree Centigrade",,BAO_0000019,,,,Autocuration,9680,,U,0,CHEMBL631158,,,
14361,1,"K2, The intrinsic biomolecular reactivation rate constant on sarin at 25 degree Centigrade",,BAO_0000019,,,,Autocuration,9680,,U,0,CHEMBL631159,,,
14362,1,Observed second order rate constant,,BAO_0000019,,,,Autocuration,10026,,U,0,CHEMBL631160,,,
14363,1,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,,BAO_0000019,,,,Autocuration,10281,,U,0,CHEMBL631161,,,
14364,1,Rate constant for decay of compound was determined in 50 mM phosphate buffer (pH 7.4) at 24 degree celsius,,BAO_0000019,,,,Autocuration,10014,,U,0,CHEMBL631162,,,
14365,1,Rate constant for decay of compound was determined in 50 mM phosphate buffer (pH 7.4) at 37 degree celsius,,BAO_0000019,,,,Autocuration,10014,,U,0,CHEMBL630313,,,
14366,1,"k2, The intrinsic biomolecular reactivation rate constant on paraxon at 25 degree Centigrade",,BAO_0000019,,,,Autocuration,9680,,U,0,CHEMBL630314,,,
14367,1,"k2, The intrinsic biomolecular reactivation rate constant on sarin at 25 degree Centigrade",,BAO_0000019,,,,Autocuration,9680,,U,0,CHEMBL630315,,,
14368,1,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,BAO_0000019,,,,Autocuration,13028,,U,0,CHEMBL630316,,,
14369,1,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,BAO_0000019,,,,Autocuration,13028,,U,0,CHEMBL630986,,,
14370,1,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,BAO_0000019,,,,Autocuration,13028,,U,0,CHEMBL630987,,,
14371,1,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0(or )in RMPI 1640 cell culture medium containing 10%FCS,,BAO_0000019,,,,Autocuration,13028,,U,0,CHEMBL630988,,,
14372,1,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,BAO_0000019,,,,Autocuration,13028,,U,0,CHEMBL630989,,,
14373,1,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,,BAO_0000019,,,,Autocuration,13028,,U,0,CHEMBL630990,,,
14374,1,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,,BAO_0000019,,,,Autocuration,13028,,U,0,CHEMBL630991,,,
14375,1,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,BAO_0000019,,,,Autocuration,13028,,U,0,CHEMBL630992,,,
14376,1,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,BAO_0000019,,,,Autocuration,13028,,U,0,CHEMBL630993,,,
14377,1,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,BAO_0000019,,,,Autocuration,13028,,U,0,CHEMBL630994,,,
14378,1,Rate constants of compound was determined at muscarinic receptor in the rat cerebral cortex,,BAO_0000218,,Rattus norvegicus,,Intermediate,10014,,N,1,CHEMBL630995,,,
14379,1,Association constant for compound at 31 degree C was determined,,BAO_0000019,,,,Autocuration,9962,,U,0,CHEMBL629252,,,
14380,1,Calculated antagonist equilibrium dissociation constant of the compound,,BAO_0000019,,,,Autocuration,12029,,U,0,CHEMBL629253,,,
14381,1,Calculated antagonist equilibrium dissociation constant of the compound; No statistically significant antagonism observed,,BAO_0000019,,,,Autocuration,12029,,U,0,CHEMBL629944,,,
14382,1,Dissociation constants vs LTE4 on guinea pig trachea,Trachea,BAO_0000218,,Cavia porcellus,,Intermediate,10583,,N,1,CHEMBL629945,,3126.0,
14383,1,"Tested for hydrolysis in presence of boric acid by UV spectrophotometry, dissociation constant was evaluated at the pH < 8",,BAO_0000019,,,,Autocuration,568,,U,0,CHEMBL629946,,,
14384,1,"Tested for hydrolysis in presence of boric acid, rate constant was evaluated at the pH 8.5",,BAO_0000019,,,,Autocuration,568,,U,0,CHEMBL629947,,,
14385,1,"Tested for hydrolysis in presence of boric acid, rate constant was evaluated at the pH 9.5",,BAO_0000019,,,,Autocuration,568,,U,0,CHEMBL629948,,,
14386,1,"Tested for hydrolysis in presence of phenylboronic acid, rate constant was evaluated at the pH 9.5",,BAO_0000019,,,,Autocuration,568,,U,0,CHEMBL856024,,,
14387,1,Affinity constant KD value was derived from TMP,,BAO_0000019,,,,Autocuration,7493,,U,0,CHEMBL629949,,,
14388,1,Apparent dissociation (binding) rate constant was evaluated,,BAO_0000019,,,,Autocuration,8371,,U,0,CHEMBL629950,,,
14389,1,Dissociation constant (KD) of the compound,,BAO_0000100,,,,Autocuration,13114,,U,0,CHEMBL630127,,,
14390,1,Dissociation constant determined by heteronuclear 1H/15N correlation NMR spectroscopy,,BAO_0000100,,,,Autocuration,15515,,U,0,CHEMBL630128,,,
14391,1,Dissociation constant from ESR titration experiments,,BAO_0000100,,,,Autocuration,522,,U,0,CHEMBL630129,,,
14392,1,Dissociation constant was evaluated which is similar to Ki (inhibitory constant),,BAO_0000019,,,,Autocuration,13888,,U,0,CHEMBL630130,,,
14393,1,Dissociation constant was evaluated.,,BAO_0000100,,,,Autocuration,2616,,U,0,CHEMBL875234,,,
14394,1,Dissociation constant was reported,,BAO_0000100,,,,Autocuration,3798,,U,0,CHEMBL630131,,,
14395,1,Dissociation constant was determined in rat pituitary cells.,,BAO_0000218,,Rattus norvegicus,,Intermediate,8731,,N,1,CHEMBL630132,,,
14396,1,Equilibrium dissociation constant of CA complex for enantiomer 1 of compound,,BAO_0000019,,,,Autocuration,11892,,U,0,CHEMBL630133,,,
14397,1,Equilibrium dissociation constant of CA complex for enantiomer 2 of compound,,BAO_0000019,,,,Autocuration,11892,,U,0,CHEMBL630134,,,
14398,1,Equilibrium dissociation constant of the compound,,BAO_0000019,,,,Autocuration,2582,,U,0,CHEMBL630135,,,
14399,1,Equilibrium dissociation constant was determined,,BAO_0000019,,,,Autocuration,11892,,U,0,CHEMBL630136,,,
14400,1,Kinetic constant KD was evaluated,,BAO_0000019,,,,Autocuration,13396,,U,0,CHEMBL630137,,,
14401,1,Tested for dissociation constant of the compound; Value ranges from 0.1-0.3,,BAO_0000019,,,,Autocuration,603,,U,0,CHEMBL630138,,,
14402,1,Equilibrium association constant interacting with unilamellar vesicles of electroneutral in PBS buffer at pH 7.4,,BAO_0000019,,,,Autocuration,15673,,U,0,CHEMBL630139,,,
14403,1,Rate constant for hydrolysis in aqueous acetone.,,BAO_0000019,,,,Autocuration,10368,,U,0,CHEMBL630140,,,
14404,1,Disassociation constant (KI) was obtained from Cheng and Prusoff equation for quercetin trypsin complex,,BAO_0000019,,,,Autocuration,14228,,U,0,CHEMBL875235,,,
14405,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.43/2.86,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL876439,,,
14406,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.44/2.68,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL630605,,,
14407,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.45/1.55,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL630606,,,
14408,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.48/0.95,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL630607,,,
14409,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.5/1.79,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL630608,,,
14410,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.51/0.66,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL630609,,,
14411,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.52/2.02,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL630610,,,
14412,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.61//0.37,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL630611,,,
14413,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.71/0.36,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL629552,,,
14414,1,Mean sodium excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL629733,,,
14415,1,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL629734,,,
14416,1,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL629735,,,
14417,1,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL629736,,,
14418,1,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL629737,,,
14419,1,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL629738,,,
14420,1,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL629739,,,
14421,1,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL629740,,,
14422,1,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL629741,,,
14423,1,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL629742,,,
14424,1,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL629743,,,
14425,1,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL629744,,,
14426,1,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL629745,,,
14427,1,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL629746,,,
14428,1,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL629747,,,
14429,1,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL629748,,,
14430,1,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL629749,,,
14431,1,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL629750,,,
14432,1,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL629751,,,
14433,1,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL629752,,,
14434,1,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL629753,,,
14435,1,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL629754,,,
14436,1,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL629755,,,
14437,1,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL629756,,,
14438,1,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL629757,,,
14439,1,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL629758,,,
14440,1,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL629759,,,
14441,1,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL629760,,,
14442,1,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,N,1,CHEMBL876443,,,
14443,1,Na+ excretion mequiv /kg in 6 conscious female dogs administered perorally during 0-6 hr,,BAO_0000218,,Canis lupus familiaris,,Intermediate,8310,,N,1,CHEMBL629761,,,
14444,1,Na+ excretion mequiv /kg in conscious female dogs administered perorally during 0-6 hr,,BAO_0000218,,Canis lupus familiaris,,Intermediate,8310,,N,1,CHEMBL629762,,,
14445,1,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 10 ml/kg perorally,,BAO_0000218,,Mus musculus,,Intermediate,8310,,N,1,CHEMBL629763,,,
14446,1,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 2 ml/kg perorally,,BAO_0000218,,Mus musculus,,Intermediate,8310,,N,1,CHEMBL629764,,,
14447,1,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 2 ml/kg perorally,,BAO_0000218,,Mus musculus,,Intermediate,8310,,N,1,CHEMBL629765,,,
14448,1,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 50 ml/kg perorally,,BAO_0000218,,Mus musculus,,Intermediate,8310,,N,1,CHEMBL629766,,,
14449,1,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 10 ml/kg perorally,,BAO_0000218,,Mus musculus,,Intermediate,8310,,N,1,CHEMBL629767,,,
14450,1,Na+ excretion mequiv/kg in 4 conscious female dogs administered perorally during 0-6 hr,,BAO_0000218,,Canis lupus familiaris,,Intermediate,8310,,N,1,CHEMBL629768,,,
14451,1,Na+ excretion mequiv/kg in 4 saline-loaded mice administered at a dose 50 ml/kg perorally,,BAO_0000218,,Mus musculus,,Intermediate,8310,,N,1,CHEMBL629769,,,
14452,1,Na+ excretion mequiv/kg in 6 conscious female dogs administered perorally during 0-6 hr,,BAO_0000218,,Canis lupus familiaris,,Intermediate,8310,,N,1,CHEMBL629770,,,
14453,1,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 0.3 ml/kg perorally,,BAO_0000218,,Canis lupus familiaris,,Intermediate,8310,,N,1,CHEMBL629771,,,
14454,1,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 10 ml/kg perorally,,BAO_0000218,,Mus musculus,,Intermediate,8310,,N,1,CHEMBL629772,,,
14455,1,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 10 ml/kg perorally,,BAO_0000218,,Mus musculus,,Intermediate,8310,,N,1,CHEMBL629773,,,
14456,1,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 2 ml/kg perorally,,BAO_0000218,,Mus musculus,,Intermediate,8310,,N,1,CHEMBL625455,,,
14457,1,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 250 ml/kg perorally,,BAO_0000218,,Mus musculus,,Intermediate,8310,,N,1,CHEMBL625456,,,
14458,1,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 3 ml/kg perorally,,BAO_0000218,,Mus musculus,,Intermediate,8310,,N,1,CHEMBL625457,,,
14459,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 25.9 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL625458,,1088.0,
14460,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 259 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL625459,,1088.0,
14461,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 26.5 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL875483,,1088.0,
14462,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 265 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL634779,,1088.0,
14463,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 27 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL625460,,1088.0,
14464,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 27.9 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL626117,,1088.0,
14465,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 270 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL626118,,1088.0,
14466,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 279 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL628342,,1088.0,
14467,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.2 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL628343,,1088.0,
14468,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.22 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL628344,,1088.0,
14469,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.9 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL628345,,1088.0,
14470,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 282 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL628346,,1088.0,
14471,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 289 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL628347,,1088.0,
14472,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 3.40 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL628348,,1088.0,
14473,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 3.76 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL628349,,1088.0,
14474,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 30.2 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL875611,,1088.0,
14475,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 302 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL628350,,1088.0,
14476,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 31.6 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL628351,,1088.0,
14477,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 316 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL628352,,1088.0,
14478,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 32.4 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL628353,,1088.0,
14479,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 324 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL628354,,1088.0,
14480,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.0 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL626667,,1088.0,
14481,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.1 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL626668,,1088.0,
14482,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.8 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL626669,,1088.0,
14483,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 341 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL626670,,1088.0,
14484,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 348 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL626671,,1088.0,
14485,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 37.6 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL626672,,1088.0,
14486,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 50.8 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL626673,,1088.0,
14487,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 58.4 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL626674,,1088.0,
14488,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 65.2 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL626675,,1088.0,
14489,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 68.1 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL626676,,1088.0,
14490,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 7.94 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL626677,,1088.0,
14491,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 71.6 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL626678,,1088.0,
14492,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 71.8 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL626679,,1088.0,
14493,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 74.8 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL875612,,1088.0,
14494,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 77.5 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL626680,,1088.0,
14495,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 79.4 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL626681,,1088.0,
14496,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 80.9 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL626682,,1088.0,
14497,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 83.8 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL626683,,1088.0,
14498,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 84.5 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL626684,,1088.0,
14499,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 84.7 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL626685,,1088.0,
14500,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 86.7 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL626686,,1088.0,
14501,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 86.9 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL626687,,1088.0,
14502,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 9.06 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL624978,,1088.0,
14503,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 90.6 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL624979,,1088.0,
14504,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 94.9 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL624980,,1088.0,
14505,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 97.1 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL624981,,1088.0,
14506,1,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,N,1,CHEMBL624982,,1088.0,
14507,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d),Prostate gland,BAO_0000218,,,,Autocuration,13257,In vivo,U,0,CHEMBL627564,,2367.0,
14508,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v),Prostate gland,BAO_0000218,,,,Autocuration,13257,In vivo,U,0,CHEMBL627565,,2367.0,
14509,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v)/blood,,BAO_0000218,,,,Autocuration,13257,In vivo,U,0,CHEMBL627566,,,
14510,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v)/muscle,Muscle tissue,BAO_0000218,,,,Autocuration,13257,In vivo,U,0,CHEMBL627567,,2385.0,
14511,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in spleen,Spleen,BAO_0000218,,,,Autocuration,13257,In vivo,U,0,CHEMBL627568,,2106.0,
14512,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hr in kidney,Kidney,BAO_0000218,,,,Autocuration,13257,In vivo,U,0,CHEMBL627569,,2113.0,
14513,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in bladder,Urinary bladder,BAO_0000218,,,,Autocuration,13257,In vivo,U,0,CHEMBL627570,,1255.0,
14514,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in blood,Blood,BAO_0000218,,,,Autocuration,13257,In vivo,U,0,CHEMBL627571,,178.0,
14515,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in bone,Bone element,BAO_0000218,,,,Autocuration,13257,In vivo,U,0,CHEMBL627572,,1474.0,
14516,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in fat,,BAO_0000218,,,,Autocuration,13257,In vivo,U,0,CHEMBL627573,,,
14517,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in kidney,Kidney,BAO_0000218,,,,Autocuration,13257,In vivo,U,0,CHEMBL627574,,2113.0,
14518,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in liver,Liver,BAO_0000218,,,,Autocuration,13257,In vivo,U,0,CHEMBL627575,,2107.0,
14519,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in lung,Lung,BAO_0000218,,,,Autocuration,13257,In vivo,U,0,CHEMBL627576,,2048.0,
14520,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in muscle,Muscle tissue,BAO_0000218,,,,Autocuration,13257,In vivo,U,0,CHEMBL627577,,2385.0,
14521,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d),Prostate gland,BAO_0000218,,,,Autocuration,13257,In vivo,U,0,CHEMBL627578,,2367.0,
14522,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d)/biood,Prostate gland,BAO_0000218,,,,Autocuration,13257,In vivo,U,0,CHEMBL627579,,2367.0,
14523,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d)/muscle,Muscle tissue,BAO_0000218,,,,Autocuration,13257,In vivo,U,0,CHEMBL627580,,2385.0,
14524,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v),Prostate gland,BAO_0000218,,,,Autocuration,13257,In vivo,U,0,CHEMBL627581,,2367.0,
14525,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v)/blood,,BAO_0000218,,,,Autocuration,13257,In vivo,U,0,CHEMBL627582,,,
14526,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v)/muscle,Muscle tissue,BAO_0000218,,,,Autocuration,13257,In vivo,U,0,CHEMBL627583,,2385.0,
14527,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in spleen,Spleen,BAO_0000218,,,,Autocuration,13257,In vivo,U,0,CHEMBL627584,,2106.0,
14528,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d)/biood,Prostate gland,BAO_0000218,,,,Autocuration,13257,In vivo,U,0,CHEMBL627585,,2367.0,
14529,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d)/muscle,Muscle tissue,BAO_0000218,,,,Autocuration,13257,In vivo,U,0,CHEMBL627586,,2385.0,
14530,1,Biodistribution of the Radiolabeled FBWAY compound in rat Cerebellum at 30 min co-injected with 200 nmol of WAY 100635,,BAO_0000218,,Rattus norvegicus,,Intermediate,15413,In vivo,N,1,CHEMBL627587,,,
14531,1,Biodistribution of the Radiolabeled FBWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,,BAO_0000218,,Rattus norvegicus,,Intermediate,15413,In vivo,N,1,CHEMBL627588,,,
14532,1,Biodistribution of the Radiolabeled FBWAY compound in rat cortex at 30 min co-injected with 200 nmol of WAY 100635,,BAO_0000218,,Rattus norvegicus,,Intermediate,15413,In vivo,N,1,CHEMBL628250,,,
14533,1,Biodistribution of the Radiolabeled FBWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,,BAO_0000218,,Rattus norvegicus,,Intermediate,15413,In vivo,N,1,CHEMBL628251,,,
14534,1,Biodistribution of the Radiolabeled FBWAY compound in rat hippocampus at 30 min co-injected with 200 nmol of WAY 100635,Hippocampus,BAO_0000218,,Rattus norvegicus,,Intermediate,15413,In vivo,N,1,CHEMBL628252,,10000000.0,
14535,1,Biodistribution of the Radiolabeled FBWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,Hippocampus,BAO_0000218,,Rattus norvegicus,,Intermediate,15413,In vivo,N,1,CHEMBL628253,,10000000.0,
14536,1,Biodistribution of the Radiolabeled FBWAY compound in rat hypothalamus at 30 min co-injected with 200 nmol of WAY 100635,Hypothalamus,BAO_0000218,,Rattus norvegicus,,Intermediate,15413,In vivo,N,1,CHEMBL628254,,1898.0,
14537,1,Biodistribution of the Radiolabeled FBWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635,Hypothalamus,BAO_0000218,,Rattus norvegicus,,Intermediate,15413,In vivo,N,1,CHEMBL877493,,1898.0,
14538,1,Biodistribution of the Radiolabeled FCWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,,BAO_0000218,,Rattus norvegicus,,Intermediate,15413,In vivo,N,1,CHEMBL628255,,,
14539,1,Biodistribution of the Radiolabeled FCWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,,BAO_0000218,,Rattus norvegicus,,Intermediate,15413,In vivo,N,1,CHEMBL628256,,,
14540,1,Biodistribution of the Radiolabeled FCWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,Hippocampus,BAO_0000218,,Rattus norvegicus,,Intermediate,15413,In vivo,N,1,CHEMBL628257,,10000000.0,
14541,1,Biodistribution of the Radiolabeled FCWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635,Hypothalamus,BAO_0000218,,Rattus norvegicus,,Intermediate,15413,In vivo,N,1,CHEMBL628258,,1898.0,
14542,1,Biodistribution of the Radiolabeled MeFBWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,,BAO_0000218,,Rattus norvegicus,,Intermediate,15413,In vivo,N,1,CHEMBL628259,,,
14543,1,Biodistribution of the Radiolabeled MeFBWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,,BAO_0000218,,Rattus norvegicus,,Intermediate,15413,In vivo,N,1,CHEMBL628429,,,
14544,1,Biodistribution of the Radiolabeled MeFBWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,Hippocampus,BAO_0000218,,Rattus norvegicus,,Intermediate,15413,In vivo,N,1,CHEMBL626862,,10000000.0,
14545,1,Biodistribution of the Radiolabeled MeFBWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635; Not determined,Hypothalamus,BAO_0000218,,Rattus norvegicus,,Intermediate,15413,In vivo,N,1,CHEMBL626863,,1898.0,
14546,1,Biodistribution of the [11C]-radiolabeled compound in rat cerebellum,Cerebellum,BAO_0000218,,Rattus norvegicus,,Intermediate,15413,In vivo,N,1,CHEMBL625886,,2037.0,
14547,1,Biodistribution of the [11C]-radiolabeled compound in rat cerebellum co-injected with 50 nM of WAY 100635.,Cerebellum,BAO_0000218,,Rattus norvegicus,,Intermediate,15413,In vivo,N,1,CHEMBL625887,,2037.0,
14548,1,Biodistribution of the [11C]-radiolabeled compound in rat cortex,,BAO_0000218,,Rattus norvegicus,,Intermediate,15413,In vivo,N,1,CHEMBL625888,,,
14549,1,Biodistribution of the [11C]-radiolabeled compound in rat cortex co-injected with 50 nM of WAY 100635.,,BAO_0000218,,Rattus norvegicus,,Intermediate,15413,In vivo,N,1,CHEMBL625889,,,
14550,1,Biodistribution of the [11C]-radiolabeled compound in rat hippocampus,Hippocampus,BAO_0000218,,Rattus norvegicus,,Intermediate,15413,In vivo,N,1,CHEMBL625890,,10000000.0,
14551,1,Biodistribution of the [11C]-radiolabeled compound in rat hippocampus co-injected with 50 nM of WAY 100635.,Hippocampus,BAO_0000218,,Rattus norvegicus,,Intermediate,15413,In vivo,N,1,CHEMBL625891,,10000000.0,
14552,1,Biodistribution of the [11C]-radiolabeled compound in rat hypothalamus,Hypothalamus,BAO_0000218,,Rattus norvegicus,,Intermediate,15413,In vivo,N,1,CHEMBL625892,,1898.0,
14553,1,Biodistribution of the [11C]-radiolabeled compound in rat hypothalamus co-injected with 50 nM of WAY 100635.,Hypothalamus,BAO_0000218,,Rattus norvegicus,,Intermediate,15413,In vivo,N,1,CHEMBL625893,,1898.0,
14554,1,Biodistribution of the [18F]-radiolabeled compound in rat cerebellum,Cerebellum,BAO_0000218,,Rattus norvegicus,,Intermediate,15413,In vivo,N,1,CHEMBL625894,,2037.0,
14555,1,Biodistribution of the [18F]-radiolabeled compound in rat cortex,,BAO_0000218,,Rattus norvegicus,,Intermediate,15413,In vivo,N,1,CHEMBL625895,,,
14556,1,Reaction rate parameter value for phosphate with transfer with respect to ATP,,BAO_0000019,,,,Autocuration,12404,,U,0,CHEMBL625896,,,
14557,1,"Tested for hydrolysis in presence of boric acid, dissociation constant was evaluated at the pH 8.5(Apparent inhibition constant)",,BAO_0000019,,,,Autocuration,568,,U,0,CHEMBL625897,,,
14558,1,"Tested for hydrolysis in presence of boric acid, dissociation constant was evaluated at the pH 9.5(Apparent inhibition constant)",,BAO_0000019,,,,Autocuration,568,,U,0,CHEMBL625898,,,
14559,1,"Tested for hydrolysis in presence of phenylboronic acid, dissociation constant was evaluated at the pH 9.5(Apparent inhibition constant)",,BAO_0000019,,,,Autocuration,568,,U,0,CHEMBL625899,,,
14560,1,Reaction rate parameter value for phosphate with transfer with respect to ATP,,BAO_0000019,,,,Autocuration,12404,,U,0,CHEMBL626124,,,
14561,1,Ability to inhibit Escherichia coli adenylate kinase II activity expressed as half maximal velocity,,BAO_0000218,,Escherichia coli,,Intermediate,7624,,N,1,CHEMBL628500,,,
14562,1,"Ability to inhibit rat adenylate kinase II, activity expressed as half-maximal velocity",,BAO_0000218,,Rattus norvegicus,,Intermediate,7624,,N,1,CHEMBL857856,,,
14563,1,"Ability to inhibit rat adenylate kinase III, activity expressed as half-maximal velocity",,BAO_0000218,,Rattus norvegicus,,Intermediate,7624,,N,1,CHEMBL628501,,,
14564,1,"Compound was evaluated for the Michaelis-Menten constant, Km in a generic protein phosphatase stopped assay system",,BAO_0000019,,,,Autocuration,4643,,U,0,CHEMBL628502,,,
14565,1,Kinetic parameter KM (nM) for the MAO-B catalyzed oxidation of the compound.,,BAO_0000019,,,,Autocuration,11532,,U,0,CHEMBL628503,,,
14566,1,Kinetic parameter KM at pH 7.4 and 37 degree Centigrade,,BAO_0000019,,,,Autocuration,11018,,U,0,CHEMBL628504,,,
14567,1,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as KM; Not determined",,BAO_0000019,,,,Autocuration,2276,,U,0,CHEMBL628505,,,
14568,1,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as KM",,BAO_0000019,,,,Autocuration,2276,,U,0,CHEMBL874452,,,
14569,1,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as KM; Not determined",,BAO_0000019,,,,Autocuration,2276,,U,0,CHEMBL628506,,,
14570,1,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as KM; Not determined",,BAO_0000019,,,,Autocuration,2276,,U,0,CHEMBL628507,,,
14571,1,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as KM",,BAO_0000019,,,,Autocuration,2276,,U,0,CHEMBL628508,,,
14572,1,Michaelis constant (KM) was evaluated,,BAO_0000019,,,,Autocuration,8949,,U,0,CHEMBL628509,,,
14573,1,Reaction rate parameter value for phosphate with transfer with respect to ATP,,BAO_0000019,,,,Autocuration,12404,,U,0,CHEMBL628510,,,
14574,1,Substrate concentration for half maximal velocity was reported for rat hexokinase I,,BAO_0000019,,,,Autocuration,7625,,U,0,CHEMBL628511,,,
14575,1,Substrate concentration for half maximal velocity was reported for rat hexokinase II,,BAO_0000019,,,,Autocuration,7625,,U,0,CHEMBL628512,,,
14576,1,Substrate concentration for half maximal velocity was reported for rat hexokinase III,,BAO_0000019,,,,Autocuration,7625,,U,0,CHEMBL628513,,,
14577,1,Substrate concentration for half maximal velocity was reported for yeast hexokinase,,BAO_0000019,,,,Autocuration,7625,,U,0,CHEMBL628514,,,
14578,1,Pseudo-first-order rate constant for alkylation of NBP in 50% aqueous acetone at 66 degrees celsius with 50 uM and 25 uM of NBP.,,BAO_0000019,,,,Autocuration,12908,,U,0,CHEMBL628515,,,
14579,1,Rate constant for alkylation of 4-(4-nitrobenzyl)pyridine,,BAO_0000019,,,,Autocuration,10368,,U,0,CHEMBL628516,,,
14580,1,Bimolecular rate constant (KOH) at 25 degree C (m = 0.5),,BAO_0000019,,,,Autocuration,13108,,U,0,CHEMBL628517,,,
14581,1,its bimolecular rate constant (KOH) at 25 degree C (m = 0.5),,BAO_0000019,,,,Autocuration,13108,,U,0,CHEMBL628518,,,
14582,1,Acid dissociation constant evaluated towards Hematin mu-oxo dimer,,BAO_0000019,,,,Autocuration,15217,,U,0,CHEMBL628519,,,
14583,1,Acid dissociation constant evaluated towards Hematin mu-oxo dimer; Not available,,BAO_0000019,,,,Autocuration,15217,,U,0,CHEMBL628520,,,
14584,1,Binding constant was determined,,BAO_0000019,,,,Autocuration,10933,,U,0,CHEMBL628521,,,
14585,1,Alkylation of 4-(4-nitrobenzyl)pyridine (NBP) by the compound at a temperature of 66 degree Centigrade,,BAO_0000019,,,,Autocuration,2363,,U,0,CHEMBL630443,,,
14586,1,Alkylation of 4-(4-nitrobenzyl)pyridine (NBP) by the compound at a temperature of 66 degree centigrade; Not determined,,BAO_0000019,,,,Autocuration,2363,,U,0,CHEMBL630444,,,
14587,1,Rate constant with triethylamine at 30 degree C in 0.1 M potassium chloride was expressed as Kamine,,BAO_0000019,,,,Autocuration,2276,,U,0,CHEMBL857732,,,
14588,1,Octanol-water apparent distribution coefficient measured in TRIS buffer at a pH 7.4.,,BAO_0000100,,,,Autocuration,14915,,U,0,CHEMBL630445,,,
14589,1,Catalytic rate constant of the compound,,BAO_0000019,,,,Autocuration,8847,,U,0,CHEMBL630446,,,
14590,1,inactivation rate constant calculated from experimental IC50 value for dipeptidyl peptidase IV inhibition,,BAO_0000019,,,,Autocuration,15357,,U,0,CHEMBL630447,,,
14591,1,Catalytic constant expressed as Kinetic behavior of enzyme (PicK/6-His),,BAO_0000019,,,,Autocuration,2869,,U,0,CHEMBL630448,,,
14592,1,Catalytic rate constant against phospholipase A2 was determined,,BAO_0000019,,,,Autocuration,3484,,U,0,CHEMBL630449,,,
14593,1,"Compound was evaluated for catalytic constant, Kcat",,BAO_0000019,,,,Autocuration,1373,,U,0,CHEMBL630450,,,
14594,1,Compound was tested for hydrolysis by acetylcholinesterase and the kinetic constant (kcat) which is a first-order rate constant was determined,,BAO_0000019,,,,Autocuration,8142,,U,0,CHEMBL630451,,,
14595,1,Kcat calculated from 0.693/T1/2,,BAO_0000019,,,,Autocuration,14131,,U,0,CHEMBL630452,,,
14596,1,Kcat was determined,,BAO_0000019,,,,Autocuration,17269,,U,0,CHEMBL630453,,,
14597,1,Kcat against class A PCI beta-lactamase catalyzed lactone hydrolysis,,BAO_0000019,,,,Autocuration,3485,,U,0,CHEMBL630454,,,
14598,1,Kcat against class A TEM beta-lactamase catalyzed lactone hydrolysis,,BAO_0000019,,,,Autocuration,3485,,U,0,CHEMBL630455,,,
14599,1,Kcat against class C P99 beta-lactamase catalyzed lactone hydrolysis,,BAO_0000019,,,,Autocuration,3485,,U,0,CHEMBL631487,,,
14600,1,Kcat value was determined,,BAO_0000019,,,,Autocuration,5962,,U,0,CHEMBL631488,,,
14601,1,Kinetic constant for the hydrolysis by the catalyst CPA was evaluated,,BAO_0000019,,,,Autocuration,3133,,U,0,CHEMBL876440,,,
14602,1,Kinetic constant for the hydrolysis by the catalyst McAbIIF9D8 was evaluated,,BAO_0000019,,,,Autocuration,3133,,U,0,CHEMBL631489,,,
14603,1,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as Kcat; Not determined",,BAO_0000019,,,,Autocuration,2276,,U,0,CHEMBL857742,,,
14604,1,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat",,BAO_0000019,,,,Autocuration,2276,,U,0,CHEMBL631490,,,
14605,1,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as Kcat; Not determined",,BAO_0000019,,,,Autocuration,2276,,U,0,CHEMBL631491,,,
14606,1,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as Kcat; Not determined",,BAO_0000019,,,,Autocuration,2276,,U,0,CHEMBL631492,,,
14607,1,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat",,BAO_0000019,,,,Autocuration,2276,,U,0,CHEMBL631493,,,
14608,1,Kinetic parameter for rate of conversion to PABA was determined,,BAO_0000019,,,,Autocuration,4892,,U,0,CHEMBL631494,,,
14609,1,Rate acceleration expressed as ratio of Kcat to Kuncat was evaluated,,BAO_0000019,,,,Autocuration,3133,,U,0,CHEMBL631495,,,
14610,1,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 48-72 hr",Feces,BAO_0000218,,Rattus norvegicus,,Intermediate,11488,,N,1,CHEMBL631496,,1988.0,
14611,1,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 0-24 hr",Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,11488,,N,1,CHEMBL631497,,1088.0,
14612,1,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 24-48 hr",Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,11488,,N,1,CHEMBL631498,,1088.0,
14613,1,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 0-24 hr",Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,11488,,N,1,CHEMBL629776,,1088.0,
14614,1,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 24-48 hr",Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,11488,,N,1,CHEMBL629777,,1088.0,
14615,1,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 48-72 hr",Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,11488,,N,1,CHEMBL629778,,1088.0,
14616,1,Cumulative dose excreted after intraduodenal administration at 0-0.5 hours in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,11488,,N,1,CHEMBL630456,,,
14617,1,Cumulative dose excreted after intraduodenal administration at 0.5-1.0 hours in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,11488,,N,1,CHEMBL630457,,,
14618,1,Cumulative dose excreted after intraduodenal administration at 1.0-1.5 hours in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,11488,,N,1,CHEMBL630458,,,
14619,1,Cumulative dose excreted after intraduodenal administration at 1.5-2.0 hours in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,11488,,N,1,CHEMBL630459,,,
14620,1,Cumulative dose excreted after intraduodenal administration at 2-3 hours in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,11488,,N,1,CHEMBL630460,,,
14621,1,Cumulative dose excreted after intraduodenal administration at 3-4 hours in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,11488,,N,1,CHEMBL876550,,,
14622,1,Cumulative dose excreted after intraduodenal administration at 4-6 hours in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,11488,,N,1,CHEMBL630461,,,
14623,1,Cumulative dose excreted after intraduodenal administration at 6-8 hours in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,11488,,N,1,CHEMBL630462,,,
14624,1,Cumulative dose excreted after intraduodenal administration at 8-24 hours in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,11488,,N,1,CHEMBL630463,,,
14625,1,Cumulative dose excreted after intravenous administration at 0-0.5 hours in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,11488,,N,1,CHEMBL630464,,,
14626,1,Cumulative dose excreted after intravenous administration at 0.5-1 hours in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,11488,,N,1,CHEMBL630465,,,
14627,1,Cumulative dose excreted after intravenous administration at 1.0-1.5 hours in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,11488,,N,1,CHEMBL630466,,,
14628,1,Cumulative dose excreted after intravenous administration at 1.5-2 hours in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,11488,,N,1,CHEMBL630467,,,
14629,1,Cumulative dose excreted after intravenous administration at 2-3 hours in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,11488,,N,1,CHEMBL630633,,,
14630,1,Cumulative dose excreted after intravenous administration at 3-4 hours in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,11488,,N,1,CHEMBL630634,,,
14631,1,Cumulative dose excreted after intravenous administration at 4-6 hours in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,11488,,N,1,CHEMBL630635,,,
14632,1,Cumulative dose excreted after intravenous administration at 6-8 hours in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,11488,,N,1,CHEMBL630636,,,
14633,1,Cumulative dose excreted after intravenous administration at 8-24 hours in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,11488,,N,1,CHEMBL630637,,,
14634,1,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated (total)",Feces,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,7132,,N,1,CHEMBL630638,,1988.0,
14635,1,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 0-24 h",Feces,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,7132,,N,1,CHEMBL630639,,1988.0,
14636,1,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 24-48 h",Feces,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,7132,,N,1,CHEMBL630640,,1988.0,
14637,1,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 48-72 h",Feces,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,7132,,N,1,CHEMBL876551,,1988.0,
14638,1,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated (total)",Urine,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,7132,,N,1,CHEMBL630641,,1088.0,
14639,1,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 0-6 h",Urine,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,7132,,N,1,CHEMBL630642,,1088.0,
14640,1,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 24-48 h",Urine,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,7132,,N,1,CHEMBL630643,,1088.0,
14641,1,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 48-72 h",Urine,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,7132,,N,1,CHEMBL630644,,1088.0,
14642,1,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 6-24 h",Urine,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,7132,,N,1,CHEMBL630645,,1088.0,
14643,1,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated (total)",Feces,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,7132,,N,1,CHEMBL625599,,1988.0,
14644,1,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 0-24 h",Feces,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,7132,,N,1,CHEMBL625600,,1988.0,
14645,1,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 24-48 h",Feces,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,7132,,N,1,CHEMBL625601,,1988.0,
14646,1,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 48-72 h",Feces,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,7132,,N,1,CHEMBL625602,,1988.0,
14647,1,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated (total)",Urine,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,7132,,N,1,CHEMBL627470,,1088.0,
14648,1,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 0-6 h",Urine,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,7132,,N,1,CHEMBL627471,,1088.0,
14649,1,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 24-48 h",Urine,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,7132,,N,1,CHEMBL627472,,1088.0,
14650,1,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 48-72 h",Urine,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,7132,,N,1,CHEMBL627473,,1088.0,
14651,1,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 6-24 h",Urine,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,7132,,N,1,CHEMBL627474,,1088.0,
14652,1,Biodistribution in rat blood post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,13925,In vivo,N,1,CHEMBL627475,,178.0,
14653,1,Biodistribution in rat blood post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,13925,In vivo,N,1,CHEMBL627476,,178.0,
14654,1,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,N,1,CHEMBL627477,,1088.0,
14655,1,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,N,1,CHEMBL627478,,1088.0,
14656,1,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,N,1,CHEMBL627479,,1088.0,
14657,1,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,N,1,CHEMBL627480,,1088.0,
14658,1,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,N,1,CHEMBL627481,,1088.0,
14659,1,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,N,1,CHEMBL627482,,1088.0,
14660,1,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,N,1,CHEMBL627483,,1088.0,
14661,1,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,N,1,CHEMBL875636,,1088.0,
14662,1,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,N,1,CHEMBL625764,,1088.0,
14663,1,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 10.1 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,N,1,CHEMBL625765,,1088.0,
14664,1,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 102 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,N,1,CHEMBL625766,,1088.0,
14665,1,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 3.40 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,N,1,CHEMBL625767,,1088.0,
14666,1,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 3.76 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,N,1,CHEMBL625768,,1088.0,
14667,1,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 34.1 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,N,1,CHEMBL625769,,1088.0,
14668,1,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 50.8 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,N,1,CHEMBL625770,,1088.0,
14669,1,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 68.1 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,N,1,CHEMBL625771,,1088.0,
14670,1,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 9.060 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,N,1,CHEMBL625772,,1088.0,
14671,1,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 9.6 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,N,1,CHEMBL625773,,1088.0,
14672,1,Total electrolytic excretion of sodium in urine of rats after intravenous administration of 7.94 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL625774,,1088.0,
14673,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 0 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL625775,,1088.0,
14674,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 1.01 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL625776,,1088.0,
14675,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 1.13 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL625777,,1088.0,
14676,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 10.1 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL625778,,1088.0,
14677,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 102 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL625779,,1088.0,
14678,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 105 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL625780,,1088.0,
14679,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 11.3 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL625781,,1088.0,
14680,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 113 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL875637,,1088.0,
14681,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 19.5 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL626473,,1088.0,
14682,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 195 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL626474,,1088.0,
14683,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 21.7 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL626475,,1088.0,
14684,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 217 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL626476,,1088.0,
14685,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 23.9 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL634397,,1088.0,
14686,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 239 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL626477,,1088.0,
14687,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 24.9 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL631069,,1088.0,
14688,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 249 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL631070,,1088.0,
14689,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 25.9 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL631071,,1088.0,
14690,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 259 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL631072,,1088.0,
14691,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 26.5 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL631073,,1088.0,
14692,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 265 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL631074,,1088.0,
14693,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 27 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL631075,,1088.0,
14694,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 27.9 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL631725,,1088.0,
14695,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 270 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL631726,,1088.0,
14696,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 279 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL631727,,1088.0,
14697,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 28.2 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL631728,,1088.0,
14698,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 28.9 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL631729,,1088.0,
14699,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 282 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL631730,,1088.0,
14700,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 289 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL631731,,1088.0,
14701,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 3.40 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL631910,,1088.0,
14702,1,Biodistribution of the [18F]-radiolabeled compound in rat hippocampus,Hippocampus,BAO_0000218,,Rattus norvegicus,,Intermediate,15413,In vivo,N,1,CHEMBL631911,,10000000.0,
14703,1,Biodistribution of the [18F]-radiolabeled compound in rat hypothalamus,Hypothalamus,BAO_0000218,,Rattus norvegicus,,Intermediate,15413,In vivo,N,1,CHEMBL631912,,1898.0,
14704,1,Biodistribution of the [18F]-radiolabeled compound in rat hypothalamus; Not determined,Hypothalamus,BAO_0000218,,Rattus norvegicus,,Intermediate,15413,In vivo,N,1,CHEMBL631913,,1898.0,
14705,1,Biodistribution in blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL631914,,178.0,
14706,1,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL631915,,178.0,
14707,1,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL875778,,178.0,
14708,1,Biodistribution in blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL631916,,178.0,
14709,1,Biodistribution in blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL631917,,178.0,
14710,1,Biodistribution in blood of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL631918,,178.0,
14711,1,Biodistribution in blood of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL631919,,178.0,
14712,1,Biodistribution in blood of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL631920,,178.0,
14713,1,Biodistribution in blood of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL631921,,178.0,
14714,1,Biodistribution in blood of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL631922,,178.0,
14715,1,Biodistribution in blood of immature femalee rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL631923,,178.0,
14716,1,Biodistribution in fat of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL631924,,,
14717,1,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL630234,,,
14718,1,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL630235,,,
14719,1,Biodistribution in fat of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL630236,,,
14720,1,Biodistribution in fat of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL630237,,,
14721,1,Biodistribution in fat of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL630238,,,
14722,1,Biodistribution in fat of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL630239,,,
14723,1,Biodistribution in fat of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL630303,,,
14724,1,Biodistribution in fat of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL630304,,,
14725,1,Biodistribution in fat of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL630305,,,
14726,1,Biodistribution in kidney of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL630306,,2113.0,
14727,1,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL630307,,2113.0,
14728,1,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL630308,,2113.0,
14729,1,Biodistribution in kidney of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL630309,,2113.0,
14730,1,Biodistribution in kidney of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL629309,,2113.0,
14731,1,Biodistribution in kidney of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL629993,,2113.0,
14732,1,Biodistribution in kidney of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL629994,,2113.0,
14733,1,Biodistribution in kidney of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL629995,,2113.0,
14734,1,Biodistribution in kidney of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL631993,,2113.0,
14735,1,Biodistribution in kidney of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL631994,,2113.0,
14736,1,Biodistribution in kidney of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL631995,,2113.0,
14737,1,Biodistribution in liver of Iimmature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL631996,,2107.0,
14738,1,Biodistribution in liver of Iimmature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL631997,,2107.0,
14739,1,Biodistribution in liver of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL631998,,2107.0,
14740,1,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL631999,,2107.0,
14741,1,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL632000,,2107.0,
14742,1,Biodistribution in liver of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL632001,,2107.0,
14743,1,Biodistribution in liver of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL874424,,2107.0,
14744,1,Biodistribution in liver of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL632002,,2107.0,
14745,1,Biodistribution in liver of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL632003,,2107.0,
14746,1,Rate acceleration expressed as ratio of Kcat to Kuncat was evaluated,,BAO_0000019,,,,Autocuration,3133,,U,0,CHEMBL632004,,,
14747,1,Compound was tested for amidase rate in the presence of N62C fully characterised enzyme,,BAO_0000019,,,,Autocuration,2742,,U,0,CHEMBL632005,,,
14748,1,Compound was tested for amidase rate in the presence of N62C screen enzyme,,BAO_0000019,,,,Autocuration,2742,,U,0,CHEMBL632006,,,
14749,1,Compound was tested for amidase rate in the presence of S166C fully characterised enzyme,,BAO_0000019,,,,Autocuration,2742,,U,0,CHEMBL632007,,,
14750,1,Compound was tested for amidase rate in the presence of S166C screen enzyme,,BAO_0000019,,,,Autocuration,2742,,U,0,CHEMBL632008,,,
14751,1,Compound was tested for esterase rate in the presence of N62C fully characterised enzyme,,BAO_0000019,,,,Autocuration,2742,,U,0,CHEMBL632009,,,
14752,1,Compound was tested for esterase rate in the presence of N62C screen enzyme,,BAO_0000019,,,,Autocuration,2742,,U,0,CHEMBL632010,,,
14753,1,Compound was tested for esterase rate in the presence of S166C fully characterised enzyme,,BAO_0000019,,,,Autocuration,2742,,U,0,CHEMBL857750,,,
14754,1,Compound was tested for esterase rate in the presence of S166C screen enzyme,,BAO_0000019,,,,Autocuration,2742,,U,0,CHEMBL632011,,,
14755,1,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",,BAO_0000019,,,,Autocuration,2276,,U,0,CHEMBL632012,,,
14756,1,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",,BAO_0000019,,,,Autocuration,2276,,U,0,CHEMBL632013,,,
14757,1,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as Kcat/KM",,BAO_0000019,,,,Autocuration,2276,,U,0,CHEMBL632014,,,
14758,1,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",,BAO_0000019,,,,Autocuration,2276,,U,0,CHEMBL629622,,,
14759,1,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",,BAO_0000019,,,,Autocuration,2276,,U,0,CHEMBL629623,,,
14760,1,"Rate constant at 30 degree C in phosphate buffer pH 7.1, 0.5 % acetonitrile was expressed as Kcat/KM",,BAO_0000019,,,,Autocuration,2276,,U,0,CHEMBL629624,,,
14761,1,Ratio of Kcat to that of Km was determined,,BAO_0000019,,,,Autocuration,17269,,U,0,CHEMBL629625,,,
14762,1,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat/Kuncat",,BAO_0000019,,,,Autocuration,2276,,U,0,CHEMBL629626,,,
14763,1,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat/Kuncat",,BAO_0000019,,,,Autocuration,2276,,U,0,CHEMBL629627,,,
14764,1,"Compound was evaluated for constant, Kd",,BAO_0000019,,,,Autocuration,15917,,U,0,CHEMBL629628,,,
14765,1,Deacylation rate constant(Kd fast) was determined by proflavin displacement assay,,BAO_0000019,,,,Autocuration,10933,,U,0,CHEMBL629629,,,
14766,1,Deacylation rate constant(Kd slow) was determined by proflavin displacement assay,,BAO_0000019,,,,Autocuration,10933,,U,0,CHEMBL629630,,,
14767,1,Dissociation Constant of compound determined,,BAO_0000019,,,,Autocuration,14293,,U,0,CHEMBL856030,,,
14768,1,Dissociation constant for the binding of compound to PDZ3 from PSD-95 was determined,,BAO_0000019,,,,Autocuration,6698,,U,0,CHEMBL629631,,,
14769,1,Dissociation constant for the binding of compound to PDZ3 from PSD-95 was determined; No data,,BAO_0000019,,,,Autocuration,6698,,U,0,CHEMBL629632,,,
14770,1,Dissociation constant of compound with Fructose was determined,,BAO_0000100,,,,Autocuration,4318,,U,0,CHEMBL629633,,,
14771,1,Dissociation constant of compound with Fructose was determined; Not determined,,BAO_0000100,,,,Autocuration,4318,,U,0,CHEMBL629634,,,
14772,1,Dissociation constant of compound with Lactulose was determined,,BAO_0000100,,,,Autocuration,4318,,U,0,CHEMBL629635,,,
14773,1,Dissociation constant of compound with Lactulose was determined; Not determined,,BAO_0000100,,,,Autocuration,4318,,U,0,CHEMBL629636,,,
14774,1,Dissociation constant of the Compound,,BAO_0000100,,,,Autocuration,14959,,U,0,CHEMBL629637,,,
14775,1,Dissociation constant by non-linear regression analysis,,BAO_0000100,,,,Autocuration,5913,,U,0,CHEMBL629638,,,
14776,1,Dissociation constant was determined,,BAO_0000100,,,,Autocuration,14218,,U,0,CHEMBL629639,,,
14777,1,Dissociation constant of the compound; value ranges from 0.81-1.2 nM,,BAO_0000100,,,,Autocuration,10689,,U,0,CHEMBL629640,,,
14778,1,Dissociation constant was determined,,BAO_0000100,,,,Autocuration,13925,,U,0,CHEMBL629641,,,
14779,1,Dissociation constant was determined,,BAO_0000100,,,,Autocuration,16359,,U,0,CHEMBL631344,,,
14780,1,Equilibrium dissociation constant based on membrane concentration in rat smooth muscle,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,10944,,N,1,CHEMBL631345,,2385.0,
14781,1,The dissociation constant determined by fluorescence displacement assay,,BAO_0000019,,,,Autocuration,11080,,U,0,CHEMBL631346,,,
14782,1,kd value surface plasmon resonance (SPR) method,,BAO_0000019,,,,Autocuration,17805,,U,0,CHEMBL631524,,,
14783,1,Equilibrium dissociation constant based on aqueous concentration in rat smooth muscle,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,10944,,N,1,CHEMBL631525,,2385.0,
14784,1,First dissociation constant of the binding of compound to V30M TTR,,BAO_0000019,,,,Autocuration,16645,,U,0,CHEMBL631526,,,
14785,1,Second dissociation constant of the binding of compound to V30M TTR,,BAO_0000019,,,,Autocuration,16645,,U,0,CHEMBL631527,,,
14786,1,"Compound was evaluated for equilibrium constant, Ke",,BAO_0000019,,,,Autocuration,7793,,U,0,CHEMBL631528,,,
14787,1,Equilibrium constant from the dorsal raphe and the ventromedial hypothalamus,Hypothalamus,BAO_0000019,,,,Autocuration,12199,,U,0,CHEMBL631529,,1898.0,
14788,1,Equilibrium constant from the dorsal raphe and the ventromedial hypothalamus; inactive,Hypothalamus,BAO_0000019,,,,Autocuration,12199,,U,0,CHEMBL631530,,1898.0,
14789,1,Keff is the effective biomolecular rate constant on VX for reactivation at pH 7.8 at 25 degree Centigrade,,BAO_0000019,,,,Autocuration,9680,,U,0,CHEMBL631531,,,
14790,1,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,,BAO_0000019,,,,Autocuration,9680,,U,0,CHEMBL631532,,,
14791,1,Keff is the effective biomolecular rate constant on sarin for reactivation at pH 7.8 at 25 degree Centigrade,,BAO_0000019,,,,Autocuration,9680,,U,0,CHEMBL631533,,,
14792,1,In vitro biotransformation of compound along with coformycin in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,,BAO_0000218,,Mus musculus,,Intermediate,13758,,N,1,CHEMBL876552,,,
14793,1,In vitro biotransformation of compound along with coformycin in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-A) analyte,,BAO_0000218,,Mus musculus,,Intermediate,13758,,N,1,CHEMBL631534,,,
14794,1,In vitro biotransformation of compound in mice brain homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,,BAO_0000218,,Mus musculus,,Intermediate,13758,,N,1,CHEMBL631535,,,
14795,1,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,,BAO_0000218,,Mus musculus,,Intermediate,13758,,N,1,CHEMBL631536,,,
14796,1,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-hypoxanthine(ara-H) analyte,,BAO_0000218,,Mus musculus,,Intermediate,13758,,N,1,CHEMBL631537,,,
14797,1,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-A) analyte,,BAO_0000218,,Mus musculus,,Intermediate,13758,,N,1,CHEMBL631538,,,
14798,1,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-H) analyte,,BAO_0000218,,Mus musculus,,Intermediate,13758,,N,1,CHEMBL631539,,,
14799,1,In vitro biotransformation of compound in mice serum 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,,BAO_0000218,,Mus musculus,,Intermediate,13758,,N,1,CHEMBL631540,,,
14800,1,Pharmacokinetic Parameter [Kel(1/h)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,14393,,N,1,CHEMBL625637,,,
14801,1,Pharmacokinetic parameter [Kel(1/h)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,14393,,N,1,CHEMBL625638,,,
14802,1,"The Kel value in female wistar rat at 100 mg/kg, p.o. dose",,BAO_0000218,,Rattus norvegicus,,Intermediate,15078,,N,1,CHEMBL625639,,,
14803,1,Biodistribution in rat brain post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,13925,In vivo,N,1,CHEMBL625640,,955.0,
14804,1,Biodistribution in rat brain post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,13925,In vivo,N,1,CHEMBL625641,,955.0,
14805,1,Biodistribution in rat heart post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,13925,In vivo,N,1,CHEMBL625642,,948.0,
14806,1,Biodistribution in rat heart post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,13925,In vivo,N,1,CHEMBL625643,,948.0,
14807,1,Biodistribution in rat kidney post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,13925,In vivo,N,1,CHEMBL625644,,2113.0,
14808,1,Biodistribution in rat kidney post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,13925,In vivo,N,1,CHEMBL625645,,2113.0,
14809,1,Biodistribution in rat liver post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,13925,In vivo,N,1,CHEMBL625646,,2107.0,
14810,1,Biodistribution in rat liver post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,13925,In vivo,N,1,CHEMBL625647,,2107.0,
14811,1,Biodistribution in rat lung post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,13925,In vivo,N,1,CHEMBL625648,,2048.0,
14812,1,Biodistribution in rat lung post intravenous injection for 60 min of [99mTc]-TRODAT ligand expressed as percent dose per organ,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,13925,In vivo,N,1,CHEMBL625649,,2048.0,
14813,1,Biodistribution in rat muscle post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,13925,In vivo,N,1,CHEMBL625650,,2385.0,
14814,1,Biodistribution in rat muscle post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,13925,In vivo,N,1,CHEMBL625651,,2385.0,
14815,1,Biodistribution in rat skin post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Zone of skin,BAO_0000218,,Rattus norvegicus,,Intermediate,13925,In vivo,N,1,CHEMBL625652,,14.0,
14816,1,Biodistribution in rat skin post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Zone of skin,BAO_0000218,,Rattus norvegicus,,Intermediate,13925,In vivo,N,1,CHEMBL625653,,14.0,
14817,1,Biodistribution in rat spleen post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,13925,In vivo,N,1,CHEMBL625654,,2106.0,
14818,1,Biodistribution in rat spleen post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,13925,In vivo,N,1,CHEMBL625655,,2106.0,
14819,1,Biodistribution of Compound in rat blood after 15 minutes of administration,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,9712,In vivo,N,1,CHEMBL625656,,178.0,
14820,1,Biodistribution of Compound in rat blood after 2 minutes of administration,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,9712,In vivo,N,1,CHEMBL625657,,178.0,
14821,1,Biodistribution of Compound in rat brain after 15 minutes of administration,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,9712,In vivo,N,1,CHEMBL625658,,955.0,
14822,1,Biodistribution of Compound in rat brain after 2 minutes of administration,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,9712,In vivo,N,1,CHEMBL625659,,955.0,
14823,1,Biodistribution of Compound in rat heart after 15 minutes of administration,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,9712,In vivo,N,1,CHEMBL625660,,948.0,
14824,1,Biodistribution of Compound in rat heart after 2 minutes of administration,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,9712,In vivo,N,1,CHEMBL625661,,948.0,
14825,1,Biodistribution of Compound in rat liver after 15 minutes of administration,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,9712,In vivo,N,1,CHEMBL625662,,2107.0,
14826,1,Biodistribution of Compound in rat liver after 2 minutes of administration,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,9712,In vivo,N,1,CHEMBL625663,,2107.0,
14827,1,Biodistribution of Compound in rat lung after 15 minutes of administration,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,9712,In vivo,N,1,CHEMBL875621,,2048.0,
14828,1,Biodistribution of Compound in rat lung after 2 minutes of administration,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,9712,In vivo,N,1,CHEMBL628382,,2048.0,
14829,1,Biodistribution of Compound in rat muscle after 15 minutes of administration,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,9712,In vivo,N,1,CHEMBL628383,,2385.0,
14830,1,Biodistribution of Compound in rat muscle after 2 minutes of administration,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,9712,In vivo,N,1,CHEMBL628384,,2385.0,
14831,1,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 2 mins,,BAO_0000218,,Rattus norvegicus,,Intermediate,13925,,N,1,CHEMBL628385,,,
14832,1,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 30 mins,,BAO_0000218,,Rattus norvegicus,,Intermediate,13925,,N,1,CHEMBL875753,,,
14833,1,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 60 mins,,BAO_0000218,,Rattus norvegicus,,Intermediate,13925,,N,1,CHEMBL628386,,,
14834,1,Organ distribution in rat blood 2 minutes after intravenous injection,,BAO_0000218,,Rattus norvegicus,,Intermediate,6941,,N,1,CHEMBL628387,,,
14835,1,Organ distribution in rat blood 2 hr after intravenous injection,,BAO_0000218,,Rattus norvegicus,,Intermediate,6941,,N,1,CHEMBL628388,,,
14836,1,Organ distribution in rat blood 30 minutes after intravenous injection,,BAO_0000218,,Rattus norvegicus,,Intermediate,6941,,N,1,CHEMBL628389,,,
14837,1,Organ distribution in rat blood 30 min after intravenous injection,,BAO_0000218,,Rattus norvegicus,,Intermediate,6941,,N,1,CHEMBL632756,,,
14838,1,Organ distribution in rat brain 2 minutes after intravenous injection,,BAO_0000218,,Rattus norvegicus,,Intermediate,6941,,N,1,CHEMBL628390,,,
14839,1,Organ distribution in rat brain 2 hr after intravenous injection,,BAO_0000218,,Rattus norvegicus,,Intermediate,6941,,N,1,CHEMBL631811,,,
14840,1,Organ distribution in rat brain 30 minutes after intravenous injection,,BAO_0000218,,Rattus norvegicus,,Intermediate,6941,,N,1,CHEMBL631812,,,
14841,1,Organ distribution in rat heart 2 minutes after intravenous injection,,BAO_0000218,,Rattus norvegicus,,Intermediate,6941,,N,1,CHEMBL631813,,,
14842,1,Organ distribution in rat heart 2 hr after intravenous injection,,BAO_0000218,,Rattus norvegicus,,Intermediate,6941,,N,1,CHEMBL631814,,,
14843,1,Organ distribution in rat heart 30 minutes after intravenous injection,,BAO_0000218,,Rattus norvegicus,,Intermediate,6941,,N,1,CHEMBL631815,,,
14844,1,Organ distribution in rat kidney 2 minutes after intravenous injection,,BAO_0000218,,Rattus norvegicus,,Intermediate,6941,,N,1,CHEMBL631816,,,
14845,1,Organ distribution in rat kidney 2 hr after intravenous injection,,BAO_0000218,,Rattus norvegicus,,Intermediate,6941,,N,1,CHEMBL875758,,,
14846,1,Organ distribution in rat kidney 30 minutes after intravenous injection,,BAO_0000218,,Rattus norvegicus,,Intermediate,6941,,N,1,CHEMBL631817,,,
14847,1,Organ distribution in rat liver 2 minutes after intravenous injection,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,6941,,N,1,CHEMBL631818,,2107.0,
14848,1,Organ distribution in rat liver 2 hr after intravenous injection,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,6941,,N,1,CHEMBL631819,,2107.0,
14849,1,Organ distribution in rat liver 30 minutes after intravenous injection,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,6941,,N,1,CHEMBL631820,,2107.0,
14850,1,Organ distribution in rat lung 2 minutes after intravenous injection,,BAO_0000218,,Rattus norvegicus,,Intermediate,6941,,N,1,CHEMBL631821,,,
14851,1,Organ distribution in rat lung 2 hr after intravenous injection,,BAO_0000218,,Rattus norvegicus,,Intermediate,6941,,N,1,CHEMBL631822,,,
14852,1,Organ distribution in rat lung 30 minutes after intravenous injection,,BAO_0000218,,Rattus norvegicus,,Intermediate,6941,,N,1,CHEMBL631823,,,
14853,1,Organ distribution in rat muscle 2 minutes after intravenous injection,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,6941,,N,1,CHEMBL631824,,2385.0,
14854,1,Organ distribution in rat muscle 2 hr after intravenous injection,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,6941,,N,1,CHEMBL631825,,2385.0,
14855,1,Organ distribution in rat muscle 30 minutes after intravenous injection,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,6941,,N,1,CHEMBL631826,,2385.0,
14856,1,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Blood (B),,BAO_0000218,,Mus musculus,,Intermediate,14439,In vivo,N,1,CHEMBL631827,,,
14857,1,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Heart (H),,BAO_0000218,,Mus musculus,,Intermediate,14439,In vivo,N,1,CHEMBL631828,,,
14858,1,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Lung (L),,BAO_0000218,,Mus musculus,,Intermediate,14439,In vivo,N,1,CHEMBL631829,,,
14859,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 3.76 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL875759,,1088.0,
14860,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 30.20 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL631830,,1088.0,
14861,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 302 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL631831,,1088.0,
14862,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 31.6 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL631832,,1088.0,
14863,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 316 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL631833,,1088.0,
14864,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 32.4 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL631834,,1088.0,
14865,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 324 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL631835,,1088.0,
14866,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.0 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL631836,,1088.0,
14867,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.1 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL631837,,1088.0,
14868,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.8 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL631838,,1088.0,
14869,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 341 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL631839,,1088.0,
14870,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 348 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL631840,,1088.0,
14871,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 37.6 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL631841,,1088.0,
14872,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 58.4 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL631842,,1088.0,
14873,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 65.2 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL631843,,1088.0,
14874,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 71.6 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL631844,,1088.0,
14875,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 71.8 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL631845,,1088.0,
14876,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 74.8 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL631846,,1088.0,
14877,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 77.5 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL875760,,1088.0,
14878,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 79.4 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL632199,,1088.0,
14879,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 80.9 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL631847,,1088.0,
14880,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 83.8 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL631848,,1088.0,
14881,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 84.5 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL628707,,1088.0,
14882,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 84.7 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL628708,,1088.0,
14883,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 86.7 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL628709,,1088.0,
14884,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 86.9 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL628710,,1088.0,
14885,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 9.06 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL628711,,1088.0,
14886,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 90.6 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL628712,,1088.0,
14887,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 94.9 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL628713,,1088.0,
14888,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 97.1 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,N,1,CHEMBL628714,,1088.0,
14889,1,"excretion rate in rats after the dose of 5 mg/kg intravenously, at the dose 4 hour Rate of biliary excretion; 0.06-0.15%/h",,BAO_0000218,,Rattus norvegicus,,Intermediate,7415,,N,1,CHEMBL628715,,,
14890,1,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 3.75-120 uM,,BAO_0000019,,,,Autocuration,7313,,U,0,CHEMBL629179,,,
14891,1,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 30 uM,,BAO_0000019,,,,Autocuration,7313,,U,0,CHEMBL629180,,,
14892,1,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 7.5-120 uM,,BAO_0000019,,,,Autocuration,7313,,U,0,CHEMBL875108,,,
14893,1,Percent lipid extracted at 0.5 hr from adrenal cortex liver using CHCl3/CH3OH.,Adrenal cortex,BAO_0000019,,,,Autocuration,7570,,U,0,CHEMBL629181,,1235.0,
14894,1,Percent lipid extracted at 0.5 hr from adrenal cortex liver using CHCl3/CH3OH.,Adrenal cortex,BAO_0000019,,,,Autocuration,7570,,U,0,CHEMBL629182,,1235.0,
14895,1,Percent lipid extracted at 0.5 hr from liver plasma using CHCl3/CH3OH.,,BAO_0000019,,,,Autocuration,7570,,U,0,CHEMBL629183,,,
14896,1,Percent lipid extracted at 0.5 hr from liver using CHCl3/CH3OH.,,BAO_0000019,,,,Autocuration,7570,,U,0,CHEMBL629184,,,
14897,1,Percent lipid extracted at 24 hours from adrenal cortex using CHCl3/CH3OH.,Adrenal cortex,BAO_0000019,,,,Autocuration,7570,,U,0,CHEMBL629185,,1235.0,
14898,1,Percent lipid extracted at 24 hours from adrenal cortex liver using CHCl3/CH3OH.,Adrenal cortex,BAO_0000019,,,,Autocuration,7570,,U,0,CHEMBL629186,,1235.0,
14899,1,Percent lipid extracted at 24 hours from liverliver using CHCl3/CH3OH.,,BAO_0000019,,,,Autocuration,7570,,U,0,CHEMBL629187,,,
14900,1,Percent lipid extracted at 24 hours from plasma using CHCl3/CH3OH.,,BAO_0000019,,,,Autocuration,7570,,U,0,CHEMBL629887,,,
14901,1,Percent lipid extracted at 24 hours from plasmaliver using CHCl3/CH3OH.,,BAO_0000019,,,,Autocuration,7570,,U,0,CHEMBL629888,,,
14902,1,Percent lipid extracted at 24 hr from liver using CHCl3/CH3OH.,,BAO_0000019,,,,Autocuration,7570,,U,0,CHEMBL629889,,,
14903,1,Percent parent compound extracted at 0.5 hr from adrenal cortex using CHCl3/CH3OH.,Adrenal cortex,BAO_0000019,,,,Autocuration,7570,,U,0,CHEMBL629890,,1235.0,
14904,1,Percent parent compound extracted at 0.5 hr from liver using CHCl3/CH3OH.,,BAO_0000019,,,,Autocuration,7570,,U,0,CHEMBL629891,,,
14905,1,Percent parent compound extracted at 0.5 hr from plasma using CHCl3/CH3OH.,,BAO_0000019,,,,Autocuration,7570,,U,0,CHEMBL629892,,,
14906,1,Percent parent compound extracted at 24 hours from adrenal cortex using CHCl3/CH3OH.,Adrenal cortex,BAO_0000019,,,,Autocuration,7570,,U,0,CHEMBL629893,,1235.0,
14907,1,Percent parent compound extracted at 24 hours from liver using CHCl3/CH3OH.,,BAO_0000019,,,,Autocuration,7570,,U,0,CHEMBL629894,,,
14908,1,Percent parent compound extracted at 24 hours from plasma using CHCl3/CH3OH.,,BAO_0000019,,,,Autocuration,7570,,U,0,CHEMBL629895,,,
14909,1,"+Ratio of intravenous to oral integrated area under the concentration vs time curve, for compound in dog plasma",,BAO_0000218,,Canis lupus familiaris,,Autocuration,14122,In vivo,U,0,CHEMBL875109,,,
14910,1,Absolute bioavailability in male cynomolgus monkeys,,BAO_0000218,,Macaca fascicularis,,Autocuration,16449,In vivo,U,0,CHEMBL629896,,,
14911,1,Absolute bioavailability in maleSprague-Dawley rats,,BAO_0000218,,Rattus norvegicus,,Autocuration,16449,In vivo,U,0,CHEMBL629897,,,
14912,1,Biodistribution in liver of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL629898,,2107.0,
14913,1,Biodistribution in liver of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL630057,,2107.0,
14914,1,Biodistribution in liver of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL630058,,2107.0,
14915,1,Biodistribution in lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL630059,,2048.0,
14916,1,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL630060,,2048.0,
14917,1,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL630061,,2048.0,
14918,1,Biodistribution in lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL630062,,2048.0,
14919,1,Biodistribution in lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL630063,,2048.0,
14920,1,Biodistribution in lungs of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL630064,,2048.0,
14921,1,Biodistribution in lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL630065,,2048.0,
14922,1,Biodistribution in lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL630066,,2048.0,
14923,1,Biodistribution in lungs of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL630067,,2048.0,
14924,1,Biodistribution in lungs of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL630068,,2048.0,
14925,1,Biodistribution in muscle of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL631113,,2385.0,
14926,1,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL631114,,2385.0,
14927,1,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL631115,,2385.0,
14928,1,Biodistribution in muscle of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL631116,,2385.0,
14929,1,Biodistribution in muscle of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL630528,,2385.0,
14930,1,Biodistribution in muscle of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL630529,,2385.0,
14931,1,Biodistribution in muscle of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL630530,,2385.0,
14932,1,Biodistribution in muscle of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL630531,,2385.0,
14933,1,Biodistribution in muscle of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL630532,,2385.0,
14934,1,Biodistribution in muscle of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL630533,,2385.0,
14935,1,Biodistribution in normal mice blood after 120 hr,Blood,BAO_0000218,,Mus musculus,,Intermediate,15045,In vivo,N,1,CHEMBL630534,,178.0,
14936,1,Biodistribution in normal mice blood after 24 hr,Blood,BAO_0000218,,Mus musculus,,Intermediate,15045,In vivo,N,1,CHEMBL630535,,178.0,
14937,1,Biodistribution in normal mice blood after 4 hr,Blood,BAO_0000218,,Mus musculus,,Intermediate,15045,In vivo,N,1,CHEMBL630536,,178.0,
14938,1,Biodistribution in normal mice bone after 120 hr,Bone,BAO_0000218,,Mus musculus,,Intermediate,15045,In vivo,N,1,CHEMBL630537,,10000001.0,
14939,1,Biodistribution in normal mice bone after 24 hr,Bone,BAO_0000218,,Mus musculus,,Intermediate,15045,In vivo,N,1,CHEMBL630538,,10000001.0,
14940,1,Biodistribution in normal mice bone after 4 hr,Bone,BAO_0000218,,Mus musculus,,Intermediate,15045,In vivo,N,1,CHEMBL630539,,10000001.0,
14941,1,Biodistribution in normal mice heart after 120 hr,Heart,BAO_0000218,,Mus musculus,,Intermediate,15045,In vivo,N,1,CHEMBL630540,,948.0,
14942,1,Biodistribution in normal mice heart after 24 hr,Heart,BAO_0000218,,Mus musculus,,Intermediate,15045,In vivo,N,1,CHEMBL630541,,948.0,
14943,1,Biodistribution in normal mice heart after 4 hr,Heart,BAO_0000218,,Mus musculus,,Intermediate,15045,In vivo,N,1,CHEMBL630542,,948.0,
14944,1,Biodistribution in normal mice kidney after 120 hr,Kidney,BAO_0000218,,Mus musculus,,Intermediate,15045,In vivo,N,1,CHEMBL630543,,2113.0,
14945,1,Biodistribution in normal mice kidney after 24 hr,Kidney,BAO_0000218,,Mus musculus,,Intermediate,15045,In vivo,N,1,CHEMBL630544,,2113.0,
14946,1,Biodistribution in normal mice kidney after 4 hr,Kidney,BAO_0000218,,Mus musculus,,Intermediate,15045,In vivo,N,1,CHEMBL630545,,2113.0,
14947,1,Biodistribution in normal mice liver after 120 hr,Liver,BAO_0000218,,Mus musculus,,Intermediate,15045,In vivo,N,1,CHEMBL630546,,2107.0,
14948,1,Biodistribution in normal mice liver after 24 hr,Liver,BAO_0000218,,Mus musculus,,Intermediate,15045,In vivo,N,1,CHEMBL630547,,2107.0,
14949,1,Biodistribution in normal mice liver after 4 hr,Liver,BAO_0000218,,Mus musculus,,Intermediate,15045,In vivo,N,1,CHEMBL630548,,2107.0,
14950,1,Biodistribution in normal mice spleen after 120 hr,Spleen,BAO_0000218,,Mus musculus,,Intermediate,15045,In vivo,N,1,CHEMBL630549,,2106.0,
14951,1,Biodistribution in normal mice spleen after 24 hr,Spleen,BAO_0000218,,Mus musculus,,Intermediate,15045,In vivo,N,1,CHEMBL630550,,2106.0,
14952,1,Biodistribution in normal mice spleen after 4 hr,Spleen,BAO_0000218,,Mus musculus,,Intermediate,15045,In vivo,N,1,CHEMBL876426,,2106.0,
14953,1,Biodistribution in spleen of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL630551,,2106.0,
14954,1,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL630552,,2106.0,
14955,1,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL630553,,2106.0,
14956,1,Biodistribution in spleen of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL630554,,2106.0,
14957,1,Biodistribution in spleen of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL630555,,2106.0,
14958,1,Biodistribution in spleen of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL630556,,2106.0,
14959,1,Biodistribution in spleen of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL630557,,2106.0,
14960,1,Biodistribution in spleen of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL630558,,2106.0,
14961,1,Biodistribution in spleen of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL630559,,2106.0,
14962,1,Biodistribution in spleen of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL630560,,2106.0,
14963,1,Biodistribution in thyroid of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,N,1,CHEMBL876427,,2046.0,
14964,1,The Kel values in female wistar rats.,,BAO_0000218,,Rattus norvegicus,,Intermediate,14941,,N,1,CHEMBL630561,,,
14965,1,The equilibrium constant pair at a pH of 7.0 and temperature of 25 degree Centigrade,,BAO_0000019,,,,Autocuration,4646,,U,0,CHEMBL630562,,,
14966,1,Hydrolysis rate constant of the compound,,BAO_0000019,,,,Autocuration,8847,,U,0,CHEMBL630563,,,
14967,1,Headecane/water partition coefficient expressed as the equilibrium ratio of the molar concentration in n-hexadecane to that in the buffer,,BAO_0000100,,,,Autocuration,11778,,U,0,CHEMBL629673,,,
14968,1,"Hydrolysis in acetone/water (50:50) at a pH of 8.0, T=66 degree Centigrade",,BAO_0000019,,,,Autocuration,2363,,U,0,CHEMBL629674,,,
14969,1,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree Centigrade",,BAO_0000019,,,,Autocuration,2363,,U,0,CHEMBL629675,,,
14970,1,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree centigrade; No data",,BAO_0000019,,,,Autocuration,2363,,U,0,CHEMBL629676,,,
14971,1,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree centigrade; Not determined",,BAO_0000019,,,,Autocuration,2363,,U,0,CHEMBL629677,,,
14972,1,Apparent inactivation rate constant was evaluated,,BAO_0000019,,,,Autocuration,8371,,U,0,CHEMBL629678,,,
14973,1,Compound was evaluated for equilibrium constant K obtained from the ratio of reverse rate constants at 25 degree Centigrade.,,BAO_0000019,,,,Autocuration,14883,,U,0,CHEMBL629679,,,
14974,1,Compound was evaluated for equilibrium constant K obtained from the ratio of reverse rate constants at 37 degree Centigrade,,BAO_0000019,,,,Autocuration,14883,,U,0,CHEMBL629680,,,
14975,1,Compound was evaluated for the Ki value for peptide alcohol for competitive inhibition in the presence of Mn2+ ions at pH 7.5,,BAO_0000019,,,,Autocuration,4643,,U,0,CHEMBL629681,,,
14976,1,Compound was tested for the inhibition of antibody-catalyzed hydrolysis.,,BAO_0000019,,,,Autocuration,3519,,U,0,CHEMBL629682,,,
14977,1,DBH (dopamine beta-hydroxylase) activity expressed as Ki value determined by degree to which compound inhibited conversion of tyramine to octopamine,,BAO_0000019,,,,Autocuration,10600,,U,0,CHEMBL629683,,,
14978,1,Dissociation constant against constrictor response to the compound blocked competitively by phentolamine for alpha-mediated events,,BAO_0000019,,,,Autocuration,8501,,U,0,CHEMBL629684,,,
14979,1,Dissociation constant was determined,,BAO_0000100,,,,Autocuration,8505,,U,0,CHEMBL629685,,,
14980,1,Dissociation constant was determined,,BAO_0000100,,,,Autocuration,9778,,U,0,CHEMBL629686,,,
14981,1,Dissociation constant at pH 7.4,,BAO_0000100,,,,Autocuration,9778,,U,0,CHEMBL872932,,,
14982,1,Dissociation constant in presence of 1 mM dithiothreitol,,BAO_0000100,,,,Autocuration,9778,,U,0,CHEMBL629687,,,
14983,1,Kinetic Parameter Ki for Inhibition of Type 1 5-alpha-reductase,,BAO_0000019,,,,Autocuration,13007,,U,0,CHEMBL872931,,,
14984,1,Kinetic Parameter Ki for Inhibition of Type 1 5-alpha-reductase,,BAO_0000019,,,,Autocuration,13007,,U,0,CHEMBL628151,,,
14985,1,Kinetic Parameter Ki for Inhibition of Type-2 5-alpha-reductase,,BAO_0000019,,,,Autocuration,13007,,U,0,CHEMBL628152,,,
14986,1,Kinetic Parameter Ki for Inhibition of Type-2 5-alpha-reductase,,BAO_0000019,,,,Autocuration,13007,,U,0,CHEMBL628153,,,
14987,1,Kinetic constant for aromatization of androstenedione,,BAO_0000019,,,,Autocuration,11482,,U,0,CHEMBL628154,,,
14988,1,Kinetic constant for aromatization of testosterone,,BAO_0000019,,,,Autocuration,11482,,U,0,CHEMBL628155,,,
14989,1,Kinetic parameter for hydrolysis of 1 by Antibody 2D10 after addition of compound 12,,BAO_0000019,,,,Autocuration,2303,,U,0,CHEMBL628156,,,
14990,1,Local inhibition constant was determined,,BAO_0000019,,,,Autocuration,11964,,U,0,CHEMBL628157,,,
14991,1,Rate of inactivation of sterol methyl transferase from Saccharomyces cerevisiae using mechanism based inhibitor,,BAO_0000218,,Saccharomyces cerevisiae,,Intermediate,3140,,N,1,CHEMBL857533,,,
14992,1,Dissociation constant value of the compound,,BAO_0000100,,,,Autocuration,10650,,U,0,CHEMBL628158,,,
14993,1,In vitro permeability through cornea without epithelium,Cornea,BAO_0000019,,,,Autocuration,4667,,U,0,CHEMBL628159,,964.0,
14994,1,In vitro permeability through intact cornea,Cornea,BAO_0000019,,,,Autocuration,4667,,U,0,CHEMBL875616,,964.0,
14995,1,Evaluated for first order rate constant (Kin) for transcorneal penetration in anesthetized rabbits,Cornea,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,9199,,N,1,CHEMBL628160,,964.0,
14996,1,Rate of enzyme inactivation for the compound was determined,,BAO_0000019,,,,Autocuration,11966,,U,0,CHEMBL628161,,,
14997,1,In vitro permeability through cornea without epithelium,Cornea,BAO_0000019,,,,Autocuration,4667,,U,0,CHEMBL628162,,964.0,
14998,1,In vitro permeability through intact cornea,Cornea,BAO_0000019,,,,Autocuration,4667,,U,0,CHEMBL628163,,964.0,
14999,1,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0300 mM [HOX] in the conditions of 25degreeC,pH 7.6",,BAO_0000019,,,,Autocuration,8354,,U,0,CHEMBL628164,,,
15000,1,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0384 mM [HOX] in the conditions of 25degreeC,pH 7.6",,BAO_0000019,,,,Autocuration,8354,,U,0,CHEMBL628165,,,
15001,1,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0395 mM [HOX] in the conditions of 25degreeC,pH 7.6",,BAO_0000019,,,,Autocuration,8354,,U,0,CHEMBL628166,,,
15002,1,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0500 mM [HOX] in the conditions of 25degreeC,pH 7.6",,BAO_0000019,,,,Autocuration,8354,,U,0,CHEMBL628167,,,
15003,1,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.050 mM [HOX] in the conditions of 25degreeC,pH 7.6",,BAO_0000019,,,,Autocuration,8354,,U,0,CHEMBL628168,,,
15004,1,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0767 mM [HOX] in the conditions of 25degreeC,pH 7.6",,BAO_0000019,,,,Autocuration,8354,,U,0,CHEMBL628169,,,
15005,1,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0790 mM [HOX] in the conditions of 25degreeC,pH 7.6",,BAO_0000019,,,,Autocuration,8354,,U,0,CHEMBL628170,,,
15006,1,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0800 mM [HOX] in the conditions of 25degreeC,pH 7.6",,BAO_0000019,,,,Autocuration,8354,,U,0,CHEMBL628171,,,
15007,1,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.100 mM [HOX] in the conditions of 25degreeC,pH 7.6",,BAO_0000019,,,,Autocuration,8354,,U,0,CHEMBL627434,,,
15008,1,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.200 mM [HOX] in the conditions of 25degreeC,pH 7.6",,BAO_0000019,,,,Autocuration,8354,,U,0,CHEMBL627435,,,
15009,1,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.300 mM [HOX] in the conditions of 25degreeC,pH 7.6",,BAO_0000019,,,,Autocuration,8354,,U,0,CHEMBL628110,,,
15010,1,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.384 mM [HOX] in the conditions of 25degreeC,pH 7.6",,BAO_0000019,,,,Autocuration,8354,,U,0,CHEMBL628111,,,
15011,1,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.395 mM [HOX] in the conditions of 25degreeC,pH 7.6",,BAO_0000019,,,,Autocuration,8354,,U,0,CHEMBL628112,,,
15012,1,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",,BAO_0000019,,,,Autocuration,8354,,U,0,CHEMBL628260,,,
15013,1,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",,BAO_0000019,,,,Autocuration,8354,,U,0,CHEMBL628261,,,
15014,1,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Muscle (M),,BAO_0000218,,Mus musculus,,Intermediate,14439,In vivo,N,1,CHEMBL628262,,,
15015,1,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Tumor (T) cells,,BAO_0000218,,Homo sapiens,,Intermediate,14439,In vivo,N,1,CHEMBL628263,,,
15016,1,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Blood (B),,BAO_0000218,,Mus musculus,,Intermediate,14439,In vivo,N,1,CHEMBL628264,,,
15017,1,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Heart (H),,BAO_0000218,,Mus musculus,,Intermediate,14439,In vivo,N,1,CHEMBL628265,,,
15018,1,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Lung (L),,BAO_0000218,,Mus musculus,,Intermediate,14439,In vivo,N,1,CHEMBL628266,,,
15019,1,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Muscle (M),,BAO_0000218,,Mus musculus,,Intermediate,14439,In vivo,N,1,CHEMBL628267,,,
15020,1,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Tumor (T) cells,,BAO_0000218,,Mus musculus,,Intermediate,14439,In vivo,N,1,CHEMBL628268,,,
15021,1,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Blood (B),,BAO_0000218,,Mus musculus,,Intermediate,14439,In vivo,N,1,CHEMBL628269,,,
15022,1,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Heart (H),,BAO_0000218,,Mus musculus,,Intermediate,14439,In vivo,N,1,CHEMBL628270,,,
15023,1,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Lung (L),,BAO_0000218,,Mus musculus,,Intermediate,14439,In vivo,N,1,CHEMBL628271,,,
15024,1,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Muscle (M),,BAO_0000218,,Mus musculus,,Intermediate,14439,In vivo,N,1,CHEMBL628272,,,
